<SEC-DOCUMENT>0001144204-12-011082.txt : 20120227
<SEC-HEADER>0001144204-12-011082.hdr.sgml : 20120227
<ACCEPTANCE-DATETIME>20120227161318
ACCESSION NUMBER:		0001144204-12-011082
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		25
CONFORMED PERIOD OF REPORT:	20111231
FILED AS OF DATE:		20120227
DATE AS OF CHANGE:		20120227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		12642099

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>v303493_10k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>FORM 10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR ANNUAL AND TRANSITION REPORTS PURSUANT
TO SECTIONS 13 OR 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt"><B>For the fiscal year ended December&nbsp;31, 2011</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings; color: black"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Commission file number) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-weight: bold; text-align: center">Florida</TD>
    <TD STYLE="width: 4%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; font-weight: bold; text-decoration: underline; text-align: center">65-0643773</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of incorporation or organization</B></P></TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
<TR>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>2 Snunit Street</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Science Park</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>POB 455</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>Carmiel, Israel</U></B></P></TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>20100</U></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(b)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-weight: bold; text-align: center">Title of each class</TD>
    <TD STYLE="width: 4%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; font-weight: bold; text-align: center">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">Common stock, par value $0.001 per share</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">NYSE AMEX</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities registered pursuant to Section&nbsp;12(g)
of the Act: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>None</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">Indicate by check mark if the registrant is
a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">Indicate by check mark if the registrant is
not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><FONT STYLE="color: black">Indicate by check
mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files). </FONT>&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">Indicate by check mark if disclosure of delinquent
filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&rsquo;s
knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment
to this Form&nbsp;10-K.&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><FONT STYLE="color: black">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. </FONT>See definition of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting
company&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 25%; text-indent: 0in">Large accelerated filer</TD>
    <TD NOWRAP STYLE="width: 5%; text-indent: 0in; font-family: Wingdings">&uml;</TD>
    <TD NOWRAP STYLE="width: 40%; text-indent: 0in">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 25%; text-indent: 0in">Accelerated filer</TD>
    <TD NOWRAP STYLE="width: 5%; text-indent: 0in; font-family: Wingdings">x</TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD NOWRAP STYLE="text-indent: 0in; font-family: Wingdings">&uml;</TD>
    <TD NOWRAP STYLE="text-indent: 0in">(Do not check if a smaller reporting company)</TD>
    <TD NOWRAP STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD NOWRAP STYLE="text-indent: 0in; font-family: Wingdings">&uml;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">The aggregate market value of the voting common
equity held by non-affiliates of the Registrant, as of June 30, 2011 was approximately $365 million (based upon a per share price
equal to $6.26, the closing price for shares of the Registrant&rsquo;s common stock reported by the NYSE Amex for such date). Shares
of common stock held by each officer, director and holder of 5% or more of the outstanding common stock have been excluded in that
such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination
for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">On February 23, 2012, approximately 90,815,396
shares of the Registrant&rsquo;s common stock, par value $0.001 per share, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 80%; font-weight: bold; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: right">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD COLSPAN="3" STYLE="tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">PART I</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Cautionary Statement Regarding Forward-Looking Statements</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">1</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 1.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Business</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">3</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 1A.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Risk Factors</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">38</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 1B.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Unresolved Staff Comments</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">59</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 2.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Properties</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">59</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 3.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Legal Proceedings</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">59</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 4.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Mine Safety Disclosures</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">59</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">PART II</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 5.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">60</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 6.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Selected Financial Data</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">62</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 7.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">63</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 7A.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">73</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 8.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Financial Statements and Supplementary Data</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">74</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 9.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">74</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 9A.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Controls and Procedures</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">74</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 9B.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Other Information</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">75</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="3" STYLE="tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">PART III</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 10.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Directors, Executive Officers and Corporate Governance</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">76</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 11.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Executive Compensation</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">79</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 12.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">89</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 13.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Certain Relationships and Related Transactions, and Director Independence</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">91</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 14.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Principal Accountant Fees and Services</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">93</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD COLSPAN="3" STYLE="tab-stops: 45.0pt right dotted 6.95in; font-weight: bold; text-align: center">PART IV</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Item 15.</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Exhibits and Financial Statement Schedules</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">94</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">Signatures</TD>
    <TD STYLE="vertical-align: top; tab-stops: 45.0pt right dotted 6.95in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; tab-stops: 45.0pt right dotted 6.95in; text-align: right">98</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Except where the context otherwise requires, the terms, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The statements set forth under the
captions &ldquo;Business,&rdquo; &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations&rdquo; and &ldquo;Risk Factors,&rdquo; and other statements included elsewhere in this Annual Report on Form
10-K, which are not historical, constitute &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of
the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934,
as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the
future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect&rdquo; and &ldquo;intend&rdquo; and words or phrases of similar import, as they relate
to our company or our subsidiaries or our management, are intended to identify forward-looking statements. We intend that all
forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to
future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of
updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement
is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking
statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any
future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Examples of the risks and uncertainties include, but are not limited
to, the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in the review by the U.S. Food and Drug Administration, or
FDA, of our response to the Complete Response Letter, or CRL, we received from the FDA relating to our New Drug Application (NDA)
for taliglucerase alfa;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in the approval or the potential rejection of any application
we file with the FDA, or any other regulatory authority, including the NDA we filed with the FDA, the marketing application we
submitted to the Israeli Ministry of Health, or the Israeli MOH, and the Marketing Authorization Application (MAA) we submitted
to each of the European Medicines Agency, or the EMA, the National Sanitary Vigilance Agency, or ANVISA, an agency of the Ministry
of Health of Brazil, and the Australian Therapeutic Goods Administration, or the Australian TGA, for taliglucerase alfa;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks relating to our ability to finance our research programs, the
expansion of our manufacturing capabilities and the ongoing costs in the case of delays in regulatory approvals for taliglucerase
alfa;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks relating to potential restrictions on the marketing and sale
of certain of our product candidates in certain territories due to the orphan drug status that may be granted to competing products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of development of competing therapies and/or technologies
by other companies; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the effect of the orphan drug designation granted by the EMA/European
Commission to VPRIV<SUP>&reg;</SUP> in the European Union on the marketing of taliglucerase alfa in the European Union; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability of reimbursement to patients from health care payors
for taliglucerase alfa or any of our other product candidates, if approved;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in our preparation and filing of applications for regulatory
approval in the United States, the European Union, Israel, Brazil, Australia and elsewhere;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any lack of progress of our research and development (including the
results of our clinical trials);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to establish and maintain strategic license, collaboration
and distribution arrangements, and to manage our relationships with Pfizer Inc., or Pfizer, Teva Ltd., or Teva, or with any other
collaborator, distributor or partner;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to obtain, on a timely basis, if at all, sufficient patient
enrollment in our clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to biosimilar legislation and/or healthcare reform in the United States or elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the inherent risks and uncertainties in developing the types of drug
platforms and products we are developing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the risk that we will not be able to develop a successful sales and
marketing organization for taliglucerase alfa in Israel or for any other product candidate in a timely manner, if at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to enter into supply arrangements with the Ministry of
Health of Brazil or other parties and to supply drug product pursuant to such arrangements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">potential product liability risks, and risks of securing adequate
levels of product liability and clinical trial insurance coverage;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the possibility of infringing a third party&rsquo;s patents or other
intellectual property rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the uncertainty of obtaining patents covering our products and processes
and in successfully enforcing our intellectual property rights against third parties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the possible disruption of our operations due to terrorist activities
and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our
manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites;
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">other risks and uncertainties detailed in Section 1A of this Annual
Report on Form 10-K.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Companies in the pharmaceutical and biotechnology industries have
suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or
preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the FDA or foreign regulatory authorities may not accept or approve an NDA or MAA, as applicable, filed by a pharmaceutical or
biotechnology company for the drug product. These and other risks and uncertainties are detailed under the heading &ldquo;Risk
Factors&rdquo; in this Annual Report on Form 10-K and are described from time to time in the reports we file with the Securities
and Exchange Commission, or the Commission.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Item&nbsp;1.</TD><TD>Business</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression system,
or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar versions of recombinant therapeutic
proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets and that rely
upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins
for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx protein expression
system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant
proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent versions of highly
active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with
relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Taliglucerase alfa, our proprietary, lead product candidate, is
a recombinant form of glucocerebrosidase (GCD) that we are developing for the treatment of Gaucher disease using ProCellEx. Gaucher
disease is a rare and serious lysosomal storage disorder with severe and debilitating symptoms. Gaucher disease patients suffer
from mutations in or deficiencies of GCD, which is an enzyme that is naturally found in human cells. The U.S. Food and Drug Administration,
or the FDA, has granted taliglucerase alfa a Prescription Drug User Fee Act (PDUFA) date of May 1, 2012. We first filed a New Drug
Application, or NDA, for taliglucerase alfa with the FDA on December 9, 2009, and on February 25, 2011, the FDA issued a complete
response letter, or CRL, indicating that the FDA's review was complete but questions remain that preclude the approval of the NDA
in its then-current form. The main questions raised by the FDA regarding the NDA related to the clinical and chemistry, manufacturing
and controls (CMC) sections. In the clinical section of the CRL, the FDA requested additional data from our ongoing switchover
trial and our long-term extension trial. At the time the NDA was submitted, full data from these trials was not available. In the
CMC section of the CRL, the FDA requested information regarding testing specifications and assay validation. The FDA did not request
additional clinical studies in the CRL. We met with the FDA in May 2011 to clarify the FDA's requests, and in August 2011, we submitted
our reply to the CRL. In August 2011, the FDA notified us that it had accepted for review the resubmission of the taliglucerase
alfa NDA, had deemed the resubmission a class 2, or 6-month, response and established February 1, 2012 as the new PDUFA date. In
December 2011, the FDA notified us that it had decided to extend the PDUFA date to May 1, 2012. In its notification, the FDA stated
that its decision related to certain clinical information regarding taliglucerase alfa we had submitted in November 2011 in response
to an FDA request. The requested information related mainly to the presentation of select data provided in the NDA. As this information
was requested and provided within 90 days of the February 1, 2012 PDUFA goal date, the FDA had the option to extend the PDUFA goal
date to provide adequate time for the FDA to complete its review. A three-month extension cycle is the standard period granted.
No additional data was requested by the FDA in the notification, nor were we notified of any specific deficiency in the taliglucerase
alfa NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the fourth quarter of 2010, Pfizer, our commercialization partner,
filed, with our cooperation, a Marketing Authorization Application, or MAA, for taliglucerase alfa with the European Medicines
Agency, or EMA. As part of its ongoing review of the MAA, the EMA delivered a list of outstanding points to be addressed by the
applicant. Among the topics currently in discussion, is the orphan drug designation and exclusivity granted by the EMA/European
Commission to VPRIV, Shire plc's, or Shire's, Gaucher disease treatment, which could prevent the marketing authorization of taliglucerase
alfa in the European Union for a 10-year market exclusivity period commencing as of the August 2010 marketing authorization of
VPRIV in the European Union. As part of the MAA procedure, Pfizer, with our cooperation, is challenging VPRIV's orphan market protection
with respect to taliglucerase alfa pursuant to the EU orphan drug regulation. The EU orphan drug regulation provides for the possibility
of such a challenge, and for an exception to this exclusivity to be granted, based on a number of factors, including contribution
to patient care, clinical, supply, capacity and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Following the submission of the taliglucerase alfa MAA to the EMA,
a good manufacturing practices, or GMP, audit of our manufacturing facility was performed and it was found compliant with EMA GMP
in December 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In January 2010, the EMA's Committee for Orphan Medicinal Products,
or COMP, after reviewing all relevant clinical data, recommended that the European Commission grant orphan drug designation to
taliglucerase alfa for the treatment of Gaucher disease and in March 2010, the European Commission granted orphan designation to
taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, marketing applications have been submitted for taliglucerase
alfa with each of the Israeli Ministry of Health, or Israeli MOH, the National Sanitary Vigilance Agency, or ANVISA, an agency
of the Ministry of Health of Brazil, and the Australian Therapeutic Goods Administration, or Australian TGA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In February 2010, the Israeli MOH completed a successful GMP audit
of our manufacturing facilities in Carmiel, Israel. The audit was performed as part of the Israeli MOH's evaluation of our manufacturing
process for taliglucerase alfa. On February 20, 2011, we received a letter from the FDA notifying us that the FDA had completed
its review of the Establishment Inspection Report in connection with the FDA's inspection of our facility in Carmiel, Israel, and
that the FDA had classified our facility as acceptable. In June 2011, ANVISA completed a successful GMP audit of the facility and
determined that the facility is acceptable. In December 2011, following the submission of the taliglucerase alfa MAA to the EMA,
the Irish Medicines Board, or IMB, completed a successful GMP audit of our facility and issued a Certificate of GMP Compliance
of a Manufacturer for the facility. The IMB certificate is accepted by all health authorities in the European Union under the European
Union's centralized marketing authorization procedure, and by authorities of several other countries that recognize EU certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to the completed phase III clinical trial we completed
in September 2009, we initiated a double-blind, follow-on extension study as part of the trial during the second quarter of 2008.
Eligible patients who completed nine months of treatment in our phase III clinical trial were offered the opportunity to participate
in the extension study and continue to receive taliglucerase alfa at the same dose they received in the phase III clinical trial
for an additional 15 months in a blinded manner. In February 2012, we announced data from 26 adult patients enrolled in the trial.
According to the data, after 24 months, patients continued to demonstrate statistically significant improvement in all parameters
with a similar safety profile as seen in the phase III clinical trial. Furthermore, those patients who were followed specifically
for their bone parameters using Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over time.
We have also initiated a home care treatment program for patients enrolled in the extension study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the second quarter of 2011, we successfully completed a
nine-month, worldwide, multi-center, open-label, switch-over clinical study evaluating the safety and efficacy of switching
Gaucher patients currently treated with Cerezyme<SUP>&reg;</SUP>, which is produced by Genzyme Corporation, or Genzyme (which
was acquired by Sanofi-Aventis, or Sanofi, in April 2011), with taliglucerase alfa. The results of the switchover
trial demonstrate that over the nine-month treatment period, patients remained stable with regard to spleen volume, liver
volume, platelet count and hemoglobin concentration, the efficacy endpoints of the switchover trial, after switching from
Cerezyme to taliglucerase alfa. The safety analysis of the switchover trial demonstrated that taliglucerase alfa was well
tolerated, and no drug-related serious adverse events were reported. In December 2009, we filed a proposed pediatric
investigation plan to the Pediatric Committee of the EMA, which was approved during the first quarter of 2010. We have since
initiated the pediatric study and have enrolled all of the na&iuml;ve pediatric patients required according to the study
protocol. All of the enrolled patients are in the final stages of pediatric patient treatment. Patients in the extension
trial and the switchover trial are still being treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The current standard of care for Gaucher patients is enzyme replacement
therapy with either Cerezyme or, since its U.S. approval in February 2010, VPRIV. Enzyme replacement therapy is a medical treatment
in which recombinant enzymes are infused into patients in whom the enzyme is lacking or dysfunctional. Taliglucerase alfa has an
amino acid, glycan and three-dimensional structure that is very similar to Cerezyme, which is a mammalian cell expressed version
of the same protein. We believe taliglucerase alfa may prove more cost-effective than the currently marketed alternatives due to
the cost benefits of expression through our ProCellEx protein expression system. In July 2007, we reached an agreement with the
FDA on the final design of our pivotal phase III clinical trial of taliglucerase alfa through the FDA's special protocol assessment
(SPA) process. The FDA did not originally require our switch-over study in the SPA as a prerequisite for approval of taliglucerase
alfa. However, the FDA requested data from the switchover trial in the CRL which had not been available when the NDA was initially
filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 30, 2009, Protalix Ltd., our wholly-owned subsidiary,
and Pfizer entered into an exclusive license and supply agreement, which we refer to as the Pfizer Agreement, pursuant to which
Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase alfa. Under the terms and conditions
of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa in Israel. In connection with the
execution of the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60.0 million in connection with the execution
of the agreement and subsequently paid Protalix Ltd. an additional $5.0 million upon its filing of a proposed pediatric investigation
plan to the Pediatric Committee of the EMA. Protalix Ltd. is also eligible to receive potential milestone payments totaling $50.0
million for the successful achievement of other regulatory milestones. According to the Pfizer Agreement, Pfizer and Protalix Ltd.
are required to share future revenues and expenses for the development and commercialization of taliglucerase alfa on a 60% and
40% basis, respectively, and have agreed to a specific allocation of the responsibilities for the continued development efforts
for taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Although taliglucerase alfa has not yet been approved for commercial
sale, patients are being treated with taliglucerase alfa, both in the framework of our clinical trials and related studies and
in compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments
are available to Gaucher patients in light of recent shortages of approved treatments. In July 2009, following a request by the
FDA, we submitted a treatment protocol to the FDA in order to address an expected shortage of the current enzyme replacement therapy
approved for Gaucher disease. The treatment protocol was approved by the FDA in August 2009, and we are continuing to treat patients
in the United States under this protocol. On July 13, 2010, we announced that the French regulatory authority had granted an Autorisation
Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease.
An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to
patients in France when a genuine public health need exists. This ATU allows Gaucher disease patients in France to receive treatment
with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase
alfa has been secured through government allocations to hospitals. In addition to the United States and France, taliglucerase alfa
is currently being provided to Gaucher disease patients under special access agreements or Named Patient provisions in Brazil and
in other countries. Hundreds of patients, in the aggregate, have been treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 10, 2010, Pfizer entered into a $30 million short-term
supply agreement with the Ministry of Health of Brazil pursuant to which Protalix and Pfizer have provided taliglucerase alfa to
the Ministry of Health of Brazil for the treatment of patients with Gaucher disease. During the first quarter of 2011, we and Pfizer
supplied the remaining products deliverable under the short-term supply agreement. Revenue generated from the Ministry of Health
of Brazil was recorded by Pfizer, and we recorded our share of the revenue in accordance with the terms and conditions of the Pfizer
Agreement. During the second quarter of 2011, the Ministry of Health of Brazil requested that Pfizer consider the replacement of
certain vials that might expire during 2012. As a result, Pfizer recorded an allowance for sales return. If and when such vials
are replaced, revenues will be recorded upon the supply of such replaced vials, and if it is determined that there is no longer
a need for the replacement of vials, the allowance will be reversed and the revenues will be recognized accordingly. In addition,
we and the Ministry of Health of Brazil are in discussions relating to a possible long-term supply agreement that contemplates,
among other matters, providing certain components of our manufacturing technology to the Ministry of Health of Brazil for implementation
by it in Brazil. We are currently unable to assess whether these discussions will result in an agreement and we can make no assurance
that we will be able to enter into such an agreement on favorable terms, if at all. In any event, we do not expect to enter into
a long-term supply agreement with the Ministry of Health of Brazil until we receive marketing approval of taliglucerase alfa from
the FDA or ANVISA, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In September 2009, the FDA&rsquo;s Office of Orphan Product Development
granted taliglucerase alfa Orphan Drug Status. The Orphan Drug designation in the United States for taliglucerase alfa for the
treatment of Gaucher disease provides special status to taliglucerase alfa provided that it meets certain criteria. As a result
of the Orphan Drug designation, we are qualified for the tax credit and marketing incentives of the Orphan Drug Act of 1983. A
marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not
subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Although Gaucher disease is a relatively rare disease,
it represents a large commercial market due to the severity of the symptoms and the chronic nature of the disease. According
to public reports by Sanofi, consolidated sales of Cerezyme from April 1, 2011 through the end of the year were &euro;441.0
million (or $579.6 million), a growth of 11.1% compared to the same period in 2010. According to Genzyme, it has suffered
interruptions and other limitations in its Cerezyme production and release since September 2009 and, as a result, Cerezyme
supplies have been limited. Shire reported annual worldwide sales of VPRIV of approximately $256 million in 2011, a growth of
79% compared to the same period in 2010 (VPRIV was approved for sale in the United States in February 2010 and in the
European Union in August 2010).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:
(1) PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans;
(2) PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications;
(3) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor
(TNFR) and an antibody portion, which is being developed as a treatment of certain immune diseases such as rheumatoid arthritis,
juvenile idiopathic arthritis, spondylitis, psoriatic arthritis and plaque psoriasis; (4) an orally-administered glucocerebrosidase
enzyme for the treatment of Gaucher disease patients utilizing oral delivery of the recombinant enzyme produced within carrot cells;
and (5) two additional undisclosed therapeutic proteins, both of which are being evaluated in animal studies. We participated in
a pre-investigational new drug, or IND, meeting with respect to one of the undisclosed product candidates in the first quarter
of 2012 and a pre-IND meeting for the second candidate is planned for later this year. In March 2010, we initiated a preliminary
phase I clinical trial of PRX-105 which we completed in June 2010. We are currently preparing for further efficacy trials of this
product candidate in larger animals. In our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that
we will use live nerve gas rather than an analogue in the proposed additional efficacy trials in animals. In December 2010, we
held a pre-IND meeting with the FDA with respect to PRX-102. We completed preclinical trials in small and large animals with respect
to PRX-102, and we expect to submit an IND to the FDA during the second quarter of 2012 in connection with an anticipated phase
I/II clinical study of PRX-102 in Fabry patients, and to initiate the trial once the IND is approved, if at all. In December 2011
we held a pre-IND meeting with respect to PRX-106 and we expect to submit an IND around the fourth quarter of 2012. We are also
conducting pre-clinical trials of our orally-administrated glucocerebrosidase enzyme for the treatment of Gaucher disease in small
and large animals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Except for the rights to commercialize taliglucerase alfa worldwide
(other than Israel) which we licensed to Pfizer, we hold the worldwide commercialization rights to our proprietary development
candidates, and we intend to establish an internal, commercial infrastructure and targeted sales force to market taliglucerase
alfa in Israel and our other products, if approved, in North America, the European Union and in other significant markets, including
Israel. In addition, we are continuously evaluating potential strategic marketing partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our pr-antiTNF product candidate has an amino
acid sequence that is similar to Enbrel<SUP>&reg;</SUP> which is one of the treatments for patients of those diseases. We believe
that we may be able to reduce the development risks and time to market for our product candidates as our product candidates are
based on well-understood proteins with known biological mechanisms of action. Based on our pre IND meeting with the FDA held in
December 2011, we believe we may submit an IND around year end and, if approved, commence a phase I clinical trial shortly thereafter
with no need for an external partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ProCellEx protein expression system consists of a comprehensive
set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology
and plant cell-based protein expression methods. Through our ProCellEx protein expression system, we can develop highly complex
recombinant therapeutic proteins all the way to the scale-up of a purified product produced in compliance with current. We believe
that our plant cell-based expression technology will enable us, in certain cases, to develop and commercialize recombinant proteins
without infringing upon the method-based patents or other intellectual property rights of third parties. The major elements of
our ProCellEx system are patent protected in most major countries. <FONT STYLE="color: black">Moreover, we expect to enjoy method-based
patent protection for the proteins we develop using our proprietary ProCellEx protein expression technology, although there can
be no assurance that any such patents will be granted. In some cases, we may be able to obtain patent protection for the compositions
of the proteins themselves. We have filed for United States and international composition of matter patents for taliglucerase alfa.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ProCellEx protein expression system is built on flexible custom-designed
bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. These bioreactors
entail low initial capital investment, are rapidly scalable at a low cost and require less hands-on maintenance between cycles,
compared to the highly complex, expensive, stainless steel bioreactors typically used in mammalian cell-based production systems.
As a result, through our ProCellEx protein expression system, we believe that we can develop recombinant therapeutic proteins yielding
substantial cost advantages, accelerated development and other competitive benefits as compared to mammalian cell-based protein
expression systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have successfully demonstrated the feasibility of our ProCellEx
system through: the clinical and preclinical studies performed by us to date, including the positive efficacy and safety data in
our phase III study for taliglucerase alfa, our switchover study and our extension study; preclinical results in well-known models
in our enzyme for each of Fabry disease and pr-antiTNF; extensive animal studies for our acetylcholinesterase enzyme; and by expressing,
on an exploratory, research scale, many additional complex therapeutic proteins belonging to different drug classes, such as enzymes,
hormones, monoclonal antibodies, cytokines and vaccines. The therapeutic proteins we have expressed to date in research models
have produced the intended composition and similar biological activity compared to their respective human-equivalent proteins.
Moreover, several of such proteins demonstrated advantageous biological activity when compared to the biotherapeutics currently
available in the market to treat the applicable disease or disorder. We believe that the clinical success of taliglucerase alfa
represents a strong proof-of-concept for our ProCellEx protein expression system and plant cell-based protein expression technology.
We also believe that the significant benefits of our ProCellEx protein expression system, if further substantiated in clinical
trials and in the commercialization of our product candidates, have the potential to transform the industry standard for the development
of complex therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our goal is to become a leading fully integrated biopharmaceutical
company focused on the development and commercialization of proprietary and biosimilar or generic versions of recombinant therapeutic
proteins. To that end, we are leveraging our ProCellEx protein expression system to develop a pipeline of proprietary and biosimilar
versions of recombinant therapeutic proteins. In addition to the product candidates that we are developing internally, we have
entered into agreements for additional compounds with academic institutions, including a licensing agreement with the technology
transfer arm of Israel&rsquo;s Weizmann Institute of Science and an agreement with the technology transfer arm of the Hebrew University
of Jerusalem. In addition, we are collaborating with other pharmaceutical companies to develop therapeutic proteins that can benefit
from the significant cost, intellectual property and other competitive advantages of our ProCellEx protein expression system. We
entered into an agreement with Teva in September 2006 under which we have agreed to collaborate on several matters. We and Teva
identified two proteins for research and development activities under the agreement, but in 2009 both of the projects were terminated
for commercial reasons. Other elements of our collaboration with Teva, as well as the exploration of new collaborations, are currently
ongoing. We also continuously review and consider additional development and commercialization alliances with other pharmaceutical
companies and academic institutions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Industry Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Recombinant proteins have revolutionized the treatment of a variety
of diseases and disorders. Recombinant proteins are forms of human proteins that are produced, or expressed, using a mammalian,
plant, bacterial or yeast cell as a production engine. In the early 1970s, a number of key scientific breakthroughs, including,
among others, the demonstration of genetic engineering and genetic sequencing techniques, as well as the synthesis of genes, led
to the advancement of recombinant protein technology. As a result, the market for pharmaceutical therapeutics has undergone a transformation
as recombinant proteins and other biologic products have become an increasingly significant portion of the global drug market and
the focus of research worldwide. The IMS Institute for Healthcare Informatics reports that global biologic spending was $138 billion
in 2010 (<FONT STYLE="font-family: Times New Roman, Times, Serif">Report by the IMS Institute for Healthcare Informatics</FONT>,
May 2011).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mammalian cell-based systems are the current industry standard for
expression of recombinant therapeutic glycoproteins (complex proteins that contain sugar residues), including catalytic enzymes
and monoclonal antibodies. Mammalian cell-based systems were first introduced in the late 1980s and are currently used to produce
many of the biotechnology industry&rsquo;s largest and most successful therapeutic proteins, including Epogen<SUP>&reg;</SUP>,
Neupogen<SUP>&reg;</SUP>, Cerezyme, Rituxan<SUP>&reg;</SUP>, Enbrel, Neulasta<SUP>&reg;</SUP>, Remicade and Herceptin<SUP>&reg;</SUP>.
Mammalian cell-based expression technology is based on the introduction of a human gene encoding for a specific therapeutic protein
into the genome of a mammalian cell. The cells most often used in connection with mammalian cell-based protein expression are Chinese
hamster ovary (CHO) cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mammalian cell-based expression systems have become the dominant
system for the expression of recombinant proteins due to their capacity for sophisticated, proper protein folding (which is necessary
for proteins to carry out their intended biological activity), assembly and post-expression modification, such as glycosilation
(the addition of sugar residues to a protein which is necessary to enable specific biological activity by the protein). While bacterial
and yeast cell-based expression systems were the first protein expression systems developed by the biotechnology industry and remain
cost-effective compared to mammalian cell-based production methodologies, proteins expressed in bacterial and yeast cell-based
systems lack the capacity for sophisticated protein folding, assembly and post-expression modifications, which are key factors
of mammalian cell-based systems. Accordingly, such systems cannot be used to produce glycoproteins or other complex proteins and,
therefore, bacterial and yeast cell-based systems are limited to the expression of the most basic, simple proteins, such as insulin
and growth hormones. Due to their significant advantages, mammalian cell-based expression systems can produce proteins with superior
quality and efficacy compared to proteins expressed in bacteria and yeast cell-based systems. As a result, the majority of currently
approved therapeutic proteins, as well as those under development, are produced in mammalian cell-based systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Despite the utility and widespread use of mammalian cell-based systems,
they are subject to a number of disadvantages. CHO cells and other mammalian cells are highly sensitive and can only be grown under
near perfect conditions, requiring highly complex, expensive, stainless steel bioreactors which tightly regulate the required temperature,
pH and oxygen levels. As a result, such bioreactor systems are very costly and complicated to operate. CHO cells and other mammalian
cells are also susceptible to viral infections, including human viruses, and several cases of viral contamination have occurred
recently. The FDA and other regulatory authorities require viral inactivation and other rigorous and detailed procedures for mammalian
cell-based manufacturing processes in order to address these potential hazards, thereby increasing the cost and time demands of
such expression systems. Furthermore, the current FDA and other procedures only ensure screening for scientifically identified,
known viruses. Accordingly, compliance with current FDA and other procedures does not fully guarantee that patients are protected
against transmission of unknown or new potentially fatal viruses that may infect mammalian cells. In addition, mammalian cell-based
expression systems require large quantities of sophisticated and expensive growth medium to accelerate the expression process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Several companies and research institutions have explored alternatives
to mammalian cell-based production technologies that overcome some of these disadvantages, focusing primarily on the expression
of human proteins in genetically-modified organisms, or GMOs, such as transgenic field-grown, whole plants and transgenic animals.
However, these alternate techniques may be restricted by regulatory and environmental risks regarding contamination of agricultural
crops and by the difficulty in applying cGMP standards of the pharmaceutical industry to these expression technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">ProCellEx: Our Proprietary Protein Expression System</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ProCellEx is our proprietary production system. We have developed
ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins. Our
expression system consists of a comprehensive set of capabilities and proprietary technologies, including advanced genetic engineering
and plant cell culture technology, which enables us to produce complex, proprietary and biologically equivalent proteins for a
variety of human diseases. Our protein expression system facilitates the creation and selection of high expressing, genetically
stable cell lines capable of expressing recombinant proteins. The entire protein expression process, from initial nucleotide cloning
to large-scale production of the protein product, occurs under cGMP-compliant, controlled processes. Our plant cell culture technology
uses plant cells, such as carrot and tobacco cells, which undergo advanced genetic engineering and are grown on an industrial scale
in a flexible bioreactor system. Cell growth, from scale up through large-scale production, takes place in flexible, sterile, polyethylene
bioreactors which are confined to a clean-room environment. Our bioreactors are well-suited for plant cell growth using a simple,
inexpensive, chemically-defined growth medium as a catalyst for growth. The reactors are custom-designed and optimized for plant
cell cultures, easy to use, entail low initial capital investment, are rapidly scalable at a low cost and require less hands-on
maintenance between cycles. Our protein expression system does not involve mammalian or animal components or transgenic field-grown,
whole plants at any point in the production process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ProCellEx system is capable of producing proteins with an amino
acid structure practically equivalent to that of the desired human protein, and with a very similar, although not identical, glycan,
or sugar, structure. Our internal research and external laboratory studies have demonstrated that ProCellEx is capable of producing
recombinant proteins that exhibit a glycan and amino acid structure similar to their naturally-produced human counterparts. In
collaboration with the Weizmann Institute of Science, we have demonstrated that the three-dimensional structure of a protein expressed
in our proprietary plant cell-based expression system retains the same three-dimensional structure as exhibited by the mammalian
cell-based expressed version of the same protein. In addition, proteins produced by our ProCellEx system maintain the biological
activity that characterize that of the naturally-produced proteins. Based on these results, we believe that proteins developed
using our ProCellEx protein expression system have the intended composition and correct biological activity of their human equivalent
proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To date, our manufacturing facility, which uses our ProCellEx system,
was determined to be acceptable by each of the FDA, EMA, ANVISA and the Israeli MOH after GMP inspections performed as part of
their respective reviews for marketing approval of taliglucerase alfa.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Competitive Advantages of Our ProCellEx Protein Expression
System</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We believe that our ProCellEx protein
expression system, including our </FONT>advanced genetic engineering technology and plant cell-based protein expression methods<FONT STYLE="color: black">,
affords us a number of significant advantages over mammalian, bacterial, yeast and transgenic cell-based expression technologies,
including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Ability to Penetrate Certain Patent-Protected
Markets.</I> </B>We seek to develop recombinant proteins that we believe we can produce and commercialize without infringing upon
the method-based patents or other intellectual property rights of third parties. <FONT STYLE="color: black">Certain biotherapeutic
proteins available for commercial sale are not protected by patents that cover the compound and are available for use in the public
domain. Rather, the process of expressing the protein product in mammalian or bacterial cell systems is protected by method-based
patents. Using our plant cell-based protein expression technology, we are able to express an equivalent protein without infringing
upon these method-based patents. Moreover, we expect to enjoy method-based patent protection for the proteins we develop using
our proprietary ProCellEx protein expression technology, although there can be no assurance that any such patents will be granted.
In some cases, we may be able to obtain patent protection for the compositions of the proteins themselves. We have filed for United
States and international composition of matter patents for taliglucerase alfa, PRX-102 and certain of our other product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Significantly Lower Capital and Production
Costs.</I></B> <FONT STYLE="color: black">Plant cells have a number of dynamic qualities that make them well-suited for the production
of therapeutic proteins. Plant cells grow rapidly under a variety of conditions and are not as sensitive to temperature, pH and
oxygen levels as mammalian cells. Our ProCellEx protein expression system, therefore, requires significantly less upfront capital
expenditures as it does not use the highly complex, expensive, stainless steel bioreactors typically used in mammalian </FONT>cell-based<FONT STYLE="color: black">
production systems to maintain very specific temperature, pH and oxygen levels. Instead, we use simple polyethylene bioreactors
that can be maintained at the room temperature of the clean-room in which they are placed. This system also reduces ongoing production
and monitoring costs typically incurred by companies using mammalian cell-based expression technologies. Furthermore, while mammalian
cell-based systems require very costly growth media at various stages of the production process to achieve target yields of their
proteins, plant cells require only simple and much less expensive solutions based on sugar, water and microelements at infrequent
intervals to achieve target yields. We believe that these factors will potentially result in lower capital and production costs
for the commercial scale production of proteins by our </FONT>ProCellEx<FONT STYLE="color: black"> system thereby providing us
with a competitive advantage over competing protein expression technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Elimination of the Risk of Viral Transmission
or Infection by Mammalian Components.</I> </B>By <FONT STYLE="color: black">nature, plant cells do not carry the risk of infection
by human or other animal viruses. As a result, the risk of contamination of our products under development and the potential risk
of viral transmission from our products under development to future patients, whether from known or unknown viruses, is eliminated.
Because our product candidates do not bear the risk of viral transmission, we are not required by the FDA or other regulatory authorities
to perform the constant monitoring procedures for mammalian viruses during the protein expression process that mammalian cell-based
manufacturers are required to undertake. In addition, t</FONT>he production process of our ProCellEx protein expression system
is void of any mammalian components which are susceptible to the transmission of prions, such as those related to bovine spongiform
encephalopathy (commonly known as &ldquo;mad-cow disease&rdquo;). <FONT STYLE="color: black">These factors further reduce the risks
and operating costs of our ProCellEx system compared to mammalian cell-based expression systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>More Effective and Potent End Product
Relative to Mammalian Based Systems.</I> </B><FONT STYLE="color: black">Our ProCellEx protein expression system produces enzymes
which have uniform glycosilation patterns and therefore do not require the lengthy and expensive post-expression modifications
that are required for certain proteins produced by mammalian cell-based systems, including the proteins for the treatment of Gaucher
disease. Such post-expression modifications in mammalian cell-produced proteins are made in order to expose the terminal mannose
sugar residues, which are structures on a protein that are key elements in allowing the produced protein to bind to a target cell
and subsequently be taken into the target cell for therapeutic benefit. In the production of Cerezyme, exposing these terminal
mannose sugar residues involves a multitude of highly technical steps which add time and cost to the production process. In addition,
these steps do not guarantee the exposure of all of the required terminal mannose sugar residues, resulting in potentially lower
effective yields and inconsistency in potency from batch to batch. Our ProCellEx protein expression system, by contrast, produces
taliglucerase alfa in a &ldquo;ready to use&rdquo; form that does not require additional glycosilation or other modifications to
make taliglucerase alfa suitable for use in enzyme replacement therapy for Gaucher disease. We believe this quality increases the
potency and consistency of the expressed proteins, thereby further increasing the cost advantages of our ProCellEx protein expression
system over competing protein expression methodologies. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Broad Range of Expression Capabilities.</I></B>
<FONT STYLE="color: black">Our ProCellEx protein expression system is able to produce a broad array of complex glycosilated proteins,
which differentiates our system from bacterial and yeast cell-based systems which are unable to produce complex proteins. </FONT>We
have successfully demonstrated the feasibility of our ProCellEx system by producing, on an exploratory, research scale, a variety
of therapeutic proteins belonging to different classes of recombinant drugs, such as enzymes, hormones, monoclonal antibodies,
cytokines and vaccines. We have demonstrated that the recombinant proteins we have expressed<B> </B>to date have the intended composition
and correct biological activity of their human-equivalent protein, with several of such proteins demonstrating advantageous biological
activity compared to the currently available biotherapeutics. In specific cases, we have been successful in expressing proteins
that have not been successfully expressed in other production systems.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Our Strategy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Our goal is to become a leading fully
integrated biopharmaceutical company focused on the development and commercialization of proprietary </FONT>and biosimilar<FONT STYLE="color: black">
or generic versions of recombinant therapeutic proteins. </FONT> To achieve our goal, we intend to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Facilitate the successful development and
commercialization of taliglucerase alfa by Pfizer.</B> We intend to work with our licensee, Pfizer, to develop and commercialize
taliglucerase alfa. We have been collaborating with Pfizer to facilitate the transition of certain of our taliglucerase alfa assets
to Pfizer&rsquo;s organization. We are cooperating with Pfizer with respect to our Expanded Access protocol for taliglucerase alfa
in order to facilitate the participation of additional physicians in additional sites in the protocol. Pfizer is promoting the
protocol to new clinical sites and is recruiting additional patients. Pfizer has also taken an active, collaborative role in our
ATU in France and similar programs in Brazil and other countries. We have also begun to facilitate relationships between Pfizer
and the Gaucher community and third-party payors. We intend to actively participate and provide our expertise in Pfizer&rsquo;s
development and commercialization efforts with respect to taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Obtain Regulatory Approval for Taliglucerase
Alfa for the Treatment of Gaucher Disease.</B> We completed successfully our pivotal phase III clinical trial of taliglucerase
alfa in September 2009 and announced the positive top-line study results in October 2009 and full study results in February 2010.
We filed an NDA with the FDA in December 2009 and taliglucerase alfa was originally granted a PDUFA date of February 25, 2011.
On<FONT STYLE="font-family: Times New Roman, Times, Serif"> February 24, 2011, the FDA issued a CRL indicating that the FDA&rsquo;s
review was complete but questions remain that preclude the approval of the NDA in its then current form. In July 2011 we submitted
our reply to the CRL and in August 2011, the FDA notified us that it had established February 1, 2012 as the new PDUFA date. In
December 2011, the FDA notified us that it had decided to extend the PDUFA date to May 1, 2012. In its notification, the FDA stated
that its decision related to </FONT>certain clinical information regarding taliglucerase alfa we had submitted in November 2011
in response to an FDA request. The requested information related mainly to the presentation of select data provided in the NDA.&nbsp;&nbsp;As
this information was requested and provided within 90 days of the February 1, 2012 PDUFA goal date, the FDA had the option to extend
the PDUFA goal date to provide adequate time for the FDA to complete its review. A three-month extension cycle is the standard
period granted. No additional data was requested by the FDA in the notification, nor were we notified of any specific deficiency
in the taliglucerase alfa NDA. In addition, in November 2010 we submitted a marketing application to the Israeli MOH, and with
our partner Pfizer, an MAA to each of the EMA, ANVISA and the Australian TGA for taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Develop a Pipeline of Innovative or Biosimilar
Versions of Recombinant Therapeutic Proteins. </B>We are leveraging our ProCellEx protein expression system to develop a pipeline
of innovative or biosimilar versions of recombinant proteins, with an emphasis on therapeutic treatments with large market opportunities.
We select additional therapeutic candidates for development through in-house testing, licensing agreements with academic institutions
and collaborations with pharmaceutical partners. We have currently identified several product candidates that are mainly oriented
towards the specialty disease and therapeutic market segments, including treatments for Fabry disease and an acetylcholinesterase
enzyme based therapy for biodefense and nerve gas toxicity treatments. We have also identified several other product candidates
that are chemical equivalents of approved therapeutic products that will no longer be patent protected within the next couple of
years, such as pr-antiTNF, our proprietary product candidate for the treatment of certain immune diseases such as rheumatoid arthritis.
We believe our cost-effective technology will be an important asset for the commercialization of such drug candidates. We believe
that the clinical and regulatory pathway for many of our pipeline product programs candidates is already established, and that
this may reduce the risks and costs associated with our clinical development programs. Furthermore, established markets already
exist for the development of most of our current product candidates. We plan to apply the manufacturing, clinical and regulatory
experience we have gained from the development of our lead product candidate to advance a number of our preclinical product candidates
into clinical trials over the next few years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Collaborate with Third Party Pharmaceutical
Suppliers and Build a Targeted Sales and Marketing Infrastructure.</B> We have licensed to Pfizer the right to commercialize taliglucerase
alfa worldwide, except in Israel. We plan to establish our own, internal sales and marketing capabilities for taliglucerase alfa
in Israel, and, for our other product candidates, in North America, the European Union and in other significant markets, including
Israel. We believe that the focus of our current clinical pipeline is mainly on relatively rare genetic disorders with small patient
populations and a highly concentrated group of physicians focused on treating patients with such disorders may facilitate our creation
of a targeted internal sales force. In addition we are continuously evaluating potential strategic marketing partnerships with
respect to our other product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Establish Development and Commercialization
Alliances with Corporate Partners.</B> We believe that our technology and know-how has broad applicability to many classes of proteins
and can be used to develop and potentially enhance numerous existing marketed protein therapeutics. We intend to leverage our technology
and know-how by pursuing development and commercialization alliances with corporate partners for specific products and territories
in order to enable us to optimize our resources and effectively penetrate a wider range of target diseases and therapeutic markets.
In November 2009, we entered into a license and supply agreement with Pfizer for the development and commercialization of taliglucerase
alfa. We entered into an agreement with Teva in September 2006 for the development of two proteins. Although programs relating
to two proteins to be developed under the agreement were terminated for commercial reasons in 2009, other elements of our collaboration
are still ongoing and we are exploring other potential ways to collaborate. Last, we are engaged in confidential discussions with
a number of multinational pharmaceutical companies to discuss additional potential collaboration arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Acquire or In-License New Technologies, Products
or Companies.</B> We continuously seek attractive product candidates and innovative technologies to in-license or acquire. We intend
to focus on product candidates that would be synergistic with our ProCellEx protein expression system and expertise and that represent
large potential market opportunities. We believe that by pursuing selective acquisitions of technologies in businesses that complement
our own, we will be able to enhance our competitiveness and strengthen our market position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Leverage Strength and Experience of Our Management
Team and Board of Directors. </B>Our management team has extensive experience in the biotechnology and pharmaceutical industry.
The Interim Chairman of our Board of Directors, Mr. Zeev Bronfeld, is a highly experienced Israeli health care investor. In February
2008, we appointed Professor Roger D. Kornberg, a renowned biochemist and laureate of the Nobel Prize in Chemistry, to our Board
of Directors. We will continue to leverage their experience and established track record as well as their relationships across
the biotechnology and pharmaceutical industries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Our Pipeline Drug Candidates</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Our Lead Product Candidate, Taliglucerase Alfa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Taliglucerase alfa, our lead proprietary product candidate, is a
plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease<FONT STYLE="color: black">.
</FONT>In July 2007, we reached an agreement with the FDA on the final design of our pivotal phase III clinical trial of taliglucerase
alfa through the FDA&rsquo;s special protocol assessment (SPA) process. We successfully completed our phase III pivotal clinical
trial of taliglucerase alfa in September 2009 and announced positive top-line results of the clinical trial in October 2009 and
full study results in February 2010. We submitted an NDA to the FDA in December 2009. In January 2010, the FDA requested additional
data regarding the CMC section of the NDA. We provided the requested data to the FDA in April 2010 and in July 2010 we received
notification from the FDA that it had accepted the filing of our NDA and assigned it a PDUFA date of February 25, 2011. <FONT STYLE="font-family: Times New Roman, Times, Serif">On
that date, the FDA issued a CRL indicating that the FDA&rsquo;s review was complete but questions remain that preclude the approval
of the NDA in its then current form. The main questions raised by the FDA regarding the NDA related to the clinical and CMC sections.
In the clinical section of the CRL, the FDA requested additional data from our ongoing switchover trial and our long-term extension
trial. At the time the NDA was submitted, full data from these trials was not available. In the CMC section of the CRL, the FDA
requested information regarding testing specifications and assay validation. The FDA did not request additional clinical studies
in the CRL. We met with the FDA in May 2011 to clarify the FDA&rsquo;s requests, and in July 2011 we submitted our reply to the
CRL. In August 2011, the FDA notified us that it had accepted for review the resubmission of the taliglucerase alfa NDA, had deemed
the resubmission a class 2, or 6-month, response and established February 1, 2012 as the new PDUFA date. In December 2011, the
FDA notified us that it had decided to extend the PDUFA date to May 1, 2012. In its notification, the FDA stated that its decision
related to </FONT>certain clinical information regarding taliglucerase alfa we had submitted in November 2011 in response to an
FDA request. The requested information related mainly to the presentation of select data provided in the NDA. As this information
was requested and provided within 90 days of the February 1, 2012 PDUFA goal date, the FDA had the option to extend the PDUFA goal
date to provide adequate time for the FDA to complete its review. A three-month extension cycle is the standard period granted.
No additional data was requested by the FDA in the notification, nor were we notified of any specific deficiency in the taliglucerase
alfa NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the fourth quarter of 2010, Pfizer, our commercialization partner,
filed, with our cooperation, an MAA for taliglucerase alfa with the EMA. As part of its ongoing review of the MAA, the EMA delivered
a list of outstanding points to be addressed by the applicant. Among the topics currently in discussion, is the orphan drug designation
and exclusivity granted by the EMA/European Commission to VPRIV, which could prevent the marketing authorization of taliglucerase
alfa in the European Union for a 10-year market exclusivity period commencing as of the August 2010 marketing authorization of
VPRIV in the European Union. As part of the MAA procedure, Pfizer, with our cooperation, is challenging VPRIV's orphan market protection
with respect to taliglucerase alfa pursuant to the EU orphan drug regulation. The EU orphan drug regulation provides for the possibility
of such a challenge, and for an exception to this exclusivity to be granted, based on a number of factors, including contribution
to patient care, clinical, supply, capacity and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Following the submission of the taliglucerase alfa MAA to the EMA,
a GMP audit of our manufacturing facility was performed and it was found compliant with EMA GMP in December 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In January 2010, COMP, after reviewing all relevant clinical data,
recommended that the European Commission grant orphan drug designation to taliglucerase alfa for the treatment of Gaucher disease
and in March 2010, the European Commission granted orphan designation to taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, marketing applications for taliglucerase alfa have
been submitted with each of the Israeli MOH, ANVISA and the Australian TGA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In September 2009, the FDA&rsquo;s Office of Orphan Product Development
granted taliglucerase alfa Orphan Drug Status. The Orphan Drug designation in the United States for taliglucerase alfa for the
treatment of Gaucher disease provides special status to taliglucerase alfa provided that it meets certain criteria. As a result
of the Orphan Drug designation, we are qualified for the tax credit and marketing incentives of the Orphan Drug Act of 1983. A
marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not
subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In July 2009, following a request by the FDA, we submitted a treatment
protocol to the FDA in order to address an expected shortage of the current enzyme replacement therapy approved for Gaucher disease.
The treatment protocol was approved by the FDA in August 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the third quarter of<FONT STYLE="color: black"> 2008</FONT>,
we initiated a double blind, follow-on extension study as part of our phase III clinical trial of taliglucerase alfa. <FONT STYLE="font-family: Times New Roman, Times, Serif">
Eligible patients who successfully completed nine months of treatment in our phase III clinical trial were offered the opportunity
to participate in the extension study and continue to receive taliglucerase alfa at the same dose they received in the phase III
clinical trial for an additional 15 months in a blinded manner. In February 2012, we announced data from 26 adult patients enrolled
in the trial. According to the data, after 24 months, patients continued to demonstrate a significant improvement in all parameters
with a similar safety profile as seen in the phase III clinical trial. </FONT>Furthermore, those patients who were followed specifically
for their bone parameters using Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over time.<FONT STYLE="font-family: Times New Roman, Times, Serif">
We have also initiated a home care treatment program for patients enrolled in the extension study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In February
2010, the Israeli MOH completed a successful good manufacturing practices, or GMP, audit of our manufacturing facilities in Carmiel,
Israel. The audit was performed as part of the Israeli MOH&rsquo;s evaluation of our manufacturing process for taliglucerase alfa.
On February 20, 2011, we received a letter from the FDA notifying us that the FDA had completed its review of the Establishment
Inspection Report in connection with the FDA&rsquo;s inspection of our facility in Carmiel, Israel, and that the FDA had classified
our facility as acceptable. In June 2011, ANVISA completed a successful GMP audit of the facility and determined that the facility
is acceptable and in </FONT>December 2011, the Irish Medicines Board, or IMB, completed a successful GMP audit of our facility
and issued a Certificate of GMP Compliance of a Manufacturer for the facility. The IMB certificate is accepted by all health authorities
in the European Union under the European Union's centralized marketing authorization procedure, and by authorities of several other
countries that recognize EU certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the fourth quarter of 2008 we announced the enrollment of the
first patient in a worldwide, multi-center, open-label, switch-over trial which has been reviewed by the FDA and is designed to
assess the safety and efficacy of taliglucerase alfa. The switch-over trial, which was not a prerequisite for approval, was originally
designed to include 15 patients with Gaucher disease that are currently undergoing enzyme replacement therapy with imiglucerase
(Cerezyme). Due to the then shortage of the currently available enzyme replacement therapy for Gaucher disease, after fully enrolling
15 patients, we extended the trial to include additional patients. In August 2011, we announced top-line results from the switch-over
trial. A total of 26 adult patients were enrolled in the switchover trial. Patients enrolled in the trial were switched from imiglucerase
(doses ranging from around 10-60 U/kg every other week) to an equivalent dose using the same number of units of taliglucerase alfa
over a nine-month period. <FONT STYLE="font-family: Times New Roman, Times, Serif">The results of the switchover trial, which were
announced in February 2012, demonstrate that over the nine-month treatment period, patients remained stable with regard to spleen
volume, liver volume, platelet count and hemoglobin concentration, the efficacy endpoints of the switchover trial, after switching
from imiglucerase to taliglucerase alfa. The safety analysis of the switchover trial demonstrated that taliglucerase alfa was well
tolerated, and no drug related serious adverse events were reported. Patients in the extension trial and the switchover trial are
still being treated with taliglucerase alfa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, in December 2009, we filed a proposed pediatric investigation
plan to the Pediatric Committee of the EMA,<FONT STYLE="font-family: Times New Roman, Times, Serif"> which was approved during
the first quarter of 2010. </FONT>We have since initiated the pediatric study and have enrolled all of the na&iuml;ve pediatric
patients required according to the study protocol. All of the enrolled patients are in the final stages of pediatric patient treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In clinical trials of healthy subjects and in vivo primate studies,
taliglucerase alfa has demonstrated an increased half-life and prolonged presence of the enzyme in the blood serum of the subjects
as compared to Cerezyme, the only enzyme replacement therapy currently marketed to treat Gaucher disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that taliglucerase alfa, if approved, has the potential
to offer patients and healthcare payors a more effective and cost efficient treatment of Gaucher disease compared to the currently
available enzyme replacement therapies because of the following advantages:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Increased Glycan Efficacy and Consistency</I></B>.
We believe that our ProCellEx protein expression system produces recombinant proteins that exhibit consistent enzymatic activity
from batch to batch. This results in a highly active product that may achieve a desired therapeutic effect more effectively than
the activity demonstrated in proteins produced through mammalian cell-based expression systems due to its greater glycan efficacy
and consistency. This quality increases the effective consistency in potency and further increases the cost advantages from using
our plant cell-based expression technology compared to competing protein expression methodologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Longer Half-Life</I></B>. The data generated
in preclinical and human clinical trials relating to the half-life of taliglucerase alfa in the subjects&rsquo; blood serum after
infusion showed that the half-life of taliglucerase alfa is significantly longer than that of Cerezyme when measured and compared
to publicly available data on Cerezyme.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Cost-Effective</I></B>. Taliglucerase
alfa is potentially less expensive to produce as the manufacturing process does not require the large initial set-up investments
involved in mammalian cell-based protein production, the extensive ongoing costs associated with growth media and monitoring throughout
the production process nor any of the post-expression modification costs in order to modify the glycosilation of the proteins produced
through the mammalian cell-based methodologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We intend to pursue post-marketing studies to confirm these advantages.<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT>Although Gaucher disease is a relatively rare disease, it represents a substantial commercial market due to the severity
of the symptoms and the chronic nature of the disease. We believe that the approval of taliglucerase alfa as a treatment for Gaucher
disease, if at all, with its potentially longer acting profile and more cost-effective development process, may lead to an increase
in the number of patients who will be able to have access to and afford such treatment, thereby expanding the size of the market
for Gaucher disease treatments.<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, we are developing a new method for delivering active
recombinant proteins systemically through oral administration of transgenic plant cells expressing biotherapeutic proteins. We
have commenced pre-clinical studies of an oral form of taliglucerase alfa. If proven effective, our experimental oral taliglucerase
alfa would be the first protein to be administered orally rather than through intravenous therapy. Our oral taliglucerase alfa
is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the
GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity
of the cell&rsquo;s cellulose wall to protect the enzyme against degradation in the digestive tract in an <I>in-vitro </I>model
of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active
enzyme in the target organs; the spleen and liver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that oral delivery of taliglucerase alfa presents a number
of advantages. First, the development of oral taliglucerase alfa has the advantage of leveraging the well-characterized mechanism
of action of our intravenously-administered taliglucerase alfa product candidate. In addition, we believe that oral delivery of
taliglucerase alfa may dramatically change the treatment paradigm for Gaucher patients, compared to the intravenous delivery of
taliglucerase alfa, and contribute to increased compliance and the facilitation of treatment management. Further, oral delivery
of GCD targets the disease-specific organs without the need for lifetime dependence on repeated intravenous infusions. Last, our
oral enzyme replacement therapy does not have the unpredictable long term untoward effects of the inhibition of other non-disease-specific
compounds that are common in oral substrate reduction therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our oral taliglucerase alfa product candidate is a recombinant form
of the GCD enzyme, not a small molecule. This differentiates our oral product candidate from other early clinical stage, experimental,
small molecule, oral drugs which are being developed for the treatment of Gaucher disease by Genzyme and Amicus Therapeutics, Inc.,
or Amicus Therapeutics. Small molecule based treatments for Gaucher disease, such as Zavesca, have different mechanisms of action
than those associated with enzyme replacement therapy, and may be associated with a number of side effects. We have filed patent
applications with respect to this new protein delivery mechanism in other countries with commercially significant markets. Currently,
we are the exclusive owners of all rights to this technology.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Gaucher Disease Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Gaucher disease</FONT>, a hereditary,
genetic disorder with severe and debilitating symptoms, <FONT STYLE="color: black">is the most prevalent lysosomal storage disorder
in humans. Lysosomal storage disorders are metabolic disorders in which a lysosomal enzyme, a protein that degrades cellular substrates
in the lysosomes of cells, is mutated or deficient. Lysosomes are small membrane-bound cellular structures within cells that contain
enzymes necessary for intracellular digestion. Gaucher disease is caused by mutations or deficiencies in the gene encoding GCD,
a lysosomal enzyme that catalyzes the degradation of the fatty substrate, glucosylceramide (GlcCer). The normal degradation products
of GlcCer are glucose and ceramide, which are easily excreted by the cells through normal biological processes. Patients with Gaucher
disease lack or otherwise have dysfunctional GCD and, accordingly, are not able to break down GlcCer. The absence of an active
GCD enzyme leads to the accumulation of GlcCer in lysosomes of certain white blood cells called macrophages. Macrophages affected
by the disease become highly enlarged due to the accumulation of GlcCer and are referred to as &ldquo;Gaucher cells.&rdquo; Gaucher
cells accumulate in the spleen, liver, lungs, bone marrow and brain. Signs and symptoms of Gaucher disease may include enlarged
liver and spleen, abnormally low levels of red blood cells and platelets and skeletal complications. In some cases, the patient
may suffer an impairment of the central nervous system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Current Treatments for Gaucher Disease</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The standard of care for Gaucher disease is enzyme replacement
therapy using recombinant GCD to replace the mutated or deficient natural GCD enzyme. The latest studies estimate that there
are approximately 12,000 patients suffering from Gaucher disease worldwide, but only approximately 6,000 patients are
undergoing treatment. <FONT STYLE="color: black">Enzyme replacement therapy is a medical treatment in which recombinant
enzymes are injected into patients in whom the enzyme is lacking or dysfunctional. </FONT>Cerezyme and VPRIV, enzyme
replacement therapies commercialized by Genzyme and Shire, respectively, are the only recombinant GCDs currently available on
the market for the treatment of Gaucher disease. As enzyme replacement therapy does not cure the genetic disorder, but rather
provides an external source for transfusion of the missing or mutated enzyme, Gaucher disease patients generally receive the
treatment over their entire lifetime. According to public reports by Sanofi, consolidated sales of Cerezyme from April 1,
2011 through the end of the year were &euro;441.0 million (or $579.6 million), a growth of 11.1% compared to the same period
in 2010. According to Genzyme, it has suffered interruptions and other limitations in its Cerezyme production and release
since September 2009 and, as a result, Cerezyme supplies have been limited. Shire reported annual worldwide sales of VPRIV of
approximately $256 million in 2011, a growth of 79% compared to the same period in 2010 (VPRIV was approved for sale in the
United States in February 2010 and in the European Union in August 2010).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Cerezyme is produced through a mammalian cell-based protein expression
process in CHO cells and VPRIV is produced using a human cancer cell line. There are no known severe side effects to the use of
Cerezyme or VPRIV, and Cerezyme's approved use over the past decade suggests that it is an effective treatment of Gaucher disease.
However, Cerezyme and VPRIV are both subject to the limitations of most mammalian cell-based therapeutic proteins, including lengthy
and costly production processes and contamination risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Zavesca (miglustat), which is marketed by Actelion Ltd., or Actelion,
is a small molecule drug for the treatment of Gaucher disease. Zavesca has been approved by the FDA for use in the United States
as an oral treatment. However, it has many side effects and the FDA has approved it only for administration to those patients who
cannot be treated through enzyme replacement therapy, and, accordingly, have no other treatment alternative. As a result, Zavesca&rsquo;s
use has been extremely limited. Actelion has reported sales of Zavesca of approximately CHF 68.4 million (approximately $74.4 million)
in 2011.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Taliglucerase Alfa Development Program</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We believe the clinical development and
regulatory path for taliglucerase alfa will be similar to that followed by the existing enzyme replacement therapy currently on
the market. After completion of laboratory testing and preclinical studies of taliglucerase alfa, we commenced a </FONT>phase I
clinical trial which was completed in June 2006<FONT STYLE="color: black">. </FONT>After the conclusion of the phase I clinical
trial and discussions with the FDA, we proceeded directly with a pivotal phase III clinical trial of taliglucerase alfa without
undergoing a phase II clinical trial. We reported positive top-line results of the phase III clinical trial in October 2009 and
full study results in February 2010. This study was summarized in a recent publication in BLOOD, the Journal of the American Hematological
Society (Zimran, <U>et</U>. <U>al</U>., September 2011). In February 2012, we announced positive results from our extension study
in na&iuml;ve patients and from our switchover study.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Laboratory Testing and Preclinical Studies of Taliglucerase
Alfa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We conducted several <I>in vitro</I> tests and <I>in vivo</I> preclinical
studies of taliglucerase alfa. Our preclinical rodent and primate trials generated extensive toxicological and safety data that
demonstrated no adverse effects, even with very high doses of taliglucerase alfa being administered via intravenous infusions.
In short term repeat dose studies in rodents and primates and nine-month repeat dose studies in primates, no toxicity was observed
at dosage levels of up to 10 times the current dose recommended for GCD in clinical use. Furthermore, no neutralizing antibodies
were detected in any of the primates treated in the studies. The presence of neutralizing antibodies would have implied a likelihood
of the host rejecting the therapeutic enzyme or reacting to it in a less efficient manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our laboratory and preclinical data demonstrate that taliglucerase
alfa has the potential to be an efficacious enzyme replacement therapy for the treatment of Gaucher disease. Data produced from
these preliminary development studies show that, relative to Cerezyme, taliglucerase alfa has:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an equivalent to superior level of enzymatic activity;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>enhanced uptake based on observed GlcCer substrate degradation; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a prolonged half-life.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Phase I Clinical Trial</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The phase I clinical trial, which we completed in June 2006, was
a single-center, non-randomized, open label, dose ranging study designed to evaluate the safety and pharmacokinetics of taliglucerase
alfa in healthy subjects. The trial was conducted on healthy subjects over a four-week period in which subjects received three
single escalating doses of taliglucerase alfa administered via intravenous infusions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All doses administered to subjects in the phase I clinical trial,
including the highest dose, which was the same dosage currently suggested with respect to the treatment by Cerezyme, demonstrated
a strong safety profile. The data from our phase&nbsp;I clinical trial showed that taliglucerase alfa was safe and well tolerated
at all doses. There were no serious adverse events and no subjects withdrew from the trial or discontinued treatment due to an
adverse event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, the half-life of taliglucerase alfa was found to be
significantly longer than that of Cerezyme, based upon data disclosed publicly by Genzyme, which was consistent with our preclinical
data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Further, as in the laboratory and preclinical testing phase, no
neutralizing antibodies or adverse immunological responses were detected in any of the subjects treated in the phase I clinical
trial.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Phase III Clinical Trial and Related Studies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">After the conclusion of the phase I clinical trial and discussions
with the FDA, we applied to commence a pivotal phase III clinical trial of taliglucerase alfa without the requirement to first
complete a phase II clinical trial. In April 2007, we received approval from the FDA to initiate a pivotal phase III clinical trial.
We submitted to the FDA a request for a special protocol assessment (SPA) of the final design of our pivotal phase III clinical
trial for taliglucerase alfa. In July 2007, we reached an agreement with the FDA on the design that we submitted in the SPA request,
and in the third quarter of 2007 we initiated enrollment and treatment of naive patients in the phase III clinical trial. In accordance
with the terms of the SPA, the phase III clinical trial was a multi-center, world-wide, randomized, double-blind, parallel group,
dose-ranging study to assess the safety and efficacy of taliglucerase alfa in 31 treatment-naive patients suffering from Gaucher
disease. In the trial, patients were selected randomly for one of two dosing arms (60 U/kg or 30 U/kg) and received intravenous
infusions of taliglucerase alfa once every two weeks for a nine-month period. The primary endpoint of the study was a 20% mean
reduction from baseline in spleen volume after nine months, as measured by MRI. Major secondary endpoints were an increase in hemoglobin,
decrease in liver volume and increase in platelet count. Patients enrolled in the trial were treated in 11 selected leading medical
centers throughout Europe, Israel, North America, South America and South Africa. We commenced enrollment and treatment of patients
in our phase&nbsp;III clinical trial in the third quarter of 2007 and completed enrollment in the fourth quarter of 2008. We successfully
completed the trial in September 2009 and announced positive top-line results of the trial in October 2009 and full study results
in February 2010. We submitted an NDA to the FDA in December 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">During the third quarter of<FONT STYLE="color: black"> 2008</FONT>,
we initiated a double blind, follow-on extension study as part of our phase III clinical trial. <FONT STYLE="font-family: Times New Roman, Times, Serif">Eligible
patients who successfully completed nine months of treatment in our phase III clinical trial were offered the opportunity to participate
in the extension study and continue to receive taliglucerase alfa at the same dose they received in the phase III clinical trial
for an additional 15 months in a blinded manner. Accordingly, the extension trial included two treatment groups; one treated with
a 60 U/kg dose and the other with a 30 U/kg dose. The major endpoints of the study were spleen volume, liver volume, hemoglobin
concentration, platelet count, and chitotriosidase activity. Twenty-six patients were enrolled in the extension trial which was
performed in centers throughout Europe, Israel, North America, South America and South Africa. We have also initiated a home care
treatment program for patients enrolled in the extension study. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, in the fourth quarter of 2008, we announced the enrollment
of the first patient in a worldwide, multi-center, open-label, switch-over trial to assess the safety and efficacy of taliglucerase
alfa. The switch-over trial, which was not a prerequisite for approval, was originally designed to include 15 patients with Gaucher
disease that are currently undergoing enzyme replacement therapy with imiglucerase (Cerezyme). Due to the shortage of Cerezyme
in 2009, after fully enrolling 15 patients, we extended the trial to include additional patients. A total of 26 adult patients
were enrolled in the switchover trial. Patients enrolled in the trial were switched from imiglucerase (doses ranging from approximately
10-60 U/kg every other week) to an equivalent dose using the same number of units of taliglucerase alfa over a nine-month period.
In February 2012 we reported full results from the trial. <FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>Results of our Phase III Clinical Trial and Extension
Trial</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We reported positive top-line results of our phase III clinical
trial of taliglucerase alfa in October 2009 and full study results in February 2010. In the clinical trial, taliglucerase alfa
significantly reduced mean spleen volume after nine months compared with baseline in both treatment groups, thereby meeting the
trial's primary endpoint of reduced mean spleen volume after nine months. In February 2012, we announced data from 26 adult patients
enrolled in our extension trial. According to the data, after 24 months (nine months in the phase III clinical trial and 15 months
in the extension trial), patients continued to demonstrate a significant improvement in all parameters with a similar safety profile
as seen in the phase III clinical trial. Furthermore, those patients who were followed specifically for their bone parameters using
Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the phase III clinical trial, the 60 U/kg group demonstrated
a statistically significant mean reduction in spleen volume of 38.0% (p&lt;0.0001) and the 30 U/kg group demonstrated a significant
mean reduction in spleen volume of 26.9% (p&lt;0.0001). In addition, the primary endpoint was achieved in both treatment groups
after only six months of therapy. Patients treated with taliglucerase alfa in the extension trial continued to demonstrate a statistically
significant reduction in mean spleen volume after 24 months, compared with baseline, in both treatment groups; reductions of 54.0%
(p&lt;0.0001) in the 60 U/kg group and of 41.0% (p&lt;0.0001) in the 30 U/kg group. See Figure 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Figure 1. Naive Patient Study: Spleen Volume
at 24 Months (30 units/kg (n=12) ; 60 units/kg (n=14)); Mean Change from Baseline (%)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="pg19.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">P-value&lt;0.0001</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the phase III clinical trial, statistically significant improvements
were also observed for the secondary endpoints, including increase in hemoglobin level, decrease in liver size and increase in
platelet count, after nine months when compared to baseline for the 60 U/kg dose. These improvements continued in the extension
trial. In the phase III clinical trial, patients in both dosage groups demonstrated mean increases in hemoglobin from baseline;
mean increases from 11.4 g/DL to 13.6 g/DL (p&lt;0.0001) (22.2%) in the 60 U/kg group and from 12.2 g/DL to 14.0 g/DL (p&lt;0.0010)
(14.8%). In the extension trial, statistically significant mean increases in hemoglobin concentration were also demonstrated by
both groups; mean increases from baseline (from 11.6 g/DL to 13.9 g/DL (p&lt;0.0020)) (19.8%) in the 60 U/kg group and mean increases
from baseline (from 12.4 g/DL to 13.6 g/DL (p&lt;0.0314)) (9.7%) in the 30 U/kg group. Anemic patients demonstrated a mean increase
from baseline in hemoglobin concentration (from 9.5 g/DL to 12.9 g/DL (p&lt;0.0013) (35.8%)). See Figure 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Figure 2. Naive Patient Study: Hemoglobin
Concentration at 24 Months (30 U/kg n=12, 60 U/kg n=14, Anemic patients n=10); Mean Change from Baseline (%)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="pg20a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">P value change from baseline for 30U dose &lt;0.0314</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">P value change from baseline for 60U dose &lt;0.0020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><img src="pg20b.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the phase III clinical trial, patients in both dosage groups
demonstrated mean increases in liver volume; reductions of 11.1% (p&lt;0.0001) in the 60 U/kg group and of 10.48% (p&lt;0.0041)
in the 30 U/kg group. In the extension trial, both groups demonstrated statistically significant mean reductions in liver volume;
reductions of 17.5% (p&lt;0.0003) in the 60 U/kg group and of 20.6% (p&lt;0.0001) in the 30 U/kg group; patients with Hepatomegaly
demonstrated a reduction in liver volume of 25.2% (p&lt;0.0001). See Figure 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Figure 3. Naive Patient Study: Liver Volume
at 24 Months (30 units/kg (n=12), 60 units/kg (n=14), Hepatomegaly (n=12)); Mean Change from Baseline</B> <B>(%)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="pg21.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the phase III clinical trial, patients in both dosage groups
demonstrated mean increases in platelet count; an increase in platelet count of 41,494 ml or 72.1% (p=0.0031) in the 60 U/kg group
and a nominal increase of 11,427 ml or 13.7% (p=0.0460) in the 30 U/kg group. Accordingly, the lower dose group did not meet the
secondary endpoint relating to platelet count. However, in the extension trial, both groups demonstrated statistically significant
mean increases in platelet count for both groups; increases from 69,043 to 141,071 (p&lt;0.0016) in the 60 U/kg group and from
64,900 to 93,333 (p&lt;0.0105) in the 30 U/kg group. See Figure 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Figure 4. Naive Patient Study: Platelet Count
at 24 Months (30 U/kg (n=12), 60 U/kg (n=14)); Mean Change from Baseline (%)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="pg22a.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">P value change from baseline for 30U dose &lt;0.0105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">P value change from baseline for 60U dose &lt;0.0016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Last, 30 patients in the phase III clinical trial had chitotriosidase
measurements, a biomarker for clinical symptoms of Gaucher disease. In these patients, chitotriosidase decreased from baseline
in both the 30U/kg and 60U/kg groups by 47.3% and 58.4%, respectively. In the extension trial, statistically significant mean reductions
in chitotriosidase activity were demonstrated by both groups; a reduction of 76% (p&lt;0.0001)) in the 60 U/kg group and of 61%
(p&lt;0.0001) in the 30 U/kg group. See Figure 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Figure 5. Naive Patient Study: Chitotriosidase
Activity at 24 Months (30 U/kg (n=12), 60 U/kg (n=13*)); Mean Change from Baseline (%)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="pg22b.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">P value for both dose groups &lt;0.0001&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">*1 patient did not have chitotriosidase activity; tested for CCL18
which showed improvement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The safety analysis for both treatment groups in the phase III clinical
trial showed that taliglucerase alfa was well tolerated and no serious or severe adverse events were reported. Two patients in
the trial developed antibodies to taliglucerase alfa and no patients developed neutralizing antibodies. In addition, two patients
experienced hypersensitivity reactions to taliglucerase alfa. No anti-taliglucerase antibodies were detected in these patients
and both reactions were treated in the physicians&rsquo; clinic and reversed. The safety analysis in the extension trial for both
treatment groups also demonstrates that taliglucerase alfa was well tolerated, and no drug related serious adverse events were
reported. Two patients who participated in the extension trial developed neutralizing IgG antibodies that were determined to be
positive in an in vitro assay, but were determined to be negative in a cell-based assay. In addition, one patient in the 60 U/kg
dose group experienced a hypersensitivity reaction during month 10 of treatment. Treatment of this patient has been continued with
premedication for an additional 32 months without any treatment related adverse event reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the phase III clinical trial, most adverse events were considered
unrelated to taliglucerase alfa. The most frequent mild to moderate adverse event was headache. Other mild to moderate adverse
events included dizziness, muscle spasm, chest discomfort, nausea, skin irritation and arthalgia. Adverse events in the extension
trial included headache, pruritus, abdominal pain, infusion related reactions (dizziness, chills, nausea), muscle spasm and fixed
drug eruption.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>Results of Our Switchover Trial</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In November 2010, we announced positive preliminary data from the
first 15 patients that completed our switchover trial of taliglucerase alfa, and in February 2012 we reported full results from
the trial. <FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>The results of the trial demonstrate that over a nine-month
treatment period of the study, patients remained stable with regard to the efficacy endpoints&mdash;spleen volume, liver volume,
platelet count and hemoglobin concentration&mdash;after switching to taliglucerase alfa from imiglucerase. See Figures 6-9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-weight: bold">Figure 6. Platelet Count (Stratified by Dose)</TD>
    <TD STYLE="width: 4%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 48%; font-weight: bold">Figure 7. Hemoglobin Concentration (Stratified by Dose)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><img src="pg24a.jpg"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><img src="pg24b.jpg"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">Figure 8. Spleen Volume (Stratified by Dose)</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">Figure 7. Liver Volume (Stratified by Dose)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><img src="pg24c.jpg"></TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="text-align: center"><img src="pg24d.jpg"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The safety analysis presented for the switchover trial demonstrates
that taliglucerase alfa was well tolerated, and no drug related serious adverse events were reported. One patient developed neutralizing
IgG antibodies that were determined to be positive in an in vitro assay, and were determined to be negative in a cell-based assay.
Another patient experienced a hypersensitivity reaction, which was treated in a physician&rsquo;s office and resolved. The patient
declined to continue infusions with premedication. Additionally, all drug-related adverse effects were mild or moderate and transient
in nature.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Other Drug Candidates in Our Pipeline</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are developing other innovative recombinant therapeutic proteins
to be expressed by our ProCellEx protein expression system, with an emphasis on treatments for which there are large, established
pharmaceutical markets and where our proprietary protein expression system enables us to develop and commercialize recombinant
proteins that are patent-protected and therapeutically equivalent or superior to the existing treatments. We select additional
therapeutic candidates for development by testing candidates in-house and through collaborations with academic partners. We have
identified several product candidates oriented towards specialty disease and therapeutic market segments, including: <FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans; (2)
PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications;
(3) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor
(TNFR) and an antibody portion, which is being developed as a treatment of certain immune diseases such as rheumatoid arthritis,
juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis; (4) an orally administrated glucocerebrosidase
enzyme for treating Gaucher disease patients utilizing the oral delivery of the recombinant enzyme produced within carrot cells;
and (5) two additional undisclosed therapeutic proteins, both of which are being evaluated in animal studies. We participated in
a pre IND meeting with respect to one of the undisclosed product candidates in the first quarter of 2012 and a pre IND meeting
for the second candidate is planned for later this year. In March 2010, we initiated a preliminary phase I clinical trial of PRX-105
which we completed in June 2010. We are currently preparing for further efficacy trials of this product candidate in larger animals.
In our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that we will use live nerve gas rather
than an analogue in the proposed additional efficacy trials in animals. In December 2010, we held a pre- IND meeting with the FDA
with respect to PRX-102. We completed preclinical trials in small and large animals with respect to PRX-102, and we expect to submit
an IND to the FDA during the second quarter of 2012 in connection with an anticipated phase I/II clinical study of PX-102 in Fabry
patients, and to initiate the trial once the IND is approved, if at all. In December 2011 we held a pre IND meeting with respect
to PRX 106 and we expect to submit an IND around the fourth quarter of 2012. We are also conducting pre clinical trials of our
orally-administrated glucocerebrosidase enzyme for the treatment of Gaucher disease in small and large animals.</FONT> Last, we
are conducting research programs in the fields of enzymes, monoclonal antibodies, cytokines and vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">PRX-102</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are developing PRX-102, our proprietary plant cell expressed
modified version of the recombinant alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease
is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme.
Fabry disease causes harmful accumulations of lipids in the kidneys, automatic nervous system and cardiovascular system that result
in the risk of heart attack and stroke, and can be life-threatening. Fabry disease affects more than 8,000 people globally. We
believe that the treatment of Fabry disease is a specialty clinical niche with the potential for high growth. Currently there are
two drugs available on the market to treat Fabry disease. Fabrazyme, made by Genzyme (acquired by Sanofi), was approved for the
treatment of Fabry disease in the European Union in 2001 and the United States in 2003. Sanofi reported &euro;109&nbsp;million
(approximately $143.2 million) in worldwide sales of Fabrazyme in 2011, a growth of 9.4% compared to 2010. According to Genzyme,
supplies of Fabrazyme have also been affected by the production interruptions that have occurred since 2009. The other approved
drug for the treatment of Fabry disease in the European Union is Replagal, which is sold by Shire. Shire reported $475.2 million
in sales of Replagal in 2011, compared to $351.3 million in sales of Replagal in 2010. According to public reports by Shire, it
filed a BLA with the FDA for Replagal in the United States in December 2009. Shire subsequently received Fast Track designation
for Replagal, withdrew the BLA in 2010 and in October 2010, initiated a rolling BLA submission. Shire has reported that it withdrew
the December 2009 filing in August 2010 in order to update the filing with additional clinical information. According to public
reports by Shire, it submitted a a rolling BLA with the FDA for Replagal in the United States in November 2011, which the FDA has
accepted and a priority review. The FDA has assigned Replagal an action date of May 17, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We completed the animal evaluation testing phase of the development
of PRX-102, which tests are based on a well established mouse model for Fabry disease. In pre-clinical studies, PRX-102 demonstrated
preliminary efficacy in a Fabry animal model. Chemical modifications made to PRX-102 improved the enzyme&rsquo;s activity and stability
resulting in prolonged activity profiles and enhanced bioavailability in animals. The modifications also have the potential to
decrease the immunogenicity of the enzyme, which is a major drawback of currently approved therapies for Fabry disease. <FONT STYLE="font-family: Times New Roman, Times, Serif">We
currently expect to submit an IND to the FDA during the second quarter of 2012 in connection with an anticipated phase I/II clinical
study of PRX-102 and to initiate the trial once the IND is approved, if at all. </FONT>As was the case in our development of taliglucerase
alfa, our development of PRX-102 involves the expression by our proprietary protein expression system of a naturally occurring
enzyme to be used in enzyme replacement therapy for the treatment of Fabry disease. Based on the pre IND meeting we held with FDA
in 2010, the experience with taliglucerase alfa and the experience of other companies developing enzyme replacement therapies for
Fabry disease, we have reason to believe that, if favorable data is accumulated in preclinical and phase I/II clinical trials,
the FDA may allow us to proceed directly with a pivotal phase III clinical trial. However, there can be no assurance that we will
initiate phase I/II clinical trials and if we do, that such trials will result in favorable data. In addition, there can be no
assurance that the FDA will allow us to proceed directly with a phase III clinical trial after completion of a phase I/II clinical
trial.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Acetylcholinesterase</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">In August 2007, Protalix Ltd. licensed
the rights to certain technology under a research and license agreement with Yissum Research and Development Company, or Yissum,
and the Boyce Thompson Institute, Inc., or Boyce Thompson. Pursuant to the agreement, we are developing PRX-105, a proprietary
plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications,
as well as in a biodefense program and an organophosphate-based pesticide treatment program. To date, our <I>in vitro</I> experiments
of PRX-105 have shown that the acetylcholinesterase enzyme expressed in our ProCellEx protein expression system demonstrates promising
biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase
expressed in our ProCellEx protein expression system was able to successfully treat animals exposed to the nerve gas agent analogues,
both when injected with our acetylcholinesterase product candidate immediately before exposure or when injected after exposure.
We filed an IND with the FDA for PRX-105, our plant cell expressed pegylated recombinant acetylcholinesterase enzyme (AChE) product
candidate, during the last quarter of 2009, and in March 2010 we initiated a preliminary phase I clinical trial of PRX-105. The
trial established the pharmokinetics of PRX-105 and demonstrated that single dose intravenous administration of PRX-105 is safe
and well tolerated. We are currently preparing for further efficacy trials of PRX-105 in larger animals. <FONT STYLE="font-family: Times New Roman, Times, Serif">In
our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that we will use live nerve gas in the proposed
additional efficacy trials in animals.</FONT> In March 2010 we initiated a preliminary phase I clinical trial of PRX-105 which
we completed in June 2010. <FONT STYLE="font-family: Times New Roman, Times, Serif">In December 2010, we held a pre-investigational
new drug, or IND, meeting with the FDA with respect to PRX-105. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Under the terms of the agreement, Yissum
and Boyce Thompson granted us an exclusive, worldwide right and license to certain technology, including patents and certain patent
applications relating to AChE for the therapeutic and prophylactic indications as well as an exclusive license not limited to such
indications <FONT STYLE="color: black">with respect to certain of those patents and patent applications. As consideration for the
license, we are obligated to pay Yissum and </FONT>Boyce Thompson, collectively,<FONT STYLE="color: black"> an annual, non-refundable
initial maintenance fee of $20,000, </FONT>commencing on the fourth anniversary of the execution of the agreement, which is subject
to a 12% annual increase.<FONT STYLE="color: black"> In addition, we are obligated to make royalty payments equal to varying low,
single-digit percentages of net sales of products under the agreement. These royalty rates are evaluated on a country-by-country
basis, and are subject to reduction if a third party commercializes a competing product or commercializes an authorized generic
version of the applicable product, subject to certain conditions. We also have the right to grant sublicenses relating to the licensed
technology under the agreement, subject to the payment of sublicensing fees. The fees payable in connection with any sublicense
are equal to varying percentages, in the low-teens through the low-twenties, of the consideration we receive in connection with
the sublicense, depending on the level of clinical development of the product at the time we enter into the sublicense. Last, we
are obligated to pay Yissum and </FONT>Boyce Thompson, collectively, milestone payments equal to $700,000, in the aggregate, upon
the achievement of certain milestones under the license agreement.<FONT STYLE="color: black"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The license agreement remains in effect until the expiration of
all obligations to <FONT STYLE="color: black">Yissum and </FONT>Boyce Thompson under the agreement, determined on a country-by-country
basis. We have the right to terminate the agreement for any reason upon 60 days&rsquo; prior written notice to <FONT STYLE="color: black">Yissum
and </FONT>Boyce Thompson. Subject to certain conditions, <FONT STYLE="color: black">Yissum and </FONT>Boyce Thompson may terminate
the agreement immediately upon written notice to us in connection with certain events relating to bankruptcy, lapses in our insurance
coverage, failures to defend against third party claims or claims we may make regarding the validity or enforceability of any licensed
patent. We or <FONT STYLE="color: black">Yissum and </FONT>Boyce Thompson may terminate the agreement within 60 days after receiving
written notice if the non-terminating party passes a resolution for a voluntary wind up, if a receiver or liquidator is appointed
for the non-terminating party, or the non-terminating party enters into an insolvency or bankruptcy proceeding. In addition, either
party may terminate the agreement due to a material breach by the other party if the breaching party is unable to cure the breach
within 60 days after receiving written notice of the breach from the non-breaching party. Any termination of the agreement will
result in a loss of our rights to the licensed technology, which will revert back to <FONT STYLE="color: black">Yissum and </FONT>Boyce
Thompson.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are currently in discussions with different U.S. civil and military
organizations regarding certain grants for which our acetylcholinesterase program is eligible. We anticipate applying for specific
U.S. grants during 2012 to support the further development of our acetylcholinesterase program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, we are researching other indications for which PRX-105
may serve as a therapy. A paper entitled: &quot;Adaptive Alternative Splicing Correlates with Less Environmental Risk of Parkinsonism,&quot;
has been published in the Journal of Neurodegenerative Diseases (Neurodegener Dis. 2012;9(2):87-98. Epub 2011 Oct 27). The research
includes an investigation of the effect of PRX-105 on alternative splicing patterns in the striatum, which may confer protection
in Parkinson's disease. The research highlights that a splice shift, either inherited or induced by environmental factors (e.g.
neurotoxins), from the more common 'synaptic form' of acetylcholinesterase (AChE-S) to the monomeric 'read-through' variant of
AChE (AChE-R), is important in conferring protection against Parkinson-like symptoms. Furthermore, according to the article, intravenous
injection with PRX-105 induced a protective gene expression profile in the striatum of the brain. We recently filed a joint PCT
patent application entitled: &quot;Methods for Treating or Preventing Parkinson's Disease,&quot; with the Hebrew University. These
filings are part of our continuing collaboration with Yissum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">pr-antiTNF</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">pr-antiTNF is an antiTNF (Tumor, Necrosis Factor) protein that we
are expressing through our proprietary ProCellEx system. We have designed this antiTNF as pr-antiTNF. pr-antiTNF is a candidate
for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis,
psoriatic arthritis and plaque psoriasis. Our pr-antiTNF product candidate has an amino acid sequence that is similar to Enbrel
which is one of the treatments for patients of those diseases. Amgen Inc. reported total sales of Enbrel of $3.7 billion in the
United States and Canada for 2011 and Pfizer has reported total sales of Enbrel outside of the United States and Canada of $3.7
billion for 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">pr-antiTNF is a plant cell-expressed recombinant fusion protein
made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody domain. pr-antiTNF has
an identical amino acid sequence to Enbrel and our in vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits
similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors
and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner. In a proof-of-concept <I>in vivo</I> study using
an established arthritis animal model, pr-antiTNF, when injected in mice, significantly improved the clinical arthritis parameters
associated with this accepted arthritis mouse model, including joint inflammation, swelling and tissue degradation. We intend to
conduct additional animal studies to collect additional data to form a basis for a discussion with the FDA to explore the regulatory
pathway for our antiTNF program. Patents for the Enbrel start to expire as early as 2012, and we expect to use our cost effective
manufacturing platform to facilitate entry into this market upon approval of our pr-antiTNF product, if at all. <FONT STYLE="font-family: Times New Roman, Times, Serif">In
December 2011, we held a pre IND meeting with respect to </FONT>pr-antiTNF, <FONT STYLE="font-family: Times New Roman, Times, Serif">and
we expect to submit an IND around year end. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Oral Glucocerebrosidase</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are developing an orally delivered glucocerebrosidase (GCD) enzyme
for the potential treatment of Gaucher disease. Oral GCD is a plant cell-expressed form of GCD that is naturally encapsulated within
carrot cells that are genetically engineered to express the GCD enzyme. Plant cells have the unique attribute of a cellulose cell
wall which makes them resistant to enzyme degradation when passing through the digestive tract. The plant cell itself serves as
a delivery vehicle to transport the enzyme in active form to the bloodstream. We are currently conducting large animal studies
of oral GCD to demonstrate the stability of the enzyme in the cell and the capacity of the cellulose wall to protect the enzyme
against degradation in the digestive tract in an <I>in vitro</I> model of the stomach and intestines. We intend to plan a phase
I clinical trial of oral glucocerebrosidase in healthy individuals who are carriers of Gaucher disease and who show reduced enzymatic
activity at baseline based on the final results of the animal studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Commercialization Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">On November&nbsp;30,
2009, Protalix Ltd. and Pfizer entered into a license and supply agreement pursuant to which Pfizer was granted an exclusive, worldwide
license to develop and commercialize taliglucerase alfa. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd.
retained the right to commercialize taliglucerase alfa in Israel. In connection with the execution of the Pfizer Agreement, Pfizer
made an upfront payment to Protalix Ltd. of $60.0 million in connection with the execution of the agreement and subsequently paid
to Protalix Ltd. an additional $5.0 million upon our filing of a proposed pediatric investigation plan to the Pediatric Committee
of the EMA. Protalix Ltd. is also eligible to receive potential milestone payments of up to $50.0 million, in the aggregate, for
the successful achievement of other regulatory-related milestones and to payments equal to 40% of the net profits earned by Pfizer
on sales of taliglucerase alfa. In calculating the net profits, there are certain agreed upon limits on the amounts that may be
deducted from gross sales for certain expenses and costs of goods sold. Protalix Ltd. retained the manufacturing rights to taliglucerase
alfa and Pfizer and Protalix Ltd. have agreed to a specific allocation of the responsibilities for the continued development efforts
for taliglucerase alfa. Protalix Ltd. will manufacture all of the taliglucerase alfa needed for all purposes under the agreement
and Pfizer will purchase the taliglucerase alfa from Protalix Ltd., subject to certain terms and conditions. </FONT>The Pfizer
Agreement also provides for reimbursement by Pfizer of certain costs to be incurred by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the upfront and milestone payments made under
the Pfizer Agreement, Protalix Ltd. has paid a sublicense fee equal to $1.6 million to the academic institution from who it licensed
certain technology relating to taliglucerase alfa. Future milestone payments will be subject to a 2.5% royalty, and all of revenues
generated under the agreement will be subject to a 0.75% royalty payable to the same institution until 2016, when a patent related
to taliglucerase alfa licensed to us will expire. We are also required to pay a royalty equal to 3% of the revenues of taliglucerase
alfa Pfizer records under the Pfizer Agreement to the OCS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 10, 2010, Pfizer entered into a $30 million short-term
supply agreement with the Ministry of Health of Brazil pursuant to which Protalix and Pfizer have provided taliglucerase alfa to
the Ministry of Health of Brazil for the treatment of patients with Gaucher disease. During the second and fourth quarters of 2011,
the Ministry of Health of Brazil requested that Pfizer consider the replacement of certain vials that might expire during 2012.
As a result, Pfizer recorded an allowance for sales returns. If and when such vials are replaced, revenues will be recorded upon
the supply of such replaced vials, and if it is determined that there is no longer a need for the replacement of vials, the allowance
will be reversed and the revenues will be recognized accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, we and the Ministry of Health of Brazil are in discussions
relating to a possible long-term supply agreement that contemplates, among other matters, providing certain components of our manufacturing
technology to the Ministry of Health of Brazil for implementation by it in Brazil. At this time, we are unable to assess whether
these discussions will result in an agreement and there can be no assurance that we will be able to enter into such an agreement
on favorable terms, if at all. In any event, we do not expect to enter into a long-term supply agreement with the Ministry of Health
of Brazil until we receive marketing approval of taliglucerase alfa from the FDA or ANVISA, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We will be subject to a withholding tax on the U.S. revenue source
portion of the payments made to us for our share of Pfizer&rsquo;s in net profits under the Pfizer Agreement. Currently, the withholding
tax rate is 15%.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Strategic Collaborations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>Teva Pharmaceutical Industries</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In September 2006, we entered into a Collaboration and Licensing
Agreement with Teva for the development and manufacture of two proteins to be identified by Teva and us using our ProCellEx protein
expression system. The agreement also identifies additional matters for collaboration between Teva and us. Subsequently, two proteins
were identified to be researched and developed under the agreement but in 2009, both of the projects were terminated for commercial
reasons. Pursuant to the agreement, we have agreed to collaborate on certain additional matters regarding proteins, including the
research and development of proteins utilizing our ProCellEx protein expression system. See &ldquo;Risk Factors&mdash;Our strategy,
in many cases, is to enter into collaboration agreements with third parties to leverage our ProCellEx system to develop product
candidates. If we fail to enter into these agreements or if we or the third parties do not perform under such agreements or terminate
or elect to discontinue the collaboration, it could have a material adverse affect on our revenues.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><I>Weizmann Institute of Science</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">In March 2006, Protalix Ltd. entered into
a research and license agreement with the Yeda Research and Development Company Limited, or Yeda, the technology transfer arm of
the Weizmann Institute of Science. Under the terms of the agreement, Yeda agreed to use its technology to design a next generation
of glucocerebrosidase (GCD) for the treatment of Gaucher disease that can be expressed using our ProCellEx protein expression system
and that may have certain benefits over the first generation treatments used today. The technology licensed from Yeda provides
a methodology for the rational design of an improved drug for the treatment of Gaucher disease by enzyme replacement therapy, based
on the three-dimensional crystal structure of glucocerebrosidase that was solved by scientists from the Weizmann Institute of Science.
Yeda has granted us an exclusive worldwide license to use their technology and discoveries for the development, production and
sale of enzymatically active mutations of glucocerebrosidase (GCD) and derivatives thereof for the treatment of Gaucher disease.
Under the terms of the agreement, we are required to take all necessary steps to develop and commercialize the products subject
to the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">As consideration for the license, we agreed
to pay Yeda a fixed research budget amount, subject to certain conditions. We have since completed the research phase of the arrangement
with Yeda. Accordingly, we are no longer making any research-related payments to Yeda under the agreement. In addition, we are
obligated to make an annual non-refundable license fee of $10,000 during the term of the agreement, commencing on the fifth anniversary
of the execution of the agreement until, and including, the 19<SUP>th</SUP> anniversary thereof. We are also obligated to make
<FONT STYLE="color: black">royalty payments equal to </FONT>varying <FONT STYLE="color: black">low, single-digit percentages of
net sales of products under the agreement. Sublicenses relating to the licensed technology may be granted under the agreement,
subject to the payment of sublicensing fees. The fee for any sublicense is equal to a percentage, ranging from the low-teens through
the low-twenties, of the consideration we receive in connection with the sublicense, depending on the level of clinical and regulatory
development of the products under the agreement at the time we enter into the sublicense. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The license agreement remains in effect until the earlier of the
expiration of the last patent licensed under the agreement or if there are no commercial sales of any products for a continuous
period of 20 years. Yeda may modify the exclusivity component of the agreement by written notice to us and without our consent.
Yeda may terminate the agreement by written notice to us if we fail to satisfy any one or more specified milestones, and we fail
to cure any such failure within a certain time period after we receive the notice. Yeda is not entitled to exercise this termination
right if we demonstrate that we are making all necessary efforts to achieve such milestones, that our inability to satisfy the
milestones is due to factors beyond our control, and that the total delay with respect to any one milestone does not exceed 12
months and the total cumulative delay in respect of all milestones has not exceeded 30 months. Yeda may also terminate the agreement
if we contest the validity of any of the patents included in the agreement. We or <FONT STYLE="color: black">Yeda may</FONT> terminate
the agreement due to a material breach by the other party if the breach is unable to be cured or, if curable, the breach is not
cured within 21 days after the breaching party&rsquo;s receipt of written notice of the breach from the non-breaching party. In
addition, either party may terminate the agreement in connection with certain events relating to a wind up or bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain a proactive intellectual property strategy which
includes patent filings in multiple jurisdictions, including the United States and other commercially significant markets. As
of December 31, 2011, we hold, or have license rights to, 31 patents and 81 pending patent applications with respect to
various compositions, methods of production and methods of use relating to our ProCellEx protein expression system and our
proprietary product pipeline. As of December 31, 2011, we also hold, with a third party, one joint patent and one
joint patent application, and licensed rights to six patents and seven patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our competitive position and future success depend in part on our
ability, and that of our licensees, to obtain and leverage the intellectual property covering our product candidates, know-how,
methods, processes and other technologies, to protect our trade secrets, to prevent others from using our intellectual property
and to operate without infringing the intellectual property of third parties. We seek to protect our competitive position by filing
United States, European Union, Israeli and other foreign patent applications covering our technology, including both new technology
and improvements to existing technology. Our patent strategy includes obtaining patents, where possible, on methods of production,
compositions of matter and methods of use. We also rely on know-how, continuing technological innovation, licensing and partnership
opportunities to develop and maintain our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2011, our patent portfolio consists of several
patent families (consisting of patents and/or patent applications) covering our technology, protein expression methodologies and
system and product candidates, as follows:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect to our ProCellEx protein expression system, we have been issued, and hold licensed rights to, patents in the United
States, Australia, the European Union, Israel, Canada, the Czech Republic, Hungary, Japan, Poland, Mexico, Hong Kong and India,
and to eight pending patent applications. Among other things, the patents cover the methods that we use for culturing and harvesting
plant cells and/or tissues in consecutive cycles. The issued patents in this patent family are expected to expire in 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect to our ProCellEx protein expression system, we also hold 14 patent applications relating to the large scale production
of proteins in cultured plant cells. The patents to issue in the future based on the pending patent applications in this patent
family are expected to expire in 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a patent family containing nine granted patents in India, South Africa, Russia, Australia, China, the United States
and the Ukraine, and 35 patent applications, relating to the production of glycosylated lysosomal proteins in our plant culture
platform, particularly proteins having a terminal mannose glycosylation, including taliglucerase alfa. The issued patents and any
patents to issue in the future based on pending patent applications in this patent family are expected to expire in 2024 and 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a patent family containing two granted and two pending patent applications relating to a system and method for production
of antibodies in a plant cell culture, and antibodies produced in such a system. The patents to issue in the future based on the
patent applications in this patent family are expected to expire in 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a patent family containing two issued patent in South Africa and Singapore and 12 pending patent applications relating
to a new method for delivering active recombinant proteins systemically through oral administration of transgenic plant cells.
The issued patents and any patents to issue in the future based on patent applications in this patent family are expected to expire
in 2026.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We hold a patent family containing one granted patent in South Africa and six pending patent applications relating to saccharide
containing protein conjugates. The patents to issue in the future based on the patent applications in this patent family will expire
in 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Our patent portfolio includes a patent that we co-own that covers human glycoprotein hormone and chain splice variants, including
isolated nucleic acids encoding these variants. More specifically, this patent covers a new splice variant of human FSH. This patent
was issued in the United States and is expected to expire in 2026.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect to taliglucerase alfa, we have licensed the rights to two patents from Virginia Tech Intellectual Properties,
Inc., or Virginia Tech, that are expected to expire in 2016. We also hold the licensed rights from Yeda to one granted and two
pending patent applications with respect to the research and development of the glucocerebrosidase protein which are expected to
expire in 2024.</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>With respect to acetylcholinesterase, we have licensed the rights to three patents issued in the United States that are expected
to expire in 2014, 2017 and 2021, and to five patent applications from Yissum.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are aware of U.S. patents, and corresponding international counterparts
of such patents, owned by third parties that contain claims covering methods of producing GCD. We do not believe that, if any claim
of infringement were to be asserted against us based upon such patents, taliglucerase alfa would be found to infringe any valid
claim under such patents. However, there can be no assurance that a court would find in our favor or that, if we choose or are
required to seek a license to any one or more of such patents, a license would be available to us on acceptable terms or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In April 2005, Protalix Ltd. entered into a license agreement with
Icon Genetics AG, or Icon, pursuant to which we received an exclusive worldwide license to develop, test, use and commercialize
Icon&rsquo;s technology to express certain proteins in our ProCellEx protein expression system. Under the terms of the agreement,
we are also entitled to a non-exclusive worldwide license to make and have made other proteins expressed by using Icon&rsquo;s
technology in our technology. As consideration for the license, we are obligated to make <FONT STYLE="color: black">royalty payments
equal to </FONT>varying <FONT STYLE="color: black">low, single-digit percentages of net sales of products by us, our affiliates,
or any sublicensees under the agreement. </FONT>In addition, we are obligated to make milestone payments equal to $350,000, in
the aggregate, upon the achievement of certain milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">Our license agreement with Icon
remains in effect until the earlier of the expiration of the last patent under the agreement or, if all of the patents under the
agreement expire, 20 years after the first commercial sale of any product under the agreement. Icon may terminate the agreement
upon written notice to us that we are in material breach of our obligations under the agreement and we are unable to remedy such
material breach within 30 days after we receive such notice. Further, Icon may terminate the agreement in connection with certain
events relating to a wind up or bankruptcy, if we make a general assignment for the benefit of our creditors, or if we cease to
conduct operations for a certain period. Icon may also terminate the exclusivity granted to us by written notice if we fail to
reach certain milestones within a designated period of time. Notwithstanding the termination date of the agreement, our obligation
to pay royalties to Icon under the agreement may expire prior to the termination of the agreement, subject to certain conditions.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In January 2005, Protalix Ltd. entered into a license agreement
with Virginia Tech, pursuant to which we received a non-exclusive worldwide license to make, have made, use, sell, offer for sale
and import certain of Virginia Tech&rsquo;s patents. As consideration for the license, we made a one-time license fee payment to
Virginia Tech, and we are obligated to make royalty payments equal to varying low, single-digit percentages of net sales of licensed
products by Protalix Ltd., its subsidiaries and/or their affiliates. Upon commercialization of a licensed product, the royalty
payment is subject to a low, annual minimum amount. In addition, we are obligated to make milestone payments equal to $150,000,
in the aggregate, upon the achievement of certain milestones. We have the right to grant sublicenses under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our license agreement with Virginia Tech remains in effect until
the earlier of the expiration of the last patent under the agreement or 10 years after the first commercial sale of any licensed
product. Virginia Tech may terminate the agreement upon written notice to us that we are in material breach of our obligations
under the agreement if we are unable to remedy such material breach within a fixed number of days after we receive such notice,
which number may be doubled if we are making good faith efforts to achieve a cure and the extension will not increase the damages
suffered by Virginia Tech. We have the right to terminate the agreement at any time upon prior written notice delivered an agreed-upon
number of days prior to the date of termination.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Manufacturing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are obligated to manufacture all of the taliglucerase alfa drug
product needed under the Pfizer Agreement, subject to certain terms and conditions. Our drug product candidates, including taliglucerase
alfa, must be manufactured in a sterile environment and in compliance with cGMPs set by the FDA and other relevant foreign regulatory
authorities. We use our current facility, which has approximately 20,000 sq/ft of clean rooms built according to industry standards,
to develop, process and manufacture taliglucerase alfa and other recombinant proteins We intend to use our current manufacturing
space to produce all of the taliglucerase alfa we need in the near future, included the taliglucerase alfa to be purchased by Pfizer.
Current capacity of our facility can serve approximately 30% of the Gaucher disease patients that are currently under treatment.
We intend to expand our current facility in order to reach a capacity of approximately 80% of the Gaucher disease patients that
are currently under treatment and to house the laboratory space necessary for further development of other product candidates in
our pipeline. Total expected cost for such expansion is currently estimated to be approximately $25 million and the process is
expected to be completed during 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In February
2010, the Israeli MOH completed a successful GMP audit of our manufacturing facilities in Carmiel, Israel. The audit was performed
as part of the Israeli MOH&rsquo;s evaluation of our manufacturing process for taliglucerase alfa. On February 20, 2011, we received
a letter from the FDA notifying us that the FDA had completed its review of the Establishment Inspection Report in connection with
the FDA&rsquo;s inspection of our Carmiel facility and that the FDA had classified our facility as acceptable. In June 2011, ANVISA
completed a successful GMP audit of the facility and determined that the facility is acceptable. In </FONT>December 2011, after
the taliglucerase alfa NDA was filed with the EMA, the IMB completed a successful GMP audit of our facility and issued a Certificate
of GMP Compliance of a Manufacturer for the facility. The IMB certificate is accepted by all health authorities in the European
Union under the European Union's centralized marketing authorization procedure, and by authorities of several other countries that
recognize EU certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have engaged a contract manufacturer in Europe to act as an additional
source of fill and finish activities for taliglucerase alfa. According to our agreement with Pfizer, Pfizer will be responsible
for the fill and finish activities for taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our current facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and we have elected to participate in the alternative benefits program. Our facility is located in a
Zone A location, and, therefore, our income from the Approved Enterprise will be tax exempt in Israel for a 10-year period commencing
with the year in which we first generate taxable income from the relevant Approved Enterprise. We currently anticipate that the
benefits of this program will be available to Protalix Ltd. until 2017 and, accordingly, we expect to be entitled to similar tax
benefits for a number of years thereafter. To remain eligible for these tax benefits, we must continue to meet certain conditions,
and if we increase our activities outside of Israel, for example, by future acquisitions, such increased activities generally may
not be eligible for inclusion in Israeli tax benefit programs. In addition, our technology is subject to certain restrictions with
respect to the transfer of technology and manufacturing rights. &ldquo;See Risk Factors&mdash;The manufacture of our products is
an exacting and complex process, and if we or one of our materials suppliers encounter problems manufacturing our products, it
will have a material adverse effect on our business and results of operations.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Raw Materials and Suppliers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that the raw materials that we require throughout the
manufacturing process of our current and potential drug product candidates are widely available from numerous suppliers and are
generally considered to be generic industrial biological supplies. We rely on a single approved supplier for certain materials
relating to the current expression of our proprietary biotherapeutic proteins through ProCellEx. We have identified additional
suppliers for most of the materials required for the production of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Development and regulatory approval of our pharmaceutical products
are dependent upon our ability to procure active ingredients and certain packaging materials from sources approved by the FDA and
other regulatory authorities. Since the FDA and other regulatory approval processes require manufacturers to specify their proposed
suppliers of active ingredients and certain packaging materials in their applications, FDA approval of a supplemental application
to use a new supplier in connection with any drug candidate or approved product, if any, would be required if active ingredients
or such packaging materials were no longer available from the specified supplier, which could result in manufacturing delays. From
time to time, we intend to continue to identify alternative FDA-approved suppliers to ensure the continued supply of necessary
raw materials.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Competition</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The biotechnology and pharmaceutical industries are characterized
by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the
fields in which we operate is intense and expected to increase. Most of these companies have substantially greater research and
development, manufacturing, marketing, financial, technological personnel and managerial resources than we do. In addition, many
specialized biotechnology companies have formed collaborations with large, established companies to support research, development
and commercialization of products that may be competitive with our current and future product candidates and technologies. Acquisitions
of competing companies by large pharmaceutical or biotechnology companies could further enhance such competitors&rsquo; financial,
marketing and other resources. Academic institutions, governmental agencies and other public and private research organizations
are also conducting research activities and seeking patent protection and may commercialize competitive products or technologies
on their own or through collaborations with pharmaceutical and biotechnology companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We specifically face competition from companies with approved treatments
of Gaucher disease, including Genzyme, which was recently acquired by Sanofi, and to a much lesser extent, Actelion. In addition,
in February 2010, the FDA approved VPRIV, Shire&rsquo;s enzyme replacement therapy for the treatment of Gaucher disease and the
European Commission granted marketing authorization to VPRIV in August 2010. In addition, we are aware of other early clinical
stage, experimental, small molecule, oral drugs which are being developed for the treatment of Gaucher disease by Genzyme and Amicus
Therapeutics. Amicus Therapeutics reports that it has suspended its development of its Gaucher disease treatment. We also face
competition from companies with approved enzyme treatments of Fabry disease, including Genzyme and Shire, and we are aware of other
early stage drugs which are being developed for the treatment of Fabry disease, including a drug being developed by Amicus Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also face competition from companies that are developing other
platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative
technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed
proteins. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson &amp;
Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck &amp; Co. Inc.). Other companies are developing alternate
plant-based technologies, include Biolex, Inc., Chlorogen, Inc., iBIO, Medicago, Greenovation Biotech GmbH, and Symbiosys, none
of which are cell-based. Rather, such companies base their product development on transgenic plants or whole plants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Several biogeneric companies are pursuing the opportunity to develop
and commercialize follow-on versions of other currently marketed biologic products, including growth factors, hormones, enzymes,
cytokines and monoclonal antibodies, which are areas that interest us. These companies include, among others, Novartis AG/Sandoz
Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Key differentiating elements affecting the success of our product
candidates are likely to be their potency and efficacy profiles, as well as their cost-effectiveness as compared to other existing
therapies. See &ldquo;Risk Factors&mdash;Developments by competitors may render our products or technologies obsolete or non-competitive
which would have a material adverse effect on our business and results of operations.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Scientific Advisory Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Members of our scientific advisory board, who are experts in the
fields of plant molecular and cell biology as well as Gaucher disease and various hematological and genetic disorders, consult
with our management within their professional areas of expertise; exchange strategic and business development ideas with our management;
attend scientific, medical and business meetings with our management, such as meetings with the FDA and comparable foreign regulatory
authorities, meetings with strategic or potential strategic partners and other meetings relevant to their areas of expertise; and
attend meetings of our scientific advisory board. We expect our scientific advisory board to convene at least twice annually, and
we frequently consult with the individual members of our Scientific Advisory Board. Our scientific advisory board currently includes
the following people:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Name</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 59%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Affiliation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Professor Aaron Ciechanover, M.D., D.Sc.</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Laureate of the Nobel Prize in Chemistry</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Distinguished research Professor at the Cancer and Vascular Biology
        Research Center of the Rappaport Research Institute and Faculty of Medicine at the Technion</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">American Academy of Arts and Sciences, Member</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Professor Gad Galili, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>Former Chairman of the Department of Plant Sciences, The Weizmann Institute of Science, Rehovot, Israel</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Professor Ari Zimran, M.D.</TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Director of the Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem,
        Israel</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Associate Professor of Medicine, Hebrew University-Hadassah Medical
        School, Jerusalem, Israel</P></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Government Regulation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The testing, manufacture, distribution, advertising and marketing
of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States,
including the FDA, and by similar authorities in other countries. Any product that we develop must receive all relevant regulatory
approvals or clearances, as the case may be, before it may be marketed in a particular country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The regulatory process, which includes overseeing preclinical studies
and clinical trials of each pharmaceutical compound to establish its safety and efficacy and confirmation by the FDA that good
laboratory, clinical and manufacturing practices were maintained during testing and manufacturing, can take many years, requires
the expenditure of substantial resources and gives larger companies with greater financial resources a competitive advantage over
us. Delays or terminations of clinical trials that we undertake would likely impair our development of product candidates. Delays
or terminations could result from a number of factors, including stringent enrollment criteria, slow rate of enrollment, size of
patient population, having to compete with other clinical trials for eligible patients, geographical considerations and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA review process can be lengthy and unpredictable, and we
may encounter delays or rejections of our applications when submitted. Generally, in order to gain FDA approval, we must first
conduct preclinical studies in a laboratory and in animal models to obtain preliminary information on a compound and to identify
any potential safety problems. The results of these studies are submitted as part of an IND application that the FDA must review
before human clinical trials of an investigational drug can commence. Clinical trials may be terminated by the clinical trial site,
sponsor or the FDA if toxicities appear that are either worse than expected or unexpected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Clinical trials are normally performed in three sequential phases
and generally take two to five years, or longer, to complete. Phase I consists of testing the drug product in a small number of
humans, normally healthy volunteers, to determine preliminary safety and tolerable dose range. Phase II usually involves studies
in a limited patient population to evaluate the effectiveness of the drug product in humans having the disease or medical condition
for which the product is indicated, determine dosage tolerance and optimal dosage and identify possible common adverse effects
and safety risks. Phase III consists of additional controlled testing at multiple clinical sites to establish clinical safety and
effectiveness in an expanded patient population of geographically dispersed test sites to evaluate the overall benefit-risk relationship
for administering the product and to provide an adequate basis for product labeling. Phase IV clinical trials may be conducted
after approval to gain additional experience from the treatment of patients in the intended therapeutic indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">After completion of clinical trials of a new drug product, FDA and
foreign regulatory authority marketing approval must be obtained. Assuming that the clinical data support the product&rsquo;s safety
and effectiveness for its intended use, an NDA is submitted to the FDA for its review. Generally, it takes one to three years to
obtain approval. If questions arise during the FDA review process, approval may take a significantly longer period of time. The
testing and approval processes require substantial time and effort and approval on a timely basis, if at all, or the approval that
we receive may be for a narrower indication than we had originally sought, potentially undermining the commercial viability of
the product. Even if regulatory approvals are obtained, approved products are subject to continual review and holders of an approved
product are required, for example, to report certain adverse reactions and production problems, if any, to the FDA, and to comply
with certain requirements concerning advertising and promotional labeling for the product. Also, quality control and manufacturing
procedures relating to a product must continue to conform to cGMP after approval, and the FDA periodically inspects manufacturing
facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the area
of production and quality control to comply with cGMP and other aspects of regulatory compliance. The later discovery of previously
unknown problems or failure to comply with the applicable regulatory requirements with respect to any product may result in restrictions
on the marketing of the product or withdrawal of the product from the market as well as possible civil or criminal sanctions. See
also &ldquo;&mdash;International Regulation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Orphan Drug Act of 1983, the FDA may grant orphan drug
designation to drugs and biological products intended to treat a rare disease or condition, which is generally a disease or condition
that affects fewer than 200,000 individuals in the United States. In September 2009, we received orphan drug designation for taliglucerase
alfa for the treatment of Gaucher disease. The FDA grants orphan drug designation to drugs that may provide a significant therapeutic
advantage over existing treatments and target conditions affecting 200,000 or fewer U.S. patients per year. Orphan drug designation
does not convey any advantage in or shorten the duration of the regulatory review and approval process. Among the other benefits
of orphan drug designation are possible funding and tax savings to support clinical trials and for other financial incentives and
a waiver of the marketing application user fee and most likely priority review.<B> </B>If a significant therapeutic advantage over
existing treatments is shown in the marketing application, FDA may grant orphan drug approval and provide a seven-year period of
marketing exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The FDA has a fast track program that is intended to expedite or
facilitate the process for reviewing new drugs and biological products that meet certain criteria. Specifically, new drugs and
biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition
and demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to the combination
of the product and the specific indication for which it is being studied. For a fast track product, the FDA may consider for review
on a rolling basis sections of the NDA before the complete application is submitted, if the sponsor provides a schedule for the
submission of the sections of the NDA, the FDA agrees to accept sections of the NDA as they become available and determines that
the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. We used
the rolling submission option for our NDA for our lead product candidate, taliglucerase alfa, which we completed in April 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None of our products under development has been approved for marketing
in the United States or elsewhere. We may not be able to obtain regulatory approval for any of our products under development in
a timely manner, if at all. Failure to obtain requisite governmental approvals or failure to obtain approvals of the scope requested
will delay or preclude us, or our licensees or marketing partners, from marketing our products, or limit the commercial use of
our products, and thereby would have a material adverse effect on our business, financial condition and results of operations.
See &ldquo;Risk Factors&mdash;We may not obtain the necessary U.S. or worldwide regulatory approvals to commercialize our drug
candidates in a timely manner, if at all, which would have a material adverse effect on our business and results of operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The United States federal government regulates healthcare through
various agencies, including but not limited to the following: (i) the FDA, which administers the Federal Food, Drug, and Cosmetic
Act (FDCA), as well as other relevant laws; (ii) the Center for Medicare &amp; Medicaid Services (CMS), which administers the Medicare
and Medicaid programs; (iii) the Office of Inspector General (OIG) which enforces various laws aimed at curtailing fraudulent or
abusive practices, including by way of example, the Anti-Kickback Law, the Anti-Physician Referral Law, commonly referred to as
Stark, the Anti-Inducement Law, the Civil Money Penalty Law and the laws that authorize the OIG to exclude healthcare providers
and others from participating in federal healthcare programs; and (iv) the Office of Civil Rights, which administers the privacy
aspects of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). All of the aforementioned are agencies within
the Department of Health and Human Services (HHS). Healthcare is also provided or regulated, as the case may be, by the Department
of Defense through its TriCare program, the Department of Veterans Affairs, especially through the Veterans Health Care Act of
1992, the Public Health Service within HHS under Public Health Service Act &sect; 340B (42 U.S.C. &sect; 256b), the Department
of Justice through the Federal False Claims Act and various criminal statutes, and state governments under the Medicaid and other
state sponsored or funded programs and their internal laws regulating all healthcare activities. Many states also have anti-kickback
and anti-physician referral laws that are similar to the federal laws, but may be applicable in situations where federal laws do
not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Medicare is the federal healthcare program for those who are (i)
over 65 years of age, (ii) disabled, (iii) suffering from end-stage renal disease or (iv) suffering from Lou Gehrig&rsquo;s disease.
Medicare consists of part A, which covers inpatient costs, part B, which covers services by physicians and laboratories, durable
medical equipment and certain drugs, primarily those administered by physicians, and part D, which provides drug coverage for most
prescription drugs other than those covered under part B. Medicare also offers a managed care option under part C. Medicare is
administered by CMS. In contrast, Medicaid is a state-federal healthcare program for the poor and is administered by the states
pursuant to an agreement with the Secretary of Health and Human Services. Most state Medicaid programs cover most outpatient prescription
drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2010, the Patient Protection and Affordable Care Act, as
amended by the Health Care and Education Affordability Reconciliation Act, or collectively, PPACA, became law in the United States.
PPACA substantially changes the way healthcare is financed by both governmental and private insurers and significantly affects
the pharmaceutical industry. Key provisions of PPACA specific to the pharmaceutical industry, among others, include the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-family: Symbol">&nbsp;</TD>
    <TD STYLE="width: 3%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 94%">An annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents into the United States, apportioned among these entities according to their market share in certain federal government healthcare programs (excluding sales of any drug or biologic product marketed for an orphan indication), beginning in 2011;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>An increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>A new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D, beginning in 2011;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-family: Symbol">&nbsp;</TD>
    <TD STYLE="width: 3%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 94%">Extension of manufacturers&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, effective March 23, 2010;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>Expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals beginning in April 2010 and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level beginning in 2014, thereby potentially increasing both the volume of sales and manufacturers&rsquo; Medicaid rebate liability;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>Expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program, effective January 2010;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>New requirements to report certain financial arrangements with physicians and others, including reporting any &ldquo;transfer of value&rdquo; made or distributed to prescribers and other healthcare providers and reporting any investment interests held by physicians and their immediate family members during each calendar year beginning in 2012, with reporting starting in 2013;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>A new requirement to annually report drug samples that manufacturers and distributors provide to physicians, effective April 1, 2012;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>A licensure framework for follow-on biologic products; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>A new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">International Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are subject to regulations and product registration requirements
in many foreign countries in which we may sell our products, including in the areas of product standards, packaging requirements,
labeling requirements, import and export restrictions and tariff regulations, duties and tax requirements. The time required to
obtain clearance required by foreign countries may be longer or shorter than that required for FDA clearance, and requirements
for licensing a product in a foreign country may differ significantly from FDA requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pharmaceutical products may not be imported into, or manufactured
or marketed in, the State of Israel absent drug registration. The three basic criteria for the registration of pharmaceuticals
in Israel is quality, safety and efficacy of the pharmaceutical product and the Israeli MOH requires pharmaceutical companies to
conform to international developments and standards. Regulatory requirements are constantly changing in accordance with scientific
advances as well as social and ethical values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The relevant legislation of the European Union requires that medicinal
products, including generic versions of previously approved products, and new strengths, dosage forms and formulations, of previously
approved products, shall have a marketing authorization before they are placed on the market in the European Union. Authorizations
are granted after the assessment of quality, safety and efficacy by the respective health authorities. In order to obtain an authorization,
an application must be made to the competent authority of the member state concerned or in a centralized procedure to the EMA.
Besides various formal requirements, the application must contain the results of pharmaceutical (physico-chemical, biological or
microbiological) tests, of preclinical (toxicological and pharmacological) tests as well as of clinical trials. All of these tests
must have been conducted in accordance with relevant European Union regulations and must allow the reviewer to evaluate the quality,
safety and efficacy of the medicinal product. On January 2010, the Committee for Orphan Medicinal Products (COMP) of the EMA recommended
that the European Commission grant orphan drug designation to taliglucerase alfa. Orphan drug designation in the European Union
is granted to medicinal products intended for the diagnosis, prevention and treatment of life-threatening diseases and very serious
conditions that affect not more than five in 10,000 people in the European Union. Orphan drug designation is generally given to
medicinal products that treat conditions for which no current therapy exists or are expected to bring a significant benefit to
patients over existing therapies. If granted by the European Commission, orphan drug designation will provide us a centralized
procedure for obtaining marketing authorization for taliglucerase alfa, with a single marketing authorization valid throughout
all EU Member States. We may also be eligible for a number of additional incentives including protocol assistance, reduction in
registration fees and eligibility for grants and initiatives supporting research and development related to the orphan drug designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Israeli Government Programs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a summary of the current principal Israeli tax
laws applicable to us and Protalix Ltd., and of the Israeli Government programs from which Protalix Ltd. benefits. Some parts of
this discussion are based on new tax legislation that has not been subject to judicial or administrative interpretation. Therefore,
the views expressed in the discussion may not be accepted by the tax authorities in question. The discussion should not be construed
as legal or professional tax advice and does not cover all possible tax considerations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">General Corporate Tax Structure in Israel</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Protalix Ltd.'s income, other than income from Approved
Enterprises, is taxed in Israel at the regular rate. According to the provisions of the Law for Amending the Israel Income Tax
Ordinance, 2005, corporate tax rates will be gradually lowered, resulting in a corporate tax rate for 2009 and thereafter: 2009
&ndash; 26% and for 2010 and thereafter &ndash; 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On July 14, 2009, the Israel Economic Efficiency Law (Legislation Amendments
for Applying the Economic Plan for 2009 and 2010), 2009, became effective, stipulating, among other things, an additional gradual
decrease in tax rates in 2011 and thereafter, as follows: 2011 &ndash; 24%, 2012 &ndash; 23%, 2013 &ndash; 22%, 2014 &ndash; 21%,
2015 &ndash; 20% and 2016 and thereafter &ndash; 18%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On December 5, 2011, the Tax Burden Distribution Law was
officially published, discontinuing a previously approved gradual decrease in corporate tax provided in the 2009 amendment, and
setting the corporate tax rate in Israel for 2012 and thereafter to 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Capital gains on the sale of assets are subject to capital
gains tax according to the corporate tax rate in effect for the year the assets are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">In addition to the corporate taxes in Israel, we are subject
to a withholding tax on the U.S. revenue source portion of the payments made to us for our share of Pfizer&rsquo;s net profits
under the Pfizer Agreement. The withholding tax rate is 15%. See &ldquo;Business&mdash;Commercialization Agreement.&rdquo;&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Law for the Encouragement of Capital Investments, 1959</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Law for the Encouragement of Capital Investments, 1959, or the
Investment Law, provides certain incentives for capital investments in a production facility (or other eligible assets). Generally,
an investment program that is implemented in accordance with the provisions of the Investment Law, referred to as an &ldquo;Approved
Enterprise,&rdquo; is entitled to benefits. These benefits may include cash grants from the Israeli government and tax benefits,
based upon, among other things, the location of the facility in which the investment is made and specific elections made by the
grantee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Investment Law was significantly amended effective in April
2005. Protalix Ltd. will continue to enjoy the tax benefits under the pre-revision provisions of the Investment Law. If any new
benefits are granted to Protalix Ltd. in the future, Protalix Ltd. will be subject to the provisions of the amended Investment
Law with respect to these new benefits. Therefore, the following discussion is a summary of the Investment Law prior to its amendment
as well as the relevant changes contained in the new legislation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Investment Law prior to its amendment, a company that
wished to receive benefits had to receive approval from the &ldquo;Investment Center&rdquo; of the Israeli Ministry of Industry,
Trade and Labor, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment
program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics
of the facility or the asset, e.g., the equipment to be purchased and utilized pursuant to the program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">An Approved Enterprise may elect to forego any entitlement to the
grants otherwise available under the Investment Law and, instead, participate in an alternative benefits program under which the
undistributed income from the Approved Enterprise is fully exempt from corporate tax for a defined period of time. Under the alternative
package of benefits, a company&rsquo;s undistributed income derived from an Approved Enterprise will be exempt from corporate tax
for a period of between two and 10 years from the first year of taxable income, depending upon the geographic location within Israel
of the Approved Enterprise. Upon expiration of the exemption period, the Approved Enterprise is eligible for the reduced tax rates
otherwise applicable under the Investment Law for any remainder of the otherwise applicable benefits period (up to an aggregate
benefits period of either seven or 10 years, depending on the location of the company or its definition as a foreign investors&rsquo;
company). If a company has more than one Approved Enterprise program or if only a portion of its capital investments are approved,
its effective tax rate is the result of a weighted combination of the applicable rates. The tax benefits from any certificate of
approval relate only to taxable profits attributable to the specific Approved Enterprise. Income from activity that is derived
from different Approved Enterprises does not enjoy these tax benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A company that has an Approved Enterprise program is eligible for
further tax benefits if it qualifies as a foreign investors&rsquo; company. A foreign investors&rsquo; company eligible for benefits
is essentially a company in which more than 25% of the share capital (in terms of shares, rights to profit, voting and appointment
of directors) is owned (measured by both share capital and combined share and loan capital) by non-Israeli residents. A company
that qualifies as a foreign investors&rsquo; company and has an Approved Enterprise program is eligible for tax benefits for a
10-year benefit period and may enjoy a reduced corporate tax rate of 10% to 25%, depending on the amount of the company&rsquo;s
shares held by non-Israeli shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If a company that has an Approved Enterprise program is a wholly
owned subsidiary of another company, then the percentage of foreign investments is determined based on the percentage of foreign
investment in the parent company. The tax rates and related levels of foreign investments are set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Percent of Foreign<BR> Ownership</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Rate of Reduced<BR> Tax</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; width: 48%"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; width: 49%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center">&nbsp;&nbsp;0-49%</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;25%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">49-74%</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">20%</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: center">74-90%</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">15%</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">90-100%</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">10%</TD><TD STYLE="text-align: left"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our original facility in Israel has been granted &ldquo;Approved
Enterprise&rdquo; status, and it has elected to participate in the alternative benefits program. Under the terms of its Approved
Enterprise program, the facility is located in a top priority location, or &ldquo;Zone A,&rdquo; and, therefore, the income from
that Approved Enterprise will be tax exempt in Israel for a period of 10 years, commencing with the year in which taxable income
is first generated from the relevant Approved Enterprise. The current benefits program may not continue to be available and Protalix
Ltd. may not continue to qualify for its benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A company that has elected to participate in the alternative benefits
program and that subsequently pays a dividend out of the income derived from the Approved Enterprise during the tax exemption period
will be subject to corporate tax in respect of the amount distributed at the rate that would have been applicable had the company
not elected the alternative benefits program (generally 10% to 25%, depending on the extent to which non-Israeli shareholders hold
such company&rsquo;s shares). If the dividend is distributed within 12 years after the commencement of the benefits period (or,
in the case of a foreign investor&rsquo;s company, without time limitation), the dividend recipient is taxed at the reduced withholding
tax rate of 15% applicable to dividends from approved enterprises, or at the lower rate under an applicable tax treaty. After this
period, the withholding tax rate is 25%, or at the lower rate under an applicable tax treaty. In the case of a company with a foreign
investment level (as defined by the Investment Law) of 25% or more, the 12-year limitation on reduced withholding tax on dividends
does not apply. The company must withhold this tax at its source, regardless of whether the dividend is converted into foreign
currency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Investment Law also provides that an Approved Enterprise is
entitled to accelerated depreciation on its property and equipment that are included in an approved investment program. This benefit
is an incentive granted by the Israeli government regardless of whether the alternative benefits program is elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The benefits available to an Approved Enterprise are conditioned
upon terms stipulated in the Investment Law and regulations and the criteria set forth in the applicable certificate of approval.
If Protalix Ltd. does not fulfill these conditions in whole or in part, the benefits can be canceled and Protalix Ltd. may be required
to refund the received benefits, linked to the Israeli consumer price index with the addition of interest or alternatively with
an additional penalty payment. We believe that Protalix Ltd. currently operates in compliance with all applicable conditions and
criteria, but there can be no assurance that Protalix Ltd. will continue to do so. Furthermore, there can be no assurance that
any Approved Enterprise status granted to Protalix Ltd.&rsquo;s facilities will entitle Protalix Ltd. to the same benefits to which
it is currently entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the March 2005 amendment to the Investment Law, the
approval of the Investment Center is required only for Approved Enterprises that receive cash grants. Approved Enterprises that
do not receive benefits in the form of governmental cash grants, but only tax benefits, are no longer required to obtain this approval.
Instead, these Approved Enterprises are required to make certain investments as specified in the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The amended Investment Law specifies certain conditions for an Approved
Enterprise to be entitled to benefits. These conditions include:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-family: Symbol">&nbsp;</TD>
    <TD STYLE="width: 3%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 94%">the Approved Enterprise&rsquo;s revenues from any single country or a separate customs territory may not exceed 75% of the Approved Enterprise&rsquo;s total revenues; or</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>at least 25% of the Approved Enterprise&rsquo;s revenues during the benefits period must be derived from sales into a single country or a separate customs territory with a population of at least 12 million.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">There can be no assurance that Protalix Ltd. will comply with the
above conditions in the future or that Protalix Ltd. will be entitled to any additional benefits under the Investment Law. In addition,
it is possible that Protalix Ltd. may not be able to operate in a manner that maximizes utilization of the potential benefits available
under the Investment Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">From time to time, the Israeli Government has considered reducing
the benefits available to companies under the Investment Law. The termination or substantial reduction of any of the benefits available
under the Investment Law could materially impact the cost of our future investments.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Encouragement of Industrial Research and Development Law, 1984</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To date, Protalix Ltd. has received grants from the Office of the
Chief Scientist of the Israeli Ministry of Industry, Trade and Labor, the OCS, for the financing of a portion of its research and
development expenditures in Israel. As of December 31, 2011, the OCS approved grants in respect of Protalix Ltd.&rsquo;s continuing
operations totaling approximately $23.9 million, measured from inception. Protalix Ltd. is required to repay up to 100% of grants
actually received (plus interest at the LIBOR rate applied to the grants received on or after January 1, 1999) to the OCS through
payments of royalties at a rate of 3% to 6% of the revenues generated from an OCS-funded project, depending on the period in which
revenues were generated. As of December 31, 2011, Protalix Ltd. either paid or accrued royalties payable of $2.8 million and Protalix
Ltd.&rsquo;s contingent liability to the OCS with respect to grants received was approximately $19.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Israeli Law for the Encouragement of Industrial Research
and Development, 1984, and related regulations, or the Research Law, recipients of grants from the OCS are prohibited from manufacturing
products developed using these grants outside of the State of Israel without special approvals, although the Research Law does
enable companies to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased
royalties. If Protalix Ltd. receives approval to manufacture the products developed with government grants outside of Israel, it
will be required to pay an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending
on the manufacturing volume that is performed outside of Israel, as well as at a possibly increased royalty rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, under the Research Law, Protalix Ltd. is prohibited
from transferring the OCS-financed technologies and related intellectual property rights outside of the State of Israel, except
under limited circumstances and only with the approval of the OCS' Research Committee. Protalix Ltd. may not receive the required
approvals for any proposed transfer and, if received, Protalix Ltd. may be required to pay the OCS a portion of the consideration
that it receives upon any sale of such technology by a non-Israeli entity. The scope of the support received, the royalties that
Protalix Ltd. has already paid to the OCS, the amount of time that has elapsed between the date on which the know-how was transferred
and the date on which the OCS grants were received and the sale price and the form of transaction will be taken into account in
order to calculate the amount of the payment to the OCS. Approval of the transfer of technology to residents of the State of Israel
is required, and may be granted in specific circumstances only if the recipient abides by the provisions of applicable laws, including
the restrictions on the transfer of know-how and the obligation to pay royalties. No assurance can be made that approval to any
such transfer, if requested, will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In March 2005, Research Law was amended. One of the main modifications
included in the amendment was an authorization of the Research Committee to allow the transfer outside of Israel of know-how derived
from an approved program and the related manufacturing rights. In general, the Research Committee may approve transfer of know-how
in limited circumstances as follows:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-family: Symbol">&nbsp;</TD>
    <TD STYLE="width: 3%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 94%">in the event of a sale of know-how itself to a non affiliated third party, provided that upon such sale the owner of the know-how pays to the OCS an amount, in cash, as set forth in the Research Law.&nbsp; In addition, the amendment provides that if the purchaser of the know-how gives the selling Israeli company the right to exploit the know-how by way of an exclusive, irrevocable and unlimited license, the research committee may approve such transfer in special cases without requiring a cash payment.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>in the event of a sale of a company which is the owner of know-how, pursuant to which the company ceases to be an Israeli company, provided that upon such sale, the owner of the know-how makes a cash payment to the OCS as set forth in the Research Law.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>in the event of an exchange of know-how such that in exchange for the transfer of know-how outside of Israel, the recipient of the know-how transfers other know-how to the company in Israel in a manner in which the OCS is convinced that the Israeli economy realizes a greater, overall benefit from the exchange of know-how.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Another provision in the amendment concerns the transfer of manufacturing
rights. The research committee may, in special cases, approve the transfer of manufacture or of manufacturing rights of a product
developed within the framework of the approved program or which results therefrom, outside of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The State of Israel does not own intellectual property rights in
technology developed with OCS funding and there is no restriction on the export of products manufactured using technology developed
with OCS funding. The technology is, however, subject to transfer of technology and manufacturing rights restrictions as described
above. For a description of such restrictions, please see &ldquo;Risk Factors&mdash;Risks Relating to Our Operations in Israel.&rdquo;
OCS approval is not required for the export of any products resulting from the research or development or for the licensing of
any technology in the ordinary course of business.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Special Provisions Relating to Taxation under Inflationary
Conditions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Protalix Ltd. is subject to Israel's Income Tax Law (Inflationary
Adjustments), 1985, or the Inflationary Adjustments Law. The Inflationary Adjustments Law is highly complex, and represents an
attempt to overcome the problems presented to a traditional tax system by an economy undergoing rapid inflation. The provisions
that are material to us are summarized below:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-family: Symbol">&nbsp;</TD>
    <TD STYLE="width: 3%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 94%">Where a company&rsquo;s equity, as calculated under the Inflationary Adjustments Law, exceeds the depreciated cost of its fixed assets (as defined in the Inflationary Adjustments Law), a deduction from taxable income is permitted equal to this excess multiplied by the applicable annual rate of inflation.&nbsp; The maximum deduction permitted under this provision in any single tax year is 70% of taxable income.&nbsp; The unused portion linked to the Israeli consumer price index, may be carried forward.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>Where a company&rsquo;s depreciated cost of fixed assets exceeds its equity, the excess multiplied by the applicable annual rate of inflation is added to taxable income.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>Subject to specified limitations, depreciation deductions carryforwards on fixed assets and losses are adjusted for inflation based on the change in the consumer price index.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Inflationary Adjustments Law, results for tax purposes
are measured in real terms, in accordance with changes in the Israeli consumer price index. The difference between the change in
the Israeli consumer price index and the exchange rate of Israeli currency in relation to the U.S. dollar may in future periods
cause significant differences between taxable income and the income measured in dollars as reflected in our consolidated financial
statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Law for the Encouragement of Industry (Taxes), 1969</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe that Protalix Ltd. currently qualifies as an &ldquo;Industrial
Company&rdquo; within the meaning of the Law for the Encouragement of Industry (Taxes), 1969, or the Industry Encouragement Law.
The Industry Encouragement Law defines &ldquo;Industrial Company&rdquo; as a company resident in Israel that derives 90% or more
of its income in any tax year (other than specified kinds of passive income such as capital gains, interest and dividends) from
an &ldquo;Industrial Enterprise&rdquo; that it owns. An &ldquo;Industrial Enterprise&rdquo; is defined as an enterprise whose major
activity in a given tax year is industrial production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following corporate tax benefits, among others, are available
to Industrial Companies:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-family: Symbol">&nbsp;</TD>
    <TD STYLE="width: 3%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 94%">amortization of the cost of purchased know-how and patents over an eight-year period for tax purposes;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>accelerated depreciation rates on equipment and buildings;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>under specified conditions, an election to file consolidated tax returns with other related Israeli Industrial Companies; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&nbsp;</TD>
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>expenses related to a public offering are deductible in equal amounts over three years.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Eligibility for the benefits under the Industry Encouragement Law
is not subject to receipt of prior approval from any governmental authority. It is possible that Protalix Ltd. may fail to qualify
or may not continue to qualify as an &ldquo;Industrial Company&rdquo; or that the benefits described above will not be available
in the future.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Tax Benefits for Research and Development</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under specified conditions, Israeli tax laws allow a tax deduction
by a company for research and development expenditures, including capital expenditures, for the year in which such expenditures
are incurred. These expenditures must relate to scientific research and development projects and must be approved by the OCS. Furthermore,
the research and development projects must be for the promotion of the company and carried out by or on behalf of the company seeking
such tax deduction. However, the amount of such deductible expenditures is reduced by the sum of any funds received through government
grants for the finance of such scientific research and development projects. Expenditures not so approved are deductible over a
three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2011, we had 235 employees, of whom 34 have an
M.D. or a Ph.D. in their respective scientific fields. We believe that our relations with these employees are good. We intend to
continue to hire additional employees in research and development, manufacturing and administration in order to meet our operating
plans. We believe that our success will greatly depend on our ability to identify, attract and retain capable employees. The Israeli
Ministry of Labor and Welfare is authorized to make certain industry-wide collective bargaining agreements that apply to types
of industries or employees including ours (&ldquo;Expansion Orders&rdquo;). These agreements affect matters such as cost of living
adjustments to salaries, length of working hours and week, recuperation, travel expenses, and pension rights. Otherwise, our employees
are not represented by a labor union or represented under a collective bargaining agreement. See &ldquo;Risk Factors&mdash;We depend
upon key employees and consultants in a competitive market for skilled personnel. If we are unable to attract and retain key personnel,
it could adversely affect our ability to develop and market our products.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Company Background</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our principal business address is set forth below. Our executive
offices and our main research manufacturing facility are located at that address. Our telephone number is +972-4-988-9488. From
May 2001 through December 31, 2006, our company had no operations. We were originally formed as Embassy Acquisition Corp., a Florida
corporation, in November 2005 and changed our name to Orthodontix, Inc., in April, 1992. On December 31, 2006, we acquired, through
a merger with our wholly-owned subsidiary, Protalix Acquisition Co. Ltd., all of the outstanding shares of Protalix Ltd., in exchange
for shares of our common stock. As a result, Protalix Ltd. is now our wholly-owned subsidiary. In connection with the merger, we
completed a one-for-ten reverse stock split and on February 26, 2007, we changed our name to Protalix BioTherapeutics, Inc. Unless
otherwise indicated, all share numbers in this Annual Report on Form 10-K give effect to such reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our wholly-owned subsidiary and sole operating unit, Protalix Ltd.,
is an Israeli corporation and was originally incorporated in Israel as Metabogal Ltd. on December 27, 1993. During 1999, Protalix
Ltd. changed its focus from plant secondary metabolites to the expression of recombinant therapeutic proteins in plant cells, and
in April 2004 changed its name to Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ProCellEx<SUP>&reg;</SUP> is our registered trademark. Each of the
other trademarks, trade names or service marks appearing in this Annual Report on Form 10-K belongs to its respective holder.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Available Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our corporate website is www.protalix.com. We make available on
our website, free of charge, our Commission, filings, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and any amendments to these reports, as soon as reasonably practicable after we electronically file
these documents with, or furnish them to, the Commission. Additionally, from time to time, we provide notifications of material
news including press releases and conferences on our website. Webcasts of presentations made by our company at certain conferences
may also be available from time to time on our website, to the extent the webcasts are available. The content of our website is
not intended to be incorporated by reference into this report or in any other report or document we file and any references to
these websites are intended to be inactive textual references only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are also listed on the Tel Aviv Stock Exchange, or
the TASE, and, accordingly, we submit copies of all our filings with the Commission to the Israeli Securities Authority and
the TASE. Such copies can be retrieved electronically through the  TASE&rsquo;s
internet messaging system (www.maya.tase.co.il) and through the MAGNA distribution site of the Israeli Securities Authority
(www.magna.isa.gov.il).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our website also includes printable versions of our Code of Business
Conduct and Ethics and the charters for each of the Audit, Compensation and Nominating Committees of our Board of Directors. Each
of these documents is also available in print, free of charge, to any shareholder who requests a copy by addressing a request to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">2 Snunit Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Science Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">POB 455</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Carmiel 20100, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Attn: Mr. Yossi Maimon, Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt">Item&nbsp;1A.&nbsp;&nbsp;&nbsp;&nbsp;
Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>You should carefully consider the risks described below together
with the other information included in this Annual Report on Form 10-K. Our business, financial condition or results of operations
could be adversely affected by any of these risks. If any of these risks occur, the value of our common stock could decline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Our Financial Condition and Capital Requirements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We currently have no significant product revenues and will need
to raise additional capital to operate our business, which may not be available on favorable terms, or at all, and which will have
a dilutive effect on our shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">To date, we have generated no significant
revenues from product sales and only minimal revenues from research and development services and other fees, other than the milestone
payments we received in connection with our license and supply agreement with Pfizer. For the years ended December 31, 2011, 2010
and 2009, we had net losses of $</FONT>36.5<FONT STYLE="color: black"> million, $</FONT>29.0<FONT STYLE="color: black"> million
and $31.4 million, respectively, primarily as a result of expenses incurred through a combination of research and development activities
and expenses supporting those activities, which includes share-based compensation expense. Drug development and commercialization
is very capital intensive. Until we receive approval from the FDA and other regulatory authorities for our drug candidates, we
cannot generate significant sales from our drugs and will not have product revenues, except for certain regulatory-related milestone
payments under the Pfizer Agreement which we expect to earn prior to any sales of taliglucerase alfa. Therefore, until we generate
significant sales, we will have to fund all of our operations and capital expenditures from our cash on hand, potential regulatory-related
milestone payments under the Pfizer Agreement, other licensing fees and grants and the net proceeds of any equity or debt offerings.
Over the next 12 months, we expect to spend a minimum of approximately $</FONT>30.0<FONT STYLE="color: black"> million building
an internal sales and marketing force for the sale of taliglucerase alfa in Israel and on preclinical and clinical development
for our products candidates. Based on our current plans and capital resources, we believe that our cash and cash equivalents together
with the net proceeds from our public underwritten offering of February 2012 will be sufficient to enable us to meet our planned
operating needs for at least 12 months. However, changes may occur that could consume our existing capital at a faster rate than
projected, including, among others, the cost and timing of regulatory approvals, changes in the progress of our research and development
efforts and the costs of protecting our intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We may seek additional financing to implement and fund product development,
preclinical studies and clinical trials for the drugs in our pipeline, as well as additional drug candidates and other research
and development projects. If we are unable to secure additional financing in the future on acceptable terms, or at all, we may
be unable to commence or complete planned preclinical and clinical trials or obtain approval of our drug candidates from the FDA
and other regulatory authorities. In addition, we may be forced to reduce or discontinue product development or product licensing,
reduce or forego sales and marketing efforts and other commercialization activities or forego attractive business opportunities
in order to improve our liquidity and to enable us to continue operations which would have a material adverse effect on our business
and results of operations. Any additional source of financing will likely involve the issuance of our equity securities, which
will have a dilutive effect on our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are not currently profitable and may never become profitable
which would have a material adverse effect on our business and results of operations and could negatively impact the value of our
common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect to incur substantial losses for the foreseeable future
and may never become profitable. We also expect to continue to incur significant operating and capital expenditures, and we anticipate
that our expenses will increase substantially in the foreseeable future as we:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">seek regulatory approvals for our drug candidates;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>continue to undertake preclinical development and clinical trials for our current and new drug candidates;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>hire additional personnel;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>implement additional internal systems and infrastructure; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>seek to license-in additional technologies to develop.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also expect to continue to experience negative cash flow for
the foreseeable future as we fund our operating losses and capital expenditures. As a result, we will need to generate significant
revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability
in the future. Any failure to achieve or maintain profitability may have a material adverse effect on our business and results
of operations and may negatively impact the value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have a limited operating history which may limit the ability
of investors to make an informed investment decision. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a clinical stage biopharmaceutical company. To date, we have
not commercialized any of our drug candidates or received any FDA or other approval to market any drug. The successful commercialization
of our drug candidates will require us to perform a variety of functions, including:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">continuing to undertake preclinical development and clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>participating in regulatory approval processes;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>formulating and manufacturing products; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>conducting sales and marketing activities.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Our operations have been limited to organizing
and staffing our company, acquiring, developing and securing our proprietary technology and undertaking, through third parties,
preclinical trials and clinical trials of our principal drug candidates. To date, we have commenced a phase III clinical trial
in connection with only one drug candidate, taliglucerase alfa, which trial was completed in August 2009, and we have not commenced
any additional clinical trial for any of our other drug candidates, except for our </FONT>acetylcholinesterase product candidate<FONT STYLE="color: black">.
These operations provide a limited basis for investors to assess our ability to commercialize our drug candidates and whether to
invest in our company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our ProCellEx protein expression system is based on our proprietary
plant cell-based expression technology which has a limited history and any material problems with the system, which may be unforeseen,
may have a material adverse effect on our business and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our ProCellEx protein expression system is based on our proprietary
plant cell-based expression technology. Our business is dependent upon the successful development and approval of our product candidates
produced through our protein expression system. <FONT STYLE="color: black">Our</FONT> <FONT STYLE="color: black">ProCellEx protein
expression system is novel and is still in the early stages of development and optimization, and, accordingly, is subject to certain
risks. Mammalian cell-based protein expression systems have been used in connection with recombinant therapeutic protein expression
for more than 20 years and are the subject of a wealth of data; in contrast, there is not a significant amount of data generated
regarding plant cell-based protein expression and, accordingly, plant cell-based protein expression systems may be subject to unknown
risks. In addition, the protein glycosilation pattern created by our protein expression system is not identical to the natural
human glycosilation pattern and its long term effect on human patients is still unknown. Lastly, as our protein expression system
is a new technology, we cannot always rely on existing equipment; rather, there is a need to design custom-made equipment and to
generate specific growth media for the plant cells, which may not be available at favorable prices, if at all. </FONT>Any material
problems with the technology underlying our plant cell-based protein expression system may have a material adverse effect on our
business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We currently depend heavily on the success of taliglucerase alfa,
our lead product candidate. Any failure to commercialize taliglucerase alfa, or the experience of significant delays in doing so,
will have a material adverse effect on our business, results of operations and financial condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have invested a significant portion of our efforts and financial
resources in the development of taliglucerase alfa. Our ability to generate product revenue, depends heavily on the successful
development and commercialization of taliglucerase alfa. In November 2009, we granted to Pfizer an exclusive worldwide license
to develop and commercialize taliglucerase alfa except in Israel. We retained such rights in Israel. The successful commercialization
of taliglucerase alfa will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">obtaining marketing approvals from the FDA and other foreign regulatory authorities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>successful completion of our ongoing studies of taliglucerase alfa;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the successful audit of our facilities by additional regulatory authorities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>maintaining the cGMP compliance of our manufacturing facility or establishing manufacturing arrangements with third parties;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>Pfizer&rsquo;s efforts under the Pfizer Agreement;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>our development of a successful sales and marketing organization for taliglucerase in Israel;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>a continued acceptable safety and efficacy profile of our product candidates following approval;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the availability of reimbursement to patients from healthcare payors for our drug products, if approved; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>other risks described in these Risk Factors.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Any failure to commercialize taliglucerase alfa or the experience
of significant delays in doing so will have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our strategy, in certain cases, is to enter into collaboration
agreements with third parties to leverage our ProCellEx system to develop product candidates. If we fail to enter into these agreements
or if we or the third parties do not perform under such agreements or terminate or elect to discontinue the collaboration, it could
have a material adverse affect on our revenues. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Our strategy, in certain cases, is to
enter into arrangements with pharmaceutical companies to leverage our ProCellEx system to develop additional product candidates</FONT>.
<FONT STYLE="color: black">Under these arrangements, we may grant to our partners rights to license and commercialize pharmaceutical
products developed under the applicable agreements. Our partners may control key decisions relating to the development of the products
and we may depend on our partners&rsquo; expertise and dedication of sufficient resources to develop and commercialize our product
candidates. The rights of our partners limit our flexibility in considering alternatives for the commercialization of our product
candidates. </FONT>To date, we have entered into a license and supply agreement with Pfizer relating to the development and commercialization
of taliglucerase alfa and an agreement with Teva, which relates to the development by us of two proteins, and the licensing by
Teva of such proteins in consideration for royalties and milestone payments. <FONT STYLE="color: black"> </FONT>Subsequently, two
proteins were identified to be researched and developed under the agreement but in 2009, both of the projects were terminated for
commercial reasons. We may not identify any additional proteins to be developed through a collaboration between us and Teva under
the agreement, which may have a material adverse effect on our business, results of operations and financial condition. <FONT STYLE="color: black">If
we or any of our partners breach or terminate the agreements that make up such arrangements, our partners otherwise fail to conduct
their obligations under such arrangements in a timely manner, there is a dispute about their obligations or if either party terminates
the applicable agreement or elects not to continue the arrangement, we may not enjoy the benefits of the agreements or receive
a sufficient amount of royalty or milestone payments from them, if any, which may have a material adverse effect on our business,
results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>All of our product candidates other than taliglucerase alfa and
our acetylcholinesterase product are in preclinical or research stages. If we are unable to develop and commercialize our product
candidates, our business will be adversely affected. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A key element of our strategy is to develop and commercialize a
portfolio of new products in addition to taliglucerase alfa. We are seeking to do so through our internal research programs and
strategic collaborations for the development of new products. Research programs to identify new product candidates require substantial
technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs
may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development
for many reasons, including the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">a product candidate is not capable of being produced in commercial quantities at an acceptable cost, or at all;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>a product candidate may not be accepted by patients, the medical community or third-party payors;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>competitors may develop alternatives that render our product candidates obsolete;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the research methodology used may not be successful in identifying potential product candidates; or</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory approval.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Any failure to develop or commercialize any of our other product
candidates may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>Clinical
trials are very expensive, time-consuming and difficult to design and implement and may result in unforeseen costs which may have
a material adverse effect on our business and results of operations.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">Human
clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory
requirements. The clinical trial process is also time-consuming. Other than taliglucerase alfa and our acetylcholinesterase product,
our drug candidates are in the preclinical studies or research stages. Other, ongoing clinical trials of taliglucerase alfa and
our acetylcholinesterase product, and anticipated clinical trials of our other potential drug candidates which have not yet been
initiated, will take at least several years to complete. Preliminary and initial results from a clinical trial do not necessarily
predict final results, and failure can occur at any stage of the trials. We may encounter problems that cause us to abandon or
repeat preclinical studies or clinical trials. Companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in advanced clinical trials, even after obtaining promising results in earlier trials. Data obtained from tests are susceptible
to varying interpretations which may delay, limit or prevent regulatory approval. Failure or delay in the commencement or completion
of our clinical trials may be caused by several factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">unforeseen safety issues;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>determination of dosing issues;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>lack of effectiveness during clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>slower than expected rates of patient recruitment;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>inability to monitor patients adequately during or after treatment;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>lack of sufficient funding to finance the clinical trials.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Any failure or delay in commencement or completion of any clinical
trials may have a material adverse effect on our business, results of operations and financial condition. In addition, we or the
FDA or other regulatory authorities may suspend any clinical trial at any time if it appears that we are exposing participants
in the trial to unacceptable safety or health risks or if the FDA or such other regulatory authorities, as applicable, find deficiencies
in our IND submissions or the conduct of the trial. Any suspension of a clinical trial may have a material adverse effect on our
business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>If
the results of our clinical trials do not support our claims relating to any drug candidate or if serious side effects are identified,
the completion of development of such drug candidate may be significantly delayed or we may be forced to abandon development altogether,
which will significantly impair our ability to generate product revenues.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">The results of our clinical
trials with respect to any drug candidate might not support our claims of safety or efficacy, the effects of our drug candidates
may not be the desired effects or may include undesirable side effects or the drug candidates may have other unexpected characteristics.&nbsp;&nbsp;Further,
success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the
results of later clinical trials may not replicate the results of prior clinical trials and preclinical testing.&nbsp;&nbsp;The
clinical trial process may fail to demonstrate that our drug candidates are safe for humans and effective for indicated uses.&nbsp;&nbsp;In
addition, our clinical trials may involve a specific and small patient population.&nbsp;&nbsp;Results of early clinical trials
conducted on a small patient population may not be indicative of future results.&nbsp;&nbsp;Adverse or inconclusive results may
cause us to abandon a drug candidate and may delay development of other drug candidates.&nbsp;&nbsp;Any delay in, or termination
of, our clinical trials will delay the filing of NDAs with the FDA, or other filings with other foreign regulatory authorities,
and, ultimately, significantly impair our ability to commercialize our drug candidates and generate product revenues which would
have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>We
may find it difficult to enroll patients in our clinical trials, which could cause significant delays in the completion of such
trials or may cause us to abandon one or more clinical trials.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">Many
of the diseases or disorders that our drug candidates are intended to treat are relatively rare and we expect only a subset of
the patients with these diseases to be eligible for our clinical trials.&nbsp;&nbsp;Given that each of our drug candidates, other
than taliglucerase alfa and our acetylcholinesterase product, is in the preclinical or research stages, we may not be able to initiate
clinical trials for any of our drug candidates if we are unable to locate a sufficient number of eligible subjects to participate
in the clinical trials required by the FDA and/or other foreign regulatory authorities.&nbsp;&nbsp;The requirements of our clinical
trials generally mandate that a patient cannot be involved in another clinical trial for the same indication.&nbsp;&nbsp;We are
aware of certain companies that have ongoing clinical trials for products that are competitive with our drug candidates, and subjects
who would otherwise be eligible for our clinical trials may be involved in such trials, rendering them unavailable for testing
of our drug candidates.&nbsp;&nbsp;Our inability to enroll a sufficient number of patients for any of our current or future clinical
trials would result in significant delays or may require us to abandon one or more clinical trials altogether, which will have
a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>Patients
may discontinue their participation in our clinical trials, which may negatively impact the results of these studies and extend
the timeline for completion of our development programs.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Patients enrolled in our clinical
studies may discontinue their participation at any time during the study as a result of a number of factors, including withdrawing
their consent or experiencing adverse clinical events, which may or may not be judged related to our drug candidates under evaluation.&nbsp;&nbsp;If
a large number of patients in any one of our studies discontinue their participation in the study, the results from that study
may not be positive or may not support a filing for regulatory approval of the applicable drug candidate, which would have a material
adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Because our clinical trials depend upon third-party researchers,
the results of our clinical trials and such research activities are subject to delays and other risks which are, to a certain extent,
beyond our control, which could impair our clinical development programs and our competitive position. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We depend upon independent investigators and collaborators, such
as universities and medical institutions, to conduct our preclinical and clinical trials. These collaborators are not our employees,
and we cannot control the amount or timing of resources that they devote to our clinical development programs. The investigators
may not assign as great a priority to our clinical development programs or pursue them as diligently as we would if we were undertaking
such programs directly. If outside collaborators fail to devote sufficient time and resources to our clinical development programs,
or if their performance is substandard, the approval of our NDA, MAAs and other applications, and our introduction of new drugs,
if any, may be delayed which could impair our clinical development programs and would have a material adverse effect on our business
and results of operations. The collaborators may also have relationships with other commercial entities, some of whom may compete
with us. If our collaborators also assist our competitors, our competitive position could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The manufacture of our products is an exacting and complex process,
and if we or one of our materials suppliers encounter problems manufacturing our products, it will have a material adverse effect
on our business and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">The FDA and foreign regulators require
manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance
with cGMP or similar requirements that the FDA or foreign regulators establish. We or our materials suppliers may face manufacturing
or quality control problems causing product production and shipment delays or a situation where we or the supplier may not be able
to maintain compliance with the FDA&rsquo;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing
our drug candidates. Any failure to comply with cGMP requirements or other FDA or foreign regulatory requirements could adversely
affect our clinical research activities an</FONT>d our ability to market and develop our products. To date, our current facility
has passed audits by the FDA, the Israeli MOH, ANVISA and the IMB on behalf of the EMA but remains subject to audit by other foreign
regulatory authorities. There can be no assurance that we will be able to comply with FDA or foreign regulatory manufacturing requirements
for our current facility or any facility we may establish in the future, which would have a material adverse effect on our business,
<FONT STYLE="color: black; background-color: white">results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We rely on third parties for final processing of taliglucerase
alfa, which exposes us to a number of risks that may delay development, regulatory approval and commercialization of our product
candidates or result in higher product costs.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have no experience in the final filling and freeze drying steps
of the drug manufacturing process. According to our license and supply agreement with Pfizer, we currently are responsible for
the fill and finish activities for taliglucerase alfa, but such functions will be transferred to Pfizer in the future. In addition,
we have engaged a European contract manufacturer to act as an additional source of fill and finish activities for taliglucerase
alfa. We currently rely primarily on other third-party contractors to perform the final manufacturing steps for taliglucerase alfa
on a commercial scale. We may be unable to identify manufacturers and/or replacement manufacturers on acceptable terms or at all
because the number of potential manufacturers is limited and the FDA and other regulatory authorities, as applicable, must approve
any manufacturer and/or replacement manufacturer, including us, and we or any such third party manufacturer might be unable to
formulate and manufacture our drug products in the volume and of the quality required to meet our clinical and commercial needs.
If we engage any contract manufacturers, such manufacturers may not perform as agreed or may not remain in the contract manufacturing
business for the time required to supply our clinical or commercial needs. In addition, contract manufacturers are subject to the
rules and regulations of the FDA and comparable foreign regulatory authorities and face the risk that any of those authorities
may find that they are not in compliance with applicable regulations. Each of these risks could delay our clinical trials, the
approval, if any, of taliglucerase alfa and our other potential drug candidates by the FDA and other regulatory authorities, or
the commercialization of taliglucerase alfa and our other drug candidates or could result in higher product costs or otherwise
deprive us of potential product revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If physicians, patients, third party payors and others in the
medical community do not accept and use our drugs, our ability to generate revenue from sales of our products under development
will be materially impaired. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if the FDA or other foreign regulatory authorities approve
any of our drug candidates for commercialization, physicians and patients, and other healthcare providers, may not accept and use
such candidates. Future acceptance and use of our products will depend upon a number of factors including:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">perceptions by physicians, patients, third party payors and others in the medical community about the safety and effectiveness of our drug candidates;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the prevalence and severity of any side effects, including any limitations or warnings contained in our products&rsquo; approved labeling;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>pharmacological benefits of our products relative to competing products and products under development;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the efficacy and potential advantages relative to competing products and products under development;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>relative convenience and ease of administration;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>effectiveness of education, marketing and distribution efforts by us and our licensees and distributors, if any;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>publicity concerning our products or competing products and treatments;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>coverage and reimbursement of our products by third party payors; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the price for our products and competing products.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Because we expect sales of our current
drug candidates, if approved, to generate substantially all of our product revenues for the </FONT>foreseeable<FONT STYLE="color: black">
future, any lack of market acceptance of our drug candidates would have a material adverse effect on our business and financial
condition, and revenues from sales of our products would be materially impaired. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We have no experience selling, marketing or distributing products
and no internal capability to do so. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We currently have very limited sales, marketing or distribution
capabilities and no experience in building a sales force and distribution capabilities. To be able to commercialize taliglucerase
alfa upon approval, if at all, in Israel, and to commercialize any of our other product candidates, we must either develop internal
sales, marketing and distribution capabilities, which will be expensive and time consuming, or make arrangements with third parties
to perform these services. In November 2009, we granted to Pfizer an exclusive, worldwide right to develop and commercialize taliglucerase
alfa, but retained such rights in Israel. If we decide to market any of our products directly, we must commit significant financial
and managerial resources to develop a marketing and sales force with technical expertise and with supporting distribution capabilities.
Factors that may inhibit our efforts to commercialize our products directly and without strategic partners include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the inability of sales personnel to obtain access to an adequate numbers of physicians or to pursuance them to prescribe our products;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;&nbsp;and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>unforeseen costs and expenses associated with creating and sustaining an independent sales and marketing organization.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We may not be successful in recruiting the sales and marketing personnel
necessary to sell any of our products upon approval, if at all, and even if we do build a sales force, it may not be successful
in marketing our products, which would have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may enter into distribution arrangements and marketing alliances
for certain products and any failure to successfully identify and implement these arrangements on favorable terms, if at all, may
impair our ability to commercialize our product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">While we intend to build a sales force to market taliglucerase alfa
in Israel and other product candidates worldwide, we do not anticipate having the resources in the foreseeable future to develop
global sales and marketing capabilities for all of the products we develop, if any. We may pursue arrangements regarding the sales
and marketing and distribution of one or more of our product candidates, such as our license and supply agreement with Pfizer,
and our future revenues may depend, in part, on our ability to enter into and maintain arrangements with other companies having
sales, marketing and distribution capabilities and the ability of such companies to successfully market and sell any such products.
<FONT STYLE="color: black">Any failure to enter into such arrangements and marketing alliances on favorable terms, if at all, could
delay or impair our ability to commercialize our product candidates and could increase our costs of commercialization. Any use
of distribution arrangements and marketing alliances to commercialize our product candidates will subject us to a number of risks,
including the following: </FONT></P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 96%; text-indent: 0in">we may be required to relinquish important rights to our products or product candidates;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD STYLE="text-indent: 0in">we may not be able to control the amount and timing of resources that our distributors or collaborators may devote to the commercialization of our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 96%; text-indent: 0in">our distributors or collaborators may experience financial difficulties;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD STYLE="text-indent: 0in">our distributors or collaborators may not devote sufficient time to the marketing and sales of our products; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD STYLE="text-indent: 0in">business combinations or significant changes in a collaborator&rsquo;s business strategy may adversely affect a collaborator&rsquo;s willingness or ability to complete its obligations under any arrangement.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We may need to enter into additional co-promotion arrangements with
third parties where our own sales force is neither well situated nor large enough to achieve maximum penetration in the market.
We may not be successful in entering into any co-promotion arrangements, and the terms of any co-promotion arrangements we enter
into may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If the market opportunities for our current product candidates
are smaller than we believe they are, our revenues may be adversely affected and our business may suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A substantial focus of our current clinical pipeline is on relatively
rare disorders with small patient populations, in particular Gaucher disease and Fabry disease. Currently, most reported estimates
of the prevalence of these diseases are based on studies of small subsets of the population of specific geographic areas, which
are then extrapolated to estimate the prevalence of the diseases in the broader world population. As new studies are performed,
the estimated prevalence of these diseases may change. There can be no assurance that the prevalence of Gaucher disease or Fabry
disease in the study populations, particularly in these newer studies, accurately reflect the prevalence of these diseases in the
broader world population. If the market opportunities for our current product candidates are smaller than we believe they are,
our revenues may be adversely affected and our business may suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Developments by competitors may render our products or technologies
obsolete or non-competitive which would have a material adverse effect on our business, results of operations and financial condition.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We compete against fully integrated pharmaceutical
companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government
agencies and other public and p</FONT>rivate research organizations. Our drug candidates will have to compete with existing therapies
and therapies under development by our competitors. In addition, our commercial opportunities may be reduced or eliminated if our
competitors develop and market products that are less expensive, more effective or safer than our drug products. Other companies
have drug candidates in various stages of preclinical or clinical development to treat diseases for which we are also seeking to
develop drug products. Some of these potential competing drugs are further advanced in development than our drug candidates and
may be commercialized earlier. Even if we are successful in developing effective drugs, our products may not compete successfully
with products produced by our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We specifically face competition from companies with approved treatments
of Gaucher disease, including Genzyme, Shire and to a much lesser extent, Actelion. In February 2010, the FDA approved VPRIV, Shire&rsquo;s
enzyme replacement therapy for the treatment of Gaucher disease, and the European Commission granted marketing authorization to
VPRIV in August 2010. In addition, we are aware of other early stage, experimental, small molecule, oral drugs which are being
developed for the treatment of Gaucher disease by each of Genzyme and Amicus Therapeutics. According to Amicus Therapeutics, its
trial of a small molecule, oral drug for the treatment of Gaucher disease has been suspended. We also face competition from companies
with approved treatments of Fabry disease, including Genzyme and Shire, and we are aware of other early stage drugs which are being
developed for the treatment of Fabry disease, including a drug being developed by Amicus Therapeutics. Amicus Therapeutics reports
that it has suspended its development of its Gaucher disease treatment. We also face competition from companies with approved enzyme
treatments of Fabry disease, including Genzyme and Shire, and we are aware of other early stage drugs which are being developed
for the treatment of Fabry disease, including a drug being developed by Amicus Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also face competition from companies that are developing other
platforms for the expression of recombinant therapeutic pharmaceuticals. We are aware of companies that are developing alternative
technologies to develop and produce therapeutic proteins in anticipation of the expiration of certain patent claims covering marketed
proteins. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson &amp;
Johnson), Shire and GlycoFi Inc. (which was acquired by Merck). Other companies are developing alternate plant-based technologies,
include Biolex, Inc., Chlorogen, Inc., iBIO, Medicago, Greenovation Biotech GmbH and Dow Agroscience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Several biogeneric companies are pursuing the opportunity to develop
and commercialize follow-on versions of other currently marketed biologic products, including growth factors, hormones, enzymes,
cytokines and monoclonal antibodies, which are areas that interest us. These companies include, among others, Novartis AG/Sandoz
Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our competitors, either alone or together with their collaborative
partners, operate larger research and development programs, staff and facilities and have substantially greater financial resources
than we do, as well as significantly greater experience in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%; font-family: Symbol">&middot;</TD>
    <TD STYLE="width: 93%">developing drugs;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>undertaking preclinical testing and human clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>obtaining marketing approvals from the FDA and other regulatory authorities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>formulating and manufacturing drugs; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-family: Symbol">&middot;</TD>
    <TD>launching, marketing and selling drugs.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">These organizations also compete with us to attract qualified personnel,
acquisitions and joint ventures candidates and for other collaborations. Activities of our competitors may impose unanticipated
costs on our business which would have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we in-license drug candidates, we may delay or otherwise adversely
affect the development of our existing drug candidates, which may negatively impact our business, results of operations and financial
condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to our own internally developed drug candidates, we
proactively seek opportunities to in-license and advance other drug candidates that are strategic and have value-creating potential
to take advantage of our development know-how and technology. If we in-license any additional drug candidate, our capital requirements
may increase significantly. In addition, in-licensing additional drug candidates may place a strain on the time of our existing
personnel, which may delay or otherwise adversely affect the development of our existing drug candidates or cause us to re-prioritize
our drug pipeline if we do not have the necessary capital resources to develop all of our drug candidates, which may delay the
development of our drug candidates and materially and adversely impact our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we are unable to successfully manage our growth, there could
be a material adverse impact on our business, results of operations and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have grown rapidly and expect to continue to grow. We expect
to hire more employees, particularly in the areas of drug development, manufacturing, regulatory affairs and sales and marketing,
and increase our facilities and corporate infrastructure, further increasing the size of our organization and related expenses.
To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems,
expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited resources, we may not
be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion
of our operations may lead to significant costs and may divert our management and business development resources. Any inability
on the part of our management to manage growth could delay the execution of our business plans or disrupt our operations. If we
are unable to manage our growth effectively, we may not use our resources in an efficient manner, which may delay the development
of our drug candidates and materially and adversely impact our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we acquire companies, products or technologies, we may face
integration risks and costs associated with those acquisitions that could negatively impact our business, results of operations
and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If we are presented with appropriate opportunities, we may acquire
or make investments in complementary companies, products or technologies. We may not realize the anticipated benefit of any acquisition
or investment. If we acquire companies or technologies, we will face risks, uncertainties and disruptions associated with the integration
process, including difficulties in the integration of the operations of an acquired company, integration of acquired technology
with our products, diversion of our management&rsquo;s attention from other business concerns, the potential loss of key employees
or customers of the acquired business and impairment charges if future acquisitions are not as successful as we originally anticipate.
In addition, our operating results may suffer because of acquisition-related costs or amortization expenses or charges relating
to acquired intangible assets.<FONT STYLE="color: black"><B> </B></FONT>Any failure to successfully integrate other companies,
products or technologies that we may acquire may have <FONT STYLE="color: black">a material adverse effect on our business and
results of operations</FONT>. Furthermore, we may have to incur debt or issue equity securities to pay for any additional future
acquisitions or investments, the issuance of which could be dilutive to our existing shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We depend upon key employees and consultants in a competitive
market for skilled personnel. If we are unable to attract and retain key personnel, it could adversely affect our ability to develop
and market our products.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We are highly dependent upon the </FONT>principal
members of our management team, especially our President and Chief Executive Officer, Dr. David Aviezer, Ph.D., as well as the
Interim Chairman of our Board of Directors, Zev Bronfeld, our other directors, our scientific advisory board members, consultan<FONT STYLE="color: black">ts
and collaborating scientists. Many of these people have been involved with us for many years and have played integral roles in
our progress, and we believe that they will continue to provide value to us. A loss of any of these personnel may have a material
a</FONT>dverse effect on aspects of our business, clinical development and regulatory programs. We have employment agreements with
Dr. Aviezer and five other officers that may be terminated by us or the applicable officer at any time with varying notice periods
of 60 to 90 days. <FONT STYLE="color: black">Although these employment agreements generally include non-competition covenants and
provide for severance payments that are contingent upon the applicable employee&rsquo;s refraining from competition with us, the
applicable noncompetition provisions can be difficult and costly to monitor and enforce. The loss of any of these persons&rsquo;
services may adversely affect our ability to develop and market our products and obtain necessary regulatory approvals. Further,
we do not maintain key-man life insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We also depend in part on the continued service of our key scientific
personnel and our ability to identify, hire and retain additional personnel, including marketing and sales staff. We experience
intense competition for qualified personnel, and the existence of non-competition agreements between prospective employees and
their former employers may prevent us from hiring those individuals or subject us to suit from their former employers. While we
attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are likely to
have greater resources and more experience than we have, making it difficult for us to compete successfully for key personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our collaborations with outside scientists and consultants may
be subject to restriction and change. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">We work with chemists, biologists and other
scientists at academic and other institutions, and consultants who assist us in our research, development, regulatory and commercial
efforts, including the members of our scientific advisory board. These scientists and consultants have provided, and we expect
that they will continue to provide, valuable advice regarding our programs. These scientists and consultants are not our employees,
may have other commitments that would limit their future availability to us and typically will not enter into non-compete agreements
with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services.
In addition, we will be unable to prevent them from establishing competing businesses or developing competing products. For example,
if a key scientist acting as a principal investigator in any of our clinical trials identifies a potential product or compound
that is more scientifically interesting to his or her professional interests, his or her availability to remain involved in our
clinical trials could be restricted or eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Under current U.S. and Israeli law, we may not be able to enforce
employees&rsquo; covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise
of some of our former employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have entered into non-competition agreements with all of our
employees. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for
our competitors for a limited period. Under current U.S. and Israeli law, we may be unable to enforce these agreements against
most of our employees and it may be difficult for us to restrict our competitors from gaining the expertise our former employees
gained while working for us. <B> </B>If we cannot enforce our employees&rsquo; non-compete agreements, we may be unable to prevent
our competitors from benefiting from the expertise of our former employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If product liability claims are brought against us, it may result
in reduced demand for our products and product candidates or damages that exceed our insurance coverage.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The clinical testing, marketing and use of our products and product
candidates exposes us to product liability claims if the use or misuse of those products or product candidates cause injury, disease
or results in adverse effects. Use of our products or product candidates, whether in clinical trials or post approval, could result
in product liability claims. We presently carry clinical trial liability insurance with coverages of up to $10.0 million per occurrence
and $10.0 million in the aggregate, an amount we consider reasonable and customary . However, this insurance coverage includes
various deductibles, limitations and exclusions from coverage, and in any event might not fully cover any potential claims. We
may need to obtain additional clinical trial liability coverage prior to initiating additional clinical trials. We expect to obtain
product liability insurance coverage before commercialization of our product candidates; however, such insurance is expensive and
insurance companies may not issue this type of insurance when we need it. We may not be able to obtain adequate insurance in the
future at an acceptable cost. Any product liability claim, even one that was not in excess of our insurance coverage or one that
is meritless and/or unsuccessful, may adversely affect our cash available for other purposes, such as research and development,
which may have a material adverse effect on our business, results of operations and financial condition. Product liability claims,
even if without merit, may result in reduced demand for our products, if approved, which would have a material adverse effect on
our business, financial condition and results of operations. In addition, the existence of a product liability claim could affect
the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Coverage and reimbursement may not be available for our product
candidates, which could diminish our sales or affect our ability to sell our products profitably. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Market acceptance and sales of our product candidates will depend
on worldwide coverage and reimbursement policies. Government authorities and third-party payors, such as private health insurers
and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure
that coverage and reimbursement will be available for any of our product candidates, if approved for marketing and sale. <FONT STYLE="color: black">Obtaining
reimbursement approval for an approved product from governments and other third party payors is a time consuming and costly process
that requires us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products, if and when
approved, to every payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement
or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of approved products, if any,
to such payors&rsquo; satisfaction. Such studies might require us to commit a significant amount of management time and financial
and other resources. Even if a payor determines that an approved product is eligible for reimbursement, the payor may impose coverage
limitations that preclude payment for some uses that are approved by the FDA or other regulatory authorities. In addition, there
is a risk that full reimbursement may not be available for high priced products. Moreover, eligibility for coverage does not imply
that any approved product will be reimbursed in all cases or at a rate that allows us to make a profit or even cover our costs.
</FONT>Also, limited reimbursement amounts may reduce the demand for, or the price of, our product candidates. Except with respect
to taliglucerase alfa, we have not commenced efforts to have our product candidates covered and reimbursed by government or third-party
payors. If coverage and reimbursement are not available or are available only to limited levels, the sales of our products, if
approved may be diminished or we may not be able to sell such products profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Reforms in the healthcare industry and the uncertainty associated
with pharmaceutical pricing, reimbursement and related matters could adversely affect the marketing, pricing and demand for our
products, if approved.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Increasing healthcare expenditures have been the subject of considerable
public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs.
Numerous proposals that would affect changes in the U.S. healthcare system have been introduced or proposed in the U.S. Congress
and in some state legislatures within the United States, including reductions in the pricing of prescription products and changes
in the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products. Legislation
passed in recent years has imposed certain changes to the way in which drugs, including our product candidates, are covered and
reimbursed in the United States. For example, federal legislation and regulations have implemented new reimbursement methodologies
for certain drugs, created a voluntary prescription drug benefit, Medicare Part D, and have imposed significant revisions to the
Medicaid Drug Rebate Program. The recently enacted Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Affordability Reconciliation Act (collectively, the &ldquo;PPACA&rdquo;), imposes yet additional changes to these programs.
We believe that legislation that reduces reimbursement for our product candidates could adversely impact how much or under what
circumstances healthcare providers will prescribe or administer our products, if approved. This could materially and adversely
impact our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our
products, if approved. In addition, we believe the increasing emphasis on managed care in the United States has and will continue
to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales, upon approval, if
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are subject to healthcare reform measures, including legislation,
regulatory proposals and healthcare payor initiatives that may increase our costs and adversely affect our profitability and/or
ability to obtain adequate reimbursement for our product candidates.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The United States and some foreign jurisdictions are considering
or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our
ability to sell our products profitably. Among policymakers and payors in the United States and elsewhere, there is significant
interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or
expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly
affected by major legislative initiatives. For example, the PPACA which was enacted in the United States in March 2010 substantially
changes the way healthcare is financed in the United States by both governmental and private insurers and significantly affects
the pharmaceutical industry. Although we cannot predict their full impact, we anticipate that PPACA, as well as other healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage and reimbursement criteria and in additional
downward pressure on the price that we receive for any approved product, and could adversely affect our profits and our business
generally.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We may be subject, directly or indirectly, to federal and state
healthcare fraud and abuse and false claims laws and regulations. If we are unable to comply, or have not fully complied, with
such laws, we could face substantial penalties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If we obtain FDA approval for any of our product candidates and
begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers,
subject to various state and federal fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the
federal False Claims Act and HIPAA. These laws may impact, among other things, our proposed sales, marketing and education programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The federal Anti-Kickback Statute prohibits persons from knowingly
and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce either the referral of
an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal
healthcare program, such as the Medicare and Medicaid programs. The term &ldquo;remuneration&rdquo; has been broadly interpreted
to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements,
payments of cash, waivers of co-payments and deductibles, ownership interests and providing anything at less than its fair market
value. The reach of the Anti-Kickback Statute was also broadened by PPACA, which, among other things, amends the intent requirement
of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. &sect; 1320a-7b,
effective March 23, 2010. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this
statute or specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes
a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute,
which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health
program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
The federal Anti-Kickback Statute is broad, and despite a series of narrow safe harbors, prohibits many arrangements and practices
that are lawful in businesses outside of the healthcare industry. Penalties for violations of the federal Anti-Kickback Statute
include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid and other
state or federal healthcare programs. Many states have also adopted laws similar to the federal Anti-Kickback Statute, some of
which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid
programs, and do not contain identical safe harbors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The federal False Claims Act imposes liability on any person who,
among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare
program. The &ldquo;qui tam&rdquo; provisions of the False Claims Act allow a private individual to bring civil actions on behalf
of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any
monetary recovery. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these
state laws apply where a claim is submitted to any third-party payer and not merely a federal healthcare program. When an entity
is determined to have violated the False Claims Act, it may be required to pay up to three times the actual damages sustained by
the government, plus civil penalties of $5,500 to $11,000 for each separate false claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Also, the Health Insurance Portability and Accountability Act of
1996, or HIPAA, created several new federal crimes, including health care fraud, and false statements relating to health care matters.
The health care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program,
including private third-party payers. The false statements statute prohibits knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
of or payment for health care benefits, items or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are unable to predict whether we could be subject to actions
under any of these or other fraud and abuse laws, or the impact of such actions. Moreover, to the extent that our products will
be sold in a foreign country, we may be subject to similar foreign laws and regulations. If we are found to be in violation of
any of the laws described above and other applicable state and federal fraud and abuse laws, we may be subject to penalties, including
civil and criminal penalties, damages, fines, exclusion from government healthcare reimbursement programs and the curtailment or
restructuring or our operations, all of which could have a material adverse effect on our business, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Governments outside the United States tend to impose strict price
controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">In some countries, particularly European
Union member states, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing
negotiations with governmental authorities can take considerable time (six to 12&nbsp;months or longer) after the receipt of marketing
approval for a product. To obtain reimbursement or pricing approval in some countries with respect to any product candidate that
achieves regulatory approval, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product
candidate to other available therapies. If reimbursement of our products upon approval, if at all, is unavailable or limited in
scope or amount, or if pricing is set at unsatisfactory levels, our prospects for generating revenue, if any, could be adversely
affected which would have a material adverse effect on our business, results of operations and financial condition. Further, if
we achieve regulatory approval of any product, we must successfully negotiate product pricing for such product in individual countries.
As a result, the pricing of our products, if approved, in different countries may vary widely, thus creating the potential for
third-party trade in our products in an attempt to exploit price differences between countries. This third-party trade of our products
could undermine our sales in markets with higher prices </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">which could
have a material adverse effect on our business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our ability to utilize net operating loss carryforwards may be
limited.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The net operating loss carryforwards, or &ldquo;NOLs&rdquo;, of
the Company as of December 31, 2011, equal to approximately $11.7 million, may be restricted under Section 382 of the Internal Revenue
Code of 1986, as amended, or the &ldquo;Code.&rdquo; Section 382 of the Code imposes limitations on a corporation&rsquo;s ability
to utilize NOLs to offset taxable income if the corporation experiences an &ldquo;ownership change.&rdquo; In general terms, an
&ldquo;ownership change&rdquo; may result from transactions increasing the ownership of certain stockholders in the stock of a
corporation by more than 50% over a three-year period. In the event that an ownership change has occurred, or were to occur, utilization
of our NOLs would be subject to an annual limitation under Section 382, which is generally the fair market value of the pre-change
entity multiplied by the long-term tax exempt rate, which is published monthly by the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>All liabilities of our company have survived the merger and there
may be undisclosed liabilities that could harm our revenues, business, prospects, financial condition and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Protalix Ltd. and its counsel conducted due diligence on us that
was customary and appropriate for the reverse merger transaction consummated on December 31, 2006. However, the due diligence process
may not have revealed all our material liabilities then existing or that could be asserted in the future against us relating to
our activities before the consummation of the merger. Any such potential liabilities survive the merger and could harm our revenues,
business, prospects, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We are a holding company with no operations of our own. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a holding company with no operations of our own. Accordingly,
our ability to conduct our operations, service any debt that we may incur in the future and pay dividends, if any, is dependent
upon the earnings from the business conducted by Protalix Ltd. The distribution of those earnings or advances or other distributions
of funds by our subsidiary to us, as well as our receipt of such funds, are contingent upon the earnings of our subsidiary and
are subject to various business considerations and U.S. and Israeli law. If Protalix Ltd. is unable to make sufficient distributions
or advances to us, or if there are limitations on our ability to receive such distributions or advances, we may not have the cash
resources necessary to conduct our corporate operations which would have a material adverse effect on our business, results of
operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Regulatory Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>We
are subject to extensive governmental regulation including the requirement of FDA approval before our drug candidates may be marketed.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">Both
before and after approval of our drug candidates, we, our drug candidates, our suppliers, our contract manufacturers and our contract
testing laboratories are subject to extensive regulation by the FDA or comparable foreign regulatory authorities. Failure to comply
with applicable requirements of the FDA or comparable foreign regulatory authorities could result in, among other things, any of
the following actions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warning letters;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines and other monetary penalties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>unanticipated expenditures;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the FDA&rsquo;s or other foreign regulatory authorities&rsquo; approving, or the refusal of any regulatory authority
to approve, any drug candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product recall or seizure;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>interruption of manufacturing or clinical trials;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>operating restrictions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>criminal prosecutions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">In
addition to the approval requirements, other numerous and pervasive regulatory requirements apply, both before and after approval,
to us, our drug candidates, and our suppliers, contract manufacturers, and contract laboratories. These include requirements related
to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>testing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>quality control;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>labeling;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>advertising;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>promotion;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>distribution;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>export;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reporting to the FDA certain adverse experiences associated with use of the drug candidate; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtaining additional approvals for certain modifications to the drug candidate or its labeling or claims.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">We
also are subject to inspection by the FDA and comparable foreign regulatory authorities, to determine our compliance with regulatory
requirements, as are our suppliers, contract manufacturers, and contract testing laboratories, and there can be no assurance that
the FDA or any other comparable foreign regulatory authority, will not identify compliance issues that may disrupt production or
distribution, or require substantial resources to correct. We may be required to make modifications to our manufacturing operations
in response to these inspections which may require significant resources and may have a material adverse effect upon our business,
results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">The
approval process for any drug candidate may also be delayed by changes in government regulation, future legislation or administrative
action or changes in policy of the FDA and comparable foreign authorities that occur prior to or during their respective regulatory
reviews of such drug candidate. Delays in obtaining regulatory approva</FONT>ls with respect to any drug candidate may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay commercialization of, and our ability to derive product revenues from, such drug candidate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delay the regulatory-related milestone payments we anticipate receiving from Pfizer;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>require us to perform costly procedures with respect to such drug candidate; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>otherwise diminish any competitive advantages that we may have with respect to such drug candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">Delays
in the approval process for any drug candidate may have a material adverse effect upon our business, financial condition and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>We
may not obtain the necessary U.S., EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely
manner, if at all, which would have a material adverse effect on our business, financial condition and results of operations.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">We
need FDA approval to commercialize our drug candidates in the United States, EMA approval to commercialize our drug candidates
in the European Union and approvals from foreign regulators to commercialize our drug candidates elsewhere. In order to obtain
FDA approval of any of our drug candidates, we must submit to the FDA an NDA or a Biologic License Application (BLA) demonstrating
that the drug candidate is safe for humans and effective for its intended use. This demonstration requires significant research
and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials.&nbsp;&nbsp;In
the European Union, we must submit an MAA to the EMA. Satisfaction of the FDA&rsquo;s, the EMA's and foreign regulatory authorities&rsquo;
regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the drug candidate and requires
substantial resources for research, development and testing. In December 2009, we completed the filing of an NDA for taliglucerase
alfa for the treatment of Gaucher disease and received a PDUFA date of February&nbsp;25, 2011. In addition, we have submitted a
marketing application for taliglucerase alfa to the Israeli MOH, and MAAs have been submitted to each of the EMA, ANVISA and the
Australian TGA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="color: black; background-color: white">In
February 2011, we received a CRL from the FDA regarding our NDA for taliglucerase alfa for the treatment of Gaucher disease. The
main questions raised by the FDA regarding the NDA related to clinical and CMC.&nbsp;&nbsp;In the clinical section of the CRL,
the FDA requested additional data from the ongoing switchover trial and the long-term extension trial relating to taliglucerase
alfa.&nbsp;&nbsp;At the time the NDA was submitted, full data from these trials was not available.&nbsp;&nbsp;In the CMC section
of the CRL, the FDA requested information regarding testing specifications and assay validation. The FDA did not request additional
clinical studies in the CRL. In May 2011, we had a meeting with the FDA to clarify the FDA&rsquo;s requests and in July 2011, we
submitted a reply to the CRL. In August 2011, the FDA notified us that it had accepted for review the resubmission of the taliglucerase
alfa NDA, had deemed the resubmission a class 2, or 6-month, response and established February 1, 2012 as the new PDUFA date. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
In December 2011, the FDA notified us that it had decided to extend the PDUFA date to May 1, 2012. In its notification, the FDA
stated that its decision related to </FONT>certain clinical information regarding taliglucerase alfa we had submitted in November
2011 in response to an FDA request. The requested information related mainly to the presentation of select data provided in the
NDA.&nbsp;&nbsp;As this information was requested and provided within 90 days of the February 1, 2012 PDUFA goal date, the FDA
had the option to extend the PDUFA goal date to provide adequate time for the FDA to complete its review. A three-month extension
cycle is the standard period granted. No additional data was requested by the FDA in the notification, nor were we notified of
any specific deficiency in the taliglucerase alfa NDA. <FONT STYLE="color: black; background-color: white">There can be no assurance
that the FDA will not make any additional request regarding our NDA.&nbsp;&nbsp;In the past, the FDA has made additional requests
to other applicants after the delivery of a CRL.&nbsp;&nbsp;Any additional requests from the FDA relating to the NDA may delay
or preclude the FDA&rsquo;s review of our reply to the CRL.&nbsp;&nbsp;Even if we comply with all of the FDA&rsquo;s requests in
the CRL or otherwise, if any, the FDA may ultimately reject the NDA, or fail to approve the NDA in a timely manner, which would
have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">Even
if we comply with all the requests of the FDA, EMA and comparable foreign authorities, the authorities may ultimately reject the
NDA, MAA or other filing or submission we filed for taliglucerase alfa or one or more of the NDAs or other filings or submissions
we file in the future, if any, or we might not obtain regulatory clearance in a timely manner for taliglucerase alfa or any of
our other drug candidates.&nbsp;&nbsp;Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks
in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or in preliminary findings or other
comparable authorities for such clinical trials.&nbsp;&nbsp;Further, even if favorable testing data is generated by the clinical
trials of a drug candidate, the FDA, EMA or other regulatory authority may not accept or approve an NDA, MAA or other comparable
submission, as applicable, filed by a pharmaceutical or biotechnology company for the drug candidate.&nbsp;&nbsp;Failure to obtain
approval of the FDA, EMA or comparable foreign authorities of any of our drug candidates in a timely manner, if at all, will severely
undermine our business, financial condition and results of operation by reducing our potential marketable products and our ability
to generate corresponding product revenues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">Our
research and clinical efforts may not result in drugs that the FDA, EMA or foreign regulatory authorities consider safe for humans
and effective for indicated uses, which would have a material adverse effect on our business, financial condition and results of
operations.&nbsp;&nbsp;After clinical trials are completed for any drug candidate, if at all, the FDA, EMA and foreign regulatory
authorities have substantial discretion in the drug approval process of the drug candidate in their respective jurisdictions and
may require us to conduct additional clinical testing or perform post-marketing studies which would cause us to incur additional
costs.&nbsp;&nbsp;Incurring such costs may have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>We
have only limited experience in regulatory affairs, and some of our drug candidates may be based on new technologies. These factors
may affect our ability or the time we require to obtain necessary regulatory approvals.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">We have only limited experience
in filing and prosecuting the applications necessary to gain regulatory approvals for medical devices and drug candidates. Moreover,
some of the drug candidates that are likely to result from our development programs may be based on new technologies that have
not been extensively tested in humans. The regulatory requirements governing these types of drug candidates may be less well defined
or more rigorous than for conventional products.&nbsp;&nbsp;As a result, we may experience a longer regulatory process in connection
with obtaining regulatory approvals of any products that we develop</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white"><B>If
Shire or any of our other competitors are able to obtain orphan drug exclusivity for any products that are competitive with our
products, we may be precluded from selling or obtaining approval of our competing products by the applicable regulatory authorities
for a significant period of time.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">In
the United States, orphan drug status may be designated for a drug that has the potential to treat a &ldquo;rare disease or condition,&rdquo;
which generally is a disease or condition that affects fewer than 200,000 individuals within the United States. Orphan drug designation
does not convey an advantage in, or shorten the duration of, the review and approval process.&nbsp;&nbsp;If a drug candidate which
has orphan drug designation subsequently receives the first approval for the indication in a jurisdiction for which it has such
designation, the drug candidate is entitled to orphan exclusivity in that jurisdiction, meaning that the applicable regulatory
authority may not approve any other application to market the same drug for the same indication, except in very limited circumstances,
for seven years.&nbsp;&nbsp;There can be no assurance that a drug candidate that receives orphan drug designation will receive
orphan drug marketing exclusivity. More than one drug can have orphan designation for the same indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="color: black; background-color: white">Foreign
regulations regarding orphan drugs are similar to those in the United States but there are several conceptual differences. For
example, the exclusivity period in the European Union is generally 10 years.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
The EMA/European Commission has granted orphan drug designation and exclusivity to VPRIV in the European Union. This designation
may preclude the marketing authorization of taliglucerase alfa in the European Union for a 10-year period commencing upon the August
2010 marketing authorization of VPRIV in the European Union. Any marketing protection granted to VPRIV by the EMA/European Commission
in connection with the orphan drug designation may have a </FONT><FONT STYLE="color: black; background-color: white">material adverse
effect on our business, financial condition and results of operations</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black; background-color: white">From time to
time, we may apply to the FDA or any comparable foreign regulatory authority for orphan drug designation for any one or more of
our drug candidates. For example, in September 2009, the FDA&rsquo;s Office of Orphan Product Development granted taliglucerase
alfa orphan drug status.&nbsp;&nbsp;In January 2010, the COMP, after reviewing all relevant clinical data, recommended that the
European Commission grant orphan drug designation to taliglucerase alfa for the treatment of Gaucher disease. However, none of
our other drug candidates have been designated as an orphan drug and there is no guarantee that the FDA will grant such designation
in the future. In addition, neither orphan drug designation nor orphan drug exclusivity prevents competitors from developing or
marketing different drugs for that indication. Even if we obtain orphan drug exclusivity for one or more indications for one of
our drug candidates, we may not be able to maintain the exclusivity. For example, if a competitive product that is the same drug
or biologic as one of our drug candidates is shown to be clinically superior to the drug candidate, any orphan drug exclusivity
granted to the drug candidate will not block the approval of the competitive product. The grant of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">orphan
drug designation to VPRIV may preclude our ability to receive the same designation for taliglucerase alfa. </FONT><FONT STYLE="color: black; background-color: white">Failure
to obtain or maintain orphan drug exclusivity for taliglucerase alfa or any of our other drug candidates may have a material adverse
effect on our business, results of operation and financial condition. If VPRIV or any other drug receives orphan drug exclusivity
in any jurisdiction for Gaucher disease or any other indication for a product that competes with one of the indications for one
of our drug candidates, we may be prevented from marketing the applicable drug candidate in the jurisdiction during the applicable
exclusivity period which will have a material adverse effect on our business, results of operations and financial condition</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Intellectual Property Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we fail to adequately protect or enforce our intellectual
property rights or secure rights to third party patents, the value of our intellectual property rights would diminish and our business,
competitive position and results of operations would suffer.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">As of December 31, 2011, we had 81  pending patent
applications, one joint pending patent application with a third party and license rights to seven pending patent
applications. However, the filing of a patent application does not mean that we will be issued a patent, or that any patent
eventually issued will be as broad as requested in the patent application or sufficient to protect our technology. Any
modification required to a current patent application may delay the approval of such patent application which would have a
material adverse effect on our business, results of operations and financial condition. In addition, there are a number of
factors that could cause our patents, if granted, to become invalid or unenforceable or that could cause our patent
applications to not be granted, including known or unknown prior art, deficiencies in the patent application or the lack of
originality of the technology. Our competitive position and future revenues will depend in part on our ability and the
ability of our licensors and collaborators to obtain and maintain patent protection for our products, methods, processes and
other technologies, to preserve our trade secrets, to prevent third parties from infringing on our proprietary rights and to
operate without infringing the proprietary rights of third parties. We have filed U.S. and international patent applications
for process patents, as well as<FONT STYLE="font-family: Times New Roman, Times, Serif"><B> </B></FONT>composition of matter
patents, for taliglucerase alfa. However, we cannot predict:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the degree and range of protection any patents will afford us against competitors and those who infringe upon our patents,
including whether third parties will find ways to invalidate or otherwise circumvent our licensed patents;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if and when patents will issue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether or not others will obtain patents claiming aspects similar to those covered by our licensed patents and patent applications;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether we will need to initiate litigation or administrative proceedings, which may be costly, and whether we win or lose.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">As of December 31, 2011, we hold, or
have license rights to, 38 patents (including one joint patent). If patent rights covering our products
or technologies are not sufficiently broad, they may not provide us with sufficient proprietary protection or competitive advantages
against competitors with similar products and technologies. Furthermore, if the </FONT>U.S.<FONT STYLE="color: black"> Patent and
Trademark Office or foreign patent offices issue patents to us or our licensors, others may challenge the patents or circumvent
the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from or to third
parties may not provide any protection against our competitors and those who infringe upon our patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Furthermore, the life of our patents is limited. The patents we
hold relating to our ProCellEx protein expression system will expire in 2017. If patents issue from other currently pending patent
applications, those patents will expire between 2024 and 2028.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>We rely on confidentiality agreements that could be breached
and may be difficult to enforce which could have a material adverse effect on our business and competitive position.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our policy is to enter agreements relating to the non-disclosure
of confidential information with third parties, including our contractors, consultants, advisors and research collaborators, as
well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries
and inventions of our employees and consultants while we employ them. However, these agreements can be difficult and costly to
enforce. Moreover, to the extent that our contractors, consultants, advisors and research collaborators apply or independently
develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual
property. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can
be costly and unpredictable. In addition, we rely on trade secrets and proprietary know-how that we seek to protect in part by
confidentiality agreements with our employees, contractors, consultants, advisors or others. Despite the protective measures we
employ, we still face the risk that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements may be breached;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>these agreements may not provide adequate remedies for the applicable type of breach; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our trade secrets or proprietary know-how will otherwise become known.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Any breach of our confidentiality agreements or our failure to effectively
enforce such agreements would have a material adverse effect on our business and competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we infringe the rights of third parties we could be prevented
from selling products, forced to pay damages and required to defend against litigation which could result in substantial costs
and may have a material adverse effect on our business, results of operations and financial condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We have not received to date any claims of infringement by any third
parties. However, as our drug candidates progress into clinical trials and commercialization, if at all, our public profile and
that of our drug candidates may be raised and generate such claims. Defending against such claims, and occurrence of a judgment
adverse to us, could result in unanticipated costs and may have a material adverse effect on our business and competitive position.
If our products, methods, processes and other technologies infringe the proprietary rights of other parties, we may incur substantial
costs and we may have to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>obtain licenses, which may not be available on commercially reasonable terms, if at all;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>redesign our products or processes to avoid infringement;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>stop using the subject matter claimed in the patents held by others, which could cause us to lose the use of one or more of
our drug candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial
diversion of management resources; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>pay damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Any costs incurred in connection with such events or the inability
to sell our products may have a material adverse effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>If we cannot meet requirements under our license agreements,
we could lose the rights to our products, which could have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We depend on licensing agreements with
third parties to maintain the intellectual property rights to ce</FONT>rtain of our product candidates. Presently, we have licensed
rights from the Yeda which allow us to use their technology and discoveries for the development, production and sale of enzymatically
active mutations of GCD and derivatives thereof for the treatment of Gaucher disease. In addition, pursuant to our agreement with
the Yissum Research and Development Company, or Yissum, the technology transfer arm of the Hebrew University of Jerusalem, Israel,
and the Boyce Thompson Institute for Plant Research, at Cornell University, we have received an exclusive worldwide right and license
to certain technology, including patents and additional patent applications relating to acetylcholinesterase (AChE), for all therapeutic
and prophylactic indications as well as an exclusive license not limited to such indications with respect to certain of these patents
and patent applications. Under the agreement with Yissum, we intend to develop a proprietary plant cell-based acetylcholinesterase
(AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, including a biodefense program.
In addition, we have licensed certain rights relating to our production of taliglucerase alfa from Virginia Tech. Our license agreements
require us to make payments and satisfy performance obligations in order t<FONT STYLE="color: black">o maintain our rights under
these agreements. All of these agreements last either throughout the life of the patents that are the subject of the agreements,
or with respect to other licensed technology, for a number of years after the first commercial sale of the relevant product. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, we are responsible for the cost of filing and prosecuting
certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our
license agreements in a timely manner, we could lose the rights to our proprietary technology which could have a material adverse
effect on our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Relating to Our Operations in Israel </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Potential political, economic and military instability in the
State of Israel, where the majority of our senior management and our research and development facilities are located, may adversely
affect our results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Our executive office and operations are
located in the State of Israel. Accordingly, political, economic and military conditions in Israel directly affect our business.
Since the State of Israel was established in 1948, a number of armed conflicts have occurred between Israel and its Arab neighbors.
Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or
a significant downturn in the economic or financial condition of Israel, could affect adversely our operations. </FONT>Since October
2000 there have been increasing occurrences of terrorist violence. Ongoing and revived h<FONT STYLE="color: black">ostilities or
other Israeli political or economic factors could harm our operations and product development and cause our revenues to decrease.
Furthermore, several countries, principally those in the Middle East, still restrict business with Israel and Israeli companies.
These restrictive laws and policies may limit seriously our ability to sell our products in these countries. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Although Israel has entered into various agreements with Egypt,
Jordan and the Palestinian Authority, there have been times since October 2000 when Israel has experienced an increase in unrest
and terrorist activity. The establishment in 2006 of a government in the Palestinian Authority by representatives of the Hamas
militant group has created additional unrest and uncertainty in the region. In mid-2006, there was a war between Israel and the
Hezbollah in Lebanon, resulting in thousands of rockets being fired from Lebanon up to 50 miles into Israel. Our current facilities
are located in northern Israel, are in range of rockets that were fired from Lebanon into Israel during the war and suffered minimal
damages during one of the rocket attacks. Our insurance policies do not cover us for <FONT STYLE="color: black">these types of
damages or for any resulting disruption in our operations. The Israeli government, as a matter of law, provides coverage for the
reinstatement value of direct damages that are caused by terrorist attacks or acts of war; however, the government may cease providing
such coverage or the coverage might not be enough to cover potential damages. </FONT>If our facilities are damaged as a result
of hostile action, our operations may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to the foregoing, since the end of 2010, numerous acts
of protest and civil unrest have taken place in several countries in the Middle East and North Africa, many of which involved significant
violence. The civil unrest in Egypt, which borders Israel, resulted in the resignation of its president Hosni Mubarak, and to significant
changes to the country's government. In Syria, also bordering Israel, large civilian protests are continuing to take place. The
ultimate effect of these developments on the political and security situation in the Middle East and on Israel's position within
the region is not clear at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our operations may be disrupted by the obligations of our personnel
to perform military service which could have a material adverse effect on our business. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Many of our male employees in Israel, including members of senior
management, are obligated to perform up to one month (in some cases more) of annual military reserve duty until they reach the
age of 45 and, in the event of a military conflict, could be called to active duty. Our operations could be disrupted by the absence
of a significant number of our employees related to military service or the absence for extended periods of military service of
one or more of our key employees. A disruption could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Because a certain portion of our expenses is incurred in New
Israeli Shekels, or NIS, our results of operations may be seriously harmed by currency fluctuations and inflation. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We report our financial statements in U.S. dollars, our
functional currency. Although most of our expenses are incurred in U.S. dollars, we pay a  portion of our expenses in New
Israeli Shekels, or NIS and, as a result, we are exposed to risk to the extent that the inflation rate in Israel exceeds the
rate of devaluation of the NIS in relation to the U.S. dollar or if the timing of these devaluations lags behind inflation in
Israel. In that event, the U.S. dollar cost of our operations in Israel will increase and our U.S. dollar-measured results of
operations will be adversely affected. To the extent that the value of the NIS increases against the dollar, our expenses on
a dollar cost basis increase. Our operations also could be adversely affected if we are unable to guard against currency
fluctuations in the future. To date, we have not engaged in hedging transactions. In the future, we may enter into currency
hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S. dollar
against the NIS. These measures, however, may not adequately protect us from material adverse effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The tax benefits available to us require that we meet several
conditions and may be terminated or reduced in the future, which would increase our taxes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">We are</FONT> abl<FONT STYLE="color: black">e
to take advantage of tax exemptions and reductions resulting from the &ldquo;Approved Enterprise&rdquo; status of our faci</FONT>lities
in Israel. To remain eligible for these tax benefits, we must continue to meet certain conditions, including making specified investments
in property and equipment, and financing at least 30% of such investments with share capital. If we fail to meet these conditions
in the future, the tax benefits would be canceled and we may be required to refund any tax benefits we already have enjoyed. These
tax benefits are subject to investment policy by the Investment Center and may not be continued in the future at their current
levels or at any level. In recent years the Israeli government has reduced the benefits available and has indicated that it may
further reduce or eliminate some of these benefits in the future. The termination or reduction of these tax benefits or our inability
to qualify for additional &ldquo;Approved Enterprise&rdquo; approvals may increase our tax expenses in the future, which would
reduce our expected profits and adversely affect our business and results of operations. Additionally, if we increase our activities
outside of Israel, for example, by future acquisitions, such increased activities generally may not be eligible for inclusion in
Israeli tax benefit programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The Israeli government grants we have received for certain research
and development expenditures restrict our ability to manufacture products and transfer technologies outside of Israel and require
us to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received
together with interest and penalties which could have a material adverse effect on our business and results of operations. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our research and development efforts have been financed, in part,
through grants that we have received from the OCS. We, therefore, must comply with the requirements of the Israeli Law for the
Encouragement of Industrial Research and Development, 1984, and related regulations, or the Research Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the Research Law we are prohibited from manufacturing products
developed using these grants outside of the State of Israel without special approvals, although the Research Law does enable companies
to seek prior approval for conducting manufacturing activities outside of Israel without being subject to increased royalties.
<FONT STYLE="color: black">We may not receive the required approvals for any proposed transfer of manufacturing activities. </FONT>Even
if we do receive approval to manufacture products developed with government grants outside of Israel, we may be required to pay
an increased total amount of royalties (possibly up to 300% of the grant amounts plus interest), depending on the manufacturing
volume that is performed outside of Israel, as well as at a possibly increased royalty rate. This restriction may impair our ability
to outsource manufacturing or engage in similar arrangements for those products or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Additionally, under the Research Law, we are prohibited from transferring
the OCS-financed technologies and related intellectual property rights outside of the State of Israel, except under limited circumstances
and only with the approval of the OCS' Research Committee. We may not receive the required approvals for any proposed transfer
and, if received, we may be required to pay the OCS a portion of the consideration that we receive upon any sale of such technology
by a non-Israeli entity. The scope of the support received, the royalties that we have already paid to the OCS, the amount of time
that has elapsed between the date on which the know-how was transferred and the date on which the OCS grants were received and
the sale price and the form of transaction will be taken into account in order to calculate the amount of the payment to the OCS.
Approval of the transfer of technology to residents of the State of Israel is required, and may be granted in specific circumstances
only if the recipient abides by the provisions of applicable laws, including the restrictions on the transfer of know-how and the
obligation to pay royalties. No assurance can be made that approval to any such transfer, if requested, will be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">These restrictions may impair our ability
to sell our technology assets or to outsource manufacturing outside of Israel. The restrictions will continue to apply for a certain
period of time even after we have repaid the full amount of royalties payable for the grants. </FONT>For the years ended December
31, 2010 and 2011, we recorded grants totaling $3.8 million and $3.3 million from the OCS, respectively. The grants represent 10%
and 9%, respectively, of our gross research and development expenditures for the years ended December 31, 2010 and 2011. <FONT STYLE="color: black">If
we fail to satisfy the conditions of the Research Law, we may be required to refund certain grants previously received together
with interest and penalties, and may become subject to criminal charges, any of which could have a material adverse effect on our
business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Investors may have difficulties enforcing a U.S. judgment, including
judgments based upon the civil liability provisions of the U.S. federal securities laws against us, our executive officers and
most of our directors or asserting U.S. securities laws claims in Israel. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Most of our directors and officers are not residents of the United
States and most of their assets and our assets are located outside the United States. Service of process upon our non-U.S. resident
directors and officers and enforcement of judgments obtained in the United States against us, some of our directors and executive
officers may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that investors
may find it difficult to assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment
based on the civil liability provisions of U.S. federal securities laws against us, our officers and our directors. Israeli courts
may refuse to hear a claim based on a violation of U.S. securities laws against us or our officers and directors because Israel
is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine
that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable
U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed
by Israeli law. There is little binding case law in Israel addressing the matters described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Israeli courts might not enforce judgments rendered outside Israel
which may make it difficult to collect on judgments rendered against us. Subject to certain time limitations, an Israeli court
may declare a foreign civil judgment enforceable only if it finds that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment may no longer be appealed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in
Israel and the substance of the judgment is not contrary to public policy; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment is executory in the state in which it was given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Even if these conditions are satisfied, an Israeli court will not
enforce a foreign judgment if it was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts
(subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of the State of Israel.
An Israeli court also will not declare a foreign judgment enforceable if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was obtained by fraud;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there is a finding of lack of due process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment was rendered by a court not competent to render it according to the laws of private international law in Israel;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the judgment is at variance with another judgment that was given in the same matter between the same parties and that is still
valid; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at the time the action was brought in the foreign court, a suit in the same matter and between the same parties was pending
before a court or tribunal in Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Investing in Our Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The market price of our common stock may fluctuate significantly.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The market price of our common stock may fluctuate significantly
in response to numerous factors, some of which are beyond our control, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the results of our ongoing studies regarding our lead product candidate taliglucerase alfa, or communications from the FDA
or other regulatory authorities regarding our NDA or other marketing authorization applications, including the approval of any
such filings by the FDA or other applicable regulatory authorities, or any delay or failure by the FDA or other applicable regulatory
authorities to approve any such filings;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments concerning intellectual property rights and regulatory approvals;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the announcement of new products or product enhancements by us or our competitors;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>variations in our and our competitors&rsquo; results of operations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in earnings estimates or recommendations by securities analysts, if our common stock is covered by analysts;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments in the biotechnology industry; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general market conditions and other factors, including factors unrelated to our operating performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Further, stock markets in general, and the market for biotechnology
companies in particular, have recently experienced price and volume fluctuations. Continued market fluctuations could result in
extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. Price volatility
of our common stock may be worse if the trading volume of our common stock is low. We have not paid, and do not expect to pay,
any cash dividends on our common stock as any earnings generated from future operations will be used to finance our operations.
As a result, investors will not realize any income from an investment in our common stock until and unless their shares are sold
at a profit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Our common stock is listed for trade on more than one stock exchange,
and this may result in price variations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is listed for trade on both
the NYSE Amex and   the TASE. Dual-listing may result in price variations between the exchanges due
to a number of factors. First, our common stock is traded in U.S. dollars on the NYSE Amex and in NIS on the TASE. In addition,
the exchanges are open for trade at different times of the day and on different days. For example, the TASE opens generally during
Israeli business hours, Sunday through Thursday while the NYSE Amex opens generally during U.S. business hours, Monday through
Thursday. The two exchanges also have differing vacation schedules. Differences in the trading schedules, as well as volatility
in the exchange rate of the two currencies, among other factors, may result different trading prices for our common stock on the
two exchanges. Other external influences may have different effects on the trading price of our common stock on the two exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Future sales of our common stock could reduce
our stock price.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The market price of our common stock could drop significantly if
our existing shareholders sell a large number of shares of our common stock or are perceived by the market as intending to sell
them. All of the shares sold in our public offering in October 2007 were freely tradable without restriction or further registration
under the federal securities laws, unless purchased by our &ldquo;affiliates&rdquo; as that term is defined in Rule&nbsp;144 under
the Securities Act. In addition, all of the outstanding shares of our common stock are freely tradable without restriction or further
registration under the federal securities laws, unless owned by our affiliates. At December&nbsp;31, 2011, there were options issued
and outstanding to purchase 7,379,722 shares of our common stock with a weighted average exercise price of $3.87 per share. Also
at December&nbsp;31, 2011, there were 47,920 shares of common stock remaining available for future for issuance in connection with
future grants of incentives under our 2006 Stock Incentive Plan. In addition, four of our executive officers have entered into
trading plans established under Rule 10b5-1 under the Securities Act that allow for sales of approximately 1.3 million shares upon
receipt of FDA approval of taliglucerase alfa, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Directors, executive officers, principal shareholders and affiliated
entities own a significant percentage of our capital stock, and they may make decisions that an investor may not consider to be
in the best interests of our shareholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our directors, executive officers, principal shareholders and affiliated
entities beneficially own, in the aggregate, approximately 44% of our outstanding common stock. As a result, if some or all of
them acted together, they would have the ability to exert substantial influence over the election of our Board of Directors and
the outcome of issues requiring approval by our shareholders. This concentration of ownership may have the effect of delaying or
preventing a change in control of our company that may be favored by other shareholders. This could prevent the consummation of
transactions favorable to other shareholders, such as a transaction in which shareholders might otherwise receive a premium for
their shares over current market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>
<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Failure to maintain effective internal controls in accordance
with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and operating results. In addition,
current and potential shareholders could lose confidence in our financial reporting, which could have a material adverse effect
on the price of our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective internal controls are necessary for us to provide reliable
financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our results
of operation could be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section 404 of the Sarbanes-Oxley Act of 2002 requires annual management
assessments of the effectiveness of our internal controls over financial reporting and a report by our independent registered public
accounting firm addressing these assessments. We continuously monitor our existing internal controls over financial reporting systems
to confirm that they are compliant with Section 404, and we may identify deficiencies that we may not be able to remediate in time
to meet the deadlines imposed by the Sarbanes-Oxley Act. This process may divert internal resources and will take a significant
amount of time and effort to complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If, at any time, it is determined that we are not in compliance
with Section 404, we may be required to implement new internal control procedures and reevaluate our financial reporting. We may
experience higher than anticipated operating expenses as well as increased independent auditor fees during the implementation of
these changes and thereafter. Further, we may need to hire additional qualified personnel. If we fail to maintain the adequacy
of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to conclude
on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley
Act, which could result in our being unable to obtain an unqualified report on internal controls from our independent auditors.
Failure to maintain an effective internal control environment could also cause investors to lose confidence in our reported financial
information, which could have a material adverse effect on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Compliance with changing regulation of corporate governance and
public disclosure may result in additional expenses, divert management&rsquo;s attention from operating our business which could
have a material adverse effect on our business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">There have been other changing laws,
regulations and standards relating to corporate governance and public disclosure in addition to the Sarbanes-Oxley Act, as well
as new regulations promulgated by the Commission and rules promulgated by the national securities exchanges, including the </FONT>NYSE
Amex<FONT STYLE="color: black"> and the NASDAQ. These new or changed laws, regulations and standards are subject to varying interpretations
in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance
is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher
costs necessitated by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving
laws, regulations and standards are likely to continue to result in increased general and administrative expenses and a diversion
of management time and attention from revenue-generating activities to compliance activities. Our board members, Chief Executive
Officer and Chief Financial Officer could face an increased risk of personal liability in connection with the performance of their
duties. As a result, we may have difficulty attracting and retaining qualified board members and executive officers, which could
have a material adverse effect on our business. If our efforts to comply with new or changed laws, regulations and standards differ
from the activities intended by regulatory or governing bodies, we may incur additional expenses to comply with standards set by
regulatory authorities or governing bodies which would have a material adverse effect on our business, financial condition and
results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The issuance of preferred stock or additional shares of common
stock could adversely affect the rights of the holders of shares of our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Board of Directors is authorized to issue up to 100,000,000
shares of preferred stock without any further action on the part of our shareholders. Our Board of Directors has the authority
to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock. Currently, we
have no shares of preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Board of Directors may, at any time, authorize the issuance
of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive
dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares,
together with a premium, before the redemption of our common stock, which may have a material adverse effect on the rights of the
holders of our common stock. In addition, our Board of Directors, without further shareholder approval, may, at any time, issue
large blocks of preferred stock. In addition, the ability of our Board of Directors to issue shares of preferred stock without
any further action on the part of our shareholders may impede a takeover of our company and may prevent a transaction that is favorable
to our shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under the rules of the TASE, other than incentives under our 2006
Stock Option Plan, we were prohibited from issuing any securities of any class or series different than the common stock that is
listed on the TASE for the 12-month period immediately succeeding our initial listing, which occurred on September&nbsp;6, 2010.
As of the date hereof, the rules of the TASE allow us to issue securities with preferential rights with respect to dividends but
such other securities may not include voting rights. The foregoing does not limit our liability to issue and grant options and
warrants for the purchase of shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Item&nbsp;1B.&nbsp;&nbsp;Unresolved Staff
Comments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt">Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Properties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our manufacturing facility and executive offices are located in
Carmiel, Israel. The facilities currently contain approximately 16,000 sq/ft of manufacturing space and additional 48,000 sq/ft
of laboratory, warehouse and office space and are leased at a rate of approximately $75,000 per month. In addition, we are entitled
to use an additional 13,000 sq/ft in the same facility, which we intend to utilize in connection with an anticipated expansion
of our manufacturing facilities. Our facilities are equipped with the requisite laboratory services required to conduct our business,
and we believe that the existing facilities are adequate to meet our needs for the foreseeable future. We have leased the facility
through 2017, subject to three options exercisable by us to extend the term for a five-year period, for an aggregate of 15 additional
years. Upon the exercise of each option to extend the term of the lease, if any, the then current base rent shall be increased
by 10%. We also lease an office in Ramat Gan, Israel, for approximately $2,200 per month.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">Item&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal
Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We are not involved in any material legal proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">Item&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-weight: normal; color: black">Mine
Safety Disclosures</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 28.05pt"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.25pt; text-indent: -38.25pt">Item&nbsp;5.&nbsp;&nbsp;&nbsp;Market
for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.25pt; text-indent: -38.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our common stock began trading on the NYSE Amex
on March 12, 2007 under the symbol &ldquo;PLX.&rdquo; Our common stock is also listed on the TASE under the
symbol &quot;PLX.&quot; The following table sets forth the quarterly high and low closing prices for our common stock on the NYSE
Amex.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Price Range</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">High</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Low</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Fourth Quarter 2011</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">6.57</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4.42</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.36</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Second Quarter 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.09</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter 2011</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.83</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Fourth Quarter 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.40</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third Quarter 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.99</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Second Quarter 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.84</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">First Quarter 2010</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.56</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">These quotations reflect prices between dealers
and do not include retained mark-ups, mark-downs and commissions and may not necessarily represent actual transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">There were approximately 46 holders of record
of our common stock at February 1, 2012. A substantially greater number of holders of our common stock are &ldquo;street name&rdquo;
or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions. To date, we have not
declared or paid any cash dividends on our common stock. We do not anticipate paying any dividends on our common stock in the foreseeable
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B>STOCK PERFORMANCE GRAPH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following graph compares the cumulative total
shareholder return data for our common stock from December 31, 2006 through December 31, 2011 to the cumulative return over such
time period of (i) The AMEX Composite Index and (ii) The AMEX Biotechnology Index. The graph assumes an investment of $100 on December
31, 2006 in each of our common stock, and the stocks comprising the AMEX Composite Index and the stocks comprising the AMEX Biotechnology
Index, including dividend reinvestment, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B><I>The stock
price performance shown on the graph below represents historical price performance and is not necessarily indicative of any future
stock price performance. The historical performance of our common stock prior to March 11, 2007, represents the performance of
our common stock prior to its listing for trade on the NYSE AMEX. </I></B></FONT><B><I> Notwithstanding anything to the contrary
set forth in any of our previous filings under the Securities Act  or the Exchange Act, which might incorporate
future filings made by us under those statutes, this Stock Performance Graph will not be incorporated by reference into any of
those prior filings, nor will such report or graph be incorporated by reference into any future filings made by us under those
Acts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.35pt; text-indent: -37.35pt"><FONT STYLE="font-weight: normal"><img src="pg64.jpg"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.35pt; text-indent: -37.35pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.35pt; text-indent: -37.35pt">Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selected
Financial Data</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.35pt; text-indent: -37.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The selected consolidated financial data below
should be read in conjunction with &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and our consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. The selected
consolidated statements of operations data for the years ended December&nbsp;31, 2011, 2010 and 2009 and the selected consolidated
balance sheet data as of December&nbsp;31, 2011 and 2010, are derived from the audited consolidated financial statements included
elsewhere in this Annual Report. The statement of operations data for the years ended December 31, 2008 and 2007 and the balance
sheet data as of December 31, 2009, 2008 and 2007 are derived from audited financial statements not included in this Annual Report.
The historical results presented below are not necessarily indicative of future results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="18" STYLE="font-size: 10pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B>&nbsp;</P>

</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2007</B></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2008</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2009</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2010</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-size: 10pt; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; font-style: italic; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD STYLE="font-weight: bold; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-style: italic"><I>&nbsp;</I></TD>
    <TD COLSPAN="18" STYLE="font-size: 10pt; text-align: center; font-style: italic"><I>(in thousands, except share and per share
    amounts)</I></TD><TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; font-size: 10pt; padding-left: 9pt">Consolidated Statement of Operations Data:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="width: 35%; text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Revenues</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 10pt">-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 10%; text-align: right; font-size: 10pt">-</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 10%; text-align: right; font-size: 10pt">388</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 10pt">$</TD><TD STYLE="width: 10%; text-align: right; font-size: 10pt">6,642</TD><TD STYLE="width: 1%; text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">8,386</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Company&rsquo;s share in collaboration agreement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4,602</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,418</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Cost of revenues</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,575</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4,383</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,525</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Gross profit (loss)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">-</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(3,187</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,861</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">1,443</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Research and development expenses, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">13,570</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">17,401</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt"></TD><TD STYLE="text-align: right; font-size: 10pt">21,638</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">29,951</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">31,043</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">General and administrative expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">20,594</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,770</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">7,144</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,876</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,931</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: justify; padding-bottom: 1pt; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Financial income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,080</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,757</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">529</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">968</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,084</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,414</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">31,440</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">28,998</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">36,529</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Net loss per share of common stock, basic and diluted</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.48</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.30</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.41</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.36</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">0.43</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt; text-indent: -9pt">Weighted average number of shares of common stock used in computing net loss per share of common stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,187,329</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,890,633</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">76,942,840</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">80,960,300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">84,645,364</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="font-weight: bold; text-align: justify; text-indent: -9pt; font-size: 10pt; padding-left: 9pt">Consolidated Balance Sheet Data:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">61,813</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">42,596</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">81,266</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">35,900</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">$</TD><TD STYLE="text-align: right; font-size: 10pt">27,001</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,324</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">8,215</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">17,405</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">28,829</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">24,804</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Total assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">68,137</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">50,811</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">98,671</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">64,729</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">51,805</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">3,762</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">5,527</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">21,530</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">18,903</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">18,693</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 10pt">
    <TD STYLE="text-align: justify; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">4,452</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">6,464</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">82,788</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">76,052</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">77,882</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 10pt">
    <TD STYLE="text-align: left; font-size: 10pt; padding-left: 9pt; text-indent: -9pt">Shareholders&rsquo; equity (net of capital deficiency)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">63,685</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">44,347</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">15,883</TD><TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(11,323</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD><TD STYLE="text-align: right; font-size: 10pt">(26,077</TD><TD STYLE="text-align: left; font-size: 10pt">)</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-indent: 0in; font-size: 10pt; font-weight: bold">*</TD>
    <TD STYLE="width: 95%; text-indent: 0in; font-size: 10pt; font-weight: normal; text-align: left">Represents less than $1.</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><B>Item&nbsp;7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>You should read the following discussion and
analysis of our financial condition and results of operations together with our consolidated financial statements and the related
notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis,
particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements
that involve risks and uncertainties. You should read &ldquo;Risk Factors&rdquo; in Item 1A of this Annual Report on Form 10-K
for a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements contained in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression system.
Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar or &ldquo;generic&rdquo; versions of recombinant
therapeutic proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets
and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins,
including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx
protein expression system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior
to existing recombinant proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent
versions of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process
is associated with relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic
proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our lead
product development candidate is taliglucerase alfa for the treatment of Gaucher disease, which we are developing using our ProCellEx
protein expression system. The FDA has granted taliglucerase alfa a Prescription Drug User Fee Act (PDUFA) date of May 1, 2012.
We first filed an NDA for taliglucerase alfa with the FDA on December 9, 2009, and on February 25, 2011, the FDA issued a CRL indicating
that the FDA&rsquo;s review was complete but questions remain that preclude the approval of the NDA in its then current form. The
main questions raised by the FDA regarding the NDA related to the clinical and CMC sections. In the clinical section of the CRL,
the FDA requested additional data from our ongoing switchover trial and our long-term extension trial. At the time the NDA was
submitted, full data from these trials was not available. In the CMC section of the CRL, the FDA requested information regarding
testing specifications and assay validation. The FDA did not request additional clinical studies in the CRL. We met with the FDA
in May 2011 to clarify the FDA&rsquo;s requests, and in July 2011 we submitted our reply to the CRL. In August 2011, the FDA notified
us that it had accepted for review the resubmission of the taliglucerase alfa NDA, had deemed the resubmission a class 2, or 6-month,
response and established February 1, 2012 as the new PDUFA date. In December 2011, the FDA notified us that it had decided to extend
the PDUFA date to May 1, 2012. In its notification, the FDA stated that its decision related to </FONT>certain clinical information
regarding taliglucerase alfa we had submitted in November 2011 in response to an FDA request. The requested information related
mainly to the presentation of select data provided in the NDA.&nbsp;&nbsp;As this information was requested and provided within
90 days of the February 1, 2012 PDUFA goal date, the FDA had the option to extend the PDUFA goal date to provide adequate time
for the FDA to complete its review. A three-month extension cycle is the standard period granted. No additional data was requested
by the FDA in the notification, nor were we notified of any specific deficiency in the taliglucerase alfa NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the fourth quarter of 2010, Pfizer, our commercialization partner,
filed, with our cooperation, an MAA for taliglucerase alfa with the EMA. As part of its ongoing review of the MAA, the EMA delivered
a list of outstanding points to be addressed by the applicant. Among the topics currently in discussion, is the orphan drug designation
and exclusivity granted by the EMA/European Commission to VPRIV, which could prevent the marketing authorization of taliglucerase
alfa in the European Union for a 10-year market exclusivity period commencing as of the August 2010 marketing authorization of
VPRIV in the European Union. As part of the MAA procedure, Pfizer, with our cooperation, is challenging VPRIV's orphan market protection
with respect to taliglucerase alfa pursuant to the EU orphan drug regulation. The EU orphan drug regulation provides for the possibility
of such a challenge, and for an exception to this exclusivity to be granted, based on a number of factors, including contribution
to patient care, clinical, supply, capacity and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Following the submission of the taliglucerase alfa MAA to the EMA,
a good manufacturing practices, or GMP, audit of our manufacturing facility was performed and it was found compliant with EMA GMP
in December 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In January 2010, the EMA's Committee for Orphan Medicinal Products,
or COMP, after reviewing all relevant clinical data, recommended that the European Commission grant orphan drug designation to
taliglucerase alfa for the treatment of Gaucher disease and in March 2010, the European Commission granted orphan designation to
taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition, marketing applications have been submitted for taliglucerase
alfa with each of the Israeli MOH, ANVISA and the Australian TGA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In February
2010, the Israeli MOH completed a successful GMP audit of our manufacturing facilities in Carmiel, Israel. The audit was performed
as part of the Israeli MOH&rsquo;s evaluation of our manufacturing process for taliglucerase alfa. On February 20, 2011, we received
a letter from the FDA notifying us that the FDA had completed its review of the Establishment Inspection Report in connection with
the FDA&rsquo;s inspection of our facility, and that the FDA had classified our facility as acceptable. In June 2011, ANVISA completed
a successful GMP audit of the facility and determined that the facility is acceptable and in </FONT>December 2011, the IMB completed
a successful GMP audit of our facility and issued a Certificate of GMP Compliance of a Manufacturer for the facility. The IMB certificate
is accepted by all health authorities in the European Union under the European Union's centralized marketing authorization procedure,
and by authorities of several other countries that recognize EU certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In addition
to the completed phase III clinical trial we completed in September 2009, we initiated a double-blind, follow-on extension study
as part of the trial during the second quarter of 2008. Eligible patients who successfully completed nine months of treatment in
our phase III clinical trial were offered the opportunity to participate in the extension study and continue to receive taliglucerase
alfa at the same dose they received in the phase III clinical trial for an additional 15 months in a blinded manner. In February
2012, we announced data from 26 adult patients enrolled in the trial. According to the data, after 24 months, patients continued
to demonstrate a significant improvement in all parameters with a similar safety profile as seen in the phase III clinical trial.
</FONT>Furthermore, those patients who were followed specifically for their bone parameters using Quantitative Chemical Shift Imaging
(QCSI) MRI continued to show bone marrow improvement over time.<FONT STYLE="font-family: Times New Roman, Times, Serif"> We have
also initiated a home care treatment program for patients enrolled in the extension study. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the second quarter of 2011 we successfully completed a nine-month,
worldwide, multi-center, open-label, switch-over clinical study evaluating the safety and efficacy of switching Gaucher patients
from with Cerezyme<SUP> </SUP>to taliglucerase alfa. The results of the switchover trial demonstrate that over the nine-month treatment
period, patients remained stable with regard to spleen volume, liver volume, platelet count and hemoglobin concentration, the efficacy
endpoints of the switchover trial, after switching from Cerezyme to taliglucerase alfa. The safety analysis of the switchover trial
demonstrated that taliglucerase alfa was well tolerated, and no drug related serious adverse events were reported. Patients in
the extension trial and the switchover trial are still being treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In December 2009, we filed a proposed pediatric investigation plan
to the Pediatric Committee of the EMA, which was approved during the first quarter of 2010. We have since initiated the pediatric
study, completed enrollment of all the na&iuml;ve pediatric patients required according to the study protocol and are in the final
stages of pediatric patient enrollment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 30, 2009, Protalix Ltd. and Pfizer entered into the
Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase
alfa. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa
in Israel. In connection with the execution of the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60.0 million
in connection with the execution of the agreement and subsequently paid Protalix Ltd. an additional $5.0 million upon its filing
of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. is also eligible to receive potential
milestone payments totaling $50.0 million for the successful achievement of other regulatory milestones. According to the agreement,
Pfizer and Protalix Ltd. are required to share future revenues and expenses for the development and commercialization of taliglucerase
alfa on a 60% and 40% basis, respectively, and have agreed to a specific allocation of the responsibilities for the continued development
efforts for taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Although taliglucerase alfa has not yet been approved for commercial
sale, patients are being treated with taliglucerase alfa, both in the framework of our clinical trials and related studies and
in compassionate use programs, special access agreements, named patient provisions and other programs designed to make sure that
treatments are available to Gaucher patients in light of recent shortages of approved treatments. In July 2009, following a request
by the FDA, we submitted a treatment protocol to the FDA in order to address an expected shortage of the current enzyme replacement
therapy approved for Gaucher disease. The treatment protocol was approved by the FDA in August 2009, and we are continuing to treat
patients in the United States under this protocol. On July 13, 2010, we announced that the French regulatory authority had granted
an ATU for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health
Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.
This ATU allows patients with Gaucher disease in France to receive treatment with taliglucerase alfa before marketing authorization
for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations
to hospitals. In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher disease patients
under special access agreements or Named Patient provisions in Brazil and in the rest of the world. Hundreds of patients, in the
aggregate, have been treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On August 10, 2010, Pfizer entered into a $30 million short-term
supply agreement with the Ministry of Health of Brazil pursuant to which Protalix and Pfizer have provided taliglucerase alfa to
the Ministry of Health of Brazil for the treatment of patients with Gaucher disease. During the first quarter of 2011, we and Pfizer
supplied the remaining products deliverable under the short-term supply agreement. Revenue generated from the Ministry of Health
of Brazil was recorded by Pfizer, and we recorded our share of the revenue in accordance with the terms and conditions of the Pfizer
Agreement. During the second and fourth quarters of 2011, the Ministry of Health of Brazil requested that Pfizer consider the replacement
of certain vials that might expire during 2012. As a result, Pfizer recorded an allowance for sales return. If and when such vials
are replaced, revenues will be recorded upon the supply of such replaced vials, and if it is determined that there is no longer
a need for the replacement of vials, the allowance will be reversed and the revenues will be recognized accordingly. In addition,
we and the Ministry of Health of Brazil are in discussions relating to a possible long-term supply agreement that contemplates,
among other matters, providing certain components of our manufacturing technology to the Ministry of Health of Brazil for implementation
by it in Brazil. We are currently unable to assess whether these discussions will result in an agreement and we can make no assurance
that we will be able to enter into such an agreement on favorable terms, if at all. In any event, we do not expect to enter into
a long-term supply agreement with the Ministry of Health of Brazil until we receive marketing approval of taliglucerase alfa from
the FDA or ANVISA, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Although Gaucher disease is a relatively rare disease,
it represents a large commercial market due to the severity of the symptoms and the chronic nature of the disease. According
to public reports by Sanofi, consolidated sales of Cerezyme were &euro;441.0 million (or $579.6 million), a growth of 11.1% compared
to the same period in 2010. According to Genzyme, it has suffered interruptions and other limitations in its Cerezyme
production and release since September 2009 and, as a result, Cerezyme supplies have been limited. Shire reported annual
worldwide sales of VPRIV of approximately $256 million in 2011, a growth of 79% compared to the same period in 2010 (VPRIV
was approved for sale in the United States in February 2010 and in the European Union in August 2010).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:
(1) PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans;
(2) PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications;
(3) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor
(TNFR) and an antibody portion, which is being developed as a treatment of certain immune diseases such as rheumatoid arthritis,
juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis; (4) an orally administrated glucocerebrosidase
enzyme for treating Gaucher disease patients utilizing the oral delivery of the recombinant enzyme produced within carrot cells;
and (5) two additional undisclosed therapeutic proteins, both of which are being evaluated in animal studies. We participated in
a pre IND meeting with respect to one of the undisclosed product candidates in the first quarter of 2012 and a pre IND meeting
for the second candidate is planned for later this year. In March 2010, we initiated a preliminary phase I clinical trial of PRX-105
which we completed in June 2010. We are currently preparing for further efficacy trials of this product candidate in larger animals.
In our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that we will use live nerve gas rather
than an analogue in the proposed additional efficacy trials in animals. In December 2010, we held a pre- IND meeting with the FDA
with respect to PRX-102. We completed preclinical trials in small and large animals with respect to PRX-102, and we expect to submit
an IND to the FDA during the second quarter of 2012 in connection with an anticipated phase I/II clinical study of PRX-102 in Fabry
patients, and to initiate the trial once the IND is approved, if at all. In December 2011 we held a pre IND meeting with respect
to PRX 106 and we expect to submit an IND around year end. We are also conducting pre clinical trials of our orally-administrated
glucocerebrosidase enzyme for the treatment of Gaucher disease in small and large animals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Except for the rights to commercialize taliglucerase alfa worldwide
(other than Israel) which we licensed to Pfizer, we hold the worldwide commercialization rights to our proprietary development
candidates, and we intend to establish an internal, commercial infrastructure and targeted sales force to market taliglucerase
alfa in Israel and our other products, if approved, in North America, the European Union and in other significant markets, including
Israel. In addition we are continuously evaluating potential strategic marketing partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">In September 2009, we announced preliminary preclinical
data regarding pr-antiTNF. Our pr-antiTNF product candidate has an amino acid sequence that is similar to Enbrel<SUP>&reg;</SUP>
which is one of the treatments for patients of those diseases. We believe that we may be able to reduce the development risks and
time to market for our product candidates as our product candidates are based on well-understood proteins with known biological
mechanisms of action. Based on our pre IND meeting with the FDA held in December 2011, we believe we may submit an IND around year
end and, if approved, commence a phase I clinical trial shortly thereafter with no need for an external partner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our business is conducted by our wholly-owned
subsidiary, Protalix Ltd., which we acquired through a reverse merger transaction effective December 31, 2006. The merger transaction
was treated as a recapitalization for accounting purposes and, as such, the results of operations discussed below are those of
Protalix Ltd. Prior to the merger transaction, we had not conducted any operations for several years. Protalix Ltd. was originally
incorporated in Israel in December 1993. Since its inception in December&nbsp;1993, Protalix Ltd. has generated significant losses
in connection with its research and development, including the clinical development of taliglucerase alfa. Since we do not generate
significant revenue from any of our product candidates, we expect to continue to generate losses in connection with the continued
clinical development of taliglucerase alfa and the research and development activities relating to our technology and other drug
candidates. We except that our expenditures in connection with the research and development activities will continue to represent
a significant portion of our expenses for the next several years, and will require further financial resources if the activities
are successful. As a result, we believe that our operating losses may continue to be substantial over the next several years. However,
if taliglucerase alfa is launched successfully, we anticipate that we will generate revenues to offset any such losses. We may
need to obtain additional funds for the commercialization of our lead product, taliglucerase alfa, and to further develop the research
and clinical development of our other programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our significant accounting policies are more fully described in
Note&nbsp;1 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K. We believe that the
accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments,
including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates
under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Functional Currency</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">The currency of the primary economic
environment in which our operations are conducted is the U.S. dollar. </FONT>As we have no significant source of revenues, we considered
the currency of the primary economic environment to be the currency in which we expend cash. Most of our expenses and capital expenditures
are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars.<FONT STYLE="color: black">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Currently, our sole source of revenues comes from
sales of taliglucerase alfa pursuant to our license agreement with Pfizer. We recognize revenue when the earnings process is complete,
which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery
of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We recognize revenue and milestone payments received
pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements
with multiple deliverables. Pursuant to this guidance, we determine whether our arrangement with Pfizer involves multiple revenue-generating
deliverables that should be accounted for as a combined unit of accounting or separate units of accounting for revenue recognition
purposes. If we determine that there are multiple units of accounting, the consideration from the arrangement is allocated among
the separate units based on a relative fair value allocation. If the arrangement represents a single unit of accounting, the revenue
is recognized over the performance obligation period. As the arrangement with Pfizer requires our continued involvement with respect
to the proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payments we received from Pfizer
are deferred and recognized over the related performance period. We estimated the performance period of 14 years based on the date
that the last relevant patent relating to taliglucerase alfa expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under the terms and conditions of the Pfizer Agreement,
we are entitled to 40% of the net profits or loss from sales of taliglucerase alfa by Pfizer and reimbursement of our certain related
expenses we incur in connection with Pfizer's sales. We retained all rights to taliglucerase alfa in Israel. We recognize our share
of net profit or loss under the Pfizer Agreement based on reports we receive from Pfizer summarizing the results of the collaborative
activities under the agreement for the applicable period. Under the terms of the Pfizer Agreement, for its subsidiaries operating
outside the United States, financial information is included based on the fiscal year ending November 30, while financial information
for the U.S. entity is included based on the fiscal year ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We recognize revenues received from the sale of
a product to Pfizer upon delivery to Pfizer. The revenues represent our cost with respect to the product sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Research and Development Expense</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect our research and development expense to remain our primary
expense in the near future as we continue to develop our product candidates. Research and development expense consists of:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="width: 3%; font: 10pt Symbol">&middot;</TD>
    <TD STYLE="width: 94%; font-size: 10pt">internal costs associated with research and development activities;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&middot;</TD>
    <TD STYLE="font-size: 10pt">payments made to third party contract research organizations, investigative sites and consultants;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&middot;</TD>
    <TD STYLE="font-size: 10pt">manufacturing development costs;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&middot;</TD>
    <TD STYLE="font-size: 10pt">personnel-related expenses, including salaries, benefits, travel, and related costs for the personnel involved in research and development;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&middot;</TD>
    <TD STYLE="font-size: 10pt">activities relating to the advancement of product candidates through preclinical studies and clinical trials; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Symbol">&nbsp;</TD>
    <TD STYLE="font: 10pt Symbol">&middot;</TD>
    <TD STYLE="font-size: 10pt">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, as well as laboratory and other supplies.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table identifies our current major research and development
projects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: windowtext 1pt solid; font-size: 10pt; font-weight: bold"><B>Project</B></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; border-bottom: windowtext 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Status</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: windowtext 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><B>Expected Near Term Milestones</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">taliglucerase alfa for the treatment of Gaucher disease</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NDA and MAA (EMA, ANVISA and the Israeli MOH)
        filed</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">PDUFA date of May 1, 2012 from the FDA; respond to EMA query</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">PRX 102 &ndash; alpha-GAL-A</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Preclinical</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">File IND and initiate phase I/II clinical trials</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><BR>Acetylcholinesterase</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Phase I clinical trial</P></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Additional phase I clinical trials</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">pr-antiTNF</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Research</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Complete pre clinical development; file IND and initiate phase I clinical trials</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All of our projects, other than taliglucerase alfa and our acetylcholinesterase
product, are in the preclinical or research phase with relatively immaterial costs. Most of our research and development costs
were incurred in connection with our phase III clinical trial of taliglucerase alfa. Our internal resources, employees and infrastructure
are not tied to any individual research project and are typically deployed across all of our projects. We currently do not record
and maintain research and development costs per project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The costs and expenses of our projects are partially funded by grants
we have received from the OCS. Each grant is deducted from the related research and development expenses as the costs are incurred.
For additional information regarding the grant process, see &ldquo;Business&mdash;Israeli Government Programs&mdash;Encouragement
of Industrial Research and Development Law, 1984&rdquo; in Item 1 of this Annual Report. There can be no assurance that we will
continue to receive grants from the OCS in amounts sufficient for our operations, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At this time, due to the inherently unpredictable nature
of preclinical and clinical development processes and given the early stage of our preclinical product development programs,
we are unable to estimate with any certainty the costs we will incur in the continued development of the product candidates
in our pipeline for potential commercialization. Clinical development timelines, the probability of success and
development costs can differ materially from expectations. While we are currently focused on advancing each of our product
development programs, our future research and development expenses will depend on the clinical success of each product
candidate, as well as ongoing assessments of each product candidate&rsquo;s commercial potential. In addition, we cannot
forecast with any degree of certainty which product candidates may be subject to future collaborations, when such
arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital
requirements. See &ldquo;Risk Factors&mdash;All of our product candidates other than taliglucerase alfa and our
acetylcholinesterase product are in pre-clinical or research stages. If we are unable to develop and commercialize our
product candidates, our business will be adversely affected&rdquo; and &ldquo;&mdash;We may not obtain the necessary U.S.,
EMA or other worldwide regulatory approvals to commercialize our drug candidates in a timely manner, if at all, which would
have a material adverse effect on our business, financial condition and results of operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We expect our research and development expenses to continue to be
our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development programs
for our product candidates other than taliglucerase alfa. The lengthy process of completing clinical trials and seeking regulatory
approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical
trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development
expense to increase and, in turn, have a material adverse effect on our operations. We filed a revised NDA for taliglucerase alfa
with the FDA in the third quarter of 2011 and currently have a PDUFA date of May 1, 2012. In addition, during 2010, we submitted
a marketing application regarding taliglucerase alfa to the Israeli MOH and similar applications have been submitted to each of
the EMA, ANVISA and the Australian TGA. Due to the factors set forth above, we are not able to estimate with any certainty when
we would recognize any net cash inflows from our projects. See &ldquo;Risk Factors&mdash;Clinical trials are very expensive, time-consuming
and difficult to design and implement and may result in unforeseen costs which may have a material adverse effect on our business
and results of operations.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Share-Based Compensation</I> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The discussion below regarding share-based compensation
relates to share-based compensation paid by Protalix Ltd., our wholly-owned subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">In accordance with the guidance, we record the
benefit of any grant to a non-employee and remeasure the benefit in any future vesting period for the unvested portion of the grants,
as applicable. In addition, we use the straight-line accounting method for recording the benefit of the entire grant, unlike the
graded method we use to record grants made to employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We measure share-based compensation cost for all
share-based awards at the fair value on the grant date and recognition of share-based compensation over the service period for
awards that we expect will vest. The fair value of stock options is determined based on the number of shares granted and the price
of our ordinary shares, and calculated based on the Black-Scholes valuation model. We recognize such value as expense over the
service period, net of estimated forfeitures, using the accelerated method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For purposes of determining the fair value of the options to purchase
common stock granted to employees and non-employees during the fiscal year ended December 31, 2011, including shares held by non
employees that vested during such period, our management used the fair value of our common stock which was the closing sale price
of our common stock on the NYSE Amex on the date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The guidance  requires companies to estimate
the expected term of the option rather than simply using the contractual term of an option. Because of lack of data on past
option exercises by employees, the expected term of the options could not be based on historic exercise patterns.
Accordingly, we adopted the simplified method, according to which companies may calculate the expected term as the average
between the vesting date and the expiration date, assuming the option was granted as a &ldquo;plain vanilla&rdquo;
option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">In performing the valuation, we assumed an
expected 0% dividend yield in the previous years and in the next years. We do not have a dividend policy and given the lack
of profitability, dividends are not expected in the foreseeable future, if at all. The guidance stipulates a number of
factors that should be considered when estimating the expected volatility, including the implied volatility of traded
options, historical volatility and the period that the shares of the company are being publicly traded. As we did not have
any traded shares or options for periods before December 31, 2006, the expected volatility figures used in this valuation
have been calculated utilizing a blended approach by using the historical volatility of traded shares of similar companies
for periods prior to December 31, 2006 and our own traded shares for periods subsequent to December 31, 2006. In addition, we
examined the standard deviation of shares of similar biotechnology companies that engage in research and
development, generally with no significant revenues. We found that the volatility of our shares and the shares of comparable
companies was in the range of 40%-75% over periods of three to six years. The volatility used for each grant differed based
on its expected term. For the term of each grant of our options, the historical volatility was calculated based upon the
overall trading history of the common stock of comparable companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
risk-free interest rate described above has been based on the implied yield of U.S. federal reserve zero&ndash;coupon government
bonds. The remaining</FONT> term of the bonds used for each valuation was equal to the expected term of the grant. This methodology
has been applied to all grants valued by us. The guidance requires the use of a risk&ndash;free interest rate based on the implied
yield currently available on zero&ndash;coupon government issues of the country in whose currency the exercise price is expressed,
with a remaining term equal to the expected life of the option being valued. This requirement has been applied for all grants valued
as part of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Year Ended December&nbsp;31, 2011 Compared to the Year Ended
December&nbsp;31, 2010</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We recorded revenue of $8.4 million for the year
ended December&nbsp;31, 2011, an increase of $1.8 million or 27%, compared to revenue of $6.6 million for the year ended December
31, 2010. The increase resulted primarily from increases in the supply of taliglucerase alfa vials to Pfizer during the year ended
December 31, 2011. Revenues also include the amortization of the $65 million upfront and milestone payments received from Pfizer.
The payments were recorded as deferred revenue and the amounts will be<FONT STYLE="font-family: Times New Roman, Times, Serif">
amortized over the performance period, estimated at approximately 14 years, at a rate of approximately $1.1 million per quarter</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We recorded $5.4 million of loss as our
share in the collaboration under the Pfizer Agreement during the year ended December&nbsp;31, 2011, a decrease of $10.0
million, or 217%, compared to the $4.6 million of income recorded for the year ended December 31, 2010. Our share in the
collaboration's loss for the year ended December 31, 2011 resulted primarily from our 40% share of the allowance for sales
return of taliglucerase alfa recorded by Pfizer in connection with the short term supply agreement between Pfizer and the
Ministry of Health of Brazil. During 2011, the Ministry of Health of Brazil requested that
Pfizer consider the replacement of certain vials that might expire during 2012. As a result, Pfizer recorded an allowance for
sales return. The allowance was partially offset by our share in the income generated through sale of taliglucerase alfa via
the ATU program in France. Under the terms and conditions of the Pfizer Agreement, we record income or loss equal to 40% of
the profit or loss realized from sales of taliglucerase alfa and related expenses incurred based on reports we receive from
Pfizer summarizing the results of the collaborative activities under the Pfizer Agreement for the applicable period. Under
the terms and conditions of the Pfizer Agreement, financial information of Pfizer&rsquo;s subsidiaries that operate outside
the United States is included based on the fiscal year ending November 30, while financial information for the U.S. entity is
included based on the fiscal year ending December 31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Research and development expenses were $37.8&nbsp;million
for the year ended December&nbsp;31, 2011, an increase of $127,000 from $37.7&nbsp;million for the year ended December&nbsp;31,
2010. The research and development expenses for the year ended December 31, 2011 were partially offset by grants received from
the OCS of approximately $3.3 million, and $3.4 million of reimbursements for certain expenses in accordance with the terms and
conditions of the Pfizer Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We expect research and development expenses to
continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our
product candidates<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">General and administrative expenses were $6.9&nbsp;million for the
year ended December&nbsp;31, 2011, an increase $55,000 from $6.9&nbsp;million for the year ended December&nbsp;31, 2010. We expect
that our general and administrative expenses will increase as we become a commercial company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Financial income was $2,000 for the year ended December 31, 2011,
a decrease of $966,000, or 99%, from $968,000 for the year ended December 31, 2010. The decrease resulted primarily from the devaluation
of the New Israeli Shekel against the U.S. dollar and lower interest rates available for short term deposits during the year ended
December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Year Ended December&nbsp;31, 2010 Compared to the Year Ended
December&nbsp;31, 2009</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We recorded revenue of $6.6 million for the year
ended December&nbsp;31, 2010 compared to revenue of $388,000 for the year ended December 31, 2009. The increase resulted primarily
from the amortization of the $65.0 million of upfront and milestone payments received from Pfizer over the entire fiscal year.
Such payments were amortized over one month for the year ended December 31, 2009. The payments were recorded as deferred revenue
and the amounts will be<FONT STYLE="font-family: Times New Roman, Times, Serif"> amortized over the performance period, estimated
at approximately 14 years, at a rate of approximately $1.1 million per quarter</FONT>. The amortization during the year ended December
31, 2010 resulted in the recognition of revenue of $4.6 million, or an increase of $4.2 million, from $388,000 recognized during
the year ended December 31, 2009. <FONT STYLE="font-family: Times New Roman, Times, Serif">In addition, we recorded revenues in
the amount of approximately $2.0 million in connection with products delivered to Pfizer under our license agreement. No products
were sold during 2009.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We recorded $4.6 million of income as our share
in the collaboration under the Pfizer Agreement during the year ended December&nbsp;31, 2010. This income resulted primarily from
our share of the approximately $21.8 million of revenues generated by Pfizer&rsquo;s sale of taliglucerase alfa to the Ministry
of Health of Brazil under the short term supply agreement during Pfizer's 2010 fiscal year. No share in the collaboration was recorded
for the year ended December&nbsp;31, 2009. Under the terms and conditions of the Pfizer Agreement, we recorded revenue equal to
40% of the profits realized from sales of taliglucerase alfa, and related expenses incurred based on reports we received from Pfizer
summarizing the results of the collaborative activities under the agreement for the applicable period. Under the terms of the Pfizer
Agreement, for its subsidiaries operating outside the United States, financial information is included based on the fiscal year
ending November 30, while financial information for the U.S. entity is included based on the fiscal year ending December 31<FONT STYLE="font-family: Times New Roman, Times, Serif">.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Research and development expenses were $37.7&nbsp;million
for the year ended December&nbsp;31, 2010, an increase of $10.3 million, or 38%, from $27.4&nbsp;million for the year ended December&nbsp;31,
2009. The increase resulted primarily from an increase of $2.7&nbsp;million in development expenses related to salaries for personnel
involved in research and development, and $4.1 million in related subcontractors and consultants expenses, mainly in connection
with our expanded access program for taliglucerase alfa. The increase in research and development expenses was partially offset
by the recognition of grants from the OCS and Pfizer&rsquo;s reimbursement of us, collectively equal to $7.7 million. The offsets
to our research and development expenses for the year ended December 31, 2010 represent an increase of approximately $2.0 million,
or 35%, compared to the recognition of grants from the OCS equal to $5.7 million that offset our research and development expenses
for the year ended December 31, 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">General and administrative expenses were $6.9&nbsp;million
for the year ended December&nbsp;31, 2010, a decrease of $268,000, or approximately 4%, from $7.1&nbsp;million for the year ended
December&nbsp;31, 2009. The decrease resulted primarily from a $389,000 decrease in salaries expense during 2010. We expect that
our general and administrative expenses will increase as we add additional personnel and continue to comply with the reporting
and other obligations applicable to public companies in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Financial income was $968,000 for the year ended
December&nbsp;31, 2010, an increase of $439,000, or approximately 83%, compared to $529,000 for the year ended December&nbsp;31,
2009. The increase resulted primarily from increases in the exchange rate that resulted in income of approximately $546,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">As a result of our significant research and development
expenditures and the lack of any approved products to generate significant product sales revenue, we have not been profitable and
have generated operating losses since our inception. To date, we have funded our operations primarily with proceeds equal to $31.3&nbsp;million
from the sale of  convertible preferred and ordinary shares of Protalix Ltd., and an
additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection with the sale of such  shares,
through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50&nbsp;million in connection with
an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we generated gross proceeds
of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings of our common stock. We believe
that the funds currently available to us as are sufficient to satisfy our capital needs for at least 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table summarizes our past funding
sources:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid">Security</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Number&nbsp;of&nbsp;Shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">Amount(1)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%">Ordinary Shares</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1996-2000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">18,801,527</TD><TD STYLE="width: 1%; text-align: left">(2)&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Series&nbsp;A Convertible Preferred Shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2001</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,635,090</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Series&nbsp;B Convertible Preferred Shares(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2004-2005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,175,621</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Series&nbsp;C Convertible Preferred Shares(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2005</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,513,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Ordinary Shares(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,637,880</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2007</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2012</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 15%"></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">(1)</TD>
    <TD STYLE="width: 96%; font-size: 10pt">Gross proceeds; does not include proceeds from warrant exercises.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">(2)</TD>
    <TD STYLE="font-size: 10pt">Includes the issuance of ordinary shares to founders.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">(3)</TD>
    <TD STYLE="font-size: 10pt">During 2005, 1,035,569 Series&nbsp;B Preferred Shares were converted on a 1:1 basis into Series&nbsp;C Preferred Shares for no additional consideration.&nbsp; Also, in connection with such funding, warrants to purchase 181,228 Series&nbsp;B Preferred Shares were issued for no additional consideration with an aggregate exercise price of $103,000.&nbsp; As of the closing date of the merger, 168,034 of such warrants were exercised for net proceeds equal to approximately $96,000 and 13,194 of such warrants were forfeited.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">(4)</TD>
    <TD STYLE="font-size: 10pt">In connection with such funding, warrants to purchase an additional 8,862,803 Series&nbsp;C Preferred Shares were granted to the investors for no additional consideration with a total exercise price equal to $9.0 million.&nbsp; As of the closing date of the merger, 5,296,279 of such warrants were exercised for net proceeds equal to $8.7&nbsp;million, 3,384,502 were assumed by our company and 182,022 expired.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">(5)</TD>
    <TD STYLE="font-size: 10pt">In connection with such funding, warrants to purchase 3,875,416 ordinary shares were issued for no additional consideration with an aggregate exercise price equal to $5.3&nbsp;million.&nbsp; These warrants were exercised in full on January&nbsp;31, 2007.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In addition to the foregoing, <FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently
paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.'s meeting a certain milestone. Protalix Ltd. is also eligible
to receive potential milestone payments of up to $50.0 million for the successful achievement of other regulatory-related milestones.
Protalix Ltd. is also entitled to payments equal to 40% of the net profits earned by Pfizer on its sales of taliglucerase alfa.
In calculat</FONT>ing net profits there are certain agreed upon limits on the amounts that may be deducted from gross sales for
certain expenses and costs of goods sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Cash Flows </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Net cash used in operations was $23.6
million for the year ended December 31, 2011. The net loss for 2011 of $36.5 million was further increased by a decrease in
deferred revenues of approximately $3.0 million. The net loss was partially offset by non-cash charges for share-based
compensation of $886,000, depreciation of $3.6 million and a decrease in accounts receivable of approximately $3.9 million
and an increase in accounts payable of $6.1 million. Net cash used in investing activities for 2011 was $5.9 million and
consisted primarily of purchases of property and equipment.  Net cash provided from financing activities during 2011 was
approximately $20.9 million primarily due to our underwritten public offering of common stock in the first quarter of
2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Net cash used in operations was $38.5 million
for the year ended December 31, 2010. The net loss for 2010 of $29.0 million was further increased by an increase in accounts receivable
of approximately $6.9 million and a decrease of $4.6 million in deferred revenues. The net loss was partially offset by non-cash
charges for share-based compensation of $1.3 million, and depreciation of $3.1 million. Net cash used in investing activities for
2010 was $8.0 million and consisted primarily of purchases of property and equipment. Net cash provided from financing activities
during 2010 was approximately $501,000 due to option exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We expect that our operating losses may continue
to be substantial over the next several years. However, we anticipate that we will generate revenues to offset any such losses
upon the successful launch of taliglucerase alfa, if at all. We expect to incur significant research and development expenses,
including expenses related to the hiring of personnel and the advancement of our additional pipeline of product candidate into
the various clinical trials. We expect that general and administrative expenses will increase as we expand our finance and administrative
staff, add infrastructure, and incur additional costs related to our preparation for the commercial phase for our lead product
candidate, taliglucerase alfa. In addition, we are working on the expansion of our manufacturing facility that would meet approximately
half of the market for our lead product candidate, which would increase our capital expenditures significantly and is estimated
to cost approximately $25.0 million in total.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We believe that our existing cash and cash equivalents
and the <FONT STYLE="color: black">net proceeds from our public underwritten offering of February 2012 </FONT>will be sufficient
to enable us to fund our operating expenses and capital expenditure requirements at least for the next 12 months. We have based
this estimate on assumptions that are subject to change and may prove to be wrong, and we may be required to use our available
capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development
and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating
expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our future capital requirements will depend on
many factors, including the progress and results of our clinical trials, costs of commercialization activities, including product
marketing, sales and distribution and whether these efforts will be performed internally or through some form of collaboration
with third parties, the duration and cost of discovery and preclinical development, and laboratory testing and clinical trials
for our product candidates, the timing and outcome of regulatory review of our product candidates, the costs involved in preparing,
filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights and the number and
development requirements of other product candidates that we pursue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We may need to finance our future cash needs through
public or private equity offerings, debt financings, or additional corporate collaboration and licensing arrangements. We currently
do not have any commitments for future external funding, other than the potential regulatory-related milestone payments from Pfizer.
We may need to raise additional funds more quickly if one or more of our assumptions prove to be incorrect or if we choose to expand
our product development efforts more rapidly than we presently anticipate. We may also decide to raise additional funds even before
we need them if the conditions for raising capital are favorable. Any sale of additional equity or debt securities will likely
result in dilution to our shareholders. The incurrence of indebtedness would result in increased fixed obligations and could also
result in covenants that would restrict our operations. Additional equity or debt financing, grants or corporate collaboration
and licensing arrangements may not be available on acceptable terms, if at all. If adequate funds are not available, we may be
required to delay, reduce the scope of or eliminate our research and development programs, reduce our planned commercialization
efforts or obtain funds through arrangements with collaborators or others that may require us to relinquish rights to certain product
candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Inflation generally affects us by increasing our
cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the years ended December&nbsp;31, 2009, 2010 or 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Currency fluctuations could affect us by increased
or decreased costs mainly for goods and services acquired outside of Israel. We do not believe currency fluctuations have had a
material effect on our results of operations during the years ended December&nbsp;31, 2009, 2010 or 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We have no off-balance sheet arrangements as of
December&nbsp;31, 2010 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table summarizes our significant
contractual obligations at December 31, 2011 (in thousands):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Less&nbsp;than&nbsp;1&nbsp;year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">1-3&nbsp;years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">3-5&nbsp;years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">More&nbsp;than&nbsp;5 <BR>years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 35%; text-align: left; text-indent: 0in">Operating lease obligations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5,046</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,415</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,110</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,521</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Purchase obligations (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,758</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,758</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">Certain clinical contract and building contractor obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">821</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">657</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Liability for employee rights
    upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: 0in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,325</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,830</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,274</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,521</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,700</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;(1) Represents open purchase orders issued
to certain suppliers and other vendors mainly in connection with our research and development activities that were outstanding
as of December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The foregoing table does not include (i) annual license
fees, which are currently immaterial, (ii) payments we may be required to make to certain of our licensors in the time periods
set forth above upon the achievement of agreed-upon milestones and (iii) royalty payments payable by us to certain of our licensors
in connection with the commercial sale of our product candidates, if any. If all of the contingencies with respect to milestone
payments under our research and development agreements are met, the aggregate milestone payments payable would be approximately
$950,000 and would be payable, if at all, as our projects progress over the course of a number of years. The royalty payments
payable in connection with sales of each of our product candidates, if at all, shall not exceed low, single-digit percentages of
net sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Selected Quarterly Financial Data (unaudited)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="30" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2010</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="30" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center">(U.S. dollars in thousands)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">March 31</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">June 30</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Sept. 30</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec. 31</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">March 31</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">June 30</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Sept. 30</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Dec. 31</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 28%; font-size: 10pt">Revenues</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">1,141</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">1,141</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">3,184</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">1,176</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">4,128</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">764</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">1,132</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 6%; font-size: 10pt; text-align: right">2,362</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7,955</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">10,041</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,474</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">8,528</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">5,052</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">13,689</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">8,875</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">8,913</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Net loss per share of common stock, basic and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.12</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.11</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.06</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Item&nbsp;7A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quantitative
and Qualitative Disclosures About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the dollar. We are currently have no significant source of revenues; therefore we consider
the currency of the primary economic environment to be the currency in which we expend cash. Approximately 50% of our expenses
and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars.
Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using
the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue
and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency
translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Approximately 35% of our costs, including salaries, expenses and
office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Year&nbsp;Ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 61%">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.933</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.733</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">3.578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at year-end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.821</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To date, we have not engaged in hedging transactions. In the future,
we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate
of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to
the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our exposure to market risk is confined to our
cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.25pt; text-indent: -38.25pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38.25pt; text-indent: -38.25pt"><B>Item&nbsp;8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Supplementary Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">See the Index to Consolidated Financial Statements
on Page F-1 attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.05pt; text-indent: -40.05pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.05pt; text-indent: -40.05pt"><B>Item&nbsp;9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
in and Disagreements with Accountants on Accounting and Financial Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.95pt; text-indent: -40.95pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.95pt; text-indent: -40.95pt"><B>Item&nbsp;9A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Controls
and Procedures</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Evaluation of Disclosure Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-K. The
controls evaluation was conducted under the supervision and with the participation of management, including our Chief Executive
Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure
that information required to be disclosed in our reports filed under the Exchange Act, such as this Form 10-K, is recorded, processed,
summarized and reported within the time periods specified in the Commission&rsquo;s rules and forms. Disclosure controls and procedures
are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief
Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The evaluation of our disclosure controls
and procedures included a review of the controls&rsquo; objectives and design, our implementation of the controls and their effect
on the information generated for use in this Form 10-K. In the course of the controls evaluation, we reviewed identified data errors,
control problems or acts of fraud, and sought to confirm that appropriate corrective actions, including process improvements, were
being undertaken. This type of evaluation will be performed on a quarterly basis so that the conclusions of management, including
the Chief Executive Officer and Chief Financial Officer, concerning the effectiveness of the disclosure controls and procedures
can be reported in our periodic reports on Form 10-Q and Form 10-K. The overall goals of these various evaluation activities are
to monitor our disclosure controls and procedures, and to modify them as necessary. Our intent is to maintain the disclosure controls
and procedures as dynamic systems that change as conditions warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Based on the controls evaluation, our Chief Executive Officer and
Chief Financial Officer have concluded that, as of the end of the period covered by this Form 10-K, our disclosure controls and
procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports
is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information
related to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief
Financial Officer, particularly during the period when our periodic reports are being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Management Report on Internal Control over Financial Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of
our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted
accounting principles. Internal control over financial reporting includes those policies and procedures that: (i) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of our company are being made
only in accordance with authorizations of management and our directors; and (iii) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Management assessed our internal control
over financial reporting as of December 31, 2011, the end of our fiscal year. Management based its assessment on criteria established
in Internal Control&mdash;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Management&rsquo;s assessment included evaluation of elements such as the design and operating effectiveness of key financial reporting
controls, process documentation, accounting policies and our overall control environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Based on our assessment, management has
concluded that our internal control over financial reporting was effective as of the end of the fiscal year to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes
in accordance with U.S. generally accepted accounting principles. We reviewed the results of management&rsquo;s assessment with
the Audit Committee of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The effectiveness of our internal control over financial
reporting as of December 31, 2011 has been audited by Kesselman &amp; Kesselman, an independent registered public accounting firm,
as stated in their report included herein.&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Our management, including our Chief Executive
Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial
reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide
only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control system
must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.
Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">There were no changes in our internal control over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended December 31,
2011 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in">Item&nbsp;9B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PART III</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43.65pt; text-indent: -43.65pt"><B>Item&nbsp;10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors,
Executive Officers and Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our directors and executive officers, their ages
and positions as of February 1, 2012 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE ALIGN="RIGHT" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: windowtext 1pt solid; font-weight: bold">Name</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: center">Age</TD>
    <TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 61%; border-bottom: windowtext 1pt solid; font-weight: bold">Position</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; font-weight: bold; text-indent: -0.15in">Directors</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Zeev Bronfeld</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">60</TD>
    <TD>&nbsp;</TD>
    <TD>Interim Chairman of the Board</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">David Aviezer, Ph.D., MBA</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">47</TD>
    <TD>&nbsp;</TD>
    <TD>Director, President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Yoseph Shaaltiel, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">58</TD>
    <TD>&nbsp;</TD>
    <TD>Director and Executive VP, Research and Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Alfred Akirov (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">71</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Amos Bar Shalev (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">59</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Yodfat Harel (1)(2)(3)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">39</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Roger D. Kornberg, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">64</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Eyal Sheratzky</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">43</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; font-weight: bold; text-indent: -0.15in">Executive Officers</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Einat Brill Almon, Ph.D.</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">52</TD>
    <TD>&nbsp;</TD>
    <TD>Senior Vice President, Product Development</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Yossi Maimon, CPA</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">41</TD>
    <TD>&nbsp;</TD>
    <TD>Vice P<FONT STYLE="color: black">resident, </FONT>Chief Financial Officer, Treasurer and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Sandra L. Lauterbach</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">43</TD>
    <TD>&nbsp;</TD>
    <TD>Vice President, Sales and Commercial Affairs</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.15in; text-indent: -0.15in">Tzvi Palash</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">55</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Operating Officer</TD></TR>
</TABLE><BR STYLE="clear: both"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%; margin-left: 0.25in">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">(1) Member of Nominating Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">(2) Member of Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">(3) Member of Compensation Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black"><B>Zeev Bronfeld.</B>&nbsp;&nbsp;Mr.
Bronfeld has served as a director of Protalix Ltd. since 1996 and as our director since December 31, 2006. Mr. Bronfeld brings
to us vast experience in management and value building of biotechnology companies. Mr. Bronfeld is an experienced businessman who
is involved in a number of biotechnology companies. He is a co-founder of Biocell Ltd. (TASE:BCEL), an Israeli publicly traded
holding company specializing in biotechnology companies and has served as its Chief Executive Officer since 1986. Mr. Bronfeld
currently serves as a director of Biocell Ltd., D. Medical Industries Ltd. (NASDAQ:DMED, TASE:DMDC), Biomedix Incubator Ltd. (TASE:BMDX),
D.N.A. Biomedical Solutions Ltd. (TASE:DNA), Gefen Biomed Investments Ltd. (TASE:GEFEN) and Nasvax Ltd. (TASE:NSVX), all of which
are public companies traded on the TASE (except D. Medical which is dual-listed on the TASE
and the Nasdaq Stock Market LLC). Mr. Bronfeld is also a director of each of the following privately-held companies: Ecocycle Israel
Ltd., Contipi Ltd., Spring Health Solutions Ltd., G-Sense Ltd., L.N. Innovative Technologies, A.T.I Ashkelon Industries Information
Technologies Ltd., The Trendlines Group, MOFET B'Yehuda &ndash; Industrial Research &amp; Development in Judea Ltd., Incubator
for Management of Technological Entrepreneurship Misgav Ltd., A.Y.M.B. Holdings and Investments Ltd., Spring-Set Health Solutions
Ltd., TransBiodiesel Ltd., Nanutra Ltd., Entera Bio Ltd., Incubator for Management of Technological Entrepreneurship Misgave Ltd.,
M.B.R.T. Development and Investments Ltd., Macrocure Ltd., Nanothera Ltd., Spearhead Investment Ltd. and Stimatix G.I. Ltd. Mr.
Bronfeld received a B.A. in Economics from the Hebrew University in 1975. We believe Mr. Bronfeld's qualifications to serve on
our Board of Directors include his years of experience in the management of private and public Israeli companies, including life
science companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black"><B>David Aviezer, Ph.D., MBA.</B>&nbsp;&nbsp;Dr.
Aviezer has served as Chief Executive Officer of Protalix Ltd. since 2002 and its director since 2005 and as our director since
December 31, 2006. On December 31, 2006, he became our President and Chief Executive Officer. Dr. Aviezer has over 15 years of
experience in biotechnology management, advancing products from early-stage research up to their regulatory approval and commercialization.
Prior to joining Protalix Ltd., from 1996 to 2002, he served as General Manager of ProChon Biotech Ltd., an Israeli company focused
on orthopedic disorders. Previously, Dr. Aviezer was a visiting scientist at the Medical Research Division of American Cyanamid,
a subsidiary of Wyeth which was subsequently acquired by Pfizer (NYSE:PFE), in New York. Since 1996, Dr. Aviezer has served as
an Adjunct Lecturer at Bar Ilan University. Dr. Aviezer is the recipient of the Clore Foundation Award and the J.F. Kennedy Scientific
Award. He holds a Ph.D. in Molecular Biology and Biochemistry from the </FONT>Weizmann Institute of Science<FONT STYLE="color: black">,
an MBA from the Bar Ilan University Business School, an M.Sc. in Biology from the </FONT>Weizmann Institute of Science<FONT STYLE="color: black">
and a B.Sc. in Biology from Bar Ilan University. We believe Dr. Aviezer's qualifications to serve on our Board of Directors include
his position as our President and Chief Executive Officer as well as his previous experience in the management of biotechnology
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black"><B>Yoseph Shaaltiel, Ph.D.</B>&nbsp;&nbsp;Dr.
Shaaltiel founded Protalix Ltd. in 1993 and has served as a member of our Board of Directors and as our Vice President, Research
and Development since December 31, 2006. Prior to establishing Protalix Ltd., from 1988 to 1993, Dr. Shaaltiel was a Research Associate
at the MIGAL Technological Center. He also served as Deputy Head of the Biology Department of the Biological and Chemical Center
of the Israeli Defense Forces and as a Biochemist at Makor Chemicals Ltd. Dr. Shaaltiel was a Postdoctoral Fellow at the University
of California at Berkeley and at Rutgers University in New Jersey. He has co-authored over 40 articles and abstracts on plant biochemistry
and holds seven patents. Dr. Shaaltiel received his Ph.D. in Plant Biochemistry from the </FONT>Weizmann Institute of Science<FONT STYLE="color: black">,
an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Ben Gurion University. We believe Dr. Shaaltiel's
qualifications to serve on our Board of Directors include his role in founding our company and his continued role in the management
of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Alfred Akirov.</B> Mr. Akirov has served as our director since
January 2008. Mr. Akirov is the founder, chairman of the Board of Directors and chief executive officer of Alrov (Israel) Ltd.
(TASE: ALRO), or Alrov Israel, an Israeli publicly-traded company listed on the TASE. Mr. Akirov founded Alrov
Israel in 1978 and it is currently one of Israel's largest real-estate companies. Alrov Israel holds shares of our company directly
and indirectly through its subsidiary, Techno-Rov Holdings (1993) Ltd., of which Alrov Israel owns 80% of the outstanding capital
stock. Mr. Akirov serves in different capacities, including chairman, chief executive officer and director, for a number of private
companies in Alrov Israel's subsidiaries and the Techno-Rov portfolios. We believe Mr. Akirov's qualifications to serve on our
Board of Directors include his years of experience in the management of Israeli businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-left: white 0.25pt solid"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Amos Bar Shalev.</B> Mr. Bar Shalev has served as our director
since July 2008. Mr. Bar Shalev served as a director of Protalix Ltd. from 2005 through January 31, 2008, and as our director from
December 31, 2006 through January 31, 2008. Mr. Bar Shalev was not nominated for reelection at our annual meeting of shareholders
on January 31, 2008. On July 14, 2008, our Board of Directors appointed Mr. Bar Shalev to serve on the board, at which time he
was reappointed to the board of directors of Protalix Ltd. as well. Mr. Bar Shalev brings to us extensive experience in managing
technology companies. Currently, Mr. Bar Shalev serves as a director of Technorov Holdings (1993) Ltd. and manages its portfolio.
In addition, he has served on the board of directors of Aposense Ltd. (TASE: APOS), an Israeli publicly-traded company listed on
the TASE, since 2011, and Highcon Systems Ltd., a privately-held Israeli company, since 2010. From 1997 through 2004, he was a
Managing Director of TDA Capital Partners, a management company of the TGF (Templeton Tadiran) Fund. From 2004 through 2007, he
was the President of Win Buyer Ltd. He has served on the board of directors of many other companies, including, among others, NESS
Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation Ltd.), Objet Geometrix, Verisity, Scitex Vision (acquired
by Hewlett Packard), Golden Wings Investment Company Ltd., the venture capital fund of the Israeli Air Force Veterans Business
Club, Win Buyer Ltd. and Sun Light Ltd. He received his B.Sc. in Electrical Engineering from the Technion, Israel in 1978 and M.B.A.
from the Tel Aviv University in 1981. He holds the highest award from the Israeli Air Force for technological achievements. We
believe Mr. Bar Shalev's qualifications to serve on our Board of Directors include his years of experience in the management of
Israeli businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Yodfat Harel.</B>&nbsp;&nbsp;Ms. Harel has served as our director
since June 2007. Since 2006, Ms. Harel has been a Managing Director of Tamares Capital Ltd., a private investment group with interests
in real estate, technology, manufacturing, leisure and media. At Tamares Capital, Ms. Harel serves as the Business Development
Director and the head of the Israel office. Prior to joining Tamares Capital, from 2004 to 2006, she was the Head of the Medical
Desk of Orbotech, Ltd. (NASDAQ:ORBK), a company providing high-tech inspection and imaging solutions for bare printed circuit board
(PCB), flat panel display (FPD) and PCB assembly manufacturing worldwide. Prior to that, from 1994 to 2003, she was a Managing
Director of Harel-Hertz Investment House Ltd., a business investment company with offices in Tel Aviv, Israel and Tokyo, Japan.
In 2002, Harel-Hertz Investment House became the Israeli representative office for ITX Corporation, a publicly-traded company in
Japan. Ms. Harel currently serves on the board of directors of Tamares Capital, Tamares Hotels, Tamares Real Estate, Storewiz and
Halman-Aldubi Provident Funds, Ltd. Ms. Harel holds a B.A. in Communication and Political Science from Bar Ilan University and
an executive M.B.A. from Bradford University, Great Britain. She has also completed programs in Directors' Studies and Advanced
Advertising and Marketing at the Israel Management Center. We believe Ms. Harel's qualifications to serve on our Board of Directors
include her experience in the management of Israeli and other businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Roger D. Kornberg, Ph.D.</B>&nbsp;&nbsp;Professor Kornberg has
served as our director since February 2008. He has served as a director of Teva Pharmaceuticals (NASDAQ:TEVA, TASE:TEVA) since
2007. Professor Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department
of Structural Biology at Stanford University, Stanford, California. He has been a member of the faculty of Stanford University
since 1972. Prior to that, he was a professor at Harvard Medical School. Professor Kornberg is a renowned biochemist and in 2006
he was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of eukaryotic transcription,
the process by which DNA is copied to RNA. Professor Kornberg is also the recipient of several awards, including the 2001 Welch
Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopold Mayer Prize, the highest
award granted in the field of biomedical sciences from the French Academy of Sciences. He received his B.S. in Chemistry from Harvard
University in 1967 and his Ph.D. in Chemistry from Stanford University in 1972. He holds honorary degrees from universities in
Europe and Israel, including the Hebrew University in Jerusalem, where he currently is a visiting professor. We believe Professor
Kornberg's qualifications to serve on our Board of Directors include his expertise in chemistry and medicine and his experience
in the academic arena.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Eyal Sheratzky.</B> Mr. Sheratzky has served as a director of
Protalix Ltd. since 2005 and as our director since December 31, 2006. Mr. Sheratzky has served as a director of Ituran Location
&amp; Control (NASDAQ:ITRN), a publicly-traded company listed on the Nasdaq, since 1995 and as a Co-Chief Executive Officer since
2003. Prior to such date, he served as an alternate Chief Executive Officer of Ituran from 2002 through 2003 and as Vice President
of Business Development from 1999 through 2002. Mr. Sheratzky serves as a director of Moked Ituran Ltd. and certain of Ituran's
other subsidiaries. Mr. Sheratzky also serves as a director of D. Medical Industries Ltd. (NASDAQ:DMED, TASE:DMDC), as well as
of Nilimedix Ltd., its subsidiary. From 1994 to 1999 he served as the Chief Executive Officer of Moked Services, Information and
Investments Ltd. and as legal advisor to several of Ituran's affiliated companies. Mr. Sheratzky holds LL.B and LL.M degrees from
Tel Aviv University School of Law and an Executive M.B.A. degree from Kellogg School of Management at Northwestern University.
We believe Mr. Sheratzky's qualifications to serve on our Board of Directors include his years of experience in the management
of Israeli public and private businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Einat Brill Almon, Ph.D.</B> Dr. Almon joined Protalix Ltd. in
December 2004, originally as a Senior Director and later as a Vice President and then Senior Vice President, Product Development,
and became our Senior Vice President, Product Development on December 31, 2006. Dr. Almon has many years of experience in the management
of life science projects and companies, including biotechnology and agrobiotech, with direct experience in clinical, device and
scientific software development, as well as a strong background and work experience in Intellectual Property. Prior to joining
Protalix Ltd., from 2001 to 2004, she served as Director of R&amp;D and IP of Biogenics Ltd., a company that developed an autologous
platform for tissue-based protein drug delivery. Biogenics, based in Israel, is a wholly-owned subsidiary of Medgenics Inc. Dr.
Almon has trained as a biotechnology patent agent at leading IP firms in Israel. Dr. Almon holds a Ph.D. and an M.Sc. in molecular
biology of cancer research from the Weizmann Institute of Science, a B.Sc. from the Hebrew University and has carried out Post-Doctoral
research at the Hebrew University in the area of plant molecular biology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Yossi Maimon, CPA.</B>&nbsp;&nbsp;Mr. Maimon joined Protalix
Ltd. on October 15, 2006 as its Chief Financial Officer and became our Vice President and Chief Financial Officer on December 31,
2006. Prior to joining Protalix, from 2002 to 2006, he served as the Chief Financial Officer of Colbar LifeScience Ltd., a biomaterial
company focusing on aesthetics, where he led all of the corporate finance activities, fund raisings and legal aspects of Colbar
including the sale of Colbar to Johnson and Johnson. Mr. Maimon has a B.A. in accounting from the City University of New York and
an MBA from Tel Aviv University, and he is a Certified Public Accountant in the United States (New York State) and Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Sandra L. Lauterbach.</B>&nbsp;&nbsp;Ms. Lauterbach has served
as our Vice President, Sales and Commercial Affairs since December 18, 2009. Prior to joining our company, Ms. Lauterbach was the
Vice President of Marketing, Endocrinology of EMD Serono, Inc., from July 2008 through July 2009. Prior to that, from August 2003
through July 2008, she served in a number of positions at Genzyme Corporation, the last position being the Senior Director, Global
Marketing of Fabrazyme. Ms. Lauterbach holds a B.Sc. in Molecular Biology from the University of Wisconsin--Madison and an MBA
from the University of South Florida.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Tzvi Palash.</B> Mr. Palash has served as Protalix
Ltd.&rsquo;s Chief Operating Officer since September 6, 2010. Prior to joining Protalix Ltd., from 2006 through 2010, Mr. Palash
served as a General Manager of ColBar LifeScience Ltd., a biotechnology company specializing in reconstructive medicine and tissue
engineering that was acquired by a division of Johnson &amp; Johnson in 2006. In that position, Mr. Palash served as a member of
the Global Aesthetic Management Team at the Consumer Group of Johnson &amp; Johnson. Prior to that, from 2001 through 2006, Mr.
Palash served as the Vice President, Operations of ColBar LifeScience, and he has served in different positions at Teva. Mr. Palash
holds an M.Sc. in Biochemistry from the Hebrew University and a B.Sc. in Biology from the Tel Aviv University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Section 16(a) Beneficial Ownership Reporting
Compliance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Section 16(a) of the Exchange Act requires our
directors, executive officers and holders of more than 10% of our common stock to file with the Commission reports regarding their
ownership and changes in ownership of our equity securities. We believe that all Section&nbsp;16 filings requirements were met
by our officers and directors during 2011. In making this statement, we have relied solely upon examination of the copies of Forms
3, 4 and 5, Schedule 13s and written representations of our former and current directors, officers and 10% shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We require that all Audit Committee members possess
the required level of financial literacy and at least one member of the Audit Committee meet the current standard of requisite
financial management expertise as required by the NYSE Amex and applicable rules and regulations of the SEC. Messrs. Bar Shalev
and Akirov, and Ms.&nbsp;Harel have been appointed by the Board of Directors to serve on the Audit Committee until their respective
successors have been duly elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Audit Committee operates under a formal charter
that governs its duties and conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">All members of the Audit Committee are independent
from our executive officers and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our independent registered public accounting firm
reports directly to the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Audit Committee meets with management and
representatives of our registered public accounting firm prior to the filing of officers&rsquo; certifications with the Commission
to receive information concerning, among other things, effectiveness of the design or operation of our internal controls over financial
reporting, as required by Section 404 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Audit Committee has adopted a Policy for Reporting
Questionable Accounting and Auditing Practices and Policy Prohibiting Retaliation against Reporting employees to enable confidential
and anonymous reporting of improper activities to the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Messrs. Bar Shalev and Akirov qualify as &ldquo;audit
committee financial experts&rdquo; under the applicable rules of the SEC. In making the determination as to these individuals&rsquo;
status as audit committee financial experts, our Board of Directors determined they have accounting and related financial management
expertise within the meaning of the aforementioned rules, as well as the listing standards of the NYSE Amex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Code of Business Conduct and Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">We have adopted a Code of Business Conduct and
Ethics that includes provisions ranging from restrictions on gifts to conflicts of interest. All of our employees and directors
are bound by this Code of Business Conduct and Ethics. Violations of our Code of Business Conduct and Ethics may be reported to
the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The Code of Business Conduct and Ethics includes
provisions applicable to all of our employees, including senior financial officers and members of our Board of Directors and is
posted on our website<FONT STYLE="color: black"> (</FONT>www.protalix.com<FONT STYLE="color: black">)</FONT>. We intend to post
amendments to or waivers from any such Code of Business Conduct and Ethics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.3pt; text-indent: -42.3pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.3pt"><B>Item&nbsp;11.</B></TD><TD><B>Executive
                                                                                                               Compensation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation Discussion and Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The primary goals of the Compensation Committee
of our Board of Directors with respect to executive compensation are to attract and retain the most talented and dedicated executives
possible, to tie annual and long-term cash and stock incentives to achievement of specified performance objectives, and to align
executives&rsquo; incentives with shareholder value creation. To achieve these goals, the Compensation Committee intends to implement
and maintain compensation plans that tie a portion of executives&rsquo; overall compensation to key strategic goals such as developments
in our clinical path, the establishment of key strategic collaborations, the build-up of our pipeline and the strengthening of
our financial position. The Compensation Committee evaluates individual executive performance with a goal of setting compensation
at levels the committee believes are comparable with executives in other companies of similar size and stage of development operating
in the biotechnology industry while taking into account our relative performance and our own strategic goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>Elements of Compensation</B><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45pt; background-color: white">Executive compensation
consists of following elements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Base Salary.</I></B> Base
salaries for our executives are established based on the scope of their responsibilities taking into account competitive
market compensation paid by other companies for similar positions. Generally, we believe that executive base salaries should
be targeted near the median of the range of salaries for executives in similar positions with similar responsibilities at
comparable companies. The Compensation Committee did not make any compensation decisions during 2011. <FONT STYLE="color: black">The
companies reviewed by the Compensation Committee in making its compensation decisions in February 2010 include, among
other companies, the following:</FONT></P>

<P STYLE="font: 10pt Symbol; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Keryx Biopharmaceuticals, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Savient Pharmaceuticals, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Biomarin Pharmaceutical Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Amicus Therapeutics, Inc.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Mannkind Corporation</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Nektar Therapeutics</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Theravance, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Compensation Committee intends to continue
reviewing and revising the peer group periodically to ensure that it continues to reflect companies similar to us in size and development
stage. The Compensation Committee also reviews an executive compensation report and analysis of publicly-traded biotechnology companies
prepared by a third party for additional data and other information regarding executive compensation for comparative purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Base salaries are usually reviewed
annually, and adjusted from time to time to realign salaries with market levels after taking into account individual
responsibilities, performance and experience. The Compensation Committee has decided to delay awarding any increases in the
salaries of our executive officers, or awarding any cash bonuses, until after the anticipated FDA approval of our lead
product candidate. The base salaries of our named executive officers are set forth in
&ldquo;Employment Arrangements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Annual Bonus</I>.</B> The Compensation Committee has the authority
to award discretionary annual bonuses to our executive officers. For 2010, the Compensation Committee established a formal bonus
plan for certain milestones, as described below. The discretionary annual bonus awards were intended to compensate officers for
achieving financial, clinical, regulatory and operational goals and for achieving individual annual performance objectives. For
any given year, the compensation objectives vary, but relate generally to strategic factors such as developments in our clinical
path, the execution of a license agreement for the commercialization of product candidates, the establishment of key strategic
collaborations, the build-up of our pipeline and financial factors such as capital raising. Bonuses are awarded generally based
on corporate performance, with adjustments made within a range for individual performance, at the discretion of the Compensation
Committee. The Compensation Committee determines, on a discretionary basis, the size of the entire bonus pool and the amount of
the actual award to each named executive officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Compensation Committee selects, in its discretion, the executive
officers of our company or our subsidiary who are eligible to receive bonuses for any given year. Any bonus granted by the Compensation
Committee will generally be paid in the first quarter of the year, unless such bonus was, by its terms, made payable upon the achievement
of a specific milestone. The Compensation Committee has not fixed a minimum or maximum award for any executive officer&rsquo;s
annual discretionary bonus, unless specified in the officer&rsquo;s employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each of our executive officers is eligible for a discretionary annual
bonus under his or her employment agreement. The Compensation Committee determined the discretionary annual bonus to be paid to
our executive officers for performance in 2009 and 2010. The Compensation Committee has not fixed a minimum or a maximum
amount for any officer&rsquo;s annual discretionary bonus, nor is any executive officer entitled to a minimum or maximum bonus
amount under his or her employment agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">On February&nbsp;25, 2010, our Board of Directors,
acting upon the resolution of a majority of our independent directors, decided to pay bonuses to our executive officers and other
employees in two tranches. The aggregate amount of all of the bonuses awarded or reserved for award by the Board of Directors pursuant
to the resolution was approximately $2.6&nbsp;million. The first tranche of bonus payments awarded in February 2010 to our named
executive officers and other employees was for approximately $1.1 million in the aggregate. These bonuses were made on a discretionary
basis to acknowledge and compensate our executive officers for their contributions towards the completion of our phase&nbsp;III
clinical trial of our lead product candidate, taliglucerase alfa, the upgrade of our manufacturing facility during the years 2008
and 2009, and specifically with the execution of the license and supply agreement with Pfizer relating to taliglucerase alfa. The
decision to grant the awards constituting the first tranche of bonuses in 2010 was not based on any predetermined goal set for
any named executive officer. However, in making this compensation decision, the Compensation Committee took into account the Board
of Directors&rsquo; decision to refrain from awarding bonuses to our executive officers and others in 2009 due to the general market
conditions and our cash balance at that time. Of the approximately $1.1&nbsp;million made available for the first tranche of the
bonuses, our Board of Directors awarded Dr. Aviezer $500,000; Dr. Shaaltiel $160,000; Dr. Brill Almon $160,000; and Mr. Maimon
$160,000. These bonus payments were made in March 2010.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The remaining $1.5&nbsp;million approved by our
Board of Directors in February 2010 was reserved for future payment to our named executive officers and other employees. The second
tranche of bonus payments will generally become payable upon the achievement of the milestones described in the following tables,
if at all:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>First shipment of taliglucerase alfa</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Anticipated Bonus Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">David Aviezer, Ph.D., MBA</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; text-indent: 0in">Yoseph Shaaltiel, Ph.D.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 27%; text-align: right">100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Yossi Maimon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>Approval of taliglucerase alfa by the
FDA</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Anticipated Bonus Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left; text-indent: 0in">David Aviezer, Ph.D., MBA</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 27%; text-align: right">400,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Yoseph Shaaltiel, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: 0in">Einat Brill Almon, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in">Yossi Maimon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: 0in; padding-left: 9pt">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">820,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The first shipment of taliglucerase alfa
was made in 2010 and bonuses were paid accordingly. Other than the achievement of the corporate milestones set forth above, the
anticipated amounts allocated to each executive officer were not based upon any predetermined goals with respect to any individual
named executive officer. Further, no individual goals have been communicated to any individual named executive officer with respect
to the eventual payment of the bonuses. The remaining approximately $500,000 was allocated to other employees, subject to the same
criteria.<FONT STYLE="color: black"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Options.</I></B> Our 2006 Stock Option
Plan authorizes us to grant options to purchase shares of common stock to our employees, directors and consultants. Our Compensation
Committee is the administrator of the stock option plan. Stock option grants are generally made at the commencement of employment
and following a significant change in job responsibilities or to meet other special retention or performance objectives. The Compensation
Committee reviews and approves stock option awards to executive officers based upon a review of competitive compensation data,
its assessment of individual performance, a review of each executive&rsquo;s existing long-term incentives, and retention considerations.
The exercise price of stock options granted under the 2006 Stock Incentive Plan must be equal to at least 100% of the fair market
value of our common stock on the date of grant; however, in certain circumstances, grants may be made at a lower price to Israeli
grantees who are residents of the State of Israel. We have not awarded stock options to any of our executive officers since February
2010, except in connection with the hiring of our Chief Operating Officer and our Vice President, Human Resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="color: black"><B><I>Severance
and Change in Control Benefits.</I></B> Pursuant to the employment agreements entered into with each of our executive officers
based in Israel, the executive officer </FONT>is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu
of severance. The intention of such Manager&rsquo;s Policies is to provide the Israel-based officers with severance protection
of one month&rsquo;s salary for each year of employment. <FONT STYLE="color: black">In addition, </FONT>stock option agreements
with each of our named executive officers, as amended, <FONT STYLE="color: black">provide that all of the outstanding options of
each Named Executive Officer are subject to accelerated vesting immediately upon a change in control of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Other Compensation.</I></B> Consistent
with our compensation philosophy, we intend to continue to maintain our current benefits for our executive officers; however, the
Compensation Committee in its discretion may revise, amend, or add to the officer&rsquo;s executive benefits if it deems it advisable.
As an additional benefit to all of our Israel-based Named Executive Officers and for most of our employees, we generally contribute
to certain funds amounts equaling a total of approximately 15% of their gross salaries for certain pension and other savings plans
for the benefit of the Named Executive Officers. In addition, in accordance with customary practice in Israel, our Israel-based
executives&rsquo; agreements require us to contribute towards their vocational studies, and to provide annual recreational allowances,
a company car and a company phone. We believe these benefits are currently equivalent with median competitive levels for comparable
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B><I>Executive Compensation.</I></B> We
refer to the &ldquo;Summary Compensation Table&rdquo; set forth in Section 11 of the Annual Report on Form 10-K for information
regarding the compensation earned during the fiscal year ended December&nbsp;31, 2011 by: our President and Chief Executive Officer,
our Executive Vice President, Research and Development, our Senior Vice P<FONT STYLE="color: black">resident,</FONT> Product Development,
our Vice President and Chief Financial Officer and our Chief Operation Officer, who we refer to collectively as the &ldquo;Named
Executive Officers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">The Compensation Committee is currently
in the process of reviewing all the compensation elements of the named executive officers and of other members of the management
team, and updating the peer companies. The Compensation Committee expects to adopt new benefits plans prior to the anticipated
FDA approval of taliglucerase alfa, if at all, which plans will likely be subject to the FDA's approval of taliglucerase alfa on
or about the upcoming May 1, 2012 action date. Any new bonus plan is expected to be based on our achievement of one or more major
milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation Committee Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><I>The above report of the Compensation Committee
does not constitute soliciting material and shall not be deemed filed or incorporated by reference into any other filing by us
under the Securities Act of 1933 or the Securities Exchange Act of 1934.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The Compensation Committee has reviewed and discussed
the Compensation Discussion and Analysis set forth below with our management. Based on this review and discussion, the Compensation
Committee has recommended to our Board of Directors that the Compensation Discussion and Analysis be included in our Annual Report
on Form 10&ndash;K and our annual proxy statement on Schedule 14A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Respectfully submitted on February 27, 2012, by
the members of the Compensation Committee of the Board of Directors<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>Yodfat Harel</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>Alfred Akirov</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"><I>Amos Bar Shalev</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table sets forth a summary for the
fiscal years ended December 31, 2011, 2010 and 2009, respectively, of the cash and non-cash compensation awarded, paid or accrued
by us or Protalix Ltd. to each of our President and Chief Executive Officer, our Executive Vice President, Research and Development,
our Senior Vice P<FONT STYLE="color: black">resident,</FONT> Product Development, our Vice President and Chief Financial Officer
and our Vice President and Chief Operating Officer, who we refer to collectively as the &ldquo;Named Executive Officers.&rdquo;
There were no restricted stock awards, long-term incentive plan payouts or other compensation paid during fiscal years 2011, 2010
and 2009 by us or Protalix Ltd. to the Named Executive Officers, except as set forth below. All of the Named Executive Officers
are employees of our subsidiary, Protalix Ltd. All currency amounts are expressed in U.S. dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Name and Principal Position</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Year</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Salary($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Bonus
    ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Option
    <BR>Award(s) ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">All
    Other <BR>Compensation ($)(1)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Total
    ($)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 34%; text-align: left"><FONT STYLE="font-size: 8pt">David Aviezer, Ph.D., MBA</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">531,608</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">53,578</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">113,971</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt">699,157</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">President and</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">508,868</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">145,537</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">107,972</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">762,377</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Chief Executive Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2009</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">427,970</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">500,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">529,951</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">62,167</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">1,520,088</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Yoseph Shaaltiel, Ph.D</FONT>.</TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">305,280</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">27,830</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">80,063</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">413,173</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Executive Vice President,</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">292,095</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">100,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">70,286</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">76,491</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">538,872</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Research and Development</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2009</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">196,271</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">160,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">225,336</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">37,981</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">619,588</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Einat Brill Almon, Ph.D</FONT>.</TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">263,357</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">32,557</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">71,074</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">366,988</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Senior Vice President,</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">251,940</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">97,007</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">66,591</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">435,538</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Product Development</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2009</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">172,210</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">160,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">283,388</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">36,927</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">652,525</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Yossi Maimon, CPA</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">286,220</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">18,304</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">69,290</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">373,814</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Vice President,</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">268,154</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">20,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">63,175</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">68,156</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">419,485</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Chief Financial Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2009</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">186,478</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">160,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">253,030</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">41,051</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">640,559</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">Tzvi Palash (2)</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">233,452</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">339,011</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">76,490</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">648,953</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-style: italic; text-align: left; padding-left: 9pt"><FONT STYLE="font-size: 8pt">Chief Operating Officer</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">2010</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">71,956</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">207,075</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">24,094</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">303,125</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Includes employer contributions to pension and/or insurance plans and other miscellaneous payments.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Mr. Palash joined our company in September 2010.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">No awards were granted to any Named Executive
Officer during 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table sets forth information with
respect to the Named Executive Officers concerning equity awards as of December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt">&nbsp; &nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD COLSPAN="13" STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;<B>Option
                                                                                           Awards</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>&nbsp;Name</B></FONT></TD><TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>&nbsp;
                                                                                                  Number <BR>of Securities <BR>Underlying
                                                                                                  <BR>Unexercised <BR>Options
                                                                                                  Exercisable (#)</B></FONT></TD><TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Number
                                                                                                  <BR>of Securities Underlying
                                                                                                  <BR>Unexercised <BR>Options
                                                                                                  Unexercisable (#)</B>&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Option
    Exercise&nbsp;Price ($)&nbsp;</B></FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Option
                                                                 Expiration<BR>
                                                                 Date&nbsp;</B></FONT></TD><TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 25%; text-align: left"><FONT STYLE="font-size: 10pt">David Aviezer</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">326,267</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">0.120</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">12/8/2013</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">977,297</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.972</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">9/10/2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">533,332</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66,668</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/7/2018</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">250,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2020</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Yoseph Shaaltiel</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">122,162</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.001</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">6/30/2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">234,424</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">29,304</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/7/2018</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">145,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2020</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Einat Brill Almon</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">116,848</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.972</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8/13/2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">276,688</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34,584</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/7/2018</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">130,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2020</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Yossi Maimon</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75,964</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.972</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">9/19/2016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">155,556</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19,444</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.00</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/7/2018</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.65</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2019</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: transparent">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">130,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.90</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2/25/2020</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Tzvi Palash</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">110,000</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7.55</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8/29/2020</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">(1) Pursuant to a divorce settlement, Dr. Shaaltiel
is required to transfer 50% of these options to his former spouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">There were no option exercises by, or vesting
of stock awards of, any Named Executive Officer during the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Potential Payments upon Termination or Change-in-Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: black">Each of our Named Executive Officers
</FONT>is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance upon termination. The intention
of such Manager&rsquo;s Policies is to provide the Israel-based officers with severance protection of one month&rsquo;s salary
for each year of employment. We do not provide any change in control benefits to our <FONT STYLE="color: black">Named Executive
Officers</FONT> except that their stock option agreements, as amended, <FONT STYLE="color: black">provide that all of the outstanding
options of each Named Executive Officer are subject to accelerated vesting immediately upon a change in control of our company,
as defined in our 2006 Stock Incentive Plan. Since as of December 31, 2011 all options that have not been fully vested on such
date, had exercise price higher than the closing price on that date, if we had experienced a change of control on December 31,
2011, the value of the acceleration of the stock options held by each of Dr. Aviezer, Dr. Shaaltiel, Dr. Brill Almon, Mr. Maimon
and Mr. Palash would be zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Employment Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>David Aviezer, Ph.D., MBA.</B> Dr. Aviezer originally served
as Protalix Ltd.&rsquo;s Chief Executive Officer on a consultancy basis pursuant to a Consulting Services Agreement between Protalix
Ltd. and Agenda Biotechnology Ltd., a company wholly-owned by Dr. Aviezer. On September 11, 2006, Protalix Ltd. entered into an
employment agreement with Dr. Aviezer pursuant to which he agreed to be employed as Protalix Ltd.&rsquo;s President and Chief Executive
Officer, which agreement supersedes the Consultancy Services Agreement. Dr. Aviezer currently serves as our President and Chief
Executive Officer. Dr. Aviezer&rsquo;s current monthly base salary is NIS 148,000 (approximately $38,730) and he is entitled to
an annual bonus at the Board&rsquo;s discretion. The monthly salary is subject to cost of living adjustments from time to time.
Dr. Aviezer is eligible to receive a substantial bonus in the event of certain public offerings or acquisition transactions, which
bonus shall be at the discretion of the Board, and certain specified bonuses in the event Protalix achieves certain specified milestones.
In connection with the employment agreement, in addition to other options already held by Dr. Aviezer granted to Dr. Aviezer options
to purchase 16,000 ordinary shares of Protalix Ltd. at an exercise price equal to $59.40 per share, which we assumed as options
to purchase 977,297 shares of our common stock at $0.97 per share. Such options vest quarterly retroactively from June 1, 2006,
over a four-year period. In addition, in 2008 we granted to Dr. Aviezer an option to purchase 600,000 shares of our common stock
at an exercise price equal to $5.00 per share. The option vests variably over a five-year period that commenced on January 1, 2008.
In 2009, we granted Dr. Aviezer an option to purchase 100,000 shares of our common stock at an exercise price equal to $2.65 per
share. As of December 31, 2009, all of those options had fully vested. In 2010, we granted Dr. Aviezer an option to purchase 250,000
shares of our common stock at an exercise price equal to $6.90 per share, which option vests quarterly over a three-year period
commencing upon FDA approval of taliglucerase alfa, if at all. Dr. Aviezer&rsquo;s employment agreement is terminable by either
party on 90 days&rsquo; written notice for any reason and we may terminate the agreement for cause without notice. Dr. Aviezer
is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational
studies, annual recreational allowances, a company car and a company phone. Dr. Aviezer is entitled to 26 working days of vacation.
All stock options that have not vested as of the date of termination shall be deemed to have been forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Yoseph Shaaltiel, Ph.D.</B> Dr. Shaaltiel founded Protalix
Ltd. in 1993 and currently serves as our Executive Vice President, Research and Development. Dr. Shaaltiel entered into an
employment agreement with Protalix Ltd. on September 1, 2001. Pursuant to the employment agreement, his current monthly base
salary is NIS 85,000 (approximately $22,250) per month. The employment agreement is terminable by Protalix Ltd. on 90
days&rsquo; written notice for any reason and we may terminate the agreement for cause without notice. In 2008 we granted to
Dr. Shaaltiel an option to purchase 263,728 shares of our common stock at an exercise price equal to $5.00 per share. The
option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we granted Dr. Shaaltiel an option
to purchase 50,000 shares of our common stock at an exercise price equal to $2.65 per share. As of December 31, 2009, all of
those options had fully vested. In 2010, we granted Dr. Shaaltiel an option to purchase 145,000 shares of our common stock at
an exercise price equal to $6.90 per share, which option vests quarterly over a three-year period commencing upon FDA
approval of taliglucerase alfa, if at all. Dr. Shaaltiel is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s
Policy in lieu of severance, company contributions towards vocational studies, annual recreational allowances, a company car
and a company phone. Dr. Shaaltiel is entitled to 33  working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Einat Brill Almon, Ph.D.</B> Dr. Brill Almon joined Protalix
Ltd. on December 19, 2004 as its Vice President, Product Development, pursuant to an employment agreement effective on December
19, 2004 by and between Protalix Ltd. and Dr. Brill Almon, and currently serves as our Senior Vice President, Product Development.
Pursuant to the employment agreement, her current monthly base salary is NIS 73,500 per month (approximately $19,240). She is also
entitled to certain specified bonuses in the event that Protalix achieves certain specified clinical development milestones within
specified timelines. In connection with the employment agreement, Protalix agreed to grant to Dr. Brill Almon options to purchase
7,919 ordinary shares of Protalix Ltd. at exercise prices equal to $24.36 and $59.40 per share, which we assumed as options to
purchase 483,701 shares of our common stock at $0.40 and $0.97 per share. The options vest over four years. In addition, in 2008
we granted to Dr. Brill Almon an option to purchase 311,272 shares of our common stock at an exercise price equal to $5.00 per
share. The option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we granted to Dr. Brill Almon
an option to purchase 50,000 shares of our common stock at an exercise price equal to $2.65 per share. As of December 31, 2009,
all of those options had fully vested. In 2010, we granted Dr. Almon an option to purchase 130,000 shares of our common stock at
an exercise price equal to $6.90 per share, which option vests quarterly over a three-year period commencing upon FDA approval
of taliglucerase alfa, if at all. The employment agreement is terminable by either party on 60 days&rsquo; written notice for any
reason and we may terminate the agreement for cause without notice. Dr. Brill Almon is entitled to be insured by Protalix Ltd.
under a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies, annual recreational allowances,
a company car and a company phone at up to NIS 1,000 per month. Dr. Brill Almon is entitled to 28 working days of vacation. All
stock options that have not vested as of the date of termination shall be deemed to have been forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Yossi Maimon, CPA.</B> Mr. Maimon joined Protalix Ltd. as its
Chief Financial Officer pursuant to an employment agreement effective as of October 15, 2006 by and between Protalix Ltd. and Mr.
Maimon and currently serves as our Chief Financial Officer. Pursuant to the employment agreement, his current monthly base salary
is NIS 73,500 (approximately $19,240) and Mr. Maimon is entitled to an annual discretionary bonus and additional discretionary
bonuses in the event Protalix achieves significant financial milestones, subject to the Board&rsquo;s sole discretion. The monthly
salary is subject to cost of living adjustments from time to time. In connection with the employment agreement, Protalix agreed
to grant to Mr. Maimon options to purchase 10,150 ordinary shares of Protalix Ltd. at an exercise price equal to $59.40 per share,
which we assumed as options to purchase 619,972 shares of our common stock at $0.97 per share. The first 25% of such options shall
vest on the first anniversary of the grant date and the remainder shall vest quarterly in 12 equal increments. In addition, in
2008 we granted to Mr. Maimon an option to purchase 175,000 shares of our common stock at an exercise price equal to $5.00 per
share. The option vests variably over a five-year period that commenced on January 1, 2008. In 2009, we granted to Mr. Maimon an
option to purchase 50,000 shares of our common stock at an exercise price equal to $2.65 per share. As of December 31, 2009, all
of those options had fully vested. In 2010, we granted Mr. Maimon an option to purchase 130,000 shares of our common stock at an
exercise price equal to $6.90 per share, which option vests quarterly over a three-year period commencing upon FDA approval of
taliglucerase alfa, if at all. The employment agreement is terminable by either party on 60 days&rsquo; written notice for any
reason and we may terminate the agreement for cause without notice. Mr. Maimon is entitled to be insured by Protalix Ltd. under
a Manager&rsquo;s Policy in lieu of severance, company contributions towards vocational studies, annual recreational allowances,
a company car and a company phone. Mr. Maimon is entitled to 28 working days of vacation. All stock options that have not vested
as of the date of termination shall be deemed to have been forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Tzvi Palash. </B>Mr. Palash joined Protalix Ltd. as its Chief
Operating Officer pursuant to an employment agreement effective September 6, 2010 and currently serves as our Chief Operating Officer.
Pursuant to the employment agreement, Mr. Palash&rsquo;s current monthly base salary is NIS 69,000 (approximately $18,060) and
Mr. Palash is entitled to an annual discretionary bonus for performance subject to the sole discretion of our compensation committee.
The monthly salary is subject to cost of living adjustments from time to time as may be required by law. In connection with the
employment agreement, we granted to Mr. Palash options to purchase 160,000 shares of our common stock with an exercise price equal
to $7.55 per share. The first 25% of such options vested on the first anniversary of the grant date and the remainder vest quarterly
in 12 equal increments. The employment agreement is terminable by either party on 60 days&rsquo; written notice for any reason
and we may terminate the agreement for cause without notice. Mr. Palash is entitled to be insured by Protalix Ltd. under a Manager&rsquo;s
Policy in lieu of severance, company contributions towards vocational studies, annual recreational allowances, a company car, a
company phone, a company laptop and lodging accommodations in the Carmiel area. Mr. Palash is entitled to 24 working days of vacation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>2006 Stock Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Board of Directors and a majority of our shareholders
approved our 2006 Stock Incentive Plan on December 14, 2006 and cancelled our 1998 stock option plan (no options were outstanding
under the 1998 plan at that time). We have reserved 9,741,655 shares of our common stock for issuance, in the aggregate, under
the 2006 Stock Incentive Plan, subject to adjustment for a stock split or any future stock dividend or other similar change in
our common stock or our capital structure. As of December 31, 2011, options to acquire 47,920 shares of common stock remain available
for grant under our 2006 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our 2006 Stock Incentive Plan provides for the
grant of stock options, restricted stock, restricted stock units, stock appreciation rights and dividend equivalent rights, collectively
referred to as &ldquo;awards.&rdquo; Stock options granted under the 2006 Stock Incentive Plan may be either incentive stock options
under the provisions of Section 422 of the Internal Revenue Code, or non-qualified stock options. Incentive stock options may be
granted only to employees. Awards other than incentive stock options may be granted to employees, directors and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The 2006 Stock Incentive Plan is also designed
to comply with the provisions of the Israeli Income Tax Ordinance New Version, 1961 (including as amended pursuant to Amendment
132 thereto) (the &ldquo;tax ordinance&rdquo;) and is intended to enable us to grant awards to grantees who are Israeli residents
as follows: (i) awards to employees pursuant to Section 102 of the tax ordinance; and (ii) awards to non-employees pursuant to
Section 3(I) of the tax ordinance. For this purpose, &ldquo;employee&rdquo; refers only to employees, office holders and directors
of our company or a related entity excluding those who are considered &ldquo;Controlling Shareholders&rdquo; pursuant to, or otherwise
excluded by, the tax ordinance. In accordance with the terms and conditions imposed by the Tax Ordinance, grantees who receive
awards under the 2006 Stock Incentive Plan may be afforded certain tax benefits in Israel as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Board of Directors or the Compensation Committee,
referred to as the &ldquo;plan administrator,&rdquo; will administer our 2006 Stock Incentive Plan, including selecting the grantees,
determining the number of shares to be subject to each award, determining the exercise or purchase price of each award, and determining
the vesting and exercise periods of each award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The exercise price of stock options granted under
the 2006 Stock Incentive Plan must be equal to at least 100% of the fair market value of our common stock on the date of grant;
however, in certain circumstances, grants may be made at a lower price to Israeli grantees who are residents of the State of Israel.
If, however, incentive stock options are granted to an employee who owns stock possessing more than 10% of the voting power of
all classes of our stock or the stock of any parent or subsidiary of our company, the exercise price of any incentive stock option
granted must equal at least 110% of the fair market value on the grant date and the maximum term of these incentive stock options
must not exceed five years. The maximum term of all other awards must not exceed 10 years (or five years in the case of an incentive
stock option granted to any participant who owns stock representing more than 10% of the voting power of all classes of our stock
or the stock of any parent or subsidiary of our company). The plan administrator will determine the exercise or purchase price
(if any) of all other awards granted under the 2006 Stock Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under the 2006 Stock Incentive Plan, incentive
stock options and options to Israeli grantees may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any
manner other than by will or by the laws of descent or distribution and may be exercised during the lifetime of the participant
only by the participant. Other awards shall be transferable by will or by the laws of descent or distribution and to the extent
and in the manner authorized by the plan administrator by gift or pursuant to a domestic relations order to members of the participant&rsquo;s
immediate family. The 2006 Stock Incentive Plan permits the designation of beneficiaries by holders of awards, including incentive
stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">If the service of a participant in the 2006 Stock
Incentive Plan is terminated for any reason other than cause, the participant may exercise awards that were vested as of the termination
date for a period ending upon the earlier of 12 months from the date of termination (or such shorter or longer period set forth
in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator. If the service
of a participant in the 2006 Stock Incentive Plan is terminated for cause, the participant may exercise awards that were vested
as of the termination date for a period ending upon the earlier of 14 days from the date of termination (or such shorter or longer
period set forth in the award agreement) or the expiration date of the awards unless otherwise determined by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">In the event of a corporate transaction, all awards
will terminate unless assumed by the successor corporation. Unless otherwise provided in a participant&rsquo;s award agreement,
in the event of a corporate transaction and with respect to the portion of each award that is assumed or replaced, then such portion
will automatically become fully vested and exercisable immediately upon termination of a participant&rsquo;s service if the participant
is terminated by the successor company or us without cause within 12 months after the corporate transaction. With respect to the
portion of each award that is not assumed or replaced, such portion will automatically become fully vested and exercisable immediately
prior to the effective date of the corporate transaction so long as the participant&rsquo;s service has not been terminated prior
to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">In the event of a change in control, except as
otherwise provided in a participant&rsquo;s award agreement, following a change in control (other than a change in control that
also is a corporate transaction) and upon the termination of a participant&rsquo;s service without cause within 12 months after
a change in control, each award of such participant that is outstanding at such time will automatically become fully vested and
exercisable immediately upon the participant&rsquo;s termination. In addition, <FONT STYLE="color: black">the stock options issued
to each of our Named Executive Officers are subject to accelerated vesting immediately upon a change in control of our company,
as defined in our 2006 Stock Incentive Plan. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under our 2006 Stock Incentive Plan, a corporate
transaction is generally defined as:</P>

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
merger or consolidation in which we are not the surviving entity, except for the principal purpose of changing our company&rsquo;s
state of incorporation;</P>

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
sale, transfer or other disposition of all or substantially all of our assets;</P>

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
complete liquidation or dissolution of our company;</P>

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
reverse merger in which we are the surviving entity but our shares of common stock outstanding immediately prior to such merger
are converted or exchanged by virtue of the merger into other property, whether in the form of securities, cash or otherwise, or
in which securities possessing more than forty percent (40%) of the total combined voting power of our outstanding securities are
transferred to a person or persons different from those who held such securities immediately prior to such merger; or</P>

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>acquisition
in a single or series of related transactions by any person or related group of persons of beneficial ownership of securities possessing
more than fifty percent (50%) of the total combined voting power of our outstanding securities but excluding any such transaction
or series of related transactions that the plan administrator determines not to be a corporate transaction (provided however that
the plan administrator shall have no discretion in connection with a corporate transaction for the purchase of all or substantially
all of our shares unless the principal purpose of such transaction is changing our company&rsquo;s state of incorporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under our 2006 Stock Incentive Plan, a change
of control is defined as:</P>

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
direct or indirect acquisition by any person or related group of persons of beneficial ownership of securities possessing more
than fifty percent (50%) of the total combined voting power of our outstanding securities pursuant to a tender or exchange offer
made directly to our shareholders and which a majority of the members of our board (who have generally been on our board for at
least 12 months) who are not affiliates or associates of the offeror do not recommend shareholders accept the offer; or</P>

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>a
change in the composition of our board over a period of 12 months or less, such that a majority of our board members ceases, by
reason of one or more contested elections for board membership, to be comprised of individuals who were previously directors of
our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Unless terminated sooner, the 2006 Stock Incentive
Plan will automatically terminate in 2016. Our Board of Directors has the authority to amend, suspend or terminate our 2006 Stock
Incentive Plan. No amendment, suspension or termination of the 2006 Stock Incentive Plan shall adversely affect any rights under
awards already granted to a participant. To the extent necessary to comply with applicable provisions of federal securities laws,
state corporate and securities laws, the Internal Revenue Code, the rules of any applicable stock exchange or national market system,
and the rules of any non-U.S. jurisdiction applicable to awards granted to residents therein (including the Tax Ordinance), we
shall obtain shareholder approval of any such amendment to the 2006 Stock Incentive Plan in such a manner and to such a degree
as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B><I>Impact of Israeli Tax Law</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The awards granted to employees pursuant to Section
102 of the Tax Ordinance under the 2006 Stock Incentive Plan may be designated by us as approved options under the capital gains
alternative, or as approved options under the ordinary income tax alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">To qualify for these benefits, certain requirements
must be met, including registration of the options in the name of a trustee. Each option, and any shares of common stock acquired
upon the exercise of the option, must be held by the trustee for a period commencing on the date of grant and deposit into trust
with the trustee and ending 24 months thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under the terms of the capital gains alternative,
we may not deduct expenses pertaining to the options for tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Under the 2006 Stock Incentive Plan, we may also
grant to employees options pursuant to Section 102(c) of the Tax Ordinance that are not required to be held in trust by a trustee.
This alternative, while facilitating immediate exercise of vested options and sale of the underlying shares, will subject the optionee
to the marginal income tax rate of up to 50% as well as payments to the National Insurance Institute and health tax on the date
of the sale of the shares or options. Under the 2006 Stock Incentive Plan, we may also grant to non-employees options pursuant
to Section 3(I) of the Tax Ordinance. Under that section, the income tax on the benefit arising to the optionee upon the exercise
of options and the issuance of common stock is generally due at the time of exercise of the options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">These options shall be further subject to the
terms of the tax ruling that has been obtained by Protalix Ltd. from the Israeli tax authorities in connection with the merger.
Under the tax ruling, the options issued by us in connection with the assumption of Section 102 options previously issued by Protalix
Ltd. under the capital gains alternative shall be issued to a trustee, shall be designated under the capital gains alternative
and the issuance date of the original options shall be deemed the issuance date for the assumed options for the calculation of
the respective holding period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation of Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth information with respect to compensation
of our non-employee directors during fiscal year 2011. The fees to our current directors were paid by Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 65%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Fees <BR>Earned or <BR>Paid in <BR>Cash ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Total <BR>($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current Directors</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left">Zeev Bronfeld</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; font-size: 10pt; text-align: center">33,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: center">33,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Alfred Akirov</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Amos Bar Shalev</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Yodfat Harel</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Roger D. Kornberg</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Eyal Sheratzky</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">33,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Board of Directors will review director compensation
annually and adjust it according to then current market conditions and corporate governance guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Compensation Committee Interlocks and Insider
Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Our Compensation Committee currently consists
of Messrs. Akirov and Bar Shalev and Ms. Harel, who were appointed to the Committee during 2009. No member of our Compensation
Committee or any executive officer of our company or of Protalix Ltd. has a relationship that would constitute an interlocking
relationship with executive officers or directors of another entity. No Compensation Committee member is or was an officer or employee
of ours or of Protalix Ltd. Further, none of our executive officers serves on the board of directors or compensation committee
of any entity that has one or more executive officers serving as a member of our Board of Directors or Compensation Committee.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt">&nbsp;</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45pt">Item&nbsp;12.</TD><TD>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>Security Ownership of Certain Beneficial Owners
and Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table sets forth information, as
of February 1, 2012, regarding beneficial ownership of our common stock:</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each person who is known by us to own beneficially more than 5% of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each director;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>each of our Chief Executive Officer, our Executive Vice President, Research and Development, our Senior Vice President, Product
Development, our Chief Financial Officer, our Vice President, Sales and Commercial Affairs and our Chief Operating Officer; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>all of our directors and executive officers collectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Unless otherwise noted, we believe that all persons
named in the table have sole voting and investment power with respect to all shares of our common stock beneficially owned by each
of them. For purposes of these tables, a person is deemed to be the beneficial owner of securities that can be acquired by such
person within 60 days from February 1, 2012 upon exercise of options, warrants and convertible securities. Each beneficial owner&rsquo;s
percentage ownership is determined by assuming that options, warrants and convertible securities that are held by such person (but
not those held by any other person) and that are exercisable within such 60 days from such date have been exercised. The information
set forth below is based upon information obtained from the beneficial owners, upon information in our possession regarding their
respective holdings and upon information filed by the holders with the SEC. The percentages of beneficial ownership are based on
85,631,957 shares of our common stock outstanding as of February 1, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The address for all directors and officers is
c/o Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park, POB 455, Carmiel, Israel, 20100.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount and Nature of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Beneficial Ownership</B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Percentage of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Class</B></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Board of Directors and Executive Officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left">David Aviezer, Ph.D., MBA (1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">1,953,653</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">2.3</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Yoseph Shaaltiel, Ph.D. (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,177,663</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Alfred Akirov (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,286,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Amos Bar Shalev (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,680</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Zeev Bronfeld (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,466,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Yodfat Harel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Roger D. Kornberg, Ph.D. (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Eyal Sheratzky</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Einat Brill Almon, Ph.D. (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">452,182</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Yossi Maimon (8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">286,381</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tzvi Palash (9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Sandra E. Lauterbach (10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80,000</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All executive officers and directors as a group (12 persons) (11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,812,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27.8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">5% Holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Biocell Ltd. (12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,466,319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Federated Investors Inc. (13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,646,942</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Al-Rov (Israel) Ltd. (14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,286,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Baillie Gifford &amp; Co. (15)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,852,882</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 40%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">* less than 1%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Consists of 1,953,653 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 1,
2012. Does not include 300,001 shares of common stock issuable upon exercise of outstanding options that are not exercisable within
60 days of February 1, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Consists of 763,754 shares of our common stock held by Dr. Shaaltiel and 413,912 shares of our common stock issuable upon exercise
of outstanding options within 60 days of February 1, 2012. Does not include 166,978 shares of common stock issuable upon exercise
of outstanding options that are not exercisable within 60 days of February 1, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>Consists of 3,600,000 shares of our common stock held by Al-Rov (Israel) Ltd., or Al-Rov Israel, and 1,686,046 shares of our
common stock held by Techno-Rov Holdings (1993) Ltd., or Techno-Rov Holdings. Al-Rov Israel owns 100% of the outstanding shares
of Al-Rov Technologies Holdings LTD, the holder of 80% of Techno-Rov Holdings. Mr. Akirov is the Chairman of Al-Rov Israel and
the Chief Executive Officer of Techno-Rov Holdings and has the power to control their respective investment decisions. Mr. Akirov
disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>Mr. Bar Shalev is a director of Techno-Rov Holdings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD>Consists of 14,466,319 shares of our common stock held by Biocell Ltd. Mr. Bronfeld is a director and Chief Executive Officer
of Biocell. Mr. Bronfeld disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD>Consists of 50,000 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 1, 2012.
</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD>Consists of 452,182 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 1,
2012. Does not include 155,938 shares of common stock issuable upon exercise of outstanding options that are not exercisable within
60 days of February 1, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD>Consists of 286,381 shares of our common stock issuable upon exercise of outstanding options within 60 days of February 1,
2012. Does not include 144,583 shares of common stock issuable upon exercise of outstanding options that are not exercisable within
60 days of February 1, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD>Consists of 60,000 shares of common stock issuable upon exercise of outstanding options that are not exercisable within 60
days of February 1, 2012. Does not include 100,000 shares of common stock issuable upon exercise of outstanding options that are
not exercisable within 60 days of February 1, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD>Consists of 80,000 shares of common stock issuable upon exercise of outstanding options that are not exercisable within 60
days of February 1, 2012. Does not include 80,000 shares of common stock issuable upon exercise of outstanding options that are
not exercisable within 60 days of February 1, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(11)</TD><TD>Consists of 20,516,119 shares of our common stock and 3,296,038 shares of our common stock issuable upon exercise of outstanding
options within 60 days of February 1, 2012. Does not include 947,500 shares of common stock issuable upon exercise of outstanding
options that are not exercisable within 60 days of February 1, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(12)</TD><TD>The address is Moshe Aviv Tower, 7 Jabotinsky Street, Ramat Gan, Israel. Biocell Ltd.&rsquo;s investment and voting decisions
are made collectively by its board of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(13)</TD><TD>Based solely on a Schedule 13G/A filed by Federated Investors Inc. on February 10, 2012.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(14)</TD><TD>The address is Alrov Tower, 46 Rothschild Blvd., Tel Aviv, Israel 66883. Consists of 3,600,000 shares of our common stock held
by Al-Rov Israel directly and 1,686,046 shares of our common stock held by Techno-Rov Holdings. Al-Rov Israel owns 100% of the
outstanding shares of Al-Rov Technologies Holdings LTD, the holder of 80% of Techno-Rov Holdings. Mr. Akirov is the Chairman of
Al-Rov Israel and the Chief Executive Officer of Techno-Rov Holdings and has the power to control their respective investment decisions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(15)</TD><TD>Based solely on a Schedule 13G/A filed by Baillie Gifford &amp; Co. on January 17, 2012. According to Baillie Gifford &amp;
Co., it has sole dispositive power over 4,852,882 shares of common stock and sole voting power over 2,305,339 shares of common
stock.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Equity Compensation Plan Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">The following table provides information as of
December&nbsp;31, 2011 with respect to the shares of our common stock that may be issued under our existing equity compensation
plan.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">A</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">B</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">C</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number&nbsp;of&nbsp;Securities&nbsp;Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number&nbsp;of&nbsp;Securities</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Available for Future Issuance</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">to be Issued</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted&nbsp;Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Under&nbsp;Equity&nbsp;Compensation&nbsp;Plans</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Upon Exercise of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise Price of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(Excluding Securities Reflected in</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Plan Category</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding&nbsp;Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Column A)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 46%; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Equity Compensation Plans Approved by Shareholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">6,747,856</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">3.27</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">47,920</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9.35pt; padding-left: 9.35pt">Equity Compensation Plans Not Approved by Shareholders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">631,866</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10.24</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.25in">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,379,722</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.87</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">47,920</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 45.35pt; text-indent: -45.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 45.35pt">Item 13.</TD><TD>Certain Relationships and Related Transactions, and Director Independence</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On March 17, 2005, Protalix Ltd. entered into a Management Services
Agreement with Pontifax Management Company, Ltd. in connection with the purchase of Protalix&rsquo;s Series B Preferred Shares
by the Pontifax Funds. Pursuant to the Management Services Agreement, Mr. Hurvitz served as a member of our Board of Directors
and later as the Chairman of our Board of Directors until his resignation in March 2010. In consideration for Mr. Hurvitz&rsquo;s
services, Protalix was required to pay Pontifax Management Company a fee equal to $3,000 per month plus required taxes on such
payment. In addition, in connection with the execution of the Management Services Agreement and the later appointment of Mr. Hurvitz
as Chairman of our Board of Directors, Protalix issued to Pontifax, in the aggregate, a number of options that, upon our December
2006 merger transaction, were converted into options to purchase 3,384,502 shares of our common stock. Under the terms of the assumed
Management Services Agreement, we are obligated only to use our best efforts to nominate Mr. Hurvitz for election to our Board
of Directors, which remains subject to the review and approval of the Nominating Committee of the Board of Directors and the entire
Board of Directors, as applicable. During the year 2010 through the date of Mr. Hurvitz&rsquo;s resignation, the fee payable under
this agreement was increased to $33,000 per annum, which is the same fee payable to the other non-executive directors. No further
payments were due to Pontifax Management Company after Mr. Hurvitz&rsquo;s resignation from our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On September 14, 2006, Protalix Ltd. entered into a collaboration
and licensing agreement with Teva for the development and manufacture of two proteins using ProCellEx, our proprietary protein
expression system. Mr. Hurvitz, our former Chairman, was the chairman of Teva&rsquo;s board of directors when we entered into the
agreement. Phillip Frost, M.D., a former director and a major shareholder of our company, is the chairman of Teva&rsquo;s board
of directors and Professor Kornberg, a member of our Board of Directors also serves as a member of Teva&rsquo;s board of directors.
The agreement provides that we will collaborate with Teva on the research and development of two proteins using ProCellEx. We and
Teva identified two proteins for research and development activities under the agreement, but in 2009 both of the projects were
terminated for commercial reasons. Other elements of our collaboration with Teva are currently ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">All related party transactions are reviewed
and approved by the Audit Committee, as required by the Audit Committee Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Corporate Governance and Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In compliance with the listing requirements of the NYSE Amex, we
have a comprehensive plan of corporate governance for the purpose of defining responsibilities, setting high standards of professional
and personal conduct and assuring compliance with such responsibilities and standards. We currently regularly monitor developments
in the area of corporate governance to ensure we are in compliance with the standards and regulations required by the NYSE Amex.
A summary of our corporate governance measures follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -34.6pt">&nbsp;</P>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-indent: -34.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Independent Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We believe a majority of the members of our Board of Directors are
independent from management. When making determinations from time to time regarding independence, the Board of Directors will reference
the listing standards adopted by the NYSE Amex as well as the independence standards set forth in the Sarbanes-Oxley Act of 2002
and the rules and regulations promulgated by the SEC under that Act. In particular, our Audit Committee periodically evaluates
and reports to the Board of Directors on the independence of each member of the Board. We anticipate our audit committee will analyze
whether a director is independent by evaluating, among other factors, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether the member of the Board of Directors has any material relationship with us, either directly,
or as a partner, shareholder or officer of an organization that has a relationship with us;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-align: justify; text-indent: -34.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether the member of the Board of Directors is a current employee of our company or any of our
subsidiaries, or was an employee of our company or any of our subsidiaries within three years preceding the date of determination;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-align: justify; text-indent: -34.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether the member of the Board of Directors is, or in the three years preceding the date of determination
has been, affiliated with or employed by (i) a present internal or external auditor of our company or any affiliate of such auditor
or (ii) any former internal or external auditor of our company or any affiliate of such auditor, which performed services for us
within three years preceding the date of determination;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-align: justify; text-indent: -34.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether the member of the Board of Directors is, or in the three years preceding the date of determination
has been, part of an interlocking directorate, in which any of our executive officers serve on the Compensation Committee of another
company that concurrently employs the member as an executive officer;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-align: justify; text-indent: -34.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether the member of the Board of Directors receives any compensation from us, other than fees
or compensation for service as a member of the Board of Directors and any committee of the Board of Directors and reimbursement
for reasonable expenses incurred in connection with such service and for reasonable educational expenses associated with Board
of Directors or committee membership matters;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-align: justify; text-indent: -34.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether an immediate family member of the member of the Board of Directors is a current executive
officer of our company or was an executive officer of our company within three years preceding the date of determination;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-align: justify; text-indent: -34.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether an immediate family member of the member of the Board of Directors is, or in the three
years preceding the date of determination has been, affiliated with or employed in a professional capacity by (i) a present internal
or external auditor of ours or any of our affiliates or (ii) any former internal or external auditor of our company or any affiliate
of ours which performed services for us within three years preceding the date of determination; and</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0 0 0 1in; text-align: justify; text-indent: -34.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify; width: 90%">Whether an immediate family member of the member of the Board of Directors is, or in the three
years preceding the date of determination has been, part of an interlocking directorate, in which any of our executive officers
serve on the Compensation Committee of another company that concurrently employs the immediate family member of the member of the
Board of Directors as an executive officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The above list is not exhaustive and we anticipate that the Audit
Committee will consider all other factors which could assist it in its determination that a director will have no material relationship
with us that could compromise that director&rsquo;s independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under these standards, our Board of Directors has determined that
Messrs. Akirov and Bar Shalev and Ms.&nbsp;Harel are considered &ldquo;independent&rdquo; pursuant to the rules of the NYSE Amex
and Section 10A(m)(3) of the  Exchange Act. In addition, our Board of Directors has determined that
at least two of these directors are able to read and understand fundamental financial statements and have substantial business
experience that results in their financial sophistication, qualifying them for membership on any audit committee we form. Our Board
of Directors has also determined that Messrs. Akirov, Bar Shalev, Bronfeld and Sheratzky, Ms.&nbsp;Harel and Dr. Kornberg are &ldquo;independent&rdquo;
pursuant to the rules of the NYSE Amex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The position of chairman of the board is not held by our chief
executive officer at this time. The Board of Directors does not have a policy mandating the separation of these functions. We
believe it is in our best interest that Mr. Bronfeld serve as the interim chairman of the board. This decision was based on
Mr. Bronfeld&rsquo;s experience in the healthcare industry in Israel and globally and his years of experience serving on the
board of directors of many public and private companies. Our non-management directors hold formal meetings, separate from
management, at least twice per year. We have no formal policy regarding attendance by our directors at annual shareholders
meetings, although we encourage such attendance and anticipate most of our directors will attend these meetings. Messrs.
Bronfeld and Bar Shalev, Dr. Aviezer, Dr. Shaaltiel and Ms. Harel, attended our 2011 annual meeting of shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>The Board&rsquo;s Role in Risk Oversight </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Board of Directors oversees an enterprise-wide approach to risk
management, designed to support the achievement of business objectives, including organizational and strategic objectives, to improve
long-term organizational performance and enhance shareholder value. The involvement of our Board of Directors in setting our business
strategy is a key part of its assessment of management&rsquo;s plans for risk management and its determination of what constitutes
an appropriate level of risk for the company. The participation of our Board of Directors in our risk oversight process includes
receiving regular reports from members of senior management on areas of material risk to our company, including operational, financial,
legal and regulatory, and strategic and reputational risks. While the full board has the ultimate oversight responsibility for
the risk management process, various committees of the board also have responsibility for risk management. For example, financial
risks, including internal controls, are overseen by the audit committee and risks that may be implicated by our executive compensation
programs are overseen by the compensation committee. Upon identification of a risk, the assigned board committee or our full Board
of Directors discuss or review risk management and risk mitigation strategies. Additional review or reporting on enterprise risks
is conducted as needed or as requested by our Board of Directors or a committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-indent: -40.5pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 40.5pt"><B>Item 14.</B></TD><TD><B>Principal Accountant Fees and Services</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth fees billed to us by our independent
registered public accounting firm during the fiscal years ended December 31, 2011 and 2010 for: (i) services rendered for the audit
of our annual financial statements and the review of our quarterly financial statements; (ii) services by our independent registered
public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and that
are not reported as Audit Fees; (iii) services rendered in connection with tax compliance, tax advice and tax planning; and (iv)
all other fees for services rendered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Year&nbsp;ended&nbsp;December&nbsp;31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2011</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 76%; text-align: left">Audit Fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">252,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">289,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Audit Related Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28,353</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Tax Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">44,448</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">63,008</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All Other Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Policy on Audit Committee Pre-Approval of Audit and Permissible
Non-Audit Services of Independent Auditors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to entering into the engagement letter with our independent
registered accountants, our Audit Committee approved the 2011 audit fees. For fiscal year 2012, our Audit Committee has approved
fees for certain permissible non-audit services to be rendered by our independent registered accounting firm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.75pt"><B>Item 15.</B></TD><TD><B>Exhibits and Financial Statement Schedules</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">The following documents are filed as part of
this Annual Report on Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1.<I> &nbsp;&nbsp;Financial Statements</I>.
The following Consolidated Financial Statements of Protalix BioTherapeutics, Inc. are included in Item&nbsp;8 of this Annual Report
on Form 10-K:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 8%; font-weight: bold; text-align: left; border-bottom: Black 1pt solid; font-size: 10pt">Page</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Report of Independent Registered Public Accounting Firm</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">F-2</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Consolidated Balance Sheets as of December 31, 2010 and 2011</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">F-3</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Consolidated Statements of Operations for the years ended December 31, 2009, 2010 and 2011</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">F-4</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9.35pt; text-indent: -9.35pt; font-size: 10pt">Consolidated Statements of Changes in Shareholders&rsquo; Equity (Capital Deficiency) for the years ended December 31, 2009, 2010 and 2011</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">F-5</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2009, 2010 and 2011</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">F-6</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Notes to Consolidated Financial Statements</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt">F-8</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.<I>&nbsp;&nbsp;Financial Statement Schedule.
</I>Financial statement schedules have been omitted since they are either not required, are not applicable or the required information
is shown in the consolidated financial statements or related notes. <FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0in">3.<I>&nbsp;&nbsp;Exhibits.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><B>Incorporated&nbsp;by&nbsp;Reference</B></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; width: 10%">&nbsp;Exhibit</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 34%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%"><B>File</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 10%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 10%">&nbsp;Filed</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&nbsp;Number</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Exhibit&nbsp;Description&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Form</B></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Number</B></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Exhibit</B></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding: 0; border-bottom: Black 1pt solid; text-indent: 0">&nbsp;Date</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">&nbsp;Herewith</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Articles of Incorporation of the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-4</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">333-48677</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">March 26, 1998</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated June 9, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 13, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 26, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated February 26, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-Q</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">August 8, 2008</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>2006 Stock Incentive Plan</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">July 13, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.2</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement between Protalix Ltd. and Yoseph Shaaltiel, dated as of September 1, 2004</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.3</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0">January 8, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">10.3</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 34%">Employment Agreement between Protalix Ltd. and Einat Almon, dated as of December 19, 2004</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">8-K</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">001-33357</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">10.3</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">January 8, 2007</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.4</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement between Protalix Ltd. and David Aviezer, dated as of September 11, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.4</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.5</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement between Protalix Ltd. and Yossi Maimon, dated as of October 15, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.5</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.6&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>License Agreement entered into as of April 12, 2005, by and between Icon Genetics AG and Protalix Ltd.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K/A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.6</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">September 20, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.7&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Research and License Agreement between Yeda Research and Development Company Limited and Protalix Ltd. dated as of March 15, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K/A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.7</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">September 20, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.8&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Agreement between Teva Pharmaceutical Industries Ltd. and Protalix Ltd., dated September 14, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K/A</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.8</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">September 20, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.9</TD>
    <TD>&nbsp;</TD>
    <TD>Lease Agreement between Protalix Ltd. and Angel Science Park (99) Ltd., dated as of October 28, 2003 as amended on April 18, 2005</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.9</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.10</TD>
    <TD>&nbsp;</TD>
    <TD>Merger Agreement and Plan of Reorganization made and entered into as of August 21, 2006, by and among the Company, Protalix Acquisition Co., Ltd. and Protalix Ltd.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.10</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">January 8, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.11</TD>
    <TD>&nbsp;</TD>
    <TD>Stock Option Award Agreement grant by and between the Company and Steven Rubin, dated as of December 31, 2006</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.13</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 30, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.12</TD>
    <TD>&nbsp;</TD>
    <TD>First Amendment to the December 31, 2006 Stock Option Award Agreement by and between the Company and Steven Rubin, effective as of February 28, 2007</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.16</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 30, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.13</TD>
    <TD>&nbsp;</TD>
    <TD>Scientific Advisory Board Agreement dated August 5, 2007 by and between the Company and Aaron Ciechanover, M.D.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 6, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.14&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Research and License Agreement made on August&nbsp;8,&nbsp;2007, by and between Yissum Research Development Company of Jerusalem, the Boyce Thompson Institute and Protalix Ltd.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-Q</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 14, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">10.15</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 34%">Unprotected Lease Agreement</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">10-K</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center">001-33357</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">10.21</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">March 17, 2008</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.16&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>Exclusive License and Supply Agreement dated as of November 30, 2009 between Protalix Ltd. and Pfizer Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.16</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 26, 2010</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.17</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement by and between the Company and Sandra Lauterbach dated as of December&nbsp;17, 2009</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">December 27, 2009</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.18</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement by and between Protalix Ltd., and Tzvi Palash dated as of August&nbsp;29, 2010</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">September 7, 2010</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>10.19&dagger;</TD>
    <TD>&nbsp;</TD>
    <TD>License Agreement between Protalix BioTherapeutics Ltd. and Virginia Tech Intellectual Properties, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-Q</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10.2</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 8, 2010</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>21.1</TD>
    <TD>&nbsp;</TD>
    <TD>Subsidiaries</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">21.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 26, 2010</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>23.1</TD>
    <TD>&nbsp;</TD>
    <TD>Consent of Kesselman &amp; Kesselman, Certified Public Accountant (Isr.), A member of PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.2</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">101.SCH</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 34%">XBRL SHEMA FILE</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;&dagger; Portions of this exhibit were
omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&rsquo;s
application requesting confidential treatment under Rule 24b-2 of the Exchange Act.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the
Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized, as of February 27, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="RIGHT" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 95%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>David Aviezer, Ph.D.</TD></TR>
</TABLE><BR STYLE="clear: both">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">POWER OF ATTORNEY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">KNOW ALL PERSONS BY THESE PRESENTS, that each
person whose signature appears below constitutes and appoints David Aviezer, Ph.D. and Yossi Maimon, and each of them, as his true
and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and
stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite
and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby
ratifying and confirming that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may
lawfully do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 10pt">Signature</TD>
    <TD STYLE="width: 1%; padding-left: 12.5pt; font-weight: bold; text-align: center; padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 38%; padding-left: 12.5pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 10pt">Title</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: right; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 22%; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ David Aviezer</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">President, Chief Executive Officer</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">David Aviezer, Ph.D.</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">(Principal Executive Officer) and Director</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Yossi Maimon</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">Chief Financial Officer, Treasurer and</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">Secretary (Principal Financial</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">and Accounting Officer)</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Yoseph Shaaltiel</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">Executive VP, Research and Development</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">Yoseph Shaaltiel, Ph.D.</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">and Director</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Alfred Akirov</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">Alfred Akirov</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Amos Bar Shalev</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">Amos Bar Shalev</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Zeev Bronfeld</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">Zeev Bronfeld</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Yodfat Harel</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">Yodfat Harel</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Eyal Sheratzky</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">Director</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="text-align: center; font-size: 10pt">Eyal Sheratzky</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 12.5pt; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 25.9pt">&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.1pt"><B>CONSOLIDATED
FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 8%; font-weight: bold">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 16.8pt; font-weight: bold; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in; font-weight: bold; text-indent: -0.1in"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD>F-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; font-weight: bold; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in; font-weight: bold; text-indent: -0.1in">CONSOLIDATED FINANCIAL STATEMENTS</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; font-weight: bold; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">Consolidated Balance Sheets as of December 31, 2010 and 2011</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD>F-3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Consolidated Statements of Operations for the years ended December 31, 2009, 2010 and 2011</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">F-4</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Consolidated Statements of Changes in Shareholders&rsquo; Equity (Capital Deficiency) for the years ended December 31, 2009, 2010 and 2011</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">F-5</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">Consolidated Statements of Cash Flows for the years ended December 31, 2009, 2010 and 2011</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">F-6</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">Notes to Consolidated Financial Statements</TD>
    <TD STYLE="padding-left: 16.8pt; text-indent: -16.8pt">&nbsp;</TD>
    <TD>F-8</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The dollar amounts are stated in U.S. dollars
($)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the shareholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In our opinion, the accompanying consolidated balance sheets and
the related statements of operations, changes in shareholders&rsquo; equity (capital deficiency) and cash flows present fairly,
in all material respects, the financial position of Protalix BioTherapeutics, Inc. and its subsidiaries at December 31, 2010 and
2011, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2011,
in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the Company
maintained, in all material respects, effective internal control over financial reporting as of December 31, 2011, based on criteria
established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO). The Company&rsquo;s management is responsible for these financial statements, for maintaining effective internal control
over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in
the accompanying &ldquo;Management Report on Internal Control over Financial Reporting&rdquo; appearing under Item 9A. Our responsibility
is to express opinions on these financial statements and on the Company&rsquo;s internal control over financial reporting based
on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial
statements are free of material misstatement and whether effective internal control over financial reporting was maintained in
all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts
and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining
an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing
and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included
performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable
basis for our opinions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A company&rsquo;s internal control over financial reporting is a
process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A company&rsquo;s internal control
over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance
that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations
of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the company&rsquo;s assets that could have a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
or procedures may deteriorate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Tel-Aviv, Israel</TD>
    <TD STYLE="width: 50%; text-align: center">/s/ Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>February 27, 2012</TD>
    <TD STYLE="text-align: center">Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Certified Public Accountant (Isr.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 11.55pt">&nbsp;</TD>
    <TD STYLE="text-align: center">A member firm of PricewaterhouseCoopers</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 11.55pt">&nbsp;</TD>
    <TD STYLE="text-align: center">International Limited</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/10pt Times New Roman, Times, Serif; margin: 0"><img src="rule.jpg"></P>

<P STYLE="font: italic 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 9pt Arial; color: Red"><B></B></FONT>Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 68125, Israel, P.O Box 452 Tel-Aviv 61003
Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.co.il</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
CONSOLIDATED BALANCE SHEETS<BR>
</B>(U.S. dollars in thousands, except shares and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">35,900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">27,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,013</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,231</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,837</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,333</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,491</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">942</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17,454</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.5in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">64,729</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,805</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,032</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,563</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,121</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,903</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,693</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">55,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,923</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Long term liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,663</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">57,149</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">76,052</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">77,882</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">COMMITMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CAPITAL DEFICIENCY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Common Stock, $0.001 par value:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.5in">Authorized - as of December 31, 2010 and 2011,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.5in">150,000,000 shares; issued and outstanding - as of December 31, 2010 and 2011, 81,248,472&nbsp; and 85,630,157 shares, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">145,814</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(135,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(171,977</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total capital deficiency</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,077</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">64,729</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,805</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>The accompanying notes
are an integral part of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
</B>(U.S. dollars in thousands, except shares and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 55%; font-weight: bold">REVENUES</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">388</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6,642</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">8,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,602</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,418</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,575</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,383</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,525</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GROSS PROFIT (LOSS)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,187</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,861</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,443</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,691</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,818</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt">Less &ndash; grants&#9;and reimbursements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,740</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,775</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,638</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,951</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><B>GENERAL AND ADMINISTRATIVE <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: black">EXPENSES</FONT></B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,144</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,876</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,969</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,966</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,531</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">968</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS FOR THE YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(31,440</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(28,998</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(36,529</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="text-transform: uppercase">Net loss per
    share of common stock &ndash; basic and diluted:</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.41</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.36</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.43</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="text-transform: uppercase">Weighted average
    number of shares of common stock used in computing loss per share of common stock, basic and diluted:</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">76,942,840</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">80,960,300</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">84,645,364</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS&rsquo;
EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(CAPITAL DEFICIENCY)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands, except share data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR>shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 35%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at January 1, 2009</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">75,938,059</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">76</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">119,281</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">(75,010</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">44,347</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in">Changes during 2009:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9pt; padding-left: 0.3in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Exercise of options granted to employees and non-employees (includes net exercise)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">4,903,178</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">288</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Net Loss</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,440</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,440</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2009</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">80,841,237</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">81</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">122,252</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(106,450</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">15,883</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in">Changes during 2010:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.3in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Exercise of options granted to employees and non-employees (includes net exercise)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">407,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left"></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">*</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Net Loss</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,998</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,998</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2010</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">81,248,472</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">81</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">124,044</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(135,448</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(11,323</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.3in">Changes during 2011:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.3in">Common stock&nbsp;&nbsp;issued for cash (net of issuance costs of $1,410) (see note 7c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,586</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,590</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.3in">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Exercise of options granted to employees and non-employees (includes net exercise)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">381,685</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">298</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">299</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 0.3in">Net Loss</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36,529</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2011</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">85,630,157</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">86</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">145,814</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(171,977</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(26,077</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* Represents an amount less than $1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(31,440</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(28,998</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(36,529</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Depreciation and write down of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,990</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,133</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,631</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Financial &nbsp;expenses (income), net (mainly exchange differences)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(591</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in accrued liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Gain on amounts funded in respect of employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(81</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(26</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Loss on sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Increase (decrease) in deferred revenues (including non-current portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,563</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,005</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Decrease (increase) in accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,224</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,860</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,891</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Decrease (Increase) in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,189</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">910</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Increase (decrease) in accounts payable and accruals (including long term )</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,784</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,029</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Net cash provided by (used in) operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">44,452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,464</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(23,570</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,195</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(7,855</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,705</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Proceeds from sale of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Amounts funded in respect of employee rights upon retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(137</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,174</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,992</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,868</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Issuance of shares, net of issuance cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,650</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">501</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">277</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">501</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,927</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">589</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(388</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,670</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,366</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,899</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in"><B>BALANCE OF CASH AND CASH EQUIVALENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>AT BEGINNING OF YEAR</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">81,266</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">81,266</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,900</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,001</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(CONTINUED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -12.05pt; padding-left: 12.05pt">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 61%; text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">4,525</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">2,720</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">1,473</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Issuance cost not yet paid and accruals &ndash; other</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8.8pt">Exercise of options granted to employees</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>The accompanying notes are an integral part
of the consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 1 - </B></FONT><B>SIGNIFICANT
ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>General</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Operation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries,
&ldquo;The Company&rdquo;), and its wholly-owned subsidiary, Protalix Ltd. (the &ldquo;Israeli Subsidiary&rdquo; or &ldquo;Protalix
Ltd.&rdquo;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins
based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP> protein expression system (&ldquo;ProCellEx&rdquo;). In September
2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands in connection with the European Medicines
Agency (&quot;EMA&quot;) application process in Europe. The Company&rsquo;s two subsidiaries are referred to collectively herein
as the &ldquo;Subsidiaries.&rdquo; The Company&rsquo;s lead product development candidate is taliglucerase alfa for the treatment
of Gaucher disease which the Company is developing using ProCellEx. In addition to taliglucerase alfa, the Company is developing
certain other products using ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In September 2009, the Company successfully completed its
phase III pivotal trial of taliglucerase alfa. In July 2010, the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) notified
the Company that it had accepted for review the Company&rsquo;s new drug application (&quot;NDA&quot;) for taliglucerase alfa for
the treatment of Gaucher disease and that it granted to taliglucerase alfa a Prescription Drug User Fee Act (PDUFA) action date
of February 25, 2011. <FONT STYLE="font-family: Times New Roman, Times, Serif"> On February 25, 2011, the FDA issued a Complete
Response Letter (&quot;CRL&quot;) indicating that the FDA&rsquo;s review of the taliglucerase alfa NDA was complete but questions
remain that precluded the approval of the NDA in its then current form. In August 2011, the Company submitted a revised NDA in
response to the CRL. During the same month, the FDA notified the Company that it had accepted the revised NDA for review, had deemed
the resubmission a class 2, or 6-month, response and established February 1, 2012 as the new PDUFA date. In December 2011, the
FDA notified the Company that it had decided to extend the PDUFA date to May 1, 2012. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In the fourth quarter of 2010, Pfizer Inc. (&quot;Pfizer&quot;),
the Company's commercialization partner, filed, with the Company's cooperation, a Marketing Authorization Application (&quot;MAA&quot;)
for taliglucerase alfa with the EMA. As part of its ongoing review of the MAA, the EMA delivered a list of outstanding points to
be addressed by the applicant. Among the topics currently in discussion, is the orphan drug designation and exclusivity granted
by the EMA/European Commission to VPRIV, Shire plc's (&quot;Shire&quot;) Gaucher disease treatment, which could prevent the marketing
authorization of taliglucerase alfa in the European Union for a 10-year market exclusivity period commencing as of the August 2010
marketing authorization of VPRIV in the European Union. As part of the MAA procedure, Pfizer, with the Company's cooperation, is
challenging VPRIV's orphan market protection with respect to taliglucerase alfa pursuant to the EU orphan drug regulation. The
EU orphan drug regulation provides for the possibility of such a challenge, and for an exception to this exclusivity to be granted,
based on a number of factors, including contribution to patient care, clinical, supply, capacity and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Following the submission of the taliglucerase alfa MAA
to the EMA, a good manufacturing practices, or GMP, audit of the Company's manufacturing facility was performed and it
was found compliant with EMA GMP in December 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In January 2010, the EMA's Committee for Orphan Medicinal
Products, after reviewing all relevant clinical data, recommended that the European Commission grant orphan drug designation to
taliglucerase alfa for the treatment of Gaucher disease and in March 2010, the European Commission granted orphan designation to
taliglucerase alfa. In September 2009, the FDA&rsquo;s Office of Orphan Product Development granted <FONT STYLE="font-family: Times New Roman, Times, Serif">taliglucerase
alfa </FONT>Orphan Drug Status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">On November&nbsp;30, 2009, Protalix Ltd. and Pfizer entered
into an Exclusive License and Supply Agreement (the &ldquo;Pfizer Agreement&rdquo;) pursuant to which Protalix Ltd. granted Pfizer
an exclusive, worldwide license to develop and commercialize taliglucerase alfa, except in Israel. Under the terms and conditions
of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize taliglucerase alfa in Israel. See Note 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Although taliglucerase alfa has not yet been approved for
commercial sale, patients are being treated with taliglucerase alfa, both in the framework of the Company's clinical trials and
related studies and in compassionate use programs, special access agreements, named patient provisions and other programs designed
to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. In July 2009,
following a request by the FDA, the Company submitted a treatment protocol to the FDA in order to address an expected shortage
of the current enzyme replacement therapy approved for Gaucher disease. The treatment protocol was approved by the FDA in August
2009, and the Company is continuing to treat patients in the United States under this protocol. On July 13, 2010, the Company announced
that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for
Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health
Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.
This ATU allows Gaucher disease patients in France to receive treatment with taliglucerase alfa before marketing authorization
for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations
to hospitals. In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher disease patients
under special access agreements or Named Patient provisions in Brazil and in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">On August 10, 2010, Pfizer entered into a short-term supply
agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the
Ministry of Health of Brazil for the treatment of Gaucher disease patients. During the remainder of 2010 and the first quarter
of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011,
Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health
requested that Pfizer consider the replacement of certain vials that might expire during 2012. Revenue, net of allowance for sales
returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues
in accordance with the terms and conditions of the Pfizer Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Liquidity and Financial Resources</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Successful completion of the Company&rsquo;s development
programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior
to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally.
Each FDA and EMA approval triggers a $25,000 milestone payment from Pfizer, pursuant to the Pfizer Agreement. There can be no assurance
that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before
the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial
expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental
periods. Obtaining marketing approval will be directly dependent on the Company&rsquo;s ability to implement the necessary regulatory
steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome
of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Based on its current cash resources and commitments, and
cash received in a public underwritten offering on February 2012 (see note 11b), the Company believes it will be able to maintain
its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although
no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general
and administrative expenses or research and development expenses, the Company may need to seek additional financing during the
next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Basis of presentation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company&rsquo;s financial statements have been prepared
in accordance with generally accepted accounting principles in the United States (&ldquo;U.S. GAAP&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Use of estimates in the preparation of financial statements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The preparation of financial statements in conformity
with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities,
the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results may differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">d.</FONT></TD><TD>Functional currency</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The dollar is the currency of the primary economic environment
in which the operations of the Company and its Subsidiaries are conducted. The Company&rsquo;s revenues are derived in dollars.
Most of the Company&rsquo;s expenses and capital expenditures are incurred in dollars, and the major source of the Company&rsquo;s
financing has been provided in dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Transactions and balances originally denominated in dollars
are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current
exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items (stated below)
reflected in the statements of operations, the following exchange rates are used: (i) for transactions &ndash; exchange rates at
the transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation
and amortization, etc.) &ndash; historical exchange rates. Currency transaction gains and losses are carried to financial income
or expenses, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">e.</FONT></TD><TD>Cash equivalents</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company considers all short-term, highly liquid investments,
which include short-term bank deposits with original maturities of three months or less from the date of purchase, that are not
restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">f.</FONT></TD><TD>Inventories</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Inventories are valued at the lower of cost or market.
Cost of raw and packaging materials and purchased products is determined using the &ldquo;moving average&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Manufacturing costs for product candidates are expensed
as research and development expenses. The Company considers regulatory approval of product candidates to be uncertain, and product
manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs
for product candidates incurred prior to regulatory approval are not capitalized as inventory. Inventories for which there are
orders or are probable to be sold even without the regulatory approval, are capitalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Cost of finished products that are capitalized is determined
as follows: the value of the raw and packaging materials component is determined primarily on a using the &ldquo;moving average&rdquo;
basis; the value of the labor and overhead component is determined on an average basis over the production period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">g.</FONT></TD><TD>Property and equipment</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><FONT STYLE="font-weight: normal">Property and equipment are stated at cost, net of accumulated depreciation and amortization.
</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD><FONT STYLE="font-weight: normal">The Company&rsquo;s assets are depreciated by the straight-line method on the basis of their
estimated useful lives as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 83%; padding-left: 81.1pt">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 15%">Years</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Laboratory equipment</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Furniture</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">10-15</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">Computer equipment&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Leasehold improvements are amortized by the straight-line
method over the expected lease term, which is shorter than the estimated useful life of the improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">h.</FONT></TD><TD>Impairment in value of long-lived assets:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company tests long-lived assets for impairment if
an indication of impairment exists. If the sum of expected future cash flows of definite life assets (undiscounted and without
interest charges) is less than the carrying amount of such assets, the Company recognizes an impairment loss, and writes down the
assets to their estimated fair values, calculated based on expected future discounted cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">i.</FONT></TD><TD>Income taxes</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><FONT STYLE="font-weight: normal">Deferred income taxes</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Deferred taxes are determined utilizing the assets and liabilities
method based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and
liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when
those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available
evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided
a full valuation allowance with respect to its deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The guidance prohibits the recognition of deferred tax liabilities
or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured
from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing
for tax purposes. Consequently, the above mentioned differences with respect to Protalix Ltd. were not reflected in the computation
of deferred tax assets and liabilities.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD><FONT STYLE="font-weight: normal">Uncertainty in income taxes</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Tax benefits recognized in the financial statements are
those that the Company&rsquo;s management deems at least more likely than not to be sustained, based on technical merits. The amount
of benefits recorded for these tax benefits is measured as the largest benefit the Company&rsquo;s management deems more likely
than not to be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">j.</FONT></TD><TD>Revenue Recognition</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company recognizes revenue when the earnings process
is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists,
delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><FONT STYLE="font-weight: normal">Revenues from the license and supply agreement with Pfizer</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The Company recognizes revenue and milestone payments received
pursuant to the Pfizer Agreement in accordance with guidance regarding revenue recognition and accounting for revenue arrangements
with multiple deliverables. As the arrangement with Pfizer requires the Company&rsquo;s continued involvement with respect to the
proposed commercialization of taliglucerase alfa, the non-refundable, up-front license payment the Company received from Pfizer
was deferred and recognized over the related performance period. The Company estimated the performance period of 14 years (commencing
upon the date of the Company's receipt of the up-front license payment payable by Pfizer under the Pfizer Agreement) based on the
date the last relevant patent expires. See Note 2. The Company adjusts the performance periods, if appropriate, based on the applicable
facts and circumstances.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD><FONT STYLE="font-weight: normal">Revenues from selling products to Pfizer</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The Company recognizes revenues from products sold to Pfizer
upon delivery, when the sales price is fixed or determinable and collectability is reasonably assured.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">3.</TD><TD><FONT STYLE="font-weight: normal">Company&rsquo;s share in the collaboration agreement</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">Under
the terms and conditions of the Pfizer Agreement, the Company is entitled to 40% of the profits or loss from sales of taliglucerase
alfa, and related expenses incurred, except with respect to sales in Israel, where the Company retained exclusive marketing rights.
Since Pfizer bears most of the risks and rewards relating to the agreement, the Company&rsquo;s share in the profits and loss in
the agreement is recognized on a net basis. The Company recognizes its share of net profit or loss from the Pfizer Agreement based
on reports it receives from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable
period. Under the terms of the Pfizer Agreement, for its subsidiaries operating outside the United States, financial information
is included based on the fiscal year ending November 30, while financial information for the U.S. entity is included based on the
fiscal year ending December 31.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">k.</FONT></TD><TD>Research and development costs</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Research and development costs are expensed as incurred
and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials), facilities, equipment
and supplies for research and development activities. Grants received by the Israeli Subsidiary from the Office of the Chief Scientist
of Israel&rsquo;s Ministry of Industry, Trade and Labor (the &ldquo;OCS&rdquo;) are recognized when the grant becomes receivable,
provided there is reasonable assurance that the Company or the Subsidiary will comply with the conditions attached to the grant
and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses
as the applicable costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Reimbursements received from Pfizer are recognized when
the reimbursements become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached
to the reimbursements and there is reasonable assurance the reimbursements will be received. The reimbursements are deducted from
the research and development expenses as the applicable costs are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">In connection with purchases of assets, amounts assigned
to intangible assets to be used in a particular research and development project that have no alternative future use are charged
to research and development costs at the purchase date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Nonrefundable advance payments for goods or services
that will be used or rendered for future research and development activities are deferred and amortized over the period that the
goods are consumed or the related services are performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">l.</FONT></TD><TD>Comprehensive loss</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company has no other comprehensive loss components
other than net loss for the reported periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">m.</FONT></TD><TD>Concentration of credit risks and trade receivable</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Financial instruments that potentially subject the Company
to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated
financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial
institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant
credit risk on these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"><FONT STYLE="color: black">The Company's trade </FONT>receivable<FONT STYLE="color: black">
represents amounts to be received from Pfizer, as the Company currently receives all of its revenues from Pfizer. The Company does
not require Pfizer to post collateral with respect to the receivables. The Company performs periodic credit evaluations of Pfizer&rsquo;s
financial condition and believes there is no significant risk with respect to Pfizer&rsquo;s payment of the receivables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">n.</FONT></TD><TD>Share-based compensation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company accounts for employee&rsquo;s share-based
payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions
is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures
based on historical experience and anticipated future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company elected to recognize compensation cost for
an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option
award approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">When stock options are granted as consideration for services
provided by consultants and other non-employees, the grant is accounted for based on the fair value of the consideration received
or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is
measured on a final basis at the end of the related service period and is recognized over the related service period using the
straight-line method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">o.</FONT></TD><TD>Net Loss per share</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company's Common Stock, par value $0.001 per
share (the &quot;Common Stock&quot;) outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Diluted LPS does not include options to purchase 10,660,447,
7,761,168 and 7,469,088 shares of Common Stock for the fiscal years ended December 31, 2009, 2010 and 2011, respectively, because
the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">NOTE 2 - </FONT>LICENSE AND SUPPLY
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">On November&nbsp;30, 2009, Protalix Ltd. and Pfizer entered
into the Pfizer Agreement pursuant to which Pfizer was granted an exclusive, worldwide license to develop and commercialize taliglucerase
alfa, except in Israel. Under the terms and conditions of the Pfizer Agreement, Protalix Ltd. retained the right to commercialize
taliglucerase alfa in Israel. Under the Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd. of $60,000 in connection
with the execution of the agreement and shortly thereafter paid Protalix Ltd. an additional $5,000 upon the Company&rsquo;s filing
of a proposed pediatric investigation plan to the Pediatric Committee of the EMA. Protalix Ltd. is also eligible to receive additional
potential milestone payments totaling up to $50,000 for the successful achievement of other regulatory milestones. Protalix Ltd.
is entitled to 40% of the profits earned on Pfizer&rsquo;s sales of taliglucerase alfa. Such profit will be calculated while, in
addition to other adjustments, taking into account Protalix Ltd.&rsquo;s cost of goods sold and Pfizer&rsquo;s commercial expenses,
with certain expenses capped or borne solely by one party (&quot;Collaboration Operation&quot;). Of the losses incurred by the
Collaboration Operation through December 31, 2011, 40% will be deducted from the Company's share in the profits from future years.
This deduction will limited to a certain percentage of any quarterly profit. As of December 31, 2011, the Company accrued a liability
in respect of these losses equal to $7,888, out of which $6,566 is classified as a long term liability, and the remainder is included
in accounts payable and accruals-other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Company has determined that the initial, non-refundable
upfront license fee payment of $60,000 together with the first $5,000 payment will be recognized on a straight line basis as revenue
over the estimated relationship period. The Company has estimated that the relationship period for its arrangement with Pfizer
will be approximately 14 years (commencing upon the Company&rsquo;s receipt of the up-front license payment) based on the Company&rsquo;s
last material patent relating to taliglucerase alfa to expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Company&rsquo;s deliverables under this collaboration
include an exclusive license to taliglucerase alfa as an enzyme replacement therapy for the treatment of Gaucher disease, certain
research and development services as required under the Pfizer Agreement for taliglucerase alfa, manufacturing of taliglucerase
alfa and optional participation in a joint steering committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">According to the terms and conditions of the Pfizer Agreement,
the Company retained manufacturing rights and sells its products to Pfizer. In addition, Pfizer is required to reimburse the Company
for certain costs it incurs in connection with certain development expenses for taliglucerase alfa. In connection with the payments
received under the Pfizer Agreement, Protalix Ltd. is obligated to pay certain royalties. See Note 6a.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 3 - </B></FONT><B>PROPERTY
AND EQUIPMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD><FONT STYLE="font-weight: normal">Composition of property and equipment grouped by major classifications is as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 58%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Laboratory equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">11,478</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">13,079</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Furniture and computer equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,522</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Leasehold improvements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,705</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Equipment under construction</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,038</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 14.55pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,043</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">29,419</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Less &ndash; accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,589</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,148</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,454</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,271</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.3pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD><FONT STYLE="font-weight: normal">Depreciation and amortization in respect of property and equipment totaled $1,990, $3,133
and $3,631 for the years ended December 31, 2009, 2010 and 2011, respectively, out of which the Company recorded a total write
down of $0, $43 and $10, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 4 - </B></FONT><B>INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD><FONT STYLE="font-weight: normal">Inventory at December&nbsp;31, 2010 and 2011 consisted of the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 58%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">553</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">279</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">636</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">279</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD><FONT STYLE="font-weight: normal">During the year ended December 31, 2010 and 2011,<FONT STYLE="color: black"> the Company
recorded a $2,692 </FONT>and $363, respectively, write-down of inventory under cost of revenues. See Note 9d. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 5 - </B></FONT><B>LIABILITY
FOR EMPLOYEE RIGHTS UPON RETIREMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Israeli Subsidiary is required to make a severance
payment upon dismissal of an employee, or upon termination of employment in certain circumstances. The severance pay liability
to the employees (based upon length of service and the latest monthly salary - one month&rsquo;s salary for each year employed)
is recorded on the Company&rsquo;s balance sheets under &ldquo;Liability for employee rights upon retirement.&rdquo; The liability
is recorded as if it were payable at each balance sheet date on an undiscounted basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The liability is funded in part from the purchase of insurance
policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities
are included in the Company&rsquo;s balance sheets under &ldquo;Funds in respect of employee rights upon retirement.&rdquo; These
policies are the Company&rsquo;s assets. However, under labor agreements and subject to certain limitations, any policy may be
transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended December
31, 2009, 2010 and 2011, the Company deposited $79, $174 and $181, respectively, with insurance companies in connection with its
severance payment obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">In accordance with the current employment agreements with
certain employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable
employee in order to secure the employee&rsquo;s rights upon retirement. The Company is fully relieved from any severance pay liability
with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these
employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company&rsquo;s balance sheets,
as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been
irrevocably transferred to the applicable insurance companies (the &ldquo;Contribution Plans&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The amounts of severance pay expenses were $488, $1,118
and $816 for the years ended December 31, 2009, 2010 and 2011, respectively, of which $335, $531 and $641 in the years ended December
31, 2009, 2010 and 2011, respectively, were in respect of a Contribution Plan. Gain on amounts funded in respect of employee rights
upon retirement totaled $81, $26 and $14 for the years ended December 31, 2009, 2010 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">The Company expects to contribute approximately $779 in
the year ending December 31, 2012 to insurance companies in connection with its severance liabilities for its operations for that
year, $607 of which will be contributed to one or more Contribution Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">During the five-year period following December 31, 2011,
the Company expects to pay future benefits to one<B> </B>employee upon the employee's normal retirement age. The Company anticipates
that the benefits payable will be immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 6 -</B></FONT><B>
COMMITMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>Royalty commitments</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><FONT STYLE="font-weight: normal">The Company is obligated to pay royalties to the OCS on proceeds from the sale of products
developed from research and development activities that were funded, partially, by grants from the OCS. At the time the grants
were received, successful development of the related projects was not assured.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">In the case of failure of a project that was partly financed
as described above, the Company is not obligated to pay any such royalties or repay funding received from the OCS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under the terms of the funding arrangements with the OCS,
royalties of 3% to 6% are payable on the sale of products developed from projects funded by the OCS, which payments shall not exceed,
in the aggregate, 100% of the amount of the grant received (dollar linked), plus, commencing upon January&nbsp;1, 2001, interest
at annual rate based on LIBOR. In addition, if the Company receives approval to manufacture products developed with government
grants outside the State of Israel, it will be required to pay an increased total amount of royalties (possibly up to 300% of the
grant amounts plus interest), depending on the manufacturing volume that is performed outside the State of Israel, and, possibly,
an increased royalty rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Royalty expenses to the OCS are included in the statement
of operations as a component of the cost of revenues and were approximately $1,950, $769 and $158 during the years ended December&nbsp;31,
2009, 2010 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">At December&nbsp;31, 2011, the maximum royalty amount payable
by the Company under these funding arrangements is approximately $19,820 (without interest, assuming 100% of the funds are payable).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD><FONT STYLE="font-weight: normal">The Company is a party to certain research and license agreements. Under the<FONT STYLE="color: black">
agreements, the Company is obligated </FONT>to pay royalties at varying rates from its future revenues. The aggregate royalties
payable under all of the agreements is equal to a percentages of net sales of licensed products in the teens. Royalty expenses
under the agreements are included in the statement of operations as a component of the cost of revenues and were approximately
$1,625, $115 and $19 during the years ended December&nbsp;31, 2009, 2010 and 2011, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under each agreement, the Company is also obligated to pay
milestone, licensing and other payments to the counterparties of the agreement. The payments under the agreements are for varying
amounts and are subject to varying conditions. If all of the contingencies with respect to milestone payments under the research
and license agreements are met, the aggregate milestone payments payable would be approximately $950 and would be payable, if at
all, as the Company&rsquo;s projects progress over the course of a number of years. In addition, milestone payments of $70 and
$100 were paid in respect of the said agreements during the years ended December 31,2009 and 2010, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">None of the agreements has a fixed termination date. Subject
to earlier termination for other reasons, each agreement terminates after a certain number of years following the first commercial
sale of any licensed product under the agreement or after a certain number of years without the initiation of commercial sales
of any product under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Subcontracting Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company has entered into sub-contracting agreements
with several clinical providers and consultants<B> </B>in Israel, the United States and certain other countries in connection with
its primary product development process and with expenditure of the company&rsquo;s manufacturing facilities. As of December 31,
2011, total commitments under said agreements were approximately $821.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 6 &ndash; COMMITMENTS </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Lease Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company is a party to a number of lease agreements
for its facilities, the latest of which expires in 2017. The Company has the option to extend certain of such agreements on three
occasions for additional five-year periods, for a total of 15 additional years. Under the leases, the aggregate monthly rental
payments are approximately $75. As of December 31, 2011, the Company provided bank guarantees of approximately $208, in the aggregate,
to secure the fulfillment of its obligations under the lease agreements. The future minimum lease payments required in each of
the next five years under the operating leases for such premises are approximately as follows: 2012 - $901, 2013 - $890, 2014 -
$883, 2015 &ndash; $883 and 2016 &ndash; $638. Lease expenses totaled $780, $891 and $994 for the years ended December 31, 2009,
2010 and 2011, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">d.</FONT></TD><TD>Vehicle Lease and Maintenance Agreements</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">In July 2004, the Company entered into several three-year
lease and maintenance agreements for vehicles which are regularly amended as new vehicles are leased. The current monthly lease
fees aggregate approximately $46. The minimum expected lease payments for the years ending December 31, 2012, 2013 and 2014 are
$514, $267 and $70, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">e.</FONT></TD><TD>Teva Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">On September 14, 2006, the Company entered into an agreement
(the &ldquo;Teva Agreement&rdquo;) with Teva Pharmaceutical Industries Ltd. (&ldquo;Teva&rdquo;) under which the Company agreed
to collaborate on the research and development of two proteins to be identified by Teva and the Company, using ProCellEx. The Teva
Agreement also identifies additional matters for collaboration between Teva and the Company. Subsequently, two proteins were identified
to be researched and developed under the agreement but in 2009, both of the projects were terminated for commercial reasons. Other
elements of the Company&rsquo;s collaboration with Teva are currently ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">f.</FONT></TD><TD>Yissum Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left">On August 8, 2007, the Company signed
an agreement with the Yissum Research and Development Company, the technology transfer arm of the Hebrew University of Jerusalem,
Israel, and the Boyce Thompson Institute for Plant Research, at Cornell University, Ithaca, New York, to develop a proprietary
plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications,
including a biodefense program and organophosphate-based pesticide treatment. Pursuant to the agreement, the Company has received
an exclusive worldwide right and license to certain technology, including patents and additional patent applications relating to
AChE (the &ldquo;Licensed Technology&rdquo;), for all therapeutic and prophylactic indications. In consideration for the license,
the Company is required to make certain milestone payments equal to up to $700, in the aggregate, upon its achievement of clinical
milestones and royalties from sales derived from any drugs developed by the Company with the Licensed Technology. The agreement
does not terminate until either party to the agreement elect to terminate the agreement, subject to certain terms and conditions
set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 7 - </B></FONT><B>SHARE
CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>Rights of the Company&rsquo;s Common Stock</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Company&rsquo;s common stock is listed on the NYSE
Amex and, since September 6, 2010, on the Tel Aviv Stock Exchange. Each share of Common Stock is entitled to one vote. The holders
of shares of Common Stock are also entitled to receive dividends whenever funds are legally available, when and if declared by
the Board of Directors. Since its inception, the Company has not declared any dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Stock based compensation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">On December 14, 2006, the Board of Directors adopted
the Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the &ldquo;Plan&rdquo;). The grant of options to Israeli employees
under the Plan is subject to the terms stipulated by Sections&nbsp;102 and 102A of the Israeli Income Tax Ordinance. Each option
grant is subject to the track chosen by the Company, either Section 102 or Section 102A of the Israeli Income Tax Ordinance, and
pursuant to the terms thereof, the Company is not allowed to claim, as an expense for tax purposes, the amounts credited to employees
as a benefit, including amounts recorded as salary benefits in the Company&rsquo;s accounts, in respect of options granted to employees
under the Plan, with the exception of the work-income benefit component, if any, determined on the grant date. For Israeli non-employees,
the share option plan is subject to Section 3(i) of the Israeli Income Tax Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">As of December 31, 2011, 47,920 shares of Common Stock
remain available for grant under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">For purposes of determining the fair value of the options
granted to employees and non-employees, the Company&rsquo;s management uses the fair value of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">From January 1, 2009 through December 31, 2011, the Company
granted options to certain employees and non-employees as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Options granted to employees:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD>Below is a table summarizing all of the option grants to employees for each of the three years in the period ended December
31, 2011:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 80%; font: 8pt Times New Roman, Times, Serif; margin-left: 1.25in">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year&nbsp;of <BR>Grant</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">No.&nbsp;of&nbsp;options <BR>granted</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise <BR>price&nbsp;range</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Vesting&nbsp;period</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair&nbsp;value <BR>at&nbsp;grant</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration <BR>Period</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD COLSPAN="2" STYLE="text-align: left">2009*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">504,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">2.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Upon achievement of certain milestones*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: left">2009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">2.65</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD COLSPAN="2" STYLE="text-align: left">2010</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,016,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">$</TD><TD NOWRAP STYLE="text-align: right">6.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3 years commencing upon achievement of a certain milestone</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10 years</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: left">2010</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">428,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: right">6.32-$9.66</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">4 years</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">2,147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">10 years</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: left; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 1pt; text-align: left; border-bottom: Black 1pt solid; width: 1%">&nbsp;&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: right; border-bottom: Black 1pt solid; width: 10%">&nbsp;&nbsp;</TD><TD STYLE="font-size: 1pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left; width: 1%">&nbsp;</TD><TD NOWRAP STYLE="text-align: right; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 35%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 10%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,068,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">* The milestone was achieved as of December 31, 2009
and the options vested in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">Set forth below are grants made by the Company to employees
(including related parties) during the three-year period ended December 31, 2011 (such grants appear in the table above):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">1.</FONT></TD><TD><FONT STYLE="font-weight: normal">In February, 2009, the Company&rsquo;s Board of Directors approved the grant of options to
purchase 624,400 shares of Common Stock to the Company&rsquo;s Chief Executive Officer and certain officers and employees of the
Company with an exercise price equal to $2.65 per share. The options vest as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: 0in"><FONT STYLE="font-weight: normal">(i)
504,000 of the options vest immediately upon the achievement of certain clinical and operational performance milestones, which
milestones must be achieved within one year of the date of grant or the options will be forfeited. The options expire within a
period of 10 years from the date of grant. The vesting conditions of these options were satisfied prior to December 31, 2009. Accordingly,
these options were fully vested at December 31, 2009 and the Company recognized all of the expenses for these options during 2009.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: 0in"><FONT STYLE="font-weight: normal">(ii)
120,400 of the options vest as follows: 25% within one year from the date of grant, with the remainder vesting in 12 equal quarterly
tranches over 36 months. The options expire within a period of 10 years from the date of grant. The Company&rsquo;s management
assumed the simplified method to reflect the expected life regarding these options. The Company used the simplified method in 2009
as the Company did not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term
due to the limited period of time its equity shares have been publicly traded. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">2.</FONT></TD><TD><FONT STYLE="font-weight: normal">In February 2010, the Company&rsquo;s Board of Directors approved the grant of options to
purchase 1,016,000 shares of Common Stock, in the aggregate, to the Company&rsquo;s Chief Executive Officer and certain officers
and employees of the Company with an exercise price equal to $6.90 per share. The options vest quarterly over a three-year period
commencing upon the FDA&rsquo;s approval of taliglucerase alfa, if at all. The Company treated the awards as performance-based
awards and, given that the performance condition is outside the Company's control, concluded that the performance condition was
not probable until the performance condition actually occurs. As a result, no share-based compensation expense was recognized as
of December 31, 2011.&nbsp;&nbsp;The Company will start recording these expenses following the FDA&rsquo;s marketing approval of taliglucerase
alfa, if at all.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">3.</FONT></TD><TD><FONT STYLE="font-weight: normal; color: black">In February 2010, the Company&rsquo;s Board of Directors approved the grant
of options to purchase 160,000&nbsp;shares of Common Stock with an exercise price equal to $6.81 per share to a new executive officer
of the Company. The options expire on the tenth anniversary of the date of grant, unless terminated earlier. The first 25% of the
options vest on the first anniversary of the date of grant and the remaining 75% vest in 12 equal tranches on a quarterly basis
for three years thereafter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">4.</FONT></TD><TD><FONT STYLE="font-weight: normal">In September&nbsp;2010, the Company&rsquo;s Board of Directors approved the grant of options
to purchase 160,000 shares of Common Stock to a new executive officer of the Company with an exercise price equal to $7.55 per
share and options to purchase 40,000 shares of Common Stock to a new employee of the Company with an exercise price equal to $6.32
per share. The options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date
of the grant and the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. <FONT STYLE="color: black">The
options expire on the tenth anniversary of the date of grant, unless terminated earlier. </FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">NOTE 7&ndash; SHARE CAPITAL <FONT STYLE="font-weight: normal">(continued)</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">5.</FONT></TD><TD><FONT STYLE="font-weight: normal">In November&nbsp;2010, the Company&rsquo;s Board of Directors approved the grant of options
to purchase 68,000 shares of Common Stock to a new officer of the Company with an exercise price equal to $9.66 per share. The
options vest over a four-year period, with the first 25% vesting on the first anniversary of the applicable date of the grant and
the remaining 75% vesting in equal tranches on a quarterly basis for a three-year period thereafter. <FONT STYLE="color: black">The
options expire on the tenth anniversary of the date of grant, unless terminated earlier.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">6.</FONT></TD><TD><FONT STYLE="font-weight: normal">In September 2010, the Company&rsquo;s Board of Directors modified the terms of the options
previously granted to an executive in 2001, by extending the life of the options until 2016. At the date of modification, all of
the options were fully vested. The Company concluded that there was no incremental increase in the value of the awards and therefore
no accounting charges need to be recorded in connection with the modifications. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD>The fair value of options granted during the years ended December 31, 2009 and 2010 were $1,280 and $7,820 respectively. The
fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model, with the following
weighted average assumptions:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 58%; text-align: left; padding-bottom: 2.5pt; text-indent: 0; padding-left: 0; padding-right: 0">Dividend yield</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; border-bottom: Black 2.5pt double; text-align: right">0%</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; border-bottom: Black 2.5pt double; text-align: right">0%</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 0; padding-left: 0; padding-right: 0">Expected volatility</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">75%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 0; padding-left: 0; padding-right: 0">Risk-free interest rate</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.74%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.23%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 0; padding-left: 0; padding-right: 0">Expected life &ndash; in years</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.2</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.8</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The expected volatility is based on the historical volatility
of the Common Stock and those of comparable companies. The risk-free interest rate assumption is based on observed interest rates
appropriate for the expected term of the stock options granted in dollar terms. The Company&rsquo;s management uses the contractual
term or its expectations, based on historical incidence of option exercises, as applicable (during 2009 - using the simplified
method), of each option as its expected life. The pre-vesting forfeiture rate of approximately 6.3% is estimated based on pre-vesting
forfeiture experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The total unrecognized compensation cost of
employee stock options at December 31, 2011 is $6,218 (net of forfeiture rate) out of which $5,639 is expected to be
recognized over a three-year period commencing upon the FDA&rsquo;s approval of taliglucerase alfa, if at all. The remaining
compensation cost of $579 is expected to be recognized over a weighted average period of 0.9 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The total cash received from employees as a result of
employee stock option exercises for the years ended December 31, 2009, 2010 and 2011 was $293, $501 and $277, respectively. The
Company did not realize any tax benefit in connection with these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">During 2011, the Company issued 181,685 shares of Common
Stock in connection with the exercise of 182,093 options by certain employees of the Company. The Company received cash proceeds
equal to $268 in connection with such exercises. Of such options, 2,132 options were exercised on a &ldquo;net-exercise&rdquo;
basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Options granted to consultants, directors, and other service providers:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"><FONT STYLE="font-weight: normal">As of
December 31, 2011, the Company has recognized and recorded all compensation costs related to outstanding options for consultants,
directors and other services providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">No cash was received from consultants as a result of consultant
stock option exercises for the years ended December 31, 2009, 2010, and $0.2 was received in 2011. The Company did not realize
any tax benefits in connection with these exercises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">During 2009, the Company issued 3,853,441 shares of Common
Stock in connection with the exercise of 3,866,093 options by certain consultants, directors, and other service providers of the
Company. The Company did not receive cash proceeds in connection with such exercises as all of such options were exercised on a
&ldquo;net-exercise&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">During 2011, the Company issued 200,000 shares of Common
Stock in connection with the exercise of 200,000 options by certain consultant of the Company. The Company received cash proceeds
equal to $0.2 in connection with such exercise.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">3.</TD><TD><FONT STYLE="font-weight: normal">A summary of share option plans, and related information, under all of the Company&rsquo;s
equity incentive plans for the years ended December&nbsp;31, 2009, 2010 and 2011 are as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>Options granted to employees:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 22%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Outstanding at beginning of year</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,890,641</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.118</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5,366,729</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2.476</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">6,367,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Changes during the year:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">624,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,444,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.076</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Forfeited and Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.551</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,856</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.207</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Exercised (*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,146,912</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.733</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">429,309</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.602</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182,093</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1.652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,366,729</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.476</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,367,979</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,141,030</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.563</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,680,382</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.785</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,267,850</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.183</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,647,834</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2.581</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -0.2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 1in; text-indent: 0in; text-align: left">(*)
The total intrinsic value of options exercised during the years ended December 31, 2009, 2010 and 2011, was $7,258, $3,050 and
$1,252, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD>Options granted to consultants, directors, and other service providers:</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">average</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 22%; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Outstanding at beginning of year</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">5,304,785</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">1.285</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">1,438,692</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">4.697</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">1,438,692</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 10%; padding-bottom: 1pt; text-align: right">4.697</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Changes during the year-Exercised (*)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,866,093</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.016</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">200,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Outstanding at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,438,692</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,438,692</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,238,692</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.385</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.1in">Exercisable at end of year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,407,234</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.674</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,421,734</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4.653</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,235,567</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5.385</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63.8pt"></TD><TD STYLE="width: 14pt">(*)</TD><TD>The total intrinsic value of options exercised during the years ended December 31, 2009, 2010 and 2011, was $41,281, $0 and
$1,886, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 77.8pt; text-indent: -14pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD>The following tables summarize information concerning outstanding and exercisable options as of December 31, 2011:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options outstanding</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options exercisable</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Number of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">options</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">options</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">outstanding</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">exercisable</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">at end of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">at end of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">prices</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">life</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">year</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">life</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">0.001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">719,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; text-align: right">3.54</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">719,207</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3.54</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">987,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2.30</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">987,356</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.399</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3.35</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,673</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.35</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.972</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,325,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4.47</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,325,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.82</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">604,956</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7.15</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">573,550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.15</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,720,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">6.10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,559,210</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,010,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.15</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.66</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.660</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">8.84</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.84</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">16.700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">387,542</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1pt">5.00</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">387,542</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">5.00</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,379,722</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,883,401</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The aggregate intrinsic value of the total outstanding
and of total vested and exercisable options as of December 31, 2011 is $15,551 and $15,371, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 7&ndash; SHARE CAPITAL </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">The following table illustrates the effect of share-based
compensation on the statement of operations:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 65%; margin-left: 1in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 49%; text-align: left; text-indent: -12.6pt; padding-left: 12.6pt">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,489</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">630</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">422</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -12.6pt; padding-left: 12.6pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,194</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">464</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,683</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,282</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">886</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Public Offering</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">On March 23,&nbsp;2011, the Company issued and sold 4,000,000
shares of Common Stock in an underwritten public offering at a price to the public of $5.50 per share. The net proceeds to the
Company were approximately $20,590&nbsp;(net of underwriting commissions and issuance costs of $1,410).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">In February 2012, the Company issued and sold 5,175,000
shares of Common Stock. See Note 11b.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 8 - </B></FONT><B>
TAXES ON INCOME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD>The Company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Protalix BioTherapeutics, Inc. is taxed according to
U.S. tax laws. The Company's income is, or will be, taxed in the United States at the rate of up to 39%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD>Protalix Ltd.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The Israeli Subsidiary is taxed according to Israeli
tax laws:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Measurement of results for tax purposes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Since 2008, the Company has measured the results of the
Israeli Subsidiary for tax purposes in nominal terms in NIS. Pursuant to the Israel Income Tax Law (Adjustments for Inflation),
1985 (the &ldquo;Adjustments Law&rdquo;), the Subsidiary&rsquo;s results for tax purposes have been measured through 2007 on a
real basis, based on changes in the Israel consumer price index.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Tax rates</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The income of the Israeli Subsidiary, other than income
from &ldquo;Approved Enterprises,&rdquo; is taxed in Israel at the regular rate. See 3 below. According to the provisions of the
Law for Amending the Israel Income Tax Ordinance, 2005, corporate tax rates will be gradually lowered, resulting in a corporate
tax rate for 2009 and thereafter: 2009 &ndash; 26% and for 2010 and thereafter &ndash; 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">On July 14, 2009, the Israel Economic Efficiency Law (Legislation
Amendments for Applying the Economic Plan for 2009 and 2010), 2009, became effective, stipulating, among other things, an additional
gradual decrease in tax rates in 2011 and thereafter, as follows: 2011 &ndash; 24%, 2012 &ndash; 23%, 2013 &ndash; 22%, 2014 &ndash;
21%, 2015 &ndash; 20% and 2016 and thereafter &ndash; 18%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">On December 5, 2011, the &quot;Tax Burden Distribution Law&quot;
(hereinafter - the 2011 amendment) was officially published, discontinuing a previously approved gradual decrease in corporate
tax provided in the 2009 amendment, and setting the corporate tax rate in Israel for 2012 and thereafter to 25%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Capital gain is subject to capital gain tax according to
corporate tax rate in the year of selling the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 8 &ndash; TAXES ON INCOME </B>(continued)<B>:</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>The Law for the Encouragement of Capital Investments, 1959 (the &ldquo;Encouragement of Capital Investments Law&rdquo;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under the Encouragement of Capital Investments Law, including
Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the &ldquo;Approved Enterprise&rdquo;
or &ldquo;Benefited Enterprise&rdquo; status the Israeli Subsidiary is entitled to various tax benefits as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -37.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a.</TD><TD><B>Reduced tax rates</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">Income derived from the Approved Enterprise during a
10-year period commencing upon the year in which the enterprise first realizes taxable income is tax exempt, provided that the
maximum period to which it is restricted by the Encouragement of Capital Investments Law has not elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Israeli Subsidiary has an &ldquo;Approved Enterprise&rdquo;
plan since 2004 and &ldquo;Benefited Enterprise&rdquo; plan since 2009. The period of benefits in respect of the main enterprise
of the Company has not yet commenced. The period during which the Company is entitled to benefits in connection with the Benefited
Enterprise expires in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">If the Israeli Subsidiary subsequently pays a dividend
out of income derived from the &ldquo;Approved Enterprise&rdquo; or &ldquo;Benefited Enterprise&rdquo; during the tax exemption
period, it will be subject to a tax on the amount distributed, including any company tax on these amounts, at the rate which would
have been applicable had such income not been exempted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">In addition to the corporate taxes in Israel, the Company
might be subject to a withholding tax on the U.S. revenue source portion of the payments made to the Company for its share of Pfizer&rsquo;s
net profits under the Pfizer Agreement. The withholding tax rate is currently 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b.</TD><TD><B>Accelerated depreciation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Israeli Subsidiary is entitled to claim accelerated
depreciation, as provided by Israeli law, in the first five years of operation of each asset, in respect of buildings, machinery
and equipment used by the Approved Enterprise and the Benefited Enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c.</TD><TD><B>Conditions for entitlement to the benefits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Israeli Subsidiary&rsquo;s entitlement to the benefits
described above is subject to its fulfilling the conditions stipulated by the law, rules and regulations published thereunder,
and the instruments of approval for the specific investment in an approved enterprise. If there is any failure by the Israeli Subsidiary
to comply with these conditions, the benefits may be cancelled and the Subsidiary may be required to refund the amount of the benefits,
in whole or in part, with interest. The Company received a final implementation approval with respect to its &ldquo;Approved Enterprise&rdquo;
from the Investment Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d.</TD><TD><B>Amendment of the Law for the Encouragement of Capital Investments, 1959</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Encouragement of Capital Investments Law was amended
as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the &ldquo;Capital
Investments Law Amendment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 8 &ndash; TAXES ON INCOME</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The Capital Investments Law Amendment sets alternative
benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">The benefits granted to the Benefited Enterprises will
be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period.
The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria are
similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in">Under the transitional provisions of the Encouragement
of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of
Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital
Investments Law. The Company will be allowed to set the &ldquo;year of election&rdquo; no later than tax year 2012, provided that
the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company
will be able to elect that the Capital Investments Amendment apply to the Company, thereby making the tax rates described above
available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>The Law for the Encouragement of Industry (Taxation), 1969:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The Israeli Subsidiary is an &ldquo;industrial company,&rdquo;
as defined under the Law for the Encouragement of Industry (Taxation), 1969 (the &ldquo;Law for the Encouragement of Industry&rdquo;).
As such, the Israeli Subsidiary is entitled to claim depreciation at increased rates for equipment used in industrial activity,
as stipulated by regulations published under Law for the Encouragement of Industry, and has done so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">Under the provisions of the Income Tax Regulations &ldquo;Accelerated
Depreciation in respect of Equipment acquired during the Defined Period&rdquo; (Temporary Orders), industrial companies whose operations
are mostly &ldquo;eligible operations&rdquo; are entitled to claim accelerated depreciation at a rate of 50% on machinery and equipment
acquired from June 1, 2008 to May 31, 2009.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD>Tax losses carried forward to future years</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">As of December 31, 2011, the Company had aggregate net
operating loss (NOL) carry-forwards equal to approximately $63,040 that are available to reduce future taxable income as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>The Company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">The NOL carry-forward of the Company equal to approximately
$11,740 may be restricted under Section 382 of the Internal Revenue Code (&ldquo;IRC&rdquo;). IRC Section 382 applies whenever
a corporation with NOL experiences an ownership change. As a result of IRC Section 382, the taxable income for any post change
year that may be offset by a pre-change NOL may not exceed the general IRC Section 382 limitation, which is the fair market value
of the pre-change entity multiplied by the IRC long-term tax exempt rate.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Protalix Ltd.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">At December 31, 2011, the Israeli Subsidiary had approximately
$51,300 of NOL carry-forwards that are available to reduce future taxable income with no limited period of use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 8 &ndash; TAXES ON INCOME</B> (continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">d.</FONT></TD><TD>Deferred income taxes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The components of the Company&rsquo;s net deferred tax
assets at December 31, 2010 and 2011 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>In respect of:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 12.6pt">Research and Development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4,119</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 12.6pt">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(143</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(149</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12.6pt">Holiday and recreation pay</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">296</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 12.6pt">Severance pay obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12.6pt">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,691</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,746</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 12.6pt">Net operating loss carry forwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,599</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,573</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,764</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">Deferred taxes are computed using the tax rates expected
to be in effect when those differences reverse. The Company used tax rates of 39%, 25% and 0%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">e.</FONT></TD><TD>Reconciliation of the theoretical tax expense to actual tax expense</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">The main reconciling items between the statutory tax
rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry
forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">f.</FONT></TD><TD>Tax assessments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">In accordance with the Income Tax Ordinance, as of December
31, 2011, all of Protalix Ltd.&rsquo;s tax assessments through tax year 2007 are considered final.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">A summary of open tax years by major jurisdiction is
presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; border-bottom: windowtext 1pt solid; font-weight: bold">Jurisdiction:</TD>
    <TD STYLE="width: 4%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: windowtext 1pt solid; font-weight: bold; text-align: right">Years:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Israel</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2008-2011</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>United States (*)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2002-2011</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Netherlands</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2009-2011</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">(*) Includes federal, state and local (or similar provincial
jurisdictions) tax positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 9 - </B></FONT><B>
SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt"><B>Balance sheets:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -26.45pt; padding-left: 26.45pt">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable - other:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; text-indent: -0.1in; padding-left: 0.6in">Deferred costs*</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,558</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.6in">Institutions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">634</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">State of Israel (see Note&nbsp;6a )</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">878</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,296</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">Restricted deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">354</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.6in">Sundry</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">139</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">165</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,231</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,837</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">* Manufacturing costs of inventory, paid by Pfizer, but not delivered.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">b. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accruals &ndash; other:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">Payroll and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,199</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,108</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">Provision for vacation and recreation pay</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,221</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,030</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,327</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">Royalties payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.6in">Liability in connection with collaboration operation- current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.6in">Property and equipment supplier</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,720</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,473</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 0.6in">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,068</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,540</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NOTE 9 &ndash; SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION
</B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt"><B>Statement of operations:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0">c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 52.2pt">Deferred revenues from the license and supply agreement with Pfizer</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 12%; padding-bottom: 1pt; text-align: right">388</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 12%; padding-bottom: 1pt; text-align: right">4,563</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="width: 12%; padding-bottom: 1pt; text-align: right">4,563</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 45pt">Revenues from selling products to Pfizer</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,079</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,823</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.35pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">388</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,642</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,386</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 5.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; text-indent: 0">d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Cost of products sold</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">807</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">985</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Write down of inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,692</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">363</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Royalties expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,575</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">884</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">177</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.35pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,575</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,383</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,525</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 5.35pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; text-indent: 0">e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses - net:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Payroll and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,479</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,176</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,042</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Subcontractors and consultants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,469</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,550</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,314</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Materials and consumables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,852</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,947</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Rent, insurance and maintenance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,238</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,457</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Patent registration and licensing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">571</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Depreciation and write down</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,456</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,057</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,166</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,534</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,418</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,390</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,691</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,818</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.5in">Less - grants and reimbursements:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 45pt">Development costs reimbursements from Pfizer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,922</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,430</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 45pt">Grants (see Note 6a)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,752</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,818</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">21,638</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,951</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">31,043</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; text-indent: 0">f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Payroll and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,415</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,481</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Management and consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">681</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Rent, insurance and maintenance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">463</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">498</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,326</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Travel</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">251</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 50pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">191</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">363</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 50pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">596</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">886</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">819</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,144</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,876</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,931</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.3pt; text-indent: -17.3pt">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 10 - </B></FONT><B>RELATED
PARTY TRANSACTIONS</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 36pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2009</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2010</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -20.7pt; padding-left: 20.7pt; padding-bottom: 2.5pt; width: 55%"><B>a. &nbsp;&nbsp;&nbsp;&nbsp;</B>Management and consulting fees to the Chairman of the Board</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 12%; text-align: right; border-bottom: Black 2.5pt double">33</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 12%; text-align: right; border-bottom: Black 2.5pt double">6</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="width: 12%; text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -20.7pt; padding-left: 20.7pt; padding-bottom: 2.5pt"><B>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Compensation to the non-executive directors (except the Chairman of the Board in 2009, and includes the interim Chairman of the Board in 2010 and 2011)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">209</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">215</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">215</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><FONT STYLE="font-size: 10pt"><B>NOTE 11 - </B></FONT><B>
SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20.7pt"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD><FONT STYLE="font-weight: normal">During January and February 2012, the Company issued a total of 10,239 shares of Common Stock
in connection with the exercise of options to purchase 10,239 shares of Common Stock by certain employees of the Company. The Company
received aggregate cash proceeds equal to approximately $5 in connection with the exercise of such options.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 56.7pt; text-indent: -20.7pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 20.7pt"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD><FONT STYLE="font-weight: normal">On February 22,&nbsp;2012, the Company issued and sold 5,175,000 shares of Common Stock in
an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately
$25,389&nbsp;(net of underwriting commissions and issuance costs of $1,567). The offering included the exercise by the underwriters
of an over-allotment option to purchase 675,000 shares of Common Stock.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>v303493_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: underline; text-align: left">CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: none; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-decoration: none; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We hereby consent to the incorporation by reference in the Registration
Statement on Form S-3 (No. 333-171615) and Registration Statement on Form S-8 (No. 333-148983) of Protalix BioTherapeutics, Inc.
of our report dated February 27, 2012 relating to the financial statements and the effectiveness of internal control over financial
reporting, which appears in this Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">/s/ Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Certified Public Accountants (lsr.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;A member firm of PricewaterhouseCoopers International Limited</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Tel-Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">February 27, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: italic 10pt/10pt Times New Roman, Times, Serif; margin: 0">Kesselman &amp; Kesselman, Trade Tower, 25 Hamered
Street, Tel-Aviv 68125, Israel, P.O Box 452 Tel-Aviv 61003 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.co.il&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>v303493_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, David Aviezer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">Dated: February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">David Aviezer, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>v303493_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">1.</TD><TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Dated: February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12pt; text-indent: -12pt">Chief Financial Officer, Treasurer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>v303493_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;<B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2011 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as
of the date hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best
of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">(2) the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12.2pt; text-indent: -12.25pt">This Certification has not been,
and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Dated: February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12pt; text-indent: -12pt">David Aviezer, Ph.D.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12pt; text-indent: -12pt">President and Chief Executive Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>v303493_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Annual Report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ended December&nbsp;31, 2011 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify
as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the
best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt">(2) the information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12.2pt; text-indent: -12.25pt">This Certification has not been,
and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">Dated: February 27, 2012</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12pt; text-indent: -12pt">Yossi Maimon</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 12pt; text-indent: -12pt">Vice President and Chief Financial
        Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>plx-20111231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.13.8 -->
<!-- Round: 1 -->
<!-- Creation date: 2012-02-25T02:22:53Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:plx="http://www.protalix.com/20111231" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="plx-20111231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_0_20120223_0" unitRef="shares" decimals="INF">90815396</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat contextRef="eol_PE5673----1110-K0006_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">365000000</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-K0006_STD_0_20081231_0" unitRef="iso4217_USD" decimals="-3">42596000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20081231_0" unitRef="iso4217_USD" decimals="-3">44347000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20081231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-75010000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_0_20081231_0_452905x444581" unitRef="shares" decimals="INF">75938059</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20081231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">76000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20081231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">119281000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-K0006_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">81266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">15883000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-106450000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_0_20091231_0_452905x444581" unitRef="shares" decimals="INF">80841237</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">122252000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">18903000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccountsPayableOtherCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">8068000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">4563000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-135448000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">7013000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">64729000</us-gaap:Assets>
  <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">2231000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">942000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">55486000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:CommonStockValue>
  <us-gaap:InventoryNet contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1189000</us-gaap:InventoryNet>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">57149000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="shares" decimals="INF">81248472</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">46333000</us-gaap:AssetsCurrent>
  <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1663000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">35900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableTradeCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">6272000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">64729000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">124044000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-11323000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="shares" decimals="INF">81248472</us-gaap:CommonStockSharesIssued>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">17454000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">76052000</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-135448000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0_452905x444581" unitRef="shares" decimals="INF">81248472</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">124044000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">18693000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccountsPayableOtherCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">7540000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">6121000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">-171977000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1374000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">51805000</us-gaap:Assets>
  <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">3837000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1043000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">50923000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">86000</us-gaap:CommonStockValue>
  <us-gaap:InventoryNet contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">279000</us-gaap:InventoryNet>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">59189000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="shares" decimals="INF">85630157</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">32491000</us-gaap:AssetsCurrent>
  <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1700000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">6566000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">27001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableTradeCurrent contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">5032000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">51805000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">145814000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">-26077000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="shares" decimals="INF">85630157</us-gaap:CommonStockSharesIssued>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">18271000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">77882000</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-171977000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0_452905x444581" unitRef="shares" decimals="INF">85630157</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-K0006_STD_0_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">145814000</us-gaap:StockholdersEquity>
  <us-gaap:GrossProfit contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-3187000</us-gaap:GrossProfit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">2683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">293000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">73000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-6174000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">1224000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">388000</us-gaap:Revenues>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">44452000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">5752000</us-gaap:ReimbursementRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">2683000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">7784000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">52000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-29000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">293000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-31440000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">27390000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">166000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:CostOfRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">3575000</us-gaap:CostOfRevenue>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">6195000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-31969000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">529000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">38670000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">99000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">265000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">64612000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">7144000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">293000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.41</us-gaap:EarningsPerShareBasicAndDiluted>
  <plx:DepreciationAmortizationAndAssetImpairment contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">1990000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">4525000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">21638000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0" unitRef="shares" decimals="0">76942840</plx:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-31440000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x444581" unitRef="shares" decimals="INF">4903178</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">2683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">288000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:GrossProfit contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">6861000</us-gaap:GrossProfit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">501000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-7992000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">6860000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">6642000</us-gaap:Revenues>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">26000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-38464000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">7740000</us-gaap:ReimbursementRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">1282000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-1029000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">137000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">510000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-28998000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">37691000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">591000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:CostOfRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">4383000</us-gaap:CostOfRevenue>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">7855000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-29966000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">968000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-45366000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">589000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">377000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">1189000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-4563000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">6876000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">501000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.36</us-gaap:EarningsPerShareBasicAndDiluted>
  <plx:DepreciationAmortizationAndAssetImpairment contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">3133000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">2720000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">29951000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="shares" decimals="0">80960300</plx:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <plx:OtherGainsLosses contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">4602000</plx:OtherGainsLosses>
  <plx:CashlessExerciseOfStockOptions contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">9000</plx:CashlessExerciseOfStockOptions>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-28998000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x444581" unitRef="shares" decimals="INF">407235</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3" id="fnid_45950121_6001_50000009">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">1282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">510000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityVoluntaryFilers contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">No</dei:EntityVoluntaryFilers>
  <dei:TradingSymbol contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">PLX</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">Yes</dei:EntityCurrentReportingStatus>
  <dei:AmendmentFlag contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">2011-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GrossProfit contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">1443000</us-gaap:GrossProfit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">277000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 7 -&lt;/b&gt;&lt;/font&gt; &lt;b&gt;SHARE
CAPITAL&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Rights of the Company&amp;#x2019;s Common Stock&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company&amp;#x2019;s common stock is listed on the NYSE Amex and,
since September 6, 2010, on the Tel Aviv Stock Exchange. Each share
of Common Stock is entitled to one vote. The holders of shares of
Common Stock are also entitled to receive dividends whenever funds
are legally available, when and if declared by the Board of
Directors. Since its inception, the Company has not declared any
dividends.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Stock based compensation&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On December 14, 2006, the Board of Directors adopted the Protalix
BioTherapeutics, Inc. 2006 Stock Incentive Plan (the
&amp;#x201C;Plan&amp;#x201D;). The grant of options to Israeli employees
under the Plan is subject to the terms stipulated by
Sections&amp;#xA0;102 and 102A of the Israeli Income Tax Ordinance.
Each option grant is subject to the track chosen by the Company,
either Section 102 or Section 102A of the Israeli Income Tax
Ordinance, and pursuant to the terms thereof, the Company is not
allowed to claim, as an expense for tax purposes, the amounts
credited to employees as a benefit, including amounts recorded as
salary benefits in the Company&amp;#x2019;s accounts, in respect of
options granted to employees under the Plan, with the exception of
the work-income benefit component, if any, determined on the grant
date. For Israeli non-employees, the share option plan is subject
to Section 3(i) of the Israeli Income Tax Ordinance.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
As of December 31, 2011, 47,920 shares of Common Stock remain
available for grant under the Plan.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
For purposes of determining the fair value of the options granted
to employees and non-employees, the Company&amp;#x2019;s management uses
the fair value of the Common Stock.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
From January 1, 2009 through December 31, 2011, the Company granted
options to certain employees and non-employees as follows:&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;Options granted to employees:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;a)&lt;/td&gt;
&lt;td&gt;Below is a table summarizing all of the option grants to
employees for each of the three years in the period ended December
31, 2011:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; FONT: 8pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Year&amp;#xA0;of&lt;br /&gt;
Grant&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;No.&amp;#xA0;of&amp;#xA0;options&lt;br /&gt;
granted&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Exercise&lt;br /&gt;
price&amp;#xA0;range&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;Vesting&amp;#xA0;period&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Fair&amp;#xA0;value&lt;br /&gt;
at&amp;#xA0;grant&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Expiration&lt;br /&gt;
Period&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left" colspan="2"&gt;2009*&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;504,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" nowrap="nowrap"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" nowrap="nowrap"&gt;2.65&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center"&gt;Upon achievement of certain
milestones*&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,068&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;120,400&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" nowrap="nowrap"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" nowrap="nowrap"&gt;2.65&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center"&gt;4 years&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;212&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,016,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" nowrap="nowrap"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" nowrap="nowrap"&gt;6.90&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center"&gt;3 years commencing upon achievement
of a certain milestone&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;5,673&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt" colspan="2"&gt;
2010&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;428,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;
$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;
6.32-$9.66&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"&gt;4 years&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;2,147&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;10 years&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 10%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%; FONT-SIZE: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 1pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 1pt"&gt;
&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; WIDTH: 35%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,068,400&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
* The milestone was achieved as of December 31, 2009 and the
options vested in full.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Set forth below are grants made by the Company to employees
(including related parties) during the three-year period ended
December 31, 2011 (such grants appear in the table above):&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1.25in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;1.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;In February, 2009, the
Company&amp;#x2019;s Board of Directors approved the grant of options to
purchase 624,400 shares of Common Stock to the Company&amp;#x2019;s
Chief Executive Officer and certain officers and employees of the
Company with an exercise price equal to $2.65 per share. The
options vest as follows:&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;(i) 504,000 of the options vest
immediately upon the achievement of certain clinical and
operational performance milestones, which milestones must be
achieved within one year of the date of grant or the options will
be forfeited. The options expire within a period of 10 years from
the date of grant. The vesting conditions of these options were
satisfied prior to December 31, 2009. Accordingly, these options
were fully vested at December 31, 2009 and the Company recognized
all of the expenses for these options during 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;(ii) 120,400 of the options vest
as follows: 25% within one year from the date of grant, with the
remainder vesting in 12 equal quarterly tranches over 36 months.
The options expire within a period of 10 years from the date of
grant. The Company&amp;#x2019;s management assumed the simplified method
to reflect the expected life regarding these options. The Company
used the simplified method in 2009 as the Company did not have
sufficient historical exercise data to provide a reasonable basis
upon which to estimate expected term due to the limited period of
time its equity shares have been publicly traded.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1.25in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;2.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;In February 2010, the
Company&amp;#x2019;s Board of Directors approved the grant of options to
purchase 1,016,000 shares of Common Stock, in the aggregate, to the
Company&amp;#x2019;s Chief Executive Officer and certain officers and
employees of the Company with an exercise price equal to $6.90 per
share. The options vest quarterly over a three-year period
commencing upon the FDA&amp;#x2019;s approval of taliglucerase alfa, if
at all. The Company treated the awards as performance-based awards
and, given that the performance condition is outside the Company&apos;s
control, concluded that the performance condition was not probable
until the performance condition actually occurs. As a result, no
share-based compensation expense was recognized as of December 31,
2011.&amp;#xA0;&amp;#xA0;The Company will start recording these expenses
following the FDA&amp;#x2019;s marketing approval of taliglucerase alfa,
if at all.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1.25in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;3.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="COLOR: black; FONT-WEIGHT: normal"&gt;In February
2010, the Company&amp;#x2019;s Board of Directors approved the grant of
options to purchase 160,000&amp;#xA0;shares of Common Stock with an
exercise price equal to $6.81 per share to a new executive officer
of the Company. The options expire on the tenth anniversary of the
date of grant, unless terminated earlier. The first 25% of the
options vest on the first anniversary of the date of grant and the
remaining 75% vest in 12 equal tranches on a quarterly basis for
three years thereafter.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1.25in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;4.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;In September&amp;#xA0;2010, the
Company&amp;#x2019;s Board of Directors approved the grant of options to
purchase 160,000 shares of Common Stock to a new executive officer
of the Company with an exercise price equal to $7.55 per share and
options to purchase 40,000 shares of Common Stock to a new employee
of the Company with an exercise price equal to $6.32 per share. The
options vest over a four-year period, with the first 25% vesting on
the first anniversary of the applicable date of the grant and the
remaining 75% vesting in equal tranches on a quarterly basis for a
three-year period thereafter. &lt;font style="COLOR: black"&gt;The
options expire on the tenth anniversary of the date of grant,
unless terminated earlier.&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1.25in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;5.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;In November&amp;#xA0;2010, the
Company&amp;#x2019;s Board of Directors approved the grant of options to
purchase 68,000 shares of Common Stock to a new officer of the
Company with an exercise price equal to $9.66 per share. The
options vest over a four-year period, with the first 25% vesting on
the first anniversary of the applicable date of the grant and the
remaining 75% vesting in equal tranches on a quarterly basis for a
three-year period thereafter. &lt;font style="COLOR: black"&gt;The
options expire on the tenth anniversary of the date of grant,
unless terminated earlier.&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1.25in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;6.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;In September 2010, the
Company&amp;#x2019;s Board of Directors modified the terms of the
options previously granted to an executive in 2001, by extending
the life of the options until 2016. At the date of modification,
all of the options were fully vested. The Company concluded that
there was no incremental increase in the value of the awards and
therefore no accounting charges need to be recorded in connection
with the modifications.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;b)&lt;/td&gt;
&lt;td&gt;The fair value of options granted during the years ended
December 31, 2009 and 2010 were $1,280 and $7,820 respectively. The
fair value of each option granted is estimated on the date of grant
using the Black-Scholes option-pricing model, with the following
weighted average assumptions:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 58%; PADDING-RIGHT: 0px"&gt;
Dividend yield&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 18%"&gt;
0%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 18%"&gt;
0%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px"&gt;
Expected volatility&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
75%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
75%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px"&gt;
Risk-free interest rate&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
2.74%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
3.23%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px"&gt;
Expected life &amp;#x2013; in years&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
9.2&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
8.8&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The expected volatility is based on the historical volatility of
the Common Stock and those of comparable companies. The risk-free
interest rate assumption is based on observed interest rates
appropriate for the expected term of the stock options granted in
dollar terms. The Company&amp;#x2019;s management uses the contractual
term or its expectations, based on historical incidence of option
exercises, as applicable (during 2009 - using the simplified
method), of each option as its expected life. The pre-vesting
forfeiture rate of approximately 6.3% is estimated based on
pre-vesting forfeiture experience.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The total unrecognized compensation cost of employee stock options
at December 31, 2011 is $6,218 (net of forfeiture rate) out of
which $5,639 is expected to be recognized over a three-year period
commencing upon the FDA&amp;#x2019;s approval of taliglucerase alfa, if
at all. The remaining compensation cost of $579 is expected to be
recognized over a weighted average period of 0.9 years.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The total cash received from employees as a result of employee
stock option exercises for the years ended December 31, 2009, 2010
and 2011 was $293, $501 and $277, respectively. The Company did not
realize any tax benefit in connection with these exercises.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
During 2011, the Company issued 181,685 shares of Common Stock in
connection with the exercise of 182,093 options by certain
employees of the Company. The Company received cash proceeds equal
to $268 in connection with such exercises. Of such options, 2,132
options were exercised on a &amp;#x201C;net-exercise&amp;#x201D; basis.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;Options granted to consultants, directors, and other service
providers:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;As of December 31, 2011, the
Company has recognized and recorded all compensation costs related
to outstanding options for consultants, directors and other
services providers.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
No cash was received from consultants as a result of consultant
stock option exercises for the years ended December 31, 2009, 2010,
and $0.2 was received in 2011. The Company did not realize any tax
benefits in connection with these exercises.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
During 2009, the Company issued 3,853,441 shares of Common Stock in
connection with the exercise of 3,866,093 options by certain
consultants, directors, and other service providers of the Company.
The Company did not receive cash proceeds in connection with such
exercises as all of such options were exercised on a
&amp;#x201C;net-exercise&amp;#x201D; basis.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
During 2011, the Company issued 200,000 shares of Common Stock in
connection with the exercise of 200,000 options by certain
consultant of the Company. The Company received cash proceeds equal
to $0.2 in connection with such exercise.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;3.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;A summary of share option
plans, and related information, under all of the Company&amp;#x2019;s
equity incentive plans for the years ended December&amp;#xA0;31, 2009,
2010 and 2011 are as follows:&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;a.&lt;/td&gt;
&lt;td&gt;Options granted to employees:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 100%; FONT: 8pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22"&gt;Year ended December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Number&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Number&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Number&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
exercise&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
exercise&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
exercise&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 22%"&gt;
Outstanding at beginning of year&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;5,890,641&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;2.118&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;5,366,729&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;2.476&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;6,367,979&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;3.576&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Changes during the year:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;624,400&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2.650&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,444,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;7.076&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt"&gt;Forfeited and
Expired&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,400&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2.650&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;13,441&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.551&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;44,856&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.207&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt"&gt;
Exercised (*)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,146,912&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0.733&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
429,309&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1.602&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
182,093&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1.652&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Outstanding at end of year&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
5,366,729&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
2.476&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
6,367,979&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
3.576&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
6,141,030&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
3.563&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Exercisable at end of year&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
3,680,382&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1.785&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
4,267,850&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
2.183&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
4,647,834&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
2.581&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.2in; MARGIN: 0px 0px 0px 84.95pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN-TOP: 0px; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 6pt; MARGIN-LEFT: 1in"&gt;
(*) The total intrinsic value of options exercised during the years
ended December 31, 2009, 2010 and 2011, was $7,258, $3,050 and
$1,252, respectively.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;b.&lt;/td&gt;
&lt;td&gt;Options granted to consultants, directors, and other service
providers:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;table style="WIDTH: 100%; FONT: 8pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22"&gt;Year ended December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Number&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Number&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
Number&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
exercise&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
exercise&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;
exercise&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;options&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;price&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 22%"&gt;
Outstanding at beginning of year&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%"&gt;
5,304,785&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%"&gt;
1.285&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%"&gt;
1,438,692&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%"&gt;
4.697&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%"&gt;
1,438,692&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%"&gt;
4.697&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Changes during the year-Exercised (*)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,866,093&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0.016&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
200,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0.001&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Outstanding at end of year&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,438,692&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
4.697&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,438,692&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
4.697&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,238,692&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
5.385&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Exercisable at end of year&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,407,234&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
4.674&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,421,734&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
4.653&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,235,567&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
5.385&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 63.8pt"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 14pt"&gt;(*)&lt;/td&gt;
&lt;td&gt;The total intrinsic value of options exercised during the years
ended December 31, 2009, 2010 and 2011, was $41,281, $0 and $1,886,
respectively.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -14pt; MARGIN: 0px 0px 0px 77.8pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;c.&lt;/td&gt;
&lt;td&gt;The following tables summarize information concerning
outstanding and exercisable options as of December 31, 2011:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 70%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="16" nowrap="nowrap"&gt;December 31, 2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="9" nowrap="nowrap"&gt;Options outstanding&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap"&gt;Options exercisable&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Number of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Weighted&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;options&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;average&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;outstanding&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
remaining&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;exercisable&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;remaining&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;Exercise&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;at end of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
contractual&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;at end of&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;contractual&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;prices&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;year&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt;life&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;year&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;life&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;0.001&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;719,207&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;3.54&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;719,207&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;3.54&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.120&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;987,356&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2.30&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;987,356&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2.30&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.399&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;26,673&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.35&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;26,673&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.35&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.972&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,325,988&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4.47&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,325,988&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4.47&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2.350&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;160,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.82&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;120,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.82&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2.650&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;604,956&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;7.15&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;573,550&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;7.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.020&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;50,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.10&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;46,875&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.10&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;5.000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,720,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.10&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,559,210&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.10&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.810&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;160,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.10&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;70,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.10&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.900&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,010,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.15&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;7.550&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;160,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.66&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;50,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.66&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;9.660&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;68,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.84&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;17,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;8.84&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;16.700&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
387,542&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;5.00&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
387,542&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"&gt;5.00&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
7,379,722&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
5,883,401&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The aggregate intrinsic value of the total outstanding and of total
vested and exercisable options as of December 31, 2011 is $15,551
and $15,371, respectively.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-INDENT: -49.5pt; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 6pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 0.25in"&gt;d.&lt;/td&gt;
&lt;td style="TEXT-ALIGN: justify"&gt;The following table illustrates the
effect of share-based compensation on the statement of
operations:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 65%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt; WIDTH: 49%"&gt;
Research and development expenses&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;1,489&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;630&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 14%"&gt;422&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt"&gt;
General and administrative expenses&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,194&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
652&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
464&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
2,683&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,282&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
886&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;c.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Public Offering&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On March 23,&amp;#xA0;2011, the Company issued and sold 4,000,000
shares of Common Stock in an underwritten public offering at a
price to the public of $5.50 per share. The net proceeds to the
Company were approximately $20,590&amp;#xA0;(net of underwriting
commissions and issuance costs of $1,410).&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In February 2012, the Company issued and sold 5,175,000 shares of
Common Stock. See Note 11b.&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 6 -&lt;/b&gt;&lt;/font&gt;
&lt;b&gt;COMMITMENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Royalty commitments&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;The Company is obligated to
pay royalties to the OCS on proceeds from the sale of products
developed from research and development activities that were
funded, partially, by grants from the OCS. At the time the grants
were received, successful development of the related projects was
not assured.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In the case of failure of a project that was partly financed as
described above, the Company is not obligated to pay any such
royalties or repay funding received from the OCS.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Under the terms of the funding arrangements with the OCS, royalties
of 3% to 6% are payable on the sale of products developed from
projects funded by the OCS, which payments shall not exceed, in the
aggregate, 100% of the amount of the grant received (dollar
linked), plus, commencing upon January&amp;#xA0;1, 2001, interest at
annual rate based on LIBOR. In addition, if the Company receives
approval to manufacture products developed with government grants
outside the State of Israel, it will be required to pay an
increased total amount of royalties (possibly up to 300% of the
grant amounts plus interest), depending on the manufacturing volume
that is performed outside the State of Israel, and, possibly, an
increased royalty rate.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Royalty expenses to the OCS are included in the statement of
operations as a component of the cost of revenues and were
approximately $1,950, $769 and $158 during the years ended
December&amp;#xA0;31, 2009, 2010 and 2011, respectively.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
At December&amp;#xA0;31, 2011, the maximum royalty amount payable by
the Company under these funding arrangements is approximately
$19,820 (without interest, assuming 100% of the funds are
payable).&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;The Company is a party to
certain research and license agreements. Under the &lt;font style="COLOR: black"&gt;agreements, the Company is obligated&lt;/font&gt; to pay
royalties at varying rates from its future revenues. The aggregate
royalties payable under all of the agreements is equal to a
percentages of net sales of licensed products in the teens. Royalty
expenses under the agreements are included in the statement of
operations as a component of the cost of revenues and were
approximately $1,625, $115 and $19 during the years ended
December&amp;#xA0;31, 2009, 2010 and 2011, respectively.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Under each agreement, the Company is also obligated to pay
milestone, licensing and other payments to the counterparties of
the agreement. The payments under the agreements are for varying
amounts and are subject to varying conditions. If all of the
contingencies with respect to milestone payments under the research
and license agreements are met, the aggregate milestone payments
payable would be approximately $950 and would be payable, if at
all, as the Company&amp;#x2019;s projects progress over the course of a
number of years. In addition, milestone payments of $70 and $100
were paid in respect of the said agreements during the years ended
December 31,2009 and 2010, respectively.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
None of the agreements has a fixed termination date. Subject to
earlier termination for other reasons, each agreement terminates
after a certain number of years following the first commercial sale
of any licensed product under the agreement or after a certain
number of years without the initiation of commercial sales of any
product under the agreement.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Subcontracting Agreements&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company has entered into sub-contracting agreements with
several clinical providers and consultants in Israel, the United
States and certain other countries in connection with its primary
product development process and with expenditure of the
company&amp;#x2019;s manufacturing facilities. As of December 31, 2011,
total commitments under said agreements were approximately
$821.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;c.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Lease Agreements&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company is a party to a number of lease agreements for its
facilities, the latest of which expires in 2017. The Company has
the option to extend certain of such agreements on three occasions
for additional five-year periods, for a total of 15 additional
years. Under the leases, the aggregate monthly rental payments are
approximately $75. As of December 31, 2011, the Company provided
bank guarantees of approximately $208, in the aggregate, to secure
the fulfillment of its obligations under the lease agreements. The
future minimum lease payments required in each of the next five
years under the operating leases for such premises are
approximately as follows: 2012 - $901, 2013 - $890, 2014 - $883,
2015 &amp;#x2013; $883 and 2016 &amp;#x2013; $638. Lease expenses totaled
$780, $891 and $994 for the years ended December 31, 2009, 2010 and
2011, respectively.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;d.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Vehicle Lease and Maintenance Agreements&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In July 2004, the Company entered into several three-year lease and
maintenance agreements for vehicles which are regularly amended as
new vehicles are leased. The current monthly lease fees aggregate
approximately $46. The minimum expected lease payments for the
years ending December 31, 2012, 2013 and 2014 are $514, $267 and
$70, respectively.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;e.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Teva Agreement&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On September 14, 2006, the Company entered into an agreement (the
&amp;#x201C;Teva Agreement&amp;#x201D;) with Teva Pharmaceutical Industries
Ltd. (&amp;#x201C;Teva&amp;#x201D;) under which the Company agreed to
collaborate on the research and development of two proteins to be
identified by Teva and the Company, using ProCellEx. The Teva
Agreement also identifies additional matters for collaboration
between Teva and the Company. Subsequently, two proteins were
identified to be researched and developed under the agreement but
in 2009, both of the projects were terminated for commercial
reasons. Other elements of the Company&amp;#x2019;s collaboration with
Teva are currently ongoing.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;f.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Yissum Agreement&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On August 8, 2007, the Company signed an agreement with the Yissum
Research and Development Company, the technology transfer arm of
the Hebrew University of Jerusalem, Israel, and the Boyce Thompson
Institute for Plant Research, at Cornell University, Ithaca, New
York, to develop a proprietary plant cell-based
acetylcholinesterase (AChE) and its molecular variants for the use
in several therapeutic and prophylactic indications, including a
biodefense program and organophosphate-based pesticide treatment.
Pursuant to the agreement, the Company has received an exclusive
worldwide right and license to certain technology, including
patents and additional patent applications relating to AChE (the
&amp;#x201C;Licensed Technology&amp;#x201D;), for all therapeutic and
prophylactic indications. In consideration for the license, the
Company is required to make certain milestone payments equal to up
to $700, in the aggregate, upon its achievement of clinical
milestones and royalties from sales derived from any drugs
developed by the Company with the Licensed Technology. The
agreement does not terminate until either party to the agreement
elect to terminate the agreement, subject to certain terms and
conditions set forth therein.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 1 -&lt;/b&gt;&lt;/font&gt; &lt;b&gt;SIGNIFICANT
ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;General&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;Operation&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Protalix BioTherapeutics, Inc. (collectively with its subsidiaries,
&amp;#x201C;The Company&amp;#x201D;), and its wholly-owned subsidiary,
Protalix Ltd. (the &amp;#x201C;Israeli Subsidiary&amp;#x201D; or
&amp;#x201C;Protalix Ltd.&amp;#x201D;), are biopharmaceutical companies
focused on the development and commercialization of recombinant
therapeutic proteins based on the Company&amp;#x2019;s proprietary
ProCellEx&lt;sup&gt;&amp;#xAE;&lt;/sup&gt; protein expression system
(&amp;#x201C;ProCellEx&amp;#x201D;). In September 2009, Protalix Ltd. formed
another wholly-owned subsidiary under the laws of the Netherlands
in connection with the European Medicines Agency ("EMA")
application process in Europe. The Company&amp;#x2019;s two subsidiaries
are referred to collectively herein as the
&amp;#x201C;Subsidiaries.&amp;#x201D; The Company&amp;#x2019;s lead product
development candidate is taliglucerase alfa for the treatment of
Gaucher disease which the Company is developing using ProCellEx. In
addition to taliglucerase alfa, the Company is developing certain
other products using ProCellEx.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In September 2009, the Company successfully completed its phase III
pivotal trial of taliglucerase alfa. In July 2010, the U.S. Food
and Drug Administration (&amp;#x201C;FDA&amp;#x201D;) notified the Company
that it had accepted for review the Company&amp;#x2019;s new drug
application ("NDA") for taliglucerase alfa for the treatment of
Gaucher disease and that it granted to taliglucerase alfa a
Prescription Drug User Fee Act (PDUFA) action date of February 25,
2011. &lt;font style="FONT-FAMILY: Times New Roman, Times, Serif"&gt;On
February 25, 2011, the FDA issued a Complete Response Letter
("CRL") indicating that the FDA&amp;#x2019;s review of the taliglucerase
alfa NDA was complete but questions remain that precluded the
approval of the NDA in its then current form. In August 2011, the
Company submitted a revised NDA in response to the CRL. During the
same month, the FDA notified the Company that it had accepted the
revised NDA for review, had deemed the resubmission a class 2, or
6-month, response and established February 1, 2012 as the new PDUFA
date. In December 2011, the FDA notified the Company that it had
decided to extend the PDUFA date to May 1, 2012.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In the fourth quarter of 2010, Pfizer Inc. ("Pfizer"), the
Company&apos;s commercialization partner, filed, with the Company&apos;s
cooperation, a Marketing Authorization Application ("MAA") for
taliglucerase alfa with the EMA. As part of its ongoing review of
the MAA, the EMA delivered a list of outstanding points to be
addressed by the applicant. Among the topics currently in
discussion, is the orphan drug designation and exclusivity granted
by the EMA/European Commission to VPRIV, Shire plc&apos;s ("Shire")
Gaucher disease treatment, which could prevent the marketing
authorization of taliglucerase alfa in the European Union for a
10-year market exclusivity period commencing as of the August 2010
marketing authorization of VPRIV in the European Union. As part of
the MAA procedure, Pfizer, with the Company&apos;s cooperation, is
challenging VPRIV&apos;s orphan market protection with respect to
taliglucerase alfa pursuant to the EU orphan drug regulation. The
EU orphan drug regulation provides for the possibility of such a
challenge, and for an exception to this exclusivity to be granted,
based on a number of factors, including contribution to patient
care, clinical, supply, capacity and others.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Following the submission of the taliglucerase alfa MAA to the EMA,
a good manufacturing practices, or GMP, audit of the Company&apos;s
manufacturing facility was performed and it was found compliant
with EMA GMP in December 2011.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In January 2010, the EMA&apos;s Committee for Orphan Medicinal Products,
after reviewing all relevant clinical data, recommended that the
European Commission grant orphan drug designation to taliglucerase
alfa for the treatment of Gaucher disease and in March 2010, the
European Commission granted orphan designation to taliglucerase
alfa. In September 2009, the FDA&amp;#x2019;s Office of Orphan Product
Development granted &lt;font style="FONT-FAMILY: Times New Roman, Times, Serif"&gt;taliglucerase
alfa&lt;/font&gt; Orphan Drug Status.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On November&amp;#xA0;30, 2009, Protalix Ltd. and Pfizer entered into an
Exclusive License and Supply Agreement (the &amp;#x201C;Pfizer
Agreement&amp;#x201D;) pursuant to which Protalix Ltd. granted Pfizer an
exclusive, worldwide license to develop and commercialize
taliglucerase alfa, except in Israel. Under the terms and
conditions of the Pfizer Agreement, Protalix Ltd. retained the
right to commercialize taliglucerase alfa in Israel. See Note
2.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Although taliglucerase alfa has not yet been approved for
commercial sale, patients are being treated with taliglucerase
alfa, both in the framework of the Company&apos;s clinical trials and
related studies and in compassionate use programs, special access
agreements, named patient provisions and other programs designed to
ensure that treatments are available to Gaucher patients in light
of recent shortages of approved treatments. In July 2009, following
a request by the FDA, the Company submitted a treatment protocol to
the FDA in order to address an expected shortage of the current
enzyme replacement therapy approved for Gaucher disease. The
treatment protocol was approved by the FDA in August 2009, and the
Company is continuing to treat patients in the United States under
this protocol. On July 13, 2010, the Company announced that the
French regulatory authority had granted an Autorisation Temporaire
d&apos;Utilisation (ATU), or Temporary Authorization for Use, for
taliglucerase alfa for the treatment of Gaucher disease. An ATU is
the regulatory mechanism used by the French Health Products and
Safety Agency to make non-approved drugs available to patients in
France when a genuine public health need exists. This ATU allows
Gaucher disease patients in France to receive treatment with
taliglucerase alfa before marketing authorization for the product
is granted in the European Union. Payment for taliglucerase alfa
has been secured through government allocations to hospitals. In
addition to the United States and France, taliglucerase alfa is
currently being provided to Gaucher disease patients under special
access agreements or Named Patient provisions in Brazil and in
other countries.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On August 10, 2010, Pfizer entered into a short-term supply
agreement with the Ministry of Health of Brazil pursuant to which
the Company and Pfizer have provided taliglucerase alfa to the
Ministry of Health of Brazil for the treatment of Gaucher disease
patients. During the remainder of 2010 and the first quarter of
2011, the Company and Pfizer completed the supply of products
deliverable under the short-term supply agreement. During 2011,
Pfizer recorded an allowance for sales returns in connection with
the supply agreement because the Brazilian Ministry of Health
requested that Pfizer consider the replacement of certain vials
that might expire during 2012. Revenue, net of allowance for sales
returns, generated from the Brazilian Ministry of Health was
recorded by Pfizer, and the Company recorded its share of such
revenues in accordance with the terms and conditions of the Pfizer
Agreement.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;Liquidity and Financial Resources&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Successful completion of the Company&amp;#x2019;s development programs
and its transition to normal operations is dependent upon obtaining
necessary regulatory approvals from the FDA prior to selling its
products within the United States, and foreign regulatory approvals
must be obtained to sell its products internationally. Each FDA and
EMA approval triggers a $25,000 milestone payment from Pfizer,
pursuant to the Pfizer Agreement. There can be no assurance that
the Company will receive regulatory approval of any of its product
candidates, and a substantial amount of time may pass before the
Company achieves a level of revenues adequate to support its
operations, if at all. The Company also expects to incur
substantial expenditures in connection with the regulatory approval
process for each of its product candidates during their respective
developmental periods. Obtaining marketing approval will be
directly dependent on the Company&amp;#x2019;s ability to implement the
necessary regulatory steps required to obtain marketing approval in
the United States and in other countries. The Company cannot
predict the outcome of these activities.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Based on its current cash resources and commitments, and cash
received in a public underwritten offering on February 2012 (see
note 11b), the Company believes it will be able to maintain its
current planned development activities and the corresponding level
of expenditures for at least the next 12 months, although no
assurance can be given that it will not need additional funds prior
to such time. If there are unexpected increases in general and
administrative expenses or research and development expenses, the
Company may need to seek additional financing during the next 12
months.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Basis of presentation&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company&amp;#x2019;s financial statements have been prepared in
accordance with generally accepted accounting principles in the
United States (&amp;#x201C;U.S. GAAP&amp;#x201D;).&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;c.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Use of estimates in the preparation of financial
statements&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The preparation of financial statements in conformity with U.S.
GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results may differ
from those estimates.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;d.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Functional currency&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The dollar is the currency of the primary economic environment in
which the operations of the Company and its Subsidiaries are
conducted. The Company&amp;#x2019;s revenues are derived in dollars.
Most of the Company&amp;#x2019;s expenses and capital expenditures are
incurred in dollars, and the major source of the Company&amp;#x2019;s
financing has been provided in dollars.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Transactions and balances originally denominated in dollars are
presented at their original amounts. Balances in non-dollar
currencies are translated into dollars using historical and current
exchange rates for non-monetary and monetary balances,
respectively. For non-dollar transactions and other items (stated
below) reflected in the statements of operations, the following
exchange rates are used: (i) for transactions &amp;#x2013; exchange
rates at the transaction dates or average rates; and (ii) for other
items (derived from non-monetary balance sheet items such as
depreciation and amortization, etc.) &amp;#x2013; historical exchange
rates. Currency transaction gains and losses are carried to
financial income or expenses, as appropriate.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;e.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Cash equivalents&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company considers all short-term, highly liquid investments,
which include short-term bank deposits with original maturities of
three months or less from the date of purchase, that are not
restricted as to withdrawal or use and are readily convertible to
known amounts of cash, to be cash equivalents.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;f.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Inventories&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Inventories are valued at the lower of cost or market. Cost of raw
and packaging materials and purchased products is determined using
the &amp;#x201C;moving average&amp;#x201D; basis.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Manufacturing costs for product candidates are expensed as research
and development expenses. The Company considers regulatory approval
of product candidates to be uncertain, and product manufactured
prior to regulatory approval may not be sold unless regulatory
approval is obtained. As such, the manufacturing costs for product
candidates incurred prior to regulatory approval are not
capitalized as inventory. Inventories for which there are orders or
are probable to be sold even without the regulatory approval, are
capitalized.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Cost of finished products that are capitalized is determined as
follows: the value of the raw and packaging materials component is
determined primarily on a using the &amp;#x201C;moving average&amp;#x201D;
basis; the value of the labor and overhead component is determined
on an average basis over the production period.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;g.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Property and equipment&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Property and equipment are
stated at cost, net of accumulated depreciation and
amortization.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;The Company&amp;#x2019;s assets
are depreciated by the straight-line method on the basis of their
estimated useful lives as follows:&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="PADDING-LEFT: 81.1pt; WIDTH: 83%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 2%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 15%"&gt;
Years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td&gt;Laboratory equipment&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center"&gt;5&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="VERTICAL-ALIGN: top"&gt;Furniture&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt;10-15&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="VERTICAL-ALIGN: top"&gt;Computer equipment&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom"&gt;3&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Leasehold improvements are amortized by the straight-line method
over the expected lease term, which is shorter than the estimated
useful life of the improvements.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;h.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Impairment in value of long-lived assets:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company tests long-lived assets for impairment if an indication
of impairment exists. If the sum of expected future cash flows of
definite life assets (undiscounted and without interest charges) is
less than the carrying amount of such assets, the Company
recognizes an impairment loss, and writes down the assets to their
estimated fair values, calculated based on expected future
discounted cash flows.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;i.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Income taxes&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Deferred income
taxes&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Deferred taxes are determined utilizing the assets and liabilities
method based on the estimated future tax effects of the differences
between the financial accounting and tax bases of assets and
liabilities under the applicable tax laws. Deferred tax balances
are computed using the tax rates expected to be in effect when
those differences reverse. A valuation allowance in respect of
deferred tax assets is provided if, based upon the weight of
available evidence, it is more likely than not that some or all of
the deferred tax assets will not be realized. The Company has
provided a full valuation allowance with respect to its deferred
tax assets.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The guidance prohibits the recognition of deferred tax liabilities
or assets that arise from differences between the financial
reporting and tax bases of assets and liabilities that are measured
from the local currency into dollars using historical exchange
rates, and that result from changes in exchange rates or indexing
for tax purposes. Consequently, the above mentioned differences
with respect to Protalix Ltd. were not reflected in the computation
of deferred tax assets and liabilities.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Uncertainty in income
taxes&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Tax benefits recognized in the financial statements are those that
the Company&amp;#x2019;s management deems at least more likely than not
to be sustained, based on technical merits. The amount of benefits
recorded for these tax benefits is measured as the largest benefit
the Company&amp;#x2019;s management deems more likely than not to be
sustained.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;j.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Revenue Recognition&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company recognizes revenue when the earnings process is
complete, which is when revenue is realized or realizable and
earned, there is persuasive evidence a revenue arrangement exists,
delivery of goods or services has occurred, the sales price is
fixed or determinable and collectability is reasonably assured.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Revenues from the license and
supply agreement with Pfizer&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company recognizes revenue and milestone payments received
pursuant to the Pfizer Agreement in accordance with guidance
regarding revenue recognition and accounting for revenue
arrangements with multiple deliverables. As the arrangement with
Pfizer requires the Company&amp;#x2019;s continued involvement with
respect to the proposed commercialization of taliglucerase alfa,
the non-refundable, up-front license payment the Company received
from Pfizer was deferred and recognized over the related
performance period. The Company estimated the performance period of
14 years (commencing upon the date of the Company&apos;s receipt of the
up-front license payment payable by Pfizer under the Pfizer
Agreement) based on the date the last relevant patent expires. See
Note 2. The Company adjusts the performance periods, if
appropriate, based on the applicable facts and circumstances.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Revenues from selling
products to Pfizer&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company recognizes revenues from products sold to Pfizer upon
delivery, when the sales price is fixed or determinable and
collectability is reasonably assured.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;3.&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Company&amp;#x2019;s share in the
collaboration agreement&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;Under the terms and conditions of
the Pfizer Agreement, the Company is entitled to 40% of the profits
or loss from sales of taliglucerase alfa, and related expenses
incurred, except with respect to sales in Israel, where the Company
retained exclusive marketing rights. Since Pfizer bears most of the
risks and rewards relating to the agreement, the Company&amp;#x2019;s
share in the profits and loss in the agreement is recognized on a
net basis. The Company recognizes its share of net profit or loss
from the Pfizer Agreement based on reports it receives from Pfizer
summarizing the results of the collaborative activities under the
agreement for the applicable period. Under the terms of the Pfizer
Agreement, for its subsidiaries operating outside the United
States, financial information is included based on the fiscal year
ending November 30, while financial information for the U.S. entity
is included based on the fiscal year ending December 31.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;k.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Research and development costs&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Research and development costs are expensed as incurred and consist
primarily of personnel, subcontractors and consultants (mainly in
connection with clinical trials), facilities, equipment and
supplies for research and development activities. Grants received
by the Israeli Subsidiary from the Office of the Chief Scientist of
Israel&amp;#x2019;s Ministry of Industry, Trade and Labor (the
&amp;#x201C;OCS&amp;#x201D;) are recognized when the grant becomes
receivable, provided there is reasonable assurance that the Company
or the Subsidiary will comply with the conditions attached to the
grant and there is reasonable assurance the grant will be received.
The grant is deducted from the research and development expenses as
the applicable costs are incurred.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Reimbursements received from Pfizer are recognized when the
reimbursements become receivable, provided there is reasonable
assurance that the Company will comply with the conditions attached
to the reimbursements and there is reasonable assurance the
reimbursements will be received. The reimbursements are deducted
from the research and development expenses as the applicable costs
are incurred.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In connection with purchases of assets, amounts assigned to
intangible assets to be used in a particular research and
development project that have no alternative future use are charged
to research and development costs at the purchase date.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Nonrefundable advance payments for goods or services that will be
used or rendered for future research and development activities are
deferred and amortized over the period that the goods are consumed
or the related services are performed.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;l.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Comprehensive loss&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company has no other comprehensive loss components other than
net loss for the reported periods.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;m.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Concentration of credit risks and trade receivable&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Financial instruments that potentially subject the Company to
concentration of credit risk consist principally of bank deposits.
The Company deposits these instruments with highly rated financial
institutions, mainly in Israeli banks, and, as a matter of policy,
limits the amounts of credit exposure to any one financial
institution. The Company has not experienced any credit losses in
these accounts and does not believe it is exposed to any
significant credit risk on these instruments.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="COLOR: black"&gt;The Company&apos;s trade&lt;/font&gt; receivable
&lt;font style="COLOR: black"&gt;represents amounts to be received from
Pfizer, as the Company currently receives all of its revenues from
Pfizer. The Company does not require Pfizer to post collateral with
respect to the receivables. The Company performs periodic credit
evaluations of Pfizer&amp;#x2019;s financial condition and believes
there is no significant risk with respect to Pfizer&amp;#x2019;s payment
of the receivables.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;n.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Share-based compensation&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company accounts for employee&amp;#x2019;s share-based payment
awards classified as equity awards using the grant-date fair value
method. The fair value of share-based payment transactions is
recognized as an expense over the requisite service period, net of
estimated forfeitures. The Company estimates forfeitures based on
historical experience and anticipated future conditions.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company elected to recognize compensation cost for an award
with only service conditions that has a graded vesting schedule
using the accelerated method based on the multiple-option award
approach.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
When stock options are granted as consideration for services
provided by consultants and other non-employees, the grant is
accounted for based on the fair value of the consideration received
or the fair value of the stock options issued, whichever is more
reliably measurable. The fair value of the options granted is
measured on a final basis at the end of the related service period
and is recognized over the related service period using the
straight-line method.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;o.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Net Loss per share&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Basic and diluted loss per share (&amp;#x201C;LPS&amp;#x201D;) are computed
by dividing net loss by the weighted average number of shares of
the Company&apos;s Common Stock, par value $0.001 per share (the "Common
Stock") outstanding for each period.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Diluted LPS does not include options to purchase 10,660,447,
7,761,168 and 7,469,088 shares of Common Stock for the fiscal years
ended December 31, 2009, 2010 and 2011, respectively, because the
effect would be anti-dilutive.&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-5868000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-3891000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">8386000</us-gaap:Revenues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">1410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">14000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-23570000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">6775000</us-gaap:ReimbursementRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">886000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">6147000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">165000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 11 -&lt;/b&gt;&lt;/font&gt; &lt;b&gt;SUBSEQUENT
EVENTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -20.7pt; MARGIN: 0px 0px 0px 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 36pt"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 20.7pt"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;During January and February
2012, the Company issued a total of 10,239 shares of Common Stock
in connection with the exercise of options to purchase 10,239
shares of Common Stock by certain employees of the Company. The
Company received aggregate cash proceeds equal to approximately $5
in connection with the exercise of such options.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -20.7pt; MARGIN: 0px 0px 0px 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 36pt"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 20.7pt"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;On February 22,&amp;#xA0;2012,
the Company issued and sold 5,175,000 shares of Common Stock in an
underwritten public offering at a price to the public of $5.25 per
share. The net proceeds to the Company were approximately
$25,389&amp;#xA0;(net of underwriting commissions and issuance costs of
$1,567). The offering included the exercise by the underwriters of
an over-allotment option to purchase 675,000 shares of Common
Stock.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">299000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 5 -&lt;/b&gt;&lt;/font&gt; &lt;b&gt;LIABILITY
FOR EMPLOYEE RIGHTS UPON RETIREMENT&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Israeli Subsidiary is required to make a severance payment upon
dismissal of an employee, or upon termination of employment in
certain circumstances. The severance pay liability to the employees
(based upon length of service and the latest monthly salary - one
month&amp;#x2019;s salary for each year employed) is recorded on the
Company&amp;#x2019;s balance sheets under &amp;#x201C;Liability for employee
rights upon retirement.&amp;#x201D; The liability is recorded as if it
were payable at each balance sheet date on an undiscounted
basis.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The liability is funded in part from the purchase of insurance
policies or by the establishment of pension funds with dedicated
deposits in the funds. The amounts used to fund these liabilities
are included in the Company&amp;#x2019;s balance sheets under
&amp;#x201C;Funds in respect of employee rights upon retirement.&amp;#x201D;
These policies are the Company&amp;#x2019;s assets. However, under labor
agreements and subject to certain limitations, any policy may be
transferred to the ownership of the individual employee for whose
benefit the funds were deposited. In the years ended December 31,
2009, 2010 and 2011, the Company deposited $79, $174 and $181,
respectively, with insurance companies in connection with its
severance payment obligations.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In accordance with the current employment agreements with certain
employees, the Company makes regular deposits with certain
insurance companies for accounts controlled by each applicable
employee in order to secure the employee&amp;#x2019;s rights upon
retirement. The Company is fully relieved from any severance pay
liability with respect to each such employee after it makes the
payments on behalf of the employee. The liability accrued in
respect of these employees and the amounts funded, as of the
respective agreement dates, are not reflected in the
Company&amp;#x2019;s balance sheets, as the amounts funded are not under
the control and management of the Company and the pension or
severance pay risks have been irrevocably transferred to the
applicable insurance companies (the &amp;#x201C;Contribution
Plans&amp;#x201D;).&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The amounts of severance pay expenses were $488, $1,118 and $816
for the years ended December 31, 2009, 2010 and 2011, respectively,
of which $335, $531 and $641 in the years ended December 31, 2009,
2010 and 2011, respectively, were in respect of a Contribution
Plan. Gain on amounts funded in respect of employee rights upon
retirement totaled $81, $26 and $14 for the years ended December
31, 2009, 2010 and 2011, respectively.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company expects to contribute approximately $779 in the year
ending December 31, 2012 to insurance companies in connection with
its severance liabilities for its operations for that year, $607 of
which will be contributed to one or more Contribution Plans.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
During the five-year period following December 31, 2011, the
Company expects to pay future benefits to one employee upon the
employee&apos;s normal retirement age. The Company anticipates that the
benefits payable will be immaterial.&lt;/p&gt;
&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-36529000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">37818000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-350000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:CostOfRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">1525000</us-gaap:CostOfRevenue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">20590000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">5705000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-36531000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">2000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 4 -&lt;/b&gt;&lt;/font&gt;
&lt;b&gt;INVENTORIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Inventory at
December&amp;#xA0;31, 2010 and 2011 consisted of the
following:&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 58%"&gt;Raw materials&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 18%"&gt;553&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 18%"&gt;279&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished
goods&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
636&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total
inventory&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,189&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
279&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;During the year ended
December 31, 2010 and 2011, &lt;font style="COLOR: black"&gt;the Company
recorded a $2,692&lt;/font&gt; and $363, respectively, write-down of
inventory under cost of revenues. See Note 9d.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 3 -&lt;/b&gt;&lt;/font&gt; &lt;b&gt;PROPERTY
AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Composition of property and
equipment grouped by major classifications is as
follows:&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 58%"&gt;
Laboratory equipment&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 18%"&gt;11,478&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 18%"&gt;13,079&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Furniture and computer equipment&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,306&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,522&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Leasehold improvements&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;11,221&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;13,705&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
Equipment under construction&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,038&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,113&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 14.55pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;25,043&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;29,419&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt"&gt;
Less &amp;#x2013; accumulated depreciation and amortization&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(7,589&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(11,148&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
17,454&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
18,271&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 4.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="FONT-WEIGHT: normal"&gt;Depreciation and amortization
in respect of property and equipment totaled $1,990, $3,133 and
$3,631 for the years ended December 31, 2009, 2010 and 2011,
respectively, out of which the Company recorded a total write down
of $0, $43 and $10, respectively.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-8899000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-388000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 8 -&lt;/b&gt;&lt;/font&gt; &lt;b&gt;TAXES ON
INCOME&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;a.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;The Company&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws.
The Company&apos;s income is, or will be, taxed in the United States at
the rate of up to 39%.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;b.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Protalix Ltd.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Israeli Subsidiary is taxed according to Israeli tax laws:&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;Measurement of results for tax purposes&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Since 2008, the Company has measured the results of the Israeli
Subsidiary for tax purposes in nominal terms in NIS. Pursuant to
the Israel Income Tax Law (Adjustments for Inflation), 1985 (the
&amp;#x201C;Adjustments Law&amp;#x201D;), the Subsidiary&amp;#x2019;s results for
tax purposes have been measured through 2007 on a real basis, based
on changes in the Israel consumer price index.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;Tax rates&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The income of the Israeli Subsidiary, other than income from
&amp;#x201C;Approved Enterprises,&amp;#x201D; is taxed in Israel at the
regular rate. See 3 below. According to the provisions of the Law
for Amending the Israel Income Tax Ordinance, 2005, corporate tax
rates will be gradually lowered, resulting in a corporate tax rate
for 2009 and thereafter: 2009 &amp;#x2013; 26% and for 2010 and
thereafter &amp;#x2013; 25%.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On July 14, 2009, the Israel Economic Efficiency Law (Legislation
Amendments for Applying the Economic Plan for 2009 and 2010), 2009,
became effective, stipulating, among other things, an additional
gradual decrease in tax rates in 2011 and thereafter, as follows:
2011 &amp;#x2013; 24%, 2012 &amp;#x2013; 23%, 2013 &amp;#x2013; 22%, 2014 &amp;#x2013;
21%, 2015 &amp;#x2013; 20% and 2016 and thereafter &amp;#x2013; 18%.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On December 5, 2011, the "Tax Burden Distribution Law" (hereinafter
- the 2011 amendment) was officially published, discontinuing a
previously approved gradual decrease in corporate tax provided in
the 2009 amendment, and setting the corporate tax rate in Israel
for 2012 and thereafter to 25%.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Capital gain is subject to capital gain tax according to corporate
tax rate in the year of selling the assets.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;3.&lt;/td&gt;
&lt;td&gt;The Law for the Encouragement of Capital Investments, 1959 (the
&amp;#x201C;Encouragement of Capital Investments Law&amp;#x201D;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Under the Encouragement of Capital Investments Law, including
Amendment No. 60 to the Encouragement of Capital Investments Law as
published in April 2005, by virtue of the &amp;#x201C;Approved
Enterprise&amp;#x201D; or &amp;#x201C;Benefited Enterprise&amp;#x201D; status the
Israeli Subsidiary is entitled to various tax benefits as
follows:&lt;/p&gt;
&lt;p style="TEXT-INDENT: -37.1pt; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;a.&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Reduced tax rates&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Income derived from the Approved Enterprise during a 10-year period
commencing upon the year in which the enterprise first realizes
taxable income is tax exempt, provided that the maximum period to
which it is restricted by the Encouragement of Capital Investments
Law has not elapsed.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Israeli Subsidiary has an &amp;#x201C;Approved Enterprise&amp;#x201D;
plan since 2004 and &amp;#x201C;Benefited Enterprise&amp;#x201D; plan since
2009. The period of benefits in respect of the main enterprise of
the Company has not yet commenced. The period during which the
Company is entitled to benefits in connection with the Benefited
Enterprise expires in 2021.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
If the Israeli Subsidiary subsequently pays a dividend out of
income derived from the &amp;#x201C;Approved Enterprise&amp;#x201D; or
&amp;#x201C;Benefited Enterprise&amp;#x201D; during the tax exemption period,
it will be subject to a tax on the amount distributed, including
any company tax on these amounts, at the rate which would have been
applicable had such income not been exempted.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In addition to the corporate taxes in Israel, the Company might be
subject to a withholding tax on the U.S. revenue source portion of
the payments made to the Company for its share of Pfizer&amp;#x2019;s
net profits under the Pfizer Agreement. The withholding tax rate is
currently 15%.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;b.&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Accelerated depreciation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Israeli Subsidiary is entitled to claim accelerated
depreciation, as provided by Israeli law, in the first five years
of operation of each asset, in respect of buildings, machinery and
equipment used by the Approved Enterprise and the Benefited
Enterprise.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;c.&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Conditions for entitlement to the benefits&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Israeli Subsidiary&amp;#x2019;s entitlement to the benefits
described above is subject to its fulfilling the conditions
stipulated by the law, rules and regulations published thereunder,
and the instruments of approval for the specific investment in an
approved enterprise. If there is any failure by the Israeli
Subsidiary to comply with these conditions, the benefits may be
cancelled and the Subsidiary may be required to refund the amount
of the benefits, in whole or in part, with interest. The Company
received a final implementation approval with respect to its
&amp;#x201C;Approved Enterprise&amp;#x201D; from the Investment Center.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 1in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;d.&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Amendment of the Law for the Encouragement of Capital
Investments, 1959&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Encouragement of Capital Investments Law was amended as part of
the Economic Policy Law for the years 2011-2012, which was passed
by the Israeli Knesset on December 29, 2010 (the &amp;#x201C;Capital
Investments Law Amendment&amp;#x201D;).&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Capital Investments Law Amendment sets alternative benefit
tracks to those currently in effect under the provisions of the
Encouragement of Capital Investments Law.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The benefits granted to the Benefited Enterprises will be unlimited
in time, unlike the benefits granted to special Benefited
enterprises, which will be limited for a 10-year period. The
benefits shall be granted to companies that will qualify under
criteria set in the law; for the most part, those criteria are
similar to the criteria that were set in the Encouragement of
Capital Investments Law prior to its amendment.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Under the transitional provisions of the Encouragement of Capital
Investments Law, the Company is entitled to take advantage of the
tax benefits available under the Encouragement of Capital
Investments Law prior to its amendment until the end of the
benefits period, as defined in the Encouragement of Capital
Investments Law. The Company will be allowed to set the &amp;#x201C;year
of election&amp;#x201D; no later than tax year 2012, provided that the
minimum qualifying investment was made not later than the end of
2010. On each year during the benefits period, the Company will be
able to elect that the Capital Investments Amendment apply to the
Company, thereby making the tax rates described above available to
the Company. An election to have the Capital Investments Amendment
apply is irrecoverable.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;4.&lt;/td&gt;
&lt;td&gt;The Law for the Encouragement of Industry (Taxation),
1969:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Israeli Subsidiary is an &amp;#x201C;industrial company,&amp;#x201D; as
defined under the Law for the Encouragement of Industry (Taxation),
1969 (the &amp;#x201C;Law for the Encouragement of Industry&amp;#x201D;). As
such, the Israeli Subsidiary is entitled to claim depreciation at
increased rates for equipment used in industrial activity, as
stipulated by regulations published under Law for the Encouragement
of Industry, and has done so.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Under the provisions of the Income Tax Regulations
&amp;#x201C;Accelerated Depreciation in respect of Equipment acquired
during the Defined Period&amp;#x201D; (Temporary Orders), industrial
companies whose operations are mostly &amp;#x201C;eligible
operations&amp;#x201D; are entitled to claim accelerated depreciation at
a rate of 50% on machinery and equipment acquired from June 1, 2008
to May 31, 2009.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;c.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Tax losses carried forward to future years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
As of December 31, 2011, the Company had aggregate net operating
loss (NOL) carry-forwards equal to approximately $63,040 that are
available to reduce future taxable income as follows:&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;1.&lt;/td&gt;
&lt;td&gt;The Company&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The NOL carry-forward of the Company equal to approximately $11,740
may be restricted under Section 382 of the Internal Revenue Code
(&amp;#x201C;IRC&amp;#x201D;). IRC Section 382 applies whenever a corporation
with NOL experiences an ownership change. As a result of IRC
Section 382, the taxable income for any post change year that may
be offset by a pre-change NOL may not exceed the general IRC
Section 382 limitation, which is the fair market value of the
pre-change entity multiplied by the IRC long-term tax exempt
rate.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.75in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;2.&lt;/td&gt;
&lt;td&gt;Protalix Ltd.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
At December 31, 2011, the Israeli Subsidiary had approximately
$51,300 of NOL carry-forwards that are available to reduce future
taxable income with no limited period of use.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;d.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Deferred income taxes:&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The components of the Company&amp;#x2019;s net deferred tax assets at
December 31, 2010 and 2011 were as follows:&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 70%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;In respect of:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt; WIDTH: 70%"&gt;
Research and Development expenses&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;4,119&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt"&gt;Property and
equipment&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(143&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(149&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt"&gt;Holiday and
recreation pay&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;296&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;305&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt"&gt;Severance pay
obligation&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;130&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;164&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt"&gt;Deferred
revenues&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,691&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,746&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt"&gt;Net operating
loss carry forwards&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,599&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,579&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Valuation
allowance&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(7,573&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(13,764&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Deferred taxes are computed using the tax rates expected to be in
effect when those differences reverse. The Company used tax rates
of 39%, 25% and 0%.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;e.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Reconciliation of the theoretical tax expense to actual tax
expense&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The main reconciling items between the statutory tax rate of the
Company and the effective rate is the provision for full valuation
allowance in respect of tax benefits from carry forward tax losses
due to the uncertainty of the realization of such tax benefits (see
above).&lt;/p&gt;
&lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-WEIGHT: normal"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 0.25in"&gt;&lt;font style="FONT-WEIGHT: normal"&gt;f.&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;Tax assessments&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
In accordance with the Income Tax Ordinance, as of December 31,
2011, all of Protalix Ltd.&amp;#x2019;s tax assessments through tax year
2007 are considered final.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
A summary of open tax years by major jurisdiction is presented
below:&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; WIDTH: 48%; FONT-WEIGHT: bold"&gt;
Jurisdiction:&lt;/td&gt;
&lt;td style="WIDTH: 4%; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: right; WIDTH: 48%; FONT-WEIGHT: bold"&gt;
Years:&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td&gt;Israel&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2008-2011&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td&gt;United States (*)&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2002-2011&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td&gt;Netherlands&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2009-2011&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;
(*) Includes federal, state and local (or similar provincial
jurisdictions) tax positions.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">155000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-910000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-3005000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 10 -&lt;/b&gt;&lt;/font&gt; &lt;b&gt;RELATED
PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;
&lt;table style="WIDTH: 93%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 36pt" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -20.7pt; PADDING-LEFT: 20.7pt; WIDTH: 55%"&gt;
&lt;b&gt;a. &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;Management and consulting fees to
the Chairman of the Board&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"&gt;
33&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"&gt;
6&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"&gt;
-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -20.7pt; PADDING-LEFT: 20.7pt"&gt;
&lt;b&gt;b.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;Compensation to the
non-executive directors (except the Chairman of the Board in 2009,
and includes the interim Chairman of the Board in 2010 and
2011)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
209&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
215&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
215&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">6931000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;&lt;b&gt;NOTE 9 -&lt;/b&gt;&lt;/font&gt;
&lt;b&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;table style="WIDTH: 90%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6"&gt;December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -26.45pt; PADDING-LEFT: 26.45pt; FONT-WEIGHT: bold"&gt;
a.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Accounts
receivable - other:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in; WIDTH: 70%"&gt;
Deferred costs*&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 12%"&gt;1,558&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Institutions&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;634&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;375&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;State
of Israel (see Note&amp;#xA0;6a )&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;878&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,296&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Restricted deposit&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;226&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;208&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Prepaid expenses&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;354&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;235&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Sundry&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
139&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
165&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
2,231&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
3,837&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;* Manufacturing costs of inventory,
paid by Pfizer, but not delivered.&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;b.
&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Accounts payable
and accruals &amp;#x2013; other:&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Payroll and related expenses&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,199&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,108&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Provision for vacation and recreation pay&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,235&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,221&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Accrued expenses&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,030&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,327&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Royalties payable&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;884&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;89&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Liability in connection with collaboration operation- current
portion&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,322&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
Property and equipment supplier&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,720&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,473&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
8,068&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
7,540&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Statement of operations:&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10"&gt;Year ended December 31,&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0px; FONT-WEIGHT: bold"&gt;
c.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Revenues:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 52.2pt; WIDTH: 55%"&gt;
Deferred revenues from the license and supply agreement with
Pfizer&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 12%"&gt;
388&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 12%"&gt;
4,563&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 12%"&gt;
4,563&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt"&gt;
Revenues from selling products to Pfizer&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,079&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,823&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
388&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
6,642&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
8,386&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold"&gt;
d.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Cost
of Revenues:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Cost of products
sold&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;807&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;985&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Write down of
inventories&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,692&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;363&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Royalties
expenses&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,575&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
884&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
177&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
3,575&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
4,383&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
1,525&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold"&gt;
e.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Research
and development expenses - net:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Payroll and
related expenses&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10,479&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;13,176&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;14,042&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Subcontractors and
consultants&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;7,469&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;11,550&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;11,314&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Materials and
consumables&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,852&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,947&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,425&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Rent, insurance
and maintenance&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,238&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,457&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,113&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Patent
registration and licensing&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;387&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;571&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;449&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Depreciation and
write down&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,799&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,456&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,057&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Other&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,166&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,534&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,418&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 5.4pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;27,390&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;37,691&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;37,818&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.5in"&gt;Less - grants and
reimbursements:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt"&gt;Development costs
reimbursements from Pfizer&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,922&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,430&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt"&gt;Grants
(see Note 6a)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
5,752&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,818&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,345&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.4pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
21,638&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
29,951&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
31,043&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold"&gt;
f.&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;General
and administrative expense:&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Payroll and
related expenses&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,804&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,415&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,481&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Management and
consulting fees&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;681&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;221&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;215&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Rent, insurance
and maintenance&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;347&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;463&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;498&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Professional
fees&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,274&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,274&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,326&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Travel&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;251&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;308&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;229&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Depreciation&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;191&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;309&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;363&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt"&gt;Other&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
596&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
886&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
819&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.4pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
7,144&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
6,876&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt;
6,931&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">20927000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.43</us-gaap:EarningsPerShareBasicAndDiluted>
  <plx:DepreciationAmortizationAndAssetImpairment contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">3631000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:SupplementalOfferingAndStockIssuanceCosts contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">60000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">1473000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">31043000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="shares" decimals="0">84645364</plx:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <plx:CollaborativeAndLicenseArrangementDisclosureTextBlock contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0">&lt;div&gt;
&lt;p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 2 -&lt;/font&gt; LICENSE AND SUPPLY
AGREEMENT&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
On November&amp;#xA0;30, 2009, Protalix Ltd. and Pfizer entered into
the Pfizer Agreement pursuant to which Pfizer was granted an
exclusive, worldwide license to develop and commercialize
taliglucerase alfa, except in Israel. Under the terms and
conditions of the Pfizer Agreement, Protalix Ltd. retained the
right to commercialize taliglucerase alfa in Israel. Under the
Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd.
of $60,000 in connection with the execution of the agreement and
shortly thereafter paid Protalix Ltd. an additional $5,000 upon the
Company&amp;#x2019;s filing of a proposed pediatric investigation plan
to the Pediatric Committee of the EMA. Protalix Ltd. is also
eligible to receive additional potential milestone payments
totaling up to $50,000 for the successful achievement of other
regulatory milestones. Protalix Ltd. is entitled to 40% of the
profits earned on Pfizer&amp;#x2019;s sales of taliglucerase alfa. Such
profit will be calculated while, in addition to other adjustments,
taking into account Protalix Ltd.&amp;#x2019;s cost of goods sold and
Pfizer&amp;#x2019;s commercial expenses, with certain expenses capped or
borne solely by one party ("Collaboration Operation"). Of the
losses incurred by the Collaboration Operation through December 31,
2011, 40% will be deducted from the Company&apos;s share in the profits
from future years. This deduction will limited to a certain
percentage of any quarterly profit. As of December 31, 2011, the
Company accrued a liability in respect of these losses equal to
$7,888, out of which $6,566 is classified as a long term liability,
and the remainder is included in accounts payable and
accruals-other.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company has determined that the initial, non-refundable upfront
license fee payment of $60,000 together with the first $5,000
payment will be recognized on a straight line basis as revenue over
the estimated relationship period. The Company has estimated that
the relationship period for its arrangement with Pfizer will be
approximately 14 years (commencing upon the Company&amp;#x2019;s receipt
of the up-front license payment) based on the Company&amp;#x2019;s last
material patent relating to taliglucerase alfa to expire.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company&amp;#x2019;s deliverables under this collaboration include
an exclusive license to taliglucerase alfa as an enzyme replacement
therapy for the treatment of Gaucher disease, certain research and
development services as required under the Pfizer Agreement for
taliglucerase alfa, manufacturing of taliglucerase alfa and
optional participation in a joint steering committee.&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
According to the terms and conditions of the Pfizer Agreement, the
Company retained manufacturing rights and sells its products to
Pfizer. In addition, Pfizer is required to reimburse the Company
for certain costs it incurs in connection with certain development
expenses for taliglucerase alfa. In connection with the payments
received under the Pfizer Agreement, Protalix Ltd. is obligated to
pay certain royalties. See Note 6a.&lt;/p&gt;
&lt;/div&gt;</plx:CollaborativeAndLicenseArrangementDisclosureTextBlock>
  <plx:OtherGainsLosses contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-5418000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">20650000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:CashlessExerciseOfStockOptions contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">31000</plx:CashlessExerciseOfStockOptions>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-36529000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="INF">381685</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="INF">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">886000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">298000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">20586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <context id="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20111231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20091231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_365_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20111231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20111231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20111231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20091231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20091231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20081231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20081231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20081231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20081231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-K0006_STD_0_20120223_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2012-02-23</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#fnid_45950121_6001_50000009" xlink:label="fnid_45950121_6001_50000009" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_45950134" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount less than $1.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="fnid_45950121_6001_50000009" xlink:to="footnote_45950134" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>plx-20111231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: 1 -->
<!-- Creation date: 2012-02-25T02:22:53Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31"
  xmlns:us-types="http://fasb.org/us-types/2011-01-31"
  xmlns:plx="http://www.protalix.com/20111231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2011-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31"
  targetNamespace="http://www.protalix.com/20111231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation" id="DocumentDocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>107 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <link:definition>109 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
        <link:definition>110 - Disclosure - LICENSE AND SUPPLY AGREEMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>111 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock" id="Role_NotesToFinancialStatementsInventoryDisclosureTextBlock">
        <link:definition>112 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>113 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
        <link:definition>114 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>115 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>116 - Disclosure - TAXES ON INCOME</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock" id="Role_NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock">
        <link:definition>117 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>118 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>119 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="plx-20111231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="plx-20111231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="plx-20111231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="plx-20111231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
  <element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborativeAndLicenseArrangementDisclosureTextBlock" id="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentDocumentandEntityInformationAbstract" id="plx_DocumentDocumentandEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NotesToFinancialStatementsAbstract" id="plx_NotesToFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherGainsLosses" id="plx_OtherGainsLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberBasicDilutedSharesOutstanding" id="plx_WeightedAverageNumberBasicDilutedSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>plx-20111231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: 1 -->
<!-- Creation date: 2012-02-25T02:22:53Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfIncome" roleURI="http://www.protalix.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1900" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="plx_OtherGainsLosses" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="1.0300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="us-gaap_ReimbursementRevenue" order="1.0600" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="1.1500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="plx_DepreciationAmortizationAndAssetImpairment" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitContributions" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>plx-20111231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: 1 -->
<!-- Creation date: 2012-02-25T02:22:53Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfIncome" roleURI="http://www.protalix.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrentAbstract" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="plx_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_OtherGainsLosses" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="plx_DepreciationAmortizationAndAssetImpairment" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitContributions" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_SupplementalOfferingAndStockIssuanceCosts" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_CashlessExerciseOfStockOptions" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>plx-20111231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: 1 -->
<!-- Creation date: 2012-02-25T02:22:53Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negatedTotal" roleURI="http://xbrl.us/us-gaap/role/label/negatedTotal"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable And Accrued Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable Other Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable Trade Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract_lbl" xml:lang="en-US">Accounts Receivable Net Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract_lbl" xml:lang="en-US">Accounts receivable:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid In Capital Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Common stock issued for cash, issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Cashless exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Cashless Exercise Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Exercise of options granted to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CashlessExerciseOfStockOptions" xlink:to="plx_CashlessExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative and License Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Collaborative And License Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl" xml:lang="en-US">LICENSE AND SUPPLY AGREEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, $0.001 par value: Authorized - as of December 31, 2010 and 2011, 150,000,000 shares; issued and outstanding - as of December 31, 2010 and 2011, 81,248,472 and 85,630,157 shares, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost Of Revenue</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Defined Benefit Plan Assets For Plan Benefits Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DepreciationAmortizationAndAssetImpairment_lbl" xml:lang="en-US">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DepreciationAmortizationAndAssetImpairment_lbl" xml:lang="en-US">Depreciation Amortization And Asset Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DepreciationAmortizationAndAssetImpairment_lbl" xml:lang="en-US">Depreciation and write down of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DepreciationAmortizationAndAssetImpairment" xlink:to="plx_DepreciationAmortizationAndAssetImpairment_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_DocumentDocumentandEntityInformationAbstract" xlink:label="plx_DocumentDocumentandEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document Documentand Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DocumentDocumentandEntityInformationAbstract_lbl" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentDocumentandEntityInformationAbstract" xlink:to="plx_DocumentDocumentandEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share of common stock - basic and diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect Of Exchange Rate On Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitiesTable_lbl" xml:lang="en-US">Entities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitiesTable" xlink:to="dei_EntitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign Currency Transaction Gain Loss Before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">FINANCIAL INCOME - NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain Loss Unrealized</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses (income), net (mainly exchange differences)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain Loss On Sale Of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on sale of fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">GROSS PROFIT (LOSS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals (including long term )</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (decrease) in deferred revenues (including non-current portion)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase Decrease In Inventories</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (Increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Increase Decrease In Stockholders Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US">Changes during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities net of capital deficiency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES NET OF CAPITAL DEFICIENCY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes To Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="plx_NotesToFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherGainsLosses_lbl" xml:lang="en-US">Other Gains Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherGainsLosses_lbl" xml:lang="en-US">Other Gains Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OtherGainsLosses_lbl" xml:lang="en-US">COMPANY'S SHARE IN COLLABORATION AGREEMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherGainsLosses" xlink:to="plx_OtherGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Long term liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments For Proceeds From Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xml:lang="en-US">Pension And Other Postretirement Benefit Contributions</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension And Other Postretirement Benefit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock Net Of Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_lbl" xml:lang="en-US">Issuance of shares, net of issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:to="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds From Sale Of Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property Plant And Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReimbursementRevenue_lbl" xml:lang="en-US">Reimbursement Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReimbursementRevenue_lbl" xml:lang="en-US">Less - grants and reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReimbursementRevenue" xlink:to="us-gaap_ReimbursementRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet_lbl" xml:lang="en-US">Research Development And Engineering Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet_lbl" xml:lang="en-US">Research Development And Engineering Expense Net</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negatedTotal" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total capital deficiency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">CAPITAL DEFICIENCY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHARE CAPITAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued for cash (net of issuance costs of $1,410) (see note 7c) (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options granted to employees and non-employees (includes net exercise) (in shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued for cash (net of issuance costs of $1,410) (see note 7c)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options granted to employees and non-employees (includes net exercise)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts_lbl" xml:lang="en-US">Supplemental offering and stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts_lbl" xml:lang="en-US">Supplemental Offering And Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts_lbl" xml:lang="en-US">Issuance cost not yet paid and accruals - other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalOfferingAndStockIssuanceCosts" xlink:to="plx_SupplementalOfferingAndStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="plx_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number Basic Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares of common stock used in computing loss per share of common stock, basic and diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:to="plx_WeightedAverageNumberBasicDilutedSharesOutstanding_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>plx-20111231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version: 6.13.8 -->
<!-- Round: 1 -->
<!-- Creation date: 2012-02-25T02:22:53Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfIncome" roleURI="http://www.protalix.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsInventoryDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsCommitmentsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="plx-20111231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_DocumentDocumentandEntityInformationAbstract" xlink:label="plx_DocumentDocumentandEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentDocumentandEntityInformationAbstract" xlink:to="dei_EntitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:label="us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrentAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_OtherGainsLosses" xlink:label="plx_OtherGainsLosses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="us-gaap_ReimbursementRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:label="plx_ResearchDevelopmentAndEngineeringExpenseNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_WeightedAverageNumberBasicDilutedSharesOutstanding" xlink:label="plx_WeightedAverageNumberBasicDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_OtherGainsLosses" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" order="1.0400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0600" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReimbursementRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ResearchDevelopmentAndEngineeringExpenseNet" order="1.0800" preferredLabel="http://xbrl.us/us-gaap/role/label/negatedTotal" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0900" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_WeightedAverageNumberBasicDilutedSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_CashlessExerciseOfStockOptions" xlink:label="plx_CashlessExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:label="plx_DepreciationAmortizationAndAssetImpairment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:label="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:label="plx_SupplementalOfferingAndStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="plx_DepreciationAmortizationAndAssetImpairment" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="1.1800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitContributions" order="1.2000" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.2100" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_SupplementalOfferingAndStockIssuanceCosts" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="plx_CashlessExerciseOfStockOptions" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0800" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0200" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="1.0400" preferredLabel="http://xbrl.us/us-gaap/role/label/negated" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" xlink:label="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_CollaborativeAndLicenseArrangementDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="plx-20111231.xsd#plx_NotesToFinancialStatementsAbstract" xlink:label="plx_NotesToFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1P!=`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4)_
MS8.PJO:'=?6U!3XNGKDJ>K35M+-4SPLC?WLS</C"Q(P(M'>_UY]\Q_ON1"3W
M&VDDT_W2#_M*GZZ)_<\V&+=>0=TGDE9"N\%:``_\1H37)^?56W^FW)?\\]0_
M^=U7_P!>O>&?TP]3UEK_`%.MO^4A_P#>5_S]'Z_E^_(_*[=WYO\`F3:=!5FL
MVMAJ<J<I5P^,?QZVL'[2;5?R_2P^GU]Y-_=?YNGY&YEW2\MH%N6N+**,AF*:
M0)JU%`U>/#K';[QOMM9[SR]ML+WDD8CO)&J$4U_2X?$/3K8Y0ZE5B+%E!(_I
M<`V_V'OK0I)4$X-.N8+"C$>AZY>]]:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[K5L_GK9"OI/D?T_'25U73(W2.MDIZF:%&?^_>YUU%8W4%K`"_U
ML/?-#[[`'^N!M9\_W,O_`&DW'75;[AL,4GMGO!D56/[]/$`_\1+?UZI(_C69
M_P"=MD__`#OJO^OOO#/K.'Z6V_WW'_O(_P`W1C_C9N;<E'N/<;TFX,W2NV(H
M`S4V5KX&8+DT90S13J2`PN/\?9#OVZ;GM4,<NUW,]M*SD,8I'C)`%0"4()`.
M0#YYZ`//^V[=<6$"W%O#(HE:FI%:G8?4'J]O_2AV8(+CL/>X(A%K;JS?'[8^
MG^6^XOF]XO=U8GT\U<R"BG_EIWOI_P`UNL(1RERH9,[9MWQ?\H\/K_I.KE?O
M:S_0[_$?NZG^(?Z-/O?OO/)]W]Y_=;S_`'?W.KS?<^;UZ[ZM7-[^_H$_>%__
M`,#W^]?'F_>G]3/%\;6WB^+^[=?B^)77XFOOUUU:NZM<]8)>!!_7SZ70GTW[
MWTZ*#3I^HIIT\--,4I2F.'0E^YEZ"/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW6GG_`,*+.R*+9GRJZ.Q]5F:G&O5?'U:Q88*2>=9%_P!(V[X/(7B@E`:\
M5K$@\>\"?O8<L7.]\Y;?<PP)*J;8BU+`4_7N#3)'KUU7^X9!=R^V>\-;_`-]
M-<@9^DM_7JA+;W>>WILO21UVYJZ6E;S>6-\96LK6@E*7"T@;AP#Q[Q)W#D+=
M([1WAM8Q(*4.M/4?TNLZ;;;MRFF6.E:^6H?Y^C@=#]^=68?.9V;(;@J88YL9
M1QQD83,2W=:]7(M%1L1Z1^?<;<R<@<U7=O$L%NI(<D_JQC\/S;HIYMY2W[<+
M2*.TA5G5V)[T&"M/-AU;^?F5\=_#;^^M??Q6M_=/<_UT6_YUG]?<'S^T7/QB
M>EFGPG_1X?0_T^L75]G?<+Q`?HDIJ_W_``^O^GZN.'\P[XFGIXT'^D7(?<+U
MLM"4_N1O6_W#[5>)4U?P'Q\LAYU:?\??T'_U=W;_`('G]W>&/K/ZEZ-.I?B_
M=E*5K3CY\.L(/^!M]X/Z\_6?NV+P/WMKK]5:_#]16M/%KP^5?EU99[E;K%;K
MWOW7NO>_=>Z][]U[KWOW7NBD=G?/7X7=+;WS/6O;/R>Z6Z[W_MX8]LYL_=N^
M\)AMP8E<MC:3,8TUV-JZF.HIQ78NNAJ(M0&N*56'!'L.7W-_+&V73V.X7]M#
M=I34CN`PJ`PJ#PJI!^PCJ2N7_9OW5YJVF+?N6^7]UOMFGU>'-#;N\;Z&*-I8
M"ATNK*?0@CRZ07_#I'\NC_O-/XY_^C.VW_\`5GM)_7[DO_HYV7_.1?\`/T<_
M\#U[X_\`3*;Y_P!DLO\`FZUH/YV?7&__`.8Q\@^H^V_@?M',?+7K'9?33]=[
MMWWT8M+OG;6WM]4^^-P[CGVGE<GCJHPTN<BP.>HJMH#ZA!51M]&'N"?=7;KO
MGC=X-PY20W]E%;+&[P@R*L@>5BA*@T8*Z-0^3`^?6>WW4-[V?V.Y(W+EOWAN
M8N6]_N]U^IAM]P)MY9;<V\40F1'%3&9(Y$U<-2,/+JGK#_RN?YC,.0@DE^%G
MR!CC42ZG?9,P47B<"Y^Y_)/N(;[VUYX>V94VV[+&F!$_J/Z/65UA]X?V*CNU
M=^;-D"BN3<#T/RZ&[8W\M;^8!05M;)6_#[O6F22FB5&FV=(@9EG#$`FIY(7G
MV$K[VM]PS&OA[/?.:^43>GS`Z/+C[QWL(Z@+S?L7_92/\W1L_P#9!?FSHM_L
MKG<=]/\`SR[?T_ZB?85D]IO<XHP&P[E6A_T(_P"?H+C[P?L;7_E;-D_[*!_F
MZ.DOP[^57]R):'_0!V;]Z=M04PI?X#^\:A<)40-"%^X_S@F8+;^I]]3M#?ZU
MO[JH?WE_5WP?"_'XOT6CPZ?Q:^VGKCJ&C[T^T?[[$_\`6/:?!^I+:O&%*>(#
M7APIGK;E]J^N-/7O?NO=>]^Z]U[W[KW7O?NO=4L?+7^17\3?F1W_`+Y^1G9N
M^^]\-O7?\>VH\QC=F;HV;CMN4Z[6VMA]I8_^'T>5V%FJ^(RX["1/+KJ9-4S,
M1I4A1%G,?M)R[S/O$V]7TUVEU-IU!&C"C2BH*!HV/!17)S7K*KVV^]Y[C^U_
M)EGR/L%GL\NU67BZ&GBG:4^+,\S:F2XC4T:0@44=M`:G/1<?^@8[X(_\_/\`
MD_\`^AKUY_\`:N]D?^L+RE_RD7W^]1?]:>AU_P`'W[O_`/1OY?\`^<%S_P!M
M?5JWP0^!/4/\O?K#=/5'36?W]N';V[=]5?8&1J^P\KA<MEH<Q68+![?EIZ2?
M![?V[31X]:/`0L$:%W\C.=9!`$A\H<G[;R782;?MCS/#+-XA,A4G5I5*#2JB
ME%'EQKGK'7WA]Y.9O>O?[;F+FB&R@O;:S%LHMDD1"@DDD!8222DMJD85#`4`
MQYD[_L6=1+U[W[KW7O?NO=>]^Z]U1#\JO^%)_P#*`^*,E7B\M\HL5WENVCF>
M&3:'QEQC]S51DB;1,AWAAZJCZMIY87N&CFW!%*""--Q[]U[H/^]/^%17\HGH
M?`=;Y/*]P[Q[$W'V+L;9N_Y>O.H=FT^_-V]>XO>VW\7N/'X;LNNI,_2;"VUO
M+%4F56+)89,W59&@J8I(Y(@0"WNO=6#_`!N_FQ_R_OE/\7MU_,3K/Y(;$QW1
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MWK/0;5WUD>MJVEIMERD5YKZS>.-:EI@[I"ZNDSR)"3(ONO=);^7Q_.`^$O\`
M,IZ7[3[RZ&WQF=J[5Z.KQ2]QX[NK&XOKG-=;8^;%5N<Q^Y]TSOG<QM:EVED\
M5BZR:+(QY.6G04-0LIB>%U'NO=$"WU_PJ;_E<X/?F[=A=31_)[Y65.Q,)N#<
MV[]R?&7H/)[YVE@ML[3IVJ]T;JJ<MN3/;)FGVAM^D1IJK,P02XJ.!3+]P8B'
M/NO=64?R]?YJWPF_F?;0W'N?XE]J-N?*;(./&_NNMT86NV?V7L=<L:A<559W
M:V3&J?$Y)Z25(<C035N.DEC>(3^5&0>Z]U8M[]U[KWOW7NO>_=>Z^5G_`,*Z
M_C_T3\<_YA?2&R_C]TSU;TAM#)_$39^XLEM?J78>V.O=OY#/U/;?<>/J,W6X
M?:F,Q6/J<M/08VG@>H:,RM#!&A8A%`]U[K9Y[%_DW_R^OD)_((V%N^/XO]+=
M==XX7^6YL3O/:_>/7O7^WME]C0]K[>^.V'['DSNY-T;=HL=E-VT>[]P4#IFX
M,G)5QUD59-)9:@131^Z]UJ__`/"1?<"Y[^8]V+\:]Y[7P'8_17R*^-6^:+MG
MK'>^WL3O#8&X:CK/.[8WOL;.[DVMGZ/(83)U&W<K#44]&]1!((6R<FD!G!'N
MO=-W8&Q.NNGO^%9^T-D==;1V=UAUOLO^8_T`N%VIM#"XC:&R]J8>*MZ[RE<,
M;AL33T&&PF,BDEFJ)1%'%"A9W(`N??NO=0?^%$_RH[@_F7[PSGS<VI5F#^7I
MT3\@ZWX._%.2>HJ8XNTM[4VT<SV!V]W)@*)HDAJL=GYMMT"&L.@_PR7$TP7S
MT]9I]U[JXS$]U]==:?\`",_J[K7=&;*]C?)?%=@=)=%["Q5)/F-W]D]CY;YA
M[US4>"VU@*%9<A7_`&6(Q$]14RHA2(!([F>>GBE]U[JIC^8G\/>X_P"3'_)F
M^.?QMW)E*_;?>7\S+N+*]O\`R_H<56/&N"V7T)M3;L_5GQPK:NDE-)DZ';N8
M[/\`XSFRA99<]$\*234D$3R^Z]U?3_PE_P#A)UKW1_(S^7N#PE5B]H=I_-C-
M?([H??';,6$@SNX-M;=GZVI.N]HXN6D-5C)LAA=J'<M9F(\=]U`D\V2E)D4R
M!D]U[HY/\AG_`(3M;S_E%=]=Q_(3LWY)X#M_<>^NLZGI_:FUM@;7SFVMN4>V
M<CNW;>[LGN3=,^=R,]37[@DJMI44-)20Q&GHD>H8SSM(GB]U[K:;]^Z]U[W[
MKW7O?NO=?,0_X6H_]O,>@_\`Q2S9/_OYN\/?NO=61]G_`,W#Y:]M_P`HSI3^
M7_\`!/\`E@?S#=P]M=C?#/J3XZ;B[QW?\=]UX7JZAV?5]18#8V]-V=6Y?!1[
MB7>-%O#`15:8?*U<N'HZ>EK8Z[5(T8A/NO='A_X3(?R(NU?Y<5-O_P"6_P`N
M\?B]O_);MS94'7NS.K:#)8[/5'3_`%C79/%[DW#_`'KS6*J*W#3[\WEE\+CA
M)34,\\6+HJ'QM/)-53PTWNO=:S/\T+^6K\Z?EU_/^^1VT^D^B^\,+A^Y/DE@
M<-M[OB3K;L/%]5[:V_7;+VI2[@W]7=D4^'IL"NV=MX>&LJ*F2"M+SI`T$.N9
MTC;W7NKPO^%*_P#+HK^D?Y2'\OCX=_"SH_LSLO;/0W>M)CY,9UEU[N3?>YZT
M'J?L%MR]B[PH=FXC*SPY3>N\,G/7Y"J=$@>OKF5-(*(/=>Z>/^$V?\I_Y!;L
MV[\=_F1_,3V]N?";>^(.`WEUU_+R^,?8>VJ_;,O7$VX=_P"Y=[]A?(/=>R<W
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M@[#V[N"I?)9CK3*S9=J;'Y1EC6KFI)[(H7W[KW7T`/Y'WRG7Y&?`7X[[8D^/
M?RDZ+KNBOCK\;^NJG)_(GIS,]9[8[6BHNJ<3BZ+?G1>YZ^HJ<9V?UUEJ?;WW
M4&1HRFBFK*4NBB>,M[KW5P_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
0NO>_=>Z][]U[KWOW7NO_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pg19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg19.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!G0)+`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`VGOB]\0?CSW7T9LGM/M'8)W?V!O.3=&4W1N;([FW8E=F
M<BN[\]2?>52TN;IZ?RFGID4Z44'3?Z^_=>Z'W_AN[X=_\^=I/_0IWI_]D/OW
M7NO?\-W?#O\`Y\[2?^A3O3_[(??NO=>_X;N^'?\`SYVD_P#0IWI_]D/OW7NO
M?\-W?#O_`)\[2?\`H4[T_P#LA]^Z]U[_`(;N^'?_`#YVD_\`0IWI_P#9#[]U
M[KW_``W=\._^?.TG_H4[T_\`LA]^Z]U[_AN[X=_\^=I/_0IWI_\`9#[]U[KW
M_#=WP[_Y\[2?^A3O3_[(??NO=>_X;N^'?_/G:3_T*=Z?_9#[]U[IHS_P/^#N
MT\)E=S;IZXV[MK;>!H:C*9S<&?WWNC#X7#XVDC,M5D,IE,AN>GH:"BIHE+22
MRNJ(HN2![]U[I&=5_%3^6[WGMMMX]*X_K'MS::5D^.DW+UKVWD][8.+(4Q*U
M%#+D]N;QR-'%60D>J)G#@<VY]^Z]U&Z_^,'\M+MC-[TVUU=#U3V/N+KC*_P+
ML'!;%[AK]UYC8^9\M1!_"MV8[![SKJO`9#STDJ>*J2)]<3K:ZL![KW2QPGP=
M^"&Y:_<F+V[L+:V>R6S<PNWMW4&'W_N;)5FV,\^/H\LN$S]/2;HFEQ&6.+R-
M/4?;SA)?#,CZ=+*3[KW2B_X;N^'?_/G:3_T*=Z?_`&0^_=>Z]_PW=\._^?.T
MG_H4[T_^R'W[KW7O^&[OAW_SYVD_]"G>G_V0^_=>Z]_PW=\._P#GSM)_Z%.]
M/_LA]^Z]U[_AN[X=_P#/G:3_`-"G>G_V0^_=>Z]_PW=\._\`GSM)_P"A3O3_
M`.R'W[KW7O\`AN[X=_\`/G:3_P!"G>G_`-D/OW7NO?\`#=WP[_Y\[2?^A3O3
M_P"R'W[KW7O^&[OAW_SYVD_]"G>G_P!D/OW7NO?\-W?#O_GSM)_Z%.]/_LA]
M^Z]U[_AN[X=_\^=I/_0IWI_]D/OW7NO?\-W?#O\`Y\[2?^A3O3_[(??NO=>_
MX;N^'?\`SYVD_P#0IWI_]D/OW7NO?\-W?#O_`)\[2?\`H4[T_P#LA]^Z]U[_
M`(;N^'?_`#YVD_\`0IWI_P#9#[]U[KW_``W=\._^?.TG_H4[T_\`LA]^Z]U[
M_AN[X=_\^=I/_0IWI_\`9#[]U[KW_#=WP[_Y\[2?^A3O3_[(??NO=>_X;N^'
M?_/G:3_T*=Z?_9#[]U[KW_#=WP[_`.?.TG_H4[T_^R'W[KW7O^&[OAW_`,^=
MI/\`T*=Z?_9#[]U[KW_#=WP[_P"?.TG_`*%.]/\`[(??NO=>_P"&[OAW_P`^
M=I/_`$*=Z?\`V0^_=>Z]_P`-W?#O_GSM)_Z%.]/_`+(??NO=>_X;N^'?_/G:
M3_T*=Z?_`&0^_=>Z]_PW=\._^?.TG_H4[T_^R'W[KW7O^&[OAW_SYVD_]"G>
MG_V0^_=>Z]_PW=\._P#GSM)_Z%.]/_LA]^Z]U[_AN[X=_P#/G:3_`-"G>G_V
M0^_=>Z]_PW=\._\`GSM)_P"A3O3_`.R'W[KW7O\`AN[X=_\`/G:3_P!"G>G_
M`-D/OW7NO?\`#=WP[_Y\[2?^A3O3_P"R'W[KW7O^&[OAW_SYVD_]"G>G_P!D
M/OW7NO?\-W?#O_GSM)_Z%.]/_LA]^Z]U[_AN[X=_\^=I/_0IWI_]D/OW7NO?
M\-W?#O\`Y\[2?^A3O3_[(??NO=>_X;N^'?\`SYVD_P#0IWI_]D/OW7NO?\-W
M?#O_`)\[2?\`H4[T_P#LA]^Z]U[_`(;N^'?_`#YVD_\`0IWI_P#9#[]U[KW_
M``W=\._^?.TG_H4[T_\`LA]^Z]U[_AN[X=_\^=I/_0IWI_\`9#[]U[KW_#=W
MP[_Y\[2?^A3O3_[(??NO=>_X;N^'?_/G:3_T*=Z?_9#[]U[KW_#=WP[_`.?.
MTG_H4[T_^R'W[KW7O^&[OAW_`,^=I/\`T*=Z?_9#[]U[KW_#=WP[_P"?.TG_
M`*%.]/\`[(??NO=>_P"&[OAW_P`^=I/_`$*=Z?\`V0^_=>Z]_P`-W?#O_GSM
M)_Z%.]/_`+(??NO=>_X;N^'?_/G:3_T*=Z?_`&0^_=>Z]_PW=\._^?.TG_H4
M[T_^R'W[KW7O^&[OAW_SYVD_]"G>G_V0^_=>Z]_PW=\._P#GSM)_Z%.]/_LA
M]^Z]U[_AN[X=_P#/G:3_`-"G>G_V0^_=>Z]_PW=\._\`GSM)_P"A3O3_`.R'
MW[KW7O\`AN[X=_\`/G:3_P!"G>G_`-D/OW7NO?\`#=WP[_Y\[2?^A3O3_P"R
M'W[KW7O^&[OAW_SYVD_]"G>G_P!D/OW7NO?\-W?#O_GSM)_Z%.]/_LA]^Z]U
M[_AN[X=_\^=I/_0IWI_]D/OW7N@`_P!DK^,_]_\`^`?Z-(/X1_LPO]P?LO[Q
M;KT?W3_V6;_27_"-?\;\GA_OQ_E^J_E\GIU>/T^_=>Z,O\"_^R3.HO\`J$W5
M_P"]QN7W[KW1O??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW5)W\X#9&*^0F__P"6M\-=^R5E1T9\D_F#55'>NU(*^NQM#V5LCI?JO>/9
MM#UKN&?'34U34[;W)NG&T,E92^15J8Z32>/?NO=%\F^)/5_PX_FH8'IWX1;4
MVM\<-I?.#^7M\EL;OO8'7H?;>Q*7M?IS+[/I>K.VZ+9N+44&`SN*I=]55'4U
MU''$U2FG4&E&IO=>Z*-\<=L]T?"]N@>Y*GX2[NZ`WA\1/A?N3X<;[7)Q;-Q]
M3\]?F)VOO7K_`&YT[M_KC^Z&<RF4[5VME-]X*NW+4[IRT=/5T=-D96*DFHM[
MKW5K_P#+G^3?Q+V564_PNQ/<51O[Y1U^Y^S=S=Q]EUNQ-XX#97R&^3-#DI,O
M\DY>M^S<Q@J'9G9.7V!N*:2AGHL76U,N,Q5!##;QTY*^Z]U<=[]U[JH#^9#_
M`##H/CIB<ML#KZIJZS<[-2[9WIF-NF.GW-L#(;GQU1D<)/AJG+PMAGR4F+HY
M9-12?P%XV%FX`9]Q.?MG]GN4[;GOF:PN;_;I[];>.*)T34?#DD+.6![!X>F@
MH23Z5ZF_[N?W?N9OO/\`N/<^V7*.ZV&T;C;;/+?O/=Q33(4CFAA\-5A*L')F
M#:B:`*?,CI2?!#^8WM'OG96)H.U<UC]F;MFHJN/;4^X98Z:KW;C]K.,7G<QE
MLC3*,#3Y9JM4D:)#"'$A*J3<!9R1S5MWN;R-![C<OVD]GLUQ<S1&*5T=HVB?
M2.Y0*JWEBHI0]$GOK[/;]]WKW9OO9_FC<++<]XL;2TG^HM8Y8HG6ZA\4*$E+
M.&088UH3D=6&?Z;.G_\`GYVQO_0EQ?\`]4>SKJ*^O?Z;.G_^?G;&_P#0EQ?_
M`-4>_=>Z]_ILZ?\`^?G;&_\`0EQ?_P!4>_=>Z]_ILZ?_`.?G;&_]"7%__5'O
MW7NO?Z;.G_\`GYVQO_0EQ?\`]4>_=>ZXKW=TZVK3VAL1M+%&T[GQ3:'7]2/:
MI.EUOR#8CW[KW7+_`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\_.V-_P"A
M+B__`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/_P#/SMC?^A+B_P#Z
MH]^Z]U[_`$V=/_\`/SMC?^A+B_\`ZH]^Z]UU_INZ=U:/]*&Q->G7H_O-BM>B
M^G7H^YU:-7%[6OQ[]U[KO_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/_P#/SMC?
M^A+B_P#ZH]^Z]U[_`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\_.V-_P"A
M+B__`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?NO=='N[IU=.KM#8BZF"+JW/BE
MU.;Z4754C4[6-@.3;W[KW7?^FSI__GYVQO\`T)<7_P#5'OW7NO?Z;.G_`/GY
MVQO_`$)<7_\`5'OW7NO?Z;.G_P#GYVQO_0EQ?_U1[]U[KW^FSI__`)^=L;_T
M)<7_`/5'OW7NO?Z;.G_^?G;&_P#0EQ?_`-4>_=>ZZ/=O3R@LW9^Q55069FW-
MBE55479F8U("JH%R3P![]U[KP[MZ>(!'9^Q6!`(9=S8HJP(N"I%2001]"/K[
M]U[KO_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/_P#/SMC?^A+B_P#ZH]^Z]U[_
M`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39
MT_\`\_.V-_Z$N+_^J/?NO==#N[IUKZ>T-AMI9D;1N?$MI=39D;34G2ZGZ@\C
M\^_=>Z[_`--G3_\`S\[8W_H2XO\`^J/?NO=>_P!-G3__`#\[8W_H2XO_`.J/
M?NO=>_TV=/\`_/SMC?\`H2XO_P"J/?NO=>_TV=/_`//SMC?^A+B__JCW[KW7
MO]-G3_\`S\[8W_H2XO\`^J/?NO==?Z;NG=6C_2AL/7IUZ/[SXGR:"2H?1]SK
MT%@1>UKBWOW7NN_]-G3_`/S\[8W_`*$N+_\`JCW[KW7O]-G3_P#S\[8W_H2X
MO_ZH]^Z]U[_39T__`,_.V-_Z$N+_`/JCW[KW7O\`39T__P`_.V-_Z$N+_P#J
MCW[KW7O]-G3_`/S\[8W_`*$N+_\`JCW[KW71[NZ=73J[0V(NI@BZMSXI=3F^
ME%U5(U.UC8#DV]^Z]UW_`*;.G_\`GYVQO_0EQ?\`]4>_=>Z]_ILZ?_Y^=L;_
M`-"7%_\`U1[]U[KW^FSI_P#Y^=L;_P!"7%__`%1[]U[KW^FSI_\`Y^=L;_T)
M<7_]4>_=>Z]_ILZ?_P"?G;&_]"7%_P#U1[]U[KH]V]/*"S=G[$55!9F;<V*5
M551=F9FJ0JJH%R3P![]U[KL=V=/$`CL_8I!`((W+BB""+@@BI(((^A]^Z]U[
M_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/
M_P#/SMC?^A)B_P#ZH]^Z]T(6-R6/S%!293$UM+DL;70I445?13)44E5`_P"B
M:GGC+1RQM^""1[]U[J;[]U[KWOW7NBH_\U8_\NV_^<K]^Z]U`^!?_9)G47_4
M)NK_`-[C<OOW7NC>^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NJY?YD_P^[3^5?6G5&Y?CEV-M[J?Y4_%SN?;OR%^.V\MY8>;/;$J=XX
M#%YG;V:V-O\`QE*?OI=E[^VIN"LQ]8\&J:`O'*JG18^Z]T`WPL^)OSHW#\K,
MO\[_`.9/NWH,=O;>Z9K?CYT/TG\:*7=%3UIU?LK<.YZ'=?8>\LKNO>>C<&X]
MZ;^R6$Q\>DHL-#1TWC4G5Q[KW1Q-\]`[[[9^9'57:O8%5@&Z`^.&S,EN3J/9
M]-75%5FMQ?)'>HRFVLOV'NW&R4$=!38WK;KF26BV^HGFD-=FZNI(C:&$GW7N
MJV_CO_+5^3NPNUOBSUIV+G.HE^)WP*[U[V[]Z.[!VKG=U5O>?<F4[@?L;^[.
MT>Q]MY+$4^!V;3;)@[3R(RU939'(#.R4M,4BIP9#[]U[J_/W[KW1`_GA\-=C
M_)OK[+9S(8_%3;SV7@,GF=O0999Z;`YS)8FEJ*NBI]S5.(:ES,D,<!FA@D68
MBG\[-H8<>TF[;!RCS?M\?+_/=BNX\O+<K,(R\BE)`K)K0HZ9TNPH30_L/0S]
MOO<WW*]H.8Y.<?:C>)MDYHELGM'FCC@D+P.Z2-&RSQ2J`7C1JA0PT\:5ZUYN
M\^[^^OY*W<_3/9=)L+![^^)&>V-3UO96RMH8>M>NW)L'<=3CLWO/<VTY\]79
M6LHNT.H<Q.:Q*(5*TV8PLCHZ)(T;Q0@W/$/MC[AV?M8-OM=K]K+T2';'B,II
M<2."PN7ED>LC-V8TJNJ,@48TS%W'VMF^\Y[#;O\`>1@WS=>8/O%;+)`O,%O=
M"V%=O@B9(I+&&U@A_22/]6K*[DQS(S$JM=J_HKN/I?Y+]1[$[TZ.W+MCL+JW
MLC`TFX]I;JP:4L]'7T%6OJAG3QB:@R=!.KP5=+,J3TM1&\4BJZD">NL!^A:_
MAV/_`.=?0_\`G'3_`/7OW[KW7OX=C_\`G7T/_G'3_P#7OW[KW7OX=C_^=?0_
M^<=/_P!>_?NO=>_AV/\`^=?0_P#G'3_]>_?NO=('86T9<'_?3^*XO'QG,=@[
MFSV.TQ4D_DQ.2:C:CF;2A\3OXFNA]2_GW[KW2^_AV/\`^=?0_P#G'3_]>_?N
MO=>_AV/_`.=?0_\`G'3_`/7OW[KW7OX=C_\`G7T/_G'3_P#7OW[KW7OX=C_^
M=?0_^<=/_P!>_?NO=>_AV/\`^=?0_P#G'3_]>_?NO=($;2E_TI/N;^%X_P#@
M9Z^BP(F\5)K_`(LNY)LB8?M]'DT"C<-KMIOQ]??NO=+[^'8__G7T/_G'3_\`
M7OW[KW7OX=C_`/G7T/\`YQT__7OW[KW7OX=C_P#G7T/_`)QT_P#U[]^Z]U[^
M'8__`)U]#_YQT_\`U[]^Z]U[^'8__G7T/_G'3_\`7OW[KW2!WWM*7-R;&;%X
MN@D&%[!P&>R>J*DA\6*H:7*Q54RZT'E=&JD`0>HWX]^Z]TOOX=C_`/G7T/\`
MYQT__7OW[KW7OX=C_P#G7T/_`)QT_P#U[]^Z]U[^'8__`)U]#_YQT_\`U[]^
MZ]U[^'8__G7T/_G'3_\`7OW[KW7OX=C_`/G7T/\`YQT__7OW[KW2;WEMZ/+[
M/W7B<=C:"3(93;.>QU#&:>EB$E978JKI:5&E:,+&KSRJ"QX`-S[]U[J5MO!0
M8[;N`Q];CJ!:RAPF)HJM134T@6II:"G@G42+&5<++&1<<'\>_=>Z>OX=C_\`
MG7T/_G'3_P#7OW[KW7OX=C_^=?0_^<=/_P!>_?NO=>_AV/\`^=?0_P#G'3_]
M>_?NO=>_AV/_`.=?0_\`G'3_`/7OW[KW7OX=C_\`G7T/_G'3_P#7OW[KW2"V
M#M*3!0;M3*XO'Q-E>P-WYZ@TQ4D_DQ66R/W%!,Q6,^-Y(N2A]2GZ^_=>Z7O\
M.Q__`#KZ'_SCI_\`KW[]U[KW\.Q__.OH?_..G_Z]^_=>Z]_#L?\`\Z^A_P#.
M.G_Z]^_=>Z]_#L?_`,Z^A_\`..G_`.O?OW7NO?P['_\`.OH?_..G_P"O?OW7
MND%'M*1>T:S<IQ>/_@DW7^,P4<_BI-9RM-N3+9":$T^CR!%HZI&#VTDFWU'O
MW7NE[_#L?_SKZ'_SCI_^O?OW7NO?P['_`/.OH?\`SCI_^O?OW7NO?P['_P#.
MOH?_`#CI_P#KW[]U[KW\.Q__`#KZ'_SCI_\`KW[]U[KW\.Q__.OH?_..G_Z]
M^_=>Z0.^]I2YN78C8O%X^1<)V#@\]D]45)#XL514.8AJ9E#H/,Z25:`(OJ-^
M/H??NO=+[^'8_P#YU]#_`.<=/_U[]^Z]U[^'8_\`YU]#_P"<=/\`]>_?NO=>
M_AV/_P"=?0_^<=/_`->_?NO=>_AV/_YU]#_YQT__`%[]^Z]U[^'8_P#YU]#_
M`.<=/_U[]^Z]TFMZ;=CS&SMVXC&XV@DR.5VQG\;01FGI8EDK:_$U=+2HTK1A
M8U>>506/`!N>/?NO=3=NX.GQ^W\#05F.H5JZ'"XJCJE%-32!:FEH*>"=0XC*
MN%E0BXX/X]^Z]T\?P['_`/.OH?\`SCI_^O?OW7NO?P['_P#.OH?_`#CI_P#K
MW[]U[KW\.Q__`#KZ'_SCI_\`KW[]U[J4JJBJB*J(@"JB*$15'T"JH"J!_A[]
MU[KE[]U[KWOW7NBH_P#-6/\`R[;_`.<K]^Z]U`^!?_9)G47_`%";J_\`>XW+
M[]U[HWOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z2N^O^/'WG_X:>X__=-6^_=>Z)K\K/B7MOYD
M?$"CZLR<-%%NFGV5M_/=<YRKACD&&WA1;<IUHTG9U)_A.;A=Z*M2^EZ>8D@E
M%]QG[L^WEK[D\GS[(U$W6/\`5M9>!BG0=IKQ"O\``U#P->*CK(G[K_OSN7W>
M_=>SYQC#3\L7`^EW2UXK<V,I`E4H:JSQ8EBJ#WKIX,W6B!\(?GKW]_PGZ^6V
MY^ONTMN[NW%_+H[7[,J\)V=L-8:G(9#X[=ES5,E/EL[M&DD9ACLE0&G>2;'7
MC@S^*CO$?NZ96]ASV-]PKOG'EV39>808^==F?Z>\1L.V@E4FI_3TD.>'B!LT
M(Z'_`-\[V'VSVEY]@YNY$9;CV>YMA_>&TSQYB590))+4-D?I%@T8K7PF4?$C
MT^CSUEV;U_W/U[L[M?JK=V#W[UQV!M_';IV;O';==%D<)N#!96!:BBKZ&JA)
M!5T;2Z,%DAD5HY%5U91-_6&_2Z]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%1_YJQ_Y=M_\`.5^_=>Z@?`O_`+),
MZB_ZA-U?^]QN7W[KW1O??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TE=]?\`'C[S_P##3W'_`.Z:
MM]^Z]UPV!_QXFR?_``T-L_\`NEHO?NO=:_O\Y3X5=<5-74_);<O6=/V1T=V%
MCZ/K3YC=;4\8AJ,IM.O>"BP?:6`JH4:7![UVK4B%Z7)Q!9:6OIZ60DHTP;%K
MW;VN_P#;7G&U][>68RUIJ6#=84X2PN0HE('G2BECPD6)B0"YZZ9?=4YDV/[Q
M?M)N?W,/<:X2/=BLE]RM>2FIMKV,-(UH&.=#G4RH#F-YT`P@ZH;^'_RK[O\`
M^$V/R8VE\=N_]UY[OC^3Q\L<@-Z?&[Y!4=+4Y*#KVEW$T%2<[204_FCPN>PB
M5<:;RVS&09`O\2H4+:XY,E=IW7;]\VRWWG:I%EVZYB62-QP*L*C\_(CB#4'K
MG5S/RSOO)G,5[RGS-;O:\P;=<R6]Q$PH4EB8JP^8)%58892&%00>M_':.[MK
M;_VKMW?&Q]PX?=NSMW8;';BVON?;]?3Y3"9_!9:ECK<;E<5D:226FK**MI9E
M>-T8AE/LPZ(NE%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NBH_\U8_\NV_^<K]^Z]U`^!?_9)G47_4)NK_`-[C<OOW7NC>
M^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[I*[Z_X\?>?_AI[C_\`=-6^_=>ZX;`_X\/9/_AH;9_]
MTM%[]U[J9N[:FWM][7W#LO=N+I<WMC=6'R&!SV)K8UEILABLI324E932JP-M
M<,ILPLRM8@@@'VBW+;K+>-OFVK<HUEL+B)HY$;(9&!!!_(_EQ'1QR_O^\<J[
M[9\R\OSR6N^6%S'/!*AHT<L3!T8'Y$"HX$5!J#UK:T_Q7ZDW#7=T?R5?G%AF
MWAT+VLN2[`^(&_<B8XLYMZ>J>LJJ%=F9VH1SA]Y[;JC)+3>,E#60U,#H\-7X
MWQB]JMQO?:SGFY]F.89&;:)V:?:9GX.CDL8:G%30FGE*KC\:]=)?O/[#L_WG
M?97;OOB\A0(G-EDD=AS7:1#,4\:JB7ND9T&J@N1F!XB3^D_53/P@^7GR1_X3
M<_+RG_EG?S$\WEMY_P`OWM#.U=?\7ODK+3UE1A.OJ+*Y(1PY2GF?[AJ+9KU5
M3''N;!AVDV]7.:VG5Z69C+E5US"ZWPL3E<7GL7C<Y@\E09C"YF@H\KB,OBZN
M"OQF4QF0IXZN@R..KJ5Y::LH:VEE62*6-F21&#*2"/?NO=3_`'[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14?^:L?^7;?_.5^_=>
MZ@?`O_LDSJ+_`*A-U?\`O<;E]^Z]T;WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=8:BHIZ2":JJIX:6EIHI)ZBIJ)8X*>G@B4O+-/-*RQQ11H
M"69B``+GW[KW7;SP10/523PQTL<+5,E3)+&E/'3HAE>H>=F$2P+&-1<G2%YO
M;W[KW4'$9K#;@HDR>`R^+SF-DDDBCR&'R%)DZ%Y86T2QI5T4T].TD3BS*&NI
MX/OW7NNL?G,)EZC)TF)S.)RE7A*O[#,TN.R-'75&(KAJO19."EFEEH*OT']N
M4(_!X]^Z]U*@K:*JFJZ>FK*6IJ,?,E-7P4]1#--0U$D,=3'!611NSTLST\R2
M!'"L48-:Q!]^Z]U*]^Z]TE=]?\>/O/\`\-/<?_NFK??NO=<-@?\`'A[)_P##
M0VS_`.Z6B]^Z]TK??NO=5[?S&/B=D/DKTY39_KN1\/\`('I3(CL3I?<E"?M\
MH,YB3%6U6VDJTTR"'/)1H(@256LCA8V75>&?>SV\FYXY:6]V6L?.&UO]19R+
MARZ48Q`_T](*UJ!(J'A7K+W[F_O]:>RON.^T\X@7/M'S-#^[]YMG[HO`EJBW
M)0XK`7.H\3"T@XZ:%0S'5/QK_GQ_R]<EU%\D=MQ4F]\/)/MW<]=04M/3[\Z-
M[RP5))24V^MHO4KYJ`5K#SM2R6IJZEDFHY@0K%33VB]PX?<7E*/<9:)OML?!
MO(N!2=1DZ>(60=ZUX5*\5/09^]=[`W?W?/=:XY;MF-QR3?I]9M-T#J2>QF.I
M`'&&>&OAO0FM%?@XZH3_`):OS_\`D9_(H^5-+_)^_FK9FIK/CEELCX_B#\I:
M]JR7:6"VYE,B]-@84SE<68]3Y>JE6*>GE=JC9^4=H9;4;:HY2ZQHZWGJ>HIZ
MNG@JZ2>&JI*J&*II:JFE2>GJ:>=%E@J*>>)FCF@FC8,CJ2K*00;>_=>ZS>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`3=./S>[
MNWO[J1[ZWIM+"8SK6@W$E-L^OQF->LRN0W3EL9-45\U;B,G+.L='01K&@**O
MJ-B3[-8'CM]O\<Q1R2-,5JX)H`H.*$>9Z3N&>;1J8*%KC[>G3_0[6_\`/Y^Z
M_P#T)L!_]BOMO]X+_P`H]M_O+?\`077O`/\`OR3]H_S=>_T.UO\`S^?NO_T)
ML!_]BOOW[P7_`)1[;_>6_P"@NO>`?]^2?M'^;KW^AVM_Y_/W7_Z$V`_^Q7W[
M]X+_`,H]M_O+?]!=>\`_[\D_:/\`-U[_`$.UO_/Y^Z__`$)L!_\`8K[]^\%_
MY1[;_>6_Z"Z]X!_WY)^T?YNO?Z':W_G\_=?_`*$V`_\`L5]^_>"_\H]M_O+?
M]!=>\`_[\D_:/\W7O]#M;_S^?NO_`-";`?\`V*^_?O!?^4>V_P!Y;_H+KW@'
M_?DG[1_FZ]_H=K?^?S]U_P#H38#_`.Q7W[]X+_RCVW^\M_T%U[P#_OR3]H_S
M=>_T.UO_`#^?NO\`]";`?_8K[]^\%_Y1[;_>6_Z"Z]X!_P!^2?M'^;KW^AVM
M_P"?S]U_^A-@/_L5]^_>"_\`*/;?[RW_`$%U[P#_`+\D_:/\W7O]#M;_`,_G
M[K_]";`?_8K[]^\%_P"4>V_WEO\`H+KW@'_?DG[1_FZ]_H=K?^?S]U_^A-@/
M_L5]^_>"_P#*/;?[RW_077O`/^_)/VC_`#=>_P!#M;_S^?NO_P!";`?_`&*^
M_?O!?^4>V_WEO^@NO>`?]^2?M'^;KW^AVM_Y_/W7_P"A-@/_`+%??OW@O_*/
M;?[RW_077O`/^_)/VC_-U[_0[6_\_G[K_P#0FP'_`-BOOW[P7_E'MO\`>6_Z
M"Z]X!_WY)^T?YNO?Z':W_G\_=?\`Z$V`_P#L5]^_>"_\H]M_O+?]!=>\`_[\
MD_:/\W7O]#M;_P`_G[K_`/0FP'_V*^_?O!?^4>V_WEO^@NO>`?\`?DG[1_FZ
M]_H=K?\`G\_=?_H38#_[%??OW@O_`"CVW^\M_P!!=>\`_P"_)/VC_-TU87$9
MO97;6V-O_P!_]\;KPVY-B[YR=;0;PR&+R<=/D-O9C8\&.JZ!Z+#XV:FD$.<J
M$D!9E<,.+J#[<DDBN;!Y?"B21)4`*`C#!Z@U)_A'6E5HY@NIBI4\?D1\OGT/
MGLJZ4]%1_P":L?\`EVW_`,Y7[]U[J!\"_P#LDSJ+_J$W5_[W&Y??NO=&]]^Z
M]U$R&0H,305V5RM=1XO%XRCJ<ADLGD:J"BQ^.H*.%ZBLKJZLJ7BIJ2CI*>-G
MDED941%)8@#W[KW5`OR!_P"%,O\`*NZ0W7F=C;5[#['^3FZ=N9&+'[BI?C!U
MOE>S<'A]0J4FJI=Z-/AMFU]/3U5,8&-'7U#-*?0&4,R^Z]TY_'?_`(4J?RK.
M^MRX;9&X>T][?&C>FXJMJ3!8+Y0=>YCJNCRK/74>.H9*?=\KY79$4>2JJP+%
MY\C$5,;^0)87]U[J^NDJZ6OI::NH:FGK:&MIX:NBK:2:.II*RDJ8UFIZJEJ(
M6>&HIJB%PZ.A*NI!!(/OW7NL_OW7NO>_=>Z["D\@>_=>ZH!_X4#]8_)[?GPJ
M[\W#M'Y"Q=-?&KK/IU]W[YV1L+`RGMGO#?$6Z<?24>RMT;ZKZO[':G3$6-J(
MY:ZEQM/_`!/*U`,4DR4P*O[KW2E_F>X3,=Y[/_EE_!H[NW9LOJ_YE=X[;VS\
M@*C8^?K]J[CW5TIU5TQG.S]S=;4NX\64R.+H-]9/#T%+6M"Z224:RQZ@&/OW
M7N@-Z]^)6WOY;/\`,4C^,?P*.Y.K^F?FC\$_D-NFBZ>KM][AW'L+87R4Z/R6
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M5E92"/?NO=*G_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39T_\`\_.V-_Z$F+_^
MJ/?NO=4E]Y;UV?\``_YJX'Y9=5;HP.;^/OR+R%-L[Y+;.VQDZ6O3;.YJB371
M]AP8VCF<1++*S59<!?WEJ8S;[A![Q-YWMYO9/W+A]R]M1AR-O,@@W*-1VQ2L
M:B8`8%360?TA*O&0==2?9B_L_OD?=RNONX\QRH?>KDZW>]Y;N)"-=U:(*26!
M<Y.D4BIFB&!_]"8]&)_F=_#KX+_S7?C%D>ENW.P^OJ3,QTLNYNE>X<1FL'4[
MGZPWA4T7^XW<.$J34HU=@<G&4BR>.9Q3Y"D-CIE2*6/*V">&Z@2ZMF5[>1`R
M,IJ&5A56!'$$$$'KE_>V5WMM[-MVX1O#?V\K1RQN"KQR(Q5T93D,K`@@Y!'6
MO=_)Z_FQ]M_RUOD"W\F_^:WN_&IA-LUT&WOBE\J:W.KD=CUNW)Y#%M/:^8WI
M5OX:WKS/4Q1<#E*B17Q$_P#N-K?&JQF%WI-UN>GNOJ`&Q[.V-]`1_OY<6000
M"I!%18JP-P1P1[]U[KK_`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\_.V-
M_P"A+B__`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/_P#/SMC?^A+B
M_P#ZH]^Z]U[_`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\_.V-_P"A+B__
M`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/_P#/SMC?^A+B_P#ZH]^Z
M]U[_`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\_.V-_P"A+B__`*H]^Z]U
M[_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/_P#/SMC?^A+B_P#ZH]^Z]U[_`$V=
M/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39T_\`
M\_.V-_Z$N+_^J/?NO=>_TV=/_P#/SMC?^A+B_P#ZH]^Z]U[_`$V=/_\`/SMC
M?^A+B_\`ZH]^Z]U[_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39T_\`\_.V-_Z$
MN+_^J/?NO=>_TV=/_P#/SMC?^A+B_P#ZH]^Z]U[_`$V=/_\`/SMC?^A+B_\`
MZH]^Z]U[_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?N
MO=>_TV=/_P#/SMC?^A+B_P#ZH]^Z]U[_`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[
M_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?NO=>_TV=/
M_P#/SMC?^A+B_P#ZH]^Z]U[_`$V=/_\`/SMC?^A+B_\`ZH]^Z]U[_39T_P#\
M_.V-_P"A+B__`*H]^Z]TBMJ[OVMN_OK.U6U=Q8?<5-1=/[?@JY\-D*;(14TT
MN]MQR1Q3/322+&[H"0#R0/9@?^24O_/0W_'%Z9_XD'_2#_">C">R_I[KWOW7
MNN['^A_VWOW7N@S[C[CZP^/O66\NY.Y]ZX+KKK+K_"U>X-V[OW)6)18K$8RC
M0O)))(UWGJ)6LD,,:O--*RHBLQ`+D43S/X<8[OY`>9)\@/,]59@HJ>'4OJGM
M7KKO+KG9W;?4>\,)O_K??^"H=R;0W?MRLCK\1F\/D8A-35--/&?2X!TR1N%E
MAD5D=5=2!Z6)X7,<@HP_U5!\P?(]>5@XU+PZ$&Q_H?\`8CVWU;K7U^9'R!_F
M]X[>7R3[@Z8W#\1/AS\4_BK69:CV?COF!B*ZMW#\Q/[F;3IMW;KW+1;KQN=I
MJ3K+KS,UGDP^%J(Q]_,RR5$B`*%'NO=/W;G\Q?Y;]T]/?RW.O/AAU[L/J[Y=
M_P`QSK:L[;K<KWG29;,[%^,O5^QMCX#=O9N\,GMFF6BRN\<B^2W%28_`TDGC
M6J\_DE4$`>_=>Z'W^7Q\F_ESD.]?D/\`!3Y\'JG<?R.Z!VCUOV[M/N/I3%9#
M;>Q.\.D.TZO<6(Q6YIMG96IJ:K:.Z]L;KVQ5XS(4J$4\EHY(Q8ZG]U[H3OYB
MOR9[6^-D_P`'8^K*[!T*][_/GH'X^=A_QK!PYLU?6O81W)_>:BQ7FFB_A67G
M_AD7AK%U/#8V4W]^Z]TH/YI'R([,^*/P=[C[XZ=K,-C^P]EY7J.DP57G\/%G
ML5%!O'NKKS8^<%3BYY8HJAI=O[CJDC)8>.5E<7*V]^Z]TJ/DMW?V%M'NOX3]
M%]5U^&H=S=^=O9[*=@5&3H:3*2T?0G4.P,OO+LQ\?154B&EK\WF:G!XB&L4%
MJ5LB64%@![]U[JM?HC^;UN'"?`3:G=W=>&;NWY8=P_(?Y)]&?&SX[=1X*GQ&
M]N]MT]>=X;ZV#L?;N"PE.]7#A\!@-OX.EFW+N2ITX_%TD<E3.VMHXI/=>ZL-
MZE[3[3^,7Q3D[E_FA]]=+[;WJU74[JW[DMM8VEV9U5U1'N&9),'T]M"NFGJL
M[V'5[;5A11Y"59,CFJS488=)C7W[KW0@]%?.SX?_`":W%0;/Z#^0?7?:.[<C
MLW*]@Q;7VSDYYMQ4FT,'N"CVMELMFL+54M+DMO&ASV0@IWIZ^.FJB9D<1F-@
MQ]U[HV7OW7NO>_=>Z"/.?\SRZX_\1MVK_P"[WK#V81?\DR;_`)K1?\=DZ8;_
M`'(7_2-_A7H7/9?T_P!%1_YJQ_Y=M_\`.5^_=>Z@?`O_`+),ZB_ZA-U?^]QN
M7W[KW1O??NO=%6^<^Y]K;)^%WRPWEOC8=!VGLW:GQV[@W'NKK3*Y.KPV+[`V
M_A=B9S(Y;9N2RU`KUN.Q^Y*&F>DFFB5G2.4D`GCW[KW55?QW^<?Q<^/WQG_E
M*;AZ[^%.QNG:#^9UF^ONN]N;*Z;QFS,'@NI\EN?:-9O6GDW!D!@<77[OQ&+U
M3(IT+.SR,_!)!]U[H;NU.V>B?DC_`#,]U_RM.]?B%TUVOL:D^&%+\B9NQ-_8
M;`;HK*B++]C4VTZG8<&V\IMF<XZA,T25AJX:]',J*/'<!A[KW5M^TMJ[>V+M
M;;FRMHXNGP>U=HX/%[:VUA:0R&DQ&"PM'#CL3C*7RO)**:@H:=(HPS$A%`O[
M]U[I0>_=>Z][]U[HE?R+_E[_`!5^5F^\)V3W=LG=FX]W[>P=%MS%5^#[?[>V
M%1P8G'Y*LR]+!)A=A[XVWA:J9*ZOE8S2T[S."%9RJJH]U[I+?S->A>POD'_+
MS^37Q\Z4P4&X.P]^]6Q[2V+@*_-4N*AKZZGRV$F@I:C.9JH2EI]-%0N3+42^
MHKR23[]U[H'?Y@_Q0^1/;72WQ7[(^+4VRH?EM\).S]B]W]8;3[$KYZ'8?9$N
M+V1D]B=C=1[CSV/)EPU+O3:^?J8:>O4^."LAA9BJ$NONO=!5\-NE_GGWS\TO
M]G]_F`=0=7?&6KZOZ'W!\>?CS\=NN^QH>V\U0Q[]W7A]T=G]G[^WW0T-%AY*
MG-G;%!0XN@I5_8I5D:4!SJ?W7NCG=H]-=F]X_,;I?*[SQ$&.^+OQFPK=P;;O
MF*.HJ>U?E!FFRNV=JRY/!05+5='MOH[:4M7DJ62HC45.=RU/)'?[&_OW7NJK
M_C)\`OEIM'N/X>]3[^ZPVGL_J?X$_(OY-]_0_+C']@[>S>ZOD_C^[Y>RO[M[
M3IMD8_'P;OVSE\G'V2)-X2Y>7[:63#0BG>HUQE/=>ZV-O?NO=([?U+2R[+WE
M++2TTD@VGN*TDD$3R6&'K;#6R%K#_7]^Z]U@V%CZ!MB[*9J"B+-M';3$FDIR
M23A:(DDF/DD^_=>Z5G\.Q_\`SKZ'_P`XZ?\`Z]^_=>Z]_#L?_P`Z^A_\XZ?_
M`*]^_=>Z#CM[IO87=O6>].J-\X2BK=K;XP59A,G''2P)44_G2])D:*54#0Y#
M%UBQU%.X_1+&I]D7,W+NV<V[#=<N;PFO;[N(HWJI_"ZGR=&HRGR8#H;>W/N!
MS)[6<\;9[@<HS&#?]KNDFB;R;2>^-QYQRH6CD7S1B.JM_P"7!V7N3IW?F_OY
M<O?STT_8/3+564Z4W+D*:)1V%U#-(U5CXZ"6=-53+AJ299HD%V6E9XS_`,!F
M]P%[(<Q;GRQNUW[*<WO7=]L):RD;A/:'N4+7CH4AT'DA9/\`0CUG/]\[V_Y;
M]R.5=I^^5[30A>4N9=,>]6\=#]!NX&F0R`?")G!1V-`90K_Z..EI_-T_E(=#
M?S7_`(XUG5N^*7';+[?V=3Y'+=#]TT6,B?,=>[JGA#''Y(0+'49?8>XY88XL
MKC]7*A9X=-1%&WO)KKG%U1A_)<_FN=Q_%7O63^2W_-XIALKOOK>MHME_''O#
M>3Q2XOL;`?\``;:&RLWNVMC2GS]+F*!(_P"ZF?+D9"&U#4L*J--?NO=;E7\.
MQXX./H?_`#CI_P#KW[]U[KW\.Q__`#KZ'_SCI_\`KW[]U[KW\.Q__.OH?_..
MG_Z]^_=>Z]_#L?\`\Z^A_P#..G_Z]^_=>Z]_#L?_`,Z^A_\`..G_`.O?OW7N
MO?P['_\`.OH?_..G_P"O?OW7NO?P['_\Z^A_\XZ?_KW[]U[KW\.Q_P#SKZ'_
M`,XZ?_KW[]U[KW\.Q_\`SKZ'_P`XZ?\`Z]^_=>Z]_#L?_P`Z^A_\XZ?_`*]^
M_=>Z]_#L?_SKZ'_SCI_^O?OW7NO?P['_`/.OH?\`SCI_^O?OW7NO?P['_P#.
MOH?_`#CI_P#KW[]U[KW\.Q__`#KZ'_SCI_\`KW[]U[KW\.Q__.OH?_..G_Z]
M^_=>Z]_#L?\`\Z^A_P#..G_Z]^_=>Z]_#L?_`,Z^A_\`..G_`.O?OW7NO?P[
M'_\`.OH?_..G_P"O?OW7NO?P['_\Z^A_\XZ?_KW[]U[KW\.Q_P#SKZ'_`,XZ
M?_KW[]U[KW\.Q_\`SKZ'_P`XZ?\`Z]^_=>Z]_#L?_P`Z^A_\XZ?_`*]^_=>Z
M]_#L?_SKZ'_SCI_^O?OW7NO?P['_`/.OH?\`SCI_^O?OW7NO?P['_P#.OH?_
M`#CI_P#KW[]U[KW\.Q__`#KZ'_SCI_\`KW[]U[KW\.Q__.OH?_..G_Z]^_=>
MZ]_#L?\`\Z^A_P#..G_Z]^_=>Z]_#L?_`,Z^A_\`..G_`.O?OW7NO?P['_\`
M.OH?_..G_P"O?OW7N@DHX((/D!E5@AA@5NFL$66&)(@Q&^-Q`$B-5!('LP/_
M`"2E_P">AO\`CB],_P#$@_Z0?X3T,_LOZ>Z['U'^O[]U[K5"^6W\FW^=MW;\
ME.YNU>H?YUVZ^J^K-\;[S>>Z\ZUI)>S]N4^PMH5M2TN#VA'B]H9:GP"KM^B9
M:830J&J1'Y9/W';W[KW50?\`,_\`Y$?\[FF^%>\,UO[^8'O'Y\X3K[/P[_W'
MT?39_M#(9K-X#%T#K+F\-@]UY&MHLYDMGZ)*A*&G7SU$<SNBO+#&"OMR);=K
M6/MG)K_IQY)7R(.0.#'CFG3+]KB1LH!^SY_ZN'3Q_+9_D/?SP?\`9*^O*S9'
M\Q+=WP1Q.],M5[_P714NXNT:7+;5P&<HXVIJG,8G:F2H\=A\INK4E9/12KYJ
M3QIJ"R2RCWJX81PK;2'5.IX_P#^"OGG)\E.!Y]>05<R+A#_/Y_ZN/5MWP]_D
MZ?SL>BODUTQVSW+_`#I]T]N]3;'WQB,YV-U;72]G;BINP=H4LVK,[0DQV\,K
M4X%!G:6]/]Q(I>EU^:+]Q%]H>GNA`_F/_,O^3A\C,EWA\5/YM^UMS=,;Y^*.
M_MRU?4^T-XU._P"DW5VIA<[L^G?:?=_QSJNNHA1;TGW335#TN/H)Q4S462@$
M<T0+'W[KW0`=9=Z=H_$/"_R3_GS_`#!I>R,+UZ>BODQ\9N[.V^P=KY:JW/U1
MC.U\Y@-T_%_>/>]#A:2>;;E9NK9^S*.BRU<]/IIZMP9],CGW[KW5B?P*[RV-
M\Y_YG_R]^9OQYR%3O7XM[*^+_1_Q1VCW'#@\CB-J]I=G8S?F^>T-^ML7(92F
MH*K=&!V919O'T4U8(C"M9+(D;%?4WNO="'_.Z@RNU?C_`/&SY(4^TMX;UVK\
M//G3\9_DMVMAMAX>?<.Z*7J/9FXLCB=][CQN!I$>MS']V,;N$5TT,`\GV\+O
M^E3[]U[HC7\QK^:7\)OYA/QG@^$WP4[EQGRE^2/R?[+Z*V_L_KWJ[";FR-5M
M?![>[DZ\[`WEOCL2NKL/CL?LG:FTMK;=J9:NIK9$T3!8M)8FWNO=6F]3!>Y?
MYG7R.[&,:U6V?B'T=US\7-J5A>:2G;L?MF:F[P[?GHD(-*E9C]LP[0H)W0^1
M3KC;CW[KW6NA_+]_E?[G[$^&V=_F&_%CM'?47\Q7JOY8?*[>?QMFW5O3)U74
MU%M'8_?_`&AA=T?%9-G>:7`XWK?O2C.2_C-3X?O/XQDDG\B10Z&]U[H]7:OS
MLZ3^7]5_*;^;._:"+:GQGZ8^2?;6TOF;U[V#2"1_B1\M)NJ\ELWJ\=]4-3#X
MMJXWKSL;^)4=-ELC%#112Y6@KBT2NKI[KW0J=!]L?%;N?_A0%OG>7Q>S&QMZ
M#_ALZ7&]L=D]:1X^NV9O/>5-\@=MR89*?>&%#8+>F:V]MJ>*GK*FFFJ32K)#
M3R2!XS&GNO=;$GOW7NO>_=>Z"/.?\SRZX_\`$;=J_P#N]ZP]F$7_`"3)O^:T
M7_'9.F&_W(7_`$C?X5Z%SV7]/]%1_P":L?\`EVW_`,Y7[]U[J!\"_P#LDSJ+
M_J$W5_[W&Y??NO=&]]^Z]T47Y_['W;V;\%_F)USL'`9#=>^-]_&;NW:&T-LX
ME(I,IN#<NX>N]P8K"X;'I/+!"];DLA51Q1AG52[BY`Y]^Z]UI")E?YV:]3_R
MF^KC_)8[?>'^5KOO8V]\3ECO:C5^X)-E[(J=FKC\E2"F_P!^DF2%1]RSQ25I
MC9=`!!O[]U[JX[^6Y-_,0^2W\Y??OSA^7W\OO?WPJV>_P4;H/$KG]P4FZL'E
M]P8CM3";IH]&86/'U*9'(4-=4:8!3:%2D+%[FWOW7NMJ?W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW25WU_P`>/O/_`,-/<?\`
M[IJWW[KW7#8'_'A[)_\`#0VS_P"Z6B]^Z]TK??NO=>]^Z]U[W[KW56/\S3XW
M;NW?MC:'RKZ'22@^2'Q?J_[X[=J,?&WWF[MEX^0UVXMI521V:O$5.)9X(6N)
M$:>$`^;WC][[<C[CN5A;>X/*=4YUV%O&C*CNE@4ZI(B!\6D595_$ID3\?6=W
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M]0UU6!_(Y_G)]MX?M.N_E"?S5HZ_KCYL].UIV/U;V!OBH6G'=F,Q,`7%;7S.
M;J"M)E=\OBHTGP^421HMSX\HZLU6#]Q[KW6W1[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7N@=@_[*"R?_B&<%_[W.XO9@?^24O_`#T-_P`<7IG_
M`(D'_2#_``GH8O9?T]U[W[KW7O?NO=>^G(]^Z]U[Z\GW[KW7O?NO=(;<W5_6
M>]<QA=Q;SZYV'N[<.VBK;<SVY]H;?S^:P#)4+5QMA<IE<?5UN**5:"4&!TM(
M`WU%_?NO=*+/[?P&[,/D-N[JP>'W-M_+P&ERN!W!C*+,X;)TQ97-/D,7D8*F
MAK(-:`Z)$9;@&W'OW7NL>W-L[;V=A:#;>T-O8/:FW<7&T.,P&V\308+"8Z%Y
M&E>*@Q6,IZ6AI(VE=F*QQJ"Q)^I]^Z]T],JNK(ZJZ.K(Z.H9'1A9E96!5E8&
MQ!X/OW7N@YVATYU#U[E:W.[!ZIZUV-G,G!)39',[.V+MC;.6R%-+.M5+3UN1
MPN+HJRJ@EJ5$C([LK.`Q%^??NO=+;'X?$8F7)3XK%8W&39G(/ELQ-CJ&EHI<
MME9((*63)Y.2FBC>OR$E-2Q1M-*7D*1JI-E`'NO=1\!MO;NU,<,1M;`83;.)
M6JK:Y<7M_%4.&QRUN2JI:[(U@HL=!34PJLA73O-/)IURRNSL2Q)]^Z]T13YD
M?#_L+MS";:W!\6NQ]E]"]H[<[(G["WA@MR;`I-R]%_)Z@RNWZ[;&X^O?E#LK
M"RX7);]V[D\;7>>FK&GDKL?74\4L5R./=>Z1'PT^#_:/4W=F]/E#\CMZ=,YO
MMS-]3X+H+KSK?XV]85/5G0?2O4.%W7D=\93&;0Q68R.5W+FMQ;^W=71Y#+5E
M9)&D;4T4$$8C34?=>ZL[]^Z]U[W[KW01YS_F>77'_B-NU?\`W>]8>S"+_DF3
M?\UHO^.R=,-_N0O^D;_"O0N>R_I_HJ/_`#5C_P`NV_\`G*_?NO=0/@7_`-DF
M=1?]0FZO_>XW+[]U[HWOOW7N@.^3G;57T'\;^_>\<?AWW#D.GNFNR^S:#!(D
MDAS%=L?9^7W'28XI#:5HZNHQRHP7U:2;<^_=>ZTLL_\`('^8OOK^7-\$NK]R
M?-_=.Z_E)_/;^6VW<_#NC9%13X;*?&SXMY+!XF'>VP^L3CZN$X2BQE`E*]8*
M1*002S5=*)&D,L[>Z]U9E_*?VIVO_+__`)JORI_E33_)CMCY1?'B@^,G7_RE
MZUR7<F6&Z=\=4;ISVY*;;VX]KY3/*[+20[A2N^\CIT2GAGB$,JPJ_D>7W7NM
MHSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW25W
MU_QX^\__``T]Q_\`NFK??NO=<-@?\>'LG_PT-L_^Z6B]^Z]TK??NO=>]^Z]U
M[W[KW71`8%6`92"&5@"K`BQ!!X((^OOW'!X=;!(-1@CJB6I#?RP/G(M:@?'?
M#/YFYP1U:*&7"=3]Q22$K+;_`#./QE7/4D_A?L9R.?M![Q(<'V&]U_%'9[9<
MS2Y_@M+O_`J@FO\`S28^4(ZZHP%?OQ_=<-JU)OO)>VUK5#@S;KM`'#UDD15I
MZ^.@X?4=7M*RNJNC*Z.H9'0AE96`*LK"X96!N"/K[RV!!%1D'KE<05)5@0P-
M"#Q!]#U0A_/&_DH[)_FA]6T/8_5U70]6?.;I>C&6Z/[>HII,)+N%\1/_`!6A
MZ[WKF:`Q5L6,GR,0DQ63#&?"5["5#X6F1M]:Z*C_`")_YUV]N[MRY;^6=_,?
MI*[JC^8GT345NRZ6IWO"F#JN]Z/:T1BJ(ZI9C%3?Z5L700B>H2$M!GZ&U?2%
MB95]^Z]UM/>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!V#_`+*"R?\`
MXAG!?^]SN+V8'_DE+_ST-_QQ>F?^)!_T@_PGH8O9?T]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW01YS_F>77'_B-NU?\`W>]8>S"+_DF3?\UHO^.R=,-_N0O^
MD;_"O0N>R_I_HJ/_`#5C_P`NV_\`G*_?NO=0/@7_`-DF=1?]0FZO_>XW+[]U
M[HWOOW7NFK.X/#[GP>9VUN''4N8V_N+$Y'!9W$5T0FH<KALO1S8_)XVLA;TS
M4M=15#Q2*>&1B/?NO=4<_"K_`(3U?!SX.?)I/D]U[F^Z=\[AVA!NFAZ$V1VC
MOE=T;!^.F/WI]ZNX8.L<1_#Z:>&HF@KY8H9JN6>2!)'87F;R^_=>Z,%_+D_E
M1];_`,O_`'=WYW17]M=F_)/Y-?)?<#9+M7OGMVO-7N&IV[19.MR&WMC[>HS4
MUSXG;N(^[76)*FHEJ)(8_5'%%%#'[KW5K/OW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NDKOK_CQ]Y_^&GN/_P!TU;[]U[KAL#_C
MP]D_^&AMG_W2T7OW7NE;[]U[KWOW7NO>_=>Z][]U[HO7RF^.FSOE3T?O;IC>
M<<<=/N.@:;`YGQ"2IVQNNA5YL!N*B-BRS8^MMY`MC+`TD9X<^P7[@<E;;[@<
MJ77+.Y``3)6-Z5,4RYCD'^E;B/Q*67@>I?\`8CWCYC]AO=#;/<KEMB9K.6D\
M-:+<VKT$]N_D1(E=)/PN$?BHZ);_`"ROD7O'/X+>?Q#[[EDHOD7\7ZO^ZF36
MOE+56\]@T4BT6W-TT<LIUY$4M-X899@3Y87IYN3*?<7^Q/.NY7=I<^V_-Q*<
MY["WA-J.9K=3ICD!/Q:1I4M^)#&Y^/K);[[GLYRYM.Z[;]X;VG42>SG/,?U4
M1C';9W[@O<6K@8CU-K=4--+K-'^`=6K^\A.L"NM<?^>[_)(I?Y@FV,1\IOBU
M6)U1_,0Z&@HL]UGO_`UAVU4]I4FUI/XGB-C;FSE&T$U'N+&5,(?;N99O)0U%
MJ>5OM9#XO=>Z3_\`(A_G<57S:H,O\+/F=1OU-_,9Z$CK]M;UVINBC&V:SN&D
MVBS8_+[GQ.(J4@^TWUAV@_W/8J,<&]93J:9W6#W7NMECW[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]T#L'_`&4%D_\`Q#."_P#>YW%[,#_R2E_YZ&_XXO3/_$@_
MZ0?X3T,7LOZ>Z][]U[KWOW7NL,U33TX4U%1!3A[A#/-'"'(^H7R,NJU^;?3W
M=(Y)32)68CT!/^#IN6:&$!IG5%)I5B!_AZ]#44]0&-/405`0@,8)HY@I(N`Q
MC9@I(_K[\\<D1TR*RGY@C_#UZ.:*9=4+*ZUI4$$?RZS>Z=.=4+]^_/S^8SV1
MWQW/UU_+=Z`^+NX^K?C#ON+J/LWMKY:=JYW8=)W#WE3X+$[GW+TYT1C=MB,'
M*;.H,O34=?DLE(:7^(U:QJ`(G)]U[H1?D3_,9^56`ZO^%G7G0GQ$BQ_\P3YP
M4NYY<%T!\@-TC!;-^/V.ZQPL.6[?WGV_N/:KU-;DML[3-53Q8],=IGROWD+(
M%:\+>Z]T*W\OSYG_`".[>[*[Z^)7SAZ;V%TQ\OOCIB]@[TS'^B'<^4W9TYVY
MU)V?'EX]H]F]<5^=@ASV/I(<UM^NQF0H:TO/35E/R0'TK[KW0H?/3Y7[Z^*T
MWPYCV/M_:V?'R)^;72/QHW:=SKDV.&V;V8=P?QK-X#^&5E'IW'0C$I]L9_+3
MC4VN-N/?NO=/G\R#Y.[S^&_PX[6^177V"VWN3=NP\GU=18S#;M7(O@*N+?';
MNQ.O\F]:N)JZ&N,E+BMTSS0:)5'GC35=;@^Z]TI?D7W]O+K;L_X@=0]=8;`Y
MK=WR/[GJ\#N`YY:R:#;G3FP-A[@W_P!K;KH(*&NHICEZ2GQ]!CJ)Y#)3QU>3
MC,B..#[KW1">F?YOFW*7^7U_LY/R8PF,H=[YSO;O/HOJSI7IVARN8WKW;OK8
MG<^]>LNMNO.L=K9&MR&8SV^-XTVW:=ZHJWVE(7FJ)3#31L5]U[H]7QP[4[]Q
M7QN;NG^81%TA\?-V5?\`$]ZY_:NWMQ34>S>DMAU92HP.U>P.Q-V9G^$Y[>6"
MH&"YC)4XHL:U6S)3QZ%#O[KW0U=>_(+H?MN7#0=5]T=5]DS[BVY6[PP,&Q-_
M[6W9-F=J8W*Q8'([DQD6#RE<];@\?G)DHYZJ,-#%5,(F8.;>_=>Z%[W[KW7O
M?NO=!'G/^9Y=<?\`B-NU?_=[UA[,(O\`DF3?\UHO^.R=,-_N0O\`I&_PKT+G
MLOZ?Z*C_`,U8_P#+MO\`YROW[KW4#X%_]DF=1?\`4)NK_P![C<OOW7NC>^_=
M>Z]]>![]U[HD7\ROLKLKIK^7[\Q>U^G<QDMO=J]>_'SLK=G7V<Q&,@S.4Q6Z
M\-MRLK,/78_$U5%D:?(U4%9&K)$\$JN>"I^GOW7NF_\`E@=H=H=U_P`N_P"&
M?;?=>8R6X>V^Q/C[UWNOL7.9C&087*Y3=F7P=/4YBLK\3346.I\?5353L6B2
M")4/&D>_=>Z/;[]U[KWOW7NO>_=>Z][]U[IDS>YMM[9BIY]R;AP>WH:N5H*2
M;.9?'XF*JF1=;0T\F0J*=9I53DJI)`Y]^Z]T[23PQ0/52S0Q4T4+5$E3)*B4
M\=.B&1YWF9A&D*1@L6)TA>;V]^Z]U!Q&:PVX*),G@,OB\YC9))(H\AA\A29.
MA>6%M$L:5=%-/3M)$XLRAKJ>#[]U[KK'YS"9>HR=)B<SB<I5X2K^PS-+CLC1
MUU1B*X:KT63@I9I9:"K]!_;E"/P>/?NO=2H*VBJIJNGIJREJ:C'S)35\%/40
MS34-1)#'4QP5D4;L]+,]/,D@1PK%&#6L0??NO=2O?NO=)7?7_'C[S_\`#3W'
M_P"Z:M]^Z]UPV!_QX>R?_#0VS_[I:+W[KW2M]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW5.G\RCJ#>G5>[M@_S%.@:!W[-Z+>GH^W,#1*ZKV%U!(W@RB9**$!JM\-1
MRO%*QU,M'()!;[9?>,_OCRUN?+^Y6GO3R@O^[S:B!>(,"XM.#%Z<="DJQS2,
MZO\`0EZZ-?<L]Q.6N?.7MV^YU[M2@<D<TAGVF=Z']W[N!JB,9;""9PK*!0&9
M2G^C-U9UTKW!LOOSJS97;W7^03([5WQA*7,4#!U:>AFD717XBO1?\SDL17))
M3SH0-,D9_%C[GCE;F7;.;^7[7F/9WUV%U$''JIX,C#R=&!5AY$'K!_W,]N^9
M?:?GO<_;SFZ$P[]M=TT+X.EP,QRQD_%'*A61&\U8>=>A1]B#H"]:P7\]W^21
MN'Y35F'_`)@GP%K*KJ;^8WT*]#N[$Y'9M4FW*WO"DVD@J<=CI*Z!H(8.SL/3
MT_CQ59*?'D8+X^KU1/"T7NO=#9_(L_G:;>_F4]?Y/HWOFDI>JOG]T;238;N/
MJ[)TC;=DWW%M^;^$Y/L/9N#KA#54DT5=$4SN'T^;#UK&P-,\;+[KW6PC[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7N@=@_[*"R?_`(AG!?\`O<[B]F!_Y)2_\]#?\<7I
MG_B0?](/\)Z&+V7]/=>]^Z]T33>^/^<<V[<_)L7/=.4FSVR,W]W*?)4=6^1C
MQ8L*85[RT,[-6%>9+,5U7T\6'O#+G;;_`+\DW-E_)R/?\GQ<H&Y;Z1)DD,H@
MKV>*6A<^)3X^XC573VTZR1Y8N_NNQ\OVB<TVG,<G,0A'U#1N@C,OXO#`=>S^
M'%:<<]5/?S0NIOGIV-UCUKCJ_"/V%D:#?=76T-)T=C\P<EC*4X.IAKZG/-CX
MJ!A03,\*Q!F8&0'CCV%=VY4^^5O7*-U9\\3[=>WPOK5[5=F+0RJ!'="=IVI#
MJC.J$**M1\TX'K+'[IGN%]S;D;W=FW;>'7;N79.7[J)WWV)+B!YVN;)H5A4I
M<!9M"3$MI7L!`;B"X_RQ>J_GKUWT]OC%8_#Q]?U]7V#-79"@[OQ^7&:KX6PN
M-BH*S#-D(:YVQ:+%(C`,`)0>/K[OMO*WWS-FY2LK'D:?:[*X^JNFNEW@F:9B
MPMQ"T3:9J145P14=X)IFO23[U?/WW..=O>9]ZVIOWCRZ-BL8HI-CC6WMEE26
M\:=)4"VX,P#Q$MI/85!;``MHZOH?F53[TQ<G:V:ZFK]C::H9>#`4M7%F;FGD
M^T>@=*.G3R"JT:M;:=&KB]O8^]L;'[Y=OSG:R>ZE[RI/R/23ZA;5'%Q\#>&8
MB(D&H2::ZB5TZL5IUB1SQ=?=OFY;G3D*VY@BYHJG@M.R&'XAK$@+L:::TTBN
MJGE7K5'VE\9_Y5.Y.]_YJNQ_YN/<B[1[.ZL^7O='9G4FQNSN\-W=0X7KGH_M
M;&4'8VU>Z?CW@:+/;=I=U;OW?79"KDJ\E2P92N%7CJ:F$:JD:29;=8_]#3\7
M?D1E>E,E_(C^7OS8WYF\-UQOSX]?+WXQ1]_=V-481Z&IW5N?`;C^,VX>V,UE
M*:*';&;[8ZMV3!$M9D)($GF&N:6[LQ]U[JS7X@]P=;?*W^<1\S^]OC]NC;G9
MW3'4?P^^/OQHS_;.R*J/,[+S_<4_8W87:&7VIAMUT+SX7<\^SMKY.C-3)1RR
M14TM:8F8M<#W7NE!_/%RN.Z[Z4^(7R+W4N4AZP^+G\Q'XI=V=R9K%8FMS)VA
MU;B]RY7;FX]YY*DQ\4]8N%VY+N2GFJY$1S'%=B+`^_=>Z`+^;[\[OB'\A_A7
M/\:/CG\ANI?D#WS\I>U?COL7IGJOIC>^![(WEN;(Q]X]:[TRV0EPVU*W)U6%
MPV`VIA*JNK*NN%-3P11$.X;CW[KW1]=BQQ=T_P`TSMO=C1_>[;^$_P`<MF=(
M82H>2.6CI^W_`)%9"G[3[#GH(S%JBR>-ZTVMM>EF=7NL>0:-@+GW[KW6M1\&
MOY?'R)S7Q8I/YGOQX[@WCVC\J_BU\L_EWNOXS_&3=1Q,G2$O3>-[Y[0Q'=O1
M&&PE12,U#V)W9%+D:ZGW2DJ5]-D114J$0QZA[KW5H'R&^6?QT^?-=_)M[PSU
M7C*WX(=G_(3LJ+NW;'84D5+@=H?)W;_5>5@Z/ZC^06(K'7"4%3MKL^#+TKX_
M,J*2?.T]`0KB2#7[KW2GZ(VQ\2]K_P#"A#L6E^+M)UIC,E4?RTI*WNW#=4+B
M(-JXS?51W[M<8.2IQ^W6_N[B]T93:<5/+71TR132Q+32U`+,K'W7NMB7W[KW
M7O?NO=!'G/\`F>77'_B-NU?_`'>]8>S"+_DF3?\`-:+_`([)TPW^Y"_Z1O\`
M"O0N>R_I_HJ/_-6/_+MO_G*_?NO=0/@7_P!DF=1?]0FZO_>XW+[]U[HWOOW7
MND'VEUW@NWNM=_\`56Z*O/T&V^R-G;CV/GJW:N<KML[FH\1N?%56'R%3M_<6
M,DBR.#S,%+5LU-5P,LM/,%="&`]^Z]UK\;[^`/S7^%-)@LGT#_/4WOL_;.?S
M^-V;LOKC^8SA.N>ZMD;EWAN`28K&[2QF]\Q-M?>$U2<#31KB\52>::2MIS,W
MD\C@>Z]U8%\*MV?S9Z3LO+];?/GIWXGU'6M%L_(9#:7R&^,V^=TTO\4W%B,E
MB,51;<W5U/O6E_B>*K=TXZ:IRJU%#,U%1^,TQNQ4^_=>ZM!]^Z]U[W[KW7O?
MNO==A2>0/?NO=4I?,7^4Q\._DCW)W9\NOYDN_<EV_P!/;<V#@,=U;USO?>.X
MNLNG?BSLS:^'J9M^;EH9ML[LQ$.;W5O3-2&MJLK6A)841*:-&4+;W7NJI-N]
M7]T;T^%G\NK^7UV#V/WOA/CW\ROGWW1B<+7;MW7G<!WSN#^7!UQCM^]J=2=6
M;OW*RP[IPDN_=LX?%)-',R5PPDJ0N4U%![KW1O>O?B5M[^6S_,4C^,?P*.Y.
MK^F?FC\$_D-NFBZ>KM][AW'L+87R4Z/R6V:39/96R:?=F4S=?M:KW!C=]-#E
MBLAIZB2".4^I=/OW7NB9_"?.K\-\SUSW[MOXT]^=0YWH3X2;UZU_F'_WYV/N
M[9I^5/SJW7O?8.$Z@V9A*O<(2'OGM;=W;4F:GI-TXO[ZFAQ>5"M4+'.D:^Z]
MU=I_+E[=^..UIMV?&6N^1?5?9'SXS&Y-V=R_+W;NV\]'59BK[OW#/1S]B87"
MR,BX[+8OJ6%J/;L=#CIIWQ&.QL"SQ0L6O[KW5L7OW7N@C[3[%V%M[;F\,'G=
MY;;P^9DVCG&3%Y'+T=)7LM5AZP4S"FFE64K.?T\>K\>_=>Z8]C=S=24^R=G4
M\_96R8IH-J;=AFBDW'C%>.6+#T:2(ZFH!5E92"/?NO=*G_39T_\`\_.V-_Z$
MN+_^J/?NO=>_TV=/_P#/SMC?^A+B_P#ZH]^Z]U[_`$V=/_\`/SMC?^A+B_\`
MZH]^Z]U[_39T_P#\_.V-_P"A+B__`*H]^Z]U[_39T_\`\_.V-_Z$N+_^J/?N
MO=1*_MWI+*T-;B\GV'U]7XW)4E309"AJ]P8F>EK:&LA>GJZ2IADG9)H*B"1D
M=6!#*2#[;FABN(7MYU5X)%*LI%0RL*$$>8(-"/3I1:7=S8745]92/%>PR+)&
MZ$JR.A#(ZD9#*P!!&017JEGXT=G[4_E^_,#=?Q@K=\X7(_$_O_(UF^NB]TC.
M4M7ANNMWU;M_$-F9/("5J;'053I]KZV0,RTLIMY9#[Q0Y/GF]D/<Z3V]W%F'
M(6^R&;;I&/;#,QH8:G`J:1GAGPFXNQZZA^[=K:_?/^[;;^_NPQHWOGR1;I9\
MPP1K^I>62+6.^"C+%5K-7-%^H3_0TZNR/=?4`-CV;L<$?4'<F,!'^N/N/>6?
M#KEF""*CAUU_ILZ?_P"?G;&_]"7%_P#U1[]UOK4]_GG?RQL=N_L#&?S5_P"5
MYVIM?K+Y^])U46]]X;7V+N/#XZ?OG'X"'749C%4,,ZTM9VA2XJ)X*BEE1X-T
M8\M2U"M/XS+[KW5DW\F;^>=T9_,PZ-:G[(S.U^F/EMU;2T^)[QZBSN1AP0K*
MVE'VDV_MB4F5EBJZS:>6JH7^XIO748>KU4]1Z?#+-[KW5SG^FSI__GYVQO\`
MT)<7_P#5'OW7NO?Z;.G_`/GYVQO_`$)<7_\`5'OW7NO?Z;.G_P#GYVQO_0EQ
M?_U1[]U[KW^FSI__`)^=L;_T)<7_`/5'OW7NO?Z;.G_^?G;&_P#0EQ?_`-4>
M_=>Z]_ILZ?\`^?G;&_\`0EQ?_P!4>_=>Z]_ILZ?_`.?G;&_]"7%__5'OW7NO
M?Z;.G_\`GYVQO_0EQ?\`]4>_=>Z]_ILZ?_Y^=L;_`-"7%_\`U1[]U[KW^FSI
M_P#Y^=L;_P!"7%__`%1[]U[KW^FSI_\`Y^=L;_T)<7_]4>_=>Z]_ILZ?_P"?
MG;&_]"7%_P#U1[]U[KW^FSI__GYVQO\`T)<7_P#5'OW7NO?Z;.G_`/GYVQO_
M`$)<7_\`5'OW7NO?Z;.G_P#GYVQO_0EQ?_U1[]U[KW^FSI__`)^=L;_T)<7_
M`/5'OW7NO?Z;.G_^?G;&_P#0EQ?_`-4>_=>Z]_ILZ?\`^?G;&_\`0EQ?_P!4
M>_=>Z]_ILZ?_`.?G;&_]"7%__5'OW7NO?Z;.G_\`GYVQO_0EQ?\`]4>_=>Z]
M_ILZ?_Y^=L;_`-"7%_\`U1[]U[KW^FSI_P#Y^=L;_P!"7%__`%1[]U[KW^FS
MI_\`Y^=L;_T)<7_]4>_=>Z]_ILZ?_P"?G;&_]"7%_P#U1[]U[KW^FSI__GYV
MQO\`T)<7_P#5'OW7ND5M7=^UMW]]9VJVKN+#[BIJ+I_;\%7/ALA39"*FFEWM
MN.2.*9Z:218W=`2`>2![,#_R2E_YZ&_XXO3/_$@_Z0?X3T83V7]/=>]^Z]U[
MW[KW7=R/H2/?NO=>N3]23[]U[KKW[KW1:>Z_AI\2_DCN?9^]>_OC;TIW)N_K
M^=*C9FYNQ^N-K[MSFW7CJ8:R-,=DLQC:JJCIHZJG21869HE<7"W)O[KW0D]I
M=+=1=W==Y3J/N#K+8O9G5^:I::BRG7^]ML8C<6TJNEHM'V43X+)4L]`HHO&O
MA*HIBL-!'OW7NL?3O2/3WQZV'B^K^BNL-B]0]=X5YY<7LOKS;.*VIMVDGJG\
ME34IC,/34M.U54-;R2L&D>PN38>_=>Z7^8PV'W%BLC@MP8G&9W!Y>CGQ^6PN
M9H*7*8G*4%5&8JFAR..KHIZ.MHZB)BLD4J,CJ;$$>_=>Z*ATC_+Z^#?QKWQ6
M=F=`_$KX_P#3_85?1U>/J=Z=?]7[4VWN4T60F%174L.7Q^.BK*6&KE'[BQ,@
M<<'CCW[KW1E]M;&V;LZOW;E=J[8PFW\GOW<;[OWK7XK'T]'5[JW0^,QV%;/9
MVHB029')_P`(Q%+3"60LPA@1!Z5`]^Z]TU=9]5=;=,[639'4^QML==[0CS&?
MW"FV]HXBDPF&7.;JS-9N'<F6%#11QP"OSF=R,]7526U33S.[79B??NO=5O\`
MS-^!FX\YL6K?X7;`^-&&FWGW%6]H_*?XY]L]?X:GZ2^;6(SV`J\+N#`]HYC'
M;<SN3VMO."ODI<MCMP4M%/,N0HT^X25";>Z]TCOY?'P#W]TKWSO#Y/=K]6?&
M;XZ5;=)XKX[]._&SXJ4]?7[$Z\V-'OFN[!WONW=V^\AM[9\V]]\[_P!T?9N&
M3%T\>.H*..'7,[._OW7NKD/?NO=>]^Z]T$><_P"9Y=<?^(V[5_\`=[UA[,(O
M^29-_P`UHO\`CLG3#?[D+_I&_P`*]"Y[+^G^BH_\U8_\NV_^<K]^Z]U`^!?_
M`&29U%_U";J_][C<OOW7NC>^_=>Z['U%_I?GW[KW6B;_`,*.L#_.!C["Z9KM
MU;Z^*DWQ%R'\Q7HR'X982'%NO9F![1E&1'6E9V?4S;?5*K;5'6"N.45*BHU1
M%+HPL![KW6UG_+IQ/\QG#=,;DIOYFFZNC-W=XOV!DI=L9#H&@J,?M*'KDX?"
MKC*7(15&)PSOFUS:US.WB_S+1BY(/OW7NC_>_=>Z][]U[KWOW7NB5_(O^7O\
M5?E9OO"=D]W;)W9N/=^WL'1;<Q5?@^W^WMA4<&)Q^2K,O2P2878>^-MX6JF2
MNKY6,TM.\S@A6<JJJ/=>ZIY^=^"_FM;Y^94<>S/Y<^S_`)8?"'HRDV7-T+UO
MO#Y7[+ZLV;O+L_"TU/D*WN+MG:-=%F\EV)/MVMD6CV[B<R!CL<](U<\$]5,D
MD7NO=#[WWU/_`#'/F+\8OCU\BYNA.J_C%_,)^'OR9D[QZLZ&S_;-+V1UCV)M
M;%X3,;+SNQ-P]D[;HJ"/#)VALK<U6D<BH!05E-"9&",73W7NE3\-NE_GGWS\
MTO\`9_?Y@'4'5WQEJ^K^A]P?'GX\_';KOL:'MO-4,>_=UX?='9_9^_M]T-#1
M8>2IS9VQ04.+H*5?V*59&E`<ZG]U[HYW:/379O>/S&Z7RN\\1!COB[\9L*W<
M&V[YBCJ*GM7Y09ILKMG:LN3P4%2U71[;Z.VE+5Y*EDJ(U%3G<M3R1W^QO[]U
M[JJ_XR?`+Y:;1[C^'O4^_NL-I[/ZG^!/R+^3??T/RXQ_8.WLWNKY/X_N^7LK
M^[>TZ;9&/Q\&[]LY?)Q]DB3>$N7E^VEDPT(IWJ-<93W7NMC;W[KW2.W]2TLN
MR]Y2RTM-)(-I[BM))!$\EAAZVPULA:P_U_?NO=8-A8^@;8NRF:@HBS;1VTQ)
MI*<DDX6B)))CY)/OW7NE9_#L?_SKZ'_SCI_^O?OW7NO?P['_`/.OH?\`SCI_
M^O?OW7NO?P['_P#.OH?_`#CI_P#KW[]U[KW\.Q__`#KZ'_SCI_\`KW[]U[KW
M\.Q__.OH?_..G_Z]^_=>Z]_#L?\`\Z^A_P#..G_Z]^_=>Z)U\Y_B1@?EKT)G
M]@4T5'A=_P"#D&[NJ=T0Q14M1M_?>)C:7&G[J)4EAH,L%^UJ;$61Q)RT:^XQ
M]VO;VW]QN49=I6B;U`?&M)>!CG4=HU<0L@[&H10$-Q4=9(?=8]_+_P"[W[KV
MO-;J9^4+Q?I-UM?B2YL9320%#AGBKXL=0:D%.#MT&?\`+B^3LOR,ZBK]G]FX
MREQ'R(Z*R1Z[[EV]7T=-!E)LGB6EH*'=34K1K)XLVE$XG8`JM9%+]%9+D?LC
M[A7'.G+C[9OM8^<MI?Z>\C;#EDJJRD?T])#TP)%;R(J,_OF>P=A[-^X4/,7)
M!%Q[/<U0_O#9[B/NB$4H$CVNH8K`7!0')A9/,-2Q'^'8_P#YU]#_`.<=/_U[
M]S5UAYUV*"@4AEH:)64@JPI*<$$&X((CN"#[]U[K3Z_G=_R?NXNG.Y*3^<K_
M`"G%GV!\INIJ]]\=Y]3[2HXACNUL-2)KW'O+#[;0)09K*5^*1XMRX5D,6=H2
M\Z+]XC>>RJSL$0$N30`9))\AUHD`5/#I5?#+_A0%EODI\@.M_C?VSO;XY_';
MM7<6V=NY[=^U<OU3GMT46W]U5[PME.K/[WTW;6/Q<6:BHE\HJWA:2D>I6.II
ME\3GV)'Y=I`8(Y5;?$&MX!Y)3X5;\4J\609`X9!Z0K>U?65(M#@/\_7Y*?(]
M;;*T&+D5'CHL>\<BJZ2+2TKHZ.`RNK+&5964W!'!'L,\,'CTOZHI[PK/YW_>
M'<W?.1^)%+\7/B;T/T;N:JV5U7@_DIUQ7[ZWK\LZW`X>BS&6WY'E<-7+1=<=
M:9W*SG%8J8!:MHUEGE4%5(]U[H(=_P#\T3Y-=Q?#;^7#N7X[;&Z+^//R'_F&
M;SW?U]E^R^^99,ST+\>LOU32[ADWU-!+$M*V\\WO2OVM4Q;.H:B5%R*:PQ>1
M5U>Z]U/Z;_F/_*GISJ#^9]MSY68KX_?)+M_^73U'C.W,%W;\=,?48/J#M^CW
MCLC<>Z\!LG=^+,^1.R^P-JU6$3^,4=)*P7&5$4P",UW]U[H6OCQ\U^YNCM\=
MU[#^=W9W4?<6W-C_``>ZY^>])VOUCUI0]<5.T]O[QR^?VWG.G*_:5+FL]2YY
MCEL+$^U<AYXJ[,B>2&2,R(I]^Z]U9[\2ZCN3=/0VRM[?(W%[>Q?:78"9+?M=
ML[%;>HL5#UKMW=V1J<WLOK*M*&9\IGMC;3JZ.@R=;(=53DHIV`":1[]U[HQ_
M\.Q__.OH?_..G_Z]^_=>Z]_#L?\`\Z^A_P#..G_Z]^_=>Z]_#L?_`,Z^A_\`
M..G_`.O?OW7NO?P['_\`.OH?_..G_P"O?OW7NO?P['_\Z^A_\XZ?_KW[]U[K
MW\.Q_P#SKZ'_`,XZ?_KW[]U[KW\.Q_\`SKZ'_P`XZ?\`Z]^_=>Z]_#L?_P`Z
M^A_\XZ?_`*]^_=>Z]_#L?_SKZ'_SCI_^O?OW7NO?P['_`/.OH?\`SCI_^O?O
MW7NO?P['_P#.OH?_`#CI_P#KW[]U[KW\.Q__`#KZ'_SCI_\`KW[]U[KW\.Q_
M_.OH?_..G_Z]^_=>Z]_#L?\`\Z^A_P#..G_Z]^_=>Z]_#L?_`,Z^A_\`..G_
M`.O?OW7NO?P['_\`.OH?_..G_P"O?OW7NO?P['_\Z^A_\XZ?_KW[]U[KW\.Q
M_P#SKZ'_`,XZ?_KW[]U[H']R[0["HNPUWOUW%U^\%7LJEVID\=NJ7.8V2.6A
MSN0S$%;1RX*@K(YHY4R!1UD564H""03[,8)[,VGTUUXH(D+`II/%0*&I'ITP
MZR^)XD>GX:9KZ_+K+YOD5_SJ^E/_`#_;Y_\`K![]3:?XKG_>4_Z"ZU_C7I'^
MT_YNO>;Y%?\`.KZ4_P#/]OG_`.L'OU-I_BN?]Y3_`*"Z]_C7I'^T_P";KWF^
M17_.KZ4_\_V^?_K![]3:?XKG_>4_Z"Z]_C7I'^T_YNO>;Y%?\ZOI3_S_`&^?
M_K![]3:?XKG_`'E/^@NO?XUZ1_M/^;KWF^17_.KZ4_\`/]OG_P"L'OU-I_BN
M?]Y3_H+KW^->D?[3_FZ]YOD5_P`ZOI3_`,_V^?\`ZP>_4VG^*Y_WE/\`H+KW
M^->D?[3_`)NO>;Y%?\ZOI3_S_;Y_^L'OU-I_BN?]Y3_H+KW^->D?[3_FZ]YO
MD5_SJ^E/_/\`;Y_^L'OU-I_BN?\`>4_Z"Z]_C7I'^T_YNO>;Y%?\ZOI3_P`_
MV^?_`*P>_4VG^*Y_WE/^@NO?XUZ1_M/^;KWF^17_`#J^E/\`S_;Y_P#K![]3
M:?XKG_>4_P"@NO?XUZ1_M/\`FZ]YOD5_SJ^E/_/]OG_ZP>_4VG^*Y_WE/^@N
MO?XUZ1_M/^;KWF^17_.KZ4_\_P!OG_ZP>_4VG^*Y_P!Y3_H+KW^->D?[3_FZ
M]YOD5_SJ^E/_`#_;Y_\`K![]3:?XKG_>4_Z"Z]_C7I'^T_YNO>;Y%?\`.KZ4
M_P#/]OG_`.L'OU-I_BN?]Y3_`*"Z]_C7I'^T_P";KWF^17_.KZ4_\_V^?_K!
M[]3:?XKG_>4_Z"Z]_C7I'^T_YNO>;Y%?\ZOI3_S_`&^?_K![]3:?XKG_`'E/
M^@NO?XUZ1_M/^;KWF^17_.KZ4_\`/]OG_P"L'OU-I_BN?]Y3_H+KW^->D?[3
M_FZXX#;79]?V'AMY;\_N!1T.WMJ;IP%#1[0J]Q5]9656YLEM:L>>KDS-#0P0
M4U'%ML@!`SNTW-@/>Y9K)+1K>U\4L[JQ+!0`%##%"<G5_+K:I*91))IH`1BO
MG3U^SH:?9;T_T5'_`)JQ_P"7;?\`SE?OW7NH'P+_`.R3.HO^H3=7_O<;E]^Z
M]T;WW[KW2"[3I.QJ[K3L"CZ?RVV\#VO5;-W'#UKF=XT%3E-I8S?4F)JEVM6[
MGQU&R5E9@(,SX35QQ'RM!JT>JWOW7NM:3LG^:U_,H^/<";2_F%_R--Y=Z5>U
M=P85MJ=H_$6NH.[>JMQ;MI8LC54^Z]OX/.;=W+G]G3)1QJ]-),XJZ:7R)(8G
M94'NO=*[:?\`-]_FP_+\TF"^%7\FCLCJQJY\AB,KV]\Y]Z2]8=>;,R\51B=.
M0EVY2X?#;FW904./R#3204<BSS,-,(<HZGW7NMD+9$&[Z;9FTJ?L*NPN3W[#
MMO"1;UR.VZ6HHMNUNZTQU.-P5.!HZMGJZ;#2Y42FE24F58=(?U7]^Z]TJ/?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW25WU_QX^\_P#P
MT]Q_^Z:M]^Z]UPV!_P`>'LG_`,-#;/\`[I:+W[KW2M]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U21\ZMG;C^&/R*V9_,=ZCQ535;2KZG';"^6.SL5'
MIBSFU,G/3T5)O1J:)=!K(-$223,OHK(*9V/[DA]XK^[.UWWMCSK:^]7+<;-M
MSLL&ZPIPDC<A1,0,5("@L1B58B31G/73G[K',>S?>3]G=R^YI[A3HG,$*27W
M*MY*<P74:L[V88YT-5BJ`YA>90.Q.KDMF;PVWV%M+;>^=GY6ESFUMVX;'[@P
M&6HY%DIZ[%Y.FCJJ69&4G2QCD`=3ZD<%6`((]Y,[7N=CO6VP;OMDBR[?<Q+)
M&Z\&1A4']AR.(.#GKG#S)R[O7*',%[RMS'`]KONWW,D$\3BC)+$Q5E/RJ,'@
MPH14$'I2^U_1)T%G=74.U>^>K]W]3[TDR\&W=XXN7&UM3@<K6X?*TC-ZJ>JI
M*VAF@EUT\X5C&Q:.0#2ZE21[6[=?S;9>)>V^DRH:T(J#ZC]GF,CB#7IJ:%9X
MC$]=)].OG)[A_P"$U_8/7_SY[@PO5_='3N[*'KW`57;?3.WM\]QX[9F1WAO6
MLSE;1;7VINC-PUE7GZ%(]R4KQU*",U3RH(IV2-_-((@-FM7',$4C,-54M]1\
M02C)#MQ\->(;BP[>->D1^JD!LV4#&7IVZ?D/XCPIP''HX_2G_"@?^9+\$^YN
MG?A!_,JZ4Z6^(VT]G-C=N9[N#?O4/=.[/[Q;>I<Q$D^7PM7LSL"KPN3HLECI
MY/'F,:,A0TT@1I(=&M5#-W=37UR]W<4\:1B30`"I]`,#I?%&L48C2NE13UZM
MN^2W\\7X(_);M7=OQ9P?S^Z>^.OQ=V[38:A[Y[YI-SY+_2AWGC]S86/*UW4?
MQNJ,3B:^GVEMF;%U:T6Y=Z3M][3M-)18J%:A'K(TW5^D_P#S%NQO@YO[9_\`
M+$QV\MSQ+_(;W3C.S,!OG<'45%N6FZ7K-^;&QN&PWQVVQVQFMLXT;OVMU?1Y
M3$Y<15"/2BHS%,HJ9?[1]U[I??R@J7XFYOY2?,GI7^7-)ENP_P"4_-TCLH;D
MQ&8Q^=W%T%!\I-WYO/46_MJ]19_?M$^;W3A]Q=7O3/N:EDGK:&*MT*I75H/N
MO="EE_AO\=-K=[[C^*OPRZ,PU#L7X_;?V]\J_E72+G-T;GJ.R.VMGXG*9CX1
M_%C+[CW5F<_EFVE1;EQ\F[:K;BSKC:*@HJ!%@1:]B_NO=`M_*M^1'9F[_DA\
M4<9M[Y:=J_*;)?(+XG]H]L_S"NN=_P"\Z7>N)^+'?6!R^TDVOCL/@8,70MT-
M5G=V7S.UDVJ!3I4TF.6I^W9H3.WNO=;0?OW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z*C_S5C_R[;_YROW[KW4#X%_\`9)G47_4)NK_WN-R^_=>Z-[[]U[KW
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MJ@=6!TL8Y"48>I'`8$$`^T&Z[98[UML^T;G&LNWW,31R(>#(XH1^PX/$'(ST
M=\M\Q[URAS!9<T\NSO:[[M]S'/!*AHR2Q,&5A^8R.!%0:@GJF[X*[PW)\,?D
M3O/^7%VYE:JIVE7U&0WY\3MXY5],6=VKDIJBNK-F)426C:M@"2.D2L=%9!4(
M!^Y&/>,OM-N=][8\ZW7LKS)(S;>[-/M4S\'C<EC#4XJ0"=(.)%E``#(.NCWW
MI^7=F^\G[.[;]\OV]@1.8(DCL>:K.(9@NHU5$O"HSH:JJ7([H7A8GL?J[?WE
M3US&Z][]U[H'*SX[?'W([@FW9D>B>FZ_=51D_P"-U&YJWK'9=5N&?,_<+5G+
M39J?"ODI<D:I1+YVD,OD`:]^??NO=)?Y/?$CXW?,WK3)=1?)[I[9?<6Q,BDN
MC&;LQ4536X>KD32N5VUG(?#FMLYF`@-'5T-1!.I`]5N/?NO=::'R*_X3@_,#
M^6[V5G/E/_)GWMMSN;:^EZK=?Q(^0>U-C[]S&6P-++-6';>'J=Z8J?;G8F.C
M%A#%,V)S:$_LU4TIY]U[H]'\OK_A1Q\/>UU3X1?S$^@L!_+\[NP\B[-S?6O8
M6R8L)\<,[E&JV,N-7';@Q-+'UTV0R1$B46;IOL6D?4E;(2"?=>ZVH]AX+8&W
MMJ8JAZOPVS<%L:HA.3P=)L#'83&;3GI\F?O#D,3!MV&#$2PY`R^7RP@K*6U7
M-[^_=>Z?*'"8;&5F6R&-Q&+QV0SU5#79VNH<?24E9FJZGI8:"GK<O54\4<^2
MJX*&GCA229G=(HU0$*H'OW7NFG`;&V3M3([BS&UMF[4VSEMWUZY7=N5V_MW$
M8;);IRB"0)DMQUV.HZ:IS=>@E>TU2TL@U'GD^_=>Z5/OW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z*C_`,U8_P#+MO\`YROW[KW4#X%_]DF=1?\`4)NK_P![
MC<OOW7NC>^_=>Z][]U[K14_G[;+P/4/RV^</<?R[^'_9OR3V'\D?A=LWJ?X`
M=[[;VK4=E[&^,_;>"P^6HMU;7R^WI*B.BV%N3<.[*F/+P9B.]6(@?"DGFF">
MZ]T?3^2SELW\LOYAO=?\P3J/X\]O_'7XR9CX5='_`!WW=N7M?`3[/K/E7\A=
MBU.*CJNRJ+;,M=50O3;#VKAQADKH#(DR!=;++))&ONO=;6_OW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDKOK_CQ]Y_^&GN/_W3
M5OOW7NN&P/\`CP]D_P#AH;9_]TM%[]U[I6^_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[JNW^8]\4<K\B^HJ#>/64DF(^0_1.1'8O36X<>1!E)L
MGB6BKZ[:RU*:9#%FTHE,"DE1611<!6>\*^]WM[<<Z<N)N>Q5CYRVE_J+.1<.
M66C-$#_3T@I7`D5?(GK,/[F?OY8>SGN%+RYSN%N/9[FJ']W[Q;R=T0BE!C2Z
MTG%82Y#D4)A9_,+01_@I\KL5\NNA,%OUXX\7V!M^4[/[9VJ1X:K;F_,1&L.2
M5Z1],T%%EM/W5/J465S'RT;6//:7W"M_<;E&+=FHF\PGP;N+@8YU'<=/$+(.
M]:@4!*G*GH&_>H]@[_[O7NO=<J*3/RC=K]7M5UQ6XL936.CC#/%_924)J5#\
M'7HY?N3NL;NO>_=>Z][]U[KWOW7NJX?Y@/\`*A^$'\R[9TNW?D[T_B<MNJEH
MI:7:W<&UD@VUV[LZ0HH@?#[SHX#5UE#"\:DT%>M902`6:'\^_=>ZU;LG\2OY
MY_\`PGKR%;N_X6[[R7\QG^7WB*F?)9GHG<]%DLQO#9&W8F::I\>RZ6>KW#MB
MJ@IHKMDMI2U-$Q&NIQZKZ??NO=7H_P`LS_A0I\#_`.8Z,;L&/=!^.GR7-J+*
M]`=R5]'A,K7YF%GAK*7K_=51]GA-ZJE1&56F4TV54FSTBVO[]U[H^OR^E[_P
MVYNBY^H?D#E.K<7V'V]LSJ;/;;I>L.N-\1O1YVAW9ELINFCK]VXFMR=-DJ6#
M#PH$#M21Q(S-&6.H65'8$J"0HJ:"M!PJ?0?/K1(''SZ.-M#$Y[!;8PN'W1NN
MJWSN''T24V7W?6XC$8&JW!6*S%\A/AL!3TF&QTD@(!CIXTC%N![KUOI1^_=>
MZ][]U[KWOW7NO>_=>Z#WLKMKJ_IO`1[J[9[!V?UMMF:NCQL>?WMG\=MO#O7R
MPSU,=(,CE)Z:E$[4]-(^DL#H1C]`??NO=1NLNY^I.Z<9D,UU%V5LGLS$8JKB
MH<ED]C[CQ>Y:"AK)X%JH*:IJL54U,,4LU,XD0%O4A!''OW7NA+]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5'_`)JQ_P"7;?\`
MSE?OW7NH'P+_`.R3.HO^H3=7_O<;E]^Z]T;WW[KW7O?NO=:R7S*RO\X'Y@?S
M*^\OB5\)OEUUU\&.I/C+TSTYOJ"OW=UYB]X;J[TR';<&2GR>Y<53Y3"YJIR>
MU=J9'$OC))Z7Q4U!61".75//9/=>Z./_`"Z?B'_-QZ#[FW'NWYX_S&=F_+?J
M.OZ_R&"P'7&W>JZ#9%5A][39C"56-W0<E1X#$ZZ:BQ-'64Y@U,&-2K6]/OW7
MNKIO?NO=>]^Z]U[W[KW7O?NO=-&8W#@-O1TTV?SF'P45;4+1T<N9R=#BXZNK
M?]%+3/73P+/4/^$0EC_3W[KW3I-+%3Q2SU$L<$$$<DT\TSI%###$I>6665RJ
M1Q1HI+,2``+GW[KW3?B,UAMP429/`9?%YS&R2211Y##Y"DR="\L+:)8TJZ*:
M>G:2)Q9E#74\'W[KW76/SF$R]1DZ3$YG$Y2KPE7]AF:7'9&CKJC$5PU7HLG!
M2S2RT%7Z#^W*$?@\>_=>ZE05M%535=/35E+4U&/F2FKX*>HAFFH:B2&.IC@K
M(HW9Z69Z>9)`CA6*,&M8@^_=>ZE>_=>Z2N^O^/'WG_X:>X__`'35OOW7NN&P
M/^/#V3_X:&V?_=+1>_=>Z5OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[JBWY`T%;_+=^9V&^6.UJ.HB^+WR9R]'LWY%8''PL<=LW?%9,
M\E!OJ*EB'BIUJI6>K!`74_W<7'EC'O$SG&&;V0]SHO<+;U(Y"WR00[C&H[89
MF)(F`&!4UD'#/C)^-1UU,]H[NU^^?]VRY]@=^D1O?/DBW>\Y>GD(\2\LD4"2
MQ+'+%0!%3-%^G?\`T-SU>/05]#E:"BRF,JZ>OQN2I*;(8^NI)4GI:VAK(4J*
M2KIIXR8YH*B"171E)#*01[RNAFAN84N+=E>"10RL#4,K"H(/F"#4'TZY=W=I
M=6%U+8WT;Q7L$C1R(X*LCH2KHRG(96!!!R"*=2_;O2?KWOW7NO>_=>Z][]U[
MKL$CZ>_=>ZH:_F<_\)[?@G_,8@S78:;2?X^?)X1/D<+WOTS24&`RV7SU(GFQ
MTF_=MQ_9X'>&JJB4-5N*;)K>ZU:V'O8`)H30>O7NM&+YU_-+^:_\!>TOCK\1
MMY=J]\9[*_%[.4^4V7NWLJMJ,UF>RLW45$,46,PE73_=5TVU<73&.BH8I:NM
MR)0AC,8C&I&L]Q)L"PVNU(LMK.H9I"NH7-<&.GX44G3H^+5DYIT5(@O"\EP2
MLB&@6M-'S^9/&O"G6SGC?^%8/7G0VU.K=H_+?XG]]R=KS['Q.4[5S'6^,Q=3
M@-KYJKIX)H,=6)G7PE%69BIHI!45"T53+#"S:248E%)=^L;2QNPEL:,RAGB.
M3"Q_T,MP8CY9`PV>E5G+)-%608!H&\F'J!_J^71A-A_\*]OY/^[6BBW%GOD%
MUK+);4V[.FZK(TT1-KZY]F9O=#%0?R$N1^/9'TKZ.ML'_A1A_)B["@CFHOG+
MUUMF24HJ4N_<)OC951=S8!_X]MFE@CL?KJ<`>_=>Z.YL+^9/_+X[/2G;8?S7
M^+VXFJ[?;T]+W9L"GK9=5K6H*[.4M:";_F,>_=>Z-7@-_;$W6L3[6WMM#<J3
M@-"^W]RX7,K,K<JT38ZMJ!(K`\$7O[]U[HK7\PGNKIWHGXB]X[J[JW3MS:NW
M\GUMOC;&)GW%)1>.KW!N+:^4PV-BI8:LV;Q3UZO-(.(80S,?H"8;=ML^YS^#
M"55`*N[81%\V8^0_F3@=,SSI`FIZDG``XD^@Z$;XE;WZT[%^.G3^[>J-P[;W
M5M.NZ^V?2Q9W;`IEHJRMQFWL=0U8GCIU1X:J*6$W20!PI!%U():O;*XV^X:V
MN120?L8'@RG@5(R".K12I,@=#C_!\C\^C&>TG3G7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14?^:L?^7;?_.5^_=>Z@?`O_LDSJ+_J
M$W5_[W&Y??NO=&]]^Z]T'W;/:&S.D>KNQ>Y.QLG)A>O^JMD[F["WMEX:.JR,
MN,VKM##U>=SU?%044<U96R4F-H9'$42-(Y6R@D@>_=>ZT0_YDG:'\A/Y0_+V
M;Y8=I?S/?G;TIV3VCU%UEE\!ANE]L[UQ>W\/UMG=J8JMV_3X.9>O,CD\/2;C
MI((LA74)J%4UCL[QAS[]U[H_'\@+_AK7_9O.P/\`9*/YBOS<^6O:)Z+S_P#&
M>N_DBV[1LO%;.&[=G_?[IQHSNT<#2/GZ')FDIX[2LZPU4EEL21[KW6X+[]U[
MKWOW7NO>_=>Z["D\@>_=>ZUTOYN'PI^+]5FNSOG!\[NMOE1\^-ETF'V#U=\=
M?B5\?\%OBK/1=8F,SE9N;?&#P>P=WX67*;@W;GHQ45^Y*\*,3!'#`D<BA??N
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MV7')NC;B21[3VY&Z-G<6K(Z8:B5U8&JN&5A8^_=>Z5?]\=H_\]7MK_S_`&*_
M^J_?NO=>_OCM'_GJ]M?^?[%?_5?OW7NO?WQVC_SU>VO_`#_8K_ZK]^Z]U[^^
M.T?^>KVU_P"?[%?_`%7[]U[KW]\=H_\`/5[:_P#/]BO_`*K]^Z]U[^^.T?\`
MGJ]M?^?[%?\`U7[]U[KW]\=H_P#/5[:_\_V*_P#JOW[KW7O[X[1_YZO;7_G^
MQ7_U7[]U[KW]\=H_\]7MK_S_`&*_^J_?NO=!;W7M#IWOSJS>O4/8&;VOD-J[
MXPE5AZ]3F\0U1132+KH,M0,U5^SDL37)'40.+:9(Q^+CV'^:>6MLYOY?NN7-
MX3787410^JGBKKZ.C`,I\B.AU[9^XG,OM/SWMGN'RC,8=^VNZ6:/)"N!B2*0
M#C'*A:-U\U8^=.JUOY:W?>8ZNW!V!_+][ZW1BYM]]#235'5&[ZK*4OV&_P#J
M.5UFQ7V60DJ#%//AJ2IBDB0L7%)+XS_P';W!'L?S)NG+VY7?LOS@W^[S:B39
MN<"XM.*Z*\="D,@XB-M/^AMUF_\`?2]N^6N?N7MJ^^-[21`<D<T@)NT"4/[O
MW<#3*)`,()G#*QP#,NO_`$9>K6I.W^I8:EJ*;M+KF*L2H^T>DDWQMA*E*NX7
M[5H&R@E6HU&V@C5?\>\E^N<W2A_OCM'_`)ZK;7_G^Q7_`-5^_=>Z]_?':/\`
MSU>VO_/]BO\`ZK]^Z]U[^^.T?^>KVU_Y_L5_]5^_=>Z]_?':/_/5[:_\_P!B
MO_JOW[KW7O[X[1_YZO;7_G^Q7_U7[]U[JM7YZ=$_&+N7?WP][![#V7UOO[<N
M`^3FQ-J4V3RDN(K)4PF>PF[9ZB&>>*;S,U'5XR&6$ZP5`=.4=A[.-OWR^VV!
MX+<J4;*ZA4QMPUQ_PO2HK\_4#I--:13L'>M1QIC4/0^HZL$R]+T[EZ%<+G:;
MK+*XNGC2FCQ.7BVI74,,$2"..!:&L66".*.-0JJ%``%K6]E#,68LQ)8FI)XD
M]*0`!0<.BR]@?"K^7)VK$\/8GQD^(6[DD#+(<OUGU5-+(&^NN=,9',Y/]2U_
M>NO=$IWY_(@_D>]AO++F/AO\>\/42A@T^R=Q978K!F%M:0[3W9B:56'X_;L/
MZ>_=>Z)+OK_A*;_)%W<:J;"8[LGKRJJ`3$^TOD+43TE*QO8Q4.Y_[PPE5O\`
M0GW[KW14,U_PD-^&^'EEK>C_`.8I\F>I,CK9Z:0[IV!FH8.2437A/[FU[+'Q
MSY]1M]??NO=5[?S:/Y#7RQZE^$FVL7U+\QMQ?+O;W6&X\MN'>&W=P;CR,>YM
MRTV4F@7'U]=CL]OG=RF7"*JPT\=)4147T,D*2%9?8KL2NZ[2-ELJ0[@'U:0:
M"Y]`2?\`1%_"M=)'"AZ+Y0;>Y^JE[H:4K_!^7H?,\1]G4[X*[%_GR_RD_B_U
MENSXW=)8GY.;.WS32;UW]U9N7L#;>:I]G8FJATXG:F`ZZH=UX7?T=?3TX>K?
M)0EU4R"&*!H_JWNL\5MMT>RR%9[Z)JF3B(?6%&'Q"OQ5J`<+YGKULK23M=+5
M(6&!_%_2(\OEY^O5BG3_`/PL#Z>VON2'KC^8+\+>_/BCOVED6#-UF!I'WEA:
M*1GC3[B;;6XZ/9N\Z2E56+MXHJU@O"ZS]0QT8=7^_&#^</\`RS_F$E#!T5\P
M^G<WN"OCC>/9.Z-Q1]>;Y224N$I?[J;Z3;^6J:H^,G1`DW'Y]^Z]U89_>W:G
MCCF_O/MWPS()(I?XWC/'*C?I>-_NM+HWX()!]^Z]UP_OCM'_`)ZO;7_G^Q7_
M`-5^_=>Z]_?':/\`SU>VO_/]BO\`ZK]^Z]U[^^.T?^>KVU_Y_L5_]5^_=>Z]
M_?':/_/5[:_\_P!BO_JOW[KW7O[X[1_YZO;7_G^Q7_U7[]U[KW]\=H_\]7MK
M_P`_V*_^J_?NO=>_OCM'_GJ]M?\`G^Q7_P!5^_=>Z]_?':/_`#U>VO\`S_8K
M_P"J_?NO=>_OCM'_`)ZO;7_G^Q7_`-5^_=>Z]_?':/\`SU>VO_/]BO\`ZK]^
MZ]U[^^.T?^>KVU_Y_L5_]5^_=>Z]_?':/_/5[:_\_P!BO_JOW[KW7O[X[1_Y
MZO;7_G^Q7_U7[]U[KW]\=H_\]7MK_P`_V*_^J_?NO=>_OCM'_GJ]M?\`G^Q7
M_P!5^_=>Z]_?':/_`#U>VO\`S_8K_P"J_?NO=>_OCM'_`)ZO;7_G^Q7_`-5^
M_=>Z]_?':/\`SU>VO_/]BO\`ZK]^Z]U[^^.T?^>KVU_Y_L5_]5^_=>Z]_?':
M/_/5[:_\_P!BO_JOW[KW7O[X[1_YZO;7_G^Q7_U7[]U[KW]\=H_\]7MK_P`_
MV*_^J_?NO=>_OCM'_GJ]M?\`G^Q7_P!5^_=>Z]_?':/_`#U>VO\`S_8K_P"J
M_?NO=>_OCM#_`)ZO;7_G^Q7_`-5^_=>Z?:>HIZN"*II)X:JFG020U%-+'/!-
M&WT>*:)GCD0_U!(]^Z]UF]^Z]U[W[KW14?\`FK'_`)=M_P#.5^_=>Z@?`O\`
M[),ZB_ZA-U?^]QN7W[KW1O??NO=!)WZ=_#HWN#_15LK:G9'9O^C3>W^C[K[?
M34Z;*WOO/^[V0_NWM3=CU4U-3+MW/9;Q4U89)$002-=@.??NO=:H>>W1_P`*
M"H::')[L_DT?RF::DH*2@Q<.3W/FNL:.CHJ*F1*3&XV*NR_:L5/2TL":8J>`
M.%465!^/?NO=63?RMI_YHL_>^Z6^:/\`+O\`@W\4.JO]&N3_`(/V-\:9MGR;
MURN\CF]O28[:N1_N[N_<50VWJ_$25-5+KC11+3PG4=0]^Z]U?C[]U[KWOW7N
MO>_=>Z)7\B_Y>_Q5^5F^\)V3W=LG=FX]W[>P=%MS%5^#[?[>V%1P8G'Y*LR]
M+!)A=A[XVWA:J9*ZOE8S2T[S."%9RJJH]U[HEOR9S?\`.(^-WR%WKN;X>]/=
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M_L;^_=>ZJO\`C)\`OEIM'N/X>]3[^ZPVGL_J?X$_(OY-]_0_+C']@[>S>ZOD
M_C^[Y>RO[M[3IMD8_'P;OVSE\G'V2)-X2Y>7[:63#0BG>HUQE/=>ZV-O?NO=
M!CV9LW9^8VMO'*9?:FVLKE%VEGE7)9'!XRNKU6##UG@5:RII9:@+#_9&KT_C
MW[KW37L3K7KB;8^S)9NOMD2RR[3VY)++)M3!/))(^'HF=W8T-V=F)))Y)]^Z
M]TJO]&/6G_/N]B_^@E@?_J#W[KW7O]&/6G_/N]B_^@E@?_J#W[KW7O\`1CUI
M_P`^[V+_`.@E@?\`Z@]^Z]U[_1CUI_S[O8O_`*"6!_\`J#W[KW7O]&/6G_/N
M]B_^@E@?_J#W[KW7O]&/6G_/N]B_^@E@?_J#W[KW7O\`1CUI_P`^[V+_`.@E
M@?\`Z@]^Z]U[_1CUI_S[O8O_`*"6!_\`J#W[KW7O]&/6G_/N]B_^@E@?_J#W
M[KW7O]&/6G_/N]B_^@E@?_J#W[KW58'\R[XCRY;9NT_E!\?-IX'&=X_&>O&\
MJ/$8K`8]:3?6R*&5:W<6V\EBH*84V5DI*:-YX4=&+PF>(<R+;'OWVY*W.[M;
M7W)Y1JG.FPMXJE1W36ZG5)&0,MH%6"_B0R(/C'6>GW(_>+EO:MTW+[N_NR5E
M]FN>H_I91(1IL[]QHM[I"?[/6VA'<?"XAD.$/21^+<GQ.^6GR,VKW/M7I+I>
M:FW3\0:'.;@PLO7>R*RLVUV/0]TY&CW!3Y)&P\DL><H:Z-E2J<">:G\;AM+#
MW*/('.NV\_\`*MKS-MI`$R4DCK4Q2KB2-OL/PG\2%6&#UC5[[^SG,?L-[H[I
M[:<RJQGLIJP3%2$N;63NM[B,D4(DC(U4KH<,ARO5MO\`HQZT_P"?=[%_]!/!
M?_4/L9]1!U[_`$8]:?\`/N]B_P#H)8'_`.H/?NO=>_T8]:?\^[V+_P"@E@?_
M`*@]^Z]U[_1CUI_S[O8O_H)8'_Z@]^Z]U[_1CUI_S[O8O_H)8'_Z@]^Z]T`G
M:WP/^&G>.;QVY.VOC3U!OK.8BBAQ^,R6;VACY)Z"EIYIZB!*7[=((XGAFJI&
M20+Y%UFS6/OW7NA9VCT)TCL/;.%V=M#J3KS!;8V[0QXW"8>CVGAC2XZAB+-'
M30>:DEET*SD^IF-S]??NO=*+_1CUI_S[O8O_`*"6!_\`J#W[KW7O]&/6G_/N
M]B_^@E@?_J#W[KW7O]&/6G_/N]B_^@E@?_J#W[KW7O\`1CUI_P`^[V+_`.@E
M@?\`Z@]^Z]T6SY;X#96T_C]V?#M[HC*[XW+N[8^]-F;:Q/4W4U+N[<T.X-P;
M0SE'AZR6EQ5)%-C<?'D&C5JQW2.&1T)9;W&U9D8,I(8'!&"/L/6B`10\.I?Q
M?IM@[\ZIVM#D^@MP[$SNSML[0VUG*7MSIN+8^9R&9H-M8Z'(5F-CR]&\N8I(
MZN%U>IC9D,@(U'Z^]=;Z%3L#XU?'7M?"5NW.S.A^G=_8+(TLM%6XS=W6^T<]
M2STTZZ)8F3)8FH*AU^I4@_X^_=>ZHN^4'_"5S^4A\B'R&7VCU3NOXR;OJQ+)
M3YSH3=M7A</35LLHE^Z.R-Q1[AVJH1AZ8Z>GID4$Z;>_=>ZJJK/^$Z7\W?X,
M3UF8_EF_S*<=OC;<4YJX.J.\L4N$CR&A'M2S4FX*'LGKZL=XE2(,8,>-1)U(
M#Q[KW4(?S7OYVGP$E2@_F-?R<ME]V;&QM28\IV_T=U[1XXR44/C>IKCF^OZ+
ML3K]DCIV/,]+C5+_`%8#CW[KW1__`(R_\*=?Y+7><U'@NTL)6_%'>DC+3Y#$
M=U]0XR3;M!6C6)Z9MY[-HL_CHDIY%TL]9%16/]FUS[]U[J_[IGL+X9?(K!4^
MY>AMT?'+N#"5,"5$==UU6=?[L6.-XTE'W4.'-54T4HC<%DF1'6]F`/OW7NAJ
M_P!&'6@^O76Q?_02P7_U![]U[KW^C'K3_GW>Q?\`T$L#_P#4'OW7NO?Z,>M/
M^?=[%_\`02P/_P!0>_=>Z]_HQZT_Y]WL7_T$L#_]0>_=>Z]_HQZT_P"?=[%_
M]!+`_P#U![]U[KW^C'K3_GW>Q?\`T$L#_P#4'OW7NO?Z,>M/^?=[%_\`02P/
M_P!0>_=>Z]_HQZT_Y]WL7_T$L#_]0>_=>Z]_HQZT_P"?=[%_]!+`_P#U![]U
M[KW^C'K3_GW>Q?\`T$L#_P#4'OW7NO?Z,>M/^?=[%_\`02P/_P!0>_=>Z]_H
MQZT_Y]WL7_T$L#_]0>_=>Z]_HQZT_P"?=[%_]!+`_P#U![]U[KW^C'K3_GW>
MQ?\`T$L#_P#4'OW7NO?Z,>M/^?=[%_\`02P/_P!0>_=>Z]_HQZT_Y]WL7_T$
ML#_]0>_=>Z]_HQZT_P"?=[%_]!+`_P#U![]U[KW^C'K3_GW>Q?\`T$L#_P#4
M'OW7NO?Z,>M/^?=[%_\`02P/_P!0>_=>Z]_HQZT_Y]WL7_T$L#_]0>_=>Z]_
MHQZT_P"?=[%_]!+`_P#U![]U[KW^C'K3_GW6Q?\`T$L#_P#4'OW7NE?145%C
M:2"@QU)2T%#2QK#2T5%3Q4M)30K^F*GIX$2&&);\*H`'OW7NI/OW7NO>_=>Z
M*C_S5C_R[;_YROW[KW4#X%_]DF=1?]0FZO\`WN-R^_=>Z-[[]U[KWOW7NM#/
M_A03G^G^POF)\WNM?G_WQVWU3M/JGX0;1WY_+(ZDQV;W!L_I7N/MJNH<A5;[
MW)F,EA*"MH=W;_Q6^:6''T^/K3"/MM0\JB--7NO=61_RA?D3M;OO^:I\FL_\
M1>YMX]T?%'._"#XT9CY"5E;/FJKJ7:7R^V_C,%LK$X/J"3*4=%!3D]=8:7^+
MQQ+ZZQ)/4ZQH5]U[K:I]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]TE=]?\>/O/_P`-/<?_`+IJWW[KW7#8'_'A[)_\-#;/_NEH
MO?NO=*WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW3-N,E=O9]@;%<)EB#_`$(H*@W_`-A[>ME5[B-'`*%U!!X$$BH/RZ8N7DCM
MI)(B5E5&((P00"001Y@\.M+GJ;MCOO9?R@II))MW;?ZKQ_8F<ES4V#VC!@L?
M5[1PE3D<PM-)F,;B:!JRF=*)'C#SD32:;DEK^\5.6.;_`'PL??FXV3<+6]A]
MJH]TO]:KML4-N;6%+AHSXJ6Z5&E$TN7JW;W&O76GW']J?NB[Y]S"SYNV>]V:
M\^\?/RQLPADEWZ>ZOUW&ZELDF7Z:6^E*MKFE\2$0Z8ZN1&-/6WST9\A.H/DG
MLBB[#Z:WIB]X;=JUC6H%))XLKA:QXUD?&Y_$3:*_$9&'59HYD6]KJ66Q,_<I
M\Y<N<[[4N\<M7*7%H<,!AXVI71(A[D8>A'S!(SUSG]U/:'W$]EN:9>3_`'(V
MR?;MXC)TZQ6*9`:"2"452:,^3(33@P!QT,WL3]1KU[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UZ]OI[]U[KNY/U)/OW7NNO?NO=>]^
MZ]U[W[KW7B`RLC`,C*59&`965@0RLIN"I!Y!]^Z]U7_\F?Y5O\N[Y@P5'^S"
M?$/I7?&5J$E']ZX-HT6U=[123,7DGBWEM$8/<GG:0ZB6J6#'Z@CW[KW5`'<W
M_"0;XV8_.S[^^!_RT^1WPZWW`3/B88=PU6]-O4]2NJ6**+*4.0VEOJAIS4!;
MDY*JTH+:&/OW7N@6/2__``K3_EUF27K;N3K/^9'U5A618<#NFLQNZ=Y5N-IG
M63Q+2;U&R^Q8JFH4Z`M-FL@ZJ./?NO=*?9/_``K+WMT+N&FZ]_FA?RV>^/C5
MNJ"=*/*;GV1092;#&2$O!4UM+M+L6DV[634TE2ED%)EZY;7L[\>_=>ZO-^+/
M\]O^51\OVQN/ZK^7O76%W9E!^QL3MB>IZGW>LG[*^`46]X<305DYEF"`4M3/
MK8'3<6)]U[JVJAKJ+*4=/D,964F1H*J,34M=05,-91U,1)`E@JJ=Y()HR1]5
M8CW[KW4KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]T5'_FK'_EVW_P`Y7[]U[J!\"_\`LDSJ+_J$W5_[W&Y??NO=&]]^Z]U[
MW[KW6J]_-:^;VQ*_N7YY[$[[^&7QW^0OQ1_EJ_$S9':6X<AW5A<9N'=N[_E;
MW]78E.AMF;4BKU%1A=BFG>9<L]*R5$Y5SK.F)??NO=.O\A3Y+?)#9V^D^"'R
MF^,'Q?\`COD]_P#Q6V3\\N@D^*FT:38NWY>I>Q-Q+MZHVEV5M3'))3T6^<#6
M5,!$\LTE0Z%XW>70CCW7NMHSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW25WU_QX^\_P#PT]Q_^Z:M]^Z]UPV!_P`>'LG_`,-#
M;/\`[I:+W[KW2M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]UTRJZLCJKHZE65@&5E8$,K*00RL#8@\$>_<,CCU[C@\.B4#:^W9
M/G/5X.3;N%?`M\1J2M;#/B:)L.<A)W%DJ9ZPXUH#1&MDI!XS)H\C1^F^GCVI
M>\O)(S%)+*T3*5*EV(((H0030@C!'ITFBLK*"9;F&&)+A'#*ZHH96!J&#`5#
M`Y!!J#GHK_=W\M3+;/WK6?(+X`[[?X[=SJ[UN7V+#(Z]1=BD-YYL;E,&5FH\
M.U?("&'AEHRS7\<1]?O&?FKV.N=LW-N</9^[.S<RBI:W!I:7'F59:$)J/EI:
M/).E3W==%?;'[ZNW\Q<LQ^T7WMMJ'./ML0$BOF`.[;?C2)(I\/,(QP.M9@!\
M<@[>G?X_?S,*5MYT_P`?OFOLF?XR?(.F:&AIZC/AZ;K+?TI;P19';6Y*B1Z*
M@&1<!HUDFDI7+6CG)L@4\G>^:?O,<G^Z-J=CYO6B@R56VG\@R2$D)JQ2K&,D
MT60G'1?[N?<FG'+3^[GW9MS7G?VB<%V6"C;E8#XC'<VR@/)X8J&*HLJT[XJ=
MW5KT<B2QI+$Z2Q2HLD4L;*\<D;J&22-U)5T=2"""01[R%5@P#*05(J".!'6`
MKHT;F.0%74D$$4((P00<@CS'7/WOJO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=(K?G6O77:>#J-L=F[!V7V)MRJ0I4X'?&V,+NK$3*P(/DQ^<HJZE8BYL=-Q^
M/?NO=47_`"@_X3&_RA_DP,CDJ;X^U'0.[JXRS)NCX^[BK=B1Q5TB.%JI-HS#
M*[)E59'UE%Q\>MAR??NO=52U_P#PG%_FD?":JJ=P_P`JW^;/O_&8FAO-C.IN
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MKW7O?NO=>]^Z]U[W[KW7O?NO=%1_YJQ_Y=M_\Y7[]U[J!\"_^R3.HO\`J$W5
M_P"]QN7W[KW1O??NO=>]^Z]UI[_SRNJ_Y$,'SDV!V!\__E-VOTYW'G]H[!S'
M<'1G4\F[,YM3O/8>P,M42]9-W3M_;6U]Q#$M331S0T4OEIJFIHX?0JZ%E]^Z
M]T:W^5!\B_Y87R0_F*_++N_XG_(WMGY']^=U=;;>AAQNYNMMY[/ZU^-OQWZN
M;;>&PG4.PJC<N,H**EH:[<>12M6*)M<I#%8841VE]U[K9;]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TE=]?\`'C[S_P##3W'_
M`.Z:M]^Z]UPV!_QX>R?_``T-L_\`NEHO?NO=*WW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%1RGP<^*&:[#J^V,ITMMN
MK['KLH,S5[P>OW(F9GKQDQF0S3Q9N-!2C*C[@4X44XE]6BY/OW7NC7DWY/OW
M7N@'^0'QHZ5^3^RZC8O=&R,9NO%LLAQN19%I=Q;=JW4JN0V[GH5%?BJN,F_H
M;QN0!(CKQ["/./(O*_/FV':^9K5)X:'0_P`,L9/XHY!W(?L-#P8$8ZE7VC]Z
M_<OV-YE3FGVUW2>PO@1XD8.JWN$!_L[B!OTY4/#N&I<E&4YZJ@DV_P#-W^6%
M(U5M&7._,CX:4$AEJ=L5KR2]P]3X96=Y#C9E6HEKL9017-XUEI"!ZHJ:^KWC
MT;/W4]AV,FW&7F3VT0U,1K]7:IQ[3DZ5%?A#1G%5BX]9])N_W8?OQ((.85M?
M;C[R,HHMR@`VC=9J`#Q!VA)9#3XBDH/"2:FGJT'XT_+?HOY8[27=73N\J7+3
MTT:?Q_:60TX[>6U:IO2])G\!,YJJ;1)Z1,GDIY#^B0^YZY']QN4_<+;_`*[E
MNY5Y%`\2%NV:(^CQG-/1A5#Y,>L&O>O[OONG[`<P'8?<;;9+>)R?`NXZR6=T
MOD\$X&EJC)1M,B_B0=&5]CGJ%>N[$_0'W[KW77OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z[N1^??NO=$O^2/\NKX+_+RAJ:+Y'_%7I7M.>J256SN;V1B*
M7=L+RQ>'STN\<1!CMT4M1&GZ'CJU9#]+>_=>ZU]N^_\`A(1\(<]FIM\_#WO3
MY"?#3?L#2U>(DVQNFHWMMC'Y`OJA-*F2J\3O;'4\()"B#-AEN3<_3W[KW1;?
M]DO_`.%5W\O-0_QN^7^P/GOUA@HE-)LOLG)TF;W'-011M&E#%B>UXZ#.Q&*F
MC`"4.Y6/D/H5C[]U[I\P'_"H_P"6GQ5RU+L[^:I_*J[FZ7JX7AIJ_L'K3'Y[
M&X1P&C^XKXL)ONEDP=<L-/JD=:/<,H/&D*/?NO=7+_%W_A1)_*.^5K8_';3^
M5NV>L]UY%X(8=F=\T=5U+F14SA_\F3);B"[3JWC*>HP9*5.1SS[]U[JYO;FY
MMM;QQ-+G]H[BP6ZL%71K+19K;>7Q^<Q-9$Z+(DM+D<7455'41O&X8%7(((/O
MW7NGSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=%1_YJQ_Y=M_\`.5^_=>Z@?`O_`+),ZB_ZA-U?
M^]QN7W[KW1O??NO=>]^Z]UK$?/[^4]V?W7\E/YD'8QV7\?=X;$^8_P`3.J8^
MENVNS<KAJ+L+HWY3?&R>CGV!UQCEW'3FGI.O^UJBCCJ*ROHYHVA$3Q3@Q7#>
MZ]UC_DT[+^<._?F]WY\LNYO@[LW^79TGN#XW===+9WJ?9M;MZ?!]\=Y;)W+4
MUH[KQ&.VTE)B*>GQ>WZNKQBUM-!XYZ5H(3/4O&[K[KW6SW[]U[KWOW7NO>_=
M>Z][]U[KBS*BL[LJ(BL[N[!41%%V=V8A550+DG@#W[KW6&.LI):1:^*JII:!
MZ<5:5T<\3T;TI3RBI6J5S`U/X_5K#:=/-[>_=>ZPXW*8S,TB5^'R-!EJ&1WC
MCK<964]?2/)$Q21$J:226%GC<68!K@\'W[KW7&CRV*R,U?38[)XZOJ,54?9Y
M2GHJVFJYL;5\G[6OBIY9)*.H])]$@5N/I[]U[J3%54L\M3#!4T\\U%*L-9##
M/%++23/$DZ0U4:,ST\KPR*X5P"58'Z'W[KW6?W[KW25WU_QX^\__``T]Q_\`
MNFK??NO=<-@?\>'LG_PT-L_^Z6B]^Z]TK??NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[Z@@\@BQ
M!Y!!^H(^A!]^XX\NO<,CCU5W\EOY:.TM^;M;O;XQ[LK?C%\E,=))D*3=^RA)
M0;4W96ZC(U-O+;U#HIW6N;TS5$,9\@_ST4WN!.>/8W;MVW#^M?(EPVQ<[(2P
MEA[8I6])47`U>;*,_C1QCK.?V4^^QS!RIR^/:OWOV^+GCV5F`C>TO:275JG#
M59W#U8:!E(W;M_T.2/H,^J?YCF_^DMY8WH3^8]L0]/[YFD6@VQWEAZ:2HZB[
M#5'\,=?/7TRO2X:>>UWEC)IT8VECIN1[(N7O>O>.5MR3E'WKM#MVZDZ8KY`3
M:7`&-18=JU\V6JC\:Q\.AOS]]S7E+W.Y<F]V/N9[K_6+E=1XESLDS!=VV\D5
M,:QL0TRKP56_4('8\W0\?,O8V"W[E?C'O+!=G]M86BWUWQUIUOD)^IN\=_;)
MVQN78FX,=O/*5D1HMD[CH,-725\])"WWJ*:EHXD590@M[R2M[FWNX$N;61)+
M>0`JRL&5@>!5@2"#Y$=<Z[VQOMLO)-OW&&6WOX7*21R(R2(RX*NC`,K`X((!
M'1]=H;6H-D;9PNTL76Y[(X_`4,>/I*[=&X,ONK<-5#&699LMN//U=?F<O5MJ
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M&N@>HJJ/879&1SN.PSDAWCH6SFP*J'#UB/ICBO6;?F!2^MB"??NO=,8^9/\`
MPJO_`)=P9?DA\2-@?/\`ZNP<3&LWIUIC*3.;DEQM/)&\]?\`Q7JK^%[BBJ)(
M&TQFOVS(0U]2L??NO=&/Z%_X5\?"3-Y:+9/S%Z*^0GPVW]!(E'EXMQ[5J=\;
M8H:Y-2U?W+8VCQ.]L?!!,-%I<*7!^H'OW7NM@KXW_P`Q;X+?+NBIZOXY?*KI
M3M*HJ8U=<#A-\8BEW;%=$9TJ=GY>?';GIY(2X5P]*-+<'GW[KW1T2"/J#[]U
M[KKW[KW7O?NO=`SWSW#+T5UUF>R6ZU[`[.Q>VZ7(Y;<.*ZY3:LV<Q&WL/B:_
M,Y?/S4^[=S[5HJBBH*/'L#'#/)4N[*$C:Y(]U[KW2';F3[FVF-W5O4O9'4U%
M5QXRKPE#V4-F+DL_B<MC8,G29?'Q;,W=NZGAI/#4*CI42P3+)<:+<^_=>Z&;
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5'_`)JQ_P"7;?\`SE?OW7NH'P+_
M`.R3.HO^H3=7_O<;E]^Z]T;WW[KW35G,[A-L87+;DW+F,7M_;V!QU9F,YG<W
M7TN+P^&Q..IY*O(93*Y*ME@HZ#'T-+$TDTTKK'&BEF(`)]^Z]UIK_+O;?P7_
M`)H'\V+N+K#YU?S#,/@_B7U9T%U+N;XA=7]7_)796S.J=_YO.0Y:'N#?.7WS
MC\O7X%M_[/W)`M&<?4M%D9**IC>,M3)8^Z]T8K^33MCJ3XU_S-OE=\.O@K\P
MLE\D/@=MCXX['['K]C[L[5QO:*=/?(3*[RFQ%1MGJ[<5/4K_`!S"S[/IQ79B
M:ABDHZ:>M@AGD^X5;^Z]UM9^_=>Z][]U[KWOW7NNP">0/]]_Q/OW7NJ9_P"9
M?V#OKY`[0^07PSZ-W#N':F!V9\?.Q.QOF-W-M.2HH<EL39C[!W!EMC]#['W'
M"?%0]M=QU%&)ZYDURX;:<,TS*)J^C/OW7NB";[QFY.[_`.77_(=^#J[SWEL+
MKOYHXWH?:_?^1V/N#(;6W=N3I#K'XUU':6[.O*'<]$?XGBJ;?U=B:"DK)8G6
M62C,JAK.;^Z]T)'6_P`4,3_+3_F&#XN_!*MWAL+I7YE_!;Y";PP_3V=[`W%N
MW9/7GR7Z.R.VJ79W8FQQO'*YO([:FW-C-\F+++Y6IIY:>.4\C2/=>Z)E\(-U
M4?P]S?7W?VV>@/D#UAF>COA'O?8W\R-=^[-WUM3_`&97YV;DWML+"]1[+Q=3
MNN-*7NSN+=_;$V;:BW%A_OJ6/%90*U0L4R(ONO=7>_RYNU/C[MA]W_'#*_(K
MJCL?Y]9S<>Y^ZOF!M3;.Z*7(9V+N;<TE%/OC;^*A#M35>&ZEI/LMN0T5%)*<
M708V$3QPLS7]U[JUKW[KW2#[#S.'H]G[QI*O+8NDJFVEN`K3560I*>H(DP]8
M(R(9IDDLY^AMS[]U[J)L/<NW$V-LM'W#@E=-I;;1U;+X\,K+AJ)65@:BX*L+
M'W[KW2K_`+S[:_YZ+`_^?C'?_5/OW7NO?WGVU_ST6!_\_&._^J??NO=>_O/M
MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/18'_S\8[_`.J??NO=>_O/MK_GHL#_`.?C
M'?\`U3[]U[KW]Y]M?\]%@?\`S\8[_P"J??NO=>_O/MK_`)Z+`_\`GXQW_P!4
M^_=>Z]_>?;7_`#T6!_\`/QCO_JGW[KW7O[S[:_YZ+`_^?C'?_5/OW7NO?WGV
MU_ST6!_\_&._^J??NO=>_O/MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/18'_S\8[_
M`.J??NO=>_O/MK_GHL#_`.?C'?\`U3[]U[KW]Y]M?\]%@?\`S\8[_P"J??NO
M=>_O/MK_`)Z+`_\`GXQW_P!4^_=>Z]_>?;7_`#T6!_\`/QCO_JGW[KW0;]K[
M'Z.[QV;DNO\`MC';%WQM+*QLM1BLW6XNH6&4J0E;CZD5"U6-R$!-XYX'CE0_
M1O9'S#RUL7->VOM',-K%=;>_%7%:'R93\2,/)E((\CT-.0?<3G;VNYDAYNY`
MW*ZVOF"`U66%RM1YI(OPR1M^*-U93YCK4\^9=3W#\7^WH^B/C+N3L6HZ=ZWH
M:&NVG%24TF](<7EI*S(UHR$667'UD,.6H(\CXDFB,<L<?]"S$XP^ZVY^\OM+
M<;/R7[+1;D>3X=H1JQ6*W59I+BX+ZYC;R5>F@$5%`%P*]=2?NQ\O_=9^]+M/
M,WO#][63ET^Z]_S1*A^HW9]L(M8K*R6(16HO8`L1?Q&#!2"[.`Q`H+LOC)_,
MZ^-%+1;?Z$[<W_D>O^U=H8[%X7(9;L6*6EV_NNMJ*2"K3(8_=;23TB+,U8$T
MUIIV5EL";<31N7O;R/8\Y77)_,4S[=O=L8D8SIX<,CM%&Q97':FIF.'T9X5Z
MPML_N7^]6\>U]E[N^WUC%S!R1?BXE5+"47%U:QI<SQI'-`3XC%4C4AH_$U*0
M32O5JE-N[:=;24]?1[IVY5T-9$D])6TV<QD])50R*'CFIZB.J:*:)T8$,I((
M/N3+>X@NX%N;5TEMF%5="&4CY,"0?R/6+U]8WNV7C[?N4,MON$1H\4J-'(A&
M"&1P&4U\B!UE_O/MK_GHL#_Y^,=_]4^WNDO7O[S[:_YZ+`_^?C'?_5/OW7NO
M?WGVU_ST6!_\_&._^J??NO=>_O/MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/18'_S
M\8[_`.J??NO=>_O/MK_GHL#_`.?C'?\`U3[]U[KW]Y]M?\]%@?\`S\8[_P"J
M??NO=>_O/MK_`)Z+`_\`GXQW_P!4^_=>Z]_>?;7_`#T6!_\`/QCO_JGW[KW7
MO[S[:_YZ+`_^?C'?_5/OW7NO?WGVU_ST6!_\_&._^J??NO=>_O/MK_GHL#_Y
M^,=_]4^_=>Z]_>?;7_/18'_S\8[_`.J??NO=>_O/MK_GHL#_`.?C'?\`U3[]
MU[KW]Y]M?\]%@?\`S\8[_P"J??NO=>_O/MK_`)Z+`_\`GXQW_P!4^_=>Z]_>
M?;7_`#T6!_\`/QCO_JGW[KW7O[S[:_YZ+`_^?C'?_5/OW7NO?WGVU_ST6!_\
M_&._^J??NO=>_O/MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/18'_S\8[_`.J??NO=
M>_O/MK_GHL#_`.?C'?\`U3[]U[KL;HVT/IN/`_\`GXQW_P!4^_=>Z+AWU\9?
MAA\I,-/@?D5TWT#W+CJA=+?W_P!M;-S]?$+ZO\DR]5$V7H6#&]X9XS?F]P/?
MNO=:^OR1_P"$HO\`*F[7K:G<_0>]>Q_B%OCSM68[(=7=E4^XMK4%6JLT!AVU
MO*KR5=20K4$.5I,C2D``(4'OW7NB8)_+1_X46?R^"E1\%/YGFR?ECUYAI7DQ
MO5'=&[J45\]!`RRQ40P?;=3NC;T<\YN&6CS]%=>`PX'OW7NIU%_PI6_F6_"6
MII=O_P`T[^5MN.AQ%`11Y'MOIBHKL%C*YT,E/_$(OO)=Y=>5QJITUHD&:HU*
M<!??NO=6W?%[_A3G_*&^3)Q^-F^0-3T'NRN$$1VS\@MN5NQ8EK9FBC^V@W=3
MOF-E5`,LME8Y",L`257W[KW5@WS#^7GQCVU\*N\.SZKO3J_);!W%U3OG;.$W
M5MW>NW=Q8;)Y;=>U\MA,5%29##Y&KI98ONZL-*X?3%&C,QXM[7[=MT^YW'@0
MZ54"K.QHB+YLQ\A_A.!TS/.D":GJ230`<2?0#H=_C7VOU?OSH#IS<^R>P-J;
MFVW6]<[0IJ#,T&8HEIJI\=@*"AJ@(YIDFADCJ*=@R.`P_P!8@EJ]L[BPN&M;
ME=,J_L(/!@?-2,@CCU:*5)D$B&JG_50_,=#=_>?;7_/18'_S\8[_`.J?:7IS
MKW]Y]M?\]%@?_/QCO_JGW[KW7O[S[9_YZ/`_^?C'?_5/OW7NG>&:&IBCGIYH
MJB"50\4\$B30RH?H\<L;,CJ?Z@D>_=>ZR^_=>Z][]U[HJ/\`S5C_`,NV_P#G
M*_?NO=0/@7_V29U%_P!0FZO_`'N-R^_=>Z-[[]U[I#]F];[+[CZYWWU-V/A8
MMR=?]F;1W#L3>VWYJBJI(<WM7=6+JL+G<5+4T,]-6T\=?C:R2(O%(DBAKJP-
MC[]U[JE7_H&<_DI?]X88?_T9G;W_`-G7OW7NC:?#G^4!_+Q^`G968[>^*'Q[
MQW5?8>>VC7;%RFXJ;=^^MP35&ULCDL7EZW%BEW-N3,4425&0PM-(72-9+Q`:
MK7!]U[JR[W[KW7O?NO=>]^Z]T2KY%_R^_C)\J=^8/LGN3`]B9/=>W<'1;=Q=
M1M/N_N7KC&1XO'Y.LR]+'48#K_?.VL'65*UU=(6J):=YY$*HSE%51[KW5:_R
MX_D!?%KNBL^3_<^U-^?,'!]R]SXC>F[WVCL;Y2;QV1UUN7LM]C?P#;=-7[9I
M_%BI*"N?$T-'/]Y*ZO3+ID?1]/=>Z!O:O\I[Y$_'_P#EM?`RB^,%355?S=^&
M/8_7ORHCZW^07:60WCM'=6_\EU>NP.]/C]1[VIIIZ?9^R<YALE54^%6C<XZ@
MJ8(B&\;M(/=>Z-3\-^H?G=\A?FPOS^^>O2/7GQ67JKH3<7QY^//QXV;V31]N
M;GB?L#=F&W/VCVAO_>V)HZ/`@Y4;7H*#$T-*-45,)'E`<AG]U[HY_:O3W9O>
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M&B)9F8DDGDGW[KW2J_T4=6_\^WV)_P"@I@__`*B]^Z]U[_11U;_S[?8G_H*8
M/_ZB]^Z]U[_11U;_`,^WV)_Z"F#_`/J+W[KW7O\`11U;_P`^WV)_Z"F#_P#J
M+W[KW7O]%'5O_/M]B?\`H*8/_P"HO?NO=>_T4=6_\^WV)_Z"F#_^HO?NO=>_
MT4=6_P#/M]B?^@I@_P#ZB]^Z]U[_`$4=6_\`/M]B?^@I@_\`ZB]^Z]U[_11U
M;_S[?8G_`*"F#_\`J+W[KW7O]%'5O_/M]B?^@I@__J+W[KW7O]%'5O\`S[?8
MG_H*8/\`^HO?NO=>_P!%'5O_`#[?8G_H*8/_`.HO?NO=>_T4=6_\^WV)_P"@
MI@__`*B]^Z]U[_11U;_S[?8G_H*8/_ZB]^Z]U[_11U;_`,^WV)_Z"F#_`/J+
MW[KW7O\`11U;_P`^WV)_Z"F#_P#J+W[KW7O]%'5O_/M]B?\`H*8/_P"HO?NO
M=%`^7#]6;&KOBYBO+U[LR2K^5/5HK\<T^V]N25NW9</OK[M*RD>2C>KP\L\*
M^175H7=!<$CA3'>WD2A(II50<`'8#]@/226PL9W,D\,+R'S9%)_:03T.G87Q
ME^,/?>UI,=O3J3K#>VWLU']Q!E*+!X=*B4.CQQUV+W)@TIZ^*103IE@J!R/8
M0YHY-Y7YU@-OS1907@/!G7]1?FL@I(I^88=2I[:>\'N=[.[DNZ>VF]W^T3A@
M2L$A$+TIB2`UAD!I0AT..JN]T_RE=]]*9JNWS\%^\'VI42-YY^H^Z,70[[V'
ME8X27CQL61R%!73TL#'T+YJ>5E4_YT6O[@:?V-YLY+F;</9[?KBS2M397+&2
MW:E>T&C`5/FT;-_3'6<5E]]?VM]X[6/8_O=\B[?O,VD(-YVM!:[C'Y:V4%=9
M'$Z)54G_`$,]-.,^;.X/CO7TNUOY@GP7H.O(%E6C7NGJK9&'W7UOD=),?WU1
M3T]-4K1I*;,PBJG<"]H1;3[U![Y\U\F3+M_O!L5Q:)6GUMJOB6[4_$5J0*GR
M60M_0ZW??<F]KO>&TDWW[HW/.W[Q*5+_`+FW1Q:[C'YZ%9@NLC@-<2@X_4-:
M]6=],[U^'GR$P<>X.FINF-^43QK)-3X?#[>.8H-2AC'D\%444&8QTB<@B:%.
M0;7M[G?EGG;E3G&V%URU?6]VE,JK?J+\GC-'4C^DHZP?]R?9OW1]H=T;:/<C
M8]PVFY#$!IHCX,F:5BG75#(#_0<\16G0U?Z)^K?^?;[$_P#03P?_`-1>Q3U&
M?1;OEKTKM>I^/_:.=V743=3;DV+L7>V^\1N3KG`;%H\K49':^T,YD\?C<E_>
M':6XZ&KPDU=#')/`(4>0QJ-8%P?=>ZD_&'X_[3P/4VT\SNS*Y7M[,[WVML_=
ME9E.S\-L#(U>)J\MMK'5=;08,;<V7MBGI,7+55#2>-XY6#'AK<>_=>Z,1_HH
MZM_Y]OL3_P!!3!__`%%[]U[KW^BCJW_GV^Q/_04P?_U%[]U[KW^BCJW_`)]O
ML3_T%,'_`/47OW7NO?Z*.K?^?;[$_P#04P?_`-1>_=>Z]_HHZM_Y]OL3_P!!
M3!__`%%[]U[KW^BCJW_GV^Q/_04P?_U%[]U[KW^BCJW_`)]OL3_T%,'_`/47
MOW7NO?Z*.K?^?;[$_P#04P?_`-1>_=>Z]_HHZM_Y]OL3_P!!3!__`%%[]U[K
MW^BCJW_GV^Q/_04P?_U%[]U[KW^BCJW_`)]OL3_T%,'_`/47OW7NO?Z*.K?^
M?;[$_P#04P?_`-1>_=>Z]_HHZM_Y]OL3_P!!3!__`%%[]U[KW^BCJW_GV^Q/
M_04P?_U%[]U[KW^BCJW_`)]OL3_T%,'_`/47OW7NO?Z*.K?^?;[$_P#04P?_
M`-1>_=>Z]_HHZM_Y]OL3_P!!3!__`%%[]U[KW^BCJW_GV^Q/_04P?_U%[]U[
MKW^BCJW_`)]OL3_T%,'_`/47OW7NO?Z*.K?^?;[$_P#04P?_`-1>_=>Z]_HH
MZM_Y]OL3_P!!3!__`%%[]U[KJHZFZJJZ26@J^L]@5=!.K+-0U>S\!54<RL"K
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M0S-%593'QT6MI*>&%XP[2MQX1&&INTT-MMT6SS%9]PB-3)_OD><*,/B`/Q5J
M%.%\^O6RM).UTE4@8</XOZ1'E\O7SZV7_P#11U;_`,^WV)_Z"F#_`/J+V%^C
M#KW^BCJW_GV^Q/\`T%,'_P#47OW7NO?Z*.K?^?;[$_\`03P?_P!1>_=>Z6M#
M0T.,HZ?'XVCI<?04<2P4E#0T\5+24L*?HAIZ>!4BAC7\*H`'OW7NI7OW7NO>
M_=>Z*C_S5C_R[;_YROW[KW4#X%_]DF=1?]0FZO\`WN-R^_=>Z-[[]U[KWOW7
MNM7SYQ=D?S:_D3_,N[A^(OQ$^9_1WP#ZOZ%Z3ZF[(VO6]F;.QF<W+\A5[*CK
MDW-N?"5.>P>:&3PNQ,[CFQ=2*'Q14$QC68/+4`K[KW1P?Y:_0/\`-9ZM[NW-
MG_G!_,MZ5^8O555UWD\9A.M>NMD8/;N;P^])<W@Y\?NVHKL9MS#3-CJ+%T]9
M3/&9&5GJ4-O3?W[KW5X7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NDKOK_`(\?>?\`X:>X_P#W35OOW7NN&P/^/#V3_P"&AMG_
M`-TM%[]U[I6^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[HHOS>[5^1W4?0F3S/Q*Z3'?'R"W/NG9_7O7>U\C/)1[*VSD-
MYYJ#$U?9G9]?3S05M%UOU]CI)<CDVIR:B1(EB07DU+[KW5:/Q,^8GSNZG^:.
M6^%7S\W]\6?D-)F?CCOGY+8?M[XJX?/;8R/5%)U[GL1@\YL/MS864J\A_#Z'
M-0USSX/)%X9:V>&:`JYC)3W7NBMT'S^_G';EZ"W%_->P&S/B=C_@)A:+<G:.
M)^(6:BW.?D7N7XN;3JZQ<GV>W;5-*=MXKLRLVOC:C,TF&:%J-M"0,+N`?=>Z
M,=\M_P"85\G\EV%VI+\0-X=0]?=:_%OX![%_F#[P_P!,.RZC<]7\B,!V)+O#
M,X#K&BRD.XL*.K<#!M/KVI2JS<$=?4ID<E$H31$0WNO='EVW\L]]=[]\_&7J
MSI>CHMO8FMZ-VM\K?E75YS$C-5.R^O\`LG;,E/U#T[CZAIZ:/&;_`-][KJ*J
MNEE>/RTN&P$T@2]3$??NO=6,^_=>Z"K?71/2/:.4I<WV7T]U?V'F:*C7'T66
MWOL/:^ZLE1T"2R3I1TM;G,775-/2I-,[A$8*&=B!<GW[KW2\V]MW;^TL)C=M
M;5P>(VUMS#4J46'P&`QU)B,-BJ.,DI28[&4$,%'14R%B0D:*H)^GOW7NGGW[
MKW4')XO&9J@J<5F<;09?%UL30UF-RE'3Y"@JX7%GAJ:.KCEIYXF!Y5E(/MFX
MM[>[A:WNHTEMW%&5U#*1Z%2""/M'2JQOK[;+M+_;9I;>^B;4DD3M'(A'`JZ$
M,I'D00>JP^YOY2_QRWSG)-_=-5NZOB]VK%*U91;QZ;R4^%QQKKF02UVV(YX:
M!D>6Q<4KTI(O>]_<$<S?=XY+W6Y_>O++W&Q;\#J66S8HFKCF*H`!/'PS'7K.
M'VV_O`?>7E?:QRG[D1V'//(3+H>SWB-9I-'"B7)4R5`X&42TQPIT"O\`?G^:
MK\,O1O\`VA@/G1T]C>)-U;,UX?MW'8R%=3SUN-C@-7D:F*$78M35NLJ;RB]_
M86_>OO\`^V6-WMHN:N6D_P!%AJMVJ@5)8`:R:>J2U\W\^I,_JO\`<,^\EW<I
M;C=^UGN--PM;RDVTR2DT"I(6T1J3P`DAH"/TS2G6+M;^;=\:NP/CSV)BY,3V
M+LW,;OVUO#J;/XK=NV*BBK]B;PW;L_+4>.I\M2T_W$V0I`DTDK20`'1"055R
MJF2-B]\_;G<>59.;-[NI]IM(+Q+21)[>1Y$N)(WE"4B#U&B-SJQE:$`]03S?
M]QC[P6Q>Y$'MKRK9;=S)N-YM,NZ6T]E?6RV\UA#/';/,'N'C`82S1KX>3W54
ML`3T>[X+_(?8_P`ANC-NY#84>2?$["P^V]A5&2KZ=J6/+5^W\%28RLK*&GE5
M*F*F-10O82JK6(/N3-CWW8>:MBM^9N5[H7FQW1D5)!&\=6B<QR`I(%8484R,
M^76-G/\`[?\`._M3SG>>WON-8?NSG"Q2!YH/&AG"I<1B:%A)`SQG5&0:!JC@
M<]'+]F701Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[HNORXS."POQ@^0<N?RV(Q%-5=*=K4=--F<A18ZGJ*Z38.X
M7IZ:&6OFABEJ79+H@):ZW`X]V5F1@Z$AP:@@T(^P]:(!%#D=*GH+<N#W-TYU
ME4X7<.(W$:;KS8L&1J<3F*+,^"N.U<4\D59/15-2$J6)+$.=1^ONO')X];Z&
M'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5'_FK'_EVW_P`Y7[]U[J!\"_\`
MLDSJ+_J$W5_[W&Y??NO=&]]^Z]U[W[KW6A'_`#;<G_*>WO\`SJ?D5MC^;3\C
M.^:79VS_`(^]&4OQ^P?4];OK'[?ZCRM9BY,CV'LS/Q[>VWFJM<KNTUE%FZ66
MABDH9XZB454JU$<:>_=>ZL*_D2[6_D'X3Y8[[JOY7G='?/8??4G26?AW-A.T
M,MV768*#K4[KVBV7R-+!O#9VWL8<E!G5QZ*RRO,J2L`NEF/OW7NMM+W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW25WU_QX^\__
M``T]Q_\`NFK??NO=<-@?\>'LG_PT-L_^Z6B]^Z]TK??NO=>]^Z]U[W[KW7O?
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MJD66!(^3[KW5;':F[?C+C^AN^_BC\?\`^9?\KMR[`W]5]I]/]+?R2\QU?%MW
MY!;;[LWKNC,X3%]1[KWK!B\CV'B>@<#O.L?,RTT-3#1-M\!7JY8GD27W7NMG
MCY%?#'X0;+^)?47<'SAZRQ6_,E\-/C=L?9>4RE)F-R8B?>]+M/";;I:?JO+X
M?;.8Q5#VA@MV[_QM/!C-O9>&OH*C(U:HL%YY`_NO=5F]IX'??2N_.D<#\I?D
MYOGX&8[Y6=2_)#YC?(#N3K+L3$]7RY/Y0[8I>O,/TA\68=\YC'5<$6R?CWTS
M+X<;MB"1(L]-BYSXY@[H?=>ZOI_ET=H=R=U?!?XM=K_(+'SX[N/??4.V<]OE
M:K$C`562R%3%(E%N2JP:Q4ZX>JW7B(Z?)R4HCC6!ZLH$4+I'NO='1]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=51_P`S/X18#Y%[#KM_RYJCV;0]6;9W9V'N
M@8+$446X]XR[6P&1R4--+7-3&"HF_A\$L,3U&HQLXYTW'L"<_P#MERC[E\N?
MU<W]KFTB%\ET9+181)(Z1/"!(9%.H!9#0\1PK3J??8+[RON/]W/G9^=>48;'
M=9WV>7;EM]R>Y:""&6XAN':!89%*,7A6H%%-22*T/1=>G?Y:GR#V3U'UUF?C
M=\RMR]05LV`AW108C^"G(8#<4&\8Z?<T$>]:.*6*CJ*[$FM^W1DI9T,8/'/L
M`[I[-;OLO+>T\O\`M;S%N&VQ;4MQ3QPK"=KB<SDR+$0G:24%8W[:?.LZ[']\
M3D?G'GOF;G+[R'MUL?,<G,DE@3]+)+%)8I8V@M`MJ\^N3]90)'_53OX8Z$,;
M]_G)="<;KZKZ8^6FV:.R-D]D9$;5WC4TT/!D6@#8O76S_6PHIP/Z>PS^]_O+
M<HDC<+#;>8;!:`-"PCF(!R2!X9U$9H(FZ')Y4_NX/=C.P;]S+[?[W)GP[V/Z
MJS5CY&3]6B+\YD^WIUPW\XSKW:M;'@_D]\>N_?CCF598*FKSVT*O/[;2=>)Y
M4R5+!0U;4D3?VDIY2?Z>U-K]Y7:+";Z3GK9MVV:Y!`)>(R1UK0T-$<J#YA#T
M@W+^[EYOWZV;=/8_G#E/G/;2-2I!=I!<E?P@QLSIK/H9%Z/1U1\W/B;W:D`Z
MW[ZZYS=;4+&4P]5GZ;!9S7*+I!_!\\<;D&G_`-H5&/N5N7_=3V\YGHNS[O9O
M.0/TV<129X#1)H:ORIUBUS]]V+W_`/;%G/.?*>\VMLA-9E@:>"@XMXT'B1A?
MF6`Z-'%)'/&DT,B30R*'CEB=9(W0_1DD0LC*?Z@^Q^K*ZAD(*G@1D=04Z/$Y
MCE!60&A!%"#Z$'(ZY^]]5Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z1>^>M^O.S\3#@.RMB;/[!P5/61Y&#"[VVUA]TXJ&OBCEABK8L?FZ.MI$
MJXX9G02!-05V%[$^_=>ZP[#ZNZTZLH:W%]9=>;(Z[QN3JDKLCC]C[6PFU:&O
MK(XE@CJZREP=%0P5-1'`H17=2P06!M[]U[I=V/\`0_[;W[KW6M-_PHN_FU=L
M_`_HJ?I_X;325?RSW-M0]J[OW3CL7C=Q1_'/X^8/<F)V_D^SMS4&4@K,31UN
M]-U92FP6$6LC=99)*F18W:%`?=>Z.1\GOY@G>_QU^&?Q-SW3?QR[#^7GRW^4
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MQ>'QV.WANJ:;<.0V=@\?AZ&@I(<#L3^(KAZ1BC330T0ED=G<GW[KW4+_`)JQ
M_P"7;?\`SE?OW7NH'P+_`.R3.HO^H3=7_O<;E]^Z]T;WW[KW7O?NO=:R?\QS
MM;Y0_(?YJ[Z^%W\M#X8_#3L?O#IWK[K_`+"^4?RJ^6_7VS-P;8V2N^Z2IJ^M
MNM<-'7X7(9C<.?S&W<6\LDTB5:TT+(B1Q"-Y1[KW0P_RG.\.UMN_(_MSX-?.
M'X??&;X[?.'K#J3;_;6#[:^,6S=I8#K7Y$]#[ESJ8&HW#MZHQ>+H,UCJW!;N
MI5I<C0L5IS*@;Q0O'9O=>ZV"_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=)7?7_'C[S_\`#3W'_P"Z:M]^Z]UPV!_QX>R?_#0V
MS_[I:+W[KW2M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW4>LHZ/(TE5C\A24U?05U--1UU#6P155'64E3&T-32U=-.KP
MU%-40N4='4JRD@@@^_=>Z1FPNK>L>JJ"MQ?5_7&PNML9DJI:[(X[8.T-O[.H
M<A6K&(DK*VDV]C\=3U54D0TB1U9PO%[>_=>ZQ1]2]4P[[E[3BZQZ\B[.G@--
M-V/'LO;:;\FIC3+1&GEW>N-&X'A-&BPZ34%?$`MM(`]^Z]TJLW@,#N6A_A>Y
M,)B-PXS[NAK_`.&YS&T>6H/OL760Y'&5OV=?#/3_`'>.R%-'/!)IUPS1JZ$,
MH(]U[IFWIU[L#LC&TV&[%V-L[?\`AZ+)4N9HL3O7;.%W5C:3+T)9J+*TM#G*
M*NI:?)49<F*=%$L=SI87]^Z]TKE555550JJ`JJH"JJJ+*JJ+!54"P`^GOW7N
MN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1?/E?F\+@OC/W[49S,XG"T]3TQ
MVI14]1E\E1XR">LGV#N'PTL,U=-!%)42Z3I0$L;'CW[KW3U\>-P[?W!TGU2V
M`SV%SJ4'6G7])6OA<K096.DJEVCB":>IDH*BH2&:POI8@VY]^Z]T-/OW7NFO
M,8/";BHI<;N##8G.XZ92DV/S..H\I13*WU66EK89X)%/]"I'M/=6EI>Q&"]B
MCF@/%7574_:&!'2[;MTW/9[E;W:+FXM+Q3420R/$X/J&0JP_(]$7[6_E@?![
MM]ZBKSO1FWMMYFH:20[@Z]DJMCY5)I#=IT_@4M/CWE!^AD@>WN*-_P#8?VLY
MBU/<[5%;W#&I>V)@:M:UHA"$U]5/64W(/WY/O0>W:I;[5S3>7NVH`/I]P"WL
M1`_"?'#2`?Z60=%;D_E8]P]2R/6_$?YT=U=9+&VNDVAOVJ;>NT@J']BEE42P
MK]I&O!#4DU_Z>P"WL%S+RZQE]N^:MRL<XAG)EB`!J%HI"T\C6-NIT3[]WMS[
M@(+7[P?M9RSO;$4>[L%%E=Y^)@:'O/J)4ZX#?W\Y+H3C=G5/3'RTVS1^ALGL
M?(C:N\:FFA-C(N/#8O76S@WL**<#^GNO[W^\MRC7]X;?MO,%@M!JA81S$`Y)
M`\,ZB,T$3=7_`*I_W<'NQG8-_P"9?;_>Y,B*]C^JLU8^1D_5HB_.9#\^G7#?
MSC.O-JUL>#^3OQ[[]^..:5A#4U6?V?69_;:3J;3R)DJ6"AJVI(FXU)3R$_T]
MJ;7[RFSV$WTG/6S;MLUR"`2\1DCK6AH:(Y4>H0](-R_NY.<-^MFW3V/YOY3Y
MSVTC4JP7:07)4_"#&S.FL^AD7H]'5'S;^)W=J4XZW[ZZYS=;4+&8\/59^EP6
M<URBZ0?P;.G'9!I_ZHL;$>Y7Y?\`=/V\YGHNS;M9R3&GZ;.(I,\!HDT-7Y4Z
MQ9Y^^['[_>V+.><^4]YM;9":S+`T\%!Q;QH/$C"_,L!T:.*2.:-)H9$FAD4/
M'+$ZR1NA^C)(A964_P!0?8^5E=0R$%3P(R.H+='B<QR`K(#0@BA!]"#D=<_>
M^J]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2_\S_Y;7S,^2?RMVWWQTW_`#3N
M^_BUU1AZ'KZER7QVV#AZRJV?F9MI9:6OW#63UD&\\-"LV\J5Q!4:J1PJJ+ZQ
MZ??NO=:U7\UKXG?S>^G_`(U_S<^\.YNMOAYV+U_\M=Z[3K-\]Q8G?/8F;^16
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M,O\`OXZS8.'HYMT5%'-=HY)\?#9?0J^Z]T"W\D?YA?(KM_Y+]#[=S_R9[%^3
M.([\^`6X?D9\Q-O;VW'C=W8[XU?*:@[LGVIA]E[>QN,QM"W2$%=MZ6>C_NE-
MH+QT:U`BNA<^Z]UL3?\`-6/_`"[;_P"<K]^Z]U`^!?\`V29U%_U";J_][C<O
MOW7NC>^_=>Z][]U[K62^8O1_RKR?\R#OSNO^35\O>C=L?,FDZJZ>VE\X/B/W
MOALAD-E;BV_'CII.E>UX*],-7)C,S2;9R4U,!`0)3``TH9I(F]U[HV?\LOX"
M_,KKGOGN'Y[?S+.[=C=P_,3N#KG;'3&WMK=38J7&]2]%].[9RTVX)-H[2-50
MT$];7[CW+)][62I$B:@2S2R2.R^Z]U=U[]U[KWOW7NO>_=>Z][]U[KL`GZ#W
M[KW7K$&UN??NO=>((^H]^Z]UX@CZ@^_=>ZZM[]U[KWOW7NDKOK_CQ]Y_^&GN
M/_W35OOW7NN&P/\`CP]D_P#AH;9_]TM%[]U[I6^_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I&;YZXZ][.Q$6
M`[)V+L_L'`P5D>1APN]=MX?=&)BKX8Y8HJV/'9NCK:1:J.*=U60)J"NPO8GW
M[KW4?8?5W6?5E#78SK'KS9'76-R=2E;DL?L?:N$VI15]9%$((JJLI<'14,%3
M41P*$5W4L%%@;>_=>Z7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z:\S@\)N*BEQNX
M<-B<]C9U*38_,XZCRE%,I^JRTM=#/!(I_H5(]I[JSM+Z(P7L4<T!XJZJZG[0
MP(Z7[;NFY[/<K>[1<W%I>J:K)#(\3@^H9"K#\CT1;M;^5_\`![MYZBKSG1FW
MMM9FH:20[@Z]EJMCY6.:0W:=/X'+3X]Y0?H7IWM[BC?_`&']K.8M3W.U16]P
MQJ7MB8&K6M:(0A-?53UE+R#]^3[T'MXJ6^U\TWE[MJ`#Z?<`M[$0/PGQPT@'
MR60=%<D_E9=Q]2R/6_$CYT]U=9I$VNCVAOZI;>NT@$_S%+,HEA7[2,<%6I)K
M_P!/8!;V!YEY=8R^W?-6Y6.<0SGQ8@`:A:*0M.(S&W4Z)]^WVX]P$%M]X/VL
MY9WMF%'N[!197>?B88/>?42IUQ&__P"<CT)<;LZHZ9^6>V:.R-D]C9$;5WC4
MTT/!D7'AL7KK9QS844P']/=?WQ]Y;E&O[PV_;>8+%:#5"PCF(!R2!X9U$9H(
MFZM_5+^[A]U\\O[_`,R^W^]R9\*]C^JLU8^1D_5HB_.9/MZ=,+_.,Z[VK6QX
M/Y._'SOSXXYI66&IJL_L^LSVVTF7B>5<E2P4-6U)$W&I*>0G^GM3:_>5V>PE
M^DYYV?=MFN00"7B,D=:T-#1'*@^80](=R_NY.<-^MCNGL?S?RGSGMI&I5@NT
M@N2I^$&-F=-9'D9%Z/3U1\VOB?W:D'^C?OKKG-UE0L93#U6?I<%G-<HND!P^
M=..R#5']46-B/<K\O^Z?M[S/1=FW:SDF-/TV<1R9X#1)H:ORIUBSS]]V3W^]
ML6?^NG*F\VMLA-9E@:>"@XMXT'B1A?F6`Z-%%)'-&DT,B30R*'CEB=9(W0_1
MDD0LK*?Z@^Q\K*ZAD(*G@1D=06Z/$YCD!60&A!%"#Z$'(ZY^]]5Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[K%/3P54+T]5!#4P2@"2"HBCGAD`(8!XI59&`(OR/?NO=<U544(JJJ*H
M1450$5`-(0*`%"A>+?2WOW7NL5/34U)$(*2G@I80S,(::&."(,YU.PCB5$#.
MQN3:Y/OW7NF3";0VEMK(;BRVW-K;<V_E=X9-,UNW)X3"8W%9'=.9CIXZ./+;
MCK:&F@J<WDTI(EB6>I:641J%#:0![]U[IOVMUSUYL:NW'D]D["V7L[);QR7\
M9W?D=J[6P>WJ[=68'D_W*[DJ\10TD^<R7[K_`+]2TLOJ/JY/OW7N@#_YJQ_Y
M=M_\Y7[]U[J!\"_^R3.HO^H3=7_O<;E]^Z]T;WW[KW0<]P]I[2Z-ZF[-[IW[
M/54NR.I=A;M[(W=44%/]Y71;;V7@J[<.9:AI#)$*JL_A^/D\4990\EA<7O[]
MU[K4DWK\5=N?S3?G)VA\X_A9_.([=^'O8>=^/WQL;<_6>$V(=LYW976/9_7E
M-O/K_`9?<T'8F#PVZ)LO#3S9&JI8VK'Q%9,T+NK6'OW7NK8?Y;'P#^4WQ;[N
MW+O[NW^;IVW\\MK9/KO);9HNH]\^`X?!YFKS>#KZ??$6G?FZ7%=CJ7'S4B6@
M0:*Q[O\`0>_=>ZO`]^Z]U[W[KW7O?NO==V)^@/OW7NM/#^<'V]\:M^_S/,YU
M!\E,Y_,-W'L[H3XD]9UVWNJ?Y=C=IS;U;?/:&^]X[@W+O;LF/KZ6#&4>WL+L
MS$8F&`UTL<SR5H\2NH-O=>Z'+-;AZNWE\(?Y=7PZ_EH?*_OFFZ2^?'RCW3L3
M>GR$W%V+G]U_)+9?5>U]N;R[.[YV%3[LWFD.Y=E=@_?8*/;[031+4XB*:58U
M(TEO=>Z&7I_J#M;^69\X,G\/.@.[.]^Z>D/D_P#"KO;N3IK8_P`AM^5?;&:Z
MH^3/1M?@:1?[J;TW&4R<^W>QZ'>4$E7CZC5%%54BN"%;CW7NB8_R_/D[M?H3
M=FRN\,3V;\@]ZTNV?@MV1V'_`#:L)V9F>SMQT.$^9='NG9='L':@QF__`#XS
M:7>^Z>Q\IN'`XO`[?2"FJ,<T8\)1(7/NO=7[?R_LG1XO:>Z]O=J]P;,W5\S>
MQ-P5W??R6ZFQO9>+W1N+IC.[^CHC@^LJ;9BYFMRVSMI=9;6I\=@H$-/##/44
MDM22SU!)]U[JP_W[KW2#[#S.'H]G[QI*O+8NDJFVEN`K3560I*>H(DP]8(R(
M9IDDLY^AMS[]U[J)L/<NW$V-LM'W#@E=-I;;1U;+X\,K+AJ)65@:BX*L+'W[
MKW2K_O/MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/18'_S\8[_`.J??NO=>_O/MK_G
MHL#_`.?C'?\`U3[]U[KW]Y]M?\]%@?\`S\8[_P"J??NO=>_O/MK_`)Z+`_\`
MGXQW_P!4^_=>Z]_>?;7_`#T6!_\`/QCO_JGW[KW7O[S[:_YZ+`_^?C'?_5/O
MW7NO?WGVU_ST6!_\_&._^J??NO=>_O/MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/1
M8'_S\8[_`.J??NO=>_O/MK_GHL#_`.?C'?\`U3[]U[KW]Y]M?\]%@?\`S\8[
M_P"J??NO=>_O/MK_`)Z+`_\`GXQW_P!4^_=>Z]_>?;7_`#T6!_\`/QCO_JGW
M[KW7O[S[:_YZ+`_^?C'?_5/OW7NO?WGVU_ST6!_\_&._^J??NO=>_O/MK_GH
ML#_Y^,=_]4^_=>Z]_>?;7_/18'_S\8[_`.J??NO=>_O/MK_GHL#_`.?C'?\`
MU3[]U[KW]Y]M?\]%@?\`S\8[_P"J??NO=>_O/MK_`)Z+`_\`GXQW_P!4^_=>
MZ]_>?;7_`#T6!_\`/QCO_JGW[KW7O[S[:_YZ+`_^?C'?_5/OW7NO?WGVU_ST
M6!_\_&._^J??NO=>_O/MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/18'_S\8[_`.J?
M?NO=>_O/MK_GHL#_`.?C'?\`U3[]U[KW]Y]M?\]%@?\`S\8[_P"J??NO=>_O
M/MK_`)Z+`_\`GXQW_P!4^_=>Z]_>?;7_`#T6!_\`/QCO_JGW[KW7O[S[:_YZ
M+`_^?C'?_5/OW7NO?WGVU_ST6!_\_&._^J??NO=>_O/MK_GHL#_Y^,=_]4^_
M=>Z]_>?;7_/1X'_S\8[_`.J??NO=-69JNOMQ44N-W#4[+SV.F4K-C\U/@LI1
M3*?JLM+7//!(I_H5/M/=6=I?1&"]BCF@/%7574_:&!'2_;=UW39KE;W:+FXM
M+Q3420R/$X/J&0JP_(]$7[6_ES?R^>WGJ*O.=7[!VUF:AI)#N#KS.P;'RL<T
MANTZ#!UU/CWEO]#)3O;W%&_^P_M9S%J>YVJ*WN&-2]L3`U:UK1"$)KZJ>LIN
M0?OR_>A]O%2WVOFF\O=M0`?3[@%O8B!^$^.&D`^2R#HKDG\MK?\`U)))6_$C
M^89V9UHD;:Z/9^_MPT.]=I`(?V*65171+]I&O&EJ2:_L`M[!<S<NL9?;OFO<
MK$5!$,Y\6(`&H6BD+2F,QMU.B??M]M_<%!;?>#]K.6=[9A1[NP465WGXF&#W
MGU$J==+W+_-MZ&#?WLV3\>OEGMFBLKY38VZ\9M3>-131<&1<>:S%EZR<<\44
MP']/>AN_WEN4J_O#;]MY@L%(&J%A',0#DD#PSJ(SB)NO-RG_`'<'NL1^X.8.
M9?;_`'N7(BOH_JK-6/EXE):(O#,R'I]P/\Z;J+;N2@V[\E.D^YOCUN`LL$\F
M7P<>Y,")EXFEBK:$TE?+21M_:CII2?Z>U%M]Y79]OF%GSULV[[-=8!+Q&2.M
M:&AHCD#U"'HOW#^[HYMY@MFW/V/YPY2YSVTBJK!=K!<$>0,;%T#GT,B]'YZH
M^;OQ-[M2G'6_?776:K:E8]&'J\]38'.B27]$!P^>.-R#5'^T*C'W*W+_`+J>
MWG,]%V?=[-YB!^FSB*3/`:)-#5^0'6+W/WW8??\`]L6<\Y\I[S;6R$UF2!IX
M*#BWC0>)'I^98#HQS;BV\JAFSV$56Y5FRM`%8?X$U%C['ZD.@D3,9X$9!_/J
M")%:*4P2@K,O%3AA]H.1^?7#^\^VO^>BP/\`Y^,=_P#5/O?6NO?WGVU_ST6!
M_P#/QCO_`*I]^Z]U[^\^VO\`GHL#_P"?C'?_`%3[]U[KW]Y]M?\`/18'_P`_
M&._^J??NO=>_O/MK_GHL#_Y^,=_]4^_=>Z]_>?;7_/18'_S\8[_ZI]^Z]U[^
M\^VO^>BP/_GXQW_U3[]U[K)%N';\[:(,[A9G`U%(LK02,!>U]*5!-KGW[KW7
M<NX,!`P6?.8:%B+A9<I0QL1>UP'G!(O[]U[K%_>?;7_/18'_`,_&._\`JGW[
MKW7O[S[:_P">BP/_`)^,=_\`5/OW7NO?WGVS_P`]'@?_`#\8[_ZI]^Z]T[PS
M0U,4<]/-%402J'BG@D2:&5#]'CEC9D=3_4$CW[KW67W[KW7O?NO=%1_YJQ_Y
M=M_\Y7[]U[J!\"_^R3.HO^H3=7_O<;E]^Z]T;WW[KW26WQLK:W9.R]W==[XP
MU)N/9>^]LYS9^[<!7J7HLUMO<F-J</FL75*K*_@KL=5R1L5(8!K@@\^_=>ZU
M:]K?\)`/Y:V([*[0W%F]X_(/)=;;E7::]9]=X7LK(;>R'7*8K&U$&Y8,EO%8
MZ^MWK39K(21RTBSP0-CX4\0,MR_OW7NK./@!_(X^#G\M7M_<'=_QK7NL;WW+
ML7(]=Y+_`$B]JY#>V$_N[E,OALW5?;XFIQU'%%D?O<%!HGU$HFM0/6??NO=7
M"^_=>Z][]U[KWOW7NB8?(?X68OY%;YPF^JWY+_,?IV7"82CP:;5^/WR`S?5F
MR,DE%DJS)#*9C;F-QM7!7YNI:L,,U2S!I*>..,BR^_=>Z(5\@OD7\^OA/\J^
MTLUM7^7IN7YU?'WM[:G7"]4=@_&N#8>W^\]E;CV;@1A=S;)^0V1W#-3Y+=N%
MK*^1:W#9F1VCI89)(-!(('NO=$BH?@-\\>I?C+US\Q]M]0;,S'S<V?\`S'>S
M_P"9#NSX;[.W?1T6VTV%W7MG)]>[\^.6R-W.L6`&^J/KRHI:UJI1]E79Z&8#
M69!K]U[HY?Q#I?EG\U/G[BOGG\@_B;OKX3]1]`?'7>?0G2'5G;V?PF3[?[!W
MQVMNS;6X.R-^[@PFW*JHQNVMJ8+%;1I,?C5D)GK'FDE!TBR^Z]T<ONWK'?/R
M$^773'766V3DL+\7>AH\?\ENPMSU=%2T^`[N[WI\A7XGIGKBG"MY,OC>KZJF
MJ-VYAID,1R,6'C]15]/NO=4\_$7X;]_;7^2_Q(VGD?B_NOK#MOXK_)?Y<=P_
M*GYU9+$;1QVT?E+UOW+4]C2;8P6V-[8G+3[O[-R78LN\<)/78W)4L2;<;!-J
ML5CO[KW6TC[]U[H+>S=D;+S6V-XY?,[1VSELLFTLZJY/)8/&UV05:?#UI@45
ME3325`6'^P-7I_%O?NO=-&Q>K.L9MD;-FFZZV/+++M/;DLLLFU<([R228>C=
MW=C1$LS,223R3[]U[I5?Z*.K?^?;[$_]!3!__47OW7NO?Z*.K?\`GV^Q/_04
MP?\`]1>_=>Z]_HHZM_Y]OL3_`-!3!_\`U%[]U[KW^BCJW_GV^Q/_`$%,'_\`
M47OW7NO?Z*.K?^?;[$_]!3!__47OW7NO?Z*.K?\`GV^Q/_04P?\`]1>_=>Z]
M_HHZM_Y]OL3_`-!3!_\`U%[]U[KW^BCJW_GV^Q/_`$%,'_\`47OW7NO?Z*.K
M?^?;[$_]!3!__47OW7NO?Z*.K?\`GV^Q/_04P?\`]1>_=>Z]_HHZM_Y]OL3_
M`-!3!_\`U%[]U[KW^BCJW_GV^Q/_`$%,'_\`47OW7NO?Z*.K?^?;[$_]!3!_
M_47OW7NO?Z*.K?\`GV^Q/_04P?\`]1>_=>Z]_HHZM_Y]OL3_`-!3!_\`U%[]
MU[KW^BCJW_GV^Q/_`$%,'_\`47OW7NO?Z*.K?^?;[$_]!3!__47OW7NO?Z*.
MK?\`GV^Q/_04P?\`]1>_=>Z]_HHZM_Y]OL3_`-!3!_\`U%[]U[KW^BCJW_GV
M^Q/_`$%,'_\`47OW7NO?Z*.K?^?;[$_]!3!__47OW7NO?Z*.K?\`GV^Q/_04
MP?\`]1>_=>Z]_HHZM_Y]OL3_`-!3!_\`U%[]U[KW^BCJW_GV^Q/_`$%,'_\`
M47OW7NO?Z*.K?^?;[$_]!3!__47OW7NO?Z*.K?\`GV^Q/_04P?\`]1>_=>Z]
M_HHZM_Y]OL3_`-!3!_\`U%[]U[KW^BCJW_GV^Q/_`$%,'_\`47OW7NO?Z*.K
M?^?;[$_]!3!__47OW7NO?Z*.K?\`GV^Q/_04P?\`]1>_=>Z]_HHZM_Y]OL3_
M`-!3!_\`U%[]U[KW^BCJW_GV^Q/_`$%,'_\`47OW7NO?Z*.K?^?;[$_]!3!_
M_47OW7NO?Z*.K?\`GV^Q/_04P?\`]1>_=>Z]_HHZM_Y]OL3_`-!3!_\`U%[]
MU[KW^BCJW_GV^Q/_`$%,'_\`47OW7NO?Z*.K?^?;[$_]!3!__47OW7NO?Z*.
MK?\`GV^Q/_04P?\`]1>_=>ZX5/4?4]:@BK>L.O:R,#2$K-F[>JD"_P"I"SX^
M0`?X?3VQ=6MM?0FWOHXYH#Q610ZG[0P(Z6;;N.X;-=+?;/<3VEZIJ)(9'B<'
MU#(5(/SKT4;M?^6#\'^WWJ*O/=%[=VYF:AI)&W!U])5;'RR32&[3I_`I::@>
M8'Z&2![>XGW_`-B/:SF+4]SM45O<,:E[<F!JUK6B$(37U4]93\@_?C^]![=J
MEOM7--Y>[:@`^GW`+>Q$#\)\<-(!_I7'1+,A_)OW#UM75.;^*_RNWUU_5O(9
M8]N=D8/$;_VY,5_S-/5330)(].H'.NEF)]@(^P7,O+C--[=<U[G89Q%.?%B%
M#4+0$"GD:QMU.0^_5[;^X:"V^\+[5\L[XS"CW=BOT5WGXF&#W'Y2I3IM_@W\
MT+H6XW9\9/BY\M=LTEE?*;)P>!VKO.JIHC8RBA^SQ;25M0.;"CG`_I[K^]_O
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M[V;S$#]-G$4F>`T2:&K\J=8M<_?=B]__`&Q9SSGRGO-M;(369(&G@H.+>-!X
MD87YE@.C21=6=4SQI-!UWL":&10\<L6UL#)%(A^C)(E&R,I_J#['ZLKJ&0@J
M>!&1U!3H\3F.4%9%-""""#Z$'(ZY_P"BCJW_`)]OL3_T%,'_`/47O?5>O?Z*
M.K?^?;[$_P#04P?_`-1>_=>Z]_HHZM_Y]OL3_P!!3!__`%%[]U[HJ_S5^,OQ
M]["^,7=4.\.G]B99=J]7]D;RVZZX2#&5&(W/@]A[BGQ.9HJO#G'U<5903'7&
MVNRL`;7`(]U[IX^*GQ0^-G5?3.R$V#TIU_MX;OV=LC<VY"F#BR4N6SM3M3%^
M?(U-1F7R-09Y=9U6<!B22"23[]U[HR'^BCJW_GV^Q/\`T%,'_P#47OW7NO?Z
M*.K?^?;[$_\`04P?_P!1>_=>Z]_HHZM_Y]OL3_T$\'_]1>_=>Z6M#0T.,HZ?
M'XVCI<?04<2P4E#0T\5+24L*?HAIZ>!4BAC7\*H`'OW7NI7OW7NO>_=>Z*C_
M`,U8_P#+MO\`YROW[KW4#X%_]DF=1?\`4)NK_P![C<OOW7NC>^_=>Z][]U[K
M5-_FU?/'^9)F>Z?FYT?\!.T^J/C9L/\`ER_&/9WR+[[[%W=A*+>/;7:F9WGB
MJO=^&V7UGMS)8W+T&(VW1;>QK15N1GI3']TVAIE#QJ?=>Z/S\0?FW\D,_P#S
M*^U_A=W;7;+WMU[N?X:]$_,+HK<6U:6*#=W7N-SF+VYLOL#8O;4=+%!!#E]Q
M[UDJ<OC%9`5HV'C+1NJQ^Z]U=S[]U[KWOW7NO>_=>Z][]U[KNY'T)'OW7NNO
M?NO=>O?Z^_=>Z][]U[KU_P`?CW[KW7O?NO=)7?7_`!X^\_\`PT]Q_P#NFK??
MNO=<-@?\>'LG_P`-#;/_`+I:+W[KW2M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=->8P>$W%12XW<&&Q6=QTZE)L?F<=1Y2B
MF4_59:6MAG@D4_T*GVGNK2TO8C!>Q1S0'BKJKJ?M#`CI=MVZ;GL]RM[M%S<6
MMXIJLD,CQ.#ZAD*L/R/1%^U_Y8'P>[?>HJ\[T7MW;>9J&DD;<'7LE5L?*QS2
MF[3I_`I:;'O*#]#)`]O<4;_[#^UG,6I[G:HK>X8U+VQ,#5K6M$(0FOJIZRFY
M!^_']Z#V[5+?:N:;R]VU`!]/N`6]B('X3XX:0#_2R#HK<G\K'N'J622N^)'S
MH[KZR6-M='M#?M4V]=I!8_\`@/22J)85^TC'U5J2:_\`3V`6]@>9.76,WMWS
M5N5B*XAG)EB`!J%HI"T\LQMU.B??N]NO<!!:_>#]K.6=[)%'N[%197>?B<&A
M[SZB5*=<!OW^<ET)QNOJKICY:;9H[(V2V1D1M7>5330\&1<>&Q>NMG^MA1S@
M?T]U_>_WEN4:C<+#;>8;%:#5"PCF(!R2!X9U$9H(FZO_`%3_`+N#W8SL&_<R
M^W^]R9\.]C^JLU8^1D_5HB_.9#\^G3#?SC.O=J5L>#^3WQZ[]^..95EAJ:O/
M;/K,_MM)UXGD3)4L%#5M21-_:2GD)_I[4VOWE-GL)?I.>MFW;9KD$`EXC)'6
MM#0T1R`?,(>D&Y?W<G-^_6QW3V.YOY3YSVTC4J07:07)7\(,;,Z:SZ&1>CT]
M4?-OXG=VI`.M^^NN<W65"QE,/59^EP6<URBZ0'#YXXW(-/\`U18V(]RMR_[J
M>WG,]%V?=[-YR!^FSB*3/`:)-#5^5.L6N?ONQ>__`+8LYYSY3WFUMD)K,L#3
MP4'%O&@\2,+\RP'3_P#*3-X6/XY=YX^3+XQ,AG^D.V*7`T#5]**S-U,^Q,Y3
MP4^)IO+YLC/-43HB)"'9G=5`)('N1K:VN+Q=5I&\J^J`L/\`C->H"N[FWL'\
M.^D2"2M*2,$-?2C4/2LZ)RN,R/3_`%E#C\C0UTV,Z\V+09**CJX*F7'5T.U<
M4LM%71PR.])5Q,I#1R!74CD>_36]Q;-HN$>-SY,"I_8:=>@N;>Z3Q+:1)$K2
MJL&'[03T+?MGI[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*C_S5C_R[;_YROW[K
MW4#X%_\`9)G47_4)NK_WN-R^_=>Z-[[]U[KWOW7NM'__`(4"]K?R8]]_,//=
M1_)X?/;IWY=[3ZZV]LW=O:_Q`V;CI:?M#J7<&-IMTT^R=UP93/P8WL+`T%/D
M51WFH[TK:H2[H@5?=>Z1O\I[^:O_`"%_Y?>X=QX?8&5^=>4[/[;R.U-E=R?+
M'Y6]?2YS)X[&8M_M-H8/>.:PVX<D-C;'PIFB00043!+++*3'&OC]U[K>FQV1
MH,QCJ#+XJMILCB\K14N2QF1HIHZFCK\?701U5'6TE1$S13TM532J\;J2K*P(
M-C[]U[J9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2N
M^O\`CQ]Y_P#AI[C_`/=-6^_=>ZX;`_X\/9/_`(:&V?\`W2T7OW7NE;[]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[IKS&#PFXJ*7&[@PV)SV.F4K-C\SCJ/*44RGZK+2UL,\$BG^
MA4^T]U:6E[$8+V*.:`\5=5=3]H8$=+MNW3<]GN5O=HN;BTO%-1)#(\3@^H9"
MK#\CT1?M;^5_\'NWWJ*O.]%[>VWF:AI)&W!U[+5;'RJ32&[3I_`I:?'O+?Z&
M2![>XHW_`-A_:SF+4]SM45O<,:E[8F!JUK6B$(37U4]93<@_?D^]#[=JEOM?
M--Y>[:@`^GW`+>Q$#\)\<-(!\ED'5-WSR_EX[^Z+V1@-M_'3<O='8VWI\Y5;
MSR$N[-TSSP=:[>P6)K:6LHZ7<BO04]%@V61:F=92@4Q>0\*2`%S=[&\Y[9[:
MMRU[2[AN$U])OD5PRR7B6[0P);31Z4<O$&0R.M5]0#3%>LB_9_[ZGM5S;[]+
M[@_>>V7EW;=LM^4+BP22VVAKJ.\O)=PM;@2S6ZPW&B98HY%66@&@E*BM#9+_
M`">^O^R>NOCIGL/VEA\WB]QU>[#E(Y<U--7/D\97PSU6.KJ3*RO-'DJ2:CF1
MDDCD=0I`O[F/VLV#FWE;VRVK8>>9&DYHA>[:4M.+AM,EPSQ5E5W!["*#4=(Q
MCK$'[UO/'MC[D?>'W_G+V<6%?;RZM]N6W\*S:QC+PV<<=QIMFBA*'Q0VIO#&
ML]U36O5M'L<]8_=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14?\`FK'_`)=M_P#.
M5^_=>Z@?`O\`[),ZB_ZA-U?^]QN7W[KW1O??NO=>]^Z]UJV_-ON7Y0_RX/YH
MG=/S.W'\`NT/GM\:N_NC.G>MNKM[=)82FWAV;\<L_L2/,1[IZZ@P#X_*SX?:
MW868KY<M6S)%`M7,(29G:-X5]U[HB6^J?^89\_\``_S'?E#U'_+$W9TGU1\N
M_BOUW\,NN?CSVC1X7;/8';?:&Y=]U&)J?EIO_$5M#C(=O)TCM7.5R/D)H$,M
M'34T:SR&%FC]U[K<@^/?7N3ZDZ#Z0ZJS59'D,SUIU%UQL++UT$K305F4VCL_
M#X#(5-/,ZH\E/-5T#LC$`E2+CW[KW0O^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NDKOK_CQ]Y_^&GN/_P!TU;[]U[KAL#_CP]D_^&AM
MG_W2T7OW7NE;[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`OY0_]DS?(H?@]$]O
M7'X/_&/MP_4>_=>Z5'2O_,F^I/\`Q&.P?_>4Q/OW7NA,]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=%1_YJQ_Y=M_\Y7[]U[J!\"_^R3.HO\`J$W5_P"]QN7W
M[KW1O??NO=>]^Z]UJP_-?9GSU^:/\U+N_P",FQ_YG.ZOY;G3O0W0O3V^^HMM
M;":DI-S=\_W_`%R2;^WR77<NTY\SB]F;CH/X75>2JF-#(].JP()6ED]U[H\/
M\MKX#?*GXO=W[F[`[O\`YNW;OSTVQE.N\EMFCZDWVT+XG"9BKS6#KJ?>\9&_
M-TR??8ZEQ\U(EH4&BL>[_0>_=>ZN]]^Z]U[W[KW7O?NO=>]^Z]UV`3]![]U[
MKUC]+&_]/?NO=>((^H]^Z]UX@CZ@^_=>ZZM[]U[KWOW7NDKOK_CQ]Y_^&GN/
M_P!TU;[]U[KAL#_CP]D_^&AMG_W2T7OW7NE;[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z+5\NJ[>2_'WM#;FPNK=Z=L[GW_L;>VP,5M_9-1M&DK*&MW5L_.8JA
MR^5J=Y;FVMC8,+3UU1&D[QS2S)Y`5B8`V]U[IP^,NYMWYSJO;.'WIU#V#T_F
M-E;<VIM.?%]@3[*J*C,SXG;F/I*S)8:79.[=W4DF,2J@:,-/)!*Q%PEC?W[K
MW1A??NO==A2>0/?NO==?3@^_=>Z[L?Z'W[KW7B"/J/?NO=>((^OOW7NBH?\`
M-6/_`"[;_P"<K]^Z]U`^!?\`V29U%_U";J_][C<OOW7NC>^_=>Z][]U[K2&_
MGL[9_P"$_.S/GCN'<OSO;YJ;K^4F\=A[(SN]L9\;,[6U&V]D;;_AM+MK9-/F
M89YL918&OW)08Q)8Z:":9I;B5PAF37[KW0Q?\)]*'^4!5?+WLK*?RWNK?G_C
MM^X;I;-X?LG>?R7DK&ZSV[@<GN/9V1QVV@KUE=!'O?<4],E31QR&*3[*EJ'0
M,I;W[KW6XO[]U[KWOW7NO>_=>Z[L3]`??NO=:=/\S/Y-=(]Y?.GY%=+_`"D[
MB^>\W4?Q7INMMF=6_$#^730;WD[7WKO'<>RJ7?/9OR3[<KM@1)D:;8VT8-T4
M&W\/'6U<-)),\[HDD@8>_=>Z'*O[*WWV_P#!3^6[\2/C=_,%[5[>VC\Y_DWN
MCJ7*?+X8R#9/R5VG\7>N\!O;?^].J<Y65$KY'$]W;<Q6WZ;:.2R]1%!D3:65
MH@S7;W7NALZ?Z@[6_EF?.#)_#SH#NSO?NGI#Y/\`PJ[V[DZ:V/\`(;?E7VQF
MNJ/DST;7X&D7^ZF]-QE,G/MWL>AWE!)5X^HU1155(K@A6X]U[HF/\OSY.[7Z
M$W9LKO#$]F_(/>M+MGX+=D=A_P`VK"=F9GL[<=#A/F71[IV71[!VH,9O_P`^
M,VEWONGL?*;AP.+P.WT@IJC'-&/"42%S[KW5^W\O[)T>+VGNO;W:O<&S-U?,
MWL3<%=WW\ENIL;V7B]T;BZ8SN_HZ(X/K*FV8N9K<ML[:766UJ?'8*!#3PPSU
M%)+4DL]02?=>ZL/]^Z]TEM]`_P!Q]Y\'_CT]Q_C_`*L];[]U[KAL%3_<39/!
M_P"/0VT/H?QA:+W[KW2ML?Z'_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[KW7K'
M^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW
M7K'^A_VQ]^Z]UZQ_H?\`;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W
M[KW7K'^A_P!L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_
M`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[KW7K
M'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[K
MW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'
MW[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'
M_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L
M?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[
MKW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_P!L??NO=,.0W3MC
M$UL>-RNY,!C,C,(C%C\AF<=15LHG?QP&.DJ:F*=Q-(-*64ZCP/?NO=?/%_FX
M_)GXU=D_SE?F?M;Y8_,3Y\=!=1]#[-Z&ZRV!B?A/49;)4L6X4VU_&.RMP]AT
M,F1@P.$Q."KLR!)+&AKJEY`JI)XB![KW6TCD?EKU-_+]_E+?'7-?&CL_=7S3
MW'V'M?9_2OP;RFZ,NVY.P/D_W)V=59"'KN/.5@@IZF:/&UM1+5YV62*(T&/Q
MLZ2^.10OOW7NJ./Y;O9?\Q'_`(:*_GJUU%V7V-VC\ZNMOD?W;MO';AP>:S&\
M=P8W>^#PVW:;?W^BJEK&J6H!CH!E9\32X^"-(I40T\6H(/?NO="]\7?FUNCX
MI];_`,Q;<_Q>W)V5W+\><_2?"WIO^7OC.P<_V-O9=[?/_O?JVGP/:6T-BYWM
M,U6[LK0X7L>MBS&YJ6-GH:!J.I"",ZD'NO=;/_PBZ0C^-7QEZMZ)KNQLIVOO
MCKW;T$':N_=P;FJ-T;CW/VIG9)=P]@9W,UE;75U91G*;IR55)34KLJTM)XXD
M4(@'OW7NN7_-6/\`R[;_`.<K]^Z]U`^!?_9)G47_`%";J_\`>XW+[]U[HWOO
MW7NO>_=>ZU[/F=_*QW[VEWU_,*WUB>T.DL'U;_,!^*6P=GQ+V-1FC[$ZO^5'
MQRDHJGI'<FV=PS*]/5=8U\L,=3EZ6,_<P54`=(V&F_NO=(S^4_TY_,EW7\Z>
M[/F3\]]O_'3HZMK/C1L7XVX_JKX\;UVWNBG[FR>R=URY^/O/>M-MS/;B@2JH
M8JRHI*&HJ)H:E*>M^W2".")=7NO=;(WOW7NO>_=>Z][]U[HF'R'^%F+^16^<
M)OJM^2_S'Z=EPF$H\&FU?C]\@,WU9LC))19*LR0RF8VYC<;5P5^;J6K##-4L
MP:2GCCC(LOOW7NJK.T<;\M?Y:?SX^5?R;Z0^"N__`)X=)_.C;725?E:WI;<N
MV*3O#JGN'IS:-3L.?![NH-UO3?Q+K7>>%CBR(R%.Q2CR!970EN?=>Z`JA^"O
MSTZK^)O3?RQVWTSLO)?-/K+^8KW%_,:W%\.-H[NHJ+"-L'Y`4>XML]B?'3:6
M\W$>"DWW1;&S$%8M1_P#JLW%*JZM:AO=>Z.#\0Z7Y9_-3Y^XKYY_(/XF[Z^$
M_4?0'QUWGT)TAU9V]G\)D^W^P=\=K;LVUN#LC?NX,)MRJJ,;MK:F"Q6T:3'X
MU9"9ZQYI)0=(LONO='+[MZQWS\A/EUTQUUEMDY+"_%WH:/'_`"6["W/5T5+3
MX#N[O>GR%?B>F>N*<*WDR^-ZOJJ:HW;F&F0Q'(Q8>/U%7T^Z]U3S\1?AOW]M
M?Y+_`!(VGD?B_NOK#MOXK_)?Y<=P_*GYU9+$;1QVT?E+UOW+4]C2;8P6V-[8
MG+3[O[-R78LN\<)/78W)4L2;<;!-JL5CO[KW6TC[]U[H&NU^LMB;EP&\-P9S
M;M-D,Q'M'-(E=)4Y"-PE)AZTTZ^.GK(8"(_^"\_GW[KW2?V/T9U14[*V?43;
M-HGFGVKMZ:5_O\R-4DN(HY':RY(`79C]/?NO=*C_`$#=1_\`/%T7_G?FO_KG
M[]U[KW^@;J/_`)XNB_\`._-?_7/W[KW7O]`W4?\`SQ=%_P"=^:_^N?OW7NO?
MZ!NH_P#GBZ+_`,[\U_\`7/W[KW7O]`W4?_/%T7_G?FO_`*Y^_=>Z]_H&ZC_Y
MXNB_\[\U_P#7/W[KW7O]`W4?_/%T7_G?FO\`ZY^_=>Z]_H&ZC_YXNB_\[\U_
M]<_?NO=>_P!`W4?_`#Q=%_YWYK_ZY^_=>Z]_H&ZC_P">+HO_`#OS7_US]^Z]
MU[_0-U'_`,\71?\`G?FO_KG[]U[KW^@;J/\`YXNB_P#._-?_`%S]^Z]U[_0-
MU'_SQ=%_YWYK_P"N?OW7NO?Z!NH_^>+HO_._-?\`US]^Z]U[_0-U'_SQ=%_Y
MWYK_`.N?OW7NO?Z!NH_^>+HO_._-?_7/W[KW7O\`0-U'_P`\71?^=^:_^N?O
MW7NO?Z!NH_\`GBZ+_P`[\U_]<_?NO=>_T#=1_P#/%T7_`)WYK_ZY^_=>Z]_H
M&ZC_`.>+HO\`SOS7_P!<_?NO=>_T#=1_\\71?^=^:_\`KG[]U[KW^@;J/_GB
MZ+_SOS7_`-<_?NO=>_T#=1_\\71?^=^:_P#KG[]U[KW^@;J/_GBZ+_SOS7_U
MS]^Z]U[_`$#=1_\`/%T7_G?FO_KG[]U[KW^@;J/_`)XNB_\`._-?_7/W[KW7
MO]`W4?\`SQ=%_P"=^:_^N?OW7NO?Z!NH_P#GBZ+_`,[\U_\`7/W[KW7O]`W4
M?_/%T7_G?FO_`*Y^_=>Z]_H&ZC_YXNB_\[\U_P#7/W[KW7O]`W4?_/%T7_G?
MFO\`ZY^_=>Z]_H&ZC_YXNB_\[\U_]<_?NO=>_P!`W4?_`#Q=%_YWYK_ZY^_=
M>Z]_H&ZC_P">+HO_`#OS7_US]^Z]U[_0-U'_`,\71?\`G?FO_KG[]U[KW^@;
MJ/\`YXNB_P#._-?_`%S]^Z]U[_0-U'_SQ=%_YWYK_P"N?OW7NO?Z!NH_^>+H
MO_._-?\`US]^Z]U[_0-U'_SQ=%_YWYK_`.N?OW7NO?Z!NH_^>+HO_._-?_7/
MW[KW7O\`0-U'_P`\71?^=^:_^N?OW7NO?Z!NH_\`GBZ+_P`[\U_]<_?NO=>_
MT#=1_P#/%T7_`)WYK_ZY^_=>Z]_H&ZC_`.>+HO\`SOS7_P!<_?NO=>_T#=1_
M\\71?^=^:_\`KG[]U[KW^@;J/_GBZ+_SOS7_`-<_?NO=>_T#=1_\\71?^=^:
M_P#KG[]U[KW^@;J/_GBZ+_SOS7_US]^Z]U[_`$#=1_\`/%T7_G?FO_KG[]U[
MKW^@;J/_`)XNB_\`._-?_7/W[KW56ORF_D&?R^OE]\A\'\F^U<3W+0=BX"BV
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MYB>B]F2P8ZER4/G@@SF7J61P8B6]U[JM[^1-TQW7LKY1=0Y*AZ>[QZAI=D_`
MW<'7_P#,@RG:NUM\;1Q_:GSCG[KJ<K@LY/D-Y2/0]L;VIMM"MG;<6):JIEQL
MZQ&HLZ1#W7NMD[_FK'_EVW_SE?OW7NH'P+_[),ZB_P"H3=7_`+W&Y??NO=&]
M]^Z]TE=\[WVEUGLO=G8N_L_CMJ;'V+MW,;MW?N?+S&GQ6WMM;?H)\IFLSD9P
MKF&BQN/II)96`-D0FWOW7NM%?Y:=I?R7/YC_`/-$[QW%\ZOYC@RWQMQG0W3L
MWQ!3JKN?.[4ZNVUD*$Y7'=T83=%51X6OBPG8M3N/P5M/3R0QC(XVI,HE=H1%
M'[KW5M/\FKXS?R)^G/DMO/<W\LGY3Y'NWO.KZCS.(W-M:K[QRW9$5%US4;DV
MQ4Y3,C!5N"Q<$,E/FZ2@B%1K9HQ,5`LY]^Z]ULT^_=>Z][]U[KWOW7NO>_=>
MZ]>WT]^Z]U[W[KW7KW^OOW7NO>_=>Z]?\?CW[KW7O?NO=)7?7_'C[S_\-/<?
M_NFK??NO=<-@?\>'LG_PT-L_^Z6B]^Z]TK??NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7=R/H3[]U[KKW[KW7=R?J2??NO==7]^Z]UW<GZ
MD^_=>Z*A_P`U8_\`+MO_`)ROW[KW4#X%_P#9)G47_4)NK_WN-R^_=>Z-[[]U
M[I-[RV=M7L/:6Y]A;YP&+W7LO>F!RNU]V;8S=)'78;<&W<[138W,8;*T4H,5
M7C\E05#Q31L-+HY!X/OW7NM;C!_#K^65OW^9[O'X&=;?RA_BYFNK^B.D,/V/
M\D_D#7]=[;IZ#9O8'9$$>0Z>ZSVYB`D;9"LSF"I*RLKIV\I1`JJB!'<^Z]T,
M'\NG'_%[I'^93\O?B+A/Y;_37PK[MZ[V.-^](]M]7X7`T=/\C?B/N'=U-@J7
M<'W&/U5F.RM%N[$Q)D:,.\0E1;K$\94^Z]UL%^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2N^O^/'WG_X:>X__=-6^_=>ZX;`
M_P"/#V3_`.&AMG_W2T7OW7NE;[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBH_\U8_\NV_^<K]^Z]U
M`^!?_9)G47_4)NK_`-[C<OOW7NC>^_=>Z][]U[JA_P">/\J[Y9=@?)S._-?^
M6O\`."J^&/R#[-V-M/K3OG"[GVG!OOJOMC;VQQ/%M#<-7B*JCRRXC>.VZ&44
ML,ZT4XD@!"M"7E,ONO="+_+5_EE]Y?&7MCM'Y=_.'Y9Y;YF_,_MC9.'ZKEWP
M,!!M;8'674^"S51N"FV-UUM]88&I8,KF9$JZV9(**-Y4L(-1DDD]U[JYOW[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW25WU_P`>
M/O/_`,-/<?\`[IJWW[KW7#8'_'A[)_\`#0VS_P"Z6B]^Z]TK??NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T5'_`)JQ_P"7;?\`SE?OW7NH'P+_`.R3.HO^H3=7_O<;E]^Z]T;WW[KW
M33GL]@]K83+;EW-F<5MW;F`QU9F,[G\YD*7%8;"XG'0/59#*97)UTL%%C\?0
MTL32332ND<:*68@`GW[KW1=_E3\J^O\`XJ_%;M7Y9YR"JWYL3K39`WC2T.R:
MW&UL^\VR%70XK;.,P67:H.'2'<.;RU)`*Z27[6GBF,[MXT8^_=>ZK]^&7\S/
MY'=M_)7`?%_YB?"S'_%?>?:77&\>TNC\ULSY#];_`""P&[,!UY4X.+>.+W6V
MR7AKMFYJCIMS4<U,TL<E-5#R('#J`WNO=70>_=>Z][]U[KWOW7NO>_=>ZY!2
M?Q[]U[KJQ'%C[]U[KQ!'U'OW7NO$$?4'W[KW75O?NO=>]^Z]TE=]?\>/O/\`
M\-/<?_NFK??NO=<-@?\`'A[)_P##0VS_`.Z6B]^Z]TK??NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M5'_FK'_EVW_SE?OW7NH'P+_[),ZB_P"H3=7_`+W&Y??NO=&]]^Z]T'7<$G6<
M/4W9T_=$&`J>GX-@;OJ.TZ?==)%D-LS]>08"OFWC%N"@FBFCK<.^WTJ!4Q%'
M$D6I;&]O?NO=::_5N:Z2WYV#FN@?Y5F[ODM\>=C=ZX7=T.VO@_\`S*/CSV95
M_P`M'YA8(XBKRVX]D=&[DWG-7;RZAR6Z=EQ25U&N,FBA>CM,E'=#&/=>ZLF_
ME%];?#?XQ_(G='2Z_P`L3?W\O?YO;JV1E9ZVOSE5NON[J7L786VJBEJ=P-T-
M\D:[*[AP9VP<A)%-48=_X37D+%Y89?&"ONO=;(_OW7NO>_=>Z][]U[KNQ/T!
M]^Z]UKN_S;OY?'PTV_M3Y!_S!.[^U/G%!NJ/$8-<3U7TO\K^P.N=N[Y[%J:;
M#["ZRZVV%LW#EJ+&9??NZ)*"BTTZM^_4R5#*;.??NO=%RJ_BU\DOB?\`";^7
MK_+3H?DSW/M?M[^8%\H,FOR5[FAW]F-S=G=8];-U_GNV>V.K.IM[[GJZS+8Q
M\9A]OT&V*7)EFJ75JJK"JTY0>Z]T._3_`%!VM_+,^<&3^'G0'=G>_=/2'R?^
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MKW7#8*G^XFR>#_QZ&VA]#^,+1>_=>Z5MC_0_[8^_=>Z]8_T/^V/OW7NO6/\`
M0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>
MZ]8_T/\`MC[]U[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`
MMC[]U[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KU
MC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_
M=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>Z]8_T/
M^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>Z]8_T/^V/OW7NO
M6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8
M^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_
MT/\`MC[]U[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]
MU[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_
M[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>ZZ
M]^Z]U[W[KW7O?NO=%1_YJQ_Y=M_\Y7[]U[J!\"_^R3.HO^H3=7_O<;E]^Z]T
M;WW[KW2([,ZYVAW!USOWJ?L'%)G=B=F;.W)L+>6%>66!<KMC=F(J\%G*#SP,
MD\!JL;72('1@Z$W!!'OW7NJI_C)_)TVIT!W7U[VWOOYD?,SY4X+HILC+\;NH
M/D7VA1[NZWZ-KJO!5FSZ',;<QU#AL959?-X#9%=)BJ"IKI)&@@=G`,C:A[KW
M5QQ5697959TU:'90634-+:&(+)J'!M]1[]U[KOW[KW7O?NO=>]^Z]T2_Y$?"
MS%_(K?.$WU6_)?YD=.RX3"4>#3:OQ]^0&;ZLV1DDH\E69(93,;<QN-JX*_-U
M+5AAFJ6<-)3QQQVLOOW7NB]?.GI#L3OCY*_RPNL:;9^[-T?'OKGO_=7R([TW
M<`E=@<;GNB.M*ZIZ)QF^IYG7[G^\79&=2KANC:ZW'(_!%_?NO=1_YJ_3'R'W
M1M[XP_)WXH[%I.V^\OA%\A*+O"@Z6J,Y3[:J^Y.N<QL_<NP>T^O=O9VM84&/
MW9D-M[B%5C?N/VI:FC6,W+A3[KW0#?$.E^6?S4^?N*^>?R#^)N^OA/U'T!\=
M=Y]"=(=6=O9_"9/M_L'?':V[-M;@[(W[N#";<JJC&[:VI@L5M&DQ^-60F>L>
M:24'2++[KW1R^[>L=\_(3Y==,==9;9.2POQ=Z&CQ_P`ENPMSU=%2T^`[N[WI
M\A7XGIGKBG"MY,OC>KZJFJ-VYAID,1R,6'C]15]/NO=4\_$7X;]_;7^2_P`2
M-IY'XO[KZP[;^*_R7^7'</RI^=62Q&T<=M'Y2];]RU/8TFV,%MC>V)RT^[^S
M<EV++O'"3UV-R5+$FW&P3:K%8[^Z]UM(^_=>Z#W<W5'7F\J^7)[GVO1YBNGI
MDHYYJFHR"B:EC1HU@DA@K(:=X_&Q!!7U`\W]^Z]TPQ]!=/Q1I%%L?'Q11(L<
M<45;F(XXXT`5(XXTR01$10````!]/?NO=<_]`W4?_/%T7_G?FO\`ZY^_=>Z]
M_H&ZC_YXNB_\[\U_]<_?NO=>_P!`W4?_`#Q=%_YWYK_ZY^_=>Z]_H&ZC_P">
M+HO_`#OS7_US]^Z]U[_0-U'_`,\71?\`G?FO_KG[]U[KW^@;J/\`YXNB_P#.
M_-?_`%S]^Z]U[_0-U'_SQ=%_YWYK_P"N?OW7NO?Z!NH_^>+HO_._-?\`US]^
MZ]U[_0-U'_SQ=%_YWYK_`.N?OW7NO?Z!NH_^>+HO_._-?_7/W[KW7O\`0-U'
M_P`\71?^=^:_^N?OW7NO?Z!NH_\`GBZ+_P`[\U_]<_?NO=>_T#=1_P#/%T7_
M`)WYK_ZY^_=>Z]_H&ZC_`.>+HO\`SOS7_P!<_?NO=>_T#=1_\\71?^=^:_\`
MKG[]U[KW^@;J/_GBZ+_SOS7_`-<_?NO=>_T#=1_\\71?^=^:_P#KG[]U[KW^
M@;J/_GBZ+_SOS7_US]^Z]U[_`$#=1_\`/%T7_G?FO_KG[]U[KW^@;J/_`)XN
MB_\`._-?_7/W[KW7O]`W4?\`SQ=%_P"=^:_^N?OW7NO?Z!NH_P#GBZ+_`,[\
MU_\`7/W[KW7O]`W4?_/%T7_G?FO_`*Y^_=>Z]_H&ZC_YXNB_\[\U_P#7/W[K
MW7O]`W4?_/%T7_G?FO\`ZY^_=>Z]_H&ZC_YXNB_\[\U_]<_?NO=>_P!`W4?_
M`#Q=%_YWYK_ZY^_=>Z]_H&ZC_P">+HO_`#OS7_US]^Z]U[_0-U'_`,\71?\`
MG?FO_KG[]U[KW^@;J/\`YXNB_P#._-?_`%S]^Z]U[_0-U'_SQ=%_YWYK_P"N
M?OW7NO?Z!NH_^>+HO_._-?\`US]^Z]U[_0-U'_SQ=%_YWYK_`.N?OW7NO?Z!
MNH_^>+HO_._-?_7/W[KW7O\`0-U'_P`\71?^=^:_^N?OW7NO?Z!NH_\`GBZ+
M_P`[\U_]<_?NO=>_T#=1_P#/%T7_`)WYK_ZY^_=>Z]_H&ZC_`.>+HO\`SOS7
M_P!<_?NO=>_T#=1_\\71?^=^:_\`KG[]U[KW^@;J/_GBZ+_SOS7_`-<_?NO=
M>_T#=1_\\71?^=^:_P#KG[]U[KW^@;J/_GBZ+_SOS7_US]^Z]U[_`$#=1_\`
M/%T7_G?FO_KG[]U[KW^@;J/_`)XNB_\`._-?_7/W[KW7O]`W4?\`SQ=%_P"=
M^:_^N?OW7NO?Z!NH_P#GBZ+_`,[\U_\`7/W[KW7O]`W4?_/%T7_G?FO_`*Y^
M_=>Z]_H&ZC_YXNB_\[\U_P#7/W[KW7O]`W4?_/%T7_G?FO\`ZY^_=>Z]_H&Z
MC_YXNB_\[\U_]<_?NO=>_P!`W4?_`#Q=%_YWYK_ZY^_=>Z]_H&ZC_P">+HO_
M`#OS7_US]^Z]U[_0-U'_`,\51?\`G?FO_KG[]U[H3<5B\?A,=18C%4RT>.QU
M.E+14J-(Z001_HC5YGDE8+?ZLQ/OW7NG#W[KW7O?NO=%1_YJQ_Y=M_\`.5^_
M=>Z@?`O_`+),ZB_ZA-U?^]QN7W[KW1O??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>O?Z^_=>Z][]U[KU_Q^/?NO=>]^Z]U@JJ
MJEHJ>>LK:FGHZ2FB>:IJJJ:.GIJ>&,:GEGGF9(H8D47+,0`/?NO=<**NH<G2
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MJ*Y]:1:*."IGBEJG\DBK9`QU,!]2/?NO=.WOW7NO>_=>Z][]U[KWOW7NL,U1
M3TXC-1/#`)IHZ>$S2QQ"6HF.F&"(R,ODFE;A4%V8_0>_=>Z@Y7-X7!0QU.<S
M&*PU/++X(I\MD*3&PRS:2_ACEK)H4>70I.D$FPO[]U[KK%9W!YZ*6?!YG$YJ
M&"013S8G(T>2BAE9=:QRR4<TR1R,G(#$$CGW[KW3K[]U[KWOW7NO>_=>ZXNZ
M1(\LKI'%&C2222,J1QQHI9W=V(5$10222``/?NO=<4FBDA2HCEBDIY(EFCG2
M1&A>%EUK,DJDQM$R&X8&Q'-_?NO=0L9F,1FZ=JO"Y7&Y>D29Z=ZK%UU+D*=*
MB,*TD#S4DLT:S(KJ2I.H`CCGW[KW3C[]U[KWOW7NO>_=>ZQ3SP4L$U54S0TU
M-30R5%145$B0P4\$*&2::>:1ECBABC4LS,0%`N3[]U[J)C,OB<W2_?8;*8[+
MT7D>'[S%UU-D*7S1V\D7W%)+-#Y$U"ZWN+\^_=>ZEO401S0T\D\*5%2LK4\#
MRQK/4+3A#.T$3,))5@$BERH(74+VO[]U[K+[]U[KWOW7NO>_=>Z][]U[IJH\
M]@\C75N,Q^:Q%?DL<77(8^BR5%5UU`T<AA<5M)!/)44I28:#K5;-P>??NO=3
MZFIIZ.GFJZNH@I:6FB>:HJ:F6."G@AC!:26::5DBBB11<LQ``]^Z]UE!#`,I
M#*P#*RD%64BX92+@J0;@CZ^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14?\`
MFK'_`)=M_P#.5^_=>Z@?`O\`[),ZB_ZA-U?^]QN7W[KW1O??NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U1M_-!ZWB^8_S`^`/\O3?FY=WX?XV]K4'R#[\^1FT]F[FRNT*OM_`=(;
M?VO2;&ZTSN<P4]'F%V=6[NW@M5DZ6">$U4<"`L"BD>Z]TP_`3HO;_P#+^_F3
M_(_X)=&Y3>%+\3-\?%?J_P"6'6/5FZ=X9S>N,Z;W]_I%W1U9V#@]@UVY<CE<
MWB=I;IIZ*@R,E'+,T:UNLI<$V]U[J^?W[KW7O?NO=>]^Z]U[W[KW1=OEGTWO
M[Y"?'?M'I/K/N?/?'S=?9>!3:L7;VU,8F4W5L_"Y'(4:;HFVQ&]?C!0Y_)[;
M%514M:)0]!-4"H0,\:@^Z]UJ]_%KKWXD_%C^=9T7\=/A!LSY$?$Z';&'[YVE
M\F]P_(S=G9.*ZP^<U=AMN4E-MS$=.XWL',9N@[B[(PVYM6?DSE$U`L-!'.8X
MY-87W[KW6X;[]U[KWOW7NO>_=>Z][]U[IAW5G4VOM?<NYI*=ZN/;FW\SGGI(
MV"/5)A\;4Y!J=&/"O,*?2">`3[]U[KY\^UMV?$SOSK''?.OY*]"?S-.Q>S-]
M;HK>P.W/YNO3^5W?ANN?A+O"LWE4S[>VCTSMFHS4%!ENI>@L?-C\9EJBGP59
MB[FOU23C7I]U[KZ">S:RDR&S]IY#'[B_OA05VV<#64.[;TQ.Z:2IQ=+-3;C)
MHXX:2^;A<5/[2)'^[Z0%L/?NO=*/W[KW7O?NO=>]^Z]U[W[KW6IAWMU=\"?E
MU_,Z^>FT_P";GWBFU5^/V(ZCQ_P]Z9[&[SR_0W7.W>E=Q]>4.X,]WIUR])N3
M:E/O#?N4[`>MIZNN6:IEQ[TBP^,@+X_=>ZLT_D3=WY_N;X29W&Y;?N[^U,!T
M9\D^_OC_`-5]E=A2Y"IW_O;I3KG><D746<WG79:"ERV4SLFQ,E11-5U4:3U4
M,4<KC4Q)]U[JYOW[KW7O?NO=>]^Z]TWY8Y1<5DVP:4,F;7'5QPT>4:=,8^5%
M+*<<F1>FO4+0M6:!,8_6([Z>;>_=>ZU]OACUW\E.O/YT?=S_`"H^0G^G;LW?
M?\O/9V^:K&[:P$FT.GNH**L^0^<QE'UMTWMBHK*W)IM?'4F/CDGR.2EDRF4K
M&>><KJ6-?=>ZY?,?^4/\'MW5WRP^:_\`,S[;[![8R.6RN4S75V[3OO>O6M)\
M7>MZ'$T>-Z^ZPZ.VOM+=D5%E=\1;@3STU0:>>NSV:J($6G,A"R>Z]U9!_*ZP
M?R$VU_+\^*^#^4^1W1E>\\?UA0Q[PK=\S"HWVU$^1R,VS8=]3?J;>E+LB3'1
M94.3*E<DJR$R!B?=>Z/O[]U[KWOW7NO>_=>ZUU?YCW7GRI/SB_ET]L=D?(&A
MI/C]!_,9Z=V+T_\`&;K;!56*PN2I*_8^_LED.S.\]UY*KER6[M]TU?C3!BL=
M1QPX?&TK&2TM1([+[KW04?S[*KK_`+3^4OP%^-_9GQ/[^^;NRJ7:?R1[PRWQ
MN^/U/FJ3<&]-QT.)VGL;862W#NS&Y[;-)M7;FV7RN7K))ZBL`ED1(A&[.![]
MU[HW_P#)!_V0W#]8=\;'^'OQK[-^&W9.T>R<30?*?XQ]UUN[ZGM#KS?XP6G:
M]9DCNO<.XX,AM[/[;7RXZOQLPHZN-6X#J??NO=7A>_=>Z][]U[KWOW7NJ7OY
MWO77RI[%^%_R`CZA^05#\?.D-G_''N??'<5?L[`U&0[S[)K=N[3RE?@^L]K[
MEK*J+!;#V#N"*!ESV0BBFR\T!^WIC$DDK^_=>Z!;^8ME,_C_`.1CU75XKM$]
M6X&?JOX?P]G)B]]1]<;Y[.ZEJJ'8J]C=+=5;RF$E1CNTNSMN&;'8=(0T];.Y
MIQ83,P]U[HB7\G5_B_B/YEE3@/@%U]\B/A5T+4?%?<%?W3\8/EU7[UV=O#O;
M?_\`>C")LGLSIWJ#LG<.Y-P3Q;#Q\=7'N'<E)4BGE%9#3>(>MS[KW6WO[]U[
MKWOW7NO>_=>Z(7\^/A`/GQLWK'IO=_<&]>O>@\=V/!NWY`]=;#FK<'E?D+LO
M&8?(PXKJC+[VQ&6Q>;VMM"IW%4P5F36D+R9"&F%.="L6'NO=5J_R_P#XD]3?
M$O\`F@=X=>?R^ZW>6%^%VV/CG38CY/\`73[[W/OKIO:OS"J-Y8FIV-B=B5VZ
M<GG)*3LVDZPAK9MU4M)5.*"*IHDJ@DTR1)[KW3;LOKWY3[2_GE?'#=WRC^0-
M'V;F>R_B9\N,CM#J/K[!5.V.C^C-HX'>G5%#@L1LZER-55;AW5N_-T-4)<]G
M,FPEJ*A5BIXXJ:*-??NO=;&'OW7NO>_=>Z][]U[H%?D=UUO_`+=Z'[9ZNZL[
M6R'1G878&Q\YM+:W<&)PL&X<OUUD,Y2M0-NG#XBIK,?#59?&TLTC4I::/Q5&
MB0&ZV]^Z]UK@=B_RKOC-\%ODG_+]IOY?.7[7P'SUS7?6Q<MV[FH^V]][PR7;
MOQ9QDK2?*#L/Y*X3/YW-82':.8I5`I:N6"E6IW)604U())21%[KW0I?SONP]
M^?*3XF_.WK7J?<.Y=I_'+XF]5YC-=]]D;7GJL7/V]WYBYL+F=L?'7:>=@9%J
MMF]>T\L64W]+!Y!)4S4>(U(PKE7W7NMB3K<..N]@AU*O_<G:FM6!#*PP-`&!
M#>H$-P;\^_=>Z6?OW7NO>_=>Z][]U[KWOW7NO>_=>Z*C_P`U8_\`+MO_`)RO
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M'/NO=;._4W7N.ZDZKZTZJQ%74Y#%=9[`V?L#&U]:2:RNH=G[?Q^WZ6LJBSR'
M[BI@QZN_J-F8\^_=>Z$#W[KW7O?NO=>]^Z]U[W[KW6O5_,DZ3^;.Z_DYC-Y;
M9_EE_"3^9CU71T.V*_X[Y_N',[1ZX[(^+6^\?!%%N:#?%;N[%Y?_`$C["SFX
M(X,O2B@,4U,J30,FHH[>Z]U9/_+D^+.^/B3\9L=L?MS=."WMWKV!OWL/O3OO
M=.U*2HH=I9'MWMS<M7NG=%%L^BJPM32[1VU'44^*QB.%(HJ&,Z5OI'NO='N]
M^Z]U[W[KW7O?NO=>]^Z]U7+ANA.U*7^;)O;Y-5&W8DZ5S'P.V=TMC]V?Q;&-
M-/V/BN[\_O"NP1P@J#EXXH=O5L<_W+1"G8MH#:@1[]U[JH_OG,?S?]Q_.7?/
M<&<_E5XCY2=-].[VDI?A9MG<GRYZQZ[V#L6@P\<E!)W7F>NI(LXFZNX]VSZZ
MFAR>69WVY12)!0P4\XDG?W7NMAOXW[U[F[$Z2V!O3Y"=/TG0?<F>Q=34[YZB
MH=Z8WL.DV5DH\E6TU/CX=XXB"FQ^;6HQ\,-1Y(T4*9M!Y4^_=>Z&_P!^Z]U[
MW[KW7O?NO=5Q_/\`Z$[4[OWE_+]RW6>W(L_0='_.[K#N?LR:7+8S%G`=<[=V
MAO[%9C.Q1Y&IIWRDM+79RF44U.)*APY*J0I]^Z]TA/G3EOYGW4/<_7G?/P<V
M!L'Y5]2G8&7Z\[:^(N\]Z;>ZEW`FYZG.P9?;7<O7O9^4PU4%J*&E5\?D\55S
MFGEI],L41ENZ>Z]TU_RXOC?\H<1VQ\J/G/\`-G;^P>N?D5\NYNK<#1]']9Y]
M]W;=Z2Z;Z9P62Q.Q-HYO>HAI:7>F_,C5YVLK<K6P1"GC>1(H6*+I3W7NK:_?
MNO=>]^Z]U[W[KW13/GIUCO7NKX3?+#J'K?$IGNP.S/C[VML?9>%EKJ/&1Y7<
MVY=FY;$X:@?(9"6"AHEJJZJ1#+*ZQH#=B`/?NO=$<^6OPJ^0W;7P1^%FWNG8
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M)N_YL[;JZ/X^]M?RL]E_!'XY[,V3E<EM;=>V/DSM+N>LRV\WRU`SX_-XW&8^
M/<>8SVYQ6U=?D,[7U-15557&SU$DDLVKW[KW0]=G=`]K;B_FG?%#Y(XC;D-5
MTYUI\6?DCUOO3=#9?&0S8K>._P#=/6N2VIBTPLM0N5KDR-'M^K8S0Q-%#XP'
M(++?W7NK(??NO=>]^Z]U[W[KW1>_E=NOOK9'QR[?W/\`%SKC']M?(;&[,R(Z
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MKWOW7NBH_P#-6/\`R[;_`.<K]^Z]U`^!?_9)G47_`%";J_\`>XW+[]U[HWOO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KL@CZCW[KW7K&
MU[<>_=>ZZ]^Z]U[W[KW7O?NO==V/]#S]/?NO==?3@^_=>Z][]U[KWOW7NO>_
M=>Z][]U[KL@CZCW[KW77OW7NN6AOZ?[R/^*^_=>ZZ((^OOW7NNO?NO=>]^Z]
MU[W[KW7K6^OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[HJ/_-6/_+MO_G*_?NO=0/@7_P!DF=1?]0FZ
MO_>XW+[]U[HWOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZP51(
MI:H@D$4U0002""(7L01R"/?NO=?/7_X3??)7O?K7Y_YJO[O[@["WET?\QMQ_
M+CI7:K=C[XW#N#`[2[-^,U5MOMBDCQ4FY,]7P4E1D]F;AKXM$$,;:$`)*CCW
M7NIO\LGO[Y#]R?\`"A3JWY%[[[3[)CZ-^8VWOF1WCUGUUE-Y[E7KW$=5[-R/
M:77.SIX-N5&>JMM?:1XKKZ*O$B0)%&[ZUY&KW[KW5WF4_G\]Y[ZQ_<WR&^)_
M\L[M?Y'_`,OGX[[MW1M;LGY/8[LW:FU=S[JI=@UE1%O_`'ATYU-DZ";+;XVO
MMJ@5*EI!4([1*YD$3*RI[KW0]?+?^>UUGT1L'^6SW'TATWNSY0]6_P`Q?=&9
MV[LN/9%?'C.Q<;54V+P!PN$Q&TZZE>CRN[*S=6?7$UE)4UM''03P2LTK!??N
MO=<_BM_-\^0O:_RN[Q^!_P`CO@7F/C7\N=E?'_,?(KIG83=R;5[`VEVWM6FC
M%/A\)5[ZQ&.I<5MK+Y3,SQ4S3**JFA9*@2%##9_=>ZI+^$WSJ_F/?(CX'_SW
MLM\BMG[KI-O[0QWS3JL7WK)W?C\CG.D>T]H;,QF.PWQDV-MC!P8^OI-O["QD
MDM329_'O!3/,A:QD?5[]U[H6O@S_`#KOD/\`$/\`EQ_RY=_=U?!_N;>GP[S>
M+V'TIV1\T-W=L[=EWG6[_P!T[GSV'CW7A.M\E/F-W;EV/3Y*/Q193(U=(V0%
M.XA`O%K]U[JVKYK?S@NS.G_F'2_!/X;_`!2Q'RI[]Q74>([KWU%OKO\`Z_\`
MCMM3&;1W*TW]W<;L[)[Y\E1OS<]72Q"KGIZ.,+3TQN22'T>Z]U8W\%_D[O'Y
M=_'+:'=/8/QU[7^+.]\I5Y?";IZ?[?QC4.>PV:V_6OCJZOP5<8J8;CV;E)XS
M)CLCX*<U,7UC4CGW7NB4?.C^:ON[H7Y.;#^"/P]^+6X_FK\T-Y;#J>V<YUUC
M=\8/K/8O5G6%-5BEAW+V-O\`SM/74N(GS31R+10>$!V,0:0-/"C^Z]T7J+^<
M/VUWQ\-_Y@&.ZP^+VZ>I_P"8]\+-EY*A[?\`BMOGL#;>+R.QTR^&K)$[@V3V
M&:63"[NVC@L-!5YF@D6GC:M:BCA`(J(9']U[HN/_``EDZ][GS?QCW7\L^]\)
MWC/NSO[%X2?"=K]I_)[+=TX#NK%0;HWG5YO=NV>L*^\?355C<W_D4\+-)+7*
MBN"$73[]U[K9P[.V1'V9UMV#UQ-G<WM>'?\`LG=&RY=R[:JOLMQ;?CW/A*W"
MOF\#6$$4N9Q:UIGII+>B9%;\>_=>ZT*>\OY+];U5_-F^%W\OO%_S(_YA>0ZY
M^2O1?;W:6Z=YUW=59_?'!9CKQ<W_``G'8%8##A1C:]L8OW'GIY9%!.@CZ>_=
M>ZM@ZQ^>G?OP+^0VZ?Y)'Q)^+G;'\P#MSXW=:['[!VUW!V_WYA-L9;=VU>P3
M3;WWSG>V-V9S`M0;<I]FOO2CQN*6%JN7(-H31'IY]U[HP?=W\\7N/%=P=[==
M?$KX)UWRKVI\+X**B^9?8M-WSL/K+%[2WQ2X;^/[UZ]Z8QV[*89'MW.[,QU'
M6+.T"0"6HA"*EBK/[KW1D>Q_YL>[-X?%7XE?(C^7]\..WOFQE?F7424W7^`Q
M5=C=@[0ZQEQE--4;A7O;?M='EJ#84F-J,?6T49>)Z>>JHY/WU7Q^7W7NBA;;
M_G1?)'OWXL_S.=K;/^'U3U/_`#!/@-@*O&;]Z9?N/:.X-M8>DW#C<Z_^DC:O
M9D>+_@.5K>N\-BJK*RXZ2!ONIZ-(8V;RV7W7NB<?#W^<_P#+CXG_`,COI_YG
M?*WXY9WM9).U.L>M]D]BY?NJ#<^^OD=M?M'=V]VW;VE64=/B,EE-O[@VKD,8
M<=1X>JL:W0FF2)![]U[HVV0_GV_)W9?R<P/Q0[/_`)3G=^V>XOD'U]'V#\+-
MD8KMKKK.9KM/'2U%6I7MRN5J;;O3E-B,=1S5>8E>JR#8A:9XIHRS(Q]U[HS_
M`,1?YV&S.U?C]\YNTOEQTMN'XB=B_P`N/<F9V[\I.M:G<%%V-3XQJ2BKJ["S
M;)W!BZ7&KN2JS\E"U%!3^*,R5K1^-WBF1_?NO=`/T?\`SZ.QLOV1\9Y?EE\%
M-Q_%OXS_`#=WAB-C_%SO23NOK[LC+3[BWC`^1ZYQW<_7&WC#G>LVWSBI(9()
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBH_\`-6/_`"[;_P"<
MK]^Z]U`^!?\`V29U%_U";J_][C<OOW7NC>^_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[K!4JSTU2B@LS4\ZJH^K,T3A5`_))-O?NO=?/+R?\J?^
M8IB_Y-6?FZU^/W<FQ_FKU+_-#[>[NZJVGAJ*BI.S\EU#VSLRGZRW1FL'3_?.
M8\1D\;5AYEU@S4U,[:2MB?=>ZM9ZM_E@]S]0_P`Q[^4;CL7T_O$_'[I+^5/O
MSXW]S]J8>BA@VSM#LC=NQ^PJ#<.-RE5'6F;';ARNX-X32I8-Y)IU8-PVGW7N
M@I^-^VOYL'\MCX9]U_RCMF_RV]X_)*NR^6[KVA\:OEGLC?.TZ+H*JZ_[SRN>
M2FW3W#/EJNDS&VLKM:/.5-7/2.%E=?'"^G_.R^Z]TK^S_P"5-\D_CULK_A-[
MT)L/8^XN[XOA;\F,EO'Y*[^V/CON]K;$7<N>V7NG/YNNEJYJ>>EVM09.>M@I
M9F0O+!1%RJLP7W[KW5A^7^-_?$__``I&VI\I8NJ-WR?'6B_ES9'J^J[C6A@.
MR8.PYM_Y/)Q[0?(?<^<9EJ"59='BTZ6'J]^Z]U6#\9/CI\Y.G/CM_/=^"6\?
MA#W9][\C,_\`.3OCH_O3#2[:RW5G9DG8^`I<)L#KC;+0Y-<I5[QW5'/YZ<:?
M&NEXIO%(AO[KW2J^27P@^7.ZO^$SWPH^*&WOC[V/F?DAL'<7QGGWETW18F&3
M>VW*?:'9>5RNXILGCFJTC@BQ.-D264^0Z4<$_FWNO="#_.8^)M;WAWIU_4]Q
M_P`F[?OS0ZBI>C=N[<VA\D_B#VR-E_+79F_:"IQ]?D-H[TP]34XO%#8]!3QU
M<5*U5'DDO5L8I(V>6$>Z]U8/_(#^.?S/^-7PIS>T_F9D=_T&2W'W%O'=W1_5
M':V^T[,[)Z2Z,R4&-BV?U]O'>,=14PU68IWIYJB2EC8)2-*1HB9FAC]U[HMO
MRYZ6^97PB_FZ9;^:=\;/B[NGYM=-_(+XX8/X^=\]1=89W#X[N?K[/;2J\7)M
MG=NSL9N*IBH\W@,BFWZ!:F.(A8O\I:3QDQ.WNO=);XL?#SYC]F;A_G`_S&_D
M5TC5]%=G_.[XZY?IOH7XEQY7'[G['V]L/9/6.9P.U:GL"OQLRXJ/?^\Z^.BC
M6@B*F"02:](=`/=>ZL?_`)&G37:?Q\_E2_#CISNS8NX.M.T=C;!SF-W=L?=-
M*M%G\!75&_-UY&"FR-*LDHAEFH*V*51J)T2"]CQ[]U[JV+W[KW5"GRC^.?>F
M[_Y^O\M[Y';8ZMW;F^B>K/B_W]M+L3M.@H8Y=H[0W+N4;H_@6%S5>9U>GKLD
M:F+Q($;5Y5_QM[KW2?\`CU\:N^]M?\*+?GE\G]P=3;OQ/Q][#^'O3NR-B]O5
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M<6)HZ:JF$=XX:DM:X('NO=%!^!G\L[KJ3LKXO=4=S?\`">7N79/9G6N1VU'W
MG\K-T_*'-XOIW#;HZ]:C6/MSK:F_O]D:?>:YK<..CR*XNGCB)AD9(`Z+[]U[
MJWS^6G\8OD%U3_-1_GC]P]C]1;RV;UC\@M_]89+I/?.;Q\5/@>RZ##X7=E+D
MJC:U4M1(];%1S5<(<E4`\J_FX'NO=5<[&_EO?-K.?\)G?E7\0F^/N]<'\E]R
M?(WLCL;;'3NXX\?A=V[EVQ'W7M/>--48:&JKA15%1E=OXV>6CC:9#4M'H3U,
MH/NO=;47P![1[&[:^*756?[7^._:'Q=WM@L'2;#R?4_;W\(_OC2KLBAH]OQ;
MB;^"U-32?PC<8HS4TFHK+XF&M0??NO='+]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW14?^:L?^7;?_`#E?OW7N@6^&E?WO!\:NLX=E;5ZARFUT@W,,1D-T
M;^WK@,_50_WRW"9'R>'Q/6NY,=0SB<NH6*NJ5*!6U`DJ/=>Z,]_%/E!_SPW0
M7_HUNQ?_`+37OW7NO?Q3Y0?\\-T%_P"C6[%_^TU[]U[KW\4^4'_/#=!?^C6[
M%_\`M->_=>Z]_%/E!_SPW07_`*-;L7_[37OW7NO?Q3Y0?\\-T%_Z-;L7_P"T
MU[]U[KW\4^4'_/#=!?\`HUNQ?_M->_=>Z]_%/E!_SPW07_HUNQ?_`+37OW7N
MO?Q3Y0?\\-T%_P"C6[%_^TU[]U[KW\4^4'_/#=!?^C6[%_\`M->_=>Z]_%/E
M!_SPW07_`*-;L7_[37OW7NO?Q3Y0?\\-T%_Z-;L7_P"TU[]U[KW\4^4'_/#=
M!?\`HUNQ?_M->_=>Z]_%/E!_SPW07_HUNQ?_`+37OW7NO?Q3Y0?\\-T%_P"C
M6[%_^TU[]U[KW\4^4'_/#=!?^C6[%_\`M->_=>Z]_%/E!_SPW07_`*-;L7_[
M37OW7NO?Q3Y0?\\-T%_Z-;L7_P"TU[]U[KW\4^4'_/#=!?\`HUNQ?_M->_=>
MZ]_%/E!_SPW07_HUNQ?_`+37OW7NO?Q3Y0?\\-T%_P"C6[%_^TU[]U[KW\4^
M4'_/#=!?^C6[%_\`M->_=>Z]_%/E!_SPW07_`*-;L7_[37OW7NO?Q3Y0?\\-
MT%_Z-;L7_P"TU[]U[KW\4^4'_/#=!?\`HUNQ?_M->_=>Z]_%/E!_SPW07_HU
MNQ?_`+37OW7NO?Q3Y0?\\-T%_P"C6[%_^TU[]U[KW\4^4'_/#=!?^C6[%_\`
MM->_=>Z]_%/E!_SPW07_`*-;L7_[37OW7NO?Q3Y0?\\-T%_Z-;L7_P"TU[]U
M[KW\4^4'_/#=!?\`HUNQ?_M->_=>ZY?Q3Y17_P"/&Z$O_P")6[&O;_T37OW7
MNNOXI\H>?]^-T':_/_&5NQOK_C_QAKZ^_=>Z]_%/E#;C8W0=OS_QE;L:W_OF
MO?NO=>&4^4/-MC=!_P"-NUNQO]Y_XPU[]U[KW\4^4-O^/&Z#M_XE;L:W_OFK
M>_=>Z]_%/E#Q_OQN@_\`#_C*W8W^PM_QAKW[KW7OXI\H;_\`'C=!W_\`$K=C
M7_\`?->_=>Z\,I\H?QL;H/\`V':W8W_VFO?NO==?Q3Y0?\\-T%_Z-;L7_P"T
MU[]U[KL93Y0_C8W0?^P[6[&_^TU[]U[KW\4^4-_^/&Z#O_XE;L:__OFO?NO=
M>.4^4'YV-T'?_'M;L7_[37OW7NNOXI\H/^>&Z"_]&MV+_P#::]^Z]UW_`!3Y
M0V_X\;H.W_B5NQK?^^:]^Z]U[^*?*&W_`!XW0=O_`!*W8UO_`'S7OW7NO#*?
M*'\;&Z#_`-AVMV-_]IKW[KW7AE/E#^-C=!_[#M;L;_[37OW7NO'*?*'\[&Z#
MM?\`/:W8WU_]$U]??NO==_Q3Y1?\\-T)_P"C6[&_^TU[]U[KK^*?*&W_`!XW
M0=O_`!*W8UO_`'S7OW7NO'*?*'B^QN@_\+]K=C?[Q_QAKW[KW7OXI\H;<[&Z
M#M^/^,K=C6_]\U[]U[KW\4^4-N=C=!V_'_&5NQK?^^:]^Z]U[^*?*&_.QN@[
M_C_C*W8U_P#WS7OW7NO'*?*'\[&Z#_V/:W8W_P!IKW[KW77\4^4'_/#=!?\`
MHUNQ?_M->_=>Z]_%/E!_SPW07_HUNQ?_`+37OW7NO?Q3Y0?\\-T%_P"C6[%_
M^TU[]U[KW\4^4'_/#=!?^C6[%_\`M->_=>Z]_%/E!_SPW07_`*-;L7_[37OW
M7NO?Q3Y0?\\-T%_Z-;L7_P"TU[]U[KW\4^4'_/#=!?\`HUNQ?_M->_=>Z]_%
M/E!_SPW07_HUNQ?_`+37OW7NO?Q3Y0?\\-T%_P"C6[%_^TU[]U[KW\4^4'_/
M#=!?^C6[%_\`M->_=>Z]_%/E!_SPW07_`*-;L7_[37OW7NO?Q3Y0?\\-T%_Z
M-;L7_P"TU[]U[KW\4^4'_/#=!?\`HUNQ?_M->_=>Z]_%/E!_SPW07_HUNQ?_
M`+37OW7NO?Q3Y0?\\-T%_P"C6[%_^TU[]U[KW\4^4'_/#=!?^C6[%_\`M->_
M=>Z]_%/E!_SPW07_`*-;L7_[37OW7NBV?Q#OW_27K_NGTY_$?]F8\O@_TA;X
H^Q_O+_LI7A^Q^[_T8_<?P;^ZO^4_=>'S?Q'_`";[?P?Y5[]U[K__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pg20a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg20a.jpg
M_]C_X``02D9)1@`!`@$`EP"7``#_X1KW17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````I````-``%PIP```G
M$``7"G```"<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S`#(P,3(Z,#(Z
M,C,@,C`Z,3(Z-38``````Z`!``,````!__\``*`"``0````!```"6*`#``0`
M```!```!I@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!G!````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B
M95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`<0"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]+Q**GXU;WMW.<V22222J/4>J]-Z=DMQ
M\BHC>ZAH>/H@WNO8-_[C:VXMGN_J+1POZ)5_5",0#R)X_#4)*<KI_4,+-MS:
MQ06?8;34X@[Y@N9]&K=Z=FZM[_1_G/L_V?(_[4*V#A$`BMY!U!].S_R*L.:U
MK'0`)&L?"$V/_1ZOZC?R)*0?J?\`HW_]MV?^02_4_P#1O_[;L_\`(*VDDIJ?
MJ?\`HW_]MV?^02_4_P#1O_[;L_\`(*VDDIJ?J?\`HW_]MV?^02_4_P#1O_[;
ML_\`(*VLT_6#ID6!CWVV54G)=376]UGI![J-_I;=WNL8_9^^DI/^I_Z-_P#V
MW9_Y!+]3_P!&_P#[;L_\@K-=C+:VV,,L>`YI@C0B1H5))34_4_\`1O\`^V[/
M_()?J?\`HW_]MV?^04\7-9DV9-;6/8<6WT7[Q`+MK+MU>OOK].YGO5A)34_4
M_P#1O_[;L_\`()?J?^C?_P!MV?\`D%/!S:,[&;E8YFIY<T$^+'.J?Q/Y[%/)
MR*<7&MRKR6TT,=98X`N(:P;WG96'/?[6_18U)2']3_T;_P#MNS_R"7ZG_HW_
M`/;=G_D$?'R*LG'JR:3NJN8VRMQ!:2UPWL.UX:]OM/YR(DIJ?J?^C?\`]MV?
M^03WT4C&L>UL'8X@Z@C3_.:GNZE@46&JZ]C+&NJ:YI.H-[C5C;_W?7L;Z=2&
M>H8.77FTXU]=UN*'5Y#&.#BQT'VV`?1_\GZG^C24_P#_T/0W=19@X-!]*S(L
M>WVU5;`8:-UECGY%E%%==?[UMS/\]#RNLY=;F.Q\"Z^I_P!F,[',<QM]KJ<F
MRVNQK7_J=+?6?6S?=_Q=/Z=8_P!:^GNSNF8+64U760]C"^R]KVN>&^ELIP;<
M>S)KMM971=[_`-7]2O,_FL>U=8P;6-;`;``VC4#R"2G.P.HY>4_/9=C&MF-8
M64N`(WMU`_GA4U[MC69'J5?H/2R:JO4]:JY6J+K!16/0L/M;K+/#_C$:YQ;2
M]P;N(:2&@@$P/HR[VK,MZ_A8=&+2]MEN??4Q]73J`+<@AP^DZMAV54M<W8_+
MNLJP_P#NPDIM9G4'8F,_(?BW/:R);7Z9<9(9[6^JW]Y5L[ZR],P+CC7N<[,B
M685(]?(>(+O9B8INR-OM_G;*V5?\(L'ZS.ZG=TE^3UR[[#BDL-/2,)[?7L)=
M2[];SW[/4=CN]2Q]'3_18S_N7E+8Z?9T[I]9Q^C](O962"[TJ!C[C&WU+79C
ML1UMG_"6?I$TSB#5Z]NOV,D<&241,1/`;'&?3#T[^N7I<OK'4NN963TMPP*.
MF4G-8,9_4W"VU]KJ;]NS#P7O92YK?4V/?G>KZG^"6EM^NP((LZ:\?G--5S#Y
M;7#)O_ZA0ZGF]9??T_T<#TIR@&^M<P$S5>T[VXYN]NPOL_G'_0_FU>_9_4LC
M^F9[FM,35B,%+?[5MAR,G^U5=0AQWM&1^G#_`--=[%49Y(1OM+W9?9A]SA_Z
MIP.-DV?6IO6<,6'I3;A3>6[GW-,$T?1KW>_Z/[O^E3V=*Z[=4ZMV-T@LLK=2
MXM]8%U3SOLIWL(=Z3WG?Z:M9'2>D5=9PV64XSV6TY!L^U$VW/?NQ_1V/R76.
MMV[K?I_V%4O^J.4:K1CMQ&6NQS6UY8(]3U7VBQK/0<RES,8_9_7;ZEGZ3?Z?
MZI5ZQ_6=0-=M3_WJ".7_`$9ST^:XPW_\,0UV_6*GKF8ZW*Z7BN;BXPL<:[+7
M%H=E[-SK<S!]S=_OWV?0MI1&YF0]Y.5]9C)T%6!5B#_H6_M>_P#Z:O=/Z5@U
M]=R6/PJ&OKP\1Q>RIC:][GY;;GT5[GOKW^DS_MM;OL8WLUC1\``$OUG]4?;+
M_O$G[N-ADEWUAB_9F>&Z;COLRLX8O4.NWO.29<WT1/Z.EOZ3[517CU.W,_1L
M_1;*?36D,'ZUO<649F=2V`&V9-G3R?G7C].R=W_;RLX'6<.G)ZD&6/SK+,K>
MQF*W[0=OI8[&^['K;5CM]OI?K%O^"L_3*[Z_7LD_H<:K!KGZ>4[U;(_\*XCO
M1_\`A@G>SD_2EP_00_YLN*:P\QAVQXA+SE++*_[V/VL?^-%P_JY7]9K^GU98
MZKZM3WV_H_1QK1+;+*W_`*SCWTM=^D8Y_M_F_P";1>J8?UO^QY-HZJUM3*K'
M.J;A,W.`:YWILLKS;+FO?]%CZV;U;Z1@]3=@M-?5`UF^V!1CTMK_`)RS=M;%
MGYW\I$ZE@]29T[+?;U2:VTV%XMII]/:&NW>M[1^BV_31]F'^<!Z;Y?\`O4?>
MLEV,0&MZ8\&CD=/ZE]<.GX&.[*PSF8HIK>VZAOJNVEH]EE._&SJGM;]/T\/J
M=B)E_7+U\&UN*U]>94^L6-QW566L;ZM==K;,/-95G4OL;^A;]HZ;].QBT^FC
MKK.GX;Z'X650::RQ@:^CVEK=NRZM^;6YNW]W'6;];*VY_2C5UGHOJ!MM(;<Q
M[;6M!MJ]3T[J0WJ-/J,_1_H<3_@TO8.T)_\`.O\`YN7UI',QN\N(2[^GVS7]
M[E_U?^-QNEU+'Z/;?<[,W56O=BNN'KLK)].RP]-_P['5^IE>IZ&ST_6OJ_X)
M6*,'IN*.HV8C6C*R`'YID%^\5!M8NV_1_1_I/^NV7_X99'UDNPF9V2R^LDO'
M2V7'UQ3ZC'96;]GJHW5/_3U7-?=_/8_L_P"U.+Z/J(G2/L_[6^L1JIO#G-QW
M/R[+`^N^:7;+*&UM;76[9]/:^S]&^C^8K]+'K"Q__]'M^LXF3E=(Q*Z:;+VM
MLK?=72,=SW,:??4:^I[,=U5S-U=GZ>FUG_#5>K0\V7D==!J=50:FG[,7,8&W
M0766?;:WN+ZO97C"OWU_X7^:]59_UI9G6?5^FK$>X"YKJ;JFM,6,M8ZGTWW>
MVNANY_T[+:O^!_3^G59TM)8:6&L@L+1M+3N;$>W:[\YJ2G'==U-V'UC]I;L;
M&8+1CW,/I/;5M?\`I*;:/M-GLH]*YE_I^O\`:O7K]#]#4N<JP\"SH[<;`J95
M3;A6NRL_,#[A:)QGY>7:Q]563U',QO\``_S>+4]_Z+^C_9EW.4P68UK"P6AS
M'`UNB'2#[';_`&^[^4JN-T_&NZ?C,R:&RW%^SN9,@,L;6+J1L]FQWI,0(-[T
M/^<OB8")N/%.]+/ZOA_N_O.!=TX4'JN4<VN_-<W'Q\F_,NAM,.^T"MCJ\?\`
M5J\EN36_[,S]%_-?Z1=/OSO]#5_VZ[_TBN?ZV_%I&?5TG&%_4+PQV=<'.%=>
MP@TLR;I=^F?O]F-5^E]/]+;Z=7Z1:AZ1D9!GJ.?=<TD_H,><6J#_`,0[[6[_
M`*YF6,4@Q@`<1$1VWG_B_P#?L<LAD30,CW^6/\O[C1Z_U!E61TUN1:RFVK+9
M;Z-%Q=:\&N^IK/L[,=]]U=EEC&>G77[U9+OK#GM&VMO2\<@S+VORC^[_`(._
M$QO_`&;?_P`4B6]%II.$.FXV/171DMNO;MV2T5VT[F^FQV^_]*UWZ1:B7%$?
M*+/[T_V0_P#1UM2/S'3M'_OG`'U>K;F56'I^)D5>G8W(LR;'77O>XU^D\VWT
M6NMVM98S])9[/4_1+,=?ALIOMP<6S#%6.<K]6S#4T!EEE!K.*-V.Q]CJG_9_
M4Q?1R-EO^A79(7V;']06^DSU```_:-T`[@-W]8I>Y/\`>/VI]N'[H^QYS'PN
MMV]6R669EC)Q,9SX-+;H<[*VTVWUXCZ?T+VY'OHIK_G/YU7V]!QBX.OPZ\QX
M$;LO(LR3_9&57:UG_6UJMQ\=M[\AM3&WV-:RRT-`>YK9]-C[/I.:S>_8B)>[
M/H>'^Z.#_H(]N/47_>/'_P!)S<'!R,%V2ZFJJ,J[UW-#M@:=E=.QOIT>_P#F
M=^]_OWO5K?G?Z&K_`+==_P"D%823+M>UF?:ZVAC,>EC1PUMA`UU[4)R_-(@T
MU$'_`(5W_I!6$DE-??FC04U?]NN_]((&;CY>9CFA[&U@N8\/KM(<#6]MS/IX
M[V_3K5]))37WYW^AJ_[==_Z04LB?LENX`.]-T@&1,>.B,A97]&M_J._(4E/_
MTNP^LMF"SZNT_;,<93194]E9O=CEKFN!]=M]`?DM]#Z7ZO79:CY'2^J86/3A
M=!<W'P\=M#*:BX$C:Z[U=S[F7/?5[L1U_O\`5NIKMKI?5:J7UO?4WZN4LLR'
M5;RV*6V5U&R/=S?5>YWH?SWZ%OZ*S]/=^AJL75-^B.>.^I^:2G+Q6=9K;U)^
M7:S:Y[GX?JP6M;#G-W^D*-E+*_1K>QS_`%?7KR;O7].VI93.MY&<,;`.2S"K
MR:=[<FNNP/N]-OJ9-?30YSG,J;6VS;FV_I;/^T5-G]*72Y5?JXUU4-/J,<V+
M&[V&06_I*Y;ZE?[[-RK8O3J#AX0N8UUN-0VMEE0-8;+6"ST&M>Y]+7^G_I/Y
MO]'O3HD#6KETO8(()TO3JU<3`Q<OHU%&.W&MZ7?6RVJI]#BUS7;<BNRQEMNY
MUCG_`*9WJ_I?5]]GZ1:&S/\`]+5_VV[_`-+*>+BX^'CUXV,P5TU-VL8.P^)]
MSG?O/<BII))LZVG9K[,__2U?]MN_]+);,_\`TM7_`&V[_P!+*PDDIK[,_P#T
MM7_;;O\`TLELS_\`2U?]MN_]+*PDDIK[,_\`TM7_`&V[_P!+);,__2U?]MN_
M]+*PDDIK[,__`$M7_;;O_2R6S/\`]+5_VV[_`-+*PDDIK[,__2U?]MN_]+);
M,_\`TM7_`&V[_P!+*PDDIK[,_P#TM7_;;O\`TLELS_\`2U?]MN_]+*PDDIK[
M,_\`TM7_`&V[_P!+*61N^R6[H+O3=)&@F$9"ROZ-;_4=^0I*?__3[#ZT,=9]
M6:FL#G6BVAU0J-@LWM>'L]!N,6766>W_``;_`%*:_4R:OTU%=:M9'0+F=&P>
MF=-R'8S<%U4$O>2YE;7-]-[Z_2<[W.;9M]G\W^C^S_H[::/UM?5_S;QZ7ACG
MVVT^FRT@,<6N#ML74Y6-:_\`T=.15^D?_->I?Z5:Z@$[1N@'OX2DISL+`S,<
M9INR"[[1:ZVJ"Y^QI]W_`&I-K6_Z+TJMF-LJ_1TUO?:CT8]YIK(RK!+6Z;:_
M#_BU9>1L=Y`S]RCC_P!'J_J-_(DI']GR/^Y5G^;7_P"DDOL^1_W*L_S:_P#T
MDK"22FO]GR/^Y5G^;7_Z22^SY'_<JS_-K_\`22L))*:_V?(_[E6?YM?_`*22
M^SY'_<JS_-K_`/22L))*:_V?(_[E6?YM?_I)+[/D?]RK/\VO_P!)*PDDIK_9
M\C_N59_FU_\`I)+[/D?]RK/\VO\`])*PDDIQ.MWY>$,5S<O*V66.%K<:FNVY
MP%=CVMJJ^SW;OTC6_1K6:SK-]K;MMW6*'5"TM?F8M./0?28Z[?;EOZ>^O'HM
MV^RVW_MM;/5['59G3;&UNN+;K"*ZXW']!?\`1WN8S_IH%GUCOKQ,O)=TK,;]
MD%A`>UC0_8-S?<;/H/\`]*UEE3/IH&0!`.Y\%\<4I1E,5PQ^;U1'_-<_'ZR7
M5WW9/4<W&JI-0W%N*XS:USFUW-&#^@N_1[F5?X3'R,&__M9Z3&'7L;U-K^J9
M];`X,=8^K%:&D_9]N_?AM=[F9M%OZ/U/T7J>MZ7IK0I^L[2,NW(Q;68^/8QE
M;VM<7'U`[9ZU3V5^C;[:[/3_`$GZ',PO\);Z;%_SKQ@\"S#RJV;@PO<P""?0
M,[-^Y[?3RV6_H/5>RNJ_U&?H45CGLZM?8VRIN?G5YK&Y#O2?7C%C?LQ&[UK!
MA,^EZE'T?\);Z'J^HNFR1&+:"9BMVI^"YW*ZKB9KWU9&`:>JMIR@RUS6GTZZ
MO:_;=9Z5SF7,L:S]!4^KU?M%3+/T5[UT>5_1K?ZCOR%)3__4]"MZ5B=3P,>K
M*-H97ML:*;K:/<T[ZW.=BV4N?Z;VMLKW_P"$1>J=-/4&8[6WV8[L:]F0UU?Y
MQ9N_1V-=[7L]^[W_`.%]-Z/A?T2K^J$2RVJIH?:]M;2YK`YQ`&Y[A76S7\ZR
MQ[:V?RTE-'"Z17@MS2+"[[7:ZYVP"N"[W'W5>Y]N[_M0_P#3/K]*NS^91J,.
MLTUGU+=6M_PK_#^LB5Y6-DMN&/:RXTN=5:&.#MEC1[ZG[?HV-W?04\?^8K_J
M-_(DI']BK_TEW_;K_P#R:7V*O_27?]NO_P#)JPDDIK_8J_\`27?]NO\`_)I?
M8J_])=_VZ_\`\FK"22FO]BK_`-)=_P!NO_\`)I?8J_\`27?]NO\`_)JPDDIK
M_8J_])=_VZ__`,FE]BK_`-)=_P!NO_\`)JPDDIK_`&*O_27?]NO_`/)I?8J_
M])=_VZ__`,FK"22G'ZDPXN9TZVIEV2\7612+)<Z:+OH_:;*Z?;_+L8G_`&YE
MBG(M?TC-8W'%AXJ<7;&[VMKKIOLOM=<[]'7Z-5K/Y:T,G#Q\KT_6:2:G%];F
MN<QS7%KJR6OK<Q_\W8]B'^S,7QN_[?N_]*IP(HCA!\=4$&P;KP:'_..\O<P=
M)SIU+":P`1[-GTG>W=ZGO_T7IO3U_6%^S)MOP<C'KQJ[;G&UNR6U-:YS6%Q]
M.QSO?^?_`-_5_P#9N-^]?_V_=_Z53'IF*003<0="#?<01YCU4U+C9/4V=0HO
M-O3;L>P4WMIRWU_1:&U-=MO#=U'VKUK/L_\`I:J?S+?T#-[)$8MH':MW.O9"
M=TO$>TM?ZKV'EC[K7-/?W,?:6.1LK^C6_P!1WY"DI__5].POZ)5_5"AU#IN)
MU&NJO*87"BZO(J():6VU.]2FP%O[KE/"_HE7]4(Z2G.^R873,;,R'>I8RS=9
M:''<8U?Z-+?;M9ZC['5U?Z2Y%PZ\+)Q:KJZBUCFB&O$.:1[7,LU_G&.&QZM6
M5UVUNJM:+*[`6O8X`M<TC:YKFN^DUR:JJJFIE-+&UU5M#*ZV`-:UK1M:QC6^
MUK6M24T^I?8<+`NR[JG&FEN^WTOIA@/Z1X]S/YMGZ1^W\Q6?LF-_HPI9&/CY
M-3J,FMMU+XW5O`<TP=S=S7>WZ341)3GYEG2\6[%IR"*[,JWTZ&S&YVUQA^OT
M/S?=_A_0K_G;*E:^R8W^C">[&QKW5NOJ9:ZEPLJ+VAQ8\<65[OH/_E(J2G-N
MR.F4]5Q^FV,<,C)K>^D[7>FX,@O;O^CZC6C=_P`'_(]>GUKGV3&_T87.X?6/
MK/OQKNI=$8ZVRG'`=C.>7,-_J.SFV.OJ;Z#OU?%_4_YBK_M7U+^CJ0^L/UE=
M;C@]$=6QVUU[=[WNV%M[KA59Z-=3;:HP_P"?]/U;;+:/YO\`7*4ITF9'3WYP
MQV4V.<]SZ2\-)K:^D>J6O]WZ/U66^V[9Z3_3]*RSU/L]=E[[)C?Z,+GLOJ/4
M&8]&;B]`/[2?5EN:7"?2M;[`W<RMECV9OHU6_I/LGK8[*_3]7*]+'1[^I_6;
M#NROU)G4:JG$4MI8ZAQ8REF0ZSU7VYC;WVWV?9:JFTT?S5GZ3_!I*;>!E]+S
M,FRBECMXK9D?I!`+7NLHBG<[_!OQOTNSV5^I_P`(KE]6)139>^L;*FE[H$F&
MC<5S]75NI59+G8OU=]%\,K=:=S-\UF^NJNRO%<[T:LEU];[+F5U5_P`Y_/7_
M`&='?UWKCAZ-G0'N#Z["Z;=U9(K9973_`#&[]+98ZF[U*F5LV?H?M=GZ!)3>
MZ=E=+SK<BC'K=NQ7`6&P$3OEP+'$^YNYKV?V/]'Z:-G_`&3#QG7OH?8P$-<*
M1N>`X[#8UNYKW>GNW_HOTW^AKLM]BK=!LLM?EONZ8WIEA?7HT:V`UL?O=9Z5
M5;_3L?;7[7_\;Z*TLC&Q\JKT<FMMU<M=L>`X;FD65NVN_.8]N]B2D&(W!R:2
M^IDM8^RDETSNI>_&LY_X2IWN0NHOP,)E;LBMS:7OBR]NC:@`;?5O?N:YE'Z/
M;8]OT/\`#?J_JV*_7774TMK:&-)<XAH`&YY-ECM/SGV.<]ZA=C8][JGW5-L=
M0_U*7.`)8^"SU*Y^@_8YS4E(,(]/S\.C-QVAU&56RZIQ!!++&BQDM_-]KD;(
M`;BV@:`5N`'R1*ZZZJVU5-;776T-8QH`:UH&UK6M;[6M:U0ROZ-=_4=^0I*?
M_];LG_SC_P"L[\I45\]))*?H5)?/222GZ%27STDDI^A4E\]))*?H5,OGM))3
M]")+Y[224_0B2^>TDE/T*DOGI))3]"I+YZ224_0J1X/P7STDDI__V?_M'\Q0
M:&]T;W-H;W`@,RXP`#A"24T$)0``````$``````````````````````X0DE-
M`^T``````!``EP````$``0"7`````0`!.$))300F```````.````````````
M`#^````X0DE-!`T```````0````>.$))3009```````$````'CA"24T#\P``
M````"0```````````0`X0DE-)Q````````H``0`````````".$))30/U````
M``!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!
M`%H````&```````!`#4````!`"T````&```````!.$))30/X``````!P``#_
M____________________________`^@`````________________________
M_____P/H`````/____________________________\#Z`````#_________
M____________________`^@``#A"24T$"```````$`````$```)````"0```
M```X0DE-!!X```````0`````.$))300:``````-_````!@`````````````!
MI@```E@````E`$8`;P!R`&T`(``Q`#``+0!+`"``*`!&`%D`,@`P`#$`,0`I
M`"``*`!0`'(`:0!N`'0`90!R`',`(`!V`&4`<@!S`&D`;P!N`"D````!````
M``````````````````````$``````````````E@```&F````````````````
M``````$`````````````````````````$`````$```````!N=6QL`````@``
M``9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````
M``````!,969T;&]N9P``````````0G1O;6QO;F<```&F`````%)G:'1L;VYG
M```"6`````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2
M````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I
M9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4
M>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P``
M``$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`
M`````````$)T;VUL;VYG```!I@````!29VAT;&]N9P```E@````#=7)L5$58
M5`````$```````!N=6QL5$585`````$```````!-<V=E5$585`````$`````
M``9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(
M8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E
M2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI
M8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````1
M15-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````
M``````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``
M```````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````"/_``
M```````X0DE-!!$```````$!`#A"24T$%```````!`````$X0DE-!`P`````
M&=T````!````H````'$```'@``#3X```&<$`&``!_]C_X``02D9)1@`!`@``
M2`!(``#_[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$``P("`@)
M"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,
M#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`'$`H`,!
M(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)
M"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%
M`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A
M\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!
M``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:B
MLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/2\2BI^-6][=SG-
MDDDDDJCU'JO3>G9+<?(J(WNH:'CZ(-[KV#?^XVMN+9[OZBT<+^B5?U0C$`\B
M>/PU"2G*Z?U#"S;<VL4%GV&TU.(.^8+F?1JW>G9NK>_T?YS[/]GR/^U"M@X1
M`(K>0=0?3L_\BK#FM:QT`"1K'PA-C_T>K^HW\B2D'ZG_`*-__;=G_D$OU/\`
MT;_^V[/_`""MI)*:GZG_`*-__;=G_D$OU/\`T;_^V[/_`""MI)*:GZG_`*-_
M_;=G_D$OU/\`T;_^V[/_`""MK-/U@Z9%@8]]ME5)R74UUO=9Z0>ZC?Z6W=[K
M&/V?OI*3_J?^C?\`]MV?^02_4_\`1O\`^V[/_(*S78RVMMC#+'@.:8(T(D:%
M224U/U/_`$;_`/MNS_R"7ZG_`*-__;=G_D%/%S69-F36UCV'%M]%^\0"[:R[
M=7K[Z_3N9[U824U/U/\`T;_^V[/_`""7ZG_HW_\`;=G_`)!3P<VC.QFY6.9J
M>7-!/BQSJG\3^>Q3R<BG%QK<J\EM-#'66.`+B&L&]YV5ASW^UOT6-24A_4_]
M&_\`[;L_\@E^I_Z-_P#VW9_Y!'Q\BK)QZLFD[JKF-LK<06DM<-[#M>&O;[3^
M<B)*:GZG_HW_`/;=G_D$]]%(QK'M;!V.(.H(T_SFI[NI8%%AJNO8RQKJFN:3
MJ#>XU8V_]WU[&^G4AGJ&#EUYM.-?7=;BAU>0QC@XL=!]M@'T?_)^I_HTE/\`
M_]#T-W468.#0?2LR+'M]M56P&&C=98Y^1911777^];<S_/0\KK.76YCL?`NO
MJ?\`9C.QS',;?:ZG)LMKL:U_ZG2WUGULWW?\73^G6/\`6OI[L[IF"UE-5UD/
M8POLO:]KGAOI;*<&W'LR:[;65T7>_P#5_4KS/YK'M76,&UC6P&P`-HU`\@DI
MSL#J.7E/SV78QK9C6%E+@"-[=0/YX5->[8UF1ZE7Z#TLFJKU/6JN5JBZP45C
MT+#[6ZRSP_XQ&N<6TO<&[B&DAH(!,#Z,N]JS+>OX6'1BTO;9;GWU,?5TZ@"W
M((</I.K8=E5+7-V/R[K*L/\`[L)*;69U!V)C/R'XMSVLB6U^F7&2&>UOJM_>
M5;.^LO3,"XXU[G.S(EF%2/7R'B"[V8F*;LC;[?YVRME7_"+!^LSNIW=)?D]<
MN^PXI+#3TC">WU["74N_6\]^SU'8[O4L?1T_T6,_[EY2V.GV=.Z?6<?H_2+V
M5D@N]*@8^XQM]2UV8[$=;9_PEGZ1-,X@U>O;K]C)'!DE$3$3P&QQGTP]._KE
MZ7+ZQU+KF5D]+<,"CIE)S6#&?U-PMM?:ZF_;LP\%[V4N:WU-CWYWJ^I_@EI;
M?KL""+.FO'YS35<P^6UPR;_^H4.IYO67W]/]'`]*<H!OK7,!,U7M.]N.;O;L
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MZ%O[7O\`^FKW3^E8-?7<EC\*AKZ\/$<7LJ8VO>Y^6VY]%>Y[Z]_I,_[;6[[&
M-[-8T?``!+]9_5'VR_[Q)^[C89)=]88OV9GANFX[[,K.&+U#KM[SDF7-]$3^
MCI;^D^U45X]3MS/T;/T6RGTUI#!^M;W%E&9G4M@!MF39T\GYUX_3LG=_V\K.
M!UG#IR>I!EC\ZRS*WL9BM^T';Z6.QONQZVU8[?;Z7ZQ;_@K/TRN^OU[)/Z'&
MJP:Y^GE.]6R/_"N([T?_`(8)WLY/TI</T$/^;+BFL/,8=L>(2\Y2RRO^]C]K
M'_C1</ZN5_6:_I]66.J^K4]]OZ/T<:T2VRRM_P"LX]]+7?I&.?[?YO\`FT7J
MF'];_L>3:.JM;4RJQSJFX3-S@&N=Z;+*\VRYKW_18^MF]6^D8/4W8+37U0-9
MOM@48]+:_P"<LW;6Q9^=_*1.I8/4F=.RWV]4FMM-A>+::?3VAKMWK>T?HMOT
MT?9A_G`>F^7_`+U'WK)=C$!K>F/!HY'3^I?7#I^!CNRL,YF**:WMNH;ZKMI:
M/993OQLZI[6_3]/#ZG8B9?UR]?!M;BM?7F5/K%C<=U5EK&^K77:VS#S659U+
M[&_H6_:.F_3L8M/IHZZSI^&^A^%E4&FLL8&OH]I:W;LNK?FUN;M_=QUF_6RM
MN?THU=9Z+Z@;;2&W,>VUK0;:O4].ZD-ZC3ZC/T?Z'$_X-+V#M"?_`#K_`.;E
M]:1S,;O+B$N_I]LU_>Y?]7_C<;I=2Q^CVWW.S-U5KW8KKAZ[*R?3LL/3?\.Q
MU?J97J>AL]/UKZO^"5BC!Z;BCJ-F(UHRL@!^:9!?O%0;6+MOT?T?Z3_KME_^
M&61]9+L)F=DLOK)+QTMEQ]<4^HQV5F_9ZJ-U3_T]5S7W?SV/[/\`M3B^CZB)
MTC[/^UOK$:J;PYS<=S\NRP/KOFEVRRAM;6UUNV?3VOL_1OH_F*_2QZPL?__1
M[?K.)DY72,2NFFR]K;*WW5TC'<]S&GWU&OJ>S'=5<S=79^GIM9_PU7JT/-EY
M'70:G54&II^S%S&!MT%UEGVVM[B^KV5XPK]]?^%_FO56?]:69UGU?IJQ'N`N
M:ZFZIK3%C+6.I]-]WMKH;N?].RVK_@?T_IU6=+26&EAK(+"T;2T[FQ'MVN_.
M:DIQW7=3=A]8_:6[&QF"T8]S#Z3VU;7_`*2FVC[39[*/2N9?Z?K_`&KUZ_0_
M0U+G*L/`LZ.W&P*F54VX5KLK/S`^X6B<9^7EVL?55D]1S,;_``/\WBU/?^B_
MH_V9=SE,%F-:PL%H<QP-;HAT@^QV_P!ON_E*KC=/QKNGXS,FALMQ?L[F3(#+
M&UBZD;/9L=Z3$"#>]#_G+XF`B;CQ3O2S^KX?[O[S@7=.%!ZKE'-KOS7-Q\?)
MOS+H;3#OM`K8ZO'_`%:O);DUO^S,_1?S7^D73[\[_0U?]NN_](KG^MOQ:1GU
M=)QA?U"\,=G7!SA77L(-+,FZ7?IG[_9C5?I?3_2V^G5^D6H>D9&09ZCGW7-)
M/Z#'G%J@_P#$.^UN_P"N9EC%(,8`'$1$=MY_XO\`W['+(9$T#(]_EC_+^XT>
MO]095D=-;D6LIMJRV6^C1<76O!KOJ:S[.S'??=7998QGIUU^]62[ZPY[1MK;
MTO'(,R]K\H_N_P"#OQ,;_P!FW_\`%(EO1::3A#IN-CT5T9+;KV[=DM%=M.YO
MIL=OO_2M=^D6HEQ1'RBS^]/]D/\`T=;4C\QT[1_[YP!]7JVYE5AZ?B9%7IV-
MR+,FQUU[WN-?I/-M]%KK=K66,_26>SU/T2S'7X;*;[<'%LPQ5CG*_5LPU-`9
M990:SBC=CL?8ZI_V?U,7T<C9;_H5V2%]FQ_4%OI,]0``/VC=`.X#=_6*7N3_
M`'C]J?;A^Z/L><Q\+K=O5LEEF98R<3&<^#2VZ'.RMM-M]>(^G]"]N1[Z*:_Y
MS^=5]O0<8N#K\.O,>!&[+R+,D_V1E5VM9_UM:K<?';>_(;4QM]C6LLM#0'N:
MV?38^SZ3FLWOV(B7NSZ'A_NC@_Z"/;CU%_WCQ_\`2<W!P<C!=DNIJJC*N]=S
M0[8&G973L;Z='O\`YG?O?[][U:WYW^AJ_P"W7?\`I!6$DR[7M9GVNMH8S'I8
MT<-;80-=>U"<OS2(--1!_P"%=_Z05A))37WYHT%-7_;KO_2"!FX^7F8YH>QM
M8+F/#Z[2'`UO;<SZ>.]OTZU?224U]^=_H:O^W7?^D%+(G[);N`#O3=(!D3'C
MHC(65_1K?ZCOR%)3_]+L/K+9@L^KM/VS'&4T65/96;W8Y:YK@?7;?0'Y+?0^
ME^KUV6H^1TOJF%CTX707-Q\/';0RFHN!(VNN]7<^YESWU>[$=?[_`%;J:[:Z
M7U6JE];WU-^KE++,AU6\MBEME=1LCW<WU7N=Z'\]^A;^BL_3W?H:K%U3?HCG
MCOJ?FDIR\5G6:V]2?EVLVN>Y^'ZL%K6PYS=_I"C92ROT:WL<_P!7UZ\F[U_3
MMJ64SK>1G#&P#DLPJ\FG>W)KKL#[O3;ZF37TT.<YS*FUMLVYMOZ6S_M%39_2
METN57ZN-=5#3ZC'-BQN]AD%OZ2N6^I7^^S<JV+TZ@X>$+F-=;C4-K994#6&R
MU@L]!K7N?2U_I_Z3^;_1[TZ)`UJY=+V"""=+TZM7$P,7+Z-11CMQK>EWULMJ
MJ?0XM<UVW(KLL9;;N=8Y_P"F=ZOZ7U??9^D6ALS_`/2U?]MN_P#2RGBXN/AX
M]>-C,%=-3=K&#L/B?<YW[SW(J:22;.MIV:^S/_TM7_;;O_2R6S/_`-+5_P!M
MN_\`2RL))*:^S/\`]+5_VV[_`-+);,__`$M7_;;O_2RL))*:^S/_`-+5_P!M
MN_\`2R6S/_TM7_;;O_2RL))*:^S/_P!+5_VV[_TLELS_`/2U?]MN_P#2RL))
M*:^S/_TM7_;;O_2R6S/_`-+5_P!MN_\`2RL))*:^S/\`]+5_VV[_`-+);,__
M`$M7_;;O_2RL))*:^S/_`-+5_P!MN_\`2RED;OLENZ"[TW21H)A&0LK^C6_U
M'?D*2G__T^P^M#'6?5FIK`YUHMH=4*C8+-[7A[/0;C%EUEGM_P`&_P!2FOU,
MFK]-176K61T"YG1L'IG3<AV,W!=5!+WDN96US?3>^OTG.]SFV;?9_-_H_L_Z
M.VFC];7U?\V\>EX8Y]MM/ILM(#'%K@[;%U.5C6O_`-'3D5?I'_S7J7^E6NH!
M.T;H![^$I*<["P,S'&:;L@N^T6NMJ@N?L:?=_P!J3:UO^B]*K9C;*OT=-;WV
MH]&/>::R,JP2UNFVOP_XM67D;'>0,_<HX_\`1ZOZC?R)*1_9\C_N59_FU_\`
MI)+[/D?]RK/\VO\`])*PDDIK_9\C_N59_FU_^DDOL^1_W*L_S:__`$DK"22F
MO]GR/^Y5G^;7_P"DDOL^1_W*L_S:_P#TDK"22FO]GR/^Y5G^;7_Z22^SY'_<
MJS_-K_\`22L))*:_V?(_[E6?YM?_`*22^SY'_<JS_-K_`/22L))*<3K=^7A#
M%<W+RMEECA:W&IKMN<!78]K:JOL]V[](UOT:UFLZS?:V[;=UBAU0M+7YF+3C
MT'TF.NWVY;^GOKQZ+=OLMM_[;6SU>QU69TVQM;KBVZPBNN-Q_07_`$=[F,_Z
M:!9]8[Z\3+R7=*S&_9!80'M8T/V#<WW&SZ#_`/2M994SZ:!D`0#N?!?'%*49
M3%<,?F]41_S7/Q^LEU=]V3U'-QJJ34-Q;BN,VM<YM=S1@_H+OT>YE7^$Q\C!
MO_[6>DQAU[&]3:_JF?6P.#'6/JQ6AI/V?;OWX;7>YF;1;^C]3]%ZGK>EZ:T*
M?K.TC+MR,6UF/CV,96]K7%Q]0.V>M4]E?HV^VNST_P!)^AS,+_"6^FQ?\Z\8
M/`LP\JMFX,+W,`@GT#.S?N>WT\MEOZ#U7LKJO]1GZ%%8Y[.K7V-LJ;GYU>:Q
MN0[TGUXQ8W[,1N]:P83/I>I1]'_"6^AZOJ+ILD1BV@F8K=J?@N=RNJXF:]]6
M1@&GJK:<H,M<UI].NKVOVW6>E<YES+&L_05/J]7[14RS]%>]='E?T:W^H[\A
M24__U/0K>E8G4\#'JRC:&5[;&BFZVCW-.^MSG8ME+G^F]K;*]_\`A$7JG33U
M!F.UM]F.[&O9D-=7^<6;OT=C7>U[/?N]_P#A?3>CX7]$J_JA$LMJJ:'VO;6T
MN:P.<0!N>X5ULU_.LL>VMG\M)31PND5X+<TBPN^UVNN=L`K@N]Q]U7N?;N_[
M4/\`TSZ_2KL_F4:C#K--9]2W5K?\*_P_K(E>5C9+;ACVLN-+G56AC@[98T>^
MI^WZ-C=WT%/'_F*_ZC?R)*1_8J_])=_VZ_\`\FE]BK_TEW_;K_\`R:L))*:_
MV*O_`$EW_;K_`/R:7V*O_27?]NO_`/)JPDDIK_8J_P#27?\`;K__`":7V*O_
M`$EW_;K_`/R:L))*:_V*O_27?]NO_P#)I?8J_P#27?\`;K__`":L))*:_P!B
MK_TEW_;K_P#R:7V*O_27?]NO_P#)JPDDIQ^I,.+F=.MJ9=DO%UD4BR7.FB[Z
M/VFRNGV_R[&)_P!N98IR+7](S6-QQ8>*G%VQN]K:ZZ;[+[77._1U^C5:S^6M
M#)P\?*]/UFDFIQ?6YKG,<UQ:ZLEKZW,?_-V/8A_LS%\;O^W[O_2J<"*(X0?'
M5!!L&Z\&A_SCO+W,'2<Z=2PFL`$>S9])WMW>I[_]%Z;T]?UA?LR;;\'(QZ\:
MNVYQM;LEM36N<UA<?3L<[W_G_P#?U?\`V;C?O7_]OW?^E4QZ9BD$$W$'0@WW
M$$>8]5-2XV3U-G4*+S;TV['L%-[:<M]?T6AM37;;PW=1]J]:S[/_`*6JG\RW
M]`S>R1&+:!VK=SKV0G=+Q'M+7^J]AY8^ZUS3W]S'VECD;*_HUO\`4=^0I*?_
MU?3L+^B5?U0H=0Z;B=1KJKRF%PHNKR*B"6EMM3O4IL!;^ZY3POZ)5_5".DIS
MOLF%TS&S,AWJ6,LW66AQW&-7^C2WV[6>H^QU=7^DN1<.O"R<6JZNHM8YHAKQ
M#FD>US+-?YQCAL>K5E==M;JK6BRNP%KV.`+7-(VN:YKOI-<FJJJIJ932QM=5
M;0RNM@#6M:T;6L8UOM:UK4E-/J7V'"P+LNZIQII;OM]+Z88#^D>/<S^;9^D?
MM_,5G[)C?Z,*61CX^34ZC)K;=2^-U;P'-,'<W<UWM^DU$24Y^99TO%NQ:<@B
MNS*M].ALQN=M<8?K]#\WW?X?T*_YVRI6OLF-_HPGNQL:]U;KZF6NI<+*B]H<
M6/'%E>[Z#_Y2*DIS;LCIE/5<?IMC'#(R:WOI.UWIN#(+V[_H^HUHW?\`!_R/
M7I]:Y]DQO]&%SN'UCZS[\:[J71&.MLIQP'8SGES#?ZCLYMCKZF^@[]7Q?U/^
M8J_[5]2_HZD/K#]976XX/1'5L=M=>W>][MA;>ZX56>C74VVJ,/\`G_3]6VRV
MC^;_`%RE*=)F1T]^<,=E-CG/<^DO#2:VOI'JEK_=^C]5EOMNV>D_T_2LL]3[
M/79>^R8W^C"Y[+ZCU!F/1FXO0#^TGU9;FEPGTK6^P-W,K98]F;Z-5OZ3[)ZV
M.ROT_5RO2QT>_J?UFP[LK]29U&JIQ%+:6.H<6,I9D.L]5]N8V]]M]GV6JIM-
M'\U9^D_P:2FW@9?2\S)LHI8[>*V9'Z00"U[K*(IW._P;\;]+L]E?J?\`"*Y?
M5B44V7OK&RII>Z!)AHW%<_5U;J562YV+]7?1?#*W6G<S?-9OKJKLKQ7.]&K)
M=?6^RYE=5?\`.?SU_P!G1W]=ZXX>C9T![@^NPNFW=62*V65T_P`QN_2V6.IN
M]2IE;-GZ'[79^@24WNG972\ZW(HQZW;L5P%AL!$[Y<"QQ/N;N:]G]C_1^FC9
M_P!DP\9U[Z'V,!#7"D;G@..PV-;N:]WI[M_Z+]-_H:[+?8JW0;++7Y;[NF-Z
M987UZ-&M@-;'[W6>E56_T['VU^U__&^BM+(QL?*J]')K;=7+7;'@.&YI%E;M
MKOSF/;O8DI!B-P<FDOJ9+6/LI)=,[J7OQK.?^$J=[D+J+\#"96[(K<VE[XLO
M;HVH`&WU;W[FN91^CVV/;]#_``WZOZMBOUUUU-+:VAC27.(:`!N>398[3\Y]
MCG/>H78V/>ZI]U3;'4/]2ES@"6/@L]2N?H/V.<U)2#"/3\_#HS<=H=1E5LNJ
M<002RQHL9+?S?:Y&R`&XMH&@%;@!\D2NNNJMM536UUUM#6,:`&M:!M:UK6^U
MK6M4,K^C7?U'?D*2G__6[)_\X_\`K._*5%?/222GZ%27STDDI^A4E\]))*?H
M5)?/222GZ%3+Y[224_0B2^>TDE/T(DOGM))3]"I+YZ224_0J2^>DDE/T*D>#
M\%\]))*?_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<``@`$,`4P`T`````0`X0DE-!`8```````<`"`````$!`/_A$0IH='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#0N,BXR+6,P-C,@-3,N,S4R-C(T+"`R,#`X+S`W+S,P+3$X.C$R.C$X
M("`@("`@("`B/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(@>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!H;W1O<VAO<"\Q+C`O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z
M=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B('AM;&YS.F5X
M:68](FAT='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O(B!X;7`Z0W)E871O
M<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S0@5VEN9&]W<R(@>&UP.D-R96%T
M941A=&4](C(P,3(M,#(M,C-4,C`Z,#(Z,S`M,#4Z,#`B('AM<#I-;V1I9GE$
M871E/2(R,#$R+3`R+3(S5#(P.C$R.C4V+3`U.C`P(B!X;7`Z365T861A=&%$
M871E/2(R,#$R+3`R+3(S5#(P.C$R.C4V+3`U.C`P(B!D8SIF;W)M870](FEM
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M9CI/<FEE;G1A=&EO;CTB,2(@=&EF9CI84F5S;VQU=&EO;CTB,34Q,#`P,"\Q
M,#`P,"(@=&EF9CI94F5S;VQU=&EO;CTB,34Q,#`P,"\Q,#`P,"(@=&EF9CI2
M97-O;'5T:6]N56YI=#TB,B(@=&EF9CI.871I=F5$:6=E<W0](C(U-BPR-3<L
M,C4X+#(U.2PR-C(L,C<T+#(W-RPR.#0L-3,P+#4S,2PR.#(L,C@S+#(Y-BPS
M,#$L,S$X+#,Q.2PU,CDL-3,R+#,P-BPR-S`L,C<Q+#(W,BPS,#4L,S$U+#,S
M-#,R.S!&0D4X,T)",C<Y138R,T4Q,C)",$4S1C,W,30W.$(R(B!E>&EF.E!I
M>&5L6$1I;65N<VEO;CTB-C`P(B!E>&EF.E!I>&5L641I;65N<VEO;CTB-#(R
M(B!E>&EF.D-O;&]R4W!A8V4](C8U-3,U(B!E>&EF.DYA=&EV941I9V5S=#TB
M,S8X-C0L-#`Y-C`L-#`Y-C$L,S<Q,C$L,S<Q,C(L-#`Y-C(L-#`Y-C,L,S<U
M,3`L-#`Y-C0L,S8X-C<L,S8X-C@L,S,T,S0L,S,T,S<L,S0X-3`L,S0X-3(L
M,S0X-34L,S0X-38L,S<S-S<L,S<S-S@L,S<S-SDL,S<S.#`L,S<S.#$L,S<S
M.#(L,S<S.#,L,S<S.#0L,S<S.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L
M-#$T.#8L-#$T.#<L-#$T.#@L-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W
M,CDL-#$W,S`L-#$Y.#4L-#$Y.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3`L
M-#$Y.3$L-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR
M+#0L-2PV+#<L."PY+#$P+#$Q+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R
M+#(S+#(T+#(U+#(V+#(W+#(X+#,P.S@Q-D1%03!#,C0Q,#<U,$(V,#`W-#%"
M044Y,#A!,4-#(CX@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI
M('-T179T.F%C=&EO;CTB8W)E871E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#HV-S0S,31!1C@T-45%,3$Q.45".4%%,S8Q,3DW-3!"-2(@<W1%=G0Z
M=VAE;CTB,C`Q,BTP,BTR,U0R,#HQ,CHU-BTP-3HP,"(@<W1%=G0Z<V]F='=A
M<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S(B\^(#QR9&8Z
M;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP
M+FEI9#HV.#0S,31!1C@T-45%,3$Q.45".4%%,S8Q,3DW-3!"-2(@<W1%=G0Z
M=VAE;CTB,C`Q,BTP,BTR,U0R,#HQ,CHU-BTP-3HP,"(@<W1%=G0Z<V]F='=A
M<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S(B!S=$5V=#IC
M:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B`\+W)D
M9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\/WAP86-K970@96YD/2)W(C\^_^X`#D%D;V)E
M`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#_\``$0@!I@)8`P$1``(1`0,1`?_=``0`2__$`:(````&`@,!````
M``````````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)
M``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A
M)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"
MTN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25
MEI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X
M^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$5
M4J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)5
M9756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'
MEZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ
M^O_:``P#`0`"$0,1`#\`W`(-_P#R.[(^2OR(ZGZ_[$ZVV!M;IB#JB;&MN'JG
M)[ZRN7/86SGSM8*FLINQ=H14XH:ZCET6C?4DH4VT7;W7NA._N)\P_P#O(OIO
M_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`
M])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)
MNS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS
M?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_
M`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]
MO?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;
MW[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO
M=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW
M7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N
M)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B
M?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_
M^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_
M`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^
MF_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+
MZ;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`
MTF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_]
M)NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-
M_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?
M_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V
M]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O
M;W[KW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?N
MO=>_N)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[K
MW7O[B?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_
MN)\P_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[
MB?,/_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P
M_P#O(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/
M_O(OIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O
M(OIO_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(O
MIO\`])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO
M_P!)NS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`
M])NS?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)
MNS?_`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS
M?_V]O?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_
M`-O;W[KW7O[B?,/_`+R+Z;_])NS?_P!O;W[KW7O[B?,/_O(OIO\`])NS?_V]
MO?NO=>_N)\P_^\B^F_\`TF[-_P#V]O?NO=>_N)\P_P#O(OIO_P!)NS?_`-O;
MW[KW06]VY#Y@]-]2=A]J/WET[N%-@[5RNYFP:_'W-XILJ,9`9_LAD3W5D11&
M>UO)X)=/^I/OW7NO_]#<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW7O?NO=>
M]^Z]U[W[KW7B0!<\`>_=>ZZN/ZC^OOW7NN_?NO==7')O]/K_`(6]^Z]UW?W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=%8^;_\`V2)\B?\`Q%6ZO_<!O?NO=?_1W!>AO^RXOGC_`-07QE_]]ME/
M?NO='S]^Z]U[W[KW7O?NO=>]^Z]U1EV!V=V53?\`"BKH#I^F[#WU3=2Y;^59
MVCOK*]74^[<_!UUD][T7R(CP]%O&OV3%D$VU6;KH\232Q9&2F:LCI_VUD"<>
M_=>Z)7\ROYM/0N?_`)I6(^)^_?Y@6-^$WQA^$V7V1G>_LUMC>=+B=X_*OY([
MOJ\=N/8WQ_;,8_!Y/+[0Z:Z>Q^WI9NP,I#*<;/59$X+*/12M'(ONO=;25!7T
M61I*3(4%92U]!D:>GK,?D**>&IHJZBJHDFI*NBJ8'DAJ:6H@E5XY$)1T8%20
M1[]U[K2;ER/SK^7GPV^8W\^KK_Y]_(3J;>O1_8OR!['^(?Q6P6[I=O\`Q0I_
MBQ\1]V;FQF0V)\@>C:.BS>)WWV=V-MW;&>-?4C)U--+6RTI:J6-U6@]U[K<`
M^,/<U#\C?C;\?_D+C,?5XK'=[=*]6=Q4.,KZ>&DKL=2=E;'P6\:>AK*6GR&6
M@IJFEBS(C>-*NI1&6RRR`:S[KW0N9+/X3#M$N6R^*Q;3K(T"Y+)45`TXB*K(
M81531&01EUU$<#4/Z^_=>Z;1OC9A_P"8MVQ_L-P8DW_Q_P"!GT]^Z]UW_??9
MO_/6;9_\_P#B?_JSW[KW7O[[[-_YZS;/_G_Q/_U9[]U[KW]]]F_\]9MG_P`_
M^)_^K/?NO=>_OOLW_GK-L_\`G_Q/_P!6>_=>Z]_??9O_`#UFV?\`S_XG_P"K
M/?NO=>_OOLW_`)ZS;/\`Y_\`$_\`U9[]U[KW]]]F_P#/6;9_\_\`B?\`ZL]^
MZ]U[^^^S?^>LVS_Y_P#$_P#U9[]U[KW]]]F_\]9MG_S_`.)_^K/?NO=>_OOL
MW_GK-L_^?_$__5GOW7NO?WWV;_SUFV?_`#_XG_ZL]^Z]U[^^^S?^>LVS_P"?
M_$__`%9[]U[KW]]]F_\`/6;9_P#/_B?_`*L]^Z]U[^^^S?\`GK-L_P#G_P`3
M_P#5GOW7NO?WWV;_`,]9MG_S_P")_P#JSW[KW7O[[[-_YZS;/_G_`,3_`/5G
MOW7NO?WWV;_SUFV?_/\`XG_ZL]^Z]U[^^^S?^>LVS_Y_\3_]6>_=>Z]_??9O
M_/6;9_\`/_B?_JSW[KW7O[[[-_YZS;/_`)_\3_\`5GOW7NO?WWV;_P`]9MG_
M`,_^)_\`JSW[KW7O[[[-_P">LVS_`.?_`!/_`-6>_=>Z]_??9O\`SUFV?_/_
M`(G_`.K/?NO=>_OOLW_GK-L_^?\`Q/\`]6>_=>Z]_??9O_/6;9_\_P#B?_JS
MW[KW7O[[[-_YZS;/_G_Q/_U9[]U[KW]]]F_\]9MG_P`_^)_^K/?NO=>_OOLW
M_GK-L_\`G_Q/_P!6>_=>Z]_??9O_`#UFV?\`S_XG_P"K/?NO=>_OOLW_`)ZS
M;/\`Y_\`$_\`U9[]U[KW]]]F_P#/6;9_\_\`B?\`ZL]^Z]U[^^^S?^>LVS_Y
M_P#$_P#U9[]U[KW]]]F_\]9MG_S_`.)_^K/?NO=>_OOLW_GK-L_^?_$__5GO
MW7NO?WWV;_SUFV?_`#_XG_ZL]^Z]U[^^^S?^>LVS_P"?_$__`%9[]U[KW]]]
MF_\`/6;9_P#/_B?_`*L]^Z]U[^^^S?\`GK-L_P#G_P`3_P#5GOW7NO?WWV;_
M`,]9MG_S_P")_P#JSW[KW7O[[[-_YZS;/_G_`,3_`/5GOW7NO?WWV;_SUFV?
M_/\`XG_ZL]^Z]U[^^^S?^>LVS_Y_\3_]6>_=>Z]_??9O_/6;9_\`/_B?_JSW
M[KW7O[[[-_YZS;/_`)_\3_\`5GOW7NO?WWV;_P`]9MG_`,_^)_\`JSW[KW7O
M[[[-_P">LVS_`.?_`!/_`-6>_=>Z]_??9O\`SUFV?_/_`(G_`.K/?NO=>_OO
MLW_GK-L_^?\`Q/\`]6>_=>Z]_??9O_/6;9_\_P#B?_JSW[KW7O[[[-_YZS;/
M_G_Q/_U9[]U[KW]]]F_\]9MG_P`_^)_^K/?NO=>_OOLW_GK-L_\`G_Q/_P!6
M>_=>Z]_??9O_`#UFV?\`S_XG_P"K/?NO=>_OOLW_`)ZS;/\`Y_\`$_\`U9[]
MU[KW]]]F_P#/6;9_\_\`B?\`ZL]^Z]U[^^^S?^>LVS_Y_P#$_P#U9[]U[KW]
M]]F_\]9MG_S_`.)_^K/?NO=>_OOLW_GK-L_^?_$__5GOW7NO?WWV;_SUFV?_
M`#_XG_ZL]^Z]U/QVXMOY>9Z;%9S#Y.HCB,[P8_)T-;,D*LB-*T5-/+(L0>10
M6(M<@?D>_=>Z>??NO=>]^Z]T5CYO_P#9(GR)_P#$5;J_]P&]^Z]U_]+<%Z&_
M[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW7O?NO=>]^Z]U[W[KW5+F^OC[W5D?Y^W
M1WR>H.N<]4]`[:_EE]D=/9WM2,X\[;QO9N9[\&Z,;LV9#6C)G+5&!C^Z&FG,
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M>?$20XZAERF1J*EHH0B-//(Y&IV)]U[HR?\`LIGQ;_[QPZ+_`/14;&_^L?OW
M7NO?[*9\6_\`O'#HO_T5&QO_`*Q^_=>Z]_LIGQ;_`.\<.B__`$5&QO\`ZQ^_
M=>Z]_LIGQ;_[QPZ+_P#14;&_^L?OW7NO?[*9\6_^\<.B_P#T5&QO_K'[]U[K
MW^RF?%O_`+QPZ+_]%1L;_P"L?OW7NO?[*9\6_P#O'#HO_P!%1L;_`.L?OW7N
MO?[*9\6_^\<.B_\`T5&QO_K'[]U[KW^RF?%O_O'#HO\`]%1L;_ZQ^_=>Z]_L
MIGQ;_P"\<.B__14;&_\`K'[]U[KW^RF?%O\`[QPZ+_\`14;&_P#K'[]U[KW^
MRF?%O_O'#HO_`-%1L;_ZQ^_=>Z]_LIGQ;_[QPZ+_`/14;&_^L?OW7NO?[*9\
M6_\`O'#HO_T5&QO_`*Q^_=>Z]_LIGQ;_`.\<.B__`$5&QO\`ZQ^_=>Z]_LIG
MQ;_[QPZ+_P#14;&_^L?OW7NO?[*9\6_^\<.B_P#T5&QO_K'[]U[KW^RF?%O_
M`+QPZ+_]%1L;_P"L?OW7NO?[*9\6_P#O'#HO_P!%1L;_`.L?OW7NO?[*9\6_
M^\<.B_\`T5&QO_K'[]U[KW^RF?%O_O'#HO\`]%1L;_ZQ^_=>Z]_LIGQ;_P"\
M<.B__14;&_\`K'[]U[KW^RF?%O\`[QPZ+_\`14;&_P#K'[]U[KW^RF?%O_O'
M#HO_`-%1L;_ZQ^_=>Z]_LIGQ;_[QPZ+_`/14;&_^L?OW7NO?[*9\6_\`O'#H
MO_T5&QO_`*Q^_=>Z]_LIGQ;_`.\<.B__`$5&QO\`ZQ^_=>Z]_LIGQ;_[QPZ+
M_P#14;&_^L?OW7NO?[*9\6_^\<.B_P#T5&QO_K'[]U[KW^RF?%O_`+QPZ+_]
M%1L;_P"L?OW7NO?[*9\6_P#O'#HO_P!%1L;_`.L?OW7NO?[*9\6_^\<.B_\`
MT5&QO_K'[]U[KW^RF?%O_O'#HO\`]%1L;_ZQ^_=>Z]_LIGQ;_P"\<.B__14;
M&_\`K'[]U[KW^RF?%O\`[QPZ+_\`14;&_P#K'[]U[KW^RF?%O_O'#HO_`-%1
ML;_ZQ^_=>Z]_LIGQ;_[QPZ+_`/14;&_^L?OW7NO?[*9\6_\`O'#HO_T5&QO_
M`*Q^_=>Z]_LIGQ;_`.\<.B__`$5&QO\`ZQ^_=>Z]_LIGQ;_[QPZ+_P#14;&_
M^L?OW7NO?[*9\6_^\<.B_P#T5&QO_K'[]U[KW^RF?%O_`+QPZ+_]%1L;_P"L
M?OW7NO?[*9\6_P#O'#HO_P!%1L;_`.L?OW7NO?[*9\6_^\<.B_\`T5&QO_K'
M[]U[KW^RF?%O_O'#HO\`]%1L;_ZQ^_=>Z]_LIGQ;_P"\<.B__14;&_\`K'[]
MU[KW^RF?%O\`[QPZ+_\`14;&_P#K'[]U[KW^RF?%O_O'#HO_`-%1L;_ZQ^_=
M>Z]_LIGQ;_[QPZ+_`/14;&_^L?OW7NO?[*9\6_\`O'#HO_T5&QO_`*Q^_=>Z
M]_LIGQ;_`.\<.B__`$5&QO\`ZQ^_=>Z]_LIGQ;_[QPZ+_P#14;&_^L?OW7NO
M?[*9\6_^\<.B_P#T5&QO_K'[]U[KW^RF?%O_`+QPZ+_]%1L;_P"L?OW7NO?[
M*9\6_P#O'#HO_P!%1L;_`.L?OW7NO?[*9\6_^\<.B_\`T5&QO_K'[]U[KW^R
MF?%O_O'#HO\`]%1L;_ZQ^_=>Z]_LIGQ;_P"\<.B__14;&_\`K'[]U[KW^RF?
M%O\`[QPZ+_\`14;&_P#K'[]U[I8[)Z0Z9ZTRE1G.NNINM]AYJLH),55Y;9VR
M=M[;R53C):BFJY<=45V'QM'4S44E51Q2-$S%"\2L1=01[KW0H^_=>Z][]U[H
MK'S?_P"R1/D3_P"(JW5_[@-[]U[K_]/<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?
M/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT?H?]8_[U
M[]U[HJ_0'_,W/F1_XG?:W_P/O37OW7NC4^_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[HK'S?_P"R1/D3_P"(JW5_[@-[]U[K_]3<%Z&_
M[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]UT?H?]8_[U[]U[HJ_0'_,W/F1_XG?:W_P/O37OW7NC4^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZZ!!O8@V^MC>W^O[]U[KUQ]+B_OW7NN[@?4^_=>ZZN/ZC^GOW7NN_?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>O^/S[]U[KU[_`$_UO?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7@0?H;\VX_J/J/]<>_=>Z\2!R3;_7_QX'^\^_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBL?-__
M`+)$^1/_`(BK=7_N`WOW7NO_U=P7H;_LN+YX_P#4%\9?_?;93W[KW1\_?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_UC_O7OW7NB
MK]`?\S<^9'_B=]K?_`^]->_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
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M%;?V7ME\H<IFZR::+PXNCG*,)-!]^Z]U6#\(/YE_S!W1\YMW_P`NO^8Q\3]G
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MCD\EB]E]I;&I=[3XGM+_`$CXVCI:?=6,I\U10!<3+5T;2)4'RLHC9O=>ZL:'
MT'^L/?NO==^_=>Z][]U[KWOW7NO>_=>ZKM_F+?S`*O\`EZ];8;M6?XE_)[Y/
M;.:@WWG=_P"4^..T<'N>EZ=VEU_@:;<>9WCV;59S/X*GV]MF3%O42)5%GC5:
M*<R%`H)]U[I^_EV_.E/YA705/\A<=\<._P#XX;3SF4QW]P<;\@]N8?;F6[,V
M1G-G;7WIMSM38AP>:SE!G.O-QX_="QT->DVFHEIIM(*@,?=>Z/I[]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[I$]B]D;"ZBV/NKLSM'=^WM@=>;&PM;N
M/>6]=V96DP>VML8''1>:OR^;R]=+#1X['TD7JDEE944?4^_=>ZQ]<=F]?]P;
M%VKV=U7O';G8776^<129_9V]MHY:CSFVMSX.N#&DRV$RU!+-29"@J`IT2QLR
M&QY]^Z]T7CJO^8+\&>\NT\IT?TW\NOCKVAW!AI<W#D.M=C=N[(W)O.*7;5:<
M?GTBP.,S,]=6'$58*U'A23Q@%CZ03[]U[HX!-O\`>A_B??NO=%/V?\\/A5V%
MW/DOCIL7Y7_'G>'>V(%1_$>I=M=N['S._*>2D6B:KIAMZ@S,]?/6T@R,/E@C
M5IH]1U*-+6]U[HV/OW7NBL?-_P#[)$^1/_B*MU?^X#>_=>Z__];<%Z&_[+B^
M>/\`U!?&7_WVV4]^Z]T?/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]UT?H?]8_[U[]U[HJ_0'_,W/F1_XG?:W_P/O37OW7NC4^_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
M@>[YW=V_L7JW<VY^ANG\9WWVIC3AO[L]49CLW&=.X[<XK,[C*',M4=BYC;F[
M,=@/X+@:FIKT$E!/]T]**==#2AU]U[JLW^6C_,P^1_\`,(SW8&1S/P6Q?0_3
M75_9O;G1F\^SY/E9M3M#+47='3N2QF*W!M/'=>XKJO:F0RF"J:S(,L692N6`
MK%J$3*X/OW7NKD_?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!_R0^2/2/Q%Z8WG\AO
MD9O[']8=-=>C`-O'?.4Q^<RM#A/[T[HPFR\`)L?MO%YK-U+9/=&XZ*C004LI
M$E0I:R!F'NO=%8^(7\V;^7I\^-_[AZM^(?R6VYW/O[:>SZG?VXMMX?:?8^WZ
MO&[.I,UA=NU6=>?>NR]MT%1309K<5%3LD4LDH:H4Z--V'NO=6*\Z1?Z^F_\`
MKW%_?NO=:XG\D"3?8ZZ_GCMU3'LZI[/C_G5_S(CUU!V!4YBFV'-OU<9UV=HP
M;VJMMTU=N&DVF^?^W&2>AAFK4HC(84:32#[KW5%?=_PY_G%?$;Y0?RQ=O=F]
MM?R_M_\`;W=?\Q;M7NO97:4"?)3<^;WM\B=V==1T.X=R_(3)[IH\3-6;(V]U
MCBZ';VW<;MJEH(L71XVC@2)4221_=>ZWFZKY+?'JFK>\<;4=Y=4Q9#XRXO%Y
MGY$8]M][92NZ,Q6=V]6;MP60[7I&R2S;#I,SMC&SY"E?)BF6HI87E2Z*6'NO
M=:_G\L+Y5_$GY\_/3=_\P#>ORBZ&;O[LW;.[OCC\"OAU2]L]957<?7?Q1VED
MLKO?,;ZWQUYB=Z;DW92]W=R/@JS<&6Q`2G_NY@*98IHGD:5X?=>ZV`?D;OKO
M?KOK>;<?QSZ&PWR/[(3-8JB@ZTSO<.(Z,H*C#5;RKE<T=^9S:>]*"*;%*J%*
M0T1>IUD*Z:>?=>Z(S_*A_F+=M?S,.FJ_Y#[A^)U-\<>GLG7Y;"=9YZ7O_;_;
M^<WSG=G;UW=L+L+'Y3;&'Z^V75[*BVSG=JVIYYY:I<E%4!XU1%!?W7NK7O?N
MO=>]^Z]U[W[KW7O?NO=>O_OO]]_K^_=>Z`OY055+1?&CY$5E;54M%1TG1G;5
M35UE940TE'24T&P=P23U-755#QT]-301*6>1V5$4$D@`GW[KW5:G_">*JI:K
M^2]\`FI:FFJE@Z@R5+,U-/%4+#54_8.\XZFEE:%W$=332@I)&;/&X*L`01[]
MU[JY_P!^Z]U[W[KW7O?NO=>]^Z]U[W[KW1(_G[T;DN^OC5OS!8SOKY`?'R;:
M>`W=OF3<GQVWAM?9NY=U08C86[*5MD;JKMT[(WW25^R,L^2$U7304]-4R3TL
M+)41A2K^Z]T5/^1KT?D>I?Y;/P[W76][]^]PP]O_`!$^)N]*+:W<V[]K[FVI
MTU3S](;9JUV-TQ0X#9&TZW;6P:1<LM/!1Y"JRU5'345,AJ6:-VD]U[JX@<\^
M_=>Z][]U[KWOW7NO>_=>ZZN.>1Q]>?I]/K_M_?@0>'7N''JI/^=A\7/CY\AO
MY=ORSWCW5U9MGL;<?Q_^*/RI[-Z<S&>%>U1U_OO']([HR=)NC"&BKJ2-<A2U
MN!HY5,RRQAJ=;K:X.Z$F@&>M%E`+%@%'4?\`D6="].]'?RL/A37=3=?8+8-7
MW3\:OCYW7VE)A17*V]NU=X](=?1;GWUF/OJRKU9G/)C8#,8O'#Z!H11Q[T<<
M>O`@\#7JW6X/OW6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJK?YX0'_#0
M_P#,6;\GXH]K@_T/^X";\?2X]^Z]U!_D6J#_`"?OY=UQ_P!RP=>?U_-'*?\`
M>??NO=:\'\P?J[X\_';^>/\`RH]M5?Q?V?\`RS?B]T?V=C\AU]\W.L-GX##[
M7^6&\O[O]>Y[$]"[PK-@T&"38F#3<*56U<G7;GJJVKJJ/)5]3(HQ\[3>_=>Z
MV]?E[LSM#L?XI?)?KWI#/C:G<^^N@NX-G]2[G^[>@_N[V5N7K[<&&V1FQ71T
M]9)1'&;DK::82B&4QE-6DVL?=>Z^5=E,=L3J[K?^7;\,NLOY;_R+^,W\Y/K;
MYC[.K]S?('=,.3VMENQ,K!OBKJ]K8K9U%N3+)#DJ_P#BNX-L5,4D^/I,7@H<
M4LT53-!732'W7NOKM^_=>Z*Q\W_^R1/D3_XBK=7_`+@-[]U[K__7W!>AO^RX
MOGC_`-07QE_]]ME/?NO='S]^Z]U[W[KW7O?NO=>]^Z]UQ9M/X)_UOH.;?4V_
MK[]U[KN_%['\<6YY_P`/?NO=>#`WM^#;_C8_P/OW7NN@X-S9@`;7(_V_YOQ[
M]U[KRL&^G^O_`+R1_P`1[]U[KL_0_P"L?]Z]^Z]T5?H#_F;GS(_\3OM;_P"!
M]Z:]^Z]T:GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]TQ;FW1MS9>W\[NW>&>P^UMJ[7Q&1W!N3<VXLE187`;?P
M.(I)J_+9K-9C(STU!B\3BZ&G>:HJ)Y$AAB0L[`"_OW7NM;;_`(3(_(/I+MKH
M?YS;:ZV[-VGN_<<'\Q[Y6=MS[>QE>R9^'K+MO=6.R'6N^IL'714>6BVUO.EQ
M-4:*I:$(TE/)$VF6-T7W7NMF;W[KW7O?NO=>]^Z]U[W[KW7O?NO=-6<HL+D,
M56TNXJ3%UN$,0GR5/FZ>DJL4:>D=*MI:V&O1Z3PTS0"35(-*%`W%K^_=>ZIL
M_D79_J+>?PYWIN3J_+=;;GD@^:7\P>@R&=Z_JMK91H<7G/FSWCO/:-%6Y/;C
M3-'CLKLC/XG*8Z-W\<V(K*.>$&GD@8^Z]U=,.5`-[V%SRI_Q/Y(/OW7ND'L/
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M>T&["[Z[:ZUZ5V"F3H<*^]^U]\;9Z]VDF8RAD&,Q+[BW9D\3B5R61,+^"`R^
M270VD&Q]^Z]UK_\`_"7+NKIS-_RH]F;%PO:_7&8WKU5V%\BMQ]H;1QF]MMUV
MY>N-O;O^0O;N>VGGM]X2GR4F2VEAMS8.CEK<?55\<$-921M+$SHK$>Z]U=IV
M;\V_AITM2XFN[A^6GQJZLH\]45-)@ZKL/O+K+9L&8J:*.&6LI\7+N'<^/2OF
MI(ZB-I5B+&,.I:VH7]U[JNCLO_A1C_)BZNBW>,I\Y>NMTY+9E77X^OP_7&"W
M[V#59>NQU<<?/#M3(;8VID-O;J@DJ`6AJJ&MFHIX1Y8YFB(<^Z]U7OV9_P`+
M'/Y2FRLO08[:>"^5W<=%58X5M1N#8/46VL+B\95-55-.V(JZ?M;L?KC-S5ZP
M0+,7IZ.>E\4R@3&02(GNO=$EW-_PL:WKOJ@HXOBS_*O[IW]D\_NI,1L_(;HW
MMELIC]S8V3)5>)@AH\3UUUIG*B7=-=7I#`M%35]9'%4M)$)9F12WNO=3I_YR
M'_"H'Y`9/<D/QQ_DU8_J#!8C`8ZBJX>Z>HNW:#<E'FLS_&8XL_MO</;'8'1N
MWMP^!*96%'!ALE'1/"C59>.HC0^Z]U7W_,$Z9_X5O_*KXI28KY/[9KLCT7F*
M.LR?8G5/4F7^.FQ]RUF"H*5MT-)VU@-@97$Y?)[;PAVH)OLWJ9X%J)462%W=
M`ONO=%U_DA_!7_A0_P!D=!YO<'P-^1E;\,OC'O6KB[`VME^X]T93!]>]KYNH
MK<CM/,YOK;!8[K7MC)T]9`VVECKZQJ#%TU?%'3LDU5XU,?NO=6^[!ZK_`.%J
M'6&-R>W:/L_ISL*GDSE9D(]P;^W-\6]X9)M4%)0K%C,EG<%1Y.FPCI0":&GD
MBC:.2:1BBL[#W[KW3UNK(_\`"UK;&WLMN#Q=!;D_A-(]8<'M;%?$'+;BR0C(
MU4^(QDE)2+75I4EEC\BEK6%S8'W7NLVW/Y@__"PS!X'#X?*?RP^@]X9'&8^F
MHJW=6X=DTM)G=PU,$8CER^7IMI?+';.V(,A6L-<JT&.HJ0.3XX8ULH]U[I/[
MJ_G%?\*I^E<[LRN[>_D\;(W=M7+Y*=Z[!]0=#=Y;YS60QF)>A;+4+[@ZO[S[
M@I]AUM7!D$6DJLIC9(Y7UF*&H$,RK[KW2\7_`(43?SN[<?\`">SY#@?T/7GR
MG'U_/JZ0'!/O8%>'7N@8[6_X47_S6>TNLN_^C9/Y7^"^,O;V7V,^S<=E.X]V
M[SVOG]AU._L?$1N>IZN[4V3M"HW93ML^JJY*`>5:6.ODI99TJ*824\L:<^^[
M7)/MI/86_-M]-#)=1L\>B&24,%95:IC!`/<*5X^760WLI]USWA^\%8[[N7MC
MLUI=VFVSQQ7!ENH8"CRHSH`)&&JH4\.'GTC/AY_PH_[_`/Y;OP]^./QJ^6_P
M8R';=9U/MK"=+]>]C=*=J;8Q?\4ZPZ[P&!V[LK';EV9'MK<S?WPP.WJ:.DEK
M$JJ:GRPACD95J&G=D_)/O/[=^X$FXP\N[V3+:JK2>-&\`"N2%(:4*IR#6A[<
M$\1TN]V_NC^^WLG!L=USORBO@;C*\4'TDR7CM(@4LK);ZV6H9=)/Q&H&>-LM
M)_PJZ^)=;5T]%!\#OYH@GJJB*FA^X^//6-'!YIY%BC$U76=\04E+$78:I)72
M-!RS*H)!M)[I^V44<LK^X6RZ$4L:7D#&B@DT59"S&@P%!8\`">@U;?=G^\5=
M7$%K%[%<VB65U12^U7L:U8A1JDDA2-%J15W944=S,%!/1S>M?^%`GP>WWC<)
M4;BVG\F>H\OE8JZ6MV[V'TO45%3M_P"TEJU@3+9WK[/[[V;.V3IZ9)H#0Y*L
M7341I(8YA)'&%[W[P/L]96<EY_7BVE"D#1&LS2'(&%\,'%:GA1<\.I.V;[AG
MWLMXW6#:S[075IKU?K7-U810+I4M1Y/JFTEJ:5!7+$#SZ7&Z/YYOP>P=)33X
M*7MS?=1/4F&;'[=Z[EQE10P"*1_O:F;>^5VE0/`9%$82&:68LX.C0"P!FY_>
MO]J+&&.6VEO[QBU"L4`!4?Q'QI(EIY8)-?+J6-B_NO?O0;K<21;I!L&UP!*K
M)<;@)5=M0&@+9174@-*MJ=%2BGOJ0"`>_/\`A0?T/@):27:O1?:&8Q30L,AD
M-Z;AV3U^:2N,H6"DIHH:_=]/6),AOK:>!@U@$8'5["ES]\3EB:6./8.3-RNP
M5).MHHV%#Y+%]344R22OI3J2MJ_NH.?X;"YO>>O>;EO:=,JJAB2YN8V4^;R2
MBRT,6PJ!7U<=0(T]%7[(_P"%+NT]L3T^1Q?5'5VV=M3+%2&K[+[XQE#5RYMV
MJYI8*:3'86#'M3/11JR+J,MXY"WI`LE'WG><MYNI(.6/9V^N52.K*!/*XJ:%
MB(X``O`<"?GZ&_\`R;:]GN5=J6^]S?O9;38,]T8TD5+*"W*E*A-=W?J3,2LC
M%1^&A`PQZ(-\[OF9WE\N-P[*SO:&Q\;U=M[&8#/T6S]N[;FW&E'GMN[E&$J,
MFV?KLCD31[M1I:1/'(E'20B&H*-&X.HXY^]WN)[C<U[CM4O-?*\^QPQHX@C,
M=Q"[J2NLLTQ&L@TRBJ%K0UQUGW]SSV-]@_:[EGF[;?:CW%L^='N;BW:_N?%L
M+I(98UG$*Q);*_TRO&[562:5I"FI6`!`??Y=GSJJ/A%O#L+<68Z]W-VEM/<6
MR<%@)L5B=R3XJ'9-/A<VM109*".LH<KAJ+$RT]3+`T9%*`Z1!&L647]D?=^Y
M]M]PWB_O]HN=SLI[=4;3*P:.CJ0Q)5P:_"*@5Q1@*U<^^!]TZS^\ERMR5R[L
M?,NV\N[MM^Y331&2U1UN_$@T-`!$T4I=2BLNGQ>UG+*"`>MB7JO^='\$NP/V
M\QO;=75-7*M3(M-V3M"LI:8I3ST\,(3-;3EW7@FDKDJ#)%']SY`D;ZPI`!S1
MY?\`O-^U&\H$N-TN-ND53V7,)%`M/Q0F9<UQ5@<9`/'D!SO_`':_WJ.3R7V[
ME>PW^W!1=6VW:,U2K%B8;L6L]$*T9O"TU9=.JI(LEV-V[U7V?1'(]:]C[%["
MH0]3$U7LG=NW]TP+)1&%:R-I,)D*U0]*U1&)!]4,BZK:A>:MIYCY?WZ,S;'O
M=I>PBO=!-',*BE1^FS9%17TJ.L->:>0>>N1IQ:\Z\E[KL]S13HO;2>U:C@E#
M29$PP5M)\])I6AZ7AJ4`)(86_!`!_P!Y/LX#5X@C\CZ5Z"1."PS]GG]GK^76
M96#J&%[$7%_K_L?=NO`@BH..N7OW6^JE_P":C_,@[;_EM[!HNX-L_!SL?Y3]
M.X7:NYMV=Q]D;,[1V7L##=,T&$R.W\?BUS]!N+%Y?,YO^\)S,CQFB@<0BF;6
M#J!'NO=#]_+_`/E3W3\ONG*WM?NCX?[^^&]559JA79&S^P.P-H]AU^^]C9;:
MV`W)B.P<;D=H4])3X[&9"7-2TJTM3&M2KTK,;!@![KW2Q^>?QGR/S'^&WR6^
M+>'W91;$RG??46[NLJ+>.2Q=1G*#;D^YJ`T29:KP]+6XV?(Q4E]1B2>)F_##
MGW[KW2&^)7PWSWQL_EX=3_!^I[3JJK<?6_QW?HX=R;,Q]7MG(TV2?;V2P=/O
MG;&-DRE368?)X>:N6JHP:PR1S0J?(#8CW7NJE=W?R1OFM\K]]_'_`&]_,?\`
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MG_Q%6ZO_`'`;W[KW7__0W!>AO^RXOGC_`-07QE_]]ME/?NO='S]^Z]UAJ*BG
MI*>>KJYX:6EI89:BIJ:B5(*>GIX4:2:>>:1ECAABC0LS,0JJ"2;>_=>Z9L5N
MS:V>J'I,'N7`9FJCA:HDIL5F<=D:B.G1XXGG>&CJ9I%A625%+$:0S`7N1[]U
M[I_]^Z]U1[OWMSM6C_X4/=!]'TG9.^Z;IC,_RM.SNQ<OU-3[KS</7&4W_COD
M,F$H-[Y#9<=:NWJS=E%AC]I%D)*=JJ.F_;5PG'OW7NBF_P#"A[^9GW%T7\6/
ME+TQ\&\Z8.Z>GNN-A;M^6';^&J]RXBJ^*_6/<>]=G]?]>8G;6\\`T%/B?DEV
MSDM[4U7@,;YUKL=M6FK\VW@*XV6?W7NMES!O4-A<(:@RM5/BL<U29]7F,QI(
M3,TQD]9F+WU7YO[]U[K2PJ]W?S#/EI\/_F)_/AZN_F`=X]2Y#H?LGOW?_P`2
M/A]ALTV!^*&3^*?Q*W9G\7F-L_(KIN-,W3[P[7[&V[M?/O63)DYT-::735I&
M\"XOW7NMOCXS]S8WY&_'/H3Y!8:AJ\9B.].F.K^X<7CJ^D2@KJ'']E;(PF\:
M.CK*&/(9:.CJ::#,*CQ"JJ1&P*^62VH^Z]T,59D<?0Z%KJ^BHVE5S$*NJ@IS
M($L'*":1-874+V^E_?NO=%1Z$S.'B[9^8<DF6Q:)/WIM>2!VR%&%FC'Q_P"F
MT+QDS6=!(I4D<:E(^H('NO=&D_O!@?\`G=XC_P`^5'_U^]^Z]U[^\&!_YW>(
M_P#/E1_]?O?NO=>_O!@?^=WB/_/E1_\`7[W[KW7O[P8'_G=XC_SY4?\`U^]^
MZ]U[^\&!_P"=WB/_`#Y4?_7[W[KW6*?<^VZ:*2HJ=PX.G@B4O+-/EJ"**)!]
M6DDDJ%1%%_J2![]U[J%2;YV37R_;T.\=K5D^EG\-)N'$U$NA;:G\<-6[Z5OR
M;6'OW7NG+^\&!_YW>(_\^5'_`-?O?NO=>_O!@?\`G=XC_P`^5%_U^]^Z]UX;
M@P!^F;Q!_P!;)47X_P"GWOW7ND7V!W%U3U3M++;^[,[.Z]Z]V-@J2:NS&[][
M;QV]M?;.*HZ8QK/4U^<S60H\?31QO*JW9QZF5?JP'OW7NM8?YJ?\*\_Y=OQ^
MJ\CLSXRX+L'YJ=B1TD+4&0V+2+L7IH9"OQE?44M!/O[=5*VY\K54602CCJ5Q
M>WJVF\52^BJ,\#P>_=>ZIY[5H/\`A2+_`,*#]L8#:.\=C;&^#/P8[%J<=D*W
M%YZLGZBV9NO:J96NR.*S>[<9N'*;E[\[:%!4[7A:"DIZ&FPE36ST=6::FIIH
MZJ'W7NB._P`G[_A.#W#\R6^1V_=[?,>F^*^S^F>X=_\`QHQNXNI34;LW5V3O
M_K'<,%%OV1*5]U]>OA^NL?)'2R44]2[U.2FF#?;0K!KD]U[J[3_H$3D_[W+_
M`"%_]`QO_M^^_=>ZZ/\`PD4<<G^<O\A;?T_N:03_`(`GOZP/OW7N@%WW_P`)
M&_E&FXZI>K_YP557;/\`!2?93;\QO8>,W']SX$%>E53;>[7R^+,"U0;Q,DVH
MQD:E!!O[KW0ZT/\`(!_G8XRAH\;CO^%$7;U%C\?2T]#0T=-V]\FX::DHZ2%*
M>EIJ>).X`D4$$$:HB@`*H`'OW7NI7_#!_P#.]_[Z*^Y?_1Q?)W_[</OW7N@*
M^3G\@S^>E)\?^VH<-_.O[3^4U94;+RM-+\=,MWMWUAZ+N7%U,:P9O8+5>[^S
M\KM2:ISV&DJ(H*3)1"AKIRE-/)#'*TT?NO=5'?R0/Y0_\V7Y#[9[E[#^/WR^
M[0_EH]4Q;CFV/F-SC?7:'7&6[?[)Z^S61P6=VPFQMC[FVEELC3]85TM?15V1
MR)6&BR;R4-.LTRUPI/=>ZOF'\@_^=Y^/^%%?<MOQ;N+Y._\`VX??NO=>_P"&
M#_YWO_?17W+_`.CB^3O_`-N'W[KW7O\`A@_^=[_WT5]R_P#HXOD[_P#;A]^Z
M]U[_`(8/_G>_]]%?<O\`Z.+Y._\`VX??NO=>_P"&#_YWO_?17W+_`.CB^3O_
M`-N'W[KW1;_ES_PG=_G2;[^.O9^"S?\`..W=\RJ>/"19NE^-/8';?<\N![6R
M6WLC1YJAV]3OV)V-G]FTVXC-1>7%O7P)3MD(X4>>F1VGC]U[JN+^3#_PFYW_
M`/S!_C!NGY(=D?,6K^*G778&X=P[!V=L[8^/I=Z[D[`Q^QLYGMG[[K>QL6-]
M;.QF&P=)N:CJ*''T<[5E16+'4S/%#3O3/5>Z]UL*=2_\(Z/Y5&RJS;^4[,[P
M^2W=-5181*3<>!RG9?6VQ=EY[/R8U*>LS%'0;*V/0;UP5#'D2]51T0W#5F!2
MD4\]4%9I/=>ZL!ZR_P"$UO\`(WZVQ$V,?XM[=[#EFS#9A,QV9W!V1N?*TUZ>
MB@3%P24^^,70G#1/1&40/`^J2>76S*P5?=>ZLFZX^`G\MWI_/S;KZI^'7PRZ
MXW/48VHPTVX-D=$],[9S,F)JYJ6HJL:V2Q&V:2K-#4ST4+O%KT,T2DCTCW[K
MW1N,&VQ-L8NDP6VVVEM["T`E%#A\&</B<71K//+53BDQ]!]O24XFJIWD?0@U
M2.S'DD^_=>Z<_P"/;?\`SG,2>3]<I2'^I_,_XO[\,\.M`@\#T"7R5SVWO]ET
M[\C7-X<RR]*]JQQ)_$Z(O)(^Q<ZJHB^>[R,2`+<GVU+/!#I\:=$#<-3!:TXT
MJ1P\^E5O97EYXGT=I+*5`KH1GI7A4*#2M,>OEU6W_P`)]LKB*+^39\`Z&ORF
M/H\A2=-U:U%%55U-35=.R[]W@VF>FFD2:)M+#]2@V/\`C[K%=6T[%(+F-W`K
M16#&GK@GJ]QMVXV<8EN[">*,M0%XW0$YP"P&<$_,"O#JY%MP[>ACU-G<-&GT
M#ODZ)5)M_JFG`OQ[<FD2WC$L[A(R:`L0`32H%305(Z3VT4M[.UM9QM+<JM2J
M`NP&,E5J0!49I3(]>BT=C?.#XE=43R4F_P#Y&=282MAR59AZK&0;OQ>>S%!D
M\>K&NH<IA]NS9;)XNIIS&R,M1%$=?H_7Q[`F\>Z/MYR^QCW?G*PCN%8JR"9)
M'5EKJ#1P^(Z$8'<!G'''4V\G?=G^\'S_`!K<<I>S?,%U:&!)5D:TD@B>.0T2
M2.6X6**16!##PF?M.K"YZ(WOC^>5\)MKT<<NV*KM+L:KFI,C)'3;?Z^JL!3T
ME720QM14N5K=^U>TF@CRLTI59:6&L$(BD:15]"R1-N_WK?:K;HU-A/?7\K*Q
M`B@T#4*4#-,\5-1P"JO3B1P!RDY6_NO/O0;]<-'O-OL.SP+)&"\^X)<%T9B'
M>)+%+K48@`621H2^I1&3W%2F5G\]#MWL&LRN(^//PWR^Y:Z#;XK8I<MF=Q;N
MK\36O+)3_P`6R>V-A[9O7;>2:6!5"Y"D>5V*&1"5/L!S_>FYIWB2>WY)]J[N
MZD$6I6/C3E2334T=O""8P2/QK7^(5'4YV_\`=E^UO)L-G>>\GWHMML83>>&5
MB%I9I*J@%HH[B_N_T[G#U!@F"`!BK4(ZXYGM#^>CW>U9)A]K;"^/F(J,AA84
MI(*KJ_:U90+'#3&IK,95;XW/O;/9#%S.3)6>F9PY:*%18('+G<_O:\T"9K?9
M[;:+<LE*""&F*$CZAY)BI(U-EN-%_AZ;VWE[^ZD]LA:KNG.-[S=N*0SG7KO[
MF.0DMI61+*"R@21?@BR@IIDD)J6Z(U\OO@;_`#%*E<3O[MG><WRFGH*'>^7R
MV4VKV)4;RQ_5^%I&H<SDY33[K.UVP>*S0\TZTF+QT=%`M$$')2-(B]Q?8OWZ
MW"2QO-\NYM_NW:4_HS23K`"0VD"58_##DDJL:!`%IB@'63WL)]\_[CNSVN_[
M/R=:VO(&UPI:XN[2.T:_94E36QLS=&>2W4*&FN9WF?QBU,,[2/Y<O\M&C^4N
M"G['[[7L?K?IW>G6G7W9'1>_]JY[8^*QW9>$WS339BERM+_'L?N.JFQT^V:N
MAK(%>EI'1*H%_4=*K_:C[L.Y<P3[K'[E;;N>V6ZQH8"AB4LQ/>"7CF!H*'MI
M45S2E2'[S_\`>,<I\B;/RE<_=ZYLY;YGW>XN9UOXITO'^EB1(VA<>')::2\A
MD4G5)710!:$FW[;/\EGX`XC'14&<R78.]*U9JF1\YFNVUQM=+%(^N"!J/:,.
MWL.(J>,A59:82,.79B?>0VW?=0]IK.U2&X@OKJ:I.N2<!C7RI$D:@+P%!]OR
MP/WC^]$^]%N5_)<[=<\O[=9E5`MX-N25%H,MKNY+B8EN)!D(!H%`'0]8K^5S
M_+<Q6/Q]`W2&RLH]!24U*V2S&]]V5V3R+TT:(:W*5!W;&E96U#)KE<H`S$V`
M!M[&$'W?/9^"&&'^ID3Z%`U-+.6-!2II*!4^=``?3J+;[[_/WMKV[N[I/>*[
MMTE=F$4-M91Q1AB>R)?ICH10=*BI(4`5/'ID[*_E)?RN>V\UGLYO?X\[(J*C
M<T%-39G&;<[+[+V'M6H@I<=2XI(J?96PNQ-L[.QJ2T=(GF%+0P_<2EYI=<LD
MCL-;3VZY`L)X+JRY)VF*XB(*,MI`I4C@00E01QKQKU#VX_>%]^]WL+S:]T]Z
M^:[C;KB-HY8WW:^9'1A1E93/0JPP0<=$[[2_X38?R4.TJ;%4<O0M9L:GQDU9
M--%L#Y!=MXJ/-/5BE$9S<.8W]GX*TX\TQ-,56-HC-)R0]@*HK.S@<2V]G#')
M0BJ1HAH:5%54&AH,<.HTN]_W[<(#;;EOM]<VQ8-HFN)I5J*T(61V`.3D"N>B
MP[^_X21?R8=W[;JL)M8]Y=69>6>CF@WCL[O],UFJ2.GJ%DJ*1,?V)B-[[9D@
MKH4,4ADH&E4&\;HPO[45/KT4_/JMGYX?\)<>D?AW\+?D/WS\%?G)\E]K=D=.
M["W+W5N+:_9O9NR3L??^R.K-L9[=&Z]O(O5/7NP\YCMYO@J6=\+5S/74IJ4^
MTEAC2J-73![?.4>5>9GMI.8^6K"_>$,(S<013%`U-00R*VD-I4FE*T%>'0[Y
M.]T?<KV\BOH.0O<#>ME@NF5IEL;VXM5E9`0C2""1`Y4,P4M6@)I2IZ*-\.OY
M6_\`/ZZ?^-70_P`W?@E\Z=@=@U'R3ZBZ^[3W3\<MW=I+*U?M3>:[<W;L[;FX
M=O\`>>+R?3V]*Z/;F3+Y9JJJQ%3C0*NBHI:KSLTOMIY1Y4V&*ZAV/EG;[.&<
M`2+#;Q1"0`$`.$4:@*F@:H%>O<T^Z7N7SQ<;5=\Y^X6][K<V)8VSW=]<W#0%
MRI<PF61C&6*KJ*$%M(J30=-&YOYRF<Z,WVG2O\[7^3IMW:O8)HX)LEW%T'A\
MC\=NS<M#N*+`-5[\FP=/75'7/9V?JQ1U]4]9C<S0T*5H-'%#2O'5$A#F+V7]
ML.9VEFW/DZT6[?43)"O@2%F()9C"4\1JBM9`]*FGQ&LM^WOWPOO)^V0M;?EK
MW:W5]LB,06VO)/KK<)#J"1+'=B;PXJ,0T<)C#"E:Z5I8;\<HOY0/SVROW/P4
M_F'YGXY=LY2"AI\7T-\G*>DV%ON*OS-?C!_=K;N=J,[M>;>(@CKEIEI<+E=S
M32UD0)J)(QJ$';[]TC:4FDON2>;[O;YR:A)1XBBK9"R1F-U`4]H82$D9:AQF
MOR/_`'K7-IL;79O>3VFVK?[(,#)-;M].[Z(R%=K69+FU:5I,EXQ`BH6"Q5XV
M?-LS^=?\91&VRNX-H?)S:='3O)14E9N[:V_*^OQ\V?2:E;[/L!-K;]J*_*4L
MGD'@R5?%1T+/'',HCCL5)R]]ZOD+4FV;U%OVWQU"JT@G<J9134MP$G+@<0C.
M$1B%84P>CGC^ZU][B3S)R=/R1OL[*2Z136$2O]/Q#[>]S8"-&%%+6T+33!':
M(ZV)>\;_`#N^Z^HLI!MGY9?$');5R2OD(),AM.MS&T_NY:/-K13RXO![ZILE
M19#'XVD61&GI<U51U52B&,I'*-%X?O0\W<M3?2>Y7ME/:S=XUQK-#J97"C0E
MPKAE`J"PE(+`&H!/3$_]VK[4^Y=HVZ_=U^\I9[E;%8W$5Q]->E4>#6!)-8.D
MD;N^E@DME$8HRP?4Z4:P'J#^;Q\'NW&IZ-NTI^L,W4U])008/M[#/LZ6:6OK
M9**C:+.T]1FMGO!*R+([C)6IHI5:?Q>K3,'+/WC/:GF54";^;&=F"Z+Q#$P)
M8J"74R0^A_M*`&K$9IBE[A_W?'WI?;T2W"\B)OVV)$TC3;3,+L*$C#MJ@*PW
M889`4VP,C*1%KP20C^?O\Q>A\S_+N^0_Q@V;NFL[+[=^3G162_T28WJ["Y#L
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M*3:4]S.1;[9#N`E-M]2(OUA"8Q+H\.20?I^+'J!H>]:8ZL+_`+P8'_G=XC_S
MY4?_`%^]BGJ-.O?W@P/_`#N\1_Y\J/\`Z_>_=>Z]_>#`_P#.[Q'_`)\J/_K]
M[]U[J32Y3&5LABHLC05<JH9&CI:NGJ)%C!"ERD4CL$#,!>UKGW[KW4[W[KW7
MO?NO=%8^;_\`V2)\B?\`Q%6ZO_<!O?NO=?_1W!>AO^RXOGC_`-07QE_]]ME/
M?NO='S]^Z]UK.=H?!/NC^;[VWWO_`+-S_,3AV'\/.LNR]Q=:T/P'^#/:^S)6
MBP>U-]9/"TU5\R>UL5/FZNJW?VEMG;\E36[5DI$."&0%/!/355%5"H]U[H'<
MU_PFP_E@]`[UV`GQ7^9?R#^!WRXW:<I/T=O;:'R=P'^D'=\E)C*DSXG"["W*
MV)R_9&T*?*3T-;E*'%RT\U3%2)":F!)&;W[KW5\OP.PGS@V7U1F.M?GENGKG
MM;L_KC=9VUL_Y"]<4D.W:7Y!==-MS!93$=@;LZ]AAIXNN^P*#*Y&NPV6H(%^
MQJ9L:*VF/AJ5`]U[HFF^NA^Y,A_PH"Z+^25%UQN>IZ%V[_+%[(ZES?:T5)$V
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MND>@MK2U$^VND.HNM^HMO2U=7-D*J3"=<;.P^S\7)45U2J5-9.]%AT+2R`/(
M?4W)/OW7NG+L'I3J/MB?&5/9_6>Q.P9L'%70X:;>.V,3N&;%09%Z:6NAQ\F3
MI*EJ..MDHX3*$L',2DWL/?NO=$PZ5^+GQMS?9WRIQ>8Z'ZDR>-VIW)MS#;9H
MJ[86VZJFP.*J>D>JLY4XW$P3X^2.@H9LSEJFJ:.(*C5%1(Y&IB3[KW1CO]DW
M^)O_`'C=TE_Z+7:?_P!:_?NO=>_V3?XF_P#>-W27_HM=I_\`UK]^Z]U[_9-_
MB;_WC=TE_P"BUVG_`/6OW[KW7O\`9-_B;_WC=TE_Z+7:?_UK]^Z]U[_9-_B;
M_P!XW=)?^BUVG_\`6OW[KW2&[,_EX?!_M_8.Z^L-_P#Q=Z=R^RM[XB;`[FQ=
M#M*CVQ5UV+J)(I98*?/[4.#W%BI?)`C+-1U=/.A7TN/?NO=:Z_\`(P_ED_`W
M"_*+^;/N2D^-.QJS+?';^8#W#\<>FY=PUNZ]V4>R>EH-N;.R$6RJ3#[IW%F<
M-DD@K0TB5]=3U6476R_<A&*^_=>ZV7C\._B6+D_&[I(``DD]:[2`50+W8_PN
MRBW]??NO=4\?-G^9#_()^!U)E:3M>3XU[[[!Q5;'CING>ANO=@]O=FC(?Q+*
M8NNHLCCMO!=N;4J<-4X2K%:F<RF+-.T0B;]^:GBE]U[K7#W'_-D^:W\R^KSW
M7?\`)U_DO=<[.VGF9\CM+'_(C=W3NUNQ,WMRKJ*K;V*DS"[MW!@MN?'7K3/X
M0[E@EJ*?)U&XA0P31U9=(HG;W[KW1@.A_P#A(I\C/DGN6K[>_FM?-G(?W@S>
M5K,Q5=6?'JGH,Y-2-D8ZPO3TV]-S83%=?;`IZ6=:0)B\!M*JQT5(C4]/+`JQ
M.ONO=;1GQ<_DJ?RP/A[@*;$=-_#OJ)\O'%CS7=@=B8).U.RLI7T%%0T9R4F]
MM_G/9?$2U;X]:B2FQ;8_'BJ>26.FC:1[^Z]U-^;LG\O_`.`GQH[&^6G=GQ=V
MAF^NNKYMG#<-!UKTQLC=.]JB3>N^=M]?X=L1ALC-@:6L\&<W13/4,]7%XJ59
M'&HJ%;W7NM:__A-Q\M/Y>/R(W9WY\/JSXYY+<';_`&-\G_EO\H-A9[>_2FRI
M]E87I#/;AVS7[6VID-R39W*9##[FQ>/E5&Q<5)+24[>A*AN"?=>ZV_?]DW^)
MO_>-W27_`*+7:?\`]:_?NO=>_P!DX^)P^GQNZ2_]%KM/_P"M?OW7NO?[)Q\3
MC]?C=TE_Z+7:?_UK]^Z]U[_9-_B;_P!XW=)?^BUVG_\`6OW[KW7O]DW^)O\`
MWC=TE_Z+7:?_`-:_?NO=%_\`D%MS^7!\5MK8G>W=_472>R\%FL_#MK#5,73=
M%N"LR&;DI*K(?:4F-VSMC+9%S#14,LLDGB$<:)=F'%PASESWRKR!ML.[<U[H
M+6QDE\-3HDD)>A-`L:NW`$DTIPSD=2M[0^R7N9[[<PWW+'M=RY^\MWMK0W,H
M,T%ND<(=8];2W,L48J[JJKJU,2*`]5?_`,H#_9`]Y=>9+X_9WK+K'<7>F4[^
M^;O:>*PN5Z>:N<]3;M^5?;7876];_>>LVW+@:>#_`$7;MPK0T#5BU-$CK2R1
M1S0R1(&N4/>KVXY[W8;'RMOKW.YF-GT&WN(^U14G5+$B\/*M3U(?NE]S_P"\
M%[+\HS<]>X_)45ARS'<Q0-*M]87!$LQ(C7P[>YDDR5;(2@`J2.KOC\.OB:%U
M?[+;TH?SQUIM._/^'\+O?W*>JE:@_L_S=8RU\_+KH?#KXFG_`+EMZ4!L#8]:
M;2_(O_SJ_?J\<'CZ'KVI?XA_J_GUW_LG/Q-_[QMZ3_\`1:[2_P#K7[]7[?V'
M_-UZJ_Q#KW^R<_$W_O&WI/\`]%KM+_ZU^_5^W]A_S=>JO\0Z]_LG/Q-_[QMZ
M3_\`1:[2_P#K7[]7[?V'_-UZJ_Q#H).W^L_Y=OQ^PN)W/W+UG\;>ML%F<PN"
MQ66W/L/:E!2UV8:BJ\DN/I91B'UU7V6/FFTVY2)C^/8?YBYKY=Y3M8;WF3=X
MK.TD?0K25`+T+:1@YH">I`]O/:SW$]VMTO=D]M>3[W>MVMK?QY8K5-;QPZTC
M\1A4477(BU]6'5'_`/PG=V#\.JSX&=/]#]O["Z3R7RC7>WR2W'ENOMW;3V]D
M^R$VO/W?OW.[?R-9'6X^HF?'_P!S*^BGISY2JT<D5K#@%.Q>Y/(?-%\NV<N\
MU6E[?%20D3$DA:DD545H!7UIY5!'0JYU^[G[[>V_+DW-W/OM7N^T\M1RQQM<
MW$02)7E)"*6#$59@5`\R#Y9ZOWSOQM^#^UL7D,WN;I?XX[=PV)C\N4RN=VCU
M_A\;C8_(L.NOKLC34U+1+YG5+RNHUD#ZD>Q5>;EMVWP27.X7\%O;I34TDB(J
MU-.YF(`SC)XXZBO:MAWW?;VUVW8]CO+W<)Z>%%!!+-)+4$@1I&K,YH":*#@5
MX=`!O#+_`,H_8<%%5;J?X64$.1GEIJ-Z:DZPS1EF@B\TJ,F#AR4D(2/^U(%4
MG@$GCV$-P]T?;G:TBDO>=]L57K33<1R'%*XC9R*5&3C/4M\N?=H^\)S;+<P;
M![+<RS20H'?5M]Q"`K&@.J:.-6J?)23Y\,]%OW5\NOY)VUJG+T7]V.F=RU>)
MIY)D7:'QZKMP4.8F6C2LCH\)GZ79(VW6SSM(L(<UB4\<Y*R2)I8J!]R^\C[/
M;;-<6YYH,T\?E#;W$@9M.H*CB(1DFH'QA03W$`$B9]A_N\OO:[]!MUU_K9+9
M6]P^FMW?6$#Q#64+S0-<FY15H7(\$R%!J1&JH)8=S_S+_P"4[142'9GPN&[L
MY)5P0I@:OIKJK;1,,H83S+72YK**986"@0"+5(6X^AN";W[W7M]#`&V_9=VG
MF9@*&.*-:&N=0FD)\@`%R3Q'4T[-_=/?>!NKS5S#S;RQM^TJC$SK/=W)!IA?
M#6TCHK`UU:J#S!)IT&8_F"=$[USTV+Z2_E&;9[`IJ/%T];7TTFV,?5;BIK5#
MP5%1-A]F=4[PBIL2C2PQI4/."\KE65?3<._\%AN6ZWAM^5/:J]OD2/4P$C:Q
MFA)2*VD&D545)XG[.AXW]USRYRUM:W_N=]Z/9-HFEN"B,+>%;=NVJJ);S<+,
MF6@<LBIA!4$YZ(#\W][]D[[P_6&?WY\*]A?$;:E1G=]/L"JVUL#*[#R^]TCF
MQ-)7XK/?QXT=5F9MK0T\`648^@C>6H>5(Q'(%6`_?#GGW%YXL>6[GF_DL;5M
MR271MJQS1L^H0K)J,K9T:$[E1`:Y&13.#[FGL?[&>RF[>XFV^SOO$>:N8KBT
MVU=U"36DT5MI\9X)(_I%(19VDFI&9YV15HSZP20[^&GQO[A^5'96[^KNCLML
M+"[I3KZKSNY,AO>6&G6EVE3[IVICZN;"U\>VMSY7'9Z/)Y*C=)*-:2I:G$L?
MG5'=)`G[(;%[A[_S+N&W^W?,*[;NC;>YDE+M&3;K/;ZU1U1W5O$,3532:+35
M0D&2OO?<Y>QG(GMWROS%]X/DB??^4(]]C%I;+;K<Q_7_`$=Z8WEAEG@A>/P!
M<1GQ?%16=6\)B`RW+[/_`.$^^9RA6L[?^47FJ/XU#+4X_96PYLA%6X:-*/S-
M'E]T[BC_`(=G)U\\22-CZN"`".0I+=X_>4O_``*_,>_2-/SM[JW=T[7`=U"R
M3:P`%KXDTRZ)-)90WA.%!Q4=HYKC^\W]ON0XHK'V2^[#MFUVB63Q1N\L%H8V
M=G;P_#L;,&2V#^'*R?41-(P9:I19.CJ]<?R/?A'LAZ.IW+B=_=JU=,]>9AO7
M>4^/QM?#5I)%3P56)V/2;2IM.,5PT+(4<R*&D+_3V/ME^ZQ[5[48FO;6\W"1
M2Q_7G*@U!`!$`B..(H>/&HQU!_.G]YU]Z#FA+F'9-PVCE^"0)0V=H))4*$%F
M66]>Z;]4BDBD%=)(33QZ.!M?^7W\*]GXVCQ6%^+W2QIZ&*HCAJ<YLO&;LS+K
M4U$M3*M9N'=$67SV0L\Q"&>ID*1Z8ULB*HE/8_:WVZY<T':.2]NB=590QA62
M0JQJ=4LNN1J^C,:#`-`!UC!SK]Y;[P?N'XXYO]Y.8+FWDE20PI>2V\`=%TJR
M6]LT$$9`_P!]QK4EF:K,25LGP^^+*A8_]EUZ5$**JH@ZZVQ9`BZ$5%_ANA41
M.``!8>QY&O@JD<=%C50H`%`H7"JH&`H%`%``%.H.D#3SSW$[:YI&+,S59W=B
M2S,S$DL2:DFI9BQ)J2>O?[)Q\3_^\;^D_P#T6NT__K7[MU;JM;^:A_+_`/Y:
M&_OBWEZ;Y#1=>?&K";<R>9W1L?=VTNP]J?&G(;I[&QO76^HL#L6HW89,,=T4
M>6HZJJJ&P>N3[IZ-)O&?!<>Z]T5_^07\#_Y<.*^"73.^^M)=C_('LWMKX^?%
MS>_R*P^\.RML]\MU1VKE.HZ7,9K:U!MJ2?*R=-Z\WFLFDN$:.GF0TBPR*32>
MGW7NKR/]DX^)Q_[ENZ3Y^O\`QC7:?_UK]^Z]U[_9-_B;_P!XW=)?^BUVG_\`
M6OW[KW7O]DW^)O\`WC=TE_Z+7:?_`-:_?NO=>_V3?XF_]XW=)?\`HM=I_P#U
MK]^Z]U[_`&3CXG?]XW=)?^BUVG_]:_?NO=4[?SOOY=&.WI\%>^=]?'#?FP?B
M;0]+_'?Y+]B]J8#:7QEZCW[/WWM3"=0YG+Q]=U6X]QQ4&7ZR\D6&JH8\QA_)
M70&O,J+KABO[KW7/^1-\"]F[>_EF?%K='R`KNNODYDNWNG.FNV.OZO=?Q^ZR
MVAD>G.N-W=,]?U.$Z4BRF#BKJSL.FVE7PU<PW#DRF4R+UC&=!I'OW7NK;]Q?
M!CX9;OPM5MO=?Q4^/6Y]O5L<L57@]Q=1;&S>(G2>":EF+X[(X6HI/(U+4R1Z
M]&H+(P!L3?W7NJ1/F'_PE"_E3?)U\QGNM]C;L^(>_,D*FI3,=!9H0;'_`(E*
MV0GCEJ>I]VQY[9]%B_NJU-='A%PB"GITBA:"Y?W[KW5&&Y?^$^'\[W^6]FYM
MX_`OO[JCYH=:8.H6IBZC[&PVTTKLMA:"LHZK["HZ=[Y&Z>N(VJL9@J>GJ&P>
MY*7+20LU-2EED8'W7NI77O\`/T;XI[JQ/4'\X?\`DF[7ZJS8DI*2M[#ZWZ6H
M]B5&2BI9=N8^OS5)U5V=B_[L[C6F63(5\U3A-SQT3324])!2P`/-[:N8(+V+
MZ>\MXYK?!T2*LBU4U4Z7!6J^1I4>1Z56-]?[5<"]VF_GM+X`@2P2/#(`V&`D
MB97`8?$`U&X'JZCH?O?_`(3F?S.(<1B^H]Y]0];=E9J'"8VEZ\K:[*?%OM*G
MR<U9@95VWC]IY>HP&TMYYZIS.[X,4\^(7,_Q&<20TE54)3!TA_?_`&`]I^8"
MTDW*,-O<:0-=LS0'!)KI0B(DU(+-&6(H*X%,L>0_OW?>IY`9$L_=:\W*Q!8^
M#N:Q[@I+($'ZEPKW`5`JE$6945@6"59]1!OYEGP4P?PMWSCY.L8>S]S]+GK.
ME["W?V9N[%1U>T-G5%7NG<>*:BR^^L!M[#[5Q6-I,9CZ)P]=*LY-2K/(5=/>
M#OO/['7G)/,MCMW)6U[MN6UO9+*SF%I]$C22H8P880N%1'(H2-0/F.NS'W2?
MOF6'O3[>;US+[P<R\J\O\Q6FZM:10?61VGBP):VTHG\*]NWE)>665:I2(%"J
MK4'JQ7^23\8-M[JV_P#('(]_=`4^6IJFIZFK]@U_;'6,WVM;B\AC=\5.0K=G
MU6Z\,D%=CZN-J.2:6B:2)@T+,Q#)[GO[H.P[YL-KSY%O6SW5HTK63()HI(M5
M!=`TUJM=-0#3A4>1%<'O[UKG3DSG#=/8UN4>;MJW7Z>VW;Q?HKNWNO"UOM^@
M2>!))X>O0VD-35I-*TZO1?X=?$Q$9V^-W205%9F/^C3:9LJ@DFPQ1)X'O,SK
MD;T4GX89W^5K_,#ZCK.]/BEU5T_V-UE0;VSW7=5GZWH2?8\T>[=LT>(KLUC1
MAM^;,VWFY(Z2FSM*1.M.8)#(0CL58#W7NBE;?_F$?R!=S?*I_A?C<A\?X_D`
MW9E?TS0[=ROQUW-@]LYGM7&[DCV=5;$P78V8ZUHNO<QGCNR3^&Q)3Y-XYZP&
M*)W:P/NO=71[#Z$Z0ZIR]3N#K7J3KS8><KL?)AZO+[1VC@\!D:G%35-+6S8^
MHK,;1TTTE"]50PRM&S%"\2FUP/?NO=`+\F_YA7Q6^(G971/3'=6^-PT?;OR7
MS-=@>D>L]C]9]E=I[TWU7XVHQM'7/28/K;:FZ*G&8^FJLO`CU==]K2KJ9C($
MBE9/=>Z.O[]U[HK'S?\`^R1/D3_XBK=7_N`WOW7NO__2W!>AO^RXOGC_`-07
MQE_]]ME/?NO='S]^Z]U\R;</R3^/W6WQ+_X51]"[][>V%M#NON[YZ[VDZEZS
MSF<I:#>?8D&V_DYN:JS#;6P\A^YR\>,ABD:7QW\85B;#GW[KW1O.N?DG\?N^
M?G%_PDRV=TQW%L#L[=?0_P`9<%UYW-@-G9VGS.5ZSWQ1]`==T51M7>-/"->(
MS4%?@JZ!H)/4LM)*/HH)]U[KZ#2H!8_D"P_H!^;?T!]^Z]UVR!OK?^G^N+WL
M?]B/?NO==D`BQO\`[?G_`&_OW7NN'C7_`!_V_P#7D\?3D^_=>Z["`<<V_P!?
M_??7W[KW7:J%^G^']/Q?^@_Q]^Z]UV?H?]8_[U[]U[HJ_0'_`#-SYD?^)WVM
M_P#`^]->_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NB6?S!_G/U'_`"X_BAV9
M\M.Z%KLAM3KZ+#4>.VIA9Z.+<^^]U[ES%'@]N;-VM'6ND$V8RE;6>1BW[5-1
MP3U,Q2""61/=>Z^>C\$/^%.W:'QRS?SGJ^MOA!#V[\A?GG\Q-R_(K8FVL9OS
M<-;M?9^5WY@8,/\`W/&UL%LZOWQV/68JOP]'X(:*?%R9-*B<ZZ0Q(LONO=61
MK\#O^%/W\X9L)_L[?R$IO@)\:LQ44]96=>8&3';*S7\%KL3B*#)2-TUU/EX]
M\[HJ:R"&63^%;]W11?:UDE0L<=+#,0?=>ZN%^$/_``E5_E:?$^#:FY>S-BYO
MY?=M8&&@JZO=W>-;*=@-N*E.2^ZR6%Z7P533;,&+J5R"K'0YX[C$'VL$BR_<
M*TS^Z]UL<[8VEM;9.`Q>U-E[<P.T-K82G-+AMM;7Q&/V_M_$TIDDF--C,-B:
M:DQU!3F:9W*11HNIB;7/OW7NG\"PL+V']>?]Y]^Z]UW[]U[KJP)!_(O;_8_[
MW[]U[K7\_P"$ZO\`V39\X/\`#^;%\\!_Z^VWO?NO=;`GOW7NO>_=>Z]].3[]
MU[HK_<7S*^,?04E72=M]X=?;/RU'%532[=FS,>7W85I(J*>2*/:>!7)[DEJF
M@R,#I"M(9)$E5D!6Y`'YD]R.1>4?$',7-5E;3H"3&9-<M!2OZ48>2M&%!IJ<
MT!%>IG]NONZ^^GNTD,_MY[6;QN-@[J!<"`PVAUF0`F[N/"ME75&ZF0RZ%*T8
M@D=54]F?SY>KEKZO:WQUZ2[%[@W143#'X&KS$<>V<3D:^5:Y(WI<!BXMR;WR
M=G@AFAIA14TE9"[#R0.OO'_??O:<OB4V')?*M[N>Y.0L6O\`21V((JJJ))&H
MVGLHI;(JA&<\^2?[JOGWZ.#??>/W/V;EW9$7Q+A(B;B6.(&,D-/*;>RBPSJ\
MIFE6)PIT2*U>B#?+]/YJ_P`XMF;+RO8'Q3SV"ZVQNZ),OM/9>R=HF'.P9RHV
MRM$V;S-!F<]D=]_PN7'U-0:>>>FI:,25CQ'R.D?CAWW-C^\+[K[1MTN[<A2P
M;`DVN**&$^)K,8`9T=WN0M"U&952K$<0H&6'W=7^X7]U[FCF7;N4??NSNN=9
M[$17=Y>7=86@%SK$$+PP1V/BB18_$2.2673"LG8K.')_\-/@W\J/D7NZ.NZM
MCW3U%MZ*?LK;$W=]0NY\1M;';GZUW57[&WWL&;<&U94RB9R@WG@Z[%5-,MHT
MK,=-')REO8&Y#]B?=J^WU;=;"^V23PW/U,J3PJ*#X=:*3W4H!FIQQK28O>3[
M[/W6N7>1Y-VDYFV;G6,7<*?NNUDM;J5BVHBX\*Y5HM$0`U,>Y1(-/'JS_P#X
M9O\`GPZ7_P!GBI_4H(']_N]1R>0.*P$<^YI_X&SW>!_Z>FI'_->[_P"M?6)/
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MI_,DJR3P/]_3V=P?ZFV/^GNH]G?O`^?O0U/^>B\_Z`ZN?O?_`'`_+[ET7_9+
MMO\`ULZ+WTUU'\VOD-O+N38/2'\W[`=G[H^/NZZ38O<=)L_=_;.5Q^Q=YUG\
M2_WZN2S\6$&WJO/4+XBICK*6DJZF:@FC\=2L+LJM[_6=^\$./O.W_91=_P#0
M'6_^"_\`N!X_\`OB_P"R7;/^MG0+?/WX8_S`]@=:;*R/<_R`WA\K\#6[_BH\
M3LK;%'V3OBLV[FAMK<-0NZJC&S8>HCI:6.@BGHC-8-KK%07#'W$?O#[7^\>W
M;!MS\P\WW&_VSW0"P1M<SE&\-SXI5THH`JNH9[Z<">LI?NH?>5^Z1S9SKS)9
M^VOM'MW(.ZQ;27EO;E]NLEN(?J;9?I5D$REV9V2;1P*PDX('1,_Y>_Q6[*^6
MO;&)HNO-X[]ZNV=4;=W?D&[^V3@L_E]MT,NWIH\75[=IMS83.;7QE545^9#4
M51!!E?)%41NCQDHX6/\`VH]IN<^:N:XMO!W/8XS#*QNOII@5"KP-6@`$AH@!
M?SH`>IK^\W]Z#VF]L/:FZYG_`.0SSE<_O"WACVHW]E*9BY<M,8_#O<VZKK!:
M`BE.]"03=EB/Y`W4]7$U7V-\CNW-W[FK<C5U^=RV*PFU\)29@U-<:LR5%/G1
MO3-O7S(Q,]1)D9I)IBTME)`&3EG]SWELH9=XYTW"XW%G+.\:11`ZJFI5S,:G
MS)<U/EUSCW'^]G]P()5M^3/9KE[;MG2)$@BDFN9GAHF@:6@^CA\-&J4C6!0B
MT2I%3T9?:G\D'X$;?RM+EJS:786ZJ>&.H23`[D['S7\&JC-#)#')4?W?CV_E
M==([B2/151CR*-09;J1S9_=<]IK>=)I[&]N8Z'LDN&"FHH*^$(WJ.(HX%>-1
MCJ']Y_O.OO7;QMLEC!S#M%A.Q4B>WVZ'QETL"0OCF>*C@:6U1,=).DJ<]&.V
MO_+)^!>T:2HHL;\8>M<A%557W<DV[:/([[K4D\,,/BILCO;);@KJ.C"P@BGB
MD2#66?1K9B1GMWL;[2[5#)!:\BV3(S:CXH><UH!AIGD91CX5(6M32I/4.[[]
M];[U?,-Q#<WGOAO<,L<>@"T>.Q0BK-J:.SC@C=ZL1XCJTFFBZM(`!C=J_'WH
MK8ZX)=G].=8;:.UTHTV[-AMB;8H*O"_P^,14<F/KX,6E=3SP(HTR+)Y!];WY
M]C7;N4.5-I-NVV<M6$#P@!&2WB5DIPTL$U`_.M?/J&=^]U?<[FAMS;F+W$WR
M]%Z7-PLU]<R)-K-6$B-(492>*E=/RP.A?]B'2.@%T6WY:;-VCNCX]=U5NYMK
M;<W%68#IOM:MP55GL'B\Q486M.Q\Q(:S$RY"EJ),=5%Z:,F2$HQ,:F_I%B^^
MV?:=T$0W3;+>Z6,DJ)HTE"DTK36K4KI%:<:"O#H\V7F?F7EHW3<M\QW^W/.%
M$AM;B:W+A:Z=9A="VDLQ6M=))(I7JM__`(3V;<V])_*-^"V_WP6&??>XNEJZ
M+<&]&Q="V[<[&^_]T%TS.XS3G,Y-6-##<33.#X4O^A;-V.P['M<S7&V;+:6T
M[+I+10QQL5J#I)15)%0"1P)`/'I5O/.O.?,EK'8\Q<W[IN%DDGB+'<W<\Z!Z
M,`X661P&`9E#`5"L5&"1U=E[->@SU[W[KW7O?NO=>]^Z]U[W[KW58/\`-J_E
MY_'K^8Q\3LOUO\BXM\S;;ZAR6<[[VC'L/<T6ULC_`'\V?UMOW!8@9"KDQ.76
MLQ#4&ZZOR4_C4O(4;4--CZM.O=%3_P"$\G\O;X^?#+^7_P!(]O\`3,.^(=X?
M-KXX?%+O?NW^]FYH\]C7WWDNGJ+<=2=IT*8K'?P#"-DM]U[)3,U0PB:-3(VB
MY]U[J^KW[KW7O?NO=>]^Z]U[W[KW7O?NO=5,_P`ZKJOLSL7^7A\M<OL#Y(=C
M=$XK8'Q.^56Y=][5V-M+J3<V,[OVW!TCNBHGZ^WK5]E;"WEF]O8"MIZ">F>J
MVY4XC*+'72E*@2)"T?NO=0?Y&&P][[&_E9?"2?>?=F]>Y8-[?&;X^;UV=2[R
MV[UUM^/J+9^7Z2V`N+ZAVDVP-J;8J,[M':<E++]I7YQ\GG9Q.QJJR4!`GNO=
M6Z>_=>Z][]U[KBRAK7_'OW7ND3V%UEUSVWM:NV-VIL/9W96R\IH_B6T]^[:P
MN[MMU[17\4E7A<_19#'32PZCH<QZD))4@^_=>ZUU?F!_PE#_`)4'R9;(YSKC
M8>[_`(C;YK_W/XMT%GS#LV6K,E)IEJ>K=X)N+:%#3I34IC$&%3#1GRO(VJ4Z
M_?NO=:6_\Z#X??S!_P"39M_8GPLW'_,#[*[V^''R.VYELUM+9.+W=V!M+;-?
M2=85>R,9DMN;UZ>RFYMT8/`T.%E_@AQ\%'DJ['SPTZ66)X3&-@E3533_`&>J
MLJMIU+P-?S]>MM[_`(2'?+?Y8?*'X)=I[>^0>[,=V!UQ\<.RMN=+="[PRE=6
M5_9Z8BEV;3;GW)LC>-547&4VMLC&YW!1;<K)GDK?!4U-'(WV]#2*NB2226))
MZ\JJ@TH`%KP'#K;%JO\`@-4?\L)O^M;>_=6ZU6_^$>H#?RH=XDBU_F7WDW'_
M`(:O5/\`L;"WOW7N@6_X4JX[=FU>UOY>V[?D/T]AZ#^47T?\DMB]D]Q=O]#X
MW&3_`"1V/VUEJO=M.N*K\;6((,#T_N"IK**JKFQ-+-69BL299)$R$6)$WNO=
M;?V,RE'G<;C<OC9A4XO+T5'D\?4>.6'[BAKZ:*KHYC'.D<T1FIYE;0ZJXO8@
M&_OW7NOF@;>^4?\`,ZW-\K?YAW_"AGI'K#I+M7IOXP]W[IZ#H:;Y#9ULGO+J
MWI#`;BP%%/UYTWM>@W;'2;6KH>L=WXZGW#EJ)E>HESN0EQB2RU-?$?=>Z^B?
M\3/D%C?E?\8OCW\F\+MROVAA_D!TUUWW!CMJ92NILEDMM4G8.UL7N>#"5V1I
M(H*;(5&-3)>%IXXXUE*:@BWTCW7ND]\W_P#LD3Y$_P#B*MU?^X#>_=>Z_]/<
M%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW6J-F3_(+[9WI_-;[A[,_EU]55VW
M_P"7MO;<^3^3?R&SFT>MLWB.W>WLU4[CSF[MO;!%%O>3/YOL+*;RIY<>T.1I
M<<E3G:Q*59/,6"^Z]T5'^5/\P/Y1O:/SDZ$V70_R68?Y>W:7;^,S_:?P&[]W
MEMC$1T?<6W<1!N&*AW#@JY\+M;^[><W'A<=5BA7%3;EQT\X:!:]M=/)4>Z]U
MNSCZ"WT_'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH_0_ZQ_P!Z]^Z]T5?H
M#_F;GS(_\3OM;_X'WIKW[KW1J??NO=>]^Z]UT38$GZ#W[KW3=E,SB<'B\GG,
MWDZ##87"X^KRV8S&6K*?'8O$XK'T\M97Y+)Y"KDBI*#'T-)`\LTTKI'%&A9B
M%!/OW7NM23^8]_PJZ^.W4&5W+\>OY<>R,W\U_E'59+-;'P&X\#A\S/TCM_=\
M$,]%#68C^&4TF[N]ZG'9>.\5#M^&FQ62BB:2',>/09?=>Z(#TC_(F_FM_P`Y
M?>&W_DW_`#M_DQV7T]UM_%ER>V?C#CH<9C]^0X$4$;T1P/7N./\`HO\`C[#6
MP922FDEK,;D=UN8)EKZ2*61:@^Z]T>3_`(3F?RR/B1\>?EA_-(W_`+3V3D=T
M=A_%;YL=B?$WHW?78>3IMS;@V)U1@=MXFKJYL.8L7C,=2;UW4F=EILGEXZ=*
MB2@04L`IX9:M:KW7NMP?W[KW7O?NO=>]^Z]U[W[KW7%W5!=C87M_L3[T33KW
M0>]D=N=8].[=3=W:V_=J]=;7DR-)ATW!O'-4&`Q+96N2>2CQPKLC-!3FLJ8Z
M:1DCU:F$;&W!]E.];_LO+EF-QW_=(+*P+A/$F=8TU$$A:L0*D*2!Y@&G0LY+
MY$YT]QMX/+W(7*U_O.^"!YO`LX9+B7PHRH>31&K-H0LH9J4!8>O6O=_(+[NZ
M=ZVZ<^6/7_8/:&P]D[U[`_F6_-+LC9&V-U[IPVW\SNOK_=.Y<1E]M;SP=#E:
MNEFR&V\_BZ&:>CJT!AJ(XV*,;>PU9^Z7MMN-S':6//>TRW#D@*MS%4D`D@=P
MS05IU(.[?=J^\+L.VW.[[S[)<T6VV0Z=<C[==!5U,$&HB,TJ[!?M/IGJROO'
M^:[\(.DZVHQE?VY!V!N&BGEI*O!=44$V^'HJB!LI#)%79RB:+:E)*E=C&IWC
M->:B)Y(V>,1N']@[FO[P?M;RN\EM)S$+R^`(,=H#-2E>,@I"#5=-/$+"H.G2
M:]2S[:?<&^\_[GP0[E8^W[[3M#QATGW5Q9!U;PC6."0&Z:J2+('^G\-U5PCM
M(NGJO;)_SA_DSWZU?A?A-\,=V;@G@FJ(3N[<M-E]^14D"28>)9*[![/IL;MW
M$5=)4Y!4J8YLY5(D51%*64!O</R_>3YYYP:>T]K?;2XN`K']:17FQ6/XHXE6
M./XB#JE8493CK+RQ_NZ/9'VG%IN7WG/O+V%E$RJ?I+9X;$LU)F*I->-+<3(Z
MQDQNEE$6>.2,*S4Z:I?AA_-Z^7JPP?)7Y%T'3.Q:ZD\>1VKB,M1).U+4'-T\
M]!D-D]1#![?SDXIZYHI4KLW)'444Z))([Q!0DE]L?O&^Y"I'SSSLFV;4ZD/%
M&RCM/B*4,-IHBD[6(/B29%`7-``9VOWD_P"[S^[V)I_93V>EYEYJBD_3NI8Y
M"H91`RNE[NQGGA%8PZM!9*T<R,R(JR%B:7IC^1M\2>NJV/-=BUV^.],Q'-%.
M*?=N53;NUGD@.,EB^ZP&TQCZK)JE5137CK*VIIY::J:&:*4*K`>\L?=3]M]F
MDBN-[>ZW6X0U`E<QQ5[37PXB&;(/:\K(0Q!4TKU!/N3_`'G_`-X;G"UDVWDV
MWVKE;;71E+6L1N;JC"0'3<7>M8^UTHT4,;I)&)(W2I'5H_6?1O4W2V(_@74?
M6>QNNL6=!EI=I;<Q>&-4T<U;41-6U5)31UE<T$V1G\9FDD,8E8+93;W/>Q\J
M\N<LP-;<O;):V<!&1%&J%CJ+#4RT9J%F(U$T+$#'6"O//N7[B^Y>X_O?G_G;
M<]YW(8#W=Q+*%!"*="NQ5`1&A94"ABBEB2.O=Y]MT_1/5.Z>U:SKWMOM6#:<
M>'>7871?7^5[2[5S_P#%L]BL"%VIL3!E,GGGQ[Y05=6(B/MZ"">=O3$WL0')
MK3H%4ICJF3^0U\H<;VAT=O\`ZFINB?E1L*HQ/R1^?7:+]@=M=#[EZ]ZJR%/O
M'YW]U9>'8N(WWDZB;%9'L_;<>[$I<W@TM58S(8[(T\EVHW8^Z]U?L?H/]=?]
M['OW7NM?'^0&?\F_G(>HC_L>Q\_N;7^LO5XM_K7_`-CS^.#[]U[HMG\WO&]B
M)\WOY8W6W>G2?6W5_P#+5VM\Z/C9F>H?D+U1B\!F>W!\H:*FJGZVZ4W5MJ3<
M.!KNKNKMV;E%69LAA,-G%J8L33I4"F#"6/W7NK/OYWWRU[$^$7\KKY6_(3J2
M.3_2AAMK[8V)L;*0U[8VJVQN;N3?VUNH<;O*@GCCD8Y'9E1O;^)TJ`IY*FD0
M>1!ZA[KW5<O\KKO[Y%?R_P#M#X??RL_F%\)]B_'+&?)[KWL3<'QJ[,ZJ[AQG
M=.YNP^X^I-HCLGY(UORCS4='A7KNS]UT5;'EZG.4<#TK5LR4:-51LLU)[KW6
MS][]U[K7Z_X3"_\`;GCHU?PO;7RM51^%7_9F^U3I4?0"Y/'O9).2:GJJJJBB
MJ`/E]E/\`I]G6P+[UU;KWOW7NO>_=>Z][]U[KWOW7NJW?YGVQ^X>Q^@<?LGI
M[Y^]:_R\JO<^ZJG`;R[0[/ZSZP[1P_8&Q\YLG=^(S'5>/Q/:>YMJXK#9;*RU
MD.13(4-5_$8HL;(D:A'D=?=>Z*K_`"4OB[V5\.>MLK\>,E_,_P"G?GETKU?L
MS;&VNG^L^L>J.J-B5_1M(V=W-E\K7YS<^R.P>P-W;MAW9/D@D(S52?`:5O$Y
M!*K[KW5YGOW7NO>_=>ZQM(B7U'Z"Y_V/T]ZU"NFO=2M/.GR]>M$TI7@33\^L
M%174M)335E7,E+24T$E34U50RP4U-3PHTDT\\\A6*&&&-2SNQ"*H))L+^]BK
M.L:@ER:`#B?L'$_92N>JM(B*[N:*H)).``.-2:`4S6IZKV[N_FN_`KH2;)8S
M=??VV]R;FQ::I]I=9P5_8V:,JU--3RT<E3M:FK]O8VO@6I\S0UM?2R-"C,@:
MP!E[E?V(]U.;5@FV[E.>*QD-!+<4@3@2#20B1E-*51&%2!U$7-'OU[4\I-+!
MN/-L$M\@_LK<-</6H4@F,-&K#B0\BF@)ZH;^97\^_,]P]9;ZZO\`CST]G=@[
M9W]A,UL?(=L[WS\)W734N<Q]-3Y2GVSA-OTU5@\%F3CJBIB61\I5U2T\Z3QI
M33("N4WMM]TV'EW?-HW[F_F*"[OK2:.=;2&.L9T$E/%=V#R+4#`B5:@JQ=:@
MXH>Y?WM)^8M@WG9.4.6;BTLKN%H3=S/250Z@/X:1@B-M)9=7BN14,H5J$!)_
M+\^>O\TW<.P<;\;/B5LSJWN&@Z2VO3FFQ^\:/")N_"[-J,K44V+ICD-P=H;&
M3,8?"U$RT5.(8II*.G$$4C!?%<2>[GM1[$;=NTW.'/\`N-]MLNYW#`F$RF)I
M@NIJ*MK,49@-1#$:FU$`G50.>T'N][][EL\'*'M_L]EN4.VP5'B^&LJPEJ+F
M2XBUJA8(-(.E=*F@T]6)_P"GO_A1#_WB?TK_`-2M@?\`W17N(/ZI_<^_Z;_<
MO^SC_M@ZF/\`KA]\/_PG>W_MM_\`MNZ]_I[_`.%$/_>)_2O_`%*V!_\`=%>_
M?U4^Y]_TW^Y?]G'_`'K^O?UP^^'_`.$[V_\`;;_]MW7O]/?_``HA_P"\3^E?
M^I6P/_NBO?OZJ?<^_P"F_P!R_P"SC_O7]>_KA]\/_P`)WM_[;?\`[;NO?Z>_
M^%$/_>)_2O\`U*V!_P#=%>_?U4^Y]_TW^Y?]G'_>OZ]_7#[X?_A.]O\`VV__
M`&W=>_T]_P#"B'_O$_I7_J5L#_[HKW[^JGW/O^F_W+_LX_[U_7OZX??#_P#"
M=[?^VW_[;NB,_.GY[?S:.N^L\GTY\JM@=2].8?OG:VY=KPR;9HL!4;PR6V"E
M'0;L_ADNW^V=ZG&4<]'DUHYYJFE\4D=4T:W=O3)_M?[3_=_WK>X>8>1-ZOMP
MGVF:.8^+X@B62I,5?$M80S!EUJH:M5K0@$=19[K>[?W@]EV"XV#GS8MOVZUW
M6"6(%#&9FCTTET^'=2D*5.AB5H0Q`/6/X>_SS>Q/C[T?LKJ#=7QIQO9NQNDM
MB[7V+C-T[/W-5[*K,1M_&U"X3;7]YTBV=G]KTM+'B5I\=1HL=&U1-3@O*\LC
M78]PONG\O\P\Q[AO6Q<W#;;S<+F23Z<PK+&68:Y%A42Q-13JD;#*H)"*H`!M
M[?\`WL^8.6^6;'9MZY2;=;/;[9(C<+,\;Z5.B/QV,<RL0NF.I"LY4%F9B3U:
MUUA_PH%^"^\JJ*CWA2]N]33564CHEJ=T[-I<_BJ:ADBC<9JNKMAY?<\U-0I/
M(\3(('F7QAM)5@?<&;Q]TGW2VU6DVZ7;]Q41!@L,K(]1C0%FCB&H@5%6`XBO
M"L^;'][GVLW+2NXC<;!O$TUEA#J%QWGP&=J"M#12:`&AS2PSK#^8+\)^Y%I!
MUY\G.H<O65E'6Y"'#Y+=E%M/<246.J_LJNHJ]L[P.`W!CT2>Q7STT1EB994U
M1LKF)-\]IO<SEMI%WCD?<HD5@"ZPM+'5AJ`$L6N-JBO!C0@@T(/4O[%[N>V?
M,B1OLW.MA(S!B%:00R44T),<WAR+G^)144(J"#T;BDKZ2OI*>OH9XZVAK((:
MJCK*1TJ:6LI:F-):>JI:B!GAJ*:>*0.DB,4="&!((/N/65D=DD4JP-"#Y'S!
M]".!KY]2$DB2(DD;:HV`((R"#P(/`@@U!%13K.)D)`%^3I!MP38?D7_)M_K^
MZU!\_P#4>K5%2#C/67WOK?6OY_PI%^,?Q][8_E?_`"L[P[*ZAV1O;MSH3I+/
MUG3/8>?Q"5FY>MJO<&Z-GIF)MJY`NLF-FKQ1Q&0J"&T+?@>_=>ZL0_EN_&'X
M^?&'XG]38CX]=0;(Z?Q78_7O6?9F^J#8^)3$TVZ-^YSK;:=-EMU9=%DD:KS%
M=34,*22L266-?Z>_=>Z/A*H>*1"2`Z.I(%R`RD7`_)Y]^Z]U6M_*P_EL=??R
MK?C3E?C-UMV5O7M7;V5[6W=VS+N7?M!M['9I<GO'%;8Q=9BXZ?;='18XX^F7
M;$<B,4#EYGN=(4#W7NJ\Z_\`X3G]7;Y;8G6W?7SQ^>GR(^&G66[,'NG9?PQ[
M4[4QE?UA"FU&E.T]J[BW#CL)C]U9[:6!I*F:CA@62FG2B=8X:B)D63W[KW5N
M>0^)'E^8?7/RRQO?7>VW<'UQT-G>BJ/XPX3>,-)\;\W#E<W#E:3?N<V,:`M4
M[QQE-&*99Q-J9:.@(:-:5XZCW7NJ2^^_^$L7PG[M[Z[/[.QG>GREZ?Z=[YWV
MW:/>OQ9ZNWYBL+TWV#OF;<&7W)/D:?'38BH_@6,3+Y,34=$8*N/$D.E`U+&T
M<</NO=;).P-A[3ZOV3L_KC86!Q^UMC[!VQ@]F[/VUB8_!C,!MG;F-IL1A</1
M1?V:;'XZCCC2]V(6Y)-S[]U[H"/F_P#]DB?(G_Q%6ZO_`'`;W[KW7__4W!>A
MO^RXOGC_`-07QE_]]ME/?NO='S]^Z]UH,?)#^2]_-HR7RB^;GPHZ7VSMX?R^
M/YD/S=V%\MNYOE=2;NVWB]P;5ZZK-W[RW5OOJW*[<J]R4&;KJG!9G=GW2XVF
MQ4K9&;!T(6L\%;4HGNO=6W]V_#;M[Y$?SE_Y5^\OC_L/;5!\"OY9?2VY:.O[
MUPVY^O\`)[>K=]5.%?:T'16W]I;5W/%6T=?@-NX3;`22+%TE/2K65=X_%2P)
M)[KW6SQ[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z2^]\GN?"[+W=F=D[6@WQ
MO/$[8S^2VCLJIW!3;3IMX;GH<55U6`VO4;IK*+)4FVH-P96**D?(2TU1'1K,
M9FC=4*GW7NJ6OY?GRU^9?;GRX^7'7W8OP)V[TYM+;7?V,P/>_8--\PMC]FS=
M5[U'Q.Z=WGM3;V%V;B.K=NU_8M%N;%9/!^2OIJNCCH),M(CI(]!,)/=>ZO,!
MN`?Z_P"%O]X/OW7NN+LPMI%[W_K>_P"/Z"W]>??NO=:[7\T?_A2G\#OY=%+7
M;&VCN#'?+7Y(ZY:0=0=.[LP]3@=EU"1R$U/;79U,,OM_9YCEC*'%TB9/.EVC
M,E'!!)]RONO=:_U%\1?Y]/\`PHVWGMWL/Y=;BR?P+_E[9Q,1F,-UK"=S;-P^
MY.O9\K%E,;6;1Z;J<A)NCM3=^7PU6E12[CWB:'#3(J5-#I@,%(_NO=;9O\M[
M^2_\#?Y7>'>?XY=939'M7*8F7$;I[\[)KHMW=N[CH*IZ&>KQD>:-)18G:FWY
MZC&P.<;A*+'TCM"CS+-*&E;W7NCI_*OY&;6^)'078GR!WAM[=.[L%UYBZ2M?
M:.R(,14[OW17Y+*T.%Q&W]MQ9_+X#!?Q;*Y/)Q11&LKJ2F4F[RH.?9'S%S)L
MO*>TW.^\PWZ6NT0Z=<K!B%+L$2H16;N9@,#SST,>0O;_`)Q]T.:-NY)Y!V-]
MRYJNQ(8;='C1G$,;S2G5,\<8"11NYU.,*:5-`=8;^1S\_P#:E+\P?GML7L'I
M;N7J-OGK\V^Q/DITMN7?$7757@*:@W9B=KX3;W6>ZQLOL#=>7QW8F3GHJB5!
M3TM5AUBA;77HVE6`VS^]WM5S!NEELVS\Y0S;E<2*D:"*X!9W("J"T(45)&20
M.->IIYK^YM]YGDGEK?.<.9O:B\M>7-MMWN+F<SV+K%#&*L[)'=,Y`Q72K'-:
M4KUM(;M^2?0>P*&#)[Y[OZBVECZNL^PHZO/=A[4QM/4UA@FJ120RU67C66H\
M%.[E1]%7V+-RYVY.VB*.;<^;=MMXF?2&DN844MDT!+C-!^5#U%?+WL[[N\W7
M,UGRO[7<P;A>QQZWCM]ONI6":@H<Z8L*2P6I_$>/18=U_P`U?X$[0DSM/6?(
MS:>9K<#'5&:CVGB=U[H.2GIJ<U"T6"R6%P59@LS45/"1-!5M"TC`%QR0`MP^
M\![1[<;I9.=+>1X@<0I-+J(/!&2,QN#Y,)-/SIGJ<-B^XG][/F%=IGMO9F_M
M[.[*T>ZEMK7PE9M.JXCFG2>`+\3"2$.`,(>BM[L_GS?#3`242X'!=S;YBGCG
M>MJL3L[#8"'&/&T:P03)O/=&W:BIDJ0[$&!)4700S`D#V!-R^]M[864D26=I
MNEXK"M8H8QI^1\29#GCC%.IUY?\`[JO[R^[)<G=MPY;VR1"NE9;R:<R@@U9#
M9VUPH"T%0Y5C4:0:$]`1G?Y[VZ=QX^OFZ5^&6_=RI-E31;;W%FLWDLEA\A2Q
M9):=C7T.S=GY2.GRL],"IIH,E.E/4-I:615NP4N?O8;A?0RMRU[97<H+T1Y)
M&8$`YU1QP_%3R64T)XMYRIM?]UCL^RWEG'[G?>1VBQ=8`US;P01I*CF+4/#>
M\O(BT0;/B26T9>,5"*3AP?YQ?SCNR,G+3]<_`V@V13X_&"2OI=];-W?2&>ID
MJ)D2JH,[OG=_6F.F;Q,JFD@BJY$*&1CH;2KI]U/O)[Y<,NQ>TPM(%0:OJ;>9
M26)(JC3S0*2.WLH2*%C@X2?\#%_=R<G62OSG]ZV7=9)IZ(]A>6C:$"J2LD%E
M:[C(!JJ1,[1(P;0`&6K$J^9^W?YO&^OCC%DOE-A*+,]50[OV[E*O:NV]M=>U
M6^<1GH*O(XG!97+8WK7#U=?38L25+`NM4\'^4PB0!G"K%WNAMWWD-WY'$O/T
M*2;)]2C-#'';&9'_`%$1F%LFH+W$5+4[E!R0.LE/NU[Y_=Y\K^\CV?L/NLMM
MSX^WW$:7-S<[@ME-;E(Y9XH9=QF1&EHF%,0<^&Y4T!)K_P#@_P#%[_9MOD+L
M;JG+0;QH-@93+;GI=\[RVI@9<G%MD;/P62R]9BZ_)55%4X/#9&7+T5+CIA5'
MR4LM:A\9D*1M#7M7[9;ESKSSLG+^[6-]:[3.TOBRK"P,:I#(X.IETJ'950.W
M:"PPQ(!RJ^\?]XW9_9;V8YR]Q>5M\V3<N9K)8([6U>\C(GFGN(H"-$$GC/X4
M3R3Z4IJ$)!94U,-M/I7^5-\'.F&H<AB^G*'?6<HH(84SG:]=/V!+*\=/64LE
M6<'EU&SJ6HJZ>N9912XR")M$9"!HU(Z+\L^P'M7RNR3VW+:W=WIIXEVQN"<,
M*F-_T02&-:1`8!I45ZX&^XWW\OO0>YB7-M?^Y$NU[5)(S"':D6P4*S(P3QXO
M\<95:,%/$N78:G&HAC6P3$;>PFW\=1X?`XK'8/#XZF@H\?B</04>+Q=#24L$
M=-2TU'CZ&""DI:>FIH4CC1$54C4*```/<O6UI:V5O%:6=M'#:HH"HBJJ``:0
M`H`4````4H``!0#K$O<-QW'=KZ?<]VW">ZW*61GDEF=I)'9V+,7=R68LQ+,2
M268DDDD].R1K&"%^A)/X^I^OT`]J*4Z1]<_?NO=>]^Z]T$O>G5E;W5U7NKK+
M'=L=M='UFYTQ"0]I=&9[`;8[3VM_"\]B\V[[5SFZ-K;UP5"^6CQIH:OSXRJ$
ME!53HFAV65/=>ZIC_D-?'#-=<]&[_P"T:_Y0?*;M6DRGR2^?76J=6]L[[V3N
M'JS$U>U/G=W5BZGLW$83!]:[8SU/V=O*;;,E?FJV3)RT-5D,OD98J.G2:*.#
MW7NK]&X4VOQS_4G3S;\<FWOW7NB+?!OX-;7^$,?RQ7;&_MQ;\'RO^:/=_P`S
M\]_>'%XO%G:&Y.[_`.[;938^'&,9OO\`!8)MNIX*BHM4R&5M8X'OW7NB+[>_
MDI',?(?K?M3Y-?/;Y>?+WIKH;M2;NGH7XO\`<FX<6W7FP^R<+7SS]6[DS^?P
M24.X>PJWJ>BJI$QK5_C:2H"R3,86J*:H]U[HX7;GP`P7R0Q'S?ZU^3?<O97=
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M!]U[JM3_`(3?])],[%_E,_#CM#9'4G6.S>RNT>G%D[,["VIL':FW=\=B2XO?
MN]AC9=];MP^)H\_NZ7'B5Q"V0J*@Q:CIM<W]U[J[K>.]]I]?X6MW-OG=&W-F
M[:QT4T]=G]TYG'X'#TD5-2SUM2U1D<I4TM)'X:.EEE/KN(XV:UE)"JQV_<=U
MNH[':[*6XO'-`D:,[DD@"BJ"3W$#AQ8#I!N6Y;?M%I)?[IN$-M9H"2\K*B`!
M2QJS,`,`G[%)X=58=X?SO?@3TY#5P8;L7)=V9^CJ:RC?"=0827,4AJ*&MI*.
M9_[WY^;;VS)J-XZB2>"HIJZIAJ8:>0PLY,8>=N5ONR>[?,;1/=;)'MEFZJ1)
M>2"/B"?[)0\H84`*LBD%A6F:01S3]Z#VFY;61+7=Y-TO%8KX=HA<$A@II*YC
MB9<DAD=E(%035:U[5?\`->_F9?+&EJ*3X3_"3(;;P67D^WQ78^6PF5WY%0K_
M`'>CR$A&[-S4FR>IZ&M:5FJ:66L6JIYXFBA6&61U+RX/83V4Y"9)/<WW0CFO
M(UJUO&ZPL3KI3P8S-<LHIH<(5(-6U`#$0/[_`'O;SX'A]L_;!X8)&H+AXWF"
MTCU9G<16H8FI3Q`10A=))J><'\I/^8I\K7?,_-[YLU^$Q.3R%)45_6^V<SG=
M\4T=-2Y/,RSPQX/&U>SNK,'54T50LN.E@I\I:&I,<PC\/C9IOO">SW(+"U]K
M_;!9+B-"%N952$ZBJBOB.LUS*IH`^IXCJ&!D]77[OWO'SZWU'NC[GO%:N03;
M1.\P*AGJ#&&BMHS0DKH\0`,:Z:4ZL,Z&_DE_`CIS'TDF9ZXR'=6XHHX149[M
MS+S9NE^YA:@F=\=M'%IA]I8Z`5M"SQ@TD]2D<\D+U$L9M[B?FG[S?NSS/)*L
M&])MED2:1VD:QX((!,K:YF.EJ'O5=0U!%(!ZE[E/[L?M-RU%&]SL;[E?Z0&D
MO'+U/:3^DFF$`LM156:A*EB#3HX/R%Z$Z-J?CMV#A:KIGJBJPVQ>K^R*_9.(
MJ>N=G3XO:%>=H9.0UNU\=)A6H\!5EZ>,^2D2%[HO/`]Q!;<V<V6E[>;C:\T[
ME'N%P`)95N9EDD`X:W5PSTJ::B:5QU,-QR?RE=VEIM]URMMLNWP5\.)[:!HX
MZ\=",A5:T%=(%:9Z+5_*!ZIZPQ/\N?\`E]=I8CKK8F)[-WE\$_B_5[O[$Q>S
M]N8_?6ZZO<?2W7V;W#5[EW=28V'<&=JL]FHEK*V2JJ)7JZM1-*7D`;VWNW-'
M,^_6RV>]\R[A>6@<.$GN)I4#BH#!9'8!@&(#`5`)`-">K[7RERKL=R;W9.6=
MOL[PH4,D%M#"Y4D$J6C125)525)H2`2*@=6D6_Q/^\?\4]D?0@QZ#KUO\?\`
M>O\`BGOW7L>G7K?X_P"]?\4]^Z]CTZ];_'_>O^*>_=>QZ=>M_C_O7_%/?NO8
M].JL_P";WT)TYV!\%?EYW)O3K[;^X^T.C/AS\H=U]1[VR,$SYO8.X\/U%NC<
M^+S&!FCGCBAK*#<&"HZN,NDBB:G0D$`@C#E?W`YTY+BO8.5.8[BQBN"#((BH
M#E00I8,I!H&-*XST#^:.0.3.='M9.:^7+>^:!2$\4,=(8@L!1A@TSTD_Y,?Q
M_P"E]M?R]OAIW7@.N-M8OM3O?X;?&O<W<.]:>DD?+=A;@R_6FVMT9/+[C^YF
MGI:JLK=Q9&>M=EC0">4E0!8"_,ON)SQSBEI'S/S/=7B0.S1B1AV%A1BM`*5&
M#ZCCTWRW[=<D<GO</RQRU;61E0*_A@T95-5!#%A0$5&,'AT<GLSX*?#CN&H>
MN['^-/3FX\E-E*O-567.Q\+B,UD,K7I(M97Y3,X&FQ>4RM14F5F<U,TMY#K_
M`%@-[4[)[H^XW+BK'LO.VY00K'X83QW9%3^%4<LB@>6E13RX])MZ]KO;KF%V
MEWCDS;I9V<NSB%$D9FXEGC".Q/GJ8U.>/5?78G\@?X`;NQ\<6VL1VIUE64U-
MDE2KVOV/DL]#6U=7##'0U66H^Q*?>?G3$21%HXJ62B\HE=9&;]MHY;VG[V?N
MYMKN]Y=65_&=/;+`J:0IJ0I@,.7&"7#TH--,UA_=_NE>TE_$HV^'<-OF5&`:
M"X9ZD_"66=9L*<@(4K4ZB<4*/6?R*?D+U$]=DOB7\^][;-J'I,"Z8;<#;RV-
M!ELEA\A,]/'F,_USN6KI!B,925#244,F%K+2%X6`CE+J.X_O4<H\Q&.'W#]H
M[6ZA!<:D\&8HKJI.A)X@0[$=Y\9.`(-13J/Y?NK<X<O&>?V\]V+FSFTIV/XT
M`9D)`\22WE>JA3V5B?B1BI/7./;G_"ACXZ5HCQ>XMB_*';U)N6H*PU=9U[N>
M;.15>*;155,NXXNM-\XK;5/-2J4ABKJ66*L(NABD?5XW7W0.<8P;BSN]DO7B
M!J%G01E6)I^D;B!I&!^)HW!7%017JWT/WO\`D^4&WO;/>[=9CVL8)0X*TKJD
M^GN1&"H-`R4;-#4UQTO\ZWYM](K3TWRS_EZ[LQBQX'*5,F:PN+["ZRBKZK%5
MT*UF=2/=FW-X8JFVW043,L[+5RC65E$HC])=?[M?MAS0[-R![QVL@,ZKH9H+
MHHKU"H?"DA<R%J4J@/%=&H=47[S/N?RNJKS][03H1"[%E6>U!T'+@RQS*4"@
MZJ$@&C:@#3HAW\S[^8G\<_YE_P`4]\=:T79?SA^->]:SK:?;:=5;!RW5-5T/
MVUF=TYK;M1DJ'MAIL3N#<6Y,#LY,-*])-%/MJ:>&62T;2L(D++;[G7-T>^V<
M&Y<QV+<MM,WB30ZQ/'$`2C>#(FDNYHNA9'"FM6H*]&=S]\SD]MCOI['ER^3F
M)(T\.&;1X+R,P#KXR/J"HM6UM&I(`[16G6PI_)XQV`7X1=9;CVU\A?D#\@:#
M=&-QC5LWR(WGLW>FYNK]P;6P.(V3N#JW;E5LW8>P*?&;0P&3V[)/1T]73U-4
MR5?G,[1RQJN-WN%R7?\`M[SCO?*6X,7:UD&B2E!+$X#Q2@9'>A!(!(5@RU-.
MLE/;KG:Q]P^3]EYLL4$8N8_U(PVKPI5.F2,F@)TL#I)`+(5>@##JT6H8K3SL
MILRPRLI'X(1B#SQP?8,Z&_6M)_PG'^5?R_\`EK_*A[@[>[1[2R_?7R-QO>GR
M!VIUMN'M:JI'IYJ_;G7^Q:OK[;6:J,5!A$CVS'NC(LT]C&RI4RD.HTZ?=>ZK
M@^3.>_GV?RLNX?@I\B^[OYAFT?F9DOE3\K=G?'O?/PJVQUN^(V.^2['HJN0X
MCK:CQ.*Q>4SV-Q='0R0T^1H<;A:K&YB3'DT]=%4SQM[KW6[Z_P!`"+@LH(_P
M/']1[]U[KYTW9W\T?^:EWKLS^8'_`#)M@_S,>IOB7MOX2?([,]3]:?RZMPX/
M9;[DW=LS&[KI*+#4VZ,)G,=#6;GW!DZ+=#4,-96XZMGSF7P^0B08F&BIU3W7
MNM[SX3]_U_RK^('Q?^2^3P,&U\EWWT)U5VYDMO4M0U92X7(;^V7A]R5N,I:I
ME1IJ:DJ<@ZQEAJT`7YN??NO=8/F__P!DB?(G_P`15NK_`-P&]^Z]U__5W!>A
MO^RXOGC_`-07QE_]]ME/?NO='S]^Z]U5]M?^<]_+#W'VWO\`Z&RGS#ZGZQ[B
MZQWCO#8N\M@]W92HZ3R5#N/96\&V3D*/'Y/M"CVOMO<+97*>.?%KCJVJDR6/
MF6J@5X0[)[KW1=_Y"O\`+Z[/_EU?&KY"]>=I;^Z9[&JNY/F-VKW_`+3SW1VY
M<YNO:D&S]W;2ZVVKCL3DLIF]J[39-RT&1V15K4P4\5131(T86=FU*GNO=7D^
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNF^A_P!8^_=>ZJE_E^D#Y>?SEOS_
M`,YW]6?07Y_X;_\`AY_Q3W[KW7/^8C_.B_E^_P`L>AEH?D?W%3UO:<N.?)8C
MH+K""DWSW5E(&HXZV@EK-JT^0HJ+9E!EXID^SK=Q5F(H:NY,,SB.0I[KW6HM
M5?-#^>C_`,*3-S[WZ2^*&W]O_!WX,Y!((=X[IJLIE-N_Q;9%5-)"U+NSM<X]
M]^=HUV6TLE3B-EXZBQ6F6&FR1$#FIE]U[J_+^5W_`,)WOY;O\NRJVI/V`O7W
MRN^96/JJ/.MV%VM2X.9ML9JFH3DJ4]3=*Y+,9O%[5CQ*(U92Y.HBK\X&3[A:
MN)5CCB]U[K9),T2`#Z#]*@*;"P^E@+"UK>_8J!7B:=5+!:5XDT'20WKV-L#K
MK#U&=[`WKM;8^%@@JII,MNS/XO;M`(J6(2U+K596JI(Y/!&P+:22H(_J/:'<
M-SV[:K&XW+<[Z*WV^):O+(X1%'"I=B`,T'S)`%2>CC8M@WWFK=['EWEG9KO<
M-^NGT0V]M$\T\K'RCCC#.Q`J308`)-`">M:/^8%_,CIOF=M3-_$?XC=4;V[4
MQ&YY\57[DWG!M;<E;G,FNSL[C-VTR;"V7AJ:LS9Q/FPJFIR62CIV\:NL5,5*
MU'O!;WF]ZX/<[;+[VX]N]ANMQ@G:-I9DBD+/X4BR`00J&?3J5=3R!:Y[0*.>
MUOW2/N83_=MW[:OO!_>&]P-LV"^L1)';6375ND,1O();5OKKR5H[?Q=,Q\.W
MMFD6I4R3`AHNJD?B?\5^S?DGWOC>K]O[=["Q>/VSVJ.LNZ-Y;:VU7U-1T1N#
M&TCY+<&,WQ42FAI-G[OP=%XY'QN0GI:R\B@1L[HK0+R5[-<_;US1L>U[CRQN
M^WV$LZ"2=K6=%B7\4A,BHE54%LL"<!<D=9M>[/WM/9#DKVXYSYIV;W+Y3WW?
M;&Q:2#;DW2UG-[,658X!%;R32'632H0A5JS40.PV,]G?R#?B3@UP=1N;>O=&
M[LC0"F?-QIGMI[9P>XI8V#5,3T.'VE_'<30U1_4M/E/N4!.B<-8C,?;_`+HO
MMS;FTDW'==UNV0@NK2QI$]*U&E8C(JG%`)2PI\1ZY.<Q_P!ZY]XC=/WK#L7+
M?+.W6LI;Z<^!=7,UJ#\)#S78@E=/62UT-YQ4QT9S:G\HKX";5IZJF/0M%N;[
MNHCJ/N-Y;MWCN.HI-$2Q>#'R5F>!HZ9K:F100S<GFWL?[;]W?V@VU)53E)92
M]*F6:=R*5X'Q!3CG`)_+J$-^_O`_O;[]-!,WNQ+9&-"M+*UL[='J:EG58*,W
M&C-4@5`X]&IV7\4_C?UU+C*K8W0'3FU\CAL:,3C<SB.N=I4^>@H!2)1/`^>.
M,?,U3U-,@6:6:=Y9^3*S,22/-JY`Y&V:2WEVGD[;;:XB&E72WA$FG@:R!-;%
MEJ"69CDUZ@?F7WT]Z^<HKRWYJ]VN9+ZTN)O&DBEW&Z:`R:RX(@,OA+H8DH$C
M"1XT*H``'?&8ZCQ=''14-%1X^FC:1DI:"F@I*6-I':21HX*>..)3)(Q9B!<L
M23[%<444,:QPQ(B#R447\AU&4]U=WLAN;^X>6Y8"K.S.V```68DG2``,\`.I
M]A_0?[;VYTS0>G7K#ZV'OW7J#TZU_/\`A.MS\;?G$3R6_FQ_/$DGDDG>VW>2
M3]3[V6+?$2>JJB(*(@`^0IY4_P```^P4ZV!/>NK=>]^Z]U[W[KW7O?NO=<&D
M5/K?\?0$_4D#Z?U(]Z)H*GAU['F>B=_*_P"=WQK^'>V*[*=N]BX2BW7_``^6
MLVYUICZLY'?VYZL1ZZ&GI-NXV&OR>/Q]9-I5LA50QT4*DLSFVDR'R%[6\Z>X
M]Y%;\N;-,;$N!)<LNF"(>9,C41F`!HBL7)%`.HWY_P#=;DCVXL9KCF/>8EOP
MFJ.V5M5Q(?P@1K5E5C0>(X"#B3Y=4#_RMOYOWQQZ+ZBW)TW\@:'/];UM=W3W
M7VYAMS[;V_F=U[1JYN_^V<_V]NG&Y!:2OS.Y,968K>V_<L\+-3M1)BHXD,OF
MCM-D9[G_`'3-YM+N"[]L@L^U?3JLD4UPHG65%(>2-I51&672K:`VI7+:5"$`
M8V^U_P![G8[^TNK7W.E-ON@N':.:&`F!HG/9&ZH7</'5@&TT9`M27!+;"'4?
MSH^'G>;"FZM^1_4VZ<EY:RG7!_WMQ^$W).<=34U76U%-MG<;XC<%5004]6C&
MICIFISZ@')1PN->_>V/N%RSG>^3MP@B[>_PFDC!:M%,L>M`QH>TL&X5&1UDY
ML'NC[=\S'P]DYRL)YZL-'BK'(=(!8B*71(5`/Q!2O'.#0TT%735,$%52S1U-
M+5115%-4TS+/3U,$Z+)#4030EXYH)8W#*ZDJ5-P;>P,ZM&S)("K*2"#BA'$&
MO#\^AXCK(JNAU(P!!&00>!!'$?/AUD$L9(%[EOIQ]?Z\_P"P]TU+6@-3_G-.
MMUP#Y'K)8?T'^V]VZWUW[]U[KWOW7NM?S_A,.[O_`">>C0[LP3MGY7*@9BP1
M3\G.UI"JW)TJ7=FL/R2?S[]U[K8#]^Z]UXFP)/T')]^X=>ZPF>,?G^GX/Y^G
M^W]UU+0$'!X>A_/_`"<>O#.H4R./^'K%4U]'14L];65,%'14T,E14UE7*E-2
M4\$2EI)JBIF9(8(D47+,P`')]N(CR2)%&C-(QH``22?0`>?RZH\B1J\DC!8U
MK4D@`4XDD^7SZ)QVU_,4^$/2-7/C.Q/DOU;09NF?*05.W\'N"/>>?HZS#PT\
MU9C\EB-FQYZNQ&0(JD6*&L2!YW++&&*/ID;E[V@]S.:4679N2[Y[<A2'=/!1
ME<D*RO,8U=>TU9"P`%30$5CCF'WB]L>5W>'>.=+%;E=0,<;^-(I0`LK)")&1
ML@`.%J<"I!I4)\KOY^OQDR_779'7/2&P.QNS<WO#9FX]HT>X=T8BEV;L*F7=
M>T\CC/XE44-9E4WOEH<5DJV.*IHFHL8U0@D,-4`$=IYY-^Z#S;<[EM]YSGN=
MC:[2DJM+#&[33O&D@\2/L41+XL88HXD>F*H#6F/G._WP>4+:PW&SY)L;RZW=
MHG6*9U6*!)&C.B2A8RN8W(!4I&#0T>E*UG?`KY(_S..TNE=F?"'X,4W7FS=G
M=%;6^Q.Y\-A]G[8SFW-H9G,UM9ATRV<W165F,BCI*]:B*&7%XI:R;6PJ&D=U
M=IB]P/;/[O7M]N;<Y\[[=.D-XX6&SC$@MM<:J"L45NJ4.DJSJ\GAUR*=P,0>
MWWNC]XKW$V_^J')E]"\EJI:6[?0+C0[E@999W>JA@R*8XPP5J&O;2Q3:7\B/
MO#NC,46Y_G=\SMY=BRT<FB/;^S<_N?>]6E)#6Y2HIXJ+>_:T;P8A%DR#3Q10
M8`QTSS2H@*MJ,87_`-ZCEGEFU:Q]I_;2VM%*YDG2*)=5$%6AM<N>W+-/J;2I
M-*4ZD_;?NI\T<QSI?>Z_N3<WDX--$#RRD)5CI6:Y`\-:,>U8"HU-3)KU:CT5
M_*F^"WQ\KJ;,;0Z&V[N3<M%)!/2;J[1GJ>S,S1U$!Q<L55C8MUO78;#U<%=B
M8ZF*:DI()(*AW:(H'*B!N:O??W7YOAFM=RYLGBL)!1HK:ENC"K5#>%I9@0Y4
MAG(8!=0)4=3URI["^UO)TD<VV<J0378-?%N?\8<,--&42UC5JKJU(BLI+:2`
M:=6(4E-#1TT-+3P0TU-31I!34U/''#3T\$2+'%#!#$JQPPQHH"JH`50![B4O
M([,\KEI&)))XDDUR?,_M/SZF%$2-%CC0+&!0`"@`'D`/+]GI3J18?T'^V]Z.
M<'JWIUW[]U[HI/S<[]Z+^/WQP[+W#WQW-U7TI@-V;.WOL7:V<[9[`VIUWB-R
M;VR^Q-SUV*V?@<EN[*XBCR^Z,E18NIFIZ"G>2JFBIY62,K&Q'NO=%2_DF=]]
M&]O?RS/@]M/J?N7JSL[='3?PT^)FQ^W=N=?;_P!J[RSO5N]:;H[:E!4[0[%Q
M.WLKD*_96YZ>NPM9"]!DHZ:J66DF4IJB<+[KW5L?OW7NO>_=>Z][]U[KWOW7
MNO>_=>ZIH_GG?,?ICXR?`KY`=8]FCL&;=_RQ^-_R?Z5Z;H-C=9[T[!@R>_\`
M-=.YG`XS'[@K=IXC)TFTZ*KRF[*)%JJ]X865I&!(BDT^Z]UG_D+_`"-ZV[Z_
ME@_%7;>PDWI3YGXU]*=)?&OM:@WKL3<VQ:G&=K]<]*==_P![,;AX=RT%"^X<
M'1RY2-(<E2>2DJ2&T-=64>Z]U<A[]U[KWOW7NNK#^@_VW]/I_MO?NO4'IUZP
M_H/?NO=8YX(*F":FJ88JBGJ(I(*BGGC26">&5#'+#-%(&CEBE1BK*P(8&Q]V
M1FC971BK@@@C!!'`@^1'EU5T1U9'4%&!!!%00>((\P?/K6)_X4#?#/[7IWL;
MYZ8'(]?[:V?\9>EI<KN'KC!=>X_$[S[(S#[G@HZBKK^P,;+3"2"#%5F/IZ&&
MOI*U*`4TYBT_=.!DU[-?>#@]L-CW3;-VV>^W.YN+C4K?54CBC"@!$CD20*2^
MIY&6GB`JK`Z0>L7/>C[NL_NCO=CN>T;W9;7!#;:"OT@+R2:B2[R1LC.N@1HB
ML>PJQ!HU`=W^3S\+NW?B=UC49_/=Y8G?O4_>VR]B]IX#K:CVC4XFHV5O#<N`
MQ.0K,G_':S+9"2K-3@)(*.ICB2&&>6F2;0K7!#WO=[M<N>[$VS[C8<I2V&\V
MR^&TK3*_B0TJJ%%15U+(6?7Q[F'"E!/['^T','M'#N^W7O-<5]L]R0ZQ)"8]
M$V`9`S,6HRC24R*!#@@UN8J033S@`DF&4``7))1@``.22?<"=3]UK.?\)9^G
M>X?C1_*ZWQMCY#=1=K])[KI/E-W=O&39_9O6^]=F[SFVO/M/K=J7.8_:&:P=
M)N7*45>V,J$I&IJ67[J:%XX0[C3[]U[JFCN3YV_,WM[^;-2_-KNW^3#_`#(.
M_.A/B93YO:OP"Z8Q/1'<VV-I8'/RYZ<UWR?WSC-Z]*9R7_2ENFDQV/KL=#24
M=!+AS38]))):C&)//[KW6Y>OREW\?EOU9\:S\3N^VV-V)\>\MW9F?E#%C<5_
MH2Z[W5CLM1X^'IC=F1J*FGR$6_)Z>8NT6E:G5/3>"EJ*<Y"IQONO=:E'\Y#^
M3]UA\_\`^9]U1TO\0/@SVEUAO#>>_:7L[Y^_/.KV9VAU_P#'2/9M9D3E=XT6
MQ\CG/L>K>S>[\]!N*2NR%3B*6:?(Y8T4!J=29F>D]U[K=OZTZYV9U!U[L7JK
MKK`4.U=@=;;1V]L796V\7%'3X[!;6VMB:3"8/%4L$2HB0T6.H8T%A<VN>2??
MNO=`C\W_`/LD3Y$_^(JW5_[@-[]U[K__UMP7H;_LN+YX_P#4%\9?_?;93W[K
MW1\_?NO=5*?S>,O\%^H/B!W9\C_EY\3^DOE;B^G\+@MZ3=;;XVGUGEMY9^>O
MS..ZZQ]?M[*;TQ&1K,;D<50;IG$%9&//#`DJ0LK6]^Z]T5+^77_*^_E\24?Q
M/_F`?"/_`$]?$>LWSUKU;WI7_'[K3Y,[PS_65?M3M'K2ASU7U)VQU[G<WN_"
M9+"5&0R]%6Y04OV<D^:PT,R2(/+')[KW6PP/H/\`BM_]Y_/OW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[HJ'S<^5^!^$?Q;[F^4.YNO>Q^T\3U#M*MW)+L3JK;
M.2W/NW/RQ$0TT8AQ]+6+@]O4LTBSY?,U*?8X7&1SUM0?%`P/NO=?,;ZF_GA?
MSD_E]W_\B.C?A2F#V3W#_,?^0>-["GQO3.TJ2#L/:U7A.M-K=8P879O86<J:
M@;,VGM[J?K/&/F-P3I%6T4>+J<E][1^6H<^Z]UM8_P`O;_A*3\?>H]ZXSY(?
MS'.S<K\]?DG7Y"7<>X]N[QDK,UT2-QU$4L(J-ST>\%R6\.[*ZD4JQGS\M-CI
MW`$F,8(K-[KW1S>K,/B<)_PI@[MPF&QF/Q&&PO\`)GZHQF&Q.+HJ:@QF)QL'
MRG?PX[&4%)%%2T%!%I&F&%$C6W`]^Z]U7_\`SMOY4WQ%^.O1&]OE]TEE^\*;
M^:WVM\O^O]W_`!:[NI^WMXY_O;L/Y&=A]C8JEP?4&T\.D\N(/7VU]ERU0QF-
MQ^,IY,-08>FO5?;QRK-X`G`%3UHD*I9B`H%3U<9\O?YM?2'PMV&FWMSY.G[0
M[XVULBEJ-[[?PV5Q:;;V5GZ';&.K\G7=D[M@D7%XJ"2HF:;[6@2IJI$1O1""
MC&#/<3WUY=Y-O%Y;VB-MUYSF81Q6L#5`E8*(UF<?!J+CM0.]*UT8/6:WL%]R
M'W$]W]GE]P>;;V+E7V=MHC//N5Z"CS6\9?QVL8#3Q`BQL&FF:*W4L*/)0KUI
MS;3^37:/\XC^:A\!\_\`,#Y0[#ZM^//;I^0&/Z3ZKVSOOJV"EZPBQ.T1CMNO
MD-F2[TS-1M#M7Y`YC.)B,.-QQ2YNH44])"E<\#P^VY^3^9_<CE#F#E#G^:2V
M>:6T9[B`:(F,<OC2VUI!(:B*WTI"+J0.9Y"THUQQH.E=G[J>V/W<_=3D+W0]
MC+"+<8[2SW)(K"^?7=1K<6HM+6_W2]MU0-<7P=[QMKMC$EA;B*W+0SSSL/H+
M_'?XH]$_%C:B[4Z5V+C=KI4TF.@W#N-T2NWAO&HQL3I#D=U[EJ$;(Y:I,TTL
MRQZDI8))G$$,2'0)%Y,Y!Y4Y`V\;?RQM$<"LJB22@,LQ48:62E6-233"*2="
MJ#3K'OWA]]?=+WVY@/,'N5S7<7Q261H+:NBSM%D8%H[6V'Z<*T54+`&5U1/%
MDD90W50/\DA`_P`AOYZ%[@#^;CW(;#@77:&T#?C^M^?8R-3YG_5Y?9U$5.'V
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MF12JU=6:2@4JQ>=`K%1]R-[8<\>XUR(>5MDDDM`^E[F0>';1D9.N5J+@?A75
M(<`(:BL><]>ZG(WMS;/-S3OD<5T(]:P(1)<2`F@TPKW`$X#OICKQ<4-*)=Q_
MS&?YC'\Q[.Y+KS^7STSE^G>KI:J3$93N;+O#%FJ6G07K)LKV37P'9VQYO"=?
MV6%CR>=16'AF+NJKE/9>SGLW[.6MMO?O!S%%N6_!=:6*U*-G2--NOZLO^GF,
M<)^%T`!)Q7OO>/WE]Y[N79?:#ER3;=A8Z7O7PZTH6+7!_2B]-$6J;S1R2`!7
MZS_X3V=>Y[`Y7/?*CY!=J]@]S[LJXLGG-R[#RF/H\?BJTSF6LA.7WWA-V9W>
ME76Q*J25U?'3V'$5/&0')!O'WO\`=[6]AL^0>4+&SY9@&E([A69I%`(7MADB
M2%5)J(X]5#6KL"1T>;1]S[9[ZRFN.?\`F[<+OF:XHTDL#JJJU02-4T<KRD^;
MN$J*=E17H&_Y8?\`*(^*_>_6J]^]KU786\JC;'R/^8/4DW6]=F<-1=>[BVYT
M5\C^Y^@]FU6<CQ6`H=W'*U&W]ET.4K'I<M2PR9=69(XZ4_;>P[O'WN/<[=-N
MN+&VL]LL9W`I/!'+XJ496.GQ9I8^[3I.J-NTFE#D"+9/N>^UVS[G;;A<7VZ7
MT$9:L$\L/A254J-?@P12=I.H:9%.H"M14$Z?;W_"?KX0;ZI<C4;"K>T.G,S/
M-F:NBDP&YXMV;=IJO)%I,935.WM[TF8GDP>"JGO%34E=03R1$H]1?2ZM[%][
M?W0VDQ+NL5EN=JOA@K)&8G(6@8J\#1C6X&2R.H/!*54O<P_=&]L-T21]GEO]
MLNOU"IBD$J5?X0R2AF*(>`61&*UK)6C`JK_R<_Y@'Q]GA/P[^?N6IL/'DMNU
M$>V]S;BW_P!9T!CP]',T$V3QN`JNP=J9:DQM4D=/!C9J!J::CF991H4Q..!]
MX[VBYL$B>X_M+&TQ$@\2.."X8%W4D([BWE0L,F0.&5A50:X`)^[?[N\HLG^M
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MC*DKJ_AL'==*\#%,L!#:^UE++0>I%"?_`*K_`)R_\OCM2EI#'WC2==9>J&(C
M;`=L8'-;+K:6MS,DL$5`^2EIJW;%9)0SQ::N:ER%12TX=&:70P;W$>__`'=/
M=_E]F\3E5KN`!SKM76=2$R3I!$BZAE0\:L>`4G'4M<O_`'DO9_F",&/FI;2:
MBU2ZC>$J6K@M1HB5IW%9&4<2U,]6([/[*V#V#BZ3.;$WULG>^$K5JI*3,;/W
M3A-S8NKBH:IZ*NDI:_"U];2SI15<313,K,(Y%*M8@CW#^X;5N^TW,EKNNUW-
MM<*5!66)XV!85&I7`8%@00".!!^R8MNWK:-WMTN]JW:UNK5JD/#*DB$`D&C(
MQ!H002.!!&./5''_``G#IY^L/Y173F*[!-/LNNQ_:_RQFK(=SU=)B!!3Q_)'
MM"L:I,]741TTM*M)()3-&[Q>,ZM5O:K<N7=_V?=+C9-TV>X@W>+1KA9"74R*
MKIA:UU*RE2#0@BAZ3[?S+L&[;7;;WMF]6LVTS*Q242*$8(2KD$D4T$$,"`5/
M&G1Z>VOYL/P%Z:>6GW'\C=D[ER<4E-$</U>U=VC7.]9CYLE3,LVR*;,8H020
MQ!&E:I$<4TJ)(R,WN1>7_8?W8YE$;6/)US#$VKNN:6P&E@I[9BCFA.`%JP!*
MZNHWYC]__:7ECQ%O><;::56IIMM5R<J6`U0AHQPH27`!(#4)ZK4WE_PHEV%F
M,G-MKX[?%GMCM//5<V$HL!'N/(8[;T^1R&2K:>EJ<?+MW9U-V'FDJ)))3!0B
M(RFKJ"HL@-O<U[9]S_=X(?K.;^?=ML;9"Y?PPST158AQ)*8%%*`M4=JU-?2%
M=S^^)L]S)]+R=R+N%_.Y18Q(5C+LQ4%1'$)R2:Z5`8DM3M\B&=?\C/Y^/RE6
M->K>@Z+XX[9RF,FJZ3(R;4PFR*Y*?&;B)U3YKN[,Y7,4>7G31320B@I5JZ2*
M26*!`^LFT/)GW3N1BYW_`)M?>;F-Z%1*TRU:+@JV**NCB0QD?0Y"L^".B>3G
M3[V7/2J-BY/39[61.UC$L+`+)34S7KLP<TTZ55=2#4J4->GR3^39\[?D9535
MOS/^?F5KZ>=]P,-M;4K]Y=B8R`Y:7'%HZ'%YNKZ\V?B<1E$I;U%#2XR."(0Q
M*BLI.A(/O'^U?)J"/VV]HXD<Z`9)A%"[!0Q`9D$\CLI(H[2$FK$D4R\WW;_=
M;G)WF]R_=EWJ7(BB::YC75IKH20VT<8/F$0`!5P<:3@=3?R$?@1U_6+7;IQ7
M9?<<Z5$E2E)V'O44>'6*6@DHVHY,5U_C-E0U4*5,S52-,TDHG">K0NDQ_OOW
ML/=?>T>&UEL=NJ*%K>`%@0X:JM.TS"OPF@`(KBM*2+R[]TWVHV619;^&^W*0
M&H^IE`%"M*$0)#6E=0J21@$G-12^7G\LGX1[A^->[HJ'HG:NQ3T_L7?V_-H5
M76L/]Q<A-GL+U_60TLFZ<A@Q3U6\8I1AJ1I3E&JI9)(`Q>[RF0%['[\^Z^Q;
MCN.Z0\W3W-U=1A'%U2X0`.7'AI)41`,S=L>E:&FG"T'&^>P/M-OVW;?M<_*$
M%M:VSEE-K_B[FJJI\22.C2$A5[Y"SU%=66J47_A/-\8^IX_A!\9/G.F-RX^0
M???1&6Q78N;_`(Y7?W<K:.L[#FGG3%[3U_P?#,9-E4%F@12!&P'ZVNGY]]Z>
M??<G9X=CYJO;>2PCN!,!'!'&=:I)&M2HJ0%D;'`DUIT]R%['^WWMKN\N]\JV
M%Q'?O;-`QDF>4%'>-VPWGJB2AX@"GF:[#*J$%A<\D\VOS_K`>XG``%`.I<`I
MUR][ZWU[W[KW7O?NO=>]^Z]TEMT;(V;OB@AQ>]MI[:WCBZ:L7(4V-W5@<5N&
M@IZ^.&6GBKH*3+TE93Q5D5/421K*%#A)&%[,0?=>ZC[5Z]V'L6*MAV/LO:6S
M(LE)%-DH]I[;PVW8\C/3AQ3S5T>'HJ-*N6G$C!#(&*AC:US[]U[I8^_=>Z][
M]U[KWOW7NO>_=>Z][]U[KHB_Y(_%P?\`;\?2_OW7NN.@7!)8D?2Y_K]3_K^_
M=>ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[JF7_A09EL92?R<_GWCJS)8ZDK\AT7
M6?PZBJ:ZFIZRO,6ZMKM*M'332I-4F,,+^,,1?_6O[KW5AWQ%RV+ROQ>^.[8O
M)X[)I2=&=0TE5)CJZFKDIZN/KS;ADIIWI995BG0,"5:S`'Z>_=>Z,81<$?UX
M]^Z]UPT"][M]5M<W("F]KFYY_/Y]^Z]UR`L+7/Y^I)//^)_I[]U[KCXQ>Y)/
M^V_WGCG_`(W[]U[KVC@`LQ_!^@O]?P``/K^+>_=>ZY^_=>Z*Q\W_`/LD3Y$_
M^(JW5_[@-[]U[K__U]P7H;_LN+YX_P#4%\9?_?;93W[KW1\_?NO=:S'\]O\`
MDE=._P`S_JOLSY2],;9SW:_SGVOU%@>GN@X-N]P[<VSUQD6V-VUF*K,XC,)G
M*ZAV:V3P;;GW'%5-5Y&G*5-.(&TS1A#[KW1E_P"2K_)LZ._EA=/[5W[@=I;V
MVA\HNZ/C[TI@OE3B<_V13;[VYC^T<!MVES.^,;MC^$K+@::BHM_Y+))%+15-
M53/`$$<KI9V]U[J[NASF%R5=F,7CLOC*_)[=JJ6AW!CJ.OI*JOP5;78ZER]%
M1YFC@E>HQ=568FN@JHHYUC:2GFCD4%'4GW7NJ6=^]R]MT7_"A3H?H2B[+WM2
M])9W^5SV;V7F>I(=Q9.+KS*]AXSY!I@,=O:OVLE0,34;HI,*WVL=<\33I3@1
MJP4D>_=>Z)+_`#;?C/\`S`^B.K_EW_,\VK_-R[JZRW+T+E9.X>F/C-A(<?M/
MXC4G4VQ,U30;9Z7WQLRJR=0O9?8W8%,T4,^3KE$&5S=<,>:*6%X)8O=>ZV)O
MCAOW>':OQYZ#[1[#P$6S]_\`973'5>_=[[4BQ^5P\>V=W[PV-@MP[FV[#B<Z
M\F:QD>%S>3GIEIZQFJX1&$F)D#7]U[K46K^R_P"9%\K/B1\O_P">MT_\]NT^
MJ<=T!V7WKOCXG_#'&^'#_%W=GQ-^)6[,WB=RXOY$]:O/DZG<':W9>W]M[AEJ
MG6ODDCK$IA!5Q))2#%>Z]UMV?&ON3$?(OX[]$?(/;]+64."[TZ<ZR[APU#D*
M04%=1XOLG96$WC04U90_>Y+[.IAI<PBO%]Q/XV!7R/;4?=>Z$3>6W=H[VVKN
M78N^</@MS;/WIM_-;4W7M7<M+1Y'!;FVSN#'5&(S^`S6+KU>DR>(R^*K9:>I
MIY5:*:&5D8%6(]^Z]UK]_P`K'X!_!KI3YW?S2NP^K?C5TSL?>O3'S&VCLWIG
M<N*V_1_Q+JC:&\?A-T1NW=6W.KWKYZJ'86#W#N#MW<CU=/B5HXIH,FU(P^TI
MZ6"#W7NMAXU]$$)-;2!M/)^XA^H'_+3^O^P]^)IGKW5'/:VTL;\3?YL7;?\`
M,S[M['ZVVU\>-Y?R_=F_%[:^%I,]D<MW+G^U-M=XP;\KZ?#==46%<Y7!G"UB
M*:NGK)#!*09XXH-4RA+G#GKE7D+;&W7FC=X[:#\"_%)*<#3'&M7<@D5H**#5
MRH%1*7M-[*>Y7OGS)'RI[:<L3[CN!(\1Q2.VMU(+:[FY<K%`NE6*AV#2$%(U
M=R%.OS\D=[?S;OYK_P#,&E[G^$_7/76W>FND=D;HZ9Z6E[([*SV#H^L=N]H-
M48WLGM?=V>PF,I:?;79W<FW:&&BJJ3$5%=78[!4,5%2F:5JBHJH<A]PMG]\;
M63E[D^XYGL=N+!;FXM[>UB32XIIEGF>0H@HU5A_4DX48'2<N;OV$YK^Y3N%K
M[@>[-E[;[QOXI+MMA?WFYW4K30,&\6VL+:"W2=@3&`][_BL9()*FKK<E\//Y
M/E?L'?F+P'S"Z@^(GR0Z8WS\6<%D.W<ANZ?<.\L[M_Y:5F[\/7[DZZV'UYNF
MFJ=@9CH_$8*EFFI]T9&-=T5^15;Q4M.[P^SOVW^[_P`E^W-X^[0M-N._"1S%
M<7`4&%&PJQHITAPN'E^)JL$$:DIT"_O#_?O]XOO`;-;\J2I;[!R0;:%+FQLG
M<B\FC6CM-.X$AM2X#PV7]E#I0NUQ*@EZ5._OY'_QLQO\S#^7[\GN@/BW\..L
M_CQ\>,-WOE.[]J;?V7MG:.<W#V=E\#AYOC[O+#;4PFTI,)N/+]<;WQ?W]+6U
M=92U.)E_?IRT@`]SK^?6%`ZO5[4[CZMZ0Z[W?VUVUOO;FPNMM@X:HW#O+>6X
M,A%2X7;N$I"BU&2R50OD:*FB:102%)N1Q[]U[K6O_D'_`#&^+?9'RN_F^;*V
M)WGL#=&[.\/YA_<_R!ZEV_C,I(^1W]TI_=W96-'9>W4FIH8Z[:S9&80B<-?R
M`^FUB?=>ZVC_`+^A_P"5VD_\Z8?^C_?NO=>^_H?^5VD_\Z8?^C_?NO=>^_H?
M^5VD_P#.F'_H_P!^Z]U[[^A_Y7:3_P`Z8?\`H_W[KW7OOZ'_`)7:3_SIA_Z/
M]^Z]TG]T8+8^^,'6[8WKAMJ;PVUDC3?Q';VZ,=B-P8.O-'50UU)][B<M#5T%
M4:6MIHYH]<;:)8U=;,H(]U[K7K_X3G;$ZQQG2'S2W?1[*Z_Q>[<;_-"^=.U\
M7N:AVSMK'[@Q^U*?>NWEI-N8[+TM##D*/;M/'Z8J.*1:6-``J!0![]U[K8S.
M1QX^M=1_UM]S#>W^MK]Z)ID]>J!Q/13?E#\ZOB]\0\&<CW7VCB,/FJBADKL)
ML+"$;C[#W*J%TACP^T\:[URQ54\;1I559I*!71O)4(J.RC_D;VPYW]QK@0\J
M;&\MN'TM._9;Q^I:5NTD#.A-4A_"I)`ZCWGOW2Y']N+9Y>:=\2&["%EMT[[E
MQP[8AW`$X#OHC!^)Q0]4/;F_F1?S#_YBN=RG77\OGJ+(]-]8FH&$SW<6:KL?
M'FZ"*8(:NIR_8F4A_NEL"84<JL*+"Q9//Q*P>GF,TL*+E+:^S7LU[-6UON_N
M]S/%N6_4\1+2.NE@.`6V'ZT]6!&N8Q0'X74*I)Q3N?>?WE]Y[F;:?:'EJ3;=
M@)\.2\DT^(I/Q%KAJ10E58'1"'G!HT;DD*#-?%_^1CTUM/,1]H_,7L.K^4';
M&0K?XOE\1D<MD8>NCD;65LW-D*Z3=W8U0A52SY*HIJ&55$+T31JWE!7/?WJ>
M8MQM'V'VWVQ-AV$+H1U"FXTUXJ%'A6^,?I*SCB)`2*#KD7[JG+^W72;_`.X^
MZ2;[S"7ULC,X@#`8U%CXDY!`)+E%;@T;`5:]O;&'VALW!8W;&U<=MO;.W,-3
MK1X;`;?I,9AL-BJ-;LM+C\9CD@HJ.!7=CIC102Q)Y)/O%B[O+O<;JXOMPN9)
M[V5JO)(Q=W-`*LS$L3@<3Y4\NLJK&RM-MM(+&PMHX;.):(D:A$45)HJJ`JC/
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M`![]UOC2O2-WML[KGL;%/@=_;8V5OC"2Q5<,F*W;B<'N''^.NI9*&L1:3+05
M42?=T4SQ.5`+1L5)L?:VPW3==HG%UM&Y3VUQ_%$[(30@BI5E.&`/'B.B_<MI
MVK>+<VN[;;!=6V>V6-9%R*'#@C()'#SXTZKR[5_E"_RZ>V1Y*OHO;6P,@/L$
M_B74>=K^NB::A\UJ4X7!UZ[6*5?W!\\O\/\`N9@B!I?0ON7M@^\3[P;`VE>;
M9;N#N-+H+<&K4SK<>*"-(T@2:1Z9/4/;_P#=S]H>80))N48K6Y%.ZU9K?A7_
M`$-"836N28RQ-#7`ZHM_F'_RB]L_$#9>)[1^*>]_D+O?/[KW7-LF/KC;NV'W
MAE:/#YN#+97)5.0WAUY'A\SB]K4.$QPHFCJ\;7?Q"I>))9TUV]Y2^S_WB;KW
M$W9]D]P+#9;:VMX/':YDE6(.\>E%`BN"Z-(SOJJKIH4'2,=8K^\GW=;?V[VN
M+?.0-RWFYN9[@P_3I#X[!'5RQ,D/AN$50%TLCZB<D=$7_EM_#G'_`#NW]M[8
M?8^[.[-O=*Q8O=F5V/O78^V/[R]75&6P%14TV[MN46]\W65&R-DYR;(Q*&:F
MI,@U15TD]-/'%-I=)$]U_>':N0>7Y>8^3;G8MPW>22..4"[B,AJ=,;Z+=B]P
MJC4"ID3PPRLK$`KU&OM%[/;USYS!#RWSI%OVV[.D<CQ$VKK&&R[IKG"K"6T@
MA_#DUD:2!J#=;1'5'\E7^79UE%0OE.LINU\Q12X:K.9[0WOF<Q'/7XF.,RSR
M;;PU=@-J2T.7JD,M513T51227\?C\-XSA/O_`-YGW?WQKA8.8%L+1PX"6T4:
M:5<DT$C!Y1H':C+(K`9!!R<W^7_NP>S^PQP>+R])?W4>@Z[F9VJR#BT:-'$P
M<Y96C93P*Z<=64];]6=,]/XJ+"=5[!ZYZXQ4-,*-*#9.W=O;9I_M5J)JI*=U
MQ%-2F6):FHDD"L6`=V/U)]PWN_,7,',,OU&_[U=7DY-:S2R2FM`M>\G)``)X
MT`%33J:]FY=V'EZ`6VQ;+:V<`%*0Q)&*5+4[0*BI)SYDGH2/OZ#_`)7*/_SH
MA_'T_M^R?HYZ]]]C_P#E<H__`#HA_P"C_>J`\1UJ@].O??4'_*Y1_P#G1#_T
M?_A[\`!P'6Z#CY]%.^9'4W>??G4=5UM\>_DSM#XT9G<$^1Q6]MW[EZ1P_?\`
M#N#8&;VQG\#F=JX[;63[&ZX@P&3J:O*T]5'E!55)B%*8OMV$Q=-]>Z+?_*[^
M#_=7\O+I3`_'#?7S$VK\D.ENMMHXO:72^WZ3X\8;I;<>QZ>#-9[-9JJW#NRA
M[:[#FWV^7ES"I&LE-0_:B&^J4N=/NO=6A??T/_*[2?\`G3#_`-'^_=>Z]]_0
M_P#*[2?^=,/_`$?[]U[KWW]#_P`KM)_YTP_]'^_=>Z]]_0_\KM)_YTP_]'^_
M=>Z]]_0_\KM)_P"=,/\`T?[]U[KWW]#_`,KM)_YTP_\`1_OW7NO??T/_`"NT
MG_G3#_T?[]U[KWW]#_RNTG_G3#_T?[]U[KWW]#_RNTG_`)TP_P#1_OW7NO??
MT/\`RNTG_G3#_P!'^_=>Z]]_0_\`*[2?^=,/_1_OW7NO??T/_*[2?^=,/_1_
MOW7NO??T/_*[2?\`G3#_`-'^_=>Z]]_0_P#*[2?^=,/_`$?[]U[KWW]#_P`K
MM)_YTP_]'^_=>Z]]_0_\KM)_YTP_]'^_=>Z]]_0_\KM)_P"=,/\`T?[]U[KW
MW]#_`,KM)_YTP_\`1_OW7NO??T/_`"NTG_G3#_T?[]U[HKGR&^&WPU^6E;MC
M(_)[XY=!_(&NV3396BV=6=N]?[/WY4[8H\Y+0SYFEPDVXZ"O?&P92;&T[3K$
M5$C0(6N5'OW7NE1\??C7\9/BEMC,[+^-/3'3W0FT=PYU]T9W;74FT-M;$P>7
MW))CZ+$R9S(XW;U)04M7E7Q>,IJ<SNID,4")?2H]^Z]T/?W]#_RNTG_G3#_T
M?[]U[KWW]#_RNTG_`)TP_P#1_OW7NO??T/\`RNTG_G3#_P!'^_=>ZR15--,Q
M6&H@E8#45BECD8+<"Y",2!<^_=>ZS^_=>Z][]U[HK'S?_P"R1/D3_P"(JW5_
M[@-[]U[K_]#<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW6O?\H/Y5_S,ZI[7
M[(^4G\GKYIY+XT[X['SF0["[1^'W<.-3L7XA=P[[R6<?=V[,WAL9FJ7/U/2N
MYNS,Z99,S78FC,M34UU2\-3CA/,[>Z]T6_$]$?\`"I[Y$Y"'K7O+Y=?"KX9=
M7Y&*JEW;W!\:MBOO_N*3%34TV(J]K[2Q>ZZ#[/%5^1I\J]5%DZ>NQ%;CZFBB
ME@K$<>*7W7NKU_@[\(NK?@ATV>J^NL[OW?V>W'N"JW[V[W+VUN>MWIVUW;VA
MD\;C,1E>P>P]S5[%JS*RXG"T=#2P0I%346.HJ>GC2T99O=>Z(IOSI'M^N_X4
M%]$?(>BZVW?4]%X#^5_V7U;F^V(</42;&QG8V5^0(W%C]E5F<4&GAW'58-/N
MDIFL[0,&%Q>WNO=$9_FI]_\`?G:OS4ZHZ6S7\LKYW_*GX!?&W)?Z3>QMN]5]
M+SS;(^5GR,Q:!^N<!N*IW3NC!X3>?QVZ?J:Q,[X9**HI\]N['TX:*;'4JRU'
MNO=77]1_+WL+LG>?QWVIF?A7\G.K,=W?TOGNV-S[OW[M_;]!MOH+.X.NFH:7
MJ#MF:DS-1/BNQL[#"L])30)+$T,J$L"'T^Z]UK19/IG^9G\6_BG\N_Y&72?P
M;WAV?L[Y#]F=W[4^+?S:I<U05GQQZ[^)GRQW9F<MO+_9@]SU6-I<[0=I]8[?
MS^XX*DI2_<U%744S4M-*D5%_%/=>ZVX/CATYA?CM\?.C?C_MN>JJ=O=&]/\`
M6O4.#J:ZK>OK*C$]<;-PVT,=/55LL%+)65$U)AT9YFBC,C'454FP]U[I#_)K
MI'XR]@[9JNS/DQAL/+M/IW:>[]S9+=N?W5N+:N%V9LZBH8MP;RS67K<)F\-3
MPXG'XW;XJ:F:HUB&&G9K@:K^Z]]G6MS_`"]=P_R9.V_EY_,5V/C>W_C_`+NE
MWW\HMO;F^/.&I>]-QTK[MZLVE\*>@\IOC<>UZE=WT/\`'=O;=W;M_="UE9)+
M**>7&U49<1P*`S<W%O9P2W5W<)%;(*L[L%51ZLQ(`'J21TKV_;MQW>]MMLVF
MPFN=SG8+%%$C222.>"I&@9W8^2J"Q].G;Y1=[_!JFW&.F_@S\8U[V[6R623$
M8_>*9_MS<.RI)I*.5Y6V1@<3OJ/-;]K*.H9-4Y6#%QI%*[231@$XI<^?>9MX
M[\\L>U>VG=^8FD""4(7AKI)/@JIUS,I&"0(R`2-:T)ZC>QG]V[>7.S-[B?>D
MYB'*O(44'C26@N$MKU5UJ%^MGE'A;>KKJ(2KW3%D54CD)4-?P\_ET]4[U^5>
M0Z+^9W:4S_([:_56+^0^8^*&V*?<=16MTKF=PILO#;BWMW%BJ$;-H:6JW=*]
M&^!V]E7R:)$DK3I$QN0<H_=PY@YIW5N</>W>I+G<Y""UH)*U4`$++-&VF-%R
MG@P#`^"10:`8^Z?]X3R'[4<KGVE^YARA:6'+\,3#]ZO`8HHYG8F2:TLYU+7,
MS!5=KS<%9G9FU6[D*PMN[$^./\JWHWM'XZ=!;^V/1[1[(^4.;WMMKH/9L&6[
MPR$&]<UUSMFFW5O*E3)X#+9#`;>?#[=J$J&FRU30QU);3$\DMU]YA[;M>W;/
M86VU[59QV^W1*H2.-0B*%``HJ@`$T&HTU.<N2<]<D]]YAW_FO>;_`)CYGWNZ
MW'?KN1GFN+F1YII&8UJSR%FQP51147L0*@`!CO\`AM;X5?\`/EH?_0Z[+_\`
MLR]K^BGHOF!Z#_E0;I^0^[_B=MF@V9N+Y$]?;.IM_;]ZKPG8G:N5W!LC:M=/
MAX,?7;NFH=TSXG;E9DO[P4<M+0UE3#7U-/.)XX6A#./=>Z,$?Y:OPI-P>E82
M"+$'?7995A_1E.\K,.?S[]U[KO\`X;6^%7_/EH1^/3OGLI>";D>G>(X/]/I[
M]U[KW_#:WPJ_Y\M#_P"AUV7_`/9E[]U[KW_#:WPJ_P"?+0_^AUV7_P#9E[]U
M[KW_``VM\*O^?+0_^AUV7_\`9E[]U[KW_#:WPJ_Y\M#_`.AUV7_]F7OW7NO?
M\-K?"K_GRT/_`*'79?\`]F7OW7NN2?RV?A6CJZ]+0AD974_WZ[+-F4@@V.\K
M<$>_=>ZUFOY:F(_EM_&KXU?++,_,*#;<>ZE_F&?+RJZ[V7M_?>ZMR[ZW!UK/
MN/!3;$FV]MK8F\'%5C,ECD/@R-8T-.ZD&:I'U]S!MOL)[L[IN5CML/*,L0G@
M6832LB0+$]:,\FHJK4#:H:^.M,Q9ZAK=/O`^T6T[=>;C-SE!+X,TD)BC#M,\
ML=-2I'I!*U(`FQ`2:>+QZ3>0JNR_Y@VYYMG_`,NOX42]1=<T=='19;M_<V\-
MX9>MIF=[O+GM[;EW!6;!V<B4JLTF-Q<&6S!4%HY'8QJ,A;/V8]FO9ZVMMX]X
MN8H]RWLKK2R4MH8<*+;J?$GJU1KF,<+<&4"I./%Y[T>\_O)=2[1[.\N2;9L1
M;1)>/I,B^>HW#?IP%5).F'5.#0I(30"USXK_`,@;HS9!CW7\LMTY+Y![\K`9
M*G;F+KLWM?K3'2^,@)+4TM91[SW?5Q2'6)ZFIH:8V"FC-F:0#<[?>KYBW*W?
M9?;C;8]AV$)H5U5#<%12GAA0(;=:5&F-'8&I$M:T&_(OW5.7K"Y&]>Y.YR[]
MS`TGB,'9_`+?TRS&6X-<L9&56^%HR`*V24W\LWX1T=-%14G2%)2T<"%(*.FW
MIV-!2PH5TD14\6[UBCNO'`!]XLWEU=[A=S[AN%W)/?RFKR2,7=B>)9FJ6)X9
M)P`!PZRLL[.SVZUM[#;K2."PB%$CC4)&@]$10%4<30`5)).2:Y_^&UOA5_SY
M:'_T.^S/_LR]L]*>.3QZ]_PVM\*O^?+0_P#H==E__9E[]U[KQ_EK?"D\?Z%8
M/]COGLH_[P=Y$>_=>ZX_\-J?"C\=*P`WN"N^>RE(_'!7>(MP??NO==_\-K?"
MD"W^A6$C@6.^^S.1P.?]_E[]U[JDK^4'\8>K_D5@/YJ_^DO`U&_=Q=,_S9OF
MWT!T?5;SWMV%-C=A=:]?4^QEZXV+!#BMRTDLNU-LUF6F81OY)S%*X+L=('NO
M=$"^1G\M/Y`?RS^W_P"75VYNSYF;@^9J_)OYE=>_%[Y#?&K?^WLQMSKK+4/>
M>4K:G(;NZ#VIL[=2[KVG@^H,)054@=ZVHEIYDHYW:.CDJ:&3W7NMD#Y%_P`H
M+XN]W]0;JZUZ^K>QOC1NS.SX"3&=S]/[YW,_8.UDPVXL7FZV+!C=^8W%M\1[
M@H,?+CJKS4DC?:5<N@J^EA[KW5!'Q!_E1@_SBNQ>AJ?Y;?,7Y(_%KX1=2[/S
MGR<I>[=Y3X;;N[?D5W7M^MW#U/T_B*W9D&TZC/X3;_7&4HMUY4T[/'%4I2TM
M3)XJDT\ONO=;-T7\MSX80.'@Z;2)@03HWWV6`VDA@&']\K,`1[J55B"R@T]>
MM@L#4-3JC;_A.A\*/C-V]_*AZ:WEV%UJN?W%7]J?)NFK*X[MWSC$F@Q'R)[)
MQ6-C^QP^Y<?CX_M<?011@K$&;1J8EB2=JJJ*!%QPP*@>@/&G7BS$:2YTUK2I
M_P!7^?SZO%_X;6^%7_/EH?\`T.NR_P#[,O>^M=>_X;6^%7_/EH?_`$.NR_\`
M[,O?NO=>_P"&UOA5_P`^6A_]#KLO_P"S+W[KW7O^&UOA5_SY:'_T.NR__LR]
M^Z]U[_AM;X5?\^6A_P#0Z[+_`/LR]^Z]U[_AM;X5?\^6A_\`0Z[+_P#LR]^Z
M]U[_`(;6^%7_`#Y:'_T.NR__`+,O?NO=>_X;6^%7_/EH?_0Z[+_^S+W[KW7O
M^&UOA5_SY:'_`-#KLO\`^S+W[KW7O^&UOA5_SY:'_P!#KLO_`.S+W[KW7O\`
MAM;X5?\`/EH?_0Z[+_\`LR]^Z]U[_AM;X5?\^6A_]#KLO_[,O?NO=>_X;6^%
M7_/EH?\`T.NR_P#[,O?NO=>_X;6^%7_/EH?_`$.NR_\`[,O?NO=>_P"&UOA5
M_P`^6A_]#KLO_P"S+W[KW7O^&UOA5_SY:'_T.NR__LR]^Z]U[_AM;X5?\^6A
M_P#0Z[+_`/LR]^Z]U[_AM;X5?\^6A_\`0Z[+_P#LR]^Z]U[_`(;6^%7_`#Y:
M'_T.NR__`+,O?NO=>_X;6^%7_/EH?_0Z[+_^S+W[KW7O^&UOA5_SY:'_`-#K
MLO\`^S+W[KW7O^&UOA5_SY:'_P!#KLO_`.S+W[KW7O\`AM;X5?\`/EH?_0Z[
M+_\`LR]^Z]U[_AM;X5?\^6A_]#KLO_[,O?NO=>_X;6^%7_/EH?\`T.NR_P#[
M,O?NO=>_X;6^%7_/EH?_`$.NR_\`[,O?NO=>_P"&UOA5_P`^6A_]#KLO_P"S
M+W[KW7O^&UOA5_SY:'_T.NR__LR]^Z]U[_AM;X5?\^6A_P#0Z[+_`/LR]^Z]
MU[_AM;X5?\^6A_\`0Z[+_P#LR]^Z]U[_`(;6^%7_`#Y:'_T.NR__`+,O?NO=
M"QT]\1OCUT'N6OW?U-U['M/<63PD^W*[(IN3=^8,^&J:Z@R4]']MG\_E:.,/
M6XN!]:QK(/'8,%+`^Z]T9#W[KW7O?NO=%8^;_P#V2)\B?_$5;J_]P&]^Z]U_
M_]'<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW75A_0?6_P!/S_7_`%_?NO=5
MS_)?^9%U/\8OF?\`"WX2;NV+V+GNP?F_5[WH^N]U;:AVP^R]IR;$@I*G)R;S
MDRNX,=G(DJ4K5\/V-'6$V.H+Q[]U[JQGW[KW7K`_47]^Z]UU8?T'^^_Y%[]U
M[KUA_0?U^GOW7NO6'/`Y^O'U_P!?W[KW7?OW7NJN/YR-?4T7\OON8TM;4T1J
M,QU?0534]3-2_<4&0[-VI25M#4-$\8FHZZFD:*:)B8Y8V*N"I(]P)]YF::+V
M:YG>VE97+VZDJ2#0W$888\B.(ZSD_NX[6UO/O=^W4=U:QS(MMN;A757"NFV7
M;(X!!HR,`R-0%6`*D$5ZT_?CEU%C.]^^^H>F*C+Q[9INT-[XG:E5N"EQU+D*
MK%T5>9FJZRDHY):>.IJO!`R1*["/6P+AE!4\UO;[EYN;^;]@Y9N+V2&&\NHX
MF<#455F%:`D"OI7SZ^ACWGYV_P!:3VH]P?<ZRV2.[N]CVR:Z2$GPEDD0`*K2
M*I9%JU6*@MIJ%H2&&[[\4_@M\??B#@J:BZMV;!4[KE@>'.]G[GCH<OV'GEDE
MGE>"HSOV<#8W%KYRB4-"E/2K&JAED<&1NK/M][5<H>V]E'!L&W@WQ4>)<R!&
MGDQ0@N%[%_H1A5/F3Q/S$^_7WH_>'[Q.[RW?/7,3+R\L@:#;+=I(K"WH%74L
M&LB20A=333M+(7+%2BG0M8VP`/\`H)S^0`L+'^3KU;Q86X^4TEN/\+>Y+&``
M.'6/)`-01CKK^:+8?S;_`/A/>.`/].?S@_UO^R;\+;W[KW5OORZ[LJ?C9\4_
MDO\`(RAPL6Y:SH/H'N'N>CV]/6-CH<[6=8]>[AWG38>:O$%5]G#DI<*(7E\4
MGC#ZM)M8^Z]UJ:?RJ?F1\P_@UUK\0^Y/F1\/=I-TG_-I[SV4V[/F1@.Y<7V#
M\F>P?D7\J)\AN'X^;I[,V;+#C6Q?3=1LM8\;A<'#55LVV,,@E:5)R^/G]U[K
M</[;Z^E[6ZWWCUS#OSL3J^3>.$J<*O874NX*7:O9.T34Z&&9V;N*MQ6<I,1F
MZ?QVCGDI*A5U'T&_'NO=:_?\E/`=U[H^37\RNL[6^:/S'[WPOQ#^9O:WQ+ZM
MV-W)VSAMU[&K>OL5B-IYK%[GW=A*39.%FS'9.-J:B:.+)0U%)3B"4K]J6NY]
MU[K9)]^Z]U[W[KW6,2QL;!@3_07)_P!M;WHD#CU[HO7=_P`M?C3\;J*2L[P[
MKV#UW(D?E3$9G-Q3;GJU\<<H&-VAC%K]TY61H95=4IJ.5V0Z@"MS[%_+'(/.
MG.<J1<K\M7=Y4TU(A$8-:=TK:8DR"*LX%<=`[FCW`Y*Y,B:3F?F:TLS2NEW!
ME/#X85U2MQ![4.#7AU3=W%_PH1Z#Q<HVW\;NI.S>]=Z9$RTF&.2I#L?`/D&_
MB4-.D%`*?/;TW!(CTM/4BFI\=!]Q2S,!40RH5]Y$\N_=#YON(S>\Y\PV6S[8
ME&>C>-(0:$BI*0I^)2QE.E@"%93J&.?,/WO>5(7%ER3R]?;QND@HE088RW>`
M:4DE;NTG1H6H8C4A%.B8=X]Y_P`^'Y$]>9#>N%Z>[*Z6ZPR%=3T%#LSI[9;X
M/L3+TN7%:*>98JZ?+]QU6+I\;4VJ:]$QF-D3Q.JF8`F2>5N6?NJ<H;Q!MESS
M%9[GO*H6,UU/XENA0H3D*EH#4&BUDD))7X37J,N:N:?O7<Y;1-N=GRW>;9L3
M,%6&UA*7#APU#0Z[RFA@"_9%4`Y84Z(=_*1^*<'?7RDVQ4]I?'/<W;_Q]PNY
M^R>K]_;BEH=Q4_7G7G;/7^)GR,^#W]D\7''1U&2P&;H(\568.ME2-JC)1B96
MTB-Q[[U^\7+\?MUO,_M_[F[:O,D;1E%@EAFED5W".D:U+*U'\36@U*$-"*ZA
M'?LA[,\QM[B[-![B>V&YMRY)XNIIX9XHHI%C9TEDHJJRED$>AV"DOFM-)WNM
ML;;V]M/!T&W=K8#";9V]B85I<3@=O8J@PN%Q=(@'CIL?BL;!3T-#`GX2-%4>
M^9-W=7>X75Q>[C<R3WLK5=Y&+NQ\RSL26)]23UU#L+2TL+2&UL+6."T10%2-
M0B*.-%50`H^0`%?7B7^P'T`'^P]L>GRZ5]=^_=>Z][]U[KWOW7NO>_=>Z][]
MU[KIOI_L1_O8]^Z]U1Q_)5Z=[:Z1H/YKDW;_`%EOOK9>R?YQOS=[EZ[3=^U<
MOB:C?O4^[O\`1W+M7L+9U)44GW6X]J[F7'SB@JZ1)8ZMH6$6LBQ]U[JL[)?-
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MSBE,2!"791;W[KW5"/\`PE&^4_0?:/\`+EQ/QTV%V'2;A[GZ*WQW%NSM?9$.
M#W30U.T-O]P]_=M;DZWR,^7RF"H=O91-S82!JA$H*RJEIU&FH6%SI]^Z]UM#
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z*Q\W_P#LD3Y$_P#B*MU?^X#>_=>Z_]+<%Z&_[+B^>/\`U!?&
M7_WVV4]^Z]T?/W[KW6LYW/\`SU_GCUAW#VOUIM;^0%\_NUML]>=E;[V-MSM'
M:E%V&VUNR<%M+=66V_B-_;;:D^.>7I#@-XX['1Y&C,5751FGJ$TS2K9V]U[J
MM3(]Z_/'^9=_.9_E*=\[Z_E)_-+X;=;_`!8WEV?0[VW?VKL+L7,;1_A^_-O^
M:GS.5W17=2;"Q&U:/&U.$6!FJ9)%FDJD`9"+/[KW6\=[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z2VZ]E;1WUAJO;N]]L;=WEMRMDIIZS;VZ\'C-Q8.KEHJB
M.LHY*K$Y>EK*"HDI:N%)8V>,F.1%92&`(0[AMFV[O:2V&[;?!=6#D%HYHUEC
M)!U`E'#*2"`148(QT<;#S#S!RKND&^<L;[>[;O408)<6L\EO.@="CA98620!
MT8JP#`,I*FH-.JB?Y?W4'5!^8'\UJ5>L>NTEZK^<'6.+ZPE79.V5EZXQ<WP9
M^*6XY\;L.08P/M"@GW#GZZO>+'FGC:NK:B<CRS2.Q+:<C\E[?<P7NW\H;5!>
M1,&22.TMT=2.!5EC#*1Q!!KT+]T]X_=[?-OO-HWKW6YEO-IN$*2P3[G?30RH
M34I)%).R.A\U92#08P.KGE`4`#Z#CV)Q6@J<]1QT1G!_!O;6$_F,[X_F*Q;^
MW!/NW>_Q/V[\4JKK-\5C%VS0X/;O90[)@W?!F5<Y>7,35EZ4TY40")BURU@-
M]>ZZ^2/P;VU\C_E+\$_E%F-_[@VQFO@OO+N7>6V=I8O%8RMQ&_ZGN/8-#L'(
M4>X*^K=:[%182CH?/`U,&,KR,KBP4CW7NEUO/XT9KL/OC=V_M[]T;OW-\>=]
M_&+-_';=OPXR^%V]6=-9W+;DW/4Y+/=MY&IGIWSE5NK*;.K)=N34;DT#XZ0D
MJ7]^Z]U5E\>_Y!77/1G:70M5F_F#\HN[_BG\3-YU'9GQ<^%_;&5VKE>JNJ^R
MHC73;8W7D,KC,+C<AOB38-=G\K4X..LIXY:&>IB(F812BI]U[J_>1]`!X_/U
M-OQ?Z^Z.Q&%%6_,_X.M$TR?A\_\`/UK]?R2&*_(;^>A8:O\`L;AW+].2`=G[
M1-R/K^+?Z_O;-0#2*M7]GS/\_MZ\:BI8$+3T.?LI^1^P]6\=S?+WXT?'FAEK
M^Z>[^MNOQ%)-"N-R^YJ.?<=3/3344%73T&U,6:_<V1J*(Y*!ITIZ25X(Y!)(
M%0%@+N6^0^=>;Y!%RURO>WAH"62-O#4&M"TI`C4-I8*6902"!4X(-YC]PN2.
M4%U<R\TV5HU2`C2`RM0J#IB75(Q4L-05#2M309ZIJ[@_X4'=8-E!LOXG=#=C
M]\;PK62'&5V<I:K:F%JI';'$'';;Q5'N+?F9"F>>"024>.6.5(W1YHW)7)3E
M_P"Z+OPA&X>X/--GM&WK\:J1)(!W#ND8QPIP4BCR8)J%(ZQLY@^]]L33_N[V
M^Y4O=WOVII9@8T.%;LC4232'27!4B(AE%-0.`2;:W\^+YUE?[QYND^&G6.3`
MUT:2573]<M(\<;-?'8<[F[OEK))*$?MUM10A9Y#8102&Q^;[[J7M:&2TM7YE
MWM-.3_C2EJ^3OX5F`-62JR&@\V`J&Q8_>M]TJ/>W"<M[,_%16U8#_2IXEZ6K
M&,.RCO-*(<&,Z._X3Y?'3;U7_>?Y&]G=B?(+=50YFKZ:GK9^O]J5D[FL,CUI
MQU=E-\9/U312J7S42^6-@ZR1N4`4YG^]USG?1FRY.V.SV:P7"G2L\H`((TZ@
ML*>8H(3@XH17H7\K_=!Y+LW%YSEO=YO%X<LNHP0L2&%6TLTS&A2A$J93((-.
MKB.G/BO\=/CY32T_2G2_7/6K3M(:FOVQM;&4F;JDDE:<PU>X)8I\Y54T<SEH
MXI*AHXK^A5]XY\R<[\X<WR1R<R\R7=X5&%DD8HN*=L8(1<<=*@GS/62'+G(W
M)_**.G+7+=G9EN+1QJ)#_II#61OD&8@>0Z'A8%4J0S<&YN;ZB3<D_BY/L+*`
MM2/]CH5$>=<]:_\`_P`)V$#_`!K^<`/%OYL7SPY%@21O?;IO_2_'OQ%0:`5I
M^SKQ4&E14=;`B+H!%[W-_P#>!_Q3WI5""@'7A7S->N?NW6^O>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KHBX(_J+?[?W[KW6/Q?3U&P^@//`M;\WOQ]??NO=<]-UT
MFYXL3_7_`&]_?NO=<?'_`(V']`+<V"_@_P!![]U[KF!8`?6WOW7NH.1Q>.R]
M.:3*4%#DJ8LK_;9"C@KJ?R)^AS!4I)$76_!M<>_=>ZBXS;V"PID;#X;$XII]
M`G.,QM%CS,(BQC$IHX8#(L9=M(:X%S[]U[IY]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5CYO_P#9(GR)
M_P#$5;J_]P&]^Z]U_]/<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW6E)_-=V
M%_.*^&?8FP>U&_G:UNP.GOF!_,$VG\=.J]H2]0;-Q.V?C]M+O;=N\MQ83*[X
MWMN.J6D.R^F>O,'*M54,!+6-2QJ6A222HA]U[I6X3%?S:?@5_-#_`)9?2ORN
M_F_?[--UE\KNQ]_XC.=487K[:&U]QU-%L_9=?E,8<_MR6,93^X>XLM,M.,S3
M5BFFJZ8QB"8DV]U[K<N'T'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/655+
M0TE56UM33T=%1T\U55U=7-'3TM+34\;2SU-343,D4$$$2%G=B%5022`/?NO=
M5#_R\-[;+R/S%_G`4>.WCM/(UF?^<G6==@Z3'[DPM=59BBI?@!\0Q55>+IJ6
MMFFKZ:F>DF622)65'@D5B&C<+[KW5P'OW7NO>_=>Z][]U[KWOW7NN)=%^K`6
M]Z+``DG`X]>KD#S/5>GSY_F*])_!C8U34;ERE)NCN+,X2HKNNNG<=5A<]N*6
M29Z"ES&;D6*==N;/I*U&:>MG75,L$L=+'43*8Q+7M5[/<T>ZF[1)M\)@Y<BE
MTW-VX[(Z#440$CQ)2*41>&I2Y537J(/=KWDY6]JMIFDW*<3\PO'JM[-#^I(2
M=*NYH1'$""2S$:@K!`["G6G?\3-^_*+Y+=V9?XZ;4^5>0Z*E^5_96Y-_]@Y^
M7+9?;V.WOV+E<94RY05M=M2"DSV3RNX<71M246,ER%)CZXQ14A8.T(/0_G[8
M/;GD#EN/G*X]NX-PDV6UAAB5%A=T@!"HQ$@,9$;D,TNAY4J7J1JZYT^W_,?N
M)[A<SMR7#[D7&W#>;V2:5FDD5))&5BZ`Q]WZBU58BR1.]%P2O6PMTI_PGK^,
MNSZ]=Q=Y]A=D]\YZ1Z:JK,;]U%L#:E76"*FDK&R28F?(;OS2M712%&DRT*O!
M($FBD8:_>)/,_P![OGC<(/HN5-GL]ILQ4*P7QY@*M326"Q)VD5`B/<*JR]9>
M<L_=!Y)L)5O.;-YO=VO*94D00EB*LQ"EY2=52#XJBE`5.3U<YTY\<^B/C_A8
ML%TOU%L#K2A1%CE;:FVL;CLE7:%,2RY?.+"V;S=2(O3YJRHGE*6&JP`]XW\P
M<W\T\V7!NN9>8+J]FJ2/%D+*M36B)70@_HHH'62G+O)W*O*=N+;EOEZTLH_/
MPHU5FXY=Z:W.3W.Q.>AI*J?JJG_7`]AS2/0="7T^77(`#Z"W^M[WU[KWOW7N
MB\?*CMKM'HSHW>O:/37Q\W?\INQ=M-MI-O\`16Q-R[?VAN?>HS.Z\)@LM)CM
MP[H#82A3;6%R=1E9Q,"9:>A>-/W&7W[KW5"7\A.M^=G2.6[S^/?R0_EQ]S=!
M[)[H^37R@^6U-WIN[L?K7,[8VT_:^?P>9V_U;7;=V]4U6;R.;2*G>(Y"-D@D
M="WB13Q[KW6SI[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*Q\W_P#LD3Y$_P#B
M*MU?^X#>_=>Z_]3<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW6KO_,J^2H[N
MV)W5\0/YH?\`)V^<^8^,#=C9*#9/R$^(#8'Y$464AVONRMS/4_:V*IMBU^(W
M=UK/5==T4F0S)JXJV/&U`GQ53!4"HT'W7NBO_P`D_P"/W_"?S9ORIVSVK\9O
MG%VO\G/F%!MG-[4ZBVS\RMYUNV.S-B8<Q2XG+T77G76Y>M^HI,AELCA\W.]'
M"\&2J5QU545%%$BB:5/=>ZW*/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3!N
MS:NV=];6W+LC>NW\+NW9N\<!F-J[MVKN3&4>:V[N;;.X<=4XG/;>SV&R,-1C
M\MA<UBJN6FJJ:>-X9X)61U*L1[]U[JKSX<_`+X-=.?([Y(=B]1_#SXR]8=@=
M9=RT&&ZYWML+I'KO:FZMBXC<GQWZWI]PXS:.>PNWZ/)[=H<W3[IR:5<5')#'
M4+D*@.&$SAO=>ZMA`L+<G_7Y/OW7NN_?NO=>]^Z]UBED\86P!+&P!-N?P``"
M3?WHFE/]7R_PD=58D*2*5^?G\L5-:>75$G\Q+^<'B.C\]4_'?XD8VD[B^3U9
MN$;.ROV^$RFYMM=?9FIBCITQ=%28IHQOGL49"J6&#&TSS4E%50R)7W>/[27*
M3V>^[I<\TVZ<Y>X$S;;R.L(E6K)'+<H"34LW]A;T!)D?2SK3PJ@ZUQ7]Y/O%
MV_*EV>3O;R--RYY:9HFHKR1V[Z0*`#^UGU$`1J2J$,)`6'AL&OP:_D^9W<FZ
MI/E)_,ER.2[A[PSU;-7P=7;SS=!OO;M%3QT?\,QE=V?5S#)4>Z<S34RWH</3
M3C#XRG6)9(YI0(Z8Z]SOO#VEK8_U&]F($V[E6(`&YAC:"5B#5EMZ:3&A/QRL
MOC2-J(*BI<D]KONY75[N']?/>N9MSYHE-1:S.LT:@B@-R3K$K4H$B5O"C55#
M:JA42'\E[H[IK</R6_F[Y7-]5=>97*="_P`T_L[:72.1R.S\#6UO46UMO[8V
MM5X/;G6U3/0O-LK"8BKJ99::EQQIX())&9%!)]X[WWN3[A[G976V[CSSN\^W
MSJ5DB>[G9)%/%74N0P/F""#UD;8>V7MUM=Y:[AMO(NT6]_`RM')':0(\;*:J
M498P5(.00>/6RS[!70XZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z*Q\W_^R1/D3_XBK=7_`+@-[]U[K__5W!>A
MO^RXOGC_`-07QE_]]ME/?NO='S]^Z]U0'_PH(^4/S<^,G27PH'P!WMB]F]_]
M]?S#NC_CSB*//XG9.5VOOVE["V;VC+C=A[MFWQC*_'8;;6XMVX7&"MK:>;'U
MD$$;%*J%2Q/NO=4_]D_S"_D[NKI7/=0]]=-_%+87\YOJ/^:?\8OY>^W/EGA.
MI]A=C;"Z[S/R;P&ZY^L_DYM6?/8[+9V#*[:ZRIL_C5I(H)I:%IZ&HDI(Y*BJ
MQU)[KW5Y'\CCY7?+'Y'](_)KK?YL9_9V^?D1\)_F/VQ\-]\=H;%I*3%X+M&L
MZIPVSZB3>/\`!Z#;^VJ&AJJNKSLT;O#24RU/C$W@IRYA3W7NKLRP'U('^O[]
MU[KVH<\CCZ^_=>Z\"#]"#_K&_OW7NO7'TO\`3W[KW7@RF]B#:U[&]K\B_P#L
M/?NO=>/T/^L?]Z]^Z]T5?H#_`)FY\R/_`!.^UO\`X'WIKW[KW1J??NO=>]^Z
M]TR;CW%@=J8',[FW-FL9M[;VW\96Y?.9W,UU/C<3A\7CX'J:W(Y+(53Q4U'1
MTD$;/)([!54$GVHM;2ZO[JWL;*W>6]F<(B("SN[&BJJC)).`!GI+>7MIM]K=
M7M]<I#9PQEY'<A41%!+,S&@"@`DDD8'6L!\G/YF/?7\P;L2I^%_\MS!YREV[
MNN&IQV[^Z:P9#:NX*_`TE94T^X,E192*25NM^K):-H?/E)XES=>DHIH(89)5
MAGS<Y']D^5/:+9X/<WWKO(FNH"6@LAID02$*8PRG-S<@ZJ1J?`2FIV(74N#W
M.WO;S9[N;W-[9^RUI)]),`D]Z=2,8RQ$C*U:06^G22[?KN.T*"VA[2OY>'\K
MSJ?X.X>BWE6,O87R,W#@$HM]=H5HEGH<;-7S-6YK!]>4-8IGPF%J)VCAJ*M[
MU^46F629HU<P)`_N_P"]_,'NC=-M\*&SY,AEK!;"BLP%`CSD?&^"PC_LXM1"
M5-7,Z^S_`+&<O^UUM'N+GZOG*:/3/<MW!2:ET@K0HN=)D(UR!:G0#H![N_>X
M,/\`'OIOL+NK.;0[%WYA^M]N56YLELWJ+:-5OSLO<=+1M%&<9LW:%%44M5N#
M,RM,"E.LB:E!)(`/N$@`*D#J=:"M:9ZUM?Y#/RAJ=R_+?^9?L_/?%[YG=2'Y
M;?,?M[Y?]6[L[H^.6[.MMB4_657A-F86CP>[-TYR<4>)["K:OR-%C(5JHY(X
MV9:@D%1OK?6U9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[HK'S?_P"R1/D3_P"(JW5_[@-[]U[K_];<%Z&_
M[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW1%_YA?\O?H/^95\<\Q\=._J7.TN,&;Q
M^]^OM^;0R/\`"=\]3]GX*DR-'MOL7960=)Z2+-XFFRU53O%4134]5254T,BV
M?4ONO=4J_P#0(Y_+#R.R$IMV[E^36[N\IJ'?]9G?DEE>Y,M_I#W7V'O3)5.7
MQ':&Y,7]O)M>KW3L/(3K)0+#304]:P9\FE=,YE'NO=7#_P`M#^6_TS_*^^.D
MGQ\Z=S^\=\#.;]W7V?V!V9V)-BJK?O8N^MV34\=5G=S5F'Q^,HYYZ'#8ZBH(
M#XR_V](I=WD9V/NO=`'O;Y0]YXO^>KTK\.J'?#0?'+=O\M_L3O?<'77]WMJR
MI7]K8+O6/9^+W4=SS823>5.:7;A^W^SAR$=`_P"MX&D]?OW7NB.=S=[_`,U[
MYY?+7YT['_EK_)/K?XP=.?RWJ_"=78Z'.].[.[;ROS.^44^T*'?N]^K=T5?9
M4..JNG]G;&KH(]MG)T""*:6N^[AJ*V*4G&^Z]U;U_+/^:%+_`#`O@_\`'_Y9
MQX3&[9S':>V*U-Z[5PTV5JL1M;L;9^X<ML;L3;^*K,S0T-?6XW%;SV[6Q0RE
M94:)1HGJ$M/)[KW6O'N?YW_S?>[NE_E7_.(^,?>/4>W/@[\6.V>U*;JOX-9#
MJ?:N9A^5WQD^-6Y\EM_M[NG=?>NY(,5VEUGN;<V/QV8R%%BX*6EJ*88=84I6
M81MDO=>ZVNNCNU]K]\],=2]X;(J!5;,[DZSV)VGM*I"5\8J-M]@;7Q>ZL),L
M63H<7D8EDQN5B(6>FIYA_;BC:ZCW7NA.UWN`/ZB]Q^./I^;GZ>_=>Z*ST)KC
M[;^8[-&P#=[;5*&QLP/Q]Z:_-K?T_J>1_4>_=>Z-06`!((/%_J+'_8^]$T!/
M7NBY?)KY5],_$KK#-=J=R;HI,+BL=1U4F%P,-322[LWOE8#!%!M[9F#EJ(*C
M-Y6IJJN&-M.FGI4D\U3)#`K2@7\D\C<R<_[[;;!RY8-)<NRAY#410H:UDFDH
M1&H4$YRU-*AF(4@SG;GWEGV_V.YW[F/<%BMT5M$?^BS.I`\.&,T+L20*CM4'
M4[*@+#6ER&1^:7\]GL:?#8Z*;X^?"+9&Z8<O3U>2QU=)19)360XJ,U-3$8J;
MM7M&EI*2KG@IX7BP>#D>2.64.T<L^:*1>V?W5MJCN977=_<ZZ@TD*>Y6H2=(
M.;6U)90S$&:4*K!*`JF%4MQ[D_>IWDP0`[3[66USJ#,&[QJT"I';<W%`Y"8C
MAJ59EJ"^RM\9?B=T=\0^NHNL^C-I4^V,)+-!D<_DJB>?)[DWAGXZ*GHI]Q;J
MSE9(]7DLC4QTRD1KXJ2F!\=-##%:,87<[<]<T^X6]OOW-.Y>/=Z=$:A0D<,=
M21'&BT`4>IJY(U.[,2>LT^2/;[E;V]V1-AY8V_P;0T,C$EI)I``#)*YRS&GP
MBD:U(1%7'1D$LJA=0-A:]_\`C9]A`"G0U^T]>:Q_M6(^A!_WNQ!(O[WU[KK2
M/RY(N38M_K?X_3CZ?[:WOW7NN=Q_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U
M[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'O
MW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<
M>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_
MMQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U
M'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ
M_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO
M7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>
MZ]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]
MU[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'
MOW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[
M<>_=>Z]<'Z$>_=>Z[]^Z]U[W[KW16/F__P!DB?(G_P`15NK_`-P&]^Z]U__7
MW!>AO^RXOGC_`-07QE_]]ME/?NO='S]^Z]U45_.4^>'>OP*^-'7NY?C/U=M[
MM/Y`_(/Y$=9_%KJ"DWY5Q8SK3:F_.V:;<*X#=G8V6FW!M6CQFW*>OPL=+')4
MU])2-754"3S10N[K[KW12_B;N?\`X4R5GR+ZGI?F+UW_`"]<3\99MR,O<62Z
MJKMQR=B4FUOX9D")-JI5;ZR=,V2_B@IA9J>4>,MQ^1[KW6Q3[]U[JA?L+:VZ
M)O\`A29\>MY1;9W%+LZC_E,]IX"KW='@\H^UJ7/57R1%;3X.HW$M(</#F9J*
M,S+2M,)S%9].D@GW7NB09GY+=A_R5_F;_-"P^\/BM\B^]=G_`#O[(A^77PCW
MSTUUKD^SJ#L?NC/[`Q&V>P.A^PSM"J5NOXMO]FOCZ;&R2PFKFPTS5<I=YJ5'
M]U[H]_\`)[V__P`-\?&CX._RS.Y-L=F4'R3W;T[VG\@]R"CV;4;AZPV/E-T]
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M@H33PU%#45-/5"FJ848(PU*WNO=:YO\`+G_DK?%^A^9GSFGW)W#\R^R\+\//
MDU@.H.N=F=B_)//Y7:.Y=K[Y^&O1_8F1JNQ<?A\+@:[<>;Q>[>W,I/02T]31
M10I3T2O%(8'>;1('$]:J!Y]&J_F"YK^6?\$\#)ASUI4]H][UHICB.GL7WAV5
M1UF(I:JG6LCW)V%D*?=60J-IX!J1UDIT>$UF49U6G01^6HAFSVC]C^9O=2\-
MP#)8<K1DZ[LQE@Y!-8[<$J)9,$,P;1"`2YJ%1X.]X/?7ECVJL_`;3?<U/319
MI(%900*23E0QB3*E05U25&D:=3J4+X(_RB^S/E?N#&?(SYMTN>V)U8,K+6[3
MZ.J*7.8+<^\\-*DM331O+69),[U]U^)Y(DBUM+F<U31M(9H5:*JFGKG?W?Y&
M]F=CNO;GV0MX9-Q9:RWP<3"&5@`6\0AS<7*C4*ZA#"2`JL08T@+DCVAYX]Z-
M\M_<CWMNYTVU67P;$QF$RQ"IIX0*?3P$Z2>TRSC6Q*U65K\<=_+$^%>,Q]'C
M,=U+D<;CJ"%8*+'T79/9M-1T<*W(BIX(=XI'$ER2;#U,2QNQO[PCO;^^W6^N
M]UW.\EN-SN7+RRR-JDD=LLSGS8T%?L`&`!UG'M^WV&TV-IM>UV<=OMMO&$BB
MC73'&B\%1?PC)..)))))KU,_X;2^&_XZSS1_K;M#M+_8?\QG^?:;I9U[_AM'
MX<?\^RS?_HT.T?\`[,_?NO=>_P"&T?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^
M''_/LLW_`.C0[1_^S/W[KW7O^&T?AQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\
M^RS?_HT.T?\`[,_?NO=>_P"&T?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/
MLLW_`.C0[1_^S/W[KW7O^&T?AQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?
M_HT.T?\`[,_?NO=>_P"&T?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_
M`.C0[1_^S/W[KW7O^&T?AQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.
MT?\`[,_?NO=>_P"&T?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0
M[1_^S/W[KW7O^&T?AQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`
M[,_?NO=>_P"&T?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^
MS/W[KW7O^&T?AQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?
MNO=>_P"&T?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[
MKW7O^&T?AQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>
M_P"&T?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[KW7O
M^&T?AQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>_P"&
MT?AQ_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[KW7O^&T?
MAQ_S[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>_P"&T?AQ
M_P`^RS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[KW7O^&T?AQ_S
M[+-_^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>_P"&T?AQ_P`^
MRS?_`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[KW7O^&T?AQ_S[+-_
M^C0[1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>_P"&T?AQ_P`^RS?_
M`*-#M'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[KW7O^&T?AQ_S[+-_^C0[
M1_\`LS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>_P"&T?AQ_P`^RS?_`*-#
MM'_[,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[KW7O^&T?AQ_S[+-_^C0[1_\`
MLS]^Z]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>_P"&T?AQ_P`^RS?_`*-#M'_[
M,_?NO=>_X;1^''_/LLW_`.C0[1_^S/W[KW7O^&T?AQ_S[+-_^C0[1_\`LS]^
MZ]U[_AM'X<?\^RS?_HT.T?\`[,_?NO=>_P"&T?AQ_P`^RS?_`*-#M'_[,_?N
MO=>_X;1^''_/LLW_`.C0[1_^S/W[KW0N=,_$/H/H'<V0WAU9L_([?W!D\'/M
MRMK*O>6\]PQRXBIK\?DIJ9:+<6X,K11.U9BX&\J1K*`A4,%9@?=>Z,O[]U[K
MWOW7NBL?-_\`[)$^1/\`XBK=7_N`WOW7NO_0W!>AO^RXOGC_`-07QE_]]ME/
M?NO='S]^Z]UK._SKNU_Y9?SK^(.\>G.W/YG[_%[K'IOYD87ICO/<W4U'NC><
ME;W'@>O^QLM!\>^R=N8"AG_BN%E^PK,PKS15.*_C&U6C60UM#*D'NO=5E?RT
M,+\!L9\W?C13]3_\*2?F1\M-XT6]%I]G_%_?-;W\NPNU9J?;F8AAV?FJ3<]0
MVV%Q<%$K3I'4*(5:F0*`=/OW7NMY?W[KW7!U+<`V%OIS_O8L?]Y]^Z]UQ\;#
MZ.>6N?ZD?Z__`!2P]^Z]U[QFQ`:P/XM87M]>"&N6_P`>!Q[]U[KM4*G]3$?T
M_P!\;6_WQ]^Z]UD]^Z]UBFD2*&66618HXHWDDE=@B1QHI9Y'<D!51022>`/>
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MQ_\`%*[?_8V;R^,H:(RQQS45%/(\-%#4$13^P)[L_>(EW2U;D3VRA_=?)-NA
M@62,%)+B#2%T*.,$!->T'Q)<%RM60CSVD^[Q#MMV.>O<Z4[GSO<,)2DK"2.W
MEU:P6-2)IQ@D_!&:@!^UQ2OU!_-N[[ZSV;\0?FUNC^;ULWY%=X?)7Y,;$ZZ^
M1G\IZ?977^$I>J=G]E]BYG;N[=H;1P1J*OMSJ'-=.TU)2QT>:RL*TM<Z>J6L
MBJ46KQ7ZRPZV_/YFO8V^.GOY<OSL[7ZSW+D-F]C=:_$;Y";YV+NW$F%,IMK=
MVU>J]T9K;^=QS5,4\"UN+RM%%-$71EUH+@CCW[KW56W_``GP[8J/D#TED.\,
MG_-6[$^?^\MP]9=-TW;O2^^\+MS`R?%SMW*;5IMU;RV_14=+BL-N7)4;Y;,3
MXJ'*20/C:_\`A,GV\TLD4PC]U[K8L4W`/TO_`+[_``^OOW7NN_?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW16/F__P!DB?(G_P`15NK_`-P&]^Z]U__1W!>AO^RXOGC_`-07
MQE_]]ME/?NO='S]^Z]U0S_.I[(^+OPF^)2[I?^7KT#\O.U?DE\L-@[3ZC^/N
MY>DMG;BPO<?RY[*PF:PN,WYNJ@AV-N"?-]A?W"P>1I8L@\'\7R*K'CDJXQ4!
MA[KW54WP4[-[@^+O\Q'XK_'_`/F2?R2OY</Q.W=\F5W+-\6?DS\..A>O<)4;
M/[.VSM[*9&LVCE-Q;>R'9QI-QU>,A>&;[;+XBJQ\-=#*R5%-)(T?NO=;GX_W
MU_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1<?E;U?V7W9T!VAU'U5O\`QO5^
M[>P\!)M./?&6PM?G8<+@,S-%2;I^TH<=DL54C)5^W9*JFIIA,!3RS"0JVD#V
M+.0]]V?EKF_8]^W[:7OMNLYO%,*,$UNH+159E8460*S"G<!2HKT#^?-BW?F;
ME+>^7]CW1;*_O(3%XSJ7"HQ`EHJE2"T990U<$UZUE_Y<O\LSN+9'S5[CW+L/
MOW9V*S?P*^1VTNH=TM6;#SE;1]HX?>O075G;&YTQT$6X*67;U)D-D]SR80)+
M)4R)5TK5`?QNL?O*3G[[T/*O/O)^_P#*E_R%=JEW`0KFZC(253JBDIX6?#D"
MM3S%1YT&*O('W5N9O;_G'9>;K+GNU>:UGJ5^FD[HV71*E=>#)&SIJ%*:J\:'
MK;Q5`55M)#:01?A@?J+_`(U>\+5`P:4/6;/$#CUK'=O?R^J_YN?SB]BYNH^$
M?7_1'PA^&F^Z7Y!=P]R5W4.Q]@[P^?/S$;$/7]=FHR>/I5W+VUUCU.^X'K'R
MM<BT597U.6I*DU)F@$=NM]6G[V^>]?'\?N\.X\5\#_FSV-B.F>^-]="[UZ8/
M36#Q_</8^T=DI'#N/NWI7KK<VZ:6E[DZ<SE/6(V'EIZJGJ\[`)Q3TS21B&3W
M7NJK_P"5MU[VMWQ_-?\`E7_,HVY\(>V_Y>7Q5WU\5]H_'_%=8]U;*CZB[)^2
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M"[@ZKVOD?LSEDR"%X%F\TCQ2R!O=>Z8?AI\`?G;\AOFM\7OEKW+_`#MOB_\`
MS&=B_"K?.:SU3L3JK$=?;J@VXW8VT\OM^K"+UTLNV]N;KSE)3`T>2KH17PPT
MDGVLJ`/[]U[K;^'T'YX'/OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]TA^SNQ-
MJ]0]:]A=L[ZK*O'[(ZOV/NSL3>-?08K)YVOH=J[*P&0W+N&LHL)A:6NS&8JZ
M;$8R9XZ6D@FJ:AU$<2.[*I]U[K6[_E-_S9OA#WS\_OGMU=UCO_?68WE\Q/E7
MA^T^AJ+*=*]N;:H-S;*ZV^"O1&"W=D\OFL_L['XG9TU!E^GMP0Q4V7FH:BJ^
MUB:%'%53Z_=>ZV>P;@'^H!]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[HK'S?_[)$^1/_B*MU?\`N`WOW7NO_]/<%Z&_[+B^>/\`U!?&
M7_WVV4]^Z]T?/W[KW6NQ_P`*7<KNK%?!3J6;*9GM;"_$ZJ^9?0F(_F'3=.50
MH]Z5GPAS,^Y,9VIC8GIU.9EQ]?G:G#1314?,S,D=0&HVJ$;W7NJF_C=C_P"5
MMTO_`#<OY=N(_D-;NR.Y:[L/$]B83YU;3ZBW7W9V;U7_`++5#M7(U&#WKVA6
M;XJ<M@L+N2BW_P#:EUER,3X^LCQS&AAEJ8C4^Z]UO%^_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NNF^A_UC_A_O7OW7NBL=!,S]M_,<,[L%[WVMI!9K+_`,X^
M=,C@7XX4#_6`]^Z]T:CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=%8^;_\`V2)\B?\`Q%6ZO_<!O?NO=?_4W!>AO^RXOGC_`-07QE_]
M]ME/?NO='S]^Z]UJK?*[YP_\*",%V%V[U32?REOAMOWX[;S[1[`Z5ZHRG<'R
M1Z<V_3]^[!SF<W#@-C8BKVEO3Y*X&/<&XNS=C0K-+M_[`5E2)IHOLQI>-?=>
MZ0'\M"E_FB_%KOK#T6Z?Y%WP2_E]?&#?E>DWRA[[ZA[+ZEP^6VMU_M#!;ARU
M/N++MB>^<_6U^+V_5NS%7I:B"GCJ)9F50&D7W7NMM#`;@P6Z<-B=Q;9S.*W%
MM[/8VCS&"S^"R%'E\)F\1D($JL?E<1E<?-44&2QM=2R++#-#(\<D;!E)!!]^
MZ]T\>_=>Z][]U[KWOW7NO>_=>Z][]U[KH_0_ZQ_WKW[KW15^@/\`F;GS(_\`
M$[[6_P#@?>FO?NO=&I]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW16/F_P#]DB?(G_Q%6ZO_`'`;W[KW7__5W!>AO^RXOGC_`-07QE_]
M]ME/?NO='S]^Z]UJQ?\`"LCK[;&^OA/\0W[1?L#"=`;7_F,]#9KY']C];;:K
MMR[@ZBZ.RNR.V]G[P[%BIJ6@R<=)58I]T004+SQ&*;*55-3A7DF1']U[K5=W
M/\_?C9L[X^;T_EFXSMWY"][_`,LR7^:?\?\`L+KK>&_]B;[FSV\/Y<&SJ_)Y
MKY:[5Q.^J6#;VX<9@MM=BX[#56,CPM%A,NXJ:VH?[5J^2DB]U[K;._X2UR;1
M_P!E-^8U#TCD>P,M\0L/_,2^0>,^&%?O^/,BIJ/CO%A]AR;:DQ<N=I*+(S02
M9.6K:K\L:RKD#.LJK,)%'NO=;./OW7NM6?M3YK?S!/D?\P/G1UEU7\__`(@_
MRMMC?`#LK%[$QW6/?_5^R^R-^_(C#9'9%%O[&]M]F9SL[<6UYNO^G-ZXV)9<
M)5[7I6JEQ=75/))/+3TT\ONO=6Q_RQOG'O7Y>_RVNEOFS\B-DXOIS/[FV#O/
M=785'B(L[-M=\-UYN#=&%J^S-JTF0I)<['LW?6!VP-PXVE/WLL5%6QQ1SU=E
MFD]U[JB.G_F2_P`WC&_&O`_SN]P[[Z33^7[F^WZ";*?R^5Z[P2;BVQ\/\UOE
M.H\7W8GR6I\?-V#D>QURDD.<;&?8M2,D_D^V5+XB+W7NMOW"Y?'[@Q.-SN(J
MEK<3F<?0Y;%UBI)$M5CLE2Q5E%4"*:.*:-9Z69'`=5<!K$`\>_=>Z<S]#_K'
M_>O?NO=%8Z!!';GS(N"/^,[[6^H_\!\Z9;_>F!_UC[]U[HU'OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I*[XWOL_K39VYNP>
MP=U;>V/L;9F%R&X]V[QW9EZ#`;9VSM_$T[U>4S6<S>4GI<=B\9CZ6)I)9II%
MC1%))]^Z]U7^O\Y+^4]_:_F0_"@G_#Y']5@#_P!>;W[KW7+_`(>2_E.?][(?
MA3_Z4?U7_P#9-[]U[KW_``\E_*<_[V0_"G_TH_JO_P"R;W[KW7O^'DOY3G_>
MR'X4_P#I1_5?_P!DWOW7NO?\/)?RG/\`O9#\*?\`TH_JO_[)O?NO=>_X>2_E
M.?\`>R'X4_\`I1_5?_V3>_=>Z]_P\E_*<_[V0_"G_P!*/ZK_`/LF]^Z]U[_A
MY+^4Y_WLA^%/_I1_5?\`]DWOW7NO?\/)?RG/^]D/PI_]*/ZK_P#LF]^Z]U[_
M`(>2_E.?][(?A3_Z4?U7_P#9-[]U[KW_``\E_*<_[V0_"G_TH_JO_P"R;W[K
MW7O^'DOY3G_>R'X4_P#I1_5?_P!DWOW7NO?\/)?RG/\`O9#\*?\`TH_JO_[)
MO?NO=>_X>2_E.?\`>R'X4_\`I1_5?_V3>_=>Z]_P\E_*<_[V0_"G_P!*/ZK_
M`/LF]^Z]U/Q/\WW^5=G<KC<'A?YB/PURN9S.0HL5B<7C_D/U?5U^2R>1J8Z.
M@H**EAW(\U35UE5,D<<:`L[L`!<^_=>ZL9]^Z]U[W[KW7O?NO=%8^;__`&2)
M\B?_`!%6ZO\`W`;W[KW7_];<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW51'
M\Y_Y?;K^+GQ:V=L?K#I+9O?_`';\W>]-C_!?HWK_`+3BV_5=-S=H]]8O<]+A
M,EW%C-QL<;G.OZ.DP52*G'2(T-?-)#!4-#3233Q^Z]U5=\0=X?S&?@E\B/C9
M\`?YK>S?@_W5\7OG%M_?W4?0$GQKZLV+M#:'4N_:/;F<W9OSJ/<'4^"Z?ZUV
MYE]A=A8:=HLRK8>3'/45<,JUDJ?>4[>Z]UM']=]9]=]1;2Q&P.J=A;)ZQV%M
M]:M,%LCKS:N!V7M#"K75E1D*M<1MK;6/Q>&QHJJZKEFD\,*>261G:[,S'W7N
MES[]U[K2&^36W/B%M/YZ_P`PS)?SM_A#\G?D?N7N+M?&TW\O[=^Q.INU>VNO
MMQ?&O&;$H=N;7ZUZ'J^K<_0[<V5VCCLM+`<_%*F/KI<QDZ6HJ9VF9YO?NO=6
MR_RP=]]KXOX+?%K^6_\`/&/NK:?S)[X^+O?F7CDW3LO-;BK-I]-ONC?6W]DQ
M=F;\\57@,5VIA.L\MB_N<5FJS^,O5H8ZP?<:Q[]U[JD6H[3[OW5_*UV[_P`)
MS)?B3W]0?/2/?>!^+>ZU_N/7-TWA.AMN=JT?;4GRBA[JEJQL*KVE4]>X^GEC
M45%Y:R8K'$83$TGNO=;U.SMO1;2VGMG:D%5)70[7V[A-N0ULR)%-5Q83&4V-
M2IFBC_;BFG6G#LJW`+6''OW7N@;[Q^+?3_R(K-N5_:.*W!DY]ITV5IL*<+O3
M=6U$AAS,M!-7K41[;RN,2N:1\9#I:;R&,*0M@S7]U[HB747P%^->Z.P_DG@<
MQM_><V.Z_P"V,#MK;,<':/8E'-38BNZ>ZSW3415M32;DAJ,K4',[@JG6:I:2
M5862('1&@'NO=#Y_PV?\2_\`GE]^?^CA[3_^RWW[KW7O^&S_`(E_\\OOS_T<
M/:?_`-EOOW7NO?\`#9_Q+_YY??G_`*.'M/\`^RWW[KW7O^&S_B7_`,\OOS_T
M</:?_P!EOOW7NO?\-G_$O_GE]^?^CA[3_P#LM]^Z]U[_`(;/^)?_`#R^_/\`
MT</:?_V6^_=>Z]_PV?\`$O\`YY??G_HX>T__`++??NO=>_X;/^)?_/+[\_\`
M1P]I_P#V6^_=>Z]_PV?\2_\`GE]^?^CA[3_^RWW[KW7O^&S_`(E_\\OOS_T<
M/:?_`-EOOW7NO?\`#9_Q+_YY??G_`*.'M/\`^RWW[KW7O^&S_B7_`,\OOS_T
M</:?_P!EOOW7NO?\-G_$O_GE]^?^CA[3_P#LM]^Z]U[_`(;/^)?_`#R^_/\`
MT</:?_V6^_=>Z]_PV?\`$O\`YY??G_HX>T__`++??NO=>_X;/^)?_/+[\_\`
M1P]I_P#V6^_=>Z]_PV?\2_\`GE]^?^CA[3_^RWW[KW7O^&S_`(E_\\OOS_T<
M/:?_`-EOOW7NO?\`#9_Q+_YY??G_`*.'M/\`^RWW[KW7O^&S_B7_`,\OOS_T
M</:?_P!EOOW7NO?\-G_$O_GE]^?^CA[3_P#LM]^Z]U[_`(;/^)?_`#R^_/\`
MT</:?_V6^_=>Z]_PV?\`$O\`YY??G_HX>T__`++??NO=>_X;/^)?_/+[\_\`
M1P]I_P#V6^_=>Z]_PV?\2_\`GE]^?^CA[3_^RWW[KW7O^&S_`(E_\\OOS_T<
M/:?_`-EOOW7NO?\`#9_Q+_YY??G_`*.'M/\`^RWW[KW7O^&S_B7_`,\OOS_T
M</:?_P!EOOW7NO?\-G_$O_GE]^?^CA[3_P#LM]^Z]U[_`(;/^)?_`#R^_/\`
MT</:?_V6^_=>Z]_PV?\`$O\`YY??G_HX>T__`++??NO=>_X;/^)?_/+[\_\`
M1P]I_P#V6^_=>Z]_PV?\2_\`GE]^?^CA[3_^RWW[KW7O^&S_`(E_\\OOS_T<
M/:?_`-EOOW7NO?\`#9_Q+_YY??G_`*.'M/\`^RWW[KW7O^&S_B7_`,\OOS_T
M</:?_P!EOOW7NO?\-G_$O_GE]^?^CA[3_P#LM]^Z]U[_`(;/^)?_`#R^_/\`
MT</:?_V6^_=>Z]_PV?\`$O\`YY??G_HX>T__`++??NO=>_X;/^)?_/+[\_\`
M1P]I_P#V6^_=>Z]_PV?\2_\`GE]^?^CA[3_^RWW[KW7O^&S_`(E_\\OOS_T<
M/:?_`-EOOW7NJM?YVGP)^-G6G\I_YV[YVIMW=]/N';?1.9R6*GR'9W869HXJ
MR#,81X9)\9EMQUF/JU1P#IEC921]/?NO='L^*?\`+C_EZY[XO?&[.9WX'_#+
M-9K,]"=/97+Y?*_%WI#(93*9/(]=[<J\AD<C7U>QI:JMKZZLF>6::5VDDD<L
MQ))/OW7NA[/\L_\`EO@$G^7Y\(^/_`4NB/\`[`_?NO==+_+0_EOL+C^7Y\(_
M]C\4NB+\<?\`/!_U]^Z]UR_X;._EP?\`>OSX1_\`I*71'_V!>_=>Z+YWQT%_
M([^+<.W:CY+=%?RL/C]!NZ2OAVK+W/U1\4.LUW++BDIY,FF!_OEM[#G+'')5
MQ&?P>3P^5-=M:W]U[H8*;^7]_*UK=KT^^*/X0?`6LV56;?AW92;QI?C5\=ZC
M:M5M2HQZY>#<]/N*'9CXB;;LV)<52UJS&G-,1*'T$'W[KW06=&?&_P#DF_)_
M"YO<GQL^//\`*_[_`-O[9RD6#W)F^F.G?BMV9B]OYFHI(Z^GQ>:KMG;;S%-B
MZ^HHI5E2*9D=XSJ`M<^_=>Z'8?RSOY;Y`/\`PWY\(^>?^R4NB/\`[`O?NO=>
M_P"&SOY<'_>OSX1_^DI=$?\`V!>_=>ZZ/\L_^6^`3_PWY\)./Z?%'H@G_8`;
M"N??NO=,V#_EY?RP-S4"97;?P7^!NX<7)/44J9+!_&7X]9?'M44DS4]7`M;C
M]E5%,9J6=&21=6I&4JP!X]^Z]T\C^6?_`"WR+C^7Y\(_R/\`LE+HC\&Q_P"8
M#_J/?NO=(_L'X(_RH^I]E[D['[0^&'\OKKKK[9V+GS>[=\;W^.'QTVOM+;&&
MI=/W.6W!N'-;,HL3B,=3ZQKFJ)8XUN+D>_=>Z:MC?"W^45V=D=^8?K?XB_RZ
M=_9;JS>-;UYV9B]F_'WXU[FR'7N_L;#!4Y#96]:/#;1K)]L;JH:>ICDFH*Q8
M:J-'5F0`@^_=>Z$;_AL[^7!_WK\^$?\`Z2ET1_\`8%[]U[JK#^=1\"?@YUK_
M`"W>\MX]:_#CXM=9[SQN\_C%28?>_6_0'5&Q-[8*//?+#HW;^6EV_NW:VTL5
MN#!5=;A<I4TSS4M1%(89G6]F(/NO=7)=-?$7I'H3=>3WIUMA]RX_/Y?"56WZ
MZ?,;[WGN>D?&5F1Q^4GCCQVXLWDJ&"<UF,A(E2-9%4%0P5F!]U[HS/OW7NO>
M_=>Z*Q\W_P#LD3Y$_P#B*MU?^X#>_=>Z_]?<%Z&_[+B^>/\`U!?&7_WVV4]^
MZ]T?/W[KW55?\Y;X[_$_Y&?!'LC;WR[[MQ'QDV5L?)8?M#8'R3K\WC\!E>CN
MY=HBLDZ]WQM2MK9J:MKL^*ZKDH1C,;-#ELS2UDU#1R1U$\;K[KW6O%_*]K_B
MEV[\\NC.Q/F3_/7Q7\S[Y'=>>3;?PBZ9Q&$['Z\V7LW?V4Q.;7<F^ZW;]1BZ
M7"[H[!EVX9*:FJZD1,\.MJR2K>&A%)[KW6[B/?NO=>]^Z]UU8#_;W^IY/^/]
M??NO==:%X^O!O^HFY_QN>??NO=>T@?EOK?\`4UO]:U[6]^Z]UY5"_2X%@+7)
M``%A8$\<>_=>Z[/T/^L?]Z]^Z]T5?H#_`)FY\R/_`!.^UO\`X'WIKW[KW1J?
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW50O\
M_+_MS?\`S"O_`!7O/?\`NWPGOW7NJL?D9_PHCVE_+,POQ8^,TGPN[V^066@^
M&?QJWWEMZ[,RU!M_:U*^Z^NL;]E@\:TFWMRU&4GI*/'+)42O]L$DE\81M)<^
MZ]T3;L+_`(6;I0;%W?6;._EF=UX7=M/MW+2;8S'86^0^Q,5N`4<HQ&1W?%BM
MB8S)U.W**O,<E7#3U5+/-"K(DT+,)%]U[HBG\NS_`(6#?)SKW9^^=C?,KH3<
MWS.W?4[HR>\=C;XZKGP?7VZ,%MS-Y&KK,WM/<VW\7M')XC(;<VYD:Z"+"U,,
M%//2TLGVM0TP2!D]U[JQS_H,KVQ^/Y7/R<_]#K'_`/VMO?NO=79?-&?X\_(7
MX.==?S#<M_*SIOYAV\LO\?\`86]NN?CSOOK[9.Y.Y-N]<]R8G`;[W!B,9B]U
MX3>M-@]S[;Q];'-DZ?"TE3EZFHI/MZ8RN(E/NO=:^B4\E'_PGC^`7QKP'<E=
MN38/SI_F?=1?$[MJ#9>?[#QF:Z5ZC[8^0W8.1WO\<=C2[WAPF[<))LJDV%#@
MZB@S^(^VFH*NK1Z"2">&9O=>ZM,W!\=NC?Y=_P#/?_EEX#X>=7;0Z%V%\XOC
M1\QNE^].L^N\6FSNN-QT_P`8MA[?[<ZTWU#M+;)Q&*R7:5)D:R2@J\MDER$D
MN,=[)'4R2U3^Z]U:A_,N^<V>^`W4'3'9FW^N\3V54]I_*_H+XW56(S&X*S;<
M.&Q_<^X*W!U6ZX*JBQ66DK*[!?:J\=*Z11SZB#*EA?W7N@\[!_F/[EV5\]OD
MQ\-8.JL%D<-T%_+BKOG30[\FW7D*;)[ESM+O/)[5CZZK,#'@IZ7&XB6+&F9L
MBE3-,C'2*=AR/=>Z(CTI_.[^3FZ=H?RPN^.[/A/UYUY\9?YE/;>S/CCM;<VQ
MOD:_8/:^R.X^R,EN^BZ^SF8Z]K^MMIX3_1CN2+;8F=XLU597'015)J84G%+2
MU/NO=$6RG\Q#MOHS^0CAOD;_`"Y?C9T;\3*;/_+S>_2^6V\N_-U[JH^MHMR_
M)#)=:Y+>77M-N/9^;7<.[M_;FJ#+4/D&@H\!33S3T\%9+%!`/=>ZL9^2_P#-
ME^:7QB[BZ!^).^?C;\0,3\J>Z>K.R>W<55[S^6&_.M_B[O\`EVQO%-I[%^._
M1O>N]^@\0=W_`"AWR0:B3"9O&[>Q-`E30+_$)FKH@/=>Z'C^83O'<W?V^/Y8
MGPLCV?68/*?*GOW:'R)^0.Q\V):Z?9?Q_P#B!A\3\@-];?W1E\%BLO1X]V[G
MAV7M\U2RPT60R-3'C)'--DG(]U[JK3X4?-S"_$?N'^=#MC9VQLK\@/E;WC_.
M%[PVA\9/BQLC)45-OCMG=T&R-G5%=F<U63F:#KSIS8M)*,ANK>&3C3%8;'QM
MZI:IX*:;W7NC0_*/^=+\N>E]Q?,KKSK#XA]%=C;V_EG_`!ZZD[M^=&7W7\E,
MAL#9XR?<&Q,5V'B-I?&>BJ.NLENKLNGP.W):^6JKLW!MYJB2C6GA@%754%/6
M>Z]T*O\`,L[9W/WW_(AD[QWCB]FX7/=QX;X*]HS8WK[-[DW'LVFQV_?E7\<M
MTX$X',[PVIL;=%92SX#*4TC??8B@J(Y79&B&FY]U[J_OW[KW7O?NO=>]^Z]T
M5CYO_P#9(GR)_P#$5;J_]P&]^Z]U_]#<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?
M/W[KW6M[_P`*>\1TQ!\!NJ^U^]MV;7787QY^8W1G=E?T3N\[EAP_S"CVM#NR
MARWQ;&0VI#DLK@*SL+;.8KYX,B]#6T-"]`)JO[:F66MI_=>Z)?\`R^OYF?\`
MPGZ[F^7GQ]ZW^+W\KC(]&_)'>FZQCNL^QW^$'0'7T&P]TG;^5K:FL;L':>[Z
MS/X-(\?3U-/]W24S.PDL5",UO=>ZW$O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW71^A_UC_O7OW7NBK]`?\`,W/F1_XG?:W_`,#[TU[]U[HU/OW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JH7^?E_VYO_`)A7
M_BO>>_\`=OA??NO='O\`A]_V23\7/_%=.DO_`'VFV??NO=#=NC;&W-[;;S^S
MMXX#"[JVGNK#Y+;VYML;CQ=%F]O[AP.8I)<?EL+F\/D8:C'Y7$Y.AJ)(:BGG
MC>*:)V5E*DCW[KW1"_@A_*N^$7\MB/M)OB+T[1]?9+M_<<F>WCN#)9G+;LW,
M^.C=I</L?%;BW#/79?%;!VW+([T.,24Q)+(TLIEF;R>_=>ZL0%["_!MS;^OY
M]^Z]U6_\Z^FOYE78N=V#F_Y?_P`P>H?CG24.`W'@^R-J=R]'4?;&(W!6UE9C
M:O;&[MLY-9%R.#S>%BCK*::GD26CJ8IXW9=45F]U[HK.(_D?=4Q?RJ,A_+5S
MG<G8.0SF;W#-W1DODC14V)Q^\\=\HZC>T':A[=VM@8H5HMOX2D['IE:+#T]1
M%/\`P8R4AKA-+)5GW7NG/X1_RV?E7L[Y63?.?^8O\L]M?*SY'[.Z7;XZ]&4G
M6O6V.ZNZPZYZUS&1@W#OK<=7@?M#497L[?&=A6.?(0"D6&A22$^:*:*&C]U[
MHRG\T?X)9_\`F!_&?&]2[+[1I^H.S^NNY.J_D+U#O?*;<@W=M:D[-Z>SDN;V
MQ0[YVU(U/4Y?:61-3+'4K33PSQN8Y?WDCDIY_=>Z*-LG^69\N\]\PODQ\QOD
M?\B.@=V[O^1?\N&L^$\6T.H.GM[]>[3ZZW)5YV/.)F<:=T]B=@9[=.U(,@]9
M5R3UM;%D9Y:\PI%!!31!O=>Z3./_`).G9M%\.OY.?QG_`-,^Q6SO\LOY=_'_
M`.2&^=S_`-W,^<1V?@>G*[?E3E-L;4HC4K6X7+YF#=Z)3SU;-#$T3,ZD$+[]
MU[I(87^1MO.3^3QN7^6GN/Y`8"B[&'=>[^_MD=O;;VC5U.T:#>Q[TK>\=A8K
M<6U,W.^1K]MQY)H:+*B&=)_&7DA+:0C^Z]U)^6'\N+^:7\U.C-_=1_(SY$_R
MX^T,-VWLZ'8V9Z^SWQ![:I]F](Y#$KD6Q7>G0.^:/O@]ETW=5=D:V"NJAEI9
M,+3SXVDBIH%@%0E1[KW1\?C/\"-Y=*_(#9G;78_>.;[QQ71GPAZA^&O0]7O0
MY'([^C;%9:IW'\@.XNQ,QEJK)T]3V)W/E\!M6">HQ+48FQV!ABKQ5RPT\T?N
MO=$;P_\`(_SV&WO\T._MM=ZX;K#Y=]H_-OLSYB?$'Y*==[3FBW;T=%OS`X3#
MUW3G:E%DIA!VYU!O6FPWVFZMM5,AQ61II3-"D%9'%/'[KW5*WRNDJ_F3\]OE
MQ\@.V/B'\)/D=L/^65T+@>FOFCUOV;W0OQ+R':G<FT)(>UMT]E=6Y7"?QS?7
M9G6V/H]B+C=L8GN"=MK:82M'.)S62T_NO=71_P`P'Y%;"^6W\@.#Y(]7;.RW
M7O7W;^,^$V[=I[%S=#B\;D-H8>?Y??'ZC@VX:/"2S8>.DQ!HS!3-2D4\E,D;
MQJBL$7W7NMA[W[KW7O?NO=>]^Z]T5CYO_P#9(GR)_P#$5;J_]P&]^Z]U_]'<
M%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW6O1_P`*-.M/D-OWXN?%7<OQ8^+^
M[OE9W9T;\^.A^_-I[*VQ1#-XS;C=88/L+-U>X-\[1.*R4&[MEY6(?P&HHY'I
MHTGS4507?P^"7W7NF?XE_P`VK^:9WO\`(OJCJ/NS^1AWA\:>J]][D?#[U[UW
M'V]E\]@^M<2,5D:T9[(X>IZ-VQ#7TYK:2*GT-7TPO.#J)`5O=>ZV+_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_UC_O7OW7NBK]`?\S<^9'_`(G?:W_P
M/O37OW7NC4^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NJA?Y^7_;F_P#F%?\`BO>>_P#=OA??NO='O^'W_9)/Q<_\5TZ2_P#?
M:;9]^Z]T8OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW1/^Y_Y??P9^1G8&.[6[Z^(OQU[A[+Q4>.AHM^=
MB]1[(W9NM8,0T#8J"HS>8PU57UU/COMD6!)WE2)%"*`O'OW7NB<?SR<7C<)_
M*H[MPV&Q]#B,/B=W_$'&8K%8RD@H,;C,;0?,'X]4M#C\?0TL<5+14-%2Q)%#
M%&JQQQJ%4``#W[KW5P_OW7NO>_=>Z][]U[HK'S?_`.R1/D3_`.(JW5_[@-[]
MU[K_TMP7H;_LN+YX_P#4%\9?_?;93W[KW1\_?NO=4-_\*`>_^XNE/BY\=MF=
M3=WY+XN8[Y2_./X\?&#N+Y1X9Q1Y3X[],=A5.XLAO3LVESU168[';;6A_NY3
MTE16U5;11K3U3QK40R2*X]U[JEGX%_*K)+V[_P`)\]@=2?)7?';WR)W1@/F%
MU9\N]AR=H[F[,FSOQ@PF_P#MK([0WUW3A(LSD</#N;#9[;KUN)R=;,M;!#&Q
MCCDHTC"^Z]UO%>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NNC]#_K'_>O?NO=
M%7Z`_P"9N?,C_P`3OM;_`.!]Z:]^Z]T:GW[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4+_/R_[<W_`,PK_P`5[SW_`+M\+[]U
M[H]WP^8?[*5\71S<?'7I$'_`_P"C/;!_WH^]'M-"#7[.O$$$@C/2H[O^0'4?
MQPV2W8W=.[5V3LQ<QC=OG-S8;<&:C_B^7,XQU']GMO%9G(DU)IG]?A\:Z?4P
MN+ASFGF[E[DK:OWWS/N'TNU^($UE)'[FJ5&F-'?(4G"F@&:=2%[7^U7/WO-S
M1_4SVTV`[GS+]/+/X(FMX3X4(4R/KN988^W4,:]1\@:'H`NJ_P"9!\+N[.P-
MN=6=7]U4NZM^[NFKZ?;VWXME=D8N3(S8S%5^<KD6OSFS\9BZ?P8K&3S$S3Q@
MB,@$L0"#>7?>_P!K^;-YLN7^7^9Q<[O<%A'&+>Z35I5G;ND@1!15)RPX=2US
M[]S?[R?MCRCO'/?//MI)8<I[>J-<7!O=NE$8DECA2J07DDK:I98T`1&/=4C2
M"0=_4+:K&UK\#\>Y5K0D4/[#UC%44!\NJ^/YA7SI_P!DPZ_Z^HNO^LJGY`_*
M#Y"=@X[J#XN_&W&[CBVCENV^P*T1U6;J:S<E3C,M2;5V/UYMPR9C/Y>JA2DH
M:*$*\L;S1GWX$&M.MC(ZC_-GYSUOP!^#-;\G>[>N8=X]N8_$=<;0H^DNH\_)
MEX-^?(CLJKQ&UL#UKU]G=Q8["9S,X&JWQE&'W@Q;Y),+3S58H)'B:`[Z]T5#
MX5?S%/F-E_EO'\$/YEGQCZV^.7R![!Z5J/D1T!N3I'L#^_?4W8>Q=N9"GP78
MFP\AD<UEJC(4G;&P\I,E3/24+UL4V-=Z@K#!#!55ONO=7?*1;C\#^@'^\#Z6
M]^Z]U[4O]?J0!P>20"+<<\'W[KW7B0;CU`6_5:PY%_R/P/?NO=$DV3\NLMLG
MXO9;Y(_/GK/#_`\[<W%N'%[GV?N[M?:_:U+BL1#O&3:VP,M3[NV)0K09O+=E
MP344]#AZ*GFR2U-;'1!):@6/NO=';U?7AN#;@$F_^L/?NO=$K^>GR<W'\7>C
M,=N3K?![9W=W=VEVWU)\?^@]D;NJ<M!@MU=L]P[VQNV,6N6@V^PW-7;?V=MM
M\IN;-1XQ9:],%@JV:*-S$5]^Z]T$7P`^;N^/E_V?_,,V+O#9FT]I4/PW^:^^
M_B_LRLVU4YB>KW;M?:6%PV5H]R;F7*5$\,6>JCDR)$I5BIP%]*\:C[KW5F*N
MKBXO:Y'T/U'!`_KS_O/OW7NJA_Y[AO\`RN>_3_7?OQ,^OU_[+)^/_P!1^#[]
MU[JWKW[KW7O?NO=>]^Z]T5CYO_\`9(GR)_\`$5;J_P#<!O?NO=?_T]P7H;_L
MN+YX_P#4%\9?_?;93W[KW1\_?NO=:OOR]_X4>_R2JJL^17PM^4<?:6_\-B-R
M=B=!]U["RG1.:W!M3,9#9VXLGM'=%!3UL>2A:>&CSF'>6AR%,T-1!-%%54\D
M4R1NONO=%2_DZ?-S_A-?U#\I,#TU_+9ZI[3V+\A?DY64W7.,W-OC9W:NZ,C4
M4U%35^X/[N4V]^SMZ;PK=F;=KWQOGK8:%J>&NGIZ<U`D,$)C]U[K<O'`'OW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KH_0_ZQ_P!Z]^Z]T5?H#_F;GS(_\3OM
M;_X'WIKW[KW1J??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW50O\_*W_#-_P#,*N+_`/./>>_PY_B^%L?]@>??ORKUHBO0)2_`
M;Y"_)7JWXO\`8FP/FSO[HS:</Q,^.VWZ'KW;=-O1<=2UF/ZWP\^2S!FVWV7M
M"CJ*C+RU:EB]*TBB(#R%;!<?O<WVBYQYXYC_`'QLWNE=[18"!(Q!$)2M5+$M
M6.>($L6)J5+$4!-`H&>?W<_O8>T'LG[>R<G\W?=DVGFG?GW":X>_N'LS(R.L
M:QPTN=NNV58@AIID"G43I!)))G\Q?Y6WR^V+T^V=I/DIW3\OIANS;U%_HAH-
MO=CY^<I4&N#;I^PK^QMZP&/`%;ES1%D\W$B7YQY]S?8'W*VWE?ZB/G[=>8CX
MZCZ-8KF0Y#GQ-)GF^$BE='%N(\\\/NX_?K^[QS5[D_NN;V7Y:]NXOH+A_P![
M23[=`M5T?XJ)(]NLFK/6E/&H=&4-,$C^-/\`+X^9>[>\=@[=J.ON^OC?#DZS
M,1OW95]=[WP]/L/[?;6:K%K),E156UJJE_B[4XQH*U]/J:L"EF#%&B/V_P#9
M;W.ON;=GM'VK=]C5V?\`QXVMP@@I$YJ6_2IKIX?]HOQ^?#K*'WK^]Y]W#E_V
MPYKWF+F_E3G26&.$C94O[*5K[5<PIH$;K<JWA:OJ"#!)3P=0`(#+</)_*"^6
MK1LI_F;=N692MC'VL`+BUN.];C_8<^\GU^[C[C`@GWZW+_>;C_MLZYT?\G$/
MN^8(^X_R_C/':_\`O2=5>_S.^J=FTW\X/X&[1^?7SI[V^*_QQQ'\LC=&R]B?
M*?8/:VW.AHMY?*';V],G0]RX^O[2W$<S)UG5]A=>5&+K<E,6-3DIH\?CH9W\
M]01E=L-C=[9L>S[;N&X&[O[>UBBDG((,SI&JO*02Q!D8%SW')XGKEMSCN^U<
MP<W\U;]L.PIM6QWVY7-Q;V2'4EI#-,\D5LK:4#+`C+&"$6H7X1PZ`//[_P#D
M#V;_`"@\3\@]S[_['^6?QO\`Y8?\\#KKN#H?O/)XC(;I[J^07\OCXN=@?W33
MLILM14J3[LSN!GWADI9\YF(\7`,+AYY)YK0J\AMT'.K4:OY)=&?S)?YZ_P#+
M;W=\->RMO=Z]9_`_XT_+SN'O/M;8KU>YNM\)4_*79.%ZBZTZUBW1B:2JQV'[
M4GJL9-DJK&9)J)UQL,L:LU7!/3Q^Z]T,?_"D'.T^T_AI\:MXY3*_W>VQL_\`
MF2?"G<>\]SU-5+C\+MC:6/W[E?XOG-SY92E'B-O4:R()ZFI>.G5G52VID!]U
M[HJF^>W^O.U/YV7\RRNZM[0VCV+@=N_R#\UA\K6["WGBMU87"[G3L>NSLF.J
MZK`9"MQ]'G(L#G\?5E-0F2FK87-ED6_NO=5K=$=(]?\`17PX_P"$P_S%ZI.\
M=H?);N'YV_&3X^]G=M0=E]A9+.[UZ.[=SG;DN_>H,S29K<V2PC]>90X]8:?$
MQ4L='CH9ZA*5(355!D]U[H(MZ]?;&[!_X2V[8WQV'@X=TU'67\Q7=F7Q^=SE
M7EZFCVCA\_\`-K);3WEFZMHZU*&GII=E9&JH9JRK5_MJ.KF6-X_,Q/NO='%_
MF=]!?`_;6:V]NGX@;T^$GR&^,?PT^-.]L_W5_*Z3Y%P=;/A=K=N;IR>_MQ?+
M;XE=A[9WF,7B_E7_`'8P,XCDJI:V:FQF.HA1TYJLE1QU'NO=6Y;;WAL7YY?,
MW^5+@-A9+L3+]'?&/X@+_,6W'@^U<?5G>U9N_M7:F/Z-^';=L5<N2J,?-V%C
M:"LWON6KC,35U/EL31U<4K4U5+K]U[JD+#;Y['PG<_\`-5V-V#N7=/2_\M/L
MS^=3W7M/Y_?)3J"OR,W;.R-IY':.QZ+977FYI\>E#D>E_CSVIN2:/$;P[!Q<
MN2R&/I*C[&2+&4U3)D']U[J5_,N^&61[8^:ORR^(W6705!\SSV?\#>B\Q_*Q
MZNZF^3^&Z\VK_+>V9M>CV)UEO+M'+=?;EW9LS:F+VQV-V!X,]#78(Y[)YZ@Q
M4U'41?99&LGI?=>ZNX_F.])R?'#^0E3=$5=!L_&Y?JK;?P-V;N>GZ^HI<=L>
M3>>)^4OQOBWO7[2H)Z:BEH]OY7=QK:JEB:"`I#,H\<=M`]U[K8']^Z]U[W[K
MW7O?NO=%8^;_`/V2)\B?_$5;J_\`<!O?NO=?_]3<%Z&_[+B^>/\`U!?&7_WV
MV4]^Z]T?/W[KW6O=_P`*(MP=!S_R@OGWC\/G.GYNP?[C[?A-#CLGLI]X_P`:
MA[BV$,K#]M3SG-?Q6)HY_.NGS!E?5R#[]U[HV_\`*9W!T(_\O#^7-C:+-].O
MV&/A7\68'H,?D]CMO$9R+HK90KX7I:2<YG^,QR)(*A2OW`D#^3U:O?NO=6M>
M_=>Z][]U[JFKY!_.'NK>/\POKKX$?$C=O3^QJ3J*+9/:_P`^NZNW\++N.CV-
ML[>];C,KTU\=>IL;!NO`8RL[U[[PN.RDTL63,;XK;>G)42U,HTI[KW5N.Y=Q
M87:.WL_NW<V0BQ.W=JX7+;BW#E9EF>#%X3!T%1D\MD9D@CFF>*DH*221Q&C.
M54@`FP]^Z]UJ.Q?S./YM]!\>,#_.IS^1Z)@_ER9[N2AI\A\%_P"YM.O8FV/B
M)FMY+U+B^^9/D-'CI-PU^_?XZ\.;?&BD:@DIZ@.(D4_P^'W7NMO'"97'YW%8
M[.8BJ2NQ.9H*+*XNNC\GCK<;D::.MH:N,2I'($J*6='`90POR/?NO=.9/!')
MX_'^^_Q]^Z]T5GH$$=N?,@D$?\9WVM]01S_LOG3#6Y`OZ6!_UB/?NO=&H]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5"_P`_
M*_\`PSA_,*M_WCWGOI_09;"D_P"\>_=>Z/=\/K'XD_%L\$?[+ITE8_\`E--L
M^_=>Z,9[]U[KWOW7NO6']/?NO=!IVITUU'WGM>39'=/5?6W<&RYJJFK9]G]I
M[&VOV!M>:LHIXZFCJY<!NW%9C%/4TM1$LD<AAUHZAE((!]^Z]T_;<V'LC9^R
ML5UQM/9FU-K]>X+`0[5PNP]N;=P^$V7A]L4])_#X-N8K:V-I*?!X_`P4'[*4
M<4"4ZP^@(%X]^Z]TC.G?CYT/\>L1E]O]"=)=0]'X#/Y-,SF\'T_UILOK/#9C
M+QTL5%'E,KC=EX7"T>1R24<"0B>9'E$2*H;2`![KW2WWOL?9G96T\]L/L39^
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M9TS-M/:NXLM)'-E,_MK;S[,;$X+-9*:)6J*JEABGF907<D`^_=>Z,;BMA;*P
M.Y]S[VP.S-J83>F]Z+;6.WKO#$[<PV-W1N^@V9!D:7:%#NC/45)#E<_1[5I,
MQ5Q8V*KEFCH8ZJ980BR.&]U[I.XWI/I["T?96.PO4G6.)Q_<^4S6<[AQ^-V'
MM2@H>V<WN3'#$[CS'9E-2XJ.'?F4S^+_`,FK:C*+5355/^W*S)Q[]U[K5&^2
MW\FOY)/\AOEGN"B^%O3?S/V[VPF,Q7P#[<B^8&[/BD/Y:>R<;MFMV_M3KW9_
M4.W]OQXW;.W>L]Q5D&9I7V,1)DXZ'5,J5,WAC]U[H]_\P+J;NGHG^0+%T[\B
MNV).].\>NL?\*-K=F=LR5>8R3[WW3COF!\?XZS)_Q;<*1;@S@B4I3K7UZ1UU
M>(143HDLKJ/=>ZV'??NO=>]^Z]U[W[KW16/F_P#]DB?(G_Q%6ZO_`'`;W[KW
M7__5W!>AO^RXOGC_`-07QE_]]ME/?NO='S]^Z]UKT=M?\)>?Y0W=O:O9G<V_
M^HNT*_?G;G8.\^S][9"A[S[%QE'6[NW]N3);KW)64>-H\M'1X^EJ,SEIGC@B
M58XD8*H``]^Z]TM?C)_PFZ_E6?$3OGK/Y)=)]5]D87M;J/<!W/LG+9CN??VX
M<;0Y<X^NQAFJ\+E,I-C\A']ID)1HE1EU$'ZCW[KW5\7OW7NO>_=>Z^?%\S?C
M[\)>@_EO_./@_F8?$GY"]B=\?)SLC+]H_P`MCM_KG:W?V]]M=C#>77F1.T=J
M]4Y+8T6&VGB.S.J.P<SBZ++G*SRI#/504D"_:TZO6>Z]UM$?%CL+<6/^+WQ-
M_EL_,S?V_P"H^=O?'P-S.3WOFLCM;=F[V@ACVE4[8W=7;O["?#TNUVWWM;^*
MI!54N0K$JZZMIG/DGUB>3W7NM;R?NOLK=?\`*HV[_P`)S7^,G>M#_,57>V!^
M*>Z=I'8V2/7NWNE]N=L47;$WRD3MV1X^N*W8=3USCJ>K33D@))YKH&H_'52>
MZ]UO9;,V['M':6U]J15;UZ;8VY@MNI7RQ+!+6IA,72XQ*N2%'D6%Z@4VLH&8
M*6L"??NO=`WWG\7>K/D-5[;KNQ?[YB?:E-EJ;$_W4WWNC9L9BS$N/FK/OHMN
MY&@3(.),9%XVF#F(:@M@S7]U[HB'4?P(^/VZ.PODE@<F.SQ0=?\`:^"VUM_[
M/MW?]#4_PNNZ?ZSW34?Q.JI,W#49>L.8W!5%9ZAI)5@,<0;1&H]^Z]T/7_#:
M7QD_[^__`.CP[._^R/W[KW7O^&TOC)_W]_\`]'AV=_\`9'[]U[KW_#:7QD_[
M^_\`^CP[._\`LC]^Z]U[_AM+XR?]_?\`_1X=G?\`V1^_=>Z]_P`-I?&3_O[_
M`/Z/#L[_`.R/W[KW7O\`AM+XR?\`?W__`$>'9W_V1^_=>Z]_PVE\9/\`O[__
M`*/#L[_[(_?NO=>_X;2^,G_?W_\`T>'9W_V1^_=>Z]_PVE\9/^_O_P#H\.SO
M_LC]^Z]U[_AM+XR?]_?_`/1X=G?_`&1^_=>Z]_PVE\9/^_O_`/H\.SO_`+(_
M?NO=>_X;2^,G_?W_`/T>'9W_`-D?OW7NO?\`#:7QD_[^_P#^CP[._P#LC]^Z
M]U[_`(;2^,G_`']__P!'AV=_]D?OW7NO?\-I?&3_`+^__P"CP[._^R/W[KW7
MO^&TOC)_W]__`-'AV=_]D?OW7NO?\-I?&3_O[_\`Z/#L[_[(_?NO=>_X;2^,
MG_?W_P#T>'9W_P!D?OW7NO?\-I?&3_O[_P#Z/#L[_P"R/W[KW7O^&TOC)_W]
M_P#]'AV=_P#9'[]U[KW_``VE\9/^_O\`_H\.SO\`[(_?NO=>_P"&TOC)_P!_
M?_\`1X=G?_9'[]U[KW_#:7QD_P"_O_\`H\.SO_LC]^Z]U[_AM+XR?]_?_P#1
MX=G?_9'[]U[KW_#:7QD_[^__`.CP[._^R/W[KW7O^&TOC)_W]_\`]'AV=_\`
M9'[]U[KW_#:7QD_[^_\`^CP[._\`LC]^Z]U[_AM+XR?]_?\`_1X=G?\`V1^_
M=>Z]_P`-I?&3_O[_`/Z/#L[_`.R/W[KW7O\`AM+XR?\`?W__`$>'9W_V1^_=
M>Z]_PVE\9/\`O[__`*/#L[_[(_?NO=>_X;2^,G_?W_\`T>'9W_V1^_=>Z]_P
MVE\9/^_O_P#H\.SO_LC]^Z]U[_AM+XR?]_?_`/1X=G?_`&1^_=>Z]_PVE\9/
M^_O_`/H\.SO_`+(_?NO=>_X;2^,G_?W_`/T>'9W_`-D?OW7NO?\`#:7QD_[^
M_P#^CP[._P#LC]^Z]U[_`(;2^,G_`']__P!'AV=_]D?OW7NO?\-I?&3_`+^_
M_P"CP[._^R/W[KW7O^&TOC)_W]__`-'AV=_]D?OW7NO?\-I?&3_O[_\`Z/#L
M[_[(_?NO=>_X;2^,G_?W_P#T>'9W_P!D?OW7NJM_YV/P-Z"ZS_E0?.W?.V/]
M)O\`'=N=$9K(8W^+]M;^SF-^YBR^%*?=XK*9NJH*V&_U22-E(]^Z]U=Y\/A_
MSB5\7/\`'XZ=)?@#_FF>V../?NO=&+]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5/?\^RB@R?\`
M*J^1V,JO)]KE-V_%G&5?AE>"?[7(?+[H2CJ?!41%9:>;P3MHD4AD:S#D#W[K
MW1Z.F/B/U!T+NS)[TV!_?K^-Y?"56WZS^\W8F[]VX_\`AU9D<?E)O!C,_E:Z
MBIJK[K&1:9D02*FI0=+,#[KW1G/?NO=>]^Z]T5CYO_\`9(GR)_\`$5;J_P#<
M!O?NO=?_UMP7H;_LN+YX_P#4%\9?_?;93W[KW1\_?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71^A_UC_O7OW7NBK]`?\S<^9'_B=]K?
M_`^]->_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZJ%_GY?]N;_YA7_BO>>_]V^%]^Z]T&5+_-J^*_PSZB^+?3':E#VK
MF-ZQ_$WX];KK8]B;/Q68QF-QV>ZYQ$>+AJZ_,[GV[KK*B/'/)I@2:-$(#.'N
MHFWV_P#8#GOW(V!^9=BEL(MK$[1`W$KH69-.J@2.3%6`&H@D@T!`KU!_N']X
M#D;VTWU>7=]@W"7<C")"+>)'55;(!+RQYI1C0$`$5-:@-3?\*&/@HP*C:_R-
M4V!N.N]H7TW'_?R>-0_W@W]CEON@>ZH#4N]G:@R/'F\Z@5_Q<#-/7H`G[XWM
M2/CL-ZI_S0@_[:NB_P#QW_X40=5S;:W0?E#U[O7$;N;?&?J=HQ=0;8QF>P*=
M>UDL=1MO&Y:IW!O+#5LNYL,K24]3.L*15:(DH2-BZ@6<V_<[Y@2]L1R+N]M)
MM_TR"7ZN1D?ZA125HUCB<")\.JEBR'4M2`#T$.3?OE<NO87IYWVFZCW#ZF0Q
M"TBC:,0-0HKF2>-C(F59M(5AI.#7HP:?\*%O@C*\<<FW?D321R21I)5R]=;5
M,-+&[JKU,P@[$GJ##`A+OHCD?2#I5C8$(/\`=#]U%1F%YL[D"ND7$P+?($VZ
MJ">&6`]2!T,8_OB^T\DBQ-:[PH8TJ8(*"OF=-R6Q\@3Z`]#M\M?YF.ZOCQU=
M!WOU%\)?D+\J^A,7\>\5\HM^]U;#SG5'7FR=I=.Y2@S&;^XQE+VCO+`;UWKO
M;"[6PTF8RN#H</YL=C)Z:624M,T<>-6Z;7?;)NFY[-ND1CW.TN9(94JK!)(F
M*.H9:JP5E(U*2&X@GK)O9]TLM[VG:]ZVR<2;9=V\<T+492T<J!T8JP#`LK`E
M2`P."`>DGVI_.!V1M[>OP!V1T3\<^Z?E#D_YD'1?8/>WQ]I]AY#8.QZY,!L[
MKO;?8N'I]XTW:VY=GXW;--G,7N:F%965-<JXF)99&CG*")T/1CTA/C[_`#V_
MC;V9T9\[NW>\>M^T?BSN7^7%NS^Y?RCZD[`.VMT;GP6>R-7G,-M+#[,SVU,G
M+M'?&=WCNO;%?A:&BIJM)3DH44GP5%-42^Z]T-'QP_F@MVSW_L7X\=[?%WM#
MXB;P[ZZ]W3VE\59NS>P>G-Z0][[3V)#C,IOO#M1]8[SW/D.M>SMJ;8W)BLK5
M[9S2)DDI*FH)L:*4'W7NB.[&_P"%$^VMS?'GH'Y@;C^`7RSVE\3^[>U<YT=/
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MB2AKZ:<-&Q"DGW7NJS^R/YPG8N`^2WS-Z&Z>_EW?(3Y);=^!%=UA_LQ?8G4_
M9'2L.:QF"[/Z\I^S,=D=A=0[PW-M_?G9F8I]M19`IBL0E35U-1C_`!+H:>(-
M[KW1:\S_`#PN\NVOFG\5NJ/@S\/,M\GOCYWW\-]Q_*W`9JE[<Z/ZWWSVAC9L
M[A-I%L3)V#OFBP?76.Z3W3!E<+N3%Y>1,_D,^CQT\$=%0-/7^Z]T<["?S;\=
MOWYI=B_%+J'XJ]U=N[0Z)[HZ[^/WR+[UVAN3K(1]-=D]E::3%Y'*](93<]'W
M5G.G\%FZVFI,KO2EQ7\"IECK*F.2:GHS)+[KW4_^>R"/Y7'?@)O_`+_WXF<_
MU_YS)^/_`#_L??NO=6^>_=>Z][]U[KWOW7NBL?-__LD3Y$_^(JW5_P"X#>_=
M>Z__U]P7H;_LN+YX_P#4%\9?_?;93W[KW1\_?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW71^A_UC_O7OW7NBK]`?\S<^9'_B=]K?_`^]
M->_=>Z-3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZJ%_GY?]N;_YA7_BO>>_]V^%]^Z]T.72_P`5OC9WQ\7_`(FYWN;HKJOL
M[-XOXV=+TF/S.]=D8#/Y6EI)NM=HM)2ID:^BEK#3:J9"$9RJD<`7-Q3R_P`\
M<Y\J0SV_+7--]8V\M"ZPS.BL1P.D'2#\P*]!/?\`D3DSFJ:*YYCY7L;VYC%%
M>:%'<`^6HC53&!6@\ND%\@OY0/PF[PZ_.R-N]4[2Z&R)SF+S']_.FME[+P&\
MA!CON/-A1D*[!9&'^$Y3SC[E/'=_&O(M[D?E#[PGN7ROO`W2[W^XW6$1,G@7
M<\[PU:E'TK(O<M#IS3)QU'/-_P!WCVRYIV=MIM^7[;;',BMXUI#"DM%#=FHH
MU%):II0X&:5!+KTG_(-^*/4'9&`W[EMX;][@Q>(7)Q9#KKM7!]9[BV/N*#(X
MRJH43*T`V3!51S8ZJGCJZ>>FFAGCG@4:_&TB.,.:?O6<]\R[-<[5#MMIMURY
M!6YM9+F*>.C`G2WC$$,`5*L"*,2`&H0"N5?NE^WO+.]6N[2WESN$$88-;W26
M\D,FI2O<IBJ"I(8%2#514TJ"?Z/^73\#J62&IA^(7QZCGIIH:B&4=7;4U)/!
M*DL4@OC^621`1?\`(Y]Q-)[O^Z<L;PO[@[N8V4@CZJ7@<4^+J7T]GO:R-E9?
M;_:0PX?XM'_T#U4M_-;_`)8OR\^;??V'Q&PO]#>\_AE5_![M/H+;/378_='9
MW3>S^@/E%NS(Y/\`N[\JJCK?J[86XL/WU'M#:D.*QV&VSFF_AE#54AJHA231
MQSO'DLLL\LD\\K/,[%F9B69F)J222222222223GJ0X(8;:&*WMXE2!%"JJ@*
MJJ!0*H````%``*`8'39\5/Y:OS9V3W#_`"/.Q^ZJ'H;$4/\`+@^,OR-^.?;>
M/Z][`W/N&:JQ&Y>DMG]0]19K;DF9V;A_[T9K/U.U7R.<4#'4N,6L6"`U1@:6
M9OIWH"\5_(:[O[3QW_"@#KSN[=G7>S]G?S.._=C]R?&O<^U\WE-V5NW:WK3M
M/MGM79M7VGMN3!8)J&C&?S>`^^H:2JK&FIVJXU>\:&7W7NC,_!W^75V]TU\@
M.B]^;H_EE?RD_B_DNI7W.>QODM\;:O.;A[.[*?(]:[QV-IZ0V%4=*;#?H8;N
MSV>IZVODR.Y-P/3X#[O%JLDE2*B/W7NB[;3_`)-_S!PO\DWX??`&MJ.GO]/G
M2'S2VSW[OB6#?.6?81V/BOE/V)W)5QX/<AVBE?D\W_=;<]*B0/04Z&JUIK`4
M,WNO=*W^;1_*+^6GS4^17S4[1Z9J>IH=K]__`,K3K/X=;%&\MZY7`Y6/MS:/
MS9V+W]EI<Y1T>U,U'0;2;K_`50BK4EEE>O$<)@"N9D]U[HX'?'PC^6W7?S)^
M/7\Q3X;4O2/8G;FR_AS%\(OD%T)W?O3='7VW>RNJ(=XX7L;;^3ZS[7V[M#?`
MV)N_:^_XJBIJ)JW`UT.2QRB`(CMJ7W7NK3?C[F?D+N'KBCS7R;V+U?UEVED,
MMEYIMA=1[[SW9VUML;>6L,.WL=4=@[CVCL*IW1GIZ2+[BKJ(<-CJ:-YA#%&W
MB::3W7NM9?IC/?/2F_FW?\*`]I_!SJCX];LSN]M\?!O";A[3[^[?W1LO#=+9
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MH;:V5?=>ZV`/?NO=>]^Z]U[W[KW16/F__P!DB?(G_P`15NK_`-P&]^Z]U__0
MW!>AO^RXOGC_`-07QE_]]ME/?NO='S]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=='Z'_6/^]>_=>Z*OT!_S-SYD?^)WVM_\#[TU[]U[
MHU/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J
MM_\`F^=&=J_)C^6=\R^A>C]IR[Z[:[1Z:RVU]A[0ARV!P4N?SM3DL7/#0)E]
MT93";?H&>*G<^2JJX(AIL6!(]^Z]T7#H[Y??.7JSI3I_K'+?R;?F3D,KUSU;
MU_L3)5^.[T_E_MCZ[(;0VEB-OUE90M4?+.FJ&HZFIQ[/$9(XWT,-2J;@>Z]T
M*7^S]?-7_O3#\U?_`$>7\OG_`.ZY]^Z]U[_9^OFK_P!Z8?FK_P"CR_E\_P#W
M7/OW7NO'Y\_-0\'^3!\U2#P0>\OY?'/_`+-S[]U[KK_9^?FI_P!Z8/FIQP/^
M,Y?R^/\`[KGW[KW7O]GX^:G_`'I@^:G]/^9Y?R^/_NN?\/?NO=>_V?GYJ?\`
M>F#YJ<?3_C.7\OC\?3_N;GW[KW7?^S\_-3_O3!\U?_1Y?R^/_NN??NO==?[/
MQ\U/I_PS!\U+?T_TY?R^/_NN??NO=>_V?GYJ'Z_R8/FH?_*Y?R^/_NN??NO=
M>_V?CYI_]Z8/FI];_P#,\?Y?'U_K_P!E<_7W[KW7C\^/FH18_P`F#YJ?X?\`
M&<OY?!MQ;B_RY_H??NO=%\ZP[2[AZ;[F^1'R!ZZ_D6?-?`=M?*W*=>9KOC=+
M?)7X0Y5=[Y+JG:]5LO8=0N$S/S3R&`VU_`]MUDM/HQ5+0I4ZO).)9`''NO=&
M#_V?GYJ?]Z8/FI_7_F>7\OC_`.ZY]^Z]U[_9^?FI]/\`AF#YJ<_7_C.7\OCG
M\_\`>7/]??NO=$T^?W97SV^;OQ9WI\8]J_RE_E/UMF.QM[]#5J[YWYW;\&9]
MI;:QO7OR!ZN[.SV1S5/M3Y0;@W%-`F!V94K&E'15$SS.@"6)(]U[K8I]^Z]U
M[W[KW7O?NO=%8^;_`/V2)\B?_$5;J_\`<!O?NO=?_]'<%Z&_[+B^>/\`U!?&
M7_WVV4]^Z]T?/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]UT?H?]8_[U[]U[HJ_0'_,W/F1_XG?:W_P/O37OW7NC4^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HK'S?_P"R1/D3_P"(JW5_[@-[
M]U[K_]+<%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW7O?NO=>]^Z]U[W[KW7O
M?NO==$@"Y^GOW7NO`@WL?H;'W[KW76I3^?S;_8^_=>ZY>_=>ZZ/T/^L?]Z]^
MZ]T5?H#_`)FY\R/_`!.^UO\`X'WIKW[KW1J??NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T5CYO\`_9(GR)_\15NK_P!P&]^Z]U__T]P7
MH;_LN+YX_P#4%\9?_?;93W[KW1\_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U19_/;
M_FN9O^6O\5-\5?16`7?_`,J,SLN7<FV\31KB,QC^CNNZC=6WNOJCY&=L8:M6
MK--L#&;\W?BL%B8JB#QYW<>1@HXSXXJR2#W7NKHZG=F*VYL>;>^Z\C2XK"87
M:<NZ]S9BIU1TF,Q.,P[9?-9.H$22,E+14D,LK!02%4V!]^Z]UJ9T_P#-0_FS
MT?0^!_G+YS$=`T_\L_/]U46,K?AT=OU:=T;7^)V7W>.IL9\A*CO-:!A5[K&Y
M_%F9,;]L<?)13C2(T80P^Z]UMUXC+8_/8S'YG$545=BLM0464QM;"6,-;C\C
M31UE%5PZE5C#4TTRNI(!L?I[]U[IP/T/^L?]Z]^Z]T5?H#_F;GS(_P#$[[6_
M^!]Z:]^Z]T:GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=%8^;__`&2)\B?_`!%6ZO\`W`;W[KW7_]3<%Z&_[+B^>/\`U!?&7_WVV4]^
MZ]T?/W[KW7O?NO=>]^Z]U[W[KW7O?NO=:,/\^;^53\J>G?B=_-`^<V5_F*;@
M[0Q??V;Z-R?;'0%/\2>KMOG>>RMN]W=8;-Z9ZPI^UJ7=.X=_;?V?TU1UU#64
MT..CIX,E6XZ6JJX345M5.WNO=;-N!WOM7;VS.J?Y9'>OR2W3VK\N.[_B5V!6
MIV?7]/5^WWW]MVDPE?M3=78V2I]JT4O6&U\EBI<NFC#29:":I\2^,-J+^_=>
MZU39?D+N7=W\IC;W_"<\=`=UT7\S)MX8#XF;GZI;8N:;;VW.JMM]OTG:4_RD
M;L^6"GZNK>N)NML=#7IIS2JSSZUD;'B.OD]U[K>\V7MS^Y^T-K;36K:O3:^V
M\%MV.N:%:=JU,)BJ7&"K:G6280/4BEUE-;!-5@QM?W[KW2'[-ZBH^SJC#U%;
MOWMS9?\`!HJ^&-.LNR=P;"I\@*^2DD,F8@PE1$N4GIOM`(&E!,(DD"_K/OW7
MNB6=-_&S&9?LKY08^3MOY)8U-N]O[=QE-78SO#>N-KL[#/TKU;E&R&?K8)XY
M<]E()Z]Z5*F8N\='!!3@Z81[]U[HPO\`LIN&_P"?Z?*O_P!*)W__`/5GOW7N
MO?[*;AO^?Z?*O_THG?\`_P#5GOW7NO?[*;AO^?Z?*O\`]*)W_P#_`%9[]U[K
MW^RFX;_G^GRK_P#2B=__`/U9[]U[KW^RFX;_`)_I\J__`$HG?_\`]6>_=>ZX
MM\3\*MB>]/E9S<<?(C?Q_!^MZT6_XK[]U[HK'QQZJSW9N[?DYA=W=Z_*`T/5
MG?F<Z^V8:3O/?.-8;5H<)A:^E6KG2I#9.J%36RZIS<L"%_'OW7NC4_[*;AO^
M?Z?*O_THG?\`_P#5GOW7NO?[*;AO^?Z?*O\`]*)W_P#_`%9[]U[KW^RFX;_G
M^GRK_P#2B=__`/U9[]U[KW^RFX;_`)_I\J__`$HG?_\`]6>_=>Z]_LIN&_Y_
MI\J__2B=_P#_`-6>_=>Z]_LIN&_Y_G\J_P#THG?_`/\`5OOW7NBL?$KJK/=Q
M[,['SF^^]?D\<AMKO?MG8&'^R[TWUB4&U]HY]*#`++%#4QBJJDHS:2H(O*UR
M?Z#W7NC3_P"RFX;_`)_I\J__`$HG?_\`]6>_=>Z]_LIN&_Y_I\J__2B=_P#_
M`-6>_=>Z]_LIN&_Y_I\J_P#THG?_`/\`5GOW7NO?[*;AO^?Z?*O_`-*)W_\`
M_5GOW7NO?[*;AO\`G^GRK_\`2B=__P#U9[]U[KW^RG88?7O3Y5_T_P"RB-_'
MZ\?FMM?GW[KW0'_'OHNJ[)Z^KMQ[I[S^4O\`%*;LSN3:L7V_?>^Z"/\`@VR>
MV-Y;0VZ#!'5(&F7`86F$DI%ZB0-+_;]^Z]T.'^RFX;_G^GRK_P#2B=__`/U9
M[]U[KW^RFX;_`)_I\J__`$HG?_\`]6>_=>Z]_LIN&_Y_I\J__2B=_P#_`-6>
M_=>Z]_LIN&_Y_I\J_P#THG?_`/\`5GOW7NO?[*;AO^?Z?*O_`-*)W_\`_5GO
MW7NNC\3\,K+?O/Y5D$VM_LQ&_C>_^!K!<?ZQ]^Z]T5KX:]4YONWH/;G8787>
MORA.ZLGN+?V-K/L>\]]8>F^TV]OG<&"Q6G'Q5:+`PQ=!"';ZR."W]JWOW7NC
M3?[*;AO^?Z?*O_THG?\`_P#5GOW7NO?[*;AO^?Z?*O\`]*)W_P#_`%9[]U[K
MW^RFX;_G^GRK_P#2B=__`/U9[]U[KW^RFX;_`)_I\J__`$HG?_\`]6>_=>Z]
M_LIN&_Y_I\J__2B=_P#_`-6>_=>Z3^[?C!087:NYLS1=Y_*DUN)V]FLG1A_D
M+OZ5/NJ#&U-53ZHC5D2+YHA=2""./?NO=`K\2NF<IW%\<.H>S-^=[?*!MX[Q
MVE#E]P&A[WWWAZ1J]ZVLIV:GQD=4JT<>B`60`#_7]^Z]T8K_`&4W#?\`/]/E
M7_Z43O\`_P#JSW[KW7O]E-PW_/\`3Y5_^E$[_P#_`*L]^Z]U[_93<-_S_3Y5
M_P#I1.__`/ZL]^Z]U[_93<-_S_3Y5_\`I1.__P#ZL]^Z]U[_`&4W#?\`/]/E
M7_Z43O\`_P#JSW[KW3)N;XNX[$[;W!E*3O/Y4FKQN#RU?2ZOD+O^5?N:.@J*
MF#5&:LB1?+&+@@@_3W[KW2'Z,^/C=@=*=0[[W+WG\IAN+>?6.Q-TY_[?O_?M
M#3_QK/[7Q>4RG@HDJU2DA-=5/HB`_;6R_CW[KW0I_P"RFX;_`)_I\J__`$HG
M?_\`]6>_=>Z]_LIN&_Y_I\J__2B=_P#_`-6>_=>Z]_LIN&_Y_I\J_P#THG?_
M`/\`5GOW7NO?[*;AO^?Z?*O_`-*)W_\`_5GOW7NO?[*;AO\`G^GRK_\`2B=_
M_P#U9[]U[H-.YOCNNQ^H>U=Y;>[V^4PW#M+K;?&YL%]QW]ORNIQF,%MG)Y/&
MO/1/5L*N%:VFCUQV(=;BWOW7NH?1'Q]?L+I+J+?>YN]/E*=R;RZUV3N?<!I^
M_M^T-.<UG-N8[)91J>B2J1*.`UM0Y2("T:V7FU_?NO="O_LIN&_Y_I\J_P#T
MHG?_`/\`5GOW7NO?[*;AO^?Z?*O_`-*)W_\`_5GOW7NO?[*;AO\`G^GRK_\`
M2B=__P#U9[]U[KW^RFX;_G^GRK_]*)W_`/\`U9[]U[KW^RFX;_G^GRK_`/2B
M=_\`_P!6>_=>Z+S\KNE\CU!\=.W^R]C]Z_*)=W;,V?69G`&M[XWWEJ09"&>E
MCB,V.DK&6LCTS&Z$<_X>_=>Z%_97QDHL_L_:>;R'>?RI%?F-L8#*UP3Y![]@
M3[S(XJDK*DK"M6!$OFF-E%@/I;CW[KW2G_V4W#?\_P!/E7_Z43O_`/\`JSW[
MKW7O]E-PW_/]/E7_`.E$[_\`_JSW[KW7O]E-PW_/]/E7_P"E$[__`/JSW[KW
M0@];](4'6N;J\Y2]D=U;PDJ\7+BFQO9':NY]\X2!):JDJS6TF)S=1+2TV41J
M,(E0H\BQ22(.'/OW7NAL]^Z]U[W[KW16/F__`-DB?(G_`,15NK_W`;W[KW7_
MU=P7H;_LN+YX_P#4%\9?_?;93W[KW1\_?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT
M;D<&Q_K[]U[KAXS:VKC^A!XYO<>JX(/OW7NNPI%O5?\`PL;6_P`!?Z_[?W[K
MW7/W[KW71Y!']??NO=>`(^IO_P`1_MR3[]U[KOW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=<675;FUO]Y_XU?W[KW7'QVMS]"+#2+``_0#Z`:3;_#W[KW63W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UQ5;<_4_P"M;\`?Z]N/?NO=<O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UT1<$?U_WW^Q]^Z]UX"U_P#$W_XC^O\`0>_=>Z[]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7%E+6L;6O^.;D<$'ZBW^\^_=>ZXB.QOJYN+\#F
MWT!_J`+V_I?W[KW63W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ"V-R;FUOH
M!Q_O?OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_=>ZZ(O^;<@_Z_^!_P/OW7NO`6
MX_'X_P`!_3W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>ZXLM[$&Q'T-@??NO=<
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7`H22=7YN.!Q]?I_0\FY_Q]^Z]U
MY5L2;@D@#Z`'ZG\_XBW'TX]^Z]US]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=%8^;_\`V2)\B?\`Q%6ZO_<!O?NO=?_6W!>AO^RXOGC_`-07QE_]]ME/?NO=
M'S]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$X_F`?,7
M:GP&^(/=ORNW=A&W72]5;9BK,%LJ',4>!K-][TSN4H-M;)V5096NCGBI*O<N
MZ,O2TH9(:B<*[&*":0+$_NO=5+_&WYW_`,T3HSY7_$SI#^:IL+XST77W\PK;
M6=3HS>W0,>]=HS_'OO/;&U*KL"3X]]V0=AU%12Y[<V[\)50XK%-CIVGFS5))
M'$*F/SR0>Z]UL7#Z#W[KW7?OW7NO>_=>Z][]U[KWOW7N@:^0DG>L?2O8Z_&2
M'KN;O^?;572=4-VW-F(>LZ+=]:\-'09?>PV\KYVJV_A%G>MGIZ2U15+!X492
M^H>Z]U4%\+_F=_,$V?\`S`<U_+B_F(4?QI[0W_NGX[O\H>L^YOB+2[TP>U]I
M;4PVZFV/F]C]N;/WXT^8QV3S>5T5.&KXF@BD5)(],_D5J;W7NKXO?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T"'R/^0G5?Q0Z.[1^1O=VX_P"ZO5/3^T<CO+>>82FF
MKZN/'4"K'!C\3C*=34Y3.YO(5$-'04L7[M56SQ0H-3^_=>Z`#^7CVI\Q.]/C
M]C>[?F5UIUKTENGMNOBWYUCTGL.HW#E]P]5]/YO"XB?9^W>V]SYRM>FW!VA7
M+Y<CD/L:+'P4`K$I)($GAE1/=>Z/=[]U[KWOW7NO>_=>Z][]U[KWOW7NJE/Y
MMGSO[:^&'7/Q_P!F_'C;/7F8^1?S)^1>S/BUTGN?N7,3XCIGK/=V\8:NOEWW
MV8F,ECSF8PV,QN-F2"BHVB>6KEC9V94\$WNO=!U\`_F[\N,K\RN]/Y;'S[@^
M.NX/DIU!T3L+Y+;9[5^*]1NZ/KO>O66^-V5NULM@MY;3WH'S/7F_-FY;(8I*
M>FEDOEL95K6K%''HDG]U[JZ]>0#_`%`^G^M[]U[KOW[KW7O?NO=>]^Z]UTWT
M/U^GX^O^P^GOW7NJIML?,CN/,_SG^U/@551[0'1>S?Y?6R_DUB)HL'5IOM^R
MMP]W?Z/:V*KW$<Q)02[97`!BE(*!914$/YBHTGW7NB3_`,QCY/\`\]#XXR?)
M#Y9=(=0?#6+X3_%@0[LJ>I.P-P;ES7R+[QZ7Z\5\YV_VE0;FPU=0[+Z]@J=O
M4M9/18VH$N3I:"D$B4U95D4T_NO=7C_&WNK$_)+X]=$?(?`X;([<P7?/376/
M<^%V[F)Z.JR^"Q/:&R\+O;'8?*5./DEH)\ABZ/-I!,\#M$\D;%"5L??NO=#7
M[]U[KWOW7NO>_=>Z][]U[JJ?"?,GN'(?SJ=]?`:HCV@.AMN?RX=N?*B@FCP=
M8F_3VAEOD,G6%0DVXSF&H'VLFV0Q%']@)?N2'\^D:#[KW1`>WOFQ_,][+_FX
M_)#X)?$[N?X$=2]>]#;3^-F[:#$_)G:V^:OLKL>'MS8T6Z-UXGK^3:VYE;<V
M6PC8VNF9%HH12T\U/K+#4_OW7NME1.5'U/\`B2"2+\$D`"]O?NO=<O?NO=>]
M^Z]U[W[KW7O?NO=52X_YE=Q5/\['/?`"6/9PZ$QG\L_&?+2"9<)6?W^/:M;\
ME1U/)%+N4YC[`[47:RL?LQC_`"_=$2?<!08S[KW5?&5_F`_S8OE)VG\Y=R?"
M+!?!CI?X^_RZN^^S>BM^[6^7F6[%;N#N[,],X/'[IW9N:6LVI)0;:Z@ZSWCC
MD;^[N9K6\4]%5O522VI90GNO=7%_RZOEU+\\_A3\=/EU-UYF.J*GO'80W36[
M`S-0U;-@<A19G+;<R#8_(R4]%+EMLY:NPLE;AJUH(7K,34TT[1HTA4>Z]T=;
MW[KW7O?NO=>]^Z]T&W<FX>Q-I]2]E[GZAV#3=J]J[?V)NK+];=:5VY:+9E#O
M[?=!A:VIVIM"NW=DDEH-L4.X,Y'!2S5\J.E)%*TI5M-C[KW6OOU1\YOYN_Q9
M^<WP_P#C=_,XV+\3=_=7_/:BW'M+K+?'Q0?=&"R72O=NU,'+O',;.WM2[[S%
M34;NQ%)@`L$M11TZP3--'/35<C034LWNO='W^?GS*[C^-7RH_E;=.]=1[.?:
M'S"^3VZ>H>W&W%@ZS*Y:+:>%V#+N>CDVC74V8QT.%RSU\9#S2PU:&,@!`1<^
MZ]U:U[]U[KWOW7NO>_=>Z][]U[H/>VL]OW:O5O8^YNJ]C0]G=F[>V+NS-==]
M;U.XJ+:-+O[?&,P-?6;4V;5[JR4<V/VU2[ESL,%')7SJ\5&DQE96"6/NO=:]
M77'SG_F^_%+YN_#CH+^9IL+XF;\ZC^>\N9V#UYN_XH/NG"9GHWO#$8J3=<^T
M-Z1;]S%0^\L/1X,>">HHZ<03%_/3U;O3O2U7NO=&:_FJ_P`V1_A'V!\6_COU
M!MA]_=X]_?(_XW[`WMEFQZYW8O075/:7<&!VK-FNT7HJZGJ\/NSMW!4.?H-C
MT<S0??SXO)5ZM)%B9*:H]U[J[P&X_P!B1_MB1_4_T]^Z]UW[]U[KWOW7NO>_
M=>Z][]U[KWOW7NBL?-__`+)$^1/_`(BK=7_N`WOW7NO_U]P7H;_LN+YX_P#4
M%\9?_?;93W[KW1\_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW5//\^KXW]E?*?\`E8_);K+J#`YC=_8N)CZY[6VWLG;V,.7W#OB;IOL[
M:'9M;M#`T*U5+++F<]C=L304PC$\S2L%B@GD*1/[KW56&:^=?2W\['YZ?RB]
ML_#2'>FY<=\4>P\U\U/F!NZ?9&[:/;_QIJ,;UMD,/M'HW?-7N7";2HLCOO?&
M^FJL+'/CJBH2FDI34QP5<'G--[KW6VH#<`_U_P!]^0/?NO==^_=>Z][]U[KW
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M=HX:"&I@W'E\'5Y?'Y6*&JBDHZ!Z`9*8+'0EU]U[HC7\HK)?&*L_FP[Z3^3_
M`-N=Q=F?R_<G\6\AN_YI56]-R]U[XZYF^5>6WY60]8Y/$[F^0N-FWI_I3S>W
M7K:C(FFK%^\HDD9]:Q.J>Z]UM]^_=>Z][]U[KWOW7NO>_=>Z][]U[HGWSNZ2
M^)/>WQ8[<VE\X]L[7W)\:L-MC([Z[$JMSOE<>FSL7LJEFS\N^<+N+;<M-NS:
MV>VS!1O/!78J:*N10T:%ED>-_=>ZU_?^$W7P2V;M?>_RN_F4[;^.V[OBOL#Y
M%5%!TG\1ND]\U^]9]ZXCXO[$?`U-1V/OP[SSF;S.;W7W+NO;]#6RUE=-,X?&
M2R43+0U<;S^Z]UMA`6`'UL+<_P#&^??NO==^_=>Z][]U[KWOW7NNB;`FU_\`
M#Z?[R?I[]U[K7XV#*B_\*=/D`"PU?\,Y]7L%U#457Y3G4P4$DA?(M_\`7']1
M[]U[HM7\[[^9I\-<CVWLG^51V]\K-M]#=5]AP#=_\PCLC"5^XLMNG;W1>,6G
MJJ#XN;6CZ^VIO?-X/MGOW+5F/;)-50TL>-V-'7/-J?(4L;^Z]UL,_%+LSX_=
MP?'3J#?_`,5,U@]P?'/*[*Q>,Z>R6V</DMO[=_N3M/R[/Q>/PN$S&*PF2Q6/
MPW\`>CC@EI8#&L%@H73[]U[HPGOW7NO>_=>Z][]U[KWOW7NM?C:K+_T%!]KI
M=2Y_DG;*(0D:F4?,I0[:;W*H9%O_`*X_K[]U[JG7^>-W+_*9^26<WMC?C!MS
M?VY/YYF!^176W7_3C=1=8]O[3[_V[W)U)O.+9>*R>^,KD]OXS;.5ZIP^W,`6
MIJJBEKC5Q/BZRDU):HB]U[K=IV0NYDV9M)-ZRT\^\TVS@4W=-2>#[2;<ZXJD
M7/RTHI8H*84TF5$I3QHD>FVE0MA[]U[I4>_=>Z][]U[KWOW7NO>_=>ZU],0R
M'_A4=N^+7ID;^1E@#INH?2OSC'D(4FY"^102`0-0Y!M[]U[J@7Y$;;_E=[Y^
M5G\U3)?SMZ?N'JGYEY+Y%=H[.^&VV]H[;[LV?1]A?%;![0IZ+XP[FZFH>H<'
MD]A=S]A[KR.1GDK)-U3YE)*N>AI)H*>G,M$ONO=;:W\G3(_(+)_RQ/A3-\I-
MF3=?=WTG26#P^Z=HU6UZ/9%?B\/@*W)X+KR;*[/H#'2;9R^5ZUQ^(K*NA2"C
M^VJJB1#24;*:6'W7NK+_`'[KW7O?NO=>]^Z]TS;BW!@=IX#-[IW3F\/MG;.V
M\5D,]N'<>X<E18;`X'"8BEEK\KF<UE\E-38_%XK&4-.\U143R)%#$C.[!03[
M]U[K4/\`CW_-<_EO?.'^:Q1=\]Y?*[9U$W2G9M=\4_Y77QSBP/8N6&Y-W]A9
M>FZXWS\I=XU&(Z[R.T_[R]V9Z:EQVPUJLO$,-MIA4UM-2ULXE3W7NK`/YO\`
M(H^?O\@X,50_[/AV``"P!-NGZA>`3<W9P/\`8C^H]^Z]UL$^_=>Z][]U[KWO
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M>]^Z]U[W[KW16/F__P!DB?(G_P`15NK_`-P&]^Z]U__0W!>AO^RXOGC_`-07
MQE_]]ME/?NO='S]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]TS8O;FWL'+7SX7!8?#S92<5.3FQ6,HL?+D:E7E=:BODI((7K)U>
M=R'D+,"[&_)O[KW3S[]U[KWOW7NO>_=>Z][]U[KWOW7NL-13P5<$U+500U--
M41205%/41I-!/!,C1S0S12!HY8I8V*LK`AE)!%C[]U[IMPVW=O[<II*/;V#P
M^!I)9S52TN%QE%BZ:6I:..)JB2"A@@B>=HH44N06*J!>P'OW7NGCW[KW7O?N
MO=>]^Z]U[W[KW7O?NO==:1>]N?Z_GW[KW31AMN[?VY!+2[>P>'P--43&IGIL
M+C*+%T\]042,U$T-##!'+.8XU76P+:5`O8>_=>Z>/?NO=>]^Z]U[W[KW7O?N
MO=0<=E,9EZ1,AB<C092@DDJ88ZW'5=/6TDDU%4S459$E3322PM)25E/)%*H:
M\<J,K692![KW6+)Y##T<,,69K<92T^5JX,-3QY.II8(<E79$M!38J%*IU2LJ
MZ\W1(%U/+R`I]^Z]TY>D7-QSR>?Z?G_>/?NO==W%KWX^M_Q;^M_?NO==:A_4
M?U^H]^Z]U[4O]1Q;\C\BX_VX]^Z]TRXS<VV\W69;'8;<&$RV0P%2M%G:'&96
M@KZS"UCM,B4F6IJ6HEGQM2STT@$<RHY,;"WI-O=>Z>KJ0>1;\\_T^OOW7NF\
M8C$C)29E<9CAF):1:"7++1TPR<E`DAG2BDKQ']T]&DQUB(OH#<@7]^Z]TG*W
MKGKO(UE3D,CL39=?D*N9IZRMK=L8.JK*JH>VJ:IJ9Z&2>>9^+L[%C_7W[KW2
MFQV.QF'HX,;B:&AQ=!3*4I:#'4U/14=.A8N4IZ6F2*&)"S$V50+F_P"??NO=
M)P]B=?A\_&=];.$FU=?]Z(SN;"!]M^*H-)+_`!]37:L/XZM3$WW'CM(-)YX]
M^Z]TP_Z;NF/^?N]8?^A]M3_Z[>_=>Z6F!W+MS=-!_%=L9_";CQGFDIOXC@<K
M0Y>@^XA"F:G^\Q\]13^:(.-2:M2W%Q[]U[IZU+:]Q;ZWN+6_K?W[KW4`8G%#
M)OFAC,>,Q)1+C9,N*.G&3DQRS?<+0/7B/[IJ):C]P1%_&']5K\^_=>ZB#;NW
M1F6W(,'A1N%H/MFSXQE",TU,$\(ISE1#]\81&-`7R:0O%K>_=>Z>A8"PL!]/
M]]_C[]U[KVI>>1Q]>1Q^>?\`8>_=>Z[N/Z^_=>Z][]U[KJX_J/\`;_UY'^W`
M]^Z]TW#$X@9,YL8W'#,M0C&',"CIOXHV-$_W(QYR'C^[-$*@^01:_&']5K\^
M_=>ZPY#;VW\O58VORN#P^4K<+/\`<X>MR.-HJVJQ-2LL,WW&-J:F&6:AG$U+
M&VN)D;5&IO=1;W7NG8!+@BU^;6/^W_/OW7NN7OW7NO>_=>Z][]U[J+6T-%DZ
M.JQV2HZ7(8^NIYJ2MH:VGBJZ.LI:A&BGIJJEG22"HIYXF*NCJ592001[]U[I
M)4W6?6]%4T];1]?[(I*RCFBJ:2KIMJ8&"II:B!UE@GIYXJ!)8)H94#(RD,K`
M$&X]^Z]TIZO$8K(5%!5U^,Q]=58N<U6,J:RCIZJHQU25*&HH)IXWDI)RA(+Q
ME6MQ>WOW7NG#W[KW7O?NO=>]^Z]U[W[KW46MHJ+)4E5C\C24U?05M/-25M%6
MP155)64E3&T-12U5-.KPU%-41.5='4JZD@@CW[KW22INL^MZ*I@K*/K[9%)6
M4L\532U5-M3`P5--4P.LL%1!/%0++#/#*@9'4AE8`@W'OW7NE/D,3BLNE/'E
M<9C\G'1UD&0I(\A1TU:E+7TI8TU=3K4QRK!64Q8F.5;.A)L1[]U[IP]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=%8^;_`/V2)\B?_$5;J_\`<!O?NO=?_]'<
M%Z&_[+B^>/\`U!?&7_WVV4]^Z]T?/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7C_P`2/][]^Z]U\QG^7A\^/GE_*][0^8?S/Q.SMS=\_P`K:#Y^]S]$
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M]-5T])51SQ1>Z]T"'3O_``H7[NRO9W\OJ3Y*?RZ-Y_'?XQ?S(*C9&P/C]WAD
M>U,9N#<^2[;W+3;&QE1-6=44&WGSV,ZJS&\]U&+;F4KI*.IS.WYJ+,^&*"::
M*#W7NBW[*_FB_P`YWL#^<-_,+Z/Z6^'&Q^[]M?&K;6U-A[8^-^X/DSLCIS!=
M<;$RN=_O+M7N+/Y^2JW+MW?':W:6!RU%)DHJ6:1-OP%,?$W[4\M3[KW1*/@Q
M\R?F+\0?EI_PHH[@^/WP2;Y,;OP_RGQG:_R)QDG<FSNM]C=+;3V+5_)O<>_:
M"GW-D8J_<?8^ZJ?-Y6K3&4>)Q,B5>/QE;6/+&_@IZCW7NKN_DA_PH9Z_ZS_E
ME?#_`/F#=/=$9+?>4^:_96+ZAZUZ[["W[B>L-F[#WK2[AW1M[?J=J=IYG'KC
ML'@-K9+9&4IH<FE&:&K:-*EI(*(/.ONO=7,_"ONWM'Y$_&[KKM[N;J/!](=B
M[L@S;YO8&U>U-I=V[.BIL;N+*XO`[HV5VKL>27;.]-G;ZV_1TN:QE53$Z:2O
M2.3]Q']^Z]U7'\TOYNN^.L?F%B_Y=GP-^*&=^;WS5@V6G9O:&TY-\T/4'5'1
MNPYZ3$9?%Y3LCLS/8G(8RDR.XL3F::2FC'BITDR%!"T[5-9#3'W7NB<]A?SF
MN\?D)_+H_F>83K#X]5/2O\R7X.['[<VA\DN@\]V/CZ:GZ6VU3X3>5#7?)#JS
MM#)8"#;G:&%VMMO$5>?PU''`LN7K,>L4*34E50U=9[KW1:?^$[/\M;X^_(K^
M4'O7+?(3XQ1;0S/S7Q^YMD=E=R87NS=&Y>P/E#U)BM^#<N.WOG)(\O(G563H
MNQ*7(8G^&P0QU4T>&6LEDD^\O[]U[JN#Y"_R&_Y='7?\_OX%?R^]L=?]@TWQ
ML[]^+/:?:W9&WJGM7=M9N+(;PVI@?D37X:JQV[9ZHYG$T<53USC"\$+B.01N
M"/W&O[KW5OV^/F)\??\`A.W\C/C!_*P^-'Q)[$[)Z9^1^UNPN\<2-M]@;H[$
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MU/25-9]_`6I6J:6*DKH*M?=>ZKS^!?\`--_G@?(3YB_S*,?M'X3]<_('&]/_
M`"#VMT=G>JLW\JME=2;1^)])U]F>S]KMMC:PJZ;<%+V;G]T2X^LK-P;AHYI1
MD:S'QB+32+14\'NO=&LH_P">?_,$[@^2'\P3XY?#_P#E4X[Y%UOP/[JWIUYG
MM\K\FL'L+;V3VMLW.]B8.&?)46Z=FT=2>Q=YG9T,N(P>.EKA,%K0TH^WC,WN
MO=(+$?\`"D7Y$=Q?#P?.OXP?RO-[]C_'7I?`S97YD;PWGW9@=@4?7.<H-S&B
MSFV.DI*W;,V4[N.U]FQ19S,Y&DH(:;%Q9:E@F4R156CW7NC8?+O_`(4*=(=)
M?'WX4[UZ:V7@.QN_OGUL+:7:'2W4O;?:VU/CSUWLSKW)4\=9NW>?=G>G9'\*
MV1L+`[<DIJW'4;RL9,ODJ>T""$-(/=>Z</Y>/\]O`?--OE_U/O?JC8/6WRE^
M('4>:[JRNS^KOD1UY\C>ENU]BT=%6UT.>ZT[GZODR6$R=%A)ZK"46;TI-]E5
MYF!59Y%FA@]U[JN[9G_"HWY#Y7XF]=?/+='\K+=F)^'E-V6>IN^NZJ3N[$14
M.`WAF=QYO%[>DZ<V[D=I)N?LG;.(HJ;'IF<O+1T-#%GJN3$Q.9H#*WNO=+KY
MU?S0OYG6$_G8_%7XI?$'H/;_`&7U97?';<'R"ZUZ=S/<NV.HQ\J<1O3KO?V+
MJ>P.Q]YUT^5CVEMSK2KP&3?![8R$%+53UV-^_J8WDFQXI/=>ZV</C+N[O??G
M2&P=V_)SI_!=!]Z9BDS$N_NHML]@X[M3`[-K*?<.9HL/38_?N*I:/'[@&3VU
M34==*T,86GEJF@NQB+'W7NA\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]T5CYO_`/9(GR)_\15NK_W`;W[KW7__TMP7H7_LN+YX_P#4%\9?
M_?;97_BGOW7NCY^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ-[<?U%^
M+\7YX_/'OW7NJ'OY.7\K_M'X8=3_`#[ZL^6>+Z=[`VW\L_E_V]W'C=K8*MJM
M_;6S74_8V"PN&&W-^8O=6T\'125M9#1SQUE"8:NE:)[>1@2/?NO=./\`,M_E
MP]X_*OYN?R=.^^E#U=@NJO@'WIN[?_;6'W%G,EMK*C9^4S?1M3A<;UO@</M3
M+XS*5-)B^N:]!33U.-@A/@1&*NQC]U[H!.QOY</\Q?X>?S!?DK\X?Y4VY/C)
MOW"?.G#8NN^3'2'S.R_8>)P6UNT=H97[W;F]^MMP]88PY[(T%;19G+1K05=1
M%%CGKZD$5<<E&,?[KW07Q_R%^ZMB?RG/YB/QEQ/=&V>Y_G5_,8WU!W)W3VAN
M>7(;"Z9J>RJGMC"[XKJ/;=!CMOYG+X/`T^,3(R25$E%+45^1J3^U34_AAI_=
M>Z6?R6_E%_*OMWJW_A/?L[;&4ZAAS'\KW>OQ@W%\DY,MO'<--19&AZ>P'0N+
MW9#U7/%LFLEW7++/UMD?LA71X@3(8-?C,C"/W7NL?:_\N?\`FF_&G^9]\KOY
M@'\MG</PT[`P?S7V3L_;_9O7WR[R'9V$J-A;@V%A-HX?$Y?;-5UE@Q-DZ&9\
M)/+'&]60$E=9XY&\#Q^Z]TX_#C^4_P#,#I.7^?-DNV-P],9S</\`,WAW%5=,
MY3:6X]Q14$NY-P;*^1&&R64W[BZW9].VQ,?DMQ=JT%0E-229EJ6G:9+N8$,W
MNO=)/K;^5[\^ND_Y*/Q;_E[87J[^7O\`(KL'8FX^UJ3Y"]2?*:7LG=70.\=F
M[S[9[3[(V=F]B;PVG@]N;RPN_P#9M=N/$U4-2M)2/!/Y_#,)(897]U[JP7^1
MG_+[[G_EF_`#9WQA[W[+P?8F^J3?W8'8#X_9]5F\AL/K''[ZR5-D5ZVV-E-P
M0T&2RN$H\G#59:HJ&HJ!9,KF*O3"P_?F]U[HM7R]_EN?-?K7^9#5_P`U3^5_
MNWHO*]X=O]3Q]#?)?I#Y9Y'>-#U+N?:&&PVU:7:.[]H9[K_&U&ZL3DL:_7V'
M6JQJ201RU-*E2LQ22JIY/=>Z1G1O\FWY!;6Z#_FW=J]X=J[$["_F&?S6^E>X
M=G[KH]IOF=M_&WJ:HW7UEO+;'6'66V*ZNPU=O+*[>V9D]TK15.X:RFEK)<72
MTX%+)/'/45ONO=64?RBOB=V?\'/Y<?Q>^*?=%5M.M[/Z;VGNG";KJ]BY?(9[
M:DU7E^Q]Y[KHGPV5RF'P%=61?PO/0:S)1PE9@Z@,%#-[KW17N^_Y>'?W9?\`
M/7^#G\R#;U?UU%\?/CK\9.SNH-_X_*;ES%+V94;JW?@OD)C\7-MO;5/M>KPF
M2Q$=3V;C/++-E*614%01&QB02^Z]U%^3?\N/O+NC^>!_+V_F'85NKJGX^?%O
MI/M#8?8F*W+FLB.PY=V;IVYW=1;8R.TMK?W3R."R4.+S6^\5.*F;)T<U,T<D
ML2^2&/R>Z]T&'\S?^4IWOW)\RNHOYE_PCW)T/DOD[UQL.FZ;WYT-\O\`:0WE
M\;^Z>IERE=5Q4$T]#@<SN+8^Y<6N>K9&JJ2-I*EDI_#/1-'+]W[KW0:=@?R[
M?YNW>OPA^9/7^6[G^%7PY[Z[WV]US@^J.MOA%UGF^N>N=LX/8V7W)/V#MW?G
M>[8R+MK+-WKAZZFIGFB@FI]OPI+#%%+%65:GW7NB2?$/^13_`#%_C'_,%^%_
MS)V%LK^6'\?-K=9]=P]/]V=>="M\A:V*'8E;NC/U?8&[C5]B'/Y[MSOC?>R=
MT5>*@SV2RU+24)@H5DIY8J-6D]U[HV.P?Y;_`/-T^#/SD^=O:7P$WG\)-W_'
MW^83W=#W;O7+?)INTCVATON;<6Z-YY;<4^U]O;"Q6*P.ZHMI/OJOJ,?3U=9)
M!6P)303!9(YII_=>Z-W_`"S/Y<?R#^(ORG_G)=S=K5W6M7M#Y[?):7MOI"'9
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M6_-.L_X3I8#^50F<Z*_V9C%]S3;^GRLF^MT#JK^`2=\YKLL)#ND;`;.'(?P'
M(HGB.)5/N=2Z](UGW7NC8?-[^6%\]Y/FS\&OYD?P'W7\<,E\@?C/\::3XN[\
MZG^2]?O6AZMS^U3B-^QU6X<#FMBX*3<K5OW/860IY$>6E9U%+-&4\4\4_NO=
M7K?&:+Y'1](;`D^6]5U94_(FKH\ODNSH>D:?<--U3A\EE=PYC)XC;6RCNN6;
M<5?C=J;:JJ'&/65A\U=/225)"^4*/=>Z'KW[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW15_F^1_LHGR)Y_YI5NK_`-P&_P"*^_=>Z__3VU,/
M@^U*+Y<?*_,=$[VZ2S&<S=/TA_?S:'8>#[3I\GLR+';"EI]M&+*X2CH=O9;^
M\$+U-0WVE15&"-(UD\<A93[KW0Y:?G+_`,=OBC_YS=Q?_5?OW7NO:?G+_P`=
MOBC_`.<W<7_U7[]U[KK3\YO^.WQ0_P#.;N+_`.JO?NO==Z?G+_QV^*/_`)S=
MQ?\`U7[]U[KVGYR_\=OBC_YS=Q?_`%7[]U[KVGYR_P#';XH_^<W<7_U7[]U[
MKVGYR_\`';XH_P#G-W%_]5^_=>Z]I^<O_';XH_\`G-W%_P#5?OW7NO:?G+_Q
MV^*/_G-W%_\`5?OW7NO:?G+_`,=OBC_YS=Q?_5?OW7NO:?G+_P`=OBC_`.<W
M<7_U7[]U[KVGYR_\=OBC_P"<W<7_`-5^_=>Z]I^<O_';XH_^<W<7_P!5^_=>
MZ]I^<O\`QV^*/_G-W%_]5^_=>Z]I^<O_`!V^*/\`YS=Q?_5?OW7NO:?G+_QV
M^*/_`)S=Q?\`U7[]U[KVGYR_\=OBC_YS=Q?_`%7[]U[KVGYR_P#';XH_^<W<
M7_U7[]U[KVGYR_\`';XH_P#G-W%_]5^_=>Z]I^<O_';XH_\`G-W%_P#5?OW7
MNO:?G+_QV^*/_G-W%_\`5?OW7NO:?G+_`,=OBC_YS=Q?_5?OW7NO:?G+_P`=
MOBC_`.<W<7_U7[]U[KVGYR_\=OBC_P"<W<7_`-5^_=>Z]I^<O_';XH_^<W<7
M^P_Y2_?NO=>T_.7_`([?%'_SF[B_V/\`RE_T]^Z]U[3\Y?\`CM\4?_.;N+_Z
MK]^Z]U[3\Y?^.WQ1_P#.;N+_`.J_?NO=>T_.7_CM\4?_`#F[B_\`JOW[KW7M
M/SE_X[?%'_SF[B_^J_?NO=>T_.7_`([?%'_SF[B_^J_?NO==:?G-_P`=OBA_
MYS=Q?_57OW7NN]/SE_X[?%'_`,YNXO\`ZK]^Z]UUI^<W_';XH?\`G-W%_P#5
M7]/?NO==Z?G+_P`=OBC_`.<W<7_U7[]U[KVGYR_B;XH_^<W<7_U6??NO=>T_
M.7_CM\4?_.;N+_ZK]^Z]U[3\Y?\`CM\4?_.;N+_ZK]^Z]U[3\Y?^.WQ1_P#.
M;N+_`.J_?NO=>T_.7_CM\4?_`#F[B_\`JOW[KW7M/SE_X[?%'_SF[B_^J_?N
MO=>T_.7_`([?%'_SF[B_^J_?NO=>T_.7_CM\4?\`SF[B_P#JOW[KW7M/SE_X
M[?%'_P`YNXO_`*K]^Z]U[3\Y?^.WQ1_\YNXO_JOW[KW7M/SE_P".WQ1_\YNX
MO_JOW[KW7M/SE_X[?%'_`,YNXO\`ZK]^Z]U[3\Y?^.WQ1_\`.;N+_P"J_?NO
M=>T_.7_CM\4?_.;N+_ZK]^Z]U[3\Y?\`CM\4?_.;N+_ZK]^Z]U[3\Y?^.WQ1
M_P#.;N+_`.J_?NO=>T_.7_CM\4?_`#F[B_\`JOW[KW7M/SE_X[?%'_SF[B_^
MJ_?NO=>T_.7_`([?%'_SF[B_^J_?NO=>T_.7_CM\4?\`SF[B_P#JOW[KW7M/
MSE_X[?%'_P`YNXO_`*K]^Z]U[3\Y?^.WQ1_\YNXO_JOW[KW7M/SE_P".WQ1_
M\YNXO_JOW[KW7M/SE_X[?%'_`,YNXO\`ZK]^Z]U[3\Y?^.WQ1_\`.;N+_P"J
M_?NO=>T_.7_CM\4?_.;N+_ZK]^Z]U[3\Y?\`CM\4?_.;N+_ZK]^Z]U[3\Y?^
M.WQ1_P#.;N+_`.J_?NO=>T_.7_CM\4?_`#F[B_\`JOW[KW7M/SE_X[?%'_SF
M[B_^J_?NO=>T_.7_`([?%'_SF[B_^J_?NO=>T_.7_CM\4?\`SF[B_P#JOW[K
MW7M/SE_X[?%'_P`YNXO_`*K]^Z]U[3\Y?^.WQ1_\YNXO_JOW[KW7M/SE_P".
MWQ1_\YNXO_JOW[KW7M/SE_X[?%'_`,YNXO\`ZK]^Z]U[3\Y?^.WQ1_\`.;N+
M_P"J_?NO=>T_.7_CM\4?_.;N+_ZK]^Z]T"7R0Q?RHS'0W;>+[1W1\7MI=>U^
LQLY2[PW+C,/W3D\E@\!+3,M?DJ*@IER=35U%+&=2QQT\S,;>AOI[]U[K_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pg20b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg20b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`20"+`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`V5^V-Z_,_P"8OR2[_P"F?CO\G-O_``9^//Q5W#L_K?<7
M=6/ZXV?VCW%W3\A-P;#P?8VXMF8'%]DU;[$VWU3L'9>^L/\`<U*TDN6R&<D>
M*.2."GE7W[KW0L?+OMSY)]2[1^'WQ#Z?[0VSE_EC\K-UR]1O\C=Y;3P,,6S-
MM]<=<Y/??=GR"I>GZ/(4V%SVZ:3`8(C%X99TQ$69R=-YRT"^"7W7ND=\<.QO
ME=\;_FA@/@U\I>\JKY:;:[B^/^[>].DOD)DNH]K=2;NQ&Y>L=XX;;O9W4V]*
M/8]6NS-S4RX;>.)RV+K:6DI:VF1I8*E)4:&5?=>Z,W_+V[D["[V^.M;OOL_,
M4^>W12_(+Y:;!BR--C*/$*=K]6?*'MWK;9-'+24"1TSU&,V?M:AII)@H>H>(
MRO=W8GW7ND#_`"X/D)VK\A,1\RZKM;.46=GZB_F!?)KHK8346&H,,,5UEUWD
MMMP[1PE0M`B#)56.BR4JM5S:JB;4-;$@>_=>ZJ;^7G>O;==T-_,Q^=W6&]]V
M];92C^37QT^$71>>P&6HHLICNI_CS\C-H;'[8SF$K*$2+0P=F]N[_P!WT\AD
MC-9_#:.'3-XI51/=>ZOTH_E1U#E>_=Z?'#!9+,9_?O5VQ:;?_;N5P^"KJKK_
M`*CQN46&IVU@NQ-_,D6VL#O?=>*>3(T&#\\N4;%T[ULL,5*8I9/=>ZKZ7^>+
M\2JOMCJ7K/!]7?,K<F`[[[&P?6727>F#^*?9\_0/;6:SUFILOUWV+54%)%N[
M:<-*DU4^1HJ::!J"FFJXC)2H9O?NO=7)>_=>Z][]U[I`]HT79>2V!N>@Z=W!
MM#:G9=90+3[3W)OW;N4W=M/"5\M33K/D<MMK#9[;&1S(IJ`S-#`E?3*U0(_(
MQC#JWNO=5#=9YGYV_$'YY?&WX^=]_+C&?-3I;YF;8[T_AV1W;U#LWI_L[I/L
M+HS:"=@M5;<CZU@3;VY>NMV8.O6@J(L@#64=<L#QRZ6=9/=>Z+UVMW!W#W'\
MX?EMU#!_.DV9\"!U+V-U?UKU=\>ZK8OQ>R>X=R8[=_4^RMU4V[**7N.LI=W[
MDR.YMW[CK*.*&E$L8>E2-`&8+[]U[K85V3B,U@-F[4P6Y-UU>_-PX;;>$Q>=
MWO7X[%XBNWAF*#&TU+DMSU>)PD%-AL949VLB>J>GI8TIX6ET1C2![]U[JH;Y
M1]D_*'N?YQYOX7=5_+K$_`7:^R?COLCOC;V_X^JME=C]C?(O*[EWCO+;>\L3
MLZ7M::#9F.V9TO2[;QS9M,?3UF3:IW!2M-+3P!5?W7N@)W%\I_E%O;^69LK=
MO=';L?3&0W'\R]O?&;M/YG]246/Z\Q62^,'^S!5/5N1^5^R:W<#9[`]*XO?V
MWJ:%8,[6O-B\8]7_`!&FD^UEI7'NO=/OQT^8&]]G_';>G4_4/<N[/F;OK>?S
M#["^+GP*[?WUD,7OC-]C;(PNTMF9_=_<6^^P=OX_$8OLWJ[XZ97*;C_C&[:*
MGDIJQ,138\2254T;/[KW5C7^R?[T_AG\+_V<+Y->/_99O]!'W?\`>O%_Q'_2
M%_>W^^'^S+_??PKS?Z6ON?\`(?'?^$_PK_)/MO%Q[]U[K7;WUU'_`"BNJ_EQ
M_,EV_P#S=8\!C]^;S^2U;\A/C_CNW-V=JX/;>_NF>Q.I]E/1Y[X[[:VQFJ#"
M9[>=+O/'Y?;V97$"HSLF6QU.LB1B6D5O=>Z&"AW-N#XY="_R2/GG\MI^YZ38
M'Q\WM\@=G=F[[[$H:_<V\NJ>@?E#M7?VT?CKOOY`,L$^YL>^W-KTNRL?G\E4
MF6?'O52O7^2H#O[]U[H]?5GR)Z]^?O\`,ZZ<[5^*>\MK=R_&GXC_`!C[PQ'8
M/>&S),CD-EU'=7R%W3UI18/J?`[H^T7!;CW!A-F=:R9C(PT4LG\.AJH14NLD
M\,7OW7N@E^(W\R#X:_!7:?>OQ3^97=.W_C1W9U!\H_E;N2?:?;$==@).Q=C=
MO]]]C=W==;\ZAJ123Q=D[<W%L[?U'$O\-\U5#E$EHY(1*(_+[KW3?\:^T]S_
M`!E_E??.3YCP;=W5MS-?*'Y+?*'Y#_&K9.]\'6[+WQ65GR+WMCNO?C309K`5
MTT.:Q&1WOG?X3DA"R15E-0Y!28@\9O[KW4S^9#T1A?B9_(CG^.^$@C)V;C?B
M[LC-[E5(ZC,?WZW#\@NJYM]=JTE7.*Z%=ZY'?65KLXM7*)HAD)R[*Z>D^Z]T
ML>C=XU7QHQOS/_EP=T[/J>Q^XI^OOD/\B.B-Z;@K:?&[G_F+]3[PPN6K]SY;
M>>\J.@QF(F[]V7G,K3[0W7I-*T>._AE=2TT%`R1P^Z]U6/\``#Y0=(]I;X^#
M_4_R*_F?[@WOUKTQE^I\U\:.DMV_"[?_`,9)LQWEAMES;/V%LOM'Y(;PQIVI
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M?RV_FQ\-_E7\C\;\F>V_F?\`';>WS8[\VG5;'^/7Q;VAV9B,O!\7>D:]8=Y3
M=-[7AD2@EW=W7NQ<-!D]^9CQ^2JR%$F.H46@H(C-[KW0Q_-3Y0?R)MQ[L[IZ
MU^9-1\4MV=X[3Q><Z[WEL+LKJ:CS7?\`D].%-32X'8N/J]G3=D[DJ<I#D%_@
M=1@6F^YJ6#4,ID74ONO="I\!>S*WX5?RS_@)M_YR[NSVS>PMX_Z-.B,!%O6E
MSF=W73;K[4W%GEZ'ZPW=-0X^LKJ3=.'V*<9A\A45MDIZVCD%34,P,K>Z]T0?
M^8/NGX(]U?./MGH7^<=V!MKJKXU=1=?=9[@^&^P.R\G4];;![CS?8NS]T8_N
M3NS&=L8JEQ&X,[NW8^6K(]NKMVGRZ4F)%'#D*BGGDJX6@]U[HZ7\LGL3$9GX
M`=Q9+O7>L_;GQ`ZM['[KV=T'VYW-L+%X:F[4^"O6N'PL.P=W;APD^!Q='O';
M-'0T>5QE'EIL9"VX,=C(:SQR^=99?=>Z*/WSC,IM;XR8OYK97&[E^(W6?:79
M7073&-K-G;<K^MNR_@;_`"PLKNS$)NF7;5)M.D@J>CMY=FUU+3YC>.2H9J=]
MMXW(4H=S)A4B]^Z]T1W_`&:'X_\`G_A?_#L7RD_T3_[,;_HH_P!(W^S.[[_B
MO_#7?\._OA_LPO\`>:_E\?\`LZO_`!BO_3=H_CW\&_W`_P`3\?[OOW7NMP[<
M6P-B;OK\)E=V[*VENC*;:J?O-N9+<6V\-FZ_;]9YJ>H^ZPE9DJ*IJ,54_<4D
M4FN!HVUQ(U[J"/=>Z?,OA\1N#&5V$SV+QV;PV4II:/)XC+T--DL9D:.9=,U)
M74%9%-2U=-*ILT<B,K#ZCW[KW3;M;9VT=C8H8+9.UMN;/PBU$U6N'VM@\9M_
M%"KJ=)J*H8_$TM)2"HGT#6^C4UA<FWOW7NFS<_6G7&]LAB\MO/K_`&3N[*X,
M@X7)[GVI@L_D,.1/'5`XNMRM!5U./(J8DD_:9/W%#?4`^_=>Z!;Y$?&FF^1F
MZ/CM6;DWSF,-L+HONC#=Z9OKO%X^G:D[4W?L:AK)^K:3<>:>JCJ\=@=B[WG@
MS_VT,4HKZZ@IED*)&=?NO=&/RN(Q6=H*C%9O&8_,XNK\0JL;E:*FR-!4^&:.
MHA^XHZN*:GF\51"CKJ4Z74,.0#[]U[H'/D9T1M_Y%],]L=1Y;*9':-5VAU5V
M!U3%V'MF."'>FSL7V%@9L)E:W;N3(CJ8/U12S4XE2&K$*I+=?I[KW56E/\%O
MYA7<>WNC/C]\L>^OB-5_%GH_>O4.\JS_`$$=*]B8#NOM]?CYN+;^X.L<#N/(
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M'%8TX..CBQT>&-#2_P`*3'P1)#!0)CO%]FM'##&J)$$T*J@`6'OW7NLN1QN/
MS&/K<3EZ"BRF*R=)44&1QN1I8*['Y"AJXF@JJ.MHZE)::KI*F!V22.161U)!
M!!]^Z]TA_P#0_P!2^#[7_1=UU]K_`'5_N+]M_<G;7@_N1_$OXQ_<[P_PSQ_W
M5_B_^5?PZWVGW/[OCU^KW[KW1)?D;_-O_EZ_$SMI>D._?D5A-B]A1#`'-49V
MKO[<.`V<=S3T\6&3?V]-K[6S6SMAS5,57#4.F7KJ-X*.>*HE"02)(WNO=&S[
MN^1_1GQOZAS/?7=W9^T^O>H<%1XZMK-\YG(H^'J4S,D,."IL-]BM75;AR6X*
MBIBBQ])01U%372R(D"2,P!]U[H+OB-\\OBE\Z<!NS</Q@[9H.Q(=AY:DPN],
M-4X'=.R]W[6K,E2FMQ,N=V3OO";:W;CL;FJ9)&H:R2C6DK/#*(9':*0+[KW0
MX]2]P===Y;1FWUU;N.+=.U8-V[^V++E8:+(T"+NGK#>^?ZYWQB_M\I24547P
M>\MKUU&T@3Q2M`7B9XV5V]U[J/U5W=U7W=!OVIZKWGB]YP=8=F[OZ;WY)BUJ
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MP9^H@@Q8[`W?M/:V<VCL"29*J*=TS%=1/!1R)42A('60^Z]U8KC\A09:@H<K
MBJZCR>+R='39#&Y+'U,-;09"@K84J:.NH:RF>2GJZ.KIY%DBEC9DD1@RD@@^
M_=>Z(U\MOYF?PC^#>7PVW?DQWACMB[ESF..:I=LXK:N^>P-QT>`!JE&XL[A.
MN]L[JR6V]O2244R1UN0CIJ:5XG5'8JP'NO="'VC\TN@.K_C=A_E5_>FI[(ZH
MWE3[+_T72]/XZ7L;<7<>:[*KZ'$]<;2ZJP6$D:;=NZ=\9?)P4M!3(\:^5R9G
MACCE=/=>ZY=$?,CIKOSI+=O>N)?=W7&WNM,KO7;O<&U>Y-K5O7G8?3.Z>NZ<
M5V\]K]F;4R#U$N"S&%Q<L-:?%-4T]115,,\$LL<J,?=>Z2'^SW=9?9?=_P"C
M?O[R?[*K_LXGV/\`HJK_`+W_`$2_Q_\`@G\,T_Q#[;_2=]M_N1_NQY?XQ_#^
M?#Y_V/?NO=%`_FK[R^8.-ZA[RZ;Z`_E\8WY$].=N],Y_%=I=L8?LOKN/=>WY
M=[15&T=\5N#^.><Q]!FNX]X;5V2D>1QT!R]"N1K(H(#*JPF_NO=%YKLGT_V%
MO?\`X3S=5=65E?W/\3,CC.R]^[,W3O\`IZW+5>X,S\?/B954G362WG19"%<8
MF^L!7Y"KR)@JH158[,XPM`D34SZ?=>Z-QVK@,5M7^<Y\0MZ;=RO\/W'VY\+?
ME1L'LG"43TD(W!M7JW?/3&[>OLIG(($6LK6PV?WGDXJ.6H+)")9$AL6E!]U[
MI=?RF01\1\L""#_LVGSVX/!_[+;[]]^Z]T`G\JC=.%V#UE_,\WSNJK7%[9VA
M_,[^=>[,]DZC3%!1X';TVV,IEJXR3-%#X:6CHI69BP4:#<BQ]^Z]U7Q\DNOM
MXT_\BGY&?(WLK$5N#[2^5WR'Z]^<G86W<@M=+N2AP&]/DUU)7=7;!QN,GJ:V
MJJ-Q;>Z'VYMK%46)7[>05,/VI03AB_NO=6;_`!8[L[P^4J=[?/'%;VRD/56W
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MH*N1!/25$%1%JU1NK`$>Z]U5M\!.G>JNA?FC_,KZNZ6Z]VCU=UWMV?X5QX;9
MNR,'0[>P%$W^R]5%++5+08^&&*7(5D5'&:BIDUU%3(ODE=Y"S'W7ND__`#4-
MX?,?$=1=V]/_`!M_E]8CY%=6]N],[GQW97:>+[,ZYI-R[?R&\X:G:>[ZO$_'
MG/4..RW<N[=N[/"9&@ICEZ!<G6104[3(L9;W[KW1T?Y?<O33_![XG4_QZW?E
M-^]*8GH/K+;W7&[\[!/1[AS>V]L[6QVWJ>IW)CJG_*<1N6*;&/%D:*2ST5='
M+`P!C(]^Z]TM?DQWATG\6>HM_P#>/<3XG';>IL?2XJJHXL73Y#<_9FX:])\1
MLWK+;>'AIYLEO;>&\<E7#&8C%1)/+435115"&0CW7NJP>COY>G>N'_EA]`=,
M8K,["Z4^3G6/=-)\Q]D[9R6WOXKTWUWVC4]X[H[[Q'1.Y,%MFM2J/6NW:7=\
MFV*I\)41S4J0^>B+")$?W7NBE;VR>^>JZ;L[;WR:S>/[HVPGRCQ'>7S5VW\:
MMK9V+"][?*?L[$["V;\5/Y=O0&U=RU#Y;=F`@I-N;>SV[:S,Y.G,LT5)35SQ
MP5=73Q^Z]T>[_AY;KO[#[C_93?F3_%OX1_=3^Z7^BS$_WM_V;;^\O\,_V1[^
M"_WI\O\`LP']RO\`?[>35_=C^Y/^Y7^*>/T>_=>Z5G??1?\`-QW5OSL7;O1O
MS+^,.TOC[V#69"+%9+L'X];FS7R"ZGV[NFF^RS>)V;F]J;SV]U_N&MVA#)++
MMVMRN/,_E,8K_N?&6D]U[K)VE_+-EP7Q-^*_2GPT[5EZ)[A^"V:V]N[XT=K;
MMPXWIB:O<%%M_.[5W[BNW]MT<F*BW3MKNC`[LRT6XOM13U*SUQJ*5HG0*?=>
MZ5?Q5^'7?^*[]R_S&^<W:W57;_R8I^L9NA^LJ3H[8&9Z^ZBZKZAK-QP[PW&F
M(QV[,UN7=V<WWOS<E/`^3R%76"&&CH8*:FB1#,TGNO=`97?!O^83\>M\]LT/
M\OOY8]%;)Z![Q[2WOW5F>NODQT[NOM#<'2?8G9^7DS'8LO2.?VMO';=-5;0S
MV<K*C.0X?/15,-)F)I=$AIIWC'NO=)?Y+]!Q?'OX2]3_`,M_8.]=^=F]G_.?
MO*?J[L#M#<%'35>]]ZX?M7>N2[:^:/=6[*?"IB]OX*BEZW?/K)!3BDHJ<U]+
M1TX#O%?W7NCY?.OX@?[-O\1]P_%[:FXL+US'D\QTY5X3.Y3#9#<%!M[&]6=G
M;'WNL%)C:/,8FIEK'Q.TFI:5Y)VCCFD1I%=0??NO=%@^4/QAKN@I_G9\H.LJ
MC.YWI+O_`.+/;M;\HOB;L?:]1-NSM#N+`];UVW]J=K]*[CP+K7;)[%W3M)IL
M1N8_8Y(99:>BK1$:RFU/[KW5:?5GR([KZ*ZG^#6Y>I/YN/6_S?WUV'NOXW=7
M1?#?#].?'3+5>_MA;SJ-M8/=^,V_7=)8^C[KV1E.D.MWK,Q5[ASM544$9P<G
M\4A@:HT)[KW6U3[]U[KWOW7ND9V-3;]K-@;VI.J\IMG"=FU.U,_!U]F=Z8W(
M9G:&*WI+BZI-LY'=&(Q-9CLID]OT>8:&2LIZ>>&>6G5E1U8@CW7NJ</BA\2?
MYM?4WRV[&[[[O^2OPDWUL3Y`[CZ[R/>FU-A=)=K;<W/'@^KM@UVR=K8CJ_+9
M3>]5C\-*RS135,N3CR#2-KL5NH'NO=#?WSTI_-LS78&\<=\>?F=\8MK](;XR
M%?/0U':OQKSFX>Z^H<3GG%+7X;9.5VOOG#[!WJ-K41>HPM3G,8LS5+".O^ZC
M36_NO=#7LOXC[N^.?QG^,OQH^'O:U'U3M_H;=_6*[HS>^=DXWL3(=I]68;,U
M>4[@V[EHQ48.'#[T[8J<G55\N:I!&]+DI6=(PCD#W7NB<_-GX0?S`>YOFQU=
M\H.@.]/BK'L#I7KE<5U)T[\G.JNPNP,)UMW%ELCDO[W=X[:IMD;HVQ0S[^R&
MVI*7%4%?7?=38ND%0*40O.[M[KW1\NG=M_-^D^.V\<#WYV=\?<U\H*\;R@V5
MO_J;K[>&`ZHV_'78V*GV/6Y;9N[-PYW.9>MP&3,E16QBKCAK$"1*(QJ;W[KW
M0`=J_P`NI,E\0^N.C.F^QDVWW7TEVKLSY+=>]X=A8$;L_OA\G-I;GJM\9[L;
MM[#4-7C:O-47;>YLMD_[PP8^II)(J;)R1T9B2&&-?=>Z*?\`\-S_`,Q7[O\`
MO5_LX7QX_P!(G^DO_9T/[P_Z!=V?P?\`V>+^"?Z&O[O_`-WO[_Z/]E._V5O_
M`'Z_V7G_`+U_QS_<U]WJ_P`D]^Z]U?7[]U[KWOW7NO>_=>Z][]U[KB41F1V1
M2\>K0Y4%DU"S:&(NNH#FWU]^Z]UR]^Z]U[W[KW0,;+^.'QYZWW?D>P>N^ANF
M-A;]RZ9&/+;WV7U=L?:V[\HF8JEK<NF1W+@\'0YFM3*5J+-4B69A/*`[ZF%_
M?NO=#/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[JI?^9O\@_E5L-MC]9?"?<VT=O\`<."V'VK\L>SVW5LEM_4^5Z"^/6-QTV6Z
MSI<2L$[8K.]X[NW%1X+&5\0^\IVAJ)*<$Q2%?=>Z.-N#Y@=*;2^(9^;VY,[4
MT?0L'36&[UR.?QU&^?K*+8>8P%!N-:Q:+#&J>NJ*.@R"^5(2^EE;^A]^Z]T`
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M6PLYNJFW-V\-][>W#%MW)?&:;H7M2'Y<++44D63ILY3_`!K?;8[3J=FU&&E%
M:N<2@.(\`(-0)`8_?NO="!\F?E7T?VI_+OS/R=ZT^6>[>E.H-S+UYDL/\B.H
M]KC=.^=MR5':>U]OU6U8MEY;&U%91;DR>=,FV<O05M+%5XF:>H6=(I('`]U[
MH3_EQ_,1^-'PLR^S-H=LY3L#<O9?8&-R>?VAU#TMU;OONGM?,;4P=1!19S>G
M]R.O,)FLK0;0P]?50T\^0J5@I_N)5C1G?4J^Z]T9;I?N#8G?_5>QNYNL\A7Y
M/8O8>!IMP[=JLKA,QMK+K2SM)#/19C;NX*+'9O!9C&5L$M-5TE7!%/3U$3QN
MH*^_=>Z$_P!^Z]T6CY;?(>F^,W2F=[`I<'5;RW]E\AB>ONE^N,=!5U.6[0[K
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ML+XW[^_F,[7^3?3&T*/8?<6\]BS_`,K[</0F#J\V,KLGM.MZXHOCKG.XCFX>
MX:?Y&]@XBFAK,7''CH('S.1HT6C;'N6;W7NA\_F.?(#?F.[Y[.V[GOF?O/X&
M[?Z!^%^T_DKT;C\'D-FT5%\B.Z\WOK>F,W#M/>F)W'@Z_,=O[9V=)M'`8";:
MFWZFFKIY]V"02+--1^_=>Z/%0=S]P?)ON;I?J39,^Y>FZ7IS;_5W>/S<KL1&
M@.*WENG:=/N397Q"P^XJW'9&BR.7K\A5_P`4WB*?QST6W8*.$5$<N44+[KW5
ME_OW7NM?CK+%?-+Y:?+GY>_,[X>?)#XN;.Z=CSV(^%>P\?W1\>MY=]S9W;_Q
MKJ\I5]B;HVUN+9W=?2,VW\'N#NK?6XJ)J!CE:>LBQ4-8DR>15'NO=%?W;F-U
M==?R=?YL_P`#NZ-V;7WIVQ\(]O=A[1S>:VUM*OV+L[<?4/>>-I.\.HLGM?9N
M?W)N?)XC9V.V_O:LVU3TWW$U!2G;\E%3S5"4S2'W7NCM_P`T_'8;:VY?Y+6/
MV_CL7MZ@PO\`,^^-6WL!08>BI,71X?"R]>]AXEL+AZ6BB@AQV,?%@4WV\*I%
MX`$TZ0![]U[JNC?-+5=7?//^89@NZ/YQV^?Y8^XM]]Z;=[?V-L_<FW_CMBMA
M=Q=,[BZHV+MS9.]MA]D]W;?J<GO>7:]5M>OP&6Q5/5R0;=GH$B6&-)@S^Z]T
M*.#ZBZBZMW[_`,)R.O.KNW<Y\E>K<9VU\P-S[![>W[@Z'&93>E/F^D]Z[NI-
MR46$3!8&FQ=#29#,2?POQ4J".D6)HG9"CGW7NK+-B8W8U3_.Z^1^6Q^,VO-O
M3$_RW/BW09K+4M!C&W+0'+?(3Y,3_9Y'(QP_Q*'^(XC'8YBCN/+3T]/<%8X[
M>Z]U5W\H:+#X3^3Y_,EQF'I*#%8C&_S.NY:>EH,=!!1X^A#_`#^V=/-!34M.
ML=/3(:J=V**H`9CQS[]U[H^6ZOD5T3\,_P":Q\AMW_+K>>U.BMJ_(KXJ?'BD
M^/?>';62PNT^M\X.EMQ]N?Z9>IL+V/GJJFQF(WC35V]\)FI<"TT,V0I2M6D<
MOANONO=6D[2WSMKY+?'^@WYTGOG.;<VQW'UY69/K7LK&;=_AN>Q%#NC%U4>W
M=\XC;F]<-H6IIC/'D*2+(T)BF`0R1E&L?=>Z!GX=_&KO[XZ4>]Z/O#YO]N_,
MO^\T^#J-O5/;.Q.K-GU6Q3C:>L@R<6'GZWV[@7R%/GC/"\J5?E$+TX,6G6]_
M=>Z`CY<=*?/G>/RRZ.[J^/=#\0-]=3=)]?[O.V.N_D/O?N?8>8PO>V]YS@<G
MVM3U76_6O8>)SAP_61J,+BXZE(9*+^,9"1/5(I]^Z]U41T+U5\T_E=_+T_G=
M]&]F]<?'?:>;[`[P^8U-M2#HSL#<^_\`=VX>_P"/*39;=VR,]C]S8/;>.H\)
M]U@\5C\!7RU%)655)61R3T4*H))O=>Z%#Y/?/CXV_/+^7CTY\2/B-VGLSMGY
M/?*'(_&_J>#HNC2*N[-ZHBV]OW8=?W;N+N78]?3-G.H<=T_MS:V6EKLCF:>B
M6.MIX8J.26HJ*7R>Z]U?ED?DEU?-VOV1\<MF[FQ.Z?DKUST]1]T5_3I;*8O(
M':&?J\IA=G9*LS\^)EP-)0[CW)BGH@R333P']QX=%BWNO=:@FX.S?AAV'\=C
M_,BRGRNV[M7^>]B:.JWIM;K7:M908_LG&?(?!)FM@[0^(\OPC\"R;ZPM12Y`
M;5>OR.#J]S9&GJ/XL,NL0ADB]U[K97^3>_\`;^/Z:^,^Z>S_`(Z]9=C_`#6W
M[7;+P/QIZRWML?%;\DV#\G]T[2I\[FLO2YZ7%Y;,;$V-U/-BZK*[FW#02T\E
M'AL2[)*:AZ9']U[JG;Y@8'8OQ/WO6=*]P_/+OOXFT6POC-6?+;J?M78V_*/8
M.X?FG\\-P;XWY_I:RV^%KL)D8?D-N3"R8;:=)C.N8W).&R\5&M/-`E,U+[KW
M5U'^FGY3V_YEFE_^&^_]--K16_V:35_S+6_\*^FGG3^B_'A_/OW7NC+?'O\`
MYEW_`.35O'_WH\A[]U[H`]^?\S8^6G_BOO2/_N][C]^Z]TN?DS_Q?/BC_P"+
M.[+_`/>'[!]^Z]U4%_PH6_YEIT%_X?67_P#=#7>_=>ZM(S'_`!]_\O7_`(+N
M3_X'O,^_=>Z$?9__`&5YWC_XACHO_P!Z+M[W[KW0;]Z_]DU=S?\`B8:?_P!_
M9M;W[KW14/YV/_,AN@O_`!;+J+_Y->_=>ZN`V]_Q8,'_`-J?&?\`N%![]U[I
MX]^Z]U[W[KW0/]1?7LW_`,2UO'_H:@]^Z]U2E\!/^WN?\P'_`,-Q_P#WI-J>
M_=>ZM>V__P!EL=F?^*X=4_\`OP>S??NO=4\Y+_M_-CO_`!'T'_N+)[]U[J^7
M='_,SNJ_^H7?_P#[JL5[]U[H@O\`,<_YF/\`R_/_`!;2@_\`>%W-[]U[JTKW
%[KW7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pg21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg21.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!GP)/`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`VNOAQ\7OCQV'\9NI=Z[YZ<V%NK=NXL+DZ[.[AS>"IJ[*
MY:L&X\S!]U75<H,E1.8H54LQO91[]U[HS'^R5_$W_O'OJW_T%Z+_`(I[]U[K
MW^R5_$W_`+Q[ZM_]!>B_XI[]U[KW^R5_$W_O'OJW_P!!>B_XI[]U[KW^R5_$
MW_O'OJW_`-!>B_XI[]U[KW^R5_$W_O'OJW_T%Z+_`(I[]U[KW^R5_$W_`+Q[
MZM_]!>B_XI[]U[KW^R5_$W_O'OJW_P!!>B_XI[]U[KW^R5_$W_O'OJW_`-!>
MB_XI[]U[KW^R5_$W_O'OJW_T%Z+_`(I[]U[KIOA;\2U5F;X^]6*J@LS-MBA5
M551=F9B`%50+DGZ>_=>Z*+U-NG^3GWOVWNCH;IK<GP[[,[CV8^0CW%USL[-[
M2S6Z*)\3-)3Y58,?253MDSC)8F%1]H9_"%)>P%_?NO=&[_V2OXF_]X]]6_\`
MH+T7_%/?NO=%#ZWW5_)Q[@[IW%\<^KMS?#K?O>>U)<C!G>KML9O:64W=2U&(
M?QY:F@QM/5LV2JL6P/W$5*9I(`K%P`K$>Z]TJNY,?_*F^/.^.O.M>\8/BYU7
MOWM>I2EZ]VKO5\#A,ON9Y<E1X:*:DIZIU^VH9LM7Q4J5-08:=ZA_&KE@0/=>
MZ%K=7QV^!VQ\UL+;>[NJ.DL!N#M'<<^T>N\-D,'019+>6Y*7"Y+<=7B<#2*K
MS5U128'$5-7,5&B*"%F=@+7]U[I<?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\
M3?\`O'OJW_T%Z+_BGOW7NO?[)7\3?K_LO?5MO_#7H_\`BGOW7NO?[)7\3?\`
MO'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`
MT%Z+_BGOW7NO?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_B
MGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO
M?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3
M?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO?[)7\3?^\>^K
M?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z
M+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO?[)7\3?^\>^K?_07HO\`BGOW
M7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)
M7\3?^\>^K?\`T%Z+_BGOW7NO?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`
MO'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`
MT%Z+_BGOW7NO?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_B
MGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO
M?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3
M?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO?[)7\3?^\>^K
M?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z
M+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO?[)7\3?^\>^K?_07HO\`BGOW
M7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)
M7\3?^\>^K?\`T%Z+_BGOW7NO?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`
MO'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`
MT%Z+_BGOW7NO?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_B
MGOW7NO?[)7\3?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO
M?[)7\3?^\>^K?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3
M?^\>^K?_`$%Z+_BGOW7NO?[)7\3?^\>^K?\`T%Z+_BGOW7NO?[)7\3?^\>^K
M?_07HO\`BGOW7NO?[)7\3?\`O'OJW_T%Z+_BGOW7NO?[)7\3?^\>^K?_`$%Z
M+_BGOW7N@@[J^)7QFVYMO:E9@NCNN<55UO</2>`JJBBV[2P2SX;<G:FU,%G\
M;(R`%J3+X7(3TLZ'B2&9E/U]^Z]TO_@-_P!D?=&?^&WE/_>ISWOW7NC?>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJV?YPV_MU]9?RP
M?FWN_8^7K=O[I@Z+W'@<7G\=*U/7X+^^<]#LRMS5'4(\;T]3BL?GY:A)`RF-
MHPUQ:_OW7NJM/G'\%OBE\,?A;\#.Z?C;TYUIU1V_\6/DE\'TZZ[/VC@*#!;Y
MS]%O_L?9/6_9&$W%N?'1QY?>D79FVMVURU\62J*E:B63R7#*#[]U[JW[^:7V
M'NKJ?^7+\W.P=CY&KP^[MM_&KM>HV_F:%VBKL+DJW:M?C8,U13(R/!5X@UQJ
M8I`08WB#`BWOW7NJ7/F/\#?BC\0_Y6GQ&[L^/O4G7/6O=GQ3WW\'>PNM>YML
M82BPW8N:W/N;M'K';F_GSV\Z!!GMW'M#&;QR:5U/7U51!4RU8/&B,K[KW0N_
MS%/B9\HMU=^_--NL/BW2?)G:W\Q;X==7_&+:&_JS=6RL)@OBON_8]5V'C<OF
M^S*7=>4I-PQ[#J(^Q*?<5//MR"LK),ABWB,0E\4@]U[J#M;YH]4=;]\[:^07
M>9[?[7VQU3U_O'XM_"O;?4G6.Y^W]U[YVITE1;<Q7S3^==3@=K05CXC8>9WC
M14FV:;,NPUXS$3&`2_?,OOW7NM@[K+LK8G<G7FRNU^L-S8W>77?8FVL3N_9F
MZL1(\F-SVW<Y1Q5V,R-*9$BF19Z>8:HY$26-KHZJP('NO=)+OON;;O1'6^4W
MUN*6H5GJJ/;NW:>FQM9E&K]VYYVH]O44T-&C&"DEKB#-+(T421J;N"5!,=JV
M]MRO%MZA8@"[L2`%C3+M4^BU/2._N3:6CSJ*R!3I'JU,#'J>JH-L?/W?F.[.
MW?29VKHJG([2HL+F>RL+"#6XE=O4$9FW53;-Q\31R#+[5A:-``Y:=II"^HH!
M[(MKY-YZM-KV'WAWV+P_;SG>]N+&TA+G_=<8/$&VW+N5I(N[>'(0-*`5BH34
M5AO9O?CD7F'WAYG]E]GO&EWSEJTMYHYO"`&X.QB%["(_$)@-B)1J;5(6*L"H
MR1:IA/DETGN##XO.X_?="E!F*"ER5&E?09G&UJT]9"LT2U5!6XZ&KI)U1[-'
M(BLI^H]F5Q!+:SO;3"DT;%6%0<CCD8/Y=3<CK(@=/A(J.G3_`$]=/?\`/>X;
M_DFO_P#J/VSU;KW^GKI[_GO<-_R37_\`U'[]U[KW^GKI[_GO<-_R37__`%'[
M]U[KW^GKI[_GO<-_R37_`/U'[]U[K&/D!TR96@'8>!,Z1I,\`:L,Z0R,Z1S/
M"*3R+%(\3*K$:6*D`W!]^Z]UD_T]=/?\][AO^2:__P"H_?NO=>_T]=/?\][A
MO^2:_P#^H_?NO=>_T]=/?\][AO\`DFO_`/J/W[KW7O\`3UT]_P`][AO^2:__
M`.H_?NO=>_T]=/?\][AO^2:__P"H_?NO=8Q\@.F3*T`[#P)G2-)G@#5AG2&1
MY(XYGA%)Y%ADDB=58C2S(P!N#;W7NLG^GKI[_GO<-_R37_\`U'[]U[KW^GKI
M[_GO<-_R37__`%'[]U[KW^GKI[_GO<-_R37_`/U'[]U[KW^GKI[_`)[W#?\`
M)-?_`/4?OW7NO?Z>NGO^>]PW_)-?_P#4?OW7NL8^0'3!F:G'8>`-0L2SM3AJ
MPU"P2.\<<[0BD\JPR21LJN1I+*0#<'W[KW63_3UT]_SWN&_Y)K__`*C]^Z]U
M[_3UT]_SWN&_Y)K_`/ZC]^Z]U[_3UT]_SWN&_P"2:_\`^H_?NO=>_P!/73W_
M`#WN&_Y)K_\`ZC]^Z]U[_3UT]_SWN&_Y)K__`*C]^Z]UC7Y`=,O)+"G8>!>:
M$1F:%6K&FA$P9H3-$M(9(A,JDH6`U`&U[>_=>ZR?Z>NGO^>]PW_)-?\`_4?O
MW7NO?Z>NGO\`GO<-_P`DU_\`]1^_=>ZQS?(#IBFAEJ*CL/`T]/!&\T]1.U9#
M!!#&I>26::6D6.**-02S,0`!<^[(C2.(T!+L0`!Q)/`=:)`%3P'6(?(;I4@$
M=AX0@@$$)D2"#R"#]CR"/:_]T[C_`+Z;^7^?IGZF#^(=>_V8;I;_`)^%A/\`
MDC(__4/OW[IW'_?3?R_S]>^I@_B'7O\`9ANEO^?A83_DC(__`%#[]^Z=Q_WT
MW\O\_7OJ8/XAU[_9ANEO^?A83_DC(_\`U#[]^Z=Q_P!]-_+_`#]>^I@_B'7O
M]F&Z6_Y^%A/^2,C_`/4/OW[IW'_?3?R_S]>^I@_B'7O]F&Z6_P"?A83_`)(R
M/_U#[]^Z=Q_WTW\O\_7OJ8/XAU[_`&8;I;_GX6$_Y(R/_P!0^_?NG<?]]-_+
M_/U[ZF#^(=>_V8;I;_GX6$_Y(R/_`-0^_?NG<?\`?3?R_P`_7OJ8/XAU[_9A
MNEO^?A83_DC(_P#U#[]^Z=Q_WTW\O\_7OJ8/XAU[_9ANEO\`GX6$_P"2,C_]
M0^_?NG<?]]-_+_/U[ZF#^(=>_P!F&Z6_Y^%A/^2,C_\`4/OW[IW'_?3?R_S]
M>^I@_B'7O]F&Z6_Y^%A/^2,C_P#4/OW[IW'_`'TW\O\`/U[ZF#^(=>_V8;I;
M_GX6$_Y(R/\`]0^_?NG<?]]-_+_/U[ZF#^(=>_V8;I;_`)^%A/\`DC(__4/O
MW[IW'_?3?R_S]>^I@_B'7O\`9ANEO^?A83_DC(__`%#[]^Z=Q_WTW\O\_7OJ
M8/XAU[_9ANEO^?A83_DC(_\`U#[]^Z=Q_P!]-_+_`#]>^I@_B'7O]F&Z6_Y^
M%A/^2,C_`/4/OW[IW'_?3?R_S]>^I@_B'7O]F&Z6_P"?A83_`)(R/_U#[]^Z
M=Q_WTW\O\_7OJ8/XAU[_`&8;I;_GX6$_Y(R/_P!0^_?NG<?]]-_+_/U[ZF#^
M(=>_V8;I;_GX6$_Y(R/_`-0^_?NG<?\`?3?R_P`_7OJ8/XAU[_9ANEO^?A83
M_DC(_P#U#[]^Z=Q_WTW\O\_7OJ8/XAU[_9ANEO\`GX6$_P"2,C_]0^_?NG<?
M]]-_+_/U[ZF#^(=>_P!F&Z6_Y^%A/^2,C_\`4/OW[IW'_?3?R_S]>^I@_B'7
MO]F&Z6_Y^%A/^2,C_P#4/OW[IW'_`'TW\O\`/U[ZF#^(=>_V8;I;_GX6$_Y(
MR/\`]0^_?NG<?]]-_+_/U[ZF#^(=>_V8;I;_`)^%A/\`DC(__4/OW[IW'_?3
M?R_S]>^I@_B'7O\`9ANEO^?A83_DC(__`%#[]^Z=Q_WTW\O\_7OJ8/XAT#W=
MW=?5.=VMMF'$[XPM;-C.X.BL_6P1O4I-#AL/W)L>?*9!89J>.6:"@A8-+XPQ
M0$7'(]TDVV^B`,D;`%@HX<3P'Y^75EGB;@PP*_D.I/P&_P"R/NC/_#;RG_O4
MY[VAZ=Z-][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!
M;Y'=%;,^3_07<?QV[$%5_<CNKKG=G6^Y)J!E3(46.W5AZK%-D\<[^A,EBI*A
M:FG8W`FB4GCW[KW5&?5_\M?^:5V1N7XU],?/3Y<?'OLSX6?$#L3K_LC:E'U3
MU[NG!]X_)?,=+R";IFG[WK,Q*FV<!0;8R%#19&OCQ33_`,1K*5?)K/[J^Z]U
M;EO;IWM_OJM^8/2WR!GZOR/Q#[FZOQ/6O4V,V=!GZ?MRBHMX;(SFWNYINPZW
M)!]O.YRN0AEP#T`)AB0F8:P/?NO=4Z]>_P`K_P#FC;Z'Q^^+'S*^8/0/8O\`
M+]^+N_\`K7>F$_T>=>;HP_R/^1V&Z-RE'F.F=B=UUV2F7:6W\+@LAB<=-DY<
M7)/-7R8^/69&8R#W7NKQOE?LGN?L[H+L3K?H+>&$Z[[)[!QM)LRD["SDE:O]
MQ=L[DR=%BM][KP$5!0UTM3O3"[)J:^7!HZQP?Q84[2R)&K'W[KW1`.^O@)W1
MU]O?X^]I_P`O*HZ/VSG^F_BQO/X3R]?]]R;T@V+#TSNRNVIF\)O+"9+9-'D\
MI-OK9&X]IQU,U/4T_BSL-3*DM1!(!*?=>Z/3\+_C7C?A[\5>B_C+B]Q5.[H.
MG=A8W:U5NFKI10R;BS)EJ,GN#-1X\35`QM)D<[D*F6GIA))]M`R1:FT7/NO=
M"YVEMO/;PV-G=K[<GQ%)D<W3BB^]S4)J:2BA8ZVJXZ7P5"5%7!(B-$KJ%#"]
MP0/84YTV_?-VV"3;=@,(N9V19/$DDB#0$_K('C5G4RI6*H&%<GB!U617>&1(
MG,4[1L$?2'T.00KZ6(#:&HP4FA(H>J3L'_+%W#LOLC<&<H>SLINS=>V\"F\<
MQBH<=20OO&AW7)N.AJ\%3U$\\0&0RG\*J4)D*(K2QE6O])UY^]^?<KW5]L9/
M97<>5N3-JY6N;:"U@FCW#<Z[<;<I]+<Q!;6H-JR(ZTR0I!XGK`?DS[E5I[-^
MX,?OIR_S3S!NW.>VSRWK6XL[,ON#L&>:W;Q+@1L;D,R4<A2S#ABAC?@U\]Z+
M?&[*CXP]T5]7A^T\/+D(.K=S;CB@Q<_:^UL7+)&,3E8HR*2A[2VO!%X:^D4_
MY>D?W$0+^5%B+>.7^=O:'F:S]L_=B6TFY@N[%+FQW"V+&SW.&@\00NX5C<VY
M($R,`70I.HTOUT)]M.>/;O[U7LY=?>+]A[>[M=IVK<SMO,NQW(4;AR[N61')
M-$C-_NLW(*TMG,"5@E$ME*PDA!:V:Y_J?]N?9GT@Z]<_U/\`MS[]U[KUS_4_
M[<^_=>Z]<_U/^W/OW7ND;3;=K(>PLUNYJB`T&2V;MK;D-,#)]TE9ALUNC)5$
M\@*^(4\D.<C5+$MJ5K@"U_=>Z65S_4_[<^_=>Z]<_P!3_MS[]U[KUS_4_P"W
M/OW7NO7/]3_MS[]U[KUS_4_[<^_=>Z1U/MZLA["S&[FG@-!D=E[:VW%3`R?=
MI6X;.;JRE3/(-/B^WD@SL2I8ZM2M<`6O[KW2QN?ZG_;GW[KW7KG^I_VY]^Z]
MUZY_J?\`;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=(B#;-;%V5E-Z&HISCJ[8N
M`VM'2@R?>+78K/[CRT]0XT^+[:2#,QJI#%M2M<`6)]U[I;W/]3_MS[]U[KUS
M_4_[<^_=>Z]<_P!3_MS[]U[KUS_4_P"W/OW7NO7/]3_MS[]U[I%X7;E;C=Z[
MXW+-44[T>YZ3:5/101F3[FG?`4F3IZMJG4HC"S/6J4TDFP-[<>_=>Z6ES_4_
M[<^_=>Z]<_U/^W/OW7N@M[P)_P!#';/)_P"9<[R_)_YT%?[7;9_R48/^:J?\
M>'34W]B_^E/^#H2:-C]G2<G_`("TQ^I_XXI[1-\1^WIWJ3<_U/\`MS[UU[KU
MS_4_[<^_=>Z]<_U/^W/OW7NO7/\`4_[<^_=>Z]<_U/\`MS[]U[KUS_4_[<^_
M=>Z]<_U/^W/OW7NBY;R^87Q3Z[[>V[T!OSY(]);-[OW8E,^V^I]R]F;2PV_\
MR*U)I*%:+;%?E8,K))71P,8$\8:8#T!KB_NO=+SN+O'IWX];(KNRN]^T]A=/
M=?XVII:*MWEV1NO#;/VY!6UTGBHZ(Y7.5E'2/653@B.)6,CV)`L#;W7NGGK?
ML[KON+96`[(ZGWWM/LKK_=-%'D=N;TV/N#&;GVSFZ*0>FHQN9P]35T%4@/#!
M7)1@0P!!'OW7NL>\^T^N.NLCL;$;]WWM;9V4[-W;2[#Z[Q^Y,Y0XBLWMO6MI
M:FNH]J[8IZV>*3,YZIHZ*:5*6`/*R1L0+`^_=>ZS]A=D[!ZEVM5[W[/WIMO8
M&SJ"OPF+K=S[NS-%@L'2Y+<N;H-M[?H9\ED)H*6.JS6?RM-1TR%M4U3.D:W9
M@#[KW4C=V_ME[!CV[-O;=F!VI%N[=F"V)M9\]E*7&KN'>FYY9(-O;6P_W,B'
M(9W,RPN*>FBU2RZ&T@V/OW7NH'6_:?7'<6VSO'JG?FUNQ=J+FL]MQMQ[-SE!
MN##+G]K9:JP6Y,.<AC9YZ89'!9FBFI:J+5K@GB9&`8$>_=>Z:^L.[NH>[(-V
MU?3_`&;LGLZCV)O#+]?;QKMC;CQNYJ';F]\`R)G-JY2MQ-14TM/G,1)(%J:<
MN9(6.EP#Q[]U[H4+G^I_VY]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_P!N
M??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_`&Y]^Z]UZY_J
M?]N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]T2_Y6'_?Z_&D_D=O[/\`_?H]3>S"
M#_DG7'^FB_PMTTW]LGV-_DZ<?@-_V1]T9_X;>4_]ZG/>R_IWHWWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z"K%?\`,[-[_P#B-NNO_>@[!]^Z]U3C_-5^
M%IR$(^0W6,=9@<G1Y2DS&X:_;YDH\AM#>-'(DF%["QM11F.HHXZFJC2.O="-
M$NB8GU.?<WVO+VR?>5]L)/8GFZY^DYTV\F[Y;W(G]6UNXU)2'7\7AM\+(IJ\
M)95&N.(C#N]]P><O[NS[R5O]]?VJV[][>T6^*NU^X/+@6MKNNT7#J)KDQ?`)
MTKXD4S*1%=JCL1'//49/Y:'\QA?D50-T+WI54F!^2NQZ5J5Y*@QT=-VGB,;$
MJG<.+0^.$;BB@7R5U-&+2*?N(AH+K'A=R!SUO8WV^]J_<V`[=[K[)*T%S`_:
M)_#QXT7`,&%'.GM9&65/TVQU\]]O9+DS^I.R_>>^[=?#F'[K'.5K%>;=>Q'6
MUB;BI^BNZ5:-HGU0@R4=)4>WFI,AU6_^YBZQ'Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@M[P_P"9,=L_
M^(YWE_[H*_VNVS_DHP?\U4_X\.FIO[%_]*?\'0DT?_`.C_ZA*;_K0GM&WQ'[
M>G>I/NO7NO>_=>Z[`N;>_=>ZU].R_P#A3_\`R<^J.P][]8[I^0&\Y-S=?;IS
MFS=QG"]*]G9;%1YW;F0GQ67IZ+)T^WA!70TN0I9(_(GH8H;$CGW[KW58/\SC
M_A7+\>]@=$;<C_EMU%;VAW;O[)L\&Z.R^O=Q;<VAU_M;#Y"),AE:C!;@@QM5
MN7)YV:"6BIH59(X5$DKFX12MCCC@C%Q<+JU?"N0".!8D9`]`,D_(9:+%VT(:
M4XG_`"#HU/QT_P"%:_\`+-WG\?\`K/?_`,C=P[YZ3[<SE!/C=_=?XGK;>N^L
M-AMWX9:>/+G!;AP&*JX*W!9$5$=71F33-'#,(Y1Y$8EN>%543Q5,#UI7B".*
MG[*\?,?LZVC$DHWQC_57H_OP]_X4!?RP/G1WOMCXW?'GNG<^>[;WE1YNMVMM
M_<7578&TJ7-?W>Q=3F\I24N8S6$I\8E;!B:*>H6.61-:0M8DV!3=.=57_P`W
MWX&]/_&CX\=WKU]_+KW=\WNT/E3G.W^UN\?G[OFGQF].POBG4YO<6)KX^QY:
MK;>,INT:S%]2;>JWJMMX7;`I5BI,`L4S/Y)"_NO=&;@ZEZ"^?GSY^`77/;&>
MP_R\^,71W\K&B^2/6<>^*-\OL#NCLSL#>NV.JZ#NO<NSLGJQV:R]-L_"5#Q0
M9"&9J*IR+EE$JW]^Z]T8'^7'U;LGXI?S*?YH7Q,Z.PV-V1\>%P7Q9^2&S^I]
MOS.FU.M-_=L;6W9B.R8-K8,'[/:6,W96;5I:_P#AU,$IHR`T2(A"CW7NE3_-
MLCU]\_R;&\>L1_S/.NFU:-0C/^C3L8`EK$(3^/I?W[KW2L_GOJK?RUNSPP4C
M_31\/39K$7'R^Z/(X/Y%K^_=>Z$CO8S]S_S(_AMTDE$:W:/QSZ][*^9F_I&:
M<TD.[J^GFZ+Z-HYEC/VS5R5FY=RY*%);L/X>)%`*@^_=>ZU2?C%\\=X_[*]L
MKX';4S7;/Q<^.&^/GU\G>H?FK_,/Q6R\A!M[J6I[:[[[(S.QNB>M-YRJ,9MG
M>/;5%44]#7[RE!H]KID8@O\`E,@>/W7NMHSO#=.%_EN=*_$WX8?`/IKK>A[)
M[U[#3HGXZ;-W/5U^-Z[VG#B]KYC?'97=G9U3BM6Y]Y4FTMOXF;)Y,1S?Q3.9
M*KC5JA7F>0>Z]TA.E_E?\_MJ_P`QOK7X(_+';'QSS&U]W?&'M?OG&=X=*4.]
M<+'OVNVCO38NVZ+!Q[-W9GLQ5;&J]K?WAJ$KXWJ,C%D4FIIX982)8O?NO=7/
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)A\K
M/^/T^-/_`(E_9_\`[]'J;V80?\DZX_TT7^%NFF_MD^QO\G3C\!O^R/NC/_#;
MRG_O4Y[V7].]&^]^Z]U[W[KW7O?NO=>]^Z]UCFFAIX9JFHEBIZ>GBDGJ*B>1
M(H((8D,DLTTLA6.**-%+,S$``7/OW7NJTNU?YRW\J[I/=,NR>S/GA\=-O[H@
MIEJZC%4N^:7<CTT35%12Z:FJVM%FJ*GJ1/22*T+R+,NFY4`B_NO='$Z0^2GQ
M\^2VVHMX?'WNKK+N7;<M-259R?76\L'NA*6&NI*:NI?XC3XNLGJ\7-+25D3^
M*ICBE76`R@\>_=>Z&WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW058K_F=F]__`!&W77_O0=@^_=>Z$;*8O'9S&9##9BBI\EBL
MK15..R6/JXUFI:VAK(7@JJ6HB8%7BFA<JP_H?:BSN[K;[N.^LI&BO(9%='4T
M974U5@?(@BHZ+]UVK;=\VRXV7>(([G:KN%X9HI`&22*12KHRG!5E)!'H>M8?
MY:?!?)==]SXO&["SU3L+>\^2_O3\7NW(ZPXN.?.T52*FGZMWAFH]`IJH53+3
MT%?)_P`!Y9(C*&IJB41R!]XWV;M?O6>W<7O?[?%;#[PW*T*B[\+L:[AB!*N0
M,G`+1MG2-<350`=0A_=]_>YW/^["]_+S[GGOJLF^?<%]S+J1K!;G]5-JNKI@
MD@C+=J'442YB&GQ#X-VFF5F86B?R]?GZWR1I\STCW?BQUW\LNK/N<5OO9F1I
M_P"$G=B8:04=?N7`4$I`@K8)0/XC0(6^W=A-$6II%*XE>T7NQ_7:*7EOF6+Z
M'W`V^JW-NPTZ].#+&#Y5^-1722"*H0>NI7WK?NNCV:NK3W"]N[G]\^PV_P!)
M=MOT/B>#X@++:W#C\:BHBD8#Q`I5@)58=6A^YMZPTZ][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H+>\/^9,=L_P#B
M.=Y?^Z"O]KML_P"2C!_S53_CPZ:F_L7_`-*?\'0DT?\`P#H_^H2F_P"M">T;
M?$?MZ=ZD^Z]>Z][]U[KWOW7N@?R/QY^/^8R%;ELOT5TWE<KDJJ:MR.3R76.R
MJ[(5]94.9*BKK:RIPDM1554\C%GD=F=F-R2??NO=5?\`\T'^1O\`#G^9ATW@
MNO<OM3;_`$3OW9.:CRVP>V>JMF[;PN:P,%75TK;DPF0QE#1T%#G\+G:&%@8:
MB_AJ1',A!5@ZJ&=%7P9P6@)K0&A!]5.:5X'R/VTZ;="3J0T?_5QZ.%\;/Y<O
MPR^*_1W7G0/6G0'6-3LWKG"IB\?D-W;'VONG<^:K9F^XS&X=PY[,8FJKLGG,
M]D&:HJI6:Q=K*%154-SSM.P)`"`44#@!Z#_*>).3U9%"#YGB?7HR.V.E.F-D
M9>'<&S.H>K]HYZGBG@@S>U]@;4P&7A@J4\=3##DL5B:6MBBJ(_2ZJX#C@W'M
MGJW5$N_OBK_/3V?-W'\8^@/DQ\8M[_%;N3=._J[:_P`C/D8G8VZ?E/T'L+M7
M+Y3(;AV'0X.E\FTNQ&V129*>CV]4U<T8BI98$<(*<`>Z]TL^U?Y7WR2^-F'^
M#W9W\L#LCK9>\OA1\>:_XGY'9OR8I\NO6_R)Z,SU3M_-9*FW5F-FPOF=I[OQ
MF]\$,U25%*C0ZYY8B0M@_NO=&M_ES?#[Y!]*[E^27RC^9^_^O]_?+_Y@;DV+
MENQ*/J7&9/']4]3[#ZQVW+MOK?J+K^?.'^.9O';;I*ZJEJLE5K'+754Y8J=.
MM_=>Z$;^8[\.]\?,;I79N(Z;[2H^D_D-T9W-U[\B?CUV?E\*VY-M[>[1ZXJZ
MLT-%O'`(?+E]G[CPV4K*"OBCO(J3B10Y30WNO=5K93XF_P`Y'YY9[K?J;^8Q
MN'X6=-_$C9/9G7O;O8^"^*=3V3NCLSOG+]4;KQ.]MD[$J\IOR&GQ^Q-I2[PV
M_25^1GIO)4RQ1B!!:Y]^Z]U;+T1T%O#9WR8^8?R*[$J<'593N_<?6&TNLJ;$
MU,];/MWI'J/8L&/P6-R,D]-3BDR>:W]N'<.4J*>/R1I]S'ZR;@>Z]T4GX2?R
MVXMC_P`N[L_X-?,';VQM][>[=[-^4&9WKA=LUM1D\+D-G=T]N;NWMMN>+)U6
M,QE92;IQ6*S-+,LZ1^2AR%.CQ2$Q(_OW7NJZ^RNG?D?\3NG?A-LOY*?(3JBH
M^0WQ/^9L>P/Y;'R([%GWGD-J?)?8NY^OMV[?Q?2'RURN-P4C].;MWCULLN!_
MO`E564T^4H*&8>21I(Y?=>Z%+H/='R;[D_GA]<[I[XK^@*7*]5?R\^U8LYU#
M\=]YY?M'#](TO8?<>Q:?;-7V%V7EL3MS^,;P[5DVU55%'0PXVCCH\9BU:TI=
MI3[KW6Q[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[HF'RL_P"/T^-/_B7]G_\`OT>IO9A!_P`DZX_TT7^%NFF_MD^QO\G3C\!O
M^R/NC/\`PV\I_P"]3GO9?T[T;[W[KW7O?NO=>]^Z]U[W[KW5.'\Z!/B5N+IS
MXZ]1_,[?/R2VMU'WW\J>NNF*3;/QPS==MRI[/WKOG&;AQFU]C]J9C%5%)E:;
MJJHJW:IR`@D4O+3P@\#W[KW0.=9?RR?Y!>%[ZW-\%-H_#'X\9OO?JWK/"]O[
MHVEN[KK/[RW!2;!W?EVH,/GJ_L+>2949HU.0D$20'(S3P(%70J`>_=>Z"KX5
M?R]?Y/O?/R$[&^3/P/ZN[9^*O</PP^5>Y^E.PLCU5N'=74^T]T[\ZXBP9W7L
MZOV"<[G=G;JZHS5+-&LD<%'0+5-+(Q`)-_=>ZV1S[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H*L5_S.S>_P#XC;KK_P!Z#L'W
M[KW0J^_=>Z!'Y"='[<^0/66:V#G@E-62K_$-KYT*?NMN;EI$<XW*4\B_N",2
M-XYT'^<@=E^MB!][:\_[I[;<UP<Q[=5X`=$\7X9X&(UQL.%:90_A<`\*UA#[
MPGL?RY]X#VSO>0]]"QWK#Q;*ZIWVEX@/@S*1G34Z)5'QQ,R\:$4+]G?'3L+O
MRHJ<ULVNFZX_F1_%!Z::ER=%5IBZKO/9NW`HPE<*\^.'(;KH*(I#!6272MI9
M$CJ-4<MX@7]\S[M5ENL]C]X'V/?Z::[I-!)%10)A5GM)@,+4AA%KP#K@;L"T
MF;^Z+_O$-TY4L=X^XI]\N$[CM.W%K2]M[FLCFU)"1;K9D]TF@&,W'A49T,-Y
M'24O6S+^7O\`/O"_+;:]=L??E(FQ?DOUO$^-[-Z]KX&Q-37SXV8T%9N7`XRK
M*U*TIJTT5U);R8^I;0P\;1LT*>TWNM:^X%@^W;FGT?.MCV7=JPTD,ITF2-3G
M03Q'%&[3@J3F!]ZC[KNY^PN]0<P<N3_OCV8WO]7:=SC(D1HW&M;>=U[1.BGM
M.!,@UKD.JV2>YAZQ(Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z"WO#_F3';/_`(CG>7_N@K_:[;/^2C!_S53_`(\.FIO[
M%_\`2G_!T)-'_P``Z/\`ZA*;_K0GM&WQ'[>G>I/NO7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#GM
MCJ#JSO?8><ZN[HZ\V?VEUUN6%(<[LS?6!QVX]O9)8G$D$D^.R<$\`J:64!X9
ME"RPR`,C*P!]^Z]TBN@/BS\<?BKMW)[3^.'2?6_2VW\WD/XKFZ#K[:^-V_\`
MQK(A62.KS%520BMRDM/&Y6'SR2"%"50*#;W[KW0]^_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)A\K/^/T^-/_`(E_9_\`[]'J
M;V80?\DZX_TT7^%NFF_MD^QO\G3C\!O^R/NC/_#;RG_O4Y[V7].]&^]^Z]U[
MW[KW7O?NO=>]^Z]UK&_\*A.P]O\`4/07\OGMK=R91]H]6_S-?CMV+NPX3'R9
M7+1[9V7CMX[@SDN/QT31M65D>.H)#'%J3R/9;@GW[KW52'7/_"AG^7CMC^='
M\COG/E)N^AT3V=\,>I>CMK5=/T[D9MTOOO9V\GS>:BK]N_Q99:/$ICV!BJ?*
MWD?TZ1]??NO=6\_\)E^T]K=Y=8_S+.ZMC+F%V1VY_,Z[V['V<V?QDF&S,FV=
MX;;V-F\++D<9*\K458]#5H9(M;Z'NMR1[]U[K9H]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%6*_YG9O?_P`1MUU_[T'8/OW7
MNA5]^Z]U[W[KW1#OF-TCN;(2;?\`DATU>B[IZ@7^(^"EC8MO3:='KGK\%5PQ
M<UU13TYD\:,#YH'DB^I2V1'L?S]M5LMS[7<\_J<B;WV58_[BW#4"2J3\`+:=
M1'PN%?@&K@9]\;V1YFOY+#[Q_LU6#WFY1'C%4%3N-C'5I;:11_:NB%]"&OB1
M-)#Q,="!_(CX^R_*#;6T_P"8?\':IMA_++K_`,61W=M;"F))-ZY#"4ZIF-O9
M6@`6"KW3%1@QQ>=?%F\:X@G!8Q,F&'WG_NX\S\C<\R<Q<GDV_/\`MQ\6&1!2
M/<K7.FH^%I&6J$&H8AHF_"1U_P#[MG^\']N?>+V:B]N/=Y1?^PW,(^GNX)&U
MS\N[EC6R-ETA20B4%0"BE+F,9D1CT?`+YX;5^9>PJNERE'#LKO;82IC>U.M:
MDO355'7T[FCEW%@J2K*ULFWJ^LB961P9J"HO3S<A'D+_`&H]TMO]R=H8NOTO
M,]H=%W:M4/&XP653W>&Q!I7*M5&R*DV^]%]V;?ON[\VQI#+^\_;;=5\;:=SC
MHT5S`PUK&[I5!.B$%@#ID4B6/M:BV"^Y7ZQ=Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@M[P_YDQVS_P"(YWE_[H*_VNVS_DHP
M?\U4_P"/#IJ;^Q?_`$I_P="31_\``.C_`.H2F_ZT)[1M\1^WIWJ3[KU[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HKO;/S<^'O0_9&U.G^Z?D[T;U9VGOB
M2ABVIU_OKLK:VV]UYI\I50T.-^VPV3R5/6(F0JZA$A:1465F])/OW7NA$[J^
M0'1WQOV)4=H=^]M]>].=>4M3244N\^QMUX?:FWC6U[::*B@R.7JZ:"JK*ODQ
MQ1%Y&4%@-()'NO=/W5W;'6/=^Q<#V=T[V!L_M#KO=%*M;M[>NQ-P8S<^VLO3
ML`2]%EL34U5)*T9-G35K1N&`/'OW7NNM[]K]:=:Y+86&[`WUM?9N5[2WA2=?
M]<8[<67I,75[WWO74E57T>U=M0U,B/E<[4T5#-*E/$&D9(V(%@??NO=2.Q^S
M>O.G]IUF^^T]Z;<Z_P!F8_(8+%5NY]UY6EPV$I<EN?.8[;.W:&:OK'C@CJLU
MN'+4U'3(3>6HG1%NS`>_=>ZD[P[!V/U\FVI-[[KP>U4WEN[!;!VF<WD(*'^\
M6]=SR31[?VMAQ*P:OS>7>GD\%/&&=Q&Q`LI(]U[INZQ[8ZS[IVPV]>I-][7[
M&VDN<W#MEMQ[0R])F\.NX-IY>KP&YL,:ZBDDA&1P6;H9J6JBOJAGB9&L0??N
MO=-75'>G3?>M'NO)=,]F[+[1QFQ]XYGK[=F4V-G:+<>+PF]=O2+#G=LU>2QL
MD]"<MB)F"5$22.8G]+68$>_=>Z%;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$P^5G_'Z?&G_P`2_L__`-^CU-[,(/\`
MDG7'^FB_PMTTW]LGV-_DZ<?@-_V1]T9_X;>4_P#>ISWLOZ=Z-][]U[KWOW7N
MO>_=>Z][]U[JJG^</\YJ3X$?$J'LG$=.XCO_`+D['[.V3TC\=^HLY2TU5C-V
M]S=AU%30[<2N%1#*ZT>.I8*B>1(2DU1H$*O'Y#(GNO=4T_)GY*_S..U?D!\5
M_P"6A\/]@?#SH_YSI\/\5\H?G'V-NKKG:FZ^O.N]PU4=-CH>M-I)4;;WSCJ6
M#)9N1&6;[>MFE2M@$<R113RM[KW5L_\`)*^96^_F/\2MSUO=G7>Q^L?DG\?N
M\>QOC9\CMO\`7>.QN)VGDNTNL*BAI:_=.,QF,04U`F?Q]9!(\2M)$LR.86\!
MC`]U[JX7W[KW7O?NO=>]^Z]T$M3W[T/1Y6;!5?=O45+FZ:O?%5&&J>R=FP96
M#*1SFEDQLV/ES*U<5>E4/&8602"3TD7X]^Z]T+7OW7NDI'OS8TV[)MA0[TVE
M+OJGI?OJC94>Y,,^[8*+Q)/]Y-MQ:PYB*E\,JOY&A"Z6!O8CW[KW63.;VV7M
MC)[?PNY=W[6V[F=V5C8[:N(SNX,3B,GN;(*T*-0[?H,A5T]5F:Q7J8P8J9)'
M!D46]0O[KW3M7YC$8J7&P93*XW&SYFO7%8>'(5U+1S9;*/!/5)C<9'4RQO7Y
M!Z6EED$,0>0QQLUK*2/=>Z<??NO=>]^Z]T%6*_YG9O?_`,1MUU_[T'8/OW7N
MA5]^Z]U[W[KW7O?NO=5:=D8NN^#W>\?=^UJ6I?X\=P96GQ7;>W*")FIMF;EK
M)G:EW-14L=TAIY)Y7FCTA?K-3_VX0,N^5KNW]_\`V\/(.[N@]S=DA,FW3N>Z
MZ@4#5`S')8`!36OX)/POURR]R-JO_N/^^Z^]O*\4I^[SS?=+!OMG$I*;?>2,
M2EY&@PJEF:1*`<9K?_1(``,^=/PPWG%NW"?S`O@;718KNK;M-'NO=>W-LA7Q
M_;^W7IHZB?*XVA@9:/*YFMQ8*5M$RZ<Q3GBU4J&3EY[P^TW,6T<Q-[C>WR-9
M>X.WNPNK:FD780TD1TX&4`%64C]44_&%)^DG[I'WI/;_`)JY"3[O7OW+'N_L
M'O\`$C;;N&L.VU23#5!/#-EDMBS!T=3_`(NQ)H86D4'@^#7SAZ[^:O6O\>P>
MC;?9FUHZ6@[0ZVK9-&5VUF2GBDKZ&&;14UNV<C512"FJ"H9'5H90LJ,/8^]L
M?<W9O<K9/K;/]#>(*)=6S']2&3@<')C)!T-3Y&C`CJ#_`+R?W;N</NY<Y_N7
M>"+WE*]!EVS<HA6"]MR:J0RU59U4KXL=32H="T;*>CO>Y*ZQSZ][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H+>\/\`F3';/_B.=Y?^Z"O]
MKML_Y*,'_-5/^/#IJ;^Q?_2G_!T)-'_P#H_^H2F_ZT)[1M\1^WIWJ3[KU[KW
MOW7NO`7X]^Z]U5CO'^<C\&MC[LW+LS,;OW[+E]J9O);?RKX[K/=-50_Q'$U4
ME'6K2U+4L1J(8ZF)E#Z0&M<<6/N!=P^\E[6;;?3;?/<W1G@E:-M-O(1J1BK4
M)I45!S3/6=W+G]W#]Z/FC8++F3;MNVE=NO[6.XB$FY6JOX<JAT++J.DE2#2M
M16AST27Y.?SQZ;`U6SLI\4MOX3?6S\I3YJ@W+5=E[=W/MO)T&Y,7+03QP8ZF
M%12M4T,N-R,;,Y4@."`?J`#.=OO5;'L6UV>[<IV'[SM+F>>*0SM+;F-X5@<!
M0%.L,LU2:X(IZ]3#[1?W8/-G,O,&[\L>\6\OR[O%A9V5S;K8"UW!)X;N2[C9
MI',BB-D>UHJBI(8D^70P=(_SM^B7ZRVUDODO+E-H]H9M,AE*G!]?[%W-GMN4
M^#;*5M%AI(<D&J3)53PT3-*I:Z,;6'%S_;OO-<C'8[#<.94FL=UO+8S&&)))
MD1?&EC6DA`KJ$>HCR)(Z!7,7]VG[U3\Y[WL_M9)9[QRCM.XBT2[O+FVLIY9!
M:VUQ+JM]1"A&GT*02&`!XU'1ON@?YH7Q&^2?9N'ZCZQW/O"HWKGJ7)U>(HL[
ML/<.#HZT8BBER-;"N2J:8TL,Z4<#R`2,BL%(!U$`BSE/WU]O.=-[BY>V2>X.
MYS!M`>!T4Z%+$:J$`Z02*T!I2M>HC]V?N-?>#]E>2+GW"YXL=N3EFT>-9G@O
MK>=T\5Q&A,:MJ*EV53I!(K4BE2-3[I:G[#^071'R8^3J?R8^LOGIM3L?NKY(
M[@^9GR+[V['V?MWN??N*V]V)NK!5NQOAUB\E39C<V+P?2?6F*CQ.+J8:C%K-
MEJ)OMXQ(C2F8NL0>K6NN.N_BE\]?G/\`R[MN3[9G[;^&W3/\J"'Y%_'7JSNV
M2OWQCZO<W8?8FV^L,/NG?F%W=699-U[TV+L;`-C7DR@K9(*J=WU>2SGW7NC/
M?R\.L]C_`!A_F>?S3/C#TA@\+L3H6KV]\4OD?@NJMK*:3:77W9/:6T]V87L:
M7;NWX@F.VI3[RFVM25\E#2(E,"JM&J*=(]U[I3_S;(V?OC^3:_C9UC_F>=<E
MG"%EC)ZT[&TEGL50M8VN1?\`'OW7NE7_`#W])_EK=GAM-CW3\/19K6)_V;[H
M\@`'ZGCW[KW0D=X&I[G_`)E/P]Z9CHA6;0^-/6?9?S$W[-(9S20[SW!3U'1/
M1U$XBD%.<C&^=W3D8DE4D+1"1;$`^_=>ZU/OCE\X=]R?%'9GPDQ<_=/Q?^(.
MZOY@/R8ZC^<_\P_!;3FIL)L`=L]^]BY39G0_6N[Q5!MIUO9\5=28W/[Z,1I=
MKQY**)2)YM2^Z]UM-_('>='_`"^.G?B/\*_@!U1U;@.R>^]\_P"@;XV;8W*U
M?1]5]=8?`;1S.^>Q.Y]^P89_[Q;TH]F;=Q<E?5T\4ZY+/92LC$E2#++*/=>Z
M#/I+Y-_S#-D_S'NK/@O\M$^.>\=F;P^+O;_>V-[LZ8VUNW:E3OS*;2WQL+;E
M!A*G9>Y=QYU]AUFT4W#4)5*E5DH,K#4TTT<E.Z30^_=>ZNK]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3#Y6?\?I\:?\`Q+^S
M_P#WZ/4WLP@_Y)UQ_IHO\+=--_;)]C?Y.G'X#?\`9'W1G_AMY3_WJ<][+^G>
MC?>_=>Z][]U[KWOW7NO>_=>ZK'_FR?`3/?S"_B[1=;===ATO4?>_5':FP/D!
M\>NS,A0OD<5M3MWK+)25^`ES--#'-4G$9&GJ9Z::2))'A,BR:)`AC?W7NJ5,
M#\??F#_+%V7\N/GM\IOEI\:M]_S;_G_D>K/CE\<I]S4.2V_T'C=PT%=04&UN
MM\0TF+PT$V7R^*HGK(D>EH<?&^.@B;RF24M[KW5RO\H3X`;P_EZ?%?)[`[=W
M_C>U/D1W)VSOWY#?(KL'"P3PX7.=K=E5E/49:FPCU<%)6UF*P]%104Z3S0PO
M/(LCB.-&2-/=>ZM.]^Z]U[W[KW3%NK/T^TMK[EW56JST>V-OYK<%6D:O*[4V
M&QM3D9U2.(/*[M%3$!5!8G@"_OW7NM`#XDXWX&[=Z]Z;^2?SO_DA?("MV5V%
MV-7[[[9_F9;]AS5%MNE["[+[8SV>P^_L[U;BMSTNX\3UEC-P96CH!EIJ:*/P
M1BH>!E>S^Z]UOA=V]AOUUT/V]VSA'I\C)L3J'?W8N'DB,=325S[8V9E=R8YX
MV3R15%/4FA0@BZLI_-_?NO=:CV;_`)9?3&P/Y/.&_FGXNHWH_P#,^P74FT?G
MMDOF`.QMW1[_`-R=IU]5BNS,YM7-BIS";>K>L<AAJ^3!MA6HEA./2-!=AZO=
M>Z&3^8SUGN/N'N+O+?O8_P`3^W?D5N_Y1_`;H/;G\M;>/76QLSO'&_'_`.1A
M_O?F-Y_9;\HHA2_'+<<&]]R[;W!+N2JEH5GQ^/'[Y^V,/OW7NCCK\O.B*'Y(
M;+[J^;/>.RMC]2?#FDJOC1T7F=VFKEH^ZOFK1[,Q-#\L^\MKT./H,C7Y3;/4
M&)K5VE3Y8Q&@QU;69F1YHKHQ]U[J_K`Y_![JP>'W/MG,8S<.W-PXRAS6!SV%
MKJ;)X?-8?)TT=9CLIB\C1R34E=CZZDF26*:-V21&#*2#[]U[K!N'<^WMI4`R
MNYLUCL%C6J(J1:[)U,=)3&IF#F*`2R$+Y9!&Q`_-O?NO=%\QG<O4Z=P[RKF[
M$VD*2?KW8-+%.<Q3".2HI\[OR2>)7U:2\4<\9(_`<?U]^Z]T)O\`IPZ>_P"?
ME;._\_=)_P!'^_=>Z]_IPZ>_Y^5L[_S]TG_1_OW7NO?Z<.GO^?E;._\`/W2?
M]'^_=>Z2^]M^_'SL/:>?V3NW?.R<KMS<N-J,7E:*7-4?[D$Z^F6%]1,-532A
M989!ZHY45AR/9OL.^[IRSO-MO^S2F'=+6421L/(CR(\U855AP920>/06YWY,
MY=]Q.4[_`))YMMUNN7=RMFAFC/FK##*?PNC`/&XRCJK#('1'/BUWGA^@M]Y_
MXN]A;^Q&9V)0//ENE>R9<C"V*GPE4[5/]U<C7EA3T]7"KGQQZK1U"R1CTO#[
MR4]U-CVWW3Y/C][^3XE3<4`CWBU3)CE4`?4`#.DXU$_$A5SD/USW^[5SES#]
MVSW6G^YW[JW+R[%,S3\J[C+A;BVD9F%D6/:'!J$0&B3+)$`%>$=%'^</3V+Z
M8[-7Y[_!'L':>$[8V_+-D>V^J\+70SXCLS#U,R29S)P;?HY(QDJBO0:LK0H%
M-4%%5`4JX]3\N_<_VZWSES>C[M>UBZ.8H06O+51V7D7%SH'Q.1EU&7IK6D@J
MWTH?=L^\'R9[A\FC[J?WGI/&]O+LA-HW21@)]GNJ:85\9ZZ8*G3$S=L6HQ25
M@<A+*/B?_,&Z&^4'56*WQ'NK`;%W?3QI1;YZ\SV9I8<SM;.1`)4>-)6CFKL#
M6R`O1U@0+)&=+!95=%EGVW]Q-E]RN75WO:CHN4HEQ`2/$@E\U8<=)XHU*,OH
M:@8K_>'^[_SE]W3G^7DSFE?&V^4&6QO4!\"^MB>V6)LC4`0)8ZEHW]5*LQF_
M].'3W_/RMG?^?ND_Z/\`<@=01U[_`$X=/?\`/RMG?^?ND_Z/]^Z]U[_3AT]_
MS\K9W_G[I/\`H_W[KW7O].'3W_/RMG?^?ND_Z/\`?NO=>_TX=/?\_*V=_P"?
MND_Z/]^Z]U[_`$X=/?\`/RMG?^?ND_Z/]^Z]U[_3AT]_S\K9W_G[I/\`H_W[
MKW7O].'3W_/RMG?^?ND_Z/\`?NO=>_TX=/?\_*V=_P"?ND_Z/]^Z]U[_`$X=
M/?\`/RMG?^?ND_Z/]^Z]U[_3AT]_S\K9W_G[I/\`H_W[KW7O].'3W_/RMG?^
M?ND_Z/\`?NO=>_TX=/?\_*V=_P"?ND_Z/]^Z]U[_`$X=/?\`/RMG?^?ND_Z/
M]^Z]U[_3AT]_S\K9W_G[I/\`H_W[KW7O].'3W_/RMG?^?ND_Z/\`?NO=>_TX
M=/?\_*V=_P"?ND_Z/]^Z]U[_`$X=/?\`/RMG?^?ND_Z/]^Z]U[_3AT]_S\K9
MW_G[I/\`H_W[KW0;=R=R]49#J/L^@HNP]IU5;7;!W924E-#F*:2:HJJG"5L-
M/!$BL6>6:5PJ@?5B/:[;/^2C!_S53_CPZ:F_L7_TI_P=&4I`124@(L12TP(_
MH1"EQ[1M\1^WIWJ1[KU[KWOW7NO>_=>Z253L'8E;43U=9LG:-75U,KS5-54[
M:PL]1432'5)+/-+1/)+*[&Y9B23[+9-FVB5S)+:6S2,:DF)"23Q))6I/0@@Y
MMYJMH5M[;<]QCMT4*JK<S*J@<`JAP`!Y`"@Z)K\F?Y;WQJ^5><VMG>Q,5N#"
M3[1Q5;B<51[`R5'M+'O%D*M*NJJ:ZEHL:RU=8[Q(H=OTHH`_/L&\W^T_M_SW
M%;0\R[>)$M&D,8BD>``RZ-=1$5#$^&M"<BF./4Q^TWWJ/?;V1DW"7V]WE8I-
MT$`N#=V\=\S"W\7P@C7.LQ@>-)4*0&)!(J!T,'0OQ)Z3^/'6V*ZLV;MFGS>W
M<-692LH*O>U)BMRYU/XM625U13R96JQRS2TT51*QC4CT`V^GL]V7DOE7E[:+
M?8MJLH5VVU0K&)`)6`9VD-7D#,>]V(J<`T'0*YW]Y?<[W#YMO^>.:-WN#S%N
M4J27#6Q-I$S1Q1P*5@@98T_3B0&@[B-1R>ATQ>SMH82K6OPVU-M8FN1'C6LQ
MF"Q5!5K'*-,L:U-+213*DB\,`;$?7V<P;7MEK)XUK;01S`4U)&BFAXY`!ST"
M[WF3F+<X#:[E?WMQ:D@E)9Y9$)'`Z78BH\C3'6O+G/Y<_P#-?Z$D[O\`C7\#
M?E'\9-I_"#Y#=@=H;VHJ_N/K[=F5[\^*E-W?E:_/=H[>ZC.`G7:6]\<^<SV1
MJ\(<J86Q\M0%X"ZO:[HEZ%KN#^5I\@>BL/\`"7L?^5_V]U_LWOOX4="5WQ8_
M@7R2Q&6SG5_R#Z(SSX'*9G$[_J]I*FX-O;JH][8%,[2UM"I'W$TL9TJ1?W7N
MC3?RZOAIWKT+G/D1\DOF%VCLSMOYB?+G<FRLWVGD.LL%7X#JKKC9_6^W9-N=
M<=0]:4N8=\W7;>VE0UE2\M?6!*FNJ9R[K==;>Z]T(G\Q7X;[I^9O2>U=N]6]
MK-T7W[TOV]L+Y!?'KMU\)'N;&;.[7ZYJJI\5_>7;DLD2Y[:F=Q62JZ#(4P8,
M8:C6-130WNO=5L57PM_G!_-K<?6_6O\`,G[@^&>S?B5L/LG8/;F^=D_$?;_9
M$W8/?>X>K-SXO>6QMF[DW!V$R4^R]E1;NP5)D:]L?>IJ?$(``OJ7W7NK8>BO
MC]NO9'R2^7_R)[`R."R>:[WW-UIMSKRGP[U-1-M;I+J38M/B=MX+(S55)2^'
M*93?&=W!EJJ&(RPJU:EG)!`]U[HJOPF_EOP=:_R^NRO@[\ML7L+L_;/;/9/R
M;S6]L-MR;(5FW<ILKN[MG=N^<)3BKR6.Q=?3;CQ6,SE.YG2,/29"!9(9"8T?
MW[KW5;G:?1_?7P\Z4^&FR?D?\G^LCW3\6?F;!LK^6=\G>Q*+>F5VOVML7<^Q
M-UX##=%_-C*4F*ABZQKMV]>"7;1W+2UM3%-74E!.-4X>.;W7NA'^.FYODCW7
M_.ZV#O/NS>WQUW'DNI?Y??:-#N;K7XO;AS?8.P^BT[%[?V(FTUW?V9GJ7%5F
MX=]=JC;57614?V%`M%C<9'IBD#M._NO=;(OOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB8?*S_`(_3XT_^)?V?_P"_1ZF]F$'_
M`"3KC_31?X6Z:;^V3[&_R=./P&_[(^Z,_P##;RG_`+U.>]E_3O1OO?NO=>]^
MZ]U[W[KW7O?NO=$[^:OS?ZB^!/6NW^X.\L!VQD>M\MO*CV?G=R]6=:;B[.7K
M]*[%93(T^Z]\XO:\%7F,5L\5&-2C>MC@GT5=5`A3UW'NO=4C?-+NGX%_SL<1
M\--K?&3^8;\:MI[K^/OS"Z2^2&<V7V;E*[:V^L[2;7.4F'7E!LW<;;;S])O2
MMF5X6B:&7[::)DD4,1?W7NMG:EK:/(TT%?CZJFKJ&KC6:EK*.HBJJ6IB;],L
M%1`\D,T;6X*L1[]U[K/[]U[KH@,&5A=6!5A<BZL""+@@BX/OW7NJ^-A_RS?B
M_P!'5_8&]OCAM[=?3W<>\-A;XV=B.S8^TNUM]U&U*S>-',J[@QVV.P][;IVG
M)6XK+>&JBUT1TF'0ME9@?=>ZJ(["ZL_GO?+7HRL_EL?(_I?XW[8ZSW;083K+
MOO\`F)XOMZCS]=VEU!B,ICI-TY_9?Q_HL-0Y?!=G=E;?I!3.E4T-!15<]1(H
MC41%?=>ZO-_@O9&7WQO#XOY3IC&T'Q!'QBQ6V,!W6N_*"MW#G-WY9\IL7<'5
MM1UZU+_$Z&CPNQ8Z>N3,22M#4RS&$*&4D^Z]UKZT_P`/?YS6X/C!A_Y.&[.K
MOCU#\1\/%A.H<W_,'B[4-3NS<_Q-VWN>CK:7;M#T0U'+G:+N7*;'HX<))4RR
MC&1R+)*."LQ]U[K8B^1V-[LVS\9]T[-^)>!QM9V_+M?!];=72YG*46*PNQAE
MYL9M!NQ,I/6U%.M92=8[?J9LT**(M/D)*!*:-2THM[KW56_=/P>[G^,>^/C%
MV!\0NC<5\KMJ]3?#7M_X79GJ7>?8NU=@92CRG:>>VIN]N_ZW-;UIZC"YN;=F
MY<'6)O..)ER-5#7F6!*@ZXC[KW5D7P`^.FY/B1\+OC?\;MX[CI-U[KZBZRP^
MU]QYK&FH;$29D25.1R&/P35:1U3;>PE37-0X\R(CFBIXKHA](]U[HWSHD@TR
M(DBWOI=%=;CZ&S`BX]^Z]T$V*IZ?_35O=/MZ?2.M^NV"^"*P8[@[!!-M%KD>
M_=>Z%3[6E_Y5:;_SGA_Z,]^Z]U[[6E_Y5:;_`,YX?^C/?NO=>^UI?^56F_\`
M.>'_`*,]^Z]U[[6E_P"56F_\YX?^C/?NO=%F^5'QUQW?O7;8_&-#A.P]ISG<
M77&Y8`M+/C-P4H29*.6HC4.E!E&@1)#_`+KD"2#E.98]G_<N?VWYE^HNE\?E
M>]7P;ZW(U+)"V"VDX+Q@DCU&I#ANL8?O5_=ZL_?_`-O?HMO<6GN+M#_5[/>@
MZ'@NDHPC+C*Q3E55J'L<)*,QBJ<^(??I[DVIDMJ[WQT6#[JZOJ!MWL;`55-#
M!6355&[4<>XH("BL*?(2PL)@MUCJ`0/0R7,_>GVTBY%WF+>>7V$_(F[+X]E,
MN5"L-1A+>J`C37+)3S#4#WW1/O"W7O+RG<\I\\QFR]YN6'^CW>UD&EW>,F,7
M:H?PRLI$@%0DH8`Z&C)K4^9OQ%[.^)/;U3_,#^$.,C8T#SY/OKHVBI9#AMQX
M&605&X\YBL32`FHQ-=&&FR-'"GFHYA][2CB2,<[_`'&Y!W[D'F-O=[VN3]9>
M[<;!:B.XBK6214'G^)U`J&_43.H'OE]WOWSY']\O;Z+[IOWF9J6#D)R_ODA!
MGVZYII@@DE?_`$.M$B9VT,A^GE[?#9;1_B5\J>H?F+U1C^SNLIJ998OM\?O+
M:-:E+_']D;D:G6:HPV7@1?W('Y>CJT'@K(+.AN&59PY!Y]V#W%V"/?MADJA[
M98F_M(9*=T<@]1^%N#C(^6&'OI[&<\_=^Y\N.1.>8-,RU>VN$!,%Y;DD)/`Q
MX@\'0]\3U1Q6A)H/M:7_`)5:;_SGA_Z,]C7J&^O?:TO_`"JTW_G/#_T9[]U[
MKWVM+_RJTW_G/#_T9[]U[KWVM+_RJTW_`)SP_P#1GOW7NO?:TO\`RJTW_G/#
M_P!&>_=>Z]]K2_\`*K3?^<\/_1GOW7NO?:TO_*K3?^<\/_1GOW7NO?:TO_*K
M3?\`G/#_`-&>_=>Z]]K2_P#*K3?^<\/_`$9[]U[KWVM+_P`JM-_YSP_]&>_=
M>Z]]K2_\JM-_YSP_]&>_=>Z]]K2_\JM-_P"<\/\`T9[]U[KWVM+_`,JM-_YS
MP_\`1GOW7NO?:TO_`"JTW_G/#_T9[]U[KWVM+_RJTW_G/#_T9[]U[KWVM+_R
MJTW_`)SP_P#1GOW7NO?:TO\`RJTW_G/#_P!&>_=>Z]]K2_\`*K3?^<\/_1GO
MW7N@N[OIJ9>F>V&6FIU8=<[R((@B!!_@%?8@A+@CVNVS_DHP?\U4_P"/#IJ;
M^Q?_`$I_P="?1_\``.D_ZA*;_K2GM&WQ'[>G>I/NO7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0O9
M76'7'<FR\WUQVUL3:796P=R4_P!IG]F[WP&-W-MO+0!@Z+78C+4]513-%(H>
M-BFJ-P&4@@'W[KW20Z0^./07QIVY6[0^/G376W3&V<GD&RN3PO6^T,+M*BR>
M28%?OLDF(I*9J^I56*J\Q<HILMAQ[]U[H:??NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$P^5G_`!^GQI_\2_L__P!^CU-[,(/^
M2=<?Z:+_``MTTW]LGV-_DZ<?@-_V1]T9_P"&WE/_`'J<][+^G>C?>_=>Z][]
MU[KWOW7NO>_=>Z@Y.JQM#C<A6YJHH:3#T5%4UN5J\I+3P8RDQU)"]165>0GJ
MRM+!14U/&SRO(0B(I+$`>_=>ZU>?E'W!_)H^2G\R#9_P>[Q^-_P-[)Z]WO\`
M&K?'>V1^8478?5VW:G;>\ZC<T^'R&R!NW:*8BKI=WYE<?%7+6?WABR`U:TB/
M+'W7NKO?@I\.?C/\,NI\KM'XE9+<U5TMV'N1.RML8W*=K[B[;V?@:7*8##XN
MFH>K,QN+,9Z3%;#JJ7%)5PTM/5S4S5-1-,C?NGW[KW1U_?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!5BO^9V;W_\`$;==?^]!
MV#[]U[H5??NO=>]^Z]U[W[KW7O?NO=>]^Z]U7+\MNM]T=4[RQ'S'Z6Q^O=&T
M42D[;VO2ADIM[['.B.LKJN"$'RU5#`JK.X4N(ECF_5!<Y/\`LQS1M'.&QS>Q
M_/DE-HO26VZ=LM:W?%44G@KFI0$TU%H^$F.<GWM?;?FCVIYRL_OB>RT%>9]H
M`3?K)*A-RVW`DED51EXT`65@"P01S_%;Y.UUAV3M3N'86WNP=GUD=?@-RX]:
MB-&*//1U%C%7XG(P\^&NQ]0&AFC8?5;BZD$P'S=RKN_)7,-URSOL>C<+60J<
M=KKQ61#YHZT93Z&G$$=9N>UON7RO[N\B;=[A\FSB;9-P@#KD:XI!B2"4#X98
M7!1U/F*BJD$T:_+/XU=I?R^>W:KYU?"7%R-U[72M)\A^CJ-*B7;DN'FJS5Y+
M+4N'I1^SMN9Y'E9H5\F$JSYX;0-+&,+>?>3-]]IN87]U?;&(OM;FNY;>M?#>
M.M6EC4<`,DZ16)N]1H+*.PWL;[O\D?>HY!A^Z_\`>4NEAYH@73RWO\A'CPS:
M=,=I<2M\>JBHI<TG0"*0^*L<AN(^,OR7ZQ^5_5&#[9ZNRBU6-R")39S!U$D?
M\:VCN&.*-\AMW.TZ&\-72.]TD`\=1"5EC)5A[R$Y,YSV/GS8(>8=@EUVDHHR
MGXXG'Q1R#\+J?R(HPJ"#U@1[P^T'.WL=SW=^W_/EL8-WMFJC@'PKB$D^'<0/
MP>*0"H/%35&`92`8+V*^HOZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H+>\/\`
MF3';/_B.=Y?^Z"O]KML_Y*,'_-5/^/#IJ;^Q?_2G_!T)-'_P#H_^H2F_ZT)[
M1M\1^WIWJ3[KU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/.M.V>M>X\)
MEMR=6;VV_OS`X+=^[-@9C+;;KDR%%CMZ;$S55MS>.V:J9`!'EMN9VBEI:J+Z
MQS1LI^GOW7NA#]^Z]U[W[KW7O?NO=>]^Z]TVY3,X?!PT]1FLMC,/!65]%BJ2
M?*U]+CX:K*9*=*7'8VFDJY84GR&0JI%B@A0F261@J@D@>_=>Z<O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(#M+M3KGI'K_=':W;>\L#U[UQLJ@3*;
MLWGN>M3'8';^.DJJ>A2LR=;("E/`]95Q1@G^VX'Y]^Z]TN*6JIZVEIJVDFCJ
M*2LIX:JEJ(FU13TU1&LT$T;?VHY8G#`_D'W[KW6?W[KW7O?NO=>]^Z]U[W[K
MW1,/E9_Q^GQI_P#$O[/_`/?H]3>S"#_DG7'^FB_PMTTW]LGV-_DZ<?@-_P!D
M?=&?^&WE/_>ISWLOZ=Z-][]U[KWOW7NO>_=>Z][]U[I&[\Q.S=V;8S77>^9L
M<^"[,PF?V+6X6MR<>-GW'CMP82OHLWA\<?N*>KGJI\++.2*<F5(PSBVFX]U[
MK4QSO_"57XAR?S'MC;DPGQVV_%_+NI_C;GL5O;:LO<^_?[[57R*EW+5S8/-4
MM(^3;/\`\&@VV8HF*5RT_DN3&6^ONO=;5G4W6'6?QQZCZVZ7ZZH*39G6'5FU
M-M=<;`PE9E)98\5M[`4-/AMO8:/(Y>IDJZV:.E@CB0R2/+(1R23[]U[H5/?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!5BO^9V
M;W_\1MUU_P"]!V#[]U[H5??NO=>]^Z]U[W[KW7O?NO=>]^Z]UCEAAJ(I:>HB
MBG@GBDAG@FC66&:&5#'+%+$X9)(I$8AE(((-C[LCO&XDC)612""#0@C(((R"
M#D$<.FYH8;F%[>X19+>12K*P#*RL*,K*:@@@D$$4(P>JL**2K^!??QQ<[3?[
M*UWOFS+CIF\CT?66^*E@'IV/*4N..H`_B2BTMRU,U\O9UA^\5[<?5QZ?]=WE
MVWHXQJO[1>!]6?S^4M1@2BG*ZSEO/N&>_P!^ZYR__`N\]7NJ%C4Q[-N3G*^B
M19`/DUMI;+6K5M,DCI:ZEDAFCIZVAK:=XI8I4CJ:2LI*F,J\<B.'AJ*:HA<@
M@@JZG\@^\0'3C'*OJ""/R((/["#UU5AF^"XMW]&5E/YJRL/R((/S'6O5\B.A
MNTOY77<N1^9_Q.QE3N'XW[EKXAW[T13S3I0[<H*^KO49'%P1K+'3;>BJ9C)0
MU8C+X6H?Q2:J*1@F)/-W*V]^Q_,<ON7R#&TW)EPX.Y6"UI&"<S1`8"@FH('Z
M1-#6,D#JO[2^YG)7WTO;RV^[?[[W$=G[OV$17ES?GH7F=5[;.Z<T+LX4*REO
M\84!EI<(I>[/X_\`?_67R9ZNV]VWU/G8\UMC/PE989`L.6P&7@"C);=W!0:F
MDQN:Q<S:)8FN&!62,O&Z.V2G*O-6R<Y['#S#L$PFVZ=<'\2L/B1U_"ZG#*?M
M%003SG]S_;'G+V?YTO.0>>[1K3F"R>C`Y21#\$T+\)(9!W(XXC!HP90,D[2+
M!,T2ZI5AE:)=.K5*J,8UTZDU:G`%KB_]1[$70`ZIEV9\Q/Y@>:^24O2^<Z`Q
ME#MW%XKK_=V9SJ=.9FER,.U=Z;ZWOM26><O\B*ZEQM)2T>RI9HJX151D=I-5
M*!$HE]U[JZ`_4_Z_OW7NNO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!;WA_S)CMG_P`1SO+_`-T%?[7;
M9_R48/\`FJG_`!X=-3?V+_Z4_P"#H2:/_@'1_P#4)3?]:$]HV^(_;T[U)]UZ
M]U[W[KW7ASQ[]U[HAVXOYCGQKVSG\UMROJ=^35V"RE;B*V2DV76O2M5X^H>E
MJ?MWGG@E>)9HV`8HNH"XXM[R(VS[K_NGNNW0;I;IMRV]Q"DBAKI0VEP&6H`(
M!H1BIIU@CS!_>+_=PY;WV\Y?O9-]>]L;F2"0IM\A0R1.4?269&*ZE(!*BHR!
M2G0(=Y?S2NK<%U;GLUU+2[ER&]HZ[#4&'@W+MV3$8QGJZY)*YC/)42^62+&4
MTQT`7!(/NUO]UCW"ON:;#E#<KJTLA?I/(\\$JS2006Z`F305I1YFAA&K!UM3
MX3T'>8O[QGVEFY&W/F+V^MMSN]ZLGMXXX[NU:WADDGDH4\36Q++"DLA"BHT@
M^>10H_YF_P`;7QV*J:\;]AJJ[%8[(2QTFT9JRD5ZVCAJ'6FJTJPE1%&\A74+
M7*GZ'CVAV#[M/NEONW_5PKMJRQS2PRHUR%:.:"1HI492M5(920#Q4JW`CH0;
MS_>+?=XY?O%L-T_?RW#00R@I8,\;)-&LJ-&XD`=:-34/,$8((Z%#J7YR=$=S
M[XQG7VSJG>";BR\59-CTS.U:S'T4_P##Z:2MJ(VK%EJ(X'%-"S`R!5-K7N0"
M@YR^[][A\B[!+S+OBV1VR!E#F*X5V&M@JG30$C40#2IS6E*]#'VH^_![%^\G
M.UM[?\H2;N.8;Q9#$+BR>*-O"1I'!D#.%.A6(+44TIJJ0#K[_#/>/\Q[8?Q+
M^='<GQNW#\8=E]3_`!Z^:W\Q7L2BV=VMM#>V]-W?()=I]U[ZWIO/%9+<N$W)
MM['=0XD"CGQ>,GIJ/,54TX>><1H$0PEUE_T9SO\`_G/K7#X>=>];=N_&WX>;
MF^37Q'V=\R=[]Q?*JJJ]S;8ZSV1O0XZAVOUULG8V*S&U9>P>P=RYV2N#2SY"
MCHJ#&8Z6=A)+)%'[]U[H+JK^=AV52?$W^8JVSNPOC/\`(GY&_"7K7J_L_K_N
MOHZ#+U?1G=FT.S=U8[;U"<SL[(YFJK]C;]P.3CJL=E<8F4K:2-YJ:IAF9&:,
M>Z]T;G<7RD_F+_%+,?''NWY?S?&;=?QU^1O;?5W3._\`K;J;;>[]O;Z^+6X^
M[JF'#]<9>B[#SVX<ICNYL)C]V5E+B\ZTF,P\@:H$](K1C3[]U[I6?+OY(?,C
M;_:W;F"VQWM\-?@-TUU+MW$Y39?8ORM&)[#W1\CZBMP,N4W-N;`[/QG:6RZO
M8'66R,JL>)^YFAK,GD:Y:EDA6*.(2>Z]U43\D_EC\EOYB_PT_DV?)G8N[^GN
MF-R;O_F5];["W+B?[C9?M'9-3W;LC?>_]D;6[,VID6W5MZLR75<<VUZRO_A%
M0@J:^&O@_P`HB:`E_=>ZMWS'R$^=_P`G?D?W_P#'CX=[WZ!Z@V[\,Z?KK9?<
M?=?<'6&ZNR9^W>^][;+IMYU^S]B;%PV\-J4NSMB[5Q%93MD,A45]=6FKJEA@
MB:-#*?=>Z+IO3^:?\OLETA\;!UWU7TOM[Y9Y?^9O4?RXOD+U]NO,YS+]10[V
MV[@=\39S<^S]TX\P[FH-FY>#&XO/T+RT\N0%!*]&R>8B4>Z]TL,/WK_-I'S'
MW[_+WK.P_A]F=XR]!;=^4V`^54'4N_,5C.O]B93>V3ZZK.MJSH?_`$@5B[SW
M/5[JQ8>BRC;CHJ>''-*\\,LPC3W[KW06Y#^<UVCU;\-X\EW3)\>=M_+`?/KM
M#^7(O8^Y,OGMD_&.+>'5E5D*W<?R,W+1U<E=N?$;'Q>QJ$U\N`AJ9*NHR;)2
M0SJDFM/=>Z7/P]_FLUF;^7'5/Q.[(^7'P_\`FK1_(/`[^K=@=H?%O"Y78>XN
MN-[=>8:#<E;L[LW8%=NS?&.EVONK;<=5-B,S39".85M)+3ST^DQR^_=>ZB/\
MT?YG'=GQM[T_F&_&F'XM8WXX;)Q?>>4Z0^/&_P#;>\,IV-W!UWTY5;NPDO:N
M;[>QNY:'$[-W#N6KVW49'$X%</4TAI8(8:FI1ZAY(_=>Z%E/F)\TNT?C-\"-
MY;&SWQJZ#7Y(_&C:'<?>'RY[YGQ2=6['WSFMH[5S>,ZNZXZBJNP]I9K<^[M[
MUF4KJE#/DA0XO%4<CEYI]*>_=>ZK!^0G\P#?_P`N_P"5O_.PZ-[/WKT;W/NC
MXA46P=HT7R%^.:UE%U;W)M;?^7V_N#%9"+;];F=QC;FZML5F,J<?DZ:GKZRC
M,D:-%(P))]U[J[K:'RC[.Z^_F!=<_$[LY]I1=(=_?#O'=K?&C.TN+J,;N1.T
M>GI\70]X]=Y_+S9">CS;/M#/X_<%"5@IWAI8JA/W!&SK[KW2\_EU?)?L_P"8
M/6_;?R#W7187%]/[L^07:&WOBI18[#R8_*Y;X_\`7>8.Q<%OW<E=)D*T96N[
M#W)@LGDJ9D2&*/'24^@,&U'W7NK!??NO=>]^Z]U[W[KW1,/E9_Q^GQI_\2_L
M_P#]^CU-[,(/^2=<?Z:+_"W33?VR?8W^3IQ^`W_9'W1G_AMY3_WJ<][+^G>C
M?>_=>Z][]U[KWOW7NO>_=>Z)W\W?@MT%_,!Z@@Z;[^Q^[!BL-N2BWMLK=W7V
M[\SL/L'KS?.,HZZ@QF[MG;IPD\51096DI,E/$4F2>EFCE9)8G4V]^Z]U1;G?
MY(W\U[8!H-J_&/\`GW?)?`=7XZEJ7H<1W)M=-^[OH:ZLR-95S0MNF+,B?)4"
MPS1Z3,`XDUV"H54>Z]T:7XP?R+Z+9/;VP?DI\VOF_P#*WY[]Z]?Y[#;[VQ1]
ME[^RVV.C=I]@XW%8VC3<.!ZEPF1DQU3)C:N@UT?W,Q@TA#+`\BZ_?NO=7X^_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"K%?\`
M,[-[_P#B-NNO_>@[!]^Z]T*OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H->W
M>J]J]T]?;BZYWC2BHQ&>I#&E0J(U5BLE%>3'9C'NX/BK<=4@.I%M0NI]+$$5
M<E<X;QR)S+:\S[&^F]MGJ14Z9$.'B>G%'6H/I@C('4:>[WM5RM[T^WVX^W?-
M\0?:K^*BN`"\$RYAN(B?ADB>C*?,50]K,"3KX@]J[MV7N3-_$7N^K9>PNO8B
M_7N=JV;Q;ZV'"I-`:*IE.JKJ*"C0/%<F1J:Z'UP/[F_WKY/V7?=JM_>GD!!_
M5K<C2\A7C:79^/4H^%78D-Y!Z$8D7K#G[H/NKS;R5S+??=&][I2/<#E]:[3<
MR$TW+;%'Z7ANV9&BC`:.M6,-4;O@?JP2OH*'*T-;B\I1TN1QN2I*B@R&/KH(
MJJBKJ*KB>"JHZNFF5X:BFJ8)&1T<%64D$6]XQR1QS1M%*H:)E(92`0010@@X
M((P0<$==%H)Y[6=+JU=X[F-PZ.I*LC*0596!!5E(!!!!!`(->M=;N;JWM'^4
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M;+FV]Y'YVLY;'F7;YC'+$X_WET;@\4BT>.1:JZD$'H&,%_V7AVK_`.*B?'__
M`-_+\E?9ST$.C:^_=>Z][]U[KWOW7NJA?YLO\SG*_`;I[>U-TQTYO;OGY)1=
M6YWL[#;=Q&TLS5=9]8;!Q-1-C<CV_P!U;X/\-V]@MGX2OB9(L='7'+Y:J"PP
M0A&>9/=>Z7WSD^<797QE^*'26\^I.M<-W%\I_E%O'ISI#X_=:Y#)/MW9^;[B
M[:P[Y=LKN?(^5JK%;&VGAL;D,E6%',ABIUBUKY/(ONO=`-\/OEQ_,-Z_^7.W
M?A#_`#/=D?':3>/='5F].V_CEWK\7JG=M/U_O";K6LPT79/56YMM[W/\9Q.Z
MMKXG.TV1@JDM#54SD`%AZ?=>Z-W_`#+?F)N3X._%3<'<VQ=AT/8_9.9WMUQU
M!U=MS<&63;FQD['[>W=C=D;1S'9.ZI9(H=K=?X?*919\E6N\:A%6,.AD#K[K
MW1(OB)\Q?YC?7WS,VC\*/YE.U_BYNG<'=G2O8'=_4':7Q#R&[&QVWJ?J^JP-
M/NW9_9NS]XRR9C&TL\.;0XO-(J4E;57ID+R:O'[KW2+^)W\S#Y7]I=I?#SLC
MM/"=+/\`%;^8QV%\A.O>B-A[,Q>XJ/NCHNHZ73>U=M;+=A[EKLW7X/L:/>V*
MZ_K/XJE#08Y,)4U$-FD0./?NO=6;_$;O_?GR;SG?7:5-#M^G^,E%V-/UG\:*
M^DQ]9'N7L*CZUDK]M=J]K9'*353T=7M#<O8U-5T.W$@AC\F/Q1JV9A5(%]U[
MHZGOW7NO>_=>Z][]U[KWOW7N@M[P_P"9,=L_^(YWE_[H*_VNVS_DHP?\U4_X
M\.FIO[%_]*?\'0DT?_`.C_ZA*;_K0GM&WQ'[>G>I/NO7NO>_=>Z][]U[IJEP
M."GD>:;"XB::5B\DLN,HI))'8W9W=X"SLQ^I)N?:Q-QW"-0D<\ZH!0`2,`!Z
M`5QT42\O[#-(TTUC9O*QJ6:&,DD\225J2?4]5X?+'^7O'\J=YXK<61[5GV1@
M=O8O^&X+:F#VECY:.G>9_-7Y.JJ#5TK55?6R!5)*V2-%5?S>1O:_WOYZ]I+C
M<I]CV_9]RN-P>*L][)=^-'#$O;`OAL5""1GD)%"S-W?"M,7??S[H7+'O[N5C
M=[KO5[M&V;?"RQVMG:VWA&1VK).Y)5FD8!4%00JH`M*M49_BC\5(_C/L7(=>
MU^\8NS,&V6ERV!DS>V,?15V!-8H.0H(9A+6&>AJ)U\JJQ'C=FL+'V&><O<'F
MCG[G&ZYQW2"RVRXNXHA+%8R7/AR2Q`IX[>*V)&C"(VD=WAJQ->I#]E?878?9
MKDM>1Q>2;[MT-P\D$EY;6XE@22A:%6746C\35(H8]I=@H`/1K*7#XBAF%11X
MK&TDX!434M!24\P5OU*)(HD<!A]1?GV'9;Z]G3PYYI7C]&=B/V$D=3):[-L]
MC+]196EM#.`1J2)$:AXBJJ#0^?57OQ]^#7:?4_P>^8?QHS^Y-CUV^/D)V7\Z
M=Y[0S&*J,R^V<5COD[N[?N?V/3Y^:IQD&1BJ\/2[I@7)B""54='\)D%B4O1E
MT5^E_E@_)3IS9WPB[9^/VX?CAN/Y3?&_X<]>?#7NSK[O7!Y[-_'KO+KG:<.+
MRL,N'W'C,#5[YV)NO9V]*>IJ\1E(J&85-%5S4U33A6!'NO=`#_,2Z`^2W7?\
MIW^9[VK\H.Q.KH.P.VNMMA8_;/3WQZVRF#Z)^/VW-N;[VI1T-/M',YK"X?>V
M_MU[@RE:<EELIEEAC:9(Z>FIXH8[O[KW1LL)\/\`Y\_)^K^,NSOFYVC\:\G\
M9OCIOCJSN^"?I7!;[A[3^46^>L:.GRG6$_:N+W?"NU>L=O8?/"+*Y6@P\^3.
M3KX46.6GA4`>Z]T'N^/Y9_RBP_S1^0O?/7.V/@/W9A/D3V)MWL/;_=7RZV!O
M'?\`\@_BD^)VAC-J#:G4V&CQ>4VMN?:&V*C'/E,%0#([?CCK*J1:EI!>4^Z]
MTB=K?RC_`)3]9_R^OCC\?MH]D=);M^1/Q&^?=?\`,7KW/;O&Z\%U5VKC:;N#
M?N^,=A-[IMG!OF]D93-X'?#FICQE+54M%60B.%GB(<>Z]T:+<GQ5^?71/R`[
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M=W;QZ@^!_P`YNE?B]\Q_B9LWX6;6K/EKLS&1]W8W>VVOG?\`'O/9O.[OCW1\
M8ML]#LM-A]\9+*[SS<F/V7EYWAEDQN9I9%I:DQ1:O=>Z-_!_+'^26[^I_P"6
MIVUMSK'XB]WYGI;^7KU=\=-]?%GYVXG>&2ZWV3N:;`[8S^0[.V(=N8+=U%B^
MRX'I6P>4^\Q4CST"*D<\)1E;W7NG7)_R=?E?E^H?YLFR<YV=\<J[=O\`,,V-
M\>:?8TNR=I9SK'KGJ[<?5E#_``K-[*AV?B\5E9*38&%Q=-!!B*]9:G)5^EI*
MN.)VL/=>Z%?^>)LNIW!\;_C/L?IWLS#[-^>.![XZ;V3\8H\%7T%3OVJJ^YJ+
M(]$]P-C<)YX\\NS1TYN;<.4KZQ8XX($PR2NZF*WOW7NKJ>B.G-G_`!XZ5ZHZ
M(V!2)0[+Z@Z]VEUUMN!(88&?&;3PE'AH:NHC@1(C6U_VAGJ&`'DGD=CR3[]U
M[H5_?NO=>]^Z]U[W[KW1,/E9_P`?I\:?_$O[/_\`?H]3>S"#_DG7'^FB_P`+
M=--_;)]C?Y.G'X#?]D?=&?\`AMY3_P!ZG/>R_IWHWWOW7NO>_=>Z][]U[KWO
MW7NO$@`LS!54%F9B`JJ!=F)-@``+^_=>ZUMMD_SY^QN[_FCTKU-T7\)]X9#X
M4=J_(G?WQ?QOS6W[N&7;^#WYV?L7;>[<Y61]4[3@QK29?#S56T*FFCGJ:A4E
MTL2T;JT8]U[JT?\`EO?/7"?S!NBMP]DGK7=/279O6':V_.B^\NE-ZLDFYNLN
MT^O<@E-EL+6RK#3F>FK\95TM;`S1QNB5'C8%HRQ]U[JP+W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW058K_F=F]_\`Q&W77_O0
M=@^_=>Z%7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-?F#\?,KVMMS
M#=@];U#X;N[J>H.XMB9>D(BJ<G'1N*RIVS/*H#.M6T6JF#$H)KH1HE?W.7LE
M[E6?)VZ3\M<T*)^0=Y7P;N-LK&6&E9P/+36CTSIR.Y%ZPS^^%]WS=/=7ERS]
MPO;AS9^]O*DGU>V3QG2\RQGQ'LV89.LKJAJ=(DJC#1+)TO/B_P#(#%_(7K6E
MW&84Q6\\',<!V#MA[QU."W-1CQU/^32$3QT&0*&6`L`1ZHSZHV]AWW:]M[OV
MTYJ?:]1FV*X7QK.?BLL#97N&"Z5TO3CAAAAT//NO?>`VS[P?MM%S"R+:\YV+
M_2[K9'M>VO(Q1^P]RQ2T+Q:@".Z,]\;=#UG,'AMS8;*[=W%BZ#-X'.4%5BLQ
MA\I2PUN.R>-KH7IZRAKJ2=7AJ*:I@D*NC`@@^XIN+>"[@>UND62VD4JRL`59
M2*$$'!!&"#UDU8WU[ME[%N.W2R0;A!(LD<D;%'C="&5T92"K*0"""""*CK7@
MWAL7MK^3GW@_:74N.W#V5\%^W-R45#OCKJG>IR>7ZWS.1G,5*,<KEPE?2&0K
MBZQM*U\(%#5-Y1!,<2+[:M_^[SS1^^^78I[[VMW.X59[5`SR6LKFBF-<UJ31
M#^/$3]VACU;V3FGD7^\`]M!R9[A7%ELOWH>7-ODDL=SE*0P;M:P(7DCN7-`"
MJJ6E!/Z1U7,789HP?[ISY.=2=G?-WL3+X/)9_&XW.?'/I/9>W,GNC:F>VSB,
M]F\)O7M;=^5Q]%E,S1TE*,I1P=B4E*U*Y65JF&95OI75FLNQ;@^QP;\J.()T
M#Z&5EEC1A53(C`,A.:J0&4CN`KUR1OKVQV_>[C89;BV>\MIWB+131RQNZ,5;
MPI(V9)$)%5="5<94D=6:^R;I3U[W[KW1*/D;N;^83AM]8:E^*74OQ3WWUO+@
M:*7/9CN_MWLO8>[Z7<K9*M3(4>,PVS^M]W8JJP\6)6GDBFDJDE>=I%9`JJS>
MZ]T"/\Y)JO\`X::^<\N4BHZ?)/\`&K=;9-*.1Y:2*M%)2&JBIJF:.&:>DAJ&
M<1LZJQ2Q(!-O?NO=%)_F9;RQ71/37\I3Y>;W6KBZ9^,'REZ"W)WAGZ:AK,C3
M;$Z\[%Z7W9U8_8F9@H8*B:/![5W#NJA-1-I(B$X/OW7NLF<^3O1/S9_G%?`[
M;_Q7[)V3WKBOBIT;\I^WN\=_=8Y2BWEM'9&-[AV_LSKSK;;%=O7!U%9A$SNZ
M,I2U-0V-$K3K#3)*X6P'OW7NG/\`G1_(O:^X?@WLZJV)VMMR;XI=J_*[K3X^
M_-'O?KZ@VOVQ2]2_'K);FR>W>Y,@JRT.Y\'A:W%YNAI\1D,G)3RRX`U#RZ5F
M12/=>Z(=\-MC_!/XB_S0OBWUE_*@^01[^Q'R$ZZ[8IOF)LN+LFC^2^.V9U-L
M+;$F;ZR[)E[@KAG=Q=95Z=@S)CH<+'EXZ+*K4L6HPZ)(?=>Z.?\`)SX-_&OH
MGM;:>S?B[M_=N`^6'S4W1V9L+K&,[]W9G]D?$WK#L.$97YE?(+I+K?)9&JVC
MTW7R[+KJB$U>*IJ5JO<.7HH(R$DD0^Z]T4C:?R%[NZ/[%I,GUA\@<KM_%=,_
MS.NOOY9777\M*"AZ].U*CXMXV3;&QJ/>APT6+/:%3V;EMG32[_3<QK?LQCX)
M8S"\)>0>Z]UM?'ZG_7/OW7NNO?NO=>]^Z]U[W[KW0:]S4E57=0=I4=#2U-;6
M577N[X*6CHX)*FKJIY,#7+%3TM-"KS5%1,Y"HB`L[$``D^UNW,JW\#,0%$JY
M/`=PX]-S5\%J<=)_P=)>E^0/6:4M,C56[@R4\"L#UOV%<%8D4@C^[/!!'MYM
MIO2QQ'Q_WXG_`$%U3ZB+Y_L/^;K/_LP?67_*UNW_`-%OV%_]C/O7[IO?2/\`
MYR)_T%U[ZF+Y_L/^;KW^S!]9?\K6[?\`T6_87_V,^_?NF]](_P#G(G_077OJ
M8OG^P_YNO?[,'UE_RM;M_P#1;]A?_8S[]^Z;WTC_`.<B?]!=>^IB^?[#_FZ]
M_LP?67_*UNW_`-%OV%_]C/OW[IO?2/\`YR)_T%U[ZF+Y_L/^;KW^S!]9?\K6
M[?\`T6_87_V,^_?NF]](_P#G(G_077OJ8OG^P_YNO?[,'UE_RM;M_P#1;]A?
M_8S[]^Z;WTC_`.<B?]!=>^IB^?[#_FZ]_LP?67_*UNW_`-%OV%_]C/OW[IO?
M2/\`YR)_T%U[ZF+Y_L/^;KW^S!]9?\K6[?\`T6_87_V,^_?NF]](_P#G(G_0
M77OJ8OG^P_YNO?[,'UE_RM;M_P#1;]A?_8S[]^Z;WTC_`.<B?]!=>^IB^?[#
M_FZ2N]^ROC]V7M7,[%[$V[5[ZV7N*GCI,_M/=O3^\]P;<S5-#4P5D-/E,-E-
MI5-!70Q5=-'*JR1L%DC5AR`??OW3>^D?_.1/^@NO?4Q?/]A_S=*6'OWJRFAA
MIJ>7=,%/3Q1P000]:=@1Q0PQ((XH8HUVP%CCCC4*J@6`%O?OW3>^D?\`SD3_
M`*"Z]]3%\_V'_-UE_P!F#ZR_Y6MV_P#HM^PO_L9]^_=-[Z1_\Y$_Z"Z]]3%\
M_P!A_P`W7O\`9@^LO^5K=O\`Z+?L+_[&??OW3>^D?_.1/^@NO?4Q?/\`8?\`
M-U[_`&8/K+_E:W;_`.BW["_^QGW[]TWOI'_SD3_H+KWU,7S_`&'_`#=>_P!F
M#ZR_Y6MV_P#HM^PO_L9]^_=-[Z1_\Y$_Z"Z]]3%\_P!A_P`W7O\`9@^LO^5K
M=O\`Z+?L+_[&??OW3>^D?_.1/^@NO?4Q?/\`8?\`-U[_`&8/K+_E:W;_`.BW
M["_^QGW[]TWOI'_SD3_H+KWU,7S_`&'_`#=>_P!F#ZR_Y6]W?^BW["_^QGW[
M]TWOI'_SD3_H+KWU,7S_`&'_`#=%\S>S?@7N7M>B[WW%\>>N<[W7CIZ>JH>V
M<O\`&*KR/8E+5TD,M-25D.[ZOK^7.K64E/,R12^?R1J;*18>_?NF]](_^<B?
M]!=>^IB^?[#_`)NC!_[,'UD>35[N_P#1;]A?_8S[]^Z;WTC_`.<B?]!=>^IB
M^?[#_FZ]_LP?67_*UNW_`-%OV%_]C/OW[IO?2/\`YR)_T%U[ZF+Y_L/^;H-J
M[/?%7)]H8;N[)==8W(=R[<V[5;0V_P!K5O1.Y*KL3![6KIIYZS;N(WC/LM\_
MCL-5354K24\,Z1,97N/6U_?NF]](_P#G(G_077OJ8OG^P_YNA)_V8/K+_E:W
M;_Z+?L+_`.QGW[]TWOI'_P`Y$_Z"Z]]3%\_V'_-U[_9@^LO^5K=O_HM^PO\`
M[&??OW3>^D?_`#D3_H+KWU,7S_8?\W7O]F#ZR_Y6MV_^BW["_P#L9]^_=-[Z
M1_\`.1/^@NO?4Q?/]A_S=>_V8/K+_E:W;_Z+?L+_`.QGW[]TWOI'_P`Y$_Z"
MZ]]3%\_V'_-T5SY%=E[7W5N'I'-82/<]1B]F=F;,RVXZVHV3O#'14%'+VCU<
M(`G\1PE*U;5U34L@AIX!)/*RD(A/M0+*:"QECDT!Y)(@HUH:FK>A-`/,G`]>
MJ^*C2JRUH%:N#\NA0^`W_9'W1G_AMY3_`-ZG/>R7I3T;[W[KW7O?NO=>]^Z]
MU[W[KW7"2-)HY(94$D4J/%)&WT>.12CH;<V96(]^Z]UH@_)/X;_,[X@=S[(Z
M4^(?\UG^7/A^A?C1\F]Y?)GH/J7Y;=J[`VMVY\;]Y[^H=TTV1V-FJ;(TF3K-
MT;8H*?L'*5-+!4-%>6<2-$C_`%]U[K9/_DR_'_KKH#XP;RI=O_*OK_YI]P=K
M=X;][I^47R$ZZW%@=PX+=W?'8(QM?N"G@;`UU='CZ3%X>&BBIH9S'.8;2&.-
M9%C7W7NK<O?NO=>]^Z]U'I:NDK8S-155-60B6:`RTL\51$)Z:5X*B`R0NZ":
MGGC9'6^I'!!`(]^Z]U`HMP8')9'(8C'9S#U^6Q)`RN+HLI0U>1QA+%`,A0P3
MR5-&2XM^XJ\^_=>Z=_?NO=-%+N#`UV3KL)0YS#UN9Q:A\GB*3*4-3E,<A*J'
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M`S'1/)[RQ]M-XV[W@Y(?V7YKE5.8K5&EV>Z?B&12?IF;B12H`_%'4#NC7KF)
M]X7E/?ONK>\,7WMO;*WDEY$W&5+?FK;H?A:.5P/KD08!+$,6I1+FC$A+B6EC
M6U=T8'>VW,+NW:^2I\OM[<..ILIB<E2N'AJJ.JC$D;7'*2)<JZ&S(X*L`01[
MQ@WC:-QV'=)]EW>)H-RMI6CD1A0JRFA^T'B",$$$8/71OE3FG8.=^7++FWE>
MYCO.7]PMTG@F0U5XW%0?D1P93E6!5@"".@B^3?6^7[6Z7W=M#"[DR6VZQXJ3
M-L^,H*7)29VGV[4QYF3:]325,$SO29XT8A8P&.H5BI1N"#?9)[.WW2&2_ACF
MMO$6JN*J#J%'H<50T85\Q7CGHRW/ZS]W7`V^22*[,$@5D)5CJ1E*@@@T<$J:
M'()!P>M.'(;![I^/O96_>X^XLG4=:;`Z^?>FZL[FMW[]3%4^T8=S4&X6V%69
M.BK<BLF)GRV2D@7'AXU9YP!$"RV]XB\D^U?OER?[RR^X^]J]QR;#=;G<)&U_
M&Z3@PW1@A$0E9F,CM$FD(2NH$@$==>?=W[ROW/O<G[J5G[)<K3P6?N3=6'+M
MC+,NQR0-;/%<[>M_.;MK:-`(8XYY&<R@2!2-1#=;!_P7_FV_%7O#KSK3:FY^
MT,MMG?\`4[7P\$.>[7K,0F/[#JEA2"3-XC?F'CI]IY1LA4*Q&K[5[C25+@DC
M3EK[Q')/,VXMMN]Q/R]S`7(:UN@T<:M6FE)7H*5^$2:&(X`]8X>Z?W"?>+D+
M:3S;R*]KSQ[=$%H]PVAA._A\0\ULA:133XC%XJ`^8'5PM/44]93PU=)/#54M
M3$DU/4TTL<]//#(H:.6&:)GCEC=3<,I((^GN;HY$E021,&C85!!J"#Y@C!'6
M$\T,UO,UO<(T<Z,0RL"K*1@@J:$$'B"*CK-[OTWTE-\[%V9V;M#</7_8FU\%
MO;8^[<9/A=S[3W-C:;,8#/XFJL*C'9;&5L<M+6T<^D:HY%*FW(]^Z]UER^S-
MHY[:-;L+-[6V_G-DU^#.VZW9V7Q-!D=LU^`^T%$,%68:M@GQT^*:E01>%XVC
MT"UK#W[KW59_Q86#X^=T9CXM],?RZ.EOC-MV;!;<[;WUG.J.R>OL9B7VONW<
MN\-H8K<,NW=M]=87(;CSD=;LJJ+TDDB"&*1-,MV8#W7NC_;1Z'Z4V%L'.=4[
M,ZGZ]VUUEN;(;IRNX^O\3M/"TNSL]D=[U]5E-XUF8VXM'_"LC-N?(ULTU<9H
MG^YDD9GN2??NO=([H3XB_%KXLIN&/XW?'KIWHP;ME@FW._5O7^V]F39]Z4$4
MHRU1A,?23UL5-<F-'8HA)(`)/OW7NA>EV)LJ;?%+V9-M3`3=AT&UZO9-#O:7
M%TDFYZ+:%?DZ;-5VVZ3,-$:VFPU;EJ.&HFIT<1RS1(S`E5M[KW0?2?&SX^3=
MU0_)"7I3J^3OZGPAVY!W*^R=OMV1%A&A-*<>F[C0_P`9$7VA,`/EUB`F,'1Z
M??NO=#9[]U[KWOW7NO>_=>Z][]U[KWOW7NN[G^I_VY]^Z]UZY_J?]N??NO=>
MN?ZG_;GW[KW7KG^I_P!N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?]N??N
MO=>N?ZG_`&Y]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?\`
M;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_P!N??NO=>N?
MZG_;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_`&Y]^Z]UZY_J?]N??NO=
M>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?\`;GW[KW7KG^I_VY]^Z]UZY_J?]N??
MNO=>N?ZG_;GW[KW0$_(0G^Z6RN3_`,SX^/'Y_P"_U;(]^Z]T&WP&_P"R/NC/
M_#;RG_O4Y[W[KW1OO?NO=>]^Z]U[W[KW7O?NO=1JR58*.KG>?[5(:6IE:I""
M0TRQPNYG$9!#F$+JM^;>_=>Z^;=\0-U_\)A:C:':<'\Q?(YOM+Y8TWR$[NF[
M![CS_P#LQE1A^W*3*=@YS)[9WOLJ'9,]!'C-NUFWZFGC>ER--#DHJ^.H,AD1
MHY#[KW6XC_):K/Y55;\=^R9/Y2=%34/1J]P5R=A14\?9<9?M/^Z.UC5/,.T9
MI\X7_NH<8`82*;0%L-6KW[KW5Q5B?H"??NO=%;^6VPOD]VAUI3=>_%WN+:?Q
M]W)NS/4V)WWW)F]J3[VWAL7K>>EJQN#(]0[=EJ*;;LO:-0_BAQU5F/+CJ`/)
M4-%++'%&WNO=4'_$'NCL/XP?\)K>SNW-B;LS60[6Z\VO\K:':&_]QU)R>XI=
M^9;Y!=@;*P>^\W5RB3[S-PYW+Q9*>0@JTZDVMQ[]U[I!]M_RR^F?Y674WQ`^
M>_QFW!V_COE5M3OWXKX+Y,=E9_M[>VZ#\J=I=^[WVUUWW1C^X<%N#-56`S'\
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M?+4%:P*U`J8M/NO=6(;*^8WQGW-\P\C\J_DMWQU=U9L+&Y/>7Q0_E[8;?^ZJ
M#;K]B'"[BH=N_)GY"X&BK:CQ'$;\[,QE/M3#960K2_P?!EUE49!@WNO=7I1R
M1S1QS0R)+%*B2Q2Q.LD<L<BAXY(Y$)5XW4@@@D$&X]^Z]UCJ:JEHX_-65-/2
M0Z@GEJIXJ>+6;V3R3,B:C;@7O[]U[H'<7G,(.Y][3',X@1-USUY&LG\3HM#.
MN?[`+(&\]BR@@D?@$?U'OW7NA2_O!@/^=YAO_/I0_P#7_P!^Z]U[^\&`_P"=
MYAO_`#Z4/_7_`-^Z]U[^\&`_YWF&_P#/I0_]?_?NO=>_O!@/^=YAO_/I0_\`
M7_W[KW7O[P8#_G>8;_SZ4/\`U_\`?NO=>_O!@/\`G>8;_P`^E#_U_P#?NO=>
M_O!@/^=YAO\`SZ4/_7_W[KW7O[P8#_G>8;_SZ4/_`%_]^Z]TV9J;9>X\/E,!
MG:W;N4PN:H*K&97&UF0H)::MH*V%H*FFF0S\I+$Y'%B/J+'VKL+^\VN]AW+;
MY&AOH)%DC=31D=356!]01T5[WLFT\R;/=<O[[;QW6RWL#PSPR#4DD4BE'1AZ
M,I(]1Q%#U6MTMNIOAQW=-\<MT[AARG2'9==49KI;=D^0@J8]MY:LJ`M3M;*5
M2RLE/'+42+$Y8JHF,<PL)WTY6\[65I[\<A#W.V"-5]P-IB6/=+9!F:)1VW"*
M,F@!8<3IU)DQK7F7[0;UNGW+/>YON[<[W$LGLCS/<-<<N7\Q.FUN)'`>QED/
M:NIV$;U(`E,<P`%P^FSJ3/X0*ZQYW")-I8(9,E1,J26(0N@J59E5OJ+@D?D>
M\1^NI'5/&:ZJ[J[=^5O>/5_=/87Q![&ZK[!^,'2>)[5V5E^D=V2X3>O7.1[5
M^0=!+M_Q5O>%=2T^Z(Z".=/XG(DXB+TS1P(81KL7<J$))0'`K@5XT'E7SZU0
M`U\SUK8]^?&R@_D-=V#;_<.RY/EM_)!^0&^Y:;%Y*&<Y?N?X*[VW15%TFP&Y
M,;*F:@QT<M0;1>84.XZ6'U)'E(C]R"N</;WD_GNT^EYGL8;A@*+*!HF3_22K
M1Q]E2OJ.I@]I??OW<]CMV&[>V>]WFW58&2#5XEI,*Y$MM)JA>O#5I#CR8'J^
MK8'1GR-Z/V-M3NC^6=\OMK?(CXY[QPM%O+:'3O:VY,=G,)G=L9.`5M*NR-T&
MIAI8S+3GQZ%?%3QRCQR!I%91!;>U_NK[9DW/M5NQW#9%-?W=>T;M\UC;"UI@
M:3`>%=1ZS<C^\Q]UW[R*#;OO2\IKL/.LJA/ZQ;&OADMP$EU;@%B*FIU+<K2N
M$'1B>FOYNW5M?N:+JSY7['W#\4NVX=$%13[R5ZK8>2J+F,SX[<B1I+04L\O^
M;:IC,%OI4-[.^7/O#[.;T;#[C65QR]S",-XZM].Q]1(5!4$\"P*?\,/0*]P?
MN`<W#97Y[^[QO.W>X7M^>X&Q=/KXEX@2VP8AV`^(1L'K_H0ZM9QV[]I9C&T6
M9Q.Z-NY/$9*!*G'Y2@S>-J\?74\BZHYJ2L@J7@J(G7Z,K$'WD):7=K?VRWEC
M)'-:.*JZ,&1AZAE)!_(]8#[GMFY;+N$FT[S;S6FZ0L5DAF1HY4(P0T;@,I^T
M#J7_`'@P'_.\PW_GTH?^O_M1TAZ)UA\YA/\`AP3L>;^,XGQ?[)ITI%Y/XE1:
M/(.[N_&*:O/IU!6!M_B/Z^_=>Z.+_>#`?\[S#?\`GTH?^O\`[]U[KW]X,!_S
MO,-_Y]*'_K_[]U[KW]X,!_SO,-_Y]*'_`*_^_=>Z]_>#`?\`.\PW_GTH?^O_
M`+]U[KW]X,!_SO,-_P"?2A_Z_P#OW7NO?W@P'_.\PW_GTH?^O_OW7NO?W@P'
M_.\PW_GTH?\`K_[]U[KW]X,!_P`[S#?^?2A_Z_\`OW7NO?W@P'_.\PW_`)]*
M'_K_`._=>Z]_>#`?\[S#?^?2A_Z_^_=>Z]_>#`?\[S#?^?2A_P"O_OW7NO?W
M@P'_`#O,-_Y]*'_K_P"_=>Z]_>#`?\[S#?\`GTH?^O\`[]U[KW]X,!_SO,-_
MY]*'_K_[]U[KW]X,!_SO,-_Y]*'_`*_^_=>Z]_>#`?\`.\PW_GTH?^O_`+]U
M[KW]X,!_SO,-_P"?2A_Z_P#OW7NO?W@P'_.\PW_GTH?^O_OW7NO?W@P'_.\P
MW_GTH?\`K_[]U[KW]X,!_P`[S#?^?2A_Z_\`OW7NO?W@P'_.\PW_`)]*'_K_
M`._=>Z]_>#`?\[S#?^?2A_Z_^_=>Z]_>#`?\[S#?^?2A_P"O_OW7NO?W@P'_
M`#O,-_Y]*'_K_P"_=>Z]_>#`?\[S#?\`GTH?^O\`[]U[KW]X,!_SO,-_Y]*'
M_K_[]U[KW]X,!_SO,-_Y]*'_`*_^_=>Z]_>#`?\`.\PW_GTH?^O_`+]U[KW]
MX,!_SO,-_P"?2A_Z_P#OW7NO?W@P'_.\PW_GTH?^O_OW7NO?W@P'_.\PW_GT
MH?\`K_[]U[KW]X,!_P`[S#?^?2A_Z_\`OW7NO?W@P'_.\PW_`)]*'_K_`._=
M>ZG4M;1UR-)15E+61HVAWI*B&I1'M?2S0NZJUC>QY]^Z]U)]^Z]U[W[KW0$_
M(3_CTME?^)X^/'_OZ=D>_=>Z#?X#?]D?=&?^&WE/_>ISWOW7NC?>_=>Z][]U
M[KWOW7NO>_=>Z)=\UNT/F!U=MKJ*K^'OQYVI\B,[NGNO:.T>V\/NS=46UJ;8
MO3.5I\D=V]A8^67)8U<KD\)+#3HE)>3RB8^@V]^Z]UK5;AW5_.)3<&=3'?\`
M":_^79F,>N:RJT.7JEZ9-3E:,5]0*;)5!ES:2-/7PZ97+*&+.20#Q[]U[J^'
M^5%DOE#D^C=]3?*OX(='_P`O_>L?:%;'@.K.B#M?^[.Z]L?W:V\\>^LLFU*F
MKH$S=3E&J:%M;^0P4<9-@0/?NO=&Q^3'Q.Z?^6VVMN[3[B3L)L1M;.2[BQ'^
MCSMKLSJ/(#)34$V-D^_RO66Z=JY'*T?VL[6IZF66!7LX4,`??NO="-TSU#LO
MH7K7:_4W7J[C79^SZ2IH\*-V[QW3O[</AJJRIR$O\2W;O7+9S<V8D-35OI>J
MJI61+(I"JH'NO=4_?%7^7SV9N?\`DQ=@_`COC&R=2]A]HXCY1;<=YJS'9UMI
M5G87;78.ZNNMU/-@ZRMI*J.D.3QN1,<<ID"C0=+@@>Z]T5K&]<?S>?F[3_%K
MX:?+_P")75WQZZ4^.7;W2797R-^3^)[GQ6_:+Y&4OQNR]#N+9F&Z6V'CJ9=P
M[:;L;=FW:"LRDN79?LJ;R(FDG0?=>ZN'[RV5V/\`+_;/SF^&_8O4=;UGTOO#
MI>FZ[ZN^03;LPN>@[*R7:VP\[2[HKJ'95$(LSMF3J;<34J-]X]LBUGB*J#[]
MU[JENCZE_G"?+OK[XZ_RZ?E/\5>K>F>DND^P.BLE\B_F5B>YL5O'$=_=>?&W
M<VW]T;:QW4'6M)2_WKP.YNSLKM#%OD),JR1T:FHMIN%'NO=7M?-S&=];MZ(R
MO5OQQHZFDW[W/GL!U'D^Q*?(T&.'2/7.]*EL?V5W'&*RJIIZ_,;,V4*PXBFI
M1)429J:D;1XDD(]U[JH7YC?!3N;K[L#L7"?&SXKXCY*]0=^_RX-N?R\^N\+D
MMV["V[C/BYE]JY3>T&.WANV/>QCK:SK7<F.WO3Y++56&6KRS9'!(6II'DBE3
MW7NKROCEUGFNEOCYT9T]N3<TV]-P]5]1====YS=TYE,NY<OLW:6)V]D<XQG)
MG(R=7CWF&LZ[-ZN;^_=>Z%#-[?P.Y:(8W<>%Q.?QXFCJ10YG'TN2I!41!A%.
M*>LBEB$T8<A6M<7-O?NO=`'B^JNL&[CWG2-UUL9J6'KSK^HBICM7"&".>?/;
M]2:9(_LM*R2I"@9@+L$6_P!![]U[H3_]$/4__/LM@_\`H)8+_P"H??NO=>_T
M0]3_`//LM@_^@E@O_J'W[KW7O]$/4_\`S[+8/_H)8+_ZA]^Z]U[_`$0]3_\`
M/LM@_P#H)8+_`.H??NO=>_T0]3_\^RV#_P"@E@O_`*A]^Z]U[_1#U/\`\^RV
M#_Z"6"_^H??NO=>_T0]3_P#/LM@_^@E@O_J'W[KW7O\`1#U/_P`^RV#_`.@E
M@O\`ZA]^Z]U[_1#U/_S[+8/_`*"6"_\`J'W[KW03=W?%+JGM[KC/[+IMH[7V
MKF*J`U6W=RX7`X['5V&SM,CMCZEIZ&GAGEH7D.BHBN5DB8\:@I$A>V/N%N?M
MIS7#S#85>U/Z=S#7MG@8]Z$<*CXD)^%@/(FL$_>+]BN7OO">V=UR-O.F+<UK
M/875.^TO$!\*52.[23V2J#WQDCX@I!=?B!G=C;GI=P=&]R=:[#QG>73P?&9X
M9#:V!5]U[?H6$-'NBEF>B45C+3F/[B0?YQ7CF^DAL/O>[V\VW:);?W#Y)I+[
M?;W^I$5X6\S=SP,/PBNHH#P(9.*BL(_<[]]]_P"9[:]]AO=[5;^^/*'^+W`E
M/=?6L1"17<;'^U8*4$K#XU:.<8E-$+M;L7X0Y'YU=AXZ@WU\7ZZ#*?&GH;;V
M(H*7<O6%0N0W;_IB^0D55AL=315CFJSNFHI%D@C#3^N(%>5]X_\`6<G1[>PO
MC%\=NUMC;LZT[$Z2ZQW7L;?&#K]N;JVYE-G822ARV(R,+05--+HHTF@E"MJB
MFB9)H)`KQNKJK#W7NM.M]E=B_P#"9+Y,RT^_-FU_R3_DG?(K?BC';GR>VZ;>
M>^_AGO?<-5HBIJZ:>CJ*I\4-2HR:DI\_1Q:X@F5B>.I]U[K;?INIOAW\J^H]
MO[GQ.PNF.V^H^R]MX_/[4W7@,'@:W&9[;V4@6JQV3P.X<7!#74RLC@@PS12Q
M2`JP5U(!!S%RMR[S;9';^9+."\M?(2*"5^:-\2'YJ0>AS[?^YON![5;TO,/M
MUN]]M&[`@E[>5D5Z>4L?]G*OJLBL/EU6=O3^4]V/T9N.M[%^!_;%'B"3YJCH
M[NG'T6\=BY:"-_+_``FARN6I,@*6!V.F,5$(D0?\I(^OO'N[]D><>1KI]U]F
M=ZEMHR=1L+IB\#_T0QJN3_&NK_AHZSZVW[Z/M)[V[=%RS]\3DZUW.Z"A%W[;
M$$&X18H)'1-)8CB?#?23_H)X=9]C_.S9_6>Y,;U;\\/A?3=!;^KYHL;A=XX#
M8&+W'UEO')2R+34B8RO@HIFHGR520J&.:KA5W&IHU^AORU[W[I:[[:\H>Z.S
MW.T[]=3)#%,BE[:5W<(I!%:!B<E&D4<25'08Y_\`N3<M[YR?N/NG]U[F[;N;
MN2=NM)KNYLYI%M]TM((8VFEUQMI$AC12:,L+D#`8\4WUW\POA9O/YMY&NPVR
ML'/-O;K#8?1&.V6VPL6E?0[TV?V1V3N'.9>K=Z!</_#FH-UT\*O'*TS/2."-
M.@F8-K]Q/;?>^:#R5M&]V\_-(EFB^G$-PI,D`=I4#M$$[1&^=5#IP>L7^9?N
MT?>$Y-]MA[O\T<JW-I[;FUM;DWINK)U%O>&);:3PH[AIJ2&:+&C4NKN`H:7:
M'J#J<$C_`$9;!X/_`#R6"_\`J'V+.H3ZZ_T0]3_\^RV#_P"@E@O_`*A]^Z]U
M[_1#U/\`\^RV#_Z"6"_^H??NO=>_T0]3_P#/LM@_^@E@O_J'W[KW7O\`1#U1
M_P`^RV#_`.@E@O\`ZA]^Z]UW_H@ZI_Y]CL+_`-!'!_\`U#[]U[KK_1#U/_S[
M+8/_`*"6"_\`J'W[KW7O]$/4_P#S[+8/_H)8+_ZA]^Z]U[_1#U/_`,^RV#_Z
M"6"_^H??NO=>_P!$/4__`#[+8/\`Z"6"_P#J'W[KW7O]$/4__/LM@_\`H)8+
M_P"H??NO=>_T0]3_`//LM@_^@E@O_J'W[KW7O]$/4_\`S[+8/_H)8+_ZA]^Z
M]U[_`$0]3_\`/LM@_P#H)8+_`.H??NO=>_T0]3_\^RV#_P"@E@O_`*A]^Z]U
M[_1#U/\`\^RV#_Z"6"_^H??NO=>_T0]3_P#/LM@_^@E@O_J'W[KW7O\`1#U/
M_P`^RV#_`.@E@O\`ZA]^Z]U[_1#U/_S[+8/_`*"6"_\`J'W[KW7O]$/4_P#S
M[+8/_H)8+_ZA]^Z]U[_1#U/_`,^RV#_Z"6"_^H??NO=>_P!$/4__`#[+8/\`
MZ"6"_P#J'W[KW7O]$/4__/LM@_\`H)8+_P"H??NO=>_T0]3_`//LM@_^@E@O
M_J'W[KW7O]$/4_\`S[+8/_H)8+_ZA]^Z]U[_`$0]3_\`/LM@_P#H)8+_`.H?
M?NO=>_T0]3_\^RV#_P"@E@O_`*A]^Z]U[_1#U/\`\^RV#_Z"6"_^H??NO=>_
MT0]3_P#/LM@_^@E@O_J'W[KW7O\`1#U/_P`^RV#_`.@E@O\`ZA]^Z]U[_1#U
M/_S[+8/_`*"6"_\`J'W[KW7O]$/4_P#S[+8/_H)8+_ZA]^Z]U[_1#U/_`,^R
MV#_Z"6"_^H??NO=*C!;8VWM>GFI-L[?PNWJ6IF%144V$QE'C()YP@C$TT5'#
M"DDH10-1!-A;W[KW3Y[]U[KWOW7N@)^0G_'I;*_\3Q\>/_?T[(]^Z]T&_P`!
MO^R/NC/_``V\I_[U.>]^Z]T;[W[KW7O?NO=>]^Z]U[W[KW5?G\QKX,[D^?73
MFU^I]L?*SO7XB5VW.P*#?$W8'0.7EPVZ\Y34>$S>';:N3J8,EBI'P=3)F%J7
M3R$>>FC-C;W[KW6H/EOB-\3Z'YI;8^`.(_X46_S,M[?);<FXLWM"HVUL7-;N
MW+MS:FZMOXK)9G*[=W?O6EW4NVL1EZ.AQ-098EJ)C!)$T<OCD!7W[KW6SK_)
M(ZRZPV+\/ZO<_3?SQ[A_F$==]I]D;@W7ANW^ZLQ6Y3=.V*S$T>,V;G.NE@R=
M=6Y/#1X++[=EEEI9_&PGJ'D53'(CM[KW5PWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@JQ7_,[-[_`/B-NNO_`'H.P??NO="K
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H@GS)
MZ6W-YL-\F^EHVH^Y.J8C59&GHX@[;VV7!'(,GB:ZG`*Y">AHGD*(RL9J<O'8
MD1@9&>R'/.U/#<>TO/;:^1MY[$9C_N)=-3PY4)^`,VFIP%<*W#57`;[XGLSS
M+%=6/WGO99#%[Q<ITEF2,'_=EMT8/C02JN96CC+T4U,D)DC'<(M)0OC#\?,#
MVQWD.^\'\A-YHV4ZJZKEJMBY'J3XS463I\EMC?W8NX<UBZBJHNDZ2HCP2R[E
MCIZ:NHS39*=!)(:I@L/BQQYIEAY6]U=Y]JYCXMYM+@"Y7,-P:*SI&W#Q8$DA
M,\8):)I0K`4ZRK]FO=#:O>3VSV?W%VN-K4[I9).]K)B6!BSQL"I[C$TL4H@E
MIIF1=:GC2[@\\^[=2=T&W</3_6/?_6.]NF>YME8'L7K#L7`5VV=Y;-W+11U^
M(S>'KX]$L,T3^N&HA?3+!/$R3TTZ)+$Z2(K#W7NM/+;>X>^?^$N/R,H>O]]5
M^^>]OY(_R(WU/_<S>]3%7;DWE\-M]Y^H>0X7+?;I*SXIUTM)&JQP9VFC>IIT
MCR451#4>Z]UN5;#WWLSM#9>UNQNNMSX7>NQ-[X+';FVENS;M?!D\'N#`Y:FC
MJ\=E,;74[/%/35-/(""#=3<,`00/=>ZA=C;"V]V1M',[7W%@<!GXJRAJ?X9#
MN/%TF4HJ#,K"YQ>3CCJH)S3U%!6A)4EC`EC9`5-P/;3VFWW4T+;E!%<0PSQR
MA756`:-@RL-0-&!`((R#TNL]WWS9TN&V"]N;&ZN+:6!G@E>)FCFC:-T8H1J1
MU8JRFJL"001UK?;/_E=;XZY^5>X1LCL>CS7<FQ-@4_R%PE'DZ6FIMG5]3OO<
MO8&V=NX8U\E/]Z*JBW%M2>28RQK"8'BNY+.%A#:O8'ECE#GJZ]T^7=QW*XYI
MU7UQ!!+%`L)N+J*=55GUDA%>:M:9`SY]9R<S_?PYP]T?9W;_`+NG/'+NR6/M
MVT6SV-Y>VUS>27:V6W3VC221PE`AEDBMB-(-%+G3P'1[.J/YH^3Z]W31=,?S
M"NKLG\:>SV:*DQ^_115E9U'O%KB(9&DR\)K8\3#/(+F5)JJC75ZI(K6`=Y>]
M^I]FW!>6/>&PDV3?."W&DFUF\M=1JT`TKJ#/&*Y9>'0JY_\`N+6/.&Q2^Y7W
M0=]@YUY&`+R6.M$W:S\_#>$Z#*5&-)2*8T[4DK7JWK"9S"[EQ-!GMNY?&Y[!
MY2GCJ\;F,/74V2QE?2RB\=11UU')-35$+CZ,C$>\CK2[M;^V2\LI(YK21:JZ
M,&5@?-6!((^P]<\=SVO<MEW"7:MXMY[3=('*20S(T<L;#BKHX#*1Z$#IT]J.
MD/7O?NO==$!@RGZ,"IY(X8$'D6(X/OW7NJQ^D/C-T_B/F3\C*FCQ>]&'65-T
M!NC8M%7]O]Q9;#X#-[KPF^Z_<-7!@LKOVMPE3'E:NAA>6&>GE@)C4!`!;W[K
MW5G/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H"?D)_QZ
M6RO_`!/'QX_]_3LCW[KW0;_`;_LC[HS_`,-O*?\`O4Y[W[KW1OO?NO=>]^Z]
MU[W[KW7O?NO=8YD,L,L2RO"TL4D:S1V\D+2(R"5+\:XR;C_$>_=>Z^?ODL/\
MX/Y9N]?C1T!FOY3_`&5WSDOBW\]^U?E7C_E+\<L6N?A^6.P=]8GLS"8>7>6=
MI=L[@S&W=[Q2]BTL-6F2J1''28U(_`-(D/NO=;-7\CSXN][?'?XX]V[X^1G6
M>!Z$[-^6_P`K.WOE15?'':=70U.U^@\'V/)AZ?`]>8Z+%DXNAK*6APXJ*N&G
M)CCFFL0KAT7W7NKHO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=!5BO^9V;W_\`$;==?^]!V#[]U[H5??NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(_?V\*#8>T,[NK(DM#BJ">:&
M!5,DM95^-_M:."%;O-+/*``B@EA?V&N;N8H>5]@GW>5HQ,H"1!V"*TTA"1*S
M,0%4N1J8FBJ&8X'59'CCB>:8,88T9F"J78JH+,%45+,0**H%6-`./6M#TSW+
MWOM3Y5YCMJFV#N?$83>E96X2.AK=LY:FV_C,=JE&WHZRFIX(8Z:@IY9!YQ&5
M\2U$CCD#WDK[B[%[!;/]V?8K';^=.6]R]TN5+G]\7$D.YVC7.Y7%V0V^0(QD
M+2-<1,RVZM74UM;KZ4Y'^U?/?O\`VOWGMWYMBY3WK;N1N8XFVZ"&;;[E+.RA
MA!&TO(BQJ(XX9`OCE-.A9[AQG!NTZ2^<G679N3BV1O:&?J;M"-Q33;8W1)X<
M5E*I3HU[<STR04U;!4LI:))1%(ZD:=?U*7F'V9WB#ENVY_Y&GCY@]N[VW2>"
M[M>YQ%(H9?&B4LRE0:/IU!6!#:2*=92^TWWT>0N<>9)?;/W*@DY.]W[28P36
M%\=$,LR$J?I+E@J2*Y!:-9`C,M"GB`AB=KZ@$<@@$$<@@_0@C@@^X9ZS,!!%
M1D'H,NY>F>K?D+U?O7I?NK8^`['ZO[#P=7MW>&S=S44=?B<QBZM;,DD;VDIZ
MJFE59:>HB9)Z:=$EB=)$5A[K?6G[LO>/R`_X3`_)#'=2=K9'>O=_\DWO_?,D
M'6'9U8M5N#=7P^WGN2HEJ#MS/>`2RKAHI=33Q*B4^6I5:LI52OCJ::7W7NMR
MK:&\=K=A[2V]OK8>XL-NW9^[\+0[AVKN?!5T&3P>=PV5I4J\;D\=7TCR0U5%
M502JP92>#_7W[KW5:&P/]FZ_X<8W;_?/_9:_X1_LL/3W]XQM@]I_QC^X?^F7
MO;[`X/\`BH_A_P#>G[SR^;[C_)=&C3SJ]^Z]U8?VEU%UEW9M2MV/VOL?;N_-
MK5Z.LN)W%CH:Z.%W73]S0SLHJL;6H!Z9Z=XY4_##V2;_`,M[%S3M[;7S#:PW
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ME8+2IX"0+7\);J*_>'[B//\`R?L9]P_:*\M^>O::1#(E[MQ$D\4?'_&+9"S5
M4?$T6NF=2IPZM(1TEC26)TDBE19(Y(V5XY(W4,CQNI*NCJ0002"/<^@A@&4@
MJ14$<".L%65D<QN"KJ2""*$$8((.01Z=<O>^J]%!ZC_[+`^9'_AK_%__`-YG
ML;W[KW1OO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0$_
M(3_CTME?^)X^/'_OZ=D>_=>Z#?X#?]D?=&?^&WE/_>ISWOW7NC?>_=>Z][]U
M[KWOW7NO>_=>ZQ3O+'!/)!&)9TAE>&(D@22I&S1QDCD!W`'OW7NOG*X'Y-]T
M_.G#?'C^7UB_G!W;6?)#YU?S$OD!VG_,1IL#DLYM;=?Q6Z*Z.RLVV<=UAA:[
M110[-V)2[*VG)F5I=;41J*2/RH$1HW]U[K:'_P"$]W9F]-[?%7O_`&)7=S;I
M^2737QY^9O>?0GQ>^0N]<LV?W/VKT)L:;!_W5RN0SY'^YV'&55?44M/5@LLL
M$:A"(U15]U[J^CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW058K_F=F]__`!&W77_O0=@^_=>Z%7W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=!WV%VYUEU.=E+V3OC;VRY.R-]X#K#84.=KXZ2?
M=W8.Z7F3;^TL#3G5/D,SDS32,D<:FR1L[$*I(]U[I!?)#Y6?&[X?[#3L_P"3
M_=/7_1^Q)LG!A:/<._\`/4V'I\EEZD$Q8O$4K>3(9C(%`7,-+%-(L8+L`H)'
MNO=/O2O>G1?RDZTPG;/1'9.P^Z>KMPEFQ&[MF9?';EP4]33Z3-23M"96Q^5H
M_(/+35"15,!8!T4GVQ<VMM>1>#=QQRPUKI=0RU]:,"*];!(-1@]$K[Q^2WQK
M^(_R@[5['^3G;/772G5=/\7_`(]4=-E^P,M18G"U&Y,OW'\C*44V%Q<@DFRF
M;K(*>(2K1T\M08(59QXX[J7#EWE\"@L++C7^PB_Z!Z<-Q.10N]/M/^?I=8O>
M7\O_`/F&]'5_;6P>R^HNW.J=NPY:*I[<V-N3%T4FP?X#'--E#E,X#25>UX\5
M3TKS20Y%(X1`OE*&,AO<H\@>X_-OMG<+)RC<FWLQ\5N16V<>C0_"/M72P\CU
M!OO-]WCVG]^=J.W^XFUQ7%ZJTBO(_P!*]@/D8KA1KH*?`^N,^:'HE/QQ^46<
MCQ6X]Q_#GO;:7S\^.NP\O3X?=6#P63J*GL[KJ*IIQ64$:T=5!#FY<;68\M+0
MU4,-3CZU(V,04*Q6?5W+V6][ET;RB<J>X;C$R`?17#GS<&BJ6/'5H85^-^L*
M9-@^]Q]SMO'Y4EE]RO8F`U-I,2=VL85XB(C5(P1:D>&)HC3,,0J>K(_C)\V?
MCI\ML+5Y+I[?V.RF3Q.7S.W,]M>N8T&>Q6X=MULF+W%BXX*@1Q9@8?*P24\L
M]$\\(DC8:@00((YO]M>9^3]=U=1K=;$LSQ+>6]9+9VC8JP\0#M(((HU,U`)I
MUFA[5_>%]O/=4Q;98S2;9SHUI#<R;3?A8-PCBG021OX)8^(CH0RM&6[2"ZH3
M3H7.[^D.J?DAU1OCH_O#9&#[%ZM[%P=7M[=VT=PTB56/R6/JTL'0FTU%D**8
M+-2U4+1U%+41I+$Z2(K``=3GUJ&]:]A]\?\`"8GY%TG0_?F7WQW3_)>[YWA4
MITCW344]=N/<GQ)WAF)9ZO\`N;NJ.F266+"R.Q^X@15AKX$-?1(M2E;2M[KW
M5XW2/S1ZI[J^=^3W%USMOMS/X+?GQBZ7V?A<Q!UKFOX93E.R^UMW1;GS-6KN
MN+V76;?WECJB'*.#3.LQ!(9&7VLDV^]BLTW"2-A9R,0K4P2/]6#P-#3ATV)H
MFE,(8>*!4CJX'VCZ<Z][]U[HN?R'^)W07RFVZVW>Z.O<1N9HX7BQ>XXHQCMW
M8!W_`$SX3<E(J9&C:-O4(RSP,?U(WL$\Y^W?*'/UG])S-9QS,%(24=LT=?-)
M1W#[#53Y@]3)[/\`O][L^Q.\C>/;3=[BQ!8&6W)\2TG`_#/;O6-P1C4`'`^%
MAU5K4],_S"/Y>$LF3^/&YZ[YA?&O'OYJCIS?$\LW9>T\3'ZI(=L5J%JJJ2EB
MOI^R,BG2"U%]3[@-^6?>+V98S\FSMS'R0AJ;.:IN(D\Q'3NP/]]5%!_8]9UP
M^Y/W0_O@H+'WAL8O;KWJF%%WBR4#;;N4\#<H>U2QX^,%(J0+G@.CM_&/^9!\
M;ODLKX&#<,G5G:F-26/<74_9YBVQNC&5E*K&NBH)*]H*/-P4Q0W,+"95%WB3
MZ>Y7]OO>?D[W`E3;+61[/F<G2UE<#1-K'%8ZXEIZ+WC\2@]8N>_/W._=[V'@
M;F'<K>+>/;AEUQ;QM[>/9M$?A>8K4V]1YR?I_P`,C=*'I_<^VY/EO\JJR//X
M5Z/=.W_C91[9JTR=&U-N&KQFV]_ID:7"S"8QY.HH)*F-9DA+M$TBA@"P]S1)
MMNX0H9)H)DC'$E&`'YD=8BP[IMMPXB@N('E/`*ZDG\@:]':]HNEW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!/R$_X]+97_`(GCX\?^_IV1
M[]U[H-_@-_V1]T9_X;>4_P#>ISWOW7NC?>_=>Z][]U[KWOW7NO>_=>ZXR21P
MQO-*ZQQ1(\LDC&RQQQJ7=V/X554D^_=>ZT=:C^<Q6UWRKWGV+\.OY`4G:F7^
M5F=[LZPZX^1>+R-!LCL7Y5[9Z@EJ<1VMDL?58;K:OEF2**DDJ*Y(,A+4&`JT
MTCR*^GW7NK[?Y%/>U7WO\*FKL3\.M@?!CJ[KCLO=W4W6'06R-Y1;NR.VZ79,
MT-%OA>P(WHL5F=M;ZC[#?)15=!E*2#)E42IG,IJ%D;W7NKG_`'[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW058K_F=F]_\`Q&W7
M7_O0=@^_=>Z%7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0(GY,?&\=
M@GJ4_(#I,=J+F?[NGK0]I[(&_AN"U_X$=H'.?W@&8_Z9OM_-_M/OW7NJ-OYG
MGQ"P6%^8'\OKY@;R[1[6[,[&RW\S#XU=>]7[5W)N-:#JOHGK7+X;>M1N+;&P
M-@8.GQ^)K<SNC+8F.IR.=ROWV4E`2&.2*&-4]^Z]U9M\R/B-USV9N;#_`"VJ
M^@8/E;W]\;>I>SL+\>.A=];JP>,ZHSFZ][#'3UM7)C-W8[);1Q&]\O'B(L?%
MGJN.4T-#)(J)=K^_=>ZK6_D3U,V#[6_F4[/[6ZAI/B9\J=S_`"`VCW)VO\+]
MJX.FH>JNGMG[JV:FW^N=W]7[GQ-95;=['@[0Q^VYJ_.9G'14-,V55HEIHU12
M_NO=&U[W^+'Q0[8_F2M\DOE!MK:NXH/BI\*]E9C:53VA5XF;J;9L6]NT>^X-
MV[UW+@=QP2;<GRV(P^W%2DKZM@M!#-4%1J<,GNO=5[[-^`B?+_:_\W?N'XI;
M2P_QIZ+_`)A'QZVCT;\=L/58"NV'@>VMS=?X?=M-EODUE=A8ZGH)-E[)[0K\
MU!B,8_V<-?E,'2')O"J542O[KW4::/YA]>=C;B[4R71VV?AU\@OD_P#&WH[^
M7!\>.MZ?L'96^\S3Y?KFOWEO?N;YB;JR6PJB;;F-ZN^.W7&6K<EA8YI?OV6D
M6&IC@^[@C/NO`D&HX]#+\8,W_+N^4=+U5\;^@=L]_=![RVIU%-G/C1W1O3K3
M-]:0?)?KKKBOI=N;E[<Z[S]=4&/L^GES=9'D<C55:X_+U2Y-:U0T4K.LR>W7
MO=S;[?V_[FI%N/*3U#V5R-<6D_$(R03&3Z"J$Y*$]8F>_/W._;#WOOSS:/J-
MA]T$(:+=[!C%<:T`"&=056<*!0-5)0,+*HQT>6/NWY/?$N6GQ/R*VS-W+U+!
M(E+2=R;)@,F?Q=)J"0ON;'$1B1T2^HU`B=K<3RGCW)S<@^TWO*C7GMC=KL7.
M;`LVV71I#(WF('S0$\-&H#SC0=8[1>]GWG/NF31[3]XC;'YQ]IT8)'S#MRUN
MH4X*;R+MJ0*U\;PV-,7$QP5+\NL=MGYX_![N7K[I+$=/=[C?FTY\9/L7M"FJ
M*S#37C-2*:LQ*-!DL+NRBJHHY,?-+X?#4H)$?4JGW!&Z\E;MR/S$NT\^V<]J
M`32HK&]/A99%JKQUIJ*$FGH>L[/;GW>Y`]X^61S+[8[K:[E9,!J"M2:$GBDT
M+4DAD'"DB@$\*C/7S*_C?O/^9A\,?G[NKM;(4NY.I#T.*R7MBKFVUN%.HML=
M3;%\-/+@MO8C'4,M/5X_'XPQT]#14Z-.7EM4@!IF]U@FW%MZN+?<GA-BD2F=
M:CPE@-?"*`9%:?HE<E@?Z70X86XM4,&KQR>W^+7YZO\`GZN*?EU]1?X$?-CI
M7YW_`!VV5W3T]VYUWVM)6XJCAWP^P6R./&V-UF+57X3-;2W`R[JVK74[<&&O
MC0R$%XB\95B#;KZ;ZA_HM?TNHZ==-5/*M,5Z-8_$T#Q:>)3-.%?ET=3VQU?K
MWOW7NO>_=>Z(5\P?AKT7V]A\CW!D.MZ>3N?KZ@J=R;1W?M:&3&[ER.5QL,DM
M'CLRN.33N:BJ)&TF*ICED`_S;I["LOMSR?O7-^W\U7EJD?,%E<I+'<1GPW+)
M4J)2*"1:T^.I'D1U+^P?>&]V^2?;?>_;#:-UFE]OM[L9+6YL)QX\(CDH'>W5
MZM!(`*@Q%03\2MUK@_$KI7YD]-_("#?YZHW;O3.;`Q^4S6-V%7[DJ*P5N?R0
M^]VIB\M1K6U4^"BW`E)+]O4S1QK9&*D@'WCC[6>W/O\`^WO,FZ<V<RQS7EA%
ML]]X%N^XQ3K+<,GZ,819W:K'`.G'$TZZ0?>8]_\`[D/OG[<;%[7\C;A9[7NM
MUS/LOU=Y#L,MF]K91NPO+CQGLX5*Q@@LGB?J<`#U<QC/YQ6WMCUT6#^5?Q=[
M_P#CQET98:[(U6VIMT[7CJ3_`)QH\A%!BJMZ:,<DI#*P'X/L^@^\G9;5-])S
M]L>Z[/<+AF,9DBK\BPC8BF3I5OSZB:^_NYMXYHMFW3V%YZY2YPVXU9(UN1:W
M)7R!C+2H&/HSJ/LZ//U%\[/B+WE'3_Z.>^NO\E75"H5PN6S$>V,\K2-I2)L/
MN1<77&9C]%5&)_'N5N7O=GVZYHHNT;M:-.?]#D;P9/3X)=#?L!ZQ:]PONK?>
M%]KG?^N7*>[PVJ$_K10FY@('$B:W\5*#U)`Z-C%+%/&DT$D<\,BZHY8766*1
M3]&21"R,/\0?<AJRNH9""IX$9'4`2(\3F.52LBFA!!!'V@Y'7/WOJO7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]T!/R$_X]+97_B>/CQ_[^G9'OW7N@W^`W_9'W1G_
M`(;>4_\`>ISWOW7NC?>_=>Z][]U[KWOW7NO>_=>ZXO''*CQ2HLD4J/%)&XNL
MD<BE'1A^5920??NO=:.GS1R7P2^"NR!\2^G?YQ^#Z3^5/Q<^7>]/DM\0ZG=N
MQLQVEBOC!A^T\?E\)V7\8-\9386V-W4<^T\K/NC*U31Y&*6NI"\*U%*8RQ]^
MZ]UL$_R2?C,/C]\0LSO;+?*?:?S.["^67<6^OE+VG\@^NZU*OKC>F^NQ/X;2
M9)ME"(QQ)CJ.+"1I,QIZ.1JORAZ:`J(U]U[JX3W[KW7O?NO==V/]#[]U[KUC
M_0_[8^_=>ZZ]^Z]UW8_T/^V]^Z]UZQ_H??NO==>_=>Z][]U[KWOW7N@JQ7_,
M[-[_`/B-NNO_`'H.P??NO="K[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[H$#\9?C:>PCVX?CWT>>UCF/[Q'LX]4;$/8)W!IT_QT[S.!_O$<SIX^Z^Y\
MW^U>_=>Z`OYL_%S>'R<J_B'4;1W'MS;R_'GYF]/_`"3W0-Q)DG.<VIUU0;LI
M<K@<%_#J>HT[@KGS\1@,^BGLC:F''OW7N@7^?/Q-^:/9/9G4OR8^`'R?V]T5
MWUUEMC=/6VXMA]SXK<.]?CAV[UON_(X[+RP[NV9A:D38W>VU,SCEJ<9F*:%J
MKQN],SI$Q/OW7N@X^*?P+^8/1^V_E]\CNUOD?USW+_,P^5&R\?@:#L:7963P
M/QQZFI]@87.T_3O7FUMCT<B;BJM@[:S>=FJ\E42,N0R+.20'74_NO=$5^;O\
MG[^8!W=N/XW[NZ.^0?34V2VOL':%5\H]J_)7?WR3[,ZL[N[?VCE9=Q[<IH]@
M_P`9JZ.?IW86Z\KELEAL+63"&2;*2)603QQHOOW7NK6O@?LO^:7M+,;_`!_,
M,[=^(_9.UY<+M^FZKQ_QGZ_WILJNPF5IJJN_CTFY9-U.:>JQDV/-,E+'`MXW
M1R>"![]U[I?5/Q*R?8OR8[Q[Q[OS>'W'MO-=-#XZ_'G:F"-=%5]8]9;RQ!J>
M\<]D:BKIHH$[`[0W1)3PO4TI<4^&P]'"'N\P/NO=$S^&'\N'Y&]/]L_&#-_(
MGM?J'>/6/\OOI+?O0/Q$H>K-O[KPV\MW[=WWC]O[2;?/>LNX:B7$T6Y<)UMM
M2BQ<>/P[3T51623UK2JWCC'NO=75SP054$U-50PU--41O#/3U$:303Q2*5DB
MFAD5HY8W4D%6!!'N\<DD,BRQ,R2J00P)!!'`@C((]1TS<6]O=P/:W2)+;2*5
M9'4,K*10JRD$$$8((H1T03MCX18*FRU7VG\==VU70/9-#'/7U$N$FFI]E9H1
MAIYHLOAXB8J**7U%S&CTYO=H3]?>0G+?WBI;'9GV+W=MHM_Y(CC)=IZ&X@11
M4NDIRVE14:B'%,2#K`OW.^XSM4F_'W&^[9ND_(ON@&+4M69=ONF)KHFMUJL8
M<DZM"M$:U:!N/1)?CS\M<3NGY<[@ZZ[/H]C;@I=S;=.S<OGX=N8B'$Y_=JT=
M/2[QF>"2!X):#--2)%*&7341TS%P0P40USA[,[GRO[=[?]Z*S6^@VGF#=62Z
ML9G9S9;%=2!-AD93\+PMI>X)R!>4_`23+V6^]'<\P>^-S[`\XW=C>;G8;1%"
MM]`BQ17>\VD>K==%,>%(=:P@4'^+,U/U*`K'S#_D$;LZQ[6R'S8_DH=P-\'O
ME/"U1EMS]/8^JEI/CCWAI)K9,%E-LNE;A-K/F*E65H)*2IPLCSLWAI6_?`=Z
MSH!J*CATLO@[_P`*`,-DNTZ'X4?S6>J<A\`?G!C)*7"))OF*3%=$]O5S,E+2
MYG9&]JZ:7%X,Y^1D>GCGJZC&3NY6FKI&M$/=>ZV2X9HJB&*HIY8IZ>>*.>">
M&1)89H94#Q30RQEDDBD1@59200;CW[KW63W[KW7O?NO=%!ZB_P"RP?F0?R=K
M_%ZY_/\`Q[/8WY_V/OW7NC793$8G.4<N.S>+QV9Q]0C1ST.5H:;(T<\;BSQS
M4U7%-#(CC@@J0?;%Q;6UW$8+N..6!A0JZAE(^88$'I98[A?[7<K>;9/-;7:$
M%7B=HW4C@0R$$$>1!Z)!VQ_+.^$?<;SU6Y>AMJ87,3L[_P`>V(D^Q\K'*XL)
MD?;LM%1O)&>5\D+J#^/<5\P>QGM;S'J>[VF"&X>M7MZP-4^?Z952?2JGK)_D
M#[[/WG?;E5@V3FN_N=N4`>!?%;V(@>1%P'<`^>EP?GT4JJ_E4]K=43RY#X@_
M-_NOJA8V+46S][9"?>>TA''ZX:.4">%13L_ZRU)+<?V3[CR7[O\`S#R^[3^W
M/-.Y6'\,,Q,L0'$#M*BGJ3&W60$'W].0N?HEL_O$>U_+._DBCW=E&MG=U."X
M[3W4X4E7/F.N$>^_YR?0+$;OZPZ=^7&UJ,!&R>R*^':N\*BGB]<LXH0,2TU2
MZ\(HH9"3^#[J-W^\MR>3^\;#;N8=O7\4)$<Q`.30>&:TX`1-^?5WY5_NW_=I
M:\O;YS'[?;[)GPKV,W5HK'`77^J`HXDF9:#S'3[A?YQ?6^UZZ+!_)KX_=^_&
M_-!TIZJ?<FSJS.[<CJ2;2:,I1P4=6T$2\LPIF('X/M7:_>4V2PF^DYYVC=ME
MN@:$R1%XZ_(T1R!6I(0]%6Y?W<O.>^6K;I[(\W<I<Y[90LJVUXD%P5\JQ.SI
MJ/`#Q!]O1Z>J?FK\4>[(X3UKWUUQGJJ=8RN*FW!2X3-AI39(FPN=..R0E8_1
M1$2?<L;![H^WW,]!LV[64DQ_`T@CD],I)I:OY=8L\^_=G]_/;)V_KIRIO-I`
MI-95MVFAQQ(F@\2.GSU4Z,^CI*BR1NLD;@,DD;!T93]&5U)5@?\`#V/`0PU*
M05/F.H-961BC@JX.0<$?D>N7O?6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K!5-4K2U+44<,
MU8M/,U)%4RO!32U0C8T\=1/'%-)#`\U@[JCLJDD*3Q[]U[HD?5G=WRJW3W]N
MSIW?G3G1FW,)U[M[K_=6\MT;7[FWGN/)-A^RGW_38"/;N!R74FWX*W(4E9L"
M852U%731B.="C.01[]U[H\?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H"?D)
M_P`>ELK_`,3Q\>/_`'].R/?NO=!O\!O^R/NC/_#;RG_O4Y[W[KW1OO?NO=>]
M^Z]U[W[KW7O?NO=$2_F!_P`Q3XT?RU>H=O\`<WRDSN\=O;(W?O6FZWPM?LG9
MN3WME%W/D\)FLW2^7&XL&6GI4H,'4/YG]`D55^K`>_=>ZTE_Y:W\U'_A/]\?
M.C.T=D?*KH&3MCNS(=T=Q;JW%WANWXU)VOEOD3BMV;NS^?VOO.GJ=V4U9F-A
M5$^WLG!CY\/5&F2GJH7F\CB5I/?NO=7\_P#"77?/2'87PR^3&Z?CS3[CV;U3
MN#YT][;GV5T3FX,B:/X\[/W-%MK*[.ZQQ&3KC)39H1[8EI<A53T<DM*E56O"
MKL\3D^Z]ULN6O]/?NO=%:^6^4^6M-UK1X#X8[7ZUR/;^]-P4VUSO[M_,U-)U
M_P!*[=K:.LDRG:F7VOC8),UV-68!HHTHL#2R4QK:N:,S3)3I*??NO=5D_P`K
MCO[L;;_\E?(?(/N[L[+]E=C=>[9^8F\=X=F;OKIVK-P9?KWL7MF<Y29ZN>8X
MS'/)AD6FI5?Q4=.$AC`1%'OW7NJ+OY7FY/Y=?:7;/P^??O\`,O\`YHLORFW7
M+UYOX4787:G;NS_B#VUW?X\7NW-]1;'S&\-I4VV=W8:?,SSX^#%_>A<G!2R1
M0RR%E#^Z]UN$?.#OK(_%SX>_)OY$X6BI<EN#ISI+L3?NV\?7+KH*S=&"VW7U
M.VJ6N0,I>AFSWVZS`$$QE@"#S[]U[K74W+\9_E;_`"\^B?CO_-$JOGW\K>[^
M\<SOWXV9;YG=2]G[MI,_\>^S-A_(;>NS]I[^VKLCK&GQT5!U@O7E1OF&?#U=
M%.="8SU:?)Z?=>ZC?.GNG?&'^8'S(R=?\@>YMA?-#J+N'X9[>_EC?'C9^]=S
MXS;/<76&^SUV-_3X[I7&22;8[NPN],[F]VT&Z<G74M8^"HZ$MKI12(3[KW5Q
M75O<]/\`('YK;Y[2RO9%+LWX^_''([A^+/1>)GWK!MW;OR"^2>1.-_V83==%
MCJJOH(M^4?4]52TNS<-&(JA(\NF8EB!81LONO=6G>_=>ZXNZ1C5(Z1K>VIW5
M%N?H+L0+GW[KW038JHI_]-6]G^XI])ZXZ[4-YXK%AN#L$E;Z[7`]^Z]T*GW5
M+_RM4W_G1#_T?[]U[KWW5+_RM4W_`)T0_P#1_OW7NO?=4O\`RM4W_G1#_P!'
M^_=>Z]]U2_\`*U3?^=$/_1_OW7NO?=4O_*U3?^=$/_1_OW7NO?=4O_*U3?\`
MG1#_`-'^_=>Z]]U2_P#*U3?^=$/_`$?[]U[KWW5+_P`K5-_YT0_]'^_=>Z]]
MU2_\K5-_YT0_]'^_=>Z]]U2_\K5-_P"=$/\`T?[]U[KWW5+_`,K5-_YT0_\`
M1_OW7NO?=4O_`"M4W_G1#_T?[]U[KWW5+_RM4W_G1#_T?[]U[KWW5+_RM4W_
M`)T0_P#1_OW7NO?=4O\`RM4W_G1#_P!'^_=>Z]]U2_\`*U3?^=$/_1_OW7ND
MCOK`0;UVME=KC<#X6++PFEJZR@FI35-2,#YJ:*21_P#)_N!8&1?4H^GL-\V<
MOR<T;))LL=T]HLKH6=4234JL&,95^TJ]`&!XK53@GK1"LC1M72Z,IH2K`,""
M5895@#@C(.1D=4&];_#?-TWR^DZMR?2W6>U<=M786S.W:CL#"_);?>Y-S4-+
MNG?/8&UX*N#!5_5F&Q>9J4;97DDH7J:8?O->I<,%61>9?<_W^YOY4N^1^8><
MO'Y5O;0VLUN-FVM%,!4+H4K$#&5`'ALM"A"E:$#K&'8?N;_=XY6YBM^<-@V:
M[AYGM+@7$,QW&]8B8$L&<&3O!)[U.'4L#QZL+ZH^1&Z^ENSIOCK\E#1XVGR-
M<YZ=[-BJ9JC;N>PT\RQT."K\K5LTBRP.XBBEG820N1#-QXW:8+GV?L.8/;*Q
MYS]N;Z?=]QL+-(MUBE2..[\6-:-<^##1`645<1C2]#*F2ZB%N1/O)<T>TWO)
M>>Q'WC+2#:-NW"\>3EW<D>62QEMY7_3LVN9^\Z&;1&\S:XF(MYJ`1.R]^<_\
MOKXA?S%^J:GJ+Y6=9X'?.*B2>3;&ZJ:>##]A=?Y.:-D&8V/O"E'\4PE6NJ[Q
M7DHZD#3/#*OI]X_==".M;.1/YL__``G>EC&#EW3_`#2_Y4N%;7+0R-Y/D?\`
M&;:L4Y:6*"2&2MJ)L)BZ4LZE8ZK!LOU&+Y/OW7NMDCX+?S&OB'_,9ZLI^U?B
MQVUA-Z4D%+3R;MV56S0XCL?KNOF16?%;YV=52_Q/#3QN=*3@2450/5!-(O/O
MW7NCMFIIB"!5TZD@@,)X+J2"-0NQ%Q]1?W[KW57/173N_<5\V/DUE:_Y6]Q9
M^@P-'\<\KDL!E<=TO#B-WT59M_L&6#`9J;&=9T&4AQF-C0I&U%44M25<EY':
MS>_=>ZM'^ZI?^5JF_P#.B+_H_P!^Z]U[[JE_Y6J;_P`Z(?\`H_W[KW7ONJ7_
M`)6J;_SHA_Z/]^Z]U[[JE_Y6J;_SHA_Z/]^Z]TTYO%;8W+038O<>/P&?QE0C
MQSX_-4V.RE%-'(-+I)2UJ30NK#Z@CGVFN[*SOX3;WT4<T#"A5U5U-?4,".C#
M;-VW79;I;[9KFXM+U""LD,CQ.".!#(5(I]O1"^U_Y7?P2[=EJ*[*].;>VCG*
MAY)?[P=<9.?9.1BJ'`TSQPXBHCQ6N(BZAJ8K<_3W$?,'L#[5\PEI)ML2UN6)
M.NV9H#7UTJ?#)%,50CK*[D'[]WWHO;U$M;#F>XW#:T`'T^XHE[&5'X2909:'
MSI(#\^BT?\-E]Z=-L]5\1OGSVIL6EA)-'LGLV:#>VU1%%9H**1Q+XUA+?J84
M)-K<'V!_]8CG#EHF3VZYLW"U2M1#<_JQ4!J%QV@'S/A'J:_^#C]I?<=1!]X3
MVJY>W6=OCO=M_P`2NJG#.!2I:G`>,/MZQ2=S_P`W[H.Z[^Z+ZA^5>V*'B?<7
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M,_N6"K)@\C+1Y>*0D_I:$'W,&P^XG(W,P`V/=;*XD/X!(JR>F8WTN,^J]8D\
M]_=_][?;.1DYZY7WK;HT)K(]M(T..)$\8>(CYAR.C!-+"@!>:%`?H6EC4'_6
M)87]C/RKY=0]4:M->X>7G^SKA]U2_P#*U3?^=$/_`$?[]UOKWW5+_P`K5-_Y
MT0_]'^_=>Z]]U2_\K5-_YT0_]'^_=>Z]]U2_\K5-_P"=$/\`T?[]U[KWW5+_
M`,K5-_YT0_\`1_OW7NO?=4O_`"M4W_G1#_T?[]U[KWW5+_RM4W_G1#_T?[]U
M[KWW5+_RM4W_`)T0_P#1_OW7NO?=4O\`RM4W_G1#_P!'^_=>Z]]U2_\`*U3?
M^=$/_1_OW7NO?=4O_*U3?^=$/_1_OW7NO?=4O_*U3?\`G1#_`-'^_=>Z*3US
M44X^:/RG8U%/I;I?XG`-YXK$C,?)"X!U_4?\3[]U[HVWW5+_`,K5-_YT0_\`
M1_OW7NO?=4O_`"M4W_G1#_T?[]U[KWW5+_RM4W_G1#_T?[]U[K(DD<@)CDCD
M`-B8W5P#];$J2`;'W[KW7/W[KW7O?NO=`3\A/^/2V5_XGCX\?^_IV1[]U[H-
M_@-_V1]T9_X;>4_]ZG/>_=>Z-][]U[KWOW7NO>_=>Z][]U[IBS^U]L[LHX\?
MNG;N!W-00SK514.X,1C\U1Q5*(\:5,=-DJ>IA2=8Y&4.%#`,1?GW[KW21_T*
M=.?\^DZQ'^OL+:8_WO$^_=>Z5V`VKMG:5))0;6VY@-LT$\[54U%M[#X[#4DU
M2R)&U3+3XRGIH9)S'&JER"UE`O8>_=>Z`/Y._'O=7R'VQMS;VT_DQW[\8ZO`
MYV7,U.YOC_F-GX;/;CIY*":B&#SLN\=G[PI)L1%)*)U6**&03("7(N#[KW0D
M]+=<Y;J7K/:O7N=[1[#[HRNW*2JIJSLSM:MPN1W]NF2HK:JL6JW!6;>PNWL1
M-/3I4""/PT<($,:`@L"Q]U[JF?\`E_\`3?R(VW_)6W/U1A>G]L#Y`U<7RQ&T
M^G/DSL^L78N[<EG>Z>R\QM[:_8VULHV/EFVGOS$UD46J4K"U/6)*;Q\'W7NB
M5=O]U_(W^:3UGT/_`"^]J_RM/D5\1]T;2[BZ"W1W=V]W!L+;6P.B/C!M[HC>
MV"W5NK(_'O=V-KZG^]^?K)MKOB-L+AX80:2K#L1"6]^Z]U=9\HJ2K^;767\P
M+X%XWKWLW8687H==F8#N+>VUVQG4.^=Q]P["SE9MR;KW<\=342;E38F=I*>+
M/J(8VHY6"`.3[]U[JDW/=V_./^8%TE\=_P"6!NG^7C\EN@^S-L[^^.5#\R?D
M#V708G&?'+:_7GQTWCM/=V[]R=6=@TF3*]IUW:%5L:FBQ=#20KHCR+:RZQEC
M[KW5^7SDS'86V>HFFZ!Z[?='R4[$S&'Z,Z8WI1[4BS4G3^5[.GDP>4[<W'G%
MHJBIVWL?J[;TE;G*UV>.&KEI(J0^NI7W[KW5"'SI^#^!Z>WIE>MLI\1^T?EA
MUED_Y<&.^,7P4R?7O6]1OZNZB^7D>[M\9;>&^]T;@HZN$]/;^[2W+N+`[DJ-
M^U#TP67'51>M1U,<ONO=;*WQMVQV/LGX\=$[-[BSB;F[9VGT_P!;[<[,W"D_
MW:YO?F%VAB,=NO*"K/-8:W-T\\AF/,I;5^??NO=";N';&W=VX\8K<^$QN?QJ
MU$56*'*TD5;2BIA#K%.(9E9!+&)&`/U`)]^Z]T7O&=,=2OW#O*A;KC9S4D'7
MNP:J&G."HC%'45.=WY'/*B&/2KS1P1AB/J$7^GOW7NA-_P!!O3G_`#['9/\`
MZ#]!_P!>O?NO=>_T&].?\^QV3_Z#]!_UZ]^Z]U[_`$&].?\`/L=D_P#H/T'_
M`%Z]^Z]U[_0;TY_S['9/_H/T'_7KW[KW7O\`0;TY_P`^QV3_`.@_0?\`7KW[
MKW7O]!O3G_/L=D_^@_0?]>O?NO=>_P!!O3G_`#['9/\`Z#]!_P!>O?NO=>_T
M&].?\^QV3_Z#]!_UZ]^Z]U[_`$&].?\`/L=D_P#H/T'_`%Z]^Z]U[_0;TY_S
M['9/_H/T'_7KW[KW7O\`0;TY_P`^QV3_`.@_0?\`7KW[KW7O]!O3G_/L=D_^
M@_0?]>O?NO=>_P!!O3G_`#['9/\`Z#]!_P!>O?NO=>_T&].?\^QV3_Z#]!_U
MZ]^Z]U[_`$&].?\`/L=D_P#H/T'_`%Z]^Z]U[_0;TY_S['9/_H/T'_7KW[KW
M73='=.Z6T]8;(+:25!P%`H+6.D%O"=()_/X]^Z]U7]LKX^=S2?*[(]J;O^)?
MQSP/6.Y>LME=3Y"/$]OS;@SV#@VGOGL+==3O.#!2=/XB@RDN3HMX4T`HA5P.
MCTI)F*E??NO=''[*^)_1?9>T,MM.OV%M["/74\BX[<.!Q5)09W`UX&JFR.,K
M(D61'AF52\1/BG4:7!!X&O(//W,/MSS!'S!R])IE%%EC/]G/'6K1R+Y@^1^)
M#W*0>HA][O9+D;W\Y&GY&YYMP]NU7MKA0/'L[BE$N+=S\+#\2?!*M4<$'!$.
MGIL#\?\`L"C^.'RKV%LRNAR,SP]4=V5>$I7QNZZ)YA'28S/9&HB)6LNZQB69
M_+!*1%,2ICE,[<]\@<N>YW+\WNO[2)IN5[]RVP4\2"0C4\L2#BIRQ51I<5=*
M$,@PK]EO?#G[[N?.]K]V;[S\QDVYZ1[!S"Y;P+N`$+%;W$K\&%5C5Y&UQ,1%
M,2ICE:RK_0=TV593UALADDC>.1&V]CVCEBE4I)%(AA*2Q2QL0RD%64V((/O%
M3KID""*CAUKX_P`P+_A.SUSV+OC_`&;/^6;O6D^!GS/P$[YJ)]F4TF-Z+[6J
MX&6I&&WSL3'138C`MDY4*S5%)0ST-06O5T,Y]:^Z]T`?Q1_G`[5Z.[7P_P`)
M/YWGQ3VE\-_DZI@Q6U^_8MIX]OC7WC&G^1TVY*/<-!%4XO:TN9J(@34035&(
M,LH61Z)_V![KW5E_QV[Q^!O97S"^0&"V5/LO>55O^/H[;>S,)@NN]RY>HCKM
MJ;8W.-Q5V:IZ3;4R[.P\<V<IHUJ\K]C#*5)5F32Q-;S9MPL+6.\N4I#)^U2<
M@./PEAE0>(Z3Q74$TC1QFK+^P_9ZTX'JUO\`T&].?\^QV3_Z#]!_UZ]E72CK
MW^@WIS_GV.R?_0?H/^O7OW7NO?Z#>G/^?8[)_P#0?H/^O7OW7NO?Z#>G/^?8
M[)_]!^@_Z]>_=>Z]_H-Z<_Y]CLG_`-!^@_Z]>_=>Z]_H-Z<_Y]CLG_T'Z#_K
MU[]U[KW^@WIS_GV.R?\`T'Z#_KU[]U[KPZ.Z<'(ZQV2#_48"@_Z]>_=>X\>H
M.4^//0^<B6#.=.=:YR",$1PYK9V#RT45_KXDR-'4K%?_`&D#VDO["QW2`VVY
MP0W-N10K*BR+3['!'1GLN][SRW>KN7+MY=6%^IJ)+:62!Z^NJ)E/[>BC]J?R
MH?@UVI+/D).G*/8&X)6>:/<75V3R&R:ZFJF6T=3#1XR;^#!H6Y`^VT_X>X@W
M_P"[[[6;\3)^[A9W1)(>U=H:-_%H!,=0<Y2G66W(?W^OO1\AQI9IS')N^T*`
M#;[G''>HRCBI>0>-0^9\2O1-,K_*$[FZQR,^<^,?S`W#3$DR)M/NW;]-OC#2
MI%S%1RULXR,)BD(L["A3V"O]9+W$Y7;Q/;SFZ]BA!)$%V#)'3B%![T`/`GP:
M]3&WWS_N_P#N>/#^\'[2[)=WKT#WVTL+2XJ>+Z0(VJ/(&<]-RU/\P_H5!'VW
M\%.A?DMMVC8^?=/3,>,Q.Y:FEAN9JO\`@<<+N\DB_I3^'QF_X][_`*W_`'BN
M413F+8[/>[)2:RV;A9-(/Q:5J2:>7@C/53[4?W>_NNVOV^YXWCDG>)!VVN\0
M&6V5CP3QS0``\3]0WV]*C:W\R?X(4^2CV[WS\<]X_&W<XD2"IH>QNJ&GQ=/4
M$^M#E,92-4>.,<EGI8Q;VOV_[S/)JSBQYKL]SV:_U:2L\+,H-:'*C70<:F,"
MG1'OO]VY[QS61WCVIW;EKG38Z%E?;KV-967R/A2D+4\`!*W5@?5V[O@GW5!%
M/U7FNA=ZM,J.E%B9MO\`\642&R++AJK[?*P.QXTO"K?X>YAV'GWDOF=0=AW2
MRN6/X5E4/Z9C8AQGU7K$;GKV-]XO;.5HN?.6MXVP*2"\MM)X6.-)E#1,/F'(
MZ'C_`$&=.#_FF&R?_0?H/^O7L7=134==?Z#>G/\`GV.R?_0?H/\`KU[]UOKW
M^@WIS_GV.R?_`$'Z#_KU[]U[KW^@WIS_`)]CLG_T'Z#_`*]>_=>Z]_H-Z<_Y
M]CLG_P!!^@_Z]>_=>Z]_H-Z<_P"?8[)_]!^@_P"O7OW7NO?Z#>G/^?8[)_\`
M0?H/^O7OW7NO?Z#>G/\`GV.R?_0?H/\`KU[]U[KW^@WIS_GV.R?_`$'Z#_KU
M[]U[HJ/7G374TOS)^4%%)USLYZ6EZ;^*DU/`V#HC%#)4Y;Y%).\:&/2K2K3Q
MAK?41K_3W[KW1KO]!O3G_/L=D_\`H/T'_7KW[KW7O]!O3G_/L=D_^@_0?]>O
M?NO=>_T&].?\^QV3_P"@_0?]>O?NO=+';>T-K;.I9Z+:FW\3MZDJI_NJFFQ%
M%#10SU&@1B:6.%55Y!&H%SS;W[KW2C]^Z]U[W[KW0$_(3_CTME?^)X^/'_OZ
M=D>_=>Z#?X#?]D?=&?\`AMY3_P!ZG/>_=>Z-][]U[KWOW7NO>_=>Z][]U[KC
M()6CD$#(DQCD$+NI=$E*$1NZ`J617L2+BX]^Z]U\Z#8?37\NKM_<?>>=_FD_
MSK_DQTA\Y,%\ANY-H]T]>X7O$8/9.)DP.],E2[1?KV?$X'=6"S6T*G9HH7AF
MHJI(:>4R4I@@:`I[]U[K;%_DB]:_"KJ_XX=EX7X.?,[?_P`W.MZWN6OR6Z>Q
MNQ-^3;_RNV=Z/L_:E/-LVCR,V&PAH:"#"P4E8*<1$>2K:342Y]^Z]U<Y[]U[
MKWOW7NO7O]??NO==W)^I/OW7NNK_`(_'OW7NN[G^I]^Z]UU?W[KW7=R/H2/?
MNO==>_=>Z][]U[H*L5_S.S>__B-NNO\`WH.P??NO="K[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNN[$?4$>_=>Z]8_6QM_7W[KW77OW7NO>_=>Z][]U[H).Z^E-C=];&K]B[ZQ_
MGI)M51B<M3A$R^W,LJ%:?+XBJ928:B(FSH?VYDNC@@^QIR'SYS![=<P1\P\O
M2:9EQ)&U3'-'7NCD7S4^1XJ:,I!ZB+WL]D^1O?KD>?D?GFWUVSU>"=`!<6DX
M%$GMW(.EEX,I[)%JC@@]$EZ;[KWS\9]]T/QI^3F3>LP56XI^G>YJTNN,S>,U
MB&CPN=KIF=89(;K$LDK^2FD(CE)C,<GN>N>.0^7_`'6Y=D]U?:>()N""NY;8
MM-<4E*M+"@X@Y8A11Q5D`8,O6$?LU[U\]_=FY\A^[5]YNY:;893HY?YADJ(;
MB&NF.WN96)TE>U%:1B\+TBE)C,<G5F@(8!E(((!!!!!!%P01P01]#[Q1((-#
MQZZ<`A@&4@J14$>?5;'\U3X8Y3YM_%3='7.TL3UE7=D8%SNOKNO['Z]PF^6Q
MFYL3$U5C9MM5.7'DVYEA6PQ.)8C:H">&0:')!SL5S8VM^LM\H*T(5CD1O^%R
MOXPIS3\\])KN.62$K$<^8]1Y@'RKZ]?.O_E@_$7^;-U7_,+WGN79'^DG;79N
MSMR5M+N[(9/^*TF.[?W;64U?6;;VI5Y?)4K83"4^X):?3_$,L*>BQ\9\#V+>
M+V(;:WO=LN+B^WM]>V2#NJ=0NM65$?\`Q[6/[/Y''2*1XIT2&T%)QP\O#IQ)
M_P`%//K:SHOY_P#\\_B9-!@_YH/\H/Y"]<XJAF%'D>[?CZ?])>Q):6E+05&>
MJH::CDP*K/(%-H,NB,22B*MD4$2LC2,T:Z8RQ(6M:"N!7SH,5\^C900H#&K4
MX^O5EOQD_P"%`?\`*7^5+46/V7\N=C["W96/X?[C]X)6=/[DAJD16FI2V](<
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M>J(LE1%0135.)C,1Y"I`B^X>WW[NOM;O+^/;V3[?>`DJ]K(T=&.:A#JCP<BB
MCK+GDG^\(^\_R?"MA?;W%OVS@`&#=;>*[5E\U,A"RFOF2Y/0'M_+V^:G2:F;
MXL?/O?$^+I/W*+8?>..7=F'*1<PT'\1D.3148FS.M+#["A]G/=#E;OY!YMN6
MMUJ1!>KXBG-0NH^(H'E41KCJ4!][W[M'N:?#]]_:;:TOI,/?;))]+-4\7\,>
M&21Y`ROU%;Y/_P`USH4E>[OB!M/OO;E'S5;NZ-S9@RTU-"+S5APM/+DV#2+^
MF,T4'/X]MGGS[P/*1IS3RY;[K9+75-9-W4!^+2AD))'EX29Z4#V.^X/[KC5[
M8^XFX<I[S)\-IO<.J(,W!/&818'FWC/TO=C_`,Y;XLY"NAP'<F%[2^.>ZC*E
M/5XKL_966BH*.H8V>-\OCJ6:T<1_4\D$0]G.T_>7Y#GF6SYDBO\`9]P)H4N(
M6(!K0U9`2`/5D7'03YH_NW??:TM6W;VXN=BYRV'2627;+V(R.OD1#(RY/D%=
MSU8;UM\A.B^X:2*LZO[<Z^WS%,J,L6W]TXFMKE$GZ/+C14KD(&;\!XE/^'N8
M]CYSY2YEC$FP[E9W0/E'*A;\TKJ'Y@=8?\Z>T/NG[=7#6W//+V[[7(I()N+6
M5$QQI)I\-OM5B.AB((^OL3=1U7KKW[KW7O?NO=>]^Z]U[W[KW12.N?\`LM+Y
M4?\`B%OB;_[N/DA[]U[HV_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H"?D)_
MQZ6RO_$\?'C_`-_3LCW[KW0;_`;_`+(^Z,_\-O*?^]3GO?NO=&^]^Z]U[W[K
MW7O?NO=>]^Z]U$KW$=!7.R3RJE%5NT=*Q6ID"T\A*4["Q6=P+(1]&M[]U[KY
MP_Q-[\^'7QUV+OGJOY`_\)W/DE\G-WXCNOM_+X?O;</QXBW/O;?^SMR[YS&>
MV[5[[GW+MR=*#<F(HZ[[!HL?43XZ2GIHI8]#.Z^_=>ZV_OY+O;_0G<OQV[%W
M!\>OY?6\_P"71M/'=O5^(RO4V]NN\9UOD=X9U-J;9JYM_P!+B,714$591U%'
M514'W#H7,E$R7LH]^Z]U<+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[H*L5_S.S>__`(C;KK_WH.P??NO="K[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JM'^9_VI\VNO/C_`+PH
M_A)L#9IWA5]:=J[JW?\`(/LK<L./V5\?]K['VE59NJS-#L^@CJ]T]@=C9Z*.
M2'`4=/$M!354?W%=*(8Q'+[KW2B^#?>M+BOY7WQ>^1GR#[(E^UHOB+UIVCVU
MVGOS*F:JF"=>X[.[GW3N+*37DJZVI?R2N0&DFE;2BLS!3[KW1$_AO\AOE?W'
M_-@W;D>XL_N'9'1_;'\ONA[LZ)^+M6STL?5VT6[XH=J[6WAV'2I*T-7W!V)M
MZ/\`BN01E63!TU>F+NS4[L?=>Z/=_--^2W97Q0^$/;7:72<.*E[ORE=U_P!3
M],29VC_B.&QW9O='8.VNK]JY[)8\^C(4NV:S=/\`$33N#'.U((W!5C[]U[JK
M_;74'S0_E7_)?X3[@W[_`#".^/FYU!\R.\:3XR?(?8GR!I,)74VT>T=];&W-
MNG8G:72E=B:&*HV+MVDW;M>IHZK#R.\+459"OD=HP5]U[H$-L?*'N*;Y?8CL
M.?Y8=ER_*3,?S:-W?#S<?P)FWC03]7XSX78ALY0T^Z$Z+^R.3V[+CNN\11;R
M&_WD\4\\S*9"E0$'NO=7,?#?M+<_R>[?[M^5#[SS-%T'FJVLZ&^)?7AS)I]M
M[\V+U3G\BG8OR33`/XQE:[LOL-:NAPM8%8Q[8PM-*MA6O[]U[JR'W[KW7O?N
MO=>]^Z]T%'<W3.Q>]MCY'8F_,8E905:/)CLC$D:Y7`9,(5I\OAZIE9J:K@8\
MC]$J71P5)'L8\C<]<P>WO,$7,/+LI2X0@.A)\.:.O='(OXE/[5-&4@CJ*/>;
MV8Y&]]N2+CD;GNV6:RE!,,R@>/:S4HD]NY!*.OF/A=:HX*DCHC?3W<V^_BSO
M;&?&SY,USUNTZR04737=$^O^&9/&K(L5'@MQ5DKO]NT"R)$KRMKI&M'(6A,<
MHR!YWY&Y>]WMAE]T_:F,1[S&-6Y[6*>)&]*M-"HXUH6(44D%66CAD.#/L][R
M\]?=8YUMONW_`'EIVFY2F;P^7^8FKX,L((6.VNI&)TA050,[%[=J1R%H3'*+
M.E8,%96#*P#*RD%64BZLK"X((-P1[Q.((-#@CKIVK*ZAT(*$5!&00>!!].B?
M].QQT_R[^9D%/''!#+A?C3DY8H8TC23(UVT]]4];72!%&NIJH,=`DC'EA"M_
MI[<>>>6-(I'9HHP0H)J%!-30>53D]>"(K%E`#-Q/K]O1OY(XYHWAF1)89%*2
M12HLD4B-PRO&X9&5A]01[:ZMU6_\G?Y0G\M;Y@P51[V^'W3>X,U5(RG>.W=L
MT^P=[Q.YD8SINS9!P&:DF,DI8^6616/Z@PX]^Z]U3=G/^$QE3T1DY]V_RQ/Y
ME'R_^%^>IE:7$;+R^[:OLCK$SV6;[>KQU-6[7K6I)ZR)#(:I<C^U=2C\W]U[
MKH;]_P"%2_P@+Q[NZL^+'\TKK+#QJO\`&=AY&+K'N.MHX9/+43G'Z=G?<Y.:
M*31$D6+R;73D'CW[KW2CV7_PJ6^/.P=PQ[`_F$_$+Y<?`7?<,L=!D)]_=<9;
M>6Q5R",8JUZ3-8K'8O<=1CX*@!1+%B9@=0Y_/OW7NKN?C5_,@^"/S!HH:OXW
M_*SI?M"IF5"<!B=YXW'[OIY'ACG:"JV=G),7N>FGB24:U:E&D\'W[KW1V;$?
MCW[KW77OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I%;T
MZVZ\['H),9O_`&+M'>M!+$\+TNZ-O8K-QB)Q9U3^(4L[1:A^5(/LJW38MDWR
M$V^\VEM=0D4I+&DF/]L#3\NA-RUSISAR;=B^Y2W7<-LNU8$-:W$L!J.!/ALM
M?SKU7;V=_)[^%&_JR7-;:V;N+IG<Q=YZ?.=2;HR&VOMZIOTSIBIFKL6@B/*I
M%'$![AK??NW>V&[R&YL;>?;;T5*O:RE`I.:A&UH*>6D+UF'R1_>*_>:Y3MUV
MW>MRL^9-D`"M!NUM'<ZE'%3*-$IKYEF<]`]%\#_Y@'1#&?XQ?/3+;LPM$-5#
ML+O_``\N?H7BBYBH!E"<Y&H<_61(:7CV&5]I?=[E(Z^1>;)+BU0=MO?*64YJ
M%U'QAZ@D(GY=2*_WJ_ND^ZH\+WP]J+?;]SEP]_L,P@<$\9/"_0./)2\O6<_+
MC^9[T2!'W_\`"3#]PX&B&JMWK\?MQF:IDIHB#/6/@]>:=&*GTHT-+<^[_P"N
M+[Z\I`+SARQ'N-H@JT]@Y)H#DZ%,IX<`43IH?=\^X[[J'7[2^YUQRYNTOP66
M_P!OI4,?A03TA!^;!Y>EYL'^<Q\/]P5T6![,D[%Z`W0)$IZS$=K;*RE!2T=2
M>'BDRV*CR,,:Q?VGF2$#V<;/]Y?VZO95M-Z^MVF_."ES"U%-:$%H]=*>98+T
M%.;/[MS[Q.T6K;MR2-FYMV*A9)=KO8I&=?(B*4QDU\@C.>K%.N>[NGNWJ"+)
M]8=G;&WW23(LB-MG<N*RDZH_"&:CIZEJRG+'Z"2-3[F79.:^6>9(1/L%_:7<
M9%?TI48_FH.H?F.L.^<O;#W%]O+MK+GG8]TVJX4D'ZFVEB6HXT=ET-]JL1T*
M)]();T@"Y)X``Y))-@`![$'0%J.BA]<3PGYH_*1A-$5EZ8^)Z1,)$*RNN8^1
MY9(VU6D9`PN!<C4+_47L4<<0?V'JH=#@$5^T=&\]UZMU[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=`3\A/^/2V5_XGCX\?^_IV1[]U[H-_@-_V1]T9_X;>4_]ZG/>
M_=>Z-][]U[KWOW7NO>_=>Z][]U[K%//'303U,I814T,M1*44NXCAC:1]*CEF
MTJ;`<D^_=>ZU"^H^MOYR?\XW%;F^</6/\S:J^!?1&:['[&VU\9N@NJ-HON%H
M=F==;VSNSZ?-=Q5L==B4RNX,YE-MK+405#9!4C>55CAB983[KW5S'\G[Y;]\
M_*+X_=I[6^5<6U*CY.?$?Y&]H_$ON[=&PHQ'L?L#=G5<^-$>_-NB*&&BB3<.
M,RL+U,5.J11U*/:.'5X8_=>ZMA]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]T%6*_YG9O?_`,1MUU_[T'8/OW7NA5]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%!^3WQ][[[LR&TJOIGYI
M]I_%&EP%#EJ;.XSKOKOJ#?%/O&IKYZ.6AR&3F[-VIN*JQ\^(CIWCB6D>*.19
MF+@D*1[KW3G\B=L;EQ_P?[\V=7Y[.=E;OI/BOVQMVIW'48FAAW'OG<"=4[@Q
M[Y23![<HZ;'IE]P5_K^VHJ=(_++HB0"R^_=>ZJGQ?PA[\^7W\FG^7=T5UIWS
MD_B9OO9'7'Q8[`W36;CZQI]\PY@];[)HJ^GZ_P!\]=[GGQE)7XZ'=J45=446
M0CDA:HQT:RPL!8>Z]T5CXY_#G^:%U_\`SK-DY[O#^8/D^[L/MSX>46?[`WJG
MQ9VKLG;/8?62]T/2R?'>/+XE6PN!SKYZ2//_`']/,<B((]&CQDGW[KW5AG\P
MVHW/\^?A#\O]@?%S8/8-=WK\5^]]FU>T]K=@;1K=ATO9G:WQIW_L#N-L5U[D
M=P(*+=6VMX8S'/C\7EH3]G4UT@34`K$>Z]T4#_9P]U_S>/DE\"NNNGOBE\J>
ME]C?%_Y#83Y5_+?>WR)ZMRG5FW=@9SK?8F\,-M/I;`UF6,D786Z<[OS<9!EH
M5\$5/CS/<*Q*>Z]U9)\^ME4V:J]F]:=)=8X3#_)GYD9:7H_/_(_;_7F*_OIU
M7\>\=C!EN[]WYOLZGP[9/&O2=>TDF'V_35%:OFSF3HS"C"!]/NO=46?-#X]5
M>R/D'\F.L]E=+=N1_+O^-?"C;?\`)MWIUEM?LP[$ZEZ5ZYP77^)WIB<)OG`3
M+UWUUA-HY_%;JJM]P9>6E;+8FLBUK5B6)5]U[K<%I14K2TRUKQ25@IH!5R0B
MT+U0B05#Q"P(C::Y`L./?NO=9_?NO=>]^Z]U[W[KW06]Q=.[&[SV/DMA[]QB
MUV,K5,M'61!$R>#R2(PILOB*IE9J:MIF;_%9%NCAE)'L7\D<[\P>WW,$7,7+
MLICNXS1E-3'*GXHY%_$K?M!HRD$`]19[Q>SO(_OER1<\B<^6PFVV8:HY%H)K
M:8`A)X'()21*_P"E=:HX9202(]2]P[]^)^]L;\<ODAD'R>Q\BYI.FNY:HR?P
M^>A#^*BP&Y*V35X%I]21!I"7I&(5BT)1UR%YSY)Y=]X^7Y?=#VLB$7,,0U;G
MMBTUAZ5::!1QU9:@Q(*D`2!E."7M'[O\]?=/YXMONY_>0N&N.1KAM'+_`#"]
M?":*NF.UNY&^$)54!<ZK<D*Y:`I(O71E3\R/]G'^1.5W1U3T3C=B;@AZ`H]P
M;CQ':._<A5C`XK;^]_#4[2IJOK"AQV=S4-+7HU53RU-+%"TD8$CAM7O$2.ZM
MI;B6TCD1KJ`@2("-498:E#CBI(R`>(ZZ?JRN@D0@QL*@C((/`@^8^?5H/M_K
M?7O?NO=>]^Z]U[W[KW2-WSUSU[V?A*C;/96Q-F]A;<JT,=5@=[[8PNZL/4(W
MU6;&YRBKJ.07YY3@^_=>ZI+^1?\`PFN_E(_(.LJ-P4/QZG^/V^7DDJJ;>WQO
MW5F.K:^DR+&5TKEP-%+6[/>432:F_P!QZLVD>H?7W[KW1)*C^3/_`#COANHK
M/Y<'\X+?.]]IXH/+CND_F9CVWMAYXETRIC8-Q55%NZ@B#.GB#)0T&F(_K7BW
MNO=<(?YK?\]SX6WIOY@'\IEN_P#8V%0MFNZ?A1F)L\\U+"X^XR9VK1U>[H1=
M&!2.6/%ZC?Z>_=>Z-MT!_P`*<?Y4?<N2BVIV!VKO'XI=A)XX<GLSY.;#S/7Q
MQN0;4)*&?<L"9;;,+02H49JBII_7Q;W[KW5XO67<O47=6!I]T=/]H]?=H[=J
MH8YX<SU_O#`;MQ[1RHLB:ZG!U]:D3E&!*OI87Y`]^Z]T)-K?7W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U5?_--_FX?%[^5;TSEM[]M[EQ&Y.X<I@:ROZB^/
M6*S,4&_^SLA#**6.6.F@ILC4;>VC1U#%JW,5,`I8(XW">273&WNO=)SM_P#F
M-]\X+^7G\;OFQ\<_@[V+\I-\=^X'JS<]5\?NN<Y-4[@V7@.Q=G56Z*S+U.8H
M]O9)\CC]NU,<-')(M)&)'J%;T"_OW7NB)_"[^>Y\H_DM\^MB?`WMG^5OVM\;
MMX9_:.3[%WSEMX;\-9D>L^NJ7&Y&;&[UW+MV?9N*EI</F\U20X^E,TT+SSU4
M?C#@B_NO=7G?,+Y'8/X@_%CO[Y/[CQ;9S#]%]6;M['J<$M<N-;/3;=Q<U708
M-,@T-2M%)F<@(J993')H:4'2UK'W7NJ+OB%_,G^1G\QGM?J#87R*_D@=C]9?
M'CN+;V2W(?DAV=!%N?8N#VU)LK([NV[FTJ\KU[BC+0;J:GIJ:FEBJHF9JR-A
M<<>R/>.6>7>883!OEC:7<1%#XL2/^PL"1^1'0SY3]Q>?N0[M;WDO>=SVNY4@
M@VUS+"*CA54<*WV,".BC]3[E^!?RR^3'46T-F?&KM+XI];?+#>_R5Z_^'7R.
MZJ[IC6N[%WQ\4LI_"NS#O3I\4U54]98O(2T]3-@)14RBJB@_>$+.![AW>?NV
M^VNX2&ZVF.ZVJ_\`PO:S,H4^1"/K44\@NGK+SE#^\8^\EL-NNU\U76V<U;%0
M!H-VLXIRR^:F5!&YU>9?6>C%_'J/YO;P[$^8&WNA?E/NCLCX>_%'L4=(;@W;
MW#(<Q7]O9[;^`2O[PVQUM-'C\J8(NM9:U,5)DDK8EJLGY4C`\3>U/)7MA[H<
MH\V;6^V<U2W_`"RE_!X]O>+J;Z<2+X@5V\2KE-0P8\TSY=-^YWWE/NR^ZOM[
MS!#S-[76NQ>XTVSW/T.X;/-X<2[@8G\&2:!3%6(2:*@B4TKCHN'PFJ/E&?F-
MU=_I`?ME=B'?;B<[B%>N&,'\388):EF`)BY`I]9T\FWY]AOVAE^\@_NO(GN#
M^_\`^H7A7]?JE<6_]C+X%2PT_'HT4_%2F.IC^]=!]PN/[L*O[)_U%_UY?$V7
M3^[6C-_4S0?7:0IU?!XGC8X:JYZW'S]3_KG_`'OWDSURQZZ]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW0$_(3_`(]+97_B>/CQ_P"_IV1[]U[H-_@-_P!D?=&?^&WE
M/_>ISWOW7NC?>_=>Z][]U[KWOW7NO>_=>ZXNXBCDE97=8XWD9(T,CNJ(694C
M%R[L!8`<D^_=>ZTV.B/Y<.]/E?2=I?(G^3S_`#4?DG\"_CQV_P!U]GKW)\6=
MU[-^ZDZQ[@Q6YZS%]DXW9^$.Z\?5;&IZ[-RU]5!`\:2:9X760HJ!/=>ZV2_Y
M>GP4ZH_EU?&7;/QNZFSFY=Y4M!F]P[SWSV1O:O7)[U[/[+WC6_Q/=^^]U5:.
M\?\`$\Q5:%6)"5AIXHTU.RL[>Z]T=[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW058K_F=F]__`!&W77_O0=@^_=>Z%7W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MUW<_2YM_3W[KW7KG^IX^G^'OW7NO$D_4^_=>ZZO^/Q[]U[KNYM:YM[]U[KKW
M[KW7O?NO=>]^Z]U[W[KW7O?NO=`UW[U[USV5U9NK`]HT44^V(,;4Y%Z\&.'(
M86KI(6>FRF)K)%;[3(02`!3^E[Z7!4D>SC9?<O=_:.Y;GK9Y62>S0LR9*SC@
M(&4?'XK411QU$::-3J,?=WVAY&][N2+KD7G^W679IU+"7"RVLB@E;F&0@^&\
M7Q5^$J"K@H2#2E\0_G;2[*[)[,VMD8,[NGK_`!&"IHMH04\R5NY*O"[-2.@K
M*]#5SJ,C7/2*U8(M8)AU(G"J/<A\[?=OY@Y/CY6]V=\GBM.:>=K]HN8_$)6U
MM=PW-VGVL``4AAMR1MCM2FIHW;))ZP.]C/O@;)LU[S1[=65O>[IR+REM<;;(
ML9$E]<6&UHL%\]7;]>:6,'<`FJI19(XZ!57JZ'J7Y(]+=W4D,W7N^\/DZ^2-
M7EV]63IB]RTI(Y2HPE:T582OY:,2)_1C[).<_:WGOD&9H^9MNGBMP:"909(&
M^8E6J_DU#\NLS?:;[R/LO[V6J2^W^^VEQ?LH)M)&$-XGR:VD*R&GJ@9?1CT.
M/N/^IRZ][]U[KWOW7NO>_=>Z][]U[KWOW7NN[D?0GW[KW15OD+\'/AW\L,54
M8?Y'?&GIKN"FJ1IDJ]X[%P=;G8P6UG[3<T-+3[CH29#JO#51F_/U]^Z]U11V
M;_PE:^%]'GJK?GPI[X^4_P`"^PWJ6KZ.OZ<[2S66VK!5B[HK8+,UL.<%([J@
M:*/+)&(UTA;>_=>Z0H^/?_"H#X0PANF_E3\;_P"95UQBS),NTN]<"=C]JS8V
MF59?M*?-RR8B:HKI(XO#%KS]2+M<I?Z^Z]UQH/\`A29W-\:Z^EV[_-'_`)5'
MRM^*\T4I@RO9_7>%J>RNJE\4@%17T]96TN(B?'I"ZN#2Y+(,>0+_`%]^Z]U;
M3\6_YVG\KGY@Q8V#IWYA=41;ER<<31;"[&S2=7;ZCEF0NM+_`'>WT,)-65"@
M$,*5JA0PM>_OW7NK2Z2JIJ^EIZZAJ:>MHJJ))Z6LI)HJFEJ8)%#1S05$#/%-
M%(INK*2"/I[]U[K/[]U[JI+^9K\I?YFWQSR_4M+_`"^_@;MSYEXG=.+W;4]F
MY'.;\CV?+L3)8JIPL>V:&EIWRV+_`(@F=IJNL=FNWC-,!QJ]^Z]T4O\`FW=!
M;#W[_*F^6WS<[L^/.R]G?-O(_P`N#([)W5E:I4W+F^IX<EB(-R;KZUVIEJV6
MKIZ&CQ>ZLG51/64RI45*KS*4.D^Z]T>O^6YOC!]8_P`H?X=]D[HG--MKK[X,
M=7;WW%4@@-!A-J=24&=RLHU$*62AH'(O^??NO=$:_P"$\>Q\[VIT3WA_-`[?
MI37]_P#\R3NS>W9L^:KXX'K=N=$[+S^1V/TUUOAG"F7'[;P.,PL\L<"N5=9(
MBVHQH1[KW0M?SWMR=6]I_P`J?Y+[*B^5'3O2>V-]Y;8_5.X^W]SRYO>VP]N5
MF1WM@JC([3W.W6E%N;,87(9JEHVI$=Z=EAFF02*`X]^Z]U13\9:/MC^6)_-"
M_EG=%]&?S0-T_P`Q/J7YY;9S&U.[^H\]NC';OV_L':NU=GP56UNP]E8_&[BW
M'1;(VO0PU,TV*CB2BF-%BJFGE\L;CQ^Z]T?/Y;_`W87\L;;>V^^NE^S>Q^S^
MR,)V?VYU;_*M^*6<QVU8]J]/_*W^8!G&Q^\=QTFX,7CXMZ[]P^`DJ*_-019.
M66'#8ZEF4>2ZLONO=,7QL_F!9'^7H^/^&^R.E-K;Q^)GP_\`E)T'\!OD9W7G
M-ZYB'OWL;Y6?)JF?<^\.Z]M[-3!3[9R6Q3V3N*63(KD,@N4JHIF>$`*$'OGY
M]>XX/#K8%ZYHH%^9_P`HA]I$(H>FOBC)3?Y.@BBE;,_([R24XT:(W;QKJ*V)
MT"_Z1:YDD(H6:A^9ZH(XP:A5!'R'1O/=.K]>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW0$_(3_CTME?\`B>/CQ_[^G9'OW7N@W^`W_9'W1G_AMY3_`-ZG/>_=>Z-]
M[]U[KWOW7NO>_=>Z][]U[JO;^8E_,"ZR_E[[&Z2WAVOAJBMVKWI\A=A_'>KW
M$VY,;M+!]=0;]I,U4Y#L3=&?RT$]%28+:^,P\TTJGQM*VE0ZGGW[KW6H?T)_
M+F_X3G]^[!_TZ8G^9Y\@^BJKM3<N\-Q9W8/8_P`Q.F-@=@4F9IMU9K$U5?NC
M`TV'J9!+E6H354DTTTTLU#/"Y:[$>_=>ZVD_Y/\`\;/A;\8N@NP=G_![Y1[B
M^5_6^=[7K=R;GWQN/N7;O==3@MYR;6VUC)]L4V?VU2T=#B::'#8^DJ?LRFL/
M4-*3^Y[]U[JV;W[KW7K7^GOW7NO6M]??NO==V/\`0^_=>ZZ]^Z]UW8_T/OW7
MNO6/]#[]U[KKW[KW7O?NO=>]^Z]T%6*_YG9O?_Q&W77_`+T'8/OW7NA5]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
MA.QNO<)VAM>MV=N6HR:8')@QY6DQM4M(<E2LC(]%52^-Y/MG#7(0H20.?9!O
M^Q-OL=L([R[LI[6[BN8Y(#&&$L+!XB?$CD5@CA7`*D:E!(-.DM_866Z[?<;3
MN<2S[;=0O#+&Q8!XY%*NA*E6`925-"#0FAZK7ZF^&OQ^3Y)=W[0QFR8,##TQ
MC.F<SLS.8BKK(<^M=V%A-WUF;?(U4\]12U20OA8E@40H%1W#Z[BQYS9O?NQS
MUR]=<J<W\]\U;AR]>H%G@FELS'(`RNM=-DK`JZJZLK*RLH*D$=1!RU]W'V&Y
M-WVVYFY5Y4VNQY@LW+PSQ?4!XV*E21JG92"K,K*RE64D$$'HSG9WP5Z"[)$>
M27!UFR-YT\*"#?.QJE-OYEZV.-$7)9"DHHHL175<CKKD?P([,QLPOQ,_(7OQ
M[D<B[?#LTE\V[[)%&D;0[A_C'B*H`-9#1PS4J:'37\/EU%/NS]Q[V$]T[I]\
MAVYN7N<"2Z7^TL+2193PD:)!X#D'B3&'.>\$UZ!`;5^>?QP)?:>X\3\H.O*.
MQ7!;C+4>_*6CCLBQ4U5-,M;43+&/[-15@G_=7T]R7^^/N[>Z`IO-K-RES,_^
MBP=UHS'S90-(%?5(_P#3]0/_`%6^_A]W$Z^4]QM?<[V]AX6UW5-S2,4`5'9O
M$9@OI-<`^47#H3>O/G]T[N/*+M3LNCW!T;OE)/MZG`]BT$]!0"I#",I!G##'
M3HC27"FI2GO["G,WW;^=]KM#O'*KVW,'+Y&I9K)P[Z>-3%4L33CH+]2=[>??
M]]G^8MS'*ON5#N'(_.ZMH>VW:)HH@]=-%N=(506X&98?SX]'=Q^1Q^7HX,CB
M:^BRF/J4$E-78ZJ@K:.H0_1X:FF>2&13_4$^X"N;6YLIVM;R.2&Y0T9'4JP/
MH58`C\QUFYMVY;=N]FFX[3<0W6WRBJ2Q.LD;#U5T)5A\P>IGMCI;U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U#R./Q^7H:G%Y:@HLIC:V(P5F.R5+!74-7
M`UBT-3254<M//$Q'*LI!]^Z]U5)\G_Y&/\JCY='(UO;'PXZMQVY\F',^]^KJ
M"?J3=_EDD,KU+Y3KZ?`Q5U2TAN7JHIR?H>+CW[KW55^5_P"$YOR.^,M94;@_
ME8_S9/E)\;2C^2AZI[@S$_:75PC47^S:GIVHJ-8'\:1!JC$5CI&+EF/U]U[J
M)'\GO^%/?PBD9.__`(==!?S'^M,;(1/OGXZYRGVAV;+B:58YJJO;;M`F,GJ:
MM*=6"1#;1:1_[;?7W[KW0N=7?\*F/@PV?I-A?,;J3Y/?`?L:6M_AM9A^^>J,
M_4[:I:V-Y$JA_>7;]#+D$I:?0"TM1C*=;,/?NO=6Q2]P_P`OC^:5\?>Q.D=J
M]_=2]_=2]U;1KME[TV_USVGCZ7<];M_-0*]70FEQ>2H]W8"LDA4$WAAG0?4#
MGW[KW0Y1_$SI6#XG?[)/#@<O!\?O]"DGQ]&VX=R9F+-+UC+M9MFR8A-U1U2Y
MU:UL`YB^[$WW%SJU:N??NO=*SX[=!]9_%CI#K'X\=,X>KP'5O4.UJ+9NQ\-7
MY6NSE;C\%CS(U/!59?)S3Y#(SAIF+2RNSL3R??NO=%<Z6_E9_!_HKI'O[XX[
M3Z9H\[TK\GM^[I[([KV#V%F<QOO$;OW1O&"AI\U4M_>"KJ:C&0:<;`U,E*\1
MI)8EDA*2*&'NO=!K\'?Y*_\`+B_EV]@[@[8^+O0-+MCLS/T-7B%WSNG<^Y=_
M;CV]A,@RMD<+M&NW;DLF=L4&2$:K4?:".:>-1&[E+J?=>Z-5V?\`$7KCN#Y+
M_'?Y.;[S&[\MN#XO8[L'_11L!J_'?Z-,=O'L?&T^"R_9>1P;XJ3(U^^\7MR*
M2@QM5]VD=%3U,^B/7*['W7NBH[]_D[_$SL3Y-9SY)9JO[;I*;>O:>Q.^^S.A
M,/OQL=T)V9WYUAB)<+U]W'NW:<>,;.-O#;-(ZR(*/)TE%454,<\\$DBZC[KW
M3QT5\5NE-B_.GY`YW;>&WI3Y/9_5?QGS6!ER7<G<^XJ:'(;@K_D-1Y1Z_&[B
M[`RN+S<$D%'&(H:Z&H@IF!:%$9F)]U[JS_W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]T!/R$_X]+97_B>/CQ_[^G9'OW7N@W^`W_9'W1G_AMY3_WJ<][]U[HW
MWOW7NO>_=>Z][]U[KWOW7NB__)OXL?'_`.9/4>:Z*^3'6.WNVNK,]5X_)5VU
M]Q)5+%%EL1.*K$YC'5V/J:+)8O*XVH]44]/-'(`64DHS*?=>ZJ"ZC_X3'?R<
M^M>O\'LS<?Q:H.X<SB&R;5G8?8>ZMY#=V>_B&6KLC3KE!M?<&W\&%Q=+5I20
M>&DB_8@37J?4Q]U[JU'XC_"#XK_!#8FX.LOB9T_@^F=C[IW5-O;<&`P.0S^2
MI\GNF?%8W"2Y>>?<66S%8L[8O#TT.E9%C"Q"RWN3[KW1K/?NO=5H_/SXT?,/
MY:[CZ9ZAZ9^3.<^)OQFD.Z]P_)3LCIW)_P`*^3.Y:_&PT"]<=?\`6>9K<1D,
M7M7;.0R,E14YO(AUJVCABA1&1Y`?=>ZJ?VCWO\H/Y8U'_-DZOD^2'8?SFZD^
M'GQAZ[[JZ7[#[[EH]S=C]=?(3M5=V45-\?>P-_8NGHH=V0--#AMP1TTJ+546
M.R<2'0LJW]U[IOS73'SB_EL[:^*?SUWI_,4^1_R:S/97=?QVV)\U.ANV#@LA
MTAF-N_)+<F(V7F:WIC:V/Q<<W5%3U;NS=U-/CC#,\=11TS1RE`V@^Z]UL!_-
M7OJI^+/Q'^2GR+H,=3YC*]+]+=A=A8+$U9?[/*;AV]MNOK=NXZMT,LGV=;FU
MIXI=)#>-C8W]^Z]UKN9[J+Y[?`7I7X[?S/-Y_P`Q/Y%=_;[W5O\`^.5;\QOC
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M>A["_P"*'_;>_=>Z%6Q_H?\`;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'
M_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L
M?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[
MKW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_P!L??NO=>L?Z'_;
M'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z
M'_;'W[KW10>HP?\`9P/F/P>=K_%^W'UMMGL:]O\`6]^Z]T;ZQ_H?]L??NO=>
ML?Z'_;'W[KW0:]C].=8]NXQL5V/LC!;JIBA2*;(T2?Q&DN"`]#E(?%D:-UO<
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M`.-">A1L?Z'_`&Q]A+J4NO6/]#_MC[]U[KUC_0_[8^_=>Z]8_P!#_MC[]U[K
MUC_0_P"V/OW7NO6/]#_MC[]U[KUC_0_[8^_=>Z]8_P!#_MC[]U[KUF_H?]L?
M?NO=!3VWT1TMWWMZ?:?=W4G7/;>VZB"2FDPO8NS,!N^@$,K*TB10YR@K/M];
M*"3&5-Q]??NO=48=^?\`"7O^5?VSF)-Y=5;$['^(G8T9EFQF\OC1V)G=GKC*
MV:5I7JZ?;F4DS>#IB2UM%+%2JJ"RZ??NO=%O/\L'^?M\,&-5\&OYL&+^36R<
M5!IQO3_S7VI)D:N6*.-K4<.[JA-X2@^*%(8RE7CD!;5Z/J/=>Z;C_.[_`)LW
MPZE>@_F3?R<^R<GM;%.M/D^[_B%D:K?.TY8E9'J<N^'1MUXV"DIJ4EG$F7I;
MD6LGT]^Z]T?#XS?\*/\`^4M\E9Z;"?[,;3]#;ZEGAHI]A?(_"5O5.8I<C*Q4
MT+9C*?<;0EEC(]17(D`'GW[KW5UFSM\;*[$PM-N7K_>&UM\[=K8HYJ//;/W!
MB=R8>JBF77%)3Y+#U=91RI(O(*N;CW[KW2JL?Z'_`&Q]^Z]UZQ_H?]L??NO=
M%(ZY4_[.E\J#8_\`,EOB;^#_`,[CY(_\4]^Z]T;>Q_H?]L??NO=>L?Z'_;'W
M[KW7K'^A_P!L??NO=>L1]01[]U[KKW[KW7O?NO=`3\A/^/2V5_XGCX\?^_IV
M1[]U[H-_@-_V1]T9_P"&WE/_`'J<][]U[HWWOW7NO>_=>Z][]U[KWOW7NL<L
MGABEFT/+XHI)?'$NJ23QHS^.-1RSOIL!^2??NO=:2?Q[^6'SC^3ORE^%?SJ[
M"^?L&W>E^[?Y@'<?QA_V03K:NI=O[2Z6V!M39?;C8@=T5:Y;&Y+-[S\VQJ7(
M5%/E*-RT=1!+'41B01)[KW5X_P#(T^3O>/R+^-_>>V^^.SL3\@=P_&3Y<]V_
M&W;?R:V]3Q4^`^06S-C9''9#`[YQYIP::J-)#G3CFFC9Q*E(C,\KEY9/=>ZL
M+^4717:??.U]MX+JKY5]N?%#*X3/2Y;)[JZBP/6N>RNY\?)034B[?RT'9>T=
MW8^#'PU$BU"O310S>1`"Y6X]^Z]U43_,=^:??7\O?JSXZ?%3;%;\Q?D/V'VO
M2;E/;GS2Z^^-<?=?8_5G6=#4URU&X,1LKK[`;<ZWK.X]PUM5'C,#'5I#C\9!
M`^0JH*HQQQ3>Z]T&74^:Z'_F`_R]/FI\`/AM\;OF%\?]V5_2VX-QP;[^9G2^
MZ>M<CV[W1NFNERV,WINWLC=]=D<AV'O[<F^<#3SYNLJ&U0P2+H6.GCBBC]U[
MH,-T?*SY$_S/MG?%7^7]0_`_Y<=!]H;.[O\`CCO/YO=B=S["&S>ENI-J?&_=
MV#WOO"'9O8,E7+C>UJOL3<>SH:+"Q4$05X*KRR"R^_=>ZN5^5[4OS>ZH_F%?
M`+:FU>Q]J[_Q_0?]TJ3L'>NRZ[`]2;GW+W+L+.9+8YV'O>=I:'=T6V\O0P19
MX0(#C9'",&8CW[KW5)6Y_E'\F_YB70?QY_E>#X%_+3I/O_&;[^-F(^9G9/:6
MQ1MOX_=3[#^/6]]F[L[#W;M/M9*I\/V;%O\`EV/'!A*.@BU3)D@&U>/U>Z]U
M?1\[:_*;+ZTI-V].=08;??RPWAE</T+\<]YML&BW'E>K]V=I5%1@CV%F=U#%
M5F1V?UWUKB:FNW!EI6F@IIXJ'[8GR5*!O=>ZH)^=?PXV;T9O&?JG??Q\[I^0
MNP:?^772=*?R^<]U5U]OC>^6VO\`.ZJWIOK.=@]@9G,[-G%+UAW5VGO//[?W
M'_?')O10!:>L)KHQ')$_NO=;.OQNPO9^V_CQT3M[NW)QYKN3!=/=;X?M7+Q3
MBJ3)]AXW:&(H]XUWW8XJVJ<_#.[2BXD8EOS[]U[H2MR;:QVZL<,7DY\O3TPJ
M(JH283.9;;];Y80X137X6LHJPPD.=4>O0W%P;#W[KW1=L9T_M-^W]XT)R._O
M#!U_L*J1QV7OQ:@R5&=WY&ZR5*Y\3R1*L"Z49BJ$L0`6:_NO="9_H4V=_P`[
M/L3_`-&EV%_]D7OW7NO?Z%-G?\[/L3_T:787_P!D7OW7NO?Z%-G?\[/L3_T:
M787_`-D7OW7NO?Z%-G?\[/L3_P!&EV%_]D7OW7NO?Z%-G?\`.S[$_P#1I=A?
M_9%[]U[KW^A39W_.S[$_]&EV%_\`9%[]U[KW^A39W_.S[$_]&EV%_P#9%[]U
M[KW^A39W_.S[$_\`1I=A?_9%[]U[KW^A39W_`#L^Q/\`T:787_V1>_=>Z]_H
M4V=_SL^Q/_1I=A?_`&1>_=>Z]_H4V=_SL^Q/_1I=A?\`V1>_=>Z]_H4V=_SL
M^Q/_`$:787_V1>_=>Z]_H4V=_P`[/L3_`-&EV%_]D7OW7NO?Z%-G?\[/L3_T
M:787_P!D7OW7NO?Z%-G?\[/L3_T:787_`-D7OW7NO?Z%-G?\[/L3_P!&EV%_
M]D7OW7NO?Z%-G?\`.S[$_P#1I=A?_9%[]U[KW^A39W_.S[$_]&EV%_\`9%[]
MU[KW^A39W_.S[$_]&EV%_P#9%[]U[KW^A39W_.S[$_\`1I=A?_9%[]U[KW^A
M39W_`#L^Q/\`T:787_V1>_=>Z]_H4V=_SL^Q/_1I=A?_`&1>_=>ZZ/2>SR"!
ME>Q%)!`8=H]@FQ_!L=Q6-O?NO=$UV'\!^PMH=Q[E[7R?S$[8W12[XJMH+O79
ML^W<%A:'-8/8]+EZ#;^%I<[B,A#G\28Z/,R+-4I,\TC`,-)N#[KW1R_]"FSO
M^=GV)_Z-+L+_`.R+W[KW7O\`0IL[_G9]B?\`HTNPO_LB]^Z]U[_0IL[_`)V?
M8G_HTNPO_LB]^Z]U[_0IL[_G9]B?^C2["_\`LB]^Z]UAJ>B]BUM--1UM5ONM
MHZA&CJ*2M[*WY5TL\;`JR34U1GY(958&Q#*1[O%++!*L\#O'.IJ&4E6!]0P(
M(_(],75K:W]J]C?Q13V4@H\<J+)&X/$,C@JP^1!Z+3O/^79T7E!#E.MYMT].
M;QHI9:FAW1L_/Y2>8U<CF4RUU-DJV=YU\O/[4T#6N`>?<^<I?>,Y[V&U&T<P
M>!OW+Q&EH+U1(=/HLM"W#AK#CACK"7W.^X-[,<Y[B>:.1?J^2^=U8NEWM#F%
M`YSJ:V!""IR?!:$G.<]%[K^O/F5T+555;N.#<'RDV(LLE1-7;=[)W]M_?-#3
M`%B4QM'F8WTQ1"_CCIZM00?4/K[%C67W=O=%]=C-/R?S-)^"0![)F/H:Z5!/
M]*+_`$OEU%\>\??S^[@GA[U:V?NG[>0C^UAU1;K'&!6I%/&<JO'LNJD&KC!Z
M%/JSY!?%7L:L3`9C=G:/5N]%D6GJMI]D=D]A;>J(JR^EZ:')S[D&,F=7%@'D
MBD/^H'L$<W_=Y]Q>5X#N5E!'N^PTU+<6+>,I7R8QC]0#[`R_TNID]K?OV>P_
MN+=KL.\7DW*_.08(]CNZ?2LLGFBSM^BQ!Q1FC?\`H#HY,73.RIXHYX,QV!/!
M*BR130]J[_EBE1A=7CD3<C(ZL/H02#[@UT>-S'("LBFA!%"#Z$'(ZS)AFAN(
MEGMW62!P"K*0RL#P((J"#Y$=9/\`0IL[_G9]B?\`HTNPO_LB]UZ<Z]_H4V=_
MSL^Q/_1I=A?_`&1>_=>Z]_H4V=_SL^Q/_1I=A?\`V1>_=>Z]_H4V=_SL^Q/_
M`$:787_V1>_=>Z]_H4V=_P`[/L3_`-&EV%_]D7OW7NO?Z%-G?\[/L3_T:787
M_P!D7OW7NO?Z%-G?\[/L3_T:787_`-D7OW7NO?Z%-G?\[/L3_P!&EV%_]D7O
MW7NO?Z%-G?\`.S[$_P#1I=A?_9%[]U[KD.E]HJK*,KV+HD4K(A[2[!*2*>"L
MB'<15U(_!!'OW7NB;]^_RA_Y<?RDE^\^0/Q9V'VAF`L@CW'GY\_%N>$S?YV1
M-R8G+XW--*_Y=YV8_P!??NO=5![V_P"$MO3O7>:J][_RZOFY\O?@5O$RU%;1
M8K:'8.5WEUZ*V=Y&,<V'?*;<W"*-4?0BODJC0H^C<`>Z]T"O^@;_`(4Z?"5I
MFI-Z=)?S5.MJ!7G:'-]E;YZN[BEIHP9!2TDS[CV-'Y4@0HJK/DW:1AQ);GW7
MNE_UE_/&QNW=SU?7'SO_`);_`/,%^&^^,5M_,YW*Y^LWCV#NSJ.&GP=')6UM
M7+O;+9O:9H\8L,8O+''6A2Z@:R1[7[=MUQN=S]/!04!9F.%1!\3-\@/3/ITS
M/.D$>M_L`\R?(#JL[X0?\*1>C.U/YB79VW.V]I;VVCTMW/D=J;'ZXWMCNP^P
M9,]04&T9LU3[9CS+19E*^JHC+GZN:*.8NSFJD8>)V$1/OIMEW.FT[:"E['B.
M5N%PQXJX_!4_V7H,-QZ2>)=0?XQ/0Q'XE'X!Y$'S_I?M'6\+MWK7K3=N!PVZ
M-M[DWYE]O[AQE%F<)E:7M+L7[;(XO(TZ55%6P>3<$<GBJ*>1674H-CR/86FA
MDMY6@F!65&((/$$8(Z7JRNH=#52*CIY_T*;._P"=GV)_Z-+L+_[(O;?5NO?Z
M%-G?\[/L3_T:787_`-D7OW7NEMM?:>+VC25%'BJC.5$554?<R-G=Q9O<=0LG
MC6/3#4YRNKYX(M*_H1@E^;7]^Z]TIO?NO=>]^Z]T!/R$_P"/2V5_XGCX\?\`
MOZ=D>_=>Z#?X#?\`9'W1G_AMY3_WJ<][]U[HWWOW7NO>_=>Z][]U[KWOW7NL
M%3/]K35-5XY)?MJ>:H\4(U2R^&)I/'$O]J2338#\D^_=>Z^:1\JN[/Y+/R]^
M1/;W:^0_E-?S4,!V+B=_[@I^YT^-M72;9VG5]ATE;5-F\YN[;-*F=H]K;IR<
M7DEJC`F-EECF:21"[%_?NO=;"7\GK^=E_+AR7^@/X,="?#[OWX/=6[]J,AMK
MXWYSLK9R_P"B[M7?\DV0KLW@Z;L2CR.7;,[YSE923-)65D]0]76?LO*KZ$/N
MO=;5GOW7NN[D?0GW[KW7KD_4GW[KW7KG^I_V_OW7NNK_`(_'OW7NN[GZ7-O?
MNO==7]^Z]UW<CZ$CW[KW77OW7NO>_=>Z"K%?\SLWO_XC;KK_`-Z#L'W[KW0J
M^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!;M7X
M[],]U4DL'8NPL)FZMXVCBSD=.,?N*EN``]-FZ'P5ZLEN`SLG]5(]COD_W-YZ
MY#F$G+&XW$$(-3$3KA;Y-$]4S\@#\^H5]U/N[^S7O1:M#[A[#97EX5(6Y5?!
MNTKYI<Q:9<>09F7U4BO1.:CXG_(CHEY,E\5N\,CDL)&[2CJOM*5<GAVC#>BF
MQ^0E5Z6*T?`M'2O_`,W.?<X1>\GME[A*+7W?Y?BBOR*?O"P'ARU_B=!1CG/&
M0?T>L.KG[J'WB/8J1MS^ZSSO<7.R*Q;]R;TPFMR/)(I2#&*#`HENW_#:GJ?@
M_G?G.OLC!MCY7].[HZCRI98%W=B:&KS>RJ]BPC%0DD0GEABD(+$P2U8`_I]/
M:;</N\;?S);-NWLYOEIO5G2OTTCK%=)YZ2#0$CAWK'TOV+[]^^>W^XQ\L?>L
MY/W3E/="0HOX(I+C;Y23I#`KJ95)S^E)<`#TZ/5L;LG8/9F*3-;`W?@-VXUE
M#-/A<C3U;P:OHE53(_W5')<?IE1&!'T]X]\P<K<Q\J7AL.9+*YLKH>4J%0?]
M*WPL/FI(ZSIY&]RN0/<S:QO7(.[V&[;<14M;S)(5^4B`ZXS_`$7537RZ6WLA
MZ&_7O?NO=>]^Z]U[W[KW7O?NO=`_\@>].N/C'TCVG\A.WLP^!ZSZ=V1GM_;T
MRD-.U75083;]%)65$-!1HRO6Y.M9%@I8`0TU1(B`W;W[KW6M_P#'W_A2_4[\
M[EZ`Q?R,_E\=_?%GXL_+S>--L7XQ?*/>-7/E]N;XSNX,A2TFQSE<4FV,914V
M/W)'61%YJ#(5XI_*LBB6G629/=>Z&;Y[?\*`:WXN?)SM7XW?&WX.]S_-:?XN
M;4P^^/F%OGK7(/CMO=)8++4$.>>DO2[>W$<EE<7MIS4U+534-/'(?$';QS-'
M[KW5V_Q3^3/5WS)^.O4?R>Z7R%7D>M>Y-H4.[MMODH$I,M0I.\M+DL)FZ-)9
MDH\W@<M2ST=7$'=4J('`9A8GW7NJ<OYBO\]JJ^)WR0S?Q$^*?PV[:^=_?G6.
MP/\`2S\@,'UG55>-P'377[XV+*05&:RF-VYNNKJ\X]!5T]3+!]O##!!/&#*T
MKB,>Z]T)%=_.SV/V-\<O@WVE\4.E<[W%W%_,%WONSKGI+I3?.[,?U-3[<W?U
M?A,KGNWL?V9OG(8S-TF"BV33X2:&%Z>DJ?XE-+`T5HG++[KW7'L'^:'T?\@O
MY876_P`E,?\`'^H[AS_RJWSA_C?UG\2-S9?&T><WG\@L[OK(==9SK@[J7'Y*
MDI,9M2NP.4R-3GJ>F>*'%X\U6E+@!1:W4]E.MS;,4F0U!'^7U!\P<$=4DC25
M"CBJGJJC^7__`"+^ENF/YE/8/9>Z?BK7I382DV;O^#9>;[9ZZW9M+HY>P)=Y
MC#5,=+0T-+/O.+*Y39-=IBHHT:"(1>58TD>+V()=ZL(HC=;;#X6[S`B0_AB\
MB8?0R<2?P#"](EM9F;PYVU6J\!YM_IO6G\^)ZW'HXXX8XX88XX888TBBBB18
MXHHHU"1QQQH%1(T4`````>PP22:GB>C#ACKG[UU[KWOW7NO>_=>Z][]U[KWO
MW7N@)^0G_'I;*_\`$\?'C_W].R/?NO=!O\!O^R/NC/\`PV\I_P"]3GO?NO=&
M^]^Z]U[W[KW7O?NO=>]^Z]UPD1I(I8TE:%Y(Y$29`"\+.C*LJ!@5+1DW%^+C
MW[KW6G;T/\J_YL7\H3;F]OAUNG^4GVI\U:.B[<[9WOUO\H^@,Y65N.[AP?8N
M_,[NJAW+VG64&TMW5PWRU3FXXJN3(2TM8E,B1O&5B65_=>ZG]`?R_P#^:-O>
M?X.X#OKI[KCKG9>YOYFO:?\`-+[TQN)W1C)<1\/\%CYZ*JV#\:>NL;25E8U;
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M)8LL,R1VOZ#?WD+R[]Y/F>&R&R<_6EIS'L!%"MTB^,`>-)=)!-.!92?Z0ZP5
MY\_N^_;RZW9N;_9+=-SY#YU4AE?;Y7^D+#(#6^M652<D1RJGJAKTC#VI\V_C
M@GC[:Z^QWR$Z_H&T2;YZ_9H-VT]#&I)JLCC(X`\KJ.6,E*HN.9N;^ST<H>P?
MNBVKDS<I>6N9)!46EYFV+G\*2$T`]-,A^2>70*/NI]]C[N">'[L\OV_N!R!`
M:'<MKJM\L2CXY8E2I/KK@`QF;->C%=/_`#,Z#[G:+'X/=\6W=T-Z)MH;S5-O
M9R.H7B2"#[N3[&OD1[BT$SM<?I'N,>=O8SW&Y%!N=PLC=;0,BYM?UHB/(G2-
M:`\>]0/GUD7[0??,]A/>1TV[9MW3;>:#AK#<0+2Y##BJ:SX4I!Q2*1F^0Z-1
M^`?P>01R"/Z@_0CW$'65(((J.'7O?NO=-F;J,E287,5>&HDR>7I<7D*G%8V2
M00QY#)04DTM!0O,2HB2KJD2,M<:0U[^_=>ZHK^*/RR_F*]\YWNK:?\V'^6]T
MO\6?AYMSJ#=6\-Q]A[G[!V[V1M'-3;;RV)JFPFZ]N9/+9S&28$;>2LR,LM13
MA(VHTXU,`/=>Z(=M+>FR_P"=O\F?B_V7-FNIOCS_`"IOA#V_0;Z^->PMP;JV
M/M?MSY<=U=<53;:V7N*@ZXBR]-7]:]'[3J8/%B:.:GAJ\D@*+"5E_P`E]U[I
M"_#7NCJ3HCYI?\*@-O=Z]D;*ZYW%DMZ5G86/QF^<_C<-79G853U;V-/1Y'#1
M9B>GES5(:7/4,<=/3B5R:F)%0ZU!]U[H^/\`PF@R5!UE_);^&=-V9N+";.J-
M\9;M&JV/3;LSF.P<^?H\WVKNN;"TF!ARM73R9*?(1MY((8`SNDBE5(8$^Z]U
M0%O3K/Y>;E_G@_SHMA]/?S"]E?RVL]D(NNNYZK?&]X,;#NGMC8FW=H4K;*V]
MM7<&6K\6N,V-CH<X*C,?;RR2E13@P3)%(%]U[JW_`/ELX7??\[3^6_\`$/Y.
M=I=B9+H#YA?$7OSMJCZJ^2G46SMG34.7S^(HZC8.YMYMU_F<4NR\]B]_;1S!
MI,A$(88QDZ1IXBA4I[]U[HG\^Y>O?A#NRKW_`--[+SG<7QQ_E#;SPOP@^*F)
MWQGH<=CN_?YG?S,WI0TO?'>6_MQX['3T5)@NJ*#>1QL\U#2O+3U%;5PTB*P%
MO=>ZN\_EB_*/LSY+?*7^8SAN[M@[,Z^[J^-6<^/WQT[/H^M=RY?=76VX-P;:
MINX]W4FZ-C9+<6*PNXX<+D<)O2E1J>OIUJ(JB*2Y*D>_=>ZNC]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=`3\A/^/2V5_P")X^/'_OZ=D>_=>Z#?X#?]D?=&
M?^&WE/\`WJ<][]U[HWWOW7NO>_=>Z][]U[KWOW7NL<S2)#,\2H\J12O$LK^.
M-I%1F19).="%@+G\#W[KW6CM\9OAA\@?YBF#[5^1GR)_GV?(7XV]X5??O<FR
M^P/CCU;VSB=K;>Z0FV9O?*X/;VQC@HNQ]M4%+HVQ2TE53/1TOVDU#40NDLSF
M20^Z]ULP_P`KWXG5/Q!Z6WML*I^=':'SX;<'9-7NI.S^U=VT>\,SM19=NX'%
M'8^/R%'N7=*T^,IVQIKA$TZL)JQVT`$$^Z]U99[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H*L5_S.S>__`(C;KK_WH.P??NO=
M"K[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO7M]/?NO=%S[<^)_0_=:RS;TV)CH\XX/CW5M]1@-R
M0R?593D<>L?WC(P!`J$F7CZ>Y/Y+]X_<3D,B/8MQE.WCC;S?K0$>FAZZ:_T"
MIZQR]V_NG^Q'O2KS\X[%;IOC#%[:?XK>*?)C+$!XA!H:3+(,<*=%7?H'Y@?'
MDFJ^/G;J]L[*I+O'UEVHZRU\5*EG^TQ>4GE6'4$72OAGHKV'H-[>Y?7W']DO
M<P>#[E;+^YM^?C?;?A"Q_%)&!7CDZDE^T<>L6)/8/[W_`-WIC=?=_P";1S7R
M7#D;-O1#2J@SHAF9@M0.U?#EMN`[#6G2GVG_`#`-OX;*0;0^2?7F[.A=WE_`
M]5E<;6Y#:%7*"0TU+DXX?NHJ8D<-HFB`_P!V'V4[S]V_<KZT;>O:S<[/F+9*
M5"QNJ7*CT:,G26^55;^CT)^4OO\`VP[-ND?*'WD.7MVY$YOU:2\\,DM@[?Q)
M,%\14_I:9$'^_2.CV;8W;M;>N*@SFT-Q8;<V(J%5X<C@\C2Y*E8.+J&DI99!
M&]ARK68?D>\>MVV;=]AO&V_>[:>TO5-"DJ,C?L8"H^8QUG7RQS=RMSKM:;WR
MAN-GN>T2`%9;:5)D->%2A-#\C0CS'04?)SXW=6_+SHCL;XW=V4&;RW57:V'@
MP&]L5M[<F8VEE,GAX,G0Y4T"9W`U-'E*6FJJG'QK.D<@6>$M$X*.RDLZ$75,
M&QO^$N7\G3KG>VSNPMK=%=@TFY]B;IV_O+;E54=Y=G5E/2Y[;&6I,WB*B>CJ
M,\]/5PP9"BC9HI%*.!I8$'W[KW1Q/FC_`"5?Y;G\P#M?;G=_R<^/&.W=VEM^
M+%T=3N[!;EW1LK(;OQ&%9#BL)OO^ZV5QD.[,;01(88_NE:9*=O$)!&%5?=>Z
M&;O;^6Q\//D3A/BQMCL'JR.DVM\+]];7[$^.NV-DYK*['V_L+<&S8<9!MR*'
M%;=J**ER&'QL6'IPE'.KPGQ\@W-_=>Z"WYV?R</Y>?\`,?W3M??GRLZ'I-W;
M_P!I4L&+H-][9W'N+86[J_`TS5$E-MS<&:VGD<94[@P=+-5.\$-7Y3`S'Q,@
M+`^Z]T>#J_HGJ_HKIS!]#]#;4Q/3'6NTMLU6U]D8#85#2T%-L^EJ(:A4K\3%
M60UT-1EH:NI:J:>K6I>HJB9)S*S,3[KW1**W^5?\68?@-_LAF5H^R-R=88?(
M5'8B;YCW##_IXK^X:7>U3VK%W+#O''XZABK>V7W](:Z.K:E\4\I$,D;0DH?=
M>Z*3_+4VIL3XU_*?Y2=?;1ZO^;V>W#WM1]"]D=J]S?([9\5=NW<_9.0?O*ER
M6^>SL_0UF.PN`QU=A\518_'I08ZGI+4)41!@SM[KW5]GOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[H"?D)_QZ6RO_`!/'QX_]_3LCW[KW0;_`;_LC[HS_`,-O
M*?\`O4Y[W[KW1OO?NO=>]^Z]U[W[KW7O?NO=8:FGBJZ:HI)P3!54\U/,`Q0^
M&:)HI;..4.ACS^/?NO=?,V[MH/\`A*GM'N_LK8<7QV_F+=K9;#;_`-ZX&IWE
MUKN+-Y#9^[\_M[+U$&[:O9DM?NS%Y'*8;'Y;RQB84R!D42`:&5F]U[K;3_X3
MM4OP<'Q"[+S'\OCH_P"1O3'Q]W'W=DLI1S?)&LJJW<'86Y(=G[6Q6;W5M*6>
MORL+;2HI,<N,#0U,J-6T-1?2P8>_=>ZO\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%6*_P"9V;W_`/$;==?^]!V#[]U[H5??
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TF]U;.VGOG%3X/>6V\+NC$5".DN/
MSF.I<C3V<`,8UJ8Y##)8<,A5A^#[--GWS>>7[Q=PV.ZGM+U2"'B=D;'KI(J/
MD:CH-<U<F\I\\[4^Q\Y;;9;GM$@(:*YA25,\2`X.D_TEHP\CT0[<W\O[%[;R
MT^[_`(S=G;NZ+W26:88VEKZO*[0K92^H0U-%),*N&FL`-+&IC`'^;]Y$;5]Y
M&[W2S79?=;:;+F':.&MD6.Y44XJP&DM\QH;^EU@?S/\`<`VWES=7YN^[3S-N
MW(_--2W@I+)/82-6NEXRWB*GEI8S)0?V?3$WR.^6'QZ9:3Y&=.+V/M"FT(_:
M'5(,SK3AM`J\IC$C-.KA`6<21T7(_-[^S$>U_LW[E@S>V&^':][>I%AN&!JX
MZ8Y":TK@:3+T0M]XW[U_W>W%I]XGDX<Q\H14!WK9.XA:T#S1`:`:=S:TM?SK
MT;#J'Y1]'=WPH-B[YQLN6('EVQF77";E@<_5#B:]HY:G2P(+0&5./K;W#?.O
MM'[@<@2$\P[?*++RGB'BP$>OB)4+]CZ3\NLL/:+[TGL?[VPJ.1]\MFW<CNLK
M@BVO%/IX$I#/FHU1%UQ@TZ,%:WU]QMUD'U[W[KW7O?NO=>]^Z]U[W[KW12.N
M?^RTOE1_XA;XF_\`NX^2'OW7NC;^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
M@)^0G_'I;*_\3Q\>/_?T[(]^Z]T&_P`!O^R/NC/_``V\I_[U.>]^Z]T;[W[K
MW7O?NO=>]^Z]U[W[KW6*>&.I@GII@QAJ(98)0K%6,<T;1N%8<JVEC8CZ>_=>
MZU-LY_+<^=WPP^/_`%''\9-T_%'MOY#_``)^8'=O9OQ2VQNNOHM@U';_`,4/
MDE@\\G8/6O<-5G,G@*9.SH,MNII4K!604U3#CHV2H\HBO[KW5G?\D;X[?)GH
M#XR=KY+Y95_76+[>^0/R?[>^1F6Z@ZAS6)S?670Z=H5>-R,O7.U)<%5Y#"T$
M7\1@GR,]+1U%130SUK:99&+L?=>ZN3]^Z]U[W[KW7K6^OOW7NN['^A_VWOW7
MNNO?NO==V/\`0^_=>Z]8_P!#[]U[KKW[KW7O?NO=>]^Z]T%6*_YG9O?_`,1M
MUU_[T'8/OW7NA5]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MT0&5E8!E8%65@"K*18JRFX8$'D'WX$@U&".M,JNI1@"I%"#D$'R(Z*AVU\*_
MC_VY+)E,AM%-I;K+&:'=^Q9%VWF8ZH`F.IG2D08^MDCD]5Y86<D?J'N8^3/?
MCW(Y+06EM>F]V>E#;78\>(KYJ"QUJ",45@/EUB?[L_<K]@?=N5MTOMI&T<TU
MU+?[819W`D_"[!!X,A![JO&6K^(=%X/77SI^.),O6N^,;\D.O:#U1[0WMJI]
MYT]#&/\`@-15T\ZSSRJO"^.K<$_2'\>Y-',_W?/=#LYJV^7E;F63C<VO=:ES
M^)D`H!ZZHQ\W\^L>#[=_?F^[B?$]MM[MO<;V]@^&PW&J[@L0_!'([AV8>6BX
M8'R@\NA!V'_,"ZMR&57:/<>"W/T)OF-Q!48O?6.JHL*\_"DTV;6GC$4+2'TM
M410I:Q#'V&N8ONV\W6UF=ZY'N+3F/E\BJR6CJ90/Z46HU-.(1F/R'4A<A_W@
M/M??[H.4O>*QW/D/G=3I>'<X7%N6'$K<A!I4G@TT<2TI1CQZ/+B<OB<]CZ?+
M8+*8[,XNK024N2Q5;3Y"AJ$(!#0U5))+!(MC^&/O'Z\LKS;KEK/<(98+M#1D
MD5D=3\U8`C]G6<FT;SM&_P"WQ[KL5U;WNURBJ302)+$X]5="RG\CTX^TO1EU
M[W[KW12.N?\`LM+Y4?\`B%OB;_[N/DA[]U[HV_OW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[H"?D)_QZ6RO_$\?'C_`-_3LCW[KW0;_`;_`+(^Z,_\-O*?^]3G
MO?NO=&^]^Z]U[W[KW7O?NO=>]^Z]T`7R*^4?QY^)NRZ'?_R0[IZ[Z,VAF<U'
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M$%`.O>N>IJ',XZJQ.$H-QY.6:?,9AG\\-/3K#&C++(K>Z]T1OXH]F_*/X<=M
M_P`Q[XR=T?*3=?S3Z>^)WQBV?\E=B]\]JX[%0=K;!W9N_;_8>9SG1_9FZ,%%
M!AL[7PXW:%-G<?Y$2JI\9D(;JL;HH]U[JK?^6'W%U5\CNX?C#C-Q?\*%OEWO
M/Y-YZEV'VIO/XMU6?Q-)TOO#=?V^)WENSHO;FZ<[LNDQ>\:"E6LDQ<]%0Y*:
MMEAAG$0U(0GNO=;8_P`Q^^_]E:^*/R,^1J8N'-U72O3?8/8V,PE0SQTV9S6V
M=N5^0P>(J7C*R)39+,1002%2&".2.??NO=:\>3VU_,O^"O3_`,=OYF7;G\Q#
MM+Y"5&_>P?CS+\N_B7N_:.UZ+H7&==_)'>&V=J93$]&X[&XT9O8><ZEK]\4)
MI:EI'%9%13>72'T-[KW4WYK?*[O/:WR2^<>]<?\`++L'J7N#XD=S_#'8/PW^
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M\F7X6'R8'H`\_P#M9[=^Z>U'9O<+9[#=K#R$\2LZ'UCDQ)&?.J,IK3HC>2^"
MNZ^L<A4[E^)W=&Z.L*UG>H;9&Y*F;/[)KVOY#3,LB3/%'(PT@SP5)`MZA:_O
M(&U^\'L_-ELNU>\FPVF[6X%/JH%$-TGEJP0"1Q[&C\\'AU@YN?W%^:O;+<)>
M9?NI<Z;GRS>EBYVV\=KG;I3QT&H8@,<5EBG(%.X4KU`B^7_?/1U1%B?E9T9E
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MZ6`C,R?P^*I9*'SP.[^$T!ZF,HRJ'([6X?ET9RQ_H?\`;'V>=4Z]8_T/^V/O
MW7NO6/\`0_[8^_=>Z]8CZ@CW[KW77OW7NO>_=>Z`GY"?\>ELK_Q/'QX_]_3L
MCW[KW0;_``&_[(^Z,_\`#;RG_O4Y[W[KW1OO?NO=>]^Z]U[W[KW7O?NO=%S^
M3/Q+^,WS#V/C>O/E/TWL;NS8.W]P0[QQFW-_8]LCB<9N&AQ]?CH<W!&D].8J
MR#'9*HBU:K>.5A^??NO=:YWPD^$_\K[YS]0_++O7KC^2_P!'[>ZXZXW[V+LC
MXD5VY\4:6M^4E/USBLGBZO=4$;Y&"';F%SO96'GQM*69E2G(9Y"ZR!?=>ZLG
M_D=[S^,&]_B5NRH^.OQ`Q7P4W3M3N[?'7'R<^-5!3)#4[#^16PJ;#X#>$-7.
M',F1@J<9!1-23R1PR&FT(R:D+'W7NC]_)_IWO3N7;&V\-T1\J]U?$_.8C/2Y
M/-[JVIUGUWV=5;HQ+X^:ECV_58WL6AKJ#&T\-7(M0)Z<+,6323I)]^Z]U47_
M`#&OY@7:W\N/J_XY_%_)]@]W]R=X]S4NY/\`2'\RML?%ZJ[%R'4_7&-J:U:W
M?T'4G5V)CV=E>S<C4U,.*V[C)7AQT<D3UU<)(HC%/[KW2>^*WR-^+O?GPQ^8
M7QW^!_QH[R[?[&P_4>[-_=@[6^;_`%;V7UB_R[WWOVGK<?N"/LKM#=$--E-Y
M;Q['-'+23O&Z1T44D$,4<%%%'%'[KW1*.V_D!U?_`#).J?C'\"OB!_+K[XZ#
M^1&P>Z_CQN7=&=WM\;JCIO8WP(Q'2F]MO9WL7<V)[/J:*EQV1RF)H<#5X+%4
M^,E=\TU6-5PQ!]U[J^/Y>5F#^;O3O\Q#^7_U[0;SQG;V"^/S;9FS>ZMG9?`=
M<Y+<W<FP<WF.MUVKOC(0+A-UQ4N3QT4>7^T:3^&NP24!B![]U[JD?>?S4[2_
MF-?'3X[_`,K[:WP^^6'6'RIDWY\:-O?,.M[,ZJRNTNH^@ME_'[?NRMT=L;QJ
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MD,8@4HI)",6(_4??NO="7_H=Q'_/:]L?^C+W1_\`5GOW7NO?Z'<1_P`]KVQ_
MZ,O='_U9[]U[KW^AW$?\]KVQ_P"C+W1_]6>_=>Z]_H=Q'_/:]L?^C+W1_P#5
MGOW7NO?Z'<1_SVO;'_HR]T?_`%9[]U[KW^AW$?\`/:]L?^C+W1_]6>_=>Z]_
MH=Q'_/:]L?\`HR]T?_5GOW7NO?Z'<1_SVO;'_HR]T?\`U9[]U[KW^AW$?\]K
MVQ_Z,O='_P!6>_=>Z]_H=Q'_`#VO;'_HR]T?_5GOW7NO?Z'<1_SVO;'_`*,O
M='_U9[]U[KW^AW$?\]KVQ_Z,O='_`-6>_=>Z]_H=Q'_/:]L?^C+W1_\`5GOW
M7NO?Z'<1_P`]KVQ_Z,O='_U9[]U[KW^AW$?\]KVQ_P"C+W1_]6>_=>Z]_H=Q
M'_/:]L?^C+W1_P#5GOW7NO?Z'<1_SVO;'_HR]T?_`%9[]U[KW^AW$?\`/:]L
M?^C+W1_]6>_=>Z]_H=Q'_/:]L?\`HR]T?_5GOW7NO?Z'<1_SVO;'_HR]T?\`
MU9[]U[KW^AW$?\]KVQ_Z,O='_P!6>_=>Z]_H=Q'_`#VO;'_HR]T?_5GOW7NO
M?Z'<1_SVO;'_`*,O='_U9[]U[KW^AW$?\]KVQ_Z,O='_`-6>_=>Z]_H=Q'_/
M:]L?^C+W1_\`5GOW7NO?Z'<1_P`]KVQ_Z,O='_U9[]U[KW^AW$?\]KVQ_P"C
M+W1_]6>_=>Z]_H=Q'_/:]L?^C+W1_P#5GOW7NO?Z'<1_SVO;'_HR]T?_`%9[
M]U[KW^AW$?\`/:]L?^C+W1_]6>_=>Z]_H=Q'_/:]L?\`HR]T?_5GOW7NO?Z'
M<1_SVO;'_HR]T?\`U9[]U[KW^AW$?\]KVQ_Z,O='_P!6>_=>Z]_H=Q'_`#VO
M;'_HR]T?_5GOW7NO?Z'<1_SVO;'_`*,O='_U9[]U[KW^AW$?\]KVQ_Z,O='_
M`-6>_=>Z]_H=Q'_/:]L?^C+W1_\`5GOW7NO?Z'<1_P`]KVQ_Z,O='_U9[]U[
MKW^AW$?\]KVQ_P"C+W1_]6>_=>Z]_H<Q/_/:]L?^C+W1_P#5GOW7NJ-?D-_/
M/_E&?&/Y&97XQ=F?*WO&7?FU]Q46T]^;@V?7=E;NZYZ\W'4U[8ZLQ.[]YXB6
M6BI:O`5*D9):9*K[(JRR6D1T7W7NC4_.GY]?![^7CT]U'WM\@.ZN]ZOK?O/-
MTV$ZOS/5^YMX=BG=#5FVI=VTV5HHL1E$5\'/A$65*H.8V,T8%RX]^Z]UD_EW
M?.[X;_S0L!V=N7XJ]C_)G(XSJ+,[>P6\6W]7[ZV+-%D-T4.0R&*7&PY#)3G(
M1M3XR4R,I'C.FX]0]^Z]TI_GU\S/A/\`RT>OMO=A_++Y`=M[0IMY96;"['VG
M@-Y;VW9OW>U?2?;')#;>U,34O6U=)B(ZR)ZNID,5-`)$5I`[HK>Z]T&'QW_F
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M;<W(]!]UCID6F:IHY(YU`5Q>6]N^\W[A>WVPR0WFCF#;=(CBL;Q?&,\TA$<$
M$;G]2LDC*@!+#/#SZPL]V_N->P/.LLO-VVQR\F<QVX:=]QVE_I?#"`O)*\((
MAPH+%D$;8PWET2GXK_*^LS/RES6+W;NG>-+L3LNKQ^W\?D:;<F4Q>6@_@4/V
M6&JZG*4\B5+R9>*(S5`+6DG(!/L_]Z_NT3>UWL9R_P"Z=M%!_7[99IKGF0PJ
MH^H@W>82WAHI[DVNX:+P/X+>-P*#'6/?W8/O7S<Q?>1W7DO=KFZ?D'?8X;/:
M&N79FBDVZ+P;1F9O]$OXD=IR35KB1:DG/6P<.GL,RJR;W[7=&4,CKV9N<JRL
M`592*P@A@;CW`*.LB"1""C`$$9!!X$'T/75LBF#QZ[_T.XC_`)[7MC_T9>Z/
M_JSW;KW7O]#N(_Y[7MC_`-&7NC_ZL]^Z]TMML;7IMJTE11TN6W+ETJ:@5#3;
MFW!D=PU43"-8_%3U&1EED@@(6Y12%U<^_=>Z4WOW7NO>_=>Z`GY"?\>ELK_Q
M/'QX_P#?T[(]^Z]T&_P&_P"R/NC/_#;RG_O4Y[W[KW1OO?NO=>]^Z]U[W[KW
M7O?NO=<71)$>.1%>.1&CD1A=71U*NK#\AE)'OW7NM6"N_E=_SLOAQF-V]4_R
MM_G[TS@OA]N7?>]-^[)ZU^1>P:3<.\ND#OW.U6>S6S=K;BJ-G[P;,[9HLIE*
MFJI#Y*2TC$M$'=W?W7NKD/Y9OP1JO@)T!G-A;Q[9S/?_`'GVWVCO+OKY&]ZY
M_'0XG(]H=R]@RTC[AS<6-B>9Z'$TE+CZ>EI(I)))/'$78KKT+[KW5B/OW7NN
MP2/H??NO=>+$_4^_=>Z\23P3_OO^)]^Z]UZYM;\#W[KW7KDBU^/?NO==>_=>
MZ[!(^A]^Z]UU[]U[KWOW7N@JQ7_,[-[_`/B-NNO_`'H.P??NO="K[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI.WI_/$Z/V3_`#`Z7^7A6_'/Y79#
ML*K[7V?U$O:N+ZUII^FDS&]*3#U-%G3NHYA*@[;QZYJ,552*<^(QR<$(??NO
M=5?_`,P;HCXA=.=7]\?R?OY;OQDQW?\`\XOGSN7-[V[=J,M/5;]_V7?']F5]
M%49_Y#=]=M[B@S%7L2BPT=*:K;V+>JBG:K;SPQ`-:?W7NFG^8U_+O^>$6^OY
M(_Q7^"\74>ZZOX1]4;WGJ^U^\\IM.MV)@MZ838.V=D46ZMT=6Y2HKMQ;CI)J
M7%555C(Z?%9"F6K")*NB.3W[KW1YOY(?S6^279/;OSA^`WS7V5TYC_E=\*=W
M[3CW=V9T)M3$[4V'VIM3>U-65>W\E78_`8O#X>GSN-I3#XQ%34S/2U`62GAG
MBEU^Z]T<3^8OUG_+@ZPW9UA_,H^=^/H:O</Q.P>?VUTU_>'(9;/XZKW!O7SF
MGVWLWJ&.2IQF_NSMR5Y2+%QK1SU8GCB<%%@$D?NO=4P?%G^49VG\W>A/YN7?
M?;NP1\%LU_-O;9$?2O153A*<Y3IC8'4^6I]T==;P[2VWC8\;'1[I[%W)0PUN
M8QT:Q3P023.`DDX5?=>Z3_R"Z&^2O7/8';G47;^_NK=J_*W^<E7=3;-[S@Z&
MRF[LEU[\7OY=_P`*>J8<#\@NX)MT;MIL5N2HSV^MJF3&*\D$%/3U&9%/3F22
M)G]^Z]U<A\&OYA7PU^7\FR/BUUQT]V9UCLZ'I*@[*^+V*[5V71[6VAWI\;]B
M96/K2E["ZJBQ>9R$C;>PE7!3PFBRD5#7BGJ(IOMRC$J3;YR]LW,EJMEO<`GM
M4D615+,M'6NE@492"M<&N#GCU[!4JP!1A0@@$$'B"#4$'S!%#T9S8O677V0^
M57R$V56;-V]-M79_5GQPSVV,)_#*6.DPF8W=E.\X=RY&A>*..I2IS$6V<>LI
M+L+4B:0OJN'I?;7DN:(PS6DCPL"&5KFZ8,#Q#!IRI!\P10^?22/;MKB<216=
MDDJFH9;>!6!'`@B,$$>1!!'1YZ*CI<=1TN/HH5IZ.BIXJ6E@0L5AIX$$<42E
MV9RJ(H`N2?8PLK*UVVSBV^Q01V<,:HBBM%1115%230`4R>EA)8U/$]2?:KK7
M7O?NO=>]^Z]U[W[KW7O?NO=`3\A/^/2V5_XGCX\?^_IV1[]U[H-_@-_V1]T9
M_P"&WE/_`'J<][]U[HWWOW7NO>_=>Z][]U[KWOW7NHT]91TLE)#55=+335\Y
MI:&*HJ(89*VJ$,M0::D25U:IG$$+N40,VA";6!/OW7NB(_._YT)\,</U1A]I
M]"]H_*/O;OG=F=VETUT%U$V&HMU;QEV?MRHWAOG-5.<W'4TN#P6!VAMFF-34
MS3,[NSQHB'467W7NN7P0^<P^9^#[5QV[.@NU?BWWCT/O#$;+[EZ'[>_@U7N7
M:%;NG;E)O+9F5HL_MVIJ<)N'!;JVID(:J">'04?R1.@*:F]U[H^OOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@JQ7_`#.S>_\`
MXC;KK_WH.P??NO="K[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZX2"
M1HY!$ZQ2F-UBE,:R"*0J0DA0E?($8@VN+VM?W[KW6I%2_P#"8[O_``7:/='<
M&Q_YT'RRZZWSW_O;([\[4S6Q-I-M:MWAG*VNKJVF?.5&$[/H9,A#B5KWAI(W
M_:IX;)$J*`H]U[H]_P`KOY%&"^4_4GQ"CK_F-\@.O?F5\.MCP;#V=\Y-HUD\
M/:V],14QJNXQO>B7/TU3729B=I9XY(LG'/3RSS#R21S21M[KW2F^.O\`)$VG
M\7/AS\H^A>JOE-WC3?)SY?2KFNW_`)X9>LGK>\*K=T-;!54&7PWV^;HZK&T&
M,B^YCB@&2:H=ZV>66ID=AI]U[H#/G5_(.[)^<6%^$^+W%_,G[TV=7_"SK+;^
MW-O;EIMF4N>W'O;M[%2PMD?D#F<K4[VH*NC[!RU/14L0DU5$E+X"T4P,LFKW
M7NCB?RT/Y:/>WP.W?VIN?N#^8O\`(SYOT78FW<!A,1MWN^3)/C]BUF'R=97U
M><P9R&]-U#[_`"T52L$NE(?VXQ<M^/=>Z%C;?P0R>XOE#\U_DAWYO7$[VJ/D
M7U1A/C'TSAMM4.0QU1TA\9J3`Y1=T[7@K<M)5Q3;O[`WSGJK,Y.KIHXX&>*E
MCTLL*^_=>Z*9_+M_E&=D?$7N3J#LCN/OC9_:^&^)/QAW!\//BIBMD;"R>R\H
M.IMR[[3>>2W7W+69/.YFES/80AH*6@C3%I38\1K)*5+N+>Z]U8]US_V6E\J/
M_$+?$W_W<?)#W[KW1M_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0$_(3_CTM
ME?\`B>/CQ_[^G9'OW7N@W^`W_9'W1G_AMY3_`-ZG/>_=>Z-][]U[KWOW7NO>
M_=>Z][]U[JLW^:_MSX(Y/XKU.Y_Y@6^,QU=U5U]O'#;IV1V9LW=N]=F]H;+[
M8^SR>+VKDNILEUZ9=V5N_P"HIZ^J@I*.EIJS[A)'5X'35;W7NM;9\_O'YM=-
M#&[1[#WG_.W^&G1.^*2N&9V+5[H^)7\X'XBYJKQ==28[/XJJJJ;8M/W7@]Q;
M<FJ:.9C!1U^>I$;B5XV*>Z]U?Q_)G@_EYT/0O8&/^`]9V5/4P]@^?Y'TGR!E
M["D^3F([9EQ<5+387OA.SXHMU4NXL-MVAAI**$7H8Z&!13LZZG;W7NK@_?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!5BO^9V;
MW_\`$;==?^]!V#[]U[H5??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4KKE&'S1^4[%2%
M/2_Q.`:W!(S/R1N`?H;6]^Z]T;7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M!/R$_P"/2V5_XGCX\?\`OZ=D>_=>Z#?X#?\`9'W1G_AMY3_WJ<][]U[HWWOW
M7NO>_=>Z][]U[KWOW7NB,_/?X95OS.ZSV+A=H=R;C^/W<?2_:6#[NZ-[@V_M
M_!;TBV;V7MS$9W!4-3N#8>Z$DV[O+;U9B-QU<%11U(4KY%EB=)(U/OW7N@L^
M!'P'[/\`C'OGM[OKY+_*/+_+KY-=RX#96Q,YV5)UGL_IS;6"ZUZYJ<[6[3VG
M@=A[)!QQJ5R&XZNIK*^IEFJ)G=470B6;W7NK):/!X3'9#+9?'X;%4&6S[T<F
M>RE%CJ.ER.;DQ\!I<>^7KH(8ZG)/0TS&.$S,YB0Z5L./?NO=.GOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@JQ7_,[-[_^(VZZ
M_P#>@[!]^Z]T*OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH]724]?255#5QB:EK::>DJH2SH)
M:>IB>&>,O&R2*)(G(NI#"_!!]^Z]T5#K[X)?$WJO?M#VCL#IS$[<[`Q[1M3[
MII]P[TK,FPAAKH*:.L;);EK8,C3T<63J1!%4)+'`9Y#&JEF)]U[HV_OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[H"?D)_QZ6RO_$\?'C_`-_3LCW[KW0;_`;_
M`+(^Z,_\-O*?^]3GO?NO=&^]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW05
M8K_F=F]__$;==?\`O0=@^_=>Z%7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!/R$_P"/2V5_XGCX\?\`OZ=D>_=>
MZ#?X#?\`9'W1G_AMY3_WJ<][]U[HWWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>ZK5_F![I_F!5N0Z@Z6^!]/L/JRH[%;>^>[E^9/;N`H=Z==?
M'/9.R,13UU'14NPY<QCIMT;\[`R=4*>A^X0XVCI:>HEG=6\;+[KW1"?C3_,T
M^074727\SF7Y=;VZ<^6N1_EO;=PFX\/\D_CEACM+8/?%3N?KJKW=2]99?%T]
M9E=N8#M3:VXHJ;%Y6'&3S4\(KH2RB2^OW7ND#@OD;_.,^)4GQ>^67S?[9^,W
M:WQC^3G:W3/6G;7Q\ZYZKJ]C[N^*7^S%U])A>N<ML_L>7)R5/8]/L_=.=Q^.
MSBY)"\D<CR0:R/*ONO=7W_)CO'`_&7X\=X?(;=%'-DL#TEU7OGL[(XJFE6"J
MS$6S=NU^<CPU+,ZND-5F)Z-*:-B"%>4&Q]^Z]UKY8KY1?SEOC-LWX[?/SY?]
MF_&7L#XJ]^]@](X7N#XI;%ZMK-I[S^,.P_DCN'#[<V)N+9_:\V4>M[`S6Q,I
MNK$PYJGR2:)A-/XM6@2+[KW0D?*[YZ_,/9/;7SH[=ZV[7V#LCIC^7/V_\5^J
M<A\8]P]<87-Y'Y-TW>%/UMDMW9K*]E5E=!N[9.;K:3M%:/:5/AX7IZBNQ2B<
M2B:4+[KW5H^S^]^P.ZOF[OKK+K3+4^-Z!^*VRZ;#=[UQP^/R$V__`)$=G8[&
M;@VKUEBLY*9I<3#TYL'1EL[]HRRR5^>HJ60@0S)[]U[H]OOW7NO>_=>Z"K%?
M\SLWO_XC;KK_`-Z#L'W[KW0J^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7N@)^0G_'I;*_\3Q\>/\`W].R/?NO=!O\
M!O\`LC[HS_PV\I_[U.>]^Z]T;[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW1:?DWB?EWE]L[<A^'^\N@]F;NBSLLFZZSO[:&]]X8&LVX:"98:;!4NR-
MP[>K*/+KDC&S23/)$800%#6/OW7NB"?+'YM;?^'_`%MTAU+_`#4-J;=SG3OR
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M[KW5)/=_\SSXY?S$OA)\6_@1\<<QN/='S4[K[`^)VPNQ_C[+L+=&.WK\?_\`
M0YV/L'=/>^?[<@R^,IJ#9VW]BT6PZ^-:QJHM,\D#1'U$K[KW5Q/\PWIOX@]<
MI2_-;=_QPV+VO\O,/7;$ZN^-:92/)-DNR>_,WEI<%T#MC)X&GR5/M[==5@=W
M9?[R*OR5'65."QM/45<#Q"F!7W7NJ6OE5M^M^'6X]W=+]J_+[MOXW9+JWX&9
MOY1]";UZZ[(R.QG^7W\R7L#L7?FX>[-W9O%0T<S]V[H3>\>`H,=LJJ^]B.&S
M"1)2-&JO'[KW6TO\;]Q=D[O^//1.[.Y,+_=OMS<W3_6^?[/P'A6G.&W]E]H8
MBOW;C6ID"K2O1YV>=&B``C(*V%O?NO="1N?$YC,XT4>#W17[0K14Q3'+8['X
MG)5#0('$E(:;,TE;1B.8L"6":QI%B.??NO=!-#U#O2#/5^Y8N\-X#+Y/%XS#
MUDYVOL)HGH,/4Y.KH(U@.W]$;QSYBH+,.6#`'](]^Z]T\?Z/NQ_^?[;L_P#0
M1Z__`/L?]^Z]U[_1]V/_`,_VW9_Z"/7_`/\`8_[]U[KW^C[L?_G^V[/_`$$>
MO_\`['_?NO=>_P!'W8__`#_;=G_H(]?_`/V/^_=>Z]_H^['_`.?[;L_]!'K_
M`/\`L?\`?NO=>_T?=C_\_P!MV?\`H(]?_P#V/^_=>Z]_H^['_P"?[;L_]!'K
M_P#^Q_W[KW7O]'W8_P#S_;=G_H(]?_\`V/\`OW7NO?Z/NQ_^?[;L_P#01Z__
M`/L?]^Z]U[_1]V/_`,_VW9_Z"/7_`/\`8_[]U[KW^C[L?_G^V[/_`$$>O_\`
M['_?NO=>_P!'W8__`#_;=G_H(]?_`/V/^_=>Z]_H^['_`.?[;L_]!'K_`/\`
ML?\`?NO=>_T?=C_\_P!MV?\`H(]?_P#V/^_=>Z]_H^['_P"?[;L_]!'K_P#^
MQ_W[KW7O]'W8_P#S_;=G_H(]?_\`V/\`OW7NO?Z/NQ_^?[;L_P#01Z__`/L?
M]^Z]U[_1]V/_`,_VW9_Z"/7_`/\`8_[]U[KW^C[L?_G^V[/_`$$>O_\`['_?
MNO=>_P!'W8__`#_;=G_H(]?_`/V/^_=>Z]_H^['_`.?[;L_]!'K_`/\`L?\`
M?NO=>_T?=C_\_P!MV?\`H(]?_P#V/^_=>Z]_H^['_P"?[;L_]!'K_P#^Q_W[
MKW7O]'W8_P#S_;=G_H(]?_\`V/\`OW7NO?Z/NQ_^?[;L_P#01Z__`/L?]^Z]
MU[_1]V/_`,_VW9_Z"/7_`/\`8_[]U[KW^C[L?_G^V[/_`$$>O_\`['_?NO=>
M_P!'W8__`#_;=G_H(]?_`/V/^_=>Z]_H^['_`.?[;L_]!'K_`/\`L?\`?NO=
M>_T?=C_\_P!MV?\`H(]?_P#V/^_=>Z]_H^['_P"?[;L_]!'K_P#^Q_W[KW7O
M]'W8_P#S_;=G_H(]?_\`V/\`OW7NO?Z/NQ_^?[;L_P#01Z__`/L?]^Z]U[_1
M]V/_`,_VW9_Z"/7_`/\`8_[]U[KW^C[L?_G^V[/_`$$>O_\`['_?NO=>_P!'
MW8__`#_;=G_H(]?_`/V/^_=>Z]_H^['_`.?[;L_]!'K_`/\`L?\`?NO=>_T?
M=C_\_P!MV?\`H(]?_P#V/^_=>Z]_H^['_P"?[;L_]!'K_P#^Q_W[KW7O]'W8
M_P#S_;=G_H(]?_\`V/\`OW7NO?Z/NQ_^?[;L_P#01Z__`/L?]^Z]U[_1]V/_
M`,_VW9_Z"/7_`/\`8_[]U[KW^C[L?_G^V[/_`$$>O_\`['_?NO=>_P!'W8__
M`#_;=G_H(]?_`/V/^_=>Z]_H^['_`.?[;L_]!'K_`/\`L?\`?NO=>_T?=C_\
M_P!MV?\`H(]?_P#V/^_=>Z]_H^['_P"?[;L_]!'K_P#^Q_W[KW7O]'W8_P#S
M_;=G_H(]?_\`V/\`OW7NO?Z/NQ_^?[;L_P#01Z__`/L?]^Z]U[_1]V/_`,_V
MW9_Z"/7_`/\`8_[]U[KW^C[L?_G^V[/_`$$>O_\`['_?NO=+K:N$SN#HZFGS
MV\<GO.HFJ!-#6Y/&83%RTD/C5#2QQ8.BH8)$+@MJ=2]S:]O?NO=*CW[KW7O?
MNO=`3\A/^/2V5_XGCX\?^_IV1[]U[H-_@-_V1]T9_P"&WE/_`'J<][]U[HWW
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M9S/Q8B&2GQ,>;RT%/'7Y6/%T\K)3+/)(($8JE@3[]U[IDQ'6G7&W]TYK?.`Z
M^V/@][[E1H]Q[RP^T\#C-U9]'=)73-;AHJ"#+91&DB5B)YG!90?J![]U[I19
M+!X3,R8N7,8?%9:7"9*'-867)X^DKY,/F*>*:"#+8MZJ&5L?DX(*F1$J(BDJ
MI(P#`,;^Z]TT;EV'L;>=3M^MWCLO:6[*S:653.[5J]S;<P^>JMLYN+1XLSMZ
MHRE'52X;*QZ%TU%,8Y186;CW[KW2K]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`3\A/^/2V
M5_XGCX\?^_IV1[]U[H-_@-_V1]T9_P"&WE/_`'J<][]U[HWWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NDEO_>>)ZYV'O?L//%Q@MA;0W+O3-&,@2?PG:V&K<YD?
M&6](?[2A>U^+^_=>ZU8T^2G\Y79WQ9P'\Y[>OR(Z<K?CUFJ3:W=6[/Y<Z=/T
ME'0[4^)^[MSXN"`X'NHUR[LK.ZL+U_D*?*NU1']A+5M-%RH6,^Z]UM;X;+46
M>P^)SN-D,V.S6,H,OCYBI4RT62I8JRED*GD%X)E-O?NO=.7OW7NO>_=>Z][]
MU[I`=K[AWKM+K#L/='6VR'[+[#V]LO<N8V+UY'E:#!G>V[L?B:JIV[M=LSE*
MBEQV*CS>5CBIWJ)I$CA1RY/'OW7NM:O']^?S3_B7\F?AV/DC\X/CQ\DM_P#R
MW[FV'UWVY_+>V'U5A,/O#HK:N_L-79W<&[NJMU;;SN2W?6XCI.EA27)Y/<$*
M8ZMHHWD$C%T8^Z]UM*'@D?X^_=>ZZ]^Z]U[W[KW7O?NO=`E\D^\-N_&CX^]T
M_(/==//7;?Z9ZRWEV/D<;2MIJLLFU,'696##4C:6"UF8JJ>.EB)!`DE%_?NO
M=:U70'RF_F1[W^1_563KOYGWP/WI\@]^5NR-X]I?RAWQ&W-L)UKU#O-,)E<Y
MM/:?<%/6Y/?>0[KZXV1DH*V:*KIFCJLC'51LGA*$^Z]UMAG@FWOW7NNO?NO=
M>]^Z]U[W[KW1>?EKW[0_%?XP]^_)#(X.HW/2](]3[V[)_NY2R_;S9VHVM@ZO
M)4>(^Y*N*2+(5D,<4DUF\,;,]CIM[]U[K7TJ.Y/YPWP_Z=ZM_F:?*+Y7]$]S
M]%[_`,[TKD^]_A?MGJ*CVSANI^K^_=V;5VOAINC^X*+(R9_<^].OWWGCYI_X
MI')29%(ZD*[_`+;M[KW6T=')'-''-$VN*6-)8G%[-'(H=&%['E6'OW7NN?OW
M7NO>_=>Z][]U[JC;^<9\[?F#\9>L]S8CXD=%9P#;$'6>?[=^5^]SA,;U?U=M
M+>O96V=GIM_K;%9-ZNL[4[=RZY1D>C6E2APU+(*B>1W>*/W[KW1OOGM)\^=S
M[%ZCZL^!,VSMB;U[=W@<)VM\F-\T.)W)B_C=UI0[:J\MDMZ8?KROK:-]][UW
M%DTAQN*IE62FIYY6FJ`L:AA[KW1-?A3V1_,!^//SZRO\OKYE?(#9OS4VSO?X
MSY3Y2=;?(#"];4'4_8&P#M_?N'Z\S77G8FT]NSUFVYL+G:W(M4X2M5Q/*::=
M"S:'6/W7NKU??NO=>]^Z]U[W[KW5'7\X_P"=OR\^,756ZL5\1^C<^U3MFAZ[
MW)VU\JMZKA,=U5U1LS=_8VW-GC"=?4&4DJZOM+N+,ME3&N/2E6BQ%+)]U42,
MQBB/NO=#!_-]^1O9_P`?_AYM*KZA[JV[\>>S^Z.\^B.EL-WMNNCVYD,#U1C-
M[;C@K]^=A9;&[I*8*LQ^W-CX7)3S1S%05_25;21[KW0(?RD,SW+V?NGL'M')
M_P`Z#K;^9[U'BL'+LJ;9O7?4/66Q4V)ORHKL3EJ+<&7R^S<Q79A9#A(IH8J>
M>)()UJ"ZLQBL/=>ZO4]^Z]U[W[KW7O?NO=4._P`U3Y[_`#%Z(WIU5U[\;.E,
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M"'>'4O\`.]^0G:_?7975ORVZO^`'3_5&[LYMOXZ=/Y?J;9O<<O>.UMH4%+D(
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M=4[-[GJ^^]O;:Q]'D?\`2MW)N^KS$\FR-M[SS"O3T]!1QBKH,>DK31>32TGN
MO=&3^+O\QF?=W\KWJ3YW?(W:E-MW>FY]J38_*;`Z\6?(OV/VK3[ZR_5^V=L=
M/8[(2BLS53V_NW&0'`4Y=@8LC&S2>%'F'NO=)G^4G\B/E?WZ/G=1?+_*;7?L
M/I_YJ;LZUP.T-F4E(FVNL-ECK?KC=F&ZWQ^5AI*:LW+4;6;<LD%9DJEI9*NM
M$KHWB,8'NO=6^^_=>Z][]U[KWOW7NO>_=>Z][]U[H"?D)_QZ6RO_`!/'QX_]
M_3LCW[KW0;_`;_LC[HS_`,-O*?\`O4Y[W[KW1OO?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=!1WSL"I[7Z,[IZMHI$AK>RNINQM@4<TCB)(JO>&T,QMZFE>0D"-(
MYL@I)_`'OW7NM1G-_P`R?K[M3^4Y@/Y1F&VAVQ#_`#1\YU7LCX,;B^++=4;R
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M]0TT-<$B$:BX(]U[K=*&JRZRK/I76R`JI>PU%022%+?3D^_=>Z[]^Z]U[W[K
MW7O?NO=$K_F/=(;R^2?P(^8'0_75FW_VE\?.S=I[(AUQQ&KW97;:KFV]0)-*
MR14\F0RL44"R,0L;2!CP/?NO=:BU5V3_`"U.XOAO\1/AG\.OBWN+:W\V[:78
M/QHHZ;:=!T5NK9OR-^/?=NP]_;2R?=_;W=G;]?@Z*J;:2T=!G*FOKJK,5<64
MI<C&!&@=1#[KW6]V@<(@E97E"()71=*O(%`D95_LJSW('OW7NN7OW7NO>_=>
MZ][]U[H*>]\7@<YTCW!A]T]<U_<&V<GUCOJAW!U1BH:.HRO96&J=LY*+);&Q
M4%?54-'+E-TTC/14RR3PJ9IENZ?J'NO=:(E+@/B=\FME]>?"+XD?+G^8A\L=
M_;V['ZFP?5OP/[]QF]L9L?\`EU;9VSV#A,_V!O#O*MFVSAXLE-T9L_'UV*PZ
MY')UM-#D#"(HISHD7W7NOH%T\"4M/3TT;,R4T$-.C.06988UB5F(L"Q"\^_=
M>ZS>_=>Z][]U[KWOW7NJDOYYX9OY7_R*"J[G^*='V5%:1C_QG[K`FR(&8V')
ML/I[]U[J9_-/_FA=9_RR^D.M,]N;([9@[-[QW-1]<]2Q;V;<";"P-=%CH*S<
MG9'94VU,7F=RQ=?;`QTT=1618^FEKJ^>6"D@"M,98O=>Z+__`"G?F-_+H[H[
M)[%V[TC\OX/F#\X>TMO1]D_(7MG([!WSM#*[FPFTIJ3$X_`[,QFX=KXC";!Z
M<Z^FSZTN`VW1SM]M'4//,U35S5-3)[KW5\/OW7NO>_=>Z][]U[JI/^>@&;^5
MQ\EPJNY\_3-E1&D8_P#&>>LB=*(&8\<FP]^Z]T@?YP6?^,.S.MOB/OWYJ_%7
M<7R0^+&Q>^,'N;LS=>)?<>>VY\=,A3;+RU)M'MWLKJW;M%7OV9UW!DJQZ/(0
M544M+0>=*AXY;!#[KW1)?@YNCXD?)_\`FX[7^17\JWK>EVE\8NN/BMV+L;Y<
M=Q]==6Y;I_I#N3?.ZL_MN;I7KC$8.MP6UL;NG?.P),;D<G59"GH?)24[>"24
MZP#[KW6T)[]U[KWOW7NO>_=>ZIF_GDAF^+'0H57>W\P?X*&R(\A`'?NVBS%4
M#$*H%R?H!]??NO=%]_G;9'KK`=S?"/</SAP6_=S_`,JRBJNX*7Y-8G:^+W=N
M#KJD[EJL5MYNALY\B=N[)BFS>7ZLQT\.3-+K26BI\N8Y)T:T8/NO=(K^3KN'
MXY;J^:'R;RG\L'`[VV[_`"P*?I#8%%60G#[RVW\?LM\O3O#+S9[*?'O;V^(J
M;(4)3KGPQ;HDHX8:.;(K$64R`,?=>ZV4/?NO=>]^Z]U[W[KW6J9\Q?YU?P<[
MC^2G</PU[F^7V-^,_P`5.D]RU'77?)PNW^RJ_MWY6[GH51=V]8;0W-LS:^6H
MNN>B,75"3%;AR4-0,YN"1*BCI#2TA>HE]U[K8V^*_;/0?=WQ^ZJ[)^+>4PF6
M^/N;VO1T?555MK!UVVL`FT]O22[=H:#$8')8_%5F+Q^,_A;4\4+4\05(AI&F
MWOW7NJ^/Y%X8?`.A#*Z'_9E_F2=,B-&UC\H>TR#I<*UF4W!_(-_?NO=7">_=
M>Z][]U[KWOW7NM4_YE_SK/@YV_\`)3N#X6=Q_+JD^,OQ:Z5W#/U]\@:W#8'L
M>M[9^5.Y:9?'NOJ;8FY=D[9R]/UUTABIUDQFY<O'41YO.N)J&B^UIC)52>Z]
MT8+O7JOY2?-AO@=\J/Y._;7PK3XE]+=;;H'3^R_D'UUV2^Q,;OZ"OJ=@8;L7
M9.R\#@L34464V+L[%56&P\M;XSC/N:J2GBURK,ONO=(C^1+AOY@E!\E/YH,G
MR@WI\:=P;/I_ESO&@[*I>I-K[TPV=R/R678G4DF1S^U:C<!%-!U2^R#30Q4T
M^JM_B*RO?0>?=>ZV9??NO=>]^Z]U[W[KW7O?NO=>]^Z]T!/R$_X]+97_`(GC
MX\?^_IV1[]U[H-_@-_V1]T9_X;>4_P#>ISWOW7NC?>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[IH7;^!3,R[C3!X=-PS4XHYL\F,HES4U(JQJM++E5@%=)
M3A8E`0R%;*..![]U[IW]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3+1;;V[C<G7YO'
M;?PF/S.5U#*9>AQ-!293):Y%E?[_`"%/3QU=9KE0,?([78`_7W[KW3U[]U[K
MWOW7NO>_=>Z3NYMW[2V70QY3>6Z=N;2QDU2E'#D=SYS&8"AEJY$>1*6*KRM5
M24\E2\<3,$#%BJDVL#[]U[K(VZMKQ[=_O>^Y,`FT_L%RO]Z6S..7;G\+=0Z9
M+^.&I&,^P96!$WE\9!^OOW7NFC:E?USNJ:NWML:LV1N2HKB<5DMW;2J,!F)J
MQJ1:<G&UVX,,]3)4-3)'%>&28E`$X%A[]U[I:^_=>Z][]U[KQ(`))`"@LQ)`
M``%R238``>_=>Z3V6W=M3`'#C.[HV[A3N*LBQVWQELWC,:<[D)PIAH,-]Y50
M_P`4K)0PTQ0>1VN+#W[KW2A]^Z]TS46W=O8W)9#,X[`X7'YC+$G*Y:AQ5!29
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MD!*EM)(''OW7NE/[]U[KWOW7NN`EB:22%98FFA$;2PK(C2Q+*&,1DC!+QB0*
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M-&X`9&%P0??NO==U]!0Y2CJ<=DZ*DR6/K(S#5T-?30UE'50M^J*II:E)()XV
MMRK*0??NO=8L7B<5@Z&'&83&8[#XVF\AI\=BJ*FQU#`99&FE,-)1Q0T\1DE<
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M]D?=&?\`AMY3_P!ZG/>_=>Z-][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU-_
M^%@F`CW7_+Z^.6V)&>-=Q_.#JC`&6-D22)<SM#L+'.\;R`HCJE2;$@@'Z\>_
M=>Z(-+VOOG._R1MM?RACGV'?U1_,8JOY4.3ITK*9\[#U=M'?=3VE5Y]WFHTI
M/&O4%)34ZL%$8213?^R?=>Z;_P"3+\_,9_*M_D7;XWM!U_6=P]P[Q_F,=C_'
M/X_]0T>3BQLG8_<.?Q>P\=B<5D,TL<B8_"T5-0RU%5/&C,Y"11@-*K+[KW5R
M&Q?YE?\`,M^(GR3^+?3O\V[HCXV8#K+YM;OAZOZA[A^+.Y]T9*FZL[EJJ6&J
MQ/7':^%W;/5R9!<T]6D$>0Q[_;HZ/(K2QQR:?=>Z#:;^:)_-@[^^;?\`,E^$
MGPFZ"^+&X,W\.=_;7&VNT^Y]P[NVUMC&[%R&#EK%VQGL+A:^NR>[^P]Y9:)X
MZ"HIVQN-Q]/3RO4!BT=_=>Z))\WOYG7S#^?7_"<?MGY.]=;<V#T1O7;G8>6Z
M3^8='0;IW;196FP>TMS8#!9;(='9+#U,=70UNY]R9;'1U-%D*B>./%RUD/EF
M]+M[KW0,_P`R3</S"P7P]_X3R[H^0VR^J]_][8?YL=29;K/8_2.:S.,P&]=E
M4NR=AU746#R^X-Z)/+B]Z9^C2"+,53*])#42-(H*@^_=>ZO%^+/\QC^8!@/Y
MGP_ET_S$.F?CKMK)]Q]$[E^1/Q^W?\:MS;NSV.Q.WMK9C*4F3V3O27>"0U6;
MR\=+C:A/NXJ:A7ST@94DCJ%\7NO=5N;,_GV?S#_D?V=V)N3XM;)_EZ9/8_7_
M`'WD^JZ'X1=H=V9;8OSRWMMW;6[9-L9+*8^#<V2VWL6ES&8HJ6HR*+&*B.AA
MIY%=9F32_NO=;BV"K,AD\+ALAEL//MW+9#%8ZMRFWZFKH\A48+(55)#/6X>>
MOQ\DV/KIL94.T+30.T,I34A*D'W[KW6LK%_-._FI?-7L/Y.;P_E8?&;XU;I^
M*/Q&[(W1U7D=W_(G=>\<9OKY-;WV!'%5[RPG4%)MUJ/&;<2-(&AHY\AKAD%=
M2R-(&:2*/W7NJZ?YTW\Q'M[^8K_(IZU^1OQTQ&W.L.H=_=W8/I_Y@]=[RS6Y
MZ3L[:W8V#WY@,)B^N=MY+!?P_&9S9E?N-97S#5*HU3BI8-*+)Y$'NO=;/O\`
M*H^+F4^(/PGZPZAW+U3T1TYO3[C<&ZM[;/\`C?5;RKNJ&SNXLE))!F<-6;]K
M\EN>HK\G@(*)JUII2@JE<1@1A??NO=:E'\Y[^1C_`"[_`(Z?(W^6P.L^O-^X
M]?FG\]8>N^^QD.U-VY0Y[:>[*NCS&<HL(:VIE_NU4SUV7E:.>E"R1+91P![]
MU[H^78>3WG_(]^77QG_E:?RB_C]UYN*C^=VT^SNT8XN_M];^SPV_W)AX3@,=
MNS,[L?+S5-%UQMC:NU6J\ACX*62JJC$5AD5W`/NO="M\I/YQ_P`UNF>Z.JOY
M>VWLS_+RV7\W=L='8ON;Y>]Y?(KL[.]6?$C9N2W%4>7;'5W55)E\M2;UW+NK
M)X;(4=5))+(0D,@D$6CR&+W7NC!?%K^<K\@_F1_+Z^17</QS^,&P^W_G#\8.
MT*CHWL'I?:/<&WFZ9S&Y*:K@0=O;,[&JZV&//]456$,^2@BCG^YJ%I)HHYF5
M?-[]U[H&_B3_`#:OG^_\Q6A_EL?,+"?!K>':G;/QZWAVMU)OSXF[[W/N3:6P
MM\[:V_N'-X[9?;U/DLEE*L1Y:/!O)*M.8*B&%H)8_-'/JC]U[HA7\GSY#?S.
MMA[@_GB=X]K97X^[TVYTMO[Y([K[9:IS79.XL_1_)SK3K>3*['VOUE%E<@E/
M'\>J.FQ<D)IYI8:Z.)52$H+D>Z]TN:K^?9_-FV'\0/AW_,@[#^'GQER?Q&[J
MW9M;JK<NR]K[YW-3=\[^WAN.HW%AJ/>&SJ:KJ:K;.PML;@SN`FCQ='5MEZI%
MB1JHHE0&C]U[JR#XW?S,?YA&WOYG76OP-_F!_'[H#8&,^572.Y>]/C[D.B-X
M[CW3F>NJ+:J9FKR.QNT\EG?%1[DS<%/B)J:IJ:"EHZ=*M$D@,T,C>/W7NJ^N
MV_\`A1U\C=R[N^3'<7Q8H/@#C_B=\3-][GV56=;_`"1^04>R/EG\GZ?KM]6]
M=S]+;4I<I%18G&Y"/6,)'5TT\E:R!5\LI:%/=>Z-3\D_YZO>?^E+^4?C_@YT
MAL'N+:?\SOJC?>Z,'LSLG-U6U=R8+>]+28JAV_CLCO2AKI<-@\'L;<%?4MN,
M_8U<\U/CIDIM,K(/?NO="7\.OYBW\S#?/RA^:G\N#Y2]4_%C;GS2Z:^/=%WK
MT)OWK++[XFZ'W6FZ*3'T6V<7O2ARM55[J3&1YG+4\D]3`:>H6-)X3`"L<K^Z
M]T67_A+5N_YX[WZZ^4^?[[SG4NZNBZSY-=^BHW%3YW>^>[MJ?D?!NC;$.\J2
MHK,_45.+;J.EPX88D%ONU>P("ZO?NO=;9WOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z`GY"?\>ELK_P`3Q\>/_?T[(]^Z]T&_P&_[
M(^Z,_P##;RG_`+U.>]^Z]T;[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0I_P
MH*^$'R.^>'QL^-W6OQIV30;XW1L?YD=2=I;MH\EN7!;8IL5L/;>.W12YK,O5
M9ZMHH:Q:27)PAH(3)4.K$HC6M[]U[HH&)_DZ=]4'_"BW<WSL?`1?[)A6;8RW
M=6'G&[L,V+7Y,9GIJEZAJ(VV$U<^4I\E&T]16C)K2*"B*/+<Z??NO=%=ZD_D
M.?,3<O\`*QS?1V<AV;T=\Q.B?YF.^_G%\6I=SY[&[KV+FC22;>@V_C]T9/:M
M1EFQN(W918^0H65IZ>:GA,\01W`]U[HYTGQB_FH?S1ODU\*]W?S"_CSTY\+/
MCY\%NU,?W_68#8G:])V[OCY!]U8.CAIMO#!28B])L;K^DGAD>>*KEDJQ#4.@
M>=]#1>Z]T9K^73\*?D=T+_-&_G%_)#M'8]+M_I_Y7[YZIS/1FYHMR[?RL^[:
M#;.)W!2YB:?#8VOJ<K@OMY*Z*RUL4#.6.D&Q/OW7NJY^EOY1'S6/\A'YU_`[
M=6R-N;)^1W<_??:W9'6VVLQO3;]?A<[A*[L'9&[\$E3N7`UF4Q>)GS]#MRHB
M@\[+XIFC\PC4DK[KW2I[Z^&_\RWY>=$?R6H]_P#Q,V[U'V/\(OF=UIE>W]FX
MSNG9&[J/&](]4X'9&W\?VA'F_O*&GJZS<,6'J96Q%(:JJ@:,"[:P1[KW5C'<
M_P`/?D+NW^?)\2OFKMW9U+4_'7J_X6=L=2;PWY+G\''+ANP=S9G>=9A,5_=>
M7(0[BR$-1'EJ9C-!`T(#L&=2OOW7NJ)?GA_*C_F'?+K=7=.P=_?RJ/@1NONC
ML'L3,5/6?\R_IGM^LZ$BV/M7,YO&U>$W/O;J?'5+[LWQO#:N%Q?AGGR"UTLD
M\A95F;7)+[KW6Y3\:>KMP]'_`!ZZ0Z<W;O?(]E[HZMZKV-L+<._LLTSY#=^8
MVOMR@P^0SU2]2\M2[9"II6=3*SRE2-;,UR?=>ZUI^I?BG_./_E0[A^5GQZ^!
MGQ\Z"^6/Q@^27<F_NX^ANP=[]NT75^XOC1N;LU::ERM%V3MG(48EWMMW;UZ9
MX8<<S/4)CG?R(TY@3W7ND]W[_)"^1_6_\B+!_`3I>7%]^_)C.?)SK_Y$]KU]
M+E\/L[;60W1E.QJ;=O8#;:J]S5&)I8\!MN@IX:>F$ACJ*H0F41AG\8]U[K;/
MP%+/0X+"454@CJ:/#XRDJ(PP<)/344$,R!UNK!9$(N.#[]U[JDC^<1\,_D/\
MKNZ?Y4F[>C-E4V[<#\9OF[@NXNY*VHW'@<"=K[`H8<,M1F(:?,UU'/F9%-))
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M6D:/SQK.8U]U[I/_`!)_ER_.W`?S6?@K\XMX?`OXS?#_`*!Z_P"D^W.F-P=&
M_'C?6U<U7=.19#;VZQBMY=A9&*FP%/O;.;VW/O"80#$1Y!\?CH(TJ)6<'W[K
MW0@]"?!K^8ST%V+_`#J?C\_QSV5O#X^_/FK^4?<G5'R)Q?<.W*'(#>6_>N,K
M@.NNM:SKK(+'E::?-5F46&KK:AZ>GH9T<ZY(M+GW7ND]W'_*]^:NZ_Y$7\N#
MX6X+JJBK/D5T#WE\?=Y=I[(;>^SJ>#;VW=C[SWKEMQUT>XILPFW\J]!0Y>F<
MQ4M1+(^LA`Y4CW[KW5AWR'^&OR'WW_/+_E__`#*VOLFFR'QYZ.^+W<'7/9>]
MGW'@*6HP6[MU_P!\AAL9'MVIKX\]DQ5#+TY\U/3R0J'.IAI-_=>ZI&Q_\F#Y
M4?##L[Y!=8]7_P`J/X"?S)^MNW.Z]Q=I=%?)/Y"[HVYMC<_3>WM\9*%YNONT
M\#G*.3=&Y<3L\+KB.*J!JO)*CNTOAC]U[JR7OK^6I\A,C_,%_D8]N=0_'[JK
MK[HOX58'M*/OC;O4.XL-B.M>H\MOG&4]5-B>O\'FUV_N+<&WY=P5%4T4E/CQ
M*VK7(BEC[]U[HT/7/PY^0>"_GY?(WYMY79E-3?&W?WPFZYZ>VOOH;BP4U57[
M]P.:P-9E,0VV8JYMPTL=/#12GSRTZ0-I&ER6L/=>Z!S^1Y\:?GM\%MR?*+XK
M_(/X];*QGQ_S7>_=GR!ZV^3>V>V\-GIM\9/L;=6%.(VB>MX8%SF'@3`4[U3U
M53X6BF5H61O2_OW7NMB+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=`3\A/^/2V5_XGCX\?^_IV1[]U[HK/PJ[JVSM?XM]/;?K]K]O
MU]7B\%DZ>>LVWTCVSNK!3R'<F:E+8W<.W=GY+"96`"2WEIIY8]0(O<$#W7NC
M1_[,3L[_`)XOOO\`])Q[R_\`L"]^Z]U[_9B=G?\`/%]]_P#I./>7_P!@7OW7
MNO?[,3L[_GB^^_\`TG'O+_[`O?NO=>_V8G9W_/%]]_\`I./>7_V!>_=>Z]_L
MQ.SO^>+[[_\`2<>\O_L"]^Z]U[_9B=G?\\7WW_Z3CWE_]@7OW7NO?[,3L[_G
MB^^__2<>\O\`[`O?NO=>_P!F)V=_SQ???_I./>7_`-@7OW7NO?[,3L[_`)XO
MOO\`])Q[R_\`L"]^Z]U[_9B=G?\`/%]]_P#I./>7_P!@7OW7NO?[,3L[_GB^
M^_\`TG'O+_[`O?NO=>_V8G9W_/%]]_\`I./>7_V!>_=>Z]_LQ.SO^>+[[_\`
M2<>\O_L"]^Z]U[_9B=G?\\7WW_Z3CWE_]@7OW7NO?[,3L[_GB^^__2<>\O\`
M[`O?NO=>_P!F)V=_SQ???_I./>7_`-@7OW7NO?[,3L[_`)XOOO\`])Q[R_\`
ML"]^Z]U[_9B=G?\`/%]]_P#I./>7_P!@7OW7NO?[,3L[_GB^^_\`TG'O+_[`
MO?NO=>_V8G9W_/%]]_\`I./>7_V!>_=>Z]_LQ.SO^>+[[_\`2<>\O_L"]^Z]
MU[_9B=G?\\7WW_Z3CWE_]@7OW7NO?[,3L[_GB^^__2<>\O\`[`O?NO=>_P!F
M)V=_SQ???_I./>7_`-@7OW7NO?[,3L[_`)XOOO\`])Q[R_\`L"]^Z]U[_9B=
MG?\`/%]]_P#I./>7_P!@7OW7NO?[,3L[_GB^^_\`TG'O+_[`O?NO=>_V8G9W
M_/%]]_\`I./>7_V!>_=>Z]_LQ.SO^>+[[_\`2<>\O_L"]^Z]U[_9B=G?\\7W
MW_Z3CWE_]@7OW7NO?[,3L[_GB^^__2<>\O\`[`O?NO=>_P!F)V=_SQ???_I.
M/>7_`-@7OW7NO?[,3L[_`)XOOO\`])Q[R_\`L"]^Z]U[_9B=G?\`/%]]_P#I
M./>7_P!@7OW7NO?[,3L[_GB^^_\`TG'O+_[`O?NO=>_V8G9W_/%]]_\`I./>
M7_V!>_=>Z]_LQ.SO^>+[[_\`2<>\O_L"]^Z]U[_9B=G?\\7WW_Z3CWE_]@7O
MW7NO?[,3L[_GB^^__2<>\O\`[`O?NO=>_P!F)V=_SQ???_I./>7_`-@7OW7N
MO?[,3L[_`)XOOO\`])Q[R_\`L"]^Z]U[_9B=G?\`/%]]_P#I./>7_P!@7OW7
MNO?[,3L[_GB^^_\`TG'O+_[`O?NO=>_V8G9W_/%]]_\`I./>7_V!>_=>Z]_L
MQ.SO^>+[[_\`2<>\O_L"]^Z]U[_9B=G?\\7WW_Z3CWE_]@7OW7NO?[,3L[_G
MB^^__2<>\O\`[`O?NO=>_P!F)V=_SQ???_I./>7_`-@7OW7NO?[,3L[_`)XO
MOO\`])Q[R_\`L"]^Z]U[_9B=G?\`/%]]_P#I./>7_P!@7OW7NO?[,3L[_GB^
M^_\`TG'O+_[`O?NO=>_V8G9W_/%]]_\`I./>7_V!>_=>Z]_LQ.SO^>+[[_\`
M2<>\O_L"]^Z]U[_9B=G?\\7WW_Z3CWE_]@7OW7NO?[,3L[_GB^^__2<>\O\`
M[`O?NO=>_P!F)V=_SQ???_I./>7_`-@7OW7NO?[,3L[_`)XOOO\`])Q[R_\`
ML"]^Z]U[_9B=G?\`/%]]_P#I./>7_P!@7OW7NO?[,3L[_GB^^_\`TG'O+_[`
MO?NO=>_V8G9W_/%]]_\`I./>7_V!>_=>Z]_LQ.SO^>+[[_\`2<>\O_L"]^Z]
MU[_9B=G?\\7WW_Z3CWE_]@7OW7NO?[,3L[_GB^^__2<>\O\`[`O?NO=>_P!F
M)V=_SQ???_I./>7_`-@7OW7NO?[,3L[_`)XOOO\`])Q[R_\`L"]^Z]U[_9B=
MG?\`/%]]_P#I./>7_P!@7OW7NO?[,3L[_GB^^_\`TG'O+_[`O?NO=>_V8G9W
M_/%]]_\`I./>7_V!>_=>Z]_LQ.SO^>+[[_\`2<>\O_L"]^Z]U[_9B=G?\\7W
MW_Z3CWE_]@7OW7NO?[,3L[_GB^^__2<>\O\`[`O?NO=>_P!F)V=_SQ???_I.
M/>7_`-@7OW7N@:[Q[UVKEML[1IX-I]U4ST_<_1F39\GT)W'B8)(<1VSM')U%
?/!49+95+!49&H@I62EI49JBLJ62"%'ED1#[KW7__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pg22a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg22a.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X1>+17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G
M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S`#(P,3(Z,#(Z
M,C,@,C`Z,38Z,C0``````Z`!``,````!__\``*`"``0````!```"2:`#``0`
M```!```!,@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!95````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B
M95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`5`"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]*Q<;&.-234PDL:2=H\!Y(OV7%_T-?\`
MFC^Y+$_HM/\`Q;?R!%24T\OI]=U;!0UM3V65OD#:"UKFNLK?L^FQ[/\`!K#I
M^KG5Z\=E=KJ[W-9M=NR;FEXW[_L[[:J6;?=^L_;:Z_M/_>?_`$;]+9OYV,W)
MJK:Y_I&NVNQKI(U:]IVQN:UV_P"@W?O9O_P:YQOU>QL:DTVYV&[T:@"+F$C:
M+-FS(_66O?A^ONMV.=O_`&G^D]?_`+3)*;N)T/J5>93;D/KMK8YQL=ZEA+B0
M19?]G<ST-V=^CWXG]&Z;Z'ZE_/V+6^RTE[@*Z@!$?HQW^:Q<#HU%'4J+!G46
MV5V6#:!^F<Y@VW/W^L[]=N]1G[6L]+]/Z>-^@QEO!KC8^'N''&W_`,BDIA]C
MJ_T=7_;8_O2^QU?Z.K_ML?WHNQW^D=_T?_(I;'?Z1W_1_P#(I*1?8ZO]'5_V
MV/[TOL=7^CJ_[;']Z+L=_I'?]'_R*6QW^D=_T?\`R*2D7V.K_1U?]MC^]+['
M5_HZO^VQ_>H.ZA@-#2[/K`L+`PFRL;C87,H#?WO6?58RK_2>F]1/5.F!I<>H
MTAH:7EQMJC:'^@Y_]1M_Z'_C?T:2DOV.K_1U?]MC^]+['5_HZO\`ML?WHNQW
M^D=_T?\`R*B#NL=6+'[F`%TM`$.G;#MFUWT?S4E,/L=7^CJ_[;']Z7V.K_1U
M?]MC^]$<"UI<;'PT$F`"=/(,29+V->VQ^UP#A(`,'7Z+F;DE(_L=7^CJ_P"V
MQ_>H758=#0^_T*FN<U@<]C6@N>176P;G?3L>[8QJ,YP;8RMUK@^R=@@:[?I?
MF(>7@UY=0JN>\M#Z[6D;00ZI[+ZW#V?OUI*:MN9T2ACWW9.'6RH/-A=L`:*G
MMHOW>_\`P-[V46_N7?HOYQ,,WH=N^BJ[&?D;GU"MNP.-C&&Y];:_I.>RK]+_
M`,7^D52CZI]/^S/J9;E5?I+S79ZI=96;+Z<O?59<VQWLR,*JVOU/4_POJ^KZ
MJN#H6!CUL=4'`XUC[ZC,P74OPA5Q_,UXSF55L_X&G]Q)3__0[OJW5#TOH^/>
M+64&STZ_6LK]5C)8ZSW5B[$^GZ?I5_I_YVQBN](RK<OIU.3:]EKK07"RMAK:
MYLGTWMJ=;D[=S/\`AWJEU>HV="K(=>/3;6\C'=LD!ON9D.U=]E>WVW^FWU:_
MYZK])6KW2*&X_2\2AI<X5U,:#8US':#O58VI]7_%.KK]-)2_4*L.VNEN6]C(
MOJ=2Y^T'U6N#ZFU>I_A;-NSV?I%SM>%T!E.ZKK##76PW-LM]"PC=:YANL<^O
M]+5OL^S^G9^C];]8_I?Z9=%U!^(VJL9;BQCKJO3(!/Z0/;95]$.VMWL][OH+
M"K;T<,9&?U!US&@A_HO%QM^CZSJVX3=_47XKMCZG4^M^SOUOT/3_`%I)23I_
M3^CT]0H%'4&6VUO?571^CW'T&G;3O:/5];&;<]V1;_/Y/_:G?76M\5@V/)+N
MWYQ6%T^GH3,V@8N3D/(AE-9:[TC76'_86>J:&M^QU;\C]F7^MZ>9^F_3YGI?
MH]P5UFUY($Z)*9>DWQ=_G'^]+TF^+O\`./\`>EZ57@$O2J\`DI8MK#@PO(<Z
M2UN\R8^E`GS4A4)Y=_G'^]9;LPWYM8Z=CLRJFLM#LAUGIU[IJW-J=LM=?]';
M993OK8_]'_.(Q9U1V@JQ:O/U++?P]+&3>,=+/D/^Z9/9E^EPQ_O2B)#SA\__
M`#4571L4LC&OOI8"VNP`,`>RFR]_V9[;J7?J[K,BQGZ/_!,K]/\`1>IZN?F?
M5GIF'B0_-NHK?^@+GOJ#7"YWIV;F6U>B^[[/9=1O<S?Z=EK_`.?_`$JT<;`S
M;*W?:<PM!LL]N,QM4@O=HZRSUK?^VG5(EG1\!H:YF.VZT/8?4N/JO`#VO?\`
MILDVV?1;^\E<N@KS/_>JX<8WGQ>$!_W4^!9N?BN:&8C<C,V@-#JMQ:0!$_:K
MG58S_P#M]#K=U=V5<?LM36%E>P/R7A\?I)W^G5>S=N_=6F:ZSR)^:`RNK[5<
M(=.VOG;MC])&S;^D_>W^HE4NLOL'\>)7'`;8Q_ARE*7_`#/;_P"BU[CU<5/+
M<:DG:Z!]JLU,:<XK?^J4<<]6^SU$XM4[&R!DO_='_==7K:J_2?`UVGCGC^40
MU1QZJSCU:?F-Y@'@<["6_P":EPG]X_\`-_[U7N1_S</MR?\`JQHV/ZO]JI:W
M$K`(LEYR70-&[=S?1WN_LHWV'/M_I&:YC?W,9H9\G67G)M_[;?2C6UU_:J/:
M>'\%L<-^EN]__;:-Z57@$N'N2?K7_1X5>[7RPA'Z<?\`Z5]SA_P&MT["IQZ'
MLJWAINM<9>]Q)+W;G;GN+E8M;MHL&I]KN3/;S0L6FO8\[6B;;/H@-_/</=M^
MD_\`?>BVM#:+`W0;7?D3EA))LFR>I?_1[GKHQ+/J\S'S'-%60*JA6ZA^4+'$
M`MI^R4?K%GT=_P"@?5;5L];U?8KW17BSI>-8VQMS'L#F.95Z#0T_S==>-+_1
M94S]'L<]ZH]>>^OZK6/9::'-KI/J!SF0-U6YOJUASJ_4;^CW_P`U_IOT.]7N
MB$'HV"1QZ%<0X/'T1_A&^UZ2FU=55;7LN&Y@+7D'B6$6-_Z35R].1]7K*&/I
MPLYPL&QA%E@>;!^E<S><K?\`;&8E?K^OO]7]G,^R^O\`]I%U-CFMK<YXEH!+
MA$Z`:Z+D&=3Z$^AA_9-`%C&L+'OJ:1#OM7IV[Q[:O3;ZOK?S'VO]324Z&#9T
M,Y](Q\3(8_=NKL+G>D&/#VX=GI^NYGV2[9D-Z;5Z.S$_3>G3B>M^EV_T'J/W
M[)TYCE8.#U#I5O5:FU=/JKO=;8]MX<SU`;@[=9Z8'J_:+?1?]MI_GL/]'Z_\
MZGR6]=LZOGLQFL=B@TP#D'&+FFOW-]3'Q,W)_G-W\V_%_KH&^@M,0"=9<(^I
M^SA=/J.?@8=-@+F?:!6YU=+`U]I@$@LI^7YWZ-!IH/4FL=F%M6,X",-I;NM!
M`,YKV?FN_P"X=/Z+_3VW[_1KIMPNMUXE[*G8.$VQCM[:L:_)L<2TC<Z[UL-]
MUO\`6IL>]6&=&-[&GJ'4<S);M'Z&LNQ*Q/9K,%N/D[/^"R\G(0X2?F_Q0R<<
M8?S8-_YR7S?X$?\`)MC+R>E8F?C5Y&53BEM5@90]]=8<":6M_1O]WL_,V*]6
M,>QH?6&/:>'-@C[PLZGH_1L:QM>/T^EE#VO%VVEON<37M-LM]2USMCO?[_\`
MA$S_`*N?5EY)_9F,QQ_/KH%;_P#MVIC+/^DG,3>QJJA4\FNM@]2PG8T-'TW>
MYW\MWTK'JAG]=^K^.`Q_4,6JT65@L%K-^MC&EGIL)L]T[7>U5'=&^J^+3ZV9
MT\7A][JQZM-N40ZVU^QWIW-R',;98_\`G/YOWJ8ZU]7,7"8_!V44.BUAJI=6
MQU==]>+;Z3F5>G8[UK&,]/\`X1B2DO[>Q[FAW3^G96:TB?4%(QZ_Y)];J;L%
MMC?_``OZZ&W(Z\Z^QS</IU<LKAC\FQS@)M_G"S#]/=_4_P"W%K8_4,7)]3T7
M./I.V.W,>W7]]GJ,;ZM3O\'?7^AL_P`'8I-(%S[2XD/:UH;M.FW=^='YV])3
MDOL^L!8[]#TQOM/^%M=V_P"(8FI'U@=4S])TRH;&Q[+;.P\;<=;+WM<QS02"
MX$`[28GY)JG-KJ8PDN+&AI=M(F!$\)*<=U'7#=5/4.G-,/@##>1^9X]0W*7[
M/ZJ_^<ZQ4S_B,:IO_MR_,6LXU.L98=VYD[8W`>[G<WZ+D#J>9=C=.RLC%8++
MZ:GV5L>'P7-&X3Z;7/=_48DIATZJNG'<R[(^U/\`5M/J6BMKHWN]L4,J9[?Z
MBM6;/L]FR-NUWT>./)<OB?67K#75LLPG-%EN*ZRLT91>T9+;+LZC<VCTO6PG
M[;O]#]F_0_TE6^D==ZGU"ST<O'%;'8;[GV-JR*P+&V.I:0[+JJ9Z&93^GQ:]
MWVAGIW>JDI__TNX^L#JV_5H&QP&E&QAMKHWOW,-=?VC)_1UNW^]ONKL]GLMK
M5[H5CK>C8-CRPN=167.J>;&$[1[JKK'VOMK=_@WOL>J/U@%SOJM:*02?19O#
M`YSML-G8VO\`Z7J?H?3W^M^B5_HA<>CX1<Y[W&EA<ZW=O)V^Y[_5_2>Y)3<<
M=K2Z"8$P-2N5=UX;`6]/HI!!'IY%=E;V-;=9LLNK./N;18]C:J__`#96^SU*
M?UA=43`)\%SG[:Z[Z3'"K=N;NWC!R@0TN.VU^.ZSU&V/?^INP-WK4?\`*C[O
ML?Z))3/!ZRZ[J=5!Q*:R^RSW`.]4$@^JS^;V?:<?TV?M+])Z7Z6CT;KUN!P%
MK_89TD@<K)Q.J=9MSJJ;L?94Y[FO_5[FQ`=OJ^TO?Z'ZIMK_`%S;]GZKZ_ZB
MRK[/:M<.<+'^PGC@C_R22E_4_DN^Y+U/Y+ON3[W?Z-WWM_\`));W?Z-WWM_\
MDDI;U/Y+ON2]3^2[[D^]W^C=][?_`"26]W^C=][?_))*1VMJNVBVMS@QP>T$
M?G-U8[G\U4AT3I@&E5X,$;O6NW:Q+_4];U/5V-;1ZV[U?LOZI_1OT2T=[O\`
M1N^]O_DDM[O]&[[V_P#DDE.9D8F-A8+ZL-C\9MUU+7;7.!#76U4&JAQ<[[/4
MVIVRJJCTZZ/\#Z:)E8&-C4/O)S;=@GTZK[WO.OYC!=[D3JCG'%;+2W]/CZF/
M]/3X$JU=<RBIUKPXM;R&,=8[^S74U]C_`.RU)(!)H:DO/TYF';:^LXO5Z`Q^
MPW7OR*ZHVBSU3=Z[MM#=VU]JIX76*,G'LO?3D5MJKINLC.R'!E=KF-LON=[6
MLQ6U6/R<6]OJ?:J,;)L_0>DMT_6'`:R]YKR0W&#B\G'N&C6^L[7T_9[?]-Z2
MHXOUQQ,EMM@I+:ZFTN>XO;[?5=75=Z[=/L]>.Z[^=M]F1Z&595^CH2L'94HR
MC\P,;[BFC=UOIV.'775YCL2+35?5EW/]0UOVL]/?;35^M468^1B_IOT_J_H?
M4KI]9;[NE8_I%WJ933M)C[5=(T\KG++R_K3T2YEN/U"D6X3F7.!+?79;]FLV
M/:RIC7[_`&.QLFK_`([]'_-O6^0P8T,;L8&0UD1`C1NW\W:DA!TZ^RSI^+99
MN>]]-;GOCDEC7.<CVF:+#!'M=H?@J_2G.'2\,;"?U>K41^XW^4K%I)HL)!'M
M=H8\/))3_]/M_K#6RSZM!KZW6:4%OIBMUC7!S/2?0S(W,??ZFVNEC6OL]6S]
M&Q7/JZW;T'I[9:2W'K!VM#!(:-P]-GM9M=^:CMQL;+Z=7CY53,BBRM@?5:T/
M8X`-/OK>'-<B8F'B85#<?#HKQJ&R6U4L;6P2=SMM=8:WW.24F22224T<H]2_
M:6**-WV2'>MM]/9P9^T&S]8_T?V7[)^?ZWVK]'Z:M#U18XAH@Q!+O_,414,/
M!R*.H9F38\.KR"W8`7EQC_2->?2K]+^:K]#Z=?\`/?I$E-PFZ#[&GRW'_P`@
ME-O[K?\`./\`Y!0S*77XEU+0USK&.:&N+FM,CZ+WU?I&-=^\Q1Z?CVXV!C8U
MUGJVTU,K?9J2XM:&[R3]+<DI+NNF-C8\=Q_\@E-O[K?\X_\`D%2R.GY-O6<7
M/;=%%#'L?22>7`ZM:/:_?-?N=_->A^?ZWZ.-/UDZ'=>:&Y;&V#D/#JQ(NLZ?
MMWVM8S>[,Q[J*Z]V^S_!^Q)3?#KCRQH_M'_R"1=<.&-/]H_^06#TKJ?2>E4/
MHR^K47.MOL<QPMWAH#JZ"VRV7?I/5>RS)?9L_6LE6>K6XF5C^M3FXX%9MQ2+
M+BVAUUC?0&+D>C8W]*V[9^C_`*1_@JO3]5)3H9>/9E4&DGTI+7"QA!<US'-M
M8X"VI]?TV?GL0?L74)C[?=\8H_\`>55,/K_1L?`PFOR3Z;V/K;D%MKZIQ9IR
MG6YKZFUL96^I_P"L9/H^K_.JL^[I^-U"G/LZI0:*+,K<'7>H?TCFBREC'.L]
MU-UM&YS7_J=?ZKZ/I9'Z%*=3[%G_`/EA=_FT?^\J@WIF4&;1F6-:6AA;LQXV
M@:5_T7Z+5&_J?2<RH,HZEC[F7T2YE[?I^J'LH=Z5C7;LCT+*O1_PWOK]Z!]6
M[\1E3\)G4*NH7N+\D&JSU?T;WNKW[Y=[79%5WM_P/\S^GL_6;TI+D=$?E8YQ
M,G(??C.C=4YE&SVD.K]HQF_0<UOI[?H(HZ=F!GIMSK6L`VM:UM$`1$-;]DVH
M5_3,N[J-V0'-JK=Z'IO9;:'GTK*[[&75`BG9^C>RK9_I;_59;]IM6AEUV68M
MU=4>H^MS6;BYK=Q!#=SZOTK6_P#%^])3'&J?1CUT,:-M+16TN=J0T;&ET,_D
MJ=N[T+-P`.UW!GM\EG](Z9FX5KGWWM=2ZBJJO&;O<*S7O<_9=:_WUN=;[/U>
MNST_3JWV,IJ6C?\`S-G]5WY$E/\`_]3TG&^V_9JMOI;=C8G=X!$_7O\`@O\`
MI+Y=224_47Z]_P`%_P!)+]>_X+_I+Y=224_47Z]_P7_22_7O^"_Z2^74DE/U
M%^O?\%_TDOU[_@O^DOEU))3]1?KW_!?])<@?^9/K7?S/J^J_UX^U3OV?K'J?
M\#]G_I?_`&G^S?:/7_1>NO#$DE/OO_8S`C;L],_1^U[=GH4?SFWV?T+[-Z/J
M?]9_2^LHV?\`-;[%?O\`3^R_;7^O_2OZ7Z#OM,?G^C^S_5^U>G^I_9OM'K?X
M9>"))*?HJS]E_9<7?Z?V?<_[+'VCG=^D^C[_`.=^AO\`^MK,K_YH>M5Z&WU/
M4N]+T/MFWU9L^T>EZ'Z/[1_.?9]OZ7T/3^R_H/17A"22GWE__-#?B^K]GW;Z
M_LN_[1]+TF^C'J>W9]DV>KN]GI?SRTNC?L[U3^R=N_T*I_I&STMK/LV_UOT7
MJ>EL]/?^GV>I_P`*OG1))3]1?KW_``7_`$DOU[_@O^DOEU))3]1?KW_!?])0
MM^V^D^?2C:9^EX+Y@224_P#_V?_M'%Y0:&]T;W-H;W`@,RXP`#A"24T$)0``
M````$``````````````````````X0DE-`^T``````!``2`````$``0!(````
M`0`!.$))300F```````.`````````````#^````X0DE-!`T```````0````>
M.$))3009```````$````'CA"24T#\P``````"0```````````0`X0DE-)Q``
M``````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!
M`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T`
M```&```````!.$))30/X``````!P``#_____________________________
M`^@`````_____________________________P/H`````/______________
M______________\#Z`````#_____________________________`^@``#A"
M24T$`````````@``.$))300"```````$`````#A"24T$,````````@$!.$))
M300M```````&``$````!.$))300(```````0`````0```D````)``````#A"
M24T$'@``````!``````X0DE-!!H``````S\````&``````````````$R```"
M20````4`<`!G`#(`,@!A`````0`````````````````````````!````````
M``````))```!,@`````````````````````!````````````````````````
M`!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!2
M8W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T
M;VUL;VYG```!,@````!29VAT;&]N9P```DD````&<VQI8V5S5FQ,<P````%/
M8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'
M9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN
M````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90``
M``!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P
M(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P```3(`````
M4F=H=&QO;F<```))`````W5R;%1%6%0````!````````;G5L;%1%6%0````!
M````````37-G951%6%0````!```````&86QT5&%G5$585`````$```````YC
M96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH
M;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````
M"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0`
M```+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO
M;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````
M````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``
M````.$))300H```````,`````C_P````````.$))3001```````!`0`X0DE-
M!!0```````0````".$))300,`````!9Q`````0```*````!4```!X```G8``
M`!95`!@``?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E7T--``+_[@`.
M061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8
M$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.
M#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`S_P``1"`!4`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!
M`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#
M!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84
MD:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E
M\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>W
MQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(C
MP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#
MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`
M#`,!``(1`Q$`/P#TK%QL8XU)-3"2QI)VCP'DB_9<7_0U_P":/[DL3^BT_P#%
MM_($5)33R^GUW5L%#6U/996^0-H+6N:ZRM^SZ;'L_P`&L.GZN=7KQV5VNKO<
MUFUV[)N:7C?O^SOMJI9M]WZS]MKK^T_]Y_\`1OTMF_G8S<FJMKG^D:[:[&ND
MC5KVG;&YK7;_`*#=^]F__!KG&_5[&QJ33;G8;O1J`(N82-HLV;,C]9:]^'Z^
MZW8YV_\`:?Z3U_\`M,DINXG0^I5YE-N0^NVMCG&QWJ6$N)!%E_V=S/0W9WZ/
M?B?T;IOH?J7\_8M;[+27N`KJ`$1^C'?YK%P.C44=2HL&=1;9798-H'Z9SF#;
M<_?ZSOUV[U&?M:STOT_IXWZ#&6\&N-CX>X<<;?\`R*2F'V.K_1U?]MC^]+['
M5_HZO^VQ_>B['?Z1W_1_\BEL=_I'?]'_`,BDI%]CJ_T=7_;8_O2^QU?Z.K_M
ML?WHNQW^D=_T?_(I;'?Z1W_1_P#(I*1?8ZO]'5_VV/[TOL=7^CJ_[;']Z@[J
M&`T-+L^L"PL#";*QN-A<R@-_>]9]5C*O])Z;U$]4Z8&EQZC2&AI>7&VJ-H?Z
M#G_U&W_H?^-_1I*2_8ZO]'5_VV/[TOL=7^CJ_P"VQ_>B['?Z1W_1_P#(J(.Z
MQU8L?N8`72T`0Z=L.V;7?1_-24P^QU?Z.K_ML?WI?8ZO]'5_VV/[T1P+6EQL
M?#028`)T\@Q)DO8U[;'[7`.$@`P=?HN9N24C^QU?Z.K_`+;']ZA=5AT-#[_0
MJ:YS6!SV-:"YY%=;!N=].Q[MC&HSG!MC*W6N#[)V"!KM^E^8AY>#7EU"JY[R
MT/KM:1M!#JGLOK</9^_6DIJVYG1*&/?=DX=;*@\V%VP!HJ>VB_=[_P#`WO91
M;^Y=^B_G$PS>AV[Z*KL9^1N?4*V[`XV,8;GUMK^DY[*OTO\`Q?Z15*/JGT_[
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MOUC^E_IET74'XC:JQEN+&.NJ],@$_I`]ME7T0[:W>SWN^@L*MO1PQD9_4'7,
M:"'^B\7&WZ/K.K;A-W]1?BNV/J=3ZW[._6_0]/\`6DE).G]/Z/3U"@4=09;;
M6]]5='Z/<?0:=M.]H]7UL9MSW9%O\_D_]J=]=:WQ6#8\DN[?G%873Z>A,S:!
MBY.0\B&4UEKO2-=8?]A9ZIH:W['5OR/V9?ZWIYGZ;]/F>E^CW!76;7D@3HDI
MEZ3?%W^<?[TO2;XN_P`X_P!Z7I5>`2]*KP"2EBVL.#"\ASI+6[S)CZ4"?-2%
M0GEW^<?[UENS#?FUCIV.S*J:RT.R'6>G7NFK<VIVRUU_T=MEE.^MC_T?\XC%
MG5':"K%J\_4LM_#TL9-XQTL^0_[ID]F7Z7#'^]*(D/.'S_\`-15=&Q2R,:^^
ME@+:[``P![*;+W_9GMNI=^KNLR+&?H_\$ROT_P!%ZGJY^9]6>F8>)#\VZBM_
MZ`N>^H-<+G>G9N9;5Z+[OL]EU&]S-_IV6O\`Y_\`2K1QL#-LK=]IS"T&RSVX
MS&U2"]VCK+/6M_[:=4B6='P&AKF8[;K0]A]2X^J\`/:]_P"FR3;9]%O[R5RZ
M"O,_]ZKAQC>?%X0'_=3X%FY^*YH9B-R,S:`T.JW%I`$3]JN=5C/_`.WT.MW5
MW95Q^RU-865[`_)>'Q^DG?Z=5[-V[]U:9KK/(GYH#*ZOM5PAT[:^=NV/TD;-
MOZ3][?ZB52ZR^P?QXE<<!MC'^'*4I?\`,]O_`*+7N/5Q4\MQJ2=KH'VJS4QI
MSBM_ZI1QSU;[/43BU3L;(&2_]T?]UU>MJK])\#7:>.>/Y1#5''JK./5I^8WF
M`>!SL);_`)J7"?WC_P`W_O5>Y'_-P^W)_P"K&C8_J_VJEK<2L`BR7G)=`T;M
MW-]'>[^RC?8<^W^D9KF-_<QFAGR=9><FW_MM]*-;77]JH]IX?P6QPWZ6[W_]
MMHWI5>`2X>Y)^M?]'A5[M?+"$?IQ_P#I7W.'_`:W3L*G'H>RK>&FZUQE[W$D
MO=N=N>XN5BUNVBP:GVNY,]O-"Q::]CSM:)ML^B`W\]P]VWZ3_P!]Z+:T-HL#
M=!M=^1.6$DFR;)ZE_]'N>NC$L^KS,?,<T59`JJ%;J'Y0L<0"VG[)1^L6?1W_
M`*!]5M6SUO5]BO=%>+.EXUC;&W,>P.8YE7H-#3_-UUXTO]%E3/T>QSWJCUY[
MZ_JM8]EIH<VND^H'.9`W5;F^K6'.K]1OZ/?_`#7^F_0[U>Z(0>C8)''H5Q#@
M\?1'^$;[7I*;5U55M>RX;F`M>0>)818W_I-7+TY'U>LH8^G"SG"P;&$66!YL
M'Z5S-YRM_P!L9B5^OZ^_U?V<S[+Z_P#VD74V.:VMSGB6@$N$3H!KHN09U/H3
MZ&']DT`6,:PL>^II$.^U>G;O'MJ]-OJ^M_,?:_U-)3H8-G0SGTC'Q,AC]VZN
MPN=Z08\/;AV>GZ[F?9+MF0WIM7H[,3]-Z=.)ZWZ7;_0>H_?LG3F.5@X/4.E6
M]5J;5T^JN]UMCVWAS/4!N#MUGI@>K]HM]%_VVG^>P_T?K_SJ?);UVSJ^>S&:
MQV*#3`.0<8N::_<WU,?$S<G^<W?S;\7^N@;Z"TQ`)UEPCZG[.%T^HY^!ATV`
MN9]H%;G5TL#7VF`2"RGY?G?HT&F@]2:QV86U8S@(PVENZT$`SFO9^:[_`+AT
M_HO]/;?O]&NFW"ZW7B7LJ=@X3;&.WMJQK\FQQ+2-SKO6PWW6_P!:FQ[U89T8
MWL:>H=1S,ENT?H:R[$K$]FLP6X^3L_X++R<A#A)^;_%#)QQA_-@W_G)?-_@1
M_P`FV,O)Z5B9^-7D95.*6U6!E#WUUAP)I:W]&_W>S\S8KU8Q[&A]88]IX<V"
M/O"SJ>C]&QK&UX_3Z64/:\7;:6^YQ->TVRWU+7.V.]_O_P"$3/\`JY]67DG]
MF8S''\^N@5O_`.W:F,L_Z2<Q-[&JJ%3R:ZV#U+"=C0T?3=[G?RW?2L>J&?UW
MZOXX#']0Q:K196"P6LWZV,:6>FPFSW3M=[54=T;ZKXM/K9G3Q>'WNK'JTVY1
M#K;7['>G<W(<QMEC_P"<_F_>ICK7U<Q<)C\'910Z+6&JEU;'5UWUXMOI.95Z
M=CO6L8ST_P#A&)*2_M['N:'=/Z=E9K2)]04C'K_DGUNINP6V-_\`"_KH;<CK
MSK['-P^G5RRN&/R;'.`FW^<+,/T]W]3_`+<6MC]0Q<GU/1<X^D[8[<Q[=?WV
M>HQOJU._P=]?Z&S_``=BDT@7/M+B0]K6ANTZ;=WYT?G;TE.2^SZP%COT/3&^
MT_X6UW;_`(AB:D?6!U3/TG3*AL;'LML[#QMQULO>US'-!(+@0#M)B?DFJ<VN
MIC"2XL:&EVTB8$3PDIQW4=<-U4]0Z<TP^`,-Y'YGCU#<I?L_JK_YSK%3/^(Q
MJF_^W+\Q:SC4ZQEAW;F3MC<![N=S?HN0.IYEV-T[*R,5@LOIJ?96QX?!<T;A
M/IM<]W]1B2F'3JJZ<=S+LC[4_P!6T^I:*VNC>[VQ0RIGM_J*U9L^SV;(V[7?
M1XX\ER^)]9>L-=6RS"<T66XKK*S1E%[1DMLNSJ-S:/2];"?MN_T/V;]#_25;
MZ1UWJ?4+/1R\<5L=AON?8VK(K`L;8ZEI#LNJIGH9E/Z?%KW?:&>G=ZJ2G__2
M[CZP.K;]6@;'`:4;&&VNC>_<PUU_:,G]'6[?[V^ZNSV>RVM7NA6.MZ-@V/+"
MYU%9<ZIYL83M'NJNL?:^VMW^#>^QZH_6`7.^JUHI!)]%F\,#G.VPV=C:_P#I
M>I^A]/?ZWZ)7^B%QZ/A%SGO<:6%SK=V\G;[GO]7])[DE-QQVM+H)@3`U*Y5W
M7AL!;T^BD$$>GD5V5O8UMUFRRZLX^YM%CV-JK_\`-E;[/4I_6%U1,`GP7.?M
MKKOI,<*MVYN[>,'*!#2X[;7X[K/4;8]_ZF[`W>M1_P`J/N^Q_HDE,\'K+KNI
MU4'$IK+[+/<`[U02#ZK/YO9]IQ_39^TOTGI?I:/1NO6X'`6O]AG22!RLG$ZI
MUFW.JINQ]E3GN:_]7N;$!V^K[2]_H?JFVO\`7-OV?JOK_J+*OL]JUPYPL?["
M>."/_))*7]3^2[[DO4_DN^Y/O=_HW?>W_P`DEO=_HW?>W_R22EO4_DN^Y+U/
MY+ON3[W?Z-WWM_\`));W?Z-WWM_\DDI':VJ[:+:W.#'![01^<W5CN?S52'1.
MF`:57@P1N]:[=K$O]3UO4]78UM'K;O5^R_JG]&_1+1WN_P!&[[V_^22WN_T;
MOO;_`.224YF1B8V%@OJPV/QFW74M=M<X$-=;50:J'%SOL]3:G;*JJ/3KH_P/
MIHF5@8V-0^\G-MV"?3JOO>\Z_F,%WN1.J.<<5LM+?T^/J8_T]/@2K5US**G6
MO#BUO(8QUCO[-=37V/\`[+4D@$FAJ2\_3F8=MKZSB]7H#'[#=>_(KJC:+/5-
MWKNVT-W;7VJGA=8HR<>R]].16VJNFZR,[(<&5VN8VR^YWM:S%;58_)Q;V^I]
MJHQLFS]!Z2W3]8<!K+WFO)#<8.+R<>X:-;ZSM?3]GM_TWI*CB_7'$R6VV"DM
MKJ;2Y[B]OM]5U=5WKMT^SUX[KOYVWV9'H95E7Z.A*P=E2C*/S`QON*:-W6^G
M8X===7F.Q(M-5]67<_U#6_:ST]]M-7ZU19CY&+^F_3^K^A]2NGUEONZ5C^D7
M>IE-.TF/M5TC3RN<LO+^M/1+F6X_4*1;A.9<X$M]=EOV:S8]K*F-?O\`8[&R
M:O\`COT?\V];Y#!C0QNQ@9#61$"-&[?S=J2$'3K[+.GXMEFY[WTUN>^.26-<
MYR/:9HL,$>UVA^"K]*<X=+PQL)_5ZM1'[C?Y2L6DFBPD$>UVACP\DE/_T^W^
ML-;+/JT&OK=9I06^F*W6-<',])]#,C<Q]_J;:Z6-:^SU;/T;%<^KK=O0>GME
MI+<>L':T,$AHW#TV>UFUWYJ.W&QLOIU>/E5,R*+*V!]5K0]C@`T^^MX<UR)B
M8>)A4-Q\.BO&H;);52QM;!)W.VUUAK?<Y)29))))31RCU+]I8HHW?9(=ZVWT
M]G!G[0;/UC_1_9?LGY_K?:OT?IJT/5%CB&B#$$N_\Q1%0P\'(HZAF9-CPZO(
M+=@!>7&/](UY]*OTOYJOT/IU_P`]^D24W";H/L:?+<?_`""4V_NM_P`X_P#D
M%#,I=?B74M#7.L8YH:XN:TR/HO?5^D8UW[S%'I^/;C8&-C76>K;34RM]FI+B
MUH;O)/TMR2DNZZ8V-CQW'_R"4V_NM_SC_P"05+(Z?DV]9Q<]MT44,>Q]))Y<
M#JUH]K]\U^YW\UZ'Y_K?HXT_63H=UYH;EL;8.0\.K$BZSI^W?:UC-[LS'NHK
MKW;[/\'[$E-\.N/+&C^T?_()%UPX8T_VC_Y!8/2NI])Z50^C+ZM1<ZV^QS'"
MW>&@.KH+;+9=^D]5[+,E]FS]:R59ZM;B96/ZU.;C@5FW%(LN+:'76-]`8N1Z
M-C?TK;MGZ/\`I'^"J]/U4E.AEX]F50:2?2DM<+&$%S7,<VUC@+:GU_39^>Q!
M^Q=0F/M]WQBC_P!Y54P^O]&Q\#":_)/IO8^MN06VOJG%FG*=;FOJ;6QE;ZG_
M`*QD^CZO\ZJS[NGXW4*<^SJE!HHLRMP==ZA_2.:+*6,<ZSW4W6T;G-?^IU_J
MOH^ED?H4IU/L6?\`^6%W^;1_[RJ#>F909M&98UI:&%NS'C:!I7_1?HM4;^I]
M)S*@RCJ6/N9?1+F7M^GZH>RAWI6-=NR/0LJ]'_#>^OWH'U;OQ&5/PF=0JZA>
MXOR0:K/5_1O>ZO?OEWM=D57>W_`_S/Z>S]9O2DN1T1^5CG$R<A]^,Z-U3F4;
M/:0ZOVC&;]!S6^GM^@BCIV8&>FW.M:P#:UK6T0!$0UOV3:A7],R[NHW9`<VJ
MMWH>F]EMH>?2LKOL9=4"*=GZ-[*MG^EO]5EOVFU:&7799BW5U1ZCZW-9N+FM
MW$$-W/J_2M;_`,7[TE,<:I]&/70QHVTM%;2YVI#1L:70S^2IV[O0LW``[7<&
M>WR6?TCIF;A6N??>UU+J*JJ\9N]PK->]S]EUK_?6YUOL_5Z[/3].K?8RFI:-
M_P#,V?U7?D24_P#_U/2<;[;]FJV^EMV-B=W@$3]>_P""_P"DOEU))3]1?KW_
M``7_`$DOU[_@O^DOEU))3]1?KW_!?])+]>_X+_I+Y=224_47Z]_P7_22_7O^
M"_Z2^74DE/U%^O?\%_TER!_YD^M=_,^KZK_7C[5._9^L>I_P/V?^E_\`:?[-
M]H]?]%ZZ\,224^^_]C,"-NSTS]'[7MV>A1_.;?9_0OLWH^I_UG]+ZRC9_P`U
MOL5^_P!/[+]M?Z_]*_I?H.^TQ^?Z/[/]7[5Z?ZG]F^T>M_AEX(DDI^BK/V7]
MEQ=_I_9]S_LL?:.=WZ3Z/O\`YWZ&_P#ZVLRO_FAZU7H;?4]2[TO0^V;?5FS[
M1Z7H?H_M'\Y]GV_I?0]/[+^@]%>$))*?>7_\T-^+ZOV?=OK^R[_M'TO2;Z,>
MI[=GV39ZN[V>E_/+2Z-^SO5/[)V[_0JG^D;/2VL^S;_6_1>IZ6ST]_Z?9ZG_
M``J^=$DE/U%^O?\`!?\`22_7O^"_Z2^74DE/U%^O?\%_TE"W[;Z3Y]*-IGZ7
M@OF!))3_`/_9`#A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0
M`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`
M:`!O`'``(`!#`%,`-`````$`.$))300&```````'``@````!`0#_X1!":'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[
MOR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@
M0V]R92`T+C(N,BUC,#8S(#4S+C,U,C8R-"P@,C`P."\P-R\S,"TQ.#HQ,CHQ
M."`@("`@("`@(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C`O(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L
M96UE;G1S+S$N,2\B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS
M.G1I9F8](FAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(B!X;6QN<SIE
M>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(@>&UP.D-R96%T
M;W)4;V]L/2)!9&]B92!0:&]T;W-H;W`@0U,T(%=I;F1O=W,B('AM<#I#<F5A
M=&5$871E/2(R,#$R+3`R+3(S5#`T.C$Y.C`Y+3`U.C`P(B!X;7`Z36]D:69Y
M1&%T93TB,C`Q,BTP,BTR,U0R,#HQ-CHR-"TP-3HP,"(@>&UP.DUE=&%D871A
M1&%T93TB,C`Q,BTP,BTR,U0R,#HQ-CHR-"TP-3HP,"(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!X;7!-33I);G-T
M86YC94E$/2)X;7`N:6ED.C8Y-#,Q-$%&.#0U144Q,3$Y14(Y044S-C$Q.3<U
M,$(U(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C8Y-#,Q-$%&.#0U144Q
M,3$Y14(Y044S-C$Q.3<U,$(U(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240]
M(GAM<"YD:60Z-CDT,S$T048X-#5%13$Q,3E%0CE!13,V,3$Y-S4P0C4B('1I
M9F8Z3W)I96YT871I;VX](C$B('1I9F8Z6%)E<V]L=71I;VX](C<R,#`P,"\Q
M,#`P,"(@=&EF9CI94F5S;VQU=&EO;CTB-S(P,#`P+S$P,#`P(B!T:69F.E)E
M<V]L=71I;VY5;FET/2(R(B!T:69F.DYA=&EV941I9V5S=#TB,C4V+#(U-RPR
M-3@L,C4Y+#(V,BPR-S0L,C<W+#(X-"PU,S`L-3,Q+#(X,BPR.#,L,CDV+#,P
M,2PS,3@L,S$Y+#4R.2PU,S(L,S`V+#(W,"PR-S$L,C<R+#,P-2PS,34L,S,T
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M,3DY,2PT,3DY,BPT,3DY,RPT,3DY-"PT,3DY-2PT,3DY-BPT,C`Q-BPP+#(L
M-"PU+#8L-RPX+#DL,3`L,3$L,3(L,3,L,30L,34L,38L,3<L,3@L,C`L,C(L
M,C,L,C0L,C4L,C8L,C<L,C@L,S`[-C@R.35!1C4X,C)"14-&,C8X-$0Q.35%
M-C4S-D0W,$$B/B`\>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@
M<W1%=G0Z86-T:6]N/2)C<F5A=&5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N
M:6ED.C8Y-#,Q-$%&.#0U144Q,3$Y14(Y044S-C$Q.3<U,$(U(B!S=$5V=#IW
M:&5N/2(R,#$R+3`R+3(S5#(P.C$V.C(T+3`U.C`P(B!S=$5V=#IS;V9T=V%R
M94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,T(%=I;F1O=W,B+SX@/"]R9&8Z
M4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#PO<F1F.D1E<V-R:7!T:6]N/B`\+W)D
M9CI21$8^(#PO>#IX;7!M971A/B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(#P_
M>'!A8VME="!E;F0](G<B/S[_[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("
M`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`$R`DD#`1$`
M`A$!`Q$!_]T`!`!*_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+
M`0``!@,!`0$````````````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)
M=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9
MP=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U
M*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZ
MQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M
M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"62
M4QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34
MY/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX
M.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#:S^)G
MQ3^.7:'0NS]]]A=.[+W?O+<&2WS49S<><Q\E;ELK40;]W-213UM4]1JFECI8
M(XP?]2@]^Z]T8W_9%?A__P!X\]:_^>5O_JCW[KW7O]D5^'__`'CSUK_YY6_^
MJ/?NO=>_V17X?_\`>//6O_GE;_ZH]^Z]U[_9%?A__P!X\]:_^>5O_JCW[KW7
MO]D5^'__`'CSUK_YY6_^J/?NO=>_V17X?_\`>//6O_GE;_ZH]^Z]U[_9%?A_
M_P!X\]:_^>5O_JCW[KW7O]D5^'__`'CSUK_YY6_^J/?NO=`1\D.I_P"7!\3N
MIL_W3W=T[UYMS9>"FH<;#'C=FY;<>Y-S[FS,WV6VME;,VO@DKLWNG>>Z\FR4
MF-Q])#)-4U$BJ`!=A[KW11?@%GOB3\P/B=VU\K>Q?A!M7HK#];=K_(3:M5UU
MG-MY"H[#V]LOI#)5<.K>N$:3RTG84^-H9'KL=3ZD@J2(4+$7/NO=5N=>_*?>
M`QO07RT[R_E#_''8G\MCY1=G]<=?]:=@[6[5I]U?)+9.`[NW-3[4Z9[([&Z[
MID?"Y3$;HR-92/5XW%-]_CXL@A>YA</[KW1G/DMG-V9OY3]M?%O^6E_*Z^-'
MR)R/Q=V_LS+_`"7[([QW[-U;LJ@W=V'@HMV[2Z:ZV^P2IJ<QOZIVA)'7U574
MN*"B^YCCE4'U-[KW2BS7R7^#47\N+:OS=VS\`J#.=N;][%Q_QOVE\2FIJ6GW
MV_R[R'8-=U/-T;E]PR)'CJ-,+OG%U1J\IX!'_#:=IQ&&8)[]U[K'\3LA6K\H
M,%\/OYE'\M/XV?'/LWMCK/>';?Q^[$Z1WI4]E]1]@XKKB;%KV/UWEJK)I!D]
MO=B[,QV5AR<NJ1J2JH)-48&B\GNO=%$R'RQW'5[3W=\YMD_R>^D-Q?RG]D;U
MS^'K^U:G?[4'R@W'U1L_=,^R=V?)#:W5WVTN%GZYQF6I:FN3'2.<C-BZ.67R
M*/6GNO='`^6.X<`_?^SOB7_+2_EX?'#Y*=T5?2>!^2?9F]>Y-SU_7'2O674.
M\\C6X;KJ&JR6+CJ,WG=[=B5N.J):&DAT+!24S32!E8F/W7NC0_R]L'\6/F;U
M)O#+]B?"'8G0?R`Z0[5W5T/\C>DL@8-SKL#M;9L6.K*Q,'N:C%+2[DVAN7!Y
M>BRF)K40"6CJU!+%2S>Z]T?3_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_
M`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`
M]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#W
MCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>/
M/6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]
M:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK
M_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_
M`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`
MGE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">
M5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6
M_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_
M`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`
MZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#J
MCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/
M?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^
MZ]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[K
MW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=
M>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[
M_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]
MD5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V1
M7X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?
MA_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'
M_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_
M`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U[_9%?A_\`
M]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>//6O_`)Y6_P#JCW[KW7O]D5^'_P#W
MCSUK_P">5O\`ZH]^Z]U[_9%?A_\`]X\]:_\`GE;_`.J/?NO=>_V17X?_`/>/
M/6O_`)Y6_P#JCW[KW7O]D5^'_P#WCSUK_P">5O\`ZH]^Z]U`RWP:^(4.*R<T
M?Q[ZV62''5TL;##,"KQTTKH0147!##W[KW6NK8_ZN7_J=+_T?[]U[K__T-S3
MX(?]DL];_P#49O[_`-^+NOW[KW1O/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U&J:&BKC2_>TE)6?9UD-?1_=T\,_VE=!J$%93>9'\%7"'8)(
MMG74;$7]^Z]U09\!NP-X]5_R[?YF/9_7NTDW_OSK[Y=?S.=Z;/V7-3/7P[JW
M-MO>FZ\QA\'4T,;++D*?)9"E2.2!"))T8HOJ8>_=>ZHLH^F/B?\`'SX9_$C^
M8WTK_,$3O;Y6?Z1^BNU-E_$+-;FV)NWXS[S[M[<WKBZ/?G3G3GPNQ=(C]'[M
MVW-NS,08C(8R&/([=J\>]1:)F8I[KW5\?P\^0W1_QK_F`?S?.H?D#V=L'IK?
M.Y.[>K/E'MH]G;JP>RQO'I;=WQ^V%A$W'M_(;@GQE-G<7LO<&U:[&UO@FG-)
M.FE@M_?NO=5=8#>VW]J_`;X[_.K/4K8GXRP_S]]X_+:JW+-CJZ'!8WXX]B=X
M=D;$VQW'7Q55"]11[17)YJES)JI4"I%4+*&`(M[KW5F_RG[7ZK^5_P#-'_EU
M=4_'CL78?:^Z^J>F?F]W!V3FNN=S8O>-%U]L+L?J3"=6[$J,_F]NU&5Q&*CW
MOO+(*E+#-*D\WVBR*/'RWNO=$9Z]^:/QCVM_PFZWYTYN+L;KZ@[IV+\;^Y/A
MUN7X_93.4%/VDWR-ER&ZNKL=UP_72/3;LJ<]N7<^3IJB(0T;+)!5><L461A[
MKW1J?B'O[8WP]_F6=A=5?);>&UNI=S]Q_P`MGX%9#K3.=CYS%;2Q.Z*CH/;&
MZ^O.V-I8;/9UL;C:G-[6ST\594T2SB415/E$=@Q'NO=&*_E%;LVYW%VS_-5^
M1_6M9CL]TMW'\[:F@ZNWQ@G>HVWV'!U3TYUOUWO#=^W:]D\.7Q-1O#$5=(E9
M`\E-4/1L8R5%S[KW5TM6M6:2I&/:F2O-/**)ZU)9*-:K0?`U5'!)%-)3B0#6
M$96*WL0>??NO=`7G,[WAA,OLW$O5=3U#[OSE;A$F7"[PB6A>BVUG=QFH,?\`
M'Y#4+(F$,(6Z6,H:Y`(/NO=*CP]X_P#.UZE_]![>'_V2^_=>Z]X>\?\`G:]2
M_P#H/;P_^R7W[KW7O#WC_P`[7J7_`-![>'_V2^_=>Z]X>\?^=KU+_P"@]O#_
M`.R7W[KW7O#WC_SM>I?_`$'MX?\`V2^_=>Z]X>\?^=KU+_Z#V\/_`+)??NO=
M>\/>/_.UZE_]![>'_P!DOOW7NO>'O'_G:]2_^@]O#_[)??NO=>\/>/\`SM>I
M?_0>WA_]DOOW7NO>'O'_`)VO4O\`Z#V\/_LE]^Z]U[P]X_\`.UZE_P#0>WA_
M]DOOW7NO>'O'_G:]2_\`H/;P_P#LE]^Z]U[P]X_\[7J7_P!![>'_`-DOOW7N
MO>'O'_G:]2_^@]O#_P"R7W[KW7O#WC_SM>I?_0>WA_\`9+[]U[KWA[Q_YVO4
MO_H/;P_^R7W[KW7O#WC_`,[7J7_T'MX?_9+[]U[KWA[Q_P"=KU+_`.@]O#_[
M)??NO=>\/>/_`#M>I?\`T'MX?_9+[]U[KWA[Q_YVO4O_`*#V\/\`[)??NO=>
M\/>/_.UZE_\`0>WA_P#9+[]U[KWA[Q_YVO4O_H/;P_\`LE]^Z]U[P]X_\[7J
M7_T'MX?_`&2^_=>Z]X>\?^=KU+_Z#V\/_LE]^Z]U[P]X_P#.UZE_]![>'_V2
M^_=>Z]X>\?\`G:]2_P#H/;P_^R7W[KW7O#WC_P`[7J7_`-![>'_V2^_=>Z]X
M>\?^=KU+_P"@]O#_`.R7W[KW7O#WC_SM>I?_`$'MX?\`V2^_=>Z]X>\?^=KU
M+_Z#V\/_`+)??NO=>\/>/_.UZE_]![>'_P!DOOW7NO>'O'_G:]2_^@]O#_[)
M??NO=>\/>/\`SM>I?_0>WA_]DOOW7NO>'O'_`)VO4O\`Z#V\/_LE]^Z]U[P]
MX_\`.UZE_P#0>WA_]DOOW7NO>'O'_G:]2_\`H/;P_P#LE]^Z]U[P]X_\[7J7
M_P!![>'_`-DOOW7NO>'O'_G:]2_^@]O#_P"R7W[KW7O#WC_SM>I?_0>WA_\`
M9+[]U[KWA[Q_YVO4O_H/;P_^R7W[KW7O#WC_`,[7J7_T'MX?_9+[]U[KWA[Q
M_P"=KU+_`.@]O#_[)??NO=>\/>/_`#M>I?\`T'MX?_9+[]U[KWA[Q_YVO4O_
M`*#V\/\`[)??NO=>\/>/_.UZE_\`0>WA_P#9+[]U[KWA[Q_YVO4O_H/;P_\`
MLE]^Z]U[P]X_\[7J7_T'MX?_`&2^_=>Z]X>\?^=KU+_Z#V\/_LE]^Z]U[P]X
M_P#.UZE_]![>'_V2^_=>Z]X>\?\`G:]2_P#H/;P_^R7W[KW2FVTF_DFJ_P"^
M57LVI@,<?V`VQC<U03++J/F-6V5RF022(K;2$"D'ZD^_=>Z5WOW7NFS-_P#%
MES'_`&JLC_[AS>_=>ZU*O?NO=?_1W-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!KU=T[UATKB
M-PX#JG96$V+AMU[XW;V3N/'8*"2"FS&^]]Y-\SO#=%8LLDY?*;@RDK3U#`A6
M<\`>_=>Z*YLS^6'_`"]>NN_JCY2;'^'G0^U^_JC*Y#/+V7A]BXRES5)G\N+9
M'/8RE53AL/G:HEF:LI::&IUN[!PTCEO=>Z5OR=_E_P#PJ^:&2VCF/E3\9>H^
M],SL,2Q[2S._=K4N3S&'I)ITJI\7%E8C3U]3A)JE/(]#/)+1M(68Q$LQ/NO=
M&"R?576.:ZVJNF\KUYLNOZDK-L#9-5UE4[8PTFPI=G_9C'KMD[3^S_@BX*.A
M41)2K`(410%46'OW7N@/^+WP8^'_`,*<?N;&_%+XZ]7=$P;SK(J[=4VPMN08
M_)9^:G4)2PY3,3-59:JH:,"\%,T_VT#,QC12S$^Z]TE\K_+B^!V<^1\'R[S'
MQ-Z/R7R4IJ^'+Q=O5FQ<5/NC^.T].:6GW)+KC.-J-T4\/^;R<E.U>C`,LP8`
MCW7NEK\H?A1\3OFKMW`;4^5O0/6O>V$VKDY,SMB#?VWX<E5;=R-1`:6JJ,)E
MH6ILOBQ6P66HC@G2.H"KY%;2MO=>Z&KK?K3KWIW8NV.L>J-D[7ZYZ[V9BX,+
MM396S,+0;>VU@,93`^.CQF)QD%/24R%F+N0NJ21F=RSL2?=>Z6_OW7N@MWY_
MQ^72G_A_9S_WV6^O?NO="E[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z[L1]0??NO=>L3]`??NO==>_=
M>Z][]U[KNQ_H?]L??NO=>L?Z'_;'W[KW77OW7NFS-_\`%ES'_:JR/_N'-[]U
M[K4J]^Z]U__2W-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!7U)W=U-WSA=Q;DZ;WY@.Q-O;3W
MWNWK+/9S;-2];B:/?.Q<A_"=V[?BK_&E-73X/)`P2RT[2TYD!"NUC[]U[HG^
M#_FV_P`MK<OR9_V3S`?,3IW*_(HYZHVI#U_1YFLECJ]VTBDU&TL?N\8_^X^0
MW5'(K0_PZ#)25AJ4:`1F96C'NO=*SY:_S,?@=\%,]L_:ORS^3?7/2VZ-^PFK
MVOMO<,^5R&?K\8M2:)L[58?;F*S61P^WA6*T7\0K(Z>C,B.HD)1@/=>Z,=E.
M^ND\+TQ4_(O*]K]?T70M)LU>PI^X)MU8D==KLB2D2NBW/'NI:IL1/B:BFD4Q
M2)*PE9E5+LP4^Z]T`GQ#_F+_``C^>D6[3\1?D;L#NRJV+)`N[L-MZ?*8W<F"
M@JV\=)DZS;&Y<;A-P#"5<UXXJ]*9J.24&-92X*CW7ND5FOYK_P#+DVY\FT^'
M&=^7_3F+^2#9JGVQ)UO5YRH22EW95Z5IMH5^Z/LCLR@W?-*ZQC%39&.O\[K%
MXO(RH?=>Z$?Y>?S`/AK\"L%MK<7R[^0&QNDJ#>==4X_:=-N.3)Y#.;CJ*)4D
MKWP^V=N8[-;BKZ''K*GW%2E*:>`R()'4NH/NO=#QT_W)U3\@>M]J]P=(]@;5
M[2ZPWOCAE=J;XV7EZ7-[?S5%Y'AD:FK:5V59Z:HB>*>&0)-3S(T<B(ZLH]U[
MH2_?NO=!;OS_`(_+I3_P_LY_[[+?7OW7NA2]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1'_Y@/;?R]ZCZ(IZK
MX,]`XCY!_(K?&^]L]=;3PNZ\Y_=[8/7]'N5:\93MKL+(:X))-G['BI5EJ*>.
M:&6H>1$1B3H;W7NJ=_\`A-%V5\G>P]A_S'\?\M>X<_W-W!U]_,&[(V+N'/9#
M<N=S^V,;D\/MS;Z9O%]=4F:=1MO8B9HSR4%!304M/#$PTQ+[]U[HB7S=_F1?
M(SY%?S@OY>NW_CYO3=FT?Y?O77SPH_C!6[MVEN;+;=Q7R:[^VS38S)=U4]1#
MBYZ5=Z=:=;09&FP<0E:;&S9!JEU60D&/W7NC5?\`"D7Y&_S0=I="_(79WQ.V
M;#T9\7NJNGMH=D=V?,>3>F1P'8.ZJ[/;RHL/%TMT7%A)*;,83.T\D]+/ELHE
MQ]E(\*U%.S,LGNO=+#^:O\O/D/U!_*N_ER=:]$]I;@ZX[S^>>Z?A[\:I^\XY
MJC([LV=B^RMD8&IWMNZCRU1))7+N?),T<;5@D%5HJ)WCD2;1(ONO=`M\,MC?
M*/X,_P`T/LW^3WV%\X^^?D]T?\IO@OO/N3J[M+M?-5>4[=Z8[#@FR6T\SEMM
MYJOR>3KJ1O`M94T\25A@$E/2N$21)'?W7NJ^/E!_*E^0/5WSC^'OP'^/7\X+
M^8UVSWIWI69#M'N!MS=S[LHMM=%_%[9<CKN?L;/)B-[/63[@W#DHCC\%1R&.
M&IJE(D-GCU>Z]U:#_P`*%>^/YH'7'QK[QZK^(>T).IOC)TQ\<MJ;][P^<.=W
MQD<9V5NACGZ#;QZ@Z;;#-3YJ@WW7+]K4Y?,JI'VT\L:U%+(WK]U[J_'X:9G,
M;B^"'Q<W!N'*Y+.Y[.?%#IS+YK-9BMJ<EELQELCU/@*S(9/)Y*LDFJZ_(5]7
M,\LTTKM)+(Q9B22??NO=:Z'OW7NO_]/<T^"'_9+/6_\`U&;^_P#?B[K]^Z]T
M;SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`#\F/C]C?D_P!4
M93IK/]B=H];[4W1D<8-YY#J#=DFQMW[GVC3S,V<V#)NRCIYLQA-N[QI&-)DI
M,?)35[4;/'#/"SZQ[KW5!GPE:D^*_P#)?_F@Q]&T,>Q,?T-W)_,]I.JZ'%RU
MM0NSJ/9.6W9!MD8^>JJ*G(3381*2.2*26625I$#,Q-S[]U[HB>PL3\CNA/@K
M\2^[^Z_Y='P2KOY56W<;\8]UYWJRDKMR9/YR[+HMS[EV:^W/E[N3L*EI,1L_
M*;_J][9^FW1EL;13O6K!D989:@E9RONO=7'_``<ZDZL[I_F`_P`X[MCMK8^S
M.Q]_T??W4_Q\QK[VV_AMU2;=Z/VS\=^OLU@]J8JGS5/7QX[;.Z<CN:LR%5!&
MB15L[:Y`Y46]U[JIS;6RMJ[B^#7QQ^&V96FR/Q@7_A0IO/XV/M.I>I;:U3T1
ML+O;LK?&T>HJFCK:DBHV:NZ,538I:*0F%XX$C52ND'W7NK3/F1L38_0/\TO^
M6SVMTML_:NQ.P>Q.GOG3U-O>#9NWJ+`/OKKO8W3^![)V?C,_3X>&BH<E0;,W
MM0Q342SH\D$E61'9;CW[KW1(NM_BU\=MQ?\`"93?.\\YL?8U?O3>OQ:[J^5.
MZ>U\A@*"OWL_R(3(;M[,C[-FW9'%+N(;RVWO7%T\<-5'4K/$E&L-P@9#[KW1
MG/@_MK;?R._F9=H]K=ZX'![_`-_=8?RSOY?N(Z]AWKB\?N$[9H>ZMM;NW]VG
MN#`T656MBQ^0W7NRF2FK:J%%DE2E$1<KJ4^Z]T/_`/*6VUM[J[NS^;1T9UW1
MX[!=0]:?/:;+;`V;@J0X[;6QZSL_I3K'?>^=N;=Q:E:3%8[^]F3GK#3TR1TT
M<M6_C4`D>_=>ZN?K*@TE)558IZFK--3RSBDHHUEK*GQ(9/!2Q,\:RU$MM**6
M4%B!<>_=>Z+-O;LN>?=G4$PZT[5B^TWQF9O#+MJ@62H+]<;WA,5.JYM@\JB3
MR$$J!&CF_%O?NO="7_I3F_Y];VY_Z#&-_P#K][]U[KW^E.;_`)];VY_Z#&-_
M^OWOW7NO?Z4YO^?6]N?^@QC?_K][]U[KW^E.;_GUO;G_`*#&-_\`K][]U[KW
M^E.;_GUO;G_H,8W_`.OWOW7NO?Z4YO\`GUO;G_H,8W_Z_>_=>Z]_I3F_Y];V
MY_Z#&-_^OWOW7NO?Z4YO^?6]N?\`H,8W_P"OWOW7NO?Z4YO^?6]N?^@QC?\`
MZ_>_=>Z]_I3F_P"?6]N?^@QC?_K][]U[KW^E.;_GUO;G_H,8W_Z_>_=>Z]_I
M3F_Y];VY_P"@QC?_`*_>_=>Z]_I3F_Y];VY_Z#&-_P#K][]U[KW^E.;_`)];
MVY_Z#&-_^OWOW7NO?Z4YO^?6]N?^@QC?_K][]U[KW^E.;_GUO;G_`*#&-_\`
MK][]U[KW^E.;_GUO;G_H,8W_`.OWOW7NO?Z4YO\`GUO;G_H,8W_Z_>_=>Z]_
MI3F_Y];VY_Z#&-_^OWOW7NO?Z4YO^?6]N?\`H,8W_P"OWOW7NO?Z4YO^?6]N
M?^@QC?\`Z_>_=>Z]_I3F_P"?6]N?^@QC?_K][]U[KW^E.;_GUO;G_H,8W_Z_
M>_=>Z]_I3F_Y];VY_P"@QC?_`*_>_=>Z]_I3F_Y];VY_Z#&-_P#K][]U[KW^
ME.;_`)];VY_Z#&-_^OWOW7NO?Z4YO^?6]N?^@QC?_K][]U[KW^E.;_GUO;G_
M`*#&-_\`K][]U[KW^E.;_GUO;G_H,8W_`.OWOW7NO?Z4YO\`GUO;G_H,8W_Z
M_>_=>Z]_I3F_Y];VY_Z#&-_^OWOW7NO?Z4YO^?6]N?\`H,8W_P"OWOW7NO?Z
M4YO^?6]N?^@QC?\`Z_>_=>Z]_I3F_P"?6]N?^@QC?_K][]U[KW^E.;_GUO;G
M_H,8W_Z_>_=>Z]_I3F_Y];VY_P"@QC?_`*_>_=>Z]_I3F_Y];VY_Z#&-_P#K
M][]U[KW^E.;_`)];VY_Z#&-_^OWOW7NO?Z4YO^?6]N?^@QC?_K][]U[KW^E.
M;_GUO;G_`*#&-_\`K][]U[KW^E.;_GUO;G_H,8W_`.OWOW7NO?Z4YO\`GUO;
MG_H,8W_Z_>_=>Z]_I3F_Y];VY_Z#&-_^OWOW7NO?Z4YO^?6]N?\`H,8W_P"O
MWOW7NN2]IS%E'^B[MM;D#4VV,>%%S]6(SM](_/OW7NM9K^5U\?OE3MOI#^=9
MUC6]>?('XQ]@?*#YM?)3,]&]K9OJRNBJ,)A-_P"VX,-MWL[`X^ORV&GS-)03
M,9H9J.8H753'+J%Q[KW5(7R6^!'\YKXY=E_ROOC+UMNC<';VV?CCVYGMP?%G
M=6Q/B1U/MZGV9E<51[:KMZ=J;OQH[,RN;W8(LAFX7R]9O.3%T]15RF9JEWFN
M?=>ZVE/YS>&[T[Q_DY_)7I3;73/=G:7>VZ.G]A86IHMJ=:Q35V[MY4&Y=EUF
MYLAB=K;;R^9J(8JJIH:JI^VI$J%@C]*%E75[]U[HH/\`,\^+WR>^0/\`+7_E
MV5_Q]^/79^ZODC\$=Y_$OO\`INH-R8>BVW)O)^JMDXFAWELP2UF:26GSE/5T
M\;+3M']Q(L,D4:&9E0^Z]TG/@M-\TOFO_-SK/YI/R0^!W>'P[ZJZ@^*=;\:^
MI^N-Z8]<COW=^[-Q[B&4W)G,A3Y>#9N4BPF.@KJ[Q3G&Q4[K)"B22NLA'NO=
M&O\`Y9O5'<V^?YKG\V_YJ]^=.]J]<G-[AZP^.?QIR'9VRJW:]+D^BNOZ&L?(
MUVSJNL!ILMCL]F\91UDDU))-$2_+W8K[]U[HV_\`/*ZV["[@_E,?-[K3JK9.
MZ>Q^P]W=308W:NR-E86OW'NK<.0&\-L53T.%P>+AJ,ADJI:6GDD,<,;OH1B`
M;>_=>Z-5\/MN9_9_P:^,FU-UX;);=W1MCXL=1;?W'M_,TDU#F,%G,/U5@:#*
MXC*T,Z)/19'&UU.\,T3@/'(A4BX]^Z]UKE>_=>Z__]3<T^"'_9+/6_\`U&;^
M_P#?B[K]^Z]T;SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==C
M@@_X^_=>Z(3\5?A%C.BNC/D1T3V+N#&=J;6^0W>WR:[1W%318:IP5'_<_P"1
MNX\IE,AL:MA?(5LU3+CL3E9*26K1XA,3K5(_I[]U[JL7;/\`)/\`D])0]=_%
MKMC^93OOM'^6+U%NK9FX=G_&*KZEVOA^W-T;9ZWS^+W1U[TWVCW]1Y!LSNKJ
M_:V5Q=/'X5I8YJNCH::(^/3=?=>Z,+\I?Y:'RKR_R=[%^4_\O7YWU?POW=\B
M=J[/VE\F]G;@Z?VYW3L/?M5L'$-MC9W9VTL1G:W'_P!S.T,)M-EQWWD?DCGA
M@C+`,&+>Z]TN<U_*#Z@J_P"75MGX#8'M'LW;^6V/NG%=R[0^3D593S]PX_Y/
MXG?-3V@OR$K)=4-!7[FR78%?4U572DK#)25+TX=?3(/=>Z:?A]_+F^2>S/D7
M0?+G^8%\SV^:/>&P.M]Q=/=&4>W>I,#TKU=U7LS><N)GWSN&'9^$K\BF=['W
MPN)BI*[)3,H6@00JK7!7W7NBDY+^1S\A12[K^*>U?YB^]]L?RJ-\=@YC?&?^
M(T'5NVZSM#'[8W+NJ?>^Y^B-K=_5%:<WA^F\[N"IE1Z04S3QT%3+!=@Q8^Z]
MT;OYA?RV^\-Y]X[&^5O\OOY8)\*/D+M_J.@^/6]3E^K\-W'U)VCTM@\A4YC9
MN$W+L'.5M#'3[CZ_RE7,V)R,4K/'#4/&RVL3[KW1H?@+\+:/X1].9_9>4[/W
M5WMV[VEV1NSNSY`=[;WI:*@W)VSV]O=J09W<,F)QVJAP.%H,=CJ7'XS'Q,\=
M'04D:!B;GW[KW1X??NO=!;OS_C\NE/\`P_LY_P"^RWU[]U[H4O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7=R?J3[]U[HH_9UQ\ROB6`2`>K?E>"/Z_N="'G^I!]^Z]T;?W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=-F;_XLN8_[561_]PYO?NO=:E7OW7NO_]7<T^"'_9+/
M6_\`U&;^_P#?B[K]^Z]T;SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]UV01]??NO=>`)!/\`3W[KW7@"?I[]U[KUC>UN??NO=>((^OOW
M7NN]+?6Q_P!]_A]??NO==`$_3W[KW77OW7NO>_=>Z"W?G_'Y=*?^']G/_?9;
MZ]^Z]T*7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL<LL4*23321PPPQO+--*RQQ
M111J7DEED<JD<<:@EF)``%S[]U[I@VAO#:?8.V<+O38FY<%O+:&Y*),E@-T;
M8RE'F\!F\?*S)'78K+8Z:HH:^DD9"%DB=D-N#[]U[KAMK>FS]YG<`VANC;^Y
M_P"Z>YLGLO<_]W\O0Y<;>W?@Q!_&=KYDT,\XQV?Q/W48J:273/`7`=03[]U[
MH$\'\R?B1N?N*N^/.W/DWT+G>]L94UE%D.G<1VOLC(=DTE=CX$J:^AGV;2YJ
M7.I6T-/('FA\'DC6Y8"Q]^Z]T]]V_*/XU_&J+;LOR&[]Z>Z/3=U7+0;6/:W8
MNU-AG<59`%\]/A5W+E,<V2D@#KK\08)J%[7'OW7NA'S786P=N;(K>S=P;WVE
MA.N,=@_[SU^_\GN+$4.S*3;A@6J7/S[FJJN/#1X=Z9U=:DS>)E8$,01[]U[I
M*=,]_='?(O:C[ZZ![@ZT[JV9'7SXR;='5N]MN[YP4&2IF(J<?49+;F0R%+!6
MQ%>8G97`YM;W[KW2;PWRN^,&X>XLK\><#\B.D\QWQ@XIILOTWB^S]FUW9F-2
MF2GDJ?O-E4V8DW!#+31U4;2(8-<:L"P`]^Z]T/\`[]U[KWOW7NO>_=>Z][]U
M[H%N]<SW)MW9%;N+IB'J^HR^!I<MF<W3]I-NQ,7/AL7B:NN,.+DVDLE7'DI:
MB!5U2JT:QDFQ-@?=>Z2WQ:WQW=V=U5M3LKN6@ZHQ)[#V=L??&U,5U?/N^I7&
MXW=FW*7/5%!N"JW9%`:FMHS7QQI)3HB/I8E1<#W[KW1DO?NO=>]^Z]U[W[KW
M7O?NO=$]^8O:WR`Z0ZWS?:G4&(Z9SN`V=ADK]RXCLVKWQ19:NK:O-XW%446#
MJ]J4]5204JQ5Y>0SQNY=0``#<>Z]T87K8=I#;2_Z8?\`1_\`WR^_J]?^C0;C
M&V/X7>/[#2-T$Y7^(6U>;_=?TT_GW[KW2]]^Z]U[W[KW7O?NO=>]^Z]T6+O3
MY3[8Z!SVT\#N7K'O/=K;WRN(V]MW+]:]<3[PP59N?.OD5QFV),A3Y*E%+F:B
M/%RR:9$6)(P"T@U`>_=>Z'K:.XO[W;9PNY?X#N3:_P#&:)*W^[^\,7_!=SXG
M6[#[3-8GSU/V-:FFY3R/8$<^_=>Z4?OW7NO>_=>Z][]U[KWOW7NBC]G?]EE?
M$K_Q%ORO_P"A^A/?NO=&X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW39F_^++F/^U5
MD?\`W#F]^Z]UJ5>_=>Z__];<T^"'_9+/6_\`U&;^_P#?B[K]^Z]T;SW[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`#\F8ODM5]3Y7%?$JIZLQ/
M<^<R.,P>)W;W&F;K=E;!PV2E>#/;[DV]M^(U^\<WMJB)GQ^'::DIJ^K"1SSQ
M0ZS[]U[JM#^2%D=[[>^('?X[R[ES7;F[-A?.'YEXC??=._I8<55;D&S^QZRE
MR>ZLE2R5L^+VMB5IZ)Y5HX95HL?3*$32B>_=>Z*1V#VWW+\C_P"8W_*B^3W]
MY=Z[&^,&^/D9\A>NOC=U"CY7`4O:'7&*^,/968K/DKV=A:E*2LJ:SL/.8L-L
MZ@J(UBHMK)%6NGW->WC]U[IVW!\-<'_-X^=?SUJ?DUW%\@\)TE\,M_\`7_QM
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M/8GS*V)N;`=N[BHNJ=I[6VCELWN?:/QVH>GH*Y-D5?5-1UQ@DQ%732P^>1JR
M60R&VAO=>Z.AN[JF#^<S\U*CJ_Y`=A]N[5^*7Q]^%/Q<[ICZ9Z:[,W)U73[X
M[Z^5&*SN\I=T[TSVT:^BS^7QVQ-FXJ&EQ=+YEA2>IDD))+!_=>Z.K_*&RO8^
MQ:'YH?##L+L???<%!\'_`)35_4_4O9':&7?</8V9Z1WCU_L[L[KO#;QW%-(]
M3N+)[.I]T5&+CKI0LD]+317`TV'NO=7%>_=>Z"S?A7^^72OJ7C?V<OZE_P"?
M9;[_`,??NO="EJ7_`%:?\EK_`,5]^Z]U[4O^K3_DM?\`BOOW7NO:E_U:?\EK
M_P`5]^Z]U[4O^K3_`)+7_BOOW7NO:E_U:?\`):_\5]^Z]U[4O^K3_DM?^*^_
M=>Z]J7_5I_R6O_%??NO=>U+_`*M/^2U_XK[]U[KVI?\`5I_R6O\`Q7W[KW7M
M2_ZM/^2U_P"*^_=>Z]J7_5I_R6O_`!7W[KW7M2_ZM/\`DM?^*^_=>Z]J7_5I
M_P`EK_Q7W[KW7M2_ZM/^2U_XK[]U[KVI?]6G_):_\5]^Z]U[4O\`JT_Y+7_B
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M%ZRZFZ!^"_PYZ2VE/_,&J]Z=2;XZN[VP]'0'Y&]<8O878>`W%V9\L?D%W'A*
M6AW'!MRHQ=/D89_XA-'%G\QD8J+'TKNH6#W7N@P^=6(VEE?YK7R8S>,_EVI_
M.ESM%\:NE-D[NZOJ:7$TU+\(,C#09G(4VW:3-]G8?(=5UE1WG09`9Z6FQ#_W
MHH)8F9@L$R@^Z]T6BHP/4F%_E,_RVT[QRF]>U/Y?_3/SI[`G_F`=4X'`=F1X
M_P"/F"I<KV/6[,Z)[-V7FZ&F[,K^F_C9V9E,;C,M!6TY\]/!!5%33M'[]U[H
MV_Q,[#^#V\OYM>Q,?_*KQ5+UK\9?DU\*_D%LGNSL+H;8N2ZJZ:WOVQUAD]GU
M>QLYUUALK@L-M^L[0ZGP^XZI*S*46*\$9R$4,\DTH=%]U[H`_P"8/\-OC]\#
M9_B?U'UK\$L[UOU'U1WI\<>U^W?YVF4I,5O3M+8.:B[.DS.Z\EO?([#H:;M;
M<NY-\9N.+&9K)Y7Q;7HX,[Y'@T01JGNO=;H$533U4451!/!-!411ST\T4J21
M303*LD,T3JQ1XY8V#*P-B#<>_=>ZR:E_U:?\EK_Q7W[KW7M2_P"K3_DM?^*^
M_=>Z]J7_`%:?\EK_`,5]^Z]TA>T2O^C+L;U*?]^'O#Z,I_YA[(_T/OW7N@Z^
M)Q7_`&5CXT#4G'Q^Z;_MK_S[O;O^/OW7NA_U+_JT_P"2U_XK[]U[KVI?]6G_
M`"6O_%??NO=>U+_JT_Y+7_BOOW7NO:E_U:?\EK_Q7W[KW1/?GZ0?A]W>`RG_
M`'`87Z,I_P"8PVY_0^_=>Z.([+J/J3_8LH_']"??NO=<=2_ZM/\`DM?^*^_=
M>Z]J7_5I_P`EK_Q7W[KW7M2_ZM/^2U_XK[]U[KVI?]6G_):_\5]^Z]T3[Y=$
M&H^*EF4_\YB]._1E/_+LWM_0^_=>Z.$66Y]:?4_VU_XK[]U[KK4O^K3_`)+7
M_BOOW7NO:E_U:?\`):_\5]^Z]U[4O^K3_DM?^*^_=>Z8]Q;HVSM#'2YC=FXL
M%MC$0*SSY/<&5H,/01)&NIV>LR%13TZ!%Y-V]HKW<+#;+=KK<KZ&WME&7D=4
M44^;$#HUV;8][YBO8]NY?V>ZOMP<@+';Q/-(23042-68U/RZUMNTOYK>;A^8
M.T*%>ML1D,SU;E]Z]:[1S=%E6.W,KA^W:C9'W68R%*9I*RJ>FI=L43TS0RQJ
MP>4D,&73$&\_>`Y1V;W7M_:AN5[V>\>_M;4727,0C)NA#IE$?@DE%$P--=2!
M@YZS.Y3^X3S[S7]VFX^\D/<S:[/;X]DW#<6VV2PN&N%&WM<J]NTPG5!(YMF7
M5X=$+4(P>ME3$UK5^)QF0F\4<M;CJ&LE1'NB25-+%,Z)J8MH5I"!?FWN<)XQ
M%--"!4*Q'[#3K!>WE,T$,VFA=`W[0#TXZE_U:?\`):_\5]M].]>U+_JT_P"2
MU_XK[]U[KNX/T*G_`%F!_P!Z)]^Z]U[W[KW39F_^++F/^U5D?_<.;W[KW6I5
M[]U[K__7W-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]^Z]T5;Y;?-SXJ_!3KANU
M?E=W9LOIS:4K5D&%_O'7F3<&[<A0TXJ9\1LO:>/CK-Q[MRJ1LNJ&@I9VCUJ9
M-"G5[]U[JB[*?\*Q/Y=4.XOX?MGIGYT;\VE+44(QW96V/CH$VCF,;6Q02MG,
M939W=^%W5)C(%E8_N8Z.>01DQQL"NKW7NK:/A#_-=^`_\Q'^)4'Q5^06V][;
MQPE+4U^>ZPSE#F-B]IX6AI*ZHQ\^0K-@[QQ^&W#-CHIZ?UU%/#/!&KQZW4NH
M/NO=6)>_=>Z][]U[KWOW7NO>_=>Z['U'^N/][]^Z]U21\5?@QNSL?X*?.WXF
M_(F@[&Z5QGR7^6/S5JAE=L9/#XO?)ZK[9[-K<GMW=^ULCHS^.I(]QX.37#]Q
M#(3#(RR1"Y'OW7NJY.[/Y"W<&W/DE_+UGZ^_F!?S4.VNOMJ]P;SE[`WINKY#
M;;R\_P`<]HX?IK<J;:SNR)3M7$';/][LU24FUZLT]/5^3%5TL`2-3K7W7NC=
M=H3_`,P'^7-\S_EIVA\;_@]N+YZ_'KYQ5_7W:6)H^N>S=J;$WQTI\A-G]>X7
MK'<V.WS0;Q*TE7U_OJBV[0Y/^)T@U4LOD1OTV/NO=)"K_EN?,K:/\M+K27:\
M/7N:_F'=:_-J?^9K7=?C<,U+UIN'N7</:FX^P-Z="X[>+U'CIL15[)W348"G
MR3-]L]5"KEA$_D]^Z]T)'1^%^:?\Q'YL](_)CY4?##</P8Z"^(G5G>6V-G=?
M]D=A[:WOVGV]W+W_`(#!;,W1F(:?9KIC<+UOL_9%%+'2U%2OGK:^=B@T!A'[
MKW1(HNN/YM^R/A]O+^29@?A)!NC;F8H=]]`;%_F)'MC;-)T9C?BGOK.Y>9=[
M;IV=52C?,/:>V.O,S48Q,-!?RU\4#(&2^OW7NCF]T]:?,3^7%\M,9\G/B5\5
M=R_.?HGM3XK=*?&3MSJ;8&^=N;)[<V)O7XY0YN@ZR[.Q,&[9SB-P;9W'M/,2
M8[(QQ%JBDF@C<D*PU>Z]T<#^5CT'\@>N=G_)#Y`_*W:6"ZU^0GS9^1&=^0F\
M>H=M[ACW9CNG=LC:^V=A];];U>YJ8_8YS<>%V?M2";*5%-^P:ZID1.$]^Z]U
M:+64=+D:.JQ]=3Q5=%74\U)64LRZX:FFJ(VBG@E0\-'+&Q!'Y!]^Z]T6/>W2
M'4%-NSI^G@ZXVG'#7;WS--5QIBXU6>"/KG>U4D4B@@.BU-/&X!N-2`^_=>Z$
MK_0+TQ_S[/:'_GIA]^Z]U[_0+TQ_S[/:'_GIA]^Z]U[_`$"],?\`/L]H?^>F
M'W[KW7O]`O3'_/L]H?\`GIA]^Z]U[_0+TQ_S[/:'_GIA]^Z]U[_0+TQ_S[/:
M'_GIA]^Z]U[_`$"],?\`/L]H?^>F'W[KW7O]`O3'_/L]H?\`GIA]^Z]U[_0+
MTQ_S[/:'_GIA]^Z]U[_0+TQ_S[/:'_GIA]^Z]U[_`$"],?\`/L]H?^>F'W[K
MW7O]`O3'_/L]H?\`GIA]^Z]U[_0+TQ_S[/:'_GIA]^Z]U[_0+TQ_S[/:'_GI
MA]^Z]U[_`$"],?\`/L]H?^>F'W[KW7O]`O3'_/L]H?\`GIA]^Z]TE-^?&WJK
M<.QMZ[>P_7.RJ;+9_:.Y<'C*BHQJ0T\%?E\+6X^DDJ)84EEC@2>H4NRJS!;V
M!/'OW7NBX?`7X,[>^-GPQ^-70_;FSNN-Q=F]3=5;;V;O3.;<@J,I@\GGL5')
M][68G(Y2@Q>0JJ261]2O-3PN3]5'OW7N@?\`C'\!=X_''I;YEXZGV1T5NKN'
MM+Y,_*;O;H.+)U&8DV308[LZM3)]38/?M=)@!DL;%BJR!!E(:.GJUBBU"&24
MF_OW7NJIOC!\#OYZ/QVAJH*GJ#^35V-N3?>ZX]P]U]V[^S?R>W%W3V7)5Y>6
MKJI<KGAB,?C*>AV]C:N2FP>%HZ>CPN+@C2.GIX@7+>Z]T;?O_P#ES_.OI3Y,
M=S?(;^6D_P`(=R;:^4J;)S'<_1_S)VWV,N#V+V9L7;$.TJ3L/J3=W6S5&5>C
MW!A:6):_$5T:TZU*>5&(;0GNO=.&`_E._)SISX83[<Z9[UZ4SOSBW-W[NKY.
M=V[E[/ZEI*_XT?(+<._GKCO;H+=.RX:*MW#MGI2JQT]-1T%10:,E`]!%.ZGR
M21CW7ND_T#_*T^6N8R_9_P`@_EBOPNP??63Z1S'QP^//1WQ?V[O[KOXV?'3K
M_=V:&5[!WSM_<"8^/?E7VUO"IBAGCK8J:)*`TT:1N025]U[HD/3'\NC^:_\`
M*_H3%_$#Y"=Q_"A/AQA=][HZC[.^26T=H]CYKYN=V]==%]M93:.3VYE1N>/^
MXN%S6_*K99CJ<ZSMD12JLLHDFDD1_=>ZVH*#X[]'XVAH<;1]8;1CH\;14N/H
MHCBXW,5)0TZ4M+%K8EF\<$2K<DDV]^Z]U*_T"],?\^SVA_YZ8??NO=>_T"],
M?\^SVA_YZ8??NO=>_P!`O3'_`#[/:'_GIA]^Z]T"7?&TOC!U[L/<=+NS!=<[
M7R.Y=I[LQVVH\G2T]')E,B<)50I34CM93,TU5&HN1<N![=BMY94DE4*(E(!9
MF5%!-:"KE14T-!6N.J:B94ABAEDN&!(2.-Y6H*5.F-6:@J*FE!4=(WX>]??'
M;=OQYZ=P^,VML'.;CV5U'U;MW?-)245-5U6$W/1[)Q%)E,;DI8R\9K8,A1SH
M^EW&N-N3[])!)$D<C:3&U:,K*ZFG$:E)%1YBN.O:Z2O!)')'.@!*2(\;@'@2
MDBJU#Y&E#Y=&@_T"=,_\^RVC_P">B+VUU?KW^@3IG_GV6T?_`#T1>_=>Z]_H
M$Z9_Y]EM'_ST1>_=>ZZ_T"],?\^SVA_YZ8??NO=$T^=_5?1E%\9^W-O8W:&Q
M(=Y9#;N'EQ.!IXJ)=PU\?][<$[O08M)A7U2!()&NB,+1L?HILIM[&]NE+VUG
M+(H-*JI85_(=)+C<+&T94NKR*)B*@,RJ2/E4CHV^)ZC^/^XZ5LG@=F=?9VA:
M>2`U^*@H,C2M41']^'[BDEEB,T98:EO<7Y]M3036\IBN(F23T8$']AZ=@N(+
MF-9K:99(SYJ01^T8Z=/]`O3'_/L]H?\`GIA]M]/=>_T"],?\^SVA_P">F'W[
MKW7O]`O3'_/L]H?^>F'W[KW7O]`O3'_/L]H?^>F'W[KW10OE?T[T[1U7QDAH
MMB;0A?\`V;CJ)<I%3T4`>.A.+WFSM6(CAHJ<76[.`HO_`(^[K#,PJL+$?($]
M--/!&=,DR*WH2!_A/1MST=T@(/NO]'6R?M0GF^Z_AU+X/"!<RF:_C\:KS>]O
M=&(C#&3M`XUQ3[:\.GHU:9D2)2[L:`#))/``#C7Y=%,[?[W_`);?1BU,?8N[
M^D<?DJ979\!AOMMT[A9XQ<P?P;;:92NAG/X614O[CCF/W=]N.5?$3=^;K07*
M@DQ1MXTN/+PX@[`_:!UD%[=_=3^\-[IF!^3?:C=YK)R*3S1&UMZ'\7C7/A(5
M^:ENB2UOSPZI[,J9L1\/OY>_9O?]8;QTVY*_9B[)V0LAT^.>?)2TV3E6E<&X
M:;[8V'X]Q9+]XJ;?7>W]M_;S==WE_#*R&*#[2RB2@_TYCZR;M?[OVSY)ACW#
M[Q/WAN4^4;<9:VCG%[>T\U6-6C&L<*)XH^WK'_LLG\RWY`H?XWB/C%\-=J5R
M@FAVIMV'>F_HJ63U:&K=>:BBJC$VEO\`*Z9E?D*OXK]%]Y?G(-]5NFV<M;<X
MX1`2W`!\B?UL^1_5C/R'DY^]_P"[@]HWKMG+/,_N1O\`$?CNG^CL"P\]%(25
MKD?I2`CBQZ$_8O\`)/Z/!@K>_P#MWN7Y!9!95J9<;F]SU>V]H_<%@\@CP]#5
M5V0\-[K85J`K;TCZ>W[3[M6Q7LZW_/7-F[;YN%03XDIC2OR`+R`<>$H%#P'2
M7<_[QOGK8;)MF]B_:WE;D?9A4*;6T2>Y`X5,KJD>K@:^"37S/4#?W\MKXQ8W
MY4](X&#;F7:?L?;G;F],AN"7+2MFL/E.H1U9#M"+#.(UH$IDI]TR),)X9F<4
M\5B"'+35+[?>W%QS%:\VW'(MD_,L,D,BW!>YU"2W"+"^D3B.J"-*=E#I%0<]
M8GVOWDOO"6'(=][7V/O!N<7M[<V]W!)8B*R,30WSRO=1:S:F8+*T\I)$FH:R
M%(H*6HT_0'3,%/!`W7&U9S##%"9Y\7`\\YB54::5P`'FDTZF-A<D^Q;(YDDE
MD;BS$G[2:]0I&BQ1QQ)\*J`/L`H.LW^@7IC_`)]GM#_STP^Z]7Z]_H%Z8_Y]
MGM#_`,],/OW7NE3M?KS8^R9JN?:.U<+MV:OCCAK9<51I2O4Q0LSQ1S%#=UC=
MB1_0GW[KW2R]^Z]TV9O_`(LN8_[561_]PYO?NO=:E7OW7NO_T-S3X(?]DL];
M_P#49O[_`-^+NOW[KW1O/?NO=4K_`#K[+Z'HOYGO\K7X_=L?$3I[OS<W?^.^
M3T&S.X>SH*7.YGH6/KS:6V]X9*79&U,QM[.82MK]Y3TM/!459DHZFFC@&B1E
M9D/NO=&-^.OSYVEW9GOY@76^RNI\ALD_R[.Q\GT[6QU>4Q`P.^ZK`["DW=0U
M>W*##T,1VSA!2TZ4RP.DC1J05^FD>Z]T$/\`*VW)\?OGQ\>/C=_,ZJ?B-TIT
MK\@M[[=['HL=G-F87#UFZMK8F3>VZMI9W#Q;_I-N;8S6:QNXDQ3553#4P^,S
M3$Z2RAS[KW5O/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"W?G_`!^72G_A_9S_`-]EOKW[KW0I
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KNQ_H?]L??NO==>_=>Z][]U[K
MWOW7NO>_=>Z['U'^N/\`>_?NO=%'^%'_`#)G</\`XL3\LO\`X)KM;W[KW1M_
M?NO=8*JJIJ*GEJZVH@HZ6!#)/4U4T=/3Q(+7DEFF9(XT']20/;<DD<2,\L@5
M`*DD@`?:3@=.P0374T=O;0O).YHJJ"S$^@`!)/V#HE?<'\QKX7]'FIIMZ]][
M+JLS2DJ^W=G54F]\Z95)4P_9;7CR:03J_!69XR+\\>XOYB]Z_;'E?Q4W'FRV
M>X3C'`3<./D1$&"G_3$=9+^W?W-OO*^Z`AFY9]J-RCVZ3A<7BBR@IQU:[HQE
MEIFJ!J^710)/YI_:?;DLE#\/O@_W=VVCR>*DWKOJC_N'LH&^CSRU/CK(VA6X
M<!JN!V3\*?I&S>_V_P#,;/#[;>UVY[@*T$TX\&$_.JAE^=&E0_9UD/']Q#D3
MV]CCNOO%?>?Y8Y?<"KV5B_UU[ZZ0M4-?*HB<`^O12_F+\=_YE_RLZK6I[VV9
MU+@FPV=AW-MG;.QLH9:79&`QM!63;GEW5E5FRTM;4UD9IVIUCGJ-(@EN$)`9
MS?\`D+WE]V?;?F#E[G"XV3;MRDW.SN+6+6RI''%'=+-KDC6<EB98M(U-@-E>
M'2WVZ][_`+G7W7/?GE+G7VGCYQWS88>7MTL=QNF@B:6>XN9K%[0P02R6JI$B
MP7'B'2IJT=`XR,GPI_EZ_*6LZ/PJ8#Y-;S^-./KZA]YXO*]91-EL-VEMW>]+
M39;;^:>63)82JC&-QP5HA)$&TUGT'/M[9?8SGC8_;OE3E.W]S?W;N-E=7LLI
ML#))%*MP8/"+,3;MJ01,*:2`&Z2\^_?8]D>;??;W#]S;W[N<7-.P[KM6T6UL
M-[$=O<6CV"7*W`C2+ZM2DQF0UU@GPQ4=&Z_X;V^;]!QA_P":'W&ZRV-1_%ML
MI5$%?\WX/)N&IT<$ZK6OQ[9/LU[JQ?[B^^NX9XZXW/[*SGI-_P`%[]V"[SN/
MW&>7`5^'PKDKQXZJ6ZU^7'KQ^`WSZ7U)_,^[*UKR@;9D!4L.5U+_`!<W7^O^
M'OQ]H/>'R]]KRO\`S2;_`*W=;_X++[IO!ON-[)I/&EXU:?+]'CUC_P!DC_F6
M?C^9OF;?C_C&V/)M_4DR\GW3_6J]\_\`PNC_`/9-_P!#=7_X)[[E?_LD5M_W
M,9/\W6(_#'^:)1D+C/YEZS1NMY3ENJL74R*XX40F2"ITH5^H!'/OW^MA[]1&
MD7O?J!_BME_RA_\`)U9?O)_<8N!6^^Y05<</"W2513YT9:G]O5:O\P#XD_.6
M.+9=7O[LK(=[9G:]-FLEN3N"CI4ZVV]A]NY:?'T>W]N5\\/\.QKS8_(0SMK9
MB;U:@\D#VC]QO:7WQYEY(Y,VO;>;TW+?;2^OGGF%S%8TBF6T$*%6>$24:*9M
M0!*ZJ>?0T^[U]Z?[F/(7NI[M<Q;I[7ORMR3N>T;-#9V;V4N^:KJUDW!KR<2"
M*<PZTGMUTDJ&T8K3HWWQL^*O\RZ@Z5V'B>MOD7A?COC,+B(\5G>OM\;&.X<U
M)NNF9CE]P_Q>MQ-;-5T>5CEA6,B0K>$V]B?<.0??"/9>1=OV?W$M]ODL]D@@
MN(F"7)^I5Y3(QF"3!ZADX.0*4'481>^GW*+KGCWFW[F_V#W+F)-UYNO;RPNX
M)7VV/]W2QVZV\0LR\)B*,DI(,:DZNAU7XZ?S@L?>.C^<?3>6C?UM-DNLXHI8
MGX'BC$>V9`8P.?K]?9-_4K[R$';'[I[?(#YM`H(^7^XQZ-C[Q_W=MWWW'W7N
M9+=Q@"/<B01ZFMR,]=_Z"?YR,'[\/S'Z$JI8K21TU1UQI@G=>1%,PVHQ6)OH
M38^]_P!4OO*H=:^X^U,PX`PBA^1_Q7AU7_75_NX9?TG^[ES8D;8++N-64'S`
M^JXCRZ[_`-%?\ZO_`+R:^+W_`*`<W_V&>_?U?^]!_P!-KLG_`#C'_;)U[^OG
M]V=_X1+GG_LN'_;9UC?K_P#G=TA\-+WS\2,E$/5]U6[0R%/,2WUC\<.S-&E#
M]#]3[O\`N?[T:=J\U;!(/4I0_P`K3JZ\W?W8<X\2?VI]P8'_`(4NXV7[:M>5
MJ>J:_FILGYZR=T2OF9=U9O>AP6(QV_,WU-/7X78.:WRTE;+,-MTDQQ)D,F+^
MW`180[%#8&Q]D/NUL'WJ+^\Y/?D^ZW9XDV2%;IMMN6AM3=":X,FE%>'N\,Q!
MB4%<=2K]U_G;^[;VK9/<V/W%V_EJVBEYNNY-KBYBLEN]S3:S;68A$LW@W`*>
M,+@H!*0,X%>K7^O?Y;6Z?D1LW:6Z^]/E3WU_H[RF&QT^"Z(VIE)]IX/;%!#3
M14\V(KZNHGK'K9GK8YGE;[1';R<.>#[D/G7V2W'G;FK<=SYMY_W1MID$16RA
M?0D?Z,8='9F=&;6'U$1@DFNHG/6-_ME]\[8?9KD/:>7O:KV!Y53FVW:Y67>[
MN'ZB>X+74[12QQZ8S&@A:,1J9"`JCL'#H\G4'\MSX4])_:U&T>AMGY/,TI1E
MW'O>GDWUG'E0ZA/]QN5\A3T\P(_5#%$?9SRY[(>U_*_@O8<IV\MRG"2X!N'^
MT>*65?\`:JO4>^XGWS_O,>YOCP\P^ZVXP;9)4&WLF%C``>*Z;81LR_)W;H[-
M%1T6.I8*''4=+045,@BIZ.BIX:2FIXQ<B."G@2.&)`3]%`'N4XHHH(DA@C5(
ME%`J@``>@`H!UC)<W-Q>3R75Y</+=.:L[L79CZLS$DGYD]2O;O3'7O?NO=%'
M[._[+*^)7_B+?E?_`-#]">_=>Z-Q[]U[KWOW7NO>_=>Z][]U[KWOW7NFS-_\
M67,?]JK(_P#N'-[]U[K4J]^Z]U__T=S3X(?]DL];_P#49O[_`-^+NOW[KW1O
M/?NO=:S?\[7:_P`WME?.W^5S\S/AS\,MZ_,R?XO4'RC_`+X[)VOEZ;;E!3S=
MG;6V?M+#0Y;/O%7U.,EE@EJZF`I1U"R&D*-IN#[]U[JJ'XY_(C^>#\?=\_S$
MM[4G\C#M;<[_`,P'M[*]L97'5':5/BDZTFR>Q3L@X.BJ(]MUK[HAB0FI\[I0
M,S$IH`LP]U[K9&_D-=&]O?&[^5)\4>F.^.O\_P!7=J[-PV_H=U[%W/%3PYO!
M3Y3M'>N:H(ZV*EJ*J%#4XS(0SI9R?'(+V-P/=>ZM\]^Z]U[W[KW7O?NO=>]^
MZ]T`OR6^276/Q0ZFS/<7;%3N'^[N-K,=A,5@MF[7S>]M[[TWAGI_L=K;&V3M
M+;M'6Y;<&[-U91EI:&G1%1IG!D>.,,Z^Z]T2_P"!'\P?>?RI^'7=GRP[4Z+W
M1U;D>K>V/DCM8=%X7%5^X^UL?MWI#)UE-C=JY?"4DU:V7[;R<%"8:BCH;0-D
M9!#$+"Y]U[JO2O\`YE_\W[I';VP?F/\`+#X,_'G8_P`"-_[PZXQFXMB;.[)W
MK5?,OH;9'<VZL#L_86\.R\)G:"CV)E,KALKN.@_C>(HDBJX7K/"1"\,A7W7N
MC'_)#YS?S%NP?E;W+\8/Y8'QT^/'9,/Q,Q6PZGY(=I_)[?\`NG:&U\EOSL7;
MD>]=O=*]5T6SH7JYMV1;.J*>JK<E7L,?2R5212",J&E]U[IVRO\`.!9_Y;>S
M_F+M;X][@ROR,[![7H/BCMCXE56XJ6#*4WS*J^Q,AU-7]39O>/VL=+#M[;^\
M,15U53DU@&O%0>155G%O=>ZR?%#YP_//:WRHVQ\/?YH'1'076&].Z>L]\]K_
M`!W[?^,V]]U;HZKW4G5YQ4_975>ZZ'>]+#G,+OO:F#R\.46J20T572%A&NI"
MQ]U[HG^0_F\?S(LEL'=O\PW8?PLZ5SG\J/96ZMQ13RY'LK<E!\Q]V]);,WA4
M[-W;\C]M[;2BFV##M:@:@JLK#A9BV2FQM(]F.I9??NO='!^5WSW^8V[?D+M3
MXC?RMNG.CNV>U!T/M?Y.=L=L_)3=FZ-K=+]=]8=@Y*KQ/6&!IZ794$VZ<]OK
ML)\;5U-.D0\-)1TQ>12'+1^Z]T:S^7;\R-W_`#`ZJW^W</5=/T9\D?C[V]NS
MH#Y'=24&?&Z<'MCLK:5/C,HF4VCN,0P'-;*WEMK.4.5Q<[*7^WJ?&S.R%V]U
M[H__`+]U[H+=^?\`'Y=*?^']G/\`WV6^O?NO="E[]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KHD`$\FP)XY)L+V`_+'\>_=>Z*
M1LCYD;%W[V?DNI,/UA\C*+=>!R.&QVY9]P=%[WP>W-L?WBIJRLP61W!N.NHX
M\508G*TF/DEBJ-;)H`U6)`]^Z]T;CW[KW7O?NO=>]^Z]U[W[KW37G,-1;CPN
M6P&3:N&.S6.K,77'&97)X/(BDKH'IJ@T&:PE9C\QB:L12'QU%+/#40O9HW5@
M"/=>Z(5\5.GMK;0[^^653C\]VWE4ZZ[4VGLO96.WIWQW9V%@L!MO<'QYZ8WA
ME\?3;?WUO_<6$J7J=R[@K:M:BHIYJF&2I81R(EE'NO=6$^_=>Z][]U[KWOW7
MNO>_=>Z)-\U?F!B/BKU7E][89MJ[OW=A:FEGJMAS9VE7.O@RQAKLC'C*>LCK
MXHJ:I>%&E=1$ID`)N0/8;YBYPY?Y5V3F/>]RD^H;;;,W#VT,L:SN@EBB)`:N
ME0902Q4CRXD=2C[8>SO.?NQSOR%R;L\+;?;;_N@L8]QN;>=K**5H)[A0S(%U
MLRP,%17U')X`]5.?$O\`FH9JAV'O+#[,^->_^SI(>QMWYO&[5V:ZY3=M9NON
M7>V[NS,E+,]%#5TU)M'"5^5JJ<2&`RI'X0S,=3&(ML^\3LG-')N[\S<J<B;O
M/=VE_;6OT^M)6=KF.XD#UBCJJIX!#'2<NOSZRPYH_N_.8/;KW/Y1Y`]Q/?7E
M;;]JW39;_<6W"2.>WA@CL)[2%X:3R#Q)IC=JT:JPQ&U?+HS4F_\`^<1\A[+L
MKJSJ7X>[2K"4&8W]DHMW;YAIY+@R'&-#DFAJXD(*WQ].+\7]A\[O]Y3G/&V\
MO[?RWM[$C7.PDG`\C0B0U\\PI]O0H3E/^[H]H,\R\^<P>XO,$>?!L(S:618>
M7B5CJI.#2XDQY=9*'^4WN_M.I@RWS%^9?>'>4CMY*O9^!RU1LS97J%IJ:*G6
MJK":-Q]%AIZ33^/=HON\;EO\@N?<OW)W/=6;XH8V,4)]11BXI_I$CZI=??\`
M>7>1(9+#[N7W;^5^5D`HEW/$MY>8X,6TIWCU>26O1W.G_@%\/.C%II.O>A-A
MTV4IE4#<.X,8-W;A>15L9_XMN9LK4T\C$\^$Q*3S:_N5.7/:#VVY5\-]IY2M
M?J5%!+*OCR_;KF+D?[6@ZQD]Q/O9_>+]TC,G-_NONSV#G_<>WE^DMP/X?"MA
M$K`>6O4?GT;Z*.."*.""*.&&)%CBBB18XHHT`58XXT"HB(@L`!8#W)"HJ*J(
MH"`4`&`!Z`=8[.[RNTLK%I6-22222>)).23YGI$]H_\`,LNQO_##WA_[SV1]
MWZKT'7Q._P"R5_C/_P"*_=-_^^[V[[]U[H?_`'[KW7O?NO=>]^Z]U[W[KW1/
M/G]_V1[W>/Q_`,)Q^/\`C\=N?CW[KW1Q7_4?]A_O0]^Z]UQ]^Z]U[W[KW7O?
MNO=>]^Z]T3[Y=\U'Q3O^/F+T[;_SU[V'OW7NCA'ZG_7/^]^_=>ZZ]^Z]U[W[
MKW7O?NO=>]^Z]T4CLX$_,KXED`D#JWY7<V/Y?H2U_P"E_?NO=&W]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW39F_\`BRYC_M59'_W#F]^Z]UJ5>_=>Z__2W-/@A_V2
MSUO_`-1F_O\`WXNZ_?NO=&\]^Z]UKW_SK>[_`)993O+^71_+N^)7=]9\6]Q?
M.KL[LE.P?D1C*6.3<&UNO^FMN8K=.8VOLZL>6FEI-R[GAKW\2T\U/55+0)`L
ML<4LQ/NO=5)=O]0]]_SB_E/_`#5NXJ/YW][?'CH[^5W?J'XJ2].[UDVWL7*=
MR]7;(K]U]D;\W^M+74T>4I6W)M99:RIBEBJ4IJV$)4+'3".3W7NMD?\`DV?)
MGLCYA?RR/B!\A>WZJ?)=G[YZQ6'?&<J*./'R;ESVU<[F=GU6Z&IH42#5N,8%
M:QGC58Y'F+*`I`'NO=6;>_=>Z][]U[KWOW7NO>_=>ZX/#%*83+%%*89EFA,D
M:OXYE#(LT6L$QRA'8!A8@$B_/OW7NJ9/Y0>Z-O;,^,GS+WENS-X[;VU=I_S"
M_G]N/<VX<K51TF+P>"PG;.8R67RN2JY6\=+1XZAIY)978V5%)/OW7NBV[=^;
M?Q0_F9=@=?[T[?\`E=\8^KOA7LSL#;^].D_C?N;O;JZA[G^4G8^U,^DO7_97
M?&U:C="Y'8W6>"W)30Y';&Q9(VR>8KDIJ_,"%8H,>?=>Z47QP^6?QP^%/\P?
M^;5U!\K^Y.NOC_N'?_</6GRPZUS';>YL9L;%]F=.;EZ*V9MC(9/9^:W`]!CM
MQ2;)W/LRLQU514TTU9'-8+$>;>Z]U7'@]V4VT?Y=WQ[_`)@V<P.5QWQUHOYY
MVZ?G)DZ]=O96%,1\6.S>Z^P=F8#N+(8+[*?)4>WX:3<-'GG=HRRP5`FX!X]U
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MP3-LW9"FEE7KC>TC3HD>*2.1GB1H[.&4"0L!J4>_=>Z$S^YG8_\`S^C.?^@5
ML/\`^LWOW7NO?W,['_Y_1G/_`$"MA_\`UF]^Z]U[^YG8_P#S^C.?^@5L/_ZS
M>_=>Z]_<SL?_`)_1G/\`T"MA_P#UF]^Z]U[^YG8__/Z,Y_Z!6P__`*S>_=>Z
M]_<SL?\`Y_1G/_0*V'_]9O?NO=>_N9V/_P`_HSG_`*!6P_\`ZS>_=>Z]_<SL
M?_G]&<_]`K8?_P!9O?NO=>_N9V/_`,_HSG_H%;#_`/K-[]U[KW]S.Q_^?T9S
M_P!`K8?_`-9O?NO=>_N9V/\`\_HSG_H%;#_^LWOW7NBE=1[2W])\L/F+%%VW
MF()X<=\;?N*E=H;+=ZK7L3<^C5')BFBC*6/Z0OU_UO?NO=&U_N9V/_S^C.?^
M@5L/_P"LWOW7NO?W,['_`.?T9S_T"MA__6;W[KW7O[F=C_\`/Z,Y_P"@5L/_
M`.LWOW7NO?W,['_Y_1G/_0*V'_\`6;W[KW7!]H=AQ(TDO=F9CC0%G>39NPD1
M%'U+,<.%4#_$^]@$F@R>M$@"IP.BH=![8WO+W=\U8X.Y<G%+)WIU\5G3:>QG
M;*!?B[T/>IA1\8Z.D('@)B&F\)OZ]?NQCD0:FB8#Y@]466-S1)5)^1!Z-#E<
M)O#!44V2S??M5A<=3JSSU^6VSUWCJ*!5!9FFJJS%PP1JH!))8``>TES=6UG$
MT]U<1Q0+Q9V"J/M+$`=&%AMVX;K<QV6UV,US>.:+'$C2.Q]`J`L3]@Z(%V[_
M`#&OC7T_438RM^8]=O[<<3M"-K]4]?;,WYEIJA1Q!'/B<*V%21SP-=6HO[B#
MF+W^]K>7':%N8EO+L&GAVBF<EO36OZ0)^<@ZRS]O?N)?><]Q(HKVU]NY=IV=
M@&-SNCK8Q*O\167]8@?*(]%ZB^9W\Q3O66.'XF?'7L:#`5$H%+V'\@MN[(V=
M@YH+@BHBQL=#A5>*6(ZE*5DI'TLWL$GWB]T.;J)[=>T\ZVK5`N;]C$GR8+6-
M2#Q%)&^P]3&/ND_=K]J?U_O!_>IL)=RCR^W;!']7-7S1I=,Q!!P:Q)ZU'0DK
M\,_YC7?RJ_R<^;G^C+;M7$JUW7_QTPO\(+QD`24E3GU3#,Q="06)JU5N0#^:
M?ZV/O3SB*\]^Y_T%DX[K?;U*_EX@$7ECN\05SGJ__!(?<V]I.SV2^['^_=ZB
M/9N',,WBY\G6WK,!0Y``B-,5'2CVC_)@^,NVH=S1Y+=?:6]:G>-"V+W'EMVY
MK&U^:R&.>IIJR:B.2@QM-+'3SU=)'(_!D9D'JM<&0.3O8WV[Y2AWJ-]MFW&7
M<K0V]R]U-(S2Q-)'*1^D8]%7BC8E:-VC-.H5]S_OP_>"]RMPY4NX^8++8K38
M=R6_VZ#;;."**UN4AF@20"59O$*Q3RH`]5HY.FH!#K\!/B-L#KG:^[>QNH\G
MENMMQ93LCN;K?*KCX<?G\=D<%U=W!O'8."J):3<L&2,&2J\;M6">H>-U4SR2
M:5"$*)!Y8Y2Y0Y(LMPV_D[EJ#;K>[DC>81O,^MH@X2IFDDII#MA:5KGJ#?<_
MWE]V?>O<=AW3W9Y\NM\N]KAFBM3+%;1>"D[(TH`MH8=6LQIE]1&G%,]6)?W,
M['_Y_1G/_0*V'_\`6;V?]1MU[^YG8_\`S^C.?^@5L/\`^LWOW7NO?W,['_Y_
M1G/_`$"MA_\`UF]^Z]U[^YG8_P#S^C.?^@5L/_ZS>_=>Z179>S>Q%ZW["+]Q
MYN=1L;=VJ([,V,H<?W?R/IU1XA7!)_H1[]U[H.OBOL_L.3XO_&Z2'N'-4L4G
M0G3[Q4R[.V0ZT\9Z]V\4A#S8AY7$2D+=B6-KDW]^Z]T/7]S.Q_\`G]&<_P#0
M*V'_`/6;W[KW7O[F=C_\_HSG_H%;#_\`K-[]U[KW]S.Q_P#G]&<_]`K8?_UF
M]^Z]U[^YG8__`#^C.?\`H%;#_P#K-[]U[HHWSQVEOZG^(W=DM7VWF*Z%<!AM
M5-)L_94*O?>&W+$O3XJ-P/\`8_GW[KW1NWV9V-J:W<^;4$DA1LO8I"@\@`MA
MR3;_`!]^Z]UQ_N9V/_S^C.?^@5L/_P"LWOW7NO?W,['_`.?T9S_T"MA__6;W
M[KW7O[F=C_\`/Z,Y_P"@5L/_`.LWOW7NO?W,['_Y_1G/_0*V'_\`6;W[KW12
M?EAM'?T4_P`7?/VSF:TR?+WJ%(6?9^S8S32?PS>O[ZB#%)KT_P!&NO\`A[]U
M[HVYV9V.#;_31G/_`$"MB?\`UF]^Z]UU_<SL?_G]&<_]`K8?_P!9O?NO=>_N
M9V/_`,_HSG_H%;#_`/K-[]U[KW]S.Q_^?T9S_P!`K8?_`-9O?NO=>_N9V/\`
M\_HSG_H%;#_^LWOW7NBO[_\`@3MCLSL.G[5W7W-WBV^J&GR-'B\MM[LG>NSZ
M/"469@Q-/FJ3`X+:FYL/@<)29J/`T9K(Z:FC6I>G1I`S`D^Z]T9BFV+V'24\
M%+%W3N$Q4T,5/$9]H[)J9S'"BQH9JBHQ4D]1*44:G=F=SR22??NO=2/[F=C_
M`//Z,Y_Z!6P__K-[]U[KW]S.Q_\`G]&<_P#0*V'_`/6;W[KW2EVU@]SXB6K;
M/;YK]W1SQQI305F"V]B%HG1F,LJ/A:.DDG,BD`B0E1:XY]^Z]TK_`'[KW39F
M_P#BRYC_`+561_\`<.;W[KW6I5[]U[K_T]S3X(?]DL];_P#49O[_`-^+NOW[
MKW1O/?NO=5U?S(?Y9?0/\S?JW9W7W<F8[#V#N;K#=Z[[ZE[BZ@W%'M3L[K7<
MLE(<?D:G;V8GH\C2&CS&/(CJ8)H'5FBBD4I)$C#W7NJ)OE5\&_B7T+C_`('_
M`/"?GJ7=7RBZ@VE\TM_]D]Y]I]\[`WQ@JC>?;5-UYMK*UG8^UNY<AD5H)\M'
MV,7HA&U/2S4-"M!!&:.6,-[]U[K:7Z*Z2ZW^-O3?6G0G3^WX]K=8]2;.PNQM
MDX&.5Z@T."P5(E+3?<U,G[M77U15IJF=O7//([MRQ]^Z]T*_OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z!R/X]=%P]>=@=20]2;`AZQ[6R.\LMV5L.';6,CVKOK*=A
MSRU6^\ANC#I`M'F*O=T\[OD'F5FJF<F35<^_=>Z*#C/Y/'\JO#97'9O$_P`O
M3XAX[,8?(466Q>3H^C-AP5U!D\=4Q5E#7TU3'AQ+#54E5"DD;@AE=01[]U[H
MR??7P^^*GRFGVK5?)/XZ=,=Z56QJLUVSJOM3KK:^]:O;50TB3.V&J<[C:R>A
MCEE16>-&$;L`2I/OW7NAMK=G[2R>U:C8F1VMMVNV/5X-MLU6S:S"XVHVK4;;
M:C_A[;?FV_+3/B9,(:#]C[4Q&#Q>C3IX]^Z]T#_0'Q0^,GQ3Q&<P'QHZ!ZBZ
M'P^YLG_&-QT'5.P=M[(ASN2$:Q1UF7.!Q]))D)(8UM'Y2PC!.D"YO[KW317?
M##XC9/O>E^4&1^-'1E=\BZ)8A2=V576&T9^S('@A:F@J4W=)BFS(K8*=M$<_
ME\R)8!@`/?NO=*#O_P"+GQO^5>V,;LSY+=%=4]\;5PV3&8P^![6V/M_>V.Q.
M5\?A;(8R#/4-8*"JDB.EWBT%U`#7`'OW7NA5VAL_:77^V,%LG8FV<!LS9VV,
M;3X?;>U=K8F@P.WL#BJ1?'38[$8?&04U!CZ.!?TQQ1JH_I[]U[I1^_=>Z"W?
MG_'Y=*?^']G/_?9;Z]^Z]T*7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7ND]NS<N,V9MG.[LS;3KB=NXNLR^2:FA,]0*.BB::;P
MPA@99="\"XN?;T$+7$T4$=-;&@K@?G\NFIY5@BDF:I51Y9)^0^9X=53_`!V^
M<GQIWA\K.\ZW;W85#7CN>'J*FVK`/%#-0+UYM?-8;<M9N1JB:.##T-/7Y&()
M*7=64ECIM["^T\Z<A[_<75CL'/FU7M[!"\KQQ2DLL<=/$<ZD5=*UJ37J6.;/
M8CWTY"VJRWWG;V<YAVK8[FYAMXYY[8"-Y[BO@1+H=V+RT.@!36G1_P#<7RF^
M-.TE=MQ=^]08HQW\D<_8>UWG31]=5/!DY9Q;_@OM!>^X7(FW!C>\Y;9'3B#<
MQ5_8')_ETYL_L3[U\P,B[/[3<Q3UX%=ON@IKZ,T87^?0!;B_F@_`G;"2-6_)
M;85=)"2'AP!RV?EN#8@+B<;5JS7_``"3["=Y[\>TEDH9^=+:0'_?0DE_XXC=
M2ULWW&OO8;X4%M[*;M$C<#/X4`_ZJR)3]G0)9C^=-\'*(L,'N#LO>[J0$7:?
M6.XJGR_6QB;*Q8H$?TO;Z^PG<?>B]J8W9+2[OKIQY1VSC_JYX?4F;=_=I?>B
MNM)W7:=DVM2,_5[G;K3[?",O2+G_`)Q&*S3A.L?AM\J^Q1+_`)B:FV3+BH)+
MCT,\@@R8C0DBYYM[*V^\M;73A-B]M-_O`>!$-!\OA$G0EB_NZ+_;%U<\?>/Y
M"V<K\0:]$K#UH-4=3T@^S/FI\O>Z-@[QV=+\".T^JM@[CV]E*7+=E[FS4Z56
MV8XJ22KH:J'%1X2CDJ:FIR<$-.H60:3,";@>Q3R7[H^Y?,W,=KMR>TM]M^W3
MPW*_4R.X:)_I9C$RJT2`N90BKW"C$'H#^Y7W:/NZ^VW)UYS$_P![#8M_YDLK
MNP8;9;0!DN8S?VRW"/)XSTC6W:623M-41AY]58_![8_SFW'V[5;<I-X]@=9[
MPRVU:W&[-WWV!356;PFTMQRRT5165=1C:A:Z*7(R;96K2%9([_NJPL+'W'WM
M3LGWH+I>?K3G+=M[LEFV<K:3W[R2PQW'U=J=2K(7'B^`)PI"D@$]9&_>BYQ_
MNZMM3V@W;VPY7Y0WJ"TYL$FYV.Q(EM=W.W_NZ_41O+&L16W^L-JS]]*JN#U<
MOBOY0^`W[6PY_P"6_P`F.]_DGFCHEJ,37[FJ]K;-CF#"1H8,52U60JS3*UU&
MB:`%.-(]GEO]W"TW:5;SW%YXW7>[HT)0R&*$$>BDNP%?X63'D.H@O_[PS=N5
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M`-;U%:M912X^JH\GD.O]R;:R&4QT])4.K4U1+)`2=6G4`1[KW37TKT'UU\?M
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M0`/=>Z&K:>V,;LO;>'VKAYLU48O!T:4%%/N+<.=W9G)((RS*<EN/<^0RN?S%
M22YO-55,TI%@6L![]U[I0^_=>Z][]U[KWOW7NO>_=>ZKQ[MZ^WQE_EITSMK%
M?)/Y$;'VCVMLON[<6X-H[+W1LJ@P-!D>M8NI*?;PP*Y7K[-9/&TLO]Z:V2IC
M-5)YY9020%51[KW5@]-"::FIH#//4FG@A@-35.LE54&*)8S/4NB1(]1,5U.0
MJ@L20!]/?NO=9_?NO=>]^Z]U[W[KW7O?NO=-F;_XLN8_[561_P#<.;W[KW6I
M5[]U[K__U-S3X(?]DL];_P#49O[_`-^+NOW[KW1O/?NO=5[?.?N3^89TM4=<
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MLQ`!/OW7NBT?%3YF=`_-#JG<G>/06[O[S=3;<[#[#ZY_OY60QXO;V=KNLLD^
M+W'N7;]=-4/'7;,EGC=Z3(.8DJ(%,ND(03[KW1`^I/Y]OP![E[XVITGMFO[N
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MY>EW!514$TZPOCXJJ0*U0$#.ONO=&*^<7\TKXT?`W/\`7^P>PL3W-VYW!V=B
M<GN;9_1_QJZMS7=';%;LK"S)39??M9MC!20+BMG4-8ZP&LJ)XQ+,2L2R:)-'
MNO=&/^)_RRZ-^;'2>V^__CUNN;=77NXZG*XHG(XG([>W)MK<VWZV3&[EV=O#
M;.8@ILMMO=>W,E$T%91U$:LC@,I>-D=O=>Z,A[]U[H+=^?\`'Y=*?^']G/\`
MWV6^O?NO="E[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZZ9UC5G=E1%4N[L55555NS,Q(`4`7)/`]Z)"BIP!UL`L0J@EB:`#B3Z#JI+Y
M*?/K;N_-[S_$'XO[.R?R'[(W8\NW.Q<UM!TJ-F]:[<JR:3-Y"JST<BXVNRF/
MC8W_`'HZ.!A9Y6?]HPM<^^NU0\^;'R?R?M<V]7_U2B[>W`:.WAK25@]0CNHJ
M<LL:D49]5%ZS-V#[EG-#>S/-7O'[O<R6G)W+R[>[[5#?EH[G<;O3JMX_!TM+
M%#(P&1&\S@U2,+W]5U?&;^4I68OY#]@[0WOO.@W=M_9>)P>#[:V_3QU.!:LV
MUVWC:G-T:;?S='/-4S5D%'B726RPZ7(TL0;^P]R-]V/E7DW=>9-QO.;[C<;3
M<=LNK.2#Z;Z>JW.FI\5;B0@KI\ESY$=29[S_`-Y)SS[J\J<E[!LGM;9[#O6Q
M[_MNZ6][]>;T++MP<*#;26D2L'UU[GH*9!ZMOVW_`"G_`.7_`+:T/!\=]O9:
M9;7J-QYK=6<>4I>QDBKLY)2W_K:,`^Q'9?=[]H;%5"\HQRD?[]EG?]H:33_+
MJ*MZ^_W][?>]2R^\5Y;Q'\-O#:P`5]"D`;_C70^;9^&7Q,V:4;;?QQZ;QK1D
M%'78.WJE[C@,9*RBJ&=A^222?8LL?:[VXVTJ;+DC:T(\_IXR?VLIZB;>_O)>
M_P#S&&&]>\O,DX;B#?W"C]B.H'Y=#9AMA;%VYI&WME;2P.GA/X-MO#8O0/I9
M/LJ.#2+?T]BFUV;9[*GT6TVT-/X(D3_CJCJ,MSYKYJWK5^^.9=PNZ\?&N9I:
M_;K=NE8+*`J@*H^@4``?ZP%O9D!04'#H@.34\>O'D$'D'@@\@C_$'Z^]]>Z*
M1\?54=Z?.;TKZ._.N@GI!T`_%7H$D+QZ022>/R3_`%][J?4]:H/3HV_O76^O
M>_=>Z][]U[KWOW7ND;OW:55OC;%=MNBWKO/KVHK'I73=6P*S"4.Z*`4U1'4-
M'0U.X,%N3%)'5I'XY1)1R$QL0I4V(]U[H(_CY\<,=\=J'/XG"=L]S=AXC/YG
M/[B;%]I[AVQGJ7$Y[=>Z,UO+=&5P[X+9FV*N"ISVX=P5,\ZRRS0KK"Q)&H`]
M^Z]T8[W[KW7O?NO=>]^Z]U[W[KW0+][U';^-V)D\[TYN;KW;>;VY09G/9-NQ
M=E9_>V,R>-Q6'K*U<=1TNWM[;(JL;52U4"WJ&FJ%$=P(B;$>Z]TDOBIN7NW?
MG46RNR>Y]P]9YBM[*V+L+?>#QG6VR-R;.I=MT^Z]LT6?KL3D9MQ[ZWK-GI*>
M?(I'%.@HO3&2T9+>GW7NC*^_=>Z][]U[KWOW7NO>_=>Z(K\_,9OO$=%;U[6Z
M][P[;ZEW'L#`4SXVCZ_K=E)@LK49+<V%HGJ\_C]V;'W7+6U-/2U4D<7CE@15
M:Y5B`1[KW1K^N=D5G7VW%V[7]@;][+J%KJNL.YNR*[`Y'<K)5F,KCS4[;V[M
M;&F@HPG[*_:^0:CJ=OQ[KW2[]^Z]U[W[KW7O?NO=>]^Z]U7W\V>N:;.[A^.F
M<@WUW+M*KW3\A.L>K]PTW7?='9G7F(RVS<U!NZNRF/K,+L_<V(Q;U-;-2Q:Z
MP1+6:(U42A1;W[KW1XMI[9H=F;<P^U<75YVOQ^"HTH*2LW-N'-;KS]1#&S,)
M,IN/<5=DLYEZHEC>:IGEE(L"W`]^Z]THO?NO=>]^Z]U[W[KW7O?NO=%'[._[
M+*^)7_B+?E?_`-#]">_=>Z-Q[]U[KWOW7NO>_=>Z][]U[KWOW7NFS-_\67,?
M]JK(_P#N'-[]U[K4J]^Z]U__U=S3X(?]DL];_P#49O[_`-^+NOW[KW1O/?NO
M=%V^6?R<Z[^&?QU[3^3O;-#NS(]=]0X&GW#NFBV-A4W#NNHH*G+X["QKAL-+
M6XZ*NJ/O,K&6#3Q*L89BP"^_=>ZT^OC3_P`*K^FZGYT_,F;O#*?)3>'Q+WUD
MNF,9\/.N*#HO9DVX^NISAXZ#L4[TIJ',4&7ITS.Y9DGION:[)L8A^V(^%]^Z
M]UNV[5P&V-LX&@Q6S=NX7:NW566NH<)M_#T&"Q=*^6GDRE7+%B\9!34<$]96
M5<DTY5`9)I&=B68D^Z]TH??NO=>]^Z]U[W[KW7O?NO=`E\@?CIT_\INOFZG[
MVVF-]];56X,!N+,[,JLKF<;@]S3[<K1D,=BMU4V'K\<=Q;8EK%5JO%U;2T%<
MJB.HBEC+(?=>ZH(^,6.J=G_R;/YNF(ZPQ-'MU]M=R_S6\;LW";9H*?$X_!46
M,R&]::@Q^"QN.AAI<=28^ABT010(J1JH"@6]^Z]T^_-_`]68O_A.KTK'L6DQ
ME/@-M]0?R[LWTG+AZ6B\U'O2/LKH*39F1P`\2-!FJS(5K^6:!15,M1.>69@?
M=>Z-E_+BI<74?._^=)F<K%!)V6WRSZ7P>8J)TUY*'K?'_&+K>7K.B2:2(3+A
MC#4Y"2!`QB,C2,`&O[]U[JG+9>.VI-\7/C5M"M@IV^/,?_"E[?\`@J/'5=+2
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M3_\`.2Q6V%,&RZ7^8)3UE'2P004V+IM[9CX_=29#L<8^*D5:42SY^59:HC]U
MJIW:0!R;^Z]U<963R4U)4U,5+/72P02S1T5*8!55;QQLZTU.:F:GIQ43D:4\
MDB)J(NP'/OW7NBU;VW[N&7=G3\K=1=B0M3[XS,D<,M1L/R53GKC>T1A@\6])
M8Q(B2&0^1HUT1M8EK`^Z]T)7^D3<O_/F>R__`#HZ]_\`LY]^Z]U[_2)N7_GS
M/9?_`)T=>_\`V<^_=>Z]_I$W+_SYGLO_`,Z.O?\`[.??NO=>_P!(FY?^?,]E
M_P#G1U[_`/9S[]U[KW^D3<O_`#YGLO\`\Z.O?_LY]^Z]U[_2)N7_`)\SV7_Y
MT=>__9S[]U[KW^D3<O\`SYGLO_SHZ]_^SGW[KW7O](FY?^?,]E_^='7O_P!G
M/OW7N@U[:^4NU^B=D97L;MO9F\MD;.PR`U>5RM;U_KGF>_AH,;0P;WEKLME*
MEEM%3T\<DKGZ"P)!#S)S/L/*.TW.]\Q;E':[=$,LQRQ\E115G=N`502>AM[>
M^W'.WNMS3MO)?('+UQN7,5TU%CC&%7\4DKFB11(,O(Y"@?.@ZJ2W5VM\P_YG
MTK8OIO:N_P#H7X25%?+CMP;ZH/X)1=J=J8Z&XJ:?%PY;.X2./$UHO&8J69J6
M,FU1--;Q#&-]U]P_O"326FP>-L'M6&*R7#8N+Q1@JE#E6_A4^&/]$=S5!TDB
MY7^[_P#<(M;?=.?$M.>_O0:`\&W(0VV[0Y%5>=B"#(AH0S@RM2L440/B=68?
M'#I[KOXI[&@V)TW\;>P,%1E8Y,UG*B?KJLW3NJN1;-D=QYM][BIKZAC<J@T0
M1`VC1!Q[R&Y(Y`Y7]OMJ7:N6MO6)#3Q)#0RRL/Q2/Q8^@%%4850.L!/>;WU]
MR_?OFB3FGW'Y@DNK@$B&!:I:VJ'_`$.WA!TQJ/-LN_%V8])'J/?>?B^6'S%F
MCZG["J'GQWQK\E+%-L45%+HV'N>PG,F\TA.N_&AW^AO;CV-.H@Z-K_I$W+_S
MYGLO_P`Z.O?_`+.??NO=>_TB;E_Y\SV7_P"='7O_`-G/OW7NO?Z1-R_\^9[+
M_P#.CKW_`.SGW[KW7O\`2)N7_GS/9?\`YT=>_P#V<^_=>Z:<]W!7[7P>8W)G
M>I.S*#"8'&5N8R]:J[)K32XW'4\E76U(H\=O&KKZHP4\3-XX8I)7M958V'OW
M7NB`_$[YA;`[`^0'RRQVS-F=K9G(=B=I[2WIM*FJ=DUFVX<SMG;_`,>.F-IY
M?*T>4W9)@<-+!29_`U5,P%07,D3*`2K`>Z]U8I_I$W+_`,^9[+_\Z.O?_LY]
M^Z]U[_2)N7_GS/9?_G1U[_\`9S[]U[KW^D3<O_/F>R__`#HZ]_\`LY]^Z]U[
M_2)N7_GS/9?_`)T=>_\`V<^_=>Z]_I$W+_SYGLO_`,Z.O?\`[.??NO=>_P!(
MFY?^?,]E_P#G1U[_`/9S[]U[KW^D3<O_`#YGLO\`\Z.O?_LY]^Z]U[_2)N7_
M`)\SV7_YT=>__9S[]U[KW^D3<O\`SYGLO_SHZ]_^SGW[KW7O](FY?^?,]E_^
M='7O_P!G/OW7ND3V7V!N.3K?L.-NG^R(5;8N[P9I)]@%%_W[N1-V";W=[7XX
M!/OW7N@[^*V_]Q0_%[XVPIU#V-4I%T'T]&M1!4;"$,ZIU]MY5EB$V]HI@DH&
MI=2*UB+@'W[KW0]?Z1-R_P#/F>R__.CKW_[.??NO=>_TB;E_Y\SV7_YT=>__
M`&<^_=>Z]_I$W+_SYGLO_P`Z.O?_`+.??NO=>_TB;E_Y\SV7_P"='7O_`-G/
MOW7NBC_/'?>?JOB+W;#-U+V'0(VW\,?N*J;8C0J1O#;?#_;;SJ)A_7A#]/?N
MO=&[?L/<@=@.F^RF`)`9:CKZS`<7%]\WL1[]U[KA_I$W+_SYGLO_`,Z.O?\`
M[.??NO=>_P!(FY?^?,]E_P#G1U[_`/9S[]U[KW^D3<O_`#YGLO\`\Z.O?_LY
M]^Z]U[_2)N7_`)\SV7_YT=>__9S[]U[HI/RPWWGZB?XN&7J?L*C,'R_Z?E1:
MB;8K&I88S>H\,/@WG,!*;\:]*_[4/?NO=&W/8FY;G_C#/9?U/_*1U[_]G7OW
M7NNO](FY?^?,]E_^='7O_P!G/OW7NO?Z1-R_\^9[+_\`.CKW_P"SGW[KW7O]
M(FY?^?,]E_\`G1U[_P#9S[]U[KW^D3<O_/F>R_\`SHZ]_P#LY]^Z]T4_LK?F
MX)/F#\4YVZE["BDAZP^5*QTCS[$-14"5NB2TD13>;P!83&`VMT-W6P/-O=>Z
M-A_I$W+_`,^9[+_\Z.O?_LY]^Z]U[_2)N7_GS/9?_G1U[_\`9S[]U[KW^D3<
MO_/F>R__`#HZ]_\`LY]^Z]TIMM;FR>>EJH\AL?=.TUIXXWBFW!)MMXJQG9E:
M*F&"W!F9!)$!=O(L:V/!)X]^Z]TK??NO=-F;_P"++F/^U5D?_<.;W[KW6I5[
M]U[K_];<T^"'_9+/6_\`U&;^_P#?B[K]^Z]T;SW[KW1$_E]_,8^'7P;W3U/L
MWY=]CKU#B^\5W-3[*WSNO:V>K.JWR>U6Q#9#`;IWKC\9D<%M/*S09>.>F7)M
M3P3Q12E9+QD>_=>Z)1\9<'_*^ZD^6'RT^=NQ_GG\=]X9;YT4/467R^U<WW/T
M-!M#:-#USM<87`U&S8H\K19R+^,T4PFJ5K&9Q+^%(L/=>Z-KT[_-8^`OR*^0
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MFAV]0;[P^4QV3H7W!M^@J)*2BRU.L=7#2E8_4$6WNO=#1N#^5O\`$//_``-Q
MO\ND;/SF)^/N!P^,I]M5>+W'64_96WMXX7/?WPQ?;&-WXROE%[2I]ZELPV58
M,\M;(^M#$[1^_=>Z#KX4_P`JG:/Q.[>R_P`C.RODO\E?FG\B9]C/U1M'MOY0
M[RH-T97K/JF:MH\I6[*V#B<5C<;B\,N;RM$D^1KBKU=994+*@96]U[HMV;_X
M3_?'?+]D;B6G^1GRRP7P^WGVI/W9O/\`E[X3L]:+XM;A[#J\ZF[,CY<(,>^?
MHMD9;=D,>0JL#!5I12RJ5&E&TCW7NC1?-K^5ML?Y:]C=>=\===_=_P#PO^2'
M6VSZWK'&=X_%_<]!M/<>?ZER%4V1EZSWAB<ACZ_"9_;E!E3]UC]<:2T,S/XV
MTM8>Z]T93X6_#3J/X*](4'1_44NZ\S12[BW#OO?._P#L+/S[L[)[3[+WE6G)
M[Q[$[!W/5)'-F=R[@KB"[A4BBACCBC5411[]U[HV7OW7N@MWY_Q^72G_`(?V
M<_\`?9;Z]^Z]T*7OW7NO>_=>Z][]U[KWOW7NO>_=>Z*+7?/#XEXW>,W7]=W#
M04^]8*BKIWVT=J[[?*7H,I%A*VHB@CVN_GQU-EITIWJD+4PD=1Y/4+^Z]T;D
M$,`0;A@&!_)#"X/]>0??NO=5[?+[^8?UC\9:REZWVMBZ_NOY%[B9:/:G2VQ]
M>1RZUU8-%%/NJ>AAJVPM&SL&$(1ZR9!Z8PI\@A?W)]Y]BY%E78]NA;=.=)NV
M*RAJS!F^$S%0Q0'R0`R,."@=PR^^[O\`<^YX][K:XYSWZ^BY9]G+,%[K>;VD
M<11,NMJKE!,],:ZB%#\3ENPEBZF^`O;WR<WOBOD7_,DW`NZ<G3.F1Z_^,F&J
M6BZXZ_I)&$U-#N*EIJB2GKZY$"^:F5Y3(W_`J>8WB`%Y<]H.9.>]TM^=?>V\
M\><=T&V(:6\"G($@4D$^J`DD_P!K(_PB;_<#[V?MY[(<L;A[.?<OVDV-BZF.
M_P"99E!W&_<=K-;LRAHT)KHE(4*/["*/#FYK'X_'XFBH\7B:&CQF-Q]-#1T&
M.Q]-#14%#24Z+'!34E)3)'3TU/#&H5$10J@6`]Y.000VT,=O;0K';HH554!5
M51@!0*``#``P.N;5W>7>X75Q?7]U)/?3.7DDD8N[NQJS.[$LS,<EB22<GJ8V
MK2VFVK2VD'Z%K'2#]."WM[I/U2;\:]W?S$JGYV?(:FWSU5T1C=AUV8Z&I^S<
MGALQ4S9O$;2AVANF/!5V!@._ZX2Y.JH1KE5X*@!_I&HX]^Z]U=G[]U[KWOW7
MNO>_=>Z][]U[KWOW7NN1U?G5;_&_OW7NN/OW7NO>_=>Z][]U[KWOW7ND9V!@
M]X[BVO78G8>^CUQN:HDI#0[N&V,5O`X^.&ICDJHQ@<U+#CJK[RG5HM3M>/5J
M%R/?NO=%D^&&8[PW?L_=>\>XNXZ3LRW9';NP,+BZ'K';O7U/AX>K>WM\=?4N
M5:?#93)U.2J\[B=MT\U0DC+%%.[^,!;#W[KW1SO?NO=>]^Z]U[W[KW7O?NO=
M(7M'_F678W_AA[P_]Y[(^_=>Z#OXG@CXL?&@6((^/W3=P001_P`8[V[]1]1[
M]U[H?O?NO=>]^Z]U[W[KW7O?NO=$^^?:L_Q`[M506=\'@HT1`2SR/O+;:QHB
M#EG=B``.238>]JI<A54LWH!4_L'6B0,G`Z.&_P"H_P"P_P!Z'O76^NK'^A_V
MQ]^Z]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]UTWH4LY5%479F9551_4DD!1[]U[JJ
M?^8E\P_C1T=OCX@["[4[<VKL_=67^3_6N[*/$U]=$U0,-AJ/<=++/41Q.SP/
M4SY.,0H07=5=@-*\G&W['>[C"T\6A(ZZ5UG3XC\=$=?B:GY>1-3TFFNXH7T-
M4GB:"ND>I]!T?C-?(;H#;D"5>X^\^GMO4\T,=3%/G>S-EXB)Z>92\,ROD,U3
M*8I$!*M]"`?90RM&SHZ$.#0@X((\CTH!#"H-0>@!W9_,O_EW[%21]U?.+XIX
ME8E+R:N]NN*M@J1"9B4H-PU3FT9!^E_>NM]%OW)_/D_D\;4$O\3_`)@_QVJ9
M(6*/#@-T56Z)@ZRB)U$>W,=E-15SS_@"?H#[]U[HMNZ?^%07\E':Y=/]FWGW
M'+'_`+HVKT_W#EQ)992/'4C9$%$Q)BT_YV]V7\&_OW7N@0R?_"M/^5`C-#M2
M'Y5=AU!#"GCVC\?,N5J7"AE2-LYF\++Z_58Z#^@_BQ/NO=%?WO\`\*&\+NK^
M9S\1=H;2^+_;5?UKF>N-PQ8?*9#;E;%O&2@[BBVO59+(18BE^X@>>A3:M"DT
M0D<4<P\+EFF)0:0;!9&*UL)=;;C<1>*LR_V*"E0I_B'$2/\`@-!3!Z+'O)OU
M)UH(4;25/Q'Y_(_PCSZW!Z6H%72TU6D<\*54$%2D-5$T%3$L\22K'50/ZX9X
MP]F0\JP(/L%L-+,F#0TQPZ,P:CJ1[]U[KWOW7NO>_=>Z][]U[ILS?_%ES'_:
MJR/_`+AS>_=>ZU*O?NO=?__7W-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]^Z]T
M'O:74W5_=VR<UUMW%UYLSM'8&XJ62DS>SM^;<Q.Z=O9&&6-XB:C%YBEJZ7S(
MDA\<H42Q-ZD96`(]U[JG'<W_``FN_DJ;KW/7;LK?A%M7&UM?5T]9-C-L;_[:
MVMM>&2GCA01T6U=O[ZQ^W\=2R^`&2""GCB=F8E?4??NO=6G?'KXH?&?XF[6D
MV7\:.B.K.CMM5#:ZW&];[-PNV6R;_<5%4CYBOH*6/(YF2*>KD9&JIIC'K(6P
MX]^Z]T8+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U%2NH9:N:@BK:22NID$E
M111U,#UD$3:-$DU.KM/$C>1;%E`]0_K[]U[KU5745"(FKJRDHEGE6"!JNIAI
MA-,WZ88C,Z"29OPJW)]^Z]U)=DB5Y)&6..-&>1Y&5$C1`6=W=B$5%47))L![
M]U[K!2U=+74Z5-%54]932:A'44D\53"Y1BCA9H6>-BCJ0;'@BWOW7NN)K:(5
MB8\UM&N0>(S)0FIA%:T(O>9:4OYVB!4^H+;CW[KW7=76T>/A-37U=+0TX94,
M]940TL`=[Z4\T[QIJ:W`O<^_=>ZD`A@&4JRL`RL""K*PU!E(X*D?0CW[KW7?
MOW7N@MWY_P`?ETI_X?V<_P#?9;Z]^Z]T*7OW7NO>_=>Z][]U[KWOW7NN$DB1
M1O+(P6.-'D=C]%1%+.Q_P5>?>P"30<3UHD`5/`=5C5?RN^/LWS*V[O"/M?;)
MVY0?'[?'6];(:V05=-OC)=G[%SE)AGPIC_BAGDP^"JIFD6$QHL5F8$@%OQ]O
M^N;:_P!^;=^\PQ4P?5V_C!QQ3PO$\36*&JZ=5<4Z./ZM\W'9X^8OZD[Y_5YH
MED%W^[KP6IB8@+*+@P^#X;5%)->@U'=T`/8GS;[\^:F\,ST+_+GQ$^.VG0U;
MXOL;Y:[DHZFAVSMRG8M#51;&%1`6EK6C#&*;0];+8&&&-?W_`'BUOGNESA[G
M[G=<G^S%JT>WHVBYW:0%8XQP/@U&"14JU#(V"B*").ND?)GW9/:7[M7+FW>[
M/WQ]Q2??IHQ-MW*ELZO<W!H&0WNEL)6FM-2PK6DDCG]+HZ7Q`^`W3WQ*HZG/
M8\5G8G=&XEEGWOW1O+_<CNW-UU:?+D$QDM2]2^"Q<\I-XXW::;ZS2R&UI/\`
M;?V@Y:]NHFO8@U[S1,"9KV;NE=FRP2M?#0GB`2S<79CUC3]XC[V7N)]X"YAV
MJ[,>S>VMF0MELUG^G:0QIB,RA0HGE4<&90B<(T0<3T>Y9ZQ;Z][]U[KWOW7N
MB@=.?]E<?-#_`+5WQH_]X/='OW7NC?\`OW7NO>_=>Z][]U[KWOW7NFK.8B'<
M&%RV"JJG*45-F,=68RHK,)E*["9BEAK:>2GDJ,5F<9-39'%9"%9"T-1!)'-"
MX#(P8`^_=>Z(A\6.KHMM=]?*DOV9WQNZBZQ[/VKLC9F$[$[R[*W]MW$[?W#\
M?NG-[9.#^!;GW!D,=75C[GW+75,=34I-40_<%(W5%"CW7NK!/?NO=>]^Z]U[
MW[KW7O?NO==CZC_7'^]^_=>Z*/\`"C_F3.X?_%B?EE_\$UVM[]U[HV_OW7NN
MP"?H/?NO=%V[Q^77Q8^-.+J<Q\@?D1TQTY04D+U$W^D+L7:VVJQH8[ZWI\9D
M<G#DZO3;D10N?\/?NO=4D=U?\*G/Y6'7N5J]I=.;C[C^7>_E9J?&;8^.O5&X
ML[39:NU%8J.CW!N:/;6,JON&%DDI15(U^/S;W7NB9?(C^:-_-\^;GQ;^0H^,
M/\L7O+XE[0@Z^J\OMCM?NAY8=R;LP@D,&?Q=-@JW%;;J,)D6Q4C2(L$60ADT
M,LT\,6K4(N71;>/<$Z#N>G_%P_\`9E_Z5<:A^`-VEN/2*],@5`*^`3WD?$!\
MOEZTS3J3\:*[_A4'D_B/\9:KH^+X<4-,.NA2[AI/D53Y"/=OCIJO3MBJHI<2
MQ\E#/@60%'41Q%`(6>$H1KF-;=;FV)TC<RG^,!*>&)*^5,:B/C"]H:M//KUD
M7*-Q\"O83Q(_S>E<TZ%N/"_\*\<J;U&]/Y86UO`+*M)C<[D!6Z^2TGW&&R9B
M,6D`6*7U?GV'NEO67^Y?_"NA_0>Y/Y:,0?T&5=M9)FB#>DRJ#M!E+1@W`(()
M'T]^Z]UD_P!!W_"LK_O,?^7Y_P"B[;_[6_OW7NN2_&G_`(5;YTF6O_F!?!7:
M+4]HXZ?%]515\=8K78SRM-U/5M&\9](`*@C\>_=>Z)__`#'?BC_PHIF^%N5H
M^T_EYU#VWF:'M3:N8R%7T_AJ78E/B]H"6BHJ./((FS-JLTD6X9A))/*E7%XF
M$0$3-Y"*^7YXTM[B&RGCM][9@5DD("F,?$BL<(WF21W+VBGF77RDO&TL9>U`
MRJ\=7D2/,>GH<]'(KO@#_P`**][X;8M3MK^;+UUT1AH^NMEXC);$FZFQ.Z\[
MA\W2X2EI=QSSYI]ESU,]2]6A>)9,C5RH3I,XMP5;Y+8R[C/)MZ@0D"I`HK/3
MO9%_"K'*CR^7#I1:K*L"B8]WEZ@>0)\R!Q/37%_)\_GO9R_][?\`A0/O['J2
M*8C9W3B41%$W^=E4TNX,`PKP6.E@0PL/6/P4]*>IK?R&?YE^X`8]]?\`"A+Y
MG96*8?:U28/:^4PODQC?YV"-CV[5".I8NUI+&UQP;>_=>ZB2_P#":SN;/W;?
M7\[[^9+G6EM3U0Q&]*O!)-CD(9*90^[LH(9KDWD(8&_Z?Z^Z]UZ'_A+!UC7D
M?WW_`)G7\S'>RR/HK8\GWA3QI6T:@>.CEUXVK;QQD7!N?]8>_=>Z#7Y)_P#"
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M)L018KP>/:?J_1B-K?R8/Y4&RV1]N?R^OBU1R(`J35756W\O.0(S%>2?,P9"
M65S&2"S,23R3?GW[KW1F-M_"/X9;.6)=J_$KXT;?,%C%+B>C>LZ*H32ZN"*B
M';"U%Q(@8>K@@'\>_=>Z'#"=?["VS$(-M['V=MZ`!0(,'MG"XJ$!=6D".AHJ
M=++K-N.+G^OOW7NB@=I=<=?R_.SXH;NFV3M:;=$_5_R->3/RX/'R9;R;4?J#
M^[DR5C0F6*;$+N2N$+@AU$Y%_2FE;'NE_'92;='=,+-S4KY?YP#Y@&A\QTT8
M(6E69HP91P/^K^7IT>WVBZ=Z][]U[KWOW7NO>_=>Z][]U[ILS?\`Q9<Q_P!J
MK(_^X<WOW7NM2KW[KW7_T-S3X(?]DL];_P#49O[_`-^+NOW[KW1O/?NO=4??
MSDOEO\M>HLW\*_B1\(M[=7=-_(+YT=N;OV)A.^NY:.ER&Q^K\%UQM)-WY@08
M_(XO-XW([JW6\\-#00RT58\A+1Q0M-)&\?NO=5'3-_/P^7^'^1&ZM_\`SJV7
M_+PRO\M";)=99R3:_6U;2=6?+_LC8V,K]Y9?O+<6Z-T0;=QV,ZMW?A4Q=+'3
MP4V1Q<$C57^1QDM$?=>ZV,_Y67RQWA\Y/Y?GQ>^4_86WJ3;.^^V>NHLEO''8
MREFHL--N3"Y;*;9R^:P-+4232PX+<-;A7KJ1=;!8*A5#$`$^Z]T?_P!^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW2,[&DST77F_9=J9S#;7W1%LO=4FV]S;B\7]WMNY
M],%D&P^=SWF98?X-B,B(ZBJUD+X8VN0/?NO=?/H^,^2^,--O[X4[QZ0W+\J]
MC_S7]T?*KK[$?('YT=M=NY^L^&7>1.]ZZ+OO$X_M?*[MDZ6[GV)V;@L=546S
M,#@**/)U=1+1PZM=/,6]U[J^W,?`[I_^<'\\OY@F?^9^9[4W9U3\/^Q>O/C%
M\8^K-F]J;SZVVUUWFH>I]L=A]C]N)3;*RN(FRG8F8W5O)$I*NL>>"&CI4C:&
M150)[KW15<!F>\?D[\:O@[_*\[4[Q[3JMN[H_F'_`"V^(7R$[7QN[*G"]O\`
M<'QE^$46\]R8?:V;WQCI7R--E^Q<)#M_'YJL@D6HJ::&:Y#2./?NO=':^-/0
MFQ_Y3'\QS+?&+XVU_85'\0._OA)V1\BJ?I7>78&Y^P<%UIW1T'O?"8W-YCKW
M([QR^:W%B:+?^U-VZLI323R1RUL"2*P`6-/=>ZKDQ/\`+NQ?;'\L?=_\ZG.=
MN=[)_-"RO7G8GS:V9WKANWMX8W&;0&T\OG=[;+Z-Q'7L.9I]A?Z(%V/@X<)4
MXZ6B:1X:F:TH72@]U[HZFY>A-C?SJ?F_4[$^7==OG.?%OXZ?!_XJ]LX/H'9O
M86[>N=J;F[Z^5F'S6^,WO[=]3LG+83.YN3:&T\/2T&)B-6D5.\LS$'4P;W7N
MCN?R>X]V]44_S<^$N<WMO7L;9?PE^5V0ZUZ/W3V1GYMU;ZAZ0WYU[LWM39&T
M-P;DJ99*O.'8\FZ:O&TE1/IF-##"C*`@`]U[JY*HJ:>CIYZNLJ(*2DI8I*BH
MJJF5(*:F@B4O+//-*RQPPQQ@EF8A5`N3[]U[HO>^.SNM)MW].2P]B[$EBI=\
MYN:IDBW=@)(J>)^M][P)).ZY`B*-IY40%B`7<#ZD>_=>Z$W_`$J]6_\`/S.O
MO_0SV[_]<??NO=>_TJ]6_P#/S.OO_0SV[_\`7'W[KW7O]*O5O_/S.OO_`$,]
MN_\`UQ]^Z]TR;A[WZ2VEB:O.;F[?ZTPN(H*66KJZ^OWOMR"&.G@4M)(-62UR
MV`^B!F)X`)]E>\;UM'+UE)N.^;C!:62BI>5UC7]K$5/R%3T(N5>4>:>>=WAV
M'DWEV\W3>9&`6&UA>:2I-!58PQ`]2:`>9ZJY[2_G%]69//-UI\4NO-S_`".W
MKDI'QT>;B_WYO7-%K80U%9+GLXE/65]+2QN78K%3PD+?S`<^X&O?O$[?N&ZQ
M[+[:<M7N_P"YB0`NB.ENE"*DL5UD4R"51#_'UG-LO]W]S%R[RW-SE]Y'W'V;
MD'EOP698;B:.;<)CH)6-(4?0K,:"FN1Q7,=<=5(47P*[,A^7F-W#7[IZJ^[R
MV:RO<QVNF],(,I)L*+.T>$S$_P#%TR!P<=735^=AA\?W7E8,70%59AJV^[WN
M4?ONWNQ+SAMIV5MY>]-N!<^-X;NSF.G@^'X@U:3^IIKD-T)]P^_WR?/]S,?=
MEMO;OF(<VQ\HQ;0MZ7L39>/"J*)Z?4>,8"4U`>%KI0%./6TKUM6?'/J/9N%V
M!UON+JC9NTL#3K!CL%A=T[9IJ6%F`,\TS#(-+5UM1)ZI9Y6>65O4S$^YXV78
MMGY<VZWVC8]OCM=MB^&-!0"O$GS9CQ+,2Q.2>N>O-_.?-G/^_P!]S5SKOMQN
M7,5R09)YF+,:"@4>2(HPB(%11A0!TN_]*O5O_/S.OO\`T,]N_P#UQ]FW0:Z]
M_I5ZM_Y^9U]_Z&>W?_KC[]U[KW^E7JW_`)^9U]_Z&>W?_KC[]U[KD.T^KV#,
MO9.P&6-6=V7>.WB$11ZI'(R!"JHY)/`][`)P!U[JM3XV?-OXG[[^:/S<P&V^
M^NN*G+XW_0CC:RFJ]R8S&0QU&T=K9C$98K75]5!12@UV3C6$!P\R`N@9.?9O
M>[#?V-JMS,JE<:U!JT1;*B0?A+#(_8:''2:*[AFD:)*U\C3#4XZ3YTZLLI^T
M>L:M=5)V1L&J6U]5-O#;\XM_6\60<6]D_2GKS=H]8QFTG9&PHS_1]W[?0_[9
ML@#[]U[KA_I5ZM_Y^9U]_P"AGMW_`.N/OW7NO?Z5>K?^?F=??^AGMW_ZX^_=
M>Z]_I5ZM_P"?F=??^AGMW_ZX^_=>Z*?T%V;UK%WC\X9INQ-BPQ57?/7<M-+)
MNW`)'/&GQ8Z$@9X7:O"RHLT+H2I(#(P^H/OW7NC8?Z5>K?\`GYG7W_H9[=_^
MN/OW7NO?Z5>K?^?F=??^AGMW_P"N/OW7NLT?9O6LQM#V)L68_P#-K=N!D_Z$
MKS[]U[IAS/>O1VW(&J-P]S]38*G2^N?,]B[0Q<*V/.J6NS$""WYN??NO=$F[
M\_FZ?`#HK:F]\J/DYTUV5O;9^U\SN>+JWJ_L7:^^]\YF#"TQJ:O[7"[7R&6J
MUI:1;-4RZ"(8P38M928;7MTFYW7TZ,%15+NQ_"BY8T&20.`&2>F+B=;>/7IJ
M2:`>I/`?+J@SXL?\*?OBQL7X?UV_*SX^?(W?N[<M\@NW*3$["ZMVI09RJR&:
M[#WEN7M9Q59#)9:AAQ=&&W+*D'B6L/A15:TP9/:S<]MM([:'<]KF=]N+^&=8
M`=7`KFF"K#N!'#X3GBW!/(9&@N%`F`KC@1_G'`_MZ6[?S@/YX_RZ1U^&O\M+
MISXP;+R:(^)[5^:?=.#I*J"FG#O!DCM*JS'7U<T;0`,5AH,BJL=(9O[1'TKZ
MA5'\N7^;[\OD<_.W^>]LKJ+9N9B1LMU/\,$P.V(8897,DV,&ZZ&JZU9'I[Z5
MEDCR=Q]6/Y]U[H=^D/\`A-E_)6ZVRE/NSM[<>>^7&_BT=1E-S?(CY$+F*7)Y
M$.7FJZC;NT\IM7&U:U+'UQUQK@?Z^_=>ZO%Z1ZI^"?QKPU)@.@=F_&#I[&45
M.E+#'U]1=;[:JG@B;5$E9DL;X<G7E".&GFD;@<\#W[KW0C]F]J=8R];=AQQ=
MD["ED?8F[PD<>\=ON[-_=[(V"HN0)8^_=>Z#SXJ]H]9P?%WXVP5/8^Q(*B'H
M+IZ.>*?>&!CFCE3KW;RR)*DF0$BR(X(8,+@CGW[KW0]?Z5>K?^?F=??^AGMW
M_P"N/OW7NO?Z5>K?^?F=??\`H9[=_P#KC[]U[KW^E7JW_GYG7W_H9[=_^N/O
MW7NO?Z5>K?\`GYG7W_H9[=_^N/OW7NBA_/7LOK:L^(?=U/2=A[%JIWP&&TPT
MV[<#/(P&\-N7M''7LS"W^'OW7NC?/VKU<&(/9?7ZD&Q#;RVZ"".""/XB+'W[
MKW7'_2KU;_S\SK[_`-#/;O\`]<??NO=>_P!*O5O_`#\SK[_T,]N__7'W[KW7
MO]*O5O\`S\SK[_T,]N__`%Q]^Z]U[_2KU;_S\SK[_P!#/;O_`-<??NO=%&^6
MG9?6]5/\6C2]A;&J1!\P.GYYS3[LP,PAA7&;UU2R^.O81QB_U-A[]U[HW1[6
MZM))_P!)G7WU_P">SV[_`/7'W[KW77^E7JW_`)^9U]_Z&>W?_KC[]U[KW^E7
MJW_GYG7W_H9[=_\`KC[]U[KW^E7JW_GYG7W_`*&>W?\`ZX^_=>Z]_I5ZM_Y^
M9U]_Z&>W?_KC[]U[HIG9?9G6TGS$^*%3'V'L:2FI^L/E5'/4)NW`M!"TS=$&
M-99EKRD32")BH)!(4V^A]^Z]T;/_`$J]6_\`/S.OO_0SV[_]<??NO=>_TJ]6
M_P#/S.OO_0SV[_\`7'W[KW7O]*O5O_/S.OO_`$,]N_\`UQ]^Z]T^83=VTMS2
M5$6V]T[<W#+2(DE3'@LYC,M)31RL5CDJ$H*FH:%)&4A2P`)'OW7NE#[]U[IL
MS?\`Q9<Q_P!JK(_^X<WOW7NM2KW[KW7_T=S3X(?]DL];_P#49O[_`-^+NOW[
MKW1O/?NO=$#_`)C/Q8^&OR3Z#FW'\V-O?==:_&7*?[,GC][T-=D<7N3K:OZL
MII=SY+<6$K\2LU;-#/A\9+!6T!AJ(LA3L8S$TGC9?=>ZUG/F3_/E^&_\Q;X^
M;@Z`[$_E@?S5>TOCCOK<.U=RT6Y^K>N*/;M)V!@=E[KH=R[<KL7G\9G:JICV
MQN@8F,5$<3K*]%.\8DCD]:^Z]UM#_P`NCM3KCN7X6=!;XZ@Z#WO\7NL)=HR;
M<V-T-V+MN/:.[NN-N;*R^1VACL-D\!%/5+1I+!A140,9)'F@F21F+.3[]U[H
M['OW7NO>_=>Z][]U[KWOW7NO>_=>Z!'Y+].CY#_'7O;H4[AK-I?Z9^HNQ.KE
MW/0*6J\`^^=J97;<>7B12K3?8/D1(T8*F15*W%[^_=>ZUL,YTO\`S?\`Y"_&
M+J_^4IV5\`^@^F>I-D0])]>[[^>&'[QVAN;K.HZPZ+W!M#+4V]>E.B\?04O8
M6V^T-T8W:M,*)*PK#CJZ>H9O&JJR>Z]T;7M[9_\`,P^!GS'^4/<GPE^(VSOG
M1T9\WY^N-]9;:5;WEMSI/>70O?\`LC8.-ZQRVX<S4;QCEQFZNM-[8?`T&0JU
MH%_B,=5'(@*`*9?=>Z#&J_EH?-KH_P"'WQ1[:ZDEZN[2_F(?&SY9]N_.7L7K
MB;/U>UNJ>X]S?)BHWJ._>CMJ[QK88WP--'M[>45)A,C61I3O58F)Y=*R7'NO
M=&2^'O3_`,T_E%\QMV?/3YY_'3:_Q&QFWOC7EOBMT/\`&O']I8/N'?$>$WMO
M&FW9VMV/V-O;:,,.U5ESLV$HJ+$45*-<5&'>90Y#/[KW5??^RX?SDMF_%K=_
M\F':?QFZFW#\>=Q1;TZ<VC_,?R7=V%H<'M?XG;]W/E:NNI=P]$O35._\AW-M
M_8F:J<13+3LN-:I6%^8U,K>Z]T<SOOHWYR_`SY5X;Y5_`+XVX+YK]9=A?%WJ
M/XO]U?'NM[<V[TKV'@,O\?VRT'4O;.TMU;RAGVGDZ"IVYFYL9EJ.4&I`BB>,
M$'4ONO=&_P#Y7WQL[]Z:V3\@>Y_EC0[,V]\F_F;\@=Q?(CM/877F7FW#L[JJ
MCJ=O;=V3L#J[%;BF1!N*JVCLO:M*E=7H#%4U\LQC+(%8^Z]U9TZ)(C1R(DD;
MJ4>-U#HZ,`'1T8%65P;$'@CW[KW5>OR'W+\A=J=T]#[=V)T=\<]R;8WGVEGL
M!L[-;G[3WEM?-M5T71G9NZJ^;=F$Q'1&Z<?C*):?`UB0_:UU<SRK`S*@9_'[
MKW1X\)@HYL-BI-R;7VGC]Q28ZB?-T.$CCRV&H\JT"&OI\5E*[#8>MR&/AJ2R
MPS34E-)(@#-$A.D>Z]T4KY"_-GX:?&2.>G[-WSLU]SQ@^'8>T<=0;LWO53J2
M@IOX'B(YVQ\C/P#6/3)?^U[C'G'W@]O^1A)'O>_QM?C_`(CP_K35]"B5T?;(
M4'SZR.]H/NF^_?O<\<W)/(-R-C/Q7UV/I;)5XZO'F"B0`9_160_+HBH^2?ST
M^7C?:?$?XM[?^/O6M>-$7>'R!Q5!'EIZ.2Z?Q'`;8DH7@=RK:T$5+DU!`]:^
MXG7W$]Z/<=M'MUR<-GV-^%]?_&5."T:$::^8T1S@_P`0ZRG/W?\`[G?W>%\?
M[PGO"_-_.D63LFP9B#C/ASW(8,!7!U2VQ_HGI=]>_P`G[K_.[CI>R/F+VKO;
MY3]BZEGGHLS5U&W.O:&<MK:DH<)C9H\A44",1I3S4\#@>J"QM[,]H^[K87][
M'O?N=S/>\P;P<E7D=+=3Y@*&UE?D&1#_``#H-\T?W@?,&P[5<<G_`':?;79O
M;_E(@J)+>&.;<)%X!I)W70KGS.B1QY2USU:IM#K#K?K_`&_1;4V/L/:.T]MX
M^-(J/"8#;V*QN.A"A5#FFI:9%DE8(-4C:G8\L2>?>0&T;+M&P6<>W;+ML%I8
MJ*!(D5%_8H%3\S4GSZP0YJYNYIYXW>;?N<>8;S=-YD8EIKJ9YI*GT:0L5'HJ
MT`X``=4C[GV+\)F^?6+2N^.'R'J9GZ4[#K,B]%TM\O)J>JWB.ZMA!<]1?8X\
MT4^U4D:<_=TR_P`'"RI=M+1CV9]!WJ]E=O;?*KIP.&TZ5TC^$T0*K86!4T^I
M2!Q8_3W[KW0<=G]B]!])X&7=/<>].H^JMMP1RRR9WL3/;0V=B],*,\@CK-P5
M-!#,ZJI]*%F/T`O[]U[JCCY!?\*5?Y/_`$SDGVGU]OS,?+#L24R08K9'Q?ZM
MK.PGRF04:8*&DW364F$V=5O4R$(K4E=5<GZ6]^Z]T5P_S//YVGS.44_P"_DT
M8[H3968@U8CNOYR9.GVU%'3RO:'+1[)J!L.:10JG5%3',6/]??NO=/&*_D^?
MSF?E=E,;N'Y__P`VU>MMK?<T64FZ*^&W6N'P&VHVIY_NOX1DLY/BMFXW*4E_
MVI4K<?F(YXKAV<$@NP7$EM/#<P-2:-@RGC0C(P<'JKHKJR-\)%#TD^E?^$UW
MP9R/R+^>&RMY[G[>S&$W-B.M*/*'`;DI]LY1J7L>AJMY9%Z;(&DRT%-+)E,.
MS3*M/I+2#QF.,>+V?W>^V\EO=?1V9BO;L4G8MJ4BM2(P?A#G+5J1P7'2..T<
M-'XLVJ*/X!P/^V]:<!_/I4U7_"4'X^[.G2;XW?S`?Y@_QZ6!PU'2[?[:QF5H
MH=(_:CE@H,1M1YX4(Y76H8<'CV&^EW663^1__-XZO51\>/Y]7;TU)2%?L<%W
M;T_0[PHG5/TI65U?NK<\3_0`D4+$B_\`K'W7NL=3\:?^%5/4T8.U_EU_+M^3
M4$(_:I>P>I*+:%;4(A]*U51A^K]I2":1?J15MS]7_/OW7NN#_)[_`(4]]00%
M-_?RJ_A5\AX:=2U3D>H.T,-MJIJ(T'J:DH\MV--4!I/PHHY'_P!I]^Z]TIMD
M?SH/Y@^%W)@MK_)/^09\ANKJ3+9"+&5G8VV<G4;QV+A)YD<+79.7']6U:1XR
M*8+K>.ME(5OQ:_M58VR7=Y;VTEPL43N`7;@H/F?]7'SZ;E<QI(ZQEF`K0<3T
M1CX8?SPOF)F>POGIEW_E>=B=X[FC[:P5?MKK7KW`3XC=-=EDQ^#Z]I,745=+
MM3=-AB=H[;HI)B*::$4T"NLS3,XE$^[;59K8W4J63VCVL@0%S7ZBOG_S4'Q=
MO9H(%<`E!!<2&:-6F$BR+7'X/]CRSFO1N8OGG_PHO[O:6/I7^2;TIT5BZPZ:
M'._(SM+#M7T*N!HEK,/)N+8&1NE_4/X>?I]`?8.Z,^LU/\;O^%4W=\<B[P^5
M/\O7XAT%1<2TG675U)O;,4\#D*4IJK+;`WJZU40-P5R48N.)!?GW7NNW_P"$
M_'\P?N6"WRT_GK_*;<T=0MZO!](;2BZPH(]1O)3TE;2[Q2!8"QX(Q\8MP4]^
MZ]TJ=I?\)'_Y9@JZ?-=W[[^6WR/W$K*U;D^R>[9*2'(L#J)GCVQ@L3F%\CEB
M;5_Y_P!C[]U[JP_IK^0=_*(Z'K,;ENO?A-UK%N#$NTF.W-N?)[UWIN.BEDAD
MIWFI<ONK=&6JJ:=X964O&5:S$7M[=@N)K::.XMY&29#4$8(/5719%9'6JGRZ
M&/\`EL?'GI'I7HW<=!U;UCM+9L+]Z_(C$SR8K#TD=354NSN\.P-FX0SU!B,A
MDBP>#@$FC0CS%Y-(9V]J]QW6\W-XS<LH1!VJBA4%<DA1BK'+'S/34-O'`&$=
M:GB2:D^F?EY=6$/@L'(Q:3"XAV))+/C:)F)/U)+0$W/LOZ?ZX_W?P'_.CPW_
M`)ZZ'_KQ[]U[KW]W\!_SH\-_YZZ'_KQ[]U[KW]W\!_SH\-_YZZ'_`*\>_=>Z
M0W:&`P2]:=B,N$PZLNQ-WD$8NA!!&WLC_P`V/?NO=!U\4,#@G^+/QI=\)B'=
M^@.G&9FQE$S,S=>;=+,28+DEC<_X^_=>Z'[^[^`_YT>&_P#/70_]>/?NO=>_
MN_@/^='AO_/70_\`7CW[KW7O[OX#_G1X;_SUT/\`UX]^Z]U[^[^`_P"='AO_
M`#UT/_7CW[KW1/\`Y]8/"1?$#NYX\+B(W&`PMF3&42L+[OVX."(`?H??NO='
M"?;^!U'_`'!X;\?7%T)/T_J8/?NO=<?[OX#_`)T>&_\`/70_]>/?NO=>_N_@
M/^='AO\`SUT/_7CW[KW7O[OX#_G1X;_SUT/_`%X]^Z]U[^[^`_YT>&_\]=#_
M`->/?NO=$Q^8,&T,=6?%>"IAVQCY7^7O4$CQ5*8FDD:F_AN];N8YA&[1EA];
M6)'OW7NCDPX?;-5$E12XG`5-/,NN&>"@QTT,J$FSQRQPM&ZFWU!/OW7NLO\`
M=_`?\Z/#?^>NA_Z\>_=>Z]_=_`?\Z/#?^>NA_P"O'OW7NO?W?P'_`#H\-_YZ
MZ'_KQ[]U[KW]W\!_SH\-_P">NA_Z\>_=>Z*3V;@\&/F3\38QA<2$DZN^5I9!
MC:(*Q1^A=!*^"Q*ZC;_7/OW7NC;?W?P'_.CPW_GKH?\`KQ[]U[KW]W\!_P`Z
M/#?^>NA_Z\>_=>Z]_=_`?\Z/#?\`GKH?^O'OW7NI=+C<=0ES0T%#1M(`)&I*
M2GIBX7D!S#&A8"_%_?NO=3/?NO=-F;_XLN8_[561_P#<.;W[KW6I5[]U[K__
MTMS3X(?]DL];_P#49O[_`-^+NOW[KW1O/?NO=%?^;>6VM@OAK\KLWOCKZL[9
MV;BOCEW/D=U]88^>II:WL#;M'UYN"HS&SZ:LHHIJVAEW!CTDIA/"CS0>3R(I
M90#[KW6I[\(MQ?\`"JJF^(?QQ3H'8WP+R71,O4.R:KI27MC/TN8[&H^I:O!T
MM1USA=V97;^Z<)C<AE,#M"2CHVF--'4NL`-1JG\A/NO=;7_PNJOEM6_&GK.I
M^=&-ZVQ'REEI,T>TL?U%)++U[3U8W'EUP(P#RUV2=E;;(HVG_?D`J#)8VL/?
MNO=&C]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]UV/J/\`7'^]^_=>ZT]/YA_R"H<7\W-UX3</6F`W3D-E
M;_IZ[`[@J=]]G;?JZ2?*8:OV1K;%;<W=CL,?MMMY.:%=$,9D9M;7:]\=?=?[
MPUQ[:>X=IR+:<E65Y;O;V;F>2:=7K<1H[81@HTZJ#'"A->NCOW8ON";%]X/V
M"N_>?=/=+>-LW!+K=HA:V]K:20TV]W6/OE'B$R:!KS@DTZL\Q'QH_F%_*C%8
M[#;[^0./^-GQDI:"CQ.SMI=1BKJ.P=W[$IJ>.#"UV=S;5\U?#/E,9%'))]WD
MI&NP+4Y))]N<X>W_`+P\[\U\R;=N?."[)R'%>S1P16N;B:W61A&SLI!!9`"=
M<A&<Q=$_ME[Y_=$]D?;KD?>N6/9^7G/WQGVJVFO+K=33;[.^>)6FC@B=2&6*
M0LJE(:FG]OPZ.ST+_+M^'OQ=2+<6`Z_Q.9W=2K]Q6]E]I5=/NG<S5*@&:OCK
MLV?X9AI#)ZM5+#`5_+$\^Q7R;[(^W?)1BN;#8UN-T7/U%S^M+J\RNH:(R3G]
M-%^T\>HA]X/OF_>"]Z(YMOYAYVEL>5VPNW[</H[14\D98B))0!BDLCCY`8Z%
M+L/YO_#+J*EFJ.S?E=\=-B0T@83IN3N3K_%S0",>H/25&>6I0(/KZ./<M]8L
M')J>/1`^Q?\`A0U_)HZS6H&7^>74FX:BG#_Y+UW3[M[(>9TO>."IV5MS-XYV
M)'!,P4_U]^Z]T2O/_P#"L?\`ED3S34'3NTOEI\@<M'*(HZ+K/H/+,E2=053#
M+N#)X>H96_'[-R/I[]U[HCF9_GD_,S?W\T@;+Z"^%&>S(SOQ^K-K].XCL3#Y
M_%1Y+^\\V-WABIMUUU#2T^1Q6+R>X<=20U<J$3T\\6@Q>!6E([&Q[=X+;>(3
MK\#QOK*_IUI73Z>'^#^/7FGET4?63:O&U"FO3X5.[[?]-Y^E//HRDGQB_P"%
M0'S==I.\OF3\>_Y;?6^0G$C['^.^!3>79L.+J3K^UEW)0M7UL=?#`_C=H]T4
MZ:O5XKW4`3HWZ%;JG_A+'\&1FZ7?OS0[<^3GS^[-6?[JLSO>_;6YZ+;M1.3Y
M&5-O[?RD>:>E25V"Q5&7J(BATE#^?=>ZO+^/OPE^(/Q2QE/BOC?\:>ENF8*=
M="UFQ>OMO8C.S)<-_EVY4H7W#D&U*#>HJI#JYO<GW[KW1HKD_4GW[KW77OW7
MNB@=.?\`97'S0_[5WQH_]X/='OW7NC?^_=>Z][]U[KWOW7NO>_=>Z[N?ZG_;
MGW[KW1-OC;A</B.\?G.F)Q.,Q:COS8BC^'X^EHR5K_C;TIN*M5WIXHWD6ISV
M<K:QPQ-ZBKE?ZN?:B>\N[E(8KBX=XXETH&)(4>@]!U1(HXRQ2,`L:FGF>CDW
M)^I/M/U?KKW[KW7O?NO=>]^Z]UV/J/\`7'^]^_=>Z*/\*/\`F3.X?_%B?EE_
M\$UVM[]U[HV_OW7NO>_=>Z][]U[KWOW7N@.^0&6[(HNO<SB^LNI\AVUF]SXO
M/;=FQ=!O+9^R_P"#0Y/!UU-!EJJOWA7T%+4THJY4C:.`R3*&U:"![]U[I&?$
M$=LXCI/K[KWMSJ"LZHSG6'777.Q$>??.S-[T6Z:C;>TZ#"97)XN?:-?5M0T2
M5F.]`JTAED20$(+,![KW1I/?NO=>]^Z]U[W[KW7O?NO=$C^=.,[OWUTUNSJ7
MIOI&L[/K-^8*G@ES_P#I#V)LC%;<K<?N/#Y&.ER,.ZLA3Y*L%7244C+)2PS(
MK`*UKW'NO=&@ZYW+O/=FVUR^_.MLAU5GS7UE,VT\IN;;&[:I:*`QBER)RVT:
M_(X<I7`DB(2F6/3Z@+CW[KW2\]^Z]U[W[KW7O?NO=>]^Z]T#_8/QXZ![;RU'
MG^U>CNH.S,[04<>/H,UV!UML[>.6H*&&::>&DH\CN'#Y&KI::&>HD=$1U56D
M8BQ8W]U[H1=M;9VWLS`XO:VS]OX3:FV,'2I0X7;FW,70X3!8BBC+,E'C,3C8
M*:@H*5&8D1Q1JH)/'OW7NGOW[KW7O?NO=>]^Z]T0'Y=?S2_Y?WP0W5M78WRP
M^3O7_4.]-Z0)78+:F3&=SNXOX5),::+.9?#[3P^>K]NX&:<,L=;7I34TA1]#
MMH?3[KW2)^04'Q]AV]C?Y@^]?Y@/8?4O2>SMD93,;0[$VIN_H=^F\-LKL:GV
MI%DGVW79OIW>%=N5=XU&VL<:5&K<A5R57[=(`TGC]^Z]T,?PS_F!_#7YZ;6S
M>>^(WR%VCWI2[(FH\5N],9_$,3NS"U,T;)1UVXMIY_$;=SV/I\P:=VAJC0Q4
M=0RN(F.EE7W7N@TVS_-W_EK[R^3D_P`.=L_,'J/+_(B'-U>UX]ATV3R`IJ_=
ME#)X:O:&(WG+CH]C9G=D-0K1?PVER4U8TT;Q+&9$91[KW2V^8G\RWX+_``"F
MV?2?+OY';'Z9RN_?/)M+;^73-YS<V7H:63P5683;6U,3GL[3X"FJ#XGKYJ>.
MC$OH\FOT^_=>Z&+/?+#XS[8^/+?+/.=Y]:4'QI7:M+O5.[&W5C9NOZG;-<R1
MT.1HL]3334]>];4RK!#3P^2IEJF$"QF8Z/?NO=!K\._YAOPN^?F#W)G_`(A_
M('97=%-LZKBH]UXW"'+8C<VW7JBPHZG+[2W/C,)N:BQE>8V%/5O2"EG966.1
MF5@/=>Z-WF_^++F/^U5D?_<.;W[KW6I5[]U[K__3W-/@A_V2SUO_`-1F_O\`
MWXNZ_?NO=&\]^Z]T#'R-V'1]H_'_`+KZXR/8^7Z>QN^.K=\[7R7:V!R5-B,S
MUQCLSMS(4-?O7'Y6MGI:/'56VZ29ZM9Y9(XHO%J9@H)]^Z]U\]'!=4?R?.G\
M<G6>R?\`A4%\X=F;:V?69#$X_;?7<?=-'LG'/%7SO7?W<BVCC/[LRXZIKI))
M5FHB]/4%S(C.&U'W7NMX?^5.O5J_`GH->E_E%V!\SNM5QN[%VW\DNT6SK[Z[
M&C7?.Y5KI\Z=S10YP2X/)";&QBH76(:-!R`#[]U[JP[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=!MW+VEMKH[J+M#N?>3R1[3ZFZ^WAV-N0PE?.^%V9@*_<&0BIM7
MI-3/34#)&#]78#W[KW6LQT7\R?YHG9G>74&\)?GE_+MKNS.TYMD=AYG^3A-%
MM+;G9NR>@M^-B\H*:G[KGSE9V#4=V[0ZZR<.:J:.HQXHI:Y)X`IA"(?=>Z-U
MW3VK_,]^:/S&^3/1/\OWY#],_$/IWX0U'7FS=[=A=B]-4W=FX^]N]]\;*H>Q
M:W9,6/R=52T6S>N]G[>S%#2UM;2B3)-63.461=*Q>Z]T&M5_-&^8G<?PZ^*6
MQ^G-K=4]??S%?DW\J>S?@_O'+YJDR&Y>FNE-_P#QWJ]Y)\@^Y,7@3/-D=S8#
M$X#91K\+CJB1EDGR5/',752']U[HQ'PW[[^;_0/R[WC\#?YB'<W6'R0K\M\=
M<A\INA_DOU]UM2]/Y3/;2VINZ#:/:>P.PNO,77U^#H<KM*MRU%58VKHF(J:!
MW\S&0:4]U[H@$OS#_G+[M^->\/YQ.R>U/CQAOA_MF7>':&V?Y?F:ZE%9NG=_
MQ0V#NS(8K+[QRO?JY"#<.+[AS>S,/69NDHXHAB@ZPQDA7,7OW7NCE_(/Y(_.
MWYF_*3"_$[^7!W7UM\4]I[)^,75ORB[J^2'8?55#W3N*I?O:HR3=1=3;,V)E
MZVBV[`U9@,+4Y/+5U1*)8XC$L)O=9/=>Z-U_+&^4/>G?>PN]>J_E93[&_P!F
ME^'W?NY/CMW-G^LJ2JQVP.P9\=A,!O#9/9VV<172S56#I][;*W31U%10N0*6
ML69%5$THONO=69CZC_7'^]^_=>ZTZ?YH_P`;?YETW\Q_J0?'K'?'6LZ+[MW[
M,F3J<_LS:68S0-+$^=R]%N7,[JIZS.8^OI,#33SQ_:3TZ0LCU"AH%*((?ZO\
MF;ZVV;QN7+^T3W-K&@N9+JVAEN"(_@T.R%V4`!8@I!0TKCHSVOGOW&Y7V^ZV
M'ESW`YBV_997D9+>SW&[M[;5-_:DPQ2K&#(23(2O>":]#W4?R3?YKW:5761]
ML_SW.]MJ]>557*<!L+HG9!VO!MS;3,1B,)19_&;HVM%6C%XW1`DRT40<)J`%
M[>R>]GCN+RZGCU:'D9AJI6A)(K3%?6G1-;1+;V\,"J`J(!CA@4Z[Q7_"5+XU
M[HE%5\E/G9_,.^254S^6H_O;WHF-I:F1C>198ZC$[CK1%("19:A7`/Z_ZING
MNC,];?\`"8+^2[US-%52_%:L[%K4(::L[1[5[,W::QQR9*JA.YZ'%,SG]6BG
M0'^GOW7NC^=8_P`I_P#EG]."+_1U\$?BU@I8"&AJ:CIS9NX*Z)P=0D2OW+C,
MQ6K+<WU^35_C[]U[HZVVNO\`86RX(:79VQ]G[3I:=0E/3;9VSA<%!`H^BPPX
MNBI8XE']%`'OW7NBOUV!PB_S!ML9887%#+5'Q*WS6SY3^&T7\1EK,?VOU[BJ
M&H>O\'W1GI<9DZBG1M>H03,GZ38*/K;OZ3Z#ZA_H]6K17MU>M/\`5Z\>F_#C
M\3Q-`\6E*^=.CG>T_3G7O?NO=>]^Z]U[W[KW71-@38FP)L/J;`&PO87;\>_=
M>ZKKZ8[!W[%\J^^LYF?C+\BML;3[?JNF\-MK>6>VYL*+;M"-B;8W!A\[E-P-
MC^QLCEL7B5K*N/Q2"DE>5&#!+7M[KW5BOOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M*5\?O^9Z_.C_`,3[US_\"IT![]U[HU60R%!BJ&LRF5KJ/&8S&TT]=D<CD*F&
MBH*"AI8FGJJRMK*EXZ>EI*:%&>21V5$0$D@#W[KW0&Q_+#XLRR1Q1?)?X_32
MRND<<<7<O73R22.P5$C1=QEG=V(``Y)/OW7NEGO7N?IWK:?&TW8W;/6>P*G,
MTKUV(I][;[VMM2?*T,;K&];C8L[E:"2NI$D8*9(@Z`D"_OW7NGK!=A]?[GVK
M+OO;6^]F[BV/3PU]14;SP6Y\+EMJ008KR?Q2:;<5!75&(BAQWA?[AFF`ATG7
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M5E'_`#9.F?G9U'L?8_4N8K1@,G1?&S-8/;%-MG+83/5N=V]NO_1QB8IH?N9,
MB1B4^T,<E/7(Z3JONO=3?Y*'Q=Z%^=O\DSICXZ_.7<]3#LOJGYZ=AU/4NP_]
M*..VIBMZY_K;=#93#]1F3-25M+V'LNLRVY<C3/CHTEEDBFU0O&ZHX]U[H4?Y
M8_7N'Z)_G-_.#:?ROZ=Z\^$_R![[^)F%SG5/1GQF&!Q/Q=J/C1M2JI\3NKL%
M-]8"NQ\U/VS3Y+!M-7>?&8FGI42>>)G8^GW7NB@_S%_Y>WQJ^#N#^!>?Z[Z=
MV3C_`.6#TW\J^K>W^T_Y@O7^YMD]O_-3<_96[^P]PF@VYE]QQR[<J,CT]1;@
M;&TM5D:6;)54*Q((:7SPZIO=>ZNV_F+_`,OSJ+O/?_?ORT^,W3'0_P`T_P"8
M%N?X_;8Z0Q_2OR4[*VUE>INN.M<W'+/'V1C.O,O25=?M+>IQ-4KT$C2T459)
M,61H7EFF?W7NB9?RQ?B9_+S^9G\D7XQ_$OMSL7L:;8G5'R3R%+O?9_8N\-M=
M4;@S'RDZ^WWF=Q;HZ:GQ1R.?V[NC8U9D]R20TF,I)ZN2JH)XYE>&K!,7NO=,
M'\KOKRD^/O\`/?\`E)@?D;T;L+X=?(_O/XOXG(?'CH#XR8K;Q^,&Y>@-H9K%
M4F:W?6;BP%535%5W#/D]I^6LI9\1C:1$CGDC>1RJCW7NMN/-_P#%ES'_`&JL
MC_[AS>_=>ZU*O?NO=?_4W-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]^Z]T5;YU
M476N1^%7RVQ_<F=S>V.IZ[XV]TTG8^X]LTHKMQX+9=1UYN"'<.6P%`SQ)7YJ
M@QCR2TL#LJ33JJ,0K$^_=>ZTE?AA\T\EM/XI]";7I?\`A+/E_DAC=N];;<PN
M#[_PGQXP:T7=&W<;2"DV_P!G2_QSH/?^1;*[VP\4.0KF;-9*)JRHE,4[Q%/?
MNO=;H7\O3?4O97Q`Z>WI-\2:WX,29F@W"Q^+60P%#M>JZM%+NS.42TDF"QVV
M=G4E`N>6G&355QM*66L#,I8EC[KW1T??NO=>]^Z]U[W[KW7O?NO=>]^Z]T5[
MYN=1[C[\^''RGZ2V:Z1[O[6^/O;>P=J&4Q+&^Y=S['S6*P,,CSR10Q)/E*F)
M"[L%0-J)L/?NO=:7\6]?Y9._/@7\7/AE\8?C?D]L_P`Z#;.^/C?A*79]'TGN
MS;_ROZ?^2^P^PMG5G<O<?;'<E5MVEKSL."GQV:KJVOJLU44=5BZV&-8HU:,0
M^Z]U<90_/;X^_P`ICY\_S&=D?.;/;CZ=V1\HNP>N?E;\;NT)=@;VW-LSMJ&J
MZ<VGL#LCK[`Y;:N(SH3?^VMZ;,,<6+F6)Y8*E)`P4KJ]U[HG.U:GLKXT?'KX
M)_S2>W>I^R=O]6X[^9)\R/E-W=M7^YF4K>Q.G/C+\VX][[8V3V%NW8N*ADS%
M(FUL>F`KLO$D#34E-7.[H6#7]U[H^71'?O5_\U3^9SE>]_BGE\]OKXJ?'7X*
M]F=!9;OF39^Y-L;$WGW5\@][[?R,FTMAY#<N+PF4W')LK:&TVFRDB0^&EJ9D
MC'K;4WNO=5T;=_F1=8=8_P`I;>O\HK<6`[)I?YH.W>MNR?@OMOXITW5^\Z[=
MN[]V;ER>X=B;*[*V]DX\)5[2K^JJ[:F9ILW-F'KEA6ECF.GA;^Z]T=$?(#K#
M^3A\\J[+_-;,Y7K+X]?)#X)_$KKO9WR`.U=T[HZ\H.[_`(I8#/[$WCUMN/+;
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M'8^`VJ<!B?[N8,;4V'M88C"?90_PS&_W:K^M\=6X#[.BT1_9S4\,E/IT,BE2
MH]U[I3?Z/MT?\_G[(_\`.+KC_P"P/W[KW7O]'VZ/^?S]D?\`G%UQ_P#8'[]U
M[KW^C[='_/Y^R/\`SBZX_P#L#]^Z]UV.O]T`@_Z9NQS8@V:AZX(-OP1_<3D'
MW[KW1/J_^71@,CV/_I7F^6_SIAWJM'D<3!74??U/245'M[*9ZBW)7[7HL3%L
MP8^GV[/E\=3O]L(R%2%$!T"WOW7NC?CKW=``'^FCLDV`'-'UR2;<7)_N']3^
M3[]U[KO_`$?;H_Y_/V1_YQ=<?_8'[]U[KW^C[='_`#^?LC_SBZX_^P/W[KW7
MO]'VZ/\`G\_9'_G%UQ_]@?OW7NO?Z/MT?\_G[(_\XNN/_L#]^Z]U[_1]NC_G
M\_9'_G%UQ_\`8'[]U[KW^C[='_/Y^R/_`#BZX_\`L#]^Z]U[_1]NC_G\_9'_
M`)Q=<?\`V!^_=>Z]_H^W1_S^?LC_`,XNN/\`[`_?NO=>_P!'VZ/^?S]D?^<7
M7'_V!^_=>ZB5_6N[:RAK*2#O3M'&3U---!#D:.@ZO:LH9)8VC2KI5K.O*NC:
M>G8ZD$L4D>H>I6''OW7N@7ZV^)NXNMMX[[WK2_*GY"[DR'969H]Q[RH=QTG1
M;XW*9_&[0VUL7&Y2*'#],X>KQ[46V=IT,*Q03)`[Q&1T9F8GW7NA1W?T@V_M
MJ;EV+O7LS?&YMG;RP.7VMNK;F4QW7<N,SVW,_03XO-8;(11['BDDH<GCJJ2&
M50RDHY`(]^Z]UJX=]_R4?Y<?9?S]Z%^"?0?QSV1LG%[&V@GRQ^8W96V,%A*7
M=FUNM\=G6PG2/4VW<LM"4Q&:[BW[C*N;(LT<L@V_BI@J@3W]^Z]TA_YEG4^5
M[E_F?]J;7R_\L[O;^:AA>@/BUT5LO9.'DK.M.L^L>L9MW9S>N^MXY"#?&Z=N
M46!SVYZV@J<134N,QU+4U(CCJ#)(F@)[]U[H_7QY^'OPN_F,?R\.NNJ>BZSO
M;XQ_%'8?=VX:[Y%_"+$[>VKLG<S]D=?9"OK.Q?CKVI34N#ASU)2R;YJ(:VM2
MGJ9(,S$L/'BFLONO=$^_E(4G4>P?G[\WL9T)UOW]_+<ZUPWQJVAN.C^%G;^#
M3:W97<N6V9G,T^<^2VSNK,OM3,;-P6S:#'-!A&;$5-7D:^JJ!+4"-65/?NO=
M5@_%_9OQQVMUSUQ\I_GA_)H^0==U5O?L7<'8G='\R/>V,V#+DL'O/L7MK/Y;
M$]A9KI&3#3]B4'5>"R>3H8'R]4L*I`IJ/M]!2-O=>ZO4IO@%T5_-)_F-?/C+
M?,S([F^0/7/Q3PW0/0GQYV5N3)XI]F[8QO9?5-+VSV!O[&X/$X2AP3[IW'D<
M]2+29>*+[F.FATZV4);W7NC2?R:-K;^Q/Q_[W^.]9WCVID=M_#?YE_(SXO=8
M9#*5^S]S9E^I-@;GIJWKS'9G<&:VCDJ_+9'!X+/)1-(\S%$@6.R!`B^Z]U;M
M_H^W1_S^?LC_`,XNN/\`[`_?NO=>_P!'VZ/^?S]D?^<77'_V!^_=>Z]_H^W1
M_P`_G[(_\XNN/_L#]^Z]U[_1]NC_`)_/V1_YQ=<?_8'[]U[KW^C[='_/Y^R/
M_.+KC_[`_?NO=>_T?;H_Y_/V1_YQ=<?_`&!^_=>Z]_H^W1_S^?LC_P`XNN/_
M`+`_?NO=>_T?;H_Y_/V1_P"<77'_`-@?OW7NO?Z/MT?\_G[(_P#.+KC_`.P/
MW[KW7O\`1]NC_G\_9'_G%UQ_]@?OW7NO?Z/MT?\`/Y^R/_.+KC_[`_?NO=>_
MT?;H_P"?S]D?^<77'_V!^_=>Z]_H^W1_S^?LC_SBZX_^P/W[KW7O]'VZ/^?S
M]D?^<77'_P!@?OW7NO?Z/MT?\_G[(_\`.+KC_P"P/W[KW7O]'VZ/^?S]D?\`
MG%UQ_P#8'[]U[KW^C[='_/Y^R/\`SBZX_P#L#]^Z]U[_`$?;H_Y_/V1_YQ=<
M?_8'[]U[KW^C[='_`#^?LC_SBZX_^P/W[KW5$'SP_D:=Y?(KY);G^3?Q8_F5
M=Z?$G>?<_6M)T]\D,=186FW'ANR=AT5)28J!</0[:RVPJ3;N7EP],L,LIBG8
MR(LT;Q.TNOW7NE/V?_PGD^..Z?Y?G3OP4Z\[G[?ZT/QOW=3]O="]Q44>T*C=
M^S^^HJFORE9V;DSC<!@\EE7S65R<SSTL=?3M"GA\$R-3Q,/=>Z;OA3_(IW1U
M#W1VA\I_FQ\X^V_FU\GNR^I,S\?&WUFMO8+;&WL!TEN&D^PS^TZ3;^=.]WGJ
MLY1_M23K+`D*&3QQZYI9&]U[HGN#_P"$N6<@RFVN@MT_S)/D!NG^61L+L\=L
M[(^%M1A:.&MH,W%E)L[1X7(;]ES%3AZK$TN4KZIC(N%5W$K2+''42/-[]U[H
MV?S;_D5=E=Q?)6O^8WPG_F`]P_"?Y$;]V#C^I.[MR8?;F)W)@NS.NL/CL;BL
M+2'$;:JMAKBLUBJ##4D(J&-3K$$<B^*5-;>Z]UGK_P#A.9\;O^&X\%\"<+W9
MV_0[AV3VC'\C=@?(RI.$DWYM7Y/#6:WMBDI:&FH:MJ;+Q,*6;'/D7>*F1#%4
MK4()_?NO=+S^7)_)?WM\6?D]N7YS_,?YG]C_`#N^7V0Z]DZAV=V!N["G:6W.
MO^N)I(7JZ'$X$YO/U-;FJ^.(Q--)4)!%%),4A,L\DI]U[J]3-_\`%ES'_:JR
M/_N'-[]U[K4J]^Z]U__5W-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]^Z]U6]_,
ME^4/QUZJZ6WY\>.U/DC\>OC[VS\F^D.YML=*2_)C(TV)ZMW#DTV]3[9R(W+4
MY>CGP.0PU%6[PHEK*"1FJ:JFF?Q0RA7T^Z]U0=\8OA__`,*9.N^C^O\`K#H/
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MA(XHHT")''&H`50``!8>_=>ZR>_=>Z"[?;.-Y=*@,P#;\S@8!B+C_1COL6(!
ML19C[]U[H4??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5S?
M#?XT]F]9?)C^8M\B>X\5@X-R?)?Y`[37J_)XS-09FIF^.G4O5NV-G]9TE?'$
M-6`K1FILU/-1$ZM4P=N6%O=>Z+Q\E:'^<QT?\E>R.POAC@^A_F%\>>Z<;M2H
MQ73GR![+J^I<Y\8]Z[9PT.&S51L[.XS$/!NWKW?;D9":CD>2OI:U'"%8V4M[
MKW02;2^`_P#,<^.?Q/CWGT'\@.L\S_,"W1\M-Y?-CY([<R%#6;>^.'R0SW8U
M++CMV?'>IJVHYMR[:V9A]N08^EP.73[:H2OQL<]1ICD?3[KW3[\?OBS_`#%_
MDC\H\I\S_GQ2]-?%7=77WQP[4^-WQKZJ^.&ZI^S-Q[1K.XGPM3O3NC>79&4H
MJ>@K\I05.WZ3^!XJ!)*>`HTDRK)_G/=>Z+9O3XV_SX?DITK4_P`N+Y(R_$[_
M`$!;EIL=USW5_,$PV\LUDNW>WNDZ#)4M1G_X3T9_#*>FV_VMO_;L(QU74SO#
MCJ>H:HF2P:-C[KW1AN[/C+_,;^('RO[(^1G\LC8'Q^[XZX^2O5O3NP>V^B.]
M]]Y/K*JZ\[`Z$VQ-L3K[M7:F[:"">+.X2OV*\5%EL:^FKEFIUDC/(9/=>Z/=
M_+8^).^/A[\<)]H=P;SP/8G?_:_:G:'R'^0V]=J8^;%[2S7<?<NZ*K=&Z8-H
MT-5'%6P;6P22P8^A\ZB5X:42,%+Z1[KW0Z_+CY%8#XB_&#OSY0;IV]F-V;>Z
M$ZJWGVGE]L8">BI<SGZ/9^%JLN^(QU5D72AI:FO-.(Q+*2D88L0UM)]U[JMS
M#_S"/YHN?P^)SV(_D8]M56+S>-H<OC:EOGM\):<ST&2I8JVBF,%1O2*>(RTT
MRL5=59;V(!!'OW7NG'_9\?YJW_>BGMC_`-+\^#__`-F_OW7NO?[/C_-6_P"]
M%/;'_I?GP?\`_LW]^Z]U[_9\?YJW_>BGMC_TOSX/_P#V;^_=>Z]_L^/\U;_O
M13VQ_P"E^?!__P"S?W[KW7O]GQ_FK?\`>BGMC_TOSX/_`/V;^_=>Z]_L^/\`
M-6_[T4]L?^E^?!__`.S?W[KW7O\`9\?YJW_>BGMC_P!+\^#_`/\`9O[]U[KW
M^SX_S5O^]%/;'_I?GP?_`/LW]^Z]U[_9\?YJW_>BGMC_`-+\^#__`-F_OW7N
MO?[/C_-6_P"]%/;'_I?GP?\`_LW]^Z]U[_9\?YJW_>BGMC_TOSX/_P#V;^_=
M>Z]_L^/\U;_O13VQ_P"E^?!__P"S?W[KW7O]GQ_FK?\`>BGMC_TOSX/_`/V;
M^_=>Z]_L^/\`-6_[T4]L?^E^?!__`.S?W[KW7O\`9\?YJW_>BGMC_P!+\^#_
M`/\`9O[]U[KW^SX_S5O^]%/;'_I?GP?_`/LW]^Z]U[_9\?YJW_>BGMC_`-+\
M^#__`-F_OW7N@C[Z_FT?S`?C'TYV'W]WA_)1[;V7U+U3MRJW;OW=4?SA^'VY
M&P6WJ)XHZO(C![7W+F-P9/P&9?VJ2EGF8'TH??NO=7SXJO7*8O&Y-(VA3(T%
M'7I"[!WB6LIXZA8V90%9D$EB1P2/?NO=3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MTV9O_BRYC_M59'_W#F]^Z]UJ5>_=>Z__UMS3X(?]DL];_P#49O[_`-^+NOW[
MKW1O/?NO=%J^6&P?BWNKIC>V[/EUU;U9V=U!U/M;<_9>Y(NU-@;=[`Q>W<-M
M+`Y#+YW-8[';@QF3\&0I</2S%&IPLS?I4W(]^Z]UHP_(_=/\IO876_P_[@^&
M?PI_F-]#=_?,G:W8W9.Q>H/@MW_V#TUVKMGX\];[GW)A\IVSF]H@[^VG5P=E
M[>VY)D*>*FQLB56,HS(U=''3"23W7NMSW^5_O;"=E?`SXW=A;:^0':'R?V[O
M79,NY<'W-W7C<'B>V=PXO*9S+5%)A^P:';:)B(MT[*B<86K>,$S2T!D8LS%C
M[KW1]O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5=7=/\Q[K+J/YT?%OX%4&T
MMP[\[*^1-9NU=S;EP=5!!M+I&AP?7VX]_;;AWO6O3523;KW]1[9J6QF'5X*M
MJ"*2M:T`C\ONO=`)\MOYK^].FOD9NGXM?%'X+=[?/;M3J'9NV^P?D9%U+N':
M6R]M]+[<WA329':>&J\]NX20;I[%W%A(6KZ7`T:+424I1E=F9E3W7NE#OC^<
M5\?,/\&^FOFEUWL;M+MRN^1V[L1U+T/\<=M86EI.[M[]]93)9C!U?3>0PU34
MST6V-P[2S&W<C'FYYWD@QT-%++^X-"O[KW2L^"O\R/*_*CLSL_XY=\_%GM7X
M2_*SJ?:FW^R,UTEVMF]L[NIMS]4[JKZG%X7L3K[?^TI/X%NW#4^5IC19-8HT
M?'5K+$Y8DD>Z]T2W.?S]\;CMQ;I[/P_P2^2VZ?Y=6Q>TZSJ+=_\`,)Q%5M7^
MX-#F\1NJ'8V>WOC>KYY4WOF.GL'NZ;[6HW'&ZP"..241^C0?=>Z-I\TOYG^5
M^/W;FP/C5\7OBAVE\\_DOOCK>3NRLZRZFW-M79>"V+TN,D<+C]_;U[%W<9-O
MXF/<F85J?$TFEI:YHW*LH">3W7NC,?!?YJ;#^=G2+]N;0VAO;K'<.VMZ[JZK
M[;Z<[-H*?%=C=/\`;6Q:N.BW=L+=]#33SP"MQ\D\4U//&WCJZ.>*90NLHONO
M=')]^Z]T%N_/^/RZ4_\`#^SG_OLM]>_=>Z%+W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=5@?SK?^W1_\QK_`,5"[L_]XW(^_=>ZL`Z=_P"91=6?^(XV/_[S.+]^Z]T(
M_OW7NO>_=>Z][]U[KWOW7NNKC^H]^Z]UW[]U[HIWS*^8&QOA-U'3=N;ZZZ[W
M[8I\GN[%[(P/7_QQZFSW<O:&X,_E<7G,XD>-VE@GIQ!CJ'#;;K:FJK:RHI:.
M!(0AD\LD4;^Z]T!WQ$_FN_#+YG=,]Q]U]=;[S>Q,1\;GR=/\D]F]W[5R?5O8
MOQ^K</19;)9*D[2VQF/-'BFI:/`UI,M)4UM,TM'/"LIFAEC3W7N@:^$G\\;X
M1?/+NJ#H7JJ/O'8.^=S;,S/9/3\O?'4&8ZIV]\ANN<!DSB\IO?H[,Y:MJH]W
MX>!U:80S)0Y!Z:*>1:8BEJ_![KW5@/RP^3'7OPW^./;WRA[7I-SY#KGI3:%7
MO7=U'LO&T.9W348BCJ*:FECPF,R65P=!65IDJELDM93I:Y+BWOW7NE_LWM';
MF^>HMJ=U8:'*Q[1WCUQ@NT<53U])#!G(]M[AVS2[LH8*VABJZBGARR8NK59(
MEG=%FNH<CU'W7NB4;`_FE?&3L+^6W6_S3J"#LG"_&>@ZV['[/EH-P;6QE/V?
M)A^M-U;HV7D\5#M;&;DRV';/9O<FU9:?&QG*+32_<0/-/3HTC1^Z]TO_`(_?
M/CJ#Y&?(KO;XN;3VMVIM;MCXY==?'OLKLW'=@[6Q.`H*#%_)+8B]@[)PE%/1
M;FS%=+NC!8DFGS=--301T=<C112U"J7]^Z]T=ZX_J/S_`+Q]?]M[]U[KL$'Z
M&_\`K>_=>Z][]U[KWOW7NJCOY\__`&YV_F&?^*X;M_\`<K%^_=>ZM(VC_P`>
MIMC_`,-["_\`NMIO?NO=*'W[KW7O?NO=>]^Z]U[W[KW7O?NO=-F;_P"++F/^
MU5D?_<.;W[KW6I5[]U[K_]?<T^"'_9+/6_\`U&;^_P#?B[K]^Z]T;SW[KW1>
M_EML3K_M#XM?(WK?MC>%#UWUEO[I'L_9V_=_Y.MH<;CMD;3W'LW+XG.;LKLA
MDY8,=1TFWJ"K>K>2>1(56(EV"W(]U[K6$^*G\I'^8UTE1=M?-K>_RH^-'R/^
M0W6?P%QWQ%_EN;BPT-5A>G]N=.P8FABV_P!K=@9*?%8+$T['8TCSAJ?^(B99
MYII:JI5U1O=>ZOO_`)3O0^P_C/\`R[?BOTMUSVILSO';FT.N@T_;W7.4I\UL
M3L+<^<S>6W#O3<>T\G1SU-/5X*IW;E*U:9@U_&@#*K:E'NO=6(>_=>Z][]U[
MKWOW7NO>_=>Z][]U[HO'RU[=WST'\9N\>Y>L>K=Q]W]C=<]<[CW+L;J7:-!7
MY3<._=UT=&PP6`Q^.QD-3DJS[G(R1F6.G1IF@5]`U6]^Z]UIKTWSTBZ_[_\`
MY7E=G/Y?_P#-)?MVA^6'<?<WR`W[VK\7*;:N]ODEW%VE\>-Y;'W!7;`Q$&Z)
M8\I0;"BRL0H<2I@AP&RL.B(3X&U>Z]UL$_RZMQ;;P?ST_G0[+W'DL?B^S5^3
MO3_:61H<K5TU%F*CI_<?QIZY@V%GQ!4U(J)-N8O^%UU(U0%%/3SH\;,&-O?N
MO=4[_&?=.R\=OS^7!W/E*JBH_C_O3^=K_-*;K7<]=7P/M*?)=HXSM;"]19_'
M9>:>#'''[HW'C,S'BIELDLM8J1ABX+>Z]U;1WA.F\_YVFP]M=>U<5?OC8O\`
M*N^1B;__`(5D8JBHVY#V!VQLBGZNQVX*.GE#XNLRV:QE754(GL\T4;.BZ1K/
MNO=$VZJ[.Z<Q_P#PEDWC)D<O@8</MOX5]Z]/[NP\F7HJ*MI>Z!4;WV=D]CUT
M;3SST>]<MV-6A8J-Q]W+/5QD)>1;^Z]T8'^77/!L?^9?W5U_V/-'C.V=U?RQ
M?Y<.8VA0YF9*?,9C:>Q-K[VVQV%38B*IJ6J*T8#?\SO7I$KF&2H5I#Z@??NO
M=#G_`"K\IA]U_(_^</OG9E3!DNO,]_,!3#X/.8VOBR>"S6Z]E]#=4[;[&JL/
M74SO1SK2[FI325'BN$J:=T+,RFWNO=7)5CU4=)4R4-/%5UR02O24L]1]I!45
M*HQ@@FJEAJFIHI90%:01N4!OI/T]^Z]T6G>V=[9;=O3S3]=[0BF3?&9:DB3L
MFKD2><]<;V5XI9#L:,P(M.7<,%D)90NGU7'NO="9_'^X?^?:[,_]&=6__8%[
M]U[KW\?[A_Y]KLS_`-&=6_\`V!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[
MA_Y]KLS_`-&=6_\`V!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]KLS_
M`-&=6_\`V!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]KLS_`-&=6_\`
MV!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]KLS_`-&=6_\`V!>_=>Z]
M_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]KLS_`-&=6_\`V!>_=>Z]_'^X?^?:
M[,_]&=6__8%[]U[KW\?[A_Y]KLS_`-&=6_\`V!>_=>Z]_'^X?^?:[,_]&=6_
M_8%[]U[KW\?[A_Y]KLS_`-&=6_\`V!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[K
MW\?[A_Y]KLS_`-&=6_\`V!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]
MKLS_`-&=6_\`V!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]KLS_`-&=
M6_\`V!>_=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]KLS_`-&=6_\`V!>_
M=>Z]_'^X?^?:[,_]&=6__8%[]U[KW\?[A_Y]KLS_`-&=6_\`V!>_=>ZK>_G%
MY7?=9_*>_F.P;IVEM_`4/^R;=Y305>*WA4[AJ):N/:<Z+3-1R[8PJ10-#*[&
M7RL0RJH0ZBR^Z]U9KT[_`,RBZL_\1QL?_P!YG%^_=>Z$?W[KW7O?NO=4_?S%
M_EG_`#,_C_V7L#;GPC^".)^4O7V=V+4YO=V^*_/U%/-@-Y1Y^LH5VHN)HMPX
M&:EBBPD5/6"HD$JU)JBB:#!)J?A2!U;Q92K`^G6C7R'5=60_F7_\*`XZ&LE7
M^3_M^G>*DJ94J(Z[<64>!TA=EF3&4?8/W>1:(C4*>+]R8C0O+#V\(;0_\2?Y
M=:[O3JD;^7M_-'_F]3_*+MFKZFQ'8/S8WYV-39W<G9?0V_#N"KVQM:JQ.3%,
M=PX#%Q9/#T?2<6UJR?\`A:X^D:AH)T9*.6GDGC@>)1)!`$34^D>1]>J@FIZO
M%'\RS_A0#8?]B>MN?^?W,_\`VP?:?PK3_E)/[.K=WIU=K\=^R?E]W)\-*/??
M:?3^S?CE\P=Q[*[#_A?6.Z<CDL_L7:F^J.LW%B^M:_=O\&K*W.C:^5\&,R&2
MI()Y:V"EJ)(E?RA?:60('98VJH\^K=:3'<55WWM[X`?\*@<?\A:4U/\`,H@[
MB^'</RZW)U6V+R_1>X.B=S[BVC#U(>H-N4^`I*[;>VL9TU4[@&5FR8GSJ44L
M%17U$=:DPBIU[J]#^9:.N,%WQ_PFQJN@TQO\?I_F)LC;W37]UJ>ORM2?BIE>
MDL7BNV_X'35<-9')LF'8$F#-=5U*&KHJ0I/')$1+(/=>Z/S_`#YJ:IJ_Y.7\
MPN*DI:FJE7XY[IJ##2P35,J4U'6XNKJZAHXD>1:>CHX'FF<C3%$C.Q"J2/=>
MZ,5\<MX;4'\M'HW?1W-@!LJG^#W6^Y9]W?Q:A_NU#MZCZ(P^0J\[+FQ/_#H\
M12T,+S25!D$21*6+``GW[KW6K?\`#.#*=H_R+/Y$GP*I:0K4?-[Y@"AW]C<B
M*S$U,_QV^.'R1[M^8';=?CZZ2GA6!\KA>I<714Y2H@FJH,MK@^X37%)[KW3?
M\Q?G[V9_+]_FM?SI]T=);2QU5V_W?1_RIOC_`->]G]A4DF/^//Q_S78/2VX,
M=%VYWMO:IC&V]K[<VV=)Q]/DI8*7(5Q`D9H()XI/=>Z,5_,2^4WS(^#^[NE/
MCOW+_,S[0Z"Z7IO@YV3W13?S"&Z`ZIW_`)KY;?.#'Y_(1XKX\P86AZRS>QNN
M-H8_:CIEL1AZ"F3)Y2A\<!R%34?Y7[]U[J\?^3QE/DYNS^7K\>^ROF#OOMS>
M_?O;>U*/LK>L/=6T=A;'WALR?<%#10Q;2I=N=?[2V90T&U_]Q[97&)D*0YF*
MERBQUDAD30GNO=6<>_=>Z][]U[JH[^?/_P!N=OYAG_BN&[?_`'*Q?OW7NC_X
M#-]JQ8'"18[K[:5;CX\1C8Z&LJ>Q:NAJ*NC2CA6EJ9Z)=DU:T<T\`5WB$LHC
M8E=;6N?=>Z=_X_W#_P`^UV9_Z,ZM_P#L"]^Z]U[^/]P_\^UV9_Z,ZM_^P+W[
MKW7OX_W#_P`^UV9_Z,ZM_P#L"]^Z]TI=M9'>U;+5KNO:V#V_#''&U'+B-V3[
MC>IE9F$J313;<P@I4C0`A@TFHFUA]??NO=*[W[KW39F_^++F/^U5D?\`W#F]
M^Z]UJ5>_=>Z__]#<T^"'_9+/6_\`U&;^_P#?B[K]^Z]T;SW[KW5./\Y7^6?V
M-_,>Z!J-J]2?+7M3XO;UVUM'L7&28[;>[]PX?J#N7#;GVZ\']P^\L)BLK24M
M1M!\C21F:O\`MJV>EHY:E?!,LF@>Z]UJ8=+=&_'O=B]D?'W;G_"ESYSY&O\`
MBU\:<GV+WI!U/B^T\S\=MC=?=;8S`;;[$Q&Q-XS;]Q.*W7M+:-5ETHJ2&DI@
M:JA4&*,@%![KW6\!_+=Z%Z)^,WP9^-'3'QGWY-VGT=M;K/$UG7_9L^1I<E+V
M%C-TR5&ZZC>9GH4BH84W%D<W-5+3PHB4JR"$*-!]^Z]T=WW[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]T!_9OQXZP[=[)Z"[9WOC,G6[T^-&\=T[ZZGK:'-Y'&
MTF*W%O'8V:Z[SE1E<=231TN=IY]K;@JH4AJ5=(W<2*`P!]^Z]T3SYJ?RAO@E
M\^]_;<[6^0W5^;J.S-O;?_N;)OSKGL+>O5>Y]T;&^Z>L&Q][9/8N9PTN[=K1
MU$TACIJWR&(2NL;*K$>_=>Z&_LSX`_#_`+;^*5%\(]X]&;/E^,F%P.&P&U.L
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M/W[KW06[\_X_+I3_`,/[.?\`OLM]>_=>Z%+W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=5F_SHZ.:M_E(_S&X8`I=/ASWQ6-JU6\-!L#,U]2?2KG4*>F:W%K_4@7(]U[
MH^?3G_,HNJ__`!'&Q_\`WF,7[]U[H1_?NO=>]^Z]U[W[KW7O?NO=!SL_I[J;
MK[<^_-Z[#ZRV!LO>/:65I\YV5NK:FT,!M_<6_P#,TJS)3Y7>>9Q5!2Y#<N1A
M%3*5FK))I`TKM>[L3LDD`%B0.O4'0C>]=>Z(E\\/@9MCYW;+V#MS)]]?)?XU
M[KZNWL^_-A]L_%;LX=5]E83*U>&K=N9:A?./ALY#683,8+)3P3TS0@%F5PUU
M%_=>Z#'XK_RD/B+\6OCQWU\=HL;OKO?%?+&;<E;\J^QOD-O"I[![8^0F2W;@
MY]OYNM[`WE!38.8DX^MJ/M5H(J,T<]3+4QL*J62=_=>Z!3X1_P`B[XI_"#N_
M`=]8'L[Y-=^;JZQV3G>LOCEAODQVM!VEM/XO==;BK359':O1F&?;F(_NI":5
MWHDJ&DGJ(Z&::%6`FE+^Z]U<-NC:NWM[;6W'LG=V'Q^XMI[NP.7VON?;^5ID
MJ\5G=NY^@J,5FL+DJ22\=3C\GC*N6":-N'B<@_7W[KW6O;+_`,)H_B:D==US
MA_EI_,;VW\0<GEY<A7_!7!_+'<,'QDJ,54HKU>T&PE5A:S>O]U:RLC662(YI
MJMK6%0#ZA[KW5J6"^`/1FU>^_C%WCM1MS;:Q_P`._CEO?XU?'SIK#U]#3]3[
M$VIOV78U+F=R4^/?&R[HK]W+M7K['X9):G*S4C42F1X'J]-0/=>Z0M=_+!^-
MNXN]/GGW=O\`CW+V/%_,0ZLZEZA[XZNWA)M^LZXIMI]/;'KMB8%MGTE'M^CW
M%B\O78VN-3-55&0JY*>OCBGI/MWC6WNO=:J7R6Z,SOP0^8'0'Q@[>_F`?*'X
MF_$GX/\`7\O;'\NGYF]A?'/)_+#?N5WUVEB9MB]L?'F#=FQMA-US-UWLO9\C
MTE/M[=.W<GE*?'H(Z>K@QDR4LGNO=;._\G#Y&_*_Y3?"?;_:OS"VI+A.Q9>P
M^Q-M[/WE4]:Y?IFM[OZ@V]F4I.N>\J[J/.3S9+KJJ["QC/*<>PCA9814P1I3
MSQ#W[KW5J'OW7NO>_=>ZJ._GS_\`;G;^89_XKANW_P!RL7[]U[JT79LBR[0V
MK*FO1)MO!R)Y(I8'TOC*5EUPSI%/"]CRKJKJ>"`>/?NO=*3W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=-F;_XLN8_[561_]PYO?NO=:E7OW7NO_]'<T^"'_9+/6_\`
MU&;^_P#?B[K]^Z]T;SW[KW0`_*WJ?<G?/Q@^1/26SMQ_W/W7V[TCVCUIMO=+
M>=8\!G=[;+S.W<7E)WIF%2E/25N01Y&C_<6,$KZK>_=>ZT6>O.P?F_\`&'LO
MH#I-/Y"/<.5WUT;\"^[?@;N7;W7^TES'QR[VWOVIN'8U=ANW-Q=CTNSJ_;64
MV/N.GV745V=3(Y2:1JG*2_Y1"`WOW7NMPO\`E)_%GL3X6?RZ/BM\:>VZRFJ>
MR^N.O73>U+09`97%8#<&Y<]F-VY#:>&R$?[=5B-IRYW^'4[QDQF.F&@E;$^Z
M]U8S[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+]MSY8_%O>':^4Z(VG\D.BM
MS=VX63(0Y?J+`=L;&RW96-GQ"QOE:>MV309R?<5//C$E4U$;4X>$&[@6/OW7
MNGOMWY'_`![Z`.W%[U[TZAZ9.\*\XS::=I=C;1V$^Y<@I17H\&FZ<OC&RM1&
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MGNC)XRDJ:YXD+")'9]()M;W[KW0A8'/X'=6%Q6Y=KYO$;DVYG:&GR>$S^`R5
M'F,+F,;5Q^6ER&+RF/GJ*&OHJF)@T<L3NCJ;@D>_=>Z=O?NO=!;OS_C\NE/_
M``_LY_[[+?7OW7NA2]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW59G\Z:KJ:/^4A_,:F
MI)Y*>5_AUWM2-)$Q5FIJ[868H:V`D?6.II*B2-Q^4<C\^_=>Z/IT[_S*+JS_
M`,1QL?\`]YG%^_=>Z$?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5'?SY_
M^W.W\PS_`,5PW;_[E8OW[KW5I>UI))ML;<FE=I)9<#B)))')9WD?'T[.[,>2
MS,22?Z^_=>Z?O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TV9O_`(LN8_[561_]PYO?
MNO=:E7OW7NO_TMS3X(?]DL];_P#49O[_`-^+NOW[KW1O/?NO=52?S+_Y>G>G
MSEJ.J,CT_P#S&OD5\":+K"@WHNYX.C)*^&B[%&X7P%115^ZIZ#?FR3$VTXL)
M.*8R-.@2ME/I^I]U[K52VGL3K#??9/>O5&Q?^%6?\P#>&2^-_5&\>Z.X-Q[;
MV]VWE>N-N=>["KL7CMY96FWS2]NMMK<+X*JS,"RQ8^:J:2[&+R!3[]U[K<__
M`)?/7\W67PZZ+VL_REW5\U:9MJ2[CQ'R>WG5M7[@[:P&\<KD-UX#.U-7)F]Q
M2ST]-A\Q#24Y>LF<4].@8A@5'NO=')]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2,[
M&VA+V#U]OG8<&Z-R;(FWKM#<>TX]Y;-JJ:AW=M0[AQ%7B?[Q;7KJVEKJ2BW#
MAON_N*.:2&5(JB-&*-:Q]U[K62^6W\K#X#]4;6^+/PR^$726U,;_`#$L9V/T
M=V+L#OO:U)3P_(#KC9/6W8>WLUV]\G_DAVOA8*7.R;8W)M^CR=`\63F6/<.>
MRL-)C:5C%:F]U[H?>EOAC\9/Y@G\P3^:KVS\R^FMB_(NJZG[:ZS^)O3NV.V,
M-%N[`=4]7;9Z1V=O#/#96#RC3X_;N7WMO#>U7D9\G2QQUX>WCF0%M7NO=5R=
M4];8[NWJ[^7C_+,[1R^3WQ\6-H_S6_G7T[F]H9?<.2R=!V/T=\+8]^;RZ3Z@
MWEEA40UNYML8BOR..@GI9Y&2HBPRPR:@GOW7NK)MK=)=/_R]?YNDVW/B7UQM
M#IGJ[Y'?RZ^V^S>S>FNN:"#;FP:[LSXZ[_VW#L?L''[#Q<4&#V_EJK;V[:K&
M5%1210K6@WD4RAG;W7NJ^-J?RX_BSV'_`"&]]?.'>/7NULO\X]Y]+]J_.N?Y
MAY-GB[QPO?V+S&XNUMKYK&]G,S[BPV$VW68:CQXQ<4RXXTL+HT!,CD^Z]T<7
MISI#J+^9A_,7W3O+YI]<;1[]VY\?_P"7=\*ZOK'JOM+"4VZNN\!OCY.[?W!V
M/VMV+%L;,1U&W:S<N6;%T6-2KGII9*:"F*QE38CW7NC5?R=]GX?HC=O\RCX@
M=?#[#HOXS_-K(4?1FT(\G5Y:AZWV7VSU9L+M3)==X:HK9)JFCP.W]V[BKY*2
MC:1_M(ZK0#:WOW7NKJ*NKI:"EJ:ZMGAI**C@EJZNJJ9%B@IJ6!#)-/-(Y"I%
M%&I9F/``O[]U[HM>]^Y>I:C=O3T\'9&S)8J+?&9J*N2/<./9*>%^N-[4J2RL
M)B$1JB=$!-@6<#\^_=>Z$K_3?T[_`,_/V/\`^A'C?^O_`+]U[KW^F_IW_GY^
MQ_\`T(\;_P!?_?NO=>_TW]._\_/V/_Z$>-_Z_P#OW7NO?Z;^G?\`GY^Q_P#T
M(\;_`-?_`'[KW7O]-_3O_/S]C_\`H1XW_K_[]U[KW^F_IW_GY^Q__0CQO_7_
M`-^Z]U[_`$W]._\`/S]C_P#H1XW_`*_^_=>Z]_IOZ=_Y^?L?_P!"/&_]?_?N
MO=>_TW]._P#/S]C_`/H1XW_K_P"_=>Z]_IOZ=_Y^?L?_`-"/&_\`7_W[KW7O
M]-_3O_/S]C_^A'C?^O\`[]U[KW^F_IW_`)^?L?\`]"/&_P#7_P!^Z]U[_3?T
M[_S\_8__`*$>-_Z_^_=>Z]_IOZ=_Y^?L?_T(\;_U_P#?NO=>_P!-_3O_`#\_
M8_\`Z$>-_P"O_OW7NO?Z;^G?^?G['_\`0CQO_7_W[KW7O]-_3O\`S\_8_P#Z
M$>-_Z_\`OW7NO?Z;^G?^?G['_P#0CQO_`%_]^Z]U[_3?T[_S\_8__H1XW_K_
M`._=>Z]_IOZ=_P"?G['_`/0CQO\`U_\`?NO=>_TW]._\_/V/_P"A'C?^O_OW
M7NO?Z;^G?^?G['_]"/&_]?\`W[KW7O\`3?T[_P`_/V/_`.A'C?\`K_[]U[KW
M^F_IW_GY^Q__`$(\;_U_]^Z]U[_3?T[_`,_/V/\`^A'C?^O_`+]U[KW^F_IW
M_GY^Q_\`T(\;_P!?_?NO=5N_SB^RM@;M_E/?S',/M?>.W=PY-/AMWIDGHL1E
M:.NJ(Z"EVI+35%4\-/*[K#'49&%"Q%M4@_J/?NO=6:]._P#,HNK/_$<;'_\`
M>9Q?OW7NA']^Z]U[W[KW7O?NO=0LAD:#$T<^0R=;28Z@I8S+55U?4P4='2Q+
M8&6HJ:AXX88PQ`U,P%S[VJL[!44ECY#)ZJS*BEG8!1YG`Z3E+V%L.NJ::BHM
M[;1K*VLF2GI*.EW+A:BJJJB4VB@IJ>&M>:>:0\*B@LWX'M5+M]_"GB36,RQ^
MI1@/S)`'26/<+"9Q'#?0O)Z!U)_8"3TKP;@'^HO[2=+.@)^3/R7Z5^'W1O87
MR-^0N]\=U]U+UCA6S6Z-Q9`232?N3Q46+PV&QU.LE=G-R;BRU3!0XW'TR25-
M;6U$<,:EG'OW7N@"ZW^>>V<C\#/]G[^1'5/8WQ'V!0=;[G[<W1L'N),._8FU
MM@8BKR4FW,EEL3@:ZL6GS.]]O4]'6T6*E\.0BFR$5)-$DP-_=>Z(?\,/YW=9
M\C>_^FNC?D'\&N^?A%2_+;8&Y.S?A-V%V_N#;F?V_P#(S;.V:>ES=5AWI<%0
M451U[V%4[,K4S<6&J9*Z]!:1J@+44+5GNO=67?.WY54OPB^'W?\`\M*W9%1V
M/2]$]?U^_)]BTN?BVM4;ECH:JCI3C(MPS8C/18EI/N]7F-'46"VT&_OW7NA6
MZ[[9B[`Z"V+WJF!EQ4.]NG]L=LIMA\BE9-C8MR;+H=X+@7RRTE/'52T:5OVY
MJ!!&KE=?C4'2/=>ZK0ZT_F_[2WU_)W_X=ORW2V9VUAZGKC?^\,-T+#OK'YO/
MYO=6VNU-S=.[+V!C]\/MO#TU1DNQ=Z8>B@II(\3)40MD5CBI:N9%BF]U[H;O
MC#_,!K_D%\ROE?\`#+<71]9U=O+XF]6_%3L#=N>E[!H-X4F9S/R5ZV._:_9]
M+04.V,.E$>N:V*7&O7BKJ8\JT?G2*G4A/?NO=60^_=>Z][]U[KWOW7NO>_=>
MZJ._GS_]N=OYAG_BN&[?_<K%^_=>ZL`V_P!P]4XS`X3&Y'L79U#D,?B,;0UU
M%59['PU-'64E'#3U5+40O,'BGIYXV1U(!5@0??NO=._^F_IW_GY^Q_\`T(\;
M_P!?_?NO=>_TW]._\_/V/_Z$>-_Z_P#OW7NO?Z;^G?\`GY^Q_P#T(\;_`-?_
M`'[KW2FVWOW9.\9:J#:FZ\!N.:ACBEK(\-DJ6ODI8I69(I)Q3R.8TD=2`3]2
M/?NO=*SW[KW39F_^++F/^U5D?_<.;W[KW6I5[]U[K__3W-/@A_V2SUO_`-1F
M_O\`WXNZ_?NO=&\]^Z]T`'ROZIW/WM\7_D5TGLK<?]T-X=N=(=H];[6W0TD\
M<>!W!O39>9V]B<I++2D545/25V01I'B_<1`2OJ`]^Z]UHE]=]J?+'XN]H]`=
M(-_(8[GK.Q.E?@1W5\#MX[-V#L*FS'07?G8?:6?V'78+M;</8E+M.OP&>V+N
M:#9E17YO^(U]1*9\I)IG4!F/NO=;B_\`*.^+O8_PQ_ER?%3XW=OU,,O9O777
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M61M>I?'[KW2>W'_*"[IV/\(_C5L_H#Y";;3Y^?%;Y`;G^8N![\W]MBH/77;G
MR#[1K=X5W>F&WSMK'O49'%=>=H4>^J[&K]OY:BB@BIG"DH0/=>Z&_P"$OQ!^
M:V7^2^__`)R_S+MV=!Y/NS*]+Q?&[J+I7XW4FZJOJ3J/JBIW-_>S?&0EW+O>
M*FW'N?=W9.=HZ22I:6/QT=+3K`CLITI[KW1!*K^5I_->PG5>\/Y8VP_D5\9:
M'^5WO/<^YZ&#MG+8'>DWS!V1\<M[[MK]U;J^.^&P5-%'U_DY)J3)U>'IL]/4
M?<)0U);T:5B7W7NCD_*?X1_.+J#Y*;1^7_\`*KW-\>*;=];\?MG_`!=[IZ!^
M4*;OHNLM[[`ZQK<C7]2;UP6Z]B05.X<+O/8B9:JHFB\:PUE'*JLWI*GW7NC8
M_P`MWX?]E_$_JSLO+_(+LC`]N_*7Y+=R;I^0OR.W_M+"S;=V74[\W/18G"8W
M:FQL34DU=-LO8>TL!08O'F8)+*D#2LBE[#W7NK$??NO=!9OT#^^72GI7_C_L
MW_97\=9;[M^/?NO="GQ_1?\`DE?^*>_=>Z]Q_1?^25_XI[]U[KW']%_Y)7_B
MGOW7NO<?T7_DE?\`BGOW7NO<?T7_`))7_BGOW7NO<?T7_DE?^*>_=>Z]Q_1?
M^25_XI[]U[KW']%_Y)7_`(I[]U[KW']%_P"25_XI[]U[KW']%_Y)7_BGOW7N
MO<?T7_DE?^*>_=>Z]Q_1?^25_P"*>_=>Z]Q_1?\`DE?^*>_=>Z]Q_1?^25_X
MI[]U[KW']%_Y)7_BGOW7NO<?T7_DE?\`BGOW7NO<?T7_`))7_BGOW7NO<?T7
M_DE?^*>_=>Z]Q_1?^25_XI[]U[KW']%_Y)7_`(I[]U[KW']%_P"25_XI[]U[
MKW']%_Y)7_BGOW7NO<?T7_DE?^*>_=>Z]Q_1?^25_P"*>_=>Z]Q_1?\`DE?^
M*>_=>Z]Q_1?^25_XI[]U[JK[^=?#&?Y27\Q:HTCRQ_#_`+QB5AP`DVSZQY!8
M``W:G7_;>_=>ZL"Z=_YE%U9_XCC8_P#[S.+]^Z]T(_OW7NO>_=>ZK<^8]%_,
MIJM\;3?X59KI[';!7:LR;MAW]'C9,\^\!F*LK+$V6Q.1B_A!PAIQ"(2K"83>
M2X,=H6]RH?>F;<K!O;*]V^/:?`_5\98]9FUO4_J*PT:-&G33NUEN(ZS%^[7>
M?<L@Y9YB3[S6V\QS<V?7J;0V+2^`+3PEPPBEC(F\;Q"^O4"ABT4(>I)MR8O^
M<DF$R+=_;@Z%K>EUI)CV12[;AVU_'Y]M:"*A,3]KM^FJOO?N#%I\<B-_0^T'
MMI;?>/3GOEEN;K_;).7/J1]0L8MPYCH=6@A%(;TH0:^8Z''OE?\`]V_+[2<^
M)[2[1S7'[DFQ/[N:Y-U].+CQ(])FU3NNC3KK56'RZJ?^(6QOF7A^ZDK,-1;M
MQN]),%FJ?JRL[*RDM?LZ#L6;)8IMJODZ?)5N4H@BNCD,\+!4#?UL8^]F^3_O
M-[)O//5[S9'OD<#<NWJVAW"X>6V%XS0F"JS2R1Z@`Y!TMP-/7K(G[UON;_=\
M<T\F>T>U\DWG*-P$YWV>3=DV&QBMMQ;:4BNA?>')!;6\NFK1AE\4`L5KD`BW
MP8C^?C86W5\:K6%OV-I?T_PVN![4?2?>R_Z.FS_[S;?]:N@8-S_NFZ#_`'1<
M[?MN_P#MIZK>_G/;-^9W=.*_DJ?$_OGMOI[J/=7=OS*W_F>VNV,GLR/>?1^-
M[+ZHP+;F^/&WMU;7KLAMG9>\JO<M'E*ZGIMO5K14N;S44:)^W%*&R%Y)3FV/
MEO;EYYEMWYH[_&,-!&?U&\.@``J(]&K2`NJO7/[WHE]I9O<KF63V.M]QB]LB
MT7T:WQ)N!^C'XVJK,VDS^(8@[,XCTZC7HF_SD[X^=N?^#?\`/C_EH]\?(K"?
M-W>/P^V!\8.Z=N?*+K[:NWNL=QUG5^\NW-A[H[3ZH[9VOL.:+:F(SNR]E8&N
MJY:*.6>HEH8ZZ&>2H1H8H!9U%O5GO\PCN+J/OSY!?\)OL)\8\U@=R[HWC\KM
MD?(;8-/L.IV]2Y#`?%+:74^KM"KJ),)DO-M;:%9M^KAHJC&H119)L74T5I)*
M/P^_=>ZLQ_GC[5W)O3^4-_,$V]M'!Y+<>=G^-N]ZZGP^'IVK<A44>!6DSN7F
MIZ6.\M1]AAL945#H@9RD3!59K*?=>ZF?'CY:_&JG_E*=3?(>H[JZ^@Z9VM\,
M=DS;CWU+N+'QXS"56W>F<329O`Y.%YEKJ/=N.R,#4<F'>(9/[ZU,(#.RQGW7
MNM>SX3[0W=OW^4W_`,)W_P"7KG,5D,"_RA^2F=^0/;6V<YC'FASGQ8^+';/:
M_P`PYI,SCHYI:I-L]A[B7KZ*EJ9Z27'RIF*=)9:::HI7/NO=!5_,'^3?RE^+
M_P#,I_GE;D^,E/E=C0[UPG\JOKOO3Y88S$S[O?X:]&[IZ;SV.WKWM'L#!I6[
MUSU?B8:A(H*_&T58N$!>JD$<WVLB^Z]T+?\`,%QN5Z1WA\-NG=I=X?S$>_?@
M3VI\#>V3\0,Q\&_D)V1V=\I_D=\_(4R>_CVGVGF-J;R;LCM/9'^B68Y:DEI8
MY]IX.0LLM-2X]/"/=>ZV)/Y/'1/=/Q]_EZ_'O:7R3E[-/R*SVU*+>O>%)VSW
M)O'O#=..[#S5#0TF0IGW5O3/[DJL.E1C<52U53A*&I.+Q.3J*J&F!6[M[KW5
MG'OW7NO>_=>ZJ._GS_\`;G;^89_XKANW_P!RL7[]U[JTC:-O[J;8X7_CWL+_
M`&5_YUM-_A[]U[I0\?T7_DE?^*>_=>Z]Q_1?^25_XI[]U[KW']%_Y)7_`(I[
M]U[KW^P`_P!8`?[T/?NO=>]^Z]TV9O\`XLN8_P"U5D?_`'#F]^Z]UJ5>_=>Z
M_]3<T^"'_9+/6_\`U&;^_P#?B[K]^Z]T;SW[KW5*O\[WJ_\`FC=F_%[<F'_E
MK[XZ]I)LMU[VIMCNKK#<V&DC[#WSM?-[5FCQ\W1V]*-#6;?[,A,=124<32TD
M<D]7#*E1"\/J]U[JG+KS;G_"I"CZ*V1UM+\F?Y9&V</2]3[<V/)MSL3.-_I2
MV]C8-HTF`;"[XR:;4R,QW]B:5?#DI_N)W_B$<C&1VNQ]U[K8_P#Y7O1V[_C9
M\#OCMT5V#W=C?D1OSK7:=?@-Y]JXC<=1NW%9K<_]X\S7YG%8[<5;-/DLI1;4
MK:UL7'+5,*DI1CRJCW1?=>Z/Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@MWY_Q^72G_A_9S_W
MV6^O?NO="E[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJU/YS%%'D?Y2_P#,;II:E*.-
M/AK\@ZQIY02->-ZVW!DHH57@LU7/2K".>#)<7("GW7NCV=.?\RBZK_\`$<;'
M_P#>8Q?OW7NA']^Z]U[W[KW75A_0>_=>ZZ9$<%6564BQ5E!!']""""/?N/'K
MW6,4].""((05-P1$@(/]00MP??NM4'IUEL/Z#_;>_=;J>BS_`"U^'7QM^<_3
MF3Z$^5'5F%[:ZNR>2HLX,#E:S,XBLQ.XL;3UM+B]R[;W%MO)8?<>VMQ8VGR5
M1'#64-5!.L<\D98QR.K>Z]T&_P`3?Y;WPH^$'4&\^B?C7\?]F;'ZS[*DR+]G
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M>W]H["I*Z'8V!J:S^Z]#2BOI\='7QXZ`423+2EH3[KW3!B_A9\;<1W)\F._(
MNMJ.O[*^8.R=C]=_(ROSF8W!G\!V1LKKK:==L;:^W:_9>8RE;M'&XZ#:F2GH
MZE:*BIC7QRM]R96.H>Z]UJ?_`"A_E>4WQ9^7VW=F8_XZ?S/MR_RS^L=G4G8_
MPAPG\L[?&3['[,^/OREW56/#W=E,CN#?&]JCO#JG$;FQVN2GI,'EJ3:U46AD
M>GEK@[Q>Z]UL,_R<,?\`.;&?"?;]+\_ZG?-1VU_I#[$FZ_3MW(;6RW>M)T#-
MF4?J.C[ZR>RT7;M=VW#AC(<D\1:?Q-`*HBJ$ZK[KW5J'OW7NO>_=>ZJ._GS_
M`/;G;^89_P"*X;M_]RL7[]U[JU7!BV%Q`\0@MB\>/`"A$-J2+]H&/]LB/Z>G
MCCCCW[KW3I[]U[KWOW7NO>_=>Z][]U[KWOW7NFS-_P#%ES'_`&JLC_[AS>_=
M>ZU*O?NO=?_5W-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]^Z]T6KYF47;62^(G
MRAQW0C5J]VUWQ^[>I.IOX9*T&4/851L/.Q;37$SHZ/!EFS;0BE<,"E04-Q;W
M[KW7SB-T_P`OS^47T/M3XQ=Z_-$_-#KKI+Y<?!+=E2O8F?Q^^SV#LG^8]U/O
M"LP/;^WMT;9AVW555.FXYJB2;$T&1B^RF>@>5I_#*\B>Z]UO-_R'Z5:3^4A\
M(@O4T/2OW/5#5IV13IEX8I/O-S9ZH7>(I,Y7Y3*T+]B(XSSP23,L3Y$K&%C"
M*/=>ZMQ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW5!_RKVO\EOY@?\PW?_PJZ[^7W>/PQ^.GQ6^/W6/:79FZ/C-D,5MC
MN#M3N3NW-;G7:.W*C?65Q^5."V3L_9^U6JYJ2&!_OJFL4/PJ-'[KW1C_`.5'
MVWWSG-N?*?XP_)CLJK[N[9^$'R6SO0_^G#*8:DV_G^V^M\EM':W8O5^[]V8O
M'PQ4";O7;.[5H<C-!J2JGHS,69W9C[KW5L/OW7N@MWY?^^72O!XW]G+\'_GV
M6^_^*>_=>Z%.Q_H?]L??NO=>L?Z'_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[K
MW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'
MW[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'
M_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L
M?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[
MKW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW19?FA\;8OF%\2_D3\6:C=
MTO7\'?W4N\NJY=[18-=RR[6CW?AZG$MFX]OR97!)F7Q_GUBG-92B2UO(OU]^
MZ]U7=A?A%_.*V_AL1@,5_.@Z]I\9@\908?'0O_*]ZBE>*@QM+%14<;R'OM-;
M1T\"@FPN1?W[KW3E_LG/\YG_`+W3==_^FN>H?_M_>_=>Z]_LG/\`.9_[W3==
M_P#IKGJ'_P"W][]U[KW^R<_SF?\`O=-UW_Z:YZA_^W][]U[KW^R<_P`YG_O=
M-UW_`.FN>H?_`+?WOW7NO?[)S_.9_P"]TW7?_IKGJ'_[?WOW7NO?[)S_`#F?
M^]TW7?\`Z:YZA_\`M_>_=>Z]_LG/\YG_`+W3==_^FN>H?_M_>_=>Z]_LG/\`
M.9_[W3==_P#IKGJ'_P"W][]U[KW^R<_SF?\`O=-UW_Z:YZA_^W][]U[KW^R<
M_P`YG_O=-UW_`.FN>H?_`+?WOW7NO?[)S_.9_P"]TW7?_IKGJ'_[?WOW7NO?
M[)S_`#F?^]TW7?\`Z:YZA_\`M_>_=>Z]_LG/\YG_`+W3==_^FN>H?_M_>_=>
MZZ_V3?\`G,?][I>NO_37'4/_`-OWW[KW7?\`LG'\YG_O=-UW_P"FN>H?_M^^
M_=>Z]_LG/\YG_O=-UW_Z:YZA_P#M_>_=>Z]_LG/\YG_O=-UW_P"FN>H?_M_>
M_=>Z!?Y$_P`KG^:5\J>D.S/CMW3_`#C]EY_JKM[:U;LS?>'Q/\M+J[;N2R&W
M\BT35=-0YS']^_?8NH<PKIFB(D0BX(/(]U[J_'$X_P#A6*QF,$C3C&X^CH!.
M8_&9A1TT=.)3&&<(9/'>US:]KGW[KW3A8_T/^V/OW7NO6/\`0_[8^_=>Z]8_
MT/\`MC[]U[KUB/J#[]U[KKW[KW39F_\`BRYC_M59'_W#F]^Z]UJ5>_=>Z__6
MW-/@A_V2SUO_`-1F_O\`WXNZ_?NO=&\]^Z]U5#_,PQ_\X>NK>H/^&K<]\6,+
M01TV\1W0OR0ILE/4U-8TNWO[D-M-J#&9%5@AA7)"L#!26:&QX/OW7NJ#NS=^
M_P#"AC=VY8.B.Y?D7_(2W/O.//8XTW2_9VY-E9K<Z[H>-VQ!I^N]T8FIR8S[
MQ53&FTTGW!64Z.&-_=>ZVJ_A;0_*S&?&?K"@^;=1U;4_)JDQ^6@[*EZ7IYJ/
MK02QY_*)MV+;%/44U')%3T^UA1)*/$@\ZOI`6WOW7NC2>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7[^4?;_9/\M3^9
M'V;\O\[\9_D)\B/BG\O_`(_=3=>[ISWQBZ^E[8W[U+WET3DMW082GW1L''U-
M'F)=J[\V7N9$IZ^.3PP5=&RO]??NO=&/_E*[%[HKL/\`+KY<][=6[IZ*W3\Y
M/DWE.ZMH=+[\EIGW]UWT]MW9&TNM.L*'?5-2M)'B-UYS#;4?)U5!J)HOO5B(
M#!O?NO=6VUE+'6TE313-41Q5=/+32/2U$]'5(DR-&[T]53/%44TZAKK)&RNC
M<@@CW[KW1:]Z]2X"/=?4,4>6[&ECJ-[YB.>1^RM^5#T\:==;TF62.9\Z[T;-
M-$BET*%E)0DAR#[KW0D?Z']L_P#.\[*_]&IV#_\`9%[]U[KW^A_;/_.\[*_]
M&IV#_P#9%[]U[KW^A_;/_.\[*_\`1J=@_P#V1>_=>Z]_H?VS_P`[SLK_`-&I
MV#_]D7OW7NO?Z']L_P#.\[*_]&IV#_\`9%[]U[I`R];8]>T\?@%W'V<,%-U[
MF,Q-3CL[?WB;+TVX\)14TYJ/X]Y1*E'5RJ$UA2#?22+CW7NE]_H?VS_SO.RO
M_1J=@_\`V1>_=>Z]_H?VS_SO.RO_`$:G8/\`]D7OW7NO?Z']L_\`.\[*_P#1
MJ=@__9%[]U[KW^A_;/\`SO.RO_1J=@__`&1>_=>Z]_H?VS_SO.RO_1J=@_\`
MV1>_=>Z#_;W6^/K-_=C8>KW%V<^)PL&RVP\+=G;_`$C@;)XJOJ,DT4RYY'F,
MTT2EM3/I(XM]/?NO="!_H?VS_P`[SLK_`-&IV#_]D7OW7NO?Z']L_P#.\[*_
M]&IV#_\`9%[]U[KW^A_;/_.\[*_]&IV#_P#9%[]U[KW^A_;/_.\[*_\`1J=@
M_P#V1>_=>Z]_H?VS_P`[SLK_`-&IV#_]D7OW7ND)M3K;'Y#<_9]!7[A[.>AP
M6Z\-C\'&_9V_HTIZ"IV)M3+5,<,BYU6G1\KD*ARS%R&8J"`H`]U[I=_Z']L_
M\[SLK_T:G8/_`-D7OW7NO?Z']L_\[SLK_P!&IV#_`/9%[]U[KW^A_;/_`#O.
MRO\`T:G8/_V1>_=>Z]_H?VS_`,[SLK_T:G8/_P!D7OW7NNQT_MFX_P!SG97U
M'_-5.PO_`+(O?NO=(+K?K;'9O;E76YG<79L]9'N_?N.C>7L[?T#C'XC>N=Q>
M*B"1YV%2D.,I(D5M-W4:B23?W[KW2\_T/[9_YWG97_HU.P?_`+(O?NO=>_T/
M[9_YWG97_HU.P?\`[(O?NO=9(^I-NQ:BF>[*&I2I_P",I[_;@_\`!MP&Q_UN
M??NO=8_]#^V?^=YV5_Z-3L'_`.R+W[KW39FNIL!2X;+U5-GNRUJ:;%Y"HIV'
M:78+LL\-)/)"RHVX&!99%!`(()_!]^Z]TS[#ZOQ.6V-LO*Y7</9LV4R>T]NY
M#)32=H;^ADER%;B*2IK))(DS\:1R/42,2H50I-@![]U[I5_Z']L_\[SLK_T:
MG8/_`-D7OW7NO?Z']L_\[SLK_P!&IV#_`/9%[]U[KW^A_;/_`#O.RO\`T:G8
M/_V1>_=>Z]_H?VS_`,[SLK_T:G8/_P!D7OW7N@][5ZXH=O\`7VY\S@=Q=G4^
M7H:2GDHIXNSM_5$L<CY"CA=DAESLR.YBD8<J>#[]U[H0ST_MFY_W.=E?4_\`
M-5.PO_LB]^Z]UU_H?VS_`,[SLK_T:G8/_P!D7OW7NO?Z']L_\[SLK_T:G8/_
M`-D7OW7NO?Z']L_\[SLK_P!&IV#_`/9%[]U[KW^A_;/_`#O.RO\`T:G8/_V1
M>_=>Z#_?W6]#AWV*,3N+LV(97L/;N&RFCLW?T_FQ%9#DFK()"^=D\,4C0)J=
M=+"PLPO[]U[H0/\`0_MG_G>=E?\`HU.P?_LB]^Z]U[_0_MG_`)WG97_HU.P?
M_LB]^Z]U[_0_MG_G>=E?^C4[!_\`LB]^Z]U[_0_MG_G>=E?^C4[!_P#LB]^Z
M]U[_`$/[9_YWG97_`*-3L'_[(O?NO=(+-];4%+V)L'"TVXNSEP^6P>_:O*TZ
M]F[_`'CFJL3_`'6&*>6<YYGA:+[^?0%90^HW#6%O=>Z7O^A_;/\`SO.RO_1J
M=@__`&1>_=>Z]_H?VS_SO.RO_1J=@_\`V1>_=>Z]_H?VS_SO.RO_`$:G8/\`
M]D7OW7NE-MK96*VK+538ZOW36&LCCBE7<&[MR;DB18F9U-/%G<G7QTTA+>IH
MPK,."2/?NO=*[W[KW39F_P#BRYC_`+561_\`<.;W[KW6I5[]U[K_U]S3X(?]
MDL];_P#49O[_`-^+NOW[KW1O/?NO=%;^<&XMU;1^&7ROW1L;>N&ZVWK@/CMW
M)E=H]@;AR*X;"[-W+1;`STV#W)DLNZ2)BJ;#Y-8YFJ2I$&C60=/OW7NM%/H_
MK/\`X2G9[^77@NP.^NY9,S\L,GTS6;@[7W;N+L[MP_*3_3Q)CI*G=$VW]H8[
M*3;:RV4BWN)!AG%%5T591>*66616EE]^Z]ULH_R)?YB/Q_[?^'/Q!^,.Z/FC
MUCWO\SL3TK]SNO9N-W8VX>Q(L-@'K:W'X[<E04D&3W#LW9$E!2Y6=IG=JF"0
ML6-V/NO=7_\`OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
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M6`_V`XX]^Z]UU[]U[KWOW7NO>_=>Z][]U[KUOZC@_P!1<$?ZQX/OW7NN[&U[
M<>_=>ZZ]^Z]U[W[KW7O?NO=>]^Z]UV01]1_K7`-O\1^+CW[KW77OW7NO>_=>
MZ][]U[KWOW7NNP"?I[]U[KQ%OJ.?ZD<C^MC_`$-O?NO=>L;7_'OW7NNO?NO=
M>]^Z]U[W[KW7O?NO=-F;_P"++F/^U5D?_<.;W[KW6I5[]U[K_]#<T^"'_9+/
M6_\`U&;^_P#?B[K]^Z]T;SW[KW25WSL?9_9NS-U==]@;<Q6[]C;XP&4VMN[:
MN=I4KL+N+;N;HY<?E\-E:.3T55!D**=XI8SPR,0??NO=5J#^1Q_*#''_``W7
M\6./^_98H_[R?U>_=>Z&CH+^6'_+X^+/8M'VY\=/B!T9TUV;C\7E,+1;WV%L
MJAP>X:7$YN!:?+4$5=`=:TV0@4)*O]I>/?NO='M]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UV!<V]^Z]
MUJA[.^)_>G\SO9'RV_F(97YR?+?I'MG;7=?R.VC\%]G=)=E2;4Z=Z:V-\;]S
M[@V7L1MS]9T=-/B^R\EO_<&U*BLSQR#*\\=68TL`+>Z]U?I_+R^0>X_E=\&_
MBI\C-Y45-CMY]N=([%W;O2CHXQ#1P[RJ</!3;K-+`ITT]+)N"EJ&CC_W6A"_
MCW[KW1Q_?NO=>]^Z]U[W[KW7OK>P!-C8'Z$VXO\`X7^OOW7NM*G^9EM7)?"[
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MS/\`*Y[:W[N5J.JWQ\3-E8/)PX#K$8"JIO/M3#5U'4)3PY#')/'4/-^V?=>Z
MWHS]?I;_``]^Z]UU[]U[KWOW7NO>_=>ZJZ_G)=_]K_&O^7YV[V+TQO*#J[>F
M1W#U1UJW<M3CX\I3](;;[8[0VGUYNSN!Z*9):=I=A[?W%45D,DJF*GJ%CF?T
MQGW[KW56>,ZPQ'\ISY;_`,N>GZ/^?/R'^2N$^=7=$70G>/4'R$[RI.[L;V)0
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MXY'XZ;+V7O\`[I2AIZ?8.V>QMTUFSMB3Y>MKJ:C;);LS^-QN7RD&#P5)/)6S
MPTL#U56E/X(BCR*Z^Z]U4_\`R;,M\FI]Q?S+-K_*GNN+OGN/87S<K=LY+=N.
MQN2VWL''+_H3ZNRU-M?KG9E9D<FVT=B;?ER1IJ2G63R3*AJ)KSRR$^Z]UK55
MWR#\._:[/R_S#?F,G\^D_*\[/IOCW3]@3#X1B8]L+AZ?JU8$I?\`9?/]E]_T
M1J)'JGSRYL&\34_WMXC[KW7T#*?[C[>G^]6%:SP0FJ%/K-.*GQKYQ`9/W3")
M;Z=7.FU_?NO=9O?NO=>]^Z]T0?Y^?&'OOY>;(ZWZ6ZK^16>^-G5>;[`2K^3V
MZNN*_)8#N_=O4='AJ\KU[U)O"CI*J#9F0W/N"2G3)9%PLT6.1UA)=BI]U[JN
M?X)=);[^&7\SOLWXC]%_)/Y`_([X@P?%ZB[3[DVW\@NPJKN3,?'3Y$Y;>&+Q
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M)#X[]F_*'LO^<-U#V9W-G=Y]?]==Z_`3O/?/4_Q4K*VOHL/U7U_MWNKJW%[%
MW1O_``PEAIJWNW?^%RS9+-+/"SX))XL;$_[,Q;W7NMB+W[KW7O?NO=>]^Z]U
M[W[KW39F_P#BRYC_`+561_\`<.;W[KW6I5[]U[K_T=S3X(?]DL];_P#49O[_
M`-^+NOW[KW1O/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UV#8W]^Z]UJVX
M[<G\R/\`E[X7Y6_`CIK^7GV=\I,'W'W%WSOWX9?)38N[-KXOI3:>U_DMN'-;
MG."^0>0S&1I<IU_4=0[FW)6F<JI_B=+$GA*:UE;W7NKY?@O\=)_B-\./C/\`
M&6MS$6X,ITETUL;8.<ST`D%-F=QX7"TR;DR=()B9OLZ[.O421:_5XV6_/OW7
MNC6>_=>Z][]U[KWOW7NN+AF1U1_&[(P20J'$;E"%<H2`X1N;?GW[KW6KW\DO
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M]N8RHJ:6/<^P\]D'5Z>AGW!M@UD%#-4`TL>0:`SVBUD>Z]UK3_`7X'8O?7R>
MZ"K^COY2/97\L'X\?'[M^+Y']X;Y^1>Z?[S=M]R]H;4VIN?;_473G4RY7<N\
M<[3]2;7SVYY\U7SPU%'C'>F@2.%9"5?W7NMOWW[KW7O?NO=>]^Z]U[W[KW57
MW=O5796=_FP_!#MW#;'W%D^KM@?'3Y>;:WOOVDH3+MK:VX-Y2=7G:F'S-?K4
M4U?N`8NI^U32?)X'^EO?NO=5N?S*?DM\KMY_*_._';/?RW?GS\@O@3UWAML5
MF;H_C9M?"X[!?*_L.K6GS.2V]V1N[,YO$U]5T#M:FFBI9<%C&C_O%DHYAD)6
MHHUII?=>ZNS^%G>FY/D)T9B]\;G^*W;OPVJ<9F,ELS%]']U83`[=W;B,#MB&
MAH\1DJ'#[;JZO$T6V*VF?QT"1E`L<!`4*%O[KW1L??NO=>]^Z]U[W[KW57?5
M'5796(_F\?+SN3*;'W%0=4;R^'_Q@V9M3L&HH3'MC<&[-J[T[4KMR;>Q>0UD
M5&4PE'EZ:2HC"C0LZ&_/OW7NB2;O^6G\R'XK[W^2OQ^E_E-9_P"4>3[,[/[$
MW-\?.]_C3C.N-D=!=A[2[",E/M!_E"V3R*56T]]8*0BEW3D*P5#9.FB\ZA4=
M2WNO=66_RQOBSNWX6_!/X[?&_?\`E<7E]^[!VC75&^)=ORS2[8QV[MX[CS6]
MMQ;>VF9U1TVIMG*[CEQ^.4!5%)3)I`%@/=>Z/E[]U[KWOW7NO>_=>ZJ3^%'1
MG:^`[%_FYP[LV_NSK"D[Y^8&[<_U-O.OH32?QS:^;Z#ZXVI1=@;1EUG[^@Q^
M>H:A(I?3_E%*P_'OW7NJ-$ZX^;V#_E[U'\DMOY/&:S_:$NV:[I>D^8J9'8;_
M``YK9<CFJBOB^75?ON75O&CW[!22G<344D(S2[B01"82E4]^Z]UN#==[:R&S
M.OMA[.RV;GW)E=I[,VOMG)[CJM?W.?R.!P=#BJS-U)D=Y/-E*JE:=]3%M3FY
M/OW7NEC[]U[KWOW7NJH/YMGR5^7O0'3>P\)\-/CAWKWGO[MC?";8WKN[HC9.
M+WQNKI+J^B@CJMV[RP6*W!44NV)>P<G3SK1;>&39J"*J:2IF244XAD]U[H(/
MY5/?67;)5OQRQG\KKYR_#[:Z8;<?9VZN_OE32;:R-5VUV359'$09O,=A[YI<
M_D]Q;R[5WQ)6O5254ZF,0TC11B""*"%?=>Z'KN#JGLO,_P`W#X6=Q8G8^X<C
MU7L?XJ_*W:6\-_TE$TFV-M;GW=N#JNIVQ@LMD-8%-DL]!B:EZ:/2?(L#_2WO
MW7NK1/?NO=>]^Z]U[W[KW5$?\WSY+_,C9>[NI?CW\>OB3\SNW.E-_P"!S6X_
MDKW#\/\`;^*?LJBV\LLV,P?3W76\\_6T6+V+G-UU$$DN<S4/DRF/Q31K0>.H
MG,\/NO=(O8?4O_#G'POS_P`,(?BA\V/Y.W7/2>\>FMQ]=Y#+8?9&VMP[DEVG
MGLAN^D@VH#6;HI<]!0[BQ-/6YJ?)++/5UT\4\DDTS2M[]U[H`MA?RE/EKU=_
M-D^-/9N9_F"_S`N\NLMD_'S?N?W+V_V)E-GY+$29/']J=?U5/\:<_EJ+#TD$
M6S>S,:D^3K:18342MC$:.1+7'NO=;1OOW7NO>_=>Z][]U[KWOW7NFS-_\67,
M?]JK(_\`N'-[]U[K4J]^Z]U__]+<T^"'_9+/6_\`U&;^_P#?B[K]^Z]T;SW[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UW<_U/^W/OW7NNO?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UW<_U/^W]^Z]UU[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[JC'L3^?3\9^K_`.:CMS^5)NSK#MBB[3W+NK9>S:+MEI-DQ]5Q
M9S?VS*7=VVX*AI]RQ;G1:V:N@QPM1%OO)5L"GJ]^Z]UD_F5?SY_C-_++^2G2
MGQ<[*ZU[4[/["[GQ&"S,$W6LNR6QVS*/<N[FVA@QNF/<FY,-D(ILC4PRU$8A
MBD#01$@WL/?NO=7B2U-/!$L]3/%3Q/H`DJ)8X4U.NL)KD95+:0>+_CW[KW7.
M66*%&EFECAB4:FEE=(T52>&:1R$`)/UO[]U[KB*B!Y?`M1"\XC$OA66-IO&;
M6E\0)?Q&X]5K<^_=>Z)^/G3T'-\X3_+XH\GG:WY$4G1\GR"SE#%AGBVG@=@M
MN*BVQC8JW<E3-#!4[DR^2K0T-#3),ZP(TDC)Z0WNO=!O\)/YC?5OSCWW\Q]A
M['V5O;8U;\+_`)`97X\[YR6]Y=N)C=V;EQ<^7IY,UM-\1F,C*,+,V'<H*Q:>
MHLZW0&X'NO=6&.RQJ[R,J(BEG=V5$0*+LSLQ"JH'Y)M[]U[K'#/!4IY:>>&H
MC+%3)!+'+'J%B5UQL5U`'Z>_=>ZS"_T'Y]^Z]UA@J8*E"]+40U$:L49X)DF1
M'`#%2\;,BL`P-C^#[]U[JHS%?S>]@[[_`)@V[/Y?O3'QG^3'=6;ZHW7M?9??
M7?FR=JX`]&](9W=.+K,U3KO3.Y#<%-FACJ2@I;25,-&T<E1JBB\C(WOW7NEW
M_,O_`)FF)_EL;?ZHW!E?BW\FODZO:N9W/AH<=\;=E4^\J[:;;9H<76O6;I2H
MK*-:&DRG\3"4I!)D>&3CT^_=>ZK%^)O_``IXZ=^8'<'6?5/7?P$^=]#C^Q>S
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MB!C@876=P7!6)A]&-E/]??NO=<S44ZK"YG@"5+1I3N9HPE0THU1+`Q;3,T@Y
M4+<G\>_=>ZYR21Q(\DLD<4<8O))(ZQQH/ZL[D*H_US[]U[KAYX#"*GSPFFT>
M05'EC,'C'.OS:O'H'];V]^Z]UT*NG9XH5J8#+/&)H8A/$9)82"1+%&'U21D*
M2&`(-O?NO=%&WU\X>B-@?,/ICX+YC*9NH[_[PZ_WGVCMG%4.(U;<Q&R-C15)
MR64W+N*HJ*>EH:K(5-')!14L2SSS.A++&I1G]U[HW_OW7NO>_=>Z[N1]"??N
MO=>N?ZG_`&Y]^Z]UU[]U[KWOW7NO>_=>Z][]U[KNY'T)]^Z]UZY/U)]^Z]UU
M[]U[KWOW7NO>_=>Z][]U[KWOW7NFS-_\67,?]JK(_P#N'-[]U[K4J]^Z]U__
MT]S3X(?]DL];_P#49O[_`-^+NOW[KW1O/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\[K^9MU/F=Z_P`V+^=OV_LRFGD[
M,^'WQI^(_P`M.N*JFJ)J::DSG2NZ.@]TY71)2J:S_*=K4U?&1&5N"02/J/=>
MZ+/\ZNP<-_,+VKV[_-FH:#+#:79'\T?X._''H2;*1R4L^*ZVZCZLRL^Z*9L;
M5I)4XV*NWCN9IG19%62=BQ!(N?=>ZOHDZ!V9_.(_G6?S%/CS\[MS]EY+HKX)
M[,ZAV[\=_B_MKM'>?66V,H-\8=JW.]Z9:DV5G<+E-P9@3U6B*K$NF.+)012_
MMQQQ'W7NB*[K[2[3P/\`*%_X41_#6K[DWOW;TW\#^ZML=5?&[M?>&Y*K<N]*
M/8F2[1VE42]?5^^4GDEST>RI<6D4),I>!9I([)$8XT]U[K%\B?B9@/A;U1_(
M<_F%]2]M?(&I^7G?_P`B?AQLGO?MC=W=6_=SS]G;+[9V#BLQF-F93;V4R\VU
M\7M/#XZ@3$4>.H:*FIOX23#.D[!9![KW1M_^&_\`XM;X_P"%778T&XMAYVMC
MQ7Q)V;\V*00=A[^H1!\C*3M[!"#>3FAW%32/AU$"#^!LQPI87--S;W[KW13O
MAG_+OZ.^<V\O^%$F?[]S_;^1QG5OS)[[S?7FR-G=K;RZ_P!CX'L;'X_M'.T/
M:-?M_:&3Q-'NS>%`])3TU,,LM;0T]-&ZK3WF=C[KW2ZQNU?GM\__`/A//_+2
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M-^`.\NSMI["^;_9&\^C_`)*?&C=/:^]NS=K;]VGBL'B7@[@7#[QSV:R>'W3@
M'R+LV0IO'3QFE54$49G23W7NDM_)4^`7Q:V3_.>_F\[LVWL;.T6=^(G>>RL+
MT-53=B;_`*Z#:V.[8V/O'^_4.4HJW<<]+O%\HU0QADRZUKT8-H"G!'NO=;DJ
M?J'^Q_WH^_=>ZTZ/Y0]54Q?R'/YN$L-34Q20]I?S.)87BJ)8I(97Z[KBTL,L
M;K)#*Q4>I2&N!S[]U[HCG0?4=/\`"[_A.75_S;NH\CV9N7^8!N_XW5'56&[T
MSW86]]PU?4'5.Z^[J7JR#'=>;2K,K5;,VO3;#V7CHS1UB8_[N"HURF<7L/=>
MZF_`_P")/\R#I_O7X#?(WXD_RW/D1T+BLMG.OLE\R>Z-\_S&]A]_[4^7_2W8
MN.P]1NC>F\.L\SN&DBQ.7"Y>IW#128^%IZ9I%B2(S!9![KW2<_F7]=_%7Y3[
M?_FR_,/X\]??-3Y7]@_'_<.Z1_LZ?9/R@I>I^@OB?V#UK%A),QU=\?-FXS>.
M)W=V%C-I5=6E7C:)ML2T=1-4""+(1,@GE]U[IW^9?QXZV^:/6O\`PF#[=^3.
M.W3V3V?\IJ_I_HSO3=-1OS>6*R^_.N?[LXG-?:SRX/-42XS<=;D<W45$V8HU
MARLKRG7.UA;W7NCD[O\`@?T[\HO^%"W>GQ`[&SG;-#\8.O\`^6ET%1U746Q^
MW>P=C8[?.*VBF`VILS![VSVVMP8_=.?P^WHYUK?#)6@U==3Q25+3!65_=>ZJ
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M=;QJ,SCZ3JK$[4ERPVK@MB[6P=#345'34M'&\E.LRU3U`J9M7NO=67?,[X`?
M%CNK_A3+\/:'L#8.=RU-W9\5M[_(#L>.B[$[`PW\6[0ZGEK:?8V>I),/N*AF
MP=!BJ?:]$LN/HF@H*SQ$SQ2&1]7NO=;DA))N??NO==>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MILS?_%ES'_:JR/\`[AS>_=>ZU*O?NO=?_]3<U^""G_96>MN#S5[](X/(_P!(
MN[!<?X7'OW7NC>6/]#_MC[]U[KUC_0_[8^_=>Z]8_P!#_MC[]U[KUC_0_P"V
M/OW7NO6/]#_MC[]U[KUC_0_[8^_=>Z]8_P!#_MC[]U[KUC_0_P"V/OW7NO6/
M]#_MC[]U[KUC_0_[8^_=>Z]8_P!#_MC[]U[KUC_0_P"V/OW7NO6/]#_MC[]U
M[KUC_0_[8^_=>Z]8_P!#_MC[]U[KUC_0_P"V/OW7NO6/]#_MC[]U[KUC_0_[
M8^_=>Z]8_P!#_MC[]U[KUC_0_P"V/OW7NO6/]#_MC[]U[KUC_0_[8^_=>Z]8
M_P!#_MC[]U[KUC_0_P"V/OW7NO6/]#_MC[]U[KUC_0_[8^_=>Z]8_P!#_MC[
M]U[KUC_0_P"V/OW7NO6/]#_MC[]U[KUC_0_[8^_=>Z]8_P!#_MC[]U[KUC_0
M_P"V/OW7NJ[3_*\^+TWR1^7ORER%+O[+=C_-WI.F^/\`W;C<ENBFGV8W74&`
MQNVY*7:>"3"PSX7*56/Q,!>HEJ:JTJED5-3`^Z]T7>E_D0?!:A^$G4WP%HE[
MEI.CNF^]:/Y%;6KX-_8U.P:[LBCSN5SJU.XMQ?W5./RN)DERSP-`*&)EIHXE
M1U9`_OW7NA"^:/\`)N^'WS=[:PGR"WC4]X=*?(3#[:79%1WI\7^WL_TKV7N;
M8\<3PQ[/W=E\1#7T.X,-$K@*TU+]VL<:1";PKX_?NO=/X_E"_"?&_`3L#^6[
MLW8^Y.O?CKVE21+O^KVCN60=H[KSG]X<'N:NWEGM_;BHMPUN:W;E\KMZF^YJ
MJR*=3`OACCCB"(GNO=/_`'A_*W^,_P`@>F?AUT3OVJ[0CV/\'-]]/]B]*R8#
M=U'C<[4;@Z0V^NVMEKO?(38"MBW#0/C4!K8XH:1JB7U*T?T]^Z]TG_D/_*7^
M,7R-^8O5OSNS>Y._>L?D3U=B]J;=3<?27;N7ZYQ>_P#:FS-TKN[";/[*Q-'1
M5@W'M=LEKCJZ2.6D2NI7,509%6/1[KW2\^/?\M?XZ_&:;YJ3];U'8\C?/3L;
M>/:'>*[CW1191*3<F^*+/4&:CV&*?`X\[=QBP;DJ?!%,:UXR$N[!`/?NO=%R
MR?\`(L^!>;^$O3GP0S6%[6K^L/CWNK+;[Z1["B[)K<+WGUGO?+YO(9^IW3M?
ML+;>.PL5+D8ZW).$22ADI="1:HF>)&7W7NA/^$7\I'XJ_!'L?>_=FP,GWCW%
MWQO_`&]2[,S?>GR;[;SO=7:5/L6BGIJNGV3AMP9F"B@Q&W!5TD<K)#3B>4HJ
MO*R(B+[KW1H?EW\.OCS\ZND-Q?'GY.]>TG8O6.XZBBR+XZ2LK\1E\)GL6SR8
M?<VV-PXBHHLQMW<6)DD8PU5-*C:'>-P\4CHWNO=$S^&W\EWX=?"[MY/D!MK(
M=\=[]XXO;)V5LKM3Y4=Q9WN[=?66S9(I(:G;/6TF7I<?C-IXZKBF='>&F-4(
MI'B258I'1O=>Z,S\>_@CTA\9_D'\M?DMUQ4;ZE['^:&[MK;U[ABW+N"CRNW*
M?,[0QM?C,2NSL53X;'SX2B-/DI/*DU15L[:;,H`'OW7NCG@,#>Q_VQ]^Z]U7
M9\?_`.6%\;/C7\5_D!\/>NZSLZ;J7Y)YKNK.]BU&Y-V4&3WA%6]]8>7![X7;
M>;IMOXZFQ4,5!,?L`]+.T$@U.TIO?W7NA`Z3^`/QNZ1^$V!_E\T6U\CV-\9L
M)L/</6M5M3M:NIMTY#<NTMT97+YG+T&Y,A18W"P5<DE9FIC%+!!3O`%C,>ET
M5O?NO=$O^+W\B#X8_$WN;K[N?8.^OEWNNKZ<_B2]*=<=G?)WL'=?473]/DAX
MGQ^Q]CT\V(A7#P4(6F6AR,^0HY(8T,L4DB+(/=>Z0F]/^$Y7\MO?79/>&^\I
MB^_\;M7Y#9K<6\.RN@ML=[[PVS\=\GV)N2.9I^R!U?A_M:*KW5B\I.^0H%KI
MZW&TE;I=*30D:+[KW0R=N_R3/AWW5\3?BU\0MVYSO[';2^&55CJSX]]H[.[5
M?:7>.R:K&4<N.IYX]\8?`P8^HF_ASQPASC5>-:>%HRDB:S[KW0]],_RW.A.D
M/E/4_,7;>X.X-Q]UUWQNZ^^+F4RN_M]Q[JH<QU]UQ#B(L-FLP*G"0YC*;]R+
M86&3(9.>M?[J5I'\2ES[]U[H+]G?R??B9L;XF?++X8X2M[?;I_YF[\[%[%[@
MJ*[>F,J=XP;A[/JL=5[D79V;7:\5)A,>DN+B^WBFI*LH-6MI"Q/OW7NIW?7\
MH3X<_(SXX_'GXW;_`,5V104'Q0PNV,-\>>Y-D;]KME?('JP[6Q&,P=+D]M]F
M8.CIYHLCE,=B(%K5>E>EGDC27PK+'$Z>Z]TF>JOY,OQ,ZF^-WRA^,]%NOY+[
M[P'S#V]EML][]C=L]\[K[([6W+C\MBJC">?'YS<B56W,'E*+%U'ACJJ;$)/,
MD<8J6G\:6]U[I4]D_P`I'XK=J?!SH?\`E\;FK.V8NA/CKF>K,YU]4XK>.,H]
M_2UG4$M9+M1-P;CDVU4T.2IY#72"K6.AIS*-.@QD`^_=>ZD?,?\`E._&7YL]
MT=&_(CL'<??/6G=7Q]Q<NW=C=A]!=M97JW<%9M.?*QYFIVEN6IHJ'(+DL%4U
MPE\JQ"FGDBJ)8FE,;:1[KW5FBH555&LA4506)9B%4"[$_5B!R?R??NO==V/]
M#_MC[]U[KUC_`$/^V/OW7NO6/]#_`+8^_=>Z]8_T/^V/OW7NO6/]#_MC[]U[
MKUC_`$/^V/OW7NO6/]#_`+8^_=>Z]8_T/^V/OW7NO6/]#_MC[]U[KUC_`$/^
MV/OW7NO6/]#_`+8^_=>Z]8_T/^V/OW7NO6/]#_MC[]U[KUC_`$/^V/OW7NFS
M-*3ALOP?^+5D1]#^:.;W[KW6I3[]U[K_U;P-@?\`'M)_V5S_`,7O=?\`S)/_
M`)E?_P`?3F/^/4_Z9O\`CO\`]-7D]^Z]TM/_`$X9[]U[KW_IPSW[KW7O_3AG
MOW7NO?\`IPSW[KW7O_3AGOW7NO?^G#/?NO=>_P#3AGOW7NO?^G#/?NO=>_\`
M3AGOW7NO?^G#/?NO=>_].&>_=>Z]_P"G#/?NO=>_].&>_=>Z]_Z<,]^Z]U[_
M`-.&>_=>Z]_Z<,]^Z]U[_P!.&>_=>Z]_Z<,]^Z]U[_TX9[]U[KW_`*<,]^Z]
MU[_TX9[]U[KW_IPSW[KW7O\`TX9[]U[KW_IPSW[KW7O_`$X9[]U[KW_IPSW[
MKW7O_3AGOW7NO?\`IPSW[KW7O_3AGOW7NO?^G#/?NO=>_P#3AGOW7NO?^G#/
M?NO=>_\`3AGOW7NO?^G#/?NO=>_].&>_=>Z]_P"G#/?NO=>_].&>_=>Z]_Z<
M,]^Z]U[_`-.&>_=>Z]_Z<,]^Z]U[_P!.&>_=>Z]_Z<,]^Z]U[_TX9[]U[KW_
M`*<,]^Z]U[_TX9[]U[KW_IPSW[KW7O\`TX9[]U[KW_IPSW[KW7O_`$X9[]U[
MKW_IPSW[KW7O_3AGOW7NO?\`IPSW[KW7O_3AGOW7NO?^G#/?NO=>_P#3AGOW
M7NO?^G#/?NO=>_\`3AGOW7NO?^G#/?NO=>_].&>_=>Z]_P"G#/?NO=>_].&>
M_=>Z]_Z<,]^Z]U[_`-.&>_=>Z]_Z<,]^Z]U[_P!.&>_=>Z]_Z<,]^Z]U[_TX
M9[]U[KW_`*<,]^Z]U[_TX9[]U[KW_IPSW[KW7O\`TX9[]U[J/5_\`ZS_`+>#
F_P#`2J_S_P#P'_S$G_`C_IG_`..G^T7]^Z]T3/\`]`?W[KW7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pg22b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg22b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!8`)+`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`VG?C%\//C9W9TOMOM+M7J[&;U[!W?F-]5^YMU9?+[D.3
MS5;#OO<E#'55K4^9@A:84E+&EP@N%YYN??NO=#[_`,-T_"O_`)\+MO\`\^VZ
MO_K][]U[KW_#=/PK_P"?"[;_`//MNK_Z_>_=>Z]_PW3\*_\`GPNV_P#S[;J_
M^OWOW7NO?\-T_"O_`)\+MO\`\^VZO_K][]U[KW_#=/PK_P"?"[;_`//MNK_Z
M_>_=>Z]_PW3\*_\`GPNV_P#S[;J_^OWOW7NO?\-T_"O_`)\+MO\`\^VZO_K]
M[]U[KW_#=/PK_P"?"[;_`//MNK_Z_>_=>Z]_PW3\*_\`GPNV_P#S[;J_^OWO
MW7NO?\-T_"O_`)\+MO\`\^VZO_K][]U[KW_#='PK_P"?"[;_`//MNK_Z_>_=
M>Z[/\N?X6#Z]";;_`//MNK_Z_>_=>Z]_PW/\++7_`-`FV[?]K;=7_P!?O?NO
M=>_X;H^%G_/A-M\_]7;=7_U^]^Z]UU_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_P
MW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*
M_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#G
MPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV_
M_/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MN
MK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_
M>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>
MZ]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_P
MW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*
M_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#G
MPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV_
M_/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MN
MK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_
M>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>
MZ]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_P
MW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*
M_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#G
MPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV_
M_/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MN
MK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_
M>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>
MZ]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_P
MW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*
M_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#G
MPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV_
M_/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MN
MK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z]_PW3\*_P#GPNV__/MNK_Z_
M>_=>Z]_PW3\*_P#GPNV__/MNK_Z_>_=>Z+!_LG?QI_OM_=[_`$487^"_[-1_
MHN^P_B&X/%_<#_9?O]*']V+_`,7\GV']_O\`<GJOYO/QKT>GW[KW1N/@?_V2
MQUO_`-1N_P#_`-^-NSW[KW1O??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=5.?SA=_]P8GX_=-]%=$]CYKI[L3YF_+#H[XGGM?;
M#0P[MZ[V/V-D\GD^R]S;.JYV"4&ZX-C;:KH*&>Q>&:<.EG52/=>Z)?U?\9<E
M_*<_F*?#;J?H7O3Y"]@?&'YS;9[^Z_[(ZJ^0'9^;[@H]K]U]2[(QW8VRNUMI
M;BW&XRF!R6Z<=#4XW)T<-X)XHO(JJ555]U[HDGPK[C_T6]_=(=L[J[`[SQWR
M<V<_SDWA_.G@[#K^UJCK[8W6VRQN[*=:5F[<+N;R=;;:..RU#AH=@Q;81&KJ
M"65%\D;'W[KW5XG\OSLC;^?S&_MV]R=J[/QOS#^5U91]\Y+XS9#LG#U?8/3'
M1$6-CQW16PHNLY,U+E\%)@NMY:3(9R:.BA-1G,I5R2W`CT^Z]U:5[]U[HKGR
MY^3F%^*/4N2[2RN'_O,F*JJ-:K`4M?#391L=4F99,A34[:I9TAEC"?0+=N6'
MLOWK>=JY:V"^YGWPS#:=OMO&E\)0\A76B4169%)JXXL!2O0LY`Y&YB]S^?=F
M]MN4?I1S-OE\+6W-S(T4"N8Y):RR*DC*NF-LA&-:"G19?A?_`#,MD_,/=6Z<
M!C=GS[$H=JXF*OJ\MN/+TE+'-4U$T:4U'3I,4CE,D9=B=88:?H1<@+^WON9R
M7[I[=>[CR<U]HL)84E%Q$D=?&$A0IHEDK3PFK6GEU)WO_P#=H]U?NR[IM&U>
MZ#;.\N]P7,MN;"YEN`!:M"L@E\2"'229ETTU5H:TIU8S_?+9_P#SUFV?_/\`
M8K_ZK]CCJ!>O?WRV?_SUFV?_`#_8K_ZK]^Z]U[^^6S_^>LVS_P"?[%?_`%7[
M]U[KW]\MG_\`/6;9_P#/]BO_`*K]^Z]U[^^6S_\`GK-L_P#G^Q7_`-5^_=>Z
M[.\=H`V.Z]M`C\'/8H'_`-R_?NO==?WRV?\`\]9MG_S_`&*_^J_?NO=>_OEL
M_P#YZS;/_G^Q7_U7[]U[KW]\MG_\]9MG_P`_V*_^J_?NO=>_OEL__GK-L_\`
MG^Q7_P!5^_=>Z\-Y;0/`W7MDD\`#/8KG_P!6_?NO=>_OEM#_`)ZO;/\`Y_L5
M_P#5?OW7NO?WRV?_`,]9MG_S_8K_`.J_?NO=>_OEL_\`YZS;/_G^Q7_U7[]U
M[KW]\MG_`//6;9_\_P!BO_JOW[KW7O[Y;/\`^>LVS_Y_L5_]5^_=>Z[&\=H$
M@#=>V22;`#/8HDD_0`?=_7W[KW77]\MG_P#/6;9_\_V*_P#JOW[KW7O[Y;/_
M`.>LVS_Y_L5_]5^_=>Z]_?+9_P#SUFV?_/\`8K_ZK]^Z]U[^^6S_`/GK-L_^
M?[%?_5?OW7NO?WRV?_SUFV?_`#_8K_ZK]^Z]UV-X[0)L-U[:)_H,]BB?]L*O
MW[KW77]\MG_\]9MG_P`_V*_^J_?NO=>_OEL__GK-L_\`G^Q7_P!5^_=>Z]_?
M+9__`#UFV?\`S_8K_P"J_?NO=>_OEL__`)ZS;/\`Y_L5_P#5?OW7NO?WRV?_
M`,]9MG_S_8K_`.J_?NO==C>.T#>VZ]M&PN;9[%<#^I_ROZ>_=>ZZ_OEL_P#Y
MZS;/_G^Q7_U7[]U[KW]\MG_\]9MG_P`_V*_^J_?NO=>_OEL__GK-L_\`G^Q7
M_P!5^_=>Z]_?+9__`#UFV?\`S_8K_P"J_?NO=-.4[0ZSP8A.:[&V'AQ4%Q3G
M*;PV]CQ.8[:Q":O(P^4IJ%]-[7]^Z]TT?Z<>E/\`G\/5G_HPMH__`%W]^Z]U
M[_3CTI_S^'JS_P!&%M'_`.N_OW7NO?Z<>E/^?P]6?^C"VC_]=_?NO=>_TX]*
M?\_AZL_]&%M'_P"N_OW7NO?Z<>E/^?P]6?\`HPMH_P#UW]^Z]U[_`$X]*?\`
M/X>K/_1A;1_^N_OW7NO?Z<>E/^?P]6?^C"VC_P#7?W[KW7O]./2G_/X>K/\`
MT86T?_KO[]U[KW^G'I3_`)_#U9_Z,+:/_P!=_?NO=>_TX]*?\_AZL_\`1A;1
M_P#KO[]U[KW^G'I3_G\/5G_HPMH__7?W[KW7O]./2G_/X>K/_1A;1_\`KO[]
MU[KW^G'I3_G\/5G_`*,+:/\`]=_?NO=>_P!./2G_`#^'JS_T86T?_KO[]U[K
MW^G'I3_G\/5G_HPMH_\`UW]^Z]U[_3CTI_S^'JS_`-&%M'_Z[^_=>Z]_IQZ4
M_P"?P]6?^C"VC_\`7?W[KW7AWATJ2`.X.K"20`!V%M*Y)X`'^Y?ZD^_=>Z$Z
M.2.:..:&1)8I426*6)UDCECD4/')'(A*O&ZD$$$@@W'OW7NN?OW7NO>_=>Z)
M#_S4_P#\OF_^=`]^Z]TH?@?_`-DL=;_]1N__`/WXV[/?NO=&]]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U67_`#6OCWWGWI\=
M=D;H^+^/P6=^1WQ<^0?3_P`KNG]G[ER1PN&[%SW4&:J*G,]:U>;U*F';?6T<
MKD*"&H?]M*B2,.50LP]U[HEG0E1\U_YB7SQ^-/RC^07PMWM\$?C_`/![9_<D
M^V-G=Q[NPV>[5[@[Y[IV[B]F5=7B\7MI(J+'];;'VG2R/%6U`\E96S%4`74$
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M&P2,T/EUKT=V]1]A_P`KW;6#[X^-^R,-VAU[6]CY?;?:=+V(IW!05D6S=Q[@
MVS3;7R])64%9'MJ@WG2P>6CS5/()*#)(D;J\;:9,?-ZGY>^[7;0R<G['-_4;
M<[V`;E<-<R3S0>&)5CT1F-5`_5+!BQU%3'0$J>L]^4FYR_O%+B[VWW3YKLX?
M>3EW:KMN7["+;X+*UO?&:"2<23I*TCR#P`ABT#0KB968)(O5V7PF^2_Q%^=_
M4T'9G4&TME4V5Q<L>)[&ZUSNV-LP;[ZPW6B'[S;VZL7%2,ZIY$9J2MC!I:Z`
M"2)OU*N1-K=6E_9P[CM\J3[=<1K)%(AJCHPJK*?F/V'!SUSUWG9MVY=W>ZV#
M?K>6TWNRG>&>"12LD4L9*NC`\""/L(H1@CHX_P#HRZU_Y]YL;_T$\%_]0^WN
MBWKW^C+K7_GWFQO_`$$\%_\`4/OW7NO?Z,NM?^?>;&_]!/!?_4/OW7NNQUGU
ML"#_`*/-C#D<_P!U,%QS]?\`@#[]U[H.^J>I-GXW8&`HMP];;2@S$'\5^[BK
M]KX.6K3R9O)2T_E<T;EM5))&5N3Z2/?NO="'_HRZU_Y]YL;_`-!/!?\`U#[]
MU[KW^C+K7_GWFQO_`$$\%_\`4/OW7NO?Z,NM?^?>;&_]!/!?_4/OW7NO?Z,N
MM?\`GWFQO_03P7_U#[]U[I,[UZJV)5[-W=28KKG9LF4JMK[@IL;'2[6P:5,E
M?/B:N*DCIW%&A6=ZAU"D$68CD>_=>ZD[7ZLV#3[9VY3Y#KK9:5\&`PT-<D^U
M<$TZ5D6.IHZE)F^R-Y5F5@W)Y'OW7NGW_1EUK_S[S8W_`*">"_\`J'W[KW7O
M]&76O_/O-C?^@G@O_J'W[KW7O]&76O\`S[S8W_H)X+_ZA]^Z]U[_`$9=:_\`
M/O-C?^@G@O\`ZA]^Z]TB.R^IME9#KK?=!@NN-H39JLVCN"EQ,-%M;!QUDN1G
MQE3'1QTL@HT*5#5#*$(8$-;GW[KW2PI>L>N%IJ99.N]CB1:>!9`VT\%J#B)`
MX:U#^H,.??NO=9_]&76O_/O-C?\`H)X+_P"H??NO=>_T9=:_\^\V-_Z">"_^
MH??NO=>_T9=:_P#/O-C?^@G@O_J'W[KW7O\`1EUK_P`^\V-_Z">"_P#J'W[K
MW0>=K]2;0R77^X:';O6^TI\S.F,%'%C]KX..K<QYK&S3B)Q1QD:::-V;D74'
MW[KW0B-UEUK<VZ\V,?\`R4\%_P#4'OW7NNO]&76O_/O-C?\`H)X+_P"H??NO
M=>_T9=:_\^\V-_Z">"_^H??NO=>_T9=:_P#/O-C?^@G@O_J'W[KW7O\`1EUK
M_P`^\V-_Z">"_P#J'W[KW0>=@=2;0K9=@G"];[2D6B[&V_7YC[/:^#0186"C
MRZ5DU6!2)KHTDFC#@W%R./?NO="'_HRZU_Y]YL;_`-!/!?\`U#[]U[KW^C+K
M7_GWFQO_`$$\%_\`4/OW7NO?Z,NM?^?>;&_]!/!?_4/OW7NO?Z,NM?\`GWFQ
MO_03P7_U#[]U[HEFY.E.FMT_.O`XK<_4G6.X\72?$;<E=28W/;"VME\?2UK=
MR;:@>LIZ/(8JHIX*IX6*&15#E3:]O?NO=&0_V57XO?\`>-O0?_HG^OO_`+'O
M?NO=>_V57XO?]XV]!_\`HG^OO_L>]^Z]U[_95?B]_P!XV]!_^B?Z^_\`L>]^
MZ]U[_95?B]_WC;T'_P"B?Z^_^Q[W[KW7O]E5^+W_`'C;T'_Z)_K[_P"Q[W[K
MW7O]E5^+W_>-O0?_`*)_K[_['O?NO=,.Z/C]\-]D;>R^[=Z=(?&;:.U-OT4N
M2SVYMS]:]7X'`87'P"\U=E<QE,-2X_'TD0/JDED1!_7W[KW3%USU/\$NX=LT
M^]>I>L/B7V?L^KGJ*6EW5U]LGJ+>.WIZJDD:&JIHLSM_&9#'O44TJE9$$FI&
M%B![]U[IAP6T/Y=>Y^Q<YU!MK:?PNW#VQMF.67<?66$V_P!)Y7?^"C@"&H;+
M[0H:.?/8X4XE7R>6!-&H7M?W[KW0L_[*K\7O^\;>@_\`T3W7W_V/>_=>Z2^S
M^C?A5V'A$W+L'IKXO;WVY)793&1Y[:7775FX<,^2PF0J,3F<>F3Q.'JZ-JW$
MY2CEIJF(/K@GB:-P&4@>Z]USP'1'PNW76;EQVU^E_C#N/(;+SK[7WA0X+KCJ
MW+5>U=RQ45)D9-O[BIZ'#3RX;-1X_(03M2U`CF$4R.5TLI/NO=)_`]:?`7=6
M=IMK[8Z[^(>XMRUM-N>LH]O8/9W3^5S=71[*SXVIO&JI<70XV>MJ*;:NYS_#
MLC(B%*.N_8E*2^GW[KW0B_[*K\7O^\;>@_\`T3_7W_V/>_=>Z]_LJOQ>_P"\
M;>@__1/]??\`V/>_=>Z]_LJOQ>_[QMZ#_P#1/]??_8][]U[KW^RJ_%[_`+QM
MZ#_]$_U]_P#8][]U[I`]K?%OXR4_5O9513_'/HBGJ(.O]YRPSP=1;`BFAECV
MWDGCEBE3;ZO'(C`$,""#R/?NO="!\6"6^+_QN9F9F;H/IXLS,69B>O=O$LS,
M2S,3]2>3[]U[H>/?NO=>]^Z]T2'_`)J?_P"7S?\`SH'OW7NE#\#_`/LECK?_
M`*C=_P#_`+\;=GOW7NC>^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KNY/U)/OW7NNO?NO==W/TN;?T]^Z]UU[]U[KL?4
M?ZX_WOW[KW0!;6V3M;LCJ??6P][X6BW%M+=F\>XL'N#"Y&)9J3(8ZN[!W/%-
M%(IY1UN&C=;/'(JNI#*""_=MJV_?=LGV?=HEGVVYC,<B,*AE84(_R@C((!&1
MT>\L<S;]R9S#9\U\L7,MGS!M]PD]O-&:/'(AJI!\QY,IJ&4E6!!(ZTY_DW\2
M_E+_`"M/FKANUOB7O&?"Y/<LDK=<5.:E,>Q>]=J15"3U'379*/)3XN3==$I6
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M2[2PM9_!\UGJS*Y^KIJFM2@H\;@:#(5LC1T=))*[%`B(A)/MR.)Y3IC%2.M$
M@<>JYO\`H(O_`)2/_>2.0_\`16]E?_8S[>^CN/X>M:AT!.V?^%-OP#RG>&^M
MD;E;>FT>DL+A<=4;$[]J]OYC(8_?.>#VS6,EV3C\9-N?;V/TRI_#ZJ>-C4F.
M3RQP735<V,N@$4+>G7M0Z'8_\*,/Y2(!/^S(Y#CGCJWLHG_8#^[//NGT=Q_#
MU[4.A][SZ=^+/\W+X[]"=IR;IW9W1\5]O;HK>](^G]J@XS9WR8K=IX?/XG;V
MP^S,-F:*BR^3PN$W2'G3%M)2PU.2@C6IUQ#24[HR,5;##JW'J@'XF]G8GXW[
MI_G/]@]1_&3<W\KW=N%^"-#V+U?\",_CLGBLODJG8&U]Z4[?,+#4F,IUZPQY
M.X,S28:6DV]+4/&]&LM:3)(I->O="GW[_+)^*7PY_E0]!_-KH_8&)VA\U?CU
M3?%#Y')\I:')Y"F[:[*[#WMOWKA^UU[!WA-4RY#?.%['I=\92"3&UWF@*S11
MQ(FD#W[KW6W515'W=-25>@Q_=4T%3H-R4\\*RZ3<`W77;W[KW5,7\@:)(OY<
MNWT2)8A_LR/S+.A8Q'ZC\INURQ*`+9BWUXO?W[KW0/\`Q=[IH?C?C?Y__>]7
M!]P.JOFWVOO:CH(HO)+E\YA_B]TG/@,-#%&K--59O/&GI(U`+-),!8D^_=>Z
M(OD^T>FOY2?RX^`VY?DMN2#;J["_E!]VP[AH8Y(ZG=?9GR$[+^0W5&\=S;-V
M;25<E-/N#>N^.R,]D6B61HU&MYZB2*&.21/=>ZM;WA\U_F]USU/\?MO[VZ+Z
M6H/FS\W^X,WL[X[]"Q[LSDNQ^DM@XS:E=OC,[G^0>_:&IR%3O3(]9;/QWW6?
M3;5-3P55?5P45&UB:D^Z]U+Z$^8OS@I_YAN)^!GRRZJZ!QD,_P`4MX?(C']T
M](YC>M3M_L>?$]D[5V7046`VSO&9LQLI<%'F*F'*4=<]<\TXIYZ:I\4CQK[K
MW5POOW7NO>_=>Z#WMS_F5'9__B.][?\`O,Y/W[KW2(^*W_9+WQM_\0%T[_[[
MS;OOW7NAY]^Z]U[W[KW1(?\`FI__`)?-_P#.@>_=>Z4/P/\`^R6.M_\`J-W_
M`/\`OQMV>_=>Z-[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
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M[HQ^R>ZNN^Q=_P#;G6FS\S-F=T=&Y?;.W>RA#C:],/@]Q[KV[3[LQNWH<[+`
MF*RF;I=OUM-4UM-32RR4*U4(G"-(H/NO="M[]U[KL?4?ZX_WOW[KW05]/_\`
M'K9?_P`2/VM_[\;<WOW7ND9\H?C7U[\KNGMR=1=B4G^296$U>W\_3QH<OM#<
M]+&YQ&Y</,UFCJJ&=O6EPL\+/&W#7`+Y^Y&V;W"Y;GY<WE>R05CD`&N&4`Z)
M$KY@\1P925.#U+_L9[U<W^P?N+9>X?)\G^,0-HN(&)\*[MF(\6VF'FKJ.UJ$
MHX5QE>M6+=/Q![+WUW8G7%+OL?&_^;1\:Z1,G\=OD-0U+XC:OR[ZVQ%.SX;:
M/8-4T8@S><3#TYIZ;(U$<TE31*])7),('TQ5[-^X.];#NTGLQ[EM_P`B&R6E
MG.Q.F[MP"4"LV6=5%4)RR`J29(VKEA]Z[V2Y-YRY3@^]W]WF+5[9[U)_NVL$
M`U[/N+$"77&O]G!)(:.!V)(RNOZ4RZ;BOY<'\U2+Y([DS'Q/^6.T3\=/GUU>
M)<5OCJK<$1Q&+[&.,C_?W?UG)52-'715L"_<RT$4DI2)Q-3/-3'4F24UOH'B
M1]T)\_3[>N=P/D>/5S/M-U;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z*%/_`-E]8G_Q3S<7_OZ=L^_=>Z-[[]U[KWOW7NDQNS9&RM^XU,-O
MO9^UM[8>*JCK8L3N[;^)W)C(ZV%72*LCH<Q25E*E5$DC!9`H=0Q`//O8)7@2
M.O=!R/C/\;@01\>^C@0;@CJ?88((^A!_@/U]VUOZG]O7J#HGNP?Y1?P.ZY^3
M&_\`Y2X+I#;-1O/?N-2C.T,SC,7ENL-J9"I,O]X-P;0V-6T,N'P^7W*K(*AE
M1HH@K>!(O(]W#<2E!&3@?MZU05KT<+_99OC;_P!X]='?^BFV'_\`6'VWK?U/
M[>MT'15?G'\??E=F^O\`I_<O\NWM'9O2';?QYWI5;KP746ZZ2MQ'QP[RVGE,
M-6X;/=4=I8/:$5/58[&2BJ6LQ==21Z\;D(Q*%)8LM"234\>O=$_Z'^`/S#^1
M7:W=WR4_FH[JZ/I]Z=C?%G??PRZXZ(^,%-G*KK[K'J'LVI^\['W-DM[[SA&X
MMU[YW9700O3B1/ML?$FE;FVGW7NBS[:_ES?S<.S-B=.?R^OE)W7\6LE_+VZ+
MW9U;-F.WM@XS>8^3GR0ZEZ-W+A-Q]:=5[OVUDU_N3LB>H?;>,@S&2I))7FCH
M2RF0R,']U[K9O6RZ0JA54!550`JJ!8*`!8``6]^Z]UKK4'Q:_G,_!+<_<'7'
M\O7*?"GO/XK]E]N]E]V=<X'Y1Y#L?9?8W0N6[8W'7;QW?L*DR&Q8*G';VVLN
M\,U65U#//HGAC?Q,`#Q[KW0N;`_E?=U[;^,]'U+V5VMMGMKM7Y-?.W9/R\_F
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M.WLWUA\>MYY+M#;_`$;+V#WMMW([9Q6_NS<ABMO#<&^^RZ?;%;DX*6+'4:4>
M*HHK))K,S^Z]UL9^_=>Z][]U[H/>W/\`F5'9_P#XCO>W_O,Y/W[KW2(^*W_9
M+WQM_P#$!=._^^\V[[]U[H>??NO=>]^Z]T2'_FI__E\W_P`Z![]U[I0_`_\`
M[)8ZW_ZC=_\`_OQMV>_=>Z-[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
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M_J3;4F_9ZG;>+SL]`N+BFQU/C58"-6]^Z]UL!^_=>Z1.Y]]T&U*RFHZO`[TR
MSU,'W*3;9VAF]Q4L:B1H_'456+I9XH*BZW\;$-I(-K'W[KW0'=5=M8BDVUE(
MVVCVC,7W_P!FU`>FZVW741@5._\`<50L;/'0,JSQ+(%D3]2."IL0??NO="5_
MIDPW_/&=L_\`HK]W?_6_W[KW1!/GOTK@_E1L?"[CV#@.U]D_([J.K_O3TKV)
M2]:;NH*ZES%#(M>FV,CD8L<)5PV8JH%T,Q*TM3IE`TF57A_W>]L1S]M,=_L[
MBUYVVX^+97`.EM2G5X3.,A7(&DFH1Z-PU`Y9_=.^\FWL/S3<[+S9`=S]F>88
M_I=YV]QXB-#(/#-S'&<>-"K&H%#+'5*U"%:U>QNN^J/YL_6%`V\\;OOXX_S2
M?BR\-'#V?UYLO<1WAM7=&W*DIBLCN*#;\"U]9LC-Y6']R`O]SB*IW:G81L%F
M<]F/=1^=MKFVK?$^GYTVT^%>V[#2Q925\9%/!6((8#"/4?"5)=^]M]V^/V0Y
MGM>9>2YOWE[*<R)]5LU^A\1/#<>)])+(,>+$K=A-#+&`WQB0*,'P:_FY=B[*
MWW0_!W^:+LG/]0?+#%+28OKGL%MLY&GVM\D,297H<7F,;%%2QPT.Y\IX=09!
M'25Q:VF"HU0&:);=2GC09C\QYCK$4'R/'J\8]QX=20=F=L@@V(_T7[NX(_\`
M(?[1]6ZZ_P!,F&_YXSMG_P!%?N[_`.M_OW7NO?Z9,-_SQG;/_HK]W?\`UO\`
M?NO=>_TR8;_GC.V?_17[N_\`K?[]U[KW^F3#?\\9VS_Z*_=W_P!;_?NO=>_T
MR8;_`)XSMG_T5^[O_K?[]U[KW^F3#?\`/&=L_P#HK]W?_6_W[KW7O],F&_YX
MSMG_`-%?N[_ZW^_=>Z]_IDPW_/&=L_\`HK]W?_6_W[KW7O\`3)AO^>,[9_\`
M17[N_P#K?[]U[KW^F3#?\\9VS_Z*_=W_`-;_`'[KW7O],F&_YXSMG_T5^[O_
M`*W^_=>Z]_IDPW_/&=L_^BOW=_\`6_W[KW7O],F&_P">,[9_]%?N[_ZW^_=>
MZ]_IDPW_`#QG;/\`Z*_=W_UO]^Z]U[_3)AO^>,[9_P#17[N_^M_OW7NO?Z9,
M-_SQG;/_`**_=W_UO]^Z]U[_`$R8;_GC.V?_`$5^[O\`ZW^_=>Z]_IDPW_/&
M=L_^BOW=_P#6_P!^Z]U[_3)AO^>,[9_]%?N[_P"M_OW7NO?Z9,-_SQG;/_HK
M]W?_`%O]^Z]U[_3)AO\`GC.V?_17[N_^M_OW7NO?Z9,-_P`\9VS_`.BOW=_]
M;_?NO=>_TR8;_GC.V?\`T5^[O_K?[]U[KW^F3#?\\9VS_P"BOW=_];_?NO=>
M_P!,F&_YXSMG_P!%?N[_`.M_OW7NO?Z9,-_SQG;/_HK]W?\`UO\`?NO=>_TR
M8;_GC.V?_17[N_\`K?[]U[KW^F3#?\\9VS_Z*_=W_P!;_?NO=%VV]NRDW5\]
M**:DQ.Z,4*7X>YT.FYMM9;;DLOF[JV^%--'E:>G:I">`ZRFH)J6Y]7OW7NCS
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z#+N#I?J7Y`[!S/5G=_7&SNU>NMP"'^,;-WU@J#<.!K)::3R
MTE2:+(0RI#6T<OJAGCT30MRC*>??NO=)7H'XO_';XK[8K]F?'+ICKOIG;66R
M+9?,8S8.VJ#!+F<FVL"MS%53Q_?9:HA61EB:HED\2'2FE>/?NO=#O[]U[KWO
MW7N@][<_YE1V?_XCO>W_`+S.3]^Z]TB/BM_V2]\;?_$!=._^^\V[[]U[H>??
MNO=>]^Z]T2'_`)J?_P"7S?\`SH'OW7NE#\#_`/LECK?_`*C=_P#_`+\;=GOW
M7NC>^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[INKL/B,FT;Y+
M%8W(O$I6)Z^@I:QHE8W98VJ(I"BL1<@6!/OW7N@?^2_3"?(;XY=Y_']<[_=&
M/N;J+?\`U4NY(L:F3&W$WQM;);9&7CQ7W%$E<,8N0\H@\L0DT:=2WN/=>Z+7
MWI_+TZ]^1/P0V9\(NP-Z;LQ*=>[(Z<QNQ.Y]AS#;6_MA]H=&46`?K[M[9S>6
MKAQ>?PV?V_'5K`[RQM%))`6LVL>Z]T`7P[_EB=K]3?(?'_+?YI?-OL;YV?('
M8?7^>ZFZ0RVY-B;3ZJV'T_L7=<U'/O"NPFQ=H-44>2["WBM#%39#-SR^:2BC
M$.DCD>Z]T>+LCXWCM7Y']%=T[PW?)7;&^/>)WCF=C]0_PB,XJI[KW7!#@*'M
MW.99ZQA75^RMD39#'X:D-+:DGRM15"7R:`ONO=$4'\IMI>\8LA6?(+*3?#NB
M^6M3\\,;\5(NO,!3Y&+Y.U>1FW))75?<"U[9NLZNCW[5S[BCP7V"3C).%-8:
M=1%[]U[JXL\\^_=>ZY*3<<GZCW[KW05]/D_W6S')_P"9C]K?^_&W-[]U[H4[
MG^I_VY]^Z]UZY_J?]N??NO=5#_/WXR]A;/WKA/GU\2Z5J+OWJFF\W9.T,?')
M]GW/UQ21*,MCLC04VDY#,4.,B9&6QDJ:51I_?@AOC?[P<B;QMNZQ>[_MXI7F
MW;Q6YA48O+<#O#*/B=4%&&2Z`4[T3KH9]TOWNY1YBY9NONF?>`D\3VFW]Z;=
M=R$:]GW%S^E)'(W]G"\I!!PL<I.K]*62DCL;I[X?_P`[OXA8:NW%1&BS-.CR
M;?W;B330=J_'WM"G@C>KIJ2N41U`2GJPC24TA%)DZ30]E?0\<O>W/N%M'/\`
MR[#S'LC4U`+-"2"\,H`U1N/EQ5N#*0PXTZQ8]^O8[G'[OWN+>>WW.$9+1,7M
M;E0?!O+5B?"N(3P(8"CK6L;AD;A4D7^,'SY^0W\MOM[;?P%_FM923*;.RLZX
M7XP_.1A4R;0WY@HI5I<3MWLO,3@FCRM+$T<+5E4PJJ-RJ5A>$I5>Y`DA2=?&
MM^/FO4,`D8/6RE3U4%93T]725,-725<$532U5-,D]-4TT\:RP5%//$S13031
M,&1U)5E((-O:'JW6:Y_J?]N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?\`
M;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_P!N??NO=>N?
MZG_;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_`&Y]^Z]UZY_J?]N??NO=
M>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?\`;GW[KW7KG^I_VY]^Z]UZY_J?]N??
MNO=>N?ZG_;GW[KW7KG^I_P!N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?]
MN??NO=>N?ZG_`&Y]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]T4&<
M_P#.?6)_\4\W%_[^G;/OW7NC>^_=>Z][]U[KWOW7NO>_=>Z[L?Z'_;>_5Z]U
MU[]U[HM/RS^7/1/PEZ:S'>OR$W9-M?9.-R.+V_C*7%XG([DW9O+>&?F:EVUL
M;8NU</!4Y?=&\-R5B^&CHJ>,L[79BD:NZ^Z]T7/X4_S4/C!\Y,EV/M78]'VW
MTUV;U/@Z/>&^.G_DWUIF.D>S<7U]D6DAH.R(MO;DE>*NV'454$L!R$,[QP31
ME9A'J35[KW1?NH_Y]_\`+[[F[TVITIMK+=TX;$]E[ZJNL.F_D'O/I7>.U_C+
MW3V#3UM3CH]J]9]PU].,-FZ_)Y"BFAHGFCIJ>KDC(BD8LFOW7NKI`"3;\_\`
M%/?NO=%N^*7RFZR^9'3U)W?U%%N>'9=;O+L;8T*;OP\>"S7\;ZOWSGNOMRL^
M/CK:]!0OGMNU!II/)>:#2Y"DZ1[KW4OH_P"3/6_R!W7\AMF[#CW''F/C+W/6
M]$]D'/8J/&TDF]Z#:6U]YSR;<G2LJFRN$.&W=2::AEA8RZUT64$^Z]T"'2/\
MQGX^=_\`:G6G46PJ;L#^\7;O6/<W<6P<GF=M4M!MS.=>=(=OQ]*[CW!'DHLQ
M5R)3Y_=,JU.&!BO6XQEJ#X]00^Z]T?6Q_H>?I_C[]U[KUC_0^_=>ZZ]^Z]U[
MW[KW0>]N?\RH[/\`_$=[V_\`>9R?OW7ND1\5O^R7OC;_`.("Z=_]]YMWW[KW
M0\^_=>Z][]U[HD/_`#4__P`OF_\`G0/?NO=*'X'_`/9+'6__`%&[_P#_`'XV
M[/?NO=&]]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==CZC_7'^]^_=>Z"OI_\`X];+_P#B
M1^UO_?C;F]^Z]T*?OW7NO>_=>Z][]U[JB7Y"]?[K_EG?(*I^:'1^$KLO\9.T
MLM3X_P"4?4V'1C3;5K,E66B[!V]CXM,%)"M94M*A`"05+O`Q$-2OCQ*YRV;<
M?8WG(^YO*D32<BW\@7<[1.$1=L31J,`:B64\$<E#1)!IZI>T'-VP??9]HD^[
M7[H745O[W[%;M)RQNLQ[KI(TS87$AJSG0H5@35XPLJUDA.NR?N7I/XR?S%/C
M9_=#L+#X3M3IGM+`4^:V[FJ1HAD<5+64S'&[HVGF!&]5M[<^'E<Z9%L\4J-%
M,C+Y(SE-L>]V&][;!OFRS+-MUS&'C=34,I_RC@P.000:$=<S>;.5=_Y(YDO>
M4.:K62SYBVZX>"XAD%&21#0CY@X96%592&4D$'JA7K#OOY._R)^P]O\`QR^9
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M[KW7O?NO=>]^Z]T4*?\`[+ZQ/_BGFXO_`'].V??NO=&]]^Z]U[W[KW19OE/W
M5VET9L+&[HZE^/6\OD=N.OW#2XB?:.S,A2XZIQ..EIZB>;.Y"66FKZEJ.-X%
MB`A@D/DD&HJO/L#\^<S;]RMM<=[R_M%QO%X\P0QQ-IT+0G6U%=J5&D44Y.2!
MU-OL1[9\B^Z7-DVQ^X'.&V\F;-%9M,MW>1M(LL@95$$8#(H<ABY+NO:ITACC
MJO#*_P`POYLUV*RE%6?RTNZMD4E9C:ZEJMZ3[G#P;0IYZ66*;=$R-M2,/%@(
MV-6PU+=8B+CZ^XTVOW9]R;O<K>UNN2[Z"VDF17D,C$1JS`,Y!@`(0'402*@<
M1UE!O_W2?NV;5L5[NFV^]W+>X;C;6LLL5K';4>YDC0LENA%T:/,P$:FAHS`T
M/#JCWI#^9-\WLOW+UKB*WO#?'85#5;UQ<$NR('PU/-OA(:EY(MK03P8PSPR[
MCDA6E5ENP,OY]XV>WWWB/=K>N?['9K^Y6\V^2Y*M"MM;H9@`Q$:NL093(0%4
MJ:@D'[>@WOC]PC[KG*GLGOO-6S[*^S;S;;6LB7TE[?RI9,S1*UR\<EP8W6!7
M:1E<:2%(-/*]'_AQ;YQ$7_X:I[O4D7TG=7Z3_J21M`?0_P"'O(4^\/N@#3^H
MVX?\Y'_[9^L$3]SG[KP-/]?KE<BO_*+_`-O?1.?YE78'RF[D[G_DJ1=:];[9
MZ.[J[4[B^1L^%V_\BZ"7=FT.DNR<-TODH<+V7G=OXB6ABWKNW96U'S&1VUBI
M7ION,A/"9?&(W*SERONVX;YL-ONNZV4NW;A*I+V\AJ\9#$9-!A@`PJJFA%0#
MCK!;W.Y4V#DCGO<>5N5][L^8]@LY@L.XVJLD%RI16U(K5(TEBC4++J4Z6(H>
M@B[<W'\Y?C52?/7XA?+7N7K3Y@]B[[_E8?)/OKH#Y8;8Z=P'47=>WML[2%1M
MCL3I;>V)VVU?$=IK5YR++8>>GJ"AE259`\G^:/\`H!]&(^>>W.K<3_PGHZL@
MV52XJGV_M3J'X"9SI:?#T="\E%O&G[#Z,?9>2V]IBC-/F:VNK6#STZBIM43$
M`EF!]U[K8MH&J&I*)JL$534E,U2"+$5!@0S`BRV(DO\`@>_=>ZIH_D(1M3_R
M]*#&RF/[[#_)_P":.*RE,DL<LE!DJ7Y2]J?<452(V815$0=25-B`P/T(]^Z]
MT4SK+NVNZ.ZK_P"%!_:6T:B"7=]/\]=_[&ZS99BJUG;V]NBOC_U?L+%P-$DT
MDE9'V'N6BB=$1F#`\<&WNO=%;^:W:NZ_Y4/R^^&\/3/26]OD%O/I;^35W7UO
MM_";/P%9F\/@:C9W8W4U=NWN?M=,#'_%Z7K;:=)@*W,YAL?!+75TA6EIU6:H
M5U]U[HY.X=S=UX_JG^7=\;.M_GIV)VEN[^:'VCO3?_:/SCP-3CS/0=7;?ZFJ
M.V]V[:^+.(JXZ_;W3-!N6F:AQ.UH%AJJG$4:U50_DKE9A[KW0A=$[3^1/QI_
MF_;+^,.<^87?'R"^-6?^`W9W;&QMG=W[BQ^Y]X;<WECN[-@;<RE3N[>%#C<3
M4]AO305A_@];7P"LQ]/55%+Y)8@FGW7NKZO?NO=>]^Z]T'O;G_,J.S__`!'>
M]O\`WF<G[]U[I$?%;_LE[XV_^("Z=_\`?>;=]^Z]T//OW7NO>_=>Z)#_`,U/
M_P#+YO\`YT#W[KW2A^!__9+'6_\`U&[_`/\`WXV[/?NO=&]]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5#_`#)_F4=T]3_(:/XC_";X
M2[W^<OR&VYL'#]K]PXJA[$VQTOUSU!L'=%5D,=LT[@[%WK2U&,R.\-WUF-F>
MBQ5*C/\`:0R2NZV"GW7NDGM_^=1U0/@WVA\K^QNC.YNO.W.ENX(/B[V)\/*G
M%4^7[E_V;')9+`X7;72>T)J,KB=T'>.1W-138W*1^.&3'2M4-&I0QGW7NG[X
M@?S.^W^SOD30?$GYN_"/?OP2[[WUU[N/MSI*BS78FTNW^O>W=B[.EH8]Y4&'
MWWL^&DH\9V%LZ&NCJLAA9HC+%1,)M8%@?=>ZP_&?^:QG.^>W^E\5N3XW9'K?
MXX?+O-]T;=^'7>S]B8O<>:['RO1LV9?-P]F]9T^$H*OJI=ZX?;F0K]OZ<CEF
MJ(J4I4"G=E'OW7NCV_'CY'#Y%[E[ZGVMM1*?J+JCL^JZAV1VA_&HZR+MK=FS
M:44?;==A,1%1HM#MC8V]S)@(*W[B=<C74%6R!$B4O[KW1G_?NO==CZC_`%Q_
MO?OW7N@KZ?\`^/6R_P#XD?M;_P!^-N;W[KW0I^_=>Z][]U[KWOW7NF;<6WL%
MNW`YC:^Y\30YW;NX<;68?-X;)TZ55!D\9D('IJRBJX)`4DAG@D*D?X\<^TM]
M8V>Y6<NW[A&DUC/&R2(PJKHPHRD>8(Z,MGWC=.7]UMM]V.XEM=XLYDFAFC8K
M)%+&P9'1AD,K`$=48==9W<'\ISY%0=([[R62R7P6[]W'55?4.]LE)+51=+[W
MR,P>HVMFJM@5I\3+)(JS,2`\)2K4:EJA[Q/V6\O?N\\ZCE;=W>3VJW>8M:3M
M4BSF8U,;GR7R?U73-Q$O74KG':]H^_[[./[G<JPPP?>FY3LE3=K*,!3O-E&*
M+=0H/BE`!*#)#ZK<X:`]73]F=9=;]X]>;DZS[0VI@.PNN-\X>7%[@VWG*:')
M8;,XNMC#*P!OHD2ZRT]1"RRPR*LD;JZJPRZCD&)(R"#D$9!'D1Z@]<I9(WC=
MHI5*R*2""*$$&A!!R"#@@\#UK,97;_R:_P"$^^_JK<VR(=[?)?\`E+[SW$U7
MN39K22YOLGXH5V8JP)<GB9)#^_MQ)9?\X3'15ZJ$G^WJRD\J^J7BT-!<#]AZ
M;ROV=;*'1_>75'R0ZPVKW)TGO;#=@=<[RH$K\)N'"5`FB:X'W&/KZ=M-3B\Q
MCI3XZFDJ$CG@E!5U!]HF1D8JXHPZMQZ%CW7KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW10I_P#L
MOK$_^*>;B_\`?T[9]^Z]T;WW[KW7O?NO=>]^Z]U%KJ*DR=#68W(4\59C\A2U
M%#74=0HD@JZ.KA>GJ::>,\/#/#(RL#]0?>P2I!'$=:H.'0`8CXB_%S`93&YO
M!_'[J3$9C#5M-DL3E,=L?!4>0QV0HI5GI*VBJX*1)Z>IIYD#(ZL&!'U]ET&S
M[):SK<VMA8172&JNEK`CJ?576,,I^8(/0KON?>?MSLI-MW/?]^N=MF31)#-N
M5[+%(GFDD<D[(Z&@JK*5/IT8JY_J?9AT%:#HFWS=^$'4GSOZJQ'7'9N4WQLK
M/;'WEB.SNH.X.JMPR;1[7Z;[1V[%4Q8'?>PMS10U!H<C2QU<D4\$D<E/5TTC
M1R+RK+[KW0`?#G^5?UI\8MQ=N=H=I]T=W_-;O[O#8T/4V_\`N[Y0[DI-U[BD
MZ;IFJ'AZGV[A<=24&`VYLNJFJGFKH((2]=/9Y7.D*/=>Z+)U-_(-Z-ZT[%ZW
MFS?R@^7/:_Q;Z*[#H^T_C_\`!WLCLV/-?';JK>6&RLN;VG)3XW[!<[NC`;'R
MM3+-A\;D*F2GI&*!O(J%6]U[J^.YO?\`/OW7NJ-^W/Y)>.R_;7:W:/Q2^>GS
M4^!V/[XW7E.Q.XNK?CIOK"T_6&ZNRLXH3.[\Q>V]Q8C(+M/-[@!:2O\`LG6*
MHJ&\H5"`/?NO=&BZZ_E<?';J/HGH?X[=>5F],;L#IOY%;8^4.Z*W.Y@;LWIW
MWVUMG)Y#=']Y.YMW9F.7([ER>:WU/1YBLG&AWFQE-"@2!`@]U[H==R?$K:&Y
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M[KW0>]N?\RH[/_\`$=[V_P#>9R?OW7ND1\5O^R7OC;_X@+IW_P!]YMWW[KW0
M\^_=>Z][]U[HD/\`S4__`,OF_P#G0/?NO=*'X'_]DL=;_P#4;O\`_P#?C;L]
M^Z]T;WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$W^3?R1[RZ
M/SVU\3U/\(^[/E5CL[AZW)9;<75F\NF]L8W:E=35JTT&$RL'9F^MJ9&IKJV`
M^='IHI8%C%F<-Q[]U[I#_(SYG/U/+L3JOJCJS_2)\V.[]E4^Y]E]!UV7Q.'A
MV1AHDI:+*=B?(/?E!)6XW974O7N7R'V]96QR5-5E:F)Z/$154['1[KW54'S*
MZ&VM\+>@_AEVCVIV'B^PJ_+?SA_C;\G/FYW7/!18K:N6[&[`K,OLUMWM0>>2
MBV=UEUUEJS`8S#4\\K?P[$X^F::22<R2O[KW1J_F9N[:6^?YMO\`)[Z\V;F,
M/N/?VT(/F5V_NJBPN6@KZ[;/4.2Z:Q&THL[FJ2C>:.GP&[=S5,%)23S%5GGI
MF2+42UO=>Z+]W7\#<7\.\KU'BNC>_.WMW=D[N[`[3Z@_EM=!;G&T9]@_#_<O
MR2CS&0[][KP+X7`X[>V]\-TOUS79K+4$NX:[(PX13%20V>JC;W[KW2!Z+^7G
MR!^,PZP_N#2=1+_+\V7_`#`H/Y5&V.C)-F;CA^0\=9AMQU775;\DLOV1)GWH
M,[N_=/:M!6Y;)85L3'#+B:UZPU)GU'W[KW6SH>"1_0^_=>Z0^Z(.RI:RE.R<
MIL>@H!!:KCW1@\[E:R2K\C6>FFQ6>Q,,5/XK#2R,VJYU6X]^Z]T!O55)WB=M
M97['/]4I#_?_`+-$@JMI[MED-4-_[B%8RM'NZ-5@>I#M&MKJA`)8@D^Z]T)7
MV??O_/1]0?\`H'[Q_P#LR]^Z]U[[/OW_`)Z/J#_T#]X__9E[]U[KWV??O_/1
M]0?^@?O'_P"S+W[KW7OL^_?^>CZ@_P#0/WC_`/9E[]U[H&^_?CUO?Y*]5[HZ
M?[3K>H,IM7=%(8S-#L[=HR>#RD(+XS<.#J)-X'[3,8BIM)$_T8:D:Z.P(8YQ
MY1V7GGE^XY;WV/793K@BFJ-Q\$J$\'0Y'KE3@D=21[2^ZW./LKS[8>XO(MQX
M&^6,H.DU\.>(T$MO,H^**5*JP\C1QW*"*Z_A[WO\B?CUVU_PW3WYNC9=+N;;
M%&Q^/W9F]\+N')4W:VRQ))_",)192DS^*A^[HL?$5HXY?+4`Q24C-KBC#0-[
M3<X[QR7S`_LM[A.?WA!_R3;ICVW,&=$88\2%'Z=344:(U9%KG#]Z?VEY1]XN
M0XOOC^P,`'+UZ?\`D1[9&!XFV7^/%G\-<B)W-9B`%[DN%HLCZ;9LSMKN;<6)
MR>`W!7='YS!9JAJ<9F,+E]A[IR.*RN-K87IZS'Y&@JMW2TU91U4$C))'(K(Z
MD@BQ]Y0`D&HX]<UNM;_M[XD_,_\`DS;YWE\N_@%28KM7XL;KR%3N+Y%?#;&4
M6Y)MO[*I$'EK-Z==8>LS.5S?VF,A\DHDHY154,2^*5)Z,7C7)(EROAS8D'!O
M\AZK33D<.KK/B!\OS\Y>G</W7\?>T>FMP[=K1%2Y[!5>T-UTN[-B[A,*RUFU
M]XX4;V>HQ65HV)"L08:F,"6%G0@^TLD3Q-H<9ZV#7HTWV??O_/1]0?\`H'[Q
M_P#LR]M];Z]]GW[_`,]'U!_Z!^\?_LR]^Z]U[[/OW_GH^H/_`$#]X_\`V9>_
M=>Z]]GW[_P`]'U!_Z!^\?_LR]^Z]U[[/OW_GH^H/_0/WC_\`9E[]U[KWV??O
M_/1]0?\`H'[Q_P#LR]^Z]U[[/OW_`)Z/J#_T#]X__9E[]U[KWV??O_/1]0?^
M@?O'_P"S+W[KW7OL^_?^>CZ@_P#0/WC_`/9E[]U[KWV??O\`ST?4'_H'[Q_^
MS+W[KW7OL^_?^>CZ@_\`0/WC_P#9E[]U[KWV??O_`#T?4'_H'[Q_^S+W[KW7
MOL^_?^>CZ@_]`_>/_P!F7OW7NO?9]^_\]'U!_P"@?O'_`.S+W[KW7OL^_?\`
MGH^H/_0/WC_]F7OW7NO?9]^_\]'U!_Z!^\?_`+,O?NO=>^S[]_YZ/J#_`-`_
M>/\`]F7OW7NO?9]^_P#/1]0?^@?O'_[,O?NO=>^S[]_YZ/J#_P!`_>/_`-F7
MOW7NO?9]^_\`/1]0?^@?O'_[,O?NO=>^S[]_YZ/J#_T#]X__`&9>_=>Z]]GW
M[_ST?4'_`*!^\?\`[,O?NO=>^S[]_P">CZ@_]`_>/_V9>_=>Z]]GW[_ST?4'
M_H'[Q_\`LR]^Z]T67??7GS&Q/?N#[NZ\QWQSW_IZ;R_5.5P>Z-Q]B=8/CI:O
M?&+W?3Y>BJ<?MWLU,O%-%0F!XW6C:)@&!<,0ONO=/_\`>S^8C_SY'XC_`/I0
M7:G_`-H;W[KW7O[V?S$?^?(_$?\`]*"[4_\`M#>_=>Z]_>S^8C_SY'XC_P#I
M07:G_P!H;W[KW7O[V?S$?^?(_$?_`-*"[4_^T-[]U[KW][/YB/\`SY'XC_\`
MI07:G_VAO?NO=>_O9_,1_P"?(_$?_P!*"[4_^T-[]U[KW][/YB/_`#Y'XC_^
ME!=J?_:&]^Z]U[^]G\Q'_GR/Q'_]*"[4_P#M#>_=>Z]_>S^8C_SY'XC_`/I0
M7:G_`-H;W[KW7O[V?S$?^?(_$?\`]*"[4_\`M#>_=>Z]_>S^8C_SY'XC_P#I
M07:G_P!H;W[KW7O[V?S$?^?(_$?_`-*"[4_^T-[]U[KW][/YB/\`SY'XC_\`
MI07:G_VAO?NO=>_O9_,1'TZ1^(__`*4'VI_]H;W[KW7?][/YB1^O27Q(/_EP
M?:G_`-H;W[KW77][/YB/_/D?B/\`^E!=J?\`VAO?NO=>_O9_,1_Y\C\1_P#T
MH+M3_P"T-[]U[I/[MK_YB&Z-J;HVR>F?B/2?WCVYG,"*O_3_`-J2"E;,8NJQ
MRU+1#H=3*L#5(<J"I8"P()N/=>Z-ETULO(=;]/\`4_766JZ.ORNP.M-B;*R=
M=CQ,,?6Y':NU\7@ZVKH14*E0*.HJ:%GB\@#Z"+@'W[KW0D>_=>Z][]U[HD/_
M`#4__P`OF_\`G0/?NO=*'X'_`/9+'6__`%&[_P#_`'XV[/?NO=&]]^Z]U[W[
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MHA,N.IIHJ4S`.R%@I'NO=&LR/2G7&7[HVQ\@<I@GR':>R]@[BZUVCG:O)9&:
MDVWM7=^7Q.:W3%A\&]4<-197/U>"HTJJ](!62TU.D!D\0*'W7NB]P_R[/B%!
M\FIOERG5*-W-+N"3>XJ)=S[LFV)3]E38=-NS]LTG5LN:;KND[7GP"?9ON*/&
MKE6@)!FU$L?=>Z.U[]U[KL?4?ZX_WOW[KW05]/\`_'K9?_Q(_:W_`+\;<WOW
M7NA3]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1(_G1\.<#\N^K4QM%6#:?<6PZD[HZ
M:['I&:FR>V-UT12IIJ2:M@TU(PF6GIT2=5-XG"3)ZXP#%?NS[:6GN/L`AA;Z
M?F6T/BV=P,-'*N0I89\-R`#3*D*Z]RCK)W[K7WC=V^[SST;VYC_>'MSNJ?3;
MQMS]T=S:O56=4;M\:)68H2*,"T;=KU`9_P`OKYC9[N[$[EZ)[XHCM#Y8=&2M
MM[LG;.05:6HW518YUHZ??6'B.E:F&M]'W@BU(LLBRI^U,EB+V<]R[OFFWGY2
MYM7Z;W!VH^'<1M@S*O:)U'G7'B`8J0Z]CKT-OO=?=RVKVPW"R]U?:F7]X^P7
M-*_4;=<Q]RVKR`NUC,?PE.[PM5"55HV_4C:MD[*KJR.JNCJ5=&`965@0RLI!
M#*P-B#P1[G'K"SK7.^8G\N+O+X@=QYK^8?\`RF8XL!O]VEROR&^(D*NG6_>V
M`24UN8J-L;>@D@I:+<DHURFBA$;F<F:A:*>\4RV.=9%\&XX>1\QU4BF1U91_
M+U_F/='_`,POK6IW%L*6HV;VMLTQXSN+HS=$@I=^=;;CB8TU9#54$Z4]3D<!
M)71NE/7I$J,1XY5BF#1AB:%H6H<J>!]>M@UZL*]L];Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB0_\U/\`
M_+YO_G0/?NO=*'X'_P#9+'6__4;O_P#]^-NSW[KW1O??NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7K7^GOW7NO>_=>Z]:WU]^Z]UZWOW
M7NO>_=>Z][]U[KL?4?ZX_P![]^Z]T%?3_P#QZV7_`/$C]K?^_&W-[]U[H4_?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW55/\`,'^)^]LUD]N_,OXNN<#\I>CX
M1DVIJ"/2G;.R<<C/DMH9BFCTKE:^/'^1*=)+FI@9J>]_"4Q\]Y/;S=+B>'W.
MY"_2Y]VL:B%'^Y<"@ZHF'XV"U"@_&A,=:Z"N>GW0_?[EC;;&\^[=[YCZOV*Y
MH;P]4ASM5[(0([N%CF*,R:6D*_V;A9J4\34:KX<?+#9/S!Z:Q'9NUT&)SU*X
MP?86RJB2^4V3O*DC`R.)JX7M4"CFD!EHY74>:`C^VKJL@^V?N'M?N3RU'O=C
M2.\0^'<P$]T,P'<I\])^)&/Q+\P0(&^\=[!<S?=U]R+CDC?3]1M4@\?;[U1^
ME>V;G].5".W6!194!.AP?PE236>Y"Z@3JB_^87_*OW?N[LJF^=O\O#==/\?O
MG9LM9,C7C&M#B]B_("ABC'W>V]^X[1_"FS66IX_`U541O35P(2K%]-1&JAG`
M7PILQ'^752/,<>A=_EI_S3MK_,]=P='=R[7FZ`^;O4AFQ/;G0VZ$EQ-7D*S$
M_P"3Y+<^P8,DR5>2PK2IY)Z7UU%"'!)E@*3M6>`Q=RFL1X'K8-?MZMS]I^M]
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T2'_FI_\`Y?-_\Z![]U[I0_`__LECK?\`ZC=__P#OQMV>_=>Z-[[]U[KW
MOW7NJW/F;_-T_EX?`2O;;OR:^2VR]I[^;'U&1INK=OBOWUV=41Q4LM53Q2[,
MVA29?*X>3)B/12OD5HX9I'4![$'W[KW5?/6/_"IW^3KV1N6+;F0[G['ZH2>.
M(P;D[<Z=WCMC:;U$U53TL=%+F\=3YV*AG)J/(7J%AITB1V:0!??NO=7T=6=L
M]7]X[$P/9_3?8.SNT>N]T4JUFWMZ[#W#C-S[:R].P!+4>6Q-154DKQWLZ:M<
M;<,`>/?NO="#[]U[KWOW7NO>_=>Z][]U[JD+^9AMSY8[EWUE=R[C^?\`0?RN
M_P"7IT_USM[-YOO[9.2V2_:?9_=&Z=Q38<;?W'D=[4OV&PNOMJT#4T<$432U
M&:R-<H%EB`'NO=$\V7_,#^=6X?Y3G4F?VSOS;6\?E%\GOFA3?"/XK_*S-]</
MMG!]D=7;N[,R^W=E?,&JZMGA2"*27K+`Y#)Q4CQ14]744L=08S'(5;W7NA]Z
M1B^:_P#+P^>?QI^,??'S/WU\[OC]\WME]U4^U]R]S[3VYM_M/J3OSI7;>+WM
M-2XO.;5@6BKNNM];4J)(8:*I]5%6QED)&IG]U[HK_P`)?FYW/D>[/B)VIV%\
MP<WV)G?E-F/FV_S/^*>ZLKM'^XGP]V9\?3N[)[:W#M[:]%BZ'='25'UX=M4F
M-R<V=J9?X^,CKYD"M[]U[J[#X';W[2[OVIV!\GNQLWN+'[;^16ZUW=\?^G\T
M\=-!UE\=<#3MM[K/-?PDPPU=-N;M_'P-NK*O*9-`R=-3*0*?GW7NCY^_=>Z[
M4<C_`%Q[]U[H+.GP?[K9C@_\S'[6_P#?C;F]^Z]T*=C_`$/^V/OW7NO6/]#_
M`+8^_=>Z]8_T/^V/OW7NO6/]#_MC[]U[KUC_`$/^V/OW7NO6/]#_`+8^_=>Z
M]9OZ'_;'W[KW5'/RQZJW_P#`?O.H^?'QKP%3D^JMTU-/3?+/IS#H4H:K%S5*
MM4]@X>@C!AI)UDD,LLJK:EK#Y#^S/,%Q1]Q.7]W]H.:S[N\CQ%^7KA@-ULTP
MI4MF=%X+4DL3PCD.HT21Z=1/8#GOE/[V/M:GW3O>JZ2#GVP1FY4WB8U=90O;
M83.<NM`%52:RPC0/U8HR;@NI^U-C=W=>;5[2ZVS=/N'9N\<5!E<1D:<C6J2B
MT]%6P@LU'DL?4*T-1"WJBF1E/T]Y*<N\P;3S5LMOO^R2B;;;F,,C>8]58?A=
M3564Y#`CKG7S_P`A\T^V/.%_R)SG:O9\R;;.T4T;<*CX71N#QR+1XW&&1@1T
M(EC_`$/^V/LZZ!_52'\R7^5?M3YE_P`#[QZ<W-/\??F]U3X<KU)W]M5IL36U
MU;BKS8[;._Y,:$J<M@Y'7QQ5)$E31*Y`$D)>!U$$YC[&S$>(ZT17[>@?_EY_
MS3MV[O[(J?@A_,+VO!T%\[MCK'C*(Y1(<5L;Y!T$"%:/=&P<B2N*;-YBFB\X
MI:>1J:NN7HS?53Q6F@`7Q836(_M'6@?(\>KS['^A_P!L?:7JW7K'^A_VQ]^Z
M]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_VQ
M]^Z]UZQ_H?\`;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A
M_P!L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]U
MZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[KW7K'^A_VQ]^
MZ]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[KW7K'^A_V
MQ]^Z]UZQ_H?]L??NO=>L?Z'_`&Q]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^
MA_VQ]^Z]UZQ_H?\`;'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7
MK'^A_P!L??NO=>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ'U!'OW7NNO?NO=>]^Z]U
M[W[KW7O?NO=$A_YJ?_Y?-_\`.@>_=>Z4/P/_`.R6.M_^HW?_`/[\;=GOW7NC
M>^_=>Z['U'^N/?NO=:VO2_;7\O#;NYOYR_R[J_@%LK&]C?`GY'=K_P"F+M*M
MAV]VGVOW9GMJ8#);QS&\-K97>V.A?8DE7!7S4]'BZ>K2EIX2B!PJ@+[KW1@?
MEY\UOBWL[X>_";OO._#38O<G6?SO[E^,G6>*Z[WQMWKZC;:=+\@$CR^`W+N2
MBK-M;GPV9JMILL;O21`>27]$RVO[]U[JT3XZ?%#X[_$7;>Z-E?&OJG;/3NS-
MW[PR._<UM'9L530;:;=F7IZ6FRF6QV&>HFH<,:^*BB\D-(D-/=`50>_=>Z,)
M[]U[KWOW7NO>_=>Z)Y\F.A?DOV_GML9+HOYN[U^*F(P^'K*#.[=VMTQT_P!G
MT^Z\G45JU%-FZO(=E87)U^,FHJ4&!8*9EA=3J8:O?NO=5]_.;YPK\4^PZ;I+
MYX_#K?7R=^$V^NK-BU&S>].M>C)?D"=S]X[9GD;>VU.[.H,=0U6'VI45ST4&
M9P532TK4A(E3TM&NGW7NJM=@?''Y/83X)[N^5O2?Q-[+Z_V9UA_-3V#_`#$?
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M-_X_"=MT/3E/_*TIJB2FQ.#;=$C?Z%FZ0I^F8L?C*3`0,:^/=D8(IEE#2>_=
M>ZVZS]3;Z7]^Z]TB=S;'I]TUE-5S;EWQA&IX/MA!M;=F4V_1S`R&3RU--0NL
M<]1=K:V]6D`?0>_=>Z`_JKJJBJ]M964[Y[6@*;_[,I]%+V)GH(V%+O\`W%3B
M5T24*T\PCU2-]7D)8\GW[KW0E?Z(:'_GX';_`/Z,K</_`%]]^Z]U[_1#0_\`
M/P.W_P#T96X?^OOOW7NO?Z(:'_GX';__`*,K</\`U]]^Z]U[_1#0_P#/P.W_
M`/T96X?^OOOW7NO?Z(:'_GX';_\`Z,K</_7WW[KW7O\`1#0_\_`[?_\`1E;A
M_P"OOOW7NO?Z(:'_`)^!V_\`^C*W#_U]]^Z]U$K^D<%EJ"MQ>5WEVID\7DJ2
MIQ^1QU?V'G:JBKZ"LA>GJZ.KIY9&CGIJFGD9'5A9E8CVU-##<PO;W"+);R*5
M96%596%"I!P00:$>G2BTN[NPNHKZPED@OH)%DCDC8J\;H0R.C"A5E8`@C@1U
M2/F-G9/^5?\`(;'8JMW+V/#_`"_^]]P&+'UN`W7FZ#_09V'DC$'&7EHW=ZC%
MSK%^N3F>C!;U34[:\1XVN_NY<Z^"_B2>T&]3]I-6%A.?+Y*!_O<0K\<9U=5I
MX]L_O"?9P7</@P_>VY-L>]1I0[_M\8P1PU3+_P!4YS3$<XTW<T75V%R5%29'
M'=E=KU^/R%+3UM!74?:.=J:2MHZJ))Z6KI:B*=XIZ>HAD5T=2592"#;WES%+
M%<1+/`RO`ZAE92"&4BH((P01D$<1URHNK:YLKF2SO(WBO(79'1P5='4E61E-
M"K*P(((!!%#U*_T0T/\`S\#M_P#]&5N'_K[[<Z8Z(O\`.;^5-T1\Y-A08S>F
MY.PL+VWLZ*>MZ<[K3=63R>[NL]PB1*NDJ:.2:>%\AAFKX4>>D>0"X+PM%+:3
MV]#,T+5&5/$=:(KU6'\5?F9W3\3>\L;\!?YM.^.R=K;XR51]G\??ES0=A;AQ
M_5/=F&:=:;%8_/Y1OML?B,R;K$E7((W68B&N6.33-(_)"LB^-;\/,>8ZT#3!
MZV(DZCQ\B))'V%V[)'(JNCIV9GW1T<!E=&68JR,IN"."/:+JW7+_`$0T/_/P
M.W__`$96X?\`K[[]U[KW^B&A_P"?@=O_`/HRMP_]???NO=>_T0T/_/P.W_\`
MT96X?^OOOW7NO?Z(:'_GX';_`/Z,K</_`%]]^Z]U[_1#0_\`/P.W_P#T96X?
M^OOOW7NO?Z(:'_GX';__`*,K</\`U]]^Z]U[_1#0_P#/P.W_`/T96X?^OOOW
M7NO?Z(:'_GX';_\`Z,K</_7WW[KW7O\`1#0_\_`[?_\`1E;A_P"OOOW7NO?Z
M(:'_`)^!V_\`^C*W#_U]]^Z]U[_1#0_\_`[?_P#1E;A_Z^^_=>Z]_HAH?^?@
M=O\`_HRMP_\`7WW[KW7O]$-#_P`_`[?_`/1E;A_Z^^_=>Z]_HAH?^?@=O_\`
MHRMP_P#7WW[KW7O]$-#_`,_`[?\`_1E;A_Z^^_=>Z]_HAH?^?@=O_P#HRMP_
M]???NO=>_P!$-#_S\#M__P!&5N'_`*^^_=>Z]_HAH?\`GX';_P#Z,K</_7WW
M[KW7O]$-#_S\#M__`-&5N'_K[[]U[KW^B&A_Y^!V_P#^C*W#_P!???NO=>_T
M0T/_`#\#M_\`]&5N'_K[[]U[KW^B&A_Y^!V__P"C*W#_`-???NO=>_T0T/\`
MS\#M_P#]&5N'_K[[]U[KW^B&A_Y^!V__`.C*W#_U]]^Z]U[_`$0T/_/P.W__
M`$96X?\`K[[]U[KW^B&A_P"?@=O_`/HRMP_]???NO=>_T0T/_/P.W_\`T96X
M?^OOOW7NO?Z(:'_GX';_`/Z,K</_`%]]^Z]U[_1#0_\`/P.W_P#T96X?^OOO
MW7NO?Z(:'_GX';__`*,K</\`U]]^Z]U[_1#0_P#/P.W_`/T96X?^OOOW7NO?
MZ(:'_GX';_\`Z,K</_7WW[KW7O\`1#0_\_`[?_\`1E;A_P"OOOW7NO?Z(:'_
M`)^!V_\`^C*W#_U]]^Z]U[_1#0_\_`[?_P#1E;A_Z^^_=>Z]_HAH?^?@=O\`
M_HRMP_\`7WW[KW2KVOLV#:LE9)#N+>><-8D2,FZMT9+<,=/X6=@U''7NRTKR
M:[.5Y8`7^GOW7NEA[]U[KWOW7NO>_=>Z][]U[HD/_-3_`/R^;_YT#W[KW2A^
M!_\`V2QUO_U&[_\`_?C;L]^Z]T;WW[KW78^H_P!<>_=>ZT&N]^P?G?\`'[<7
M\^SXL[,_E:?+3O;;?\P/Y%=Y9+K[O79>V\_3;,PN$W9MF;9>-S=-0KLS+?WM
MQLJD5D4M-6P)+&0H/Y]^Z]TU[N[T_F"?*;X^?RJ?@[E_Y0OS)Z=Q_P`5/DG\
M*-P;L[QW-MS<61VK7X3I"KQFW,]E9<.-AXEL+055+,]:\DM=(M+#$VHM]??N
MO=;_`$WZC[]U[KC[]U[KWOW7NO>_=>Z][]U[KL$CZ'W[KW7KF]_S[]U[KQ)/
MU]^Z]UZYM;\>_=>Z]<VM?CW[KW77OW7NNQ]1_KC_`'OW[KW05]/_`/'K9?\`
M\2/VM_[\;<WOW7NA3]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW08=S=/;"[\ZSW9U-V7A8<YL_>&,EQV1IG`6HI)3ZZ+*XRH*L]%EL75*D]/,
MO*2(/J+@D',_+6T<W[%<<N[Y$)=NN4TL/-3Q5T/X70T96'`CTQT./;;W%YL]
MI^=MO]P.2;EK7F+;IQ)&P^%QP>*5>#Q2K5)$.&4G@:$5,_#;N+??PN[G'\O'
MY/YJ:MV]4M+5_$_N'*$PX[=NU9IW%'L:OK9F,,60I3^U31EKP5"M3<HU,3CO
M[9\S;M[8<S_ZS7/DNJR;.U7C866(GMA).`?)!7L>L7`QUS_^\?[<\J_>5]M?
M^#!]C;98MW0!.:MHBS):704:[V-!DQM\4C`4>,B?#+-2[7WE/US(Z][]U[HJ
M?S&^&/0OSIZ9S/2??NTX,]@JT25FW=P4HCIMV;#W&(6CH]T;/S/C>?%Y2D8C
M4OJ@J8P8YD="5]N1RO$VI./6B*]46=&_+;Y(_P`FWM':WPZ_F,YC+]G_``]W
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[HD/_`#4__P`OF_\`G0/?NO=*'X'_`/9+
M'6__`%&[_P#_`'XV[/?NO=&]]^Z]UV.2!_4^_=>ZU5LY_,A^8,ORL_F__*S)
M]H;8V/\`!/\`E/[#[-Z+VI\?7Q,<N9[B^0[;0QF2PF^MV5_AI\@:&FW91)#0
MKYVCEIL@L-/#K\TQ]U[JNWIK,_S*OA!!_*L_F<]T_/?M_NUOYD'?O6?6_P`D
M_B?V,\U1L'`;3^1$E1DMDR=6[:&5K:'%U^U,&8IY#04-&:.0QZ":<2QR>Z]U
MO=G@G_7]^Z]UU[]U[KWOW7NO>_=>Z][]U[KHD*"S$*J@EF)```%R23P`!]3[
M]U[IIQ6X<!GL-3[CP>=PV:V]5T\M729_$Y.BR.%JJ6!I$GJ:?*T<\U#-3PO"
MX=UD*J4()X/OW7NFG9^_]A]AT%5E.O\`>VT-]8RAK'QU;DMF[EPVYZ"CR$2)
M))0559A:VMIZ>MCCD5FB=@X#`D<^_=>ZY8G?FQ<]N//[.P6]=I9K=^TUIWW5
MM3$[DP^1W+ME:L`TC;@P5'6393#+5`WC-1%'K_%_?NO=/%-FL-69/)X2DR^+
MJLUA8Z&;,XBFKZ2?*8B+*1RRXR7*8^*5JO'QY&*!V@:5$$RHQ2X!]^Z]TY^_
M=>Z['U'^N/\`>_?NO=!7T_\`\>ME_P#Q(_:W_OQMS>_=>Z%/W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4#YJ?$'9GS&ZBJ]BYN<;?W
MK@ISN#J_L"EC89796[Z90])5PSPE*K^%USQK%61(P+1V=?W(XR(V]T?;?;/<
MKEQMJN2(=UA/B6MP!W0RC@:C.AJ`.`>%&'<JD9$?=H^\/S)]W+W#CYIVQ?K.
M6;I?I]SL&/Z5[:-AT*FJ^*@):%B,-53V.X)=/Y?'RYWGO2LW-\2/D[$=N_*_
MHQ&Q656O=4_TH[2QRI%0;WPTS:$R=6:(Q/5O%?[B*1*I19Y`@*]F_<;<]SDG
M]NN>P8?<':AH;5_Q*B2@$RG`=@-)<CXU*R@=S!9C^]Y]WOEKEJWL?O!>Q[?6
M>P7-)\6(QBO[LNY*F2RF&3$FO4L0;^S96@)JJ:K2O<_=8*=>]^Z]T$O>7174
M_P`D^K]U=-=V[*P^_NNMXT+T69P&9IUE0-I84V2QM2+5.*S..E;R4M7`T<\$
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MI["^7N2R>'BV7U!A.TVW"]!-UKV!W.<;4T^+3!MDUJIE@%6L`9O?NO=`UL+Y
ME_(+X)T'R?S.5Z;ZQ[9VO\<M_=7]J?S4.XJO?V8P':F:[W^4N,VONW<E!T'M
M&';U;MW*[&^.77VY]OXV"#)5]-][B\>M/0JLJ,S>Z]ULZ4593Y&BH\A1N9:2
MOI*:MI9"K(9*>JA2>!RC`,I:.0&QY'OW7NI/OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB0_P#-3_\`R^;_`.=`]^Z]TH?@?_V2
MQUO_`-1N_P#_`-^-NSW[KW1O??NO=>]^Z]UKN?-'_A.1\</F;\J]Z_(?)?(/
MY`]1["[SR^P]P_*;XW]:YNFH.L?D'N'KLTR8',[A$L@_AE=44])&M2[TU<WE
MUS4YIIG9S[KW02]$?'OH[^9Q_-&W[WW/VGW53])_R@>S]K?'SJ+X8Y[`XC"]
M0;9[SZ_VY78N7M+!UF/W1G$S>WUIZ"CDH(9:&BKA-2*)G-.%A?W7NMGWW[KW
M7O?NO=>]^Z]U[W[KW7C8?4J+_2[`7M_KD?U]^Z]U5]\TM_;N[^W=E?@+T;G<
MQ@*K+[%J=Y?,7M[:]3]OD.D>@LK09*&AV!M[+P3QOBN[OD"]-+08?06J,/@8
MZ_+&,,E$9/=>ZI.VKC<QN[^0K_*+^)FW=S[DV!M7YA=]]`?%WLC,[2RU9A-Q
M+TCFNQ.Q=Q]A[;Q^>HU^_P`?4[LVMLIL9)4(RO)'5.&-G;W[KW1NT^%_0W\L
M/^:3_+]E^$.S?]!/6/S$VG\D>AN^NH=K[@S=1U]NK(];=>T/9O5_9,FULUDL
ML/[[8+*4U335&1CT&6C=8Y3=RS^Z]T2?XR;2W#\3]_\`0/;/8WQG[BZ=[>^$
MDGSDW]_,Q^4^<V)/B-N_)7;V_:G=;]7[:VOV<\\:_*3<':>[<C@I]MTM.]7)
MA):<1E:=V"-[KW5M/\O[Y)_'+9?86[NH.ZN\.OJ?^9)\F][U';O??6GER0K-
MJ[NS&W:/+=?_`!LHMVSXR/:55N7H_IUL9C$V['D9,NIIZJK--::1S[KW5TWO
MW7NF'*[KVO@)X:?/;EV_A*B:/S0P9?,XW&SS0ARGEBBK:F&22+6"-0!%Q;W[
MKW0.=2]@[!IML96.HWSLZ!W["[0G5)MSX.-FAG["W)+!*%>N!,<T3AE/T92"
M."/?NO=";_I(ZZ_Y[_9/_H5X'_ZO]^Z]U[_21UU_SW^R?_0KP/\`]7^_=>Z]
M_I(ZZ_Y[_9/_`*%>!_\`J_W[KW7O])'77_/?[)_]"O`__5_OW7NO?Z2.NO\`
MGO\`9/\`Z%>!_P#J_P!^Z]U[_21UU_SW^R?_`$*\#_\`5_OW7NO?Z2.NO^>_
MV3_Z%>!_^K_?NO=>_P!)'77_`#W^R?\`T*\#_P#5_OW7NO?Z2.NO^>_V3_Z%
M>!_^K_?NO=>_TD==?\]_LG_T*\#_`/5_OW7NJQ_YA?0N$[<I=J_([X[=C[*V
MQ\LNAY%SNQ\KCMU;>IY]^86@9JJLV)EW&01:QIXS(*(2DQN99*=_VYR4@CWE
M]M;_`)B2WYVY,)@]P=I.N%DP;A%R86_B/'PZX-6C/:YIF]]T'[Q>P^WL]_[-
M>\2"^]@.:U\"]BDJRV,TE%2^A&=`4Z?&*#4`J3+WQ`,87X9?.CK'Y5].8_>U
M;F<!L;?^#F7;G9VQLUF:'&U6V]W4D86L-&N0J():G!Y-D::DEYLI:)CY(W]B
MKVJ]R;'W)Y=%^J^!OEL1'>6YJ&AF&":'N\-R"4)%1E#W*>HQ^\]]W;?/NZ^X
M!V&:3ZWDK<$^IVC<%H8[RS?N0ZEJOC1JRK*JFGPR+V.O1L_])'77_/?[)_\`
M0KP/_P!7^Y-ZQOZ]_I(ZZ_Y[_9/_`*%>!_\`J_W[KW3!NK/=*;ZVUG=F[SW!
MUGNG:>Y\95X7<.W,]G-L9/#9K$UT305F/R-!5UDM/54U1$Q#*RG^OU][!(-1
MQZ]UK%;]V+VU_(Q[4W!\A?ASN"E^0?\`+BWQG?XMWI\6H-Z8S+;MZ,DKZE%J
M=Y=<(V0GE?%4:OICJ$1RD:K!7JR".J1<'2[&B3$PX'UZKE>'#JX[L_YB?'#Y
M5_RY>^NX.ENU-J[BVEO#X[=K&D@JLOCL7N#$Y1MCYE*K;FX<#654>0Q&X<=4
M$Q34\BW+#4A>-D=D<D;QMI<4/5@:]'RP78_7B8/"J=_;*5AB,8&!W7@@0110
M`@C[_P!TZ]T[#LOKP?\`,?[)_P#0KP/^]_?^_=>ZK1WC\!?BSNWXD_*#X=0?
M(W?&U>O?EIW!VGW%V;N?;':6PZ+?E-D.Y-[4N]M];2VYEY\154./V=DYZ=J$
MT\M+/,V/GEB>5]9;W[KW14NA_P"37T#T%V?U1V1@OYI7\P3=U+U%N3;>>PO6
MV^OF9A\WUAFJ+:[1#'[3W)M*+#4=+D-HO3PK!)0HT49A4(+`>_=>ZM@[@V%T
M-WAO/HG=F^>S\74470'8\_;.V=E4F^=KP[.W'O\`@V]D]O[5SV\\;*T]1F)=
MA-F*BOQ")-"E/DBE0P=HH]/NO=%3[X^`/P\^0?>F0[HW9W;N_!8;?53US7]^
M=%;-[CV[A.C?DMDNGZJ&LZPR'=6T##55V<J-J/24T1%%6T"9"DI(:>L6>*,+
M[]U[JR-.QNMXT2./?FQHXXU5(XX]TX!$C1`%1$1:\*J(H``'`'OW7NN7^DCK
MK_GO]D_^A7@?_J_W[KW7O])'77_/?[)_]"O`_P#U?[]U[KW^DCKK_GO]D_\`
MH5X'_P"K_?NO=>_TD==?\]_LG_T*\#_]7^_=>Z]_I(ZZ_P">_P!D_P#H5X'_
M`.K_`'[KW7O])'77_/?[)_\`0KP/_P!7^_=>Z]_I(ZZ_Y[_9/_H5X'_ZO]^Z
M]U[_`$D==?\`/?[)_P#0KP/_`-7^_=>Z]_I(ZZ_Y[_9/_H5X'_ZO]^Z]U[_2
M1UU_SW^R?_0KP/\`]7^_=>Z]_I(ZZ_Y[_9/_`*%>!_\`J_W[KW7O])'77_/?
M[)_]"O`__5_OW7NO?Z2.NO\`GO\`9/\`Z%>!_P#J_P!^Z]U[_21UU_SW^R?_
M`$*\#_\`5_OW7NO?Z2.NO^>_V3_Z%>!_^K_?NO=>_P!)'77_`#W^R?\`T*\#
M_P#5_OW7NO?Z2.NO^>_V3_Z%>!_^K_?NO=>_TD==?\]_LG_T*\#_`/5_OW7N
MO?Z2.NO^>_V3_P"A7@?_`*O]^Z]U[_21UU_SW^R?_0KP/_U?[]U[KW^DCKK_
M`)[_`&3_`.A7@?\`ZO\`?NO=>_TD==?\]_LG_P!"O`__`%?[]U[KW^DCKK_G
MO]D_^A7@?_J_W[KW7O\`21UU_P`]_LG_`-"O`_\`U?[]U[KW^DCKK_GO]D_^
MA7@?_J_W[KW7O])'77_/?[)_]"O`_P#U?[]U[IYQ&YMM[@:=,!N'!9QZ54:I
M3#Y?'Y-J=9"1&TZT51.85<J0"U@;<>_=>Z>_?NO=>]^Z]U[W[KW7O?NO=$A_
MYJ?_`.7S?_.@>_=>Z4/P/_[)8ZW_`.HW?_\`[\;=GOW7NC>^_=>Z\/\`'Z>_
M=>ZI+[N_F;_-7XN]N]D;:[:_E)?)7M;HO"[US5!UIW[\1=S[/[MGWAL^JJ&?
M8U=G.HGJ,'O+;N8J<=33MF"TK4V/F$:+Y!*I]^Z]T4_^6;\[?Y-G5'>/R3QG
M5_R3[+ZN[X^=WR+G[?W/T_\`,3:&XNG=S'L/-H<;3878%-N;96VL3'A\CD*]
MZ2AIYLC655561M#$SLH4^Z]ULR?3@^_=>Z][]U[KWOW7NO>_=>Z)]\EO@+\1
M/F%GML[F^2'3=!V;G=G8>LP&VZ^LW7OW;S8S$5]8N0JZ-(-H;IV_2U"S5BA]
M<R22#Z!@./?NO=$.^0_\@3^7=\A^R=]]T[IV=W-C^Q]ZX/;N,R']R/D;W!L/
M`5G]QMEX_9&S:>3#;>W31X_1C<#AZ6F#R+(S*I9RQ9K^Z]T3?HC^2#V3TW_*
M5ZRZ'ZGS5'T]\[>O>X>K_F!A\IO;L#</;/5U'\E^E]S553MK"33M4UD.&Z]W
M;L]?X97Q8:*&*,UCS&-Y`^OW7NC3?''X_?S(_DW\T^E/F'_,=Z_Z`^/.U_B+
ML7M#;O0W0W26^:_M?(;N[1[CQF*V]O7MW>&\ZNG@H\/@\?M+'"BQ6)B9ZE9W
M:68V`+^Z]T?7Y'=(=D_(;OKXW;7S-%C*;XH]3YN;OWLV1\O329;LSN78V1H5
MZ,ZVJ-N&)YFV3M?-S3[KR<TQ:GJZ[&8Z`+Z9#[]U[JKB?^7?\N\CVY0]#56U
M>OX/C1AOYH.0_F:Q?+MNS(ZKM#(4M=N2LW\G1T'5/]W4SE#OA-PY)L'+GWR3
M8M]KPB-4\I$7OW7NMB<\DG_'W[KW3-D=N;=S4T4^9P&%RT\2>**;)XJ@KYHH
MM6KQ1RU=/*Z1ZB3I!`OS[]U[H'>I-D[,GVQEGFVAM:5U[#[1B5I-O8AV$4/8
M>Y(H8P6HR0D4:A5'T"@`<#W[KW0G_P!P]C?\\7M+_P!!O#?_`%%[]U[KW]P]
MC?\`/%[2_P#0;PW_`-1>_=>Z]_</8W_/%[2_]!O#?_47OW7NO?W#V-_SQ>TO
M_0;PW_U%[]U[KW]P]C?\\7M+_P!!O#?_`%%[]U[KW]P]C?\`/%[2_P#0;PW_
M`-1>_=>Z]_</8W_/%[2_]!O#?_47OW7NO?W#V-_SQ>TO_0;PW_U%[]U[KW]P
M]C?\\7M+_P!!O#?_`%%[]U[KW]P]C?\`/%[2_P#0;PW_`-1>_=>Z]_<38XY&
MR]I`CZ'^[>&_^HO?NO<<'AU31\X_CIN+XM]M4G\PSXU;,Q>=H\7&E%\G>F4Q
M%'/B-Y['=H4R&[\9CC2S0TN2HH(E>K>*/7%)%'5@$+4!L7?=#E?>?;KF4>]'
M($>I1C=;1<+/"2-4P`Q7%9#2JL!,,"0-TP^[/[E\H?>#]N?^`Y]][A8V8EN5
MMVDH9+"]`/AV;.Q_LG)TQ*2%=&:W-"8=-G716].A/D7U;M7M[K#![.S&T]UT
M*U$!_NY@UKL57Q63(X+,TRTKM0YC$U5XIXFY#`,"496,_P#*7->S<Z[!;\Q[
M%()-ON%K_21AAHW'X70X8?F*@@G!'W4]L.;_`&<Y[O\`V\YXMC;;_82Z6XZ)
M8SF.>%J#7#*M&1QQ!H:,"`+O]P]C?\\7M+_T&\-_]1>Q'U'O7O[A[&_YXO:7
M_H-X;_ZB]^Z]UQ?8.Q)$DBDV3M"2*:*2&:)]M85HY89D:.:&5#1%7BEC8JRF
MX920>/?NO=:17\Z[HN3^5EW-4=B_">@WEU=UG\SMB[UVEW=M&HV3A=R?'B+)
M9#5338G:\^6AKH-N[OR--43U<5$(H30HQDHI0CO#&:6Y%TFB:A*\/7JA[3CJ
MZC^5)_-J^)WS9ZSVEL+MO_0[U-\K\+24V!W%U_FZ'`8&@["DHJ6GBI-Y==39
M6FAIJZEW!'9WQB3/5TLX=51X@CE+<6KQ-503'_@^WK8:OV]7H'86QQ]=E[2_
M]!O#?_47M+U;KK^X>QO^>+VE_P"@WAO_`*B]^Z]U[^X>QO\`GB]I?^@WAO\`
MZB]^Z]U[^X>QO^>+VE_Z#>&_^HO?NO=>_N'L;_GB]I?^@WAO_J+W[KW7O[A[
M&_YXO:7_`*#>&_\`J+W[KW7O[A[&_P">+VE_Z#>&_P#J+W[KW7O[A[&_YXO:
M7_H-X;_ZB]^Z]U[^X>QO^>+VE_Z#>&_^HO?NO=>_N'L;_GB]I?\`H-X;_P"H
MO?NO=>_N'L;_`)XO:7_H-X;_`.HO?NO=>_N'L;_GB]I?^@WAO_J+W[KW7O[A
M[&_YXO:7_H-X;_ZB]^Z]U[^X>QO^>+VE_P"@WAO_`*B]^Z]U[^X>QO\`GB]I
M?^@WAO\`ZB]^Z]U[^X>QO^>+VE_Z#>&_^HO?NO=>_N'L;_GB]I?^@WAO_J+W
M[KW7O[A[&_YXO:7_`*#>&_\`J+W[KW7O[A[&_P">+VE_Z#>&_P#J+W[KW7O[
MA[&_YXO:7_H-X;_ZB]^Z]U[^X>QO^>+VE_Z#>&_^HO?NO=>_N'L;_GB]I?\`
MH-X;_P"HO?NO=>_N'L;_`)XO:7_H-X;_`.HO?NO=>_N'L;_GB]I?^@WAO_J+
MW[KW7O[A[&_YXO:7_H-X;_ZB]^Z]U[^X>QO^>+VE_P"@WAO_`*B]^Z]U[^X>
MQO\`GB]I?^@WAO\`ZB]^Z]U[^X>QO^>+VE_Z#>&_^HO?NO=>_N'L;_GB]I?^
M@WAO_J+W[KW7O[A[&_YXO:7_`*#>&_\`J+W[KW7O[A[&_P">+VE_Z#>&_P#J
M+W[KW7O[A[&_YXO:7_H-X;_ZB]^Z]TZ8S;^!PC3-AL'A\0U0$6=L7C*+'M.L
M9)19FI((3*J%B0&O:_OW7NG?W[KW7O?NO=>]^Z]U[W[KW1(?^:G_`/E\W_SH
M'OW7NE#\#_\`LECK?_J-W_\`^_&W9[]U[HWOOW7NO>_=>ZIU_FU?SA/C'_+$
MV'4[4[6W]N'97>W;G3W:V>^/`Q?7&:WYB*C>>VL0V.V_49QZ&EGQ5'20;OR=
M`'CK"L4D;,6]`;W[KW1$/Y.W\W/X:?S9MA=#]`?(&+:_>/S_`-O]8_Z5>V8M
MV?'?&X[;&-W#UQO&FR-'FMLYVHV^-KTE=MRKR&-J:,X]HRE3>6,*X)]^Z]UL
M\^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KL?4?ZX_WOW[KW05]/_P#'K9?_`,2/VM_[\;<WOW7NA3]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6&HIZ>KIYZ2K@
MAJJ2JAEIJJEJ8DGIZFGG1HIZ>H@E5HYH9HV*LK`JRD@BWNKHDJ&.0!HV!!!%
M00<$$'!!&"#QZ<AFFMYDN+=VCN(V#*RDJRLIJK*PH0P(!!!J#D=4,;MQ6<_E
M)_)'_2/M:BR-7\!_D+N2GI.P-MT:SUM/T;O_`"#%*?-XRG&MJ7#R<F(?2:D#
MTY)D@@)Q$W&WNONZ<[_OK;T=O:/>9PL\:U864[<&4>2CBG\4=8ZZDCKU;Y?O
M]K_O!/9C^IF^R0Q_>QY0LF>PN'THV]V$8JT,K8#3#@QXI*5F%$EE`O:PV9Q.
MXL1B\_@<C1YC"9J@I,IB,KCYXZFAR..KH$J:.MI*B(M'-3U$$BLK`V(/O+6U
MNK:^MH[VS=9;25`Z.IJK*PJK`CB"#4=<K=RVW<-FW"?:=VADM]SMI7BEBD4J
M\<B,5='4Y#*P((/F.G/VHZ1=>]^Z]T33^8=L39?8GPA^4.`WYM;!;OPM-TMV
M#N&FQFX,=3Y*DIL[MS;.2S&!S%-'4(_V^2Q.3I(YH)D*R1NO!M<&RLR'4A(;
MKW0/?)'^5-\&/F+USM3`]H=(;;P.<V]M3"8K9G8G65+3;`[`V934.-IDQL6%
MSV"IX!/28W0OAIJR*JID`L$'MR.XEC-5./GUH@'JL6?I/^<[_*X8U'QSW_#_
M`#+/B?A+RCJ#M6=Z7O[:6!@!`H-M9XS/DLJU#3W$*4L]7&^D?Y`O`"C7;3_&
M-$GJ.'6LCAD='O\`A[_.H^''RJS,76>X\WE_C/\`(>FE7'9OHCO^F.R-R09M
M+K48_`YC*I18?<&F8:8TU4]7)<?Y./I[:EM98QJ'<GJ.MA@>K=@0P5E(964,
MK*0RLK"ZLK"X*D?0CVFZWUW[]U[H@/\`,+VCN'_0?NKM3:7<G=_5NYMC8[;U
M'BXNK>P:C:6&K1FM^;;QM;5YK$+05U'E*\8_(2PQ2RJ?&C<#4`1[KW1S=@[,
M3K[:>*VC'N?>>\DQ*3H-Q]@[AJ-U;MR/W%3+5:LKG:J.&>N:$S>.,LHT1JJ_
MCW[KW2Q]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]T2'_FI__E\W_P`Z![]U[I0_`_\`[)8ZW_ZC=_\`_OQMV>_=>Z-[[]U[KPYX
M]^Z]U4IW!\MOY8_S`KOD7\*]V?(?H;;O?^%HNTOCGN#;7:M#MK!]F[`W-G\+
MGMN5F4V7BNS:7%?WBC@1#D:2?%SS4M0B0N9%UH??NO=9OAGLCX&?RQ?B)U+U
M5D/DC\;*BBZ+V5%LG*]_;GSW46Q,_N&ER&=J*B*?<&2H\W-+3FLJ\C%!XWK)
MO)XTN2??NO='2^,?R]^.7S+VEN;?_P`8^S\/V_L+:>\LGL#);UVU2Y5=L56Z
M<-3TE1EJ'!Y;(T-%3[@IJ%:V,-5T9FI'9OVY7'/OW7NC)^_=>Z][]U[KWOW7
MNO>_=>ZKQ^<_\T'XG_R[\CUCA?D9E^QDSO;U/NJMV5@>LNK-Y]JYNJQ^RSAE
MS^2K\7LS&Y*LQN/I9,]3()I4".[D`^D^_=>ZY]1?S1?AWW!\4>Q_FM2[WW-U
MO\=^ILMG,-OO>'=77^[NJ*S$5>!I,-55)BV[NW&46<R<5:V?I:>C--!*U;5R
M?;PAY04]^Z]U`^$G\UKX4_S`]P;KV7\>.Q<[+V'LW%0;DS'6G96PMW=5=@2[
M/JYH*6DWOA]K[WQ>)K\YM"HK*A8!74HECCE(630635[KW2BZ6_F6_$SO[O2O
M^/O7.[]T56\#/OJDV3N+-]?[MV[UCW)5]6UXQ?9]+TEV5E\93;3[2GZ^KR4R
MBXJHF\`5G77&K./=>Z,WL+O'K[LS?_<?6^S*_(9;/=#Y_;FT^Q:U<561;<H-
MU[EVY2[LAVSC=P2(,?F<YB,%D*67)04[.V/:KACFTR/I'NO="[[]U[KL?4?Z
MX_WOW[KW05]/_P#'K9?_`,2/VM_[\;<WOW7NA3]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(?LGKC9G;NQ-T=:
M]A8.DW'L[>&)J<-G<36(&CGI:E+"6%R"U/64DH66"9;/#,BNI!`/LIWS8]KY
MDVB?8]YB6;;;F,HZ'S!\P?)E-"K#*L`1D="CDOG/F7V]YJL>=.4+J2SYCVZX
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MPZ,-V7@$&V.SMNRH`()\5O/%+#DW6G(!6"I-13<<QGV['-)$>PX]/+K1`/51
M7^RK_P`W_P#EB,U;\-.X(/Y@7QBQ)\B_'+OBK--VYMC#0OK..V1NIJJ(U[4\
M!*0I3U,89@#]BWT]J/$MI_[0:)/4<.M4(X<.C>?%#^>%\3>^]SQ]/=U0;F^&
MOR2HYUQF8Z<^0](^T5DS`<0O2;=WADH,?ALD))@1&E2**H>X"QM<$MR6LBC4
MG<GJ.O!A^?1U/GQ+%4?$'M>>"6*:"II]A24\\4B20U"5'9&RS`\,J,8Y5G#C
M05)#7%KW]INK='+?]1_V'^]#W[KW7'W[KW7O?NO=>]^Z]U[W[KW10?DKW[W1
MTIN'K+';!Z+VGVC@NS=Z[<ZUH,UF>YFZ[K<9O7<T.X*VEAJL.>N-W+/@J:@P
M!:2J2I$QEF5%@(5F]^Z]T9K:%=NC)[8PE?O7;^-VINRKH(IL]MS#[@;=6,P^
M08MY:*BW$^)P+9B",`$3&CI]5_T"WOW7NE)[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HD/\`
MS4__`,OF_P#G0/?NO=*'X'_]DL=;_P#4;O\`_P#?C;L]^Z]T;WW[KW7O?NO=
M5^_,/^5A_+_^>C'(?*7XQ]==C[K3&56)HNPTHJG;'8]!2U-)-21^#?&UJG$;
M@J/L%F+TJ5,T\-/*`ZH"/?NO=5Y]5_\`"7;^3'U7NVEW?#\9\UV!/1P&.#`]
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M^.WR?SW7-)41]-=X[<RFWLCV]U%O&EPN5II%Q%/OK(KBH\O@9U:*EKDT`*CH
MB>Z]U9C\WL#M["?S:?Y.F\L!0TE!V#NC_9U>L-PUV.Q\462SW4<72F)S]5A<
MQD:=/.^#V_N1*:JI()+QQU,[2(48&_NO=$CK/BI\IO@?MGXZ56],QTAO;K#X
M([U[LVW\`L#LV7=G^FGY4=]?+C([DV1TILGMK&5N.H<!L#&;-DW]/-FWQ%9D
MOXE3T;U;B".%[>Z]T._P_P#F]MOXL_W1^/F;Z6["W)TU7_+/</Q4[*^?TN[]
ME5F$[4_F%;TRU7F>UZW)]<1U0WQ1;"SG;577X&AW%,[0QU-+!1B`1(L@]U[K
M8//''OW7ND5N;<NY<)64T&$Z]SN[X)8/++78K+[8Q\%+*)"OVTL6<R^.J'DT
M@-J162QM>_'OW7N@/ZIWQOB#;642#IK=M8C;_P"S)6DBW'L*-4EFW_N*6:G*
MS;DC<O2RN8V-M+,A*DK8^_=>Z$K^_P!O_P#Y\?O'_P!";KW_`.R?W[KW7O[_
M`&__`/GQ^\?_`$)NO?\`[)_?NO=>_O\`;_\`^?'[Q_\`0FZ]_P#LG]^Z]U[^
M_P!O_P#Y\?O'_P!";KW_`.R?W[KW7O[_`&__`/GQ^\?_`$)NO?\`[)_?NO=>
M_O\`;_\`^?'[Q_\`0FZ]_P#LG]^Z]U[^_P!O_P#Y\?O'_P!";KW_`.R?W[KW
M7O[_`&__`/GQ^\?_`$)NO?\`[)_?NO=>_O\`;_\`^?'[Q_\`0FZ]_P#LG]^Z
M]U[^_P!O_P#Y\?O'_P!";KW_`.R?W[KW7O[_`&__`/GQ^\?_`$)NO?\`[)_?
MNO=>_O\`;_\`^?'[Q_\`0FZ]_P#LG]^Z]U[^_P!O_P#Y\?O'_P!";KW_`.R?
MW[KW18_EMTL/E[T]FNJM\=&;QH:MB<MLK=]-N'KMLOLG=]+$_P#"L]C9O[SK
M*L:RD)51!@L].S*?5I90'[C>W^S^Y'+<NP;IV3?'!,!5X)@.UU\Z>3KP9"1Q
MI2;_`+OWOQS;]WCW%MN?>5SXMN/TKVT8_I7MHQ'BP2#A4CNB<BJ2`'AJ!*U\
M&OF5W)@L_D/A%\FMBYS)?)CJFC>'"Y-<UMN@7LG8F/IX_P"'9>GR&=R^/I\Y
MF::@`9IJ5IA64R^4VD27W&'LW[@;PFX3^U'N%^GSKM@TQ2,<7D"CM=6/QN%R
M&SXB=WQ*X&2?WNO8CE"78;+[T?L$OC^S',CAKJW0=VT7\AK)!*BU\*)I"4"F
MG@R]@['C/5H/]_M__P#/C]X_^A-U[_\`9/[R+ZY^]%`^8G:G8^SNOJ_LR;X!
M;1[^VWUIM;>&\MTMV?VAU/MVOVOB,#C!EJS^ZM/E-M=AC*562I*%]:J]"`T2
M`E[C3[KW0H=!;H[6Q6RIAFOA+@>BIZ[)MD*?:G5/9/5NY\!D*2IHJ1HLW6UV
M.Q77L,.5G-XGB-'*0D2GRL#8>Z]T-_\`?[?_`/SX_>/_`*$W7O\`]D_OW7NO
M?W^W_P#\^/WC_P"A-U[_`/9/[]U[KW]_M_\`_/D-X_\`H3]>_P#V3^_=>Z*%
M\K_B9T;\VMKR;9^1WPKGWU(E/)!B=V?QOKO$[]VXS+I2HV_O/&;GIL[CY("`
MRQ^5X"P]4;#CVY'+)$:H2.M$`\>M3K^:'\!?Y@WP[Z939W4?:7R;[%^`%7NS
M;E9'U[NO>>-W3NSK'>1R(I]LXW)ILZOR&0K=G_Q.2G%%4Q-3TJ9`Q":!9?'(
M3&WGBE:KJ!+Z^O52"/LZLF^-W\X?YI_#/I[9?6G\R'X$?*W<-=M+%4]$GR!V
MEM>/,3YK:Z01'`R;PQL:-CJK=--1$1U-2,C$]1H#RQB8R$LO;12L6A=<^77@
M2./1YNG_`/A0O_+V[DR"X6@W3G^N\^TXI?X1W&=N=;R_=&P,(K<OG9,8F@GU
M-)-&HYN>/;+6DZYI4?+JVH=6=[&^2%!V?C8<QUKM:E[!Q51'YH,ALOM/J#<M
M-)%_QT5\3O6J(3GZD`>TY5E^($=;Z7?]_M__`//C]X_^A-U[_P#9/[UU[KW]
M_M__`//C]X_^A-U[_P#9/[]U[HI?RMWIO6IK?BJ:CI_=="T/S"ZF>%9=Q;"D
M^Z?^[G8?[2&+<S"-^/J^E/ZL.+^Z]T;3^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[
M^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V_
M_P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#G
MQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?
M_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ
M]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`
MLG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^
MZ]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[
M^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V_
M_P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#GQ^\?_0FZ]_\`LG]^Z]U[^_V__P#G
MQ^\?_0FZ]_\`LG]^Z]TJ]K;AW#G)*Q,YL/-;-2G2%J>7+93;F12O:1G$D<*X
M+*Y%XFA"@DR!`;\7Y]^Z]TL/?NO=>]^Z]U[W[KW7O?NO=$A_YJ?_`.7S?_.@
M>_=>Z4/P/_[)8ZW_`.HW?_\`[\;=GOW7NC>^_=>Z][]U[I`]G]J]9]*;'SG9
M?;^_MH=8]?;9I_NL_O/?.X,9MG;>)A)T1FLRV6J*6DCDFD(2--1>1R%4%B![
M]U[HOO1OS^^&'R4Q?7F:Z.^1W6O8&.[;SV^MK=838_*S8Z3?VX^LJ2@R&_<)
MM2DSM+BZS-9/:^/R<%14Q0QLPIY/(H9%9A[KW1P/?NO=>]^Z]U[W[KW7O?NO
M=8I8()K&:""8K<*98HY"H/)"EU8@$^_=>ZJ2^9'\KO=W>??\?RR^*7S-[C^!
M_P`C\WL+#]4]I[SZSV]M7?VU>W.NMLU==DMI8W>'7^]4;"ON':=?D)1092-A
M-%3220Z2&#+[KW4+'?R8_CJ?A#V5\.]V[_[@WMN7N+LE?D!V1\J\SN=$^0^;
M^3U)EL5G\%WY1[EIZ=:3#;FVIE\#1+BZ2"(4=)0TXI@I5I';W7NL_P`-OY6F
MZ^BN_P"'Y7_*KYH=U?/+Y#[5V!F>INGMW=JX3:^RMM=/==[DJJ2LW3!M79.T
M(_X9-O'=LE%'%DLW/(]54TJ+"0!J+>Z]T>#L'XWT79WR.Z0[TW?NVMR.V_C_
M`('>M3L#J5L72_W>3MO>D-/@V[?RV2:=I\AG=K[(^]Q6(IVAT4)RE54(XE<:
M?=>Z)"O\IW"OWK'N2K[]W?4?%.C^5%3\X\;\1%V7M&##4WREJZJ7,S;JJ.TX
MXCO&MZ_3>=3-N"/;C1B%,O)Y/.8@(O?NO=6['GGW[KW78^H_UQ_O?OW7N@KZ
M?_X];+_^)'[6_P#?C;F]^Z]T*?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKJ_F`_#7(?(?;&`[
M4Z?R!V9\I>DIQN;J/>E!(M%59.3'2&ODV7E:M;:Z')R*?MFD)2&=B&'BEE!A
M3WC]LIN<["'F#EMOIN?MK/BVDRG27TG5X+-Z,?@)J%8T(T,X.8WW2/O(6GL]
MOEWR'[B0C<O8GF=?IMVLY!K6(2#0+R)/)X@1X@6C/&*CO1**CX&_,F@^6/7%
M=2[GH!L[OKK&J_NKW3UU5QM0Y##;BHG>CDS5'CYM,ZX3,3T[E;`_;SAX6/I4
ML8>T?N;#[A[*\5^@MN;K!O"O;<C2RR*2OB*ISH<@_P"D8,AX`DB^]9]V^[]@
M><XI]CE_>/M1OD?U6S;@AUQS6[@.(7D';XT*L`?]^)ID'$A1-^;?_9''RG_\
M5][;_P#>'S7N6^L5NC%8#_BPX3_M3XS_`-P8/?NO=.WOW7NO>_=>Z][]U[KW
MOW7NB=_/PE?B/VZ02"(MCD$?@_Z2=G<_Z_OW7NCBRJL@>.15DC==+QNH=&4C
ME61@58'^A]^Z]T4?N;X$_"WY"4\\'<GQ@Z7WS)4I*DN1K]BX6BS?[U_(\>?Q
M%/C\U%*U_P!:SAO\?;BS2I\+$=:H.JN]]_\`"<OX-561EW%T!N[Y!?%'=)E$
M]+D>G.U,U'BZ66.Y@`P^<DKW-/$]B46IC+6^H^OM0M[*!1Z,/F.M:1T@3_+Z
M_G8?'/\`>^,'\T+$]XX&@O\`P_97RFV8<C55$8^E/)GY(=TR`>,!!^[$`>1;
M\;$UJ_\`:1T^SKU&\CUVWSY_G>?'(K'\E_Y9&W.]]NT%SD-Z_%[>QK<A/20W
M5JP8!*G<KFHJ;7$8IX`M_P!(^GOW@VK_``/0_/KU6\QT2KY6_P#"CGK#,;G^
M.F`B^*_=NRMR=2?(+:?9G>.S^STQ^U]R[7Q&V<;EZ`87;5'JEJ,OG:R'<;U*
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M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HD/_-3_`/R^;_YT#W[K
MW2A^!_\`V2QUO_U&[_\`_?C;L]^Z]T;WW[KW7O?NO=:\?_"A#I[>N^-A_"OM
MZM^/&]?E_P#%WXT_)T=I?+?XO=?O7UNX^QNO6VAD<3M[<:[2HCIWQCNN\],U
M;4XR0&.ICET2:8&FD3W7NM=7X@;OQGSDWY\;OC'\,?A+WIU9G.F_YNN__FU@
MN_\`,];GJWKWXH_$S<NZ,9G,AL:@>BK6QR9/L#!82/'3X46@#4RBG\[?H]U[
MKZ(YY)_U_?NO==>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z['U'^N/][]^Z]T%?3_`/QZV7_\2/VM_P"_&W-[]U[H4_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW5.?SO\`CQV'TSV3C_YAWQ-QQ'9NQJ<?Z=^N:!)$H.W^
MN81&,O65-!3#_*LSCZ"+_*"JF5XHTG7]Z#UXS^[?)>\\K[VGO-[>)3?+45O[
M=0=-W;BFMBHXN%'?0:B`L@J\8KT;^ZI[P<G^Y/)<WW/O?^;_`)!&ZO\`[H]Q
MD(,FT;BU?"19&^&&20_I@D(K,T3?IR]H[=E?(?KOY1_RW/D!W!UKD!4X;/\`
MQS[:3(8N:2,Y7;&>@V)F%RVV\U"A)@R.,J"5-P!+&5D6Z.I]S5R/SILW/W+D
M',FR/6WE6C(2-44@^.-P.#*?R8488(ZPX]Y_9_G#V+]PK[V[YUAT;E:/6.4`
M^%<P,3X5Q"3\4<BY]5;4C=RD=6`8#_BPX3_M3XS_`-P8/8NZBOIV]^Z]U[W[
MKW7O?NO=>]^Z]U7I_,>[5VEMGX_;SZWKH-ZY+>F]<=MFOVUA-H]9=D[[?(4N
M(["VM59%GK-D[3W!CJ"6FI:.64Q5,T,K1QEE5A[]U[H[FQ-^;9[,VMB][;/J
M,E5[=S2SOCZC+[=W%M3(2+35$M),9\#NO%83/4)$\+`">FB+K9ENI!/NO=*_
MW[KW7O?NO=>]^Z]UW<CZ$CW[KW5,O\SK^7M\4_DSV?\`$/M#M?K6DR6]'^2/
M776FY,QBJF7"5&^^O<KC-TY6;:&]I*`12Y[%05V"@,!=A/#$9(DD$<C+[?BN
M)8E*H<'^7S'6B`>FCNW_`(3^_P`M[MG(S[FV=UMN?XY;Y;7-1[N^/F\LOL2:
MCKB`$K8\)Y*_`H\84`+%3Q+;W=;R=<$U'SSUK2.BYC^71_.'^*%JCX9?S*$[
MOVCC+_P[J?Y:[>.8+4B_HQM+N>0;@\6B%?&C!Z-03J]/XN9[:3^TCH?4=>H1
MP/63_AUS^9;\77:C^>/\KO>^8V]CQHR/;OQ4RK;ZVT((K/49.7"K)G5CBB@!
M8JU;!<FWI]^^G@D_LI!7T/7JD<1T;OH+^>K_`"U>_*J#"1=\0=/[RE>."79?
M>^&KNLLQ35;CUTTM=EU;;NN(\,?O;7/MM[2=,TJ/EGK>H=6O[:W3MC>>*@SN
MS]R8'=>$JD1Z;,;;R^/S>,J$D4.C0UV-J*FFD#(P(LQX/M.00:'!ZWT5SY*8
MZ@F[:^$TLN/HII9/DQFEFEEHZ>21U'QH[_L))'B9S;2/J?Q_A[UU[HWZ(D:+
M'&BQQHH1(T541$465410%50/H`+>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z)MV/\
MU=H=9=C475V8Z6^3N:W'FLEG,7M6IVETIF=P8'><VV\2,YFY]K9FFKDILC14
M&+)E:5O$K!2%NPM[]U[HW>+KAE,9CLF*2OQXR-!25XH,K2M192A%73QU'V>2
MHG9GHZ^F\FB:(DF.0%3]/?NO=3O?NO=>]^Z]U[W[KW7O?NO=$>K_`)(?(F+Y
M&9'H3%?&+:&1I*/;-'V%!O>H^0M+CUJNNZW>U;LV+,-MO_1=55,&X%;'R538
M[[EXPA5/N2Y-O=>Z/#_K>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[HD/_`#4__P`OF_\`G0/?NO=*'X'_`/9+'6__`%&[_P#_`'XV[/?NO=&]
M]^Z]U[W[KW5`'\];?WSHQ57\">F/Y?'RCQOQU[\^2/R"W/UI18K+[?P5?BM^
M82CV2VZ,WELMN#<6#S]#@,7UQB,345K0PP/792>JBIZ='?CW[KW537RMZ4_X
M40_$;.?')^SOYT_7J]:]_=X;9^/-3V-1=+;6ISU[V-V)3UL76B93;-1L=*[.
M8'=6<H&H):NFG5L=*\<DL1B8LONO=7__`,G[Y._(WY"]$=R;)^6];L_<GR*^
M(_R=[8^)_9/8>PJ(XO:W:%?U=+BC0[\H\6(X8L;6YB@RR+5111Q1>:(NL::R
MB^Z]U;+[]U[KWOW7NO>_=>Z][]U[JG/YP?.;Y:X/Y`?[)[_+VZHZ-WSW/L[K
M'!]U]_=M_)[?66V-T'T9L3=N<K]O]>[=R\FVT.XL_P!@]E5^'K7H*:!DBI:2
ME,TNI6]/NO=)O<_\RWY0=$_`K(=S?)'X<R87YEGN[;/Q8ZNZ/V/O2BRO5GR/
M[F[$SF)V_P!6;VZG[!E>>I@Z:WL,L<@]171BLH:>BJ8G#.BR'W7NL?Q9^<OS
MXV=\K]B?#G^9YT%T3UWN[Y`=>;^[(^.7;_QAWGNC=/6>Y*[JRFQV2[$Z?W9C
M-YTT6=Q>_=O[?R*9.&JB=J*MI[I&I87]^Z]TF_B?_,V^2'<7:GQ8W3VAUMT[
MA_BS_,!W+\@]L?&>GV3D-V3=W=85G1IW+7XBH[JERL\VT]SP=B[?VA72M_!:
M>D&%J?%%*TP8M[]U[JQ?XF?(;=7R=E[J[+H<5@*/X\T'9V3Z[^.FX:2/)?WB
M[,P_7;3[9[&[,R,]3-_#GVEG.QJ.NH]N_;1(9\?CS5.SK41Z?=>Z.#[]U[KL
M?4?ZX_WOW[KW05]/_P#'K9?_`,2/VM_[\;<WOW7NA3]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=<65'5DD571U9'1U#(Z,"K(ZD$,K*;$'@CWH@$4(J#UM696#*2&!J",
M$$<"#ZCK6>^:NV]F_P`O3LCNC'[-W1N3#=)_-/K/>.W=R=0XC;U/E\+MK=&Y
ML/FL15;JP$DV6QRXQ\5/4-4T\2H5>.5Z9B(Q&R8W;CM/)OW>-[EY_O-QOK?E
M/>[IXCMUO;),@F2,2-('>>(1`%AX>E6-"R'M"Z>D/+&_>Z?W_>0;;V4M-EV6
M[]T>2["*=>8;[<);29K*6;P([9XH[2X^I)"4E+O'W*DJG67#75_"OY,XOY6]
M,4/96&V]4[;QL-:V"HZ*MJ4GK9X,;300_>5,2*OVK32HX"7866^H\VGWE[?]
MFYMY<L>:^7VF.TW\3/&)E5)`$E>(ZE5W`[HVI1C4=8)>Y7MWS3[1>X6[>V'.
MHM/ZS;-/'%.UK(TMNS2P17"^'(\<3-1)E#50$-4<*'HW'LUZ!77O?NO=>]^Z
M]U[W[KW13?E;\@>T_CIM&JW_`+0Z)H.W=G86@H:C<]=)VWB^O,IBZ[*;BQFW
M<?0T.)R>U,['EHY)<K'-).:BG6-%8:68`'W7NC![#RV\\YM7%93L#9U%L'=M
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M=7B*BMJ'2/\`)^W7_`>Z_12_A*G\^O:AT;;KG^=?_*X[0^UCV_\`,7J_&5M9
MI\6-WC-E]EUJZK?YT;CQF/@B(+`'5(+>VVMIUXJ>MZAT>C9/R+^/W9,*5'7O
M>746]XI`I1MJ]C;1SI8-P/1CLO4."3Q]+WX]M%'7B"/RZW7H8XV65$EB998Y
M`&22-ED1U/T970E6!_J/=>O=$[[NK*2/Y8_!^AEJZ:.MGS'R%GIZ.2HA2KG@
MAZ=JXYIH*9W$TT4+S*&95(4L+VN/>Z&E?+KW1Q?>NO=>]^Z]U[W[KW7O?NO=
M>]^Z]T3R#_MX!E?_`!3C;_\`[^W<OOW7NCA^_=>Z][]U[JI+N;^>=_*YZ!^3
MM%\0^S_E-M;"=TRYV@VMFJ*EQ6X,QM'96YLC4M24^W]][\Q>-JMJ;3RT51H6
MHBJZI#2&5//X[FWNO=6"]^_(7IWXP=+[Y^0G>&^<1L;J3KO;M1N?<N[*Z4ST
MZ8Z*(2T\.+IZ0356:RF4=DBHJ2E26>KFD1(E9F`]^Z]T$&1^?'Q;P_Q#VI\Y
M<QV*V+^.F^MK;3W5LS<]9M_/+G]TP[\GI:+9.!P&R8L?+NO+;OW7DJV&EH<5
M!2O6U%1(J+'>]O=>Z]U[\^OBMV9\:.P?EMM[LN.BZ6ZBI]]MVUE-U8/.[0W+
MU?E.LH9I]\[6W]LC<6/QVZ]L;OV^L.F7&5-*E6[R1B-&\B:O=>Z,AUGV#@.V
M>N]C=H;4CS,6U^P]J8'>FW%W#A,CMO.'!;DQM/EL3)E,#EX*;*8BKFH:J-VI
MZB-)8]5F4&X]^Z]TM_?NO=$A_P":G_\`E\W_`,Z![]U[I0_`_P#[)8ZW_P"H
MW?\`_P"_&W9[]U[HWOOW7NO>_=>ZHW_GX[%_E[[G^(VT]T_/OOK=GQB@ZX[1
MQFYOCUWAU?5Y(=Q;-[D7%UXHGZ\PV&H<GD]R32XN"2>MI(X0HAI5E\T#QQR#
MW7NM8OXB]R_RB]^?+'X]Y_Y5?SGOFW_,2WIM+LK;=+\:.L.X.H>V]K]=;7[E
MW5E:/`[7W;EZ7+3[MI\IDZ#-U5))1N\M%3P31AY_-'Z![KW6[G\%/@[U#_+[
MZ)CZ(Z?KMW[AHJ_>>[>RM\;[["S7]X=^]C=D;ZR`R.Z=Z;LRZP4L$^3R4D<4
M86&***.*%`%+:F;W7NCD^_=>Z][]U[KWOW7NB;_)S>?SMVQGML4_Q(Z*^/7;
M6VZK#ULV[LEW/WANWJK*XG.I6JE!087&[=ZRWU!E<=/07DDGDG@=)/2(R/5[
M]U[K7/\`DKT5\/\`?'\YGOO;7\VS=N+Z\Z6^0'Q'^-G9W4/6V\>W]R=9_&OM
M7M;K'$YG8O:L>9WI!DMD4&\MT]135$7\%HJZII_\ER;U:TQE:R>Z]T`NR]\;
M2ZL^'R=P]9[JW]VI_+5^`O\`/.Z?W=T1V'GI]Q[WIMN?$C$8C'[/[(R6V,[D
M:>NSFZ>G.FNUNP*PXK(WJ$6DIY%C?1""/=>ZMN[9^370OS1_FS_RO-D_%?M'
MK_OJ3X\[>^4_R%[GW?U9G<=OC;O6^P]Y=8XKKG9%%G-V;=J<AA<5E-[[HK3&
MF-EE%8PIDD9$2Q;W7NL/R/\`@C\?^BNR]A=<?&"3LO$_)+Y:[D[5V)U#AZSL
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M$7/NO="5_!N\/^>_ZZ_]%QFO_L\]^Z]U[^#=X?\`/?\`77_HN,U_]GGOW7NO
M?P;O#_GO^NO_`$7&:_\`L\]^Z]U[^#=X?\]_UU_Z+C-?_9Y[]U[KW\&[P_Y[
M_KK_`-%QFO\`[//?NO=>_@W>'_/?]=?^BXS7_P!GGOW7NO?P;O#_`)[_`*Z_
M]%QFO_L\]^Z]U[^#=X?\]_UU_P"BXS7_`-GGOW7NO?P;O#_GO^NO_1<9K_[/
M/?NO=4]?)#^>+\2?BCW9O_X]=P?(G(1=H]7U.+HM\8O8WPV[U[&P^%K\QA*'
M<-'0/N39^9R>&FK1BLE"\D2RZXBVE@"#[]U[H?OD7_,RZ0^*/2?4'?G>?R9V
M/M/97?F&PF>Z=P-)T#V1N#M3?V.SN&Q^X(),)U1AMTU>^'DQN'RD,V05Z1/X
M?K"SE'(4^Z]TMNNOGKU)VM\5]Q_-38ORRZ3R_P`<-FXW+U^]-]3=9[JQM7LR
MKP"T_P#&=K[KVMD-YT^Y<#O>AJ:R&F.&GIER$M5/%%%&[2Q:_=>Z4GQI^7F*
M^6>V=\[FZD[CV[1GJ_(P8SLS:?:/Q_[#ZA[#Z]FK<.NXL35;RV'V!NO";CP&
M)SVW6%?CZR>%::LI+R1N0KA?=>Z%_IGL?>O?W6&S^XNLNS-F93K_`'[C9,SM
M++97IW=FWJG,X45E51TF9@Q>6WM3UZ8O++2_<44SHJU5))',ETD4GW7NA._@
MW>'_`#W_`%U_Z+C-?_9Y[]U[KW\&[P_Y[_KK_P!%QFO_`+//?NO=5Q?S%OAQ
MC^YNI=Y]U=S[N7/UG0W6N]-YX#;FS<36;/H<NVW,'E,VU!DJ^;.9RKC^_:,Q
M&1`1$""$)'L+<Z\B<F^XVSV^R<Z6L]S9VMP\T7A3M`0[HJ-4A6U"BBGIU+WL
MI[]^ZOW>.8MPYG]I[RQM-SW2RCM;CZFS2[5HHI6F30KNNAM;&I%:C'0:K_*K
M[3ZWQFSMW?$CY:;NZGW9M/:,./PF!RF-FJ=JY^&KR%3N%Z+=CPY&J2OB:IR,
MD:O+0U`"6NO'N,N;O9Z[2VVQ_:G=+O8[G:+)K>&)Y&EBE0SRW!$K4%29)G'=
M&ZA=(TXKUD=[:_?"V2_W'F*W^\_RGM/.6S\U;LE_=W$,*VEY:SI:060:S`)5
M%$-M&=*RQ,7U-KS3I,9/^8%\X?C!F:3;/S=Z7Q^W=I0B.B7OOK'8^2WYM3(R
MARIRF6IL=NG%T-%'(A5FBC-/.O/['X]A&W]Z.>^0)5V[WCV246H-!N%F-<+?
MTF4$I^QD<^474D7OW//9'WYMWW[[H/.=J^Z,I=N7]Y?P+U#Q\.&4@,U.`++*
MA\YO/JR7I;O$_(C;\>YNE_D3TGOS&&-'J(L3L?++F,:74'PY?!5&_HLOBIUO
M8K/"G(-B?K[GSECG7E7G.T^MY9OH+N*F0K4D3Y/&:.A_TRCK!;W+]G/<_P!G
MMW.R>Y6RWVTWH)"F6,^#)3SAG6L4J_-'..-.AI_@W>'_`#W_`%U_Z+C-?_9Y
M[%'4:=>_@W>'_/?]=?\`HN,U_P#9Y[]U[HI'SMQ/<$?Q.[=;)[WV%4TWV^R0
M8J;K[,4\I?\`TE[,TD2OOF55`%[W1[_2P_4/=>Z-T^&[NUMIW_UV!?@'KC-$
M@?B_^_\`3S;W[KW7#^#=X?\`/?\`77_HN,U_]GGOW7NO?P;O#_GO^NO_`$7&
M:_\`L\]^Z]U[^#=X?\]_UU_Z+C-?_9Y[]U[KW\&[P_Y[_KK_`-%QFO\`[//?
MNO=53?S$/BGWAVMOOXV;JD^5.8V&F9[KZZZOHMO[)VAN&APN#RE?1[\RM/V5
MCH8^T:(+O?&1H]+3S%2J02L+FX`]U[JQSJWJSO/K+KO9_7\G=>W=]2;2PM/A
MY-X[OV!G*K<VXGIVD8Y/-5#=B5)EKIM=F.MKV'/OW7NE[_!N\/\`GO\`KK_T
M7&:_^SSW[KW7OX-WA_SW_77_`*+C-?\`V>>_=>Z]_!N\/^>_ZZ_]%QFO_L\]
M^Z]U[^#=X?\`/?\`77_HN,U_]GGOW7NBG_(K;W;;]L_"6>OW=UW5UD/R1S\>
M-JEZWRFNADF^.'>TDSZI=[2R>&6&F(94:(EPC%CHM[]GKW1L?X/WC_S\#KO_
M`-%QF_\`[/??NO=)_/===C[JI6H=T9KIO<E$]]=)GNGZG,4KW%CJI\AO2HB:
MX^MQ[V"1PZ]T4GL;^6-\=.V?.W8'Q\^'&>J*A662N7XX18C(C7^IHZ_";SQU
M3$[?DJP/MQ9YEX,>M4'1']Y_\)R?@ONHM48;9N'ZNR(=IH,CU9D.S]M24U22
M66>*FJ>R\I3#0QN%`5?;HO;@<2"/LZUI'0>8C_A/GV'UY5R5G1W\TWY?]2W8
M-34.-R&0RU#1!>$CA6KWG#*\0`^C'GW;ZNOQHAZ]I^?5._RI_ES_`,XC:O\`
M,/\`CMAXN_\`?O?6_LI6!/CG\J:_<,^)QFT,1M*!LSN9-SXZ6:I3:E;MS&M)
M49*C6.K3+P-9#4!RBJDGM3$<!1YCUZJ0U>KOGZ$_X4;X/6,7\V?AQNCR2+&6
MS'4\U)XXX@=,\07:Q"M.?U+;CVFUV7\#?MZMW=1%VY_PIEQ;2ZNPOY?VZDD?
M1%_N&RV+>!(]7[Q48"D5ON`1=;L5/T]ZK8TX..O=W4EM^?\`"E/":O)T=\#]
MW>1A$AI]XY&@\`BO>HLV?QQ=*FXX-RMOH.??@++U?KW=TWS_`"8_X4?8XVJO
MY??Q$R:LQC1L5VWJL4O>5UD['U+'*/TW`_Q]^T6?D[?L_P!CKU6Z3-5\ZO\`
MA0;B2!7?RLNI\GK=XU_@F^YJG2\7ZWD*[XE"Q27]!-@??O!M3PD/[.O5;TZJ
MRZ*_FT?S-MY_S;,?A-V]&QTF^]VTV'^/.\OC#1[,K_-UCL7'YTY[)[JIJC)5
M^/RBU^V:VNJ,Q4Y&MKTQ]52MXPWC\-GWMH!;Z@V>.KU^76M1KUND'"]WW(7?
M_79%["_7&:!(OQ>V_2`?]C[+.K]4IY#^=GM0?.7</\O#'X3MD]Y8W>VZ.L:7
M><GQHR*]/2[MP6U\GN".M7=J]M/5O@)_L?''.*,EW8>C2;^_=>ZTROBAO7Y(
MX?\`ET_+/NS=W\K7XW?+GX?/\F=\[T^8W?\`V_F:NB[LW#FTWGAJB>FV%D,9
MO;;^^</1=?R9&&9IZ99+5==-Y3I:0GW7NMH7^:+\&^FOFO\`RV:_YQ;N[/WS
MO'I?I+^7'N#>?Q7^/."K-Q[*ZKP^?R/7T>XMD]J;^Q4FZ<YD]X[]V=@S3T%)
MYZA84\1:7SWM[]U[H5^E_ASOOYK?R`_Y8NS.K-P[<P?:G4&U/AG\F^N:;><N
M1I-F;MW;T5D,;N^BV1NS)X>FK<IA,-NN!):5JZGIZB2CE=)?%(JLI]U[HC?:
M/6^4Z6W#VC\8/E=OC9.WMM]]_(WM7^=)_-FCZXR&>W5UQTI\6]H9G!'J_P"-
M.+S=;C<9G=Y9'NOLK:=#2R^7'TTV2IJ*=(J?Q.-?NO=;*7PJ_F!]+_-1]_[8
MV+L[M7J+L'J>@V'E]U=/=V[+I]A[]QFQ.S<!_>/JS?=%AZ'*9K&U6S=\;?C:
M6AEAJ3)%XVBGBAD`4^Z]T?'W[KW1(?\`FI__`)?-_P#.@>_=>Z4/P/\`^R6.
MM_\`J-W_`/\`OQMV>_=>Z-[[]U[KWOW7NM:?_A1/GZGKG*?RU.\,;\-^UOF[
MDNC_`)1[FWU4]/;*V#7]@;$R&UGV.F$W.>P<;CL'N*7'YJ"+(P5VV*F:EFHE
MRM`R5$;QL;>Z]T7OIW^<[U=OCM[J[9='_P`)\?EGUW5[O[%V9MFE["R_Q?VG
MBL7L:HSNXL?C(=XY3*1=>4TF-H-MO4BMGG66-H8X68,"`??NO=;;I%B>;_X^
M_=>ZZ]^Z]U[W[KW7O?NO=>]^Z]T!O?7QE^._REVK1['^2'2/5_>6T<=D8\OC
MMO\`:&R\%O+'8W)QZ=-?CH<U1U?V%40@#/$49E`#7''OW7NEMB.K>M,!UW3=
M183K[9>)ZJH]NOM&FZVQ^V</2;&AVO+3O23;>3:T-&F%_@\]-(R24_A\3JQU
M`W/OW7N@ZZ!^*'QE^*N*SN$^-?0?4O1>*W1D1E]R475NQ=O;,BSN15!''594
MX2AI)*YX4%HQ(66.YT@7-_=>Z%*38&R)=^4_:,NT\!+V/2;3J-B4F^),92ON
M>DV9696#.UFV*7,-&:RGPE7F:6*IEIT81R31(S`E5M[KW0>0_&3X[4_=]3\E
MH.D.KHOD'5X4;=J>YDV5@5['GPH@CI102;K%%_%FC^SB6#5Y-9@`CU:/3[]U
M[H<O?NO==CZC_7'^]^_=>Z"OI_\`X];+_P#B1^UO_?C;F]^Z]T*?OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)9_PXM\)E^0G^RJ'Y#;+'R%7
M=R[$/5WVVY/X\-WM`M4,$:C^!_PC[S[=@W_`G1;^U?W[KW5&^U^C?YYG4&?^
M:_R*Z%J?@YL_KW=ORT[U^15!T?VA#7]B]@?(?9U-+B<9A(,MVOM3*5VV>LHZ
M[8VSHJ+%4E/(L]"Y)K/&Y8+[KW6#>'RXDD[\^"?\[6L^&G>'R'^,W=7P+J.H
M5P_2FQ$[A[@^(_;^;[#7=F2RF-V!%)05>6V[O*-*G;]3FJ`1R!:)&.B"71)[
MKW0>=4=+]D_S!>R/YX/66V>KJKXAOWG#\`N^NK^KNR\=BZ7(X'L/:>._OWM?
M-]Z[/VG+6TFQMV]S2]98^JW#C4EJ\G28VOAGG:6I71[]U[H4N\]N]^X3>GR7
MRWRMKNLNE^P_G%UWL_<?R9VMT1O3/[XPGQM_EQ?"S:6<J.[-]UW8.3V]LNOW
M1V)WUD=QMM+$)_"Z=*6'+-'%),U'*R>Z]U:]\(/GO@>^MTX_H'<'QE[-^(N[
MZ?HK9_>G2?7W8M=L;)TF_?C-DZFFVKMK=FW*C8><S5!MW(8"I^UI,GMVL,>0
MQ`J*?6&62Z^Z]U9K[]U[KWOW7NBO_-O_`+(X^4__`(K[VW_[P^:]^Z]T8K`?
M\6'"?]J?&?\`N#![]U[J5D,?C\M0U6,RM#1Y3&UT+T];C\C2P5M#64\@TR05
M5)4I+!/#(.&5E((]M300W,36]RBR0.*,K`,K`^1!J"/D>E%G>7>WW27UA+)!
M>Q,&22-F1T8<&5U(92/(@@CJJ[N_^4OTMNS<+]F_''<VYOB=W'3R-64>YNK*
MJHH=LU=<"9%.4VM3U5'%!%++;6:*6F7\E'^A@#FG[N_+&X7G[\Y*GGY?YC4Z
MEDM21$6XYB#+I!/'PV0>JGAUGC[8?W@/N7L&T#DCWEL;+G_VX<!'MMT57N43
M@?"NF5RQ`X>,LA\@R\0#$/RB_F(_"(+C/EMTO_LS?46.81+WSTLGDW-08^,A
M!6[GP,-+$KM'&I=S4TU$2;_Y0_U]AA>??>;VL_0]P]L_?G+B&GUUGF15X!I%
M"@5\SXB1?\U&X]23)[&?<\^\Z3??=]YE_J1[A3"O[BWDTMGD.=%M.6)%3@>'
M)-BGZ*\.K%OCI\V_C/\`*>@CFZA[-PV2SGC#UNR,TZ[?WUC'YUPU6VLB\=9.
M82+-)3?<07^CGW-/)?NGR/S[$#R]?1M>4J8)/TYU^V-LM_IDU+Z'K#GWC^['
M[V>Q%VT?N'LES!M>JB7L(^HL9!Y%;F,%%KY+)X;_`-'IH^?W'Q&[=)X'BV/R
M>!SV5LW\GCW(74!C/#HX[_J/^P_WKW[KW7'W[KW7O?NO=>]^Z]U[W[KW1//E
MU_P/^)G_`(N/U-_[SG87OW7NCA^_=>Z][]U[KWOW7NO>_=>Z][]U[HJ':7PO
MZ2[CWO3=A;XG[<FW-C\G%FL+)M_OKN?:&)VYF8L%6;8_BNV]O[6WQB,'@:^;
M`Y&II99::GC:6.IEUW,C$^Z]T9;;N"H=KX'#;;QLN2FQ^"QM'BJ*;,9;)9[+
M2TU%"D$,F1S68JJW*Y6M=$!DJ*B:2:5KL[%B3[]U[IY]^Z]U[W[KW7O?NO=>
M]^Z]T43NH-_LTWPFL&TC.?(`L0#8#_0W7`%OP!<V%_R??NO=&[]^Z]U[W[KW
M7O?NO=>]^Z]UW<CZ$CW[KW1'J+:^V:?^8_N'=5/MW!P;GR'PRVU3UVXHL50Q
MYRL@@[FW%30Q5642`5LZ1TT21@,YM&BK]%4#>IJ::G3Z=>Z/![UU[K`*6E$P
MJ/M:;[@'5Y_!%YKVM?RZ/)>W%[W]^Z]UJX=S_P#"8;8/8/;O:W^C+YR_)/HC
MX8_(CLK_`$K?('X4['J6_N!O;<U7E1F<W38;+C/T5%A</EJN&((E7BLE-2(N
MF.0JL(A]U[J]KO\`^(6S^W?@_P!F?!W961CZGV)O3H')_'[:V3QN*7-IL3;,
M^U!M'$5%+B)ZVA&5.'QR):.2HC,Q7U."2??NO=*#X6_'"#X??$WX]?%NGW9-
MONGZ%ZLVIUE%O&?$I@IMR1[8Q\=`N6DP\=;D4QKU:QZC$)Y0GTU'Z^_=>ZKX
MRG\J++]S='?S.MG_`"2[1PV4[G_F1[BW'C\MV=L'%9":DZJZ=VOBZ7`?'+K7
M`4>Y6CKJ_'=98^A%57Q:X(<C7UE4ZZ#(''NO=+S^79\`.X?C/VGWG\CODMVC
MUOV-WKW-UYT#THM+TSM;<>T^MMN]7?&[9TVT=G5*4N[\OFMP5^\]UFJDK<L[
M2I202A8J9=%S[]U[JV?W[KW1(?\`FI__`)?-_P#.@>_=>Z4/P/\`^R6.M_\`
MJ-W_`/\`OQMV>_=>Z-[[]U[KWOW7NJ+_`.==\B?F%U]/\&?B]\*>X=A?&_M7
MYM?(;-=83_(/L7%XW+838.)V;LBLWDN&HJ;,T.4QKY_?%=%%1TD9IIJFJ9#3
MP!9)?(GNO=:]?37R,_G#X.J^+':WRG_FX82/I[>G\PH_"?OGJ78G7/647<^R
M-\[5[.SFTZ7%5V,7;>W<G6[3WWDMK4\==5XVIAK\;A<U%5+'+ZD'NO=;\K?4
M_CGW[KW77OW7NO>_=>Z][]U[KWOW7NN['^A_VWOW7NO6/]#[]U[KUB/J"/?N
MO=>L?Z'W[KW77OW7NO>_=>Z['U'^N/\`>_?NO=!7T_\`\>ME_P#Q(_:W_OQM
MS>_=>Z%/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1/L*#[C[
MS[&B^[U:_NOM8/N-=M.OS^/RZK<7O>WOW7NM?[>7\D'MV/<':O7?0'\SKY*_
M''X.]Z[OWIO/LOXF[-VGL3-5F.J>T,G79GM+;O4_<^;ADWAUGM/>>1KYG-'3
MPS_:"JJ`C,);#W7NC._(G^5[N7.;:^.L/P1^77;'\OS>GQFZMCZ(V17;#Q&(
M[0ZXS_2XCQ.G:>^>I=\U']U]PYW'56%AJ*'.,4R5/,TI9Y1)9?=>Z,/\#?@[
M@OA)U_O?'UW:6_OD#W?W5OF;M3Y$?(?M&:E;>_;?8M1BZ'"Q5LF/QZKB]L;4
MV]AL=#0X7#4@--C:-!&K,2S'W7NNZCX+;'WME/FKEN[=Q5G:=5\T-MS]2YPR
MXV'!?Z.OCM2[.K-I[?Z<V<Z561:*EH*W.9?-5=</$V0S.3>>2$>.,#W7N@S^
M'?\`+[W=\?>U/]-O>?R1S/R>[,VCT=@OBYTOFJWKC;'5]%US\?\`;^9@W`,-
MD,7MFLR$>[NP-S96@HI,QG97IUJ5H(5BI8!KU>Z]U9G[]U[KWOW7NBO_`#;_
M`.R./E/_`.*^]M_^\/FO?NO=&*P'_%APG_:GQG_N#![]U[IV]^Z]U[W[KW71
M`965@&5@596`*LI%BK*;@@@_3WX@$4/`];!((888=5V_(S^6#\6_D%7R[NIM
MN5G3G:R2FLQ_:/44Z[3SL.24ZHJW(X^B$6)RTBR#4SM%'4-_QV'N%^=/8?D+
MF^0[A%"VV;]74MS:4B;7Y,R#L8_TJ!_1QUF'[-_?C]]?:*T7EZ:\CYCY"*Z)
M-LW9?JX#'YI'(]98@1@`,T8_WV>J-/G=2_-KXV56QNGZ_OC?G>=7]KFIFW%2
M8"KS#Y+9*U./J-G8W=6(JJ3+0OEL744]0YED:<R,%82-XUTQY[@7?W@_:_DC
M9-JY,O;_`';<'O+_`,:X@LOJG,"_3"V28O#.R,M9:58UJ>Y@,9.>PFW_`'&?
MO)>ZG-_-?N7R_L7*NQQ;9LPMK"[W<V$*7KF^_>,MGHNK19(I=-N2`@\.@[$+
M$L<WXO\`\R_*]$=)[$P'>G3GR2[(R.1Q2[FSW:FW=I5.XL5#D,H[)4X"L6H-
M&U'E<4M*'FI]:!!,ITB_L57_`+X;IREL^PP\^;/O,^\W.R6\]U<I;*BB9VE#
M+)'IB"2*%74M%I48'43Q?<JY?]U>=.<KSV1YLY,V_E2QYNO;';MNN-SU.;6&
M.W:.6&<O.9K>1I&$<FIZE6[C3HVFW_YT?P2RK10Y[>._.OJJ1E3[;?/6^X\<
MR,38B27&P9>G0+^27`'O5G]YKVJN'\*ZGO+2;^&6VD_ZQ^(/Y](-W_NU/O4V
M`:3:MNVK=X%%=5CN-O("/D)&B8_D.C);2_F&_"/>\D46WODUU1+-,%TP9/<4
M6`E4O]%D7/1XT1L#];D6]C:P]Y?:W<66.VWRP$C<`[^$?V2!>H7Y@^Y_]YWE
MA&DWCDC?UB6M6CMS.,>G@&2OY=&3V]V?UKNV)9]J]A[&W-"X!23`;LP.81@?
MH0V/KZ@&_P"/8ULN8-AW)=6WWUI.O_"YHW_XZQZA;=^1^=>7W,6_;/NEE(.(
MGM)X3^R2->EP/4`RD,K`$,IU*0>001<$$>S<&HJ.'07.#0X(Z)-\N,_@I,S\
M8Z&/-8J2MV]\MNK,ON"CCR%(]5@L33[<WV*C*9F!93)C,=3FJB\D\P2)/(EV
M&H761;?N$Z"2""9XSYJC$?M`(Z0S;GMMM(8KFX@CE'DTB*?V$@]'/HJZBR5)
M3U^-K*7(4-7&)J6MHJB*JI*F)OTRT]1`SQ31FW!4D>TKH\;%)`5<&A!%"/M'
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MO<%)N`;/.#R$=0LKT:5Q(:,TH<"_NO=6-G@_U]^Z]UU[]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[HD/_-3_`/R^;_YT#W[KW2A^!_\`V2QUO_U&[_\`
M_?C;L]^Z]T;WW[KW7O?NO=4[?SG_`)2_"[XP]#=49+Y=_'O</RJSFZ.[=L2_
M&OHK8VTGW3V)N3O#9B2[FPF=V9+"\-3MZOVS!`6>LA=I6\ZP"*83,A]U[K6<
MZZ^17P3[E_F?=:_,K+?R'OYDVT_D%V!W-LVMJMU;GPVYJ;I/;O9>X<SCL".\
M-T;);;\.)7-8.6I7(UE4TB4QE@:I>(S7D/NO=;]I^I_//OW7NNO?NO=>]^Z]
MU[W[KW7O?NO=4F?S)?A)5[DKNV_F=NW^:C\_?ASU#UKU8^Y=Y=?_`!][.VSM
M;K/`X/KS`U59F,YBL+E=M9&IDW'N&.`EU\Y-55LB(`6`]^Z]U7?UGD?YB7Q;
M_E8]71S_`"?[IW7\M/YF/RVZAZQZ$W9\F,I%V?V!\2^IN_:S3M^IRD=534F)
MS78FS^HL%59O(PBGIJ&#.UGB2$"FU2>Z]T:WI;9_RO\`Y:?S]^+GQRWU\V.]
M/F]\;OG)LWO'%TI^3<F%S_974W?_`$MM;%[]I<GM?>V%Q6.==A[\VW//1G#U
M`*4E1#Y49SJ)]U[HJ/P@^8W8W^G+XG=I[V^9&^^P.S.^\I\Y*[^8I\9-\;YQ
MV4ZW^)VPNB#O#*[9W%0]8"F2J^-%'UK4;>Q^-66I,)W)#7N7:>2S#W7NKP_@
M-N_L;M_;&_ODMVCN+<6/J/DQN5>PNFND\]ERL/4?QMP\!V]T[)2[4D\4N)W#
MV5MZ-=T9VH*:I*S,1TY(%*@]^Z]U8#[]U[KDH-QP?J/?NO=!7T^K?W6R_!_Y
MF-VJ?H?H>QMS6/\`L??NO="G8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]
MU[KUC_0_[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_
M[8^_=>Z]8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>Z]
M8_T/^V/OW7NO6/\`0_[8^_=>Z]8_T/\`MC[]U[KUC_0_[8^_=>Z+1\GNA]\?
M(78>6ZWV]WEN'IS:V[-L[IVAOJ#;VQ-B;OK=S83=.-_A4\45;O3&9-L'44=)
M+,(Y*9;EI;L#I7W[KW0A]0[)W_L/:[X/L+MG)=Q95*S70;CR>S-H[(GH<4E+
M34]/B!C-FT5#C:A('A9_,Z>5C(038`#W7NA4L?Z'_;'W[KW7K'^A_P!L??NO
M=>L?Z'_;'W[KW7K'^A_VQ]^Z]T3#Y]8^D3XL]KYF*AIH\U!3;)AI\O%31IE8
M8F[&VE&T4.01!61QM%*ZE5<`JQ'T)]OQ75U`NF&21%/DK$?X".D\UG:7#!KB
M**1AP+*K?X0>CB4F,Q^-@:CQN.HJ"D9VE:EH:.GI:9I9+>20PP1I$9'L-1M<
MVY]MRR23L7F8NQ\V))_GTY#%%;J$MU6-!P"@*!^RG23W!UCUQNT.-U=>;)W*
M)`5?^/;3P67+`BQ!-?03GZ>R:\V'8]QK]?96D]?]^0QO_P`>4]"O:.=N=.7R
M#L.[[I9:>'@74\5/^<;KT6S=O\O'X2;W\YW#\8^J)9:BYEJ<9MN+;]62?JPJ
ML"^-G!_UFX]@B_\`9KVMW&IN=CL`QXF./PF_WJ(H?Y]33R_][_[SO+&@;1SO
MOZQIP66X-PG^\SB1?Y=%NW#_`"7/@EEYONL'LK?77]2A+02['['W/C?MY+$*
M\:9"IRH])-[>P9>_=F]J;J0S6]M=VLI'&*XDH/G236.IHVC^\J^]5M\?@;IN
M6U[O`<,+W;K:34/0F-8N/2%_X:#FVO))4]/_`#>^6/6\XL:2&3>']X:&ETBR
M(D'EQ$I1?\7]DW_`XM8.)>7>:-^LW'`&76@_VJ&+A]O0I_Y.')OJ+#[B>V'(
M&]1?C(L_IW;U):DHJ?\`2]4]_-KXB?,/'=Q4>*QN5[,[;:BQ&$V-4]L9"OJ]
MKU79V\)Y<ID("*63+"/)YZLQA6-8X9*B29:5K%M#:0][O>T'OQOEWLHY*O[J
M]L[39(H)IQ?);&6=9[EV+127"MJ"21J6.K4`.XTZE[[K'WK?N6<K[-S3/[I;
M/L_+U_NG-]S>V>W'9Y-R2TL9+.QB2.&Y2QD'A>-%,RQ]NDLQT"M3=]\/_G-U
M#B:G"_$3M89;IKN/K^CQNVL-0]B4T^#Q78E.]%!5T^3VUELA!2TXJZF6I>/[
M6<J\CI>%Y=5A.#^[W*XY]O.0-\D-CS#:O%$AF(\.ZI#'WQ2_#J9M0TD]Q%49
MJXP<W+[J'N6?9S;??SDR%-\]OMU2XN9A9C5<;83=3CP;JV6LB*J!'UJM$5@)
M$CIFUNQ_H?<E=8Q]>L?Z'_;'W[KW7K'^A_VQ]^Z]UZQ_H?\`;'W[KW7K'^A_
MVQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_P!L??NO=>L?Z'_;'W[KW7K'
M^A_VWOW7NB"=Q=Q_,W9?=VP>M-C=<?&G-;;[;S.^Z'8F=W5V-V?B,WCZ#8VT
M3NR>HW;B\3UWEJ!*O)Q1201I25,B1N`S-8V]^Z]T>S%_Q1L7C6S<-%!FFQ]&
MV8AQ<M14XR+*&GC.0CQM150T]5/0)5ZQ"\D:2-&`6522![KW4^Q_H?\`;'W[
MKW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L?Z'_;'W[KW7K'^A_P!L??NO=>L?Z'_;
M'W[KW7K'^A_VQ]^Z]UZQ_H?]L??NO=>L1]0??NO==>_=>Z][]U[KWOW7NO>_
M=>Z)#_S4_P#\OF_^=`]^Z]TH?@?_`-DL=;_]1N__`/WXV[/?NO=&]]^Z]UX?
MX_3W[KW6HO\`S)U_GY]P?*O9&ZNB/Y>OQ\R&U?AA\G-P]C?$WOBM[:V[3;@W
M/L:LQN1V9EZ/>FUMR=GTN+_AW9>R,@:>M0T=%644P26F:*6-6/NO=&(ZP^9?
M_"EC-]G]>8/LW^5W\4]I]<Y?>^U:#L'<6*[KI*S,;;V)79Z@I=U[AQE`.WZ^
M:KK,-A)IIX4%/,))45-#%K'W7NMF$_4V^GOW7NNO?NO=>]^Z]U[W[KW1-_DW
M\<>]N[\]MC*]2?-WNCXJ8W!X>MQV7V[U?L;IC=>/W77U-:M3!F\I4]G[%W9D
M:2MHJ<>!(Z66*!D-V0MS[]U[HGO\U#KK?';W7_P4^&_AWUOO9_?_`,P^C-M?
M(_>N.P$U1!6=/=*8O+]U;RG[!;;U%!A]O8SL?<77&.Q\SE::B^XKA$BV98S[
MKW2Q_F\=5=S[J^/?47;_`,<^O*CM?M;X;?*7H_Y6X+J/#34U'G.RMK=893(8
M_L#8VTS/$U*=S9/86X:\X^(V,L\*QI=V0'W7NB8]0]\]A?S5_P"83\/>[MA?
M%[Y+]`?%OX,;;[TWCO;?'R>Z[J>G\[OWO7MW9N+V!MWKC96R<I5UN1S='LS"
MO4Y"MRRZ:=3-X5LS+K]U[HZGS`Z:P?</='7OQ:Z^Z>PVW,3\B:G_`$J?-_NG
M`]>T&&.Z/CSU;F,7*G3NY^P*##TTVXMR=X[SEH\2])-6RU$6W(,I(R!'0GW7
MNJ;Z7I+L6E^;]%CMN]-=R8K^8G1?S2JOM+,_(NCVAV%CNGA_++CJIH\;M=^S
MVE'6-7U1'TZM#MZFV;%(U9%N6$2?8JZ&H/NO=;<A^IM]+^_=>Z1&Y^M]D[UK
M*6NW/@8<M5TD'VE/-)5Y&G,5.9&E\82CK*:-AY&)N03_`(^_=>Z`WJGI'JRM
MVUE9JK:--+(F_P#LVE5CD<VMH*/?^XJ:G2R9-1^W!$JW^IMSS[]U[H2O]`O4
M?_/&4O\`Y\\[_P#77W[KW7O]`O4?_/&4O_GSSO\`]=??NO=>_P!`O4?_`#QE
M+_Y\\[_]=??NO=>_T"]1_P#/&4O_`)\\[_\`77W[KW7O]`O4?_/&4O\`Y\\[
M_P#77W[KW7O]`O4?_/&4O_GSSO\`]=??NO=>_P!`O4?_`#QE+_Y\\[_]=??N
MO=>_T"]1_P#/&4O_`)\\[_\`77W[KW7O]`O4?_/&4O\`Y\\[_P#77W[KW7O]
M`O4?_/&4O_GSSO\`]=??NO=>_P!`O4?_`#QE+_Y\\[_]=??NO=>_T"]1_P#/
M&4O_`)\\[_\`77W[KW7O]`O4?_/&4O\`Y\\[_P#77W[KW7O]`O4?_/&4O_GS
MSO\`]=??NO=>_P!`O4?_`#QE+_Y\\[_]=??NO=>_T"]1_P#/&4O_`)\\[_\`
M77W[KW7O]`O4?_/&4O\`Y\\[_P#77W[KW7O]`O4?_/&4O_GSSO\`]=??NO=>
M_P!`O4?_`#QE+_Y\\[_]=??NO=>_T"]1_P#/&4O_`)\\[_\`77W[KW7O]`O4
M?_/&4O\`Y\\[_P#77W[KW7O]`O4?_/&4O_GSSO\`]=??NO=%'^=W2O5^,^)_
M;=70[2I8*A(-DJ'&1S3^ENR=FAA9\FPY]^Z]T;I^ANI"[$[-I22;D_Q/.\D\
MGZ90#W[KW7'_`$"]1_\`/&4O_GSSO_UU]^Z]U[_0+U'_`,\92_\`GSSO_P!=
M??NO=>_T"]1_\\92_P#GSSO_`-=??NO=>_T"]1_\\92_^?/._P#UU]^Z]T4K
MY7],=8T%9\5$I-J4\2U7S"ZFAG7^(YIP\?\`=SL,@#R9)BA!/U%O?J#KU3T(
M?>G\O[XL_(/;55@]\=;T<&6^U$&%WSAJNMI=[[9EC<S4\V%SU14551%##4'6
M:>024TA_4A^H`7/GMMRG[BV'T?,=N&N$!$4Z46>(_P!"2E2*\4;4A\UZG'V/
M^\5[J?=[WX[S[=[@\5I,P-S92UELKI>!6:`G221@2)ID'D],=565F![_`/Y;
M>7:#OG9>5^7OQ$>NTTG;^&J,[-VOUC032!8TW51#+,:K'4B,+B5C3$+:*HB/
M[7N"H][]S?8=UM.9EEYA]M%-$ND%;FU2N!)4DZ5%,.2AIVR+A.LW9>2_NV_?
MBBDW3VV>T]O_`+R,BEY=KF8+M>Z2TJS6K``)(Y!^!1(*_J0R#]3JV?I/_92/
MD5LFB[!Z<DV[O7;58$66;'9K.BOQ54R:VQV<Q<V4CR&'R,7(:*>-&-KK=;$Y
M'<K<W<N\Z;6N\<M74=S9-@Z31D;^&1#1D8>C`?*HZYZ>YOM1[@^SO,\O*'N/
MMESMF]QDT$B_IRJ#0202BL<T9\G1B/(T-1T+W^@7J/\`YXRE_P#/GG?_`*Z^
MQ)U'G7O]`O4?_/&4O_GSSO\`]=??NO=>_P!`O4?_`#QE+_Y\\[_]=??NO=>_
MT"]1_P#/&4O_`)\\[_\`77W[KW7O]`O4?_/&4O\`Y\\[_P#77W[KW7O]`O4?
M_/&4O_GSSO\`]=??NO=>_P!`O4?_`#QE+_Y\\[_]=??NO=>_T"]1_P#/&4O_
M`)\\[_\`77W[KW13NY>E>KX/D[\+J*':=,E-69SOX5,0R.:/D\?3M9(MV;)%
MQ9HQ]#^/?NO=&Q_T"]1_\\92_P#GSSO_`-=??NO=>_T"]1_\\92_^?/._P#U
MU]^Z]U[_`$"]1_\`/&4O_GSSO_UU]^Z]U[_0+U'_`,\92_\`GSSO_P!=??NO
M=>'0W4@Y&S:6X_ZN>=_^NOOW7NB#2?$#XY5_SOR^'J^N$FQ+?&S"=BG&-NS?
M2XX;WG[CW!0S[D%"FYUI!DYJ.GCB9]',4:I^D6]^Z]T?H]#=2,23LVE))N3_
M`!/._4_^13W[KW77^@7J/_GC*7_SYYW_`.NOOW7NO?Z!>H_^>,I?_/GG?_KK
M[]U[I6;5Z^V=LF2LEVMA(<1)D$ACK&CJLA4&=(&=HE(K:NI"Z&<_I`)OS[]U
M[I9>_=>Z][]U[KWOW7NO>_=>Z)#_`,U/_P#+YO\`YT#W[KW2A^!__9+'6_\`
MU&[_`/\`WXV[/?NO=&]]^Z]U[W[KW6N?_P`*%^PZ;9.&_EXXWN+L_L_I;X.[
MK^9N#I_F-V5U>F0BJL9@\!MVJW!U-@MXY3&4U94XO8.?[!H4&3<Q2H(Z</H=
MT13[KW13OGG\_?B5\A_G/_*Y[%_EQ?,_(=P_,+&?)#:?3N0ZAZ3W1FLSUGO7
MXP[SS"5W>3=OTM+BCAZ*##XJFCJZ:HJI266%V6/]KS0^Z]UMQ'ZG_7/OW7NN
MO?NO=>]^Z]U[W[KW7O?NO=>O[]U[KWOW7NN[D_4D^_=>ZZO^/Q[]U[KNY^ES
M;W[KW77OW7NNQ]1_KC_>_?NO=!7T_P#\>ME__$C]K?\`OQMS>_=>Z%/W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1$
M?GU7=EYWIC<_4_6?0G:7;N;WQCL#4TN6V14=<T>W\+/A-\;<R]1C\[5;VW[M
M*M@JJC&XR:2$T]/4QL0JLREN/=>Z.!L3=&2WGM7%[ERVR=U==5^26=I]G[V&
M`&YL1X:F6G1<F-L9W<N$#5,<0E3P5LP\;C40UU'NO=*[W[KW7O?NO=>]^Z]U
M[W[KW1//EU_P/^)G_BX_4W_O.=A>_=>Z.'[]U[K!4TU-6TT]'64\%71U4,E/
M54E5#'44U33S(8YH*B"57BFAEC8JRL"K`V(]TDCCEC:*50T3`@@@$$'!!!P0
M?,'IV">:VF2YMG>.XC8,KJ2K*P-0RL*$$'((-0>'50W=7\M?<77^]J[Y"?R]
M=]'H#MXN];GNMC,_^B'LA5?[B7&UF&D\M#A9:V0$:#$]%J>ZK`?7[QPYH]C[
MW9]T;G'V<N_W1S%DO;5_Q2X\]!4U5-1_"08\F@C/=UT-]L_OI[/S=RS%[0_>
M^VK^MOMY0)!N-!^]MNQI$B3"CS!!FH99J"A:4=O2O^-'\RW";LWFGQ[^6.T)
M_C5\E\;+'C9<'N772;'WM5_HCK=H9^K8TT/\1/JA@EF>.6]H9Y;V!ER-[Y6N
MX;G_`%.]P[8[)SNA"%).V"9O(Q.<*6_"I8JWX)'Z#OO9]RG<]@Y:/N][`[BG
M.OLG,ID$]M1[VR3B4NX$[CX?!W1`R_Z+%'Q-J/\`Q/(_Q']1_4>\@.L#^@/W
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MFAB6*CKX\AMG*!(/N8Y`JD.`')/N!^=?O(7O+/NS#[?;3M&VW>RS3;>J7+-<
M>(Z7D5O(7[950&DQT]H`&DD'/707V>_N\^6?<'[L=Q[W<U<P<Q[;SA;6>^23
M6,45D;>*?:9[V$0DO`\M-5J!+WDU+!2,=7<[+_FE_"/(P4V`W)\A-LX3>.'A
MBQ&Z8-QXW.8%(MRX]%I,W$)JG%14)5,E#(`T;F(@74VM[D:_][_:BTWR\V:7
M=HX)[6ZEA82I*@#1R,A&IDTFA6E0:'K&:P^Y+]ZB\Y2VSFVUY2O;S:MSVZWN
MXGMG@FUQ7$*31OH24N-2.#I*AA6A%>C.[5^5?QGWM$DVU^^^I,LLFGQK%OS;
MM/-(6_2$IZROIYW)_H%O[/\`;O<3D/=EU[?O&VR#Y7$8/[&8'^74:[]["^]G
M+#F/?>4^8;=AQ)L;A@*>K)&RC]O0T8[/8+,1I-B,WB,K#(+QS8W)45=%(#^4
M>FFE5AS^#[%,%[9W2AK::*13P*NK#^1/4:WFU;KMSF/<+:X@D7B)(W0C[0R@
MCIVL?Z'VIZ+ZCKBQ"*6<A%4%F9B%55479F8V`50+DG@#W[K=1T22EW'MZ3YX
MY#+1Y[#28FH^)6W\-!E4R=$V,GS'^FC<4_\`"8:\3FEER?@E5_MU8RZ&#:;$
M'VK.WWZIK:"8)2M2C4IZUI3I$NY;<[^$MQ`92:4$BDU]*5K7H[GM)TMZ:L[D
M_P""83,YK[.IR'\(Q.1RGV%$NNLKOX?1S5?V=(ECKJ:KPZ(Q^78>_=>ZU+-^
M?\*Q]K]8XRMS_8'\JG^8+LK;5#E(,/)N;=VT<=MC;QR-=6&@QE)_&,W145`M
M5E*JT=/$9/)*[!4#'W[KW5G?SD_G?]%?!?K3XT93=_2_>?97R%^5>R\'OKK3
MXD=:;=AS?<U-A*_%X_)YN;<M(A>GQAVZ:UZ9T1)IZFJIIDCCTQ2NGNO=<.M_
MY[/Q,[6^!<?SBV=MSL>MJ7[<VO\`&V3XZ5-!BJ#N.C^3>]<WC=N[6Z8R,=;7
MT^W\;79?)Y:"1<G45$="E"7G<J8WB7W7NAFV5_-@Z-S7P^^3OROWYM#>_5%=
M\-]W=C=6_(CI/<TF!RN_=G]R]=RT5))UGB,EMW(Y';.[<EN[)9C'TV%JJ*H>
MGK9:^(>DZ@/=>ZL.ZLW=FM_]:;!WUN/966ZWSN\MG[>W1E=@9^LH<AG=F5N=
MQ=-DIMLYJLQI;'SY;#M4^"H,),8F1@"0+^_=>Z7GOW7NB0_\U/\`_+YO_G0/
M?NO=*'X'_P#9+'6__4;O_P#]^-NSW[KW1O??NO=>]^Z]TC]_=?;$[4VAG-@=
MF;-VQV!L?<U%)CMP[1WC@\=N+;N9HI1ZJ?(XC*T]515*`V9=2$HP#*00#[]U
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MH]I5J8_<YZVWCBMQU.!J945X/XI0TLQKJ2GJ5?\`:F>,0RD$(S%2![KW4SKW
MY@?%SMGN#?WQ_P"M.^NL=[]T]7?<_P!_NM=N[IQ^1W5MHT-3'19):S'PR$S/
MB:V58:Q86E-',PCF\;D#W[KW0LX'LC8>Z-X[ZZ_V[NO#9G>G6+;;3L';>/JE
MJ<GL^7=^,DS6V8,[$@*T-3F<1&:J&)F\A@*N5"LI/NO=+;W[KW78^H_UQ_O?
MOW7N@KZ?_P"/6R__`(D?M;_WXVYO?NO="G[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[HF_R>Z:^0O;>XNJ:KJOL#IO9^W.L.P-K=J14?8'7N]-VYK+;O
MVO!N.AAH9*_;O86TJ*EVU64.?!=!`U4LT-Q)I8J/=>Z-+M"+=T&V,)#OVNV[
MD]Y1T$:[CR&TL9D<+MJKR0+>6;#8K+Y3-9*AHBMM*35<[@WNQ]^Z]TH_?NO=
M>]^Z]T6KY+_$CHSY9;1.U.XMGTV6FI4D.WMV8\KCMY;4JVY2LP&?A0U5/IDL
MS0OY*:0CUQM[`W//MSRG[A[?]!S);+)(H/AS+VS1'U209IZJ:HWFIZFKV4^\
M%[I>P',/[^]N=Q>WCD(^HM)/U+.Z0<4G@)TM48#KID7\+CJKV'>GS._E>SQX
MSLR#<'RZ^&%)*M/CNP,7$]1VUU+B=2QP1;@IW>:2MQ=#%I'[SO2D"T<\'^;]
MP*NZ>YWL*X@WP2\Q>V2FBW"YNK1.`#U)[5%,,3&<Z9(\+UG-)RS]VS[\T1O>
M27M/;W[RDBZI+"4A=JW66E6-NP`"2N:_`%E!-7BE^/HP_9G='QC[TW%\+^V=
MKY+8>=P4G<]9O3<V3SV#Q=+F</M*LZ![HV_1Y'=-/EZ,9"BI?X_EJ"C5I;J9
MYH@I(*M[RIY=NEYIV*TYCV=)&VN]A66(N/#9D;@=+T85\L4/$5&>N9_/G+.Z
M^VW.>Y\A<U*D?,FT7;VURD3>,B2Q_$HDB#(:5SFJ\&`((%@F<[6Z@V#M>@S^
MX>P-@[.VD^-@J\5793<.$P6*EQ?@62G?&)45%,DM/]N046)3Z;6'M+O.^;-R
MZC2;]=V]FJ5KXTB1TIQPQ!)'H,]/<J\E\X<\W"6G)FU[ANMQ(106MO+/QX5,
M:L`#ZD@?/H@_9'\X'X5;(JI<-M7>.X^Z=S`F&FP/4>U<IN8U-41^U"N4ECHL
M8RS/Z0T4DO/X]PSO?WD/;':W^GV^XGW.]/PI:Q,X8^@=M"&M:=I;K,'DS^[M
M^\QS/`NY;]MUGRULE*M/NUU%;:5\SX0+R"@R0RICSZ"(?.+^83WH!%\:/@=D
MME82N&FCWW\@<T<#3I$_"5B89FPES$WZD#U-Q^/8;_UU?>/FP:>1^5'M;5P=
M,]^Q0#-`2C&(?,@%\=2$?NO?="]K3K][/=:'<]TB^.QV"'QV)'%#,!-Q\B1'
M]O7?^R>?S+^]?7\AOG#1]5;?KA_EVR?C[@&H9T@DYFHGS83"LP7^R[25-K>_
M?ZVOOAS8*\Y\TK86;CN@L%*\3D!U$1P.!+/U[_@B_N3^UG;[/^U\F_;M%\%[
MO\^M2PX.(:S<?-0L?0E=?_R<_AUMFMBSO8F,WSWYNG6LU7FNW-Y97-0UE2/U
MS28FBDH*-UF/ZDE\RGV?;-]VSVXV^47>\+=[M?\`F]U,QU'C4JF@&OGJU=`K
MF[^\;^\;O5LVU\G3[5RGL5*)#M-G%"47R`E<.XIY%-!ZG=L?$KXY8;Y#?%K:
MV,ZEVG2X7L++=L4NZJ<41EGK:7976$V;VG3TM;,[UF+BP62I(W@%,\154"&Z
M`*)Y2QVE'BE_=^VM/`D:H[6ENTBK"JK%21HR_P"FJJ$.JJA12E.L+&YRYY:&
MXM5W_?TL;N2>2:%-QO(X9'NG>2X+0I,L1\=Y':4:*.78L#J/1M]Q?#SXK;MI
M(Z/<WQ\ZES4<<*0F:MV3@VK9PB+'Y*O(1TD=;5U,@6[RR2-([79B22?85WGV
M]Y%Y@G>YWG:-NN+B1V=F:"/4S,:LQ(4$DDU)KQZ'7*WOY[V\DVT-GRKS9S!9
M6=O&L<4:7T^B-$`5$1&=E554`*H`````IT7G='\IO^7_`+I<RS_'G;^%E/Z9
M-KYC<NW3&Q_MQQXW+PPJW_(-O\/8)O\`[OOM)?DE]ICBJ/\`0I)8Q^Q7T_RZ
MFS8_O_?>VV%=$7.%Y<Q^EU#;7%?D3)"3_.O0-9'^2K\4H99*K8V\._NMZUO\
MS+MCM/(^&F()*F."LI9I/2?I>3V%YONP>WZ*?W3<[K92>1CN*Z?LU*3_`#ZD
MBS_O,/?N1!!S3MW*6]6PXBYVN/4WVLC`9_TO3.O\K'N/:2ENIOYB_P`G=K2`
MN88MP5Z[E@B!N47_`(NE"[*OT_UO:5/8'F3;#JY>YRWN%O25FD'\I$'\NC%O
MOW>W',#4Y_\`9OD>_3%3;I],Q]3_`&3@'K'4?%7^:=LR"7^`_/3:O8.WH8V;
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MLQ]^/ZI[1:_I[')%=?O"!K+ZO_'C9(!)^G-KF\;]3N[VU9W+&Y;_``N/>2@Z
MY>=4M4?\QCYTU'\PMOB=/_*N[EI/C6O:]?L5?FG)NBH.PFV?2XFIKJ?L<8<;
M/%/_``FLK(5@6/\`B%@7'KU>GWOKW16/DC4O_,2_GJ=)?##,-_&OB]_+<ZKQ
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M-/4RG4-/NO=7]?`+^8AN'Y<;[[DZ1[?Z-_V7WOSIS9_3/:N4V;C.P<=VEM?,
M]3_(':\V[>M=Q8W>&.P^`"9R.BIY*;+8Z2D7[.I4>*6:-M0]U[JS_P!^Z]T2
M'_FI_P#Y?-_\Z![]U[I0_`__`+)8ZW_ZC=__`/OQMV>_=>Z-[[]U[KWOW7NJ
MC-^_S;-C_&3O?>74/SQZ0[2^(^P6WUD,%TC\J=P4/]^?BYVYM<U7BP&3S/9^
MTH*J'J'=61@='GQ6XZ>DB@N?\J8"Y]U[K7NS'5'\PK?WRLR'8.Q]E_S)M^?*
M?=/R9?=G4/S(ZO\`DYLBL_E6U'QZK.T4R6V9J?9]%65N"J-@4_Q],F,K,48G
MKILH6`;S2(??NO=;P@U6&HJ6TKJ*`A"UAJ*@DD*6^G)]^Z]U[W[KW7O?NO=>
M]^Z]T#_9?R&Z`Z7KL9B^XN\NGNILGFZ2;(8;'=E]E[,V+7Y:@IYA3U%=C*/<
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MXS:FU?Y8V8^6V=3OO`;XVCE=Q?/#>?R8R6X]K]*=6]4;;Q,M3OJGSG:F[-\8
MS^/+N2&`P5]-$(C-8./=>Z/A\'/F+T-T)N5?C5VQ5]G9/Y&=N]_Y_!?(+Y-3
M=8YN/XW[M^=F]L93[JW+\;L!W$6DQ]5N;K?!_;[8P]'XDQ\5)A8Z2.<5`,/O
MW7NKV/?NO=(G<_8^R]EUE+0[FS7\,JZN#[NGA_AV6K/)3B0Q&3R8^@JXD_<4
MBS,&_P`+>_=>Z`[JGNSK"BVUE8:G=`CD??\`V;5*O\%W$]X:S?\`N*IIWO'B
M&`+P2JUOJ+V-C<>_=>Z$K_3QU1_SU@_\\6Y?_K-[]U[KW^GCJC_GK!_YXMR_
M_6;W[KW7O]/'5'_/6#_SQ;E_^LWOW7NO?Z>.J/\`GK!_YXMR_P#UF]^Z]U[_
M`$\=4?\`/6#_`,\6Y?\`ZS>_=>Z]_IXZH_YZP?\`GBW+_P#6;W[KW7O]/'5'
M_/6#_P`\6Y?_`*S>_=>Z]_IXZH_YZP?^>+<O_P!9O?NO=>_T\=4?\]8/_/%N
M7_ZS>_=>Z]_IXZH_YZP?^>+<O_UF]^Z]U[_3QU1_SU@_\\6Y?_K-[]U[KW^G
MCJC_`)ZP?^>+<O\`]9O?NO=>_P!/'5'_`#U@_P#/%N7_`.LWOW7NO?Z>.J/^
M>L'_`)XMR_\`UF]^Z]U[_3QU1_SU@_\`/%N7_P"LWOW7NO?Z>.J/^>L'_GBW
M+_\`6;W[KW7O]/'5'_/6#_SQ;E_^LWOW7NO?Z>.J/^>L'_GBW+_]9O?NO=>_
MT\=4?\]8/_/%N7_ZS>_=>Z]_IXZH_P">L'_GBW+_`/6;W[KW7O\`3QU1_P`]
M8/\`SQ;E_P#K-[]U[KW^GCJC_GK!_P">+<O_`-9O?NO=>_T\=4?\]8/_`#Q;
ME_\`K-[]U[KW^GCJC_GK!_YXMR__`%F]^Z]U[_3QU1_SU@_\\6Y?_K-[]U[K
MW^GCJC_GK!_YXMR__6;W[KW7O]/'5'_/6#_SQ;E_^LWOW7NO?Z>.J/\`GK!_
MYXMR_P#UF]^Z]U[_`$\=4?\`/6#_`,\6Y?\`ZS>_=>Z]_IXZH_YZP?\`GBW+
M_P#6;W[KW7O]/'5'_/6#_P`\6Y?_`*S>_=>Z]_IXZH_YZP?^>+<O_P!9O?NO
M=>_T\=4?\]8/_/%N7_ZS>_=>ZQS=X]0U,,M-4[FAJ*:HC>&HIY]O;BF@G@E4
MI+#-%)A&CEBD1B&5@00;'W5T21#'(`T;"A!%00>((/$'TZ<BEE@E6>!F29&#
M*RDAE8&H((H00<@C(/6IM\X?C=N_=WRKS6XNL\=BL'U_N/<]#MOKC%+1[FV_
M3YB3"T^3S\F'VOAZ?;OV\RQX3&553'##;]BGD:P"GWBU[Q?=_P"=>=^?K/F/
MDVYVJVY;M["RA$3W/@,AMT`=1$$(4`CMH:>E.NJGW3?OT>S7M#[$W_(7NQ!S
M#?>X%WNV[W3W$6WB\647QK$[W+RJ[.WXR02/,GJUOKKX#?`G./0=D]WU^_.R
M=\;@AI<YE=M;YR>^AMC;5?51QSRX'&[?QN*H1!C\7*QA2*661=`L1[D;??8/
MV\WKG'<.:=[%SN-U=WDLU))F$2ZVU:45-)*+P4,Q[<4IUC;RO]_/[P/*'M?L
MWMIR++MG+VT[7MD-KXMI9Q"[F\--!EFGD#UE>FIV55.K@>K%NMXOAUT_1Q4'
M5VT^O]BP0KH1]N==5^/JRH.H"7(1[=^_GLW/KD;GV/=DY/Y5Y;C$>P[=9VBC
MSCB16_-J:C^9ZQZYS]V?<[W%N6NN>M_W;=96-2+BZED2ORC+>&OY*.A=_P!/
M'5!_YBP?^>/<O_UF]B3J/J==?Z>.J/\`GK!_YXMR_P#UF]^Z]U[_`$\=4?\`
M/6#_`,\6Y?\`ZS>_=>Z*KW'V_P!>57R<^%E?3YZ:6EI<YW\TTJX'<E@'Z=K$
M!13AP\@U2"^D&U_?NO=&K/>_5`)!W78@V(."W,""/J"/X-P1[]U[KK_3QU1_
MSU@_\\6Y?_K-[]U[KW^GCJC_`)ZP?^>+<O\`]9O?NO=>_P!/'5'_`#U@_P#/
M%N7_`.LWOW7NO?Z>.J/^>L'_`)X]R_\`UF]^Z]T4F'N;K0?//)Y0[F`I'^'N
M`IUG_@^X-1D7NW<UUT?PGS``_DK;W[KW1MO]/'5'_/6#_P`\6Y?_`*S>_=>Z
M[_T\]4_\]9_L/X'N:W^M_P`6;W[KW1+>C>A/AG\?/D]\IOESL3=^]:GM_P"7
M]9M"K[9J=RS[BS."@39%%+08&@VCC3M:GGP&-A@E.J$SS(38BUK>_=>Z3/SD
M_EQ?`?\`FX8;:N)[WP>?S.ZNI9Y:O9?9?7F5SO7O9.SZ',RQG)X:@W+-BQ%6
M8'-/2J9Z2>&IC5U$D8CD]9]U[HROPB^"?QH_EY=)X_H3XN[#79FRX,C/GLYD
M,A7SYS=^]]T5D4,-=NG>FY:W_+<YFZJ&G1-1"0PQH(X8XXP%]^Z]T"F#_E?]
M(5/1OS;Z2[;W%N_N6/Y_[^[$WS\@]^9YL=@-XY&/>-!18/:NV=OU6`IJ>GPV
M"ZCV[B:.CVY&$?[5:8,^LLX;W7NGGX-_R[MI?"[.]H]AU_;_`&5\A>Z>W,+U
MGLK=';?:4.UL;FXNL^E]NOM;JOK_`!6$V7A<!M^CQNV,1-)YJKP-5Y&HD,L[
MLP%O=>ZL1]^Z]T2'_FI__E\W_P`Z![]U[I0_`_\`[)8ZW_ZC=_\`_OQMV>_=
M>Z-[[]U[KL?4?Z_OW7NM+7^83_,Q^3^"^3WREZJW'\Q=C=(9/K;LC-]?]#_R
MS-\_R]]W=\TWS2V%CZ##S;(K\GVL<;E:#(T'R&R%?/20/CY88L3&%60++%+[
M]U[JV_8W\J[L[X]G9?<O\MKO'<GP=RF[EVIO/N3X1;\2I[@^'62R.=BQV4WU
MMO`[(R56<WT]N.ADJJNFAR&V:R&D695_R3Q\>_=>ZO9%[#5;5I&K3?3JL-6F
M_.F_T]^Z]UW[]U[KWOW7NO>_=>Z!KL_XY_'[NROQ>5[DZ.ZC[7RF#HYL=ALE
MV-UWM+>E?B<?43BIJ*''5>XL3D)Z*CFJ!Y&CC949^2+^_=>ZJ[^4?P%^9FU/
MDUF_F%_*][ZZ2Z5[&[1ZNV!TWWMTY\ANN\ON[I#>6V^IER%/U=N[:PV5-0[@
MV;N[9N)R<^-$$`-%54+J&T&(*WNO=![!_)N[$W?\-^Y=C=M_*BNR?SO[P^1V
MS?FOE?E7M+:%)B=L=>_)_K!MNGJC^XW7;RQT[=8;"Q>V8,.M).R5-=02S22:
M9'"+[KW0@?%'X)?.S.?*W8OS*_F:?)+IKN#?W077^^.N/C?U9\<-@9S8_5FT
MY^S(\=1]@]L[KGW34S9G-]A;CP>-BQL<$:1T-'3!FC]3:5]U[H]O<_QWW7W=
M\C/CEO'=6X,%_LOWQ[J<]VO#UY&F1;<.]/D=&J8/K+<V<?QKBUVCU;@*_*5]
M%$)#-+G:J"9TTTL9]^Z]U70?Y67>-3VY3==5G:G5"_!/&?/:K_F.T.-IL'O`
M_)2J[<J]RU78@ZCKLK+7G8D76M-VAD)LF,K&#E7H@M$8@MY??NO=7K'DD_U/
MOW7NNU)N.3]1[]U[H*^GV;^ZV7Y/_,QNU1]3]!V-N:P_V'OW7NA3N?ZG_;GW
M[KW7KG^I_P!N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_
M`&Y]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?\`;GW[KW7K
MG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_P!N??NO=>N?ZG_;GW[K
MW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG_`&Y]^Z]UZY_J?]N??NO=>N?ZG_;G
MW[KW7KG^I_VY]^Z]UZY_J?\`;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N?ZG
M_;GW[KW7KG^I_P!N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?]N??NO=>N
M?ZG_`&Y]^Z]UZY_J?]N??NO=>N?ZG_;GW[KW7KG^I_VY]^Z]UZY_J?\`;GW[
MKW5>/R?["[#7N7X_Q;7^,?R)["PO3'<M5OS=&[=EX7KB?;F4P.3Z1[1V;$-L
MRY[L[`93*5M-G][T<4T4E)!I597!94!;W7NCZ[=S$^?P.'S<^&S6VYLMC:3(
M2[?W%#24V>PSU4*3-C<S3X^NR5##DJ,MHF6&HFC#@Z78<^_=>Z>;G^I_VY]^
MZ]UZY_J?]N??NO=>N?ZG_;GW[KW7M1_J?]O[]U[HH._O@7\2^T-[UG8^_.I(
M]P;WKLA7927<$N]NQJ*J@K\G2)09&HQL.,W=14>'-=11B*5:2.%9(QI8$>_=
M>Z-?BL;18/%XW"XN%J;&8?'T>+QU,9IZ@T]!CZ>.DI(#45,LU3.8J>)5UR.[
MM:[$FY]^Z]U/N?ZG_;GW[KW7KG^I_P!N??NO=>N?ZG_;GW[KW7@2>+G_`&Y]
M^Z]U6=6]\8;$?/#,YFIZX^0LVW4Z,P_3?]Z<?\>>X<AM27?=+W!G,C/2T^XZ
M3:,N)J,3'BZV*I_B22-CS3OJ$W#`>Z]U9D2P-KG_`&_OW7NNKG^I_P!N??NO
M=>N?ZG_;GW[KW7KD_4GW[KW77OW7NO>_=>Z][]U[KWOW7NB0_P#-3_\`R^;_
M`.=`]^Z]TH?@?_V2QUO_`-1N_P#_`-^-NSW[KW1O??NO=>]^Z]TV5.$PM;7T
MF5K</BJS)X\**#)56.HZBOH@KM(HI*R:%ZBF"NY8:&%B2??NO=.?OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KL
M?4?ZX_WOW[KW05]/_P#'K9?_`,2/VM_[\;<WOW7NA3]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]UW<_P!3_M_?NO==>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MHD/_`#4__P`OF_\`G0/?NO=*'X'_`/9+'6__`%&[_P#_`'XV[/?NO=&]]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=59?-S^:UU=\/>U
M=J?'C:?1OR*^87R9W/M:7L*HZ"^*NQ(=_;XV?UI%434*[]WU+69+%8?;&&K\
MA`T-$D\_W%6R,430NH^Z]TH*#^;1\-JOX.;E^?U9NS=&!Z=V9D:[:&[]I;@V
MAE<5W+MSMN@SM-M63H_)]95*+G8NV:C=-=3T,&+`/F:HCF60TS>;W[KW24^%
M?\V7K#Y<=N97X[[TZ!^3'PX^0L6R:CM/:?4'RNZZ3K_</9'5=)64V.K=];"K
M:3)9;$YNBQ5?4K'6TOF2KI00[1E`S+[KW3C\>_YK'4/R%[LVCU=B>J>Y=E[%
M[GR':^)^+WR#WEB-NT_4WR7R/2%964G95-L!\9N'([KP9QT>.J:G'G/8[&#,
M4E+-+2Z]&D^Z]T<CI_Y#;9[MWUWSM/9>#STN!Z%W]1]69;L2H%#_`'/W?V#3
MX.ES&^-M[.GAJI:VOEZVJLA!C<O-)%%%'E#+3(7>";3[KW0_^_=>Z['U'^N/
M][]^Z]T%?3__`!ZV7_\`$C]K?^_&W-[]U[H4_?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$A_YJ?_Y?-_\`
M.@>_=>Z4/P/_`.R6.M_^HW?_`/[\;=GOW7NC>^_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[HG/R:^9>&^,.>VQ@,G\=_EWW5)NC#UF9BROQOZ!
MW#W#@L(E'6K1''[DRF&K*6'#Y>H8^2*G<,\D(UCCW[KW557=4GS,^,_\PKLK
MYE_#7XN[;^;."^7W0/QXVQW+\?*WMO971?R/^.^;Z^IMRQ;#W7EX][C(_;==
M;GQ.:GAR5&\2RTV6HI#&KE7)]U[JJK;E1O:;*]C]A_(Z3KZ/`;B_X4J_$O,=
MMP[`R%;E.G]J[S@ZBVSBJ_9>*W'EDHAN>EZW[4FPF(RN8>.&GKLQ1R2>*,6C
M7W7NKT/G-)B*K^;%_)GQF(*2[_CKOG#D,I!1R4IKXNJ9.C<+1;@ES$"$9'^!
MU.=DHXX6/^3>=7!!>UO=>Z*'V#\)NVO@Q1=%Q[=^1&*[5Q_479':75G\JCX_
M2]9T^#W%M_O+Y9-N?'1;E[ZWZ=PY=>S=J?'O:&?SF6C>DQ>'5,31325;2R",
M'W7NG;XQ?-G?/Q4QO6_7V`Z<Z_S/P%VU\U*W^7-)W5)OS<<OR:WC\FZ[=E?M
M_??R,WELVIV^NTZG8W8/?TF5AJ*:.O?-(U2M8?\`)[1CW7NMD<\$C^A]^Z]T
MB=SU_8=)5TR[.VWM3-T34^JJGS^Z\E@*F&J\C`104]%MC.QS0^(`ZS(AU$C3
MQ<^Z]T%^SZ+O+:F*K,8=F]:5QJMR;KW!YE[#S\`0;FW'D\^*70VP)"6HQD?$
M7O9RFH`7M[]U[I5?QCO'_G@>MO\`T9.>_P#M>^_=>Z]_&.\?^>!ZV_\`1DY[
M_P"U[[]U[KW\8[Q_YX'K;_T9.>_^U[[]U[KW\8[Q_P">!ZV_]&3GO_M>^_=>
MZ]_&.\?^>!ZV_P#1DY[_`.U[[]U[KW\8[Q_YX'K;_P!&3GO_`+7OOW7NO?QC
MO'_G@>MO_1DY[_[7OOW7NO?QCO'_`)X'K;_T9.>_^U[[]U[KW\8[Q_YX'K;_
M`-&3GO\`[7OOW7NO?QCO'_G@>MO_`$9.>_\`M>^_=>Z]_&.\?^>!ZV_]&3GO
M_M>^_=>Z]_&.\?\`G@>MO_1DY[_[7OOW7NO?QCO'_G@>MO\`T9.>_P#M>^_=
M>Z]_&.\?^>!ZV_\`1DY[_P"U[[]U[KW\8[Q_YX'K;_T9.>_^U[[]U[KW\8[Q
M_P">!ZV_]&3GO_M>^_=>Z]_&.\?^>!ZV_P#1DY[_`.U[[]U[KW\8[Q_YX'K;
M_P!&3GO_`+7OOW7NO?QCO'_G@>MO_1DY[_[7OOW7NO?QCO'_`)X'K;_T9.>_
M^U[[]U[KW\8[Q_YX'K;_`-&3GO\`[7OOW7NO?QCO'_G@>MO_`$9.>_\`M>^_
M=>Z]_&.\?^>!ZV_]&3GO_M>^_=>Z]_&.\?\`G@>MO_1DY[_[7OOW7NO?QCO'
M_G@>MO\`T9.>_P#M>^_=>Z]_&.\?^>!ZV_\`1DY[_P"U[[]U[KW\8[Q_YX'K
M;_T9.>_^U[[]U[KW\8[Q_P">!ZV_]&3GO_M>^_=>Z]_&.\?^>!ZV_P#1DY[_
M`.U[[]U[KW\8[Q_YX'K;_P!&3GO_`+7OOW7NO?QCO'_G@>MO_1DY[_[7OOW7
MNO?QCO'_`)X'K;_T9.>_^U[[]U[KW\8[Q_YX'K;_`-&3GO\`[7OOW7NO?QCO
M'_G@>MO_`$9.>_\`M>^_=>Z]_&.\?^>!ZV_]&3GO_M>^_=>Z]_&.\?\`G@>M
MO_1DY[_[7OOW7NO?QCO'_G@>MO\`T9.>_P#M>^_=>Z]_&.\?^>!ZV_\`1DY[
M_P"U[[]U[KW\8[Q_YX'K;_T9.>_^U[[]U[KW\8[Q_P">!ZV_]&3GO_M>^_=>
MZ]_&.\?^>!ZV_P#1DY[_`.U[[]U[KW\8[Q_YX'K;_P!&3GO_`+7OOW7NO?QC
MO'_G@>MO_1DY[_[7OOW7NO?QCO'_`)X'K;_T9.>_^U[[]U[KW\8[Q_YX'K;_
M`-&3GO\`[7OOW7NO?QCO'_G@>MO_`$9.>_\`M>^_=>Z]_&.\?^>!ZV_]&3GO
M_M>^_=>Z]_&.\?\`G@>MO_1DY[_[7OOW7NO?QCO'_G@>MO\`T9.>_P#M>^_=
M>Z]_&.\?^>!ZV_\`1DY[_P"U[[]U[I5[6K=^5<E8-Y;>VQA(D2(T#[?W/D-P
M25$A9O,M2E;MS!+3(B@%2ID+$FX%N?=>Z6'OW7NO>_=>Z][]U[KWOW7NB0_\
MU/\`_+YO_G0/?NO=*'X'_P#9+'6__4;O_P#]^-NSW[KW1O??NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UW<CZ$^_=>ZK`^;7\ICXV_.+L/;W<F
MYMY_(/H3NO![7.PJ_N#XL=QY[I3?F\^NUJYLE2[!WWD<+%5T>ZMM8W+5#55(
ME3`9Z:5F$<@1G1O=>Z$>F_ED?"JE^$M?_+U7IK'2_%[*XBJH<IM*HRF6J-P9
M'.5N77<E5V%6[VEJVW14=ER[K1<L<XU3]\*]5D#@`*/=>Z#;X1?RD_C#\&.P
M]Q]S;0W)WQWCW?G]JQ]>4G<OR?[>S_='8.T.LHJR+))UQLC)YI::CVOM23)0
MK/-'34ZSSNH$DK(H4>Z]T<[</Q]V+NSO_KCY&[BJ-PY7>?4>Q=Z[(ZZP=3DX
MVV5M>3L2KQ+[PWI08'[77_?K+8C"PXK[]ISXL8TL*(OFD9O=>Z*LG\KOXVCY
M'_[,1+ENW:JBC[<F^1=%\>:GL2ND^-..^2=3C3BZCOZBZO%(JIV+-"[SEFK'
MQPR$KU@I14GR^_=>ZL;]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T2'_FI_P#Y?-_\
MZ![]U[I0_`__`+)8ZW_ZC=__`/OQMV>_=>Z-[[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ*W\S?ESU=\&_CKOSY(]NQ;BR6V-F+B<?C=K;-Q;9S>V_=Y[HRU'MW9>PMEX
M59(CE-S[MW%D:>DI8M2J&D+L0JL??NO=$=^(7\U#?W<WR%P/Q;^6OP9[M^!7
M<79VR-Q]D]`T79^YMH;[VKW)M3:"T<V[,7C-T[0>.GP'8NV:"N2LK,!5Q?<Q
M4>J0MZ=/OW7NKAO?NO=>]^Z]U[W[KW7O?NO=$4^>/SDPWPGV3U[+B^IM_?(C
MO/O/?2]7_'OX\=7_`,/@WCVGOA<179_)1G,9B2+"[6VKMG`XZ6MRV5JV,-%3
M@$JQ8#W[KW0:?`_^8OE?EEOSMKX_]V_&#M3X:_*WI'`;2WKOGH_LW*[=W=29
M#KO?M1DJ7:._=A]A;2F?;^[\#5U>*FI:KQI#)1UJ&%@Q&KW[KW5FWOW7NO>_
M=>Z][]U[KWOW7NB'_/#YT8?X5;3ZZIL+U%V)\CN_>]MWUG7WQ[^.G5$5$-Y=
MG[LQN'GSV;GJ<QE7CPVS]E;3P\'W69S5833X^!T)5RZJ?=>Z2OP2^=N_?E5F
M>T^K^^?B'W)\+/D)U!#MK-[DZO[,J<9O';F>V1O4Y$;5WAL'MC:</]S-W4\T
MN*GIZ^DA=*O'54>B1""'/NO=6->_=>Z][]U[KWOW7NO>_=>ZK.^>_P#,:/Q`
MW7U%T;U%\=NS?F)\M>^:?<>:ZS^._559B<!6#8^S/M1N_L;?F^-P@[>V)LO$
M35L5,E75!A45D@B4"S,ONO=+7X'_`#QQWS.Q/9VV]V=+]C?&'Y']![BQ&U.^
M_C?VR<9/NW8>0W%BSF-K[@PV>PLLN$WOU]O''Q2R8G-416"K%/*-"%+'W7NC
M^>_=>Z][]U[KWOW7NDEOS?VR.K=F[C[$[)W=MW8>Q-GXJJSFZ=X;MR]#@=NX
M#$42&2IK\KELC-3T='3QJ+7=QJ8A1<D#W[KW1&_@=_,CZ:_F`[,^0O:?56+S
MF`ZEZ+[?S_6%#OG=T53A_P"_F(VWM#;^ZZ[L2EP&2H,?EMN[:JX<TQI$K$\\
MU)$M0P02A%]U[JN"K_G[;KI<7)\CA_+7^4=1_+3BW(<<?G9#F=GFE?9*YQMK
M-W#%T:;;_;JW^/+J&1,BWQO^5:02(??NO=;$6+R>/S>,QN:Q-5'78K,4%'E,
M970ZO#68_(4\=71546M5;QU%-,KK<`V/OW7NIWOW7NO>_=>Z#WM7MGK+HSK[
M=/:_<6^]L=:];[)Q53F]U;TWAEZ3"X'#8ZDC:226IK*N2-7FETZ(8(]<]1*R
MQQ(\C*I]U[HJG\O?YZ]>_P`Q7I_?7>?5FUMS;6Z_VWWAV3U!MN?>,$V-SNZ\
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M5_R\_D-\']O_`"HER=)\5^T>S]Q;.W;MOLG/4."J=VT>R=XT&UW7*=6;[SVU
M*9JNBQN065Y7BEB+*8]1]U[J\'W[KW7O?NO=>]^Z]U5A\X?YDNZOC9V_L;XQ
M?&OXD=I_.+Y3;QV-6]MY/J;K;<6V=AX?KWJ"@S+;<_OUO[L3>).W\&,SN)6H
M\91%6GK98Y#=`J>3W7NA`^#'\P_97S%ZU[;W!O+KC>/Q7[8^->\*KK_Y/]*]
MV56*QV5Z9W32X6GW*E36;MBE@VWG=EY;;E2E?0YB)XJ>>ENY5`.?=>Z@_"/^
M9KT3\_NVOE%L3X]0Y/<6P_C1E.O,$O<$AEIML]IY+>V-SN0K*_8E!5T-+65F
MTL1)A?%39;4]+E=9EIM4(223W7NK'??NO=>]^Z]U[W[KW52GS-_F;[[Z*[[H
M?BC\3OA?VS\\/D=CNO\`&=M]H;,Z]W9M/K;:G4/6VX<CD<-M/*;R[`WN&PR;
MAW?E,54#'8J)#/-302S%@%56]U[HQ?P'^<>T?GAU#N#?N)Z]W]TQV)UGV'N'
MIKO;HWM&@CH=]=0=O;1AH*C<.T,O)3DT66HQ2Y.GJ:*O@TQ5E).D@5"61?=>
MZ0OQG_F0]9_*SYA?)_XL=7[3SE9@OC3L_8&XG[OFK:=MD]IY'=V=W9MO.4?7
M,,=,3F]N[/SFTJB@ES,51+2560AJ(8A:#R/[KW5C7OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NB0_\`-3__`"^;_P"=`]^Z]TH?@?\`]DL=;_\`4;O_
M`/\`?C;L]^Z]T;WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3-_.WS."V?T7\2NQM[ST]
M+U=UK_,?^&6\.TJ^O*+B<1M&'L*?$0YW-RRO'3TV(PFY\OCJB:60B.(('/Z?
M?NO=1_GKG\!N7^9)_)@V1MG(T&7W]3=N_)'MAZ/%96&>OQW46.^.NY,+G]T5
M=%32.S;:RV5S%#2153$023V1"[7`]U[JZ'W[KW7O?NO=>]^Z]U[W[KW1<>\>
MY^D]A;JZFZF["[)PO6?;'R'J]][#^.V5R>+%3E*K?./V?5Y/++M3*5F/J<+0
M[CQ^&?[F&FJIZ?\`B!C\*"4DI[]U[JD+^7UUWOGX9?S=N_\`XO=D]_\`^SS;
M_P"_/BCMCO\`W+\F=_)'%\CNL*+KS>-+L/`]*]@T>(S%;M'#=8Y2/,2Y7;])
M0T>-D%3)-(\<@</[]U[K9+]^Z]U[W[KW7O?NO=>]^Z]UKA_S6^N=]=H_S3?Y
M7W6>/^0.Z?BYLCNGJ#YC=59/N#9,^$QW8,E>]%UGNO)]:=2[GS]/64>Q.R.R
M,'A11QY:")\@F/2H2E5I2`/=>Z%7^7'CNP/BK\__`)2_RYJ;Y2=J_+3HG8'Q
MXZD^1FU<UWMNV/L?N'HC?/8&]MW[5SW5&Z>PUCIZO,XK=6-PL.>QE+61BHI(
MS)I"Q.I?W7NKY_?NO=>]^Z]U[W[KW7O?NO=4=_S"=@?)#9_SC^.GR@^"&Z/C
MGO3Y:4?0?9O4.YOB'\@-\'8C]Z=`5&[]M[IKMX=>;AI9'R6(W!U?O+P354@B
M>FFHZLI(-04'W7N@B_E:MWUO7^9[_,L[4[\W'U;N'L5>H/B'U[VKB.C)LADN
MHNHNR,;C^P<]3='X#=>589+?&Y-C;/R='/G,C414\BY#(M$L21*@/NO=;$/O
MW7NO>_=>Z][]U[I'[[Z]V)VEMJKV5V5L_;>_=GY*IQE7DMK;NPU!N#;V1J,/
MDJ7+XM\AA\G!4T%:*'*44-1&LL;JLL2M:X'OW7NJI_Y6U-3GN7^;G1?;PFC'
M\Q_?5$M&8HS2BC3I[J>G6D%.5\(IEIP$$=M`3BUO?NO=1>X,Y)_,TIMY?#SH
M.ABV]\'<3FI^O/E1\D:6GI,;A>QJ/:^86'>'QD^,M`L:1YR3(5F.;%;KW<J+
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MDV/UEN/JG%9#>=`/A[\C,)NO<N-I,;TAM7XZ55,$PT78-)GVHJ.]14YNDK]5
M1/:99C'[KW6Y9MG)5^9VWM[,97%R83*9;!8C)Y+"ROY)<17U^/IZJLQ<KV&N
M2@J)6B8VY*>_=>Z>_?NO=>]^Z]T%/:?7&P-Y4%)NG=NRMK[GW'UOC]TYSK_-
MY_!X[+Y+96;R.WZO'UN9VQ55]//)A<K44!,+5-.4F\1*A@"0?=>ZUQMC]LXS
MIG_A+OMG>>;ZYV?VOBZ[H*LV+7[/[&_BHZZFA[+[NRFP'SO8%1A)Z7,TFT=J
MG<?\3K9J6:&HCCI;QRQ/:1?=>Z1%?\7>WOY>_?/\KKN?N7YTY?\`F*[?W3WQ
MLGX\=<=0=S2&(=75W<>SJ[!Q]U_%LX#<M9)NVNV)A*,T\]5N.++U";=J6=*N
M*>0R-[KW6V.?J?\`7/OW7NNO?NO=>]^Z]T3/Y3_*;:?QRR6T-M;2Z\K.Z?E5
MW3!D,%TGTCLU,;1;RWW%@&AGRF;W5NNMC^RV#U#LF7(Q5&9SN3<4=$D@6&.H
MJI(J>3W7ND=\6_A?1[%V-WUE?D?+L[N;NGYE[M;L#Y4RP8HU'6.5J?[LXW9N
MW>I]J;?RXEDJ.L.NMD8JFPU$:]6J\FD<M55`/4&*/W7NBX_"K$8G;_\`-*_F
MR8'`XO'83!83;OP.Q>&PN'H:;&8G$XRBZ1S\%'CL9C:**"CH*&EA4+'%$B1H
MHL`![]U[JXOW[KW7O?NO=>]^Z]T1_P"4?RJQ?1&Z-N]5=0=:+W=\R.Z\/457
M6O4.#DI,(\^V\#4IC*KM'N??3TTL6P.D]CUV0"U>2JO-45$K&DQE-55;&-?=
M>ZJG^7NU>^?Y?WPWFVWU_P!??(?Y1]U?.KY,Y;=_SM[A^(NR(LGV/MZAWO@%
MJ>S,CT]M2JJ8Z39^,3:.V<?L;:M15U*SXB@89!WDR"#5[KW18OY9_P`S<9N/
M^;YV'UIL?^7G\P_C1L/<?PL^-?3>W-K=B=6X?:N(Z-VOU-E^XLSA]P[_`(*3
M<-<<'L_>HR/V.'JU-1-79*"?R@,2Y]U[K;5]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T2'_FI__E\W_P`Z![]U[I0_`_\`[)8ZW_ZC=_\`_OQMV>_=
M>Z-[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#CM[J'K+OWK/>G3?<NRL#V+U?V)@ZK;F
M]-E;FHUKL+G\/5Z6DI:N$E71XY8TEBEC9)H)D62-E=58>Z]T2'X3_P`I7X,?
MR_=V;H[`^.75F5Q_8>ZL,FU:G?V_]];P[0WAAME1U$%8FQ=JYS?.7S-7M?9X
MK*=)6H:(PQR2(I?5I6WNO=62^_=>Z][]U[KWOW7NO>_=>Z*]\NOAK\=/G/U'
M5=)_)?KZFWYLE\M0[BQ$D.1R>WMS[1W3BQ*N,W7LK=N"JJ#/[6W'CUG=8ZJC
MGC?0[(VI&*GW7N@W^$W\MWX@_P`OC#[NQ_QEZRDVYF^P:NFJ]_=A[LW)N#L+
MM#>@Q^M<30[B[`WCD,MN2NQ.'CD*4M'YUIH1R$U>KW[KW1Z??NO=>]^Z]U[W
M[KW7O?NO=%;^77PP^-_SHZI?IOY-=<T78&SX<O3;DP$Z9#)[?W5LO=E#!44^
M.W=L?=^`J\?N':FY<?%52+%54=1&^EBK:E)4^Z]TEOA=\`/BO\`-D[AV1\9.
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M&GVI,N$Q,`IQ1&,4\T8E2S\^_=>ZJ&QO_"93^5?AZ:GHL3MSY+8RAI9)):>A
MQ_RV[XH:&&2:H>KG>*CI=X14T1J*J5I)-*C7([,>23[]U[J_7"XFCP&&Q&!Q
MPF&/P>+Q^'H!4U$M74"BQE)%14HJ*J=GGJ9Q!"NN1R7=KDDD^_=>Z<_?NO=>
M]^Z]UX<<^_=>Z`CI?XV]2=!8;M+;W76`J*;#]R]M]C=V]@T&;R59N*GS6_>U
MZN*LWO5"++/4I38G*2Q`"A4?;1H2JJ`2/?NO=5X=;?R&?Y8'5'?&-^0>T?C[
M.FY-O;MEWYLW8>9W_OG/])[$WFU5]_3[DV7TUE\Y5;!P&1QE>SST7BHO'1S2
MLT*(=.GW7NKAOKR??NO=>]^Z]U[W[KW46NHX,C15F/JE9Z6OI*BBJ45VC9J>
MJA>"95=2&1FCD(!'(/OW7NB\=:_$GH+JWXRXKX?838=#G/CUB]G9K8+=?;XF
MFWGC\MM'<-7DJS,8;.RYXU<^7IJR;+3W\Q9@&`!&D6]U[HEWQ6_DE?RZ?AQW
M/2=^=,=-YO\`TC8"FR='L"M[![)WYV;B.J*7+B6&OBZKP&]\[F<5L9I:"7[1
M9:.-)HJ11$CJEP?=>ZMB]^Z]U[W[KW7O?NO=54?,S^31\)/GGW1CN_?D+B^Y
M<AV3A]CT77.)R6Q>^.S>MZ#&[0HLA5Y7^%46*V=GL51PQUN2K'GJ2!>HE"L]
MRBV]U[H=OA!_+T^./\O;:^^MH?'*F[(IL-V+G\;N7<H['[5WSVI6MD\5CCBZ
M0XVOWQE\O58JF%(WKB@9$=O402![]U[H<MC_`!XZNZ[[G[N[]VOB<A2=E_(6
M+KR#L_*5&9R%9096/JW`5.VMG"@Q%1,]!AS0XFK=)#3JGG8ZGN0#[]U[H;_?
MNO=>]^Z]U[W[KW51_P`M_P"25\%/FUWSF/DEWMBN[:SM;-[6V[LFJRNR/D#V
MEUWC8=K;7B=<3A*'"[0W!BL?24*5,TE3(BK:6JE>9KNQ/OW7NC5_"GX*]!_`
M'K?</57QXI^P*;:6Y]WU.^,JG8G9F\NT,N<[5XO&XB9J3-;URF5R-%0&CQ4-
MJ>-UB$FI[:F8GW7NA6P7QYZOVY\@NPOD]BL7DHNWNT.N=B=5;OS$N;R,^*K-
MF];Y7<N9VK14N`DF;%T%725^[:UI*B*-99A(%<D*MO=>Z&_W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1(?^:G_`/E\W_SH'OW7NE#\#_\`LECK?_J-
MW_\`^_&W9[]U[HWOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[HD/_-3_P#R^;_YT#W[KW2A^!__`&2QUO\`]1N__P#WXV[/?NO=&]]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4SYY=[;L^,'PM^4OR*V'08/*[TZ3
MZ,[&[+VOC=RP5=3M^NS>T=MUV8Q]-F:>@JZ&MFQTU13`2K%-$Y4FS`\^_=>Z
MI7_D<?SO.R?G]\??E9V)\Q-J]<]6;Y^-V!Q/<'V6PZ/*8+#YGH'/;0SF;H-Y
M?:[AW'N"J;QY39^3A><2I%;QKI#!O?NO=('^0M_.S^5O\SOY&?*CJWY'=:=4
M]9[4Z?ZPV=V?L7^Z&$W'@]PSX7?.>:7`5.YJC/;JSM'+2U6S:NDJ@T<=.=4F
MLV!TK[KW5O>R_P";Y_+'[$[U7XU;)^;70^X^ZILQ/MZBV?0;K_8RVX*<JKX+
M![KFI8MF9[,-(WCCIJ/(3S2RAHT5G5E'NO="OWO_`#"/A5\8=_UO5WR$^1_6
M_4._:#JC)]WU.W=[Y&KQ$_\`HNQ&2GP];NBGK):(XVL'\5I9*>&CAFDR%3*N
MF&!R1[]U[H-,=_-:^!&[?BCW)\S>L/DCUSV9T=T;C*VHW[N3;N1R*-@LR@2#
M";?SN(J<2-RX&LW-E*B"FHGJ*`).9@Z:T5F'NO=4C9C_`(4?5W9/\E[NC^8/
MT#A>GH_E%TMNW86*[&Z!S+;QW3M_J[$]D]S5.QMEQ;GKQ_=&IS>2SVS*)Z])
M:*H$*U%U95`"'W7NKIOCM_-9^#'?&_M@_'7#?*GI+-_*S/["VSG]P=1;:W&9
MZA-S5NT\9N'<6W<%D76?`Y/+8EZR37C:?(5.0A2)P\>J*33[KW3M\F?YLO\`
M+A^''9$/3_R7^7?4_5'9TF.H<M/LG,5N7RF=Q>.R94XZIS]-MO$YH;<6OB82
MPK7M3-)`?*H,?J]^Z]T>[:6[MK;^VO@-[;'W'A-W[.W7B:+/;9W3MO)T>:P&
M?PN2@2IH,KB,KCYIZ*OH*RGD5XY8W964\'W[KW11/E?_`#(_@I\&LAMS#_+'
MY.]8]*Y[=L!J]O;;W)DJRNW/D<>K31_Q8;:V]0YG.TV%::G>-:V:GCI6E4H)
M"XM[]U[H!OGU_-@^.WP^_E[;I^>&R=_=;]P[=S."^V^/<>'W0]?M'N3L;*4E
M74;=VE0[CVW39<4QDCH*F:J#"-X8Z.6-C'*`/?NO=!M_)"^<WR%_F$_&;<OR
M#[YWG\4]U19#=>(Q.T<;\78.R8$V,W]U\;FMS[*[4'8L2.=]82LS$".,:T]"
M(_TRR$W'NO=5<_S0OYF'\^_X![IWKV+!\:?A?/\`%+-_(;%],]$[OS.>RF8W
MQN&EWSEJNAZXGW1A<5V715-!5Y2GI"U7*U+3Q4[W#*HL3[KW1_OB_P#S#_EE
M\?3DL?\`SU*SXB?#W+]E5LD?Q?7KS=U;D:#?])LW;M=N/M9LYD8MP[RQV)?;
M./EH)(C53T7F^X*1B1](/NO='5S'\V?^7%M[XW[3^76?^6W6&#^.V_=R979^
MQ^R<N^X,;2[QW+@JR:@S>*VOM^LPD.[,]-B*FG<5+4M!+'"JEW8)ZO?NO=#]
MUY\QOBMVOT#4?*CKSY`=5[G^.M#BLCF<KW#2[NQ=-LC`T&(L,L=R97(3TB[;
MK,8S!:BFKUIZF%V57C#,`?=>Z`;XT_S8OY<GS#WUENLOC5\N>JNUNP,+A,CN
M.KVAAJO,8W.SX+$++)ELIAZ'<6(P\FX*;%P0M+4&@^Y,,-I'"H0Q]U[HAWP6
M_P"%`'Q3^9_RS^7OQ[AWIU]M+;_2V9K#\?\`.4V0W9E\UWYUWL39V?W7VYVH
M8Y=LT6-P&%VO#@V>&C9ON6IKM>1[JONO=&_P?\Z7^55N/<74VT\/\Y^B*C</
M=]/2U76V,FW!64$F7BKJZHQF/&8FR&-I:;9<^0KJ5XZ>+-OCI9_245E="WNO
M=#-T/_,?^"7R@[?WOT%\??E+U)VSW!UW#6U.ZMC[/W"*_(P4N,JEHLI5X>J:
M"'%;JH\75.$J9<5/6QTY(\A4$>_=>Z3/>/\`-1_EV?&KNK$_';O?Y>]-=8]T
M9@XE8MB;DW#)%78UL[(L>&7<^0I:2JPFSVR6M6B&5J:,M&RR?H8,?=>Z%+NO
MYR_$/XX[PZ\V'WK\@^M^J]S=K[6W=O?KRFWCF3BL9N?:6P\;#E]UYZCW')"=
MN04&*QU1')JGJXC.'40B1F`/NO=!;TW_`#3OY>OR$ZO[B[EZ6^5O5_8?7?Q_
MP%?NKN/-X6LRT55L';>.H*C)U.?S>W\CBJ+<BX3[2ED*5<5'+!*Z,B,SJ5'N
MO=%/_D[_`,YOJ'^:[M_N"/#R[0V9VOUUV%O?[7I["9+<&=SE+T7C,[0X'8/9
M>>S61P>)Q4U5O*>H9G@IB/MVLNBWK;W7NKKO?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=$A_P":G_\`E\W_`,Z![]U[I0_`_P#[)8ZW_P"H
MW?\`_P"_&W9[]U[HWOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJX/YP
MA"_RKOYA))``^(W>/)X`_P!^+E_Z^_=>ZT#-^UW;WQE^&/\`+5K>BL&U1'_-
MO_EKY+^7OOF?'@48I=VP?)A:G$[GC6&%CE]PQ[/WU4XL1R/&#3U3G6ND'W[K
MW5E,W1O9'6WR^_X4D="_$JDK*3L+:/\`+:Z!V1UW1;)ADHLY74&W>N]BXK<%
M)@Z?&M!4)N+.;2Q];'`D7[C5$ZA=1(!]U[I-]Y=R?RF-\_\`"<KI/H/X]KU!
MEOFG5;3Z.VMU/U)L3#X[_9K\5\Q*?<^WX]YYN?&8B"/L:CS-1F1EI)\I*_VM
M73SHD<CJ\2>_=>Z/KOKJ.F[!_P"%$O\`*/V7\GMJ83L+>>U/Y5L.>WKB]\8^
MAW)3'MW:F'[(-?G*ZDR$=11UN6QVY5J)UE9'`J%\B\@$>Z]U+^"NP]F8#^9S
M_P`*;>M-M;0VWC]C?W)V)DJ?8>-P6,7;"Y3(]6;IS=1+!MN*D.,62?.5TM0$
M6&WGD+`7]^Z]U4S#O[I7/_\`".;>6S-A[IZXR?;.Q]W;`C[JVWMBOP$F_-MS
M9?Y<5E3L[_2-CL>PSE(]?B&9L>]>OK@OXB5N/?NO=6F?S)^E^H.E,]_PF5RO
M4/6VQNM,K1_*'I';E/EME[;PVWLI)@LALCKFOK<?5Y3'4D%=D*>LKV,\IGDD
M,DTC.Q+NQ/NO=%4^?N#V)U)\\_YF.]?B9_,>^#^`W;OF7#9SYC?#3^8QU)C<
M?A=P9*+8]<F3PG4/9&]MLU68WA2Y/;^/6B@I<!X)*;^*Z8JNQII/?NO=;.?\
MCWO"'Y$?RN_BEVE1_'G;'Q=Q&5VCF,5@NHMBT-?CM@XW";=W7F\)C\_L>BRK
M2Y.#;&[8:'^(TXGEJ)&-0Q\TP(E?W7NJ3.B^R/BC\?\`^?'_`#;\E_-&SG5>
MS=^[^P/5F2^)F^?DLF#BV#D/C+3X:I3*;;ZXS6^14;;I*A!'CX:RE@:.>JFI
M*E$5BDZ>_=>Z(CUKMC"93^2)_P`*&=^]8[5K,?\`![>/R$['WI\%Z'.8>HIM
MKTVT8<]B<9GMU=58?.1-)@MNUE5/3P4TM,D*AXI$0*RR#W[KW6X-_*QP.!P/
M\N7X2+@<)AL(F4^+O1F7R28;%T.+3(Y6LZUVV:O*5R4$$"U>1JV4&6>0-+(1
M=F)]^Z]U59_PJ0('P'Z%N0+_`,P#XJVN0+VSFX"?K_0`G_6]^Z]T#?\`PH#V
M-M#LSYV_\)]]A[]P>-W-M#<OS*W%19[;V8IX:S%YF@2;IVI:@R-%4+)!64-1
M-"BRQ.K)(A*L"#;W[KW10/YT6UNR.N_YW7PBS%)W=\<?AWTBOQ+WSMGX]]M?
M)/I;;G97QKV-VG_>'<U;V#MY=LYF/';'VEOC<N+JZ(T^2J9(FA5DL;R)[]U[
MH(-AUW5GP+_E_P#\W_Y7;B[R^)7\W3I_O[L[J[`]F_'OH'K)^M.A=F=X9C<U
M5A<CN;=V)P5=D<9MO9M9_$**M-1@Z:,5%10Q24TVMDEC]U[I';&[.VAO_P#G
MJ_R2LAM7Y"_#GM6JHNN.R,1G<)\(NM8-A]0]8464ZVW?/M?KS([E.Y=TYG>F
MZ\GAD_RBER55%/CO$`*2$3WD]U[H[/P,W7\?MD?-O_A23U3F,MU-M+N/<'8W
M8]7TWL*M_NK@M_Y3:^)Z0[.GW;-UWAI(Z7,386CHI8I*\8]?$(V5Y18W]^Z]
MU4YO+H#I*C_X21_&;>E-UCL>#>^\_E5L++;CWO%MW%1[RR>2SG>N[-GY.HGW
M0M.,V7FVI3)0:?/I6DC5``JBWNO=7>=]=1]5='_\*`?Y(F`Z>Z^V;UEB7^(W
M=>W:BAV-M_%[8BK\+M_:^3H\'09%<13TG\1AH*>>18S-Y&L[7)O[]U[J@KK#
M9>_,A5_S<^F?E%_,/^"_PVW7O'Y4=U4'R&V-\Q_CAM[L;O'?6W=T2R+MG?O7
M6_=P5=+NVMVT<=4>3!4V!CE?&S(M5$J&:-F]U[JQ3NGXV;8P7S/_`.$KOQJ[
M9[$V%\P=H;;V!V[BO](J8C^([![:VKMZCQ&X>M\K%A\[59C^(XNAQ%%BT3[F
M2<3O2AV%FT^_=>ZL<^/G7>P=F_\`"G+Y[;+V?LK:FW=J[O\`Y=/5&5W+M'";
M?Q-!MW/92ORFSZ:NJ<C@*6DCQM9-700QK,&B(EOZP=1O[KW4+_A*[OCHP_%S
MY"=6X;<764?R`V[\N_DIFMV;%QM1MRG[3Q'7-3O3%4FWZ_-X:G$6Y*?:#9)7
MBI&E7[19052S<>_=>ZVH/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=$A_YJ?_Y?-_\`.@>_=>Z1WPS[QZ7V=\<MB[;W9VSUSMK<.,K]]QY+
M!YW>.!Q66Q\DW8&Z*B*.MQ];70U5-(\$JN`Z@E6!'!]^Z]T:'_9E_CK_`,_U
MZC_]&#M?_P"N?OW7NO?[,O\`'7_G^O4?_HP=K_\`US]^Z]U[_9E_CK_S_7J/
M_P!&#M?_`.N?OW7NO?[,O\=?^?Z]1_\`HP=K_P#US]^Z]U[_`&9?XZ_\_P!>
MH_\`T8.U_P#ZY^_=>Z]_LR_QU_Y_KU'_`.C!VO\`_7/W[KW7O]F7^.O_`#_7
MJ/\`]&#M?_ZY^_=>Z]_LR_QU_P"?Z]1_^C!VO_\`7/W[KW7O]F7^.O\`S_7J
M/_T8.U__`*Y^_=>Z]_LR_P`=?^?Z]1_^C!VO_P#7/W[KW7O]F7^.O_/]>H__
M`$8.U_\`ZY^_=>Z]_LR_QU_Y_KU'_P"C!VO_`/7/W[KW7O\`9E_CK_S_`%ZC
M_P#1@[7_`/KG[]U[KW^S+_'7_G^O4?\`Z,':_P#]<_?NO=>_V9?XZ_\`/]>H
M_P#T8.U__KG[]U[KW^S+_'7_`)_KU'_Z,':__P!<_?NO=>_V9?XZ_P#/]>H_
M_1@[7_\`KG[]U[KW^S+_`!U_Y_KU'_Z,':__`-<_?NO=>_V9?XZ_\_UZC_\`
M1@[7_P#KG[]U[KW^S+_'7_G^O4?_`*,':_\`]<_?NO=>_P!F7^.O_/\`7J/_
M`-&#M?\`^N?OW7NO?[,O\=?^?Z]1_P#HP=K_`/US]^Z]U[_9E_CK_P`_UZC_
M`/1@[7_^N?OW7NO?[,O\=?\`G^O4?_HP=K__`%S]^Z]U[_9E_CK_`,_UZC_]
M&#M?_P"N?OW7NO?[,O\`'7_G^O4?_HP=K_\`US]^Z]U[_9E_CK_S_7J/_P!&
M#M?_`.N?OW7NO?[,O\=?^?Z]1_\`HP=K_P#US]^Z]TFMX]R_$GL/:FXMB;\[
M1Z(WCLO=V'KMO[IVKN3=^S,Q@-PX/*0/2Y'$9C%5U=-1Y#'5U-(R2PRHR.A(
M((]^Z]T$M3B/Y;-9@.H-J5='\0:G;/Q^RU'G>C,!..KY,1U%FJ!D>BRO75`Q
M-/M&OIGB5DEHEA<,H-[@>_=>Z6.!W;\%MK=F;S[HVUN?XT8#MSL;&8C#;^[+
MQ&:Z_P`?O?>>)P*HF%QVYMR4U1'E<U1XI(U$$=1*ZQ!0%`M[]U[H.=O[+_E?
M;3[;K._-K[:^%FWN[:^:HJ:SM?#8SJ/';_GJJI(HZJK;=%+%%EA5U$<*AY1*
M)&`Y/OW7NA"R.Z/@EENVL!WWE-R?&?(=V[5VU6[-VUVS69G8%1V%@=J9)ZIZ
M_;F)W9)4MF:##5CUTQEIXYEB<RO<'4;^Z]U[:VY_@CL???87:.S=Q_&7:_8_
M;3X]^T-]8+,=?XS=?8+XF`TV,;>&<I*B+(;@-!3G1%]R\FA.!8>_=>Z!JGZ=
M_E+TFW.R]H4G7OP9I-J=RY/$9KMC;=)@^H*;!]C9;`9.;-8/(;RQ<$,=%N"J
MQ&7J9*FF:I20PSN72S&_OW7NA:WAF/@)V"_6$F^LS\7MWOTIF*#</4#;CR?7
MF7;K+.XNEIZ'&Y?8QK9YCMG(T-'211134GB>..-5!``]^Z]T@NY=A_RN/D3N
M7%[S[YVO\*^XMW86G2DQ6Y^R,;U)O#/4-+'+%/'2P97-QUE:M/%+"K*A<JI'
M`'OW7NC&XWY"_&/#8^AQ&'[EZ5Q.)QE+!0XW%XS>VSZ#'8^AI8UAIJ.AHJ6O
MBIJ2DIXD"I'&JHB@``#W[KW0)]X4'\N#Y,4V%H_D/#\1>[J;;=0]5M^/M+_1
M?O?^"SR+(DDF+?<!KGHC(LK!A&5!OR/?NO=*[<6\/@QNWJVMZ/W-N?XSYSIK
M)8&+:]?U5DLOU[4]?5>VX&B>'`S;2>?^!OB(7@0K3^'Q`H"!Q[]U[I7;8[P^
M*6RMN8+9^T.V>CML;4VOB*#`[<VY@MY[/QF%P6$Q5-'1XW$XK'4E?%2T./H*
M2%8XHHU5(T4```>_=>Z2':N\/@SWGM_'[3[FW5\:^T]L8G<6(W?B\!O[.;"W
M3B,?NG;\KSX/<-'09>JJJ:GS.(FD9J>H51+"S$J1?W[KW6#?>Y_@AVCN7KC>
M78^X_C+OK=G3V<EW-U3N3=>8Z_SF;ZYW#.M*LV;V9DLA4SU>W<I*M#"&GI6C
MD/B2Y](M[KW7'N+<?P,^0NT6V#WOGOC!W%LEJVGR7]U>R\GUUO/`KD:1M5+7
MQXW/35U+%60$G3*JAP"1>Q/OW7NFG;$G\O#9/55?T7M"3XD[9Z7RN.J\3E>J
ML&>KL;U_E<;7:OO:/)[4I1'A<A!5:SK$T+ZOS[]U[I$;0ZY_E7]?1==0[$VC
M\*-FQ]1[IRF]^KQMC&=2X-M@[QS<:0YC=&U),;'3287/9."-8YZJ`I-)&H4L
M5`'OW7NGW*8#^6EF^V:WOK+XWX>9+NS)X3([;R7;%9%U;/V#D,!E\-/MW*XB
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M<_V!TW'6Q=3;SRV1ZZK=R=;19&".EKHMD9>:9JS;,5731+'(M(T09%`/`]^Z
M]U.H=W?!C&=KYOO;';I^-5#W3N7;-!LS</:U+F]@P;_S6TL7)'-C=MY3=4=2
MN8K<+0RPHT5-)*T2%00`0/?NO=)?K^F_ES=4=C;U[>ZP7XD=>]I]D1RQ;_[#
MV8_6.V]X;SCGK4R4Z;DS^(:DR.76?(QB=Q-(^N8:S=N??NO=#K_LR_QU_P"?
MZ]1_^C!VO_\`7/W[KW7O]F7^.O\`S_7J/_T8.U__`*Y^_=>Z]_LR_P`=?^?Z
M]1_^C!VO_P#7/W[KW7O]F7^.O_/]>H__`$8.U_\`ZY^_=>Z]_LR_QU_Y_KU'
M_P"C!VO_`/7/W[KW7O\`9E_CK_S_`%ZC_P#1@[7_`/KG[]U[KW^S+_'7_G^O
M4?\`Z,':_P#]<_?NO=>_V9?XZ_\`/]>H_P#T8.U__KG[]U[KW^S+_'7_`)_K
MU'_Z,':__P!<_?NO=>_V9?XZ_P#/]>H__1@[7_\`KG[]U[KW^S+_`!U_Y_KU
M'_Z,':__`-<_?NO=>_V9?XZ_\_UZC_\`1@[7_P#KG[]U[KW^S+_'7_G^O4?_
M`*,':_\`]<_?NO=>_P!F7^.O_/\`7J/_`-&#M?\`^N?OW7NO?[,O\=?^?Z]1
M_P#HP=K_`/US]^Z]U[_9E_CK_P`_UZC_`/1@[7_^N?OW7NO?[,O\=?\`G^O4
M?_HP=K__`%S]^Z]U[_9E_CK_`,_UZC_]&#M?_P"N?OW7NO?[,O\`'7_G^O4?
M_HP=K_\`US]^Z]T4#_39TY_I#_B'^E3KS[#_`&<C^]/WO]\<!]K_`':_V5W^
AZ_\`>#S_`'_B_@O]Y/\`<?\`=7\'WG[.KR>GW[KW7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pg24a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg24a.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"]`3,#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_"BBB@`K
MP+]HO]H/P[^SCX(TSQ;K/A'X@_$;6_$_BW1?`'P_^&GPI\/0>)?B!\0/'7B"
M.\GTSP]H-IJ&I:)H.GK]BT_4=3U37O%.O:!X:T32=.O;_5M8LX8U$WOF1S[=
M<]1^'].H.00""*^*/V]OV@OCA^SI\"?^$I_9U^!'C+X]_%?Q5XR\._#_`$#3
M/"_@_P`0>/-(^&]MXB-W_:_QB\?^$/"5U9^+/%7@KX=Z?:W.KWGA#PO?:7K?
MC;5CI/A"TU[PP-:E\4:.`>8S?\%*_`9^$\OC?3/V?_VDM7^*=E^T%IG[,&N?
MLM0>&/`5A\?-"^,6I^%D\>QZ1?6>L_$73OAS=Z$OP]>/QW'XOTCXAZEX9O\`
MPM,+S3]1N9X;JUAZ;Q=^WH/`_@/X6:IXA_94_:BB^-WQKUWQKHWPY_90L=%^
M%.J?'/6;+X>P)J/B_P`6WUS8_%>7X2>'O!VB:3<Z9J%UKNO?$^QC$NO>'])2
M,ZWJ]GITGYPS?";X+>)OV7O!%]\5OV#/VQ?VPM!;]J'Q'\1_VH]6^,/@/Q+\
M+OVA_$?Q8\4?"N[\+:C^T7I?[.>F7&E6WQ7^'#V&HZ?\+;#X;^&-7M+#X?>`
MX;*WT+0O%@\)W@NJ'P5^&OQP_98U+]F3]IN?]F[]I#5O@#\-O$7[=W@+P)^S
M=H7F_%C]H;]GK]G/]I75/V?/%7P/L[_P+)X@U37=4T[0-?\`@-KMD_@33/$&
MMZ[\(_"WQ,\.^%Y1+I_@_5HK0`_1/Q'_`,%*_A0O@KX+>)?A%\)?VA/VC/%O
MQR\)>/?'WASX.?!WP)H\OQ7\+^#?A+KFD^%/BSJ_Q&T7QUXJ\%:-X-O/A[XV
MURP^'^I^'=2U\^(];\=2S^&?"6E^(+^UO!;U?B)_P4_^!OA?0?ASXC^&/P_^
M.O[36F>/?@=8?M/:J?@!X$L/$5U\-_V<[^XELK;XJ>/K3Q9XC\'7%JEY?:?X
MAT_2O`&@+X@^*>N7W@_QC9Z1X*NKKPUJ4:?"?P:\&?'W]C+QY\(OVM?'W[,O
MQS^(MA\6O@Y^U3X8^('PA^!>B:)\2?B;\#?&GQD_:ZU']J/X4^'/$'A.P\06
MEAJ8UOPWXQUCP3XV\5:#JTOAWP?XW\-:?%K=]_PCNIQ>(++!^"OP[_:5_P""
M>>E6&L^(_P!E_P"+/Q^USX\_L$_!KX/2^&?@%;:+XYL_AC^TG\,/B3^TYX^_
MX5=XS-SJ6DV'AGP!XCA_:@L]'B^+C7,G@;3+GX=^(YM<GLK2YT&6^`/T/^,/
M_!3KX$_"O4U?0O!OQB^-_@3P]\*/`GQ[^,GQ>^"OA/2?%/PU^`?P-^)MOJ>H
M>!/BC\2=5U7Q)H&IWNAZYX=T+Q#XS?2?AYI'CCQ7H_@70[_Q?K6@:?H4FG7=
M[^C%O<6]U##=6MQ#=6MS#%<6US;2)/;W%O/&)8)X)XBT<T,\+))%)&6CD5@\
M3$,<_P`V$7P"_:2_8[^#/[0W[+UC^S[\3OVA/$W[7'["7[-'[/?PO\>?"G3[
M#Q'\*/#/QO\`A]^R]??LN>/_``_\8-9U?4=*N/A1\.=#O(?#?Q)TSQAK%G=Z
M-X@\(:KXFT[3P/%7A\:-K']#WPT\(O\`#_X=?#_P$^H?VJ_@CP1X3\(MJ9C:
M/^TF\-:!IVBR7YB>25T^VFQ\\HTCLOF%3)(06H`[?(]?\^OT/8]#D8ZBC(]1
M^8KPO5_#NK6WCWPAH4/Q!^(,>G:YHWCC4;Z$:QIK.;C1IO"PT\0R-HI:&.`:
MM>#RU)60,@E,@C3'8_\`"`7'_10/B1_X/M-_KHM`'H>1ZC\Q1D>H_,5YY_P@
M%Q_T4#XD?^#[3?\`Y2T?\(!<?]%`^)'_`(/M-_\`E+0!Z'D>H_,49'J/S%>>
M?\(!<?\`10/B1_X/M-_^4M'_``@%Q_T4#XD?^#[3?_E+0!Z'D>H_,49'J/S%
M>>?\(!<?]%`^)'_@^TW_`.4M'_"`7'_10/B1_P"#[3?_`)2T`>AY'J/S%&1Z
MC\Q7GG_"`7'_`$4#XD?^#[3?_E+1_P`(!<?]%`^)'_@^TW_Y2T`>AY'J/S%&
M1ZC\Q7GG_"`7'_10/B1_X/M-_P#E+1_P@%Q_T4#XD?\`@^TW_P"4M`'H>1ZC
M\Q1D>H_,5YY_P@%Q_P!%`^)'_@^TW_Y2T?\`"`7'_10/B1_X/M-_^4M`'H>1
MZC\Q1D>H_,5YY_P@%Q_T4#XD?^#[3?\`Y2T?\(!<?]%`^)'_`(/M-_\`E+0!
MZ'D>H_,49'J/S%>>?\(!<?\`10/B1_X/M-_^4M'_``@%Q_T4#XD?^#[3?_E+
M0!Z'D>H_,49'J/S%>>?\(!<?]%`^)'_@^TW_`.4M'_"`7'_10/B1_P"#[3?_
M`)2T`>AY'J/S%&1ZC\Q7GG_"`7'_`$4#XD?^#[3?_E+1_P`(!<?]%`^)'_@^
MTW_Y2T`>AY'J/S%&1ZC\Q7GG_"`7'_10/B1_X/M-_P#E+1_P@%Q_T4#XD?\`
M@^TW_P"4M`'H>1ZC\Q1D>H_,5YY_P@%Q_P!%`^)'_@^TW_Y2T?\`"`7'_10/
MB1_X/M-_^4M`'H>X>H_/UI:XO2_!\VFW]M?-XQ\;ZF+=G8V.JZO8W.GW&^-D
M"W,$.EV\DBH6WH%E3$BHQW`%3V8&,],<=!@],<G)SV`[@#!)ZT`+1110`5X7
M^TI\7]4^!'P8\8?$W0?"_AWQMXCT4:/8>&/"?B[XI^#O@IX8\0>)_$FN:=X;
M\/Z5KGQ1\=LWA[P?I][JVJVEO-J+V.MZI*9%LM!\.^(-;NK#1[SW2OS6_P""
MN?P5^)GQ]_8*^+G@/X0:5X4UOQ[I_B+X-_$O3-*\<^-=+^'/A*\L?@Y\9_`7
MQ6U^+7O'6MQ3Z3X5T_\`L'P?J)GUN_AEMM/4?:9(Y%C*,`?->I^-_P#@MAX(
MOXOB)XZ^*7_!'6#PVWBCPSX1N/@+?ZU^T1X%@'BSQ/?Z3INC?#73_P!IC6;G
M5WC\>Z]+?VEKX;GO?@-,VM:[JMC9VG@LV]Q:*?V%^&^O^+_%'@3PGXA\>^`[
MGX7>-M6T6SN_%?P\N?$>C>+W\(:\R;=1T1/%7AYO[&\16UK<(_V'6K&.WCU*
MR%O=/96,\DEG!_(AI'AS]NKXN?&G4/@SXL_9V_8R\`7?[9W_``4:_9:_X*=6
M*Z#_`,%*?A!\2/B-I/P7^#U]\!+C6=1^'_PGT_X<:!XB^-WAR^\-?!:ZU^P^
M(?AVYT/2W363:PZ7<16"7T_]DW!8D<G<<>N"2>/KR1]3B@`(/4$YZ9R<X^O7
MWQG';C)R8YSDYYY[\^_7IQ[#IC)I<'.,<^G?\J.^._IW_*@!,$=^V#R1GKG.
M/7))]#SS0`0#@D9],@=`.F>?NCKDXXSBE'/3GZ<T#GISCKCG%`#<'UQTZ?[/
MW<GJ<'GGJ>>#G*@8^IZGKW)ZGKU.3U)))Y-*.<XYQUQSCZT4`>:Z[_R57X<?
M]BO\3/\`T=X#KTJO-==_Y*K\./\`L5_B9_Z.\!UZ50`4444`%%%&1ZT`%%%%
M`!1110`44AZ?X<G\*\+^-?QXTCX&Q>#YM;\"?$[QE%XV\3:=X/TI_AUX<L/$
M(MO$FLWUKI^A:;JPO-;TAK)M9NKKRK*X"S6J+#.UY-;)&C2`'NM%96AZD^LZ
M/IFKR:9JNBOJ=C;7KZ1KEO%:ZSIK7$2RFRU2V@N+N"WO[?=Y5S%%=7$:2J52
M5U`8ZM`!1110`44?0$_0$_R!H_SSQ0`4444`%%&1ZC_)Q_/CZT4`%%%%`!11
M10`4444`%%%%`!7PA_P4T_9H\=?M@?L-_'S]GGX;76@)XT\>:%X?ET;1_%VI
MZAHO@_QN?"?C/PYXTO?AKXPUG2;:\U+2?"OQ+T_P]=>!=>U*TM+I['3M?GN7
MM;F&*2WD^[Z\K^-=K\:KSX:>)(?V=];^&>@?&$+IL_@Z_P#C%X>\2^)OAO+/
M;:K97&I:9XHTSP?KWASQ,EGJ^CQW^FPZGI&I?:M(N[FWU-;+4EM6L+@`_E<\
M.?L'?&3Q3^U%\))/B%\#_P!G3P'^W?\`&[]M#X6?M^^/[OPO\2O!OB?Q-_P3
MI_X)]_LEZE\/?A=\'O@)\.=<M/#'AG7OB%8_$/3-#U_X5RQ?#?2/#OPUCO-;
M\27.N:;';6&G1G^F7]JCX?ZY\1_A;/I%K^T1KW[,7@K2=:MO%OQA^)/A2XT_
MP_XH?X1^&+34M6\8^']'^)&I:KIL/P@348K>UNM<^)L$=[J'A[P]8ZK%8KIE
MS>1ZSIOY:_"#XH_'ZY_;VU+XC_%K]BOX>?$SX_?#_P"'O@7]B[XU_&?]BG]K
M_3?B3X/^$W@7QQXQ?XSZ+>_$_P#9W^.G@_X$^-O`D<DE]HOCFXE\,ZK\7]7M
MO".J26\&L:K=67]F3?HQ^VU^QMX6_;C^$FC_``;\:_$GXE_#GPQI7Q'\&_$B
M^?X;2>"I1XMO?`=[+JN@^&/'&A_$+P?XY\*>+O`_]OKIOB#4/"NMZ#>:5JNI
M:)I7]I0W5K!);3`'Y(_"CQO\;OBMI?P!_9UTO]H/]IBT_9J_:D_:[^.LWP*_
M:`UGQ#>Z/^TEXY_8T^#_`.SM9_$'2;*V^*=WING^-M-T#XE_&"'7I_`'Q%U.
MWM/B9KOP<T_3;A=3-KKUGJ(Z#P3XF^-WQO\`B?\`![]@'Q;^TE\=M)\&^$_B
MG_P4+T7QG\:?`/C!O!OQY^*G@?\`9,UO]GO1O@[X8\2_%S0K.TU;3=8CM_VD
MK2;QUKWAZ+3]<\:7GPWMSJMPJZMKOVG]#M6_8)G\6?#/1?!_Q`_:R_:@\=?$
MKP+\46^+?PB_:-U/5?A-HOQE^$7B23PW<^$9].\*2>$?A3X?\`ZKX5U'P_JG
MB#3-:\-^-?!'B?3=9M/$%_%J,-P8=,;3\S4O^";'PO3X:?"WPIX'^+7QZ^&/
MQ6^$7BKXB>//#?[3_A'Q;X=N?CMK'C;XRS27'QIU_P`<7WBKPGXB\!^,T^*U
MT\%WXGT/7/`MQH%I<Z1X;E\.:;H@\-Z*EB`?`/P8\5?'/]L[Q]\'_P!DGXB_
MM+_'OP'I/PC^#'[5OB7Q[\6?@;XJL_A=\3?CGXT^#W[7NH?LN?";Q+XC\::'
MHYCLV\.^%_!FL>,O%_AC1["/P[XQ\;^)K&Z\1:?<:#IT.AW?/_!3QY^T?_P4
M.TG3]%\6?M0?&'X%ZW\!/V`_@U\7O^$G^`6J6/PZL_B7^TK\3_B3^T[\/S\6
M_&:PVEW9>+/!/AV#]EZPU:#X27<3?#S4;GX@>(X=;T^^M8-%BL/T=\2_\$U/
MA4_@GX+>&OA#\6?V@?V<_%OP-\(^/?`'ASXQ_"#QWI4?Q6\3^"_BUK6D>*OB
MUI'Q$UOQQX9\9:1XSO?B'XVT/3_B!J7B74M"_P"$ET3Q[')XI\)ZIH&H7E\;
MBI\1?^"8/P/\4Z!\./#?PQ\??'']F;3?`?P0L/V8=6_X4#X[L_#MW\2OV<=/
MN9;VW^%/CV\\3Z#XLN+D6E]?^(+_`$CXA:!)H7Q2T*_\8^-+W2?&MK<^)M2D
ME`/S%C^.O[1G[9/P8_:(_:BA_:#^*OP!\5?LD?L&?LS?M`_"KP7\*-<C\)?"
MG7/CC\0/V7=0_:C\?^*?BYH-S;7J_%WX>Z_?3^&?AS8^#?$UP?#^@>$-(\27
MNF11^)_$+ZUIG]$OPT\7-\0?AU\/_'CV!TE_&_@CPGXNDTPNTITZ3Q/H-AK;
MV)D=8WD-HU[]EW/&A<QAF2,DJ?AGXP_\$Q?@7\5=40:'XP^+WP0\!^(?A5X%
M^`OQF^$7P5\5Z7X7^&WQ]^!?PSM]3T[P)\+/B1I&I>']<U"QT30O#^N:_P"#
M7U?X?ZIX*\5:QX$US4/!FM:_J&@IIUG8?HO;VT%K!#:VL$-K;6T,=O;6UO%'
M#;V]O#&L,-O!!&JQ1010HD<<2*J(BA%4*H)`/S^\=?%?XN67[5OP:T32]2\)
M+\.O$'AWXRZD=/U+]GKXO7?CVPT3P;-\'_[=TVU\0V?Q2T_0=2U+Q"^O2C3M
M?_X0I=.T&*U@\_1M=>Y=H?K[_A:.A]M#\?\`?K\/O%A/7N?[-&3ZD\D\GK7R
MM\3/`_C6?]N']FO78/C+XSL=$E\"?M$ZC%X+@\/_``YFT6WT^PN/@"FH^'TU
M.[\'3^)GL-<=1+>7<NLR:K:ON&E7NG!L5]YDGDY;N<!F^N`,_@*`/(-9^-_@
M7PW8OJGB5]?\-:5')'%+JWB7PSJWA[2HI9FV0Q2ZGK4-C8QRS/\`)#$]PLDK
M_+&K-Q4>B?';X?>)H+BZ\+W>K^*;2TN6LKN[\+:#J/B6TM+U$21[*[NM"34+
M>VO$CDCD>TGECN%CDCD:,(Z,WHWB#P_X?\4Z9-I'B;0]%\2Z5*1/)I6OZ98Z
MSILL]N&E@E>RU*"YM7DA?:T4C1,T9W%<8&WYT_8@\-^&_#/[(?[,</AKP_H?
MAV'4OV?/@GJ>H0Z!I.GZ-!?:C/\`##PJLU_=QZ;;VR7-Y*B1H]Q,K2LD:*6*
MJH`!Z]_PM+1/^@'X^_\`#?>+/_E;7R!XS\2Z@G[6'P;%A\0_VD=/\(^*_"/Q
MD\9Z_P"`+;1]1B\*WNI_#F^^#$'A^SATF;P9+JJ:$8/$_B`:M9VNIHM]+?C[
M1<+Y,`B_0GG^\W_?3?XU\&_$7X0:#=?MR?LZ>,W\3_%&/4;CX>?M$>(#I=M\
M5/'=KX4CN]#U7]G>&WLH?"4.MKH$6BWB.S:KHL=BNFZK)A]0MKEN:`/JC_A:
M6A_]`/Q]_P"&^\6?_*VC_A:6B?\`0#\??^&^\6?_`"MKTKGU;_OIO\:\E^-?
MQ:L_@IX%N?'=_P"%?&'C.VMM2T[3FT/P3:V%]KTC:C*\:W,=OJ>I:7:M;6VP
MO<L;M752NQ'.10!H?\+2T3_H!^/O_#?>+/\`Y6T?\+2T3_H!^/O_``WWBS_Y
M6UYM^RU^TSX<_:N^%]A\6?"7@SX@^"/#VK)I-QI-A\1K#2=*UO4-/UOP]I'B
M33M1AMM%UO7;06TEEK$$#9O2ZW<-S&H>-$DD^D@3ZMQQ]YOTY_\`U'(H`\V_
MX6EHG_0#\??^&^\6?_*VOBS]M+]I'X9>"-,^`:>+(_B/I37G[2_P5U2T$'P:
M^+6O">TT3QC9R:DP?POX-UR.&XB6YM_L]C<M#?ZDSE-+M;YXY5B_1QB0"=S?
MBS8_'YACZY!'4'-?+O[4K,-)^!@#.I/[4WP!5\$@%3XTA!4@'A<C:5(Q@#)/
M8N!Z1H_QG\)Z]I6FZ[I.D_$.XTO6+&VU+3KB;X9>.;"6:SNXEFMY9+'4]$LM
M1LY'C=2UM?6EM=0G]W-!&ZE1H_\`"TM$_P"@'X^_\-]XL_\`E;7I.XY(+-P2
M,[B!D<'H>F1CKUZX)`HW#^^?^^V_QHW`\V_X6EHG_0#\??\`AOO%G_RMH_X6
MEHG_`$`_'W_AOO%G_P`K:](+'CEN?5FY],<GKS[\8QDBEW?[1'L7.1]>:`/S
ME_;)3X=_$:#X"S:_X=^)KS0_M#_"OPM(]C:_%GP;]I\.^+M<:'7]'NAX8O\`
M0DU6SU6/3[>.YM+X7BF.+:L.QI*^O=$\<^$O#NC:7H&C^&_B#:Z3HUA:Z9IM
MM)X'\;7LD%E9PI!;Q/=W]I<WMRR1HJM/=W$]Q(06EED<EC\]_MLZ?\5;^V_9
MX_X5OXH^'N@11_M,_"%-03QS\/O%7CJ274)->8Z5?6#^'?BA\/%LK3352\?4
M;&[BU`ZH)H!#J&D?9G>X^SM&&L0Z1ID?B*]TV_UY+&V36;[1+"\T?1[O4EB0
M7MQIFE7VJZW>Z;8S3[WMK*[UC4Y[:$K%+?7+J96`.)_X6EHG_0#\??\`AOO%
MG_RMH_X6CHA_Y@?C[_PWWBOOQ_T#>?3MC.>H%>D!\G&6YZ$,Q'?OGU!_+/2E
MR3T+?]]'V/<G&0<@]N_<4`?FOXG^.C6?[7_PW\%VG[27C;3_``QXF\/?$3Q1
MK7P7?PK\-1?KKG@O5OA18:#X,MK:[\(-\1H+;7K3Q?K4UUI_VR37KZ5K9M+N
MX(X,)]O_`/"T=#[:'X^QV_XM]XL_^5M>!^,O`W@=_P!M+X&Z[+X+\(2:[+\&
M?V@M8EUU_"^AR:V^K6'BS]GV.RU0ZLU@=1_M"SBS':W@NA<0(72*1%=]WV,,
M]V;/LS?XC^0H`\U_X6EHG_0#\??^&^\6?_*VL_5OBCI7]E:F;:U\;:-<#3KX
MP:Q=_#GQ--::3,+67R]3NX;FTMK>6UT]\7=Q%<7-O!)#"Z33PQ%Y%]:Y_O-_
MWTW^-0W$,5S!+;7,<=Q;7,4D%Q;W"+/;SP3(T<L,\,H>.6*6-F22.16C="5<
M%6(H_K[P/S@_9._:&\7^,O%7QTL?'?QWT+XWZ?\`#SXBW'PZ\.:;\.O@]9:+
MJ'V.P\$_#7Q?)XQUA_"OBOQA/)!>WGC?4-`BC,%GI<J:="\3)>1W22_;8^*.
MA@#&A^/\8XS\/O%A./<_V:,GWP/H*^?/V4O!G@_PUXU_;`F\->$_"_AV9?VG
MM2TQ9=`\/:1HLG]GI\#?@+<I8M)IEG;,UH+EVN#"Q,9G8S%3+\Y^S>?5O^^F
M_P`:`.$TKQ]I6KZA:Z;;Z3XPMYKEF6.;4O!OB'3+&,I&SGS[Z^LHK6W#*FQ6
MED7>^U!N<JI[H9Y!Z@^N?<<]^"*7GU//7DG/USG/IZXXZ<4@&!B@!:***`"O
M(_CQ\3O!?P;^$?CCXC_$4^,8O`GAS1I9/%M]X"\,^+/%WB?1]!OG33=1UVRT
M3P+I^J>+9(-$M[MM4U"_T/3[J[T:PM;C5_+$5C)(GKE>=_%OXM?#?X#_``T\
M;?&3XP>,M%^'WPP^&_A[4/%?C?QIXAN3::/X>T'2XO-NKZ[D5))93DQP6UG;
M137E_=S065E;W%U<0P2`'\N?[#/AO_@D5^Q/^T+^T+^VU#_P6'\!_$+P1\1-
M>\$>(?A-X6\0_P#!0GQ1X\\0'1;/X6P_#;7K?XZ_#[7?B/J>K_&SQJ?$$VH7
M/@B7Q!X5U77?!>DG3=)TNWL?L""OZF/AO\0=!^*G@/PG\1_"]OXAMO#?C71;
M3Q#H,?BOPOKW@OQ"VDZ@K36%QJ?A;Q18:5XAT2:[MO+NHK#6-,L+^.WEB>>U
MA9Q&/QE^%7[?O_!%GXB?M._#'Q)\)/`'PRUCXT?&'7M&\-:5^U3H7['MYI&E
MZ!\7_%EM>P>'?@K\3/VC;OX:Z9-\/?CMXCM-'-M8_#CQAX@TWQ5(DFC6EU:P
M/JVD6]Y^T7COQ[X(^%_A'Q!\0/B5XO\`#/@+P-X5TZ?5_$_C#QCK>G>'?#>@
MZ;:KNGOM6UK5KFUL+*UC&5WW$\89F$<>7<J0#L**^%[[_@H9^S[_`,,P?!C]
MK7PE;?%7XH?#']H;5O"NB_!?1_AE\,?$GBGXE_$&]\9MJ\F@KHOP]2*TUY4G
MT_0]3UBZ>^AM3I^D6LE]>K;J-B,\3_\`!0'X6^"_AK\.O'?BCX5_M.:3XM^+
MGB/Q/X7^&O[/<WP%\7S_`+2?C&_\&6=SJOBF_P!*^$5F+G68_#^B:':OKVHZ
M_?3V>CVFES6,DMVESJ-A;7(!]UT5\#^-?^"D?[-/A7X?_!CX@^'6^*OQB7X^
M^&?%7C?X:>!O@?\`"'QU\2OBCJ/@CX?/IEO\2_%NK_#W1]*7Q%X9TGX:ZGK>
MD>'O&T?B"TT_5-(\5ZE:>%5TV[\1RKIE0?%;_@I=^RQ\*]&^'7B&'6/B%\6]
M(^)/PE3]H2RO/@+\+O&GQ>/A;]G;=9I/\>?']KX3TN[O/!WPRMWO-G]J:K;I
MJEW/8:Y:Z7HVHW'A[78[$`^_Z0DCH,_YZ?C_`#P.^1\&_&G_`(*0_LO_``,\
M1Z7H/B/6O&_B[3SX%\'?%;QWXY^%'P[\4?$WX<_!3X1?$*^OK#P)\6/C7XV\
M*6=_HGP_\`^+Y-(UZ]T36;^>X:?0?#FO^)YK:#PUI5YJT7W>"&`96W*<%60[
MU92H92K#AE93E3R.3C<#NH`_,WXM_M<?`+P]_P`%#_V;_@MK/CJVL?'6G_#W
MXU:%J-K-:7"Z=IOB+XBWGPC;P5X?U#4V"P6^I>((/"VN7%H-KVZ1VL0NI[9K
MJ`-]>^+OVG?@'X':6+Q#\5?"$5U%D-8Z;J4>MWP9<`H;71Q?2JX;*LCJK9(7
M@@D_EC^U]_P2W_9O_:._:QTAO'\GC*UU3]HSPG\3?%/BGQ'X;UQ]*U_P[/\`
M"BT^%6B:-!X6NFCNK6R-W;>*+B2:[N+*YEMI[.T>S6)FG:3P;P_8_MB?\$@;
MAV^*OPCLO^"@O[%^G2&=/VA?ACX#T>S_`&Q/@?H$<@>XN?B?X1,5ROQ6T32K
M,M)<:]HNK6E^T-N]]=7%@QCT=OSC,:OBIFZIX?A3#<,\-U,/6Q6$Q^,XYRZI
MF"QJAB\3+"YMPUEW"G&>*^O8.O@ZN&P\L)Q!F/"N8TZV#EBOJM59C]4RSZRE
M/@+*90K9]/B#.L/5P]"O3I\+XNGA'A*LJ%)8C!9SBL\X<A+"U:=>-6K'$Y3E
M^?X*5.NJ,\12>$^L8W](/C1^VQ=3>!;J\^`_A3XBW6H)J.G0OXVUCX<7I\'0
MV,CR+<6\<M^PGFO;Q5$=H/L/E*-TAD3`SPW[)7Q_^,'AWX)^$_#9^!7C/XD^
M#/!.F:-X'\#^(O!4&FVDEOX2\)^'=%TG2].U"'4;L2ZW=6]G;P2QZW:Q01:A
M#*I)N)XY9W^IOA3^VW^S?\?/@K%\>O@-X\E^-7P_:6SLKL?"O0=;\:>+-#U'
M4(_ETWQ#X'T:RF\4Z!J%H23=VNJ:9:O!''Y^3;LLS>-?L[_M5_`_X4_\$^/@
MC\9/C!XJN?@U\-OAU\!/@UHVO^)OBSH.L^`K>XO+7X6>&)HU\.6NOV5I>^*?
M[07<FD+X>M]0EU::*6+3TN)(7"?FW_$'?&3$<<1XNQOTC.(L-!9.\IGPEP_P
M3E.7\,_6?;.HL=2R;/<UXIP<*_O<DJE;"XC-I)1A'.*=).C+[5>(_AM2X6>1
MX3P@R7$Q_M#^T(<0YQQ1CL;F_P!7]E&$J%3-,IP&0XF5-.+G&-+$T<N3;<\N
MJ5/WIZRO[74%HP3Q!\`/VCM$<D*S+\.5U:V4\AMT^G:H[<8&-L1W9..F#^3'
MQB_X+#_!#P?^VY\-8O$TFD^'OA[\-].\=>!O$_CO6;G48(?!EA\1]:^&0\0O
MXUTZSM+VXTS7=`/@F6<6D6^WT^!Y(M7"S3Q/;]$_Q7_;I_X*Y/)I?[.K^./V
M!/\`@GY?!K?5/VBO$NFS:?\`M2_M(:#<,5GC^"GAB5K8_"KPCJUH/LUOXUU*
M[FU5[:<ZE9-<R>;X?@]V\+?\$S/V&_@;\;/V6OA9X2_9W\`:UX<L?A7^T#J^
MI7GQ`TBW\=:_XM\1>&-;^!TFD^)O&>J>(8[QO$FM03^(M?F$^H0O:Q-K%_%;
M6D$,XB'Z)E_`7&\<73_UJ\8L[Q^`PU'%5,/@N'N$^&\AS2IF,\-4H8&IFV;*
M>-P=?+\).L\94RO#9/AZF+Q5#"_6,7'"0Q&"Q?Q=7C#ABO1K/(?#C+\)5K*G
M3>.S?/\`.LTR_P!BJM.I6679;)87%PK5HT_81S#$9E4A3H5*_P!6P]2M4I8O
M#?I!\)_VD_V?OCOI<.L_!?XU_"_XGZ=.$99O!GC;P_KLJAP-@FM+*^DO+=VS
M]RXMXG7[NTG)'L=Y=0V,$L]W<PV<*HP-Q<SQVT2L581@RRM&@)8C&6!W$8QR
M#^0OQH_X(6?\$Y_BUJLOBGPQ\)-4_9T\>M*]S!XX_9K\4ZI\)M5M;PR&1+J/
M1]'>7PKOC=R_R:#$,MM.0./S<_:E_P""?O\`P4*_9!^%6I>(?@U^VIX__:Y^
M#UCK&B0S_`/XJ?"KQ+XT^)B&ZOEL;"[\-:KX&U/4[/7;K18[B74+G4-6\/>'
M;*UMK>1YY)6"Q7'T.>3X^PU"NN%,IX5XIQTX26!P>:YYF7!LJF+J-1P^%G.&
M2<6X6=%U&O;XZKC<`J=/FE'"R>B\7*?]7ZV(P\.(<1G>3X7VM..*Q>59?@>(
MX4Z"=ZV(]EB,SX<Q,:G)_#PM*AC.:>DL3&+YE_0U^Q]*LW[)?[,&R02M!^SW
M\&;:<*^YX;F#X<^&XKBWF`W&.X@<&*6&4K(D@,<JJP('I7Q%^+?PM^#^B3^(
M_BO\2/`GPUT&WBDFDU;QUXLT/PKI^R*-I)%CN-;O;-)GVJ=D4!DE<D+&CMA&
M_E^_8X_91_X*@_MC?![3-?NOVR;K]B[]G[5M4O?LWAGP%\,_%D?QD\;;K'3)
MI_&)D\17OA3PYING>+;.6TNM$\1Z'>^(M+NK5EO+?3PT<EK)^C_PH_X(,?L#
M>#=7M_&'QC\/_$']KWXBJ4EG\:?M/>.]8^(0EN5RS20>&%ET_P`,Q6QD+N+.
MXTR\A0-M^9505MD-7CBM1I1XPR+AWAK'4U*GCL+E/$N+XIE#$TIN%2&'G_8.
M1X2>$K->TPV+>-=?V33KY=2J-TXSG']ATL16APWC,VSC"^T:PV,S7*L-D-.I
M0DKQJ3I4\US?%JO3O:KAWA8T9235+&RC:H\_XH?\%\OV&?#^K7?@WX`_\+8_
M;.^(\8DBM/"G[,_P^U3Q7IIOA@0PZEXTU;^Q_#=A:O(RB2^M;C5!&A\T6\D8
MY_-_]J3]L#_@JA^TE-\-]8TW]FB7]C7PAX.\>>&/B=\/?#'B3Q2OB3QYXL\3
M^%KZ:;P[JGBZ[NM`T32)M&2_<0#P1;Z7-:ZC<"5;Z[U&,0!?ZGO`7PU^''PL
MT6'PW\,O`/@GX=>'K=0(-"\"^%M"\*:1$%4*-FGZ%8V%J&"@`OY09L98DYKQ
M3]J@YTKX&<YS^U/\`,\Y_P"9SBQ_3\LBC-Z?'%2I2K<+YUPID%;#UHU:,L[X
M6S?BY7494Y>WCA.,>#Z%>%2G.4HT)8;EHU>24JM=02=Y1+(:%1RX@P6=9S2G
M3G"I0RO.,OX>I^^DXN#Q/#_$>(A4I35O:K$I5(7M2HN7N_AA9^,?^"_"V=GJ
M7B/X]?"CP[97UG:7\4VG_L4W_C"..WNX([E-[:1XAM2PBCDP[*`2%=]JDA!;
MC\?_`/!42,A?$7_!5#X+^"KMF_?VWB?_`()[^)]*AMW/+HMPVMSP^4C$JA:3
M?L52RAB5'],V1W;OG[QZCCGGG\>_/6HY8X9T:.=(IHV!#)*D<B-D$<JZLO0D
M8QC'&,<5\=_J]XS81N6!\6N&LP>CY.*?"7*\;"^C<(/A;B;@R4*=[Q@YJO5C
M'E=2I7DI.7N?6O#;$:8S@CB;"I:)Y%XE9CA'9;2DL\R/B3GG9)RY94X.5^2-
M.-HK^=31[+_@I#XJ*RQ_\%M_V8=/N90$%I:?LB>'M.M510-D@_X2#QKI]PLD
M@),N]0@(!5L`UZ[H_P"S)_P5>\6@&T_X+0_".:$?/!+X-_9#^&^KR3NX"^7-
MGXDE!&,YC,>YBQR4(P!^QNM_"/X4^)!)_;_PV\`ZP\H*O+?^$M"GN"&Z_P"D
MO9FX&>IVR`DCKGFO)=6_8U_9GU@F1_A1HFFS'(6?0KG5-$=&Z[D73;ZWB4KC
MY66,`=MN,UG]?^D)@')O+O!CB>$;<JIXGBO@>K42M=6J9/Q_3IRDDK7JU$GH
MY.W,]/[*\'\6E_M_BCD4G9>_/*>*H1;26LH9MP?.2B]VJ2;6JBM4?@9^V'^S
M9_P4[\(ZQ\'M)\;_`/!33X9?%@Z7\1/!/C_PJGB#X>VGP"U?P-XUTK6-0LM#
M\=7VB^#M+^($/B?P/X>/F76KZAJ^J1Q6[O<V2>%=50M.?M73O@I_P77T"PL]
M2T/]O;]B?XFV,^GVFH*GC_\`9N\1>&H9&N8$G*1Z[X/U6<W-@=ZI;WXL+1[B
M';<&SM3)Y,=K]LS]DG4_`>H?">^^"'A]?$6C^-?&OAGX6ZGI?C#XGWFD-X?U
M;Q9K,L&F:KIEWJGACQA/?6,D4TYN=*3^SXK:6U$R-=27THM_M7PK^Q!\([CP
M_P"'I_B#IGB[5_$BZ)IB:WIVI_$SQ#K^FV&I+9PI>V-C=0#18;JQMY_,BMGC
MT^SB:`*$MX5`C'R^4^(OTI\=G>?97G?@;X9X'AW+I89<*YF_$RGAX8Y8A2EF
M$L7CL%PSGV:XM4ZL:?L/;\'<,34'*/)7;4H?09CP9X&4,HR?$9=XG\=U\UK1
MQ#SC"0X0JU:N':E3^KQIT,3Q#E>#I.<>?G<>(L]46DHRI17++\^]5^./_!;W
MX8)(GBGP[_P2J^*)C5CYEA\:_B/\+[J55Y`\OQ5!%;PS2853N+Q(WJOS#SG4
M?^"NW[>?PW;R?B-_P3M^#_CLQG%Q>?!']N#P=J>Q5&&DATS4?A_J,ESDJ2D?
M]HQ$AU&_()?]F=)_9&_9KT;8;/X/>$)60Y,FJ6MQJ[EQW8ZI=7623@DXY.>`
M#FO4])^%_P`,_#Y1M"^'G@71V3;MDTSPIH5E*"F2I,L%DDK$9.&+EE)W#)R#
M]2L3X^XV24L#X*\/TW\3]IQWQA5IIVO;V;X!IU&K=533N]$?//`^%F%7[G-/
M%+-6EHI4^$.'XRMT?MZ7%\XI][RDK>9_+SK/_!>[7+G]HKP#XIU?]A7XB:;X
M@\&>%/&_PO'PFL?BQX3UGXE:WJ_Q.UKX:ZO;7NCHFBV?A^;[+%X-6"TT:>]B
MOM4;4A.+NT$"6\_TW-_P7C^)?EYM/^"5?[7PE#JOEZOXD^&VCQ%#N!:.1;N\
MDE*E0"%MR@!^:13M5OT`\::#H\?[>OP>AB_98U*>WU+PE\5_$E_\2HI_@FFE
MZIK_`(;\1?`N'0?B;+93_$2#QN[>"4U;4;.)I?#4?B5#J5R^C:1J47GS1?I*
MVU\;]K8SMW!&P#Z;ESR`,YY.,'N*^FJ?\1'Q-##PH5O#_(\3AL-2H8JO7RSB
MCB^AG&+A.<L1FN'PM+/N!*O#.'Q/-:CP_5QO&%3`P5.,N)\?*,YU/(=/A2G4
M;<^+\=1G*<X4Z>+X?R2K@Z;25/"U:]7)>)J>;5:>]3,J6%R"G7ES..38:,E&
M'\Y<O_!>#XU,%-G_`,$J_P!H+.2)%UCXP_#W1V`PNUX$&BWK3(Q)!=EB4%=J
MEVW*N;>?\%X/VAX8I+F#_@E;\15MH()YYVUC]IKP'I=Q%]G1Y9&%K%\/]2=X
M/*4,LJMOD;>D<#E`7_I`>VM)"#)!;R$="\,+$#T!*$@>PQ61K6D6-SI6JQQZ
M!I&LSSZ7J%O'I=ZEK:6NJ--:31+IEW>_8KLVEI?E_LES<FUNA!!-(YMI@"A\
MBO@_&6\G0XI\)I)-.-.KX:\;4G-)?`ZT?&.LJ;D]%55"KR7YO93MR/LI2X!T
M5;+O$'5-2E2XPX2:BV])1IS\-$Y**W@ZL7/;VD+\R_%+_@D9^WSJO[67Q#_:
MJT'Q+\*)/AMKNO\`C@_'ZP@CUC4-7MK70=<\.^`OAQ%X6GN[SP_HJ:GJ>AMX
M.MKB[UVWBTZ'41J*>5H5H(7EE_<P'(_/]#BOSB_8:TKQ7:^/OVIV\2?`_P`!
M?"Z'0?C1<^%-'O/"OQ'7QS<:;91?"WX,:XW@>QMU^'W@[[+X:BO=5OO$L,_V
MB0KJNI7]NVF1LPNY?T=!4#J!^(_QK[C+*N<8BE6Q&=X++LLQE?$3G'+<IS6M
MG678'#QI4:5*CALRQ.0<-XO$*;I3Q-3ZUESJTZV(JTEB<11A2<?%Q\<NIU84
MLKKXO%8:E1A!XK'X*GE^+Q-6\I5*M;"4<SS:A2:YE3C[#%JG*%.,_8TIRFFM
M%)D>H_,4M>D<(4444`%?/'[6'[-G@O\`:^_9Z^)W[.?C_5_$WASPY\2]&M;#
M_A*?!5_;Z9XP\(:]H^L:=XD\)>,?"]]>6E_90Z[X4\4Z-H^OZ:M_87NGS76G
MQP7]G=6DDT$GT/2?Q)TX8'GH.0,_7!.!]3VH`_F^\=_$KX._'KX_?#+X(^&O
MV,?^"F_C+X??"/\`;T\/^,_C=\=/@I\!_@1X7_99_:;_`&G_`(1W_A;P%-\6
M_CSXHN/B1X>\<:EX+^%OQ&\':)XQ\4WGA+P-HMKJ.M_#]!'I>N:1I5C:S?T/
M^)O!_A'QQ80:/XU\+>'/&&D6VLZ+X@M]*\4:)IOB#3+?7O#6JV^N>'-<@L=6
MMKNUBU;0-<L;+6-$U)(UO-*U6TL]0T^:"\M8IE_E&T/X,?$7PK_P42\<ZE\0
M?V2O^"A&MZOXE_;UU+X@:=\7?!'_``4O^'WPI^`M_P"#-=^)>CWO@7QAK?[*
M>A_&KPQ/>>%=&\)VVD6^N^#KGP7J^O?$#P]HY.I)JM[KDFD6_P#6V<_-ZY;G
MISD\CK@9Z#)QZGK0!_-S\+?A?X2\/_\`!*G_`()A:3^UO^S_`/M=ZOX:^%]S
M!JOQ`3X%W7QG\(?%;X&^([KPS\3?#VE^*?'_`(%^#=WHGQ[UCPM?IXEO/#.J
MQ>"()]7\.7/B'3M?U"U_LV&>ZM[OP@U+XJ_L_P#B;]E/]JSXJ>"OVN?%?[+?
MPZUK]OOX3?#?_A-?!7Q+^-?[27PX^`GQUU;]G'Q+^SMXE^+G@JQL_%WQZU;3
MI;SX)>/?#.AWGB#1M:^(/A?PCXP^'FG_`!%M[>]_M*^M?Z./FR3DC.>=QS@]
M02.<X"@8)`P2.<4?-DDDY/4@E2?3D$_4CH!PN2,D`_G.^!-QXZ_8N^)'PA_:
MU^-_P0^/]O\`#3XS_!/]L#19/!_PU^$'C+XL^._@SXP^+'[9^I?M._"WPE\0
MOAU\.],\1^+?#^O?$KX>^+SI=W<QZ?>Z'X:\;^$'\,^+-4T22XL+NZP?V?[+
MXF_\$\-&L=8^./[/OQT\62?'W_@GA\$?AAX/\'_!OX8>)/C.G@_X\?#7XH_M
M6>.]1_9P\21?#VPUM_!6H^(M+_::\&6&B>+/%;:5\,Y[WPIXO@O/&>FQ:)%-
M??TGX(Z$@GDG<PYZ]1R1DYY/3C!R-H`WJ1WX)!/)ZX..G&0,\`=%`H`_F`LO
MAY\7/V,?@5^TU^RU\0_@E\8?BE\2?VL?^">?[+WP(^!LOPM^'7B7XH_#?7_C
M/X*_9,U#]E[QK\(?$_CGPKIMWH7POT7PAXQBTGQ7?>*OB?>>%O"UYX"\4WNN
M:-K&I7>C:QI5G_2+\,?"M[X$^&OP\\$:G?QZMJ7@WP)X1\)ZCJD9E\K4[_PY
MX>T[2+R^1Y4CF,=W/92W"-+&D@$V9(T;-=T`1QDC'H2N3V)P?YYZGMU0\#!Q
MC''`'3!'`/`SU'(^Z,GN`?D'\6-.^#*?\%!?V>=.U3]KKQ[I_P`3)-#^.4<_
M@V/XW/I5OIWBBYE^`A\+>%[?X<P7$6@V]IKT,@DF\-OI!M?%!4&\M[V0,:_3
M8>#/%H/_`"5CQ@.3_P`P;P-@'//'_"-'\>O/O7QW\3M5^)*_M[_LY:';?%3X
M(V6CGX?_`!RO(/!.I?#WQ3<_$&'PSJ-U\&_/LY-=A^-.FZ5=:YXFD\/>(F\.
M:L?`\5EIMMH>INVA^(VMKJ2U^\[[Q%X?TL,VI:[HNG!<ES?ZMI]H$`&<L9[A
M`,*`3G`YSTZ:NC67)>E57M(*I3O3E^\@Y.*G#3WH.4914HW7-%J]TS&KB</0
MC*=:O1HP@[3G5JPIQBTHR:E*<DDU&49.[VDGLT?A=^VM_P`$MM1\*ZCXA_:]
M_8'U?XK?"[]M">XTK3]2M/@;J?@'X:>#OBWI6HZDL?B(_%+PB+'0/!^L/'83
MWFHOK*1+J[:FEO>16]UJ+F[3R+]@C_@F;KW[2O@KX*_M0_M_>,OB'\3?$7@+
M0_#%G^RY\$O&<7@;5O@;\,?A;IWAG0SX$\7Z=\/[:/7?#GBOQ'XBTC^S-0N-
M:\5V%IK$,MA;V6J:5=-9PW,O[H^/_P!I?X#?#KP]K'B#Q/\`%?P/%:Z5:3RO
MI^F>(])UG7;Z?RV6WT[2M%TV\N-0U'5+Z9X[:QL+>!IKBXD1%P"S+YG^Q+\3
M/A[XA_9A_9]\.:)XT\-:CK_@_P"#OPV\#>)-$CU:SAUO2/%'@_P?HWAW7]*O
M]&NI8-4M9[/5-/N(5$]K&)X_*N(#)!-'(WKMYI3RN4)9=5C15>+_`+2GAJ\:
M\$Z;BL,L2[05%Q4Y<B5]6N;E?*_GZ68<*XK%1A0SC)Z]:=1R^IT,SP52%3$1
M]FI5'A:=:7/6BYTN9.+]^5.<H^TY9'O0\%^*P`%^*WB]%``")HW@9$0`8"JB
M^&0J@`#"J`%&``!Q7Q%\0?`7[1__``VG^SPUK^T!X.3PC+\/?VB[BRL+WX(M
M>>,K7PQ#JO[/":]I4WBFW^)FGZ!<Z]J3N'TCQ`/`UO8:%Y*_:O#GB'S2(_TE
M.1V;GM@CIG//J0,#'U'K7Y__`!'\'_&*7]NK]G?6K7XUZ=:>"9?`'[05_!X&
M;X5:)=W%OX>T[5?V>5U[PX?%\GB%-1,VOR,LJ:XNG+<Z6J"*&VF1G+^&?3>I
M]<?\(9XM_P"BL>,?_!1X&_\`F:KCO'5[:?#/P]<>*OB%^T-J'@GPY!/#92Z[
MXGC^'VD:5%>7N]+.W:]N_#T4*SW#@B"/?OD9=J`MT]Y!S].WYG_ZWYX[5Y3\
M:/@]X.^.?@6[\`>.H'N/#]S?6.JRQ1Z?X:U-S=:4TD]L1:^*_#_B72#AF;,C
MZ6\\?6":)LE@#Y7_`&%M5TSXD?LE?L]WWP__`&@KKQ/9:#\%/A!X?UH>%_\`
MA`-8MM!URU^&OA::XT*]FBT&XDM[ZRBN(!);W+FY5'B:0%G!/UM_PAGBW_HK
M'C'_`,%'@?\`^9JOF/\`X)R_!;P7\%OV/O@/9>"('M[?QI\(_A)XWUC?IOA?
M32VM:K\,/",-U(%\+>'?#D5R&CMHP;K48K[5)3Q/J,T:HJ?<@&`!Z`#_`#P/
MY#Z4`>;GP9XL[_%GQB/KI'@?\>GAH]!DGM@'/%?GO^W_`'/Q@\%:=^SP/"7Q
M1\33K??M'_"6YN5NOV:]<^-?EWNG>,-+.FRI/\./$'@./1/+:XN"VC:HNH77
MBH%(=)N]).G7DLWZH'_/./8X/K@G'?/0@\CX8_;B^%'@+XE:9^S\_C71KK5G
MT[]IGX+Z;8M;>(_%&@&"UUWQC8)J0(\-ZWI"SRS+9P>5/=">6S*NUF\+N[,`
M>^^$/#GC[5_"OAS5-7^+7C!M5U'1M/O-1*^`O#W@P&\N+:.2<CPEX@TS6-<\
M-@R,2-%U;5M2U#3Q_H]U>W$R/(>B_P"$+\6_]%8\8_\`@H\#?_,U79Z#HFF>
M&M&TOP]HMNUKI&B6%MI6F6SW5W?/!8V42P6T3WNH3W5]=-'$JHT]W<SSR,I:
M25W)-:FX?RQ]3G'Z<_\`U^*`_K[W;\V><?\`"%^+?^BL>,?_``4>!O\`YFJ/
M^$+\6_\`16/&/_@H\#?_`#-5Z/N].<Y'!]!]/7CG'KTI?F_NGZX)[=1@<\\'
M%`'Y;?MZ:]\0OAU!^SI'IWQ?^%<2WO[1OPMU1U^./Q!T'X:3M<:)KT;6YT*+
M2/AMKPU+2\7DH\07UP\7]DC[`T=M=_:6$7W'X6T'QKKOAK0-:N_B[?SW6JZ1
MI^H7$_A`^#/$'A:::[MHYI)/#NN7'A"PGU?1G=R=/U&6RM9+NV\N9H(BY0?-
M_P"W%XJ^#ND?\,\V?Q(U/P)#?I^T=\+=5BA\41:3?3V7AS1M9-QXEU247D%T
MVF:)8I)8G5=2N/LVGV[26WVN>/,9KZ5_X7C\!=#M8;*+XK_"K3[*QMHHK:TL
M_&/AB*UM;2-?+AAM[>SOC###$B!(X8D"J@&Q`N*ZH8'&U(4ZE/!XJI3JJ3I5
M(8>K.%11ERRY)1@XRY9>Z[-V=UNCR,=G^0Y8[9EG>49>[M6QV98/".\4I27^
MT5J>JC*+:Z*2;T:-G_A"_%O_`$5CQC_X*/`W_P`S5'_"&>+?^BL>,.AZZ1X'
MQ^GAO\LY`/..*XN[_:H_9PLMWVGXV_#9-A56V^*=.EPS=`/)DDS]1G'?%8%S
M^V9^RS;@^;\<O`3`.$Q#J4EP-QY',-O(K+P<L/DSU.,J>F.2YS.W)E.9SOMR
MX#%2OZ6I.^Z/GJ_B;X;89M8GQ"X'P[6ZK\69#2:WW53'QML_N?8^;O&/B#QK
M!^VY\%?"?V/]HB[BB^&'QUT'_A/8?`7PY?P@L6J>)OV?Y&UJ'5AY<A\.Z<QC
MCU2\ETG[9:W+1+#;2I*A/W)_PA?BW_HK/C$^XTCP/@^X_P"*:Z'M7X]>-?VB
M_P!A6[_;L^'7Q.-SJ=[#X6\/^+]*UWXJV?B#QR?"\'Q.\8WOP^UCPI!'X<C\
M30":QT[2O`-Y%JEQ:>%+CP[<7FLZ=%=)<O:WEQ8?H/\`\-^_LD=OC)HG?_F&
M:_WZ_P#,+'?T`'IQ74^&.(TH/^P\UDJD%4C[/`XBHU%MQ]]4Z<G3G>+O3J*%
M1*S<4I1;X\7XN^%6`]E]?\2N`\#[>$*M!XSBW(L*L12J4J5:G6P[KX^FJ]&I
M2KT:D*U%SI3A4A*,VI(]^_X0OQ;_`-%8\8_^"CP-_P#,U69K6A:]X?T?5M?U
M7XO>,H-,T/3-0UC49UT/P7.\-AIEG->WDJ0P^&'EE>.V@D98HD>20C8BLQQ7
MBG_#?O[)'_19-$_\%FO_`/RKIK_M_P#[(J(\DGQFT54B225B-+\0DA(D9W(5
M=++L0H.%4%F/RJ"S`B7PUQ$O^9#G/_ALQJ_]PG+'QL\&Y-1CXL>&\I2:48QX
MWX:;DW9))+,FVVVDDM7==SY6_8*_:'^&7[1OC[]KC1_A'\<O&VI:E#\?M1\<
MS^;X&T[13<^'+WX1_`KP_;7LC:YX-M[=9%U.QNK9+6%H[CRU-Q+:1QLDDGZ4
MCP9XMP/^+L>,?_!1X'_^9NOB;]@_]I#X?_&WQE^U%'X3&O1S>(_BV/C#HBZI
M91BVO?`&N>!_`GP\T6_%[8W-[;V-]=:G\.]4NYM!U)K/4[2RO[*18+E4O?L_
MZ1#H/I]*\W&8+%Y?B)X3'4)X;$TU3=2C424XJI3C4@W9M>]"<9*S>]GJFE^A
M8#,,#FN$IX[+<7A\?@JTJL:6*PE6%>A4E0K5,/6C"K3<H2=*O2J4II-\M2$H
MNS31PVD^%_$>GZA;7E[\1/$NMVL)D,VEWVF>%(+6[#1.BK--I^A6EV@C9A*G
MDW$9+H%DS&2K=P.!_G]/;T]J6BN8[`HHHH`*`.5_WA^61G^6?7CBBO+?C1\-
M;[XO?#;Q%\/M,^)GQ+^#FI:X--;3_B5\(=:TW0?B#X6O=,U6RU6VN]#OM:T?
MQ!HLJ7$MDMCJFFZSH>JZ5JNDW5]IU_936]RZT`?R%?#?X=_"CQ%_P4<^*'BN
M[^%7_!#;5?$ME_P4L\<LOB+]JC]J;Q''_P`%'+;4]*^-6G/'J/AKP3IGAC4?
M#U[XOMKM!J/P"\+IJ-NEM9)X2\-ZF(=0MKS4[C^T?N?]YOQ^8\_C[<>@%?QU
MVWBKX._!W]O3X1:"NL_`;]J7Q-XE_:[U?X>?$'XP_M&?\$D/@IIWQ*\(>(OA
MS\3_``3\.=<^-%]^V'\#=:^&-]8:EXC^-7Q"\-_!SX:?%'6O@=XK'B3X[^&/
M$TFLZWHFBZ?-J\O]8GQBN/C+;>`-;'P!TCX;:Q\5;B73['PT/B]KGB70_A]I
M2WFH06VI^)/$!\'Z'K?B+7D\.Z8]YK%KX1TW^P9?%]_:0>'9/&'@V#4'\4Z6
M`>GY'7(QZYHR.N1CUS7X#_!+]IO]IK]H[]D'_@E!X'NOCMK_`(!^,?[<=EXX
MU/XR_M#>#O!?@E?&EIX=^$WP_P#&OCWQ/'\/]%UO0=;^'W@_Q'XRU/3?#FCV
M&H:GX:\16V@Z`-6CL]+OM3\C4;>YX6^,W[5'QK\>?"']A*?]ICQA\//%&D_$
MO]NSPU\4/VHO`'@WX<1_&+XB^!/V/=8^!.C^`5TZ'Q#X0\1?"KP9XR\:)^T;
MX.O?B-J5CX#OXKN;P/K4&@:/H$/B"=M,`/WLR.N1CUS2Y`ZG%?@;\,/C3^U?
M^V-XQ^$O[*R_M->*?V?O%OP^^$7[3?C3XU_''X-^`OAO/XO^+WC/X)?M27W[
M+7PSNM,L?'_ACQIX'\(>&]:/A/Q/\2?B9X8T?0;NYU+5=3T3PWHNK^&]$MYY
M=0R/A5\?OVP?V^M,TG2O!_[1^H_LK^*O@E^P]\)OCWXTU'X5^`_`>O:7\6/V
MD?B?\0?VB?A]IH\2?\+-T'Q=:GX"Z#/^S#K.K:AX$\*'P_XBUM?B,;.?X@Z>
MGAS39[L`_H(R!U('XT,,C'^?_K'T(P0>]?SI3_M9_M8_M8_"_P".G[3?PJ^.
M>I?LWVW[(_[%'[._[26A_!OPKX1\%:_X&^,'QB^)O[.EY^U!XW\.?&77O'OA
M[6O$NI?"8Z*WAOX8^&K;P#JO@76M&\[Q3XON_$.K:DVEZ;I7[^_#WQ?;_$+P
M#X&\>VEE-IUKXX\'^%_&%MIUQ)YL]A;>)M$L=;BL9Y1'"))K6*]6WDD\F(.Z
M;C$FXJ`#\\OCY^R/\&/B-^V9\)-2\3:9KT@^)_@?XH>*O&5CIWB&_P!-M-5\
M3?!]OACI_@S61+;,M_8SVVG^-=3M;RWT^]M;&\%GIDDEJ)(KMKSZ"L?V$/V4
M[-Q++\)-,U68'_6ZWK/B/57/(SN%UJSQGD#(,>3_`!<C%8OC_P`?>&'_`&K?
MV:[Q;C56M;;X7?M2Q2S?\(MXJ*!X+SX!&;8#HFZ9(5(,DD:O%M9<OET#?1X^
M+'@7_H*:C_X2?B__`.4=>Q'B#/:=&EAZ6<9E2H4*<:-*E1QF(HPA2C?E@E2J
M0O&*=HWO:*45:*27P^:^&?ASGV/J9IGG`?!^=9C5J2K5,9FW#>49EB)UI0I4
MYUI5,9A*TG6G3H4(3J_Q)PHT8RDXTX*/SQ\3?V0/@])X!UO1_AK^SG\!M9U_
M4XX[/['XYEU3P?IL=A+O%Y>VWBWPUX3\:>)-)UFQCQ<:3=Z9I:SQW2+(E[9N
MBN/G?]CS]DKX;_$G]EGX*>(OC9\#?A#I'BOQ%\+OASXGMO$'PP\5>,K_`%3Q
M#'XD\"Z!KE[XH\3ZSJ7AOP1J,'BO5=9O[^[OK,)KUK;(T*Q:O,H6&+]#F^*O
M@9U=1JFI']W+T\*>+L@>6V3_`,@,\`9)^G'-?/?[(WQ0\%VG[)W[+EO/J.HQ
MRP?LY_!**1?^$8\5RJ'C^&OAE6VO%HKQR+D$"1'9&`RK,#D1#/<[A+GAG&:1
MGS<W.L?BE+FM:[E[6[=M-7MIL:U_#GP]Q.6O)L1P+P=6RAU'6_LNIPSDLLO]
MLU%>V6#>"^KQK6C&U54U47+&TO=5J"_L6VOAL'_A5'Q^^/WPQ12&BTVU\;S>
M)_#T17&T-HGB%;B!HF(VL@F0NH"[P54CY(\8?#G]NOPQ^UW\)+72_C=X(^(5
MP_@/XB7O@#Q!XWT2+PWH(\%Z7=>"8_BGX;\5>%/#]AJ6I3>)-3U/5/`,^E>(
M=-U+R9K6SMV<67]F7EG>_J4?BOX%/75-1_\`"3\7_P#RCZ>W2OFSQS\3/!DO
M[5W[.=TFHZ@88?A#^U`DI/AGQ2I+/K'[.[`")M%\U@%0EF5&5<8)W,H/73XF
MS.\GBHX',E*G.FWF.7X3$U;5(\CE]:=&.+YE%NR==Q;LY1=E;Q\%X2<%Y1*K
M/AVAG7"SJTHT52X;XGXBRK+J,85Z.(B\/D=+,Y</T9JI0A%U(Y5SNA*MAG)X
M?$5Z51Y\>?MT>'"3K/P(^$/CV"($O-X*^)=]H%S<[<Y$,'B'3IBI./ES!QRK
M`9KAOB9^V9\9OASX&\3^(-:_8S^+%EJ>E:5<3VUW!J^D>)_!EC*8V1]4\1ZO
MHD0U6T\.Z2A;4-8NK+1KJY2P@E\N-"3+%]D_\+7\"?\`04U'T_Y%/Q?GOW_L
M//<_F?6FO\5O`C1RJ=3U$@Q2@J?"?BT@CRVW;MVA'(QDMD-D#&#DYF.;Y?.2
M>)X<RJI9IN6'KYK@Y22:;7+#,)X=7L[VP]M796T,L-P#Q1EV(HU,!XN\>5<)
M3J0E4RW.\#P+G.&K4XR7-2>+GPAA<ZBI0O%36:N<6^=N35G^?_[*?[8.G:'^
MSG\'/"NL?`G]H:2X\$>`/"_@.VU;PI\,]3\3>&/$^F^"]%L?#FF>*_#VMF;3
MGO=)\0V.G0:E`TEE"T,DTUNCW,445Y<?07_#:/AG_HA?[4G_`(974O\`Y:?Y
M]Z;^R1\4O!EO^RC^S!!<ZIJ7GQ?L\?!:.7_BF/%DRF1/AQX;5V61-$9)`6!P
MZLP8#*L0<GZ#_P"%L>!?^@IJ/_A*>+__`)1TIX_(Y3G*.03IQE*4E3CFU?E@
MFVU"/-AF^6*=E=MV2NV]32MPUXERJ2=#Q.P5.C=*G"KP'EU:JHI1BG5JPSBA
M"I4E9SG*G0H4W.3Y*5.'+"/S\/VT/#)X_P"%%_M2<_\`5%=2_P#EH?Y'Z5\>
M_M<_MJW$T7P8LO#'[/GQME73/C)X%\>3W'CGP;K'@N'7+_P3K<&I:7\/_"!@
MM=<DU;QMXMF,D>F6UQ';6D,5JS$7KSF.V_4/_A;'@;MJNI#W'A3Q?G_TQU\S
M_M._$SP?=Z5\$#;ZGJ3F+]J/X!-)GPWXKB^0^,DRH,NC+N+J&^1>7`VGJ!54
MLPR*G4C.?#\ZL8WO3GFV(4)7BTN;DP\9:-J2M)7:2;M=/7"<.>(T*REC?$K"
MXG#\LE.EAN!\MPE9MKW)4Z]3-,7"#C+XE/#55.'-%*$G&I"5/VFOCEXB4'P+
M^QI\4Y(YDC,%W\1/$WAGP!''YB`AKFT']MS!H20LT*2`AE8"7C?3AJ_[?'B8
MXL_!W[/?PP@=CB37?$GB3QAJ$:-G#+%H]H;.25%QB,F)&(8$J.*^D6^*W@7.
M#JNI$CKGPIXN//\`X(R..F>2>_7%)_PM?P)_T%-1/_<I^+__`)1_KUZ\\FI_
MM?!T_P#=N'\HI/2TZ[S''3T[QQ6.EAF^_P#LR3[+8X7X=<1XV4I9WXN^(6,I
MRDV\'E$.#^&,'&+=W3A6R;A6CG:@M%&4\[G5C%:U'+WCYO7X*_M<>)`Q\7_M
M;6GAN-S^\L/AG\*M(LOE<9*P:OK6I27<+(!A)!:.S?>8#E:1OV*=&UP`?$7X
M[?M$?$7<NV>TU7XDW^D:7.IY(;2]%CM+=`2<$*00ORKM%?2/_"U_`O\`T%=1
M_P#"3\7<Y.3G_B1^O..F<<<"C_A:_@4?\Q74OQ\*>+SC_P`H?^><=31_K)FT
M;?5ZN%P-OA_L_+<NP,X]-*N%PM*M?S=1N^M]%:?^(*\`5U_PL8//N*&_XBXN
MXTXSXJP]5Z:SP&>Y_CLMBG;6G2P=.GJUR6;O^=W[0_[$'[-/AB'X)W>E^`9T
MO?$'Q\^%O@#Q)>S^*/$US=^)/!7BG5[B#7?#&NS3:H_VW2-16)&GMU6*0-YG
ME3QK-,LGVY9?LK?LVZ:D4=E\"OA9!'`-L,8\&Z,Z1J!M"(DEJZJBJ`JJ!M0`
M!54*!7C7[3OQ)\'7UG\!?LVHZ@_D?M4?`R23=X9\4PX!U^\`"F;1D#LQ!PJY
M/'N,_3?_``MCP+_T%-1_\)3Q?_\`*.L*N?9W6LJN;YG4M?XL=B7NTW=^TN]E
M:][6LK(^CP_AQX>X3"X7!8;@7@^CA,$FL'AH<-Y.J.%YFI2]A3^IN-)SDE*;
M@HN<O>DW+4S+?X!_`VU54@^#/PIC"KM4_P#"OO"C,%SG:6DTIV8$]2S%L#&>
MF-RV^%7PPL@!9_#?P!:!4$:BV\&^'(`(Q@A`(M-4!`0,)R!C/7&*W_"V/`O_
M`$%-1_\`"4\7_P#RCH_X6QX%_P"@IJ/_`(2GB_\`^4=<DL?CI_'C,7/_`!8B
MM+\YL]:CPKPOAK/#\-Y#AVDDG1R?+Z5DK))<F'C9)))6VLCPCQ-X0\)67[8?
MP-GL_"OAFUN9_@)^T!#-<V_A_2(;F6'3O%OP.73X7N([)9C%8IJ^K):1;_+M
MTU74EB55OKH2_5?]BZ/_`-`G2Q[#3K+`]O\`4=J^/O%GQ$\*2?M9?`R_2[U4
MVL7P*_:+5YCX4\6J!GQ;^S^X<*VAAGB"JY:10438P9@2H/T:?BQX%!/_`!--
M1X]?"GBXG\<:&!^0%8RK5I6YJM67*N6/-4D[1NWRJ[=E=MV6EVV>JL'@XQC%
M87#*,(J,(JA34816T8Q4;1BNB226MMV=I_8NC_\`0*TS_P`%UE_\8H_L72`0
M1I6F`@@@_P!G6600>"#Y'!'8]C7%_P#"V/`O_04U'_PE/%__`,HZ4?%;P.Q`
M74]29B0`%\)^+R<G@`#^PCDDD`#&3G`ZU/M*G\\__`I=/F'U/"?]`N&_\$4O
M_D3PS]ES1])TGQ;^V#!I.E:9I4/_``U7K`,6FZ?9V"/YOP4^"&I2^8+6&+S#
M)J&IZC>NTF]C<7]W+G=.Y/UR!@`>@Q7Q#^SS\0O"NG^+?VN9KNZU6".Z_:LU
MCR7;POXK(=HO@1\`1*C!-$9HI$W`%9`K$'>@=!FOI<?%CP*,?\334<?]BIXN
M_P#E'^7'%*4Y3DY3E*<G:\IR<I.R25Y2;;LDDKO9)'0DDDDDDMDE9+T2/1Z*
MXC2OB'X2UJ_M],TW4+Z:]NBZP1S>'?$=E$QCC:9]UU?:3;6D7[M'*F6>(,0$
M#,Y45VJY[_3^6?R.1GJ?<`$R,=1110`5SWBW7;KPOX6\1^);'PSXA\:7OA_0
MM6UNT\'^$DT>3Q5XIN-*L9[Z'P]X:C\0ZQX>T&77M8D@6PTB+6=>T72Y+^>!
M+[5+&V,ES'T-<1\1?B5\.OA#X/U?XA_%?QYX.^&?@'P\MM+K_C7Q_P")='\(
M^$]%BN[N&QM7U7Q!KUY8:5IZW-[<V]I;M=7<2RW4\,*%I)%4@'\AW[.^K^!O
MCO\`M.:G\7O#'_!(O_@KC;>+OBI_P4"\$:IK\7QM\7^%_#'[*GPD\._"7XV>
M-/$>J:]JTT_B?4=4\-:#X>^)GC+6_P!I7QQ\#;+PAXB\&:U\<_#&@6&D_$S4
M+71M.U2?^R@'#9]&8_7DC/XCGCOV[5_%KHWCB?Q3_P`%4M0U7P)\<_@/XBN_
MC-^T5\+==B_;,T#_`(*I?"S7?#^L_#'P9^T7<?$+X=?!WPW^S7;^.[GQB-5'
MP=\0Z_\`LR6GP(T/PHG@SQ%XH\4S^/[S5-0$T%['_:5W/^\WY;C@?@./Z#I0
M!^:NA_\`!-[0/!'[+7[+?[/OPU^./Q(\!^/OV.+F+5/@;^T)I^D>#M2\8Z;J
MDNE^)?#NOP^*/"&JZ3<^"?%?ACQ;X6\6:QH'B3PO>Z=!:749T_4+:YL]3TZS
MNXJ4G_!-V'0?!?PIN/AA^TC\5_AY^TE\+/&'QA^(#_M0MH7P^\7>*?B'XL_:
M)GM+OXZR?$3X>:_X=;X;:SX?\<W^D^&[W3O#EGHNF6O@V?P7X)/AZ>W70@MS
M^F]%`'YC7_\`P36L_#'A?X++^SO^TG\8OV?OB[\'O!7Q/^'M]\<=+TKX>?$+
MQ5\5_#/QN\76'Q'^+-Q\3_#WCOPMJ/A#6_%>O_%#3U^).@>)+32-/E\&>*-0
MUA=#LO["U?4=%N*/BO\`X)@^&]/\/^`?#G[-?[0WQH_97MO#?[.VD?LF>.K[
MP)'X+\9:K\5_@/HFH:QJ^DVNO77Q#\/:]%H7Q5T/5_%GC_5O#?QA\.6]EXGT
M?4/B+XPN&BO1?V46G?J/10!^7?Q6_P""7?@;Q@-1\,_";XT_%+]G/X._$7X(
M_#?]FK]H/X.?#BT\(:KX<^,GP.^$VBZGX0\%^%K;6_&6B:YXF^&/B"/X>:YK
M7PSU_P`;>!=1L=;\1>!;K3=-OB-3\.Z%J^G?IO8:?9:58V>EZ99V^G:;IUG:
MV&GV%E#%;6EC8V4*6UI96MO"J106UK;QQP6\,:I''$BHH50`MVB@#Y9\6?L_
M_`75?VB?AS\2M4^!WP<U/XD?V7XVUT?$/4OA?X'O_'::WH,OP_71-9A\87>@
MR^(X-5TI88%T_4(=2CO+..&&."1%C0)]2@DC.YO^^F_H<?EQZ<5YMKO_`"57
MX<?]BO\`$S_T=X#KTJ@#CO'7@O3OB!X?G\-:OJWC'1[*XN;:Y>]\#>-_%GP^
M\0*;5_,2.'Q)X+U?1-<AMI22EU:17Z6]X@$=RC)@-S?P>^#O@[X&>#K+P#X!
MN/&?_"*:5#86>B:;XP^(?CCXAOH.E:3I=EHVE:'H.H>.M>\0:CI.@Z=IMA;6
M]GH]G=Q6,)C>=8?.GFEE]5HH`.?[S?\`?3?XU\P>)OA/\:]=_:&^'_Q<M/B?
M\++#P/X`TKQKX9M?`UU\'?&.H>+-1\-_$*[^'MYXB6;Q]!\;].T:#7;>3P!$
MFBZD/A[/I]K%JDOV[1K^2TCDE^GZ*`#G^\W_`'TW^(KB/B%/\2+?PW/)\*M,
M\$ZQXN-S;)!9?$+Q!XB\-^&S8NY%]++J?AGPYXJU5+N*+#6D,>DM%-)E9;FV
M&)*[>B@#YV_99\&?%KX:?`_X??#'XNP_#O\`MOX:>#O!WP_TG4OAKKGBC6-*
MUW1?!WA'1/#\6M:BGBGPWX;O=(U34+O3[F9])MEU>UL[=H=NK7,S2(GT0"2,
MEF_[Z(^G0@=/3@]12T4`'S=F;\68_P!?\^W4?'?[7>I^*H++X,6WA?X7?$WX
ME2:7\<?AMX_UG_A7^C:3JR:+X=\!^)+'4M9DU-]5\0:(([NXM+AI-*L;87<]
M^]I<HBHZQJ?L2D(S_GW!Y]N.1SDX^H`,O0]4?6]'TO6'TS6-$;5+"UOFT?78
M([/6M,-S$LIL=5M(+F[AMK^V+>5<PQ7,\<<H94E<#<=7G^\W_?3?XUXS;>*?
MBEKU]XA;POX>^'PT71O$FK^&[:77_%'B>VU2ZDT2=;6YN[BUTWPG>V=LEQ.'
M>"**[N"L)0R2>871+OVSXX_]`'X2_P#A7^-?K_T)-`'K//\`>;_OIO\`&CG^
M\W_?3?XUY-]K^.7_`$`?A+_X5_C3_P"8G\/KQUXH^U_'+_H`_"7_`,*[QKZX
MZ?\`"$^O'_ZC0!YC^T[X#^./CY/A5#\'K/X47$?@OXG^%?B9KS_$WQ3XST"2
MYF\%:A'?:;HFCQ^%/!GBM735UFO([W4KYX3I;0V\D.F:L)9$M_I/0WUR31M*
MD\2PZ9:>(7T^U;6[;0KZ^O\`1;?5&A0WT.E7VH66F7UWI\=QO6UN+S3K&YEA
M"O+:P.3&OG?VKXY=?[!^$O3/_(W^-.GT_P"$*S4-QJ7QKM(FGN]'^#]K`FW?
M/<^,_&,$*;W6--\LO@M(TWR,J+N8;G94&68`@'KW/]YO^^F_QI"2.06/(_B;
M]>>_3'<X&1G(^=M9^)_C'PYXBT;P?XBU[]G'0/%OB,VH\/>%M:^+&L:5XCUT
MWUW)860T;0[_`,,6^IZF;N^BELK465K.;B[C>VBWS(R#L?M?QR_Z`/PE_'Q?
MXT'YY\$\?_J]10!SNH?LR_!/5/BG8?&O4/!MQ<_$[2[X:CIOBIO%_CA9M/G=
MM,-Q!9Z9'XECT2VTV^;1M)EU32(=+CT?59=,L)=2L+I[:)HO>P2>26S_`+S#
M\<`\9].W2O%SXA^+JZ@FD-:?!1=6DC:6/2SX]\5C4GB1!*\B6)\'"Z:-(F$C
M.(BJQD2$A"#5[[9\<>/^)#\)>>G_`!5_C7G/3'_%$T`>M<_WF_[Z;_&J>H64
M&I6-YIUXLDEGJ%I<V-W&EQ<6[O;7<+P3HMQ;2PW-NS0R.JSV\L4\+$2121NJ
MR+YE]K^.7_0`^$W_`(5WC7_YB:/M?QR_Z`'PF_\`"N\:_P#S$T`8_P`*/V<O
M@Y\#]3\0ZQ\+_",WAC4O%KK-XENF\4^,]=.M7BQ6%M_:FHQ>)/$6LP7.L26>
ME:992ZR\1U>:PTS3M.GO'L[*UMX_<1G`R6SCGYFZ_G7DWVOXY?\`0`^$W_A7
M>-?_`)B:/M?QR_Z`'PF_\*[QK_\`,30!ZS]2?Q8D?J<4F?K^(QZ_KP>#SP>,
M5Y/]K^.7_0`^$W_A7>-?_F)KM_#;^*9+!V\7VGA^RU7[7*(XO#6H:IJ6G&Q$
M<7D2/<:MI>DW*W;2F=9HEMFA"+"Z3,SR)&`=%1110`5QOQ`^'7P]^+'A+5O`
M'Q3\">#/B5X$\01P1:]X*^(/A?0_&7A'6H;6ZAO+>/5_#GB.QU+1M2CMKR"W
MO($O+*98KF"&=-DD:.O95SWBW3==UGPMXDTCPMXD;P;XFU30M6T_PYXO32+#
MQ`WA;7;RPN+?2?$0T'5"NFZV-&OY(-0;2;YX[344MVM)Y8HYFD4`_CLT;XT?
M!7P+_P`%/=2^"'AGX`_\$Y-%^(FF?M/_``T\$_"/]D;P[^P3X#\-_'GP3X5\
M+?']O!'B?XBV?Q=LO#MOK4GBS7_@[=0_M5^'_B)866G>`/!GA/PK!HMD+S4+
MVZUQ/[,SQNP<X)P3W[]O?.??/3H/XV?A)\>OC-X3_;)\-_LP_M*?\%[/#/Q!
M^-7AG]M;3=+U[X1_`C_@GSXSU#Q]X^TR7XK)JF@_`FY_:1@OY-'^''A+Q3LE
M\.^._AW8:;XO\)_#K2X_$/A"V\6:X-$GU>W_`+)O[V1W;([=3D=N,Y`)QD8)
M`S@`'A7[0G[2/PE_9<\#67Q$^,>LZWI'AS5?%F@^!M&B\,^"O&7Q#\2Z[XM\
M327*:+H.A>#OA_H7B3Q5K-_>+9W4QCTW1[D06UO/=3^5;Q22)XYKW_!0G]EW
MPM\&_"7QQ\2^*/'N@^%/'_B?5/!G@/PSJOP0^-%E\8?&OB;18[ZYU;3/"OP+
MF\"+\8-=;3=-TS4-:OKK3_!<]G;:'9RZQ+<+IY2Y;QS_`(*;Q_`F+PI^SUKG
M[1?CW]IKX._#GPI\<I=?7XT_LZ7EUHMA\,?$TOPT\>>&]%U7XN^+M#L-7\8>
M!O!&K1^)-0T33/%GAW2'33_%]]H2:QK'A^SNQ?#\Z?A7\<-6^%'CS]C_`/:P
M_:4^('Q:\4?LA?#C6?\`@H?\%/A/^TS\:?!&NS^+[OX9_$S4/V:]<_9M^)?Q
MCN;+PQ9:_:0^*=+^%WQA\!^#_B;KGAK2KCQMH5QX.U;Q"T.J^."]T`?L'\3/
M^"A'[(?PH^&GPJ^+OB3XO6NK>!OCAHVH>)OA/>?#WPIXV^*6M>-_">B:;9:Q
MXG\7Z1X2^'7AWQ-XK/A3P7IFI:?>^.?$=SHUMI/@M+RUA\37.F75U;PN[XT_
M\%!OV0?V?]*^'.M_$KXS:1;Z3\5?"9^(W@W4?"&A^*OB39S_``HBCTB6\^,F
MMS_#O0_$Z>$_@YIT6O:/)J7Q3\3G2?`UA'J$#W&N`>9Y?XY?LY_$?PW^QQ\4
M_@?^U7^TQ9>+O@]^SO\`&3X"_ML:;\,-7\0_#SQI=)\/-7^)_P"W+<_M%>"O
M"'BC0]&\/ZIXC\">*/C+\(=>\,ZWX5\*W^D6EYKE]X)NO"ZVR^)M.LM(FY+]
MG+QAHO\`P3_\/V&J_MB^!_''@G2/CQ_P3&^!7PX^"_A&Y^&_B/Q9>'QKX&^*
MG[7'B_Q5^RC;VOAK2=;O+'XK:QX;^/\`\'[?2_AQ?);3:_<66J:?8"XF\(ZI
M'9`'[C?&K]O7]D_]GKQGX1\!?%CXNZ;H/B'QEI&B>);<Z9H7BKQ9H?A?P?XF
MUG_A'/#'CKXE>)_">AZYX<^%?@+Q1XA$NB^&_&_Q$U3PUX7UO4;74;;3=3NC
MI>HO:_8/()![=>"/Y_YQ@@D-Q_*79-<_L=_L\_M8_LT?M->%?%K_`!M_:K_X
M)H?LE?!;]GKP19^#/$'C"3XU?$3PQ^Q[X@_9Y\2?L^^#_$?AO3-8TO4/%G@C
MXO74\_B'2M6U*P32-"^(MEX[:3^P;S6=5L?Z=OA;H.N>%/AE\./"_BB]&I>)
M?#7@+P=H'B/4%G>Y&H:[HWAW3M.U:\%S)A[@7>HV]Q,)G^>3<78;G((!3UW_
M`)*K\./^Q7^)G_H[P'7I5?.NNZ#\0/\`A9W@%/\`A8ED)9?#OQ)>WF_X0?3R
MEM`)O!):`QG5AYQ;?'F5FC8B'[@#M7H`\-_$D_\`-3=//O\`\*^T[]?^)YU]
M??TH`]*HKS7_`(1KXD_]%,T__P`-]IW_`,O*/^$:^)/_`$4S3_\`PWVG?_+R
M@#TJBO-?^$:^)/\`T4S3_P#PWVG?_+RC_A&OB3_T4S3_`/PWVG?_`"\H`]*H
MKS7_`(1KXD_]%,T__P`-]IW_`,O*/^$:^)/_`$4S3_\`PWVG?_+R@#TJBO-?
M^$:^)/\`T4S3_P#PWVG?_+RC_A&OB3_T4S3_`/PWVG?_`"\H`]*HKS7_`(1K
MXD_]%,T__P`-]IW_`,O*/^$;^)/?XFZ>,\9_X5]IW7_P=F@!/AE_Q[>-_P#L
MI_CO_P!.QK(^,&B_&G7-(TJW^"GCGPCX$UF'4Y)M:OO%WA>X\407NF&W=8;6
MQAAN8%M)ENL2R221S"2,%$:,@LUCX/07]MH_B^#5-0CU6_C^)OCP7-_%91Z<
MEPQUEBC"RBFG2#;&4C($K[RAD)!<@>LX!SWXY`Y_ER#QVP3@9SM&-L/7EAJ]
M.O&G0JRIRYE#$T:6(H2T:M4H5HSI5%K=1G%I-*2UBF>9G.54<[RS%Y7B,5F>
M"HXR$:=3%9-FF.R;,Z*C5A4YL)F>6U\-C<)4DX*#J8>M3G*G*=-MPG*+_/SQ
M;\-O^"@]YX:URVTO]H3X33WT^EWL4-MI/P_N/#FKW9:WF5K72/$4DUS'H.J7
M"GR;#6&MY%TZY:.X_=!!/$>$_AK_`,%!;/PUH=KJ?[0GPG@OH-,M$GMM7^'U
MQXAU:UVPQA;35?$4<UNFN:E;#$%]JR01+?7*R3`R;O.E^Z=<U_0?#%B=4\2:
MUI7A_3%FB@;4-;U"TTNR6>4L(H?M=[-#;B>4@B-"^YR,*.,*:#XAT#Q/8_VI
MX:UO2?$.F>=-;'4=#U"UU6R^TP^7YL!NK&2:$31*R>9$7+H&3<%!`KN_UUH?
M6_[(Y.$_[2]G]=_L_P#LO)?[0>&NJ?M_J?LO:_5^;3VWL4G*\?:.RBO@?^(*
M8#ZK]=_UE\7_`*C[3ZO]<_XB?Q_[#VUU45+Z]_;"E[2S_@K$-.+3=-[K\UOV
MI/&OQQ^!'[+WC'7_`(R_MF?"/X+>(;_QIX9TSPI\4V^'FJZ7HTMG=07)O_AW
M=W]G:>)[[PIJGC$V\MIIOQ#TOPKXEO?!BI)JD/AOQ!,D6GGXV\0Z?\(OVB/^
M":'A#XA_#ZS\?&U\`?M3?!K7Y+71_P!H[XG?'G1OB)\3-,_:L^#NG:YX_P#$
MGQ%U*[TSQ=\;="7,NNZ#:_$WPUH$.@30QOJ'PY\--X=TNRTK]UO'GQ)^'WPL
MTJPU[XE^-O"W@#0=5U_1_"MAK?C+6]/\.:-<>)/$-Q]BT#1%U/5IK:P34M9O
MBECI=K+.DM_?2PV=J);J6&&3S_X]?M*_!?\`9ET/PKK_`,9_&MAX1@\<^.O"
M7PV\%:9Y5QJ&O^+?&GC;Q%I7AC1-&\/:#IT=QJ6HD:IK-C+JM[#;G3]"TQY=
M5UB[LM/ADG3BQ->6)KU*\Z="E*HTW3PU"EAJ$;1C&T*-&,*4$^6[4(Q3DW)J
M[;?WN2Y31R/*\)E6'Q>:8ZC@X3A3Q6=9ICLZS.LJE6I6;Q>:9E7Q..Q<HNHX
M4YXBO4E"C&G2BU3IPBOPZ_:WT'X<:%_P5%TCXHV/B?P%\1OVHO\`A9'['/AO
MX:?LO_%G]A;0/'7BC7_AC9>(=-M_%7CKX$_M4>)--UKQ%X(TCX>V?C#XB_%*
MX^(/P_U;PMX7^&GC[PAK6E^/-(UF]GM[BX^C?V_?VT?B%^S]\0_VE/A7X>\=
M^,/#_CWQ1^SW^RAXN_92\/:#\.;_`,5RZMXFO?CW\6/!_P"T1KGA_4+7PEK.
ME79\/^%'^&EQ\0(/$%^\/A'PW/IOB-+.RM]0DO+G[X\7_MC^!/"O[16F?LRV
M/PX_:!^('C>:'X?S^*?%/PS^#7BGQI\+/AC#\3M3UK3_``P_Q.^(]@BZ'X/5
MK;P_?:[JBWDCMI/ATV>LWZ1VU]:F2S^T_P#MF_!7]D.V\)77Q?E\=/%XLB\3
MZP?^$#^'WBGX@OX6\!^!(]'N/B-\5/&J>&;"_D\,?#/X>VFO:-?>,O$]Z/*T
MVTU&":.WNV,B1X'J'X]_M2WW[1GA_P",7@#]H;X#>$6UCQE\0O'?[<.O>)M?
MATJYN?B-X#_9R^&/AGX*_""ZU[X->%KKPY=:-\0_C1;>`/AWXC\:?!'X;>.=
M0T+PAXG\:>*KG[?J>H6TC:5JTWQ<_;"^(VD?M._#JSTC]K_XM>#(/$W[4/[`
M/PV^`?P&C^#>B:[\/_VDOV0OC+K'P,B\??';7?'FI?#4ZS-XE\:^(?%_Q)\)
MZUXLTKQ?X0L/AK-X-MO!]YX)@U_6X-4U#^BH,6P5.X.%V,ISN5AD,KCJ"N&S
MD\$'G::_)GXZZS_P3S\(_&BV_::O?"OQ)^/GQGT;XHQ>%-3\(_LWWWQP^.6A
MZ9\7/A-X+TS6+KQKX\_9Y^&OBG4?@LWQ-^#_`(#U3P[/-\1_&'@>?XB>$;%_
M"NF:3JJZK8^'K*``_6CN?8L/R)%%?!_BG_@H]^RYX8\1_"S1HO$'C3QAH7Q4
M\*?"CQ]%\3/`7PZ\7^+?A-\.O`OQXURY\,_!;Q?\9/B)IFFOX>^%^A?$WQ#9
M7^E^&KOQ1<VC"6QO+[5H]*TFUEOT^X+G4;"SE\B[U"RM9OLMWJ!ANKNW@E^P
M6!A6_OECDD1VLK(SP_:KK"P6IGA\Z12ZE@#0HKY]\1_M-_"7PM\;_A9^SYJ.
MKZG<_$?XQ:'J'B3P9#I.BWVJ^'I-(L=,\1:M%=:MXELTETK2AK%AX2\2SZ"E
MS,#JXT74/L>];>1E]8;QOX-C.CB7Q?X6C/B&RN=2T`2>(='3^W=.L?LOVZ_T
M8->#^T[*T^VVHN;JQ,\%N;RT$TJ^=&&`.JHHHH`****`"O%_VA/B/\0OA)\(
M?%WQ!^%GP1\3?M%^._#L%A/H7P>\'^*/"'@SQ#XO>YU.TL[N*Q\2>/-1TGPK
MI@TVQN+G5;B35;^".2VLI886,\D2GVBOS-_X+"_"/XT_'C_@GA\?OA'\`O!W
MB7XB^/\`QN/AUI=S\._"'C#3?`/B#X@>`8_BCX-OOBGX&L?%^K:IHMCH:^+?
MAQ:>*/#]U=S:E:HUIJ$T+,Z2M&X!^*?A7X<_M%?'+]H'X!>/[3_@G;^WM\*?
MAC<_M+W/Q0\?:SX7_:I_8(\8_"WQ+X<\8_M!^$/CV='\:ZKX9UC5?&^H_#7X
M.?'/P]KGQ/T-?`6L1>/Y;#Q3\0?`5UK6L:5JMC8V/];WKR#\QY'0Y.<CKQSZ
MG\:_E^_X)TR_ME?LA_M`?'CPIX`_X(O_`!M^`G[)/[2_QG^".O>#_A_H?[0_
M[,S_``[_`&8DMO!6B_#SXR>/8_!>E_$*]CBLO$FHZ=:^/=9T/P':O-J<>GRH
MEJ=6:*.Y_J`'USR>?49.#[YZY[YS0`HX_(@CJ"#V(/!'L>G:@\YSSD8(/((]
M"#P1]1QVHHH`,GUSD@\\C(((.#D`@@$$=,#TH_7G////3/.<$#H>HHHH`!Q^
M>1GG!P02,YP2"<D8)R<]:3`]/Z_Y_P`>>M)GT([\GH`!DDXYQCG@'J#TYH!R
M?YCN/Z8R"/<YQP#0!YOKW_)5?AQ_V*_Q,_\`1W@.O2J\UUW_`)*K\./^Q7^)
MG_H[P'7I5`!1110`4444`%%%%`!1110`4444`>:?#+_CV\;_`/93_'?_`*=J
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M\4OV%9/%OA8Z1X>^-'Q1O=1.I65V+?XG>,M=\8>&/*MQ,)7;1_,C!U`;U-G=
M[OW`\X<!S2?"O]A27PAX5;2/$7QG^)]EJ!U:_O1!\,/&6O>#?#'D7*6J1.VC
M>9(#J;^0WVR]#?Z0@MT(40Y/KL_[=O[%5O!/<O\`M:_LXR);03W,B6WQE\`W
MER\=O$TTJVUG::Y-=7=P40B&UM89KFXD*0P12RNB,VV_;P_8HN[6UNXOVM?V
M<DBO+:WNX4NOC'X#L;I8KF%+B-;FQO-<AO+*X$<B^=:7D$-U;ONBN(8I4=!^
M)OZ*G@F^*?\`7/\`U(J?VNLM_L>_]K\0?4?JO-[2WU3^T?8^WO\`\O/CM]Y^
ME_\`$?\`Q*_L+_5[_6VG_9[QW]H<WU+)_K?UA04+?6_JGMO9<J5Z7-RWU*/B
MC]FKQ4GPC\8?"SP!\5)K\_$/4K"T\3ZS^T/X>/[0VDV/@V6%[3Q/I>A>"/$6
MK:/X?O=1UG3V-M:+XHDUCPQ;7,@O=8\-Z_;P-I=UY%X]_8I'@[]BVW_9H^!U
MQJOBJ_T;X@?"+Q-HEUX_\16L+6NG:'^T%\-?B7XXL/#_`)5E9^'O`WABST#P
MUJY\-?#_`,&Z1H7A+28+>RT+0M(LX#'CZ`U;]KKX*CP)<?$KX=ZY<_M`^#M(
M\4Z;X7\7ZC^S=%8_'&\\##48)+F37_$^@^!-1U/Q#_8>E0+%<:O_`&%I6N:S
M:6ES%?KHTNGQ7EU:^%?M+?\`!0#2/@O\*]"^-7PG^$>O_M-_"X6/BSQ-\1_'
M7@?XB?"WP'X3^&G@WP#-IUOXGM;_`%?XH>)O#:ZW\7KV[U)]+\#_``5TZ"'Q
M3XDUO3-8TS4KSPN]D)Y_VO)<CRSAO+,)DF38..`RS`0G3PF#C.M4C0A4JSKS
MC&>(J5:S4JM6<_?J2:YK*T5%+\TS'-<;GF-Q&:YCBGC<;C)1G7Q4E23K2ITX
M48R:HPA3NH4XQ?+%7<;N[NSY>_:7_8T^*7Q)_;?T7XI^`?V5/A9IGB>Z^)'[
M/OCGP[_P4/TS]H/Q;X;^(OPB\`_"S4?"DOQ/^&FO_!6:VNKSQ)K/C[POX>\5
M?#G3M`\%7%K\*/B'X4\>V7_"W6TRY\.:@-<@_P""HG[)?[57[1?Q<^$/B3X/
M_#?PA\5]$^'WA_2]:^`>I>)/C!I_PTT3]E7]KK1?&.H:E8?M&?%3P!K7@KQ=
MI7[0OPAU/P?=:)X3\2>`K6TUKQ1I&BZ+XKM?"/A=O$/CNP\:>"OICQ+_`,%#
MK?2/BYI'AG1/V>/BMXB^!FF^*/@C\.OC'^T;/J7@WPMHGP9^*'[1UCX(O_A-
MX+UCX9>)M9L/B3KS1Q?$_P"&R_$_5=,TBW@^&\GC[P^EU;:S+;>+(_#'V5XQ
M^-_PC\`?\)ROC7XA>&/#1^&N@^#/%'CT:MJ"VW_")>'OB'K6N>'/`^L:T2K?
M9;+Q1KOAK7M+TB8AO/O-*NXPH,)->H<1X_HOP9\??&3]D#0?@I^U7KVM6GQ+
M\3?#O3?"_P`9O$WPL\>7&GW&I>*;4QKK^L^&O$VB>'?!D4OAOQ-=6K7K>'-1
M\*6^F7?AO47\(^*=&U:Q.H0W_P`B_&+X`?M-_#_]F.__`&<_!WP>^%O[6OPA
M\2:MXD\(:U\/OA+XYN/^"<WQ*TOX6ZMH_AZY\)'2/%/PLO['P+%J.C^+K/Q'
M9_$>;PBWPYA\2^"=4TE=*\*7UQ9Z]X;\2?3'B;]M_P"'/@SXUZW\*_%.EW/A
M_P`*^%8OB6WBSXQZOKFA6'@?PT_PC^%WPX^+/C=M5AEN/[1MK'1]!^*?A:RN
M+^98H/[5FO;=%;R&W=EX@_;:_9,\*?%/P;\$/$_Q^^&^@?%OX@67@>^\(?#W
M6-:_L_Q/K0^)>J0:/\/K%-.NHHY++6_&6HW,4/A[P]J/V77M2B$MW;Z<]I;W
M$\0!^5.J_L3_`+;7A;P1J/[/>G>%?A7\4_"_[6'[/7[+?P2^/GQQ3XE0>&$_
M9RU7X':9JO@KXB:WI/P[U#P-87OQ:T'6/A==:';?"1O#$?A?4KSXDZ/J=SX[
MT7P;X>U>'6;7[#_;N^$O[3?BWX@^#/%W[.GPI\"?%;_A)OV=/VGOV:/%0\:?
M%.+X8V_PTN_C;;?#^_\`"?Q,U))?#'B.Z\9^#=)OO!%YI?BOP]X:\GQ;&=3T
MNZT6TU*`Z@]A^G/UQD$C\02#BC`/49H`_`#X@?\`!,S]HOXP_#GX*^$-0\;S
M_!_Q+X7C\*>!O$'C7P3XLTZXU#1_A-\+?V(M7^#_`(.\#:@%LUOM8^'OC7X[
M^+OB/>_$;PIX7U?1M=U+X?>/==LM.\3:)=ZA<W<?PU^VUX4G?]H7PE\*_&?[
M(_P$\5_M'?&WPE_P3VLOA%86VIWUMXU_8RL/A)\:M(3XA?#K]FB.'X<7VF^)
M?A!=R:/KWQ#M=2^$OC#P?I-I;ZOXCT3]H_2O#/AC2=%.M?UQX'H/RHY'0#C.
M.!D`XW`$],X.<8!X/7)H`7N?]YO_`$(T4@X`'H!2T`%%%%`!2$9_/_.#P00>
M01R",TM%`#2H/3`_#Z?GTQCIR2.<Y<./\_X8'X#I110`4444`%'UHHH`_&7]
MJ3]H?]KK4/B+^V[J7[.?Q4\%?#3PE_P3C^$'@CXCZU\._$'PUTSQS)^TWX^U
MOX9^(OCKXD\#>,O%6J7MCJ/PX\"Q?#O3O#/A;PQJ?@()XG3Q?XHUWQ+K-_<:
M7X=TSP_JGZW^!?%MAX_\$^#?'>D0SP:7XV\*^'/%NF6]UL%S!I_B71[+6;."
MY\HO']HBM[V*.7RV>,.#M8C<Q_.O]IW_`()__$7XT_$+XQZ]\)_VF9?@7\/?
MVM?AMX7^$'[8?@-_A5IOQ"U?X@^#/"VG>(?"L>L?"+QG=>+/#<OP<^(^O?#G
MQ5K7PY\0>*;[1?B+I<FBVOA?5-)\-:5XC\.1:I>?I9HVDZ9X?TK2]!T6RATW
M1M$TVQTC2-.M@1;6&EZ9:Q6.GV=N&)98;6TMXH(P22$5`6;&:`/"M>^*?PY_
MX6AX!F_X3;PYY5IX=^)5M<R?VE#MAG:?P0%BDY^5R891M/.490217H'_``N#
MX7_]#[X7_P#!I#_A707_`(<CO?%'ASQ)]H6/^P-,\2Z<+(6T<BW1\1/H3>>T
MQD7RC9_V-@((Y//%T06C$?S]&(HB.8H_^^%_P]<X]L9YH`\\_P"%P?"__H??
M"_\`X-8?\*/^%O\`PO\`^A]\+_\`@UA_^MWP/8$GG&#Z)Y,7_/*/_OA?\*0Q
M1@'$4?\`W[4_EQZ9_ET)(`/.E^,?PK<N$^('A1S&P20)J]NS1.55_+E523%)
MY;QN$<*Q216QM92SO^%P?"__`*'WPO\`^#6'_"NBT3PY#HVH>++[[0ES_P`)
M/XA37C";:.(6)30-"T/[*'#N9P1HHNC,RQ'=<F/R\1AWZ+R8O^>4?_?"_P"%
M`'G?_"X/A?\`]#[X7_\`!K#_`(4?\+@^%W?Q[X7'O_:L/ZYQ@>ISQUYZ5Z)Y
M47_/*/\`[X7_``I&BBP?W<8R"/\`5J>JD9QCL"3^G?!`/.D^,?PLD1)8_B!X
M4ECE19(Y(M8MY(Y$<!E>.1"R.C`@HZDJRD,#@BG?\+@^%_\`T/OA?_P:P_X5
MTGA/P]#X8\+>&O#(E2^'AWP_HVAB]:WC@:\&DZ?;V`NC`K2B$W`MQ,8Q))Y9
MDV;WQN/0>3%_SRC_`.^%_P`*`/._^%P?"_\`Z'WPO_X-8?\`"D;XQ?"M-ID^
M('A2,,ZQH7U>W7?(YVQQ)N*[Y)&^6.-<N[?*BL>*]%\J+_GE'_WPO^%<UXF\
M-0^(H=%B-PMG_8_B?0?$F5MDF^T'0[T78M"-\?E"YP8_/^<Q`DB-\[2`>4?#
M'XD?#S['XS<^.O!Z++\3/',B";Q+HUNY1M6.UC%<7L4@#8RI9`'4AURC*S<I
M\=_A3^QA^U!HNA>'?VB_!W[/7QOT/PQJLVN>&]+^)\'@7QA::#K%S:-8W&HZ
M1'K,UU_9]U<6;FVN);7RVGAVQREE5=OTE/X?T&[FDN+O1-&N;B5@TD\^EV$T
MLAV@`O++;-(Y"@+EF/"X!P*B_P"$6\,_]"[H/_@FTS_Y%IIN+3BW%K9IM->C
M6J)G"%2+C.,9Q:LXS2E%JZ=G%IIZI/5=#\FOB;_P2F_X),>/O!^H>&/#GP2_
M9C^#>K7MQI]Q;?$'X2>'?A-X7^(&B?8+R*[=="\0-87<FEO>K&;2[G@B$SV<
MT\*NIDWAOPP_X)3_`/!)CX?^#[#POXC^"W[,OQEUBTN=2N;CX@_%[0/A-XI^
M(&M"^O9;M8]=\0)I]I+J@L%E%G9S3Q--%9QV\+LY0L?UF_X1;PS_`-"[H')Q
M_P`@;3.O3M:^O7TY.#C!Y^[^'GANZ\3Z'XC.DZ&BZ+I/B+2S8#0=,=+HZ]-H
M,YN6G\I3";3^PT01K&_G_:>700_/U?7\9[#ZK]9J^P]K[?V?.[>UY%#GO\5^
M1<OQ6MT.?ZC@[W^JX?:UO8T[?^`\O*GIO:_2Y^:_Q;_9'^#/@?X$:[\,?^">
M_P#PRO\`LN:UXQ^(GA+Q;X_MO#7B?Q)\%/#/Q%T/P_9W]C=Z'XL\2?LX>)O!
M'Q1>.XMI[:!(M&\4Z1Y]DEUIUS>K8WMY!<^4?$+]G'XW^//V9/!'P%'BS_@D
M_8:!/!XU\._%CX'Z_P#`_5O'?[--Y::WKEAJG@GXK^`]!U?QY8>,+;XN>!#;
M:EJ5Y#XFU'4M%\9>(=:FUJ?5-`U>QMM7;]H!X6\,<X\.Z!Z'&C:9]?\`GU_$
M^]'_``BWAG_H7=!_\$VF?_(M<LI2DW*3<F]W)MM^K>K.B,(0BH0C&$(Z1C&*
MC%+>RBDDM==$?CM_PR!XPT/Q/HWP]\,_M>?!O6OV6/&/B_\`9=^*/Q_MOB%%
M=:W^T7XK^(_[+'AWX.^']/F\*?$&T\>P^'5T;XS_`/"A/AC>_$2Y\4:/J6NZ
M%/;>*SX=O+QO%,)T'9_;+_9G^('[0?Q"^+5S\*OVGOV;/`OPL_:&^#GP&^&_
MQ>TWQSI-YXH^(.EZO^SG\7_'/Q.\+W'P\UK1O'NC^&[31O'VE?$C7?"GB]/$
MF@:MJ?ATZ=INN>&I;BYOI[:R_6\^%O#./^1=T#GC!T;3.<GD?\>O4C(]/7O7
M.Z%\.O#6C7GBJZ.E:)=CQ-XE?Q&(FT'38UT_?H'A_0S9JQAD\_/]AB[,^V-F
M-T8F3$*NZ*/RA^/_`.P7\-OVA+GX/:IXB_:%\!:)XI^$_CW]I?XWZ/XMT7Q&
MT-WI7Q^^*OB?P]XN^"WQ#@T&+Q5;>'O&&F?!C5_"^@--X'^(-GKOA+Q/:Z-I
MUO<:3$MM:M:?)'Q6T;]HS4/VO/#WPPT"V\$:SX`^)_[7'[$'[9'QZ^(=S\'K
M+4/A_:^+/@7;?!*/XI7WPC_:-N?C1=:'X<\!QZ5\$[:S\+>"OB;X,'QUT;Q/
M-J7AKPS8:YX$\3Z)XML_Z./^$6\,_P#0NZ#V/_(&TSL<@_\`'KV(!'OS2_\`
M"+^&O^A>T+KG_D#:9U]?^/7K[T`8Y^)/P[&[_BOO!/WF.?\`A+-``P6)Z_VA
MQU]#CT/2D'Q*^'1`(\?>"2"`01XLT#!!Y!'_`!,,8(P1@GKZ8)T+KPCX9N+6
MYMQH&@(;BWGM]_\`8NF-L\^)X=^W[,`P4ODJ2`P!4G!K-\.>`?#.@>'M`T%M
M&T*]_L/1-)T?[:^AZ9$UW_9FGV]E]I:'R)1#YXM_-\H2.(RQ0,RJK,`/_P"%
MD_#O_H??!7_A5Z!_\L:/^%D_#O\`Z'WP5_X5>@?_`"QK7_X1;PS_`-"[H/\`
MX)M,_P#D6C_A%O#/_0NZ#_X)M,_^1:`,<_$KX=C`_P"$^\$9)P`?%F@`DG.`
M/^)@<Y_/`)QP`>BTG6]&UZW>\T/5]+UJR29[=KS2-0M-2M%N(UC>2W:XLIIX
MA/&DL;O$6615D0E=K(S\EX@^'7AO7FT`KI6B6)T+Q-I?B(A-`TZ0W@TQ+M!9
M-^YB\D2F\WBX'F&+9\L99F*]K96%AI\1@T^RL[&`R-*8;*V@M83(P"M*8[>.
M)#(ZHJL^TE@JJ68(N`"Y1110`4444`%%%%`!1110`4444`%'Y<D#IGJ<#/3C
M)_#)//0E(<\8[$'\00<^^/3OZCJ`#\1_%?[6?[5":W\4/VK="^)/@JT_9A^"
M7[;&A_LC:Q^S6/AM87VL>,_`L?Q6\$_`KX@?%G4?BS=ZE!XCTGXCZ9X]\9W_
M`(D\+^'M&M5\%_\`"(>%[/1]6M=2UK7;K5=/_;@#&1V!('I@<<>G3IV.<9')
M_+OQ-_P3O\7:Y\5/$-O9?M#'3?V1?'W[1GAG]K+XC?LW7/PNT[4/%&L?&'PS
MK_A?QJ='T#XRQ>*+!]!^$GB;XB>"_#OCWQ1X.N_`>MZ]=ZPNM6&F^,-+T/6Y
M=.MOU%]3ZDGZ9_/Z]\9QDT`%>*_M)_&?2_V<?V=_CQ^T)K=@=5T?X%_!OXF_
M%_5-*6Z^PMJEC\-_!>M>+[G31>F&X%D;^/2&M?MC03+:^;Y[1NL94^U5Y_\`
M%CX8^#OC9\+/B5\&?B)IK:QX`^+7@'QA\,_'&DK*8'U/PCXZ\/:CX8\16,<X
M5FMY+K2-4NX8YT4O#(ZRK\RB@#\E?^"=_P"UG\?/BW\;[OP)\8_CEI/Q'T_Q
MM\!;/XU:-X>\5_LP?$+]F#4X;]]8\,VT_B']E#4O$6BMI_[0W[,'V;Q2VB:Q
MXG\8:QIGQ2\):S8^"M;O+75_#_Q/MET#]J5Z?T[#V'K]>_7O7YW?LV_L8_&+
MX;?$WP3\2OVB/VH#^TC>_`_X2>(/@=^S[;6WPDTCX57'AOP=XNO/!<_B_P`8
M?$V_TOQ1XE'Q(^+7B?3_`(=>"=$OO$.EVG@;PA9V6E:C<Z9X%M=2UV]NT_1$
M=/\`'_/'TYQTR>M``3@?Y]#G],Y]1D<YQ7YL?M%?M(?M/?#G]MG]BWX/>'/`
MGP_T#]F?XS_%#Q%X$\;?$C7/$K:[\2?B#K\7P&^+GQ+L?#/@?P-8:1]@\%>&
M/"5_\/[2;Q9XR\3>)/[;U^]U32-'\+>&O[*AUO66_2@U\S_&_P#9V'QE^*G[
M*'Q,;Q=)X=/[,/QA\2_%==&314U0>-3XB^#OQ%^$W]A/?MJ-DVA"T'CXZY_:
M*VVIF<Z6M@;6,7C75N`?#7[3'Q/_`&W_`(#_`!;^'OC^7XY?"2]T+XJ?M7?"
M_P""/P7_`&(O#'PVA\0ZM\5O@[XE\5>&]$\>>,]4^*NI'2/'FA?%;P7X(O/&
MGQA\2ZCHUA<_"/P#X<\)V6E:['KD=S=ZY<?K[W/L2/P[?F,&OR3T?]A3]KO0
M/VSOB/\`M:V_[7'P3\53^//%^E:?H6F?$C]DWQ!XN\<?!_\`9RT^YT@W7[.W
MP9\<1_M&:5H7P]T/7ET^\USQ=XHT/P!!J?CSQQ?6GB?QW:^)4\.>&=+TG];/
M7MDG\!V'X#`]!C`XH`/QQR,\9X^G?^7J",@_E!\%/VL_VL?$W[1'_!1WP'\8
MOAU\)?A]I_[-_P`!_P!GKXK?`/X:6WQ!M]3>.W^(\/[5(N=1^-?Q<O-+T+PW
MI.I>+[WX,:!?W]IH<=_X1^&WA:YMXI/$VOZFNOZ@?U?QGCUX_/\`+^8^HZU^
M,_Q,M/V$/%7B#]L;XG?%_P#:V\`?\*>_X*5>$_AC_P`$P[G08-:MO#$ME\4O
MA7)^TY\,/&'P]\->,3J%S/>?$77KWXT>(-&?29M'T]_"VH^#O/EN-1BO6^R@
M'F'_``2I_;O^./[3?Q83P7\0/BV?C-H?B?\`90\%_M%>*I/%7[-VM?LLZ[\'
M?B9XG\7Q>'1\-/A)IOB%+:?X_P#P<GLTU^5_B;HH\5V7A2\\/^&I=4^(FNK\
M4="T[3/WF`P`/Y=/H/8=J_*G]DCX'^)+K]H35?%WQ=_;5\'_`+5WQ$_8S\%Z
MS^S!H7A/X>?!WP_\'E^%?_"SM*^&7CS7;SXR1:3XM\9R>*?BUXH\'>&/AO<>
M3I$W@SP/HVCR-?:;X"LM0UEKFW_58;N@!.,#OG/?/I[9/7'8@T`>(?M`:5\?
MM>^'CZ!^S9XH^'W@/XBZYXB\-:5=?$#XB:5J'B.P\`^"+K5(1XW\6>&?"%G:
MO9>,O'^EZ`ERO@?PSXBO]&\)W?B":RN/$NJ#2;2ZL+[\[_@)^VI\1_!7PZ_:
MME^+/B^']K>'X*_M&Z)^SO\`LW?%/X?>#/#_`,-]=_:Q^(_B;P7X+GE^$.CZ
M!IE]+X%N?%G@+XNZ_KWPS\4?$?PW)IWP]M++P_K^L:[;:)_P@/CFXMO?OVH_
M"^J_M]?L]_%SX)?LG?M;:1\(-?T+XNQ?"/XT?$#PCH6K>-]1T:;P+>Z-K/Q5
M^!&H-X9\=_#3Q1X0UGQ1HFIZ7X>\2Z[X8\8:/XFT3P[KU\NB7UCJ5]!J%IY[
MX0_X)MZ%XP^$OP_^$G[76J_#SQ]H'P'\60:]^S/:?LB^&?C9^P-I_P`$=+3P
M?=>#[C2="_X4O^T=>>(KF673M3UJS2:W\3:78KI6JW%C/I<\LLU[.`>O_P#!
M.;XQ_&[X[?LG^#OB)^T:_@QOC1<>./C;X5\=1_#JUN[?P+::E\/OC1X]\"0Z
M=X4?4;>SU'4=$TJQ\.VVFV>M:A9V>H:XEK_:UY9VMQ>201_<HYKXO_8/_8N\
M'?L'_`NY^!W@KQ3XM\9:;>?$WXG?$JZUSQAXM^('BR^:[^(7B[4=>MM-M9?B
M'XW\>:EI]KHNC3:7HUTMCJUO::_JMCJ/C._L/^$E\2Z[>7OV@.`*`/S"_P""
MD?Q+_:8^"_@75?C)\/?C7IGP*^!GPK^'/B7Q7XLU;P=^SSXH_:H^-_Q%^*L5
MY"?!GP^M?A;INB2Z9HOPE;3+74+GQAXNLM=L_$DE]>V-H-5\":)IVI>*9/G'
M4_VJ?VR_VDEURY_9U^*_P9^#-_\`L^_L(_LY?M<?$+3+/P;IWQN\*?&[XP_M
M`Z!\5/%^C_".S\67&M0V^B_`FQT3X.W5C=^-O`VH-XWU&Z\;P7NC:NMIX8CD
MU[]`?VC/@3^TQXZ\::!X]_9K_:UF^`.H)X.U'X?>,_!_C3X5VOQN^&&NZ1?:
MHNJ6/CCP_P"#;CQEX#;PO\7O#KR7MCIOBN;5M<\/ZMI-S;Z7XH\(ZU:Z98+%
M\G:Y_P`$NO%G@SPWH/@S]E3]J36_@5X;US]E_P`"?L??'/\`X2CX8Z!\4]>^
M(GPJ^']]X]N]`\<^#M5AUSP-9_#GXZ:=;?%?XF:?8>+YM*\6^"8+?Q'IP?X<
MS1>&-)A`!^DWP*^*-I\;_@E\'_C/8:9+HME\6_A?X"^)=MHL\Z74^C1>.?"V
ME^)5TF:ZC2*.YETW^TC9R7,<:1SO"TD:*C**]5/0UR/P_P#`_AOX8^`_!7PV
M\&V+:9X0^'OA+PYX'\*Z:TTERVG^'/"FCV>@Z)9/<3%IKA[;3;"VA>>5FEF=
M&DD9F8D]=0!^,7[9?[2/[5/[,/[0'PC\4^(?C1X#\-?"KXM?M._!+X&?"+]G
M_2?@KK_BKP5XP^&/C+Q3\./"7Q,^(O[1?[46K:5HVG?`'XCP:CXS\4W'PWT:
MSOIO".H?\(UX&\,65C\1O%OC/6['0O"M!_X*-_&GXA?M<:?+X:^,6E>$_@C;
M_MK:K^QZ_P`-/$W[-'Q#E^!]U%X4\=/\,M>T;Q=^V)IV@:I'X8_:]\:Z\E]X
MJ^$?P[MDM_A3?V]Q\/\`X7^*=5TSQ=XKOO$MM]P_'S]AGXV_'?Q5X\\&ZO\`
MM?:W'^R#\8?&W@[QS\3_`(#^(/ACIOBWX@6:^%KKPK?:E\./A%\;+SQ39)\-
M_A3XSU#P9I5_K&A77P^\5^)-"N]7\7S^"O%OAN76K`Z'A7O_``3I\:O\2M3T
MK2OVD'TS]CSQ%^U'I'[97B/]G!OA3H]UXQG^,VF?$;1_C/=>&M%^-*^);6/2
M/@OKOQJT#3OBEJWA&;X=:CXM?6;K7=$M?'MKX8U2'2M/`/U-'&?K@<8^[A>G
M;IP.P]*BFG@@AEGN)HK>"&*2:>>>1(H88(D,DLTLLC*D<44:M))([!4169B`
MIQ-]>Y)_,Y__`%]O2N1\?>!?"_Q/\"^-OAIXYTLZYX)^(GA'Q)X$\8Z(-0U+
M2SK'A7Q=HU[H'B#2_P"TM'N[#5].-_I6HWEH+[2K^RU*S\[[18WEO<QPRQ@'
MY5?"7]M;]I']H3]JW]HCP7\(_#?P[L_@[%^QC;?%7]C:/XAR:UI@^*WQ`C^*
MWQ/^&UM\6_B7K.B:1J&M>$_@UX^\2>%]-@\$:3H=GK_B*^^&>FGXD-8V]]XO
MTOP]9_??[-.@_%GPOX&U?P]\<?VA-"_:-^*6F>*YAXN\2^'/`_A7X=Z5X*U#
M4?#/AC61\-[/POX8N;R6UL-&BU%->T6X\4W5SXNN]`\3:3-J]S=1O:7<_P`"
M^&/^"0WP]^!GQ9^(7QJ_9*^+OQ4^"?C?4OV,]5_99^#G_"<?%7]HK]H[P]\&
MO$L^J>*-0\/_`!/MO#7QE^/GB'2?%6A^$8]8T-/#GPEU"VLO"&BWWA]]5T=]
M.O-9U.67ZG_8"_94\6?L<_`)/@_XW^('@SXL>*6\:>(?&.N?%#PO\.-=^'OB
M#XB:QXEM=)?7/&WQ:NO%'Q)^*WB3XB_%[Q1KMIJ6M>,?B1K7BPW6M+>Z;I5M
MI6F:9H5C;@`^VZ***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@!"<=/4?X_GZ>^*_BZ_:Q_X)R_M#_M!?MG_P#!0;]F*R^&OB73
M_P!G[X8^#OVG/^"DW[)GQ,M].U]/#5_^V;^T?\(?@QX=^&OA_P`/7*6AT,^(
M?AQ\9/AC\6/%R66D-=:S:'QYJMX]E;?VG;7&I_VC=:3'UXY')P#Z@#@'Z`8[
M4`?Q6ZAX._;KO_V.OV9/VCO%G@GXH?"+PU^VU^V/^U1^UE_P4%^'NDVG[7NB
M>)?!UWXZ\':=X+_9;\)_$"R_8YN?`O[7T7@CPW8?#_P[;+:^"O[,TZW\31^"
MG\<Z.WAYI[<<'\9/#?\`P5W\C]G33?B#\2?VM1XU?]C3X$P_LN^--`\)_M;0
M^.3^TM=?%SQW_P`)Y<_$KP-\#OBQ:_"*[^,]AX%N_A7!X]M_VZ_%FK_#'5_A
MO%JDSWUIX@E^(6FR?W'\]<G)ZG/)_P`_IQC&!@[8R<>S$9SUR0<DGU/-`'\@
MWP"^$W[;GP^_;_\`V@O'/Q'L?CAHG[('CO\`;X_;LT'X4:7\$=*\>Z)K7@K]
MJSQ[\&_AW>>"OVK/B?X!\FV\.?'#X+^(;+P[XE\`?`Z/Q;>Z]\-_`_Q$ET[4
M];TY[S7$UK2?IW_@A?=?'_PS\5OC-\,/B59_M`?%?PO9_![P/K^J?M3_`!/U
MO]N[P9I?BGXG6_BK5M*U#PI\2OV<OVZ-6\3P_#_]I#4[%KOQ%XVU_P#9?\9Z
M[\%[S0['2;*[M-)O#HEI%_2Y^)_,_ESV]NAZ$8H],DG'3))]?7D]3UZ\9^ZN
M`!J\C////))(]N0.^>W)RQY)IU`&/\_Y_'N3R<DDT4`%%%%`!1110`4444`%
..%%%`!1110`4444`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pg24b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg24b.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"\`3$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_"BN=\5>
M+O"O@3PUKOC3QQXF\/>"_!WA;2[S7/$_BWQ;K6F^'/#'AS1=.A:XO]7UW7M8
MN;/2](TNR@1IKO4-0NK>UMH5>6>5$1C7Y3:+_P`%Z/\`@DGKGBY/",/[9_P^
MTR*>>&VM?'OBC0O'GA#X/7<T\EO#"8?C-XH\+:3\,5M)IKCRHM4G\4PZ3(\%
MR$OF$1)`/U[HJM9WEIJ%I:W]A=6U]8WUM!>65[9SQ75G>6=U$L]M=6EU`SPW
M%M<0NDT$\+O%+$Z2(S*P-6:`/RX\*_MX_$Q?VM?VO_A9\8O@I)\&_@C^S3^R
M;X6_:3\*:IJ^L:/XB^)_Q'\.2_$;X_>$/$WCN_T_P]K5[H'@_P`,W]I\%+N7
MP)X0O;F[\47>GR+XE\1WND2:W#X6T+PW_@GC_P`%#OC#^U3\9-"T7QA\0/V:
M_&?@WXM?!*Z^.>B^!?AMX#^,/PS\7?!>Q%UX7;1=&\'?$[XG:E?^!_V\?`QM
M_$[^&?B/\9?@GHOP_P!'^&?Q)T:UTN^\-7^C^--'N-*^V?%'['\/CK]JWX^?
M&OQGK6F:I\+/CQ^PW\.OV.M=\`6]K?VOB-(O#7Q)_:)\6>+-<DUP2M9#2]?\
M.?&^TT6PM;>W%_97^D7MW-,\-Q;I%X)^RS^Q'^TI\./B%^SS=?M#?&CX,?$/
MX;?L1?"7Q/\`!C]F&'X7?"?Q'X$^('C/2?%/AGP?X$7QS\==1UWQEXB\.:7K
MGA_X?^"[3PY!X/\`AEI5EX;U_7-7U/QE?W^GQVFA>%-*`/U+U#5-,T>V^UZM
MJ-AI=KYB1?:=1O+:QM_-D^Y'YUU+%%YDA#;4WEW()`/-8I\=>"5.&\8^%5.U
M6`/B/1@2K#*L`;WHPY!Z$<@UNWVG6&IPBVU.PLM1M@ZR?9[^U@O(/,3[DGDW
M$<B;TRVQ@%89)#+DBO)/AOX/\)R:5XB\SPMX:D*?$+X@QJ6T#2>$7Q5J("@?
M9#M``P,<`8X(```.]_X3OP1_T.7A3_PI-%_^3J/^$[\$?]#EX4_\*31?_DZI
M?^$+\'_]"GX9_P#"?TC_`.0Z/^$+\'?]"GX9_P#"?TC_`.0J`(O^$[\$?]#E
MX4_\*31?_DZC_A._!'_0Y>%/_"DT7_Y.J7_A"_!W_0I^&?\`PG](_P#D*C_A
M"_!W_0I^&?\`PG](_P#D*@"+_A._!'_0Y>%/_"DT7_Y.H_X3OP1_T.7A3_PI
M-%_^3JE_X0OP=_T*?AG_`,)_2/\`Y"H_X0OP=_T*?AG_`,)_2/\`Y"H`B_X3
MOP1_T.7A3_PI-%_^3J/^$[\$?]#EX4_\*31?_DZI?^$+\'?]"GX9_P#"?TC_
M`.0J/^$+\'?]"GX9_P#"?TC_`.0J`(O^$[\$?]#EX4_\*31?_DZC_A._!'_0
MY>%/_"DT7_Y.J7_A"_!W_0I^&?\`PG](_P#D*C_A"_!W_0I^&?\`PG](_P#D
M*@"+_A._!'_0Y>%/_"DT7_Y.H_X3OP1_T.7A3_PI-%_^3JE_X0OP=_T*?AG_
M`,)_2/\`Y"H_X0OP=_T*?AG_`,)_2/\`Y"H`B_X3OP1_T.7A3_PI-%_^3J/^
M$[\$?]#EX4_\*31?_DZI?^$+\'?]"GX9_P#"?TC_`.0J/^$+\'?]"GX9_P#"
M?TC_`.0J`(O^$[\$?]#EX4_\*31?_DZC_A._!'_0Y>%/_"DT7_Y.J7_A"_!W
M_0I^&?\`PG](_P#D*C_A"_!W_0I^&?\`PG](_P#D*@"+_A._!'_0Y>%/_"DT
M7_Y.H_X3OP1_T.7A3_PI-%_^3JE_X0OP=_T*?AG_`,)_2/\`Y"H_X0OP=_T*
M?AG_`,)_2/\`Y"H`B_X3OP1_T.7A3_PI-%_^3J/^$[\$?]#EX4_\*31?_DZI
M?^$+\'?]"GX9_P#"?TC_`.0J/^$+\'?]"GX9_P#"?TC_`.0J`(O^$[\$?]#E
MX4_\*31?_DZC_A._!'_0Y>%/_"DT7_Y.J7_A"_!W_0I^&?\`PG](_P#D*C_A
M"_!W_0I^&?\`PG](_P#D*@"+_A._!'_0Y>%/_"DT7_Y.H_X3OP1_T.7A3_PI
M-%_^3JE_X0OP=_T*?AG_`,)_2/\`Y"H_X0OP=_T*?AG_`,)_2/\`Y"H`B_X3
MOP1_T.7A3_PI-%_^3J/^$[\$?]#EX4_\*31?_DZI?^$+\'?]"GX9_P#"?TC_
M`.0J/^$+\'?]"GX9_P#"?TC_`.0J`(O^$[\$?]#EX4_\*31?_DZC_A._!'_0
MY>%/_"DT7_Y.J7_A"_!W_0I^&?\`PG](_P#D*C_A"_!W_0I^&?\`PG](_P#D
M,4`;MG>V>HVT-[875M?6=PGF6]W9SQ75M/'DKOAN('DAE3<K+NC=EW*1G((%
MFJUK9VUC!%:V=M;V=K`NR"UM(8K>W@CR6V10PI'%&N6)Q&B*,M\I9F8V:`"B
MBB@#\K?^"QOQ5TOX,?L7?\)YX@L/A)?^%;/]I']D71_&9^./A/PAXS^&>F^"
M?$?[2?PV\/\`B_7?$&D^.X9_"MF?#_AW4-2UG3_$>J(J^%-1LK7Q';2VUUI4
M%Q'^=>J_\%G/"7Q4NKWX6?#?]H?]CWQ7K^J?\%B?@Y^QQX(^'?@WQ9\-/B!J
M_P`4OV+/%6H_#73_`!'XEL/!DGBOQ#/XDM-2'B/Q1I1^(7AG3%\/V?\`91AL
MUBN+"YW?II_P5^^)TGPA_P""?OQL\9Q^!_@_XU+7_P`,/"4EQ^T%X-TKX@?!
M/X<P?$#XI^#O`TWQH^)WA#6[:YTO7/"?P;B\1/\`$2^M;Y8K(OX?B>\GM[$3
MRK_/Y\'/C#X5/[47P%_:.^#WP\_X)QZM^R[?_P#!17P/_P`$[/@AX(\"_L7?
M`K0_BO\`M-:AX6\+:78_%_\`;[^!?QP\(SC6]`T[P+\6I]3UC2/#G@S1=7\!
M6G@#0;RX?Q<FH/I>J:J`?V(>#_!WA'X>^&-#\#^`O"_A_P`%>"_"NG6^B>%_
M"7A31[#P_P"&?#FBV*^58Z-H.A:5!:Z9I&E6,(6&QTW3[:WLK.!4M[6"*&-$
M7I:0#&1G."1SUX."3]3D_C2T`%%8*^)_#;^)9O!B^(=#?QA:Z':^*+KPHNKV
M#>);;PS?W]YI5AXBGT);@ZG#H5[JNG:CIEGJ\MLEC=7^GWMG#.]Q;7$4;$\6
M>%V\4R^!AXE\/MXV@\/V_BV?P<NLZ<WBJ#PK=ZE<Z-:>)IO#XN/[6B\/W>KV
M=YI=MK$EFNGSZC9W=E%</<6\T48!T->=?#3_`)!7B7_LHOQ"_P#4JU&NOUR+
M6[C1]4@\-:AI6E>(9M/NHM#U+7-'O/$.BV&JO"XLKS5="T[6_#-]JVGV\YCE
MN].L_$6B7-Y"KP1:I8NRW"?,G[)NJ_%O6?#_`,2KSXI>(_AKKG]G_&7XK^&-
M'C^'GPW\6^`1%-X6^(/B71M7U759?%/Q;^)_]HKKDMO;7-E8V46C+H8CGM9K
MK7'E6Y@=G9NSLMWT5]K^HKJZ5U=WLNKMO9>5U?U/K&BFD^A&?3//_P"OV[XP
M>#7RK^V3XT\??#CX$>._'GPT^)?AKX?>-/!G@_QUXK\-Z;XD\*Z5XOA^(NO>
M'/!FM:SH/@.QTK4-<T.[>\UK5[*TMUBT2>;6+M'-K9(D\R2)RXO&83`8>KC,
M=BL/@L)0CSU\5BZU/#8:C!R45*K7K2A2IQ<I1BG.<4VTEJS>AAZ^*K4\/A:%
M;$XBJ^6E0H4YUJU25F^6G2IQE.;LF[1BW9-[(^K**\[^%G]M?\(3I<NO_$K1
MOBW?7$E[<+XZT'1-(\/:3JMK+=2?9HK33M#U/5]-5;%!]D>>&_F:>2)GE"2;
ME'HF>,CGT]ZTH5Z.)HTL3AJU+$8?$4J=:A7H5(5:-:C5BITJM*K3<H5*52$H
MSIU(2E&<6I1;33(J4ZE&I4I5:<Z56E.5.K2J1E"I3J0DXSIU(22E"<))QE&2
M4HR332::"BO`_BO^T3X*^#GB+POX:\5>'_BCJ-]XSNK+3/#MSX+^&'C'QII.
MH:YJ,>NW5KX?&K>'],O;&WUPZ=X<UC5)-,N)8YXM,M!=R%8I81)[O%)YL:2`
M.BR(L@25&CE574.%EC<!XY%#`.C8*,"K#=G;J02T4F><8)Z9QC/.0!S@`DX[
MC@]1UKP+2OVG/@SK7Q)D^$6G>(]?F^(D3QB?P]+\-OB?9K;VTU]K6EVNJ7.L
M7O@VUT&WT._U/P[KNGZ;X@GU.'0]3O=(O[:QU&XFA=(P#WZBD!R,TM`!129'
MJ/SKP_Q9^T7\)/!'Q`T[X7>)-=\06GCK5[:.^TO1;/X=?$G7(K^RDETV"6]M
M-:T'PAJ>@S66GS:OID6L7J:FUMH3ZA:#69+(RH&:3=[)NRN[)NR[NW3S$VEN
MTO70]QHH]NXX/UHR/7KTI#"BBC(]:`"B@<].3[8],_3IZFC!'4$9Z9QVZ]"?
M4=?PS0`449'J*,@=30`?Y_SU_D?H>E(=X/(P.W!]^N?8$G'3.>BDMG:Q%9W&
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M_P`_X^@+`!F6F@@9RW<CD^GU`/Z#UYSDNR/45VG,%%&1ZC_]?3\Z.V>WKVH`
M****`"BBB@`HHHH`\._:*^,'P8^!7P>\7_$3]H34+32?@W:6]EX>\=WVJ>%-
M8\:Z!'HWC"^MO"TD/B?0M$T;7YI_#%W)JT5EKMQ=Z9/H]IIMS--JY@TY+B2O
MS&_99UO]G[]HS]O/1_C#^S+\0OV,/B_^QW\$/V+O#OPV_9QTCX*ZW\#_`!!X
ML_9_^.7B_P")/B35?C/IOAGPGX3L_P#A-OA#9>+/A+IOPIT_7=+=="MYX-#A
MTV;1[:2&]CF_8_Q!=ZW8Z!KE_P"&M&@\1>([+1=5NM`\/W>K+H%KKNMVEC/-
MI6BW>NM9:DNC6NI7Z6]C<:LVG7RZ='<F\:RNA!]G?^9W]@NW_:)_;#_X*#_M
M0>)?VY_^"87[-NBR_L\_M(^&]1^'?QTOOB-\+/&WQ5_91\1:)\$?A]XU\*_#
M'X:^+/#W[/W@CQQ\;_#&N^*=>O?'5]XUE\;Z-I&@>(O%FMZ+/H.J3:&)9@#^
MGP=./\^GZ?I[4N<<]<<X]:09[@@GD@]03S@].>?0`]0`,4O6@#\1/A[X#\,_
MLU_\%7/V[O%_@3P]\2?B;XD\0?\`!-?X!_'KQ3H,OBS6O'WQ(^)?C1?VBOVU
MS8>%?"K^+M9DM-/\W2/#6A^`?A]X3TV70_"^CV=GI&F6UO:QI/<M\O\`_!-W
MXE>*?$__``5*^('B?XM?"#]ICP7^T#\?/V"_!?COXS7'Q8^$WBOP5X6\(Z]I
M_P`>?B)<Z!\.?"TFOZA=1Z?\,_AKX9N['X8^"-;MK2T@\>^(=#\3>*+RVAUK
M7+VWC_H]C\+^&HO$]WXUB\.Z#%XRO]!TWPM?^+XM'TZ/Q1?>%]&U#5=7TCPW
M>:^ML-5N=!TO5==UO4].TB:Z?3K#4-7U2^M;:.YU&[=U'ACPXOB27QB/#^AK
MXON-#M_#$_BM=)L!XEG\-6M_<ZK;>'9M=$`U630;?4[R\U*WTA[M["#4;NYO
M$@\^XE<@'"_&_P`.^*_&'PH\>>$_!<.GS^(/$WAC6=#M#J6K7.C11?VE83VS
M36UY;6-]F[5I%\B*?[);.[?Z1?6Z!I&_,/\`93^"?[3VD6/Q#U#X>?$#P=\/
M[7_A*]4\%:VVM6!\7#4_$7P_U[Q!H&M)90QADL8K'5$O`=0P#K,5Q!,@9(LC
M]4OBI?>*M(^&?Q"U3P)+!!XUTWP;XCO_``E+=>']4\5VJ>)+32;F?1C<^&M$
M9=8UZ`WR0)+I>EL-0NT9X;/,SIC\>?V&_P!H+]L"RTCXJQ:[^SKXZ^)/AN+Q
MYK6JW4U]I^G_``T\1Z5\0==U_7]0^)UG9MJ-K+IWBNRB\3O+:QZ5:K9:CX7E
MMIK;5)[E+VS2V_*.+OHY<)>*G&W#?B1FF=\0Y7Q)P/@,5E&3X?).-JG!OUC#
M9Q3Q]/%3>+P<\!FBJQIXJM&4\%G>7NI3<,/4AB:4ZM&K]+A_'W,_"?A+.>&7
MD]+,>'>)<32S+-,2^`LQX^EA:^7U\KI8:E4RS`X'.4X5JKHU:4:^18^E2CA\
M7C95<)]6^L4_LJ\^$'[=MP3Y?[37@6%=R[O(\&RVS;5SG!&ES@,3U^4C`!/<
M'YT_:7_9W_:'@^#GC[XD_%;XU:;XZT7X->!_'?Q2.A1V=V9[Y/!WA75M=NK'
M2@-)TJ"RU+4;/3Y;""\N9[J&%YD9H&1"I^KS^VE8Z&@_X6+^S_\`M$^`-@#3
M7=S\/Y/$&DP``[C_`&GH5U<(Q7!(VPL6&&4'I7RS^VM^TE^Q[\?/V8_C#X$U
M#Q3?:GXXU?X7_$C0/AQX1FM_B#X6U^[\=^+?`FN>&-$B&G:1)I,FHVJW6I(=
M1@U![O3;6RBN+F>$B$L<>(/HC\%<491C,ES[)?$GB#+<QIT\/BX8KQ;\6\_P
M=>*KTZT%4H5N-\PRF?[ZE3:=7#2BFDTE)1DO"X>^F5D^"SG!U<GX[\->'\[H
MNK5PF"QG`OA_PAG$''#U?;<F%S/A7)\ZA*&'=6=2W+.%.-3GM"-1'N7PX_9]
M_:^^$>@VOA?P=\<_AI+X;T=9O[&\/ZUX,U"XM46XFEO)X6N_+:\MTDNY[B0M
M'-<,OF$C9G:OH@\;_MH>%48:_P#!;X8_$R&,-FY\#^/;KPO=3G:2I%MKVG7^
M.BG*VQ[*HSBN"\#_`+8W[%_PZ\*:;X:^%/BG6_$6DOYNJ66@^%M-\?>/-8CN
MM5E:>Z@N;G6WU+4HKQ;HO!/8W>HA;"9&MA'"(V5>L_X:P^(/B(J?AG^R5\</
M$\,F[R-1\7Q:7\-=+E;`V2?:-7_M.Y$#C:PF6T;@L2@90*Z,K^C-B>&\!E^!
MX*XP\6N`<ORW`X;`Y9AJG&JS7)\-AL)1IT</##Y=XHX?BC*:5"G3IPC##8:A
M0PM.%J5&C2I<L%AG'TM_#_,<US./$:\-N/\`.98[%/-L/P[PECLTS^..EB*C
MQ<,8O"*GA,Z^N*NZD*TL7[3%>UC/VSG54V_B3]HS]K?XUQ^-_A]9^*OA3I/P
MFU#X=:]IWQ/T3PWKNJ7?B>\U+4H],\:>$8-7N=4BL_#<,GA^\L-?U6S6QMK!
MGCU+3UN5U=P6LT^KH/VQ_BQ<0PRVW[*_Q"O5:"!WG6Q\:6L;221+(&A23P)-
MOAD#"2&1)'4QR*H9L;G^+_VP/CG^VY9?$7X$++\`O^$<@TOQCHWBOP7IGA'2
MM1^*MIX@\>2P>*-,L?"OC?Q-9Z9;PPVC^$8_&4TV@^&8EU^.RGN=<*H]KI;+
M]\Q_MAZSX-BC7X^_L_\`Q4^%"&.%I_$ND69^(?@:/S$1GFFUO1+>UN["-6W%
MX;O3!-`BE9=Q4M7AY%X!>/F39YQ+FD?I*U>*L)Q!6PM7+\CK\)\(9KC>'H8.
M6)I3H8:AA\SH994EC/:PGB'D>2X2A-T(.5"G*,#UL^^DMX#?V%PRLW\',UX'
MI8>EBX5,_P`UCQ]D&59GST\!4>(S?&YAP_+$9'3H<[AAH\6YO0Q$Y2Q'L)5X
M4:TCFQ^UK\?92JVO[&_CB=G(\E9-:\0V7F*QRA:2;X=,(<J2Q$@R,;>#@CY#
M\#_M=_&?5/VD]<\4:;\+](\6>,/%'AFP^&%U\,]/U*^T:^72?AWK7Q!\5V%M
M#K4UMJAAUS1;CQIKK:Y=S:(8=1L;"W@&GZ7)ONJ_5WX=_'[X,_%A(3\/OB9X
M4\27$I"_V;;ZM!;ZTK'!VMHUZ]MJFY3@%5M2`PV[B6KX*\`^+_VW;C_@H5X_
ML/$O[,O[,FB_#)_A'\*=)UCQMH7[7WQ#\0>,-+^','Q4_:)F\.>,M.^'MW^Q
MMX<TG4O'GB)9I!XA^'LGQ#TO2?#\<=C<P?$GQ,;UK.R\7B[P;\<\SS/AFI1^
MD9Q1PW'(<XHYCF^`H>'W"^$GF^"A6PLIX&K3P\,%249PI5J:_M;"YS@/WT?:
MY=5C&I&O]QP9XL>#N+RC-\7EOAAPQQ?@\YRZ>$RO-<'QSFF:X/!XF5*M&.*H
MXJE/&J;C*K3G+^S<5EN+?LW[/&TI.G*A[U8?M!?M2WI0M^Q9?PY"$F;XR:;`
M5#,0>+KP+"<*!DJVWGKM[;@^+/[6-[@V7[*^BZ<'`*KJWQETJ8HI^3#&V\/P
M9(;$C;0,1X498FOJ;Q!XBT#PII-WKWBO7=&\,:%I\9FU#6_$.J6.BZ18PJK%
MI;S4M1N+:SMX@H8LTTR*%#9('(_,+XN_\%J?^"<?PFUB3PI;?'VP^,?CSS6M
M[7P#^SUH.L_&GQ/J5XKB);2P7P7:ZAI$UP\K(BEM52,;@SNJ'</J8^&W',TU
MB_'WQ,J1;3<,+D'@Y@(JRVA.GX7U*\8[Z.N^EV[:\?\`KCPQ#^!X4<$J25HR
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M^&M,ATC2;&*RUG2/`.@Z3J'A-=-TS4_A_P#$#P+J%]XP\8:W<:S;W'@BZUW6
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M=.U/XF?`SQ5>HKAI-T-^FJ>'+2Y=`WEJIN;=6<A@^`[,_P"'D'[?OP^:-/CK
M_P`$=?C[%:VY8:AXB_9T^,7@'X\V;H@VO>V^@_V1X.UF-9&`\NR$EY<*"A,S
MC++]6_#+BV@FLL\=/%+"+2T,9@?"O.H:.Z3GFOAMB,4ULFUB8S:^W?5?/_ZZ
M\/UO]\\+.!*[T7/AL9Q_EL^EWRX'C>EA^9[ZT'%/112/JUOVK/VB[-F_MK]C
M#Q?IT:D[GL/%>L^(?D&07`L/AU$7&`2`O.WOTS$_[:_B&R_Y#_P3\4^&!U<Z
MUHOQ*`C4@C+-:_#J<!3G(*Y!STSR?EJ+_@O)^Q1X>N5T[XY^%OVI?V7M43)O
M+3X_?LY>/_"=O88&";K5-*M-=TV)02#N-U@J0PX)*_5WPO\`^"IG_!.KXQ/;
M0_#_`/;/_9_U&[NMODV&L?$/1O".HO)(IV0&Q\6SZ)<_:'.%6$(99'"JBNY`
M9K@WQ:P_^Z>-$<7;X?\`6#PWX9QNR6D_[`Q?"KDFUKR\CLVHN-R%Q!P%5:>)
M\.*F'3O?^Q^,\YPUKVOR/.,+Q!L]N;GMI>[."^(O[:_PV\0^!/%&B^*O`?PZ
M^(NEWVGBVO\`X9>,(/'(T_QA$;NV9M(O+3Q=\(+KP[*@8"\9-5@EMP;7=Y;S
M"-3\W?L6?'_P1\"/AAJ?@3PC\!OAYX/UNY\8^,?$%Y:?#72M;6X\8)XJ\;^+
M/%>BB[B\&_"BVB+^$=$UZR\*6C:O.[&VTX#3$M=.,5G!^G7Q[GD^)W[/'Q'@
M^%4WA/XBZEJV@0)H$,'E^-?#VIW:ZII\\4<]KX?OTEU"%4ADF"6E[$Y>(2A_
MD('Q?_P2+M/BO)\`O%GB+XL:/H-AJ^N?$3QK:Z=?:#X9O_#8U33O"_Q&^(7A
MF%;L7-[=07_]E6VG6FF64MF(5AL;>WANO/O!-<2?(8WA;Z4E3C/**V$\6_#"
MEP-3RS$4LYI4_##,,/FM3,Y?7?J]:AEF*XISB>(E%3P:6*AQED^%@Z<Y5.'\
M;[":Q_T&&SSP/AP[CZ6(X!XYJ<2SQM*>7U)\;X&M@H8-?5?:PJX^CD&70HIN
M&);P\N&<QKRYXJ&:X;VL)8/VC3OVI_VA==N47PY^QSXJU73Y,@:CJGB_4_!P
M(P0K+;:]\/@H5LG:[W"C';!)'8MXQ_;4\2`_V+\'_A1\/89U_=W'C#QW>^);
MNV!R3YD&AV-FLA`;`(@4,<C"U]A[LD_,<X(]!UR3GGU)!YQCTXHX_NY`ZDC!
M]A@YYQCC)Y.,]Z^LEX:\:YCS+/\`QO\`$"M3FO>P?#65<`\*81-O54L3AN$L
M?Q#2C;W4EG[FDE)3=1<YX4>,N&L'_P`BKPQX3A--<F)SO,.+<_Q.ZLYT*W$&
M$R><KI7YLH46[KV?*W&7PGXK^$_[:_C;1KW2=1^.GPLT2QU>SN=.U32M#\%7
MXMC8WT+VUY;+J%Q#+>2++;2R1$GRF4-@.O#5\F_`;]EWXU:/XE^,4/PS^+^E
M^#]5^'?CQ?A+KM[;6E[:KKKVG@KP'\1HKZW#6&L$::L/CRTLC8S10S+=:?=S
MFZ>WN$C7]?\`Q9:WVH>%?$UAI=UK5CJ5[X?UBTTZ^\-3Z3;>([2]N=.N8;6Z
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MY/Z$MO@Q^W9;2YC_`&G?!TD("[%O?"\U])D$,=TAT2V#ACGG`(0!<LHR.ML_
MAS^W!;X\W]H;X9SC!_U_PV>X)R0V"=D!ZC:#D%4P!7VN"1V)R3C@DD\D]NG'
M4]3EL\TOS9^Z?R)]/0>_Y@C)SQ]+_P`0.X-I)+`9SXIY;963POC7XNU>B7PY
MAQKC8]%9<MELE;0\=>*'$<O]YRS@/&=?]H\,O#N+VMJ\/PQAY-M;MMR>KO=M
MGQV/#7[<=J,Q?$WX#ZL0/NWOA#Q#8EB3R";+.-B#*D9).5;)V/7R=^S5KG[7
M<OQ[UG1/&-QXJUJ#P]HFI77B70O'.N7^F^%M-?Q$+F;PQ=3RV6EZY-;?;WTV
M^DT&.#3W$MM;7$3R6RH-WZ[#=N7Y6`SG."!]#QQ]>>GY?AM^R%K,&J?M\_%E
M+/XR:OXOEDM=/MKOPL?AW^U7I1CD\$6'Q`T'7[?6M3\??M+>.?`VE0>&-9UO
M2K&&]U[PAX@TK5;R[MK?PA9^%IW@E3P<7]':ECN*.#.*\)XE>,"I\!YO#/*N
M38SC;-L^R;-X+$8&2PN=4\UEB:WU&<\-"A42Q$56CB)PD[N)Z-#Q@GA,EXBR
M'$\&^'+GQ;@)931S"APSEN49G@:GU;&.5?*Y8&&'A+&4Z52KBH?N93I?5O:)
M<D9V_7S[=\8_^A7^&/X>//%W\A\../Q[8[8H^W?&+_H5_AE_X7GB_P#^=Q7I
M:_X?CZD^^<@^XQVIU?T`?E*V7]?Y&;I3ZI)I]H^M6VGVFJM$#?6VDWESJ&FP
M39(V6E[>6&EW5S$$"D23:?:/N++Y.TASI444`%%%%`'E'QK^$UC\;?AMX@^'
M%]XV^)GPW.M?V?/8>//@]XSO_`/Q&\*:MI5_;ZEI>L>&?$=BEQ'!=6UY;1&;
M3]4T_5M!U>U:?3-;TC4],NKFSE_,>P_8/_X*<W>J#P[XN_X+5?$C4O@RJV]F
MVG>#?V*?V</!/[0MQIELUN\:77Q]>Z\2^&UU>[$4T6IZYIGP0TR>>&XS90:;
M<H;J3]&_VC?B1\4?A-\(O$OCOX-?`7Q#^TS\0=(DTA-%^#?A?QEX2\`:SXGC
MOM5M;/4)[3Q3XWF@\.:>FD6,\^J2K>RAKF*T-O;?OI4)_$3XZ?%+_@I%^VGX
MI_9)^&NO?\$I_B]^SIX1\"?MP?LN_'3QW\6/$G[37P`\6Z/X?\#?"3XB6WB+
MQ2+OP[X,UH>(-7%SI8F5+*S27S6&7AF`$$H!_0#X!\'6'P]\%>%O`VF:IXFU
MRP\*:'IVAVNM>-/$>J^+_%VKQ:?;I`-3\2^*=<N+K5]?UN^9&N=2U2_GDN+N
MZDDD;`*J.NI`>6QC&XD8]R3_`"(/XTHY('K0`45\`_"W]O+3OBO^U?\`M#_L
MT:1\$?BSH.F_`#X)^$_BY'X_\8:%J?A?4_BU/XC^(OQ<^'5[IOPL^'>MZ18Z
MQK/A/3M6^$FJVNB>/K[4["S\;:O=R0>'=&F\.6FG^*=>Y+X*_MH_M$:S\=?@
MW\&/VHOV2_#W[.TO[2_PT^)/Q-^!C^&?V@E^,GC72H/A1'X,U#Q?X(_:"\%3
M_"7X9V7PT\;VFA>//#]]YOP]\6?&GP5:ZV;_`,+7WB^UOH]%N_$`!]T?%GQG
MI_PX^&'Q&^(6J^*-!\$:7X%\#>*?&&I>,?%6D7FO^&O"VG^&]%O-8O?$&O:'
MI^N^&+_6-+TFVLI;V]TNQ\1:'>:A!"UI;:G92R+<)_,1_P`$[/\`@OM\.=?\
M&_%A/BU\,?BSXFU1OBSXV\=06?[-'[//C;Q[I?A_PS\1/$VO>++#Q)XTUNV^
M)/C.YTV;Q&UU/!IOA:30-,;P\NBW4(\2>-7N9;ZQ_JAU_4/[,T+6-4&C:EXC
M_L_2[R]_L+1;:UN]7UH6\#R_V7IMI>W5G9W%Y?[/L]M!=7EM;RS.J/.B`R#Y
M/_8UU?6K_P`-_%2UUCX4>/?AA,_QO^+WB.S7QEHWA[24U?2_%7Q'\4:KIBZ>
MWA_7=8$L^FVKJFI07"VRV<MS'%$\^9?*WA.A&A6ISHRG7G*FZ5=5>548P;<X
M^R]F^?VB;3;G'ET:^&SAQDYQ:DE%)J4.6][VL[WT::[;-GP]'_P7R_8&@D$/
MB"']ISP;(IB65?%?[+_Q=TM;<NAD?SI4T"XC(@BQ+.T;.JQ$2`NN2OSA^V+_
M`,%GO^"67Q@_9H^,_A^T^(5_XN^)4?PY\47?PK\/7WPF\>Z/XJM?B:VCWL/@
M2^T;4]8T+1[?2KNP\026%[<W$VM65M)I,-[%<F]MYI;&Y_HYRXZ;^W4,1].0
M<?7MUK\YO^"H/P*^%GQ^_99\<>$_B)\$O%_QQ\2VGAOQ_J_P8T'P=X:\8>(K
M[2/C+'\._$UCX#UVYMO"-S:"V\G5[J"VLKOQ`TFAQWMQ"+O$0\P5@ZRP^*P]
M>4Z]-4JL*CGAING7BHR4KTIJ<'">EHS4DXO5.Z,\30IXFA5H5J5&O3JPG3G2
MQ%.-6C4C.+C*-2G.,HSA*,G&491:E%N+5FSY4\+_`/!<7_@E%X!\-Z/X9^%W
MC3Q3<:1IFF6-M8>%OAI\`OB;J4VGQK;0&.RG@TSPHJ37Z[E2YD-Q<R7-VLTC
MW5RTHFEWXO\`@N%\`M?`_P"%<_LM?\%#?BJ64^2?!?[(OC=_M)*[U6$ZW<Z0
M274QE2XC7$J$E1N*_I3^S%X*^%?PW^"7@SP%\$/AWXE^%'PO\*0:AI'A7P)X
MIT+Q/X?UC0[5-3O+FXC?3O%\EQX@CM9[VYN;FSENYY$DAE!M6%L(D7WSYO\`
MII_X_P!_PY_'..V*RJSYZM2?/4GS3DU.J[U9IR=I5'S2O-JSE[SUOJS2G"-.
M$80A"G%+X*<5&";=Y<J22LY-N]DVW=ZL_D._X*`?\%[_`!M\./BK^S_HVG?L
MK_$?X-_\([XDTOXOKX-_:O\`AV_@;QYK6F"Q\??#Z+Q5H$>F_&+3(KG0+N?Q
M#>:;;:7J^CZ+#%K.@WMY-XPN+5CI-O\`J/:_MS_\%7/&]K:R_#K_`()#6.@6
MM_;17%EK_P`5OVS/`>EV<L,\:RP7#Z%X>\`:C.MO-$ZS*5UI_E<("Y_>'[L_
M:3L/B5J_C/X'/X*^!.N_$W2O`GQ,T?XB>(_$%CXF^%FBV\>FP>$OB7X4N/#U
MK:>./%NAZQ=ZM:7?B72=80+8QZ/)97%P(-56_MWM7^N8O,:.-GA>%FC4M"=K
M-"S`,8B8B\3-&?D9XF>)MH$;,@!-59T94L/&G1E3JTXS5>HZO.J[E/FA)0<(
MJER1;A9.7,K-NZ;;2DI3;DG%M<L>6SC9)/6^MWKLK'\]7CSX,?\`!73]H!Y9
MO$O['_\`P2]^$NJ7+$+XEUOQU\5_%_B?3V=R8[Q]2\#6&E&ZNH6+2*S)(6=0
M`2`H'Y3?`']C/_@HOK7_``4(\6>$?$'[=GPT^!'B#Q)X5L]+\>_$/X$?&GPK
MX\\8-X-@O/'6E^#O"7@WX<^*/$%KK]SJ-SK7@74]/O+&\DN=8\"6-UIVJWUG
M=M''IA_MQP000AP"#]TYX.>XYY`SQ\N-PW-A1\M:'^R+\.?#_P`:+KX\V>N_
M$"7QS>Q6=E=QW>K:'+H5SI.FZMXIUS3-'?38O#,,L=EI^J>,O$%U#-!=0ZI+
M]K2.\U&ZB@@C3T*6=YI3PM3!/&8BKA:E.5)4*U>O4I48R5I.A3=50IR:23LN
M5\J35KW^<PW!O">"S3%YW@>&\BP&<9A3C1S',\#E.`PF/S&C"I[6-+,,70P\
M*^,A&I[\5B)U'%_"T?EIJ/\`P;\?LZ_$+68_%'[1O[1/[5'[4OBM2DG]K?'#
MX@6_B>SCD1M_^AZ%_9\&E6-L)`'CLX(EAB8,47YC7V9\)_\`@F=\,O@9I/\`
M87P>^)?Q,^%FD;=OV3X;IX.\$R2G`4M>7^A>'+;4=0;8H4-?7=PR@`!@``/T
ME`QCY6..^UOTXX^E+S_=;_OEO\*G#9SF&#A[/#5,/1CU<<#@'4E:VLJKPSJR
M=KW<IMN^M[N_DYUX;<(\18KZYG6%S?,*UVXQK<5\6+#4^9\S5'!4\[A@Z$5)
M)QA1H0A%J/+%<JM\6/\`L<-<,?[0_:7_`&H+T``H#\33;LKY(#&2+3MSX!("
ML<#J<G@_*'B[]BA+7]KSX1Q0_M$_'_R/$'P^\?>(XM6G\7W%S\0-#F\`3^&M
M-;P]X=\<-+%+HW@SQ*GCIKO7_#D6C7$=[<V%PKW#)K4CV/[`D$]F_P"^6_P_
M^O[U\_\`C']GC1/&?Q4T#XNW7Q!^,&A^(_#&G7&DZ+I?AGQJ=)\*VFEZE/H=
MQKMB=!.DW$,L7B*;PYI#:R99I)I_LO\`HTMJLLP;KAQ1GM/FY,=;FA.G)+#8
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MQ\4/\!_VK(89(HOVR$U1'4I);Z_\"_#%S;RH[*&298_$CI(@0?*K1%68MN`5
MLCY:^)G_``33O_BV+D?$G0/V)/B;)>,S7-]XO_9&\)66LW,I*CS9=<T*>VU8
MR1*@D5VNW82<;E`#U^OF/]EOKM;_``_^MT]!1@YSA_3[K=/3IQWZ>N>N"%_K
M!C9?Q,+DM7OS\/Y''MI^[R^#MIW^^XUX/\,TO]SSWQ.P.B7^S^+_`(HU%=/=
MK&<78J$NUI0::5FK-G\P'Q8_X-_8W\.>*]6_9ZTGX'?!;XK'2;^;P7XB^%WB
MSXZ_#.RT_P`0R1(D-Q+IFC^)+JR82Q"=EC?9:BZEC2X86BR./"OV!_\`@EC_
M`,%//#OP:@N_A[_P43\8?`CPC;>*_&EKX/\``>B7NJ:OX<T^]TWQ;KFG>.[C
M6/`VN6NM:79W>I>/K7Q#=RG3]6B:_N3>:I?6WGZB)&_JW^*'@O\`X6%X`\4>
M"OL/@/4?^$BTTV'V+XI>`6^)_P`/KC_2()Q'XI\`?\)!X3_X2?308<C3AXBT
MG%P(+C[3^Y,<GS_^QI^RPO[)GP[UKP"C?!.Z75?%OB7Q0-1^"_P!?X"P77_"
M2>*/$7BAK3Q+IA^)7Q+/B&717\0OHWA^\^WZ<-.T*Q@L?LTI/F(IYW*I1G1G
MEF46J2IRDZ>">'5Z<:D4_9X6KAZ;E:H^6?*I1M:+4923][+^"?[+P57`X7BW
MC><:N(6(6*S+/WGF/HM/"/V5#&YYA<RKTL,UA7&6&4W0G]9Q,ZE.=25&='\Z
M])_9B_X+L^"+;R=`_P""CG[,GQ)2),I;_%3]G":SNKAP1MCGU;PUYDL6#E6E
MCMFWD`^6I)QR7B+5?^#B?P:)@GA/]B;XPVL0#-/X`\37G@J_G5`I!LX/&NB1
M!'EY9UE63#,P0!,,/W^V_P"RWUVMGGKSC-&WI\K<=/E;CG/IZBO-AB9TJCJ4
M:>'IN]U&>&HXJFNR4,=#%*RLM[M]6VVW[F*R+#YA@XX/,<=G6)BH\LL1A<[S
M+(<74TMS3Q'#&(R.:D[MMT^17:LERQM_,?XE_;2_X+`?#_3]7U'X[?L<?M!>
M$/#6FZ;?7_B+QE\$!\#?BQI_AW2["SEFOM<%M-<^'9C;65O#)?3O)/$(41I)
M65%-?G7^P9_P5(U;Q;JGQNTSPC<_MV>-=4OO&%UXN70_V6O@7H/QTU76?!U_
M>/:Z9\5/B@=0^)$EYX2\>^)]2$MCKR:/:WGAVXD@@M(-7OY($\G^VWQ!->6F
M@:Y<V`/VZWT?4I[/=HMYXB7[5%9S20`Z!87NEWVNJ9E3=H]GJ5A=ZF/]#M[V
MUFF2=/SH_8>U3XW2_%']I`?$G3GTS0?&7Q*O_'?AYF_9*^*?P(CUN-/AG\$?
M"<6O6/B?QI\9_B'I4%A/>:!K>F'P1/I+:_>7VF7GB-=:M=-$6GR^U1XFQU'#
MXB@J6`4JWL>2=+*,DI4X^RES?OJ$<K<,1=?`ZC3I27/"TFV?)KPKX55+$T)8
MCC'$4,6TZZQOB5XDX[$0Y6FE@L=BN+JN-RZ,G?VZP->A]9B_9U_:4XQBOS#C
M_;6^(.J`S77[/W_!=S7K5\H7MO@#X4\&+(RY65!8#6+B[@4$[?,>5Q*I$D8R
M`:K3_M,ZQJC-*_[`_P#P7!\6V9`61]?^R:()9@29D.FQZU;X0%V"R*P1DD=5
MQM&/Z=!O[^9^&_IZ<$YQZ\9ZX[D^;_II_P"/UA_K)G2^#&JC_P!@^%P6%MZ?
M5L-2M\MNAQ?\04\,9JV)X9EF2Z_VUGO$N?<VU^;^V\YS#FO:[YKIOH?S`)\8
M;>^GCGA_X(W_`/!43Q:%(CDN/%6OVME.9RP8JUK>>,X_-1B$D:<`1EW?IM-9
MW_!'/]N?]DOX^_MU?M#?#'P-\&(O@9XEL?!$%Q\!O#GC+QS9^*?%,%KX8NAI
MO[0GA?3+:._O]*T[7'\1G2O$%S8>&[S4)Y?#FGZG<R3K9Z??Q1?U(#=D?ZSK
MR2'P/4XX'^'X5\7?"NP^)</[17Q/\4>(?V<=>\&^#_'&F_#_`$W0_%U[XG^#
M>I0Z+/X`TKQS;7E_=Z5X:\:ZGXB@BUTZY8VFD-IVG7=VJ74QU6'2X8I5-2XB
MS6OAL7AL;F&98NGB:*I1A/'UE1I_O(5&Y47S0J)^SC%P]U<KFNJM[61>&7A_
MPMBX8[AG@OA;(\9&I&K/&9=D>7X;&SG"CB,/"?UNG0CB/:0H8O%4HU'4<U3Q
M->FI*G6JQG]GKWSVP/P&1_3&1P<%A]ZG4B@CJK=/[K<=3@<'C))[<D\8`I>?
M[K?]\M_A7@KS_K^OEZ(^Z"BCVZ'T/!]>G7I10`4444`?&W[>GAK]C#Q=^S'X
MW\._\%`;KP)8_LL:MJO@RS^(%Y\3/%.J>"/`UO?3>+=(A\(OXB\6:3J^A2Z!
M9MXJDTA1J-UK&G:;#.\1U"\CM6=A_+=^R=_P2P^&E[^U/\$/$?[+7[`_P"U#
MP+\(/VW%_:&\/_\`!2KX8?MR0?%SX/ZY^S?H_C#5O&?@CX?>'_@UH7BS6_$B
M^.Y?`^I^&/"5AX:UMIM(TGQ!II\?2^+=<T:6.RNO[5FC1U*2(LD;D*Z.JNCJ
MQ`*NK`JX(Z@@`D!L`CG^$GXB>(KA?VR+#XF?!OXH?\$/OA#\>-/_`&_?B7\#
M_`G@[2OV=/&W@#]LWX76'@KQQ\0;73_B+\?O#WPF^,G@'7]?\&6UMX?F\2?%
M'7_&^DS?#N7P'J2>.=<U+4["--#@`/[NNN3G.23[<\\?X]^O>CK7R_\`L4?M
M`:G^U7^R/^SC^TEK7AS3?"6K_&_X.^!?B5JGA[1=1N]7T'3;_P`4Z':ZC=KX
M>U6_L]/OM2\.W,\KWGA^_O+*WNKS1[FRN)XQ+(Q/U!0!\&7/P9^+GAW]O7X[
M?M5:!X:T/Q1X2U_]@CX*?!?P+HDWBNWT#5?$WQ>^%_QF_:?^(]_X9U&6?3M0
M3PWH6IZ9\3?!=G!XLG@OK>VN;W46;3YQICI+\L_\$^_`W[;>D_&GQ-\5OVV/
MV5[.S^.'Q0\'W.E^._VF/^&DOASX_P##W@7P]I6HMK7AG]GKX"_![P[X:L]6
M^'WP8M=4NI-0N&.N7OB3QEXDM!XS^)>M>(=8&CQZ)^S-)@#H`/PH`Q=>\/:/
MXGL1IFN6?VZQ$\5SY'VF[M29H<^5)YME/;2_+N<;-Y1L_.N,9\-^'GPD^'MS
MIGB!I?#Q8Q>/_'MLF-9\1*!%!XGU"./A=7&2J``D\N?F9BV=WT;7G7PT_P"0
M5XE_[*+\0O\`U*M1H`J_\*;^''_0NG_P=>(__EQ2CX-_#D=/#S#Z:WXC'_N8
MKTZB@#S$_!OX<DY/AYB?4ZWXC)_]/%)_PIOX<?\`0NG_`,'7B/\`^7%>GT4`
M>8?\*;^''_0NG_P=>(__`)<4?\*;^''_`$+I_P#!UXC_`/EQ7I]%`'F'_"F_
MAQ_T+I_\'7B/_P"7%'_"F_AQ_P!"Z?\`P=>(_P#Y<5Z?10!YA_PIOX<?]"Z?
M_!UXC_\`EQ1_PIOX<?\`0NG_`,'7B/\`^7%>GT4`>8?\*;^''_0NG_P=>(__
M`)<4?\*;^''_`$+I_P#!UXC_`/EQ7I]%`'F'_"F_AQ_T+I_\'7B/_P"7%'_"
MF_AQ_P!"Z?\`P=>(_P#Y<5Z?10!YA_PIOX<?]"Z?_!UXC_\`EQ1_PIOX<?\`
M0NG_`,'7B/\`^7%>GT4`>8?\*;^''_0NG_P=>(__`)<4?\*;^''_`$+I_P#!
MUXC_`/EQ7I]%`'F'_"F_AQ_T+I_\'7B/_P"7%'_"F_AQ_P!"Z?\`P=>(_P#Y
M<5Z?10!YA_PIOX<?]"Z?_!UXC_\`EQ2GX.?#D]?#S'ZZWXC/_N9KTZB@#S#_
M`(4W\./^A=/_`(.O$?\`\N*/^%-_#C_H73_X.O$?_P`N*]/HH`\P_P"%-_#C
M_H73_P"#KQ'_`/+BC_A3?PX_Z%T_^#KQ'_\`+BO3Z*`/,/\`A3?PX_Z%T_\`
M@Z\1_P#RXH_X4W\./^A=/_@Z\1__`"XKT^B@#-TG2K'1-/M-)TRW^RZ?81""
MUM_-GG\J(.S[#-<RS3R89F8-++(Y+!LJ`$.E110`4444`!&>.YX'^?\`/J>*
M_&67_@HM_P`$B/$_[96L_":&'P1XU_:P\1>-;K]E?Q'XXTK]E;QAXJO=9U^:
M[C\$ZU\*]=^.UI\+K[0]1\-6-X&\+^([._\`&,WA:R%I=:?J3QVUK*J?J+\8
MOB5JGPG\&#Q?H_PJ^)?QEO#XG\&>'O\`A"_A+IV@:IXN%KXL\5:5X=O/$[6G
MB7Q%X7TW_A'O!EIJ4OBCQ9<#53?6_AS2]1GTW3]2OHK>PN/YT?AKHO[5'PW_
M`&Z9O!?A*;_@N3HGP.N_VRO&/B&\TE_@9^P(G[%TVB^,/C)JWB/Q-=Q>+(_$
M4WQDL/V?M=FU+4-5;5;#3+;QN?"^HSZLFGV_BFZGW`']/-C8V>F65IING6EK
MI^GZ?;6]C86%C;Q6EE8V5G$EM:V=G:P)'!;6EM#$D-O;P1I#!$BQ1(J(`+5'
M&6QZ_P!!QT'`[8&,8H_Q'MT/3\:`$)/X$XSCC/H/?MU[]/E;(=P&2".,\@XS
MZ$]O7./HI`)K\)4T_P"+'P-_X**_\%%_$]C\5OB)\;_'A_X):?#/XU^`-.\:
MG0(M%\'Z\?C;^VM'X.^'/PZ\*>'-$TO1="\+:=!X-\,:?*;BVU?7_$^K)=:_
MXGUG5=1OF,?(_L5?"'X8_L^_%G_@F'XW^!_VNR\4_MP_L@?$OQW^UCXF7Q+K
MGB74?VD_$&A_"_X*?$W2OCA\3]0U'5-3M?%'CWP_X]\<ZE9:7XYE5=5MM)^)
MVH>&+:_7P])IVE6P!_03_G_/X<CU'->=?#3_`)!7B7_LHOQ"_P#4JU&NLUJ_
MU'3;+[1IF@WOB&Y\Z.,:=87FDV%QY3E]UQY^M7NGV92+;EXQ/YK;@$C;:^?%
M/AWXI\71:9XA$7PN\27&[Q_X^D9H_$?@)1'(_BC42\+>9XF0EXC\KE%:,E24
M>1"K$`^A**\Y_P"$N\9_]$G\4?\`A2?#W_YJ:/\`A+O&?_1)_%'_`(4GP]_^
M:F@#T:BO.?\`A+O&?_1)_%'_`(4GP]_^:FC_`(2[QG_T2?Q1_P"%)\/?_FIH
M`]&HKSG_`(2[QG_T2?Q1_P"%)\/?_FIH_P"$N\9_]$G\4?\`A2?#W_YJ:`/1
MJ*\Y_P"$N\9_]$G\4?\`A2?#W_YJ:/\`A+O&?_1)_%'_`(4GP]_^:F@#T:BO
M.?\`A+O&?_1)_%'_`(4GP]_^:FC_`(2[QG_T2?Q1_P"%)\/?_FIH`]&HKSG_
M`(2[QG_T2?Q1_P"%)\/?_FIH_P"$N\9_]$G\4?\`A2?#W_YJ:`/1J*\Y_P"$
MN\9_]$G\4?\`A2?#W_YJ:/\`A+O&?_1)_%'_`(4GP]_^:F@#T:BO.?\`A+O&
M?_1)_%'_`(4GP]_^:FC_`(2[QG_T2?Q1_P"%)\/?_FIH`]&HKSG_`(2[QG_T
M2?Q1_P"%)\/?_FIH_P"$N\9_]$G\4?\`A2?#W_YJ:`/1J*\Y_P"$N\9_]$G\
M4?\`A2?#W_YJ:/\`A+O&?_1)_%'_`(4GP]_^:F@#T:BO.?\`A+O&?_1)_%'_
M`(4GP]_^:FC_`(2[QG_T2?Q1_P"%)\/?_FIH`]&HKSG_`(2[QG_T2?Q1_P"%
M)\/?_FIH_P"$N\9_]$G\4?\`A2?#W_YJ:`/1J*\Y_P"$N\9_]$G\4?\`A2?#
MW_YJ:/\`A+O&?_1)_%'_`(4GP]_^:F@#T:BO.?\`A+O&?_1)_%'_`(4GP]_^
M:FC_`(2[QE_T2?Q1_P"%)\/?Z>*:`/1J*S]-NKN\LK6YO=-GTBZFB#SZ9=W%
ME=7-FY9@8II]-N;NQE;:%DWVUQ-&`VS?N.*T*`"BBB@#PO\`:-^(WQ7^$_PC
M\2>.?@E\!-8_:7^(VCRZ0NA_!S0?'7A;X;ZGXG2]U6UL]1F@\7>,PWA[35T>
MPGN-4E6]!>[2V:U@*S3(Q_E,^#G[.7[4^N_MY?"7XW:[_P`$S?BY\&OVK=5_
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M+V_^&FFZ!I"^*M!AGO9+*S@`/[<^Y],G'TS_`)P.PP.V:*.Y/3)/''')XX`&
M<G'X`')&24`>=VOPG^'EE\6M;^.MMX7LH?BUXC^'/A;X2:UXV6>^.HZA\.O!
M7B7Q?XQ\+^%Y;9KEM-2RTCQ-X^\7ZM!-%9)>R3ZW<QW%U-;I;0VWBWP)_8B_
M95_9E\9^,/B#\"O@SX=^'GB[QQI[Z+JVI:;?^(M2MM(\-2Z[>>*;GP9X`T?7
MM9U;1/A=X$O?%%]<>([_`,"?#;3O"OA#4->:WU6]T6XO;*SF@^K:*`$`Q_GZ
M=/8#`]\5YW\-`#I7B7(!_P"+B_$+K_V-6HUZ+7G7PT_Y!7B7_LHOQ"_]2K4:
M`/1,#T'Y"C`]!^0I:*`$P/0?D*,#T'Y"EHH`3`]!^0HP/0?D*6B@!,#T'Y"C
M`]!^0I:*`$P/0?D*,#T'Y"EHH`3`]!^0HVCT'Y"EHH`\IUWQ-X\E\:WWA+P=
MHW@^YCTGPOH?B*_U#Q1K>NV$LLGB#5?$6G0VEE::1H.IJ8K9?#LDL]Q<7:R2
MO=QQQVZK"\CL^T?&_P#Z`OPF_P#"E\:?A_S*7?''KVJWIO\`R67QC_V3/X=_
M^I1\3*]+?.#M`+;6V@DJ-Q&%#,%8J"<@D*V.NT\"C^M0;MK_`%_7D>4_:/C?
M_P!`7X3?^%+XT^O_`$*7IS]*3[1\;_\`H#?"7_PIO&G_`,R?^2".QQX/?^*_
MV\EOKY=/^$O[/;:>M[<BP:Y\?>)Y+A[$3.+5[AQ!;!IY+<1O*RV\*[V.(4'R
MUYC8?$G_`(*+W'Q)UK0Y/@U\(5TJRT+3[I&N=8UF#P8/-FO!'?:1XS6X;4=7
MU^[D7['JOA^>RMX-+MK2"X4@.MSJ?OPX=Q%2,I+,LA7)3522EG.!3LY0C:RJ
M.TDZBNI-)6>NA^4R\6\LC)Q?!GBGI4G2C+_B&_%'+5G"C7K_`+IO`IRC.&'J
M*$[*,JCI4KJI6I1G]C_:/C?_`-`7X3#Z^)?&@'XG_A$N*/M'QO\`^@+\)?\`
MPIO&GN/^A3[8.?0`D\`FO$_#WBC]N*77M%B\2_"KX!V_AV75+&/7;C2O'?B0
M:G;Z2]Q&M_<:>);>ZB>]@MC)-;Q26\B32HL3;0Y=?F/PC\=?&WB;]NH_#KXG
M_&:&?0K7Q?X]T?X)>`?V<?'/P>USX4W<&C^&==F6W_:8TY_$%U^T:?BEHUG:
M:C<W&AOX<T'X.:7XCTVQCM[G5;NSDNG\W&X&>!G3A/$8+$>TBYJ6"QE#%PCR
MM)JI*A.7)+WE92M=7M>SM]=PQQ5A^*:.+KX?)N*,F6$JTZ4Z7$_#F:<.UJWM
M8.<:F$IYG0H/%4H\KC4G1YU2G:-3E<X<WZ$^?\<./^))\)N>G_%2^-.?I_Q2
M7/3M2>?\<`<'1?A,#UP?$OC0<>O/A+IP>?:OQ<^+FE^,]+_9L_X*A_";Q5^U
MM;V&I-^VW^SK\.8_CM^T[\2/%G@#PCH.D_%3X7_L)>)/$7@C4/$WP4MO"U_\
M*O"?BN3Q[XE\!>$-'\"3?#VRL;SQ?IEM-XO\/7VJW_C!>A_9X_:%;]G;_@F_
M^TMXM\'S?!6.[_94^-?B#P1K/Q8\"?%+XK_%_P#9O^(DD.M?##5_&_Q,\(>+
M?CCX_P#'/CC0?#OA[2_'6K>#_'GA35OB=XOT7X8?$KP%X[T&W\8:M8:'-=5Q
M'U!^P0N/C>3@:+\)B?3_`(27QI_\R7&.^>G>C[1\;QUT7X2C'7/B7QH,?7/A
M/@>IZ#O7Y<^(_P!KF]_:7^(_Q\^!GPZ^(_A/7/A]X,_:;\+:'HOC;X4ZT]RY
M^%'PB_9&^%W[4GQ.^U>-?#6NM#J1F^-/B;PC\+M7O-"NUBLM,\93>&]1MKJ6
MPUFU;Y2^`?\`P4&_:)MOV(/"-UK6N>!?V??'>GZ1^P1\#/#.L_M%:5<_$*+X
M7_#GX^>&O".D:7^WK\:_$NF_$/1M)^(7ACXM:MJ&L:+\.O`]MXW\*Z1HOCS2
M-(\-_$WXC1>(M7\4:9X<`/WS^T?&_P#Z`OPF_P#"E\:<?7_BDN/\.>]'VCXX
M?]`7X3?^%+XT_P#F2KY@_P"">'[0GC_]HSX3?$_7OB+X_P#A!\5M8^&_[2'Q
MF^!^G_$_X%:1>Z%\-OB!H7PKU>P\/V/BK2=)O?%7C=M.U'4[@7C^(M+M/%WB
M72]&\0#4]%TG7M9TW3;;5+O[XH`\F^T?'#_H"_";_P`*7QI_\R5'VCXX?]`7
MX3?^%+XT_P#F2KUFB@#R;[1\</\`H"_";_PI?&G_`,R51S7GQOAAFF.B?"8B
M&&64@^)O&B@^5&SX+?\`"(L5!VX+!6(!R$8@*?7:J:A_QX7_`/UY7?\`Z3R4
M`8?@OQ`_BWP?X2\5/9KIS^)_#&@^(9+!+@WB6+ZWI5KJ;6:7306K7*VK71@6
MX:VMS,J"0P1M)LBZ>O./@Y_R2'X5?]DV\"_^HOI5>CT`%%%%`')>-O`/@7XF
M>'+[P9\2?!?A+X@^#M5>V;5/"?CCPYH_BSPUJ+VEU%=V;7VA:_9W^EW;6MY#
M#<VS7%K(T%Q''/$5DC0C^+'Q-\=?'GAO]HD67P2^.?\`P0X^%?C9/V[/B9\`
M/`GP3U/]A_01^UC\"M!\`>+O&UAH/Q5^(>@Z)XXT+Q3H&A^%],\)P^*/%WQ#
M2TT'PSH'@6['C^#Q0X5]$B_M[]`>A(!^A(!_0U_(7H/[3OC#Q#_P4^5=4^+_
M`(:\5?M=^-/VX/&W[)'Q/_X)VZO^Q_\`#FVET/\`X)^VUWK^C6_QCN_CA=?#
MZ;XM:AHZ_"G3?#GQ@F^).K?$B[^&/C.#7$^%EMX)A@GM+J$`_I4_8G^/^J_M
M5?LB_LW_`+2.N^'=,\)ZU\;_`(-^`_B5JOA_0[^]U30-/O\`Q5H5KJ5T/#FI
M:E9V&H:AX;NII7O?#U[?6D%W<Z-<V,UPGFNS'Z@JM9V=GI]I;6&GVUM96%E!
M#9V-G9P16UG:6=K&L%K:VMM`D<%O;6\$<<,$$*)%%$BQQJJ*`+-`%>[N[:PM
M;F^O)X[:SL[>>[N[F4XBM[:VB>>XFD(Y"10QN['G`4G!K\^?V8_^"CGPX_::
M\;>"/"%G\(OCG\([+XU_#'7/C9^S-XR^+GA_P?I?A?\`:2^$/AJZ\,Q:[XX^
M'C>%/&WBW6="BL-/\<^!?$8\/?$S1_`WBF\\,>,=#UFQT6XMVU`6/VU\2;3Q
MW?\`P\\>6/PNU?1=`^)M[X+\56GPZUWQ)9/J7AW1?'=SH.H0>$-6U[3HE:2_
MT73O$,FG7FJ64:L]U8PSP(I:0`_@!_P3-_9?\3?"/X^?`/7?`O[)O[2'[.FJ
M>!OV<?'7PT_;C\;_`+0OBJQ\0^"?B3\0=4OO#/B#0]'_`&?+6X\>^.K)M/U'
MXNP>-_B+-K_P9TKX9?#&#PE>6VE:UH%SK&IZ#H_A8`_HR!S_`"_'&<?A_P#7
MP#D#SOX:?\@KQ+_V47XA?^I5J-=9K.DC6K(67]J:SI(\Z*7[9H=__9][^[)`
MB-P(I?W,A(\V/9\V!N(QSXK\._`8GTOQ"Q\:?$.'9X_\?0D1>*&7=Y7BG45$
MC_Z%\TC\-(V!N<DX)(!`/H.BO.O^%>?]3S\1_P#PK'_^0:/^%>?]3S\1_P#P
MK'_^0:`/1:*\Z_X5Y_U//Q'_`/"L?_Y!H_X5Y_U//Q'_`/"L?_Y!H`]%HKSK
M_A7G_4\_$?\`\*Q__D&C_A7G_4\_$?\`\*Q__D&@#T6BO.O^%>?]3S\1_P#P
MK'_^0:/^%>?]3S\1_P#PK'_^0:`/1:*\Z_X5Y_U//Q'_`/"L?_Y!H_X5Y_U/
M/Q'_`/"L?_Y!H`]%HKSK_A7G_4\_$?\`\*Q__D&C_A7G_4\_$?\`\*Q__D&@
M"MIO_)9?&/\`V3/X=C\?^$H^)9_D0?QKTQAG'/J/KG@_ACJ.XXKQCPCHG]A_
M%SQM;?VOKVL>=\./AU*+C7]2.I7$07Q/\2@8H)#!`8HCNW-'A\L0V1]VO9G+
M`94;C@X7(4L1S@$_*-W0%@0#CU)H>G_`_K_@]@W'`8[Y]/I_7G)^I-)MSU/^
M''`./Z=,8&,`5\CW?Q>_:FBO+N*T_90L;FTBNIH[6YD^->AQ/<VR3,L%PT8\
M,2+"TT2K(Z;I%C9]@9ADU\Q^%_VMOVK-7^,-YX)/P6TG5/)U3Q1:#P8#?Z"T
M#:1:W\IM?^%D7EO<Z)<G3#;>8;Y=(2/71$;>R2VDNX&C_GWB/Z2_AUPQCL@P
M&8Y9XG.OQ'G=#(L`UX2>(^$3QN(J4Z<'&.:\-Y=6Q\7*K&V'R:EFF85+I4<%
M5E*"E^N9-X)\99WALUQ6"QO`SI91EE3-<7;Q#X*Q3CAJ=-U)>TEEV=XZE@;0
MB^;$9K4R_!4[/VV+IJ,W']5L<8],8_#ISUKP#0?V4OV7?"GQ);XR>%_V;/@!
MX;^+SZIK>NR?%;0?@U\.M'^)+:UXD@OK7Q'K+^.=.\.6_B=M4U^VU34;?7-1
M.J?:]4M]0OXKZ6>*[N`W(:'\6/VG+S6M)L]9_99L])TBZU&SMM3U6/XS:+>O
MIEC/.D=S?K9_\(S`;LV<3-<?95FB:<1F)9$9PP\8^%WQ,_:/U#]J;QGX)\*2
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MRRGM/$\=UX<TZP\/W,>M0WR3:+8V6ER;K&T@MQ4T/X;_``\\+>`[;X6>&O`7
M@OP[\,;+P_/X5LOAOH?A30M(\!6?A:Z@FL[CPW:^#K"PM_#UOH-S:W,]K/H\
M6G+I\\$TT,MLT4DBC\//BWI?C?3OV;O^"H7PE\4_M:V]AJK_`+;?[.OPXA^.
MG[3/Q)\5?#KPEH6D_%/X7?L)>)?$7@:[\3_!6T\-:A\*O"OBR3QYXF\!>#=)
M\"R^!+:ROO%^F6T_B_0M0U6_\7CU?]CKXX^#?@9_P3^_:H\2ZG:^';OP_P#L
MC>+_`([:'XN^('[-WQ9^*'QG^'_Q/N_"O@KP]XYU_P`>_!GQI\?_`!9\1O%N
MAC1Y_%#^#/%GA;Q'XX\;^'?A;\3_``/X[T`^)=8TK09[EOJCP#]8_"OPJ^&'
M@33[+2/!/PV\!>#-)T[0X/#.GZ9X5\&^'/#NGV'ANVL=/TRU\/65EI&F65O;
M:';Z;I>EZ;#I,,4>GQV.F6-HELEO:6\4/EGQU_9:^&/QU^%NN_"N]74?AM9:
MUX5TCP/#XJ^%=KX8\.^*M(\%:'JEKJ]GX&MCJGAO7_#FJ_#VYEM/L>L?#?Q/
MX=U_P%KVDSWFFZMX;N[:=U/X]?\`!%KXVZ9H'C_X\?L=>/?C#;_%']HK1=&\
M-_'3Q2W@CXY3_'OX$2>"M=L-$T?PUX^^&'Q'\8_$7Q=X[\2^,_BW'>CQA\<M
M,T[0_"?@KP9\1(KZ'P[X-\->#=>\!ZWX\^^OB;\5OVAM*_:;\/\`AGXA7GBO
MX'?LVV_BO28O!7BWX3?"Y_C!'\:+MM'%]'I7QA^*;0ZR_P"SWH<VO+/I`\+C
MX40_VY/9:;Y/QU6/Q"_A8@'T_P#LU?LX?#W]E;X5:7\)/AH-8N='M-4UG7]5
MUSQ'+ILWB#Q/XF\0W9O=8U_5UT/2]`\/V<D["WL[#1_#>@:!X:T#1K#3=`\/
M:)I6C:=8V5O[X20>>.,\@@GDXX//`!SCD]0,#:W\I]]\3O"'PTU']K'1O@+^
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M/P_\0>/='TVUNK;6-+T_1[B_-R_VVP>OD_\`98_;^^.GA;]AN]N]4U/PK\+=
M8^%WPL_9H\(?#74?VC+N[\=W6N^#/C;\:;'X13_M\?$?Q?I_C6UFUGX)^&[J
M_P!85/AZVN:7XCLCX#N;OXI^/?!3^-M.M_"H!_2W534/^/"__P"O*[_])Y*^
M`_\`@GU^T%\2?CIH/[1&B_$SXK_`WXZ:O\!/V@KGX'V/Q?\`V?-#N_#7@/Q[
M;:+\)OA7XNU#5KG0+GQG\08-!\70Z_XSU?3/%OA_2_&/B/2-`UBPN-.L-2FC
MMF@M_OR_.+"^/!Q971]C_H\G;T-`'!_!S_DD7PJ_[)MX%_\`47TJO1Z\P^"E
MO]G^#GPFA\^XN?+^&W@?]_=R>=<2;O#6G/F2;:F]EWE<[1\@5?7/I]`!1110
M`8!(SZC]3@C\02/QK^5?X+?M*_''XF_MRZI:>)?VG?\`@KIKFBV/[<_Q"^'E
MEX<^"7[#WA35?^">EWX,\%?&34_"^A^$KKX\W7P>U/Q!:?#G3M"T^#PS\4_%
MUYXWMK_3]9L_%%[;W=DL-G?O_51SD8ZY&/J"#^7'/H,FOY#_`(6ZYI?A[]N_
MQ'XRT;Q!_P`%"O"WP,O_`-O+PE#X1ATS_@HW8ZC\,OB#XN^+G[3WQM^#/CG4
M]>_9-M/AC!9Z#\,[+X_?"N\T.[^%,/CO4/%FJ_#G6+[Q[J?]G6]C=Z80#^O#
MN>W+<#I]X].F1V_`C@@BBDQ@L,8^8G&,>PQ[<8'J`#P"!2T`%'].GM2$X&?\
M_P"3T]LY[4$D#)';([`\9ZG`'OGA1U/6@!:\Z^&G_(+\2_\`91?B%_ZE6HUZ
M(#D?_K^H//(R,'!Y'0\UYW\-/^05XE_[*+\0O_4JU&@#T6BBB@`HHHH`****
M`"BBB@`HHHH`****`/,=-_Y++XQ_[)G\._\`U*/B97II('7Z_EUQ^%>9:;_R
M67QC_P!DS^'?_J4?$RO2W.U68*[D*S!$V[I"@+!%WLB;VQA-SHN[!9@!D`#L
M#T'Y"C)]6QG&0S8!SC'7CDC\QCBOQ>UW_@I+^W9IFN:WINE_\$8?VI]:TS3M
M7U.PT[65^,'P:M$UBPLKV>VM-6CM1)=BWCU&WBCO(X!=7)BCF6/SI2NX_&?A
MK_@X*^,'BS]IWQ)^RMX?_P"":?Q)UKXR^'[2]TZX^#^F_';X</\`$JS\6>%K
M2_UWQO97<L^FIX4O+72?#3Z;=_V?I6I7&KVLUEKC7D;QQ^59ZTJ%:LJLJ4)3
M5"DZU5I7Y*491C*;VT3DKVNTKNUDR93C!QYFESR4(WZR>R7K9[];+J?TVX`[
M`?@*1CG&3GKU^F3S]#VZ`EOX=K?CS\/_`/@HI^V[XJ\=^#/#'BG_`((\_M/>
M!/#7B+Q-HNAZ]XWOOBS\(-4L?!^E:I?P6=[XEOM-AFL9KZQT:&5KZ^MX;N"=
M[2&?[.SSB.)_8/A]^T'\<M5^,?Q.^'&DZ]H/Q?\`@G8ZG\8HIOVI_P#A6&N?
M"71OV9M7\-/XI-CX&\7WGB>^B^&/[45OX/URUM/"FH>+OA-K?@FYT1],DL_'
M>@W%];:YXH3(H^^]5\"^"->TKQ?H6N>#?"FM:'\0XYXO'^CZKX<T?4M+\=17
M6BV?AFYC\8Z=>6<UIXHCN?#NG:;H$Z:U%?++HMA9:2X:PM;>)7>$?!'@SX?^
M%-%\!>`O"'A;P1X%\-Z<FC^'O!?A#P_I/AGPEH6DQ[PFE:+X<T6TLM'TO35#
MRA;*RLH+4%W3R@&+#\#9/BO^UG\)?$WQV_9@UKX__'Z6?QK\1_V(O!7PQ^/?
MQATOX'ZUX]FT#]H;X[I\)OC?\?O@5=_#O3+GP'X>^%VK"YTKP7\(?A_\1]+U
M'QMX#^(&LV'B&[L+W0)],TK5/LOX=_M!_$3]GS]G7]K8>,/$^N?M+ZE^Q_\`
MM'+\%_"OC?QYJFE:)XW^)'A+Q7HWP+\::,GC_7_"OAB#0KOQAX"7XXW?@._U
MK1O"=BOB1/`UC>:I8V>N:EJ\T8!^A7@#X0?"3X3Z59Z%\+?A9\./AIHFGWFN
MZAI^C_#[P/X8\&:597WBFZMK_P`47UEI_AS3-.M+:Z\27MI:7NO74$2S:Q=6
MUO-J#W,T,<B>C9]"5R#GMTR3]>0<8/)!'.3C\S/BK^UCXT\4?$+XS_L]>`;6
M'P/XJ^&_[2/PZ^%L'CK2_$$.J:O?^"K#]EOP;^V;\2?$5QH]YX>DL?#,O]@:
M@/A*(;F;5H9&\6Z#K8U+3;W6K"SMOE[]FO\`X*@_$KXC?LB^!/&WAWX6V?CS
MXJ76H_LE_LT>$;/XS>-=5^"GB+XH_M(?&7P)X-\0>)/B+\2]+7X:^(=4^%7P
M'DTOQ#)XS\$>-=-\,^,/$?Q<TG3=0N/!/@:.SU3PE)K@!^QGA?X.?"/P3_PG
M9\%_"OX;>$/^%IZQJ'B'XG'PMX&\+^'S\1O$&JQ36^JZYX\_LG2K3_A,-7U.
M&XN(]1U+Q"=1O+V.>:*>:5)7SM^!?`/@;X7>$]%\!?#+P5X2^'7@7PY#/;>'
MO!7@/PUHWA#PEH-M<WESJ-S!HWAOP_9Z=H^EPW-_>7=[<065E`D]Y=7%Q(&F
MGE>OGS]D#]H+QY^T+X+^).H_$_X8^'?A+X^^%7QR^)7P,\4^%O"7Q&E^*GAF
MYU7X:W&EV5QXCT'QC<>#_`=W>:/XB:__`+3TFSU+PMH^LZ=IDMG::[I^G:W%
MJ.F67UE0!YIX,^#7P@^'-O96GP\^$_PT\!VNFWM_J.FVW@OP)X6\+6^GZAJ<
M^MW6IW]C%H>E6$=I>ZE=^)?$=S?7,")/=S^(=;FN))9-6OVFXSXJ_LW?#3XJ
M?#/7?AB+";X<6FK>"KWX>Z;XM^%=IH'A'QGX1\(:EJ^BZYJ?AWPMJ3:'J&GV
M?AG6-3\/:0_B/P=>Z5J/@_Q3:62Z=XFT'5;!Y+-O?J*`/FG]E7]E7X:?LA?"
M_P#X5=\,I-9U"RO-:F\2>(/$7B)/#EMK7B/79-+TG08;NXTWP9X=\(^"_#]C
MIGA_0-"T#1/#O@WPGX;\,Z+H^D6=KI^C0.;B6;Z+O_\`CPO_`/KRNS^<$A_K
M5NJFH?\`'A?_`/7E=_\`I/)0!P?P<_Y)#\*O^R;>!?\`U%]*KT>O./@Y_P`D
MA^%7_9-O`O\`ZB^E5Z/0`4444`>&?M&G]I<?"+Q,?V1(?@5/\>UDT@^#H_VD
M)_']M\(3"=6M/[=/B67X86]WXS64:(+TZ1_9<+(VJBU%WBT$^W^:+]B7]F_]
MLOXY?\%!OB/^V5XO_8M_X(L^%/BA\`?VM/$/P#_:&^-_@VS_`&NXOC-K5]X=
M\*^#=0^(7Q"^"^FZTEU\.)/&NL>#/'MKIVB>-/%VE:/XCOKYM4CURXCL[@W%
M[_2[^T9^SU\/?VI/A)XD^"?Q3E\;P^"?%<^CSZK+\/?B'XS^%OBL/H>JVFKV
M?]G^,_`.L:!XHTN-KVS@%W%8:I#'>VADM+E9;:66)OSM^#/_``0Q_8'^`7Q-
M\-?%OX9V7[2>D^,/#/Q#TSXIQ_;OVP/VE=;T'Q#XZTNZL;J+7/&WAG5OB3=:
M%XWN+U]-L+?5QXHL=4&L65K#8:G]JLXQ"`#]A`,9^IZ]>.!GWP`#[TM(#G)]
M23QWR2>/;N.>A'L2M`'E'QX^(\WP<^!WQE^+MMIT>KW'PK^%'Q&^(]OI,K2K
M%JD_@?P=K7B>+3I6A(F6.]DTM;:0Q$2!)3L.[%?AM_P3:\=?M`6_QQ_9Y\4?
M'#6?VM_#MA^V)^S5JGQ,T2?XW_%GPA\9_AW^T#XTM?"WP]^(6MZY:?#30[RW
M_P"&&/%W@:R\2:I=>`OA=X)3Q1X(^('PQO[^S\4ZAI/CSP'$EW_0M>V=GJ%G
M=6&HVEK?Z??6T]E?6-[!%=65[9W43V]U:7=K,DD-S:W,$DD,]O-&\4T3M$Z,
MK%3\,_L[?\$\_@K^S5XXT3QMX3\6_&OQI%\/O!NM?#?X$^#/BM\3=0\=>!_V
M</AQXDN=(N=>\$_!?1KRSM[C1]+U&+P[X=T;^T_$NH>*O$NG>%O#^D^%-*UR
MR\.VTFF3@'VOK6LIHED+V33]8U-?.BA^RZ'IMQJM\#(6`D^S6_S^1'L)EEY5
M05ZY!/B7P[^(=K!I?B(?\(E\0Y-_Q`\>RYB\&ZE(%\WQ1J#^6^PD+)&#MEC/
MS*X*8)`+?0>3]"1CN#^0/S!<$CG(ZK@M@9.C:+9Z#!=VUCYZI?:OJVMW'GRF
M5OMNMWTVHWI5BJ[(#<32B%,$1H50[BA)`.0_X63;?]"=\2/_``A]5_QH_P"%
MDVW_`$)WQ(_\(?5?\:]('044`>;_`/"R;;_H3OB1_P"$/JO^-4[7XLZ3>W&I
MVEIX7^(D]SHU[%I^J0IX(U?=97L^G6&KPVTVX*/,?3=4L+L;"ZB.ZC!(<.J^
MJ5C:=HEEI5]X@U"U$XG\3ZM;ZUJ9ED+1F]M-`T;P[$;=2H\F'^S="T\M&-VZ
M?SY@P9B@`.0_X63;?]"=\2/_``A]5_QH_P"%DVW_`$)WQ(_\(?5?\:](HH`\
MW_X63;?]"=\2/_"'U7_&J2?%K2'U*?1T\+_$-M4MK"SU2XL1X)U;SHM.U"ZO
MK.SNG&-OEW%UIM]%'ARX-M(SH$*,?5:Q8]#LHO$5[XD19_[3O]%TS0;C,I\C
M[!I-]J^HVA2':=DWVC6KWS9=Q,D?EH`IB!8`Y'_A9-M_T)WQ(_\`"'U7_&C_
M`(63;?\`0G?$C_PA]5_QKTCIP>OY=.O%%`'F_P#PLFV_Z$[XD?\`A#ZK_C5.
M7XM:1#J%GI4OACXAQZE?VM[>6=FW@G5O.N+73GM$O9HQC:4MVO;4."P8F=-H
M;:^/5*Q;G1+*YUS2_$$HG.H:18ZIIUD5E(@^S:S)I\EX)(<8DD+:;:>3)N^0
M%U&YG;:`?.VI_$[4O#OQ+UGQ!!\'?C9XDTK6?`OA+2(+KP_X)MI!;ZCHFO\`
MC2\O+:ZBU36]*GC/V;7+":&2..6*0/(F]7B8'4/[0M\?^;>_VCO_``@]#_\`
MFP]0#^'IFOH^B@#YP_X:%O\`_HWS]H__`,(/0_;_`*F_OCGUR<]L85U^T!H^
MCW5KJ5W^SE\=]/O;_5(-/M+Y_AKX9CN[C5M7=K6"%;J/Q/Y_GWKR/$\SR*K!
MSYT@5VQ]65B:WH%CKT>F)J`N`NE:YI7B"U\F4PDZAH]Q]JL_,X;S(!(%\Z+C
MS%!7(P"0#PP?M#7XQ_QCW^T?QW_X0/0\_P#J8?GZU\;Z-\!OV7M#^,6J_'FT
M_8V_:PO?B3KEWXXO-8NO$/B?XI>+/!^I'XCZ9K6C>-+*\^%WBCXZZQ\+9]&U
MK2_$6LV9T%_!IT33X[TMI6GV,D%L\/ZK#H#[=>OUY[^]%`'Y*>"_V9/V+/A]
M\.?BG\)?"O\`P3R^+UK\/OC19:)I?Q'T#5/"5]XE;6M&\*W'VWP9H&GZOXF^
M)^L:YX5\.^`M0_XFOP[\/>$-3T'1/A[K(76/!5AH6IJ+H>@V'AO]FSP#^S5K
M_P"S#'^Q7\9[#]FS5-!\5Z+XK\`ZQX*77=.UW3_'FJ:AJOC*^\3:YK?Q`U3Q
M9XA\0^)M=UG4-<UKQ7JVMWWBJ^UV]?6IM7;4U%XOZ55B>(="L?$NC:AH6IB<
MZ?J<(@N3;R&&8H)8I1Y<P5MA!B4!L'`#`<8P`?G=\)/AI^S9\"(+NW^%/[#?
MQO\`"CZA::S9ZO?IX3FUK6-</B+P_P"%/"GB+4M?UWQ!\2=7UCQ!X@U_P[X&
M\):3K?BC6+^_\1:O:Z#8?;]4N)$:1_(?VC?V?_AM\8?@7XI^$GPU_9O^,/P=
MU[6OAI\'_A#I'BW4/@3I'Q-T&R^'OP*\76?C#X8^%-?\$WWQ;\*W>MV'A*]M
M[E?#7B+1?&7A#XE>$;J[&K>#_B!X?U2U@NE_8KWQC=R/QYXHQ^G3_/TX^A(Z
M$T`?EC^PYX(TG]B7X#VGP9\/_!K]HKQ7?7OC/QQ\2O&GB:T^$6B>$=)UWQY\
M1==F\0>)]0T/PI)\2_%-UX>T9KN5(K*QU3Q9XMU^<1/J7B7Q7XF\17^JZW??
M7-U^TA-8VMS>WGP`_:,M[2SMYKNZG?P'HFR&VMHFFGE;;XO+%8XD9R%!8A<*
M"<`_2O2J.IZ?;ZMIFHZ7=^8;34[&\TZZ\IMDGV>]MY+6<1R8.R3RY6V-@[7P
M<'&*`/GJ#]HVXNK>"ZM_V?\`]HR:WN88[B"5/`>B;)()D62*1<^+PP$B,&`8
M!@",J#D5+_PT-?\`_1O?[1W_`(0>A_\`S85]!V%G%I]C96%N&%M86EO8P%V+
MN(;6&.WB#OM&YBD8W,<;FP<?-@6Z`/G'_AH:_P#^C>_VCO\`P@]#_P#FPJO=
M_M!:C-:74*?L]?M';Y;:XB0'P)H8!9X9$09_X3`@;G*C)X`R2*^EJ,YZ'D<\
M<D$>PZX]/PH`\M^"=VMS\(_AS$8+JTNM)\)Z1X9U6QOH&MKW3=?\(VZ>%O$>
MEW<+%@MSI6O:1J.GSF-Y8'DMFD@FF@>*63U*L;0]#LO#]C-8Z<)A;SZSXCUZ
M7SY#*XOO%'B'5/$VJ$,57$7]I:Q>?9XL?N+<QQ;F6,LVS0`4444`%%%%`!11
M10`4444`?$G_``48^+7C[X(_L9?&OQ]\+=8E\-?$+[+X&\"^$O%EOI]EJUUX
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M+Q]XJMOB)\9OC7\3/B9!X5TCQ9\6_C_XZ3Q_\0[KP;X!36T\`_#ZSU.UT?0=
M-TWP;X1E\3^*=3L+"RTF&\U'Q!XJ\2>)/$.H:SKFKW=\X!]7#H,=.U%%%`'@
M_P"U)\6+[X"?LS_M&?'73+"/5=2^"WP'^+WQ9T[2Y8Y)8=1OOAQ\/O$7C&TL
M98HBLLL=Y<:/';R1QLCLL@"ON9<?CU_P3C\5_'G0OCY\+$^.&L_M=>'K;]I_
M]FK4_BIX;A^/_P`5O!WQM\#?'OQ/I-K\.?$OB#QMI?A;P]>0R?L5?$'P=;>,
M;A+?X&>%HO$OP[\5_#W7;`SZEI'C7P#J-K??O5K6C:7XBTC5=`UW3K+6-#UW
M3+_1M:TC4K>.[T_5=)U2UEL=1TZ^M95>*YL[ZSGFM;JWE5HYH972164E6^+/
MV<?^"?\`\(?V:/&FG^-O#?C;XW?$2[\'^!;SX4_!G1?C'\2[SQ]X>^`'PHU&
M]TB_U#X>?"2PN;"RGTW2+Q_#_AVPN-9\3WGBGQBV@^'=!\.CQ+_8>EPZ<P!]
MS44=**`/(/COIGQAUGX7>)]*^!'CKP;\,OB5?PVEOI?Q!\<^![[XDZ1X0TM[
MV`>(]>L/!%EXI\&1>(O%6GZ!_:5QX.LM8\0VOAM?$R:9<>([;5=$AOM*O?R3
M^"E]JOQF_P""3G['_P`9_P!J/]M;XG_!KX:>%?A';?%']JKXM:3XSF^'/Q`^
M*]A8:3K-A91:Y\:=!U+2O$WP^LY/%4VG:_JEKX#C37/%]W:Z;X)TN>RL;Z2S
MU#]Q+FW2ZMY[:3=Y=Q#-!)L.UA'/$T3E3_"VUCAL<$`X;`4_FMX^_P""6GP3
M\:_!#]D[X":5\4_V@OAQX0_8Q\5:5XY^#-_X$\:^&5UK_A,?#NGZC8^$_$WC
M!/%G@CQ5H'B?6?!DFK7^J^$+V[T&.7P[KTL6NZ:8-5L[*[MP#T#_`()PGXS2
M_LPZ3=_&34OB7JD>H?$+XJ:E\&+CXX%I/CJO[-]YXYUF7X$I\:9Y;6RO9_B&
M_@%M,N=0_MJV3Q1;:7<:39>,WN/&%KKMU-]X5Y%\$/A3J'P:\!6O@?4_BY\6
MOC;=6NJ:MJ1\>?&O7-!\1>.[E-4N?M$>EW.I>&_#/A+2WTS2E_T?2X4T=)X;
M?"3W%PX\P^NT`<IXZB\;7'@WQ3!\-;[PII?Q#F\/ZM%X&U+QWI.L:]X*T[Q9
M+931Z!?^+-#\/ZSX<US6O#UGJ307.K:1I'B'0=2U.RBFL[+6])GE6_M_YX1\
M=OVFM'_X)B?'*R\1?M!>/_B?^TSJO_!3/XR?LL^&/%/@N#3OAO\`%OXVV&D_
MMUZGX(UOX._`!7O-<\.?!/QCXR^"?AKQEX7^&FN7=_?^&O@Y:1KXLU36['3_
M``U>>(K'^DC!W`@]/;/Z]O?KQTQSGX?U?_@GY\`M:^"WCOX(2R?$"PT3QI^T
M3X\_:MT[QIHGC"ZT7XF_#3X^>._BOJWQG;X@_"WQIIUK#>>$=7\+^.-:O9/#
M"Q17=O'H<]QX:UB'6M"U'5-/O@#P'_@EAXM^)=Q9?M8_"KXGW?QJ\/3?"']H
M.UT_X<?!?]IOQE:_%/\`:)^$?PB\6_##P/K_`(='C_XQZ7KWBS1/B;H7Q`\8
M#Q]XS^'FHZ;XT\>R^$_#-]'\/-9\:ZCKOA+4=(T#]7Z^9?V;/V5_`_[,]IX_
MN]%\5_$WXG_$'XL^)K#Q=\5_C#\9O%8\9?$OQ_K.B^']/\*>&TU?4K73M$T'
M2-"\*^&-*LM$\->%_"OA_P`/^&])MDNKRWTLZIJNK:A?_3&[\NN?89Y]^G7I
MU'48(!R_CG2?$VO^"_%VA>"_%2^!/%^M>&->TGPKXX?0K?Q0O@[Q%J6EW5GH
MOBH^&[R\T^SU_P#L#49K?5%T:\OK2TU)K46ES/%#*S5^&7PH^,GA/]D/XJ?M
M*_%"S_:I^.WQQ_8L_9J^!NL:)^UA\5_CO\4[CXE^"M5_;7LO&WA?3M%\$?`S
MQ+XHN!8Z=\0$M[S7?"?Q9\"^`]8MOA?X1\<^)OA_X`ETW1?'%CK6GZ;^W/Q3
M\`6GQ7^&?Q"^&-_X@\7>$M/^(G@KQ/X'OO%/@'63X<\;>'K/Q5H]WHMUK/A'
MQ"MO=-H?B/3[>\DNM&U>.WFDTZ_2VNXT+QKCXI_9O_X)N?"_]G/P7!\)#\6O
MC9\<_@#I_P`.M-^&6B_LY_'^X^%'CCX'Z'X<T6^TG4-(GL_`^E_"CPS!=:II
M\FDV^R]U>YU,7$T]SJ%]%=:M-]N`!\^_\$OOVAOB;\:OCQ_P4!T[XO\`QO\`
M!/Q)\3Z;X]_9]\7^'_AS\/\`QSX>\7>"/@9X8\>?L^^#]?N?A=X)?0M=UJ'5
M],\&:O=/H/BWX@1+8VOC_P"(UMXG\11:9HT-];:18_LM7RC\!?V)OV:?V9/B
M7\;/BK\#?A3X,^&WB3X]7/@F;QI;>#O"7A+POHME:^`O"FG>$]'TCPS8>&]`
MT@Z/HMU!IR:WJNE^=<6E[XEN[_6O+BNKN5F^KJ`&DX8=^AQZ@9)_7;D\X&3Z
M!OP6\?O\??V0/VZ_V<-=\7?$O]J;XG^%OCOXX^.=K\6OB_XN\7Z4G[)?B6_U
M[X<?&3Q5^S_^R?\`#[]G+1]>\2S_``>\;Z!J'ASP5:>&?B__`&9X:TOQ%'X0
MU'1_%7BOQUXX^*RZ9I_[U$=".Q!]N#D$]<X/(_'!!.1^?O@#_@FY\"_AU\5_
M#7Q%TKQ9\:M6\'?#SX@>+OBW\(?V<_$GQ(N=7_9U^#WQ5\=#Q0?$GCWP#X"D
MTV._AU5IO''C:[\-:9XB\0^(?#'@&\\6ZQ<>`M!\-.NF?V<`?!W[)VN_&/PM
MXI_X)??M">(OV@_C'\2M>_X*5>'_`!G+^T1\/?B)XQO-7^&NE:EXA_9D\>_M
M3>"-1^#WPV9E\.?"(_"B[\!0?"ZTM?!=MIUGX@\&ZO<7GC&'7?%@376_?,'/
MY#/IR,U\&?`W_@G9\#?@#\5-)^)WA/Q%\7=?L?`>G>.=)^!'PH\=>/YO$WPD
M_9MTWXF7T5_X]M/@GX9GTV&^T!=>$;:3;3:]K/B6Y\+^%)[GP5X.F\/^$;B3
M13]Y@8'^?\^_MT'`H`4]#VXZ^E?AK^VUI/QY_9S_`&@/A5^TE%\5?VI?$OAO
MQO\`M2_!K0/$GBWP]XJTK1OV0?V4?V;=;\1^!/A]K7P]^)W[.ECX@U;7?C'J
M7Q+U/4=6M?\`A:]OX5;6_"'BOQO8>-=0\9?#SP9\/HM&U3]R3R"/4&OS^\5?
M\$W?@7XO^+OB'XEZAXM^-EGX,\;_`!.\/?&[XC?LVZ5\2;JQ_9P^)'QF\*-X
M>N-!^(_C#P"FGMJ5QJ<6J^$?"?B/6-`TKQ+I?@KQ7XF\-Z5KWBSPSKNH+>2W
M@!^27PN^/W[1OCG]HGP?^UIXPN?VMO`GP;UW]O\`^*O[+]SX_@^)_A#6OV<M
M+\,>$_VC?B)^R]X&^!U_^Q^E[9&;X=>,[_PMH-AJW[7"WX^*GA?]HK6H;I/#
M-Y\++:_MXOZ;@,$CI@XZYZ$C\3C'/T'4&O@:#_@G+\"[;XZ_\+HA\3?&)-!_
MX7%=_M'?\,[CXB7?_#.`_:.OFGN;KXX#X>&Q-[_PE\VNW=WXU?23XB/@8_$:
MX;XC?\(G_P`)LD.NQ_?(SSGJ3D_Y_0>HY."2*`%K\$?^"K/[=NH>%-4U'X$_
M!3]HSP#\$=8^!GC7]E_Q_P#M,>*+OQ]X1T/Q]>:5\0OCA\.=-\(_L\>#-(UC
MQ#I&K:;-XZ\$ZIKWQ*^+7CV&WO;3PA\*M"TWPU'87ES\4CK'A'][J^.?VD_V
M`_V1/VL=.UJ#XT_`3X5>)?$&OZGX'U+5/B%-\-_A_>?$BZ'@'Q-X>\3:+ILO
MC76?#&JZU+I-P_ANRT+5M/FN)(;[PO/?Z$P6SO)$`!\!?M[>'O&^C_$_1_$O
MPF_:\^/.N_MA?&OQ9X$?]AO]F_X3^,Y=`^%?A;P-X4?P>GQ/\8?%;X8Z;?:S
MX2^(_P`%H8+GQ#XD^,/QD^*6FIIVFV/BKPMX`\#W&C^,;SP2FM?N"N_`WE"^
MU-Y0$(7VC>4#%F6,G[BDL0N#N8$5^9^L?\$Q?!;_`+0_Q2_:4\!_M/?M;_!W
MQK\8'^'%IXOT3X8^.OASIGA"/PK\)]$AT'P-\/?#VGZ]\*/$6J^'/AYH]H=4
MNX_"&D:U:Z2=8\1^(M9$*ZEJDMROZ8*NU54LS$*H+,<LQ``+,0`"S$;F.!EB
M3CF@!U%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7
M\WW_``79^/OCW]B/QI\%/VH?`^M>-_,^,/[//[7W[".D>&="U376T&3X_P#Q
MC\#:7XS_`&4?$UUH5G?QZ9'JNF_%#P=J6BGQ$MK#J]AI6OW@CU*"T20)_2#7
MG?Q'^%'PP^+MAX<TKXJ?#[P=\1M,\(^-?#/Q(\+:?XU\/:9XCL_#WC_P5>G4
M?"7C/1K?5+:YBT_Q+X<OF:ZT;6+98[ZPF9GMYHRS9`/XVOV=OC9\??V2/'_C
MC]EWQIXI^*WQR\4?\$!/@K_P4F_:F\<?\)+XN\7Q2_M):+\1_A-X-\9_L>Z=
MXZU4S7RZS:3^%_C-\6+:T^W0^)D\*P^"]+UG2]+CEMM(B@]\M?\`@L_^W_X2
M^&&I^&?%7@+3/&?Q,^+OB3]@G2?A'\68?@#H7@[4OA8W[<GBWQIH%T!^S=IO
M[37C6;XS>'_#VF^#X9?V<_%/B+XJ?!JP^,/BKQ);^'_$\UD-"G?6OZIM+^$/
MPJT7Q_X]^*>D?#?P/IOQ+^*&D>'=`^)'CZR\,:/;>+O'FA^$K.YL/#&D>+M>
MBM%U'Q!IV@6-W<V6DV>ISW,%E:2M;0(D.$'C?A;]AW]C+P3\+OB;\$_!_P"R
MC^SQX7^#WQFU"ZU7XM?"_0?A!X$TOP'\2=2OO($U]XU\+V>B1:1XAN8_LMJ;
M274K6=K!K6V:Q-NUO"4`/Y/?C[_P58_;<\%>,?V:/CS??##7?%?QH^#_`(9_
MX*M_L_\`BF#1]-U#PY\-$T+X->)OV<8[O]L[]H#]GOX?_$#XJ3^&K'X`>#+W
MQ/J/Q:^">G>-_$OBJR\?>&=;\+>'/%?A.P\71R:#^GGQ._X*%_M:?!O]KCX=
MZ/XZ^*'@I/V)]/D_9#\(-^T7X._9ITOXU_"GXSZY\>?#'A&'7=4^-7C+X:_M
M&:=\2OV)_&7C_P`:>-;*#X!:?J/P=^(_PQN-'NO`^N>(O%FMZ?XO-M%^VOA#
M]EO]FKP!I_PYTGP-\`O@_P"#M*^$G@_Q?\/OA?IGAGX>>%]$T[P!X'\?S6ES
MX[\*>$K+3M,M[;1-"\:W5A:WGBS3[&**#Q#>1"\U9;NY+2GSW3_V!/V'=,^(
M'PP^*NG_`+(?[.%I\3?@MHGAWPS\)/'\/P=\"CQA\.=`\(6LUCX0TCP?X@.B
MMJ>AV/A&SGDMO"MO97,2>'(=B:,+)8H@@!]?'@D9S@D?D?Y^OOV%%%%`!111
<0`4444`%%%%`!1110`4444`%%%%`!1110!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>pg24c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg24c.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"]`2@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_"B@\?YS
MCWX[#J:\/_:`_:5^`'[*?P]N?BM^TC\8/A_\$_AY:WMMI?\`PE/Q#\2:?X>L
M+W6+P2-9Z'HT=W,EYKVO7B0SO9:'HMM?ZM=QV]Q+;V<D<$K*`>X4'D&OS<_9
MJ_X*]?\`!.#]KCQO9?#+X%_M6_#S7_B5J\LL'A[X?>*(?$7PQ\9^+)X+>.ZN
M8/!?A_XEZ+X3U'QG<VD#M+>6?A>#5KRSCAN);F"**%W'Z1_Y_P`_YYZCB@#\
M[/\`@H7^U[\8/V2_"/POUCX4?`J3XE0>-_B]\'O!/CKXD>(M>TC1OAQ\(_"?
MQ"^-_P`+_A5>WVIV']K6WC#QGX[UQ/B"Z^!O"WAW35TT/INJZ_XI\0:;9:+:
MZ/XC^.OV[/\`@J'X\^!WQ^^*'P@^$?Q!_9C^'K_LY>"?ASXQ\>:;\?\`PC\7
M?&]Q\7/$OQ.M=1US0?`VI>,OA5K&E>'?V+/A-:>'K/3;&\_:R^.%AXY\`3>/
MO&VF:`/"-EIO@KQ/?ZK^D'[;/[.WB+]J+X&P_"GPOXCT3PKJL?QC_9X^)1U;
M7[2^O-.;3?@U\=?A[\6-9TL0Z;_I7V_6M)\&W>D:9.<V]OJ-Y;3W0^S1R*?D
MO]IW]AC]H[Q9\5OVFO%?[+_Q/^`W@GPE^WO\(/!WP3_:HB^-OPU\5>.?%'@>
MU\$>$_&OPZTSXI_!1?"WB7P]I'C#7+SX<^.KOP]>_"[XG-:>$8M=\/Z!XKM/
M$D=M=^*O"WB0`_6&PGFN;*TN;FT>PN+BUMIY["2:WN9+*>:%)9;-[BTDFM;A
M[:1VB::UEEMYF!>"1XV5CEGQ7X7&[/B3P^-C;'SK6EC:X)4HW^E_*P8,"K8.
M5(ZC%5?!'A#2/A]X+\(>`_#PNQH'@CPOX>\(:&+ZY-Y?_P!D>&=)L]%TO[;=
MLJ&ZO!96,(N+DHIFF,DA3G:?,?$'@?P4?BI\.(SX.\*%)]`^)DTZGPYHQ667
M/@IO-<&R.Z3,CY<Y9MS;F.2"`>J_\)?X4_Z&?P[_`.#S2O\`Y+H_X2_PI_T,
M_AW_`,'FE?\`R75+_A7W@/\`Z$GPA_X3&A__`"!1_P`*^\!_]"3X0_\`"8T/
M_P"0*`+O_"7^%/\`H9_#O_@\TK_Y+H_X2_PI_P!#/X=_\'FE?_)=4O\`A7W@
M/_H2?"'_`(3&A_\`R!1_PK[P'_T)/A#_`,)C0_\`Y`H`N_\`"7^%/^AG\._^
M#S2O_DNC_A+_``I_T,_AW_P>:5_\EU2_X5]X#_Z$GPA_X3&A_P#R!1_PK[P'
M_P!"3X0_\)C0_P#Y`H`N_P#"7^%/^AG\._\`@\TK_P"2Z/\`A+_"G_0S^'?_
M``>:5_\`)=4O^%?>`_\`H2?"'_A,:'_\@4?\*^\!_P#0D^$/_"8T/_Y`H`N_
M\)?X4_Z&?P[_`.#S2O\`Y+H_X2_PI_T,_AW_`,'FE?\`R75+_A7W@/\`Z$GP
MA_X3&A__`"!1_P`*^\!_]"3X0_\`"8T/_P"0*`+O_"7^%/\`H9_#O_@\TK_Y
M+H_X2_PI_P!#/X=_\'FE?_)=4O\`A7W@/_H2?"'_`(3&A_\`R!1_PK[P'_T)
M/A#_`,)C0_\`Y`H`N_\`"7^%/^AG\._^#S2O_DNC_A+_``I_T,_AW_P>:5_\
MEU2_X5]X#_Z$GPA_X3&A_P#R!1_PK[P'_P!"3X0_\)C0_P#Y`H`N_P#"7^%/
M^AG\._\`@\TK_P"2Z/\`A+_"G_0S^'?_``>:5_\`)=4O^%?>`_\`H2?"'_A,
M:'_\@4?\*^\!_P#0D^$/_"8T/_Y`H`N_\)?X4_Z&?P[_`.#S2O\`Y+H_X2_P
MI_T,_AW_`,'FE?\`R75+_A7W@/\`Z$GPA_X3&A__`"!1_P`*^\!_]"3X0_\`
M"8T/_P"0*`+O_"7^%/\`H9_#O_@\TK_Y+H_X2_PI_P!#/X=_\'FE?_)=4O\`
MA7W@/_H2?"'_`(3&A_\`R!1_PK[P'_T)/A#_`,)C0_\`Y`H`N_\`"7^%/^AG
M\._^#S2O_DNC_A+_``I_T,_AW_P>:5_\EU2_X5]X#_Z$GPA_X3&A_P#R!1_P
MK[P'_P!"3X0_\)C0_P#Y`H`N_P#"7^%/^AG\._\`@\TK_P"2Z/\`A+_"G_0S
M^'?_``>:5_\`)=4O^%?>`_\`H2?"'_A,:'_\@4?\*^\!_P#0D^$/_"8T/_Y`
MH`N_\)?X4_Z&?P[_`.#S2O\`Y+H_X2_PI_T,_AW_`,'FE?\`R75+_A7W@/\`
MZ$GPA_X3&A__`"!1_P`*^\!_]"3X0_\`"8T/_P"0*`+O_"7^%/\`H9_#O_@\
MTK_Y+K;MKJVO8([FSN(+JVF4/#<6TT=Q!*A)`>*:%GBD4D'YD=AQUKE_^%?^
M`QC'@GPA_P"$SH8_]L.WZC(KI;.QL]/MH+*PM+6QL[9/+M[2SMX;6U@0,6V0
M6\")#"FXEMB(!N^;KDD`M4444`(?YD8_/KT/3KT/3I7XH_\`!2+]IWX;_LV?
MMI_L+ZG\4I_V:_#FB3_LU?\`!2'Q[X2\?_M`:=X`L]4\-?%/X6Z/^RU?>`-%
M^&?Q"\;7FG7W@[4/%EQXEU*#Q%I/A#5+#5_&EEI6EV\DDD6B6_E?M<>GY?SZ
M]#C'7.#CK@]*_!'_`(+.?'+X`?"7XJ?L/Z9^U!\//V0-5^!TNG?M;?&3XC?$
M;]J_X._#SXN7T/AK]GWP#\/O%=S^SE\!(/B,L>E>'_C#^TM?:SIT&DWUA<7>
MLW5G\,[E-(\-^*-7@T_3U`.*_90_;Z\*?\%'?CW^P-\+?&FI_LI?''P]\0_^
M"8DG[9'QZ^''AFP\`?$VX^#O[6FA^./V9VT..)KC5O%GB/X5:GX3O?&OC%-+
MT+5[BU\1V.K:+;W3W:ZMX=:6+^B,9ZD8)))^IZY^AX_#D`\#^7C_`((WZ_XI
M\%_M<:'\/OB=\"?V&?`_Q&_:=_X)^>'_`-MXZ/\`LK_LF?#K]G7XF?L?:'XL
M^)'AC2],_9E^+VN^$)]2UKQ[H?C#0/%?ASQ-X9\0>++CPYXAF\2^`_&%E?>&
MKFULM/U0?U#C@=/7`'`ZD@=L?D,>E`"T5CZWK^A>&=-EUGQ+K6D>'M(AN-/M
M)M6US4[/2-,BNM6U"STG2K62^U":"UCN-3U2_LM,TZ!Y1+>:E>6UG;++<7,4
M+Q^(?$OA[PCI-SK_`(LU_0_"^A6<UE;W>M^(]6L-$T>UGU/4+;2M-AN-2U*>
MVLX)M0U2\L]-L8I)@]Y?WEM9P>9<311L`;E>8>(/^2L?#3_L7/B;_+P/7IPX
MR/0G/YG^6.?7J>37Q7\1-9^.UA^UM\"_#6D>)?@\G@'Q9X=^,6K)9ZI\-?'-
M[XUTS0?"`^$G]MZ>GB2R^+^F:!>:MXAEUR=-/U67P=!9>'8K6W:;2O$,MRXA
M:3>R;T;TUT2NWZ))M]DK@VEN[;+7NW9+YO1>9]JT49!Z?ASFN8\:/?1^%/$#
MZ7XITKP1J"Z7=-:>+];T^VU72/#DXC)35M1TV\U'2+2]M;0_O);>XU.PB=?O
M7,>`3G4J4Z-.=6K4A2I4H2J5*E2484Z=.$7*=2<Y-1A"$4Y2E)J,8IMM)%0A
M.I.-.$93G.480A"+E.<Y-1C",4FY2E)J,8I-MM))MG3T5\=?LD^,_BEX^TCQ
MUKOQ'^+_`(&^(W]F>-?&/A#2='\'^`=/\&2:/8>$_''B?P_H_B74;FT\;^+9
MK^/QKH.EZ?J]FKQ6%BZF:[TN2>QGB,?V&O0`\'G@_K^7IVZ=JQPF,PF/P]/%
MX'%8;&X6LINEB<)7I8G#U>2<J<_9UJ,ITI\E2$Z<^6;Y:D)0?O)I:5\/7PM6
M=#$T*V'KT[>THUZ4Z-6'-&,XJ=.I&,XN4)QG%22O&49*Z:8ZBO%?C'\>?`GP
M*MO#-YX[M_&LEMXNUB+P]H\WA'P#XN\<H^N7EUI]AI>EWW_"*Z3JATR\UJ^U
M*VM=&BOQ`NI2K<QVY?[+.8_4M`UFV\1:+I6O6=OJ=I::QI]MJ-O:ZUIE]HFK
MV\-U$LL<.I:/J<%OJ&FWB*VVXL[V"&Y@D!26-6!5>DQ-BBDZD#GJ.W&>.#^8
MQ[X/.#CP+2/VGO@AKGQ'G^$>E^,KNZ^(EI<PVMYX:/@OQ[;SVAN;O7-.M+NZ
MO[KPQ!I5KI6HW_AGQ#::7K,]_%I&IW6B:G#87]S):3B,`]^HI`?<9&`?K_\`
MKI<@]#0`44F><`9Y`_$^Y(`QD>N<\#`8CP+P=^T]\$OB!XWN_AQX2\7WVJ>-
M=/>*/4M#?P3X_P!*ETQKBVOKVR.J7FL>%K'3=,34[73-0N-)EO[RWBU>"UGD
MTU[M8B2TFTVDVENTM%Z]A77=:[>9[]129]2/?_/YTM(8449'J**`"BC!/12?
M?M^O7_'C-&1^/IW^A'8^U`!112$C!!([CJ/QH`/FZA3W[<<>IP<?7M@X#9!H
MSSCKZ^WZGZ8[]?4#\]?BGX=\-ZA^V1\'-)/QB^)FCZ?XD\(_&#6O&G@_0/CI
MXNT'PV/&GAN_^!</PUTJ\\,6'B""PTJ2]M-5\7RZ=H$-K:#Q(MSJ\]Q;:FD#
MBW_0@-DY)`QD8'`!XP,?PYZX.3P,'`.>/"YA@,=+$PP6.P>,G@ZTL-BX87$T
M,1+"XB#:GA\3&C.;H5XM-2I55"I&SO%'16PN*PRHRQ&&Q&'CB*2K4)5J-2DJ
M]&5N6K1=2,55I.ZM4AS1=U9ZH?129'J/SHR/4?F*[#G%HHHH`****`"BBB@!
M#TXZ\8XSSGC`XR<]`2`3QD9KX8_;5_:!_8"^$-O\+/!W[?6O?!'1/"?Q`\2W
MGB/X;2?M$>#=-U[X7P^,OAO>^'-FM3>)_%?A_5?`7@GQ1H$_B_2K[0-6\1:E
MH.H+"^JZAH]T8=&U>XM/N<],>O'3/Z<=.O7/IS7S1^UMXX^.WP]^!GBOQ'^S
MI^SOH'[4GQ)22SL8?A%XG^+WAOX)Z-J>@WS21:_K%SXW\5^#_'6A!M!L`U\N
M@W?AZX&N&-K(30!]U`'R[_P38\.P:FG[7/Q]U?6/V>?B)XJ_:"_:N^)7BKPO
M\;/@7K'PK\9W7Q&_9GTBX@TG]FFR\9_$#X9+,GB%_"7@U=2TS0]/UW4[^\T:
M">^3S!<WU]//^G(QCGIR#^''X>X/(Z'FOYYO^"`OA3Q#\5OV?/!'[:'QT_82
M^"'[/'[0_P`1O@]X1T=OVH/AI?\`POT_QK^V!X<\3WE[XD\6?$/XD_#7X3_#
M;X::3\.?$#^(=+TB:?3_`!1;>*?$-_+=22IK5O:V\D5U_0RO3_/;@_KG_P"M
MT`!^-G_!:/X/>$O&GP%^$OQ3\2ZGXQFU/X0?M5?L>W/@[PS:^-=>T;X>OXB\
M4_M@_`33'\5^)_!>EWUEHWC#Q-H>EQZAI/A.Z\31:G:^'(=?UV;2[**^OS=1
M_"__``6_^,GBW7[OQGX(^(?P,_:N7X#_`+./B3]ESX@?#76?AO\`!_Q7XJ^&
MOQV^.>N_''X=ZU=>)?%GC;0;V+2K7PU\$?#ED?"_@;P#J?[WQW\7O'MSJ>I6
MT<'@;PJ=6_I;\2^$_"_C/2UT/QCX:\/^+=$74='U=='\3:+IVO:4NK>']4L]
M<T'4UT[5;>[M5U+0];T^PUC1KX1?:-+U.RM+ZRD@N[:&97^)/"_AOQEI%QX?
M\7^'M!\5Z#=W%A=W6A^)=(T_7='N+K2[^UU73+B?3-4M[JREGTS5;*SU/3YI
M(&DM+^TM;NW:*XMXI5`+NF7RZKIVG:HEKJ%BFI65GJ*V6J6<NGZI9)>P170M
M-1L)P+BQO[<2B*[M)E6:VNHI(9%#1EJ_'?XS_!OX\:K^V!X7U+3KG0=#\0>.
MM3U/Q?X`NX_$U]JVBZ7I/PTB\#1>([VZAN;/3;F**!]:T26\T,6$7]LA;FVB
M6YAMUFD_9CL<=>?S/.3^/)]:_"_]J+XV_M;>#_\`@H1\,+#P+X%U/QWH.AF\
MT;X9:/H_PO\`$,?A[6O!/BV'P1<?'"R\2>-[R,[O$VDR:7X3%AXNT,S^$?"=
MKJFFOK5M<S7&J0G\U\3?`_AGQWRS)N'.)\US?*,-P_GV&XNP&(R;/:'#V(J9
MGE>$QF'PV'J9A7PN)2I5(XVHU"G+"U55C2JPQF']FYGU'#'BQFW@]4S;B3*L
MMHYJ\PRN608[#U<@QO$LJ>7YAC<'/$8JEE.7R^LU_JSP\*M?DH8S_9HUX_4L
M2Y*E+[GU#X:?MW71<V_[0WPOM\YP(/`EQ;8^4@8_XE]S@$_,1\V6`Y/0\/XC
M_9O_`&R/'&A:KX8\8_M%>%M2T77;,V&I6%OI5Q;6=U;2\3Q3VT/AB&>:-E"Y
M2/4+9MP+-,-V!Z2O[7OB+0"P^(W[+/[0GA$1';)>:)X=T[QYI2<G<ZWFAWL$
MS0*>3)]D3(Y5"H`K,\0?MJ?L>^-_#6O>%/B'X_O?!VB:OIMU8Z_9>,;/QK\-
M[V.P9`]XHUVR&E:AI<D:IS>:=JUK-$<&.Y`/.>8_1>X=S3`8W!9I1\4<_P`'
MC,)BL)C&_&3Q9S?"U<-BZ,Z.(A7HX'CFMEM:$Z=2494Z^'J491O&=.47.,OD
M,L^E_P`,TLRP"PO%/AKPOFD<9AIY?@L[\->".#,TEBZ=:G+#0P^'XGX/RC-E
M7=905.-+EK\\H\C4W!KYO_9<^`G[1'AC3/%OB7X4?%+P+X8M+WQMXN\#^(=.
M\0^%+[56U6]^$WB_Q-X+MKZ,O&[06=Y<0:I>VJ1S1316U[%'<":>)C']:_\`
M"2_ML^%3C5?AQ\'OBC:Q'+R^$O%FI^$]2GC7CY8==MIH/-8$$K'`ZH<D=1GX
M?_8J^/7[#OP3\(^/-4T#Q?K6@^*O$?Q-^*ES=^&M6UGXS^+?$4WA#6?B9XM\
M5^!;\>$O&>L>(GTT:SX?UBUOXM4M;2UOM65W34;JYO+>Y6/[,_X;.7Q"H'PM
M_9W_`&A/B('($-\?!J>$-"E!V^6XU3Q#=Q.8LEMSK9.T8P2A)POE\.?13PO!
M.2X'(_#W//%CPZRC+/K2P6&P7&&(Q>28>IB,97QF(G3ROQ`P_$7#M/VF,Q%:
MK6CA\#1A6K5)U:RG7J5*LO5XI^E]P;FF>8RKQMF7A?QQQ!7AA)XW!83((9EQ
M/4I?4L-'!NI3\.'A.**G-@8X:6%G5G5E]7=%T&J"IQ7QQ^U)^U3\:3?^$/"W
MB[X.Z;\)#HOB;PO\2M-L]<UZ;Q9?:UJ/@7Q):ZSI5Y'?65KX?LXM%COK`6NI
MVD4%W//&S-#J-H0IKZ'T']M;XL:IH>C:C)^RWXVNKR\TRTN[R33(O&,VEO)<
M0+,MSIEY_P`(&T5[8WR$7EK)`\L:03)$+BY4"YE^._V^?CS^VE%I?P>NK/\`
M9XO/A]H,GQ"TC6=(718(OC)XAU/XA>'=;T6Z^'WA_P`8QZ?I%G8:!X-U77+N
M!+RUMS)KNO72"TTQ1#97KR?<WAS]M+Q!X?\`#^B:G\?OV=OBK\*;34=)TZ\?
MQ-H>B:AXM\&1>?;1O,][&MCI/B;PS&CMN73M:T0:A;1&.*Y59ED5>#)O`/Q_
MROB/B'-X?22J\28#.XX2&7\.XSA/@S-LPR18*G3IRG1IY=F.`R:K6QK;>(>3
M9%AZ<VG*K0I5;2?1F_TEO`)\-\-_VGX/9MP=0IO&RJ\3X^EXC<.9/CN>M._]
MJXK/>':N/R&A04?]D?%>;8?VL)*>$K5J+Y55'[7/QUF919_L>>.[DR-^Y\S5
MO$5H)5)&UF>7X>NL&5YVN&YPO3FODWP-^V#\8K_]H[Q7XDTSX5Z/XH\6>-?#
M?AKX97_PWL-3U#2-1@TSX2Z]\5O$FCVMKK$\6IF+7=.N_BAXCC\1W,VB-%J-
MKINGQP:?I4J2RR_JU\.?CO\`!_XM1(_PZ^)'A?Q1*=KMI]CJD,>KQAN3YND7
M;0:FFWY@Y-L54C:221GX`^&WC?\`;<N?^"@WQ;TOQ#^R;^SCH7PQE^&?P%TK
M6O'VC?MC>+]?\7:+\-[7XF_M;MX4\?Z7\.)_V.O#]AJOCGQ@L]Z/%'P\D^(.
MCV'AB&PTGR?B+XM&H.FF>+Q=X/>.N99GPY.A](GB+AN.29O2Q^<8&AX><,8.
M6:X&-3"RE@9TZ:PU.+G&G5A%YGALWP?[V*J8"K&-15?NN#?%3P=Q649KC<O\
M,>'.+L'G.73PV59K@^.LTS3!87$.G62Q5'%4)8J-2TJM*<O[/Q.`Q-J;Y,73
MDZ;I?0=E^T#^T]>@%OV+]5@Z`&7XOZ3`<&,-TN_!ENQ.,`9`P?E)##%:Q^*O
M[6U]S8_LN^']-#;B#J_Q>TN8C[K#>+?1[7^`;#@@F3YAM4%*^G/%?C#PEX%T
M:Z\1^./%/ASP9X=LANO=>\6ZYIGAS1;-!EB]UJFLW5E8PJ5#,3).N-I9N?F/
MY;_$O_@MQ_P3V\#ZZ_@WP-\3?$O[2WQ&$C00_#K]EGP!XD^-7BBYN<LB012^
M'[5/#J&5P4CEN-<BA<J^QRRD+]0O#7CBKIC/'WQ.J0>]/!Y'X/9>K:74:E'P
MOGB(K97==M=&KN_&N,^&:=OJ_A1P1&2VEB,T\1L6WT7-"?'4:4N_\)7Z[(^K
M(_%O[;5TV(_A#\%-(!;`;4?'VL:AY0!W*7_L^$9XW(=J[@X+8"[17P5\"M)_
M;#\+?'3Q?=6>C:KXG\7V=EH]K\0=-\<^-KV303;^(-*U>\\&W&OWUOJMR^I)
MIMC9ZC#X?9$OQH9G^Q>78)>[7>G[:7_!5?\`:!=+;]F'_@FOIOP)\.SR$6_Q
M/_;F^*<'A>X%G<82WO1\'_A]9WGBF!X=K2RP/X@O99$DA5K>!XWW?B%^QU^R
MO_P4$\*_MO\`Q5\6?"']L7_@F'=?&Z2?2]5UJPCF\)^-=!\87]_HOBS[+H?P
MW\)>$_ACHFN^$)-%TW^VH/'EQX!N_"^H1W7V.7Q0?%#J\L?R^??1KH<6YKPY
MQ!FWC3XRK,.",95S;*'#B+AC"*OBL16P#G"IAL)P?AL'6BE@H/EJX>K"[]DX
M<M:2?O93XR5,CP&=Y7E_AMX;K"<1X:G@LP4LHSW$N%&E3Q,4Z=?%<28C$TI2
M^LS]ZG7A*ZC)24J<6OZKQ\4/VN]+"G5?V9?"FMJ,EAX;^+EA:EMH7B-;_2+P
MC.`JJV<,1@@`YYG5/VC_`-I_3BW_`!A1K4Z`\M;?%:WO>">6`T[P%=[CU.T'
M).!G(%?&Q_:#_P""X/PI"GXA_L%?LL_M'Z;:@K<:A^S[^T=JOPZU6^8,26AT
M;XF>&]8D5I%`./LPC5OE;&X4+_P6(\6>`%=?VF/^"97_``4#^"20%5NM<\-_
M#+2?C=X.MPH/GW'_``D/@76(;O[!`,,;J7187<'<L&17U/\`Q#?CC#R7]G^/
M/B1"G'X:&9Y'X3YM3>VDZTO#C#8Z:\_KL7YWNSY]\8\,5[_6_"O@UR>CJ8'-
M?$'`3M=-\L(\:5\-%NVZP_R>Q]7G]L'XM67_`"'_`-E7Q[H>!DNH\7ZS%&%P
M=SRV'@`$(H+9*HPX!P>E,'[=%A;-Y>M^%(?#+J=NS7=/^+-N%()#;FA^%-PB
MA>"V2P&XD[@&->(^!_\`@NE_P2\\9W4>EWO[3NE?#377W!M!^,7A3QK\,=5A
M=7V2)<1^*=!LK5#$^5<FY,0)SYA#!J_07X;?M+?L\_&***;X4?'?X0_$CSXU
ME2#P5\1O"7B*\"/D+YMAINKW%[;L^!B.XMT;&#C!!JUPIXQ896PGB_D6+:UC
M+B'PLP>-D]$OWG^K_%O"D9.U[N$::VTWO*SWP[K?[SX?YO0;6V4<=5<*D_[O
M]K\-Y_*R6RE*3TU=VV?C_P#M`?&+]G7XJ_&7X>^.?%/[,GP1^*-]X*UBXOM>
M\6:KI5CK3^/-)U/P#XA\'Z?X<UNZ\7_"RW\0I9>$+_7[77[:&_L-;@2\T*W3
M2K2WN98+^V^Y_P#AM+QAJNZ+X??`7Q!\1PK&.WN-!C\?Z5I4J@[8S]OUGX:V
MZVZ.%!C5X#\@R0N,'XH_;\L/VE+;]KWX.CX2_#CX7ZQX<\0ZU-';WFO_``J\
M:^)=5\1:AH?PB\8ZU<6NKZCH>FW%GK-AHFH:?9ZE86UD\MQIVH6.G27X6*,J
M?W9!;:NXG=L!;J!N*C<`#@@[L\<'``XRQKXWAK@GZ35/->*Y\7^-_!U;)LPS
M2.(X8I</^&6#CCLGRU3QGM,)A_K^-IT,%%PJ81*EG,^.L2G0C'^UTX5YX_Z/
M.N)?!6>`R&&0>&?$=/,L)@72SJIFG&M?ZKF.-<,);$5UA<+.IBFI0Q#Y\LCP
MG0_>2O@)QJ4HX3XQT_XT?M9>)K:,:7^R?IOA>Z<9:X\7_%:T>R3.>MLGAS1]
M0!0C)5E!.5"J&JS+I/[<OB**5W\5_`?X=[Q^ZMM,TCQ%XHNU#?P2W%^AMU9`
M"!)$)!\Q(7H:^Q>YX!YSSSDY"G![`<#D9Q^BD\$8QP>G0=L_@3SP._I7UJ\)
M\TQSC+B3Q@\6,\O?GH8+..'^"\(XZ>Y!<`\-\,8^,%LI2S"I5M\563NWX"X]
MP&%262^'G`65N*7+5Q.79OQ-7NK:R_UNSK/<')Z;+!0A?X81M9?BEXN_97^-
M$G[1GP_MO$/Q2\+7OQ/^(^E^//B?:^+].TB^LK+2[[X-WWPTLXQ)!]FR+Z[;
MQSI,FG2PZ>]O9+H]VUS%<O/"E?5B_!S]NRVD7['^TKX/>)7&4U70I-29D50,
M%D\*VA+98EB"/,RH.TKD_)G[1WPL_:#UK_@HG\%=<\+_`!?_`&ZM%\+7WAKX
MS:II^@_#N\_8@C^&FG>'=&U']FE-=TOPXOQ`TN3XCIX+UVZD#>.X_$]R_B^6
MZBB/@`PIYQ;]MOXC@9`W8`'N"`.<^^,`<\=2S?/</_1=\(>%\1G6+R3"<<9=
MB^(<SJYOF^)P/BQXIY;B,=F-:=2I5Q6,K97QC@:F.KSG5G*>(S"6+Q%24I2J
M5IRE.4O8S?QO\0<\I990S2OPOC:&48*GE^7T,7P!P)C:&%P=*-.%/#X>CC>'
M,33PM"$:4(PHX2-"C!12A3CRQM\16'P\_;HML>?\?OA5<X"9\_X?W4Y(`*D'
M%K;D[LAB002PR,`8K>7PY^W!:#,?Q+^`NL8SQ?\`A#Q'IIDVKP2UD\@4R-D.
M%("85E(R4'U_\W3:<_0GCUQ@9&>/?J*4!B<;6[=CCJ<\XQVZ^X)%?2OP7R2F
MK8/C/Q=P$4_<C3\6^/<9&%[;+-\\S)2U5_?YM[;'C?\`$2<SG_O'#?AYB7IS
M2EX><)8:4MMY9=E6"DMMXN-GJ?C_`.%O$W[9=M^U5I7@_P`3:IKM^9M7U;Q-
M=^&TO[S3/AWJ'@S3[Q-&N]9L"-.U+4;7P=#J>H:9:07!T^ZNTN;JT$L)9VD'
MZ9?;_C%V\*?#`=\#Q_XN]_3X:#ICKCYO1<<_CIJ/B6.X_P""J>G:7!\=M5>]
ML]&UKPK-X"A\(?M4S7%O?W?Q*\$>,U\'&XM_C''X`.F7/A33KO7YM>A\,I\.
M+>QAVZEX4G+PR1_NP.2>G4],8Y/;`&>`.>I7;VP!V^%?A14\)\OS[+ZO&/&O
M&:XBS_$<2TL7QQF4\TQV!IXRA0HQP6`Q,X0D\OC]7=6#M[]6I5G>[9R<=<>T
M^/L7E6+I\/<,<._V+E-'(ZE#A?!0P.%Q53"U:E2>)QE*$IKZ[>K[.HKKDA"$
M+>ZCS+[?\8^_A3X8]C_R/_B_G!Z9_P"%:$COC@X/:N^TQM3>PM7UFWT^TU1H
MO]-MM+O+G4-.AGR1MM+V[L=,NKB'8$.Z:QMF#%E$>%5CH45^IGPX4444`!&0
M1ZC'K^G>ODO]J?\`9R^)'QULO!NL?!S]JKXR?LH?$_X>W6K7'A[Q=\.(/#/C
M#P9XAM=;?1WO]!^*WP?\>:;JG@SXCZ&'T2S.FR3#1?%&@"?5$\->)]&76=56
M[^M#Q_\`7XY/3\S7Q/\`MA?M,?'[]G;_`(5T/@=^PS\:?VT!XQ_X2_\`X2@_
M"+QU\'_!?_"M3X>/AK^Q!XA'Q5\7>%SJ1\8?VWJQTG^PC>BS'A?41J1MS=:?
M]H`/!?AQ^Q=^WMJ/C'PYK/[5W_!4WQE\6/`_A;6K/78?AK^SE^S1X`_9#TSQ
MA/97=I?1:3\2?&5AXV^+_C_6_#37-G`DNB^#_$G@`:AI\NHZ=K5[JECJ#P1?
MJEG.2>I)SGU]/PZ#T`P<$8K\+_V</%/[8_[2G_!3KP)^T5\7OV%_CM^QQ\'_
M`(8_L2_&[X/73_%GXF?"+Q;I_B_XA_$#XS_!#Q?X=.E:1\+/''B9([C3_#_@
MKQ*LFHZM:0RJMP;:W>-"QN?W/'3T]1TP1QCZ#&`.P``H`6BOA3]MW]NCPY^Q
M?I?PO:\^%GQ)^*_B/XJ_$GX=>`]-L?!VB:M;^$/!^D^./BM\/OA7?^.?B5\2
M6T;4?"_@K1]#U#XB:1+I6CWTD_B;QMJ.=*\-Z1/;VVMZSH7(?M=_MD?M#?L[
M3_%OQ1\.OV.#\6O@C^SC\))?C1\<_BOXU^.VF?`[[9X9L--USQ-XC\/_`+/.
M@7OPW\>Z5\8/&W@OP9X9U;7O%]IX]\8_`GP=IUW?>%M!L/&^JZAJNLGPT`?H
MT>A_KT_&OYIOV]?^"N?A/]E+_@J5\%/A'XEUCPMXF\)_#_P1XAMO&H\&?#KQ
M1XO^)?@[4/C5_P`(9-I'P_BT'3_BAIL7C'QAXDM/!-K=Z9J6F:=I<?AJ#Q+I
M\4WA'Q=>*X7^CCPKXDTOQCX7\.^+]%-T^C>*]`T?Q+I#7UI/87C:7KNFVVJV
M!O+&Y1+FRNC:7D/VBTN(TFMY=T,J*\;*/B/XH:N#^VK^SU-!\#OB+K%IX=\/
M_&C2=:\?6'P_TF\\.1:IXJ3X,CP_KBZ_+J,=]+8Z9_9EY!?ZM';-/I36AB=-
MC0M)O0G0A*;KT95HRI5(0C&I[+DJ37+&JWR3YO9IN2A9)S4;NR:<34I)<LE%
MJ46VX\UXIW<=U:^U]UT[KY4_X?X?L#V#K%XIA_:<\!REMC1^,/V6OC)IK1,(
MO-F2:6U\.ZA!&UN&3SB9``7C*&2,[P[4_P#@N#_P2*\>6$WASQY\<]#ETO5X
MI--O]%^)7P<^(:6-U:W<.VZM+VQUOP1/#);E)#%<Q/'(H,@1D8,N[]IR6!/W
M^.X#$?RP?Y5Y#\;_``)\-/'GPJ^(GAKXJ^#KGQCX$\1>$==T?QEH>CZ/K&H:
M_K/AW5+)K76-.TN+PO&GBB:[O;1FA$>B2IJ+C_4'>JXR@^6<9*4H6:]^'QQ6
MB;C[T=;;+FBF]VKW"<(5(N,X0J1=GRS2E%N+4HMIIJZDDT[-IJZU/P'_`&,?
M^"M7_!)3X#_"_7H+#X@2>$?$FL_%+XIW46FR?##XB>*/B%J/@[3_`!QKMG\,
MFO\`5+'0_$.H76FP^`?["C\.V<^K,VGV$ODRVME?37HE^L%_X+P?L8ZN=O@+
MX??ME?%9P2J+\/OV3?BKJ0E)8A?*;5],T5'$A23RV#%6"MA@JYKT7_@EO^SI
M^SS^SUX;^,FE_!?X$?$/X-:SXG^(_B36->3QWX0^*.@V^L^$-'\;>.-/^$4N
MC3_$-I[!Y[/P1>V\<Z:,\6J26DUG)XA$D\=LZ_K#E^?O]3_"WJ<=1^F,=L=J
MZ,;76(Q=:O&KB:T:D^95,9-U,3*Z3?M9N=3F:ES+FYO>5I-1;:,<)A:.#P]/
M#T,/AL-3IPC!4<+2A1H14(JG%0IPA",8QA&,8Q44HQBHKW4C^3'_`(*-_P#!
M?33/`^F?!;2O#/[,7QW^%-T_Q"\/?%.ZL_VNOA-<?"N[\2^&?AEXDT76IM9\
M!VL7Q0TW4K]=(U"'[%K5GJ6G0V&IMJ5O`OB/PY-9337/Z!>#?^"C'_!3'XD^
M$O"^K_#S_@D/XGUB/Q%X>TC5K;QSXU_:7^'7PX\)ZW'JFGVU[;ZYH_AN'3/'
M>H0Z%JUO.+[3K>;Q5?2V]I/`CZC?/NF;]#/VO/#/B[Q/H_POMO!OP+UCXRWV
MD_%CP!XQUB32[[X2:?\`V#X;\#^+]"\0:O93S?%+QKX1:YN?$-G#/%I=GHZZ
MC:S3V,ZZS-I<;VDEU]3>'KBXO=#T>\NO#NH>$[BXTZTEE\,ZD^C3:AX>=X5S
MH]W+X;U/6M!::P&+9SHNKZCIA,?^B7<T.QVSG.@Z-"$*4HUJ?M76K.IS*MSR
M3IVI\B]E[**<=)RY^9R:3VW2DI3;DG%VY8\MG&RUO*_O7>NJT[G\^/CWX3?\
M%:/V@)WN]3_8+_X)O_!C5IY&>'Q3XC^,_P`1-=\46+R,K"[EO_A9HNG&\O(A
M\Q:YCG+$*!M`VC\M_P!GC]C'_@ISK?\`P4,\;^'O%W[9V@?`K7];\+Z5IGQ)
M^*OP4^-O@KXA^*Y/!-UJ7Q!TOP'X<\*>!_&7B)M:O)+C7/AMKEE)IE]9W6O>
M!K-=+OK_`$K,D=L/[;MI!RJD$8Q\K`'!R0>/NG@#T)9L'DCY$\._L7?##PQ\
M<=1_:!L-9\92^.]6?35U".XL_AP-&N+#1=7\:Z[H^F".S^'EKK%O#8:E\0/$
M\O\`:%IK,&O7Z7=M#JVLZA#862P^A3SO,X86I@IXNO7PLZ4J4:%>O7J4Z$9V
MYG0C[5*DW9723B[*\6KW^;P?!G">6YMC,]RSAS),LSC,80IYEF6797@<%C<R
MA3J>UA',,1AZ%.KC>2=Y1EB)5)QNU&23L?F%<_\`!OK^SMXUUL^+OV@OV@_V
ME_VG_&AD$S>(_CMXV_X37RY#]XVNE7(&G641<G9#;Q)#&BB!$V*H'W/\-_\`
M@GGX=^#^@Q^&/A7\:_BC\,/#\041Z-\,K+P1\/\`3&"*0IN;;PQX=T\7\X)+
M_:;U[B=F9RTC$DC]$<<YVMGUVM]/2C'.=K9_W&_P^OYGU-+#YUF&%IJEAY86
ME#2_+EV6\SM;651X1U).W64FWLWJ>+F_AAPAGN+>.S>AGV.KRYM*W&G&BH04
MG?EHX2GQ##"4(I_#"C0A&/V5&Q\7+^R!JTCB2^_:H_:BNY59=KI\1$M5V9SL
M=(+`JVYBQ+-R0VTYP*^*O@C^Q!K6C?M0_M*VT/[4/QVM)_#=EX`N/^$DT?7C
M8>-?'4/Q(L]9\01CXK>(;FXOXO&]UX-72)M*\(SC3-*.E6%[<F+`GDMD_:8@
MYSL)Z@Y0G.>V#@$8'.<9.W)`&1\V^`OV:M.\`?$[Q'\5K3XL_&[Q#KWB\:5'
MXGTKQ5XH\/:CX9UF'0++4]/\/6]SIEGX/TR>&#1+;5KL60LKVT>63R9=0>]D
MB##JCQ/G<(U(QQ<%&I%0G%8/`J+BJE.K;E6&Y?CI0>VMK=6<^&\(_#_"4J]+
M#Y)B(1Q-_;R>?<1U*TV\+CL%=8BKF\Z\)?5LQQE-2A4C).LJB:J4J,Z?G1_9
M:^+-LV=,_;0^/$`X_=ZG;^%=8CSD[V/VFPAD.<<?O,)@G!R,2_\`#/W[3EK@
M:=^VQXBX.3_:_P`'?"6JDY;)!*:[8MS@*F/N#/!W#'VEM]G]_E//&#_#GD<'
M&*-O^RW_`'RW^'^<#T%3_K'FC^+^S9_]?,CR.K_Z<RZ5[]6]?,X5X+\"Q=Z/
M^NF%W5L#XI>*.!26FT<'QC0BDGLDK+2UC\[_`!W^RU^T+\0;`Z7X^^+?P!^+
M6EE=CZ=\5?V8O"/B6R='/[Q'MM2NM6B*$;8@N""A(;#(*^!_B)_P1`^&GQ(F
MEO-?^`?[#,6JO(TPU;P+\.O'WP@U*.X9LFX@?X?:OIUG!+&0$A*6BI'\S(JD
ME3_01MSP0^/]UO<=EXX)'&.I(Y.:,=MK8]-K8&>N!C`^GKCT%+^W\0_XF`R.
MH^[R/*Z;W3WHX:E;:VEM"EX29/2:>$XM\5,$E:T(>*G'>,@K.Z]W-<[S!2Y>
MG,GY[L_BK^,O_!&+]O+X7_M/?L_VW[-OQONOAQX=OM2U6#X2Z_I_QJ^,/B2V
M^&'BG^P;W4?B7-%JOBS[9<^#[K6O!.D7<EE:Z/IFJVWB?3-%DTNX62>W>V/Z
ML>'OV*/^"W?@)D/A#_@J1X&\36MN";?3?C5\(=+\;O-@CRQ>ZUIN@Z;?S,%P
MLSB)D9LLH!;C[M_:4_8??X]_&3P;\51X9_8XO_\`A#+UKY3\9/V3[SXM^-O$
MPG\$>(O!;Z/XE\:1?%SP?%=Z%IJZ^-8T&Q;P],^E7NEV*)*S&2X'Z&JA4`;1
M@*J_)&R*-J@#8@SL08PJY)48!9CNVX8G-(XJG"G/+<NI^SA*$)488JBX<U6=
M5\D:>*C3@KS^!1<+W:BG*5_K,+PWB<&LOA1XJXGE#`451DL36R?'3S"*I8>E
M[3,L1CLFQ.*Q6(;H2JO$JO2KNIB*Z]I[/V-.C^%&LZ3_`,'#G@F$'3?%/_!/
M/XV1QH&SI]EX\^'NM7#(#^Z$.L:.NBQ>:"P+&[`1A@84DUXEK_[57_!=GP3-
M)'\0/V%=1UFTA)>;4O@'XM^$GCIFV@^9'::/J<EK=3(<9B)O\]`2V<U_2-M'
M]UO^^7Y]SQR3@9)Y.!D\"C!&<*V?H_)Q@9XY].>W'2L<-F6(PG\*G@)+^7$9
M9EN+[:<V+PE>=M/YKZZ-$9UP9E&?7>/QG%5&;5N?)^.N-N'5HT[^PX>X@RO"
MWOT=!Q:T:MHOX8?B)_P56\:V/[>WP]3XHZW^UC\.OB'X?T^'POK?AB?X.>%+
MKX\>`/%'B-;=O#_P?\!_!32/BE%X5\7>'/BD'L[[7;W4VMO$6IWHT5K'2=4D
MTC2YHOTKC_X*&>,-8D87'@O_`(+;ZI)$2UU#X?\`V(_#_@U8D8L!\]]XKG)#
M,"`EO(\J;,N`I%?HO\;]7^*MK^W)\(]>\/Z+HMQX3\*:!\5O#^HZ_+^QE\;?
M'+:'=^+[S]G^YT6.]^)7AWXCZ1X=UK5]>3PYK\6D>+-/T:VTSP;;:-=P:Q8:
MBS!T_5SYPQ'SX!(!^8DX.!V(((Y)[D].`:]6OQ/CYQP\:,,%1=&A"E)O*<EF
MG*,IS;HIY:GAZ?--M4:;]FKN5N>4IR\#$^$_"&.5".82XKQ<</"%.FGXA^(E
M'VL:=&A0A+'+#\5TXYCB/98>E&IB\:JV*K2BYU:LY3J.?\R,W[91UD*O_#-'
M_!>KQ;*C9O89?A[9>$+98G&(VVP>)T2X65]P:*-P8E0.01M6J$W[1'A3564_
M\.Q?^"RGC>=2SW2^)K7["%1LA&)F^(%M'=&5VD$D2#*C+L"K"OZ?OF_Z:?\`
MC_\`^O\`/\*,-T!D';)\SCW-8+B7/H_P\SQ%'_L'5+#?^H].E_6BTT.27@?X
M3U?][X(RG,^K>=2QV>RDU9IREG.+Q\I.Z3O)MMZMMG\CO[$7[;?[&?C/_@J_
MX?\`@M'^SUXZ_9WU:/PKXAT?0_#7QX\;Z==>)M&_:VLYGN[I[WPK:^(=>TW3
M?%&M?#Q[W0]+-QJ;ZJ=<CE$>D6U]>1W1_K?&<C=G)R/3&.0#^ON,$'J*^%-0
M\.>-)_VQM'\>+^RSXHN/`=C\.]?^'=S\0OM_[/ALIO$NK?$OP=XJL/'G]ES?
M%%/&S:'8Z?H>H7LMY)X=_P"$NBOS%':^')YY3.OW8%(/1^"?X3D@[CD\9.>,
MD@$GD@8!;CS+,:V95:-:O4Q-6K3PU*A.IBL3/%5)RAS.4U.:3A&4I-^S5TFV
M[MR9^@9-DN5Y!@HY=D^78#*\!";E2P>6X.A@L/3]R%./[JA&$)35.G3A[1QY
MG"$(MM1C9U%'/]UO^^6_PH_SR,'\CS7G'JA1110`AZ?B/\_@>??&.]?BO_P6
M7_9]_83_`&COAKX6\`?M.>.?@KX)_:<U+X8?M$Z;^P@WQM_:#\3_``$T#5?B
MSKNA^!=,O8K&;0O&WA*S\636WBV;X3K=6-U:^*-5TN&[BNM(T*\ANM5M+G]J
M&&1@8S[^_!Z>Q/<<]"#R/CG_`(*!2^&M'_8J_:E\:^)_AW\-_BE#\.O@%\6_
M'UAX0^+'PPMOC%X%U+4/"?@C6->M[;Q'\/)T:3Q+HDT^G1KK&F6DD$]U8^<%
M==@P`?C!_P`$>_V&]1^$G[6GB+]H?P?_`,$^?&W[`WPCLOV54^#6L6/Q7_:X
M7]I_Q)\9_BOK?CSPEXG'C#X?IX9\>>-?"^F^"O#WA_PSJ-IK?CK4;RPNOB!>
M^(M`_P"$<\)>&8-#UZ74_P"F5>@_S_\`K]SWZ]Z_AI_91_:`\7?L5?M1Z-XJ
M^"OBS_@C'XT\(^._!/P(UOXU^#O^">&H_M`>'O`_BC0?C;^T9X&^"R^#=%\.
M:)\5->_9\\(_'C3/$/Q$LO%?P=CUGX86?BKQ[X2TCQWH&G6'@S2+'4HKO^Y?
MH2.N"1S]>/TQ0!\0?\%!_@?\1?VA?V=(/AQ\+]/TW4_%4?QX_9:\>O::IJUM
MHEI_PCGPL_:/^%WQ(\8W(OKPB$W%IX4\*ZM=6=EGSM0NX(K&W)FGC(^,_P!O
M3PY^VU\7?C]9^!D_8U\2?M'?L*>"?#WA7Q*GPV\#?M$?`7X7VO[27Q;34)M:
MOM,_:%L_BCK&FZW=?!CP`]EH<.@_"?2+=="^)'BF34]:^)FHZQX4TW1_"%Q^
MU=)@>@_(4`9^E75]>Z9IM[J>FR:-J5W865UJ&D275K?2:5?3VT<MUIDE]9M)
M:7;Z?<N]J]W:-):7'DF:W)A9-WS_`.(/A;X)/Q0^'UN;#5_+O-#^)=S,/^$O
M\9AO.'_"%DM&P\0AH`XE99(H62)E"J5(1"OTC7F'B#_DK'PT_P"Q<^)O\O`]
M`!_PIWP#_P!`[6?_``M/'/\`\TM*/@]X"!R-/UH$="/&OCD$?C_PDM>G44`>
M9'X/^`V^]8:VV.F?&WCHX_/Q-3?^%.^`?^@=K/\`X6GCG_YI:]/HH`\P_P"%
M.^`?^@=K/_A:>.?_`)I:/^%.^`?^@=K/_A:>.?\`YI:]/HH`\P_X4[X!_P"@
M=K/_`(6GCG_YI:/^%.^`?^@=K/\`X6GCG_YI:]/HH`\P_P"%.^`?^@=K/_A:
M>.?_`)I:/^%.^`?^@=K/_A:>.?\`YI:]/HH`\P_X4[X!_P"@=K/_`(6GCG_Y
MI:/^%.^`?^@=K/\`X6GCG_YI:]/HH`\P_P"%.^`?^@=K/_A:>.?_`)I:/^%.
M^`?^@=K/_A:>.?\`YI:]/HH`\P_X4[X!_P"@=K/_`(6GCG_YI:/^%.^`?^@=
MK/\`X6GCG_YI:]/HH`\P_P"%.^`?^@=K/_A:>.?_`)I:/^%.^`?^@=K/_A:>
M.?\`YI:]/HH`\P_X4[X!_P"@=K/_`(6GCG_YI:/^%.^`?^@=K/\`X6GCG_YI
M:]/HH`\R'P@\"`8%CK8'3`\;>.L8],?\)-BF_P#"G?`/_0.UG_PM/'/_`,TM
M>GT4`>8?\*=\`_\`0.UG_P`+3QS_`/-+1_PIWP#_`-`[6?\`PM/'/_S2UZ?1
M0!YA_P`*=\`_]`[6?_"T\<__`#2T?\*=\`_]`[6?_"T\<_\`S2UZ?10!YA_P
MIWP%G_D':U]1XU\<C_W9<@YP>.P/(.,]]I>FVFC:?9Z781RQV=C"(+9)KJ[O
MI5CW$[7O+^>YO)SEF;=<7$KXPI;"KMT:*`"BBB@`KE/'?CGPA\,/!/B[XD_$
M#Q%I?A#P)X`\,ZYXR\9^*];N5L]'\->%O#6FW.L:_KNJ7396"PTO2[.YO;IR
M&Q%"V%8X%=6?\_U/'/'MSZ5\,_MV:[%X@^#WQ+_9PO?A'^T/XZT[X_?LS_M/
M6U_XU^"'PO\`!OQ,L/!</A3P)IMHWA?4-/\`&GB31](N?BA\2$\9/:?!+PM?
MZ=?Z)XOU_P`.:W9ZUJGA^"RAN;H`^8_V$?VK/^"/7[1WC?Q'\+/V%/#GP+/B
MYC9_M!>)=#\"?LM7OPCMK_5_#FH6>G:9\3K^_P!2^%GA#1]5\8Z1>^)X4TG7
M6N[CQ-:_VI<3V$ZP->./V!'`S]2><]>2<\DYZU_/G_P2?\??M?\`B'X[>(=!
M^/?C3_@KEXA\$Z?\'KYM'L?V^/V-/V3_`(`?"Y-:L]?\*6EG<Z1X_P#@CXFU
MWQOK?Q#CT]KM+?1M:5]+U+3)]<U2_O9=1L[7?_08/N_AU'/Y>OMZ]^:`$R22
M`"<`Y`'((P3ZCD$`<<'!PP/`-QP0,CO@'KR#SG'7&.N!DGJ*_(3_`(+&>&OB
M+<_`SX5^.?#'QQ^('PY\(>"/VFOV2HO%/PV\!KI.CVGQ:O\`Q3^UO\!M#T^V
M\=^+S:S^*O\`A#=#T>Y\0I<^"]`O-'L/%=_K%K<>);J^L]&MM/E^9OVS?AMX
M3_:`^+?_``55\<?%_7?%NF^)OV!_V5_AEX\_9`\2Z5\0?%OA;_AG7Q1?_!3X
MM?&#5?C[X$TKPKKND6UIXTUSQ_X9L='UOQ3K%GJ-QK'A[X4VG@T.?#@U[2]2
M`/Z%0<C\^?7!QGJ>OID_4UYCX@_Y*Q\-/^Q<^)O\O`]6?A#XDU_QC\)_A=XN
M\662Z9XI\5?#GP-XD\2:<(6MUL=?UWPSI>IZU9B!@&MQ:ZC=7%OY3J&C";-N
MX$5Y]X@\5>(!\4OAW(/ACXVW0Z#\2XXXO[2^&YDO$8^#!Y]NW_"?>4D8\M69
M;I[>8"6/$3MYJQ`'T/17GG_"9^)O^B2>/_\`P;?"O_YXM'_"9^)O^B2>/_\`
MP;?"O_YXM`'H=%>>?\)GXF_Z))X__P#!M\*__GBT?\)GXF_Z))X__P#!M\*_
M_GBT`>AT5YY_PF?B;_HDGC__`,&WPK_^>+1_PF?B;_HDGC__`,&WPK_^>+0!
MZ'17GG_"9^)O^B2>/_\`P;?"O_YXM'_"9^)O^B2>/_\`P;?"O_YXM`'H=%>>
M?\)GXF_Z))X__P#!M\*__GBT?\)GXF_Z))X__P#!M\*__GBT`>AT5YY_PF?B
M;_HDGC__`,&WPK_^>+1_PF?B;_HDGC__`,&WPK_^>+0!Z'17GG_"9^)O^B2>
M/_\`P;?"O_YXM'_"9^)O^B2>/_\`P;?"O_YXM`'H=%>>?\)GXF_Z))X__P#!
MM\*__GBT?\)GXF_Z))X__P#!M\*__GBT`>AT5YY_PF?B;_HDGC__`,&WPK_^
M>+1_PF?B;_HDGC__`,&WPK_^>+0!Z'17GG_"9^)O^B2>/_\`P;?"O_YXM'_"
M9^)O^B2>/_\`P;?"O_YXM`'H=%>>?\)GXF_Z))X__P#!M\*__GBT?\)GXF_Z
M))X__P#!M\*__GBT`>AT5YY_PF?B;_HDGC__`,&WPK_^>+1_PF?B;_HDGC__
M`,&WPK_^>+0!Z'17GG_"9^)O^B2>/_\`P;?"O_YXM'_"9^)O^B2>/_\`P;?"
MO_YXM`'H=%>>?\)GXF_Z))\0.W_,6^%?O_U488X!]"21SCE>UTZZN+VRMKJY
MTZ[TBXGC#S:9J$FGS7MFY+#R;B32K[4M.:0!0VZSO[J+:<[RV5H`O4444`!Z
M''^?\_GZ5^:7_!3CXO\`[6'@3X(ZY\-_V2OV6OCY\=_'OQO^&'QJ\&V?Q2^`
MWQ`^$G@/6OV<O%<GA?3='\!>,KV;XG>*_#5U=7]YJOB6[U?0KOPJMY>Z3)X.
MU&Y=[*]GTAY_TM)Q7PW_`,%!OBKX#\)?LR_&7X7:C^UI\&?V0OC%\=?@A\:?
M`_[/WQ&^+GQ<\,_"8Z=\0KOP5/H>F>+/#VIZUJ^F:LZ^"/$'BCPOJ.K:OX8C
MO=4\."^TV_@B%[-IZ3`'X_\`_!'WX(_$KX4_M>^.-1\&_L*?M/?L,?LX:E^S
M=>Z!\4?#WQ7_`&P?"_[4_@OXE?M5:3\0?"4X\4ZK"/BG\0->\+?$/P]X2/B7
M2Y/$%G:Z/<^,K76K[_A+?#_AB71-#@U3^F,=/7'X?_J]?;/'&*_E2_X(<^'O
MA@/VL_&'B/X`?"#]GW]B_P``^'?V/_#7PJ^+/[//PF_;7^"W[4>N_M,?&OP[
MX^TJ^M?VC'T/X1>//&#1^&?A;I#^(?"UG\:/'%MHWCOXES?&%+?6+&-='>./
M^JT=/T/;I_GIVZ=J`/,OBU\'OAU\<_"">`_BEX;C\5>%$\4^!_&BZ1-?:CIJ
M#Q-\-_&6B>/O!>I_:=)O+*ZW:-XM\.Z/JZ0>>]M=-9BVO8;BV>6&?Q/X]_L)
M_LK?M.>-_#WQ$^-?PKC\6>*=`TRP\/7EQ9^+O'/A'2_'_@_2=='BK1OA_P#&
M;PYX,\2:#X=^.'PWT3Q0)/$>B?#WXO:7XV\':/K5[JU_INB6\VM:P=0^NJ*`
M$Z\GDGDGIS].PX&!VP,\BO,=?`_X6O\`#08X_P"$<^)O'X>!Z]/KS#Q!_P`E
M8^&G_8N?$W^7@>@#T[`]!^0HP/0?D*6B@!,#T'Y"C`]!^0I:*`$P/0?D*,#T
M'Y"EHH`3`]!^0HP/0?D*6B@!,#T'Y"C`]!^0I:*`$P/0?D*4*"0,#DXZ"BE7
MJ/J/YT`>+:;XM^*'B0:K?>'/"?P]_L:S\1>(M"M)-;\;^)K35)U\/:Q>:-+=
M7=KI_@&_M+9KJ:R>X2W@O;I(89(U,[R!P-+[=\:_^A4^%/?_`)G[QGVZ_P#-
M->V1GZU+\)?^19UC_LH?Q+Q_X7&NG^61[],C.:XKXN>)OVDM&UO3+?X,?"_P
M#XV\/RZ69M4U7Q9XZG\.W]OJIN9$6Q@TZ.T"M;1VH2;[5]IN#+),T12W\C]]
MTX3"SQE>-"G4PU*4HRE[3%XFCA**45=J5;$3ITU)[1BY<TGHD]6O$X@SW#\.
M9;4S/%8'.\QI4ZM&D\+P_DF9\09E.5::A&5/+<HPV+QDZ4+N5:JJ/LZ,(N52
M45:_8?;OC7_T*OPH_P#"^\9?_.UH^W?&OK_PBOPHQZ_\)]XR^O\`T37TYKXO
M^)_Q?_X*$>&]'TR[TK]GWX=H;G7M*L[BX\+^([OQ[J69[RW6WT^XT)9;!K72
M=7??8ZGXA^T[-#A=;EUB!%Y;>CQ>/_V]GBC:7]GKX+PRM&C2PK\6[J98I2@\
MR(3?98O-$;Y3S/*3?MW;1G%>N^',4HQG_:&0VE*<5_PNY9O!0;U>)47\:M:3
M>CNEU^$_XB]DO3A/Q3;4*<Y0CX6\<RJ056>(IPYZ:R5U(N^&JR:<?=A*C*5E
M6I<_T3]M^-G/_%*?"GCK_P`5]XS]<8_Y)KUSV]CZ4?;?C9V\*?"D_3Q]XR/\
MOAK_`)R/45\1_M4_&?\`:I\#_#3X87-M%X(^%E_XCE\7I\9_^%?>)_ASXQ^.
M?A_0]-?3%T34_@!X1^,NO^!_AOXRG,$]X_C&35=5\0:_X=\_0H/"7@/QWJ-\
MUM:9_C*]\6K\9/\`@FAXT\)_M`_%_5/A1XVU[4?!TGP_\0?8M"_X6.;O]F_X
MR^-)?'_Q?FCTG2O$7B;Q=)<:'X;DL_"]S%HWA3PUJECJFI0^')-0N;.72_"J
MTW2JU*4I4Y.G.=-RI5(5:4G"3CS4ZM-RA4@[7C.$G&2LXMIIO]+P&,IYC@<'
MCZ5'%X>GC<-0Q5.AC\'B<OQU&&(IQJQI8S`8RG1Q>#Q--24:^%Q-*E7H5%*E
M5IQG&45]V_;/C9U_X13X4X]?^$^\9X^N?^%:XQ[YQ2?;OC7_`-"K\*.__,_>
M,NV,_P#--?<?F/45^(O[+&M:YX6_X*&2^+O&7Q-^%?QXC_::^+W[5_ACX?7/
MPB_;;_:I^(/BKX2V7P]O_$6IS:1\2/V6?&6OVG[.VB>&/"7A_P`-Z=\.M=O?
M!OP[\-:K\+?B)<:!:-JGC!O&TFK6?U/K/_!1>W\-_$#PYX*U_P`8?"#3;_\`
MX;P^.'[/_C30Y=1CD\5:%\$?A)\%?B-\6;KQ;<Z%#K,NJV&JV%AX6T74=6UF
M[T_^RVT74H9(;)'U33Y)(.L_1/[;\;``3X4^%.#T_P"*^\9\_3_BVM'V[XU_
M]"K\*/K_`,)]XRQST.?^%;8P?7I7X=?"#]IS]H+X=_MAZ3\-?%%QXJAT[]H?
MX:_L-^,/B)\1OB5J^I^*OA3^S_XD^-OCK]LCQM!\(M(\(W'C%=1T7XH_%\)X
M:^#'@Z^T[28?A_I%QX.TV;Q)K=YJ%KX"\'>(/<OV<OV]/CK\5/VG_@IX2\3>
M.?V8;SX;_M&^)/VO+73?@=X5TWQ'8_M%_`&P_9?OG\-V.F^/]6O?&^KZ?XSU
M7Q%J!@OOB3-<>`_AM_PKSQ!<:)X3T:T\96&M2:]IH!^J?VWXU_\`0J?"GC@_
M\5]XSZ^G_)-:/MOQL_Z%3X4_^%]XS_\`G:UZJ!C(YX)ZYS[=>>!@#/08&!C`
M6@#RG[;\;/\`H5/A3_X7WC/_`.=K1]M^-G_0J?"G_P`+[QG_`/.UKU:B@#RD
MWWQL"MCPI\*,[20#X_\`&8!VC=@D?#4D`[>2`2.H5L;3V'@OQ"/%_@[PGXM6
MS.G+XI\,Z#XC73VG%TUB-<TJTU3[&;D10"X-K]J\@SB&$2^7YGE)NVCI'^Z?
M]U__`$6]>;?!?_DCGPE_[)EX"_\`44TF@#TNBBB@!",C'Y_Y_IWZ'@U\!_\`
M!27X;?!'6OV4?CA\:OBG^SQ\`OCYXN_9Q^!?QL^)7PJ7X[_`3PM\?=.\*ZYI
M7@J;Q#?-I?AS7-,O-8BT_6[GPIH7_"467AF^TN[UBSTBR,\KMI]J8OOVO!?V
MJ?B)\1OA%^S)^T/\5O@_X';XF?%CX:?!'XI^/?AI\/%@O;H^-_'?A+P3K>N^
M%/"WV/3634[\:WK=C9:>=/TQTU+4!.;/3V%W/":`/Y$/V;_VK_'W[*7[1W@K
M6?AJW_!`SXB:'K'@3X$:M\4=2_X)W?`RY\$^-M=\%?'3]H'X??`^[^%&E_&#
MP7<7&FZ+\0?^$A\::%X]^&G@KQA9.WQ7T_PAXG:X\,^%9/#?VF3^VG&,CT)'
MX`X'3CH!P,`=``,"OY9_^"+WC[X>>*_VC?%_PA^%GQG_`&:/V[/@[XE^`'@'
M]KKXK?%GX2_L7_`K]FBU_9P_:U3QLNA^%/`FK6_PE\#^&-.U;Q!XMT+5_&^O
M^$=)\?KKGQP^%:_#O5QKOB6:'Q*)'_J7'?ZG/?WS^.<_CSS0`$XZ?Y^@XR>P
MY`[D@9-?GM^TU_P4B^$?[+_COQCX)U_X7_'_`.)]O\(/A=H?QQ_:0\;_``:\
M$^&/$_@K]F/X.>)K_P`66F@?$3XPW/B#QSX2\0SZ5J5I\/\`XA:^-&^%OASX
ME^,++PSX&\1Z]J7ANSTZ&QGO_P!"2,C\O\_7T]#@CD`U_-3_`,%,OV<_$_Q,
M_:(_:;U;XE?LX_M;_&O4O'_[.?PX\"?L#Z[^R?<:O8?#VU\8^&CX@\0>(?`?
M[54.C^+?#7P_UZ&+XUW/ASQG'#^UMH?CCX`?\*Q^T6?AZU&M?\)[HFK@']*%
MK<P7EO!=VDT5S:W4$-U:W,#K)#<6]Q&)8)X9%)5XIHF22-U8AE8$<8)\WU__
M`)*O\-#V_P"$<^)O/_A#_P"!KI?!*>+XO!GA"+X@3Z/=^/8_#'AY/&]SX>CG
MB\/W7B]-)LT\33:'%<A;B+19M:6]DTU+A1.MBT,<J!^:\B\0>#;X_%+X=Q_\
M)_X\S/H7Q,F$GVWP[YMN,^"SY$!_X1K:(/F4!9%E9=B$.#O+`'T-D>H_,49'
MJ/S%>>?\('J'_12?B1_X,?#'_P`RM'_"!ZA_T4GXD?\`@Q\,?_,K0!Z'D>H_
M,49'J/S%>>?\('J'_12?B1_X,?#'_P`RM'_"!ZA_T4GXD?\`@Q\,?_,K0!Z'
MD>H_,49'J/S%>>?\('J'_12?B1_X,?#'_P`RM'_"!ZA_T4GXD?\`@Q\,?_,K
M0!Z'D>H_,49'J/S%>>?\('J'_12?B1_X,?#'_P`RM'_"!ZA_T4GXD?\`@Q\,
M?_,K0!Z'D>H_,49'J/S%>>?\('J'_12?B1_X,?#'_P`RM'_"!ZA_T4GXD?\`
M@Q\,?_,K0!Z'D>H_,4JD9'(ZCN/6O._^$#U#_HI/Q(_\&/AC_P"96E'@/4,C
M_BY/Q(ZCKJ'AC'7O_P`4K0!1^$@_XIK6/4?$+XE_^IQKH_K_`/KZ5Z>%QCH0
M`!C'H/3IZ_3)'.>/)?@Q;-9^#]0M9+R\OV@\>_$J-K[4&@>]N2/'.ND27,EO
M!:P/*0>6CMXE.U3L4\'#^*?Q(^+7@W6=/T_X?_`C4OBGIESIOVR]UVV\<:+X
M8@LKW[3)%_9@L[VQOKJ>1856>2=E@BVRQI&)&$AC\#B7B7+.$\JJ9SF\,WJ8
M*E5HT9PR/AWB'BG,'/$5%3IN&4<,97G&;5*:DU[6O3P4J-"/OUZE.-F>KDV3
M8W/L=#+LOEE\,34IU*L99GG.49%A.6C%SFI9AGF.R[`0FTO<I3Q*JU9>Y2A.
M6A[MMYR#CMQP<'&1].,_4Y[<KM'MGGDC)]NO7%?F%\;?VPOVC_AW_P`(T)?@
M%:?#_P#MB/7F`\0:L_CXZJ--;2@7M&\-1:3_`&4-/%\OVA+WSVO_`+9!]F\K
M[',)?9]$_:"_:2U'1='U%?V1]4OUU#2M.OA?VWQ/T&PM[P7=E#<?:X+"YT>6
MYL(;CS/.CLKJ22YM%<6\[O)&S'\6P'TH?"W,.(\]X8P^'\2)9GP]2R^MF%./
MA!XH5ZL(9EAJ6*PSJ9=A.$\3G6!4J52#C+-LKRZ&(2]I@YXFA*%6?Z3BO!#C
MG!Y/E6>5JO!L<#G$\73P=27B%P/1ISE@J\L/64,;B<_H97BVJD)*4<NQ^-G1
MLX8F-"JI4X^M_&G]E;]F']I"7P[<?M$_LX?`3X^7'@^'6(/"4WQK^#_P\^*D
MWA>V\0-I[Z];>')?'7AS7I-$@UMM(TIM7CTPVR:DVEZ>UZDYLK<Q^D:7\._A
M_H>E^"-"T7P)X-TC1/AE%;6_PWT;2O"NAZ?I7P^M[+1KGPU:0>!]/M+&&U\(
MQVOAV\O-`M4T&&P6'1[NXTF-4L99+=OA7]I#XZ?'SPKX>^#OB'X>V7B;P=\<
M/$#>.UT_]EJ/X27?Q\T?XNQZ4-&7[/XG\<>$]1\(CX.V.BM+92V/Q)U?Q=HO
MAW3/^$BF77/#_BDV<6GQ1?%^^^-`_:+_`."=_C3Q%XZ\4_#72_&OC?Q!X0\>
M_LU>&-?TG5/`G_"5WG[._P`9_&6N77BWQMI^F:9K'Q,D\.ZIHF@Z;X8M3#I'
MA2SETN^\1-HEYJ=_93Z3^]Y;F&'S;+\#F>$CBHX7,,)A\;AHX[`8[*L;&AB:
M4*U)8O+<SPV#S'`8A0G'VV#Q^$PV+P]3FI8BA2JQG!?E6,PM;`XO$X+$.A*O
MA*]7#5I8;%X7'89U*,W3FZ&-P-;$X/%T>:+]GB,+B*V'K1M4HU:E.49/[/\`
M#7P.^"W@OXB>-?C#X.^#OPM\)_%KXE6ME9_$7XI>&?A[X1T#XB^/[33W633[
M3QKXXTK1[3Q+XKM;%T5[*#7-4O8;9U0PJAY&=>?L[_L_ZCXR\4_$>_\`@3\&
M[_XA>.;;3+'QOX\O?A?X)NO&7C&RT32M2T+1K3Q5XIGT-];\06NDZ+K&KZ-I
MD&KWUY'I^DZIJ-A:Q1VM_=6\GXI_LM:AKOA+_@H;+XW\;_$+X9?'%?VG/B]^
MUAX8^'.I?"+]N7]J;XB^(?A;9_#V]\1:E-HOQ'_93\8ZQI_[.N@^&?!_AOPS
MI_P^US4/!'@71=6^%_Q$N-"LI]0\4-XS.K6'EG[8G[7MC\*_^"C6G?M`>,/B
M]\3/#/[-/[/'Q!^&_P"S+XJ\.>%_C-+8>)+?]H+Q)H-[XEA\#+^S*OQ"\(_#
MS7O@?^T!I/Q*\`Z=XA^.WQCT;7?$_@[QE\.=)?P5+X,^'MWK/CNW[3F/Z*]:
M^&7PV\1MX@?Q%\/?`WB!O%EIX6T[Q4VM>$=`U9O$UAX'U2\UOP58^(#>Z?.V
MM6G@[6M0O]7\*VNH&XA\/ZG>W=[I"6EW=32O\<?!S_@G7\(?A#^TYXY_:N3Q
M3XT\>?$GQ9<^*+G2I/%NB_"JSG\+2>,1#%KK7GC;P3\-O"'Q.^*4EKI$$/AG
MP=<?&KQO\1KGP)X5^UZ#X1ETBUU&^>X]B_:I^('QX^'?@33]3^`_PYM_'.IW
MFMI8>+=:_LR]\;:A\-O"KVLKS^-=(^#VD:UX3\1?&6]M;I8+1?`_AWQEX;U>
M1;H:C#-?Q6LEA/\`B]^V=\1]*B^&WPQ_:'\%_MB?$7XD_&?X':)\%O&_C))/
MCOXE_90\5>"/A3KOQ>\3S>-/B=X3_8BL-'\(>!OVB?BA\4_^$?UKX)Z3\#_C
MQ+INE26/A>/1?#&M67C5+G3_`!B`?T>@GK@X/.<'&23QDC@COU#')&,890<C
M/;_/Y>XR<>IK\&/!/BO/[6_A3XIVWQ[^(FK?M#^+_P#@H1\?_P!F+QQ\$)?C
M=XLUOP#:_LV^"M!^(=WH&AV_[.<OB'_A!?#$?A3POX6^'WQ4MOB9IW@?3/&$
MM]XJGN-9\4ZAI/BZ#3Y/I7X\_M[:U\)OB1\=_AQ;ZM\*[3Q'X$^.?[`_PR^'
MGAOQ!?B'Q-XDT;]JOQKX1\+^)YY-&_MNWU#5+U8]1\3KX3NM/LX[.&XT.]^U
M+>1Z5J(C`/U2YXR.#ZC&3@''IQSQR<8Y.&-+7\Z>K?M;_%OP1^W7>Z_X<UWQ
M+?\`PZ_:4\%^'[*W^(7C'7-2U[]G/]F7P':_M9^*O@=X-^(OB?P,?%^GQQZM
M\7+7PYIOA_P%?>&K*RT>Y\2>+;36/B/XET'P_I4L6I?2?A']NGX\:]^U9\/O
M"ESXU_9<3X3_`!2_:\^.?[+%G\"([;Q+!^T]X!M/@!X/^)VK7GQ"U/69/&-Q
MI'B6;QSJ'@NPUK6/#$OP\\*VOP\\&Z]X,O;'Q-XWG\23-;`'[+O]T_[K_P#H
MMZ\V^"__`"1SX2_]DR\!?^HII->D9P"2`=J/G=R#A&XSD9Z_-TS@\\5Y=\#(
M)+;X*_"&"2YN+QH_ACX#!N;LPFYESX6TMLS&"&WBW+N"+LA3**"^7RS`'JE%
M%%`!7S/^VC\1_%?P>_9!_:B^+'@3Q-X6\%^-OAK^S]\7O'/A'Q=XW@:[\)^&
M?$WA?P'KNLZ)KNOV:QRF^T[3-1M+>[FL##*M\8EM'C=)F4_3%?*W[<]_\-M+
M_8M_:RU#XR:EXOT?X36G[.?QCG^).I?#Z+2Y_'EKX(3P#KO_``DS>"XM;CDT
M9O%3Z0;J+0&U8)IJ:I):O?3VULLMQ$`?D'_P2%^,WC3X@_&WQ'IFO?M9_P#!
M0CXT6FI_"*_\9ZC\/OVJ?^":G@W]CCX?67B2^UGP:UYXK3XE>$/@]X'M/$OQ
M"@-[+IT6A+XMU^'6=.O-8U>WN=:@T:+5(_Z(UZ#\.V.@`Y'MT]<8R`<BOYOO
M^"1VH_%GPK^T8OP]_:#^(?\`P4)7XB>(?@C\:KG1?A1^TW^V!\*_VLOA9HT?
MP,^-'@/X=>-4O-4\!?#WP5JEC\3M%L/&'PSU2P\4.VL^#O$EIXV\::'HOB/6
M=3\(ZC>7G](8QV_S_P#7]<\YZT`%'YCUP2,_7'7\:0G'^?\`/U/M0"3DX.!U
MP"2#QU_/'KD&@!<?Y_S_`)_*O,/$'_)6/AI_V+GQ-_EX'KTX'/\`G_/^%>8^
M(/\`DK'PT_[%SXF_R\#T`>GT444`%%%%`!1110`4444`%%%%`!2KU'U'\Z2E
M7J/J/YT`>7?"3'_",ZSG_HH7Q+_+_A.-<S7I^`>H'Y5Y?\)?^19UG_LH7Q+_
M`/4XUP9SVZ]>HZCD"ODK]K;]M/XN?LV>./#?A#X=?L$?M4_M6:?K?AE_$&H>
M-_@C9^!Y/">@7?\`:4UA'X:O9O$7B73]1;6Q%`VH7$0T^*VAM+BS,5S=/+,M
ML`?H+P/;^F<#/L"<<\#/O1@'G`.>YY_G_D=*_F]_:3_X.!?%/[+&A>%=9^-G
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M`_@%\4_#OPSUCX4_$?Q_9?$M+_\`8(^.O@#Q-J?QT^*2>%]6\.6J:AX*\8_!
M7_A83_#:X\.),/\`BH?%7@SQ-X`U"S\>:(OBB;P3+:PZH_)?M5_%;]I[X:?%
M7]F_XWZ+\0?BYX6^%_BKXG_`CP#\4_@C8^`?@5X@^#7[/WAKQEK7A33OB=<_
MM8>-K+Q!XI^+%_XT\3-XVL-`^$VM?!BX_P"$,\)^([#3KSQE'+X,O]1\7'(H
M_2OPQ\"?@=X)^(_C;XQ^"_@S\)O"/Q=^)EM:V7Q(^*GA?X=>#]`^)/Q!L[&1
M9;*T\;^.=)T:T\3>*[>UEB26S@UW4[^&WE17B161:S?$O[-_[._C/X@O\6?&
M'P"^"OBSXJR^$K_P#+\3O$WPL\"Z]\0I?`FIPS6VI>"I/&FJZ%=>)'\(ZC;W
M=U!?^''U`Z3=6]S-%/8RK-*A_-W]G[XR?M&ZE\9O@)\5O&OQLUOQ5X!_:\^+
M?[5'PIF_9NU;PCX$TKPU\#]-^"=Y\4+OX>ZQX`UO0-!LO'EUXCTRP^$M[H?Q
M3D\:>*?$VF:_J7BY;S3-/\,R:#:0WOU!-^VM;V>N^#]*OOA_!8V7B?\`;1^(
M_P"R1/J]WXQBM[72;3X=?#SX@>/KKXE2>?H444T-W;>`KNTF\.F>V73K>XGU
M!]=FBL)(I0#[GC2.)$CB18XXE$<<<:B-(UC`$<<:(`J*BA45$`0(-@("H#Y9
MXV^!'P.^)?C7X?\`Q)^)'P8^$_Q`^(OPFO+C4?A7\0/&_P`./!WBSQK\--1O
M)+::ZOOA]XJU[1[_`%WP;>W4MG:RSW7AV^TZ:>6T@>21OL\3C\C/@G_P4&^+
M!_:LT7X&^-H=0\9Z]^TC\+OV8/BO\(/"VNV4'@OP#\(_"OQ8\3?M8^-?%DOB
M?XD:?X/N8F\6-\(/`_P^TKP1\,]3DO/&GCOQ9X:O[33K72])L?'/BS1_H_X)
M?M]_$KXM?&KX3^%=2_9KTSPK\!_VB=9^/]G\"/C/;?&RQ\1^+=6TG]GPWMIK
M6H?$WX2?\(!HP\!7GCZ_LI]2\`V'AWQ[\1HU\,VE_=^.[[P3XG&F^%]3`/NZ
MT^"_P<L?BIJGQUL?A)\,;/XWZWX;M?!VM?&.T\!>%;;XJZSX0LY8IK3PKJGQ
M$ATB/Q?J'AJVG@@GMM$NM6ETR&2*%X[6-XE8T_$GP%^!GC+Q_I'Q6\8_!;X2
M^+/BIH&C6_AS0OB7XE^''@[7OB!HOARTURW\3VFA:3XSU71KOQ%INCVOB6UM
M?$5OI5GJ45A;ZW;6^K11#488YJ]:7I_GIV^F,XQS@Y&3C)6@#S/4/@O\'M6T
MV_T;5?A-\,M3T;5?!*_#35-(O_`7A6]TS4OAO'<3WB?#W4+"YTI[2\\#I=W=
MY=1^%+F*305NKJ><6`FGDD/R-X;_`."=/PCT3]L+6_VS]5\4^*_&/Q"O-1OM
M;\/:3XA\,_""`>%=6O\`1-2\-JI^)7A[X9Z%\;_&OAS0-#UK6M.\#^"OB-\3
MO%W@[P-:ZM=?\(YHUE-%8R6?Z"T4`,884^RN`>F1Y;=1_CS[#)`\W^"__)'/
MA+_V3+P%_P"HII->DO\`=/\`NO\`^BWKS;X+_P#)'/A+_P!DR\!?^HII-`'I
M=%%%`#6.!G].1G`)/(Y]_?&.]?G]_P`%!-=_;;T#X;M>?LG?"O\`8U^+7@6+
MP)\6[K]HCPS^U[XO^*7A^RU7PG8^'M-GTCP[X,T/X>?#KQ_I/BZV\4:2?'.F
M>+M+\:'2=**CP_9QO=V6HZM-8_H$>!_];/TX^N/IU&<8/Q9^V'^PO\,?VV;/
MP7IOQ-^)?[3/@#3O!-GXUTZ'3_V>?VB_B=\!;+Q7IWCVWT"UURQ^(-I\.M<T
MBW\;V<-KX?@MM(MO$"7<6DP:GX@@LT2'7-16X`/R1_X(-_LK^//A3X=TC]IK
M1/V)OV"/V7_@;^V%^SS\._B]I.N?`#XU_M0_%;X_2+XSL?#_`([^'G@;Q'IO
MQY\.7/AKP5X'L_#WBK6;[6_"WP]\<_\`"/:=XH@TQ=/TW5H,:C8?T@C..>??
MU_SV]L5^<O[&O_!,7X#?L,:_:ZS\&/B7^UEK>DZ5\.H_A7X<^'?Q?_:F^+_Q
M9^$_A+P?;W&B2Z=:>$_AEXO\0WW@[PY<:';^'K#2=`O-*TFWGT/17O=)TH6M
MCJ%Y!-^C0Z>OX`<'GH"0!SQ@D8P1P:``\`^N..QSVP>QST]Z_F__`&^OV@OV
MC_%G[1W[7?AGX5WO[;6@^$OV#?AI\'?&%SXA_9,UWX,^&/"OP^N/B!\.?&/Q
M7\2_&?XF>"OBGXGT/5/VQ]1T6RT;0=-L?V6=#FT[1'\%^&O%4]SJEGXV^(?@
MN:OZ0#T_E[GH!]2>!WSC'.*_/_\`:1_X)Y?#?]HOQWXJ\<GXL?';X,/\6_A]
MI/PB_:/\/_!+QEI7A/0OVD/A5H$VM/H7A'XCKJ?AW7M2TB[TFS\3^*/#UMX\
M^&^H^!_B++X0\2:OX1N?%5SH:Z7:V`!]O>$?$.F^+?"GA?Q5HVKV&OZ1XH\.
MZ%X@TK7M+MI['3-;T[6]+M-1L=6T^SNYKJZL['4K>ZCO;2VN;BYN+>"XBBFE
MGE5G;QCQ!\0]%'Q0^'EQ_9?C0I;:'\3;>11X$\6^8\F/!>6MT&DDW$0$9S+`
M9$&Y&8A'1C[UI>F:;HNF:?HVD6%EI6D:38V>F:5I>G6T-EI^FZ;86\=I8:?8
MV<"1V]K965I%#:VUM#&D$4$:0QHJ*$%*\T&TO?$&B>(YGN?MV@6>MV%DB2!;
M=H=?&EB\-RA0L[H=)M3;LLBA2\F]6<J0`<I_PM'0/^@1X\_\-UXT_P#E/1_P
MM'0/^@1X\_\`#=>-/_E/7I'/]YO^^F_QHY_O-_WTW^-`'F__``M'0/\`H$>/
M/_#=>-/_`)3U4/Q?\*+J$>E&Q\;#4IK"XU2*R/P]\9_:'T^UN;6RN;Q8_P"Q
MN8(;J^LX)'S\LEQ$,'?D>IY/]YO^^F_QK"DT*TE\26GB=GN/[1LM#U+P_"GF
MC[*;+4]1TK4KEY(]I<SB?2;6.-]P"1><"K%Q@`Y3_A:.@?\`0(\>?^&Z\:?_
M`"GH_P"%HZ!_T"/'G_ANO&G_`,IZ](Y_O-_WTW^-'/\`>;_OIO\`&@#S?_A:
M.@?]`CQY_P"&Z\:?_*>JJ_%_PI)?7&F)8^-VU&TL[+4+FS7X>^,S/!9:E<:A
M:Z?=2QG1OE@N[G2M2A@?=\\EC<#Y?+)/J63_`'F_[Z;_`!K%AT2TM_$.J>)(
MWG.H:MHN@:%<HSAK<6?AV_\`$FH6+11A=XG>;Q/J*W+,Y62)+9%52C>8`<C_
M`,+1T#_H$>//_#=>-/\`Y3T?\+1T#_H$>//_``W7C3_Y3UZ0#_M,?^!-_0T<
M_P!YO^^F_P`:`/-_^%HZ!_T"/'G_`(;KQI_\IZJP?&#PG/>7MA#9>-I;W2Q8
MOJ-JGP^\9&>S748Y9K`SI_8Q*"[B@F>'[Q98W/&!7J63_>;_`+Z;_&L&QT&S
ML-=U[7X)+AKWQ$FCQ7RO*#!&NAV]U;VOD(`&7>ET_GAF?<^&`&,$`^8_"/QJ
MB\'66M:+J'PD^/\`?2_\)IXVU*&\T?X/>*;_`$Z[L=8\4:IJFGW5G=I$@ECE
ML[JWD!*QR1NS1O&KJ<=2/VE-,'_-&_VE![#X)^+`.F.`%X'3`'`Q@`#-?2.?
M]H_@Q'3CH#VHY_O-_P!]-_C0!\JZO\</!GB$VXU[]GSX\ZX+43BU&L_L^ZYJ
MGV87`C%P+?[=:S^2)Q#$)A%M\WRXQ)O$:!;=A^TWX9*W&G:9\'_VB`NB20Z7
M<6-E\$O%$4>ER)96MU;V)MX8TCMPMA=6DT44:B-8)8]H484?3_/]YO\`OIO\
M:Q-,T2TTF^\07]K)<-/XCU6'5[\2R`I'=0:7INC(MN%12D)M-,@8HQ<F8R-N
M564*[NUKNRV70#\[_P!H?PU\"?VHKCPG=?%3X2_M]V5SX+L_$=AHLWP?\5_M
M<?LZR3V?BJ70YM7M_$3?L_\`Q1^&G_"71B7P[I<FEKXJ_ME="D6]?1!IYU34
MS=\/J7P(_8VUKXC>`OBOK7[*/[5NL^./A[I_P[LK*_U;2?VC-1TCQI=_"&W6
MV^%7B?XT>$[OQW+X3^/OC[X;JHF\$_$3XV:)X^\<^&[M8[[2_$%M>003Q?K'
MGL&;Z;F^GK^%'/\`>;_OIO\`&D!^9W@+P+^RO\,OC?XM_:*\$_LI?M(Z/\5_
M&3>)YM0U:7X?_&35_#>B7_CK4;'5_B)K7@#X=:WXCU'X<_##Q#\3=5TO2M3^
M)_B'X<^%/"^M?$;4-,L;[QI?:W=VZ3#@-4^!W[#?C7XH>.?C%J/[(W[1NN>/
M/%GB+7]1\370\)_'4^'=-\:Z]X$U+X8>.?$OAOP)'XN3P)X%\;>-?`.M7'A;
MXA^*_!GAO0?$/CG3!8+XJU/6)=/L);?]<,GIN;I_>;I^?ZUBZ/HEIH@U;[))
M,W]L:U?Z[=>:X8)>:B(1,L6U5VPKY*-$IRRG)+9/`!\#^)],_9P\8:OX@U_7
M?V6/VA9=;\2P_!2*_P!7L/A1\2]$U&S?]G/Q'XB\6?!6[\.7FC:I83^$M3\!
M:[XK\0W6F:IX9DTF_N8-4N=.U2YO=,86B_#_`,`OV4-`^#W[9.N_M;>(M+^.
M7BG['J7QIU/X6^`_"/[*WQD\#VG@VY^/>I65_P"/Y=6L=<^,WQ`^%MI/J*:;
M:S:O)\$_A+\#8_'OB4'QI\28?%OB&WT^>R_?(Y_O-SD?>/?KW]/3D=1@C-'?
M.3D^YS^><_EQ@`'[JX`/F\?M*:9P/^%-?M)<GO\`!+Q7U)'^Q[\?3Z9JV7[4
M7A_483<6'PD_:+O(%N;NS>:W^"OBIXUN]/NI;&^MV;9Q+:WD$UO,O(62)UR<
M`GZ9)8'@D]."20,GJ<G!QU`SGY2!U-8F@Z)9^'K"73[&2=X)M5UG5G,\@D=;
MG7-4O-9O$5@J`0QW5Y,+<$9CC5$+$@D@'A?_``TIIG_1&OVDO_#)>*__`(BC
M_AI33/\`HC7[27_ADO%?_P`17TASW9O^^F_QHY_O-_WTW^-`'S<?VD],*M_Q
M9G]I,_*^`/@EXJ).488`V<D]AD#.`2.M=]\$;F.;X/\`PTB"SQ3Z7X)\-Z!J
M5K=6T]I=Z?K7AW2K;0]<TR[MKB.*:&ZTS5=/O+*Y1DV^;`QB>2-D<^I9((Y)
M'?)+=>X&>HQV(8Y..Y&+H&AV?AZPDT^Q:=H)=2UG5G:X=7D%SKFK7FLWBJZJ
MG[I+N^G6`8RD2JK,64L0#;HH^E%`!1110`8'^?\`/T_(>E&,=***`"C`X]NG
M^?\`/;THHH`:1G`X`+#D]LX7&,CT&!T)]PI'X`_$7XG_`![FD_:%_;JT_P#:
M$^,&AC]F[]O#1/V:_"?[-=GJ>D:7\`?$?P2T+XM?##X.>-])\7^!YM'EN_%?
MQ`\=2>-/%'C'1OB'<:Q'KV@ZA_PBVF^'6L]&T^YM=1_?\@]O;'MUS_3'7H5X
MW;A^?OBG_@G;\,O%/QNOOBE+\2_C+I?P\\2_%3PI\?/B'^S#IGB/03\`?B-\
M=_`RZ*WA;XG>(](O_#-[XRM+JUO_``SX7U_6O"/ASQAHG@+Q;XJ\,:)XG\3^
M&-5UF"YNKL`_0/N1Z,1^&>/RZ'W!HH_J23]2<FB@!.K`$$@E1Q[GJ>1CO@CD
M8/K@_P`T/P:_:D_:#^)?[27@7]I7Q'XE_;2\"_!/QA^VM\2_V88O$%S_`,*8
MU;]C<:5X7^+/COX+>#?@O-^S]#XRM/B]9CQAJ7A?3G@_;!73[B[T_P"+&HQ^
M&KK1KGP',BQ_TO<Y)'7J#QQ@<`YYQGD@#DXYQD'\]K#_`()R_"_3?C1!\1[3
MXH?&Y/A99_&*^_:/T_\`92_X2K0S^SYI_P"T-J5[=ZO>?%"TTS_A&1X[CB;Q
M-?7OCR#X='QQ_P`*OM/B1=2^.[7P?#KI2X0`_0K^A(]>AQU[_6B@>_7O]>Y_
M$T4`?+'[:%W\?K#]G'XFZA^S=XU\"?#?XB:9X4\3:M)X_P#'?A?4O&J>$/#^
MD^%M>U+4M;\)>$K+4=(T_7?'5K/:67_"-6OB;4X?"\%RTE]K5KJUM:?V-J'P
M2+K6/BW_`,$W_P!AG]H#X_\`[<GQ4_9C^#^F_LA?!_XN?M,^.?`/B.V\#?%/
MXL>,_&?P<^&=[X:NKGXR6EO<>)/#Z#Q/J/B:]U/PGX'\/S^)?BIXK\0^&M$T
MV:U6S;1-?_7;QMX5L/'7@[Q;X)U6:ZM]*\8^&-?\*ZE/8O'%?06'B+2;O1[R
M:SEECFBCNXK:\E>W>6*6-)E0O&ZY4_G+\5O^"7_A3X@^!OV&_`?A;]HSX]?"
M72OV`_"&D^&_@Z/"D'PA\5V.M:WX;\`>%OAKX/\`B/X[\,?%;X8^/_!^N?$?
MP/X:\.Z@O@?Q/'H%G=>$=0\8>*=5T`6&HWT%S:`'O7[`NH?'[5OV3OA1J7[2
M[^*YOBE>0>)YUN?B+HVC>'/BK>?#U_&.OGX27WQ?\/>'+:RT'0?BU??"X^$[
MOXCZ-I=G:1Z;XLGU2SN[2UU".^MX_L>O-/A%X%\2_#?X?Z#X.\7_`!6\<?&W
MQ#I"WBW_`,2_B-9>"M/\8>(S<WMQ=0MJ]I\/?"O@OPE$;&":.PMAI7AS3E:V
MMX6N%FN3+/)Z70!\Q_M@S_'RU_9]^(EW^SAXS\!_#GXB6/AW7M1;Q]X]\,:G
MXV@\(>'].\.:U?ZKKOA7PA8ZCH]AXA\<64EO9-X:LO$VJ0>%HKMC>ZY;:I:6
MW]D:A^+WQ3^/OQY\=_L@_P#!&O1-.\:_M7^.O$G[2_[-?A+XM?'[P/\`L;>)
MO!WAG]M3XM:?HG[,GPX\0:C\1?#_`,0OB!JO@7P+X;^'OA;XJ_$#PM)\9]2N
M_B%X`UO5M1\=^"-*\,3:L;V_\/7G]#7B[PW9>,O"OB?PAJ<ES!IOBKP[K7AO
M4)K.18[R*QUW3+O2KN:U=XY8TN8K>[E>W:2.1%F"EHV4XKX6\0?\$[/`S_"W
M]DSP3\,?C%\;?@9\0_V*_A)IWP/^"'QZ^&^I>#)_B1!\,4\&>!?!7BCP?XWT
MGQSX+\7_``W\=>'?'5I\,O`>N^(M'\0^";NTC\7>$/#?B/1ETN_TF%B`=)_P
M37^)OQ&^+O[%'P-\:_&'Q:WC+XK3:5XCT+X@7]_IJZ/XMT?Q'X5\9>(O#DO@
MSXG:9%HGAJTM?B_X&L]-M/"7Q;.DZ#IGA^Z^(NC^);WPS%/X=NM,O;K[HKQ7
M]G_X#^!_V;/A9H/PF\`7'BK4]%TB]\0:WJ7B7QYXDU'QGX]\:^+?&.OZCXL\
M9^-_''B[5G?4/$7BWQ;XHU?4]=UO4I?*A>[O#!86EEI\%I8P>TY'/^<_3UZC
M\QV(H`^$OV\/"ECJ?@/2/'/Q)_;*^(/['O[-OPMLO%7B?XVZO\*=<M_A[X[\
M<75Q#HMA\/=-L_BY"E]XE\)Z5I.I2:T9O!_@O1KSQ1\3_$.L>%]`T^[A^QR:
M/X@_+KXR_MD_M5_#/_@F_#\*-3^)<W@+]NOQO^S3^T]\:-+^(?Q@MO"'AOXL
M_![]F'X:'QG-\./C'\7/`^F2Z5I%I^T;XN\+O\.?`NA>$-.T^U@E^,FM>(M3
MU&U@MOA[XUL[;]0_VQOV&;7]KWQ?^S[XVG_:`^,WP5U?]FWQ-XJ\<^!K'X<V
M/PI\0^%[_P`?>(=-T[1M'\>^)?!_Q?\`AO\`$CPOJWC'X>Z9:ZW#\-O$#Z0E
M_P"#)_%?B+4]%GM]6N8+NVQ_B5_P35_9J_:"^#UQ\._VL_"'@[]K;XCR_#7Q
MC\+[7]IOX[?!?X`^(OV@-#T'Q?\`V\T%SX4\4Z9\+-(TCPG?^%KG7I]0\+R>
M&]#TNVL=7M8-6DMY]2-Q=3`'U1^S]XEE\9_`CX*>+;C61XANO$WPH^'FN7NN
M#4(=5;5K_4?"6D76H7\FI6[/!?7%S>R3RW-S$Q2:9I&SN.%]@KSCX0?"CP+\
M#/A=X`^#OPR\.Z-X4\`_#7PKHW@_PMH&@:/I'A_2;#2=%LX[6$V^CZ!8:9H]
ME+>2+)?WR6%A:V\E]<3W"Q*TK5Z/0!^:W_!1?X<?&_Q%X)3XB?#OX@_M@OX8
M^&?A#Q-=6W[/O["FH?#KP'\=OBS\6-9U/P_'X+\3ZG\4/B7X@T[1F\!?#O2;
M/7C??#>.T-GXFN?$,^KZW9^-?[`T7P9?_!_P[\??'W_@H1IVEVMA^V7\3?A'
M/\#?^"<?[)_[1$'Q`_9QM8/AEX=^+7[4?[02?'RVU_QUXYT;QKX1&I:Q\-?A
MSK7[/4FDR?!#Q%H7A[1KJ]\3^++?QMH=K=V6BZ;H'ZJ?M'_L@1?'CQAX4^)?
M@_X_?'O]FCXH^&?"?B+X=7/CSX#^(O"MG=^*OAKXKU#3M6U?PAXG\-_$+PCX
M\\%WTMEJVEP:KX0\80>';7QQX&U"ZU:7PKXATV+6]7AO?$?'/_!+3X*:MX9\
M`>$OA!\3?C[^S#H_A+X)VW[,OBMO@;\0;>TU7XN_L\6^J:EKB?#KXC:WX[T3
MQOJ]SK=KK?B#QCK&B_%WP]>Z#\8M`U+XA?$.[TOQU!-XOU220`^K/V2/B]K/
M[0/[*W[-7QW\1Z;9:1XB^,_P&^$GQ2U_2]-69=,T_7/'G@30?$VKVFE+/)/,
M-+@U#4KA-.\Z:2=K+R6ED9@^_P"ACT^OI_3W]!D<]2!DC`\*>%?#G@;PQX:\
M$^#M$TWPUX1\&^']&\*>%?#FCVT=EI'A_P`->'M.MM(T/1-*LX@L=II^E:99
MVMA96T:B."UMXHT`555=\C(_STSR/Q%`'X]_\%6?"W[3&@_#7QM^T)\&_B;^
MV#>GX6_"V_\`^%0_`;]C6#P#H&IP?&F"/Q3K]Q\:OCSJ?C34;F[^+OPBT.UT
MWPCHUW\(M$\,>(+F'2XO$\^G>`_B-XA\3:79>'?SS_:4_;$_:"^-7B_XX>.O
MA#X^_:]N?AK^R#\#OV;/BD?BU^Q?#\(M!^"WAZQ^+WP&'[0'B/\`:.\>?##X
MS>+O#OCC]L+0[O3;S2?LW[+^@O8W'AGX7^&M:O)[^Q^)'Q!\+M)^V'[17[$&
MF_'GQU=?$+P]^T)^TA^SMK_BOP%9?";XNGX">-]%\/6GQ>^%VFZGK.J:1X>U
M^#Q1X8\6CPAXG\/S>)_%EMX<^*OPP;P1\4M%TWQ3K&GVWB][=-(72O+?BC_P
M2R^!OCJ8Z9X"\??&C]G7X<>)_@YX#_9V^-7PC^!7BW2_#G@7X[_`OX7:3=>'
M/A]\/?&JZ]X?\1^(/#A\/>$-0U3P'+XT^&>N>!_'^O?#_4IO!_B#Q/J>CV.B
M0:2`?HWH.KV'B#1-%U_2]0L]6TS6](TS5].U33UDCL-3L=3LH+VTU&QCDEF=
M+.]M[B.ZMDDEE<0R1K)(756DUFQCGU&.O7UXR>F>G/ISBJUE8V>G6EII^G6=
MKI^GV%M;V5C865O#:6=C96D*6]I9VEK;I'!;6MK!'%#;V\*)##%&J1HJJ@%H
MC/YY_P`_U'0C(/!H`_#?_@I_^VMXZ\+:G;?!S]G+XP^%/A?J'P6^*O[*'B?]
MJWX@WGB#0+3Q#IWA?XI_'KX>Z!X7_9\\$6.HWD3GQ=\2O"-WXF\9_$OQ`T26
MOP\^$VCV"W`GU+XD^'WLKW_!0#2OCCX*^(6D^-/A1^V;\:;G]JKXJ^//!NC?
ML,_LC?#6?P]HGP=U#PUX>N_!_P#PM"Y^-?P^GLM='Q,^'=GI]]XD\5?%[XU^
M+=0T6V^'OAK5?#FC>"6T3Q(FA0^)?L/]J+_@F-^PS^U[_;6J?&3]F+X":[X_
M\1:_X`UW7OBY=_`[X0:W\5]9C^'WB;P[XAL-#U3QWXG\$:WKVHZ#K%GX;M?"
M.OZ=>7<D>H^#KS4O#KE=/NY(F\RU7_@FC?6W[2'Q4_:8^%W[97[27P8\6?%N
MW^'NA:YH/@_PW^S7K^B:!\//AA8K9>$OA+X'U#XC_`OQIXK\$_"RQDFU?5I/
M!/AGQ%IFBW/B/7M7\27-M+KEQ'?Q`'ZB<9.W[N3CICKVQV//?MT'%%+W.!@$
M\#CCZ8X]_P`>>:*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`&YPP/'WEY..!D<9/'0LQ!]B#N"BOX5OC5^TE^U[X/^(_C#X"_#GX_P#[
M0[7_`/P1-^-W[5?[:'[2\M_\0OB3J4_QT_9MO_VG/@;XK_9T^$GC?Q)=Z]>Z
ME\0-$/[-WCGXXSRZ%XE&J:;8Z7X"L+&.."R:`2_W58&<_P"<\?X#\N.ISX5<
M?LP?L[7?B/XZ>+KOX*?#2Z\3?M-^$M)\!?M"ZW<^$=(GU#XS>"]#\/ZMX5TK
MPO\`$6>6W<^)]$L_#>NZMH:V&I":&33+Z6TF62$(J@'\R_@__@I-^U!X*\%_
M"?7_`(/ZKXO\8ZM_P4Y_:!_X*._M>?"KQSXZ^%'QI_:PB^&W[+W[/_C#P3X+
M^!GPU\!?`_P7XS\)ZUH7AGQSX+U#P;XIUC5-,U_0_#7PQT+4=>\42^%M?USQ
M$H&_<_\`!>;]JKQ7K^C>)_`_[,=QHGAOX4_"7]A#X@_&_P"$`^&'C7XGWGQ`
MUC]LMS/K^GZ+^T?X?\6Z#\,?@#H7@;38G@^#.M>.M`\9)\;_`!//?:=<Q>%H
MM/2.[_H)^(G[!7[%OQ:^#_PX_9_^)?[+GP.\;_!?X/V^G6?PK^&WB'X>>']0
M\+?#NTTO3ETBVM?!MA):9\/6\ND!M)U&'39;>/5]+EN-.U9;VRN9X)+GBW]A
MG]C7QW\1/A-\6O&'[+?P&\0_$CX$:7HFB?!WQCJ7PN\(S:S\.M%\+2P7/@[2
M/#$RZ6D5CIG@:[MHK_P%8^3):^!M2\S4?"46C7T\\\@!_/5^PM_P44_:L?\`
M:`_:_P#V7=$TZ7Q&OP=^+?\`P5H^+'@'7_VG_%'BRR/[87B;X2_&[5=,^'_[
M.W[-_P`6/%-_<>"/A?\`#3]G^VUSP9'\:-<\1ZAJMSX2TWQ3X?TGPIX"TGPM
MH7B+Q5!^EW_!*O\`;E^-/[3^K?%_X8?M.ZE9>&_CO\//"GPI\?:A\%_$_P"R
MY\3?V5/B_P"`-"^(">)K&^N]9T'Q3\2_C/\`#CXI?#74M;\.^5\-OBG\*_B9
MJ8U*.'5K3QEX>\-ZF-.M)?O>?]C#]DVZ@TNUN_V=?@_>VVB_$3XH?%G2X+[P
M-HE]%:?$7XW6.OZ9\8_%:I=VTRR:C\4]-\4>(+#X@),)+3Q=9ZM=V^N6U[$X
M14_9P_8P_90_9!MO%=K^S#^SW\*/@8GCF;1YO&,WPX\'Z7X>OO$J>'8+NV\-
MV.LZG;1'4;[2/#4&HZDGAO1)KIM(\/\`]J:JVCV5DVIWYN`#Z;'0=N****`"
:BBB@`HHHH`****`"BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>pg24d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg24d.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"]`20#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_"B@_P"'
MZG_/'?I7Y@?'7_@L[_P3%_9P^)>H_!_XK?M=_#K3_B-H.I2:+XJ\,^$[/Q7\
M3+KP1K$,MM#/H_CJY^&_A_Q58>#=8@:ZS<:1XBNM/U*!+6_::U06-SY0!^G]
M12N(TDD,;R>7'(_EQ#?*^Q"^V)/E#2ML*HNX9;:-PR:\O^#'QS^#7[1GP]T;
MXL?`3XI^`OC)\-/$!G31_'/PV\4:1XO\-7MQ:,([ZQ&J:+=WEM!J>G3$V^IZ
M5<O%J6FW2O:WUK;W"-$OJG4?J.^#Z^_\C]*`/Q@\._\`!4;XCZ-\)O\`@I3\
M:?CS^SW9?!BS_8JU_P`#Z?X$^$_B[XB>&M/\6:MIWCOX/^`O'7@__A=?Q$TR
M^\2?#_X?:CXB\2>/M*A\1R:1_P`)!I'PLT":9KZ^\67>DW5Q=^G?\$[OVP/B
MW^T9XU^./@/XE_$K]G;XQI\-]#^&7BBT\9?`WX8?&3]G[4?#M_\`$2;QC'=^
M"O$'P<^/?B7Q3XV\3^`3#X7AUOX,?M,^&-4B^'_QPT";7EL=`\-ZMX1OH-1M
M_$7_`()RK\9-'_X*>>"?B#X\L+/PA^W[KWP[UCPK>^']$.HZ[\+[OX??!#X;
M_#[1]8UO2]>)T+Q3<Z9X\^'UGXNAT8M'I.KZ0L6BZE)']HN77O\`]F;]GG]I
MNS^/7C3]J/\`;#\;?`;7_BO=_!WPU^SMX$\/?LW^#?''ACP1IWP]T#QGKWC[
MQ#XT\5:G\1_$.O\`B?5_&'Q`\2:II,EGX0MO+\-_"O2?#\NEZ7K_`(WU'Q-K
M7B$@'WQ?ZMI>E+&^IZEI^G),S)"]_>VMDLKJNYDB:ZEB61U4AF5"S*I!8`$$
MY[>+?"J$JWB7P\K#&5;6]+4C(SR#=@C@U;U/0M%UM;9-:T?2M82UE\RW35=/
ML]06WD<!7DMUO(9Q#(X`5GBV,R@;CP%'C/P:\">"+CX7>"YIO!GA*61]))>1
M_#6BL['[9=\EFL3_`"SGDG).0#UG_A+_``I_T,_AW_P>:5_\ET?\)?X4_P"A
MG\._^#S2O_DNJ7_"OO`?_0D^$/\`PF-#_P#D"C_A7W@/_H2?"'_A,:'_`/(%
M`%W_`(2_PI_T,_AW_P`'FE?_`"71_P`)?X4_Z&?P[_X/-*_^2ZI?\*^\!_\`
M0D^$/_"8T/\`^0*/^%?>`_\`H2?"'_A,:'_\@4`7?^$O\*?]#/X=_P#!YI7_
M`,ET?\)?X4_Z&?P[_P"#S2O_`)+JE_PK[P'_`-"3X0_\)C0__D"C_A7W@/\`
MZ$GPA_X3&A__`"!0!=_X2_PI_P!#/X=_\'FE?_)='_"7^%/^AG\._P#@\TK_
M`.2ZI?\`"OO`?_0D^$/_``F-#_\`D"C_`(5]X#_Z$GPA_P"$QH?_`,@4`7?^
M$O\`"G_0S^'?_!YI7_R71_PE_A3_`*&?P[_X/-*_^2ZI?\*^\!_]"3X0_P#"
M8T/_`.0*/^%?>`_^A)\(?^$QH?\`\@4`7?\`A+_"G_0S^'?_``>:5_\`)='_
M``E_A3_H9_#O_@\TK_Y+JE_PK[P'_P!"3X0_\)C0_P#Y`H_X5]X#_P"A)\(?
M^$QH?_R!0!=_X2_PI_T,_AW_`,'FE?\`R71_PE_A3_H9_#O_`(/-*_\`DNJ7
M_"OO`?\`T)/A#_PF-#_^0*/^%?>`_P#H2?"'_A,:'_\`(%`%W_A+_"G_`$,_
MAW_P>:5_\ET?\)?X4_Z&?P[_`.#S2O\`Y+JE_P`*^\!_]"3X0_\`"8T/_P"0
M*/\`A7W@/_H2?"'_`(3&A_\`R!0!=_X2_P`*?]#/X=_\'FE?_)='_"7^%/\`
MH9_#O_@\TK_Y+JE_PK[P'_T)/A#_`,)C0_\`Y`H_X5]X#_Z$GPA_X3&A_P#R
M!0!=_P"$O\*?]#/X=_\`!YI7_P`ET?\`"7^%/^AG\._^#S2O_DNJ7_"OO`?_
M`$)/A#_PF-#_`/D"C_A7W@/_`*$GPA_X3&A__(%`%W_A+_"G_0S^'?\`P>:5
M_P#)='_"7^%/^AG\._\`@\TK_P"2ZI?\*^\!_P#0D^$/_"8T/_Y`H_X5]X#_
M`.A)\(?^$QH?_P`@4`7?^$O\*?\`0S^'?_!YI7_R71_PE_A3_H9_#O\`X/-*
M_P#DNJ7_``K[P'_T)/A#_P`)C0__`)`H_P"%?>`_^A)\(?\`A,:'_P#(%`%W
M_A+_``I_T,_AW_P>:5_\ET?\)?X4_P"AG\._^#S2O_DNJ7_"OO`?_0D^$/\`
MPF-#_P#D"C_A7W@/_H2?"'_A,:'_`/(%`&O9^(=`U&<6NGZYH]]=,K.MM9ZI
M875PR(-SLL-O<22%449=@N%')(%;'^?RX(^H/!'8USVG>$?"ND72WND^&?#V
MEWJ(\:7>G:)I=C=*D@VR(MQ:VD4RI(ORNJN`XX8$<5T`&`!Z`?H,>IX[`9.!
MQ0`M%%%``!EE!S@[AP2#RK="""#Z$$$=0<U_)5_P3T_X+#?!SPE\$_V+_AFW
MQ2_8`^".B>/O^";O[1?[1'Q:L/!>K_"#X/Z9X#_:H\#_`!!^%/A_P)X&D\):
M/XNT;PKX2U7Q9HGB[QAK5_X+UG13XN\47'AF\U2"<0:1K0?^M8?>7Z_R!/ZX
MP?8D<=:_@E\,_$WX<_M/_#S1[#X1_!7_`((V_!CXDZ+\$/VK?V^?VLO%_B;_
M`()_?`'X@>!OV1/AA\./'-M\/OV?_P!B[XK+>7^F&Q^+?B_7]/\`%C_%GQWX
MC;2/&^CZ?#)J?A+P'>V,%E-K8!_6E_P2]U:P^)O[#O[,O[3&I^"?AUX5^+W[
M4_P`^"'QM^.VN?#OP+X?\!6_CSXF>*/AMH-WJGB76=.\.V=G#=ZBJW`L+:YO
M/M%Y;Z9:V6F?:3:6-I%!^@P&`!Z?H.P_#I7R[^Q!\1M/^,'[&G[*7Q9TKX7Z
M7\$M,^)W[.WP;^(%A\']"TJWT30OAG:^,/`&@Z_#X)T+2;2STZVL-#\.K?\`
M]FZ/;PZ?8(FG06V+.VSY*?4=`!16-9:_H6I:GK6BZ=KFD:AK/AJ:QM_$FD6.
MJ65WJGA^XU2PBU33(-;T^">2[TF74M-FAU*PCOX;>2ZT^6.\@1[>56++#Q+X
M<U36==\.Z9XAT34O$'A5M,C\4:%8:M87FM>&WUJQ_M+1H_$&EV]Q+?:.^KZ=
M_P`3#3!J,%L;ZR_TFU$L'[U@#<[K_O+_`.A"O+O@I_R2KP3_`-@@_P#I9=UU
MGBZV\8W>A7=OX"UGPSH/BF1[4:?JOB_PUJOB[0+1!=1&\>]\/:)XK\$ZCJ#-
M:><EJL/B735CNC%)*\D2O$_SE^Q+XB^(GBW]F[X<^*_B1>^!;G5/$&ER:AIU
MMX`\,^)/#6DZ5I/VJXMX]/NH_$_C7QK?:KJ*W4,]S)JB7>E6\D5S%:)I4+6Q
MN;EV=F[.R:3=M$W=I-[7:3LNMGV875[7UU=NME:[^5U?U1]944TG(QG!SVY/
M')'^>1UP?NGX>_:9\=?%GPE\0OA7I'@#]H#X:_#K2?'?BFR\)Z]H'BOX;Z/X
MMU7PU82^%O&NN/XY?4;OXB^%YX+&[U70='T.WCO],.FI+=O`EU)>W5JB<6-S
M#`9;1^LYCC<)E^'YXT_K&-Q-'"T/:3OR0]K7G3I\\K/ECS<TK.R=F;X;"XK&
M5?883#8C%5G&4_98:C4KU.2-N:7)2C*7+&ZN[65U<^XZ*JV:7$5K;17=PEU=
MQV\"75TD`M4N;E(D2>X2U66<6R32AI5MUFE6`.(A+($WFR><#('KGH`.I/3@
M9!(R,Y`)&[-=A@+17S_\+/VD_AW\7_$_B/PCX/T[XD0ZMX2N[O3O$;^*?A9X
M\\'Z7I&K6-MI=]-H]YK/B/0].TT:N]AK.G7\%BEP\]S9W4<T*LJ2E?H#(/0Y
MH`**\T^*GQ@^'?P3\,2^-/B?XA/A;PK;-<_;=<?1]?U>RT^&RT^\U:_O=3;0
M-*U5]+TVPTRPO+Z]U34$M=-M+>WD>YNX0.=;P)X_\+?$SP]#XI\&:A=:GH<]
MQ<VD5W=Z'KV@2O/:,%F4:=XCTS2-2$89T,<YM!!<QL'@E=!N8`[6BCIWZ<<_
MU]Z,CU_S_D&@`HKR7XM_'#X7?`S1[7Q#\5?$[>$]"NS=*FKR:#XEUC3[;[']
MF$\FI77A[1M6ATF`/>VL27&JO903RS);V\DLS,B]GX1\7Z#XYT"R\3^&KF\N
MM&OWN8[6;4-%UO0+TO9W,MI<1W&D^(=/TG5[1XYX9(R+JPA9BOF(KQNIIV=K
MV=GHG9V;[7V"ZVOKV.GHH!R,_P#UZ*0!111UP!R3T_Q^GJ:`"BCD=01]1_7I
M10`4F3G`&?89R>HR..@(P?J<?=-&1ZC\ZX7XC:5X9UKPGJ.G>+_$NI>$-`FE
ML'O=?T?QGJ/@"_M6AOH)+>*/Q5I6I:3?:>EW<(EK/'!?P-=Q3-;,Q$A5LJ]>
MCAJ-7$8FM2P^'H4YU:]>M4C2HT:5.+E4JU:LW&%.G3BG*<YR4813E)I)LNG3
MJ5JD*5*G.K5JSC3ITZ<93J5*DY*$*=.$4Y3G.4DHQBFV]$KV.YRW&01DG&>_
MO^6>!GGJV`-[J^*?V`[-I/V:?AOXFU/QYXZ\?^,?%?A?0-1\>:AX\^(.N^/-
M5LO%4>GXOK-DUJ_N_P#A&[DI<1S7VC6T%@N]HI9K42[9'^U<CU'IU[^E3AL5
MAL90I8K!XBABL-6CST<1AJM.O0K0>BG2K4I2IU(MIKFA)JZ:O=,=:C6P]6='
M$4JM"M3?+4HUJ<J56G*R?+4IS49PDDTVI)/46BDR/4?G2Y!Z$&MS,****`"B
MBB@`HHHH`,9(`ZY&/;&23^0..^>E?SP_&'XR_P#!/[]M2;X;?#+]C/QS^P?X
MEU/XL?MG_!?XA?M^?!3QWI'P;^'WQ)^-7P7\$IK>K>-[CXJ?!_XK>'M`\??$
M7Q-HFNQ>$V\W6/#U_K5O=V$]BM\@@O[.OZ'3^7O^G\N/?H>*_E\_X*4_$C]L
M;XF?\%(/V;OV4_$/_!*;]G[]J?\`9F\;>#OVF9=%\-?%WXU?`C5-._:'T;P?
MI/P4V?%N^O\`QU\`?%OB3]G#Q)\`I/&_B6'PQX=L=?O=9^)"^-M5DTK6-*ET
M1A(`?U`QQQPHD$,:0Q0HL<44:"...)%"1I'&H54C1%"HBJJHJA5`4"FRHTB2
MHKR1%T=%EB*B2(NA021EU=!(A.^-F1@'&&0H26Y7P#X$\'_"SP/X2^&WP_T*
MT\,>!?`?AW2/"?@_P[8-<-8Z'X;T"Q@T[2=+M)+N:YNGM[&RMXH(VN+B><I&
M#)([DD]=U[>Q!_D:`/Y[_P!G"'4/V&=4_P""V%W^SQ\,?BM^TGXX^&_QJ^"/
MB#PMX$OO%'BCXH_%?XM?$OQ1^R5\$YI]7\7>)]=O]3\4:W-J&OZLWB+Q5-9F
M2YL_#UIJ$/AG12]OIVE-+_P1NUC3K/\`:E_X*4^$7T']I.Y\;ZMKW[,7Q*^*
M7Q,_:%^$'BGX4ZS\0_B5K?P9CTWQAKTVA>(;J\C\&)K.IVXO/`_PUM9VM?"W
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M34KI]0M(;FPT_P`->'E:]O=7NK*6YBTB2X!TJVU(VL^LE=+2Z*_FC_P3^_:3
M_:-T3]GG2;#6OV:?B?\`$3X>>'M6O=%^'?BW2](L/"7BVZ\'6R02QMK/AO5#
M;VGB6\35)=6<>)?#\]KI=U"8[)K8:A9W4T_Y+Q#]&SA;Q$\0,#XK8K/N*LNX
MFRC(H\(X?`9#QY7X-I5LLJ5LQQLZSEEU7+,VG5E/'U:566'SNC3K1C1IRPE5
M4YM_1S^D-C/"[@ZMP9B\HPF+X<S3-*O$%?,*_AYF/'BPN/I+*\+"AB*.%R_/
M,+AH3A1IUZ$L9DTX4HTL97^N4&H*7UO<_"3]O*ZDY_:2\`018?*V7A2:TD+,
MP(P[>'KG:%P%R,MM+#.?FKY3^./[)'QFU?QG\.+[XB?%'0?%GB#XH>+;/X8V
M6JMIU_.VEFV\*^+/%L%W?O#IVD12:;##X<O;5+6&T$ZSWL<C3O'',!]I_P##
M=GPKTEQ#\0/!'QM^%\V0DC>-?AAK<-F&(P^S4-*.IP.B98>:`J9Y&<`'X?\`
MVL/B]_P3_P#BY\3_`-GOQ1XA^(5QK=]9?$BUO/'FJ:+X\^-7AG3O!W@&Q\"?
M$#P_::MXELO"'B70-)\)I<^)/$^F:?::W/I]MJ%^9+J/[9)8V6HB/SN+_H=\
M`\:97'*>*^'O$C/\O^LT<8HYEXG>*^?826)PL*OLJT*68\7YGEBJ1A4J.-2G
MAU42;4)Q3FI<W!?TR<'@\WE4X1\0?"[+\ZCAJE&6`PG"_ASD&<T\/5JX>,HU
M<%'(<KSF$?;*C"4:\>7GG3C.+DX6^Y[#P[^W3X:M(W_X6!\#_B),F/-L-;T'
M7?#T[X)RL6H:;;1)(TF-I:>.(*<X!&[&=XC^._[5O@G1M0O-=_98TK6IK&TN
MKJ;6O#'Q.AFT:U@MX))IKZ?3!H&I:E+#;HIGEB%Q"[HKQ&:)MK"6']N?]GFT
M@L]!^'P^(OQ.;3[2VTZQL?A[X&\4>*96MK.)+6W3^T]12W6[98XE5[JYOKBX
ME9&FN)79F=G/^T=^T'XI$L7PZ_8[\;A9XWCM=3^*OB[0?`5CYK1DP/=:;%;:
MS>O:LYVSXECECC,A\MSA3]!5^C]Q?@:=;_5GQ2\5>#'.G)4J?$'$60<3X"FG
M&T5.'BAEF>YM4IQO%OZOFU#$N*_=XB$VIKY>'TK?"/'UH0Q61<!^(<U5C&<O
M#WA7BW'XJ4E*-XJ?A`EE5*I-W7-BL#/#1=Y5:;IJHCXA_9Z_;)^)&G^,?B//
M#\,8_B)'\2->N/B1X@@\&6_B(W^@ZO\`V'X9\*Q75M8Z;8>*)YO#UW:^'["V
MV7`MVL]0N)+EM3N%,=B?K;_AL+XQ2G;:_LE_$"ZER=T;OXLM0%!&6\V7P`Z$
M@D?)C)8DYY.?@G]BK]IW]KNP^(7QZB\5_LW^,/'D6K^+9_$OC6QL?"EW\/=0
M\'>.X--T6RU?0O!M[J.DOI>M^%$\)1>$9M%T+Q#?Z7XHF(CU"-;C^T+_`.R_
MI[X9_;=^!&K:DOA[Q;JWB#X0^*\K&_AKXMZ#?>#;U922A6*^N!/I,\:M@"5;
M[:%9&(4.`?G.$?`OZ0?#.04LJQ_TA:W&]?#5<16JY[A.`N'LWQ\Z6(G&M"EB
M)8O-LVQ5.&$4U1ISKT(4U%6BIPY9+Z;BKZ1WT><5Q-4HXWPYAX<XC$QP]'"9
M3Q3Q#Q#PKE>)JQ@H0_LK,<9DF2Y+F=;%6]I4H9;F.(Q,924:T*-;GIOXV_:<
M_:J^,'B+X0>+_`/B;X`:A\+_``U\5O#_`(I^&6J>)/$NI:Q>376F>+_"VL:'
MJ=EH5O<^'_#:6>O1V5[-?:?>W$^HP(]I^]TRXC9POL'PL_:W_:0\:^$-'UG3
M?V6CX^LYTG@C\7:#X\_X1S2-3-G=RV<IATW4/#FMM:R6\D36]QOUBY$L\4LR
MB%&\J/IO^"BGC#XP)^Q;\;M6_9V^''PI^-QU;X3?%NS\4S^,OCEJ7PGT[POX
M'F^%?C(ZGXU\':UX9^#WQJ3QEXKTZ<6EOIGA":#P;::F+N2:7QKI7V8)/]*_
M`+6_C7X@^&^G7_QY^$WPZ^"_CP7EY;GP/\+/C#JOQT\*PZ)$(/[)U-?'>K?!
M[X'W,NH:C&97O=+3P,EMI[(@AU741.SQ?.TO"'QJAQKC^(,7])/BJ&1XC*89
M=2X>P7`O!.'^J8^G/"2J8VFLRR_-LEA*2H5HM0X?IXU*NE+'SBJL:WZ1_P`1
M"\-*W"V"RW">#F0ULPACGCO[<K\5\28BGBL%4A7]G04L!BLNS&<6JM&:D\XJ
M8.2IWCA$W2E2\CA^-O[45XBB#]D![&5NC:A\9=",2AB5^ZOAB"0,#AR#MR@;
MD&I/^%@?MF7A!L_V?/AMI:DH?^)M\4Q<E0=VXLME90L<$!R%7.P`8)/%WX_?
MMW_L:_LMP7#_`!]_:2^$?PTO+996ET/6O%VF7/BD&(!B!X5TJ6_\1,S,0L>=
M-"NX(4DHVWX"?_@LS:?%IFLOV%OV'/VN_P!L5_-,,7C.W\$M\#O@K(Q)\MS\
M4/B/;&5X7*.SO:>%;PH`DFUUD5A]:O##BVK_`+_X\>*^*7\N&P/A-E<;^N6^
M&&'J?/VG-U<KZGA_ZZ\/T]<-X5<!4K?:K8KQ!QKZ7NL7QU5ATVY;=DCN/VPX
MOVN?$'@"UU+QOX<\/>&?`VAKJ-SXIM/AOXOU:\M;ZUN[C0[6RB\8Z==W,":Q
M;Q7X@ET6"WM[_P`FX:[GFCB,4<I]^^&6O?MP>&/`_A_1]6^$GA/Q=-I$%SI]
MQJ/BWXEW,/C746MKR<+>:O=W,FJ6MW)<*0;:ZBN;CS;6.-Y`K-LK\`/^"KG@
MC_@J'^TW\"=%U3]J,?\`!/\`_9"^'FCZEJ6J>'OAAJGQ<35_C'XB:270S=0Z
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MP_:CTV$+/^Q])J4Z\-+IOQDT4P,,<!(QX5NY_P"\?XB05`R>:XZ;]JK]HNRE
M9=6_8P\6V,"G'G6GC'4M;RH^\1'8?#T#^(_(KL#G@L.OR0?^"AO_``4B^&9\
MGX[?\$>OBIK,%KM6]\2_LQ_'7P!\7[:<@CS)+3PKJ.F>&M16WCV[D)URZ:4,
M%1-RC?:A_P""[W['/ANYCT[X]?#_`/:W_98U-B4DA^/G[-GCSP]81LBDRNNL
M^'H/$NFO;QDL/M33QQN%#*<8%?51\/\`Q$PS;P?CSQK77V(9UPCX59A"*35D
MY9;P/D5>:MI)RQ#FTVU)2/GY<6<(5O\`>/"SAJDW\4\LXAX\PDKWNW&..XHS
M:A%]DJ/*K64;;?4W_#:OB6T`_M_X'^*O#/3<VLZ1\2#&K8.XB2S^'-R)!PPW
MJ,N!@CHM<;\0?VU_AGX@\$>)=$\6^"/AYX_T;4;#[)JGPV\4IX\2U\6VKW$!
MDTNXLO%WP??P[<IPMRT.J`VS"`9^9H\]W\+O^"IG_!.OXS&%/AY^V9\`M4GN
M(U:*SU;X@:3X2OCY@.Q#:>+IM$G\UR"JQ;2[OPJER!7NOQTU"X\=_L__`!$N
M/A8G@OXD:Q>>&W_X1JTN;5O'?A;5KUKNTEABN]/\,G4+S5;<JC3+%I_F3%HT
ME3A"4XLUX5\>O[+S'#Y%XN\%+,:V7XNCE^+SCPGJSJX?&U,/.GA,1]9P''5'
M`T9T:\J=95<1D&;8>#@I5LKQU*,L+6Z<!GGA8L=@JN:>'_$SPE/%X:IC*&7\
M?48T:V&A6A+$470Q7"<\74C4I1E3Y*.<8"M)2:IX["U)1Q%/\QOV1_CM\)O@
MAX6\5:)\.?V>_`G@[Q#K/BKQ'J^I3>!_#NH6NO\`C+3O$7CGQMXS\-Z/??\`
M""?#2[22Q^'6G^*?^$2T-=<U0*]I$)=&L=+LY)-/M?LO2_VI/V@M?N@N@_L=
M>*]1TY^$U'4O&-[X3W<Y!^S>(/`<*HI'S$M<#)Z\\CY^_P""2S_'.?P'\6+W
MXP>%O!F@V5UXZ\4P>&=1\*^!O$_A&XU>31/BW\7O#^HVFH7NOV5K!J]GX>L-
M-T31]!M]/:631M,A6UOECG<%_P!<,G(.223WR,@@XX)X.>/0$=!TKRN%.!/I
M`KAW+,#Q[XZX&6>T*=>.99GP5X=\,8;%8J4\7B*E"4\;Q#@<PRFK4IX6="CS
M83@S)Z<?9*%2ABJL:N-Q7?GW%'A/_;&,Q7"OA?BXY94E1EA,#Q)QAG=;#48P
MPU"%11PV3XC!YC3C/$1K56J_$V8SFZCG"I0I.&$H?'Q\5?ML>(P?[*^%WP<^
M'EO(5*3>+/&6K>)[R),GAHM!MH8RZX_BA4$D'`&!7F?Q/_9Y_:Y^,.B2>$O&
M?QJ^%?\`PB^H3VL^I:-I'@W4[9#)9W$=W:[)_*-U<""XB20;[JV\S:N\[0!7
MZ'`X..Y/Y]N3ZX`)]>,#G)\2_:(\.^-/%GPIU[0OA_XI^,'@SQ1>7V@-9>(?
M@3+\(HOB98P6^M6,]_\`V%)\=+:\^&8@GLDFAU0:];RNVF270TY/[0-O7HYI
MX#Y/Q+EV8Y5QMQYXJ\99?FV#Q&`S'`YAQMB<@R_%X?%49T,12KY9P+A.$\MK
M4:L)M3PV(PE;"SC^ZJT:E*4Z<^7`>*F8Y'C<)C^&>%>`N&\7@,31Q6$Q.$X8
MH9OB\/6H5(5*%2CCN*Z_$.-HU:<HIQK4,12K1E[].<*B4E^<G[+OP/\`VC[_
M`."_@[Q[\(_C1H_@;PY\3]*L/'B>'[FUFEDM+C5K.UMV&H*V@:M'<WL=M9VT
M#W-O=00L8D"V^%+2?2EE\*_V\[8_OOVC?AO<#+X^T>#+BX.UB"N<:/;`L.03
MC')_O;1Y1_P2)\'?%#PC^R1X$?XE>-OVB?&(UOPKX+O_``S%\?+C]GZ>#0=)
M71YHI-/^'8^!EK;747AIY/)N+I/B*9?$?VP1&T<6/`_4W)XPI/\`GGIDG'?`
MK/(OHY>&7#.4X').'I>(.39?EU!8?!X?*_&#Q9R_#T*2G.HE2P."XTH9;2]Z
MHW:E@H1UORW;;O-/&+C7.LPQ69YM'A#,L7C*BJXFKCO#OP_QE6K-0C!.IB<3
MPS6QDWRPBKSQ,I::O1)?&]OX+_;>@4F3XU_!N\;G"7/P]U&)`&(R3+`8W)7.
M$'EX(^\02,>0_'F+]NW1O`4]W;^)/!>I16VIV]S=W'PBTS7=.\76]C!%>S3S
MS'4U:T71((X0^HM$WV@YA52RA\_I-EO[K?7#8S^6?;I_+GXR_;VUNW\-?LW^
M*]7OO']Q\,K..ZMK.X\56^C_`!4UD1G5+:_TVTTZXMO@_P",O`WBN.#5-0O+
M2Q^U3ZQ+HD4LL/\`:>G7B&)%GB#P!P.?Y/F.28#Q(\:,GJ9KA:F!IXG">)?%
M&9UZ$JZ4(RHTLXQF8^TG>R4>9.;?+S7:#*_%C%97F."S3%\&^&N80P%:&*G1
MQ'`^08"C5C1:DU5J9;A,$X1LKN7V;<RMRF=^R;XF_:"\1?!+PYXB\0VFB>*7
M\0SW&O:+X@\>>+]=TW6M7\,ZS%::EX?OX(=,\%ZW;R:5>:?=176F7/VXRSVT
MZ^9!`R%*^D?M_P`9/^A5^&/_`(<#Q?\`_.TKX_\`^"7<\L_['GPN23QK=^/?
M[-\.>#_#YU>YT7XIZ-!87WAGX?>$?#NM>']._P"%K^,?&NI:G9Z#KNF:IIS:
MIX;OM,\(7-U%<C2-$L72Y$GZ'5^I\'<,SX,X6R#A.IFN;9W/AS*L'D\\WSVL
MZ^<YC+`T8T)8O,ZTDG4QM9P<L1)I-U+W2>B^&XBSN/$N>YMQ!'`Y?ED<YQ^(
MS&.7Y335'+,''%U'65#`THMJGA::ERT8IM*"6K.(T.Z^(TVH(GB30?!%AI9C
ME,ESH?BWQ#JVHK*%_<K'9:CX*T2U>-W`$SMJ"-&@W+%,0%KMAT_/_/\`G\,#
M@+17TIXP4444`(>QQG!Z$9!'0\=^":_(K5_V&O\`@H?X)U.YTO\`9E_X*V^,
M?!_PMGOY+O3O!O[3_P"RM\/OVN?&/A6TD6!8=!\-_%ZZ^(/PB\9:EHEH@F%L
MWQ#_`.$^\0Y-J)_$4RQ3?:_UVZD#.,D#/I_]<]!Z$YP0,5^%7CK_`(*'?M_^
M*O!7C3PK:_\`!#_]L^QN?$?A3Q-X=M+\?'7]DA5M;C5](OM,M;LO#\6C.B0R
MW,<QEB26:)=\D,<S*JN`?J)^S-\!O%WP'\':KI7Q#_:*^,W[3GC[Q+JR:WXI
M^)/QAO/#=I,]U%:1V5MI7@SP-X&T+PQX&^'WA:T@C\R'1?#VBK/=7DUQJ.L:
MIJU_,;@?2(&!@=!^'Y`<`>@&`.@&*^*_^";WPT^)'P9_X)_?L6?"3XPZ;?Z/
M\5OAK^S%\%?!'Q'TK5-1AU;4=.\:^&O`.B:3XDL[[4[>ZOH+^Y@U6UN8YKJ&
M\NHYG!=)I%(8_9TTB0QR32MLAACDED?#$+'&ADD?"@L2B*S8"L3@;<$88`FH
MK\TO@K_P4@L?CUX6_;.\7>`/V:?V@+Z+]E'Q!X?\/^%?`E_X7D\,_&;]H"7Q
M/\*/"_Q-\/W?A7X7^-K?PMJ/@2#Q*?%5CI?AJ'QYJ6FWD^F;?$GB*W\,0/+8
MVW<?LX_M8_&'QY\>/'G[,/[2_P"SUX3^`/QJ\*_!_P`"_'W0K7X9?'E_VB?A
M]XH^&'C?Q3XJ\"EKKQ=J'PD^"7B'PQXT\.>,/".H:;JWAW4_`DNA:K93V^I^
M#O&7B=+/Q!!H8!ZQ^V5^T!IW[+/[,GQC_:"U7Q/X4\)6?PL\)7?B@ZGXST74
M?$.B7MS:M$FG^'!I&E>*/!U]=:GXIU"6V\/:.\6O6R6FI:E;WEQ#>6T$MK-^
M!W_!.K_@N_\`L_:=^RSX'\/?&3PC\9)?%G@S[1X<UL?!+]GOXB>/_`GA65)5
MN[70=1\<:/K_`(KBU_7;F*^&K-=#3?"NRUO+:S/A^)K:.^U#^EWQUJ]GH/AF
M_P!4U#PGKOCBUMI;`R^&_#>@V_B36+TR7L*1RVND7,T$5R+*4K>RL9`]M##)
M-"'D15/S#^P#]LMOV6?AIH]_\._%/PVU;0M.ETW5]'\4>'+'PY>7M\+F>X.J
M6L&G7-Y;7]E+;S6]NFH"7+R021;0(5!W4Z"P\Z;HR>(=6,H5U4M&--1:E2=+
MD=^=OF<N=.\8)*R?-%I<ZES+D46G&VKDVGS7OT2M:SW?<^+K7_@OS_P30FRN
MJ_%+XF^&`2Z.OBS]G_XRZ,!^\\K;(MUX-(`?YMJD#<J/@;E*U\??M'?\%0?^
M"-7Q6^*G[,/C)?B!X/\`&<^E?%:[MOB+K=I\-O&,.G:=\/;3P=XDU2UB^)NG
M2>']/;Q/X=/CVV\'R:%IE[8>)/LVJ?:)XM.BLI]6:?\`I=FC6>,QS1+-&2"8
MYH5E0D'()5T920>1GN,!EZC\5?\`@H7^Q]^QU\8?CQ\#/&?Q7_9E^)WQ+\6:
M%KNAV/C3Q-X`\$?&C4M&TWX3:?H7Q"U;3[(77PYDMM$AO+3Q]/H=Y+_9B#Q*
MD[V9F8V>V.M<!B%AL1[25;%T(NG5@YX.;A6O4I2II)^TI+EO*\US>]'FA;WV
MUAB\)0Q<(QKX;#8GDJ4JD(XJE"K",J5:G6C**G"?+.%2E"I3DDG"K"%1-2A%
MJW)_P7K_`.":%FJ6?A'XA?$SQNN2+>U^&O[/?Q>UV*0[7;$'V+PA!:@%5R)"
MZ)]TF3!&(YO^"WOP8OH+FZ\%_L<_\%(/'UI:6US=W&J:)^R7XATW1K:ULXFN
M+B[O=6\4:]H5M8VL4$4UQ-<7)CC@@@FEE*+&QK]G-/:![.VFM+9[.VN8(KJ*
MV-F]C+$EQ$DJK/:/##+;7"JP6:&5%EBD5DD574JMET,JM'(I:-P4=70NCJP(
M971AAD9?E=6R&R0<*>>-W>K;NW=N^K?7>^^_7SOK?HC&,(QA",8PBE&,8I1C
M&*5E&,59)):)))):(_D2_8._X+D?M`?'GXK?M!Z1\#/V,+C]IV?Q#XKN_BVW
MA[X5^(M$\`:W8^'-3TSPEX$\.>*/$>J>+_B-XRL-"TVX;PK);ZEHNF:-XGB@
MU+4()8?%K1%-.7])/%'Q_P#^"NGQKTW^R[?_`())_L]>'-$FR)+3]H3]JWPS
MXPBMQ*I0R_V?H/@;3Y1*N-Q:U3SH_DV2!E#C[U_9DT7QQX=^(/QSE\2_LV>)
M_A/I/C_XC7WC7PUXHO\`4_@7=V0T%/!O@+PW!H%];?#GXD>)_$-IJ%WJ7AW4
M-0AMETJXTE+9(9KK4;>]E%N?M7;_`++'ZHWH!Z>@`]@`!P!735K4UB/;8.%3
M"1CR.G%5G.I3E&$8RDJRC3E>4E*=TDTY-+1)'/6PE#%X6K@\?1P^.P]>$J>(
MH8FA3K8>O3D]:=:A54Z=2#5DXSC*+LKH_C3_`&^_V0_^"I,/[/WC[Q+K^A_L
M3?L^?#2\TO5KSX@>`O@E\<_B/X=N]=\.:#H.J^*-4BO'^)EYIWA37)+2UT::
M6R\.Z)+<ZE>7;0S6MJ(K5Y8?L3]F'_@D_P#M*_M"?LV^`+#]KC_@I/\`M+R:
M79:?-X<N/@9\!OBOX2E^%>A:1H=S+IFFZ!<?$'P1J.JW/CV!M&M["9QJ%_`N
MF+.-.-@AMEFE_?7]H3]GWP7^TM\.]3^%_P`0;K7;7PKK-OJUEJ\>@)X=%]?Z
M;KF@:GX;U33Q<^(_#GB-;!;G2]7O(DOM)AT_5[:1HY;/4[4QL'ZKX4_"_1OA
M#X.MO!/AZ^U;4],M;V\O4N=8M?#MM>L]XR,Z-%X6\/>&-),<?EJ(V&EI<R9W
M3W$\GSKV8G.LQQE*E2QF(EC/8U55C5Q<IXJJVHN"C4^L2JTZL(QLHQJ4Y6MH
M[:/P\JX.X9R#`U\LX?R;`\/9=7J5ZTL%P_1CD5"G7Q34L17PW]D_4YX2O6<4
MYU<+.C)N[O=MO\G/A!_P0N_9'^!.J1:]\,;G6-%\2Q.LH\5ZAX<\%>*?%0F5
MF<W4&N>*='UJ[LKUF9F-[8BVNMS$^;C@?;1_9&\2LB12?M9?M.-;GY/(B\;6
M=NHB`V>5&(=.00!5(1/+50@`V`8Y^T^?[K?]\M_A2%<_PM_WR?SY4_3^7>M8
M\0YK"*A3K8:G&*M&-/+LMII>G)A(V>BUWTW/EJ_@]P#BZU7$8S+\ZQE>M-SJ
MU<9QKQOBYSE+>\L3Q#4=I=8JT7U3/QQ_;B_8RO8?V>_%/B:/]HOXX>)8_!=S
MINNS^#_B7XDE\;^`/$\5UJ5CHOV;Q!X86;11?7&F_P!IG5-"N6OECL=3MDD,
M#A_-A^H/#W[&/C7PKX=T/P_I7[97[3TKZ'I-EI2:AK'BC3-;GNC8P)`MQ*NH
MV$IVEPY2%YI&6#RK>2:8Q+*_T!\=O@5I'Q_\(/X&\2>-/B1X3\-W0E76;/X>
MZYIWA^7Q!!)+9W$5MJUU?:#K-PT-E=6$%S:?V>]A*LCS+-+-#(8AZ1X1\-W'
MA7P_8Z%<>)/%'C":R-RS^(/&-U8W_B&]-Q</<*+VZTO2]'L76`2>1`L&G0".
M!(4*R,CN=?\`6?.G"%.6*I3C"<YQ4\#@*BO4C2C*\:F%E%Z4H6NG:S:M=F\_
M"3@&>"IY>LHQM##4G2=-83B3BC!5H.C5S"O3MB\)G-#%^[5S3'RUKM2]ORRO
M&E15/Y0C_9K^/=G_`,@S]M;XH@`@K_;?@KP?K>,#$8D.ZP,@)9O,X7S1L^YL
M)9)O@=^UG%%)%:_M@Z;K$$JE6M/$GP)\-S0R1;<"*<P>))4G60-F8F`9VI\A
MRP/VMC_9;\58]>O4=2,`^P`HV_[+>WRMQCIV[>_TZ<5/^L69/XX9347_`$\R
M#(IO[Y9:Y?B<*\&>"X)?5\5Q_@VFG'ZGXN>*^&C!_P!VE3XT5%]=)4G&^MD[
M-?CU\3?^":>I?%HW#?$GP-^P=\3YKIF-QJ?B[]E+0=,UZY('[LR>(/#JV^M*
MS%FD;;?D+)@H&S\OY_?%/_@@;JUEX>\2ZY^S/I7PA^!_Q9ATJ^O/!FN_"3XM
M?M"?"W3[;Q*D:MI]Q<V.G:KJ%H&WJ[VZ8AM8KKRA/)';&21/ZAL<YVMG&,[6
MR/H<9Y[\\_B:X+XH>#F\?_#_`,5^"UTOP)JY\1:4^G#3?BAX,?X@?#^]W312
M>3XK\%IJV@-XATH^7N?3QK.G[Y1'(9P$VO,L]JROSY;D4[IIM9/@J+L^J>&I
MT6FMTUK?9HZL+X7X'`XFAB<)QEXGP^KUZ-=8?$^(O$^:X6K[&K"I['$4<YQV
M8JMAZO)[.M2D_?IRG'F7,V?R??\`!/\`_P""9W_!6WPK\'I)OA_^WSX@_9\\
M*67C#Q7I_A/X=3O-XJT6SU32?$NLZ5\09]>\$>(]'URSTJ]E\>6.LQ[=/UK&
MISP:GJ5]`AO;2>?]+=-^!/\`P7X\$VHATC]MK]BKXMK#$&CA^)?P2\2^&=0N
MI``/+DU'PAILT:!^0SB%E!&Y%7)K[\_8U_9-;]E31?&NB_V5^SE;+XJU_5=>
M74_@1^S[<_!#4[L:UXV\;^-#I7C"XN?B-\0'\3Z9X8/C'^Q/!<(?3FT73K6[
M#"9=1,-G]JX_V6]/NMWZ]N_<]:Y,9CUC*LZSP6#H5)U)5'.BL2I-RES>^JF)
MJ4YOHY.GS2^TVVV?883)\3A<16JU.(,[QE"M"G'ZCB?['CA:+IT:=)RP\\)D
M^%QU%U'!U9QAC%356I-TH4X<E.'\^7B/XD_\'#_@=)6O_P!GO]D_XKVD)+/=
M_"3XC:?H=Y,`.([:Q\?6-M<E)0>#)9,R[0'(W`'XZ_:3_P""C7_!0OX9_!?X
MBWO[5_P`_:K_`&9_"(T&>UU'XE^$/!?PE\4^"+"\U!ELK'1-0^(&D>,?"NH>
M&+#7[^:VT)M?T[&JVD&HR7.FHU["D3_UI`8Z*?\`OAO\.W;T[5Y3\:M6U70O
MAYJ^I:/]A2\@N]$"/JOPK\6?&>QAB?6+-)IG^'?@K7?#?B369((B9;>2QU>U
M339ECO[A9+>V='WPF=8G"RA:CETX1E!RY\GR:=9QC)-J%>KE]2I";2:C.[<6
M^:S:1X>.\/LCQV,I8^>/XTI8FC6A7A'#>)'B'AL#.I3G&I%5\JH<44\LK4'.
M*]IAIX1X>M!.E4IRI2E!_P`C/["W_!3K5[_]G;P]H^B77_!0[68/#6HZCI&N
M^&_V6?V2;#XT?"OX8:P1#>-\/_"GQ*NO']WK5U86&GW5GJUOI>MV&FWVEQZN
MD-OIT.G_`&,R_9R?MV:I=JIUSX2_\%X-6B<AV.G?LW^'O#0>-AO+QQZ?XD,L
M64)Q&W[U`55CN5L?K+_P3/\`^%B:;^S'X)\(?$?18/#6O^#O#OA?1[KPY#\!
M_B#\#[S2+X:41J%OJH\<>+/%4?CC4-T%N9O$/A_^RK&`XM+BU:7RV'Z%?-_T
MT_\`'ZZZ_$^9U:]6K2EA:$:E6=1*.691[9<\N9J>(CE\*E25[^_+WI;RYG=O
MR*W@]P)BJKK8W"<18V<H4X2IXKC[Q!K8)*G3A2C&GEU7BJ>!I0Y(17LZ>'C"
MZ<FN:3;_`)B7_:HTK4-SZY^P[_P7/\3PRDL#K.C922)N58P6_C"V,:O&YQ"-
MIC5C'C(KYL_:F_:\^`GPL^"/B_Q=\5/^"9O_``4,^','DM8>!/B-\>O$NF^&
M/"FC_$[4H+M/A_?76MW/Q"O+BRO(]:,-V(K#3-2OC;QWD2Z==`R0/_83\W_3
M3_Q__#_/;'%>3?&Q=3D^'>NVVE?"W5_B]J-_;76FV/A/2)O`%O=Q7-_IU[:0
MZP\WQ,\4>$O#D=K823@7+IJC:FL4S&SLKP>;&)I<49["I3<LTQWLHS@ZE*AB
M'AE."DG*'[F,8QYDK7Y&O)BH>"WA5A:]+%TN`N&JF-P\U5PV,QV7PS/%4:T;
M.-6&(S"6)K*::3YO:7;ZGQK_`,$EOBU\&OC9^P7\"?B!\&+32M,L]2T.:V^)
M.CZ?JJ:S?Z7\:K&7[/\`%2/Q)J!EDNI];OO%*7.L;[XQW,NE:AI<J6]M:M;0
MK^D=?-/[(WAWQ'X/_9]^%W@SQ=\*]4^$_BKP5X#\!>"_$FD:E<_#Z_?7-;\)
M>!?#6@ZGXDL[[X<>*/%NEWFF7=[I\UGIUUJM]8Z[-:V*27>E64#6R-]+<_W6
M_P"^6_PKQL36>(Q%?$-U&Z]:I5?M:CJU+U)N3YZK474E=^]-I.3NWN?I6'H4
M\-AZ&&HTZ5&CAZ-.A1I4*<:5&E2I0C3ITZ5*"4*5.G"*A"G!*,()1BDDDBBC
MGT(^JD?S%%8&P4444``SN7'7/&>G0Y)]<#)QQGID9R/X?/C%_P`$\O\`@GMX
MV^(6M^)O^"=7[%^D?\%*O@A\1?@%#X*\-VO[+W_!3*[\+^*_@#^T@OB/Q??Z
MUXF^+^E^._C1>:IIVD>(_#/B7X='2?$-O;:S>?#N?P?XGMO$OPSOG\0Z5<S_
M`-P1&1UQR#QUX(/&.<^F.<].:_DK_P""UGA[X7ZA^U/XD\%S:%_P1E^&-QX1
M_9"TSX^S>-?V_OAQX@^'GQN^(WB&X\8_%?P]!X=^"7QZ^'/BWP!XPO[31+7P
MP\GB*V\/:Q?:UX*UWQ+X5OH=!URX\1VTND@'](W['GPI\4?`C]D[]FGX*>.9
M-!E\;?";X#_"GX>>,I?"UUK-[X;F\5^$?!.BZ)XBGT*]\17-WKM[I4VL6=Y)
M97FK3M?75NT=Q.D+R&%/H[K^!^A!_P#U?X'N*_'C_@C7^U5\6/VA_@7XI\$?
M&*3X<ZUXE^!,'P0TS1O&7PTO/BN]OJ_@CXN_`'X??&CP;X<^(NE_&WQ)XV^)
MFA?&SP#H?C*V\/?$NT\5>-O$^J7]V-,UV\OUN]7GC'[#KT['/<=#Z'\L=/S/
M4@'Y?67PP_:M^!?BW_@JG\</@_\`"[P=\2_B1\</&7PR\;?LL>"?$7C[3/#N
MA>-]:\(?LU?#3X7$>.-4DFMV\+:/IOC3P_J<^H65S=65]J^B:8T>G7ME+J5I
M=0Y/_!-OP)\?_!&H_%K4OVCOV9OB1X'^,'Q)M?"7BGXK?M1?%7XU_`;XF^*/
MCSXPTA=2TW3_``?I'A+X,:OJ-M\*OAC\,[&^U(_"_P"'=I%#X3\(Z1KVHQVT
M^K^+-8\6>(]=_5C`]!SU]Z3`'0`?A0!SWB#PIHGBA;)-:@O9EL)VGM?L>LZU
MH[QRRA$=VDT;4-/><;47:EPTL:,`R*K%B?"_A!\*/`]]\,O!MU<:?JYEETG+
M^7XP\:PID7=T/EBB\1I&@ZG:J@9)/>OI;NO^\O\`Z$*\N^"G_)*O!/\`V"#_
M`.EEW0`[_A3O@'_H':S_`.%IXY_^:6G#X0>!%&%L=;`]!XV\=`?D/$U>FT4`
M>8?\*=\`_P#0/UG_`,+3QS_\TM'_``IWP#_T#M9_\+3QS_\`-+7I]%`'F'_"
MG?`/_0.UG_PM/'/_`,TM'_"G?`/_`$#M9_\`"T\<_P#S2UZ?10!YA_PIWP#_
M`-`[6?\`PM/'/_S2T?\`"G?`/_0.UG_PM/'/_P`TM>GT4`>8?\*=\`_]`[6?
M_"T\<_\`S2T?\*=\`_\`0.UG_P`+3QS_`/-+7I]%`'F'_"G?`/\`T#M9_P#"
MT\<__-+1_P`*=\`_]`[6?_"T\<__`#2UZ?10!YA_PIWP#_T#M9_\+3QS_P#-
M+1_PIWP#_P!`[6?_``M/'/\`\TM>GT4`>8?\*=\`_P#0.UG_`,+3QS_\TM'_
M``IWP#_T#M9_\+3QS_\`-+7I]%`'F'_"G?`/_0.UG_PM/'/_`,TM'_"G?`/_
M`$#M9_\`"T\<_P#S2UZ?10!YA_PIWP#_`-`[6?\`PM/'/_S2TH^#W@('(T_6
M@?4>-?'(/YCQ+7IU%`'F)^#_`(#;[UAK38Z9\:^.CC\_$M)_PIWP#_T#M9_\
M+3QS_P#-+7I]%`'F'_"G?`/_`$#M9_\`"T\<_P#S2T?\*=\`_P#0.UG_`,+3
MQS_\TM>GT4`>8?\`"G?`/_0.UG_PM/'/_P`TM'_"G?`/_0.UG_PM/'/_`,TM
M>GT4`<-HGP[\)^'-035-)L]3AOHHY8HY;GQ+XHU.$),@5P;35=:O;-F8`J&>
M!G0D-&R,!N[@?_J[?IV&<D`\@8R`>`M%`!1110`C?YXSU!!R#P<@D8/!)`/!
MK\IO^"A7[8/_``2?^"7C3X8?#7_@H9<_!'Q'X[M-+NOBQ\,/"7Q.^!-S\>M:
M\(:='JT6A?\`"=Z-96OP_P#'<G@=]0U?3#I^G:UC1[K5;K1+J.RFN&TB<P_J
MUU('3)QD_0G^F![U_+U^W)\3/VCO%?QF^%_[3O[.O@G_`(+5_LZZ_P#&+]E[
MP?X?\;^#OV;OV$_V1?BW>Z7IW@[XG?%._P##7AGXW/\`&/XBWEUX>^*&BW7B
M+7=3L-`TB[UC3=.\*^)+*[L]8CE\0:M9*`?T8?!KQ#\*_'_P_P!"^+/P;MM%
M_P"$'^-%E8?%FPU[1_#3>%9?&9\8Z787=MXPUS3[G3-(U:;7=6TN+3EO+K7[
M--::&WMK>]*M;+&GJH`'`_SGFO$/V:-0\4ZM^SS\$M3\<7GQ.U#QC?\`PN\$
MW?BB_P#C5X2\+^`OB]>:[/H%E)J=S\3/!/@F>Y\(>$_&\MVTK^)/#_AFXGT/
M2]4:YM-,FDM(HV/M,HD9)%B=8Y3&XBD>/S4BE*XCD>+?'YB(Q#M'OC+XV[U`
MW4`2$G/(8`X`..I)QQZ^N!@X'&=V47D$`C!(SC!_'GV/'3N#D94'^9+5_$/Q
M[_9N^"7_``7GF?\`:1^+'Q,^*W@CQ[\$+6'X[>([_0_#?B?P9#\0OV:O@5!X
MP\3_``^TO0+'3_"7PLT3P!I_BWQ'XE\':5X>T^.V\*MIT6IR7FH:HEQJ$WZ!
M?LO?!;X<_L@?M_\`Q/\`V9_V=-*U+P;\"_%_['GPW^/'B?X:/XK\:^+=#\.?
M&"W^-'Q!^'T?Q$L9/&>O>(KG3/$OQA\+P75IXVOK>\BN/&FH_"VR\0:X+_7(
MM0U.[`/UL[K_`+R_^A"O+O@I_P`DJ\$_]@@_^EEW79ZWJVH:4+1K#POKGB<S
MS,DT>B7/AJV>Q1%1EGN?^$D\0:!')%(Q*(MG)<S;E;S(T0!SXC\'O%OB*#X8
M^#(HOA;XYNT32.+BWU3X9+#(#>77*BY\?P3CM]^%.3C!QD@'T917GG_"9^)O
M^B2>/_\`P;?"O_YXM'_"9^)O^B2>/_\`P;?"O_YXM`'H=%>>?\)GXF_Z))X_
M_P#!M\*__GBT?\)GXF_Z))X__P#!M\*__GBT`>AT5YY_PF?B;_HDGC__`,&W
MPK_^>+1_PF?B;_HDGC__`,&WPK_^>+0!Z'17GG_"9^)O^B2>/_\`P;?"O_YX
MM'_"9^)O^B2>/_\`P;?"O_YXM`'H=%>>?\)GXF_Z))X__P#!M\*__GBT?\)G
MXF_Z))X__P#!M\*__GBT`>AT5YY_PF?B;_HDGC__`,&WPK_^>+1_PF?B;_HD
MGC__`,&WPK_^>+0!Z'17GG_"9^)O^B2>/_\`P;?"O_YXM'_"9^)O^B2>/_\`
MP;?"O_YXM`'H=%>>?\)GXF_Z))X__P#!M\*__GBT?\)GXF_Z))X__P#!M\*_
M_GBT`>AT5YY_PF?B;_HDGC__`,&WPK_^>+1_PF?B;_HDGC__`,&WPK_^>+0!
MZ'17GG_"9^)O^B2>/_\`P;?"O_YXM'_"9^)O^B2>/_\`P;?"O_YXM`'H=%>>
M?\)GXF_Z))X__P#!M\*__GBT?\)GXF_Z))X__P#!M\*__GBT`>AT5YY_PF?B
M;_HDGC__`,&WPK_^>+1_PF?B;_HDGC__`,&WPK_^>+0!Z'17GG_"9^)O^B2>
M/_\`P;?"O_YXM'_"9^)O^B2>/_\`P;?"O_YXM`'H=%<?I'B/6]3O4M+WP!XL
M\/6[QRN=3U>_\"7%C&\:Y2*2+0?&.L:D7G;Y(S'8O$&R9I(TP3UXZ?R)ZX]_
MITSWQD<&@!:***`$(!P"<`GD^G?\.<8/8XSD<'^/G]N3_AJ?]M+XK3^/_P!H
M#_@C-^W5KOAS0O@K8_#W]FSX?']O;X,_`[0_AE^TB_B;QSK-Q\5="3X:?&_2
M(]=\8>,],OO`6FVNOWL/B3Q'X3A^&P@T#PIKEKKMV;'^P?KP.IX&/7KG\,9_
M"OX^?^"O/Q(_9,^/?[1-I\2KB']C#_@I7\)-;_9)UWX"_"?X:/\`\%&?V=?A
M!_PR9^T9?^,O$^MZQ\<KC2_&OQ.T'1K/3OB5H&K>`=%U'XP>"[C4/B9\.#\(
M+:TLM*>SURT<@']/7[(%E\5--_91_9JTSXYS>+[CXTZ9\"/A3IGQ9NOB!<Z%
M>^.+OXC:?X*T:S\9WGBV\\,W^JZ#>:_=^((;^YU.[TO4KZVNKN66=;J=I&D;
MZ,KYQ_8\TKQ1H7[)O[,VA^-_B[HGQ_\`&>B_`3X3:1XL^.7AO6HO$OA_XN^)
M-,\#:)8ZW\1-%\20RS+XBTSQ;J<%UK5EKSRR3:S;WD>IW#&>ZDKZ.H`\4MOV
M=O@K;W_QYU";X=>']6/[3T]E+\?-.\0PR^)=`^)T=AX`TWX7QV/B/PWKTVH:
M%-I-QX#TBQ\-7^CPV$.EZG81O_:-K<2W%S+)QO[-O['G[/O[)=KXM@^!W@[6
M-#N_'<OA_P#X2SQ#XN^(/Q&^*WC'5]+\&6-YI7@3PM)XW^*OBSQGXMB\#_#_
M`$K4-0TWP#X'MM9@\)^"[+4=2A\.:/IXU/4&G^G:*`#NO^\O_H0KR[X*@'X5
M>"<_]`@_^EEU7J/=?]Y?_0A7EWP4_P"25>"?^P0?_2R[H`]0P/0?D*,#T'Y"
MEHH`3`]!^0HP/0?D*6B@!,#T'Y"C`]!^0I:*`$P/0?D*,#T'Y"EHH`3`]!^0
MHP/0?D*6B@!,#T'Y"N"\=^)M:\.)X;M?#VDZ5J^K^*?$L7AZSBUO5KW1=+M<
MZ1JFKS7=S=Z?H^N7;E8M*D@AABL</+.I>:&-'+=]7E_Q$_Y#OPB_[*4G_J&>
M+Z`(?MOQK_Z%3X4_^%]XS_\`G:T?;OC7Q_Q2OPHYZ?\`%?\`C+\_^2;=/?I7
MH6N3:K;Z-JMQH-C:ZIKD&G7LVCZ;?7K:;9:AJD=M*]C97>H);W36-M=7(C@F
MNQ;3FWCD:41.5`/QNOCW]O(A"_[/OP8#8!;'Q6N>&8#?@B`]#G)&XM\QZGYO
M0P66U<=&I*GB<NH*FU%K&YC@\%*3DFTZ<<35INI%6]Z44U%V3U9\?Q/QK@>%
M:N$HXO)>,<UEC*=6K"7#'!W$?$]&C&E*$''%ULDR[&4L+4FYITJ5><*E2$9S
MC%PC<^A?MWQK'7PK\*!VY\?>,A_/X:^XI?MWQKX_XI7X4<]/^*_\9=_^Z;5\
M6>!?C#_P4+UOQ!XZL-3_`&>OARL&BZO#:HFL^)KSPSINERM9VS#3/#.M[KA?
M'VE31?\`$RE\0I%8I:W%P;,QL7%II_T#\/?&'[6FH^+])LOB5\&OAAX:\%SM
M<C6=<T'XD3ZKJVG+';32VLMMIKVCK>[[I(8I8B80L<CS><GE;7[*^0XG#TZE
M2>.R6?LZ7M7"EG675*LHNFJJC3I*O[2I4<':,(1DYS]V'-=-^)@O%+*,=CL)
M@*?#/B32EC,:L##%8GPVXSP^7T:CQLL"ZV+Q]3)UA<)A(5H2G4Q6(J4Z-/#6
MQ4YQP\HU'ZE]N^-?_0J_"GM_S/WC/OP/^::]SP/6@7OQL/`\*?"GGG_D?O&?
M3U_Y)KTY'-?GS^S9\6/CE\7/BU\2O"WQ;^+E_P"%OBS+\._%\7PVT+X-6GPO
M^('[(VB6$M[8Z;:?$/P?XKTG5]?\??$/QIH-Q-I5V^D?'>/X77$L5QJ<>E_#
M*/2Y%U0_'/C[2/BW\1?V(OA1\((OVJ/#MGXTU3]O?]HGP-J/C_\`:<_:6^-?
MP,UKXQ:!\*OB?^T,FG>"/^%D_LWWW@CQ[<:U(GAK0M53P!X.\5?#;1+GP[X8
MO-(L;FWTO3HM#N_#/TL_<PWOQL'7PI\*0?3_`(3[QGGMV_X5K[C\Z!>_&P]/
M"GPI/T\>^,_7'_1-?4$?6OSE^"O[5]CX&_8J_8V\=:5#X9\'>%O%7[07A7]G
M/Q5K'BSXS^-?C;X.DT<?$/QU\/-;\8>!OC]\5=73QI\1?"WC'7_#<.I_##QU
MXXOI]4UK0-<T6WNH);J6*,_(_P"TW^V1X]_:!_9'_::\1>!_B(/#]O\`!SX>
M_P#!3KX@)XT^"'BK6]!GN_"G[/\`JWC#X!_`:>P\0^'O$%O-=ZEXF\1:CKWB
MK3=1M-431=3UCX5ZG>V4MB]OILE`'[I&^^-8Z^%/A2,=<^/O&8QU_P"J:^Q_
M(^AH^V_&O_H5/A3QP?\`BOO&61]1_P`*UXK\J+O]O+]H/QSX;^'6E:;K7P5_
M98^)7QG_`&J_B1\%-2M_V@O"EUXO@_9.TGX5?#S4_B!'\-OBAI/A_P"*G@SP
M]\2OCU\5]%T33?$/AU/#WQ-\/>`+;PWXQDN_"NM>.H?#5CJ'BG[Q_8-^/WBC
M]J+]DSX._'GQH?A^_B;XAZ=XHO=3G^%.HZEJ_P`-+PZ/XZ\4>&K*_P#`NKZN
ML>IZMX7U#3]$M;[1]5O8HKC4[*>&]DAA,RQ*`>S?;?C9_P!"I\*?_"^\9_\`
MSM:/MOQL_P"A4^%/_A?>,_\`YVM>K44`>4_;?C9_T*GPI_\`"^\9_P#SM:/M
MOQL_Z%3X4_\`A?>,_P#YVM>K44`>5Z)XJ\;)XTT[PAXQ\.^$]/\`[:\+>)_$
MNEZAX8\3:SK6W_A%=7\'Z5?6-_;:OX4T#ROM?_"96<UI<6\\^PV5U'-#ME1J
M]4'Z]_<]SR3U]R?K7F&K?\EG^'__`&2[XQ?^I?\``ZO3Z`"BBB@!#G@@X(/7
MW(('ZD#^?%?R.?\`!3OX??`3]GW]I/Q%\+/@A\&?^"`_[-WACP?^R-:?M#7E
MG^W?^R-\._#VK_%;Q1?^-?B3H<^A?"CQ)H^FZ+I7B.TTZT\%6@\916&FZOXA
M\*ZCXC\+,-"\01^*$.E_UQG\OUZ`GIWZ=._?BOY>/^"X/QGT*Q_:(\'?#'XW
M_M%?`+]CSX5?"C]EK7OVFOV?_B'\=OV/_@_^U-!^T%^TK:>,M?T/6?A)X6O?
MC5X.\9:7X8?X>Z'X8^'VK:WX.^%,>@?&CQZ?BAI-UH6OVMMX=@W@'Z!_\$</
MVJ?B3^T+\$/%_@CXG>'_`(#:1JGP*3X*Z=X9E_9O\&>(?A;\-[+X?_%[X"^`
M?C5X(^'^H?"/Q-/?7GPH^(GPOT'QE:^$_&'@>UU.\TS3XH=$O+*.QCOC:1?L
M*.G^1^G./IDXZ9/6OG']DC6?$/C3]G+X-_%3Q[\)-&^"'Q9^-'PT^'OQ>^-7
MP\TG2;72)]#^+OCCP1X>U+QM:ZX(8H[Z\UW3]0QI%U=ZW+<ZZD&FVMCJ=R]Q
M983Z.[<?AZ4`>;?&3XN>`/@%\)OB3\;_`(K:\GACX:?"3P1XE^(GCOQ`]M=W
MW]D>%/"6DW6M:W?)8V$-Q?7TT%C9S&"QLK>>[O)_+MK:&2:5$;P#]F?]L_PU
M^T?XN\>_#34?@Q\?OV<?B[\._"O@'XA:S\)?VD/"G@OPQXVO_AG\3[SQ9I7@
M?XB:&WP^^(/Q,\+ZAX<UC6_`?C/P_=V;^)+?Q5X:U_P[?:5XL\.:%=/9QW5O
M]OGPA\:?B!^QE^TEX&_9[T[2-9^+_BWX5^(?#WA30M9M?#=Y!X@M]42.T\4>
M'+&#QE!<^#6\1^(O"$FOZ-X4?Q?`_A.#Q1>Z/-XD*:+'?./SX_X)A?"#3_A_
M^T'\;/%/P&^!/[6GP/\`V7O$OP%^"/A;7(OVWKWX@ZI\6_$OQV^'^K>+-/TG
M2?A[J'QI\9_$#XQ0?#KX=?#:_;1/$MAJ'B"/X1CQ1J^F3_!C3Y`_CS5M2`/W
M$[K_`+R_^A"O+?@J0/A5X)R0/^)0>_\`T^7==KK6C3ZR+18?$&O^'S;S-,SZ
M%-IL37890JP7G]HZ7J:M"A&Y%B6%M[/N=AA1X?\`!_P5?W'PQ\&3+\0OB#;A
M](SY-M?^'%A3%W=`A1+X9D?MW=L<`'`H`^C,CU'YBC(]1^8KSS_A`]0_Z*3\
M2/\`P8^&/_F5H_X0/4/^BD_$C_P8^&/_`)E:`/0\CU'YBC(]1^8KSS_A`]0_
MZ*3\2/\`P8^&/_F5H_X0/4/^BD_$C_P8^&/_`)E:`/0\CU'YBC(]1^8KSS_A
M`]0_Z*3\2/\`P8^&/_F5H_X0/4/^BD_$C_P8^&/_`)E:`/0\CU'YBC(]1^8K
MSS_A`]0_Z*3\2/\`P8^&/_F5H_X0/4/^BD_$C_P8^&/_`)E:`/0\CU'YBC(]
M1^8KSS_A`]0_Z*3\2/\`P8^&/_F5H_X0/4/^BD_$C_P8^&/_`)E:`/0\CU'Y
MBO,/B&0==^$6#G_BY2_^H9XOJY_P@>H?]%)^)'_@Q\,?_,K7#>*O#%UI'BKX
M17<WC#QCKB?\+%,?V+6[O1IK$E_!?B\"5DL-#T^8RQYS&1/M#`Y5@30![X0"
M,'_/^1Q2!?ISC.>>02>_?)SZ`C(')K/UF\O;#2-3O]-TN76]1L]/O+JQT:"Y
M@LY]6O(+>26VTV&[NBMM:RWLR);I<3D0PF3S)#M4U\EQ_';]I5@I;]CO602%
M)7_A;OAG@]QDZ$`><C)')P!@$&OA^+/$/AS@JO@L/GE#BNK4S"E5K8=\.\`<
M><94E"C.%.HL3B.#^&\]H8*IS5(^SHXVIAZU6/-.E3G"$I1^ER'A+-^)*>)J
MY95R&G#"3ITZRSCBSA7ARHY58RE%T*/$.=975Q4+0:E4PL*U.G+EA4E&<XQE
M]B8SU)_S]<_XY)YYIK1JZLCJKQNI1T8!D9&!4HR$%2I4L"K`JP8JP(Y/Y8?!
M?]L[]H[X@:[JNF1_`W3_`!X;/11J']G:%=77@2XM0+^WMOMLVH^)!JMK>0D3
M>1_9]O#'<[W$_F>5#(A^N_`GQ;^.'B+Q5IFC>+_V:-5\#>'KTW*ZAXJE^(_A
M[6(=($5M)+'+-IMOIMG<7$<LJ"`BWF\V)I(W"2(C5^<\"?24\,_$7"Y9B^':
M/']2GFV8K+,)5K>%WB)4P*Q3Q,<(OK.>Y?PWC^','AXU9)U\3B<XI8?!4^:I
MCZF%A"HX_8\5>#/&O!U?&X?.:G"<*F7X3Z[B*=/CGA"GB_8>P]N_8Y5C<YP>
M<XBK*FK4:-#+JE7%24882%>4X*4GP?\`V-?V0?V>O$5WXP^`/[*G[-?P.\6W
MVD3>'[[Q3\'?@7\+_AEXCN]!N+FWO;C1+K7?!7A?1M3GTB>\M+2[FTV6YDLY
M+FUMYW@:6&)E[GQK\!/@9\2_`>K_``I^(_P5^$WQ`^&'B#5;OQ!KWPV\;?#?
MP=XJ\!:WKE_K%QX@U#6]7\&Z[HVH>'=2U>^U^[N]<NM4O--EO;O6+BXU&>9K
MR5YY/C']E[XL?M+?%6[^(G@V/7M3\>?"%?!^L)\+/VR_%WP6NO@EXF/C.XO-
M0TS2M,7X/>);A;+XTZ=I$+V^N0_$_1-`^%W@O4AID>EC0-=.JR:K;?`OC_0/
MB]\3?V(OA/\`!R+]I_P^WC75OV]_VB?!.I^./VE_VF?C1\`-<^,N@?"KXG_M
M#"P\%I\2?V;IO"?C^36)!X:T+5%\`^"/$/P[T:?PYX9O-)L9[32=.CT>X_?C
M\I/W;\6_!_X2^/OAQ<?!KQY\+/ASXU^$-YHNF^'+SX4^+O`_ACQ'\-[KP[HW
MV0:/H%QX$UC2[WPO-HVE"PLAINER:6]C8&UM%M8$$$3(R#X-_"&TT/7_``O;
M_"GX:VWAOQ9HTOASQ5X=@\!>%H-#\3^'KB74YIM!\0Z.FEK8:UHL\^M:S/+I
M>HP7-C)-JNJ.T#/>W3S?D_+^T)9:9_P2`B\2^"M<\2?!_P`1^*]$UK]F/X9^
M/-"^/>O?%+3?#_QA\5?%'6?@%X,^)NB?M3?&R^N/$6O?""^^(<]MXLT?XS>-
M;MO$D7P\N[74-/@F\3)I.G2[_P#P1R^-^B^+OA=\8OV<=0\6>,?$?QB_97^)
M4GAOXVZ'XB^(WB#XR>%_A9XF\=2ZQK&F_"CX5_&/X@?$'X@_%GXN?#7PSI.C
MKJWA?XB?$75)M3U?2/$UAILMS9:WH_B3P5X(`/K_`/:Q_8D^&'[5_@S5?"NL
MZA-\.[[Q%XG\,^*O%WB/PKX`^"OC%OB)=>#]-NM(\.:;\4O!_P`:/AC\3_AY
M\3=)T&RN5?PW!XT\)ZO<^%]0L=,U'PW=Z5=6,+'WKX*?!WP5^S_\*O!'P;^'
M5I?VO@[P!HJZ-HRZI>R:EJMWYES<:AJ.JZM?-%$;O5-9U6\O=6U.XC@M[=[^
M\N3;6EI;^7;I^>GC?X]_%0_$7XK>'OVFOB=X@_8B^&.A^!/C7)X5E\)?#\Z]
MH_B3P1I'A+5/-^.=S^UOJ5MXB\"Z#X@\#Z`S_$+3OAJO@_P-K?A.^M0WB"X\
M<V%@QB_.'P?KESX5UWXR?LD>(/CA\0/"?[.VJ?MF_LJ^';W6/#7[<WQ,^.W]
MA_L\_&SX:?&"XT2UMOVQ?$_B#1OCOX`\<_M`_$SX1:/)\3OA6NMZ%'\+[3QY
MX<LOA;XX\1:+\2H-><`_I[&><\$=0<9'?!QTX(/MG&2`&8R>0!SGCOGIGITZ
MX/<#YL$8!_'7X=_M%:_\`O\`@G3\=/BIX:\>_P#"SO"O[/'Q@^+7@3X2_$SX
MK>+M2\>0Z_\`!7P1\<X?`^C:SXJ^)>I:O+J?CJQ\)^')M7T0_$+6/$%[>:O:
M^&8=9US6M2N%OK^?BOVE_P!K?7OC-X3_`&U_@QX#^(ND:+9?#KXH:[X!\,^/
M?A3XKU+2O$6G^%?AQ^QCI'[4GQ$NKSQ=X9UQ;ZTU73/%=_I7A*\NO#\]K+I]
MMXAT[3KR+[3+<EP#]OL\X_(<@\>OI@@CW_V<#>ZOP&^#_P"WY^T)XN_9B^%J
MVNI_#KX"_%+Q[\5/V?/V9=&A_::T>^\6>(?@#9>(?@,?B1#\9OCY::%\2M'L
M?B3XH^/6FZ;;ZK\)?"VB>/O"_ARZNO%'AO1M4^(NJ^*+?Q386WZ6_L'_`!^\
M;?M)?`23XB_$&_\`A5K/B;3OBU\<OAI=:]\$KW5-2^%WB*V^$WQ7\5_#NP\0
M^$+[6+J]U"XT_6K7PXFHRB>[NQ:WEQ<6,5Y>Q6R7MR`>^ZM_R6?X?_\`9+OC
M%_ZE_P`#J]/KRC6H&D^-WPVG%U<Q+;_"[XT%[:)H1;78E\5_`Y%%T'A>4^0?
MWL!@F@(DSYAD0E*]6!R/\_7'X9Q[XSQT``M%%%`"'IZ]"!ZGL.A[^Q.>G.*_
MFR_X*P_M)?%#PI^V3X4^#>F_M5_M1?`OP%X>_9R\&_%W1_#W['7[!OA+]MWQ
M=_PL'7OB;\1?#5_XG^,!\2_##XFWOPQM;C1_#.D6OP<N=%L=+37+G2_BC-J>
MK6MSINCVFI_TFGI_3USQ@_7/TSC/%?S5?\%3M)\8>)_V]O`&D?`?Q=^W9X;^
M(LWP#\`>&?C9K/[,7[6?PC_9@^'WAWP?XL\2?M!ZU^SIIVJZ;X\\`>-]6^)O
MCWQW\0O`7Q4T)-7G_L#P;\)O#7G:UK/B:W7Q#/I5^`?O+^S+K=_XE_9W^!_B
M'5/%OC_Q]J6M_"SP/JE]XW^*W@"/X4_$OQ;=7OA^QN)O$/CWX9Q:/X>C\!>+
M=6=S>:]X330])70M1EGTX:?:"W\A/<:^9_V,/&V@?$K]D7]F/XB>%?$_Q+\:
M>&O'?P&^%7C'0?%GQFN;.]^+?B'2O$O@O1]8L=4^)=[IT%MIM[XXN8+M'\37
MFFQ?V==ZM]JN+"2:TEAE?Z8H`*/KD_4D_P`\T$XY-)GG&.W/KW_#MZ\YR.`:
M`%QRI_VE_P#0A_G\_6O+O@I_R2KP3_V"#_Z67=>H]U_WE_\`0A7EWP4_Y)5X
M)_[!!_\`2R[H`]1HHHH`****`"BBB@`HHHH`****`"O+_B)_R'?A%_V4I/\`
MU#/%]>H5Y?\`$3_D._"+_LI2?^H9XOH`]/.._P#G_(SGVSGC-&!Z5S/C7Q!=
M^$_!WBKQ38>&?$'C2^\-^'=9UZS\'^$X;&X\4^*KK2=.N+^#P]X<M]3OM-TZ
M?7-8E@6PTJ*]U"RM9+V>%9[J&,LX_'.'_@JW^T_*L1_X<R_\%"HWE5/D>T^%
M(\MI`-J,[>,`J["=I9RH4ECD\D#_`*O_`$@/VR&WG`&1UX_SZ?U]*,`=A_GZ
M=?3\2.]?S5?`G_@X>U']HGQQ\2/`/P?_`."=/[2_Q8\3>`[EKRZ\,?"[Q1\+
M_$?B?0?#%K)9>'[Z^\9Z=-XAL[>QO+?QHFJZ87T.XU;2EM'TI9KY+R26(_H7
M^S]_P4)^.?QG^+?A;X:^-/\`@F3^VI\`_#WB8ZI#>_%OXCZ?\.#X'\)-9Z9<
M7L%QXBDTWQ5<7\%K>RVRV$,MK9WTBWT]LDEI)$\C1Z5J-7#S]E6A*G-1A+ED
MK/EJ0C4@^VL91=NCNFDTTIC*,US1::NU==TVG]S3/U*+9P<\Y^4D^A'()R,`
MX)[#J1R,^0^./@!\!OB=\/\`5_A3\2?@C\(/B%\+-?UF[\0ZY\-/''PT\&>*
M_A]K?B#4-7N/$-_KNK^#-?T6_P##NI:S?>(+R[UR]U.[TZ:^N=8N;C4I9Y+V
M:2=_A/X'_M`_M"_'OP+\1?A[I7Q!\%SV:>"8+;X:?\%%O`GPPUG0/A)K7B/5
M=7M/#]HD7P:^+>IZ9I^O>-C#,^KZ'K7PR\=_%+X.ZUJ4D+7]SX>)TWPEK7R7
M\)OC9^UA\2X],_9&U[XX?M!?![QOJ_[97C7X5W/Q8^*'P^^`=I^UKX2^!?AK
M]FJ^^.WA:'7XO"_ASQ1^SG=>)_BMXCT37)/`OC/PUX9\16L?PJMGM=<TG3_B
M!8ZSI^CYE'[DZI\.?AYKG@&X^%.M>`O!>L?"Z[\-+X*N_AKJGA;0]0\`7/@V
M*PCTN+PE<>#+NPE\.3^&DTU(]-30I-.;2EL8X[1;46Z+&<CX<?!GX/?!S2;#
M0/A#\)_AK\*="TK0K'POI>C?#7P)X5\"Z1IOAG3+[5=4TOP[8:?X7TO2K6ST
M'3=4US6]3L-(MX8]/M+[6=6O+>!9[Z[EG^-/@A^U/XZM/V=?V>]>^)<%E\3?
M'GC']I35OV3?$OC33/L_A*R\17WA/XI_$CX7/\7X]%L;&_T^&;7H/AY'XCU+
MPSI8LM)BU/5KZVTV[LM/M;>-?F/]J_\`;Q^*NI?LZ?'CQ3\%9W^$'C#X,^&_
M^"B_B/5_$$%QHGC)X-#_`&,8-8^&>A:[+;ZWX<DL[:3Q;\4?$G@O6DT/[!<W
M5M;Z)KMA'=:Q'INI;P#]K;B"WNK>>TNH8;FUNH9;>ZM;F-)[:YMYXVBG@G@E
M5XI898W:.:.1'1XW(='4E6\&\/?LH_LM^$/A/XE^`OA+]FG]G_PO\"_&<VHW
M'C#X+^'O@U\.M$^$WBR?6#;'6)_$OPYTWPW;>#]=GU7['9MJ4NJZ/=/>_9[;
M[1)(((R/C"S_`."B/CKXF^$?ASJ_[._[/NB^-?%OQ]^-7Q'^&7P)\'_%KXKZ
MO\#V;PG\&-"U?6/BA\0/CJ6^%'CSQC\&-7M+CPYJUGX7^%L?@+QGX]OH]2\(
M7?BRP\%MJ.O6WA/[%_90^/%U^TU\`/A_\<+_`,!7_P`+M0\;+XG74?A[JNO:
M3XGU/PE?^%O&?B/P;>Z/?Z]H(.AZG=P7>@3-<7&CR76E^=)(EC?7UJL-Y.`>
MIV7PU^'6F_#V+X2:;X`\$Z?\*(/"LG@2'X86/A30;3X=Q>!Y-.;1G\&1^"H+
M"+PW%X4DT:2329/#ZZ9_91TUWL39/:L8JY'PE^SO^S_X`\/1^$?`?P)^#7@G
MPI!HE]X9@\+^$?A?X)\->'X?#>IZ-IOAS4_#\6BZ-HEEID>B:EX>T71M"O\`
M2%MQI]YHNE:9I5S"]C96D$?LM%`'R!^TK^Q;\)_VCOA5XF^%\MO8_#"+Q9IW
M@/0=>\0>"?AW\'M?D\1>#_AI-K4O@KX=^./!WQ2^'7C_`.'7Q%^&?AX^)?$!
MT;P!XY\(:[X:T2XU6YO]$L-.OY&N:]-_9Q_9^\!_LP?"'PO\&?AREZWASPTV
MKWKW^IQZ3!J.M:[XCU>\\0>(M;O;/P_IFA^'--EU36=1O+I-(\-Z'HGAS1K=
MX-*T'2--TFTM+*#W*B@#S#5O^2S_``__`.R7?&+_`-2_X'5Z?7F&K?\`)9_A
M_P#]DN^,7_J7_`ZO3Z`"BBB@`X)`/0G!XS]!C!SDX!&#P37\@?[:_P`!OVZ/
MVV_VM_@/^S5^V%_P3V_X)`_&7XTGX"?&+XY?#+QM)^TI^W'X6T71?AI\-?B'
M\*?!WC'P/XN\5>!_A?X1\5>)(=4\2_%;PGJFE>!-;TCQ)X"NH/\`A)+^\?2=
M0N)+35/Z_,X(/H<^O8@Y_`G_`/7Q7XD7'_!!?]DJ[\7:=X_N?V@/^"CT_CS1
MO#NM>#]%\;S_`/!0C]I6;Q;H_A'Q'J.EZQX@\+:5XEE\9/K-CX;US5=#T74]
M7T2WO(]-U34-&TN^O[:XN=/M)H@#];/@QIGC+1/A'\,M%^(?ACX;>"?'6C^`
M_"FE>+?!WP<N-2NOA-X4UW3M$LK/4/#OPTGUC0_#.J2>!=&GA;3_``N;_P`.
MZ'<KH]O:++I5BP-O'Z77#?#+P%I?PL^'?@?X::)J_B[Q!H_@+PMH?A'2]<\?
M^+-;\=^.-7L-`T^#3;74O%OC3Q+=W_B#Q5XAO(K=;C5M>UF]NM1U.\DEN[N>
M6:5W/<T`?$W_``4<_:'\2_LH_L/_`+1_Q_\`!S3P^+?A]X#$GA>^M/#7_"9W
MFC^(/$VN:/X-TC7[+P<TUNGBZ_\`#U_XAAUNR\+2S10^(KJP@TB9Q%>2$?)/
M_!.K7?BUX*_:$^/7P%^,OB3]L72M1E^&GP^^+WP_^&O[9OC?X1_''Q/K/AN[
M\9^/?"/B/XQ?#WXV_!SQ1JNCZ#:^(+JV\+Z1\3OV:]:TB&S^$/B2W\.ZQ\.M
M8O/"7CA[:V_4CXO_``E^'WQW^%WC_P"#/Q5\.VWBOX<?$[PIK/@OQIX>N)KJ
MT74]`UVSEL[V."_T^>UU+2]0A67[5I>L:7=V>JZ/J4-KJ>EWEI?VMO<Q_/O[
M-?[&^B_L^>,/&/Q*U_XU?'']H_XK>+_"?A+X;+\3/V@/$?AKQ%XG\-?"SP)?
M:YJ?A?X?>&D\)>$O!NBV-BVJ^(-1UOQ=XAFTJY\8?$/7ET_6?'.OZ[>Z1I+V
M(!]5:[XCLO#PLFO;76[H7MP8(1HN@:QKKI(@1R;F/2+.\>UC(9522=45VW*A
M+*0?#O@_\1]$L_ACX,MY-*\;.Z:1@M!X!\7W$1S>7?W98M):-A[JQQT.&RH^
MC^0P()Y(Z$C(!!(P.O&3C!)!/'`SA>&/#]EX5T#3/#NFR7+V.DV_V6V:YE\R
MX9/,DE)F=%16?=(PR%`VA1SUH`Y7_A:.@?\`0(\>?^&Z\:?_`"GH_P"%HZ!_
MT"/'G_ANO&G_`,IZ](Y_O-_WTW^-'/\`>;_OIO\`&@#S9OBEX?569M)\=JJJ
MS,Q^'7C,*JJ"S,Q_L?A54$D\8Q^!KV7Q=\*ZE966I6%AXWN[#4K.UU"PNX/A
MYXSD@N[&^MX[JSNH'&C@/#<6TT4T3X&Y'4X&<5Z9,GFQR1%FVRQR1-ACNVR*
M48@\\@-D>A&<'MF>'M&M?#>@:)X=L)+A['0-'TS1+)KF7?<-::5906%L]PZ!
M%>=X;=&E=457D+,J@$``''_\+1T#_H$>//\`PW7C3_Y3T?\`"T=`_P"@1X\_
M\-UXT_\`E/7I'/\`>;_OIO\`&CG^\W_?3?XT`>77WQ>\*Z98WNI:A8>-[/3]
M.L[O4+^[G^'OC.."SL;&WDNKR[G<Z,=D%O;Q232M@[41C@XQ5D?%+P^0"-)\
M=D$`@CX=^,R"",@@C1\$$$$$=:Z_Q%HMIXE\/Z[X;OY+A+#Q!HVIZ'?/;R;+
MA+/5[*>PN7@=PZQS)!<.T3LC!9`K%6`(.N@*JJY8!555^8@X50.<'&>#G'!.
M2"1@T`><_P#"T=`_Z!'CS_PW7C3_`.4]'_"T=`_Z!'CS_P`-UXT_^4]>D<_W
MF_[Z;_&CG^\W_?3?XT`>5ZA\8?"6DV5SJ6IV?C6QL+-%DNKNY^'OC.."!'D2
M%6D<Z.<!I9(T'!)9P.]>??$OXCVJW'@'5M/\&?%37T\->.HM4U6QT+X9^++S
M4XK%_#?B/2S<1VDNG6QFCBO;^UCF$3O)&KF0JRHV/=_$V@6?BG0M1\/ZE)<1
MV.IQ1PW#V\HCG58YXKA3&[AU4F2%0V4/R;@,D\;V2><GDG^(\<DX'(Z=,8'3
MD<4`?-Y_:4TP_P#-&OVDOP^"7BL'\]G'U'([8-'_``TKIO\`T1O]I/M_S1+Q
M7VYZ[<\GK@C=C!XKZ0Y_O-_WTW^-&3_>;_OIO\:`/D6V^/'PW\(%]4L_@#\;
M/#+3R6FF/J%C^SYK&DR2OJ5_;6MG8O<V=E#)(+W4I;6*.%V,<ER\.Y=P##JF
M_:3TP[E;X-?M),#D,#\$O%95@001@KP"I/`QZG)%>ZZ_H=GXBL%TZ^DN4@34
MM$U3-O)LD-QH6LV6N62EF5P8GO-/A2=,!GA+HK*S*1MYS_$>?1CCU]?Q_6C?
M5[]P/QY\(?LR?L:^$-&\=>&9?V?/V^_B%X2^)/@*Y^&GC#P7\<?B+^VS^T#X
M)OO"5S>Z=J*0:?X/^-WQF\?>&_#NMZ9?:3IMWX?\6^&],TGQ9X:N+.";P]K6
MF21JPU(/V=_V+X/A%J'P67]EG]L&;P[JGQ"M_BY?>-KM_P!J*^^/LOQ6LM-&
MAZ?\2U_:<O/B//\`M%0^.]-\.#_A%--\40?%"/5[#P<TO@^UNHO#$\VDR?KE
MS_>;_OIO\:.?[S?]]-_C0!^9?CCPY^RCXE_9^\)?LOZ]^R[^T/X<^"7A6;P1
MIOPZ\,^"_AW\6_AGK/@K6_!FH6^H^!=6\`>/_`&O>&_B'X1\::1JEDFH6/B[
MP]XJTWQ/+?O>W5WJ\\^H7SW.9H7PE_8Z\,?#GX@?"3P_^QM\>=*^'GQ1\$^*
M/AWXY\.6WPI^*7EZWX/\;^(/%7BSQCI?]H2ZP^K6,GBKQ/XV\3>(?$&IV%]:
MZMJ^L:I)J%]?374%K+!^ENM:)::V-+%X\ZC2=:T[7;;RI`K->:9(\ENLI97+
M6Y,C&9%PS+P&'.=D$X'+#.3C<1U.3T(SR>O>@#\5/VO_`($^#_VA?#FJI\)_
M`7QM^"/C_P`0_&3P[\;_`!+XOU3]G?\`:#UZSOO&N@>!;KX=MXB\.'X1_'/X
M`_$+X6^--6\*/8:-X@\;?"GXD>#M4\7Z1IYT'QS%XITC4+ZU;Z8_92NO`?[)
M?[.WPF_9T\%_"?\`:7U/PW\*?#"^'[#49?@'XATH7TT^H7VL:G=6VDV0DMM'
ML)]5U2]DTW2(9KE=+T]K:P:\O6MC=2_HI^)_,_X\?_7/J<F2!]X@#_:(_7KW
M]?Y#`!\RW'[47A^TEL8+OX2?M%VTVIW9L=.BF^"OBI'O+Q;6YO6M[=2F7E6T
ML[FX*CI'"[9XJV?VE-,!Q_PIK]I+C_JB7BO_`.(KW/5M#M-7O?#]]=/<+-X;
MU:36;`1R8CDNI-*U#266Y!5R\/V;4[@A4P1*J,2%!#;8/^TW_?1'L.`<#..@
MX[`D4`?.'_#2FF?]$:_:2_\`#)>*_P#XBC_AI33/^B-?M)?^&2\5_P#Q%?2'
M/]YO^^F_QHY_O-_WTW^-`'S#X>^*5GXV^,?@F?\`X0GXH^#;6W\#?$CP]!>_
M$'X?ZYX2LM1US7M8^'&NZ?I>G75_'Y-S=MI7@OQ%?2(7B6.&R"M)YD\"2?3H
MY_7\L\?F*Q-5T*SU>^\/W]T\XF\-ZM+K&GB*0!'NY=*U'1V2Y#*Q>$6VIW#A
M59&$JHV[:A5ML8``'X>_<GW)ZD_C0`M%%%`!1@>G^3U_.BB@`HHHH`*,#T_S
M_D"BB@#X1_X*!>._B#X9^&OP?^'_`,-O&OB#X9Z]^T;^TW\&?V=M1^)GA*TL
M+GQ;X"\(>/\`4]2O/&FM^$;C5;/4=,T?Q7=^&?#^I>'_``[XAO=/O1X>U;6K
M76;2VDO[*T`YK]A[4_'7@SXC_M>?LK>+?BC\0/C5H?[-OQ'^&@^&WQ'^+.NP
M^*_B?+X*^,/PFT#X@KX.\;>+XK*PN/%E_P"#_$DNOPZ9KNL0-KDWAO4M$M-3
MN[Z2RBN9OJ+]H?X!>#OVD_AI=_#;QCJ/BGPZ(]=\,^,O"/C?P)K3^'/'GPZ^
M(/@C6K3Q'X)\?>"M<6*YCL/$7AC7;&UOK5+VSU#2-3M_M>CZ]IFJ:)J%_IUS
MSG[-7[-.B?LX>'O&4`\=^/OB_P#$3XG^,Y_B%\6OC-\5+KP]=?$#XC^+&T?2
MO#6GW.J)X3T#PMX4T71?#GA;0=$\,^%?"WA;PYHGAW0-&TR&"RTY)I[VXN@#
MZ4'(!]:*/K10!^6G_!4;XU_$SX?^&OV:O@Y\)D^-(\5_M4?'^7X1RR?L\S>#
M-(^,%UH>A_"?XC_%/4M`\'^-_B#J>D^$OA9+XGF\#66BZY\5=3NO-\!>%[G7
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M\4OB9JMAK'Q`^)GQ$\2I90:OXI\27&C:7H6@6(2PTS2M#T#P[X:T+1/#/A?P
MWHVCZ#H6DV5AI\,0`/H.D/XGUP<''<`Y'/ISC(![9I:*`/RNT+Q[^U+IW_!7
M+2/A;\2OBAX5NO@#XL_8H_:,^(_PS^#G@/P_J&FV.CW7@+]H#]E[PGH_CKXD
M^)M;O+K4?&7Q(U71_'VN:<MKIEEH'A+P9I2S6>D6FL7VM:MK,GC?PWT3XX?#
M7]N[X0_#7PO^V;\;?VK/B;<0>-?&7_!0GPOXC;0$_9K^$7PP\1^%/$.H?"$>
M&?`%C:WL'[/OQ%U?Q]_PC&G_``A\`>'?$^I>*_''PZTWQUXK^(']KZ3IUIX@
M;]/M2_9]\(:E^TQX1_:HEU'7XOB#X,^!'Q(_9]TO38;FS'AJ7PA\3O'_`,,/
MB+K>HW5E)9O=2Z]::W\*/#L&GW`O4M(K&YU.*6SGDFBEB^/_`-D'_@G#K7['
M6LV<GA']M7]ISQ_X*N/%WC?X@>.?A_\`$?1OV==0MOBQX^^(,U[?^)?&WQ0\
M?:'\$-$^+7B_Q5>:O>1ZA_;NI>/I-0$>G:5HQF.@:=::7$`?IN.@_IT_"@@'
MKGKV_P`]1U'<'!!!`(`,`#T&**`/RM\.^/\`]J/3_P#@KG9_"SXF_%'PI=?`
M/Q1^Q)^T#\2OAG\'?`?A^_TS3-"G\$?M"_LV>$='\<_$?Q+K=[=:CXQ^)&JZ
M)XWUK3VM]-LM`\(^#=*6:QT>RU:\U?5=:G_.+]@[]I7]I?QE^U9^SMXT\:?$
MC]IW5?AQ^TWXK_:DM/$GQ1^*][X/O/V"_P!HGPSH4WB;7OV;M+_8'\,:*)OB
M+\.=;NO"-A8^,-&U?XF^%_A/;?$+X?>&?B'<S:E\4]9D\(WP_??4/V?/!FI?
MM,^%_P!J>XO==;Q]X4^`WQ!_9ZL=(%Q:GPK<>#/B/\0?AO\`$;6KZ]L6M&NY
M-<@UGX8:%:V5P+Z.U33KK4X9+.>66*6+Y8^"?_!-'X8_!'QS\-=6TOXP?M`^
M,/A)^S_J>OZW^R_^S3XU\9Z+>_!3]GC4/$6C:MX:D;PA9Z3X6TCQKXOL/"7A
M?7=6\)?"C2?BGXP\<Z;\)O#&HW^E^![;2A-%/$`?H^.@I,@%2>QS]3@X`SQD
MDC'3IG(QFD!'`Z=!Z]A_B!Z]^G-(22#MR"`2"!D@X.UA\K+E6[.,;AR".:`/
MPX\*'XK_``._;3^''AJ/]N/XN?M&^+M(T7XB_$[_`(*46/CJ^\,:3^R?\!_@
MA?>!O%>O?#?5=/\`"/E7&F_LV>,Y/&5OX<A^%W@_2?%M[XD\8_##1?B%XS^)
M$NK:%I$/B$:'[&?[8?Q+_:6_X*&^.=5O?B3I<'[.?Q,_8F\&?%G]F[X&6.IZ
M8VI:)X8C^.7C3P[I_P`6/'%I#<RWK?$3XO\`A6WTOQD^A>6C>`?A_>>#_#^I
MQ#Q(WB$+[7^R_P#\$Q%_9B%]X>@_:]_:'^,/PG\5ZW\2/$OQ:^#_`,8O"O[-
M/B?PS\=O$?Q8CU-?'FN_&CQ1:?`K3/B7\0M5U^?4Y'U&\U_QM=27.G6EAX<N
M-_AFRMM&C]?^$?\`P33_`&)_@'^T@/VH/@;^SC\$_@UX_B^$:_!^RL?A5\'/
MA7\/-!TO2G\2ZCXAU+Q'I<7A#P?H^HV7BO6X+]?#>MZI!J$::EX;L=/TNY@E
MAM(L`'WA5/4%O7L;Q-,FM+?4GM+E-.N+^UFOK&"_>%ULYKVRM[NPGO+.&X,<
MMS:0WUG-<1(T45U;R,LJ7*S-:T?3?$.D:IH.LV4&I:/K>FW^CZOIUT&:VO\`
M2]4M9;+4+*<*0QAN[2::WE"D$I(V"#0!_-GX_P#C]^TS_P`$Z_'G[2.F^*_B
MU^U+\9M6\+_\$[?VF_CZOC']J2Q\(:Q\'_VEOVH?@AX8\!^,X/$'['OA+X<R
MZD_P4\!^`K'7?&4GQ2^$?BS7/"?]K>']3\(P>`_"_BK_`(0?Q7\0Q]_?L^>&
M/B_^RU^V/\/OV>/%W[3?QF_:@\*_M$?LJ_%+XV>)-2^-^N:+XBUCP=\:O@/\
M0/@;X6\1^(?AS_8^CZ)#X+^&_P`5-+^/#O+\-[6*Y\*^$=3\$:)_PAT>EKJ6
MNK?=Q\,?^"8?PD\(7GD?%+XJ_'C]J+P9X<^#_CG]GSX1?#O]H;QEI/BCPO\`
M"#X*_$W1K;PQ\0_!NC3^'_#OA?Q#X[U3Q;X/L-+\%ZA\1?B[K/Q`^)-OX1T]
MM#T[Q790:UXE?6O2?V8_V'/#7[-_C/5/B)J?QI^._P"T+XXC^'NC_!;X?>*/
MC_XH\.^*=9^%'P.T/4X]:M_AIX.N_#WA7PL]\-=UBST34OB!X\\7GQ'\1_B1
M>>%/!D_C3Q5K#^%-&\@`^X*Y/Q[IOB_6?`_C'1_A[XGT[P3X^U7PMX@TWP3X
MSU?PZOB_2O"/BV]TF\MO#WB?4?"CZEHR>)K+0=6DM-4N=`DU?3(]7BM6L)-0
MLTN&GCZL<`#T`KC?B-\/_"?Q8^'_`(W^%_CS2VUOP3\1/"?B#P1XNTA+_4=*
MEU+PYXHTJZT;6+.#5M'NK'6-)N9K&\F6VU72+ZRU33KCRKW3KRUO((9XP#^;
M3X@?M1_M"?\`!/Z^_;W\"7WQ2_;!\2KX#_9B^&OC7X0^*_VN-"\(_&CQE\5/
MBSK?QVL?@9\5OVB/V4]'\"32>']0^%G@9OB9\*=2U'X!>,-9\.ZE+XSU_P`%
MV6@_#?P=X0U34-0\3??'_!.3Q%\5O"7QS_:-_9_^,OB/]L+2]7TOP-\+?BQX
M'^%_[:7C'X,_&WQI)X7\1^*OBCX5U?XM?#[X]?!/Q5K.@W7A[QE=>'M"TCQK
M\!M8TRUD^"7C'0XKWPEJ^H>"_B)I$-E[!X?_`."9/PKU#2_B9IW[17Q?_:#_
M`&P;GXA_!G5_V<].UOX_^.-(EUKX<_`[7=0T;6]9\*>!+OX:>&OAXMAXN\0>
M(_#'@WQ-XI^,NHQ:E\8?$/B'P%X#U2]\:F?PII1A]B_9I_8^T[]GWQ5XZ^)7
MB7XU_&K]I'XO>/O#?@KP!J'Q5^/.K>#]2\3Z-\,?AQ<^)+[P9\/O#5CX%\'>
M"/#.CZ/:ZGXNU_7/$NI6^A_\)'X]\1WZZ[XUUC7+VPTLV0!]B5Y)\>/C?\.O
MV;OA!X^^./Q9UH:#\/\`X<:!<:_KUY'&EQ?76UXK73-$T2Q>6$ZKXD\2:O<V
M'A_PUHT4BSZQKVIZ=IL!\ZY2O6^E</\`$CX8_#;XQ^#-9^'/Q=^'O@;XJ?#W
MQ%';Q>(/`GQ)\):!XY\&:[%9W4-_:1ZSX7\3Z?JFB:FEK?6UM>6Z7MC.L%U;
MPW$06:*-U`/QC_9(\:_M@?M07?\`P4:^&WC_`/:ET/X4_$Y/C#\![[0%^%D_
M@SXEQ_LJ_"3QU\&?AQXQ\5?"+X=ZDU[+H%_XYTG2Y_$GA?5OC!J%CJFAQ?%2
MZ\0>*M%T+4;'1=-L6][_`."9VO>--=U?]I[_`(1?XW?%O]H_]C#2_&7@+1_V
M5?C5\</$MKX[\9^--?T_0=9@_:"E\'?$E].T[6_B9\$],\7+X7T[X?>.-8&I
M6^I^((OB#8>&=<U;PEIFC7;4/&?_``1G_8[U'X>_M7_#KX0^&[?]EO2OVP[K
MX<P?%"[_`&;/`7P@^%]W!X,^'NEZ%IC_``OT>'2/AZ-.?X9^-UT:YN?B!X.U
MFRU72/%$_B7Q:M];O#XEUB.[^S/V:?@!XU^`.D>(-"\4_M)?%7X_Z3?1^'+/
MPCIGQ'\)_`KP;I/PQT?P[97M@F@^!-%^!?PG^%6CV.BWMO<643Z=J%CJ%OIL
M&CZ?::(NF68N()P#Z<^M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`'XW?\%A?CK??L::!^R'^W9J'C3XA:!\(_P!F?]IFWM?VB_#'
M@W7O$L&C>-/@I\9_ASXS^&U['XI\&Z3J%KHOC23PW\0KWX=Z[X<C\0V5_P#V
M'J,$U[I'V>\GD\[\'?V$_BW^VW%\6OV4O^"?G[07Q^^/?B?XT?M&?M`_LH?\
M%6-:\0W?Q`^(YUC3OV4O%?[.OQ'^,?QI^`<.M/K+W\'PY\(?M"_#3P1\,+GX
M>Q:M<^'-5L_&M[IMU875A-J-H_\`9+\9/@M\)OVA?AOXE^#_`,<?AWX2^*OP
MO\8PV5OXH\!^.-&M-?\`#.N1:=J-IJ^GKJ&F7J/!,UCJEA9:A:28$EO=VL,\
M3K)&IJBWP"^";_%WP[\?#\*?``^-/A#X=W7PC\+?%!/"^DIXV\/?#"\U-=9N
M/`6C:\ELM[I_A5M4#7D>CV\B6D$L]V8$C6\NEF`/Y8?!_P#P<-_M.:?\!O%W
M[5GC3]G:T\5_#7X@?LF_&G]I?X0^%+7X5?$CX4Z9\)-6^'7Q*^'W@+PAX4U_
MXO\`BKQ%K&G_`+3G@/6[+XE6.H_$?XF?"SP9X._X0'Q/X<N?#JZ!<6GBK1-3
MM,S]HO\`X*B_MH:-IGPFG\9?"KX\?$3XE?LN?\%*?V<O#UKX4^!?PH^*'[*?
MC;]LSPS\9OV3/VEO&FG?![7/V<_%_CKQSXNT/^PO&_AC2;G7;+Q-J?BOPUXG
M\&7'A+Q_H7AS4=4TZ733_2QX(_8)_8F^&WB3XQ>+?`G[)_[/GA?Q!^T%H^K>
M'?C9?Z5\*/!L/_"S?#?B"ZGO_$OAGQ;:/I,ECJ?AGQ3J5S<:MXJ\.O:KHWB?
M6)I-7UZRU#4F-T8_AE^P/^Q9\&?#/@?P=\*OV7_@IX`\-_#?XIP_'#P1IGAC
MP)HVEIH'QBMO#VI>$+7XFV]S!`+RY\;V?A+5]0\+67B*_N;K4K/PW.NA6T\6
ME06]I$`?AO\`%#_@JU^VQX(^"'[(7QYM-:^".L?`[XG_`+*R?M,?&;]J_P"%
MO[,_Q>_:(^`GA+Q+K'BV65_AW\2_`?@CXK>&?VB?V>/@GX"\'PQZ+>_M`WGP
M\^*NL>)?%H\11:M\._`4G@+Q)8+_`$U>']<TOQ/H6B^)-#O[+5-%\0:1IFN:
M/J>G7'VS3]1TO5[&#4-/O["[V1?:K*[M+F*XM+CRHS-;R1R%$+;1\3>-?^"7
MO_!.SXC)X?B\=?L6?LX>*[;PMKGC'Q#H-EK?PM\-7NGV%]\0?%]QX_\`'%J-
M/DL_L-SX?\5>-KN\\5:YX4O+>X\+:AKM]?ZC/H[7-_=O-]VQ11PQQPPQI%%$
MB1Q11HL<<<<:A$CC1`J(B(H5$0!44!5`4```?1110`4444`%%%%`!1110`44
-44`%%%%`!1110!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>pg64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg64.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!H0*"`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%0^=_:W9O17P
MK^5O<_2^!.YNV>K/C[VQOSKO""D&0^[W=M?968R^$<X]H:A<@E'6TJSM3E'$
MZQ%""&]^Z]U2#\*/Y:'\N#K/%_`7^9/A_DYV%L[Y.=S0]5;FW-\B\M\ILE5R
M_-+L'M'KMZC='3N\Z#?F<RVU=T8O>>Y'>0X#$4=)7T[8B.F@\30'3[KW01]*
M?`_XB_S;.R/GE\G/YB>=W[D/D+\<_F5WCTEM+`TGR!WAU;!\*NH^G:RBHNGL
MWLS`;8SNVZ#9F2W)@\=%NR3/Y*&HARE<!4@MX9M7NO=$=WWNOMCY%]:_R7?E
M#NGL/<?;?:_PYZ>_FF_*#KKL.+"K'F/DEMGX0?(GH#:.P]R9:CSDT:M4=Z]!
M85LC-D'U+)59!:P(R'2?=>Z,/\1]QTG?W\__`&Q\Z\+N^'>FPOEM\2?G'0]+
M9C$U%9-MB;HWXV=P[!Z#V+4X2*MEE--+N#*[2R^9J?%:GJ3DDJHP%J`/?NO=
M5V?RIOY:W<^_HOY?'?GQJ_EN[S^)6_L7O;J;N/?_`/,\R7S;I=S;?[<Z?Q^;
M^X[7QN,^+-+E9JRF7O;;57)10X>>""&BII7,C@)9_=>Z%_\`FF_S+?BQA?YF
M/<7RNJ_D#_!OD/\`RKNR_CIU%\5NAJ?"]@R-W)A5W+6U_P`_UJ=P;9VW/LFA
MIMU[+[!;;>,;+9/R)4;8JG,2Q55.S>Z]T:'^=-U/L#Y=_P`Q3HS<L/\`+OWC
M_-/V'1_RRX^WL#U]UK\BYOCKD=I[;S'>66KJ#M&ARL,]-E-_C.8:L2BI,)2Q
M3UDKU`>.%GL/?NO=<OAWM`;=_EZ?RNMR[9W/M:7I7M3^>%TIV9\=>G]G=I9S
MNG%?&3IK<$_95/A?C]7=E;IQF(W-F]T[+S=!D),S3UD*/CLG5STP5/&47W7N
M@(^5W1.WMO\`R+^77\Q/L#9/9'>6S]F?)'LG=>T?YLWP0^>.`S';?P.Z[V+7
MX"ABZ+WG\4-^;BP>TLH.KLM4Y'!Y?`4+U<^4Q%=6(*22>6$5'NO=68=@?'+X
MS_SBOYF7RGZ0^<.4W/OSICXU]&_$S??PWZ"Q_:>[NL]J=B[.[QV7NG>/8OR?
MEVOM>OVMN/>&8I]Q3TNV8JMY6BP<-.\$L:R5BA?=>ZKP[RZ_WWW!\7\]\!.C
M?E#N'.=?]#_SY_CM\>_A/\F=QU61[&SO66.AZ6/;F%VG+NW(U=1-V-3?'7MS
M+5FVZ:L:6:1:;&JC-+XE4^Z]U9-_+2^865^8'\T[<-7V1AFV9\G.@OY:%'\>
M?E_UNV,KL9#L;Y#;`^76X*?=!POW4,=/D=E[WHY(-P8"JIWD27#9*GU^.4/&
MONO=<^X?BA\??YL'\U/YG?&S^8(VZ]S==_$'K'XR9/XI_&VE[9W1UUM?=N`[
M5VMN_<':OR0J-N;/RNW,WO;-4.\?%M:.O^XEIL-!2O!(NJLCT^Z]U5C\H<!_
M?SX8;Y^$^%Q6\OYBWQR^/7\]#ICXY?&_8%=VU6;8WAW!U;6=`UV_\G\;XOD7
MF,@=:=1[\W7E=L4^X)*EFBI<.L+RD*I'NO=;"?\`)/\`B#L?XI=!]EMMO^79
ME_Y;FX>Q^S37;EZDW%\E5^46=W30[8P=%C-N[PJ-[TV1R6/PM!*:VMAI\9$X
M:/2\[\S@#W7NJR/FMTT>J/GE\@?YGWR7^-'PZ^8GQPV+\B/AATSL7(T6_MUY
M;Y<?':CQ<_7VQ\5E]C[,VWMW)['FW/M_Y"=HG+5N"R55%GLA101+#IU4RCW7
MNKM/YG/Q%W/\H.C<%N[IG<=+L+Y9?%C>=+\C/B=V%6RK#B\/VOLW'UJR[3W6
M7AJ(Y]@=H;;J*O;^;C9&44E;Y;$PA3[KW5"_9^R=W=]?R5_YD7\UOY`8;;@^
M0W\PGXG8G,[7VGM7,Y/+8+ICXGXF+"MTKT'M[+Y$4WEK<D:RKW'GZX4\#S9_
M.2J0(Z6%$]U[H8/Y.OP<V7\5OD_NSMT_R0]\_P`M>+'=%;VQE;\A-X_S`,/\
ME\168R?-[/RF1V)-L&DW#D&Q\V6I\+]^<J\82E3&O&6'FY]U[JKOX6?S2_B?
M7_S5^IOFYMCY"Q[C[E_F*_*7N[XO=\]%5>*[$Q*=5_&7+U&V=C_`[*SY+([6
MQ?6]1N3;V?ZHQ\U>V/JJV>LCWY()&$L+>+W7NDA_,NZ(Z;S_`,YOYM'R&[N_
ME/[H^:.Q^NN^>G=JYOY90_,7</0&P?CU2Y3XH?&R"BQN^^N]F0Y3>&:VKM#*
M;ECS^:W!28^I6EQE>1(52E=E]U[K;_\`C#C>\?CA_*KZLI\SO7%?*7O[J#X9
MT^7H=V;9S(W/@>XM];8ZOJ<YM6CVWNBGIHY=V83-54%'CZ'*M&:C*4WCJI-4
MLS$^Z]U2Q\$OY?'P`W[\??@M_-T[*^478FR/F9V=5]']H]H_,&?Y09#!5'9G
M;V]JRD3>_P`;<WB-V9FHZVQ^RMQ9VMJ-FOM*BQE+5T6.HTHHBDD,CM[KW5C?
MQ)W;M;#=Z_SYUS&Y,'BVVE\J-M;NW2,AE*2D.V]J5?\`+Q^,QI=RYL3RH<7@
M:D;:R/CJIM$+_85%F/A>WNO=:_N2VI7?Z*O^$]7R(PDN6DW)\&?Y2._?FGA,
M)BJ:CJ6W=CNI,U\$L1V-M:L;(21TM#1Y/J#>VX7-8VL44D23E6"$>_=>Z&CX
M>Y>+NK^>MV7\UL;NO^^>T?F-_+M^;^YNI<QCY:^7;<O2'2WR?V+\>^IWP,-?
M(\E*V=V[UM_&JI([0RS97SQ@),`/=>Z,]1[OVI5?\)^/Y.QIMRX.H&:[5_DQ
M;1PY@RE)+_%=U[;^47Q]7<6VL>4E;[O.X([3R@K*5-4U/_#JGR*/#)I]U[JT
M[^7I?_9I/YQ7]/\`AP'9UO\`TA'X=W]^Z]U07_PHC^6OQ:WK\KL-\8^X/DG_
M`*`=Q?"KXS;N^6W25;%@NP,W)NSY][CKL7/\7,")>O=MYFHQ]!L/!;1KZ_('
M(U-)222;CH2HD^WG`]U[JQ#YI=9?$#^=!_)<P'S>[BZY?=64VC\*NY?DOU)!
MC-[;SP%-UIW+2])YZHW/CIX=M9S$4.XVVAO[:CT$D.0CJZ<R4##259M?NO=%
M,V!\$_C#\-OY1'PLWW\=^OZO8^YOE#\G?Y(G;/=>0J-W[NW-_>O?C?)OX\Y!
M\Q!3[ES.4I<!&:W<]<XIL?'34X\UM%E6WNO=2OD'W+NS^7?O#^;=\!NMLM3X
M[LCYS[LZO[T_EV8&?(X['Y.J["_F);O;XY]VXW95'_>.AE%%U%W'CJW=Y2GA
MIOX=254]3,&A57?W7NBJ_P`P/^7%UW'\WOC;\3]N?RR]W?S.-F_%W^4U\=MB
M;;V;M?Y2X[XFU77-/@^\N\MMS=B9S.5F5QL>\:[L"?%N)*422/!41RS-<REC
M[KW6S9\/OBIUK4?RT=A_$7?7Q3S7Q>ZKW5U)OGK?>GQ/RW<M=VEFNO\`;&_,
MUNP;EVC5]T;<S"Y#<,^:I\[/5_>TE8LD*UHB5E,=A[KW5$W\K#^4+\".GOYC
M/\RCL'K7H?)+O3X#?(SK'%_%2)NS>RZ[^Z,&[?BGM?=>9Q$T%=NFII]TMFMQ
M;KKV63+)7/#]R%0JL:`>Z]T&?0OP6^''S(_E[[W_`)PWR>[V[)V-_,);!]_=
MF[T^5E)\@=Y;<ROPV[AV%N7?,>"ZLVSL;#9[%[6VGM[J-:"EQZ;5J<<\^0I:
MF6-05KH;>Z]U(_FO_#CH?YL?RN_A'_,D^4O4M95_-/?FR/Y:&P=[;F@W/V!M
M.GQ^`[I[;ZOA[-VN-B0;AAP&->O3LW-Q!WI/O:5JJZR!XD(]U[HTO\US`?`O
M^5M_+LZ)_EN[:S,WQF^,GR\^1^)ZYW]E9\IV'V!4[*Z!FW7#VS\HL\E:\6_>
MP*JNW/MO'G;V/%+'*U/D-PP2`Q4\$K+[KW1/NH?EEU7WS_PGS^??0'578</:
M&T_@QVY0_';K/?`IMRX^KWM\;H^_NOMS?&G>%1B]WTM)N/&QMUMD4P*Q5B+/
MY=O2DJ%*EO=>ZW6O?NO=?/%_F)=!=.YWY=_S9?D/W/\`RH]Q?*_:NU/EMMSK
MZJ^;D_S.W!T#UE\>:G.?'3XV8W;V/["ZWV;%E-V56U.O=P[N@SN9W'!0311T
M&4".RBE)'NO='`_F`?#W=_9N_OY0_07=OQ.R_P#.4W_UU_+([5KMX8?KWY0X
M[X\4>7W'A-X?%C!U7>]!V]5U>'CWSM>E7+G%TD;M]SF4RT&1E#2)(??NO=6E
M]??RH_B=WC_*8V[\=ODA_+UW/\3=F=3;H[C[KVC\6LQ\H=T=LY?8&_X8=\Q4
M&\:CMS8FZZ4;FAW+0YJ:MCH9YIX*-*H1&,%/?NO=5-]"?!KXK?&?_A-'NWY7
M]7[%DV=VY\H/C=\6]T_(3>]=O'=F6HMQMM?Y#[*S"9.3$9S-5NW=LTF.&0JI
MI304U+&(R2]U46]U[K87^66XL!7_`,U3^3GCJ#-XNLKZW#?/W<M)14E?35%3
M5[=E^/FU::+.P00RN\V(EJ:F.-:@`Q,[J`Q)]^Z]UI,]0?%+;%9M3XP[JP?\
MONM^+_?_`,EOE3E=K?'O^<5V!\X-R8#JT=NXSO[=>X*7-T/2.V*;-46W-YYG
M:^T\CAMN[?S24--G:^F*QM*SE&]U[J_WM[M3MOX4_P`YCYW_`,P*/=%5F?BE
MU9C/@9\??G7L:CVQ/E,QC^INT.G:FKVM\GL8,4DM0/\`0=V!X'R]'3PEQMW*
MY&6,2,BQ>_=>Z&[^7?\`'OY$_(7^7S_*S[$^/O>N'ZWZ_P"M,KW3O[>%/408
MFNR78.$W1V[W!M:F@V!59SJ_>3]<;FJ-B[WRM1!NA))ZB$+'0#'?Y8^1H/=>
MZV=_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]UPEBCFCDAFC26&5'BEBE19(Y(Y%*O'(C`JZ.I(((((/OW7NJONK?Y+W\L
MGICY&/\`*CKCXG;#V_V]#EZC<>`J#6[FR>QMC[FJS(]7NCKOJO+9RNZUV#N.
MHGGDE^\Q.*I)XII&DB9'.KW[KW4CY5?R;?Y;WS4[9Q_>/R)^-6!W?V=3C&19
MO<N&W/OG83[_`*+#&D7%XWM"@V%N;;>-[*Q]#2TBTT<>:AK=-(SP7\+%/?NO
M=&@W)\-OC3NK=?76[\MU1M]*WJCIKL_X][!PV(>OP&S-N]-=QT6U,;V#L*BV
M-@ZO'[13#9K&[)QM.@%%Y*6"G$<#1H2#[KW2.ZK_`)?OQ.Z5ROQ[SG6W5R;=
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M_*S!_-F/`X/<V[,5M7&_);`XAL/#V-A-JT>;BV_@Y,HDLM5DL?24\.,R60GE
MJZFGDJ)'D/NO=%^[<_DC_P`L3O/Y(2_*SLWXN;<W!V[7[BP6[]QO%N??6'Z_
MWMNO;LD,V/W'OWJ7#;FH.L=[9>::E@>LER6)J3D7@1JH3,"3[KW0N_-+^5_\
M'/Y@D>TI?E-T9BM\9W8D$U#M'>N!W!NWK?L#!X>ID6:JVY2[ZZYSNUMTR;8J
M9T$C8V6JDHO+=Q$')8^Z]TOMO_`KXD[/ZL^/_2FR^E]M;)ZN^,'9NS.X^EMG
M[/DR6W,=MCLK8=)EZ/;^[JY\574U7NK+LF>JY*Z7*R5K9.HG::K,TOK]^Z]T
MJ]K_`!$^/FR_D]V3\Q]K=?4>$^0W;W7>V>K>Q]]4.0RT(W5M#:%>N1P,&2P"
MUW]W9,O22Q11MD12BOEIX(87F:**-%]U[H%_FK_+`^#W\PD[5J_E5T?C=][C
MV3%/2;6WU@]Q[NZZ[$Q&)JY?N*O;T6_>N\]M?=51MFJJ?W7QTU5)1>8F01AR
M6/NO=+_`?`WXE[1ZO^/O2^S.F-M;)ZP^+O9FS^X>E-G[/DR6V\;M;LG8V/S6
M-P.[:UL36TM5NG+-#N*MDK9<K)6MDJF=IZLS3>OW[KW1O/?NO=$*W!_+)^$^
MY_D4ORERG3,`[6FWCM_LG.PX_=^^<3UKO3M':,7BV?VKO_IK&;DI.I]]]G[0
MTI)B\_E<-5Y2AGBCFBF66-'7W7NCV5M'3Y"CJZ"K0R4M=33T=3&&9#)3U,3P
MS('0JZ%HW(N""/Q[]U[HJ^0^$/QKRGPY7X$5NPIY/BTG4V/Z03KQ-T;JBJ4Z
MVQ5#2XV@P2[NBS*;O$L%)1QK]W]]]V2NHR$DGW[KW1%^G/Y`O\KWH7<V;W?U
METIOO#YW<7779?5.6GR/R)^0FY*:IV1VYLG-=>;[QBX_<79F4H(*G*;4W!5T
M\56D:U5&\@FIY(YD1U]U[H\&_?@C\3^ROCAC?B;NOIK;4O16$P&P=N8':>&:
MOVQ6X"AZNK\#E=@5.!W3MJLQ6Z</E]L93;%#4T];3UD=3YH`S.VIM7NO="/M
MSXV]+;7R?R#RF/V-CJN3Y3[IAWEWQ09Z:LW)A.P,W%UIM+J`_P`2P6=J,AB*
M?&5/7FQ\;CYZ*GABI)TA9WC:265G]U[IRZ#Z'ZQ^,G4&R>ANF<'6;9ZKZXQU
M7A=D;9KMP;AW1_=W`U.5R&6I\!0Y;=64S.:.#PSY%J;'4KU#PX^@BAI8%CIX
M8HU]U[HBN._DK?RP<3\EF^6E#\2.OXNXO[R/OB!VJ]S3==4'84F6.<;L;&]/
M39V3JG&[]_BK-.,K!ATJEF=I%82$O[]U[J;\JOY-G\N+YI]OT/>_R)^..+WA
MVA%#BZ/.[BQ.\NPMBIO[&X1:2'$XKLS%;%W7MS$=B8['T-&*2.++P58%%))3
MW,+E/?NO=&5S_P`)_C!N;/;5S^6ZGPK-LKXY]A_$K;6#H:W,XK:&,^//:B[1
MBWOUI3[.Q>2H]M)B,M2[%QD"RK2BKIZ>G\44J(Q4^Z]TS]4_`WXL=)[DZ,W?
MUMUC#M_<?QP^.5;\3>I<F=P;GR4F!Z$R&2VIF*C8]?#D\Q64VXU_B>S**9:[
M()4Y!7\Q\_[\NOW7NBR]:_R1?Y7_`%%\BZ;Y3=?_`!6VQ@^U\7N*3>6VU.YM
M]Y'KW9N\Y9X:O^]^R>ILGNBLZSVEN2&M22>"JH,5!)33U$TD/C>1C[]U[I)_
M([^0W_+(^5W=W87R)[LZ2WAGNV>TZ_%9/?.X<%WUWOL>DS5?A-N8?:>-JFV_
MLOL7`[?I9H,!@*2"\--&7$(9KL23[KW1^.JOB3\>NE]Q=I;MV!UKA:#<_=&=
MVAN/LC/Y9JO<V7W%D=A=;;1ZEVBDF1W%492KI,;@]C[(H*:&D@>.F6;SU.C[
MBJJ99?=>Z9-D?"KXV];]`]K?%[8_7J[=Z*[HJ>Z*C?6P*'<.Y1C9U^0,^=JN
MTZ+`U,N7ER&T\7GJC<E:\-+C):6GQ[3G[5(;"WNO=/FXOB=T)NGIGJSX^9;8
MT9ZDZ5SG1VX^M=HT>:S]!%MG)_'+<^UMX=.RQ9"CR<.6K8-J9_9..E\53/-'
M6+3Z*@2H[JWNO=0^U?AW\;N[>\_C_P#)/M#J[#;L[J^+U9NNOZ/WQ6U.5@K=
ME5.],;%C,\R45'7TV+S*R0P1RTZU\%2M'4H)X!'+Z_?NO=%D^:/\H'X$_P`P
M/LW;?</RDZGW)O7L+:>Q:7K;"9[;_;W;G6[0[-HL_G-S4N(J:+KK>NUZ"O$.
M:W'63++/')+^]IU:54#W7NC1?$[XE=&?"3I?"_'_`..FV<MM'JW;^6W!F\5A
M,UO'>&_*^#([GRD^8S,LFX]\YS<.X:A*BOJ'98Y*IHX@=*!5`'OW7NE1UG\>
M>H>G]^]Y]G=?;2CP6^ODCO?"=A]R[@_B67R%1N_=.V]EX+K_``58\.1KJNDQ
M5-C-K;<IJ>.FHHZ>GU>24H9)'9O=>Z(MV5_)-_E@]N_(Z+Y5;_\`BALO-]MO
MN6EWIG-.6W;CNN]Z[RHZAJR'=?8/4.,W!2=7;\S\E;HFJ*C*XBJ>LEAC:H\I
M7W[KW1Y.]?CETW\E.OL=U7W-LVFW=U_B]Z=<[_I-L_?Y3#4"[EZGWAA-^;%G
MD."K<;/+0XC<VW:29J0N::H2+Q2H\3,A]U[K'NGXV=*[W[QV!\C=W;$QFX^W
M>KNO]^=8["W+F'J<A!MK:79>6VEF=YP8[!5,\N"BRN8JMDX^,Y#[;[^*E66G
MCE6"HGCD]U[H#>V_Y;WPW[MJ_D56[^ZB@J)_EAU9L3IOOT8#<^[MHP;_`-C=
M:9K(9[9-/64FU\YB:7'9S!5F2D2/*4:4^2:F"0/,T2(@]U[H,/AC_*"^!OP`
M[+SW;OQ=ZPW=LK?>Y=F5FP,OD\_W3W+V-1S[7K\QAL]5446%[#WUN?#4M1)D
M\!2N*F*!*A50H'".ZM[KW1NMN_&+HW;,'R%HJ+8&+K\7\JM[Y;L+OO";BDK-
MSX+L+<N=Z\VAU5F),IA<_49'&08O);$V)C*":@@BBHG2!G,7DED9_=>Z(;W-
M_(\_EN]_;`^/O6/:'36[LWL[XM;*S_7'1M#1=Z=XX"NV5L3<64Q^5J]J)G,%
MV%CLWF,)12XBD@H8*ZHJ4H*.EAIZ?QPQH@]U[HTGQ0^`_P`8?A/TINOX]?'?
M96<VIU5O7/[CW-N/`YWL+L#?];6Y?=>"Q>VLY-'N+?FY=Q;AHX*K#X:GC6&&
MICAB92Z*KLS'W7NEUM7XC_'/9_Q?Q/PQQ?5.VZWXR8?K1>H(>I-QQU6Z=NUO
M7OV#XZ;`9AMPU.2K\RM7!(S2SU,TE0\S&4OY+,/=>Z++\.?Y1'\OCX%;_P!P
M=J?&/H"BV9V/N'%UFWWWIN#>6_\`LC<&!VUD:FGJZ_;&SLAV-NC=,VS-OULU
M)"9J7&&ECF6)%?4J@#W7NA=R/\OWXDYCXEGX/9GJ6@R_QJ2#))0[$R>;W'6U
MN&KLCN_([^CW!@-X399MY8'=6'WGE)<EC<I25\-?CJH(U/+'H6WNO=+O'?$K
MH+'Y?O\`S;[%BS%=\H]J[)V5WQ_>7+YO<])V'MKK[8E7UKMG&Y>@SV0R%$J0
M;-KYJ6H>*.-ZTR&6H,DIU^_=>Z47QP^.W4GQ,Z0Z\^.O1.VI=G]1]5X:;`;'
MVU/F<UN&7$XNHR=?F):>3-;BK\IF\@SY#)S/KJ*B5_7:]@`/=>Z&[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW22W_OC;?66Q=Y=C[QKUQ>TMA;6S^\=
MS9%@&^RP.VL759C*U(34OD>&AHW*H#=V``Y/OW7NM?'^6W\G-TT'RJ2+L[H_
MYM=4Y[Y_8K>._NP\C\F>D-];!ZXV]\E-COE-S[$Z_P"L=UYVMEVY/29#XT+)
MA4I:2GI(Y8^NJ>J`,]=,/?NO="GU+\L?YDO;.`^(NY%W5\.=IX_YM['[2VQL
MREGZQ[7S.3Z>[%V%MO>N_P#!=F973V;CJ/M?&[EVKM)Z:LVG$=M#&UDBS19F
MLBB>*;W7NE/UE\M?G=\D<?U7T5U?NKXS=8_(6@VK\B=T]X=R;PZI[!WYUCFZ
M/H3Y.[E^,>$3JSJ*@[7V;G\?4]B9;:=3F,HN1W+4)MRGE@IXFKWG$D?NO="5
MBODO\UODO@/C[A?CU6?'GHG>W8?5WR7S7:^X>U]D=@=Q8/;6^/CMW?UKTRU1
MU?MS`[SZJJ=T;,WEF<GF9Z>3*5]#/'BZBBJ`'FCDAD]U[IJV]\H/G'\@ZKH3
MKKH_*_%#JWL^/H1N^._\KV3ANP-_[?W=DL7V7GNH_P#1]U#L[#[MV)NS;VS<
M]NC9F4JJ_=5?-DY\#2U.-A&.JIZAC[]U[H9J7N+>G?G\JC??<W8%#M"BWUO_
M`.(G=&?W+C^LLU/FMCT^9.P]ZTU33;&W+-,)\WMY'I0M!D2T9K(=$]H]>E?=
M>ZK9^)OQ"H*+Y!_&S?\`\;OY4_97\MNIZ\W.FZ>W>[]]]L=05>/W]U)6=?[I
MP>=Z9@V#U'WYVY6;_K=\9[*8V8-G*2BI<(]$N3BG:MIX89/=>Z-;0_)GYW9_
M:_5M/B]U_&;&;_\`F;W'O#KWX[OD>KNPJW9O0>Q>K-M=Q;KWAN[LV6'LZ@RW
M=&_MS;;Z]I)L;A:`;7Q]+D9IH)*N>FC-2?=>ZB9'MKYM=A;CZ.ZED[,Z?V-W
M+T#\_L'T[WQV!@NK-]Y'JCY`;$K_`(F[R[NCJ-H;'F[2Q68V'DLILS<L%+68
MZORVXJ/$;DIHZN.2J@@A1O=>Z"C=_P#,L[TP?S+ZIV]LCL7K/N7XV]C_`#,I
M?B+G=N;%^(OR&Q^(ZVKJ^HKL%'79OYL[EWKCNGMS=@4>8BCDDP^$VW7T,E3#
M6XX5D<M*)Y?=>Z-YU5N#+Q[WZ_VMBX-OKE]V?(K^9I38K>&>Q5;G\MLVMPW;
MN^I,7582`9G&4TE$\TR+64LMQ44T*Q1O!^OW[KW3A\`?F!W#\M-P=N8W?.!Z
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MKD*&NI<_-!E:-_53TTE))Y_=>Z*[UE\"/B#\>/B)\X^YNB?C]L7KOMO';/\`
MYDG66-WIA9]PP99-EX/L'N3#8/;)K:K*Y+[3%T&,VGC*:,Q1:X8:*/0+@ZO=
M>Z%CLGY>?,#X8[:^0F]/DG'T-W-M_;7Q5W1\D^H]J=';/[#V/G=L938VY]G[
M/S'5.YLGNO=6]?\`21BZFI[!Q4U#GJ:GP==4?;U*28R(O"P]U[H..A/Y@GS4
MK\5\I%[>Z([.JJ/8?QV[?[]ZO[7[`^$W<GPUV'MO=&P,/+68KI+=N-[#[2[;
M?L!LRDL=92YG'9'&U)@HZV*:A4FGE]^Z]TIODU\G/F?T?MKK'J\_([X_5'RH
MW9MOLSM_*[+ZG^!_R7^3.Y=P['Q,].VU-I;%ZHZ^[@P[X##8B+[VFJ=W;IW%
MC(\W6T(2DH*=C41P^Z]TT]0_-;YO_,;'_&?#]`Y'XW=+9[O/^7EU]\N=S[E[
M0Z^[`[*IMI[]SG9&*VY7[;V]L?"]A[`K<IMO,8TU<#FMRL%1B)#'(#6O>(>Z
M]T#W;_\`-5^7V6W3MO9?1'26Z/[U;,Z7Z2[@[0INMOB-W/\`-/:&\]R=FQ;[
M>KZOIMY=<=B]25/3&!:HV,T='G*_&YVOJ(:MYEH`:1XIO=>ZM,VI\H]Y;BP7
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M?&S+]2[SI\Y%W%O.AV;OV@ZIWSV-+W51]@'9/7>Z:7>535U.`VC4;8R$V:Q]
M)1PRU=)59112^Z]U:G[]U[JM;OIN]Y/F=10X#M+;6(^/U+\&.\,KO[JNKV=G
MLCNG<>Z8-Q4N-QFX]O[O@WUB]O;>J:&?*XTJ9\)7S_;4M7`LJ?>+)3^Z]T6C
MJOY'?+[XQ=5;,WK\@*WH3LCIBI_E[;R[\V)L#JO;&_\`:W8NQ<]\;>FNMMTY
M3:6<[&W9NK<V)[/QG8&-SM0?XE_!-O5..K(8U6EJ8I':/W7NNO@-\]?F)WOW
MKAMI]R]"=P?Z)NV-F9K?&WM^9/X2=P?&/:G1=;CL=1Y["[,S?8?879_9."[M
MQF\,=7RTM%F*2#;E0*NAC?[*2*NM2>Z]TL=U1;@Z+^8ORJ^96UIMW9K;6!W?
MT+U7\GMAT^8K:[;\OQ^@Z7VKF:#N'`[7DAK(J#>'06YMXUN:R4U$(7R>TJC*
MPRK-44^/\?NO=-V_L/G-E?&VI^>'5%8,IVG\0>SOGGV#)BTW')2[?[R^.3?)
M?N/<G;_2>1R4D]9@X*?=NW]J4&7VWEWIJDXS/X7'/&11R5<<WNO=*'>/Q\SF
MYOBKG\KNO?&T8N\OFOVYU=V#V7A=V]D;NV+LCM'&Y"JQ-?@/AK@^P-IT<&\-
MM[`'3^$.U:1Z*CEDR4_WM954DYR==#+[KW11MM[$ZVZ"Z.^;_0N+^&VZ_A%V
M=OKX&=V]@IT-MCO;'=K_`!@[7QFW<'F=N[CW=U_N'$5<-9@=_8*JWAA\/GLA
M78#;5744>3I1'%D8J%)X/=>Z%?X)?"R/ISY&[2W^_P#)P^-WPZ;#X+==-#WK
MUQ\R&[EW7MN3*;?JL:</2;%_T0;0&1AW)%4M13S_`'R?;12-)9_TGW7NC"_S
M9.VJ3"]3]>?'5^OOD/VE1_)S>Z[8[6VI\6]D[AWYVY3?&K:D5/F>[,G18O:D
MU-N#&8;<<55BMHU.0IIH)Z3^]`EBD\B!6]U[H`.F?G'WG6?%3XP;4ZXVM7;>
M[QQGS*V[\$NR,5\N>N]\;"W?0[6QFRM\;CVGV;N_8L&8IMSXW=>]^HL1MK=*
M4_W+P5-3D9:4S1*QJ(?=>ZF8?Y3_`,Q#;<F'R_8.]?B1N+`](_.;KSX9=]8K
M:75/9^&S7=M!W%O?IO;^W.SMCUV2[1R5%T1E]F8/N>EGGP-5#O*#*5&.D89&
MFCJHXZ?W7N@T^/G\TKY=]W=_]?9O$?&WN;/?&WLSM;+]4/MC$?"SM[&XGKK;
MM)OS/;&B[NE^9\_9>5ZSWYAL)/@XJO+8Y-G8BG6EJ:E(:TST:?=>Z]T=7X]?
M+KO/LOYD=K_#W=F/ZS@J/C-/GMS]G]E4"UE/#W!LC?LM7/T;A>H]M?QVHFQ>
MZ-BXG(TJ]EU-2]938G*PTE)31%<Q'+2>Z]U,^1?4.S?EI\PL-\:?D;AI=V_'
M'`?&L]PX+JNHW=48?:G;'9U7V;5[/W%D=\[8PE?C<YO"@ZAP$&'EQU/52/B*
M>NW)]R\,E7#22T_NO=!SFH,!\%]M'XO?!K>^VO[Z=M_(WK_JSKSK'MG<F=['
MZK^&=1V7UANKL.JJ%VS3Y^F["@V=E=M=8YG.8':3YFCHJO+UD5+1RXV@E>2/
MW7NDSE/F%\U-DY'`?'C-K\?]V?(K!?,CISX[;M[;@V5O[:W2F]>ONZNB-_=T
M8W=^'V#_`'USNZ=J;[V=1[=BIZ[##/9.EJI(8G6LIXLC>B]U[I+8+Y5?S"]N
MS;;S78>\OB7N+;G3OSKV+\)^^L1M#JOL[#YWNBF[9WUU1MG;O:NQLAD^T,E1
M=&Y7:.&[>HZB?;M5!O"#)3X^5ADZ>.JCCI_=>Z6_QV^5?S;WIC?C[\@.S<C\
M;ZSH'N3N'>'Q]K^K=D[+["HNTL1DU[?[-V'L;MNF[%J]WYO;]5(D>SZ&GS&U
MC@(X((9ZFM3,@P?;M[KW7NMOF)\O,]4=/?*'<<G1E?\`$+Y#=_4/0FS.C-O;
M)WK1]_[!Q6[^T,UU;L/M'<?:]3OC)[1W-G*7+86*KW+MF+;./@QM!55)@R<\
MM`%J_=>Z:?B_\ZODYNWYM;@^/OR<IMH]-_WDRG9%-L+H[<WQM[ZV1F?X7LJJ
MW%_=K-=-_+>IS>Z.@_E%C]S;>V])D\DJT.S:ZDB+&CI*E(9@ONO=(FD^0O>G
M4\.U/D[C<UL&F^.O4_\`*/K.^]Y?&/`;,W-2UNX=Z[6CW-GZ&/8F\JG?]7A]
MFXYC245&BU6%RU6*2!X_.?(&C]U[I;?`?YS?,/NWO<[#[QZ([A'678.S]P;[
MVUV1F/A#W!\5-K=-9#%OC:W%=<YW=/8_:/9^)[@I]TXK*RI09FC_`(#4"HQA
M+T#QUB&F]U[IYS_97:_67=W\T/<W38V97]DIV]_+QV=LFB[0EW%+U[!6=F[;
MZDZ]KFSL>VY1FZ/'"@W7/*ST2F59E631(04;W7NI>Y/DI\YNG,1VUTUO_<GQ
M9[`^0M?VA\9MC=#]J8[9^_>J>HL3C_E5N3=NU,14=I=?Y??N]LYE,QUQD]@Y
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M'P.X>X-X93?G:--C.S^N-Z;7W_3;7WYN?+RU&3PHR/\`":KQP*].134_B]U[
MHPVS.C>J>NINOGV)LS%;3I^J^M\GU'L#&8(3T&'VUU[EZ[:&2K]O46*BF%"T
M4M;L3&/YI$>H!IS9_P!R77[KW5:/S0_ET[I[+P/0^U_CEL?X\5VU.I*7=.!3
M!]S]D_*SJW=6"P6\=PXW<FXX,!W%\=-]4.^-X;.W9/CEI]P;*W%'487.)'!)
M+4QF#QR>Z]T>3HCXL[-Z=^(FP_B#D7I=S;%VOT\.GLT,;C3M#&YC`5V#J<)G
M:7#XC$UKR;7P]135\\5'305+O0TWC1969-9]U[HS5)2P4-+345,GCIJ.GAI:
M>/4S:(*>-8HDU.69M,:`7))/OW7NBY;\^(G079/2-/\`'K=>S*J?K7&5ZYK;
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M5!08.3>->:>2GBBGC\B6<>&'1[KW2:^-_P`2NCOB7A]UT74N+W8E5O.OH\KO
M/>G9G:'9'<G8.X5PL%5#@L?FNQ^W=U[SWG4;<VM2UM0F,QS5PQ^.6IG,$4;3
MS,_NO="##U+UCE>L=Z=<4F+AKNN.VD[+R.Z*.DS%?/3;AA[NR>X=Q[]JZ3+P
M5S5<%/N6NW?6SQO2S(D"U`%.414`]U[IMW1TKTKV1N'<%9NS;6$W?E:CJ;<7
M0^[,/D\C4Y/'5'5G8$V+R^>V=N#;#UTF*-+N$8JG=I9J85,L`TB0QFWOW7N@
M1ZE_E[?%WI7;?9>T]F;:W_78/M;:.XNO-R4O8'>/=G:KXOKG<]!'C<EUWL6H
M[,[`W7/UULE:.%%@QV#:@@@*(4`,:%?=>ZS?)[X9_%#Y%YC8&;[ZQF3H<WC2
MG7>"R.VNX^QNE\AV#@,O,^5DZ9WG4=<[VV5/VUL7-ST$M0VULP<ECYF$[K37
MDG+^Z]T53L#^61\7!VCL*IW%/ANLOCMTM\.\;T!UMM/:'<G9W378?76(PG;^
M*W5)+ANQ]G;TVKN:@ZVJ<6F/PU=!)EFCJ[Q4\Z/&R@^Z]T8/M_\`E^?";?&0
MZBK]V[0J>M<AL'"[4Z<ZZEZK[D[-^/,F<V3@)LAE=L=)99>IM^;"_P!(>R8Y
MC5SP;=R(KZ=B9W2+U2EO=>Z9NV?B9_+V[X[KV+M[L2/96:[?ZUZS/5M'U#B.
M[MP[:J]P]/Q4;YBAV!VETQM7?F(H^U.O</3ULF0I,=N7%Y.@I_N))E0+*Y;W
M7NHNXNN?Y<76.^MRT>Z^R>I>O-YU?6?3746[]G;A^1<>U/+L[I+)8W=74"Y[
M863W]0T$>XMMK!3"GS$M$N5J,;HIY*B2E(C/NO=+_/\`P!^'_9/=E!\G<GL&
M7.[PR>4VYOVLI\;V+OV/IK?^[\#1XE=E]G[SZ8Q.[(NF.Q=];>I,-CI,5N#)
MX6MR%,:"CEAG#TU.\?NO=<.COA!\5>F.P=\[[Z>I=SR[N1<YM1L+FN]^W>Q]
MG=.G<]-09G+[6ZTZVW5V%N#9_1E/D\?4T,CT6WJ##LN/^WCC"4_C7W[KW0O0
M?&OKJMZ8ZQZ1WF-R[\VSU;7]59["5^[MY[JSVZ*O<_3NXL%N_9&>SN\*_*/N
M?<U?CMS;=I:F67(5-1+7>*U49M<FKW7NGW-?'_JG<&`WKMC+;;EJ<+V'V/@N
MVMVTB9K.4QR>_=M9+9N7PV9%12Y&"II8Z3(;`Q3FEB=*244Q62-TDE5_=>Z`
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M6QU%0JP,%<"677[KW0+_`!V^!'QF^*VYLENKI?:^],+5U6+DV_@L/N3N+M_L
M+9O7.UYFHC)M'J38V_\`?&Y=G]3[39<;2I_#]OT6/I1#2PQ!!'$B+[KW1BX=
ME[#VG6]E;QEHZ#''L"2BSG8^2S%:SXG()M_:F/VI%59&/*5#XN@Q]+M?"PPS
M!5B@9(R\@+%F/NO=!ALWXF=`]??&[*?$;9FP:?;WQ\R^V>R=FU/7E!ELXE%#
MMCMK)[HR^^,-C\D^2?-8VBR-9O+(>!8*B/[&.98Z;Q1QQJGNO=*?L_X^]/\`
M<W3F0Z"[-V50;MZIR6#Q&`FVS7U61ADIZ7;S44NWJ[%YNAK*7/X;<&WJS&T]
M509.DJH,A15<$<\,R2HKCW7NB]=?_P`OOXF]*==]T;7I<3O?*X;N/K_-]?\`
M:V_>X^]^X>U^PZCK&OQ.6HLAM*E[?[9W]NC?>S-G4$.9K:N*EQN3H:6DK:B2
ML0+4'RCW7NF;IS^6A\<>B^Q]L]I[)W5\K\AN?:<U7/BZ3L/YN?+KM3:$TE;C
MZK&3?QG8?8_<^Y]F;@1::L<QK6T,ZQ2A94`D16'NO=&^_P!$^PSVT>\9,(9^
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MC`YO='8'8&]]\9CM^/;>7V>-_P"_.P=X[FSF]>QMP_W7S4N/$N<KJ\+1QT\*
M@14U.D?NO=+?(?&#I#)T6X,?5[+0TVZN]]I?)?<(BS&<@DRG=.QLULS/[7WC
M4319))0^,R'7V'M2*5H9(J)8WA9&<-[KW1/_`(=_RQ.G/CK%L+?F\L-%NGO/
M9N:[3W"N6Q6^.S*GJ>FW/V)V/V%NH]AX'I_.[@7K?$]JMMC?+XNJW+#A(<RT
M,D\*U)AD(;W7NAVVY\!?BUM/Y`5GR6P6P,K2=CU.9R^ZZ7%R=@]B5G5&`W[N
M*EK:+<?9FT^CJS=,_3VTNS]QTF4K4K]PXW"4V7JS7U;R3M)5U#2^Z]U[K/X$
M_&CJ'N/)]X[&VUO:AW969'/YG$[=RG<?;^Y>I-BYO=4==#N;-]8=)[DWQE>I
M.LLOG8LK6I/48+#4$OCKZJ-"D=1*K^Z]TJT^'7QZCSG4NX4V14+D.E>J=V='
M;*B7=6[5Q,_4N]L5CL1N'8F\\$N<&%[#P-13XFGEACSM/D#254?W$!CF+.?=
M>Z37QR^"/QN^*>?RVXNF-N[XQ=57XN7;N(QV[>Y>X>S-M[`VC+)BY3LGJK:G
M8^^=U;;ZMV8AP=$J8S`TN/I%BHX(PGCAC5?=>Z%"L^./3]?N#LS=%7M9Y<WW
M!NOJ+>W8%7_&<VHS>Y.BJC;E7UA7K3ID%I\<-O3[3H&,5,L,57X;5"RAWU>Z
M]U"[%^+G1/;5/VS1]C;"I=UT?=^#V%M[LJER&7W#'%FJ#J_(9;+[`EH#1Y:F
MEVQE=K9;,S5=)6XIJ*KBJQ'.)/-&CK[KW0,[0_EO?#C9O6':'4-)U//N'9_=
MM+LV+N"??F_>Q^P=Y]EY+K^1Y=F[IWAV-O+=N;W_`);>NW9!":3,MDADZ?[.
ME\<RBE@\?NO=//7_`,!/C)UWU]/UE1[8WOO/;&1WAL_?.X9.WNY>X>Z-Q;OS
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MU!'"V6D1(GH\E0NM0U3[KW06[\^1_P`H^Z\?OS>&U_EGT[\3=L]#_!CISY+;
MLV-NOJ3&;UV[VUE>Y>K]V[RSFYNS<YNJ0[EVI\?MK9#;AQ$']SJR//"KCKFJ
MJHE:.";W7NAS[WQFZ-R?RA>OJ39?:]7TGGZKH_XB55'V?@,)MC<+[7@CS/3M
M565E-BM]4E1MVHH)J-7C<UD85('+$J1<>Z]T%W<>"^6>S=X?.#M/I[Y78[KJ
MH^/.PNF.RMUT62Z'V#O:;Y`Y_K7X^5&X-TX?L6KRE110[1VEOJAQ$$21[4AP
M^1QE5+/+%5M%XJ9/=>Z!7Y/?-/\`F.97Y2_(K:/Q3ZK[;S>TOB)F-B0)MO9&
M*^%DW5':T6[^G]D=KAOD)NKY%=U]=]V[&VO5UN7R&,I\ILNDH:2"DI*B=:JO
MJ:>:G@]U[JQ/YK=/[9^3^U?AGL/M?`Y;;$^X_D=@MX4RXC."GW?U1VAMCXR_
M(7>^R]U[5W-B9/!%O#J_?V)I*ZBJH_)2S5%$`Z2T\CQO[KW0+]:Y3'?*'O&3
MH'Y5[6V+N/L[:WQ*[TZ6^3_6$ZT-;A-R4N0[1Z4CPV_*+`NYJZ3K[NO:1@S^
M&>P^TDFFHQ+]WCIBGNO=<_AIUQOW>O=N^\5\@=ZQ]K4W\MO?63^/WQYS-?+F
M:_<^ZI]Y=5[&WJG>W;,U9(E#FNZ,?U%V%1;.6I@@9=2YG(*^O,^"D]U[HDZ]
M<=8=*;/IOE'D>A?A-\L?CAC^X]M[KIOECU_)G^HOYA>`W=N'O*JR=3N'=N6S
M&VLIFNP^R=F[LR=!A:S`4VZ<!FL[+YJ!\=%&YQ3^Z]TM]Z_$SOKN/Y)?,7>?
M6_Q`_E%]T[:J/D&,8=[_`#.V!O3<7=E9D,=TKTY#6XS(Y+!=3;RQ[[9QA=8L
M8@K6=*>X9$/!]U[JZGL3LG"?&[XY;F[/WQ0;=PV)Z>ZHGW!F,!M`PXS;BU.U
M]N*8=I;)BR*XV*&DR&3IX\;AH)%@+&6"+2K'2/=>ZI%_ET;T[YZ%^2>W,%\@
M?AGWG\9O]G=V]FLEW/V7VGO;I#>6S]__`#MP4FY.QTJ=NUG5':V^:W%-OCJB
MHS6%I#EL?BFFQNQL'1Q"2=64^Z]T+>*[3^;.?V=\9\+6?,K`[,W9\\NR-S1[
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MV$V_D<C6"E^^:@W!1X:JFBCAB>:/W7NA?VIVA\G>^JCX\?'_`*G^2&V_A_*O
MQ$H_DIN;L/;O275.\LQV+DJOL7+[#&R=G[.WO1)U[MG8VPZ;%#(;F:@QS9`O
MFL4D-3CXS*U5[KW2`Q'R)^0&[<UUM\Y7WNV.R.T/Y7/R>[4S'Q=VSM7;==U]
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M`S$4L6P<FV1W)TCA8MWTF:GAS%769^DH<-5K+F91,)8?=>Z2_9>Y?D?UQM'Y
M4?'#NSY)8SY@8'L#^7_WM\A<5V..L.N^K,UU?48F"DV;2;.?$=8A,!FNM^QZ
M?<-15[;J<@DF6BFP>1CDK\E&R_:>Z]T^]^]^?*ZHW7\VNY>N?DIL_IK8'\OO
M)04\?QFS75NQ-R1_(B*@Z<V?VY-4]G[^W)5+O[:&)[6K=R2[<VA+M=\4\%;2
M2S2-E9/\CB]U[H/LY\EOE[5MD?DU#\O^INN=AR_.GKCXB/\`#/<W4&WZB3;&
M)K_D'LGJW*[:E[%KJ2B[/E^46\\!63Y6E61I]J)B,I&T%"-,>4C]U[HW$?R*
M[FR/>^6^(R;GQV)[>QGR<I-T09T8#&UE76_!^3;L7;TFZ9L3_`JC"4L<N4:3
MJB.O.BH->$KO+]YK(]U[H,?D3O#>'7/RK^>_877&3QV`[%V=_*DZXW%L?<&3
MQ,&=Q^&W9A.ROEMD-M9/)X:H:.+,XW&YF**::D=T6HC5H]2ZM0]U[I-=K=Q?
M,SX=TOR7INPOE!L;O>KJ.@,'W#USNO??1>$ZVVC\>=PY/M[%=5;HR>6QW5D]
M;G-V]([+QF[Z?<+P922OSU-286J2HRU0DWDA]U[H`>U^^/DC\)MT?*W=^Z/D
M-L?YQ=I]$_`;9796TZR?K?9G6'8.)C[+[]RF&DJ>RL+U]7[<ZNDV'%28E<C@
MJA9,,R4>,KCE:E8-&1;W7NA-^,_<?\QK,4'R-V;\@*WM7IK:9Z%W-VYU;\J/
MDUA/@;B,OU3O7%5<24^-?8GQ?[1['VGO3I*'#N,E+D<S04E;!'25D#9*=JFE
M>C]U[HXG\N#Y,=O?+3KO?';W<=%B>M=P2;EQ^U*;XUP8BOH]S=+TFW\:SP[A
MWKE-PXS"[HS-?WK19&#=6(\E'34%-M>KQ<<"R5'WU1/[KW5C/OW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NBM=Y_"+XB?)O>.RM_\`R$^.?4G<>\.O8*JD
MVGF^P=FXK<D]!CZR033XJL@R$,M'G<-YRTB4=?'54L4DDC)&K22%O=>Z&##]
M1=8X"B?&X;8VV\?CI.NMM]124,&-@%')UCL^+.0;8V-)3,&ADVWA(-RUZ04Q
M!15JY!R&/OW7N@>[#^$'Q`[:EZGF[.^-O3N_9>C,90X/J:3=>Q\)FVV3M_&8
MUL10;<Q9KJ6;R[:I:%M*8ZH\U"'"R>+R*KCW7NA?W'U!U?O#JG)]&;IV'MC<
M/3V9V2_7&5ZXR^*IJ_:=?L5\0N!.UZG$U"O3R8E<0BP+';T(HTD$`CW7NFB#
MH/IBGV?NKK].MMJ-LO?&T,/L'>&VY\;'58O<FS<!M6+8^%V]F*>I,OWV.QNT
MH$H(E<DK`H%[\^_=>Z#/MSX-_#[OOL797;?<WQNZA[*[*Z]CA@VIO/=NS,3E
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M_*L_EW_(3LG='<'='Q+ZG["[-WK+CY]U[SSN-R+9G/3XK$4&`Q\^1EI,G2Q3
M34N&Q=/3*V@-XH4!)M[]U[HUDG1W4<W6NT^G)^O]N5/5VQ1L1=I[&J:,U.WL
M(O6.3PV9V`E-13O(KIM7*[>HJBE$A<++31DWM[]U[I2;SZ]V/V)3[>IM\;6P
MVZ(=I;PVWV!M<9>CCJGV_O;:%<N2VUNC#S,!-C\UB*L$Q3Q,KZ'>,WCD=6]U
M[H..P_B]\>.V>G&^/G9?3>P=[]*^"G@BZXW%@*3([:HOLY99J*IQM+,IDQ60
MH9IW:"JIGBJ8&=BCK<^_=>Z#+>O\OCX2=C=/==?'_>OQAZ?W!TUU)6Q9'K7K
MZJVG118+9M<@F$]5A%I/MZNGGR;5$CU[&5CD97,E5YG.KW[KW0UX;H3I7;?4
M.3Z`VUU9L;;72&8PF\MM5_5&W-N8W`;!?;O853FZO>F#I]LXB"CQ5!B=Q5.X
MZYZBG@CBB)JI-*J#[]U[H`OCW_+A^"OQ2WI4=C?'CXN]3=5[]J,5-@_[X;>V
M_P"3<5+B:G5]Y0XW*Y2HR%9B8:]6TU'VK0FHC`20LH`'NO=+/M[X1_$GOSK[
M8_57<OQ]ZR[%Z]ZTR,.5V!M;<NW:>MQ^T:R&-HM6"8&.JH:>IB;140))X*E5
M43(X1;>Z]T)64Z$Z6S.\.J>P,CU?LF?>?1F*W-@NG]Q)@*"FR/76!WEMZ+:F
MZ<!M62EBA3%X'.;=@BI)Z)%^U:*&/]L&-"ONO=!ITC\(/B%\;-X;VW_T+\<>
MHNIMY=B/*=W;@V1LS$X2OR,%1.:FHQM(::`18/"5-1I>6@H%I:*1XXRT1,<>
MGW7NH76OP/\`AMTW)V]+U5\:NHNOV[[H\AC.W1M79^-Q$>]L1E4K(\C@LA#2
MQI#2;?JUKYM>/I%IZ(L]_%<`CW7NANW/U'UEO3(YW+[KV/MS/93<_7V3ZIW#
MD,CCH9JS,];YFJDKLGLK(5%A+4;>K*R5Y6IV.C6[$6+-?W7NG2MZ\V-DMTU6
M]LAM/`5V[*[9U1UY79ZLQM-4Y"NV-5Y$Y:IVG6S31O\`=X";),TS4T@:(N[&
MWJ:_NO=`1U!\'OB)T#LOLGKSI?X[]6];;*[@?('L[;VU=L4>.H=ZP92BJ<=5
M8_.%0T]3ATH:V>*"B#K1TJ3RB&./R/J]U[IT[/\`AS\6.ZNV.NN]>V.A.L>P
M.W^IF@;KSL'<^UZ#)[CVU]G6MD\:M/5S(5K$P^5D>KH%J5G6@JW>:G$4KLY]
MU[HA?8'\J^J[1^:Z_)S>^]?C_E=IT^]=D[]HYHOB5M''?*B"?K[=.W-Z[8V,
MWR1Q^\J;`3[-QVX-K4D`R+[+;>+8%/X8V:,9,Q]U[H]77O0.>P?R*[>^1?8>
M\MN[VW+NW;N!ZMZKIL'L,;-J.M^DL'ELGN\;.S^6;<FX*C?^XLCOC<%74SY1
MDQ].M+!2Q044,@JIJKW7NA2W#TUU9NO,;QW!N38FW<SFNPNO:3JC>V2KZ%9J
MO<W6]#6[AR-'LS+2$@U.!IZ[=F2E6$\!ZV4_VO?NO=..9ZOZYW'G,QN7<.Q]
MKYW.;AV)6=7[@K\SA:')R9WKG(5E37UVQ\U%6PST^5VO65=9,\M%.DD#F:0%
M2'8'W7N@8ZA^$WQ%Z#P6X]L]-_''J#KW`;QPN>VUO#$[?V1A8*+=NV]SY"LR
M><VYNB*:FG&X=OUM5D9Q]C6>:EBAF>&-$A8I[]U[IAZN_E__``HZ5VEOK8G5
M?Q@Z;V5M#LW)TN5[!P&(V9C!0;PEH<E0Y>BH,\E5'4OD-OT>2QT4L6+=CC8V
M#!8`))`WNO=&*QO7&Q,-OK<G9F(VMB,9OS>&`VWM?=>YZ"F%)DMQ8+9T^8GV
MK0YEH"D61_N^V?K%I9)4::&*H:-7$=E'NO=+;W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2+WYV1UYU9@X]S]F[[V=UWMN7*XG
M!1;@WQN7#;4PDF;SM9'CL+B$RF=K:"A;)9:NE6&F@#^2:0A5!/OW7NE!5YS"
MX^JP]#7YC%T5;N&JFHL!1U>0I*:JSE93T%3E)Z3#T\TR2Y.J@QE%-4O'"'=8
M(GD("*Q'NO=>;-X5,U%MMLOBUW#/BZC-P8%J^D&:FPM)5TM!5Y>+%F45TF+I
M:ZMAADJ!&8DEF1"P9E!]U[IHV9OS8W8^%&Y.O-Y[3WYMUJRLQPS^S-Q8?=&%
M.0Q\O@KZ$97!UE=0FLH9O1-%Y-<3<,`??NO=*OW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:_O\^C8
MNV<QM3XO]@[DP>8JTV)O_<^(HLUN;XNO\S/C>9]_5G7F+;8'>G06W?-V?55O
M9(QHIML[@V['%-BZJEJJ*>J@&5B6;W7NA%W+T?%D_D3_`"3._,CU#O?9'9^W
M=O[CV1N?96-J^RLCUK\?MJ9/X5]BUNXME?W7R%;6[0V/6T^]UQF'_B5=##FJ
M\4$%(]1*(C&/=>ZK#[WV?_,5[4^5?S9W%E_A+\F-K]M]X_R[_G)\?.L>S,+V
M?U;ENG]L;*P'8NT\AT'ANM)=O=KY#)87*[LQ&(AGR2?8T6Y,IN?=+R&C_A=`
M)Z3W7NK9OY36!V1+N?YE=I=%]+9GI#XQ]I;ZZ'FZ>V_D.H,K\?\`'9C/;)^/
M>R]G=QY?$=.YW;^T,OMIZ'L3'3XG(5CXJF@RN2QL\T$M5&HJ']U[H]/;W9/<
MO6G:O3,5(W6.4ZD[2[7P'5=7BJG![JI^QL349C96\]P2YRFW'%N>3;-5%#D]
MK(JTSXI":>9@9=:@GW7NC3ZQ_C_O'_%??NO=>UC_`!_WC_BOOW7NO:Q_C_O'
M_%??NO=>UC_'_>/^*^_=>Z]K'^/^\?\`%??NO=>UC_'_`'C_`(K[]U[KVL?X
M_P"\?\5]^Z]U[6/\?]X_XK[]U[KVL?X_[Q_Q7W[KW7M8_P`?]X_XK[]U[KVL
M?X_[Q_Q7W[KW7M8_Q_WC_BOOW7NO:Q_C_O'_`!7W[KW7M8_Q_P!X_P"*^_=>
MZ]K'^/\`O'_%??NO=>UC_'_>/^*^_=>Z]K'^/^\?\5]^Z]U[6/\`'_>/^*^_
M=>Z]K'^/^\?\5]^Z]U[6/\?]X_XK[]U[KVL?X_[Q_P`5]^Z]U[6/\?\`>/\`
MBOOW7NO:Q_C_`+Q_Q7W[KW7M8_Q_WC_BOOW7NO:Q_C_O'_%??NO=>UC_`!_W
MC_BOOW7NO:Q_C_O'_%??NO=>UC_'_>/^*^_=>Z]K'^/^\?\`%??NO=>UC_'_
M`'C_`(K[]U[KVL?X_P"\?\5]^Z]U[6/\?]X_XK[]U[KVL?X_[Q_Q7W[KW7M8
M_P`?]X_XK[]U[KVL?X_[Q_Q7W[KW7M8_Q_WC_BOOW7NO:Q_C_O'_`!7W[KW7
MM8_Q_P!X_P"*^_=>Z]K'^/\`O'_%??NO=>UC_'_>/^*^_=>Z]K'^/^\?\5]^
MZ]U[6/\`'_>/^*^_=>Z]K'^/^\?\5]^Z]U[6/\?]X_XK[]U[KVL?X_[Q_P`5
M]^Z]U[6/\?\`>/\`BOOW7NO:Q_C_`+Q_Q7W[KW7M8_Q_WC_BOOW7NO:Q_C_O
M'_%??NO=>UC_`!_WC_BOOW7NO:Q_C_O'_%??NO=>UC_'_>/^*^_=>Z]K'^/^
M\?\`%??NO=>UC_'_`'C_`(K[]U[KVL?X_P"\?\5]^Z]U[6/\?]X_XK[]U[KV
ML?X_[Q_Q7W[KW7M8_P`?]X_XK[]U[KVL?X_[Q_Q7W[KW7M8_Q_WC_BOOW7NO
M:Q_C_O'_`!7W[KW7M8_Q_P!X_P"*^_=>Z]K'^/\`O'_%??NO=>UC_'_>/^*^
M_=>ZY`W%_?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KUK_7GZ'_`&W(_P!L??NO=>]^Z]U[W[KW7O?NO=%$^5G_
M`!\'Q#_\6[V1_P"^R[>]^Z]T;/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]TW+F,0V6EP"Y7&MGH,=!F)\&M=3',0XBJJ:BBI<K+C1+]Y'
MC:FLI)88YR@B>6)U#%E('NO=./OW7NO>_=>Z[L1]0??NO=>L?Z'_`&Q]^Z]U
MZQ_H??NO=>L?Z'_;'W[KW7K'Z6-_?NO=>L?Z'_;'W[KW7K'^A]^Z]UZQ'U!]
M^Z]UU[]U[KWOW7NB=='_`#MZ"[^^3WRI^)/7V>GK>UOB'5[#H^RJ>>.*/&Y%
M]\X1LI+)M:I65VRT6S\DIQ69LJFAR96%P-:%O=>Z.;[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z*)\K/^/@^(?_BW>R/_`'V7;WOW7NC9^_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBV]T_+;H?X^=G?'#I
M_M;>M/MK?ORN[`S/672N(EB,@W%NO![:K-SUM/53!U7&T;4]-%213R>B7(UM
M+3+^Y.@/NO=&2]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=![VEVUU;T?LS)]B]R]B[)ZJV
M%AC$N4WCV#N;#[2VY12SDK34TV7SE7147W=6RE880YEF;THK'CW[KW5=,7\Y
M/X<;KRT.+Z'I/D!\JJ5*B$9K=_QQ^/O9&]^L-K8HR`5^Y<_VYE\3M?J^+;N$
MIP]16U%-EZDP01L^@\`^Z]U1IV!VQ\Z=D=JXO^?9U#L_"9KJ#O+<N=Z)S>U>
MX.Q,YM+K[8?\OVIWGM/KGXO]C[CV3@]K9K<5/#DNRJ_(]GY?.4LC-CL%F3%]
MO)%+),ONO=;"W1VV_P":-D.R]L;J^1_;_P`)L7U-!#7S;BZNZ!ZJ[<SF<SPJ
M<=/'AQC>U^P]^8X8R.EK9(JB608&83HIC54#!Q[KW3MW_P#$WY(=S=E9#=&R
MOYB?R'^//7%9C,/0T_474O7GQ[DH<?5T%,(,GE:??>]^L=U[[:JSDA:61&J_
M%`Y'B50H]^Z]TK?C+\1<_P#'?<>Y=U[C^7GRY^2N2W-A*;"RXGY!]B[9W'LS
M`FGK5KWR^U-H[6V/M''X7-54FJ*2?5+>F/B"@`'W[KW0'[\_E4=+]C;UW;O;
M</R"^>$$V]-PY7<66VWM[YH=V[9VA3R9>KDK*C$83!8+<%!'@<#3M)XZ>EI'
MB6")0B$`>_=>Z,Q\?_B+UA\;.N]Y=8[!W'W5F]O[ZKLC7YG(=H=Z=I]K;MI9
MLGAX\'.NW=W[]W1G-P;9@BHX@T*4,\"Q5%YEM(=7OW7NB=?\,R?%+_GY_P`Y
M[$DV_P!GW^5I^IN1?_2A?_>??NO='(I_BKM;'_&=_B[ANU/D1A-LC$R8>C[/
MH^[-X57?V-@?.?QT5%%W#F:C*;I-;'+_`).LDSRD49\/*^_=>Z)XW\IS$PB^
M(_F(?S6,%(UQ--0_,S*5KSI;T(Z;@V7FH$$;$D&-$:YY)''OW7NCA]Z_''</
M<75VSNN=M?)KY&=%979M3AJF/L[J3=&U:/L'=1PV&EQ`@WQ7[HV=N7%[@ILI
M)(*NM04M/]Q5J'N%NOOW7NBO[,_E_=_;-W?M;='_``Z9\Y-UT."W!B<KFMH[
MS7X_9S;F[L1CZV&KK=M92$=,TE;14692'PS5%)-#5)"["-U)U#W7NAX^3WQY
M^0_=.<VME.D_G-VY\2L=A,574&=V_P!<]7="=A4&[ZVIJTJ*7,9&I[?Z^WCD
M<;5T$`:!8Z.6&!T-V0L+^_=>Z(3WOBOE]_+NZ5[7^6>^/GI\GOFM'UQL#<U/
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MC:!L>\GNO=6)?`+L;ONK[$^77Q_[[[P_V8O*_'[>'2LNV>U,GL#8G6V[JW"]
MS]([8[0J]M[GVWUGC\-LT#;68R<\>/GAHX:F3'RQ+4-/(GGD]U[I=?*GL/#/
MV[\1^N1B-^#-Q?*K9&3;,-UOOU-@F#_13VY5>%.RWVZO7\F0\;:?M5R35/E_
M;\>L$#W7NCW>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z@3Y7%TV1HL
M14Y/'T^6R<53/C<7/6TT62R$-$JO6345#)*M55Q4B.#*T:,(P06M?W[KW5<W
M;O\`,4R6V>S-W]+?'_X6?,3Y5=D['RRX'<U;LGK6CZPZ9P^8,,-0U%4][=WY
MCK_862T0U*.9<3)E(674%9G0I[]U[H?OCAO?Y==B[8WSEODIT3UK\:\[)61P
M=8;6VOV_)WKE8\9+CI2^3["K\?M+9.WZ7(T^2:,BBQM15Q-&'7[F]G/NO=%4
MF^)G\S;<XD;=W\V"/:?F>4FDZ2^$O2VVH:6)W?QQ455VAN/M^LU11-8/,9KL
MH)%K@^Z]T;3"])]V8SXTY#IO)?+OLO.]R5.,RU)2_*VNZ_Z;I.P\76UV9ER5
M#E8=B8_95-U)-+A<<XH8XY<.T4D"ZY`TI+^_=>ZT?.VNR<-\P=_?*3>O<'\Z
MSX<TF]>J\SD?C'\4<K\F.EL/M/L7'8GJ#>^U>R4^1&R\CU=G]J4?3NY-S=W[
M=1*/,4V'RLF8P.&A$T"T\WA?W7NMH[XV?S=]E]L_`?H/YCR]2=T=NTF>KI^M
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M[(?"[;J*C#;,W9W#U;V%T]LOLO,2XB2NQF6V9-O/`8O<V?V.M:8X:G)P8\*-
M1,*RC23[KW1/O]E(_F6]_%I_E%_,+I.AMK5LCFKZ?_E[]:X_8E1!1R6!HY_D
M;W+#OKLNKG6,6%1C,5@75B;`V'OW7NK"=O?'OK#%]1;)Z4W5A9>Y-F[$I\,,
M9-WS4+W'N')Y7`S-4XS=&XLYOJ'+U6:W735<C3)7RCS1.?VR@``]U[IX[=Z7
MZZ[QZ@WUT1V%AJJKZO[(VIDMC[NV]M[-YO94U=M;,4YI,GB:3-[/R&$SF'AK
M:1FAD:CJ(',3LFK2Q!]U[JLFL_D/?RXLCM";K[(;,^0]?L"HP2[6GV)6_-WY
MF56RYML)2)0)MN7:D_>TF!DV^E#&L*T1IS3+$H0)I`'OW7NK4^M.O-K=1]=[
M&ZLV/39"BV9USM/`;)VG19;.9K<V3H]N[9QE-B,/2UVX=R5^5S^:J:>@I(T:
MIK:F>IF(U22,Q)/NO=+?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW6*HJ8*.GGJZJ>&EI:6&6IJJJHE2"GIJ>!&EFGJ)Y&2.&"
M&-2SNQ"JH))M[]U[HAW5W\TCX"=R]DT?4_6_R7V3N3=F8W//LC:U:M'N?&;$
MWYO:F-;YMF]<=I9G`X_K/L3=H_AM04QF%RU=6S+3R-%$ZHQ'NO='^]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15OE7\
M+OCW\S]M[4VWWUM/*YA=C[BAW)M'<FT=Y;NZVWWMZ=YZ%\[B<1OW8&:V[N['
M[<WE18^*CS6/AK$ILE3(@E4R0P21>Z]TO*CXY=,5%?T!D5V/0T<OQ<-6.B*?
M&5V6QF-Z^@K>OLAU7+28_$T%?3XROHH]A9.;'PQ5D50D$9#1A'`;W[KW18>M
M_P"5I\+.J>Q.X>R]G]>;R3)?(#(=IY;N;:.X.[N[=W]1]B9;NDA>RLKN7I7=
M78.8ZFK\GN.F5:<U#8;S4]*JP0-'$JH/=>Z'_P"-'Q/Z'^(>R\CL/H79E1M;
M#9K+KG,]D,WNK=^_]W[BR-/CJ+!XIMQ;[[!SVY]YYVFVYMO&4F*Q-/55\L&*
MQ5'!1TB0T\*1CW7NDA\K/^/@^(?_`(MWLC_WV7;WOW7NC9^_=>Z][]U[KWOW
M7NO>_=>ZZ)`!)(``)))```%R23P`![]U[JNKM#^:)\7=E]DCHWJZMWK\LN_U
MR-+CLGTS\4-K3=R;AV>:BI2FGR'9FYL/40===6XS&7:2J?/YG'S)'$^B)V4K
M[]U[H3OE#TI\HN\JO9VWNFOEG6_%'K1L?DAVG5[$ZLVOO#O'<E143438S';'
MW_O:MR^TNN*6"E6=*JJ7`9.O:1U:GE@*ZC[KW2<^.'\N3XO?&;?4W<6V<#O7
MLKY!5V+K\-F/D=WYV-O#N?NW*8W*F-LI01[OWGDZZ#;6,R+1@S4.$I<90-^(
M`./?NO='LN?ZGW[KW77OW7NO>_=>Z][]U[IF.W-NL23@,(2222<30$DDW))-
M/R2??NO=.-+1TE#%X:&EIJ*'4S^&D@BIHM;6U/XX41-;6Y-KGW[KW1:\_P##
M7XS[B^0.S?E54=48+$?(?8\=?2XWM?:%3E]D[ISF*R6/J<;58'?\^TLAAJ;L
MS;O@JB\5#N"+)4U/.B2PHDB*P]U[HLW=_P`^-Y_#WN7/TOR]Z3J]H?#K.UV+
MBZT^:'6=5E=^;#V-+5P4%+5;?^56U8<9'N7IH#,32?:[FBCK]L20,@J:BB=7
M)]U[JR#!9[![IPF)W+MC,XG<>W,_CJ3+X+/X'(TF7PN:Q-?`E309/%93'S5%
M#D,?6TTBR131.\<B,&4D$'W[KW3K[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL-144]
M)!-55<\-+2TZ-+/4U,L<%/#&HNTDLTK)'&BCZDD`>_=>Z*A\HOE:WQQI]EXK
M;/0/R!^2G9'94V5I=B]?=#[%&=CFEQ$5%)4U^]^PL]7X#K?K+;BG(1`UV9RE
M,K@L8DET.![KW06_'^K_`)E?8O:.*[%^1N,^./QMZ-HZ'-K%\;-B5&>[Q[EW
M!55]&\&#JM_]Y3R[0V)MB7!56FI>BP&&R4=0286K-(\C>Z]T+E!\'OB71=[;
MJ^3E1T/L/</?V\*JBJ\EVMO7'2[[W9C#CJ*DH**EV=6[QJ,Y'L''4]/1+:FP
M:8^`NSN5+R.S>Z]T:O\`H/P.`/P!_0#Z`>_=>Z][]U[KWOW7NO>_=>Z[L?Z'
M_;>_=>ZZ]^Z]U[W[KW7O?NO=>]^Z]UW8_P!#[]U[KVEOZ'_>O][]^Z]TEL_O
MC96U,=F,QNG>.U=LXC;U$V3W!E=P;AQ&&QV"QR2I`V0S-;D:RGIL71+/*J&6
M=DC#L!>Y'OW7NBZ;N^>7PKV+-U5!NCY3]%8]^\\K_!.G&@[(VSEH>S<H,[3;
M8>CV548>OR%/GY(=Q5<=#(:=G6.J;QL0P('NO=(BH_F,_&2:N^0&&VC5]N=E
M[D^,U)-/VGMKKGH'NC<N4BJZ7<T6T*O![0J%V12X7?NX*/.2%)J/#U=9-%#&
M\[`0HT@]U[J-_L[^X<Q'T!6;&^%'S/W7BN]97DKLEDNL]M]>CI?%0;F3;M1D
M>Y,;V#O;;N8VQ+]N6R<%+%3U514XT>2-2Y">_=>ZD/WI\X,VG>])MGX+8G;=
M?L65:+H_*]I?)G8>.V]WC4)NE\54Y&K38&W]_9WK?"G;"?Q6G-=2SU,Q9:5X
MH9"S+[KW1+_YB_7?\U_Y"?![>?7G6FU_BKM7.[[Z,W;1]^==;>WGVWN+LO<.
M0&4FJ<AU=\?]]QXK9NVH9-^]?TSXDY#-4L+1U]<RH@CTRCW7NJ\,U\JNI/D+
M\#.W/A7L+?\`UYWG\DNT:3!]>?"7X1=5_%?<'0O<7PBW[AJ'1UK6]M[8W7NG
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M`KZ=TJ<?L_%[@JG9&C#(P)7W7NC*[?Z-[*[X^+V9Z;_F`S]:[XW'V/)D%[)P
MGQZJ^S>MM@0[<DS]/F<+LC"[A;=-)V+D:/'4M%#2U]:U30_Q>/RI)3I#*\3>
MZ]T-O37173'QVV1C^MNA^K-A=0;#Q87[/:G7FU\1M7#B4($:KJ*;$TM-]]7S
M`7EJ9S)/*W+NQ-_?NO="M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZAY''8_+X^NQ.6H*+*8K*4=3CLGC,E2P5V/R./K87IJRAKZ*JC
MEIJRCJZ>1HY8I%9)$8JP()'OW7NB39?KND^`/QDW31_!KXL/V/CML;MK=_P?
M&S9V_I-K3U6*W)GH,EV-2=/IO"7+[>Q&2H<<U1683:M.^+P]15K]K3FD\P;W
M[KW0J?%KY9]&_,?K.+M+HS=;YO%TN1J=N[PVMF\?5;;[$ZOWMC2(\YU[VEL3
M*K!N#8N^=OU-XJJ@K8D:X$D320NDC>Z]T9'W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7OKP/?NO=5T9K^;9_+HV]VS5]+9CY4;!H]XX[>$
M77F6R9I=SS=:83L&:LBQ\>Q<[W'!@9>I\-NW[^9*=J"IS,51'4-XG59/3[]U
M[JQ92'`9"&5@&5E(964BX92+@J0>#^??NO=<K'^A_P!M[]U[H!^^_D_\>/BY
MM9MY?(;N7K[J+`%6-'-O+<-%CLCF9%8)]IMS`!Y<_N?(N[!4I<?2U-1(Q`5"
M??NO=![LWY`;I^4GQHW)VS\2<%7;3W;FQG<5U!5_*_K#LOK/;>8K<;6Q4E)O
M3,;)J:3"=D3;!RU.TD^/E$%'/6JJ\1J2P]U[HH]+_*WJ^ZZVCW/_`#'_`)1=
MH_-#(1U=/D8.F*.:3H'XA8.MA9)H*>DZ(Z[RT-1OR*AF2R2;PS6X6F`!DCO8
M+[KW5KD%1A,5`F*IZK%X^#$T$2+CTJJ6G3'8VCBCAB!I_(IIJ2FA55!("J`/
M?NO=)C)]I]882BQ>3S/9&P<1CLW738S"Y#*;QV[0468R5.RI48[%U=5D8H*^
MN@=U#Q1,\BD@$"_OW7NF6M[YZ,QF7W?M_)=T]2X_/=?8BMS^_<)6]C[/I,OL
M?!8U:=\CFMWXV?,1UFVL1CTJXC/4UB0PQ"5"S#4+^Z]T@,K\SOB!@]N[5WAE
M_E1\=:#:6^<ODMO[+W14=S]=KMW=N=PTE+#E\-MO-#<+8W-Y3%2UT*5,%-))
M+`TR!U!87]U[IDS/SM^&NW]X=L=?9CY,]-T>^>B=H9??O<>TCO;$39_K;9VW
MQ0'-[@W=C*:::JQ%!B?XI3^<R*&B\Z:@-0]^Z]T&.0_FD_`6AV'UGVA3_)#:
MNXNO>X=TYS9?6^[MDX+>V_,+N?<NVJR@Q^?QM/5[.VQFUI&Q5=E((I9*GPQ!
MY+!C9K>Z]TS=R?S)NFMC8OY>[?V%A.V-^=P_$[I7M#M//;53H3N^BV?FLCU_
M@$KX-O8+LFMV+0;!W;5UV4KJ2)H<1E*N?P--*H*02LGNO=4!?QO>&:^`W6?\
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MJCPU4LWW?AT3&,/J]U[I-2=%?S`MR;/Z8H=Q?/#96Q]Z;5SV;RG=69ZF^*NU
M1ANV,1/GJ3(;;VU@L?V3O;>]3U_3XC"02T%75Q25<]<9S.HIV55]^Z]THYOA
M_OW,[H^0&8W5\W/EKD=N]V8K*X/;6RMM[DZ]V!C>A,?D<[0YFFJNGLUM/KVA
MW/CMQ8>FHC04^1R%97SM132B37(PD7W7NF*7^6U\><W@.C\+V+N7Y(]M57Q^
MRN6SFQMR]@?*+O2;<63RN7W)2;KEK.PIMK[WVOB^R#0Y:AB^SCS5)60T5.G@
MA1(F=&]U[I>X?X`?"G!;L[KWS1?&/J&?=?R/%>G>V8S6U*/<DW:E/D\[!N>N
MH=XP;B_BE)E<9/N"EBJ_M6C%.DT2,J#2MO=>Z'G:G3W4>P\5MO!;&ZKZWV9@
M]FPU=-M##;3V-M?;N*VI3Y"J:NKZ?;>.Q&+HZ3!PUM:YFF6E2)9)278%C?W[
MKW0CW/\`K<D\<<GDGC\DGW[KW75_?NO=>]^Z]U[W[KW7"&BHXYY*R.DIHZR=
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M]W9?-_&_M;)][[@^/5!\9^S%IMQ?("KWQM^IV_15$\?7'7!W5N6#`_?;@$$M
M;44L%-22TE3YG187;W[KW1W_`)2UOS^RNY=K]??#G`_'G9NV\W@ZRMWU\C^]
MLON?=DVP,@*[[6FPFR>A=I4^&J=]9V2AO5)59'<.+QL9M&ZR$FWNO=-GQ@^%
MVXNDM\9KNCN/Y5_(7Y5]Z;FVW)M;*;E['W)2[5ZKV]AZG(4F4K,;UG\?MA4^
M&ZSV1235U#$1424^1RPC4HU:P>77[KW1ZE"J-*JJ+=CI50JW9BS'2H`NS,23
M^2??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z*#7_"7II?EA@/F;LI]T=6=TKA:_:O:<_7.7CV_M
M/Y$[3FQE11X/#]\;3%)48G?%9LBOD2LPF6*09B@>/PBJ:F8P>_=>Z=NE?F/T
MIWGVSW7T)M^OW#M+O+H'/R8SL#J/LG`S[-WT^VYYC%MWM/:>)K9I4WEU)O)1
MJQ>?QTE11R,#%,89P8A[KW1J/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW16.
MR_G'\-NFNS<3TQVS\H^A^N.U\V:`8_K_`'EV?M+;^Z&.5*C%BKQ>1RD$^-.4
M+K]M]R(?.&!CU7'OW7NC2HZ2(LD;*Z.JNCHP9'1@&5T925964W!'!'OW7NN5
MK_3W[KW7=C_0_P"V]^Z]U'JJJEH8_-6U5-1PWMY:J>*GCO8FWDE=$O8?U]^Z
M]T@<MW#U'@,UD]MYWM/KC"[CPN#R6Y\QM_*[XVSC\YBMM8;'#+YC<.2Q-5DX
MJ^BPF*Q)^ZJ:J6-8(*?]QV"<^_=>Z+-N_P#F5_`'8G7N&[9W-\ONA:;K3<6]
MLEUM@-[XWL'"[AV]FM_8BA@R>3VABLAMV?*Q5^?HL?4Q324T6J01R*;>H7]U
M[IRJ_GU\:(.W-[]%T&?[!W'V;UYL'*]E;GP>U>D>YMPXV';.(VO1[QD7&[NQ
MNQ)MFYK/5V"R$#T6,I,A-7ULT@AAB>8%![KW0=5'\Q3"5_5.TNV.OOB%\\NS
M:'>&^<UL6DVE@/C7F=M;ZPDF#I:*LFW7NK;?969V/58#8^1BK=%%D9"4J9XG
MB"AE(]^Z]T(E3\C?D+4=K]B]>[?^"_<%7M+:.R,QN':7<VX>RNCML[![)W?2
M[=H<S@]@8?&?W[RN_P##U>>R5:V.;(UN'CH:*HIY&E81A6;W7N@ZJNW_`.9=
MG.J=E[AVQ\+^@=E=L9;?&;QF].N^S?E=5Y+#;1Z^IX*%]O;LHMW=?=2YFGW%
MG\I--4)4XI(H4I!`I6IE\GI]U[H0ZM_YAU7VGVA34-/\-L%TDNQ\W%TWE:JI
M[GW%VK)V1-A:!MN5?8>*BIL!M)-E46X#5+718^H-=/2B(Q.CEQ[]U[H`>W.D
MOYJ?8WQ<R&R<+\N_C7UK\A,AC^TJ+<>[-A_'#=64VON/"9[:\F/V%@-HG=?<
M5)D^N]S8G+M(]1GI/XHEID9*-6AN_NO=:OG5?SXZBV%L_M#^5MV9N#O?:U.G
MP`R/2M%\"*;X@=>5V5QGS2W#0TVSLYT_M_/5NSL[N3MSMO+YPG>E!NK(UAP>
M4Q^=^^G<-2F8>Z]U;C487Y(_&?XG_"'XF[[[R_FA]U_,S;O6>V][[JV[\0=B
M]95:Y&"?#X3`/UMV9WOOSK^GZ>VSU[L3.8:HQ])6Y/-_QV6%VJ:@U*O&X]U[
MHV7QS^+7\P'M'O\`[V[^^6'<'9?Q^Z@[DZMW)L+9WQ'Z\^46X>S,MU7E]Q'!
MTT._\=N["[,V=L78F[\'C,9,U$N#3*?;5E;*_P!W*`"WNO=3HOY"/\O.IS^V
M-_[LP??78G=&UMVU>\Z;Y![\^2O<F:[TK\E5M`RT%?V)#NFAR<>WJ+PD4V/I
M%I:2`2R:4'D>_NO='0K?@'\;,IV7W'VSE,=VSDMW=\[.SVP^QHJWY%_(&?:=
M5MO<M'C*#+4^V-AMV7_<K8-?)38B!8JW!4&.K:8AC#*ADD+>Z]TB9_Y6GP:K
MNN.N>I\QT_F-P;'ZGW;G-\;$Q^XNX>[<YD<1N;<D]#49JOJ=Q9+L6HW#FX:N
M3&4]J:NJJFFB6.T<:`L#[KW0@5/\OOX65W8O;_;5?\<>N,CV1WYM/.;$[CW?
MDL=69#+;_P!F;E@QU-G]KYQZVNGA;"9>'$TPGIXDCCD,2L1JN3[KW4:G_ET_
M`ZFV)L?K!/B)\?Y>O>L]P9C=G7VSJSK3;60P.SMS;@GHJG.9[;U!7T53%C,K
MEJC'4[U$T=GE:%"Q.D>_=>Z%1OBM\8GW;OO?LGQUZ.FWOVCAZ_;W9>[I^JMC
MS[C[!P&5%&,KA-Z9B;"/7;GQ.4&/@^YIJUYH9_"FM6TK;W7NL])\7_C/0;=V
M[L^A^.O1-%M+:&5KL[M+:U)U%U_3[<VOG,I+!/D\SMW"0[?3&X3+9&>FC>>H
MIHHYIGC4NQ*BWNO="=2;+V=093*YNAVEMBBS6=+G.9>DP&)I\IF3*D4<ARM?
M#2)5Y$R)`BMYG>X10?H/?NO=/T%+2TL204M+34T$9+1PP010Q(S'4S)'&BHK
M,QN2!R??NO=9)HXZF&6GJ(XZBGGBD@G@FC26&:&5#'+%-%(&CECD1B&5@00;
M'W[KW51]7_)5^(-5-6[73=GR?H/C?D]R2;IR?PGQGR)WS0_#ZOKI\DN:K,7+
MU%#*)8=F5^8'W$^W8<C%@)"3&:/PDQ'W7NK:J*BH\;1TF.QU)2T&/Q]+3T-!
M044$5+14-%21)!2T=)2P(D%-2TT$:I'&BA410``![]U[J3[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLR?I'^Q_WL^_=
M>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[JI+^;1\2^X?E-L3IA>H.I.K^X\MUOV(F>FP>YNUM\?&[MC:==DJ[;<&*
M[(Z9^3?7GWVY^M:C:$%!5G.XJ&@J#N/'U"".2.IH:>*H]U[H6\W\:.[,IN?^
M61G,_G=L[XS_`,6\GD,E\BNQ,GEZ^+<6\<W+\4M_].S;@V_'480U&X6W%V#N
MXUM1]W-1210R&30[EE7W7NJW\Q_*D^3O8M+W1T!NG<G4^SNB<1M/^9K1])]L
MXO,9[<N^>R,W_,GW+4[UI:??77,N!Q-'U[1]`Y3)U]'65%/F,L=RPR4KP0T9
M28GW7NK(/@ATE\B-E;A^1G>GR>PG6^P^S?D3N+J9VZIZMW=E>QML[$PG2O4>
MW>I:2K/868VULRIW!6;[K\)59I:88N$8FDJX*-YJJ:*68^Z]UH\]K?$'NC>6
MT?G?UE\@/A[_`#/-G;U^0?SR[*RWQ2[&ZTZPR^;V=6=*[BWOW+WAMK8$&P)=
MZ[>V_'G<YVS)%G,A)5PR5510U+/!5JU"B+[KW5HW_"9+X7[KZZH^TI.X.P>[
M_BM\Q^JNZ9MR=T_$*MPNQ<#+O+J7=^PMH?Z.][[WI-[["S'9V:VMO7.19:5J
M['YX43Y&E<#Q2Z@_NO=;'M#\:OG3M?K+L3;6V_YCF4W9V/N+=^"SFP.Q^X_B
M[T_N2GZ[VS0/D&SFRIMI]<U/5-%NVGW`*F!?OJB>&JI%IOVR3(Q]^Z]TO*+:
MWS^Q79_4+R]O_&'>'3.,V5@,5WC3Y/J+L#:?9FZM\4F.R2[CW;UU58CL+-[7
MVOBLUE32-3XNMBKOLH!*#43MH/OW7N@_I]^_S1]L=9;]RVY/CI\/^UNU\=O;
M!TO76T.MOD%V-UOM?<G7M5%D'W#E]P;DW_U1N2?![KQ$J4L=-1I!-35ODD9I
MX`BZ_=>Z$2G[]^4-)VEU;L3/_!K>K[+W?LC#9SL3N?:/=G3.>V=U/O2HP>0R
M.?V37[<S&>VOV!NR'#Y2CBH(,EC,9+%62522"..-9&7W7N@[A_F$28GJC>':
MO8WPI^=W7D>R]\879-9LF3HF#?V^<VF9IJVJ_OEM7!]8;KWC)GMBX@47CKJ]
M&7P331((W+<>Z]T(5/\`/KXY'MCK[I#+5O:>UNR^S-@8?LC;.%W5T-W3A<3'
M@,SMROW2E)GMZU&Q6V+MS<F+Q.,F-?C*W)PUU#,HBFC61T5O=>Z9MK?S-OY?
MN\NN]Q=M8/Y<])CK;:.],9USNG>.=W=3;3PVWM]YFCJ<CB=IYB?=289Z#.9#
M'T<L\4$BJ[Q1LX](O[]U[HQ>,^070F:W-A=E8?N_J'*;SW)M[&;MV]L_']D[
M.J]U9W:N:QDF;P^Y<1MV#,OE\C@<KAH7JZ>KBA>GFID:5&*`D>Z]TO,5N[:>
M<I)<AA-T;<S%!!.*6>MQ6<Q>0I(:HKK%-+4TE5-#'.4YT%@UN;>_=>Z4"D.`
M497!57!5@UT>^AA8FZL!P?H??NO=<M+?T/\`O?\`O7OW7NJO>TOYG>%V_P!L
M=E=2?'[XI_*;YE9'HG*QX#O[=7QYVEM*KV1UANHT--E:OKV+<.^=X[/IM_\`
M:&)Q-7%45V`P`KZNB$\44Y2=_$/=>Z.G\<_D/U7\JNG]H]Y=,9RISNQ=X0UZ
M4XR>*K\!N/`9O"Y&JPFYMH;PVSEH:;,;7WCM+/T%1C\GCJN*.>EJX'1@0`Q]
MU[H;['^A_P!M[]U[KO2W]/?NO=1WJ::*58):BGCG9'D6&2>))6CC!+R+&SAR
MB`$D@6`'OW7ND?G.R^M]LXN;.;E["V-M["T]=%C*C,9S=N`Q.+@R4\!J8,?-
MD*_(04D5=-3`R)$SB1D]0%N??NO=5V?-?JGXE?)O=VQ*7&?*/KCX^?.[J?!Y
M'?GQO[EV-V/L.G[TV#BI<#/NO('(;+JLRE=V5T3N?;M')5Y[`9*GFPN2Q2R5
M"F&14JH_=>ZY;0_FM?"/8_1O7.Z^_P#YT_%#.;PJA3;#W=N_J7<\^0V-NWMG
M"8#&97==#L'`4L^XMQE&I<C#7"AO4STT%2@9F%F/NO=#Z/GQ\:9^X\;T/BL]
MV'N'L7+]>+VGCH-M]'=TYS:M1LV?9$O8>/K3V%0;"FV%3Y#+[8BUTE!+DDKJ
MFJ=*5(C4NL1]U[H,4_F0[5S'3<O<VPOB9\]^Q:%.P4Z[AV)@?BUNS`=FU-5+
M@FSL6[DVAV%7;+JH^O3'HIGRSN(HZR01,H8-;W7NA/'R;[@K>X*?K;"_"7Y!
MU&SJGKP[S7NK-YGI[;6P:?<%1L<[LQO7-9CZ[L27>D&Z)LV\>`J7&->CH\FS
M,\IIHVG]^Z]T&DGR#_F(9SIW^^&UOY>.TMM=N2=B?P&+J+MKY@;&Q%''UR,)
M]Z>P:K?G7&P^S,7'D6S?^0C#)3R2Z;3F<(=/OW7NA+?-_/RO[BJ:&DV#\5=N
M="'KJ6II-P9/L#LW<7:R]J5>QA-28N7`8_9F(VLVS,-V0_V]14"L%55X>,S1
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M^\\UM+^`4NU7VWD]QU.,FRE9A9]LT,6/EIWE:*:CC$+AD]/OW7NA+VMUEUML
M;#4FW-E=>[&V?M['U4M=08+:VT=O[?PU%6SHL4]928O$X^DH::JFB0*\B(KL
MH`)L/?NO=+C4;6OQ_AQ_O7OW7NO7/]3[]U[KKW[KW7O?NO=%;^37S4^+_P`/
M<+C\M\A.WMM['K\\YIMG[(A^]W/VAO\`R)U"'$]>]7;5I<SO[>^3J)E$:Q8W
M'U!#L`Q4&_OW7N@<^1W>'R4WA\#\]W]\-=D;FV3W#7[-GWMM;KSN_HW<NXNV
M$Q-'%D9&V[1='X[=6VJZ3LS<#TU.N,H\CD8*2):D250`4H/=>ZU&HOB]O*7H
M2'O#?GPY_G%]Y?S4J7MO:GS)I-S=D_'W)4_QCQGRIQNY]M;IW9M?;_7^`WQC
MMNT&P=TX/`+M(Y2JI*RKI<7'!-3"G2(0>_=>ZWJ>H]]Y'L_JWKSL7+[$WCU=
MEM\;-V]NG*=;]@X],3OC8F2S6,IJ^NVGNS&QS5$5'GL#53/35**[*)(R0;>_
M=>Z$/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]UF3](_P!C_O9]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=%$^5G_'P?$/_P`6[V1_[[+M[W[KW06?.#X=;E[LJ-C_`"'^-^Z,7U)\Y/CW
M#D:OHWM&O@F;;6\<!7O'5;H^/G=U#1::G=/2'9JP"&KA.NIPM>8LI0%*F`B7
MW7NE]\+?F'MSY==?Y^JJ]K93J;O7J7<+==?)/X][KG@?>W2?:=#3K-683(^+
M2F;VEN"F(R.W,]3J:#.XB:*I@:_DCC]U[HY'OW7NO>_=>Z][]U[KU[?3W[KW
M7=S]+\'^O/\`O?\`7W[KW24W%L78^\,5/@MV[,VGNG"553'65.'W%MS#9O%5
M%7$KI%53X_)T55235,:2,%=D+`,0#S[]U[H/JOXU_'6OWO@^RZWH3IFJ[&VS
M@QMC;N_I^LMF/O/!;;7#S[?3;^(W.<-_&L?A(<%52T4=+%,L$=+(T2J$8J?=
M>Z+QD?Y7W\O?)=9;@Z9?XC]-XWJW=6^*#LK<6R=M[<;:>%S&_,705>*Q^Z*V
M+;%5B)I,I2XVNF@5M8'CD*VM[]U[I6I\!?BE3]K;/[LQ_6V3P_8VPMB4/6>U
M\MA.R^U,-C*#9&*VC6;%Q.#FVIC=ZTVTLDF)VO7RT]+/4T,U3`Y$R2"=5D'N
MO=!=3?RM/BGC>I,STK@JOY);?V7GNP<7V9DJC&_,+Y1R[Q;<V'Q4^%I(J3?N
M6[9R>\<;MQJ"H82XFGK8L;+*%E:$RJKCW7NJ<NG/C/OC^61WOVMC<]\:/YE7
MR2VQ)V9V]V#\9=]_%#N3=/8G5O8&U^YTRE3)M/Y&];Y[LW;*;4[DV1D\W/1R
M[LS"U5-E(8:/(_<BH@8#W7NC>_`S^4E!MGX:;VZR^3^<[ZV?NSY`_)G?ORRW
M7L+8WRN[=AW%U1D-X5533[8ZWJNWME[JP>7WCE<3MHP2;DK(YC29C/O+.?,(
MX93[KW5C4/P2Z4B[@VQW>^X^_P"JWCM+K^BZUQN/JODCW;-L>JV[0[-JMBQU
M6:V%_?8;3S>Y9L)6/)-E:FEDKY:^U8TIJE64>Z]T&]/_`"K/AE%U!F.BZO;'
M<>;ZYSF_Z'LW(4&X_E1\H-Q9[^]V-P\N"I*BDWKF.WJS>>/Q"8V=U;&05\>-
MDE;RM`90''NO="K'\!_B&G;6W>]INE<-D.W=I["HNL-O[YS&?WEFLKCMC4.S
MZG8,6!2++;CK,?-'/M"LEHJB:2%ZFJ1R\TDDGK]^Z]TGMN?RTOY?NT^LZSIG
M!?#OX^TO5.0WK3]CU_7]3UMM_*;7K-^4F-?#TN[:G%96EKJ>;.T^)=J9*A@7
M6`E`=)M[]U[HP5!\?.A,5NV@W_C.D.H,?OS%;<H]GXS>]'UKLVFWACMI8_$?
MW?H-KT6YHL,N;IMO46!_R**C2<4\=)^RJ"/T^_=>Z!_Y&_!?XV_)KJ`].;SV
M!C=J8O%9JFWEUWNWJ^EH.OM_=/\`9&+(EP/9W5>Z-OT=+5[1WO@ZE5>.IA!2
M=`8*B.:G>2)O=>Z27PVE^;.RJG?/17S`IL!VC1=9TV&FZE^9&U:C!X"/Y`;/
MR$M;3PT/9O5E/4C(;`[IVA%1QKFI:&.3;V7$R55(T+M+3I[KW1["3]"3_M_?
MNO==>_=>Z][]U[KWOW7N@IW5T1T=OO>&$[#WQTQU/O+L#;7V_P#=S?6Z^NMG
M[BWCM_[60S4O\$W-E\/69K%?;S$M'X)TT-R+'W[KW0K?7D^_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HH'RF^=WQB^'<&$H^Y^P=&_P#>(,?7
M72>Q,/E>QN]NSZTN\4-#U]U)L^ERN\MP&:>-HS4BFCH(&4F:>)59A[KW31\5
M>Y_E=WU7;UWAW3\7(_BITU68W'1=.[<WSO\`H=P?)//RS2U?\3W%V7L_:E/7
M[+ZNHI:+PFCQ0R^2RT,I8U7A(\8]U[KE\=/Y?'Q6^,6ZMP=F;"Z]FW-W;NZK
MK:S=WR#[=S^8[<[WW&]=//-+25/9V^JK,;BQ>%B6?Q0XW&R4.-AB552``>_=
M>Z.I[]U[KNY_J?\`;GW[KW77OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLR?I'^Q_WL^_=>ZY
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NHD^0H*:IHJ*IK:2GK,D\\>.I)ZF&*IKY*:!JFI2B@D=9:IZ>F0R.(
MPQ1`6-@+^_=>ZDAT+M&'4N@4N@8%T#WTEE!NH:QM?ZV]^Z]UTDD<FKQNCZ':
M-]#!M$B_J1K$Z77\@\CW[KW11_E9_P`?!\0__%N]D?\`OLNWO?NO=&S]^Z]U
M5[\W/C%VIB.P<#\^_A3CJ0?+WJ;;@V[OOK*2LCPVUOFAT'0U+Y3*]"[]G;31
MTV^,.S35NP]Q3*TN%S#&GE8T-7.J^Z]T;KXK_)_JKY@]*;6[SZAR%=+M[/M7
M8K.;<SU%)A]Z]<[ZV_4MC-Z=9=B[;J"*[:V_MCYV&6AR5!4`/%+'J4O$\<C^
MZ]T8CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=,NY=NX;>&W-P;1W'1#);
M=W5@\MMO/XXSU-*,AA<Y03XS*41J:*:FK*855#5.GDADCE35=65@"/=>ZITV
MU2?*O^5SFL5LTXWM?YM_R[\CE*+#;2S&.&0[$^7?PT@R%9%1X[`;FH6,VX/D
M=\?,5YECI\E"9MW;<I%"U*9"FB$J>Z]U=(I#*KK?2ZJRDJRFS"XNK`,K6/(/
M(]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!CY
M`]Z[.^-O5F?[;WUB-_[APF"FQ5##MOJWK_=/9^_]QYK/9.EPV#P.V-F;/QV2
MS&4R64RE;%$K%(Z:`,9)Y8H5>1?=>Z(9L;=7\SOY4[WVCNZ3:6TOY=?QFQ&X
ML/GZS:N^Z/;_`'5\P^XMOX^NBK)-O9_#T-94]2?'W!;FIH?#5)]SN+<-/%(5
M'VLOZ/=>ZLC7K/KA.PI^VDV#LU>TZG;M-L^;LC^[6'.^GVG1U5574VV?[UFC
M.<7`PUE;+**19Q!Y'+%;\^_=>Z6_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZS)^D?['_>S[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU<?YL";"VO_,W^*V_MZ)MSLC.0
MXKJ>CZWZ1[DA[QV/D<AN&F[(S[5&Y_@3W!U%DJZF_P!.M&U33OOG`UV)%/4X
MNFPOWU6M#,Z+[KW19^@W[)C_`)H_R6.RJQ)/D+D=E?S60E%MVMWU%\MJ9*7=
M^V:;XSO\SZ3-TDG6]7U@E)0T[]%28IX%3;=7CE.LI4W]U[H^_P#(VINM&WCV
M?E^A\;EJ78F1^(GPEC^0N0BI]V4V"K_Y@5(.[A\J(-XQ;F<,/D30/+A/[[?M
MI7:I:`UA9S&??NO=6<?*FL[//;_Q'HI-N["7JP?*G9$D6Y%WGN)^P'RW^BGM
MQOM7V2=A1[<CQ_WEU^X&X&D\0U>'4=`]U[H]_OW7NO>_=>ZIL^5?5_8GP5[K
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M>KNB^V$K=W?$SO3`0Y.;*_P;?NUJ`1[FZ]WB[U,D5)N_;TXKJ5&6.HIJR`>,
M>Z]TKOB5\H>P>^4WELKNSXQ]M?%[O#JT86GW[M/>5'!N3K'<#Y@Y"*DW'TEW
M5@/)M'M+9U9-BY2'04>3HP52LHX'(U>Z]T<NUO\`B/Z'_6/Y]^Z]TUSYK#4N
M6Q^!J<OBZ;.Y:DR%?B<)/D*2'+Y2AQ+4:96MQV-DE6LK:3&/D:<5$D:,D)GC
M#D:UO[KW3G[]U[KWOW7NO>_=>ZBUU=18NBJLEDZRDQV.HH9*FLKZ^IAHZ*DI
MX@6EGJ:JH>.""&-1=F=@H'U/OW7NBV].?-#XJ?(7LG??4O17>_7W<&^NL<92
M9;?V/ZXS`W?B=KTM=6_P^EAR.[,)'6;2&3EJKK]DE<]6H!9HPH)]^Z]T3[<_
M5'\SCY4;CS^([#[EV5\`/CY!G,ICJ';?QEKXNU_E1V)MNEKG@H\CEN\]Y[=H
M-B],QYV@19EAP&`R>6I/(4&0C=0_OW7NC^]"=';)^.'5>V>H.O*G>-=MG;"Y
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MY`-;JE^`38>_=>Z[CBBA#B**.(22/*XC14#RR'5)*^D#5)(W+,>2?K[]U[HI
M'RL_X^#XA_\`BW>R/_?9=O>_=>Z-G[]U[KWOW7NO>_=>ZHSW/357\GCO'*=E
MX>"1/Y6/R1W\:[MS;]'%))0?`CY!;[RR1GMO`T$"LF)^+W<>X:U5W-2Q*M-M
M/<$ZY&,1T=74HGNO=7C4U335M-3UE'405E'5P0U5)5TLT=1355-41K-3U--/
M$SQ3P3Q.&1U)5E((-O?NO=9O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW4/)8^CR^.R&(R4`JL=E**KQU?2L\B+445=!)354!>)XY8Q-!*RED96%^
M"#S[]U[JI,_RX_D#\?&EJ?Y>_P`Z^T>GMM12RU%'\<ODWCIOEG\>:=9)6E.(
MVO6;QS>*[PZXQ9)(1,?NFIIH-1*TS`*@]U[JGW?^Y?G-V[6;W_G2T5!C=^[O
M_EM[REZ6ZKZGZ-R>X,)T[\C^A>O,IF<1_,7WML['[WIZG<%=CM\9,-3[9J)V
MJ)4GV#&Z&8/&R^Z]U;WL;^8_\NNP]J[1W?M3^4?\E-P8/?6W<!O':FX<!\AO
MAOD]G9W:6Y:*ARN'S^/W1)W510M35V(KEJ8HI(8JADL#&&-O?NO='>^1_87R
MKV;MG9]7\7OC?LCO3=F<K98MU8CLGO:EZ2PNQJ`4$=1!65&8I=B=CU>X9Y*Y
MV@:&CI3HT%]14CW[KW1?.KL9_-EW?V/LO<7=VZ_@_P!*]18[-09'=_5_4NV>
MW>Y>Q]SX%$E$^VG[/WGE^NML[=K9I2I&0I,'5:%'^:8FP]U[I=_(;^7/\8_E
MEV70=B?)#$]A]O8K$X7'8?&=+[G[8[`B^/,$N.J*FI&;K^E<)G<1LC<V<K9*
M@?<2Y>GR$<@BCM&NF_OW7NC8]=]8];]0[6Q^Q^J.O]E]9[,Q2"/&[4V#MC"[
M1V[0J`!_DV'P-%04$3-:[,$U,>22??NO=+CW[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF3](_V/^]GW[KW7+W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]T43Y6?\`'P?$/_Q;O9'_`+[+M[W[KW1L_?NO=>]^
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MAK7GDK:*#`8[OJFQ,-)6R54K31+"$E:5RX)9K^Z]U8I\<_CMU'\3NE]C?'SH
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M.@^/'8$6YLEMG(UW\$V]N.3-[9QM7C9<HO[[Z/=>Z,G_`"^_F?WW\D]T;MVK
MW[U[U+LZJRG0?QT^6G4M9U#N+>&;IDZ9^3J]B/M#9'8D>\L5C)QVELI>OG&4
MK,:/X17?>(:>.+QLI]U[H6?E3V-UZ_:OQ'ZV3?FS'[%B^5FR,I+L%=T8-MZQ
MXP]5]N5(R+[5%<<ZM#]LXD\Q@\?C.J^GGW[KW1Y??NO=>]^Z]U[W[KW7O?NO
M=`;\D?CGU+\L>EM\]!]W;:3<_7N_L8M%D8(IY,?F<+DZ.>*OV_NW:>;IBM?M
MO>6T<U309#%9*F9*BBKJ>.5#=;'W7NB&_";Y&=M=6=K5W\N'YM[B.=^0VQ]O
M5FY/C?W]7PQX_&_-GX]X-XZ6#>49]%)!W[UK320T6_,-&?(\OCR].KTE6S1>
MZ]U;)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z\UD5G<A$12SNY"JJJ+LS,U@%`%R??NO=!7N_O7H_KY/)O[N;JC8\?`\F\.
MQ=H;:2Y.D#5F<Q1+RW'^O[]U[HA?S$_FG_$CI3XN?(_LOJOY>_$?=/<'7O1W
M;N\>K]G?Z=>LMQR[E['VAL3/9S:>W&V]A-WMELM+E-P4,%/]G#IGJ&?Q(0[#
MW[KW5?NS?D+\S]]=14O8.V_YY/\`+?S>[9>JZ?L*JZYP7Q?ZRS.:H<K+M`;F
MFVM40T/S+ER<=1356JE9WI5E!4DQ!@5'NO=7'?`#O?='R?\`A'\3_D'OI]O'
M?W<?Q[ZD[)WW3[6C^WPE'NW>>R,/GL[3XZ@:LKI\;2)D:V01T\DKO$OI))!/
MOW7NC>6M]??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]UF3](_V/\`O9]^Z]UR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5U?*C^7GB_E#W'L/L^I^0/<_6
MVV\;!MW%=N=1[6J=M9W8/<VW=EYFOW)L_'2T.^<+N7_1;F*'-Y2H&0S.UEQN
M5R]`Z4U3,?MJ26G]U[I.[)_E<]3[2[XW=VKD>S>UMY=9Y9_DCD-D?&C<59MA
M>INKMP_,3(T^:^3N9VUD<3MS'=B92'M#-K55:T.3S-90X:?)5AH(X/.=/NO=
M")\,/@1M#X;5&Z\I0]K]J=S[CS.R^M^G-L[C[5J]L-D-A_'SI-MU#I;IG#0;
M.VYM;&Y/&[!BWME`V:R$%5G\LU2#6U<PAA6/W7NE9\J\?0#=GQ$R(H:,9!OE
MOLB(U_VL'WAB_P!&/;R^/[K1Y]&D6MJM;CW[KW1O_?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]T3OYL?#O:?S)ZIH=K5.X<MUEV[USN.B[-^.??FTDB3?O0_<VWDD?;
M6^=LU#Z?N\?*S-1YK$S$T6;Q$\]'4*5D#)[KW08_`_YC;J[P7??QV^2NW,;U
M;\Z?C;_#L1W[UK1L\6W]YX2N:2GVC\B>F9:DB7<72?;$%.:FCF35+AZ\S8RL
M"5$`,GNO=6)>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ9E1&D=E2-%9WD=@J(B@
MLS.[$*JJHN2>`/?NO=5]]X?S3O@7T%N!]C;K^0VUMW]IWEBI>F>DZ/-]\]Q5
MU9"P1\?%UOU#C=X[GI:P.P!%5!3H@.IV5>??NO=`G'\T_P"8+WO<?%'^6[N'
MKW:U0RK1=M?/SLO$="T#12+Z*ZCZ/V#3=F=PY&%+AQ'71X/R1GB16NH]U[J2
MGQ4_F@=NHU1WQ_,GP/2N/K'O5;`^$7QTVCMM:*!A:2CINW>_*OM?=]2K?B>#
M%XV=!RI!Y]^Z]U(A_DW?%C<,RUG?'8OS#^5&0^L\W?\`\ON\\UBJIF_SJ5.S
M]D;LV)LF>D?Z"GDQSP(H`51;W[KW0L;-_E.?RS=@R-/MCX)_%^GJ'N9:K*=1
M;2W)63NP.J6IK-RX_+U-5.][M)([.Q-R2??NO=8/DM_+9^,';_QH^1?2W6OQ
MY^,W5V].Y>D.SNL-M;[Q_1/76/;:>X-Z[,S6W<#N9YL%MBFRJ_W=RF2CJT:G
M=:B-X@T160*1[KW55F0_E9?-C,]44'5.=^+O\@O,4M!L2GV.FZJGXW]W0[KD
M-/MZ/`?WD?)T='32+G93&*II%(!J.?\`'W[KW1G_`(Z?R'?AKU'\=.B>O,OM
M?/[*[SZZZGV'M'L#NWXP]P]V]!5^^-_[>VWC\9N;?DM%LK>^#QV5J]Q9BGFJ
MR^4H:F1FENXN!;W7NA=D^"?S:ZE#S_%S^:)W/4T$"H:7KWYI==;$^4^UZ@(0
MYI&WW10]7=PT"3Z?'YGS5<84Y$3F]_=>ZAR_+3^9/\>E/^S2_`+'=][.H75<
MCW#_`"]^PXM]Y!*1;^3(U?QL[?\`[E]F(P2S-!A\IN!Q9N/H/?NO=&1^.'\Q
M_P"&/RIS<NRNJ>[<%!VM0@C,]&]D4&:ZC[UP%0A83TN5ZB[*Q^V-\I)3%?7)
M#1S06(99"K*3[KW1X;6^OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZS)^D?['_>S[]U[KE[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*)\K/\`CX/B'_XM
MWLC_`-]EV][]U[HV?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JO;YT_#G<W>
MB[$[_P#CCNC%]3?.3XY'(9;H'M.O@E;;VY\57%)]V?'_`+GI:/35;FZ.[6@@
M^VR%-=I\36F')T6FII[2>Z]TOOA7\QMN?+S8&?J:S:^4ZE[XZDSYZ[^2OQYW
M7/"V]NDNTZ.F6:LPF1\>F/-[2S].1D-N9ZF4T&=Q,L=1`U_)''[KW1R_?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7K7^GOW7NB9_)+^81\.OB;5TV"[K[SVIB-_9(^/`=0[5&1[&[KW/5,I,%'M
MOI_K^BW)V)EZBK8%8S'CO&S`^H6)'NO=%6'RP_F/?)9?'\1_A#COCQL.OU+1
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MVM4Q,7@KMG=@X9\9OC9^0IY;/'/C,A2RI(H8,"`??NO=$A_V43YV_$I17_![
MY4U/?76V/34/BA\^,UF]\4\5'#&0F,ZN^5F$I*GMS93QQ`0TL&Y*7=E`GIU&
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M2)R(9FC]U[H8ZKY%])T/>%7\;ZOL3`0=U8WI^O[\RVQ9)9UKL+U!CMST&SJC
M?&<KC!_!\+BFW%D4@A6JJ(IIPDLD:/%!,Z>Z]T'WQI^;/QH^7M3ORCZ`[$FW
ME6];U&&7<]%DMF;\V-6'#[F&3;:.]-O4N_\`;&UY]X]<;T3"5C87<F)6MP66
M6EE-)52B-K>Z]TW_`"L_X^#XA_\`BW>R/_?9=O>_=>Z-G[]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[JLSYH?$SLVJ[`V_\`./X42X3;7S6ZKV__`'?S
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MPYJCS=)\`OFM48FKP]12+7T^6ILC%T4U)/C9Z%Q,DZN8VB(8'2;^_=>Z./6_
M.OX?X7X_]?\`RDW7\ANL-A]$=I;)P'8>P=^]A[EH=A4NY]J[GQ4.:PE9BL5N
MM\3G*JLKL=.LBT:4QJ_JICU`@>Z]T30_S0]]=_228K^71\,NZ_E-33/-!2]^
M=H4M3\6?BA!ILHRE%V/VCB(]]]A8^(L&MMG;&3$Z%3%*5)9?=>ZY#X3_`#K^
M2X%7\X/G5FNO]FUQD:L^-O\`+]QV1Z-V@:69`&P^Z_D+N.;.=\;RI72\<XQT
MNV(9%+#0;J5]U[HZ'QO^#_Q+^(U)51?'CH;8'7&5R0<YW>='BVS79.Z9I=)J
M*K=_9VY9LSV!NNLJG77)+D,E4.[DDF_OW7NC5>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I([[V
M!L7M':>8V'V7LS:O8.R=PTKT6>VCO7`8K<^VLQ2."&I\EA<U2UN.K(N;@/&;
M'D6/OW7NJK*W^7+W)\6JJIW5_*[^0]3TIADE:LJ?AGW^VXNWOAMGV,B2RT&S
M*6?(OV?\=IZHJ0LNU\C)BHK@'%,B@+[KW3[LO^:9A.N-T87J3^8OT[N3X#]K
M9>KI\/@=Z[VRU/O+XC=GY:4Q11+UG\H,124FSZ*JKY7UQ8G=<.W,NBL$\,C!
MC[]U[JUNCK*/(T=+D,?5TU?05U/#5T5=13Q55'64M1&LM/4TM5`\D%13SQ.&
M1T8JRD$$CW[KW4GW[KW7O?NO=>]^Z]UF3](_V/\`O9]^Z]UR]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=42?/S
MXV?*W<GSIZ"[O^,G5F\J/,SXC9VT*OY`=.]ZXGKBCP.,VSN?/9K=>V?F+U;V
M#'F-H=O]-#;N9<[8CP.*JMQ)7U>3I6FI5GI9??NO=!EM7^7K_,1'S?[P[,[*
MSOQ#W'U;\A_CW\RNH=Z]V;<I.TZ7NH8+MS=6WJOHO:64P6<R-5BD?K+;V#PF
M+H(**1\)2X7$9)F'\3KUJ*CW7NC/?RQ?C[\F^NMSY?>_R+ZIQ73#;*^(7Q#^
M%.VMMQ;^VWV'D-]5WQ5/;2[E[FQ62VC456.Q'6_8#=ATC8&@R'VN?B%-4FOH
MZ8M"']U[HQWRHVYOU>Y?B3N5^R2_7[_*?8])%UG_`'-P@\>2'57;<?\`%/[Y
M^?\`CA_RA3-X=&CG1?3[]U[H^GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZJP^7?Q0[=V;VN?GO\``N#$47REPV%H,-W9TEE:],%UO\W^JL`&
M>GV%O:KT_9[;[DVM1>0;+W>R&2BE;["N,F.F(A]U[HU_Q*^6_4WS)ZM'9/6%
M1EL7D<)F*W9G:75^\J!\!VATKV=A-$6Z.L.T=IU)^^VYNS;]6VEE<-!5PE*B
MFDFIY8Y&]U[HT'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z1O8'8O7_`%/M/*[\[1WQ
MM'KC9&"@-3FMW[ZW'B-J;:Q4`!/DK\WG*NAQU*K6L-<@+'@7/OW7NJ'OGC_-
M"V'\B/AA\S.N_A'T%\A_F7B\]\7_`)";8W'W7UQL:397QSVCB<GU-N_'YK.T
M_<?:$FU,)V+6X2BEEJ(<;M6'-U&1DA,$+"1E]^Z]U6KUU_,7I>V_C7L'9/=W
M\Z'XJ?$#9>W>@MH;6I^F?A[M7,;B[KRC87KFAQ<.'WSW]W1MW)KMK<,TT`AK
MZ;;NV8)(IM44-8&7R-[KW5G?\D_^6[\,]K_`_P"#OR%R_P`>-K[M^0&[/C/U
M%N7,=D]PPY?M#>N"R>4VKC<E+C]H-V75Y^/K?"X^HE(I,;A(,;2TD8"I&#<G
MW7NM@(``*J@*J@*JJ`%50+`*HL``!^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=)C>>R=F]C[7S6Q^PMI[;WSLS<E%+C=P;3W?A,;N/;>;
MQ\PM+197"Y>FK,=7TT@^J2QLOOW7NJI*S^6[VQ\6ZRKW9_*W^0=3T+BQ.]?5
M_#?O(9_MSX7[DD:2.6>AVGAY\D>R/CM45I0@5&T\B<9#<`XIU``]U[IZVA_-
M0PW66Y,1U9_,:Z7W7\!NS<G64^&PN_=YY&#>_P`0NR<O,8H8AUU\H,'24^T<
M;-7R/KCQF[(-N92-&"&)W#6]U[JUO&Y+'9G'T66Q%?197%9*FAK<=D\;5T]?
MCJ^CJ4$M/5T5;2R2TU533Q,&21&964W!(]^Z]U-]^Z]UF3](_P!C_O9]^Z]U
MR]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=%$^5G_'P?$/_P`6[V1_[[+M[W[KW1L_?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW57GRN^&'9>/[5F^
M<?P+R^`Z]^8N,Q%!C.Q^O]QU4V*Z2^:FP<$&:DZO[P@HXY%PF]<=2L\6UM\0
M1/DL'.ZPU'W&/9X4]U[HP7P^^:/6?S!VEGI\#C<_UIW'UIDTVIW_`/''L>*#
M$]P=#[^CCO5;:WG@U<BLQ-:5:;#YVB,V(SM`4J:29U+*GNO='!]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1
M6?DQ\U_BY\/\309'Y!=P[8V/D\ZW@VCL6%JS<_:6_:]@P@Q6P.K-JTN:W_O3
M)54RB-(\=CJC]QE#%;W]^Z]T2A?D!_,Q^78\7Q?^/.W_`(-]/9%@M-\@_FWC
M9-R=V97%NZ?[ENO_`(B[.S-.^#J'A;73OO7/XXD?KQYOQ[KW2UZ__E-]!/NO
M$]K?+7=W97\P#N[%5$>0QV]_E9F*/=6Q=I9-6:0R]8?'W#T6(Z.Z[ID=KPFF
MPD]=$+@U37:_NO=6@4M'24-)3X^BI::CH*2GCI:2AI*>*GHZ:EA010TU/2PH
MD$-/%$H5450JJ+`6]^Z]UC_AV._YU]#_`.<=/_U[]^Z]U+5510J*J*H"JJ*%
M50!8!54```>_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=)[=>TMJ;\VYF-G;YVSM_>>T=PT4N.SVUMUX;';AV[F\?.`
M)J'+87+4U7CLC22@>J.6-T/]/?NO=54U_P#+)WA\=<A5[P_EA_(C._$Z:6KE
MR>0^,78%'D^YOA+NR>5_-4T=+U9ELO3;JZ2FR$I;56;)RV.@AN/\@E`TGW7N
M@#^3'\WWY(?`WHOL+=GS0^`6\-M]A[2Q^*@V5V/U%O*7L7X9]G9[+[DQ>W:1
ML[W)C=MU>^/CWCRN3-9*F[MM1K'#!)'%4U,IB$ONO=9MP_S-OY@NU?C#V=\P
M*3X;?!OM[H7JGKC>?:^?WAT7_,IKM]0Y':6P=OUVY=R1;;FI?B=)A\MGDQV.
MD$-+)6TI,]HG*$W'NO=7L;7S:;FVUMW<D=.])'N#!8G-QTLCK*],F6H*>O2G
M>1559'A6HTE@`"1>WOW7NGWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%$^5G_'P?$/_P`6[V1_
M[[+M[W[KW1L_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=5[_,#X)4W>>Z=O?(SH+?T_P`:OG#UCBI*#K3Y";?Q<>1Q^YL$CFJ?
MJ#Y`[.62FH^W>D\]4#348ZL;[S%R/]WC9Z>H4Z_=>Z3'QB_F!U&Z^R*7XG?,
MKKR/XI?-FFH99\;L+)Y1\CU'\AL5CQXZWL#XJ]G5<5+0=B[>E*>:IP<W@W/@
MP_CK*0JAG;W7NK#*G>.T**HFI*S=>VJ2JII&AJ*:ISV*@J()D-GBFAEJTDBD
M0\%6`(/OW7NG>@R./RM,M9BZ^BR5&[.J5>/JH*VF=D.EU6>FDEB9D;@@&X/O
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M?VQE-W[LV!N'9>`WEO;%;8[CIA.^(ESGDJYJ6AEK:F$-<N^FWNO=;'&PL36X
M'8NR\'DHUBR.&VGMS$U\22)*D=;CL/1T=5&DL9*2JD\+`,I(8"X]^Z]TK/?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK
MM_S'.W^Y=A?S!.DJ^#O;N2AZ"ZVVYU9NC=G7WQ?[@ZJVAOCJ/+[NWUN?"5&_
MOD1T?V7A(1\ANE.VZ3%18BCBH<G4U^&_A&3:BQ_W<Z3GW7NNL)V/\A,/\U?E
M'O+I+Y3=R?)W:_Q[ZE^7==\I*3<[[=H/BGL7N-:&AW=\4_C)T9UGB::6MJNV
M^G-JX\0[ZKL97O)+'*CY:=,ED_LX/=>Z%/\`E)]G]D[C[`W7MS=?R0[.^0^'
M[$^#_P`%OF)EG[-W7AMZML+N'Y*KW>_9N!V#D<1AL3'M3K>J;8M#_#=M+Y:;
M$?;OX-"RLOOW7NCM?*G>>7?M_P"(^R3UIOU,/'\J=D5X[.<['_T?RS?Z*NW)
M_P"%($WL^^AD=;>'U8-:?RC_`#NBS^_=>Z/A[]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@`^2/Q<Z+^6_7DG6'?>P\?O
M7;L60I<[MZO\]9AMW;$W9CG$V&WOUWO3#3T.Y]B[TP54JRTF3QE53543+;44
M+*WNO=:>GP>^%VS=A]/;G[V^1_\`+=ZK_F7_`![SWR9^8>`SO<F(Z^A['_F!
M]:+UW\H>T^OFW!VKA=SU#R_*C;M?3[5:L:NP#TFX\?Y6A_A]9%$A7W7NKK/Y
M!VY.@<MTU\WL+\:9-NXOIO"_S(/DA/UAL3`X^MVNFR>NLIANM9]N8V/K_-4^
M-W#L;'O4I5^.AJZ*C:.99AXPP<#W7NKWO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW39FL
MUAMMXFOSVXLOB\!@L532UN4S6;R%)BL3C:.!2\U77Y&OF@HZ.FA0$O)(ZJHY
M)]^Z]U5YN7^;#U1O7/9'KOX*]8=E_P`PGL^@JY,76R]!4E)0=`;2R:2^%D[#
M^4F[WQ?3F"IX&.J2/&UN:R`6VFE8LM_=>Z3;?$SY^_+4&K^:WRJ7XZ=89`7G
M^*_P&R.7VK6UE#*IU8GLSY:;FHH.T=QB6-O%5P;6QVU::4:M,K*P`]U[H]_Q
MQ^(_QK^(VUJC:'QQZ:V5U5B\A+]SGJ[`8TS;JW;D&8R2Y?>^]LK)D-X;VS4\
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M8W?>[LKOW>-!USM'"[2I-R;QS;A\GN'+P8:DI(ZO(U14#4PLB^E`HX]^Z]T%
M7RL_X^#XA_\`BW>R/_?9=O>_=>Z-G[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJIR7\E3^75D=P;FW)#U3VEMZ
MOW?N[=&^\Y2;*^6'RTV'M^7=>],]7[HW3F*':NS.[L%MK#39K<&3J*N9*.D@
MB,\S,%!/OW7NDS_PQ_\`!#:%&V7^.^"[;^*7<\.9R^Y*/Y(]&=W=FTG>E5G,
MT8Y:U][[QWUN3>X[9P5140(SXK=4&8H`-8CCB,LC-[KW62'=O\V3XEQ_;;ZV
M#UM_,SZBQ2L!OOJ.?"_'7Y=4F*@"?Y5N'J?<]<W2'9V5AIP=1P>9V]454BDQ
MT>IPB^Z]T*76/\VCX0;]W12=<;T[+RWQD[BJG$!Z9^7>SMP_&WL(5FH1-1XV
M'LRDPVV=UR"I/B63"9/)T\T@M%(_%_=>ZL<H:VBR=)!7XRLI,C0U2"6FK:"I
MAK*2HC/TD@J:=Y(94/X*L0??NO=2O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=0\A6Q8V@KLC.':#'T=573K&`TC0TD$E1*(P2`7*1FP)`O[]U[JE_I
MG^:)\O\`Y$]6;$[QZ3_E$=^[SZC[2V]1;PZZW;5?*#X?;7GW'M++:I<-FIMN
M[@[3H\WA'R%(%E^VJXHYX@VEP"/?NO=&]^-/\P3I;O3XL[3^4O8M=@_BY@LY
MFNR=K[AVOWGV)U]@JO9>Y^J>RMW=6;NQ.3W-'G_[JUZ4VY-F5?AJ*:I>&:$J
MZGGW[KW0,9[^<E\+ZS+56U?CW6]N_-C?-*\L#[4^&O3V\^[Z>&KCX%/D^P\;
M0X[J3`E_U!J[<%."EV74![]U[I/GM#^;[\D%\?5_Q^Z$_E^[#R")XM]_)W=S
M_(COA**9B!7XKH[I[(XGKC`91(RLBP9C=U5I-TEA1@+^Z]U,PW\HKJG?^8H=
MY?.ONOO+^85O&CJ4R%/@^^]RPX'X]87(I*DZ3;8^+_7$6VNHX*:"5!XDR]+F
MYE`4M,\@\A]U[JTS:^U=K[(P&,VILO;>`V?M;"4R46%VUM;#8[;^W\11Q_YN
MDQF&Q--28Z@I8[^F.*-%'X'OW7NG[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF3](_V/\`O9]^Z]UR]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=%$^5G_'P?$/_`,6[V1_[[+M[W[KW1L_?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW0<]H=/]3=W;8J=E=R]9;`[7VA5B05&V>Q=H8#>6$=I8VB:48W<
M%!D*6.H$;$+(JK(OU!!]^Z]U7+5_R;/B5MBN?,?&?<GR/^$F:?6Q;XE_(/L/
MKC:3N;LD<O566R>ZNIQ1"0W>"'"0QR#AK^_=>ZQCXG_S0>N8Q'U)_-$PW9F+
MIV9Z?`_+/XD=>[PRTZC_`#5-5=A]*;CZ9K1`BJ%+-B)YF_47U7O[KW4G^\'\
M[3:<:K7=:_RU>Z5BO^]MOLGY%=(5E9&OZ?+3[@V3VU24=2X7U:9)8P6N!86]
M^Z]UTGR-_FXX_7_%OY971F;*Z(E.S/GM@Y%DE_W;4+_>[I':S"@X]!($YN+Q
MCGW[KW7,?+/^:#3#[6L_E(Q5E;+?P5N&^=G0CX.#7Z8Q7RY3"XW*H8WYE\5+
M+9/TZCQ[]U[K!+\C_P";M7_\6C^61T5A[CQ#^^/SXP48$Y_34M_=3I'<W^X]
M`1J(O/P;1GB_NO==1]D?SKMP-X:3XK?R].LSRGWNYOE5W9V;"#^)OL=M_'[8
MLICNP.CS!O01?U`CW7NLG]R_YV.YF*9;OG^7%U5"[&TFQ.B._NR*RGC)-B'W
MMVMMBDJ9HU;Z^*-6*C@`D#W7NH.9^&?\Q[>6#RD/8?\`-EWACWGQ>0C.*^/7
MQ$Z#ZQ6=Y:24+0P9'L:3NO(:97;Q^0NDI!NK1FQ7W7NJ'/AUU!NOJ_XM_'_I
MKY.?'G_A1CNG<O6O6^WMF[UZPZKSL.S_`([8_)X:,T]9A]C4/6O;/7V:R&T*
M5E*T<\U2*AX+'4#]/=>ZLR_E!_RF/BQL_P")W7N_OD/\$]KXKY!9/?\`W]N"
M:E^2^T*;L'M/;.T<[W]V3F.M*/.4V^<IO:DPV7;KFJQ,E2()#)/,3+.\L[22
M-[KW6P-@L#@MK8JDP6V<)B-N82@C$5#A\#C*+#XNBB'TBI,?CH*>DIXQ_J40
M#W[KW3M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZS)^D?['_>S[]U[KE[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JB
M?:?\Y;)5W9/SOGW;T=M+%]"_"?9G<6X=RSX7N_;-;\H,7DND:G)T-=%V)\;L
MSC\)F]O[:[:EQCU.T\MCZS)4?V4M-)7M3FK41^Z]T>WX5_*CMCY`5_>77O?O
M26W.C.Z>A-T['Q6Z=N;&[1/<6Q<MM_L_K[#=E;'S6`WM/LW8&0FK3@\P:;)4
MDV*A6FK:=O%+/"R2'W7NEC\JU9MP?$32";?+K9+&PO91UEV]<G^@'OW7NC::
M&_I_O(_XK[]U[KVAOZ?[R/\`BOOW7NO:&_I_O(_XK[]U[KVAOZ?[R/\`BOOW
M7NO:&_I_O(_XK[]U[KVAOZ?[R/\`BOOW7NO:&_I_O(_XK[]U[KVAOZ?[R/\`
MBOOW7NO:&_I_O(_XK[]U[KVAOZ?[R/\`BOOW7NO:&_I_O(_XK[]U[KVAOZ?[
MR/\`BOOW7ND%O;L3;NP,AUYC-P??BI[.W[3=<;8^QI#51G<E7MC=.[8OXBX=
M?L\>,1L^L+3'5:30MO5<>Z]TO=#?T_WD?\5]^Z]U[0W]/]Y'_%??NO=>T-_3
M_>1_Q7W[KW7M#?T_WD?\5]^Z]U[0W]/]Y'_%??NO=>T-_3_>1_Q7W[KW7M#?
MT_WD?\5]^Z]U[0W]/]Y'_%??NO=>T-_3_>1_Q7W[KW7M#?T_WD?\5]^Z]U[0
MW]/]Y'_%??NO=>T-_3_>1_Q7W[KW0?[@[(VYMG?O7?6^3_B']Y.SX=XS[8%/
M2&:@\>Q<909;.?Q&K#@49^TR,?A!#>1[CBWOW7NA`T-_3_>1_P`5]^Z]U[0W
M]/\`>1_Q7W[KW7M#?T_WD?\`%??NO=>T-_3_`'D?\5]^Z]U[0W]/]Y'_`!7W
M[KW7M#?T_P!Y'_%??NO=>T-_3_>1_P`5]^Z]U[0W]/\`>1_Q7W[KW7M#?T_W
MD?\`%??NO=>T-_3_`'D?\5]^Z]U[0W]/]Y'_`!7W[KW7M#?T_P!Y'_%??NO=
M(&7L;;L/:-!U`_W_`/>_);!R_9-,!2$XL[;PFXL)MBM\E?KTID!D]P4^B'3Z
MHRS7&FQ]U[I?:&_I_O(_XK[]U[KVAOZ?[R/^*^_=>Z]H;^G^\C_BOOW7NO:&
M_I_O(_XK[]U[KVAOZ?[R/^*^_=>Z]H;^G^\C_BOOW7NO:&_I_O(_XK[]U[KV
MAOZ?[R/^*^_=>Z]H;^G^\C_BOOW7NO:&_I_O(_XK[]U[KVAOZ?[R/^*^_=>Z
M]H;^G^\C_BOOW7ND`W8^W%[3AZ>/\0_OA/U_4]E1C[0_PK^[5+N*EVO+>OUZ
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M;%@R9BV3@YZ6*DPM+#2Q3&J%%"S>Z]T<OX7_`!'W=\:(NVMV]L]ZY/Y%]X]X
M[AV;ENQ^S)MBX;J[!5>.ZSV'ANL.O,3M_KK`Y3.X[;[8_9^`A?)3K63')9:>
MIJE2GBDCIH?=>Z$SM'X??&?NO<W]\>U^GMJ;[W*'QTT>5SZY&IEIZC$4DM#C
M*NDB6OCIJ.MHJ.=XHYXD254D8:K,U_=>Z0__``WK\+O^\?-D?[?-_P#UW]^Z
M]U[_`(;U^%W_`'CYLC_;YO\`^N_OW7NO?\-Z_"[_`+Q\V1_M\W_]=_?NO=>_
MX;U^%W_>/FR/]OF__KO[]U[KW_#>OPN_[Q\V1_M\W_\`7?W[KW7O^&]?A=_W
MCYLC_;YO_P"N_OW7NO?\-Z_"[_O'S9'^WS?_`-=_?NO=>_X;U^%W_>/FR/\`
M;YO_`.N_OW7NO?\`#>OPN_[Q\V1_M\W_`/7?W[KW7O\`AO7X7?\`>/FR/]OF
M_P#Z[^_=>Z]_PWK\+O\`O'S9'^WS?_UW]^Z]U[_AO7X7?]X^;(_V^;_^N_OW
M7NHU1_+H^$56]))5_&_KVKDH*I:^@>JILI4O05Z0STR5U"\V3=J2M2FJI8Q+
M'ID$<KJ#I9@?=>ZD_P##>OPN_P"\?-D?[?-__7?W[KW7O^&]?A=_WCYLC_;Y
MO_Z[^_=>Z]_PWK\+O^\?-D?[?-__`%W]^Z]U[_AO7X7?]X^;(_V^;_\`KO[]
MU[KW_#>OPN_[Q\V1_M\W_P#7?W[KW7O^&]?A=_WCYLC_`&^;_P#KO[]U[KW_
M``WK\+O^\?-D?[?-_P#UW]^Z]U[_`(;U^%W_`'CYLC_;YO\`^N_OW7NO?\-Z
M_"[_`+Q\V1_M\W_]=_?NO=>_X;U^%W_>/FR/]OF__KO[]U[KW_#>OPN_[Q\V
M1_M\W_\`7?W[KW7O^&]?A=_WCYLC_;YO_P"N_OW7NHTO\NCX0SU5)6S_`!OZ
M]GK<>*D8^MFI\I+5T`K8TAK10U4F3:>C%;#&J3>-E\JJ`UP`/?NO=2?^&]?A
M=_WCYLC_`&^;_P#KO[]U[KW_``WK\+O^\?-D?[?-_P#UW]^Z]U[_`(;U^%W_
M`'CYLC_;YO\`^N_OW7NO?\-Z_"[_`+Q\V1_M\W_]=_?NO=>_X;U^%W_>/FR/
M]OF__KO[]U[KW_#>OPN_[Q\V1_M\W_\`7?W[KW7O^&]?A=_WCYLC_;YO_P"N
M_OW7NO?\-Z_"[_O'S9'^WS?_`-=_?NO=>_X;U^%W_>/FR/\`;YO_`.N_OW7N
MO?\`#>OPN_[Q\V1_M\W_`/7?W[KW7O\`AO7X7?\`>/FR/]OF_P#Z[^_=>Z]_
MPWK\+O\`O'S9'^WS?_UW]^Z]U&/\NCX0FM3)'XW]>G)1TDF/CR)I\H<A'CY9
MXZJ6@2M.3^Z2AEJ8DD:$.(VD16(U`$>Z]U)_X;U^%W_>/FR/]OF__KO[]U[K
MW_#>OPN_[Q\V1_M\W_\`7?W[KW7O^&]?A=_WCYLC_;YO_P"N_OW7NO?\-Z_"
M[_O'S9'^WS?_`-=_?NO=>_X;U^%W_>/FR/\`;YO_`.N_OW7NO?\`#>OPN_[Q
M\V1_M\W_`/7?W[KW7O\`AO7X7?\`>/FR/]OF_P#Z[^_=>Z]_PWK\+O\`O'S9
M'^WS?_UW]^Z]U[_AO7X7?]X^;(_V^;_^N_OW7NO?\-Z_"[_O'S9'^WS?_P!=
M_?NO=>_X;U^%W_>/FR/]OF__`*[^_=>Z]_PWK\+O^\?-D?[?-_\`UW]^Z]U&
M_P"&Z/A":T9(_&_KTY):-L>N1-/E#D%Q[3K5-0+6_P`3^Z%"U4HE,(?QF0!M
M.KGW[KW4G_AO7X7?]X^;(_V^;_\`KO[]U[KW_#>OPN_[Q\V1_M\W_P#7?W[K
MW7O^&]?A=_WCYLC_`&^;_P#KO[]U[KW_``WK\+O^\?-D?[?-_P#UW]^Z]U[_
M`(;U^%W_`'CYLC_;YO\`^N_OW7NO?\-Z_"[_`+Q\V1_M\W_]=_?NO=>_X;U^
M%W_>/FR/]OF__KO[]U[KW_#>OPN_[Q\V1_M\W_\`7?W[KW7O^&]?A=_WCYLC
M_;YO_P"N_OW7NO?\-Z_"[_O'S9'^WS?_`-=_?NO=>_X;U^%W_>/FR/\`;YO_
M`.N_OW7NO?\`#>OPN_[Q\V1_M\W_`/7?W[KW0S]1?'SI;H6+<,73W7.W-@#=
MM3CJO<LF#IYDJ,W48BGFI,6^1JJF>IJ:A<=35$B0J7TQB1M(&HW]U[H9/?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U2OVEN#Y&8'YY?+K:6X_FW3]4=6YW^7#E.SNJ,@=B[>H]A
M?$>JPG9M?M>M[:SN&W+N:NQ'9F[*:%9LE5Y3+R4%(*>G6DCIXJ>-M7NO=`;\
M'=]=P9GH#MW+[.[R^2>^NC_DG\J>E]C?!7L'Y'[^J-__`"$K^J\OBMH)V_VV
M:U:;&[FVIL3=5%MC=6Z=H8W-O33C"4\<_@IX*R&%O=>ZK>HOF]\GMG?'_>7=
M^W_E+VSO?L#Y*_"7`=[]J;,W)V#AJ_:_QX[(W/\`S`NG?C5N=NEEK\)/0?&_
M&[0ZU[&W)1K#,L]+B*S#QY&JAEFQ\S/[KW5]/\HK>>_-P?'WMG9/9VY.RMT;
MYZ-^47;G3N=K>S>^\?\`*#(T;8>CVCNS'8O;_?$&R.O<YV'MBBQ.\H/%/F<9
M%E:*K:HHG9H*:G/OW7NK4O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW5!F\MY]R[.W__`#?L-\AOYAF6Z>ZTV'M7XC=IX/N+;^SL3MK%
M_%SIO=E=V74;XZ^ZVVY7YS<G@WSO'9VS3C5W*\M3FJC-Y6&MI:3RT]%1CW7N
MD1TSVU\I^MO@"N8DWOW?E-U[N[A^1W=_QN7Y!;HD[*^1F-^*?3G6>Z>].MMM
M=YY;$F">KW)O7.[0QV.R6&R=349*BPF[(L=4'[F!H8?=>Z+7UUV37Q_&KY@Y
M7L7YJ?-CM#877_PK^#?STJ,_UW\DJ_#=OT7=7=>U.^<EO7J;K_M+:F%-9M7K
M/?\`F=JX6"FVK%%/1XIBK4\2JXC;W7NMA+X0=-]I=!?%;IWJONWM_>_>O;6W
M]O5==V!V5V%N6NWCN7)[FW3F\KNS(X([HRK-E<]@MD2YS^!XFJJR:J;%8ZG:
M;]PM[]U[HUGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MK7\W?OGN#9>Z/YP&)^2G\Q+.]0=:]<3?$OL>A[CVMM#%;6IOCITIO"BW/E-Z
M=4=2;<J\WN>;$[XWGM3;IP\&Y%EK,_49W+15]+3-414E*/=>Z2/6O;_RSZI_
MEVPYRIWMW17=AY??7RQ^0G05-WQN,]F_(7$_%CI;K;?_`'5U)M+OS,8<P_Q/
M=VX\[B-N8G,XG(5-5D:3&[F2@G+5-,\<7NO=$FR/R`[ZVCTWO_JSK7Y@_)GO
M>N[<R_\`*CW%A85[MVLG<VY-W?,7`=W;G[VZ?Z:^36?APVU?CG09S;G6M)FL
M14UDHQ^%CH9,?2&F;+PR1^Z]U?;_`"DNQNP.UOY?706\NT]Z[EW_`+^>3MG;
M&X]Q;TR6-SV\HJC8/=_96PJ3;&[MUX8G#[ZW3L7&[:AP>1W%2%J7<59CI,E$
MS)5*Q]U[JQWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8IQ,8
M9A3/%'4&*0023QO-"DQ0B)YH8Y8'EB5[%E5T+#@,/K[]U[K6XS/8O96R?C9\
M[XOE]_,6[AVOC^H?YC<FU<]V=T;MJCV=VSV3LS<?2/4VX]H_$3XQ[?QV8W!F
M.L,YN#?N_J*@Q!Q%3D,U(:*<S3!JVLJXO=>ZX=J]Z_-7X[_RPNL)=W=E;OQ'
MR5ZT^-O>G>78VZ,_N3%]B;ZPNU7WO!U-U7A>S=XX>%-E[OWIL/8O<L&0S&2*
M5L+;IV9]VYGC26:3W7N@3["WKWUM7;_8WQ_V%\L/EGVYT%U#\[-W=<9;>VQO
MD1L-_F[N'9]9\(.H.\=BX?9W=6_,KM!=\=?]?]Y;WJ\MO)HJJ:LQVT2(ZCRX
MRDJHQ[KW5_?\OKMGL#OGX+?#[NOM>LH\AV;VQ\;.F>PM_P"0Q^.@Q-#D-W[M
MV#@LWN"NI,92*E)0T]9DZR21(H56%%:R`+8>_=>Z.![]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NF3<U-N"LVYGJ3:66QF!W358;)T^V\WF<//
MN'$8?.S4<T>)RF4P%-EL#49O'T%<T<LU(E=1O41H8Q-$6UCW7NM8/=?9':&,
M_E^[57O[^8%\GLMV5C/F7\TNA\+C_CC6X'K?Y*?.3M_`=Y=G;&Z0Z]ZVW5CJ
MV1NG]I[9R."7(UM)CV_@F/P%.8J^IBH*9VD]U[JT[JY/EYNG;/4W3F:[MQFU
MOD)US_+\V3)W#VLF"I^S=F-\D.VSMO`P[_R.W*?)[.VOOV;;\W5.YJ[%".2"
MDEEKWDE44SB";W7NJ4=R?(OY`[H^''Q?Q^^_F9WAUUEMF_RM/F[\SAW)L[L>
MCV'O?NOY,_&7>VRL'L*GW]FZFCR"[_V4<%N#)5^0V;$/M,BC1F59(:6,+[KW
M6UWU9G,KN?K'KG<F>(;.;AV'M#.9EE@%*K97+;?QU?D2M*H44P-94/:,`!/I
M^/?NO=+SW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)_=E)N6O
MVON*AV9FL7MO=U9A<G2[9W#F\'-N;#X//3T<T6*R^3VY3YC;\^=H<=6LDTM(
MM=1FH1"GFCU:A[KW6K]O#LGM2G_EV=6+W7\_?E#E.W_]F>^:_1.T\'\=<I@>
MN?DC\Y^]-O\`??9^Q>D=L[/WG15ENIMB;)DVT^3RM+2,FW\=M]`E?4Q45&HF
M]U[JV+8B_+7>>!V1T[4]YXG9???6WP!ZYI.U^W(=M0=E;-'R6[?_`+N4&4[&
MGVL,ILW:V]:G;"=29ZNP@5H:,MG)))X_MV%++[KW1!,QV5\L\K_)F^#_`'EM
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M7HMTO3XVEAC.;I-NUTU%'46\BTTK1@Z21[]U[IYVY\3?C#M!N[&VO\?NGL`?
MDE6UV1[_`!BNO=L4:]RUF3HJG'9&7L=(<:J;M%=1UU0LJU@E20U$S,"TLC-[
MKW2QZ:Z0Z?\`CMU]A>I^B.L]D]1=:;=-6V#V-U[MS&;6VSC9*^IDK*Z:FQ6)
MIZ:E6>LJI6DED*EY&-V)]^Z]T*7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[H!>R?BU\<.XL3VE@NU.C^L=_X?N^DV10=PXW=6S\-F*3
MLVCZUK&K^OZ?>\-72R+N./9M8YDQWW7D^T:WCM86]U[K!TM\4OC5\<MMXC9_
M0W1O674>UL!FMS;CPF`V%M+$[=Q6+SV\Z6CH=V9>AH\?3Q0T]?N*CQ\$57(H
M#3QQ*K7`'OW7NH6S/A]\5NNMC[IZSV#\>.G=E]>[WW[#VEN_9>U^O]MX/;6Y
M.Q*;<.+W72;RS.(QN/IZ*OS]%N/!T=9!42(7@FI8BFD1J![KW1CO?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%_P"R_BE\:>Y<
M1VA@.UNBNK>P<+W8=DMV]B]U[-PF9HNRVZVFCJ-@/O6"KI)$W%)LZ:%&QS5/
MD:ET+H("BWNO=<NF?BM\;OCMMG#;,Z+Z/ZSZGVGMVOW5E,%MW8NTL3M_$8G(
M[Y^R&\:R@HJ"GBAIZC<PQM.*UE`-0(4#WTCW[KW26QOP=^'&&Z?W[\?<1\7^
MBL9T?VEG<KNCL;JB@ZRVG2;"WIN3-5E/7Y'.[BVU!BTQF2RTU920R)/)&9(6
M@B\901II]U[H<NN>M^O^H-C;7ZQZKV7MGKOKO9.)I\#M'9.S<+0;>VQMS#TF
MKP8_$8;&04U#14ZL[,0B#6[,[79B3[KW2U]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=%C[1^%OQ)[LVIN;8O;GQQZ<[%V;O/LR'N?=F
MV=V;#P&8PFXNVJ?!1;9A[(S&/JJ-Z>NWFF`A6D_B$BFI,`TES[]U[I6]?_&G
MX^=4[#Q'5W7'3'6VS>N,%LO/=<XC8N"VCAJ/:M#L'=&5JLYN39D.#6E./.V<
M]EZV:HJZ)HS!42RL75M1]^Z]T'E1\#_A95]$83XOU?Q7Z%JOCOMO.4VYL!TO
M4=8;3FZZPVXZ3*39F#/X[;$F,;&TF:&2J)9&JD03OY75F*.RGW7NC54E)2T%
M+34-#34]%145/#24='20QTU+24M-&L-/34U/"J0P4\$*!$1`%50```/?NO=2
M/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW10^T?@#\).
M[-J8/8G;7Q5Z)[#V9MC=V]M_;=VMNKKC;65P.#WKV1D:G+[^W1BL944+4E!F
MMWY.LEGR$\:J]3+(S.22??NO=#[L?JKK;K3#8S;O7^QML;.P.%V7M'KG$XC;
M^'H\;C\?L+8-'7X[96T*6EIXDBBV]M:ARE3#0TH'BIXYW5``Q]^Z]T%FX_AS
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MEIJ*FMXH(9&10`2/?NO=)[_0!TA_HOP/2?\`HGV!_HAVK+MN;;76IVOB3LO`
M3;/SM%N?:DN'V^:;^'8Z3;FX<;3UM$T2*::HA1TL5!]^Z]T+WOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KJX_J/]O[]U[KUQ_4?[<>
M_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_M
MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'
M^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_
M4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7
M']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z
M]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U
M[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'O
MW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<
M>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_
MMQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U
M'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ
M_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO
M7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>
MZ]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]
MU[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'
MOW7NO7']1_MQ[]U[KUQ_4?[<>_=>Z]<?U'^W'OW7NO7']1_MQ[]U[KUQ_4?[
M<>_=>Z[N/Z_X_P"P_K[]U[K`?K_L!_O0]^Z]UU[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[K)_U[]^Z]UP/U_V`_P!Z'OW7NNO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9/^
MO?OW7NN!^O\`L!_O0]^Z]UU[]U[KWOW7N@]R';G5&)KJO&97L_KO&9*@GDI:
M['Y#>VV:.NHZF)M,M/5TE3DXYZ>>)A9D=0RGZCW[KW4,]V]+@$MV]U<JJ"S,
M>P-I@*J@DDG^+<``<^_=>Z*9LK^9;\9=[9#KN*GJM\[<V]VME:/#[#W]O':T
M6W=B9NLRF&RF?P9.=JLLS8VGSV+P\TE))50PK(=*'2[JI]U[HV?^FSIC_G[O
M5_\`Z'^T_P#Z[^_=>Z>\!V/UWNNO_A>U]_;*W)DA"]2<=@-U8+,UPIXBJRU!
MH\=7U-1X(BZZGTZ5N+GGW[KW5)FT_P"=Y/F>R<%C]Q_#_<NU^B-Q_,[<'P@Q
M7=M-\A>D]R;ED[/Q7:FX.G,9F9?C[09&G[93:^7WE@3KE6F>2EH)?NBKQ*2?
M=>Z/8O\`-)_E]/UWV5VS%\I^MYNN>H=VXC8/8.ZX3GIL=A=]9[)Y/#XO9=*L
M6%>JW#NRHR.&JXVQV,CK*R$4[M)&B*6]^Z]TEM^_S7OA5LC<_P`,L'!VQA]V
MX3YS9C<N.Z:W_M>27);'%#M?#U%;7Y;<.:@IY%Q"?QM8<2\$ZQST==*XK!3)
M!.R>Z]TT;L_FV_#J7X[_`"'^070G8^`^2M+\:3LQ>P]E[!R<N&S]/_?K=N-V
MIM^JBDW/C:".3#Y&6MFJ*7(PQST%9'22"&9R./=>Z$*7^8Y\:-I;V[=V7W3V
M+L+I9^LNR]Y=<8[+;JWM05&.W54=>]1[<[GWE/555/0PX_9V=PVS\\]3_!*^
MH_B-32TK3P)*ITK[KW2B^4OS;V1\=?A+N[YP;:VYD>YMAX;9>R=\[3P.#R,&
MS*S?>'["SVV<'M::CRF[Z2DI\!3UPW53U)EKX8EC@N7"_CW7NB6;:_F_9*D/
M?6W^\?BM5])=A=)]2;`[P@QC?)#I3M+K7=77^_.SZ/J:`U_<G6U=FMJ[#W91
M[DJM<.(RD:5.0I5\E.66Y7W7NCZUWSN^'V*^1^.^(>5^0?76.^264CH?L^J*
MO*319MZ_)XM\WCL`V0:E&WXMUY#$1FJIL0]6N4J*>TD=.R,I/NO=$1[6_FA?
M)[K/Y6[J^+,'\M/>FZ*_;_5V]/D!C=\4GRFZ'QF)W#\?-C[RI]EY/LN'#UKG
M)XZNER%9$\>!F/\`%"C_`*#8D>Z]T8[XA_S2?AQ\Q>L*G?\`L7N'8V%S>T>G
MMH]T]R;#S&YJ49+IK:FZ\1)E?N=V9R>GH,#64&$DIIZ6MKJ.6:EIJJ!HI622
MR^_=>Z=G_FG?R]HNGZ'OR;Y4];4_4N1W^W5=)NVI.X*8/V,<-6[BIMFRX*HP
MD>Y*;/9/!8Z6KH8):-&KX`KTWE#IJ]U[I7T_\Q'X357==3\<X?D9L(]VT>V*
M_>%3U[(V9AS$>%Q.S8NP\LGFFQ4>,?.XG9$PRE7B5G.5IJ2[RTZ!6M[KW4'I
M?^9-\#OD.G8$O3'RGZDWU3]6;"Q_:?8%709]L?0[:ZVR<$E13;ZJZ[-4V,I)
M]K1")HZFM@>6"CJ!X9VCF]'OW7NGWK'Y^_#;N;`;$W/UE\@-D;LP_9G:+=*;
M(EH_XS25N:[5&W\ENR/9#8C)XJAS&+S%5MC#U&0@%9!3QU%''YHG=&1F]U[H
M(-T?S6/AG@>T?B=U9BNRH=X5WS#[![6ZTZPW'MS'Y>JVU3[FZ=R>5VKNZAS-
M;_#?-3U2=A8IL!$@C*_>ZGD>.G0R^_=>ZP;._FM?#*JVYT)4=M=V=7=-[]^1
MDV3AZ\Z^R._*+=SUGV?864ZVQU34;JV]0'`8W&YW<F.%-2U>0:AIIJQVIHY)
M)8G`]U[H=-L?.SX@[T^1NX_B/M;O[86;^1NTY<O39[JRCJZTYJCR&W\?0Y7<
M&%AKY*&/`Y'<.`QN1AGKL=35<U=1Q,6FB0(^GW7NGKY??)7$_$7H/='?.<VI
ME-[8W:^X.N,!-MO#9"BQ>0K).QNR=I]<4M3#6Y!'I8X\75;K2JE5A>2*%D7U
M,/?NO=(M/YAWPED^0D7Q27Y(]<_[,/-O/*==KU4];7Q;C3?6(V_3;JJ]IU+2
MT"XRDSDFWJR.JIJ>6H1ZV,M]N)2CA?=>Z4'1_P`Y/B+\E>QNQNH^AN_^O>T>
MQ^IVG._-J[6R<U56XFGI<Q4[?J\E0SS4T%!N7#46=I'HYZ[%RUE'#5`1O(KL
MH/NO=&L]^Z]U[W[KW7O?NO=('*]K=6X+(56)S?977^&RM#)XJW&97>>W,=D*
M.72K^*JHJS)0U-/)H8'2Z@V(/OW7NGK;N\MH;PCJIMI;KVUNF&A>..MEVYGL
M5G(Z-YE9XDJGQE75+3M*J,5#D%@#;Z>_=>Z!2'Y>_&:?MG.=(IW9UV.QMN;/
MQN^LOAY=T8B&EI<!E,G4XF#_`',2U:8J3*0U-.K3T2S&J@@GAE=`DJ,?=>Z&
MZAW?M/)X.;=&-W1MS(;:IDJ9*G<5#G,95X*GCHK_`'DD^7IZJ3'Q)26/E+2`
M1V]5O?NO=-.#[,ZWW/D(\1MKL+8VX<K,DLL6,P>[<!ELC+'`ADFDCHJ#(5%3
M(D48+,0I"CD^_=>ZJN[*_G*=+=6_(;Y[?&;<?7.[H>QOA%\=Y?D9BUES.&H\
M5\@MNX?K:#LC>6V>OZVHC"8O=FT,=DJ):BEJ?+(]/4FJ5?#%(1[KW39NG^<I
ML/9,&\MM[HZ%[!H>[Z_:WQIWA\6^CZ7<6`K=S?,7#_*.AP]-LN3J')M!34$+
M[-WI5UV*W:*E7&WH<;)7SDTLD3-[KW2K^1'\UJDZ$^4FV_BO1?&?L/M;>E%U
MSUEVIW,FQM[["BW/L3:'9V[9-F4E?U9UEGJ[&;^^2[;1R=)4SYY-IT<LF+H8
MDED4O((A[KW29V=_-*[G[3[\[5ZGZE^#4F[MB=1?*+=OQ@W'VIF_EY\>.O\`
M(U68V)N#&8;=6[<3U'NS(4?860Q5'2Y(55/310O/6A#%"6?W[KW1\?F;\H,9
M\/>@-S]UU6R<WVCG:3.;'V1U]U3MBOHL5N?M/LSLO>6$V'L/8.WLADT?'T63
MS^XL_"GFG'A@B5Y)"$1B/=>Z`K!?S3?B!1_&KHKY+=V]D8CX\8/O:EW/083:
M?8=1-6;CQ'8/7E/F3VAUC4KMJCRJ5^[=@Y#;>1I:B&!2U1)2'PJY95/NO=+O
MKK^93\"NVZW>%!US\K.G]U3;`ZEH>]MX34.Y!%CL%U%D(X9(M]U67K8*7%28
M>E:HCBJ_%-)-0U#K#4I%*0GOW7NG7:W\PKX5;SZKP'=VW?D5L&LZHW)V;A>F
MJ#>]3+EL3B*'L[<E2M)@-H[G&8QE!5[+KLQ42Q"GDS$5#3RBH@*R$3PE_=>Z
M>,]\W_C1AOBCOKYKT'8U)NWXY["VWO+<U=OO:E#79"#/4NR,ID-OY.BVC3U4
M%`VX:W(;EQSXW'M"?MJZK=!%*T;B3W[KW05_&GYE=W=L[XS&T?D!\%>Z?B-A
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M]%?SG/Y?'=_5/2O:G^GG;'7$/?FXMR;7V%M3?[UN+W+_`!3;FYCM>;^\$4=#
M+1;;QU3634H3(5DT.+,U4L"U3S(ZK[KW5J/_`",$<@@_0@_D'W[KW7O?NO=>
M]^Z]TDFW]L1*O-X]][;12OVS3S5FXZ%MRX5:S;])3LB3U6;IC6B?$T\#R*'>
M=8U4L`2+CW[KW423L[K6&AQ>4F[#V+%C<W-44^%R,F[MOI0Y>>DD6*JAQ=6V
M0%/7S4TKA9%B9RC$`@$^_=>Z`7:/S=^-F]=Y2[*Q'8$--4LV1CP^X<W0U6#V
M9N:;#QRRY2+;NZ<FM/BZYJ6&GD=2S1+4QQL].94!;W[KW0^-V7UPE)B,@_8.
MQUH-P5$U)@:UMV8!:3-U5/,E/44V(J3D!#DJB"HD5'2%G978*0"0/?NO=.U!
MNW:F5S60VWC-T;=R.X<0&.6P-!F\969K%A'2-SD<53U4E=1!))%4^6-;%@#R
M??NO=4P9/^>7T7BZ3Y_8^;JS>B]@_`3N_:O5.Y^OZG/82BR':FU-W=I;9ZCH
M^VM@Y.H@6DEVWBMU9^2+)4S+)/0/!''*RM51>_=>Z%')?S8-N8[LG+_&_P#T
M"[VJ/F)2?*_'_&_"_&A=TX&+<&XMB97$/ON@^5=+N66E%!3_`!\'4E/49RIR
MAIW:EK(&Q+K]\50^Z]U,K_YJ6&/SNW)\+=J_';L??&.Z\[`ZWZJ[5[8V[NK8
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M%+@,?@Z#*25E=0S;QH(JJ-?\P92SV1)&7W7NHF,_F4_`S,;K[NV1COE1U+4;
MF^.6WMP[K[GQ_P#'988MF;=VC6IC-U94Y*>DBQ6X*;;>5E2CK_X7/6M25LB4
M\H69U0^Z]T,OQQ^47Q^^7.PJCL[XX=I;=[7V-1;BRFTLCFMOC(TSXG<^%2FD
MR>`S.)S-#B\UALK20UD,AAJJ>)VAFCD4%'5C[KW5373_`/.QR_9.\>I'W#\+
MMW;-Z/[J^2N3^+>RNV\3\@ND^PMUKOV'?.Z^O,/EL[T!MW)1=L8?:=?N+:4[
M5E8]*?X70,*N93`"_OW7NCB_\.D_$;9?2.R>\?D+VSU[T-@.P^P^T>N=HTN2
MWA'OE<WE.JMY[BVCN"LH*W:&*JGFH*`;?-3DIS3K2X8S+#5S(]BWNO=9<9_-
M.^&V0^1W>7QPF[4PF+R_Q^Z)V=\AM\[_`,C5I'UO-U]N^GDR*Y+!;MA2;#92
MEQ.%J<=52SI/XZD96G2E^X?RB/W7NA#/\Q;X0K\>)_E=)\D>O8>@*;<2;/G[
M`GGRM.L>\9:N.CAV:=L38R/>1W?/)*KQXL8XU[T["=8C"?)[]U[HNVZOYS/P
M5V-VIL7:6[^Y=DX+J;M+X\[9^0'6OR%FW)%5;"WG1[H[/R/5\&T\=CJ"AJLW
M2Y#%Y+'&?(5=2D--C@WBJ_!(K6]U[HQ?9_\`,5^#_2_;N)Z%[3^2W6FR>WLY
M7]?8W&['S.1K$R<U1VK)40]=333P4,^-HL9NVHI7BI*V>>.D,VF-I%=T5O=>
MZ4&'^=GP^S_R1RWQ"P_R$ZZKODCA/NX\CU3%E)1G(Z_'8ZER^3P5+724R8'(
M[HQ>*K(ZFKQ--5RY*E@U/+`BHY7W7NBT;&_F^_"^KZQZD[`[R[1VI\:\KW7O
M+M+:&Q-C]C;ABK<O6+U;VSF^H<AN3)5^$HI\=M[:V1S^)C9,CDFHZ"$U(B>?
M6CV]U[H=^Z?YBOP>^.O8F/ZF[K^3'677_8V3PNV]PT>T\KDZJIR3XK>6=I=M
M;0FF.*HLA34E3NG,UL<>.III(ZFM0F6&-XD=U]U[H0]L?+SXU[TCZE?:W;VV
M,TW>F\-_]?\`4]+1KE#D-X[SZK7/GLC;U)C)<='D,?7;(.UZY<E]Y%3)2O!I
M=@SQAO=>Z,=[]U[KWOW7NLG_`%[]^Z]UP/U_V`_WH>_=>ZZ]^Z]U[W[KW1#M
MY?RM_P"6]V)NW<F_=^?!7XJ;QWMO'-9#<>Z]U[DZ/V!F-P;CS^6J'J\GF<UE
M:["3UN1R5?4R-)+-*[.[DDDGW[KW28;^4)_*Q967_AO+X=#4K+=?C]UL&&I2
MMU8;?!4B_!%B/?NO=$KV/_(*^*>%'36!WMU%\(-W[+ZFSF#RF4.)^#6T]K]C
M]I46W=N9O`T6)W_ONJ[+W+0Y&'+5.4AK\JW\)85M52(52('CW7NCK?\`#0O\
MK'_O7C\.?_2?>M?_`+'_`'[KW0M]*?`#X/?&_>R=D]`?$GX]=,=@)BJ_!KO/
MK/JC9VS=S#"Y0P')8H9C!8JBKOL*XTT?EBUZ'*+<<#W[KW19_A#_`"I_CS\6
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M[=D]1_,;:.^/D=UIN3L'Y;]*?&;K#-[PQ>U.U*BFI=R?'3L*OW`^_,\^_>R-
MZYK+9'L';DL/WE-0SXS&4.1#+14<-*%4^Z]T,WRG_DR;_P#E/5=_;,SW?FT-
MI].=Y?+6K^8U338SKJ/<&_<7V-LSI;8_7_1F#-5NB3([:;:VV]][8ES6X4CI
MDGS=`8\:KPPR5#/[KW1Z_F)\2NX?F-_+EWU\2]Z;WZJQ7=?9'76Q=O;KWM2;
M0SU1T]6;MVON;:NY,U51[(?)QY^/9NXI-NR0G'_=F2&"I,?D8+J/NO=5:[=_
MD;=M5&W_`)')D-S_``F^/-=W+T;LGI3'=??"GX[;SZ@Z;SL^V.[-H=O?Z3^X
M,!F]_;AK=V;\PE+MF?#X66E%,*6ER4Y=V!T'W7NC.;F_E3]M9WY#;JFI^^.O
M:3X?=@?-[8_\P_>&RI^L,C6_(V+OS8]+M=J?96V^U9=R#;./ZJR6:V;15+2O
MB7S=)2//0P3+#(6/NO='"[6^&FXNQ/F/F/D_1;ZPN+PV3^!?9_P^CVI48BNG
MRD.X=_\`8V,WQ2;V;)1524K8?&T^/,$E((Q.[MJ#@<>_=>Z('5_R3:W<W5U+
MU!NGNC!XS:U3_*+QG\M/-5VS=H5=%DDW;C^QZ'L$]LXREJ<DE$^WI:BB"28N
M4BHF+OJG&LGW[KW3;\8/Y*VX>D(NE,[G=W=$4&\-A?,_KOY.[UH^L-F=LKM?
M<.W.K.E]X]3;7V]0Y#MWM+L_>M5O"6MW1_%FR%97_:4)!I:2".&.(CW7NF+L
MC^3YWWE_F=O'YF9;OO:_96,VKO\`^2?9G56P*C;.^Z7L3^['>WQYWGUC/TNE
M7_I`'4F)QVTMR9>FJ,374.VZ?*9$/*<C6N2BCW7N@R^.?\FCOWN/XDXS9?S&
M[>VWLW+97^6)BO@GUQL[KSJB/:&\.J<)O*MVOOW>%=W-5?WPS6'WYN_:^Z]L
M46.@@Q;8_&34D51.R"IJ7D]^Z]TO>JOY*O=G2W56TLOU;VE\:=@?)_9/RXZU
M^2^)RF&ZT[JW#T=EL;UUU;N#IU-J;PQ_8/=&[^VMP9++[:W575PK%SU*E#5N
ME-31)2QK;W7NAVZ'_E>_(/H79WP*BPW??5&Y>Q?B=\COE)VOV/FLUUKN6EVK
MV9LCY7[AWYD-\8O:V%QVZXZ[9^\,+C-Y6QTL]16T*5"$R(Z``^Z]T''1?\HS
MY0?&#*;:JND/DKT1%3;^V!L#JOY-GM'H"M[+FJ=J]4]T]C]H[.R_1]%7;LQN
M'Q.X*_#=F5>.KX-PP9.ACK((:ZG19$"CW7NEI+_*Z[VV9_,"W;\U>O.XNK-J
M[*_OEV=W6^Q=C]>=@87?7;F^=T=69#9N!V7W%AHNR:CIO<N%PF8JC6G/XG`8
MC=N3($=16%I&E'NO='5^0OQZ[E^9OP.Q'3/965V;U?WAO;']";J[#J<;C<EE
M-FX#>.P^Q-@=F;NQ&*QZ9:JR!HJF?:]114VJLG,+2JS22A26]U[HLV[?Y6&Y
M=T;XW!NS_2?M&DAW%_-7V'_,*KECVKD5RK[(VAU%3]82]8MD4K0S[IE='J*;
M(F]+!&P3Q$W)]U[I^^'?PB^9GQ$V#7=48?OKXT;NV!TMTQN#I_X?1UWQ[S&,
MWC$E;N.;/[=W)\B]Z4F]7RF=_@T"14M7C-K#"T64E9ZR73.$'OW7NK;\6N33
M&8U<U+13YE<?1KEYL9#/3XV;*+3QC(2X^GJ99ZF"ADJPYB21W=8R`S$W/OW7
MNI_OW7NO>_=>Z(YV)_++_EW]N;WW+V7VE\(_B]V'V'O/)/F=V[VWCTML3<.Z
M-R9:2..&3(YK-9/"U%?D:QXH44R2NS:5`O8#W[KW0N="_$CXN_%JEW10_&[X
M^=0=$T6]I<=/O"DZHV#MS8U/N:;$Q5<&,ESD.WZ"ACR4M!!7S)$TH8HLK`6!
M/OW7NJF\;_(@^-1WMALQN7H[X(9W;E'WSN7N#/$?#G#1[RW3M[<^2W#-6=;9
M+*5F]Z_;JX*'#9N.D@;^&ND$U'#5+%Y@2?=>ZMJVA\3_`(R=?]+YWXY;&Z"Z
MEVCT%NB'/T^XNFMN[%V_B>M<W3[I%MR0Y/9]%0PX2LBSH_X%J\)$_P#;!]^Z
M]T&W4'\NSX&?'[?>*[0Z-^'?QPZC['P=-D:/#;YZ[ZBV5M+=6,I<O12XW*4]
M#F\+B*/(4\&0H)WAF57"R1L58$>_=>ZK8^;7\E%_F)2_/G*2=R477_8_R3WG
MU1V%\=NQ<'@\@N?Z.SVQNBX^CM\87<E1'6I+N;9_;6U*BNQV8H:9H$FQM99@
MTL,;#W7NCN5/P2CKNV_Y;':F1RVRJ_(?`OK;L38M=-5[4-3F=TU.]NF=M=7T
MM?M/*SRO+MRFQM?@Y*QHY3(S1S!5*N"Q]U[HL/\`,8_E?]U?-_M6AR^'[FZ4
MQ'6&3QFQ:*"I[,Z/.Z>_/BWN'9^X4RF4[,^%W<FT\]L_/[#WMO:@")71YJ;)
M8^&JI8IH8PKRQ-[KW0![-_D^=Y]9?++M+O[;N`_ED=GTO8/R[W-\EL1V;W_\
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M'1(XIC&ONO=(O9WQ(^=_:6VN[>L_F_\`+GJW>?3_`&+\:]Y?&W"[)^.O3&2Z
MVJ\A-OC&UF!R_>>^=Q[QW9O#+Q=DTV"D6&GQV'DI,'&\\S&(^CW[KW1(*W^2
M[\B^SL)MZH[\^1W2&<WEU5M+X=]$=1?Z-.E\[LK:$OQ^^*WR+V%WM63]F8W)
M;LW#D-Q=H[\AV4N/C6EEIL!B"[/!3,)I![]U[HT-9_*]W1'V!3=ATW8FS7J*
M'^:AO3^8I/20;1K8\KD]K[@Z/S?5-%UA_$/O5)W13U.1CG.1<FF,">,17L??
MNO=$N^"O\I7Y#[OZ$Z<Q?S,[`PFR-M['^%GRC^+_`%[U1L;KB'9O<.Q(/EYE
M*JD[*K>U=\0[JW#@MUUVT\)CJ48)<;3T,-1+.U56J]0-3>Z]TOZS^33\@^RN
MO]Z4_P`@>\/C+O\`[#P/QJZ;^)/0^,Q7Q[W/A^H?]$O2/8V&[+PF;[BQ$?8\
M._:OL;<F6P4$"Y#;&9PG]V`&J,3HFD;W[KW0\?'#^5SW)U/M[X:)V1\A<)V#
MN7XX_+#O'Y*;G6'#[QJL,,'VWUKO7K_$=2]<9;>6Y]R[WDP6RVW-%40U^X\A
MD\A.JR1R2-^V1[KW5?N;_P"$[79^\J_J9^P>[/CSONAV)L6?X\Y.'</6'<\<
M-+T!A^[-Q]Q;1W#MW#;9[LVM@LOW1.-Y9'&96+/PY+:TB"GJ(*))XV+^Z]UM
M54-'3XZBH\?2(8Z6@I*:BID+,Q2GI(4@A4LQ9F*QQ@7))]^Z]U*]^Z]U[W[K
MW14:CX)?"^KW1V]O>J^*_0U1O#Y`87,[<[QW/-UCM23.]MX#<5=0Y//8;L/)
MMC35[LQF8R&-IYJB&M::.62%&8$J/?NO=)#.?RU/Y?6Y=A[)ZOSOPQ^-N2Z\
MZTJ-SUG7.SI^I-G?P'8-=O2J@KMUY#9E`F+6';&0S]=2Q3U,]$(99)HUD+:U
M!'NO=%LV]_)Z^,D>[*RLW[U[T!OK9-7)0'-XY?C?LS;_`&7VO2814&VL/\@N
MU(<MD).V<)@9J>GJ/M_X5C%KZJCIY:PS:&63W7NC15/\N?X$5>V.M=E57PX^
M-]1M#IK,9G</4VV9>HMEO@^ML[N'*T><SN8V3C&Q)I-MY++YG'0551-2+$\L
M\*.Q+*#[]U[H3]C_`!3^,_6G;N^._NO>A.IME=W]F#(+V)VSMC8VW\-V#O=<
MM7TN4RB[HW50T4.8S8K\C0PSRBHE?7+$K'D#W[KW5)7R;_D.5?R#V+V&^.[P
MQ&Q.[,Y\\.S?D_M7L3%[<RPQ]7T7VYOG86\-Z?&[L?'PY**KW-A*RMV)1Y&*
M5)%@@S5#35$<:CRAO=>ZMFR'Q+HZW^8-MWYP&IVGYL%\3MP_&X8N3;:OO)ZS
M-=IXCL"+.P;IU6AQ%/08^6D--I\A:8D,$+*?=>Z(G\@_Y7'=/>_S9V3W_DN[
M>G$ZWV;W=UAW=M3>=7TD*'YJ=0T'7LF-K,U\>^I>_=IYK;N/DZ&[*K\01E:3
M<&/RU8E)E:ZG5GC,.CW7N@1^"/\`*"[R^&O;W7NZYML?RP-W8K:79/8^Z,OW
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M\?YU[YQ-;V%V_2]OS)W#V54;JG`Q=%4)48F=]I4N&K,C3U*U<DB55/%[]U[H
MY'\KOX#[H^`.Q.^]K;IWMLS>E9WCW]E>^W38V*WWC<)M?([HV+LC;VX-LTDW
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MOO>+(X#=&&V]_<#===DYXL[AHX8JN.G9(Z&JA\:O[]U[IVZY_DV=E=3]`["3
MK?L7X^[#^576/S(IOFAM2MP_7/;&X?CE7[PH^M,ITQ#LW>6&[`[;W?W/N7'/
ML#-U,HS+;CCRD&1\/C`@A5#[KW2W[1_E1]U]S[3[R;L3O/I^M[/[R_EO[X^%
MN7W'M3I8[#VC@-_;][8W+V;D-YX#:.'S-5]IL>@CSD-%]JU0^4KY*0553.TK
MD+[KW3IWI_*9WEVYB/E?1T/;.R,3DOD3UK_+YV!ALGD-GY2NFVP?A?OBAWAN
M*?)2QY!*BOH=]&D*T4,3Q_9RMKE,GOW7NN6R_P"55VSMSY$[7J\GWOU[7?$#
MK3YN=D?S">OME475U?#\C)^]>S?[U5F1V9N[M>KW)5;<J.K<-G-^9.>)Z/%0
MYBLHXZ:AJ)C!&3[]U[HN@_DE_(7:&UMU[:ZH^3'3>*7Y#]']J_%SY1578'2^
M;WV$Z7W]WSVQVYB<]T52G=V*I=N]DXC"]P9''5,>92OP]7504U68E>%0/=>Z
M*_\`.'X0_-?'?(KMWXU?&?H?>6]_CA\J=N_RZX<KW-F\-L+<F*PNZ?B%FMB;
M=.3SW853OG`YOJ_`X7K_`&*:C(12[=SF2R>3=3CI*:.ID"^Z]U9%\%?B1V#0
M_P`POYK?*#>VP>Q^L^BL#O\`WM@OB!UMVA2[0HZFCWEW/)MS/?+WNW9F/VKF
MLVU'LOMG>>S,9)A):YH:YZ6>N+11>=T]^Z]U>-[]U[KWOW7NLG_7OW[KW7`_
M7_8#_>A[]U[KKW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW63_KW[]U[K@?K_L!_O0]^
MZ]UU[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K)_P!>_?NO=<M*_P!/][_'OW7NO:%_
MI_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7N
MO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BO
MOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\
MG_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7
M^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>
MZ]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*
M^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)
M_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_
MI_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7N
MO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BO
MOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\
MG_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7
M^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>
MZ]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*
M^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)
M_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_
MI_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7N
MO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BO
MOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\
MG_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7
M^G^\G_BOOW7NO:%_I_O)_P"*^_=>Z]H7^G^\G_BOOW7NO:%_I_O)_P"*^_=>
MZ[L/]XM_L/?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>ZBUU4*&BK*YH*JJ6CI:BJ--0P/55M2*>)YC!1TL?[E353!-,<
M:\NY`')]^Z]U6SN?^9'B)^G*3?\`T]T)VOV=V%O?NVKZ`Z2ZHSZXKIV3M7?$
M>,W!N6FRU-O;L>;%[?P&Q#LS;-7E9<I*)P8$5*:*J>6'R>Z]T/FR/E)6OT/F
M.W^^>DNT?C]NK9^?AV9O7J+)8INSMSIO*OK\#B]OXSKG)]:09S'=MXC=]?NG
M'PXK)8=7@FFJ&AG%--354<'NO=!I/\\J3)_%7H/Y#]?=);^[!WU\H(]N4'27
MQ[H<YLS`;WS^Z]S;>SFZX\+N#<>XLSC]J;7Q>VMN;;KJ[-Y*2:>''4M+(P29
M@J/[KW3%_L_^8'2U-N/_`&63LQOD[5=R57QQ7XAKNKKV/=Z=XTFTY>P)L,>R
MJS.4G7E1UW%URJ;D?=,$\U&N#E680F:]./=>Z,7\;/D%6=]=?[ASFY>LMQ]+
M]F]>;LS/7G;74&[\M@LQE-A;[PF,Q6=DQL6[-O5%3MC=6WLOMS<&.R>-R]#(
M:2LH*Z-[(XDC3W7NI69^4_0FP=E;,W?W1W+TMTQ_?#;.R=PQ4F^NY.N\7CHW
MWW`PP=+BMRUN=H<-N6BR62IZBEH*ZB=Z7)-3.U.SJ#;W7NAB;>>SU.X`VZ]M
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MOW636B4UV*KX;?Y+(WOW7NE7A/D5\?\`<W4M7WYMSO'J'/=&8^BRF2K^YL-V
M1L[)]5T./P=3+19FMK.P*+,S;4IJ7$UD#PU,CU:K!*A1RK`CW[KW3=U!\@^O
M>\\SO2#K+.8'>FT=KX_866P_8NS]SX+=NS=[8S?V!J,_CZ_;>8V_5UU#54E-
M3P:6D65UDU!E-O?NO=/NW>^NCMW]E[KZ8VGW+U7N;N#8=##D][]5;?[!VGF.
MQ]GXVH^S$.0W/LC'9:HW+@:*4Y&G`EJJ:*,FHCY_<2_NO=0MN?(OX^[Q[`?J
M?:/>?3^Z>THL%/NB3K;;O96S,UOR/;5+72XNJS[[1QN9J<^F&ILE"]/)4FG\
M,<RE&8,+>_=>Z#?Y0?+K87Q;AZ\IMRX#>>[MQ=F;ZV-LS;^!V?M_(9"+'T>\
M.S>O^KZS>6[=Q?;?W<VEM;;>:[(QOEEKJF*:LEG2"DCFE8A?=>Z#SY%?,3L?
MJOL6IZQZ-^(W;'RIW!L[:.%['[AJMD[JZZV!A>O-C9^LS]+B(,5E.R,]A8>P
MNR\Q'M>NJ*/;>-M+)3PJTU33^:$2>Z]T)N5^5NSJ7:77>],%M+?V\<?V3T5N
MOY"87`[8P!R6^1L;;6U-L[GIJ1=HQ3FLJMR[AJ-WX_%T='')Z\I4I"7L2P]U
M[H,OC1\R]W]N]A[NZ:[W^-F]?BGW#M[K?"=V8K9.[-];`[-I\_T[N#/97:M%
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M>B[%VDG=FV.J]K]S5^QI=S[;3/S[`W1F=T82+-T6"_BYW!/2X:HVR),A,:1:
M:E@R5`YE/W*@>Z]TH.LN_>B^ZJ'=63Z<[GZI[7QNQ<U5;<WMD.M^PMI;XH=H
M;@H8C/683<]7MG+Y.#`Y6E@!>2GJFBE1`25MS[]U[H#]\?.CH'$]6YWM7JGL
M#K_Y#8C:O<74_2>[*;ISLG96[SM;>':?:6S.L(:'<-=@\IEJ/#Y';U1O**NJ
M:*H,=2]/"RJNIE/OW7NC58;=FUMQUVXL9M_<>"SN1VAEUV_NRAP^6H,E5[9S
MSXZBRZX7/T]'/-+B,L<5DJ:I^WJ!'-X)XY-.EU)]U[I#;7[ZZ-WQV+O'I_9?
M<O5>[NV>O*:"MW]UAMGL':>=[!V31U)I5IZO=FS<7EJK<6WJ:9JZ`*]73PJ3
M-&+W=;^Z]UEV[W;U-OEM_P!%UQV7USV'G.L(J8;ZP>TM^[6S-9L^NR6*J,SA
M<?O#^'9.K&TILSCZ9IH#7B$-`K2BZ*3[]U[I(9[Y2=!=?;;V7F^Y.Z.ENG:S
M>F'V1D:#&;Y[AZ]Q$$M9O^"L_NWC\/F:_.T..W)%FJ_%5U/CJJC,D&3:BF:F
M+A&M[KW3UVA\B.DNG:W`X#L/M?K/:.]-Z8_-UG76Q=U=@;2VONSLB;`T$F0K
MJ'8^$SN5HLCN2ICC50XHXIO'K!:U_?NO=)Z;Y5]"[<VATKN?M7MCK'IBM[[Q
M&TJWKG;/:'8VSMH9K<N9W?BL9DJ':VVX,]EL8^Y\[%)E8H##0I*[RL`J^I0?
M=>Z%/(]E]<X>JWC19??NS<56=>8/';GW]2Y+<V%H:C9.VLO'DIL5N'=D556Q
M/M[!Y*+#5C05=6(H)A23:7/B?3[KW2W]^Z]T!F7^1/4NQMG5N]^X>R.K>G\#
M19GL>@?*[V[4V-C<#_#>N-Y9/:>4R\FXJO+T6(@:%:2GFR%*TGGP]35?9U82
MHC=??NO=3=W_`"-^/G7_`%GB^ZM]]Z=/;+Z=SE+B:W"]K;J[+V9M_KC,4>>\
M'\#J\5O?*YFDVUD:;,_<Q_:O#4NM1K706N/?NO=0Y^_=D4_8&/VB]?B_[LY#
MI#+=\IV=_>##_P!QX]F8K.8+$FL.5^X^S?&U-%G4KTKQ-]I]HA;58@^_=>Z%
M*LW9M;'Y.HPE?N7`4.9I-OU.[*O$UF8Q]-DJ7:U'4"DJ]RU-#-4)508"EJCX
MI*QE%.DGI+@\>_=>Z+'C?FCTUOE]P3]*;SZV[MV[A>H-]=IQ;[V'VYU]D>O9
MZG8>>H]NY+:61WO29>NVYMZL6OJ_\HK*NH2FHDC=IK!3;W7NA8W?\BOC]U]N
MS!["WYWET_LK?.Y]PT&TMM[,W;V5LW;NZ]P;JRM%2Y+%[;PNWLOF:/+Y3.Y+
M'UT$T%)!"\\T4T;(I#J3[KW7.O\`D-T#BNR:SIO)]W]18[MW'8G%Y[(=6U_9
M&SJ3L2AP>;R-!B,+EZS9=1F8]QTV-R^5RM+34L[TRQU$]3%'&6:1`?=>Z>^Q
M^X.I>G<=0Y?MOL_KWJ_%92MIL9C,EV%O+;NS:'(Y*MR&.Q-'CZ"JW%D<=!65
MU5E,O24T<4;-(\]3%&`6D4'W7NFR@[[Z,RO:^3Z'Q?<W562[OPF'.X<ST[0=
M@[3K.T<3@5-,&S63V#3Y:3=5#BE^\AO42TBQ`2H=7J6_NO=,67^1O46Q=F5&
M^>X^RNJNG<%393L.D?*;W[6V)CL`,9UYO6NV?D\N^Y*S,46&C\+Q4CU].9/-
MB*JL6BJ]%2C+[]U[H1MN]A;!W>F"DVGO?:.YX]T;7I][[9DV]N3#9J/<6RZN
M2FAI=W8)\;65*Y?;%1+60JE?3F2E9ID`>[K?W7ND!O?Y,_''K/:NV]]=D=_=
M+]?[)WCFFVYM'=^]NT-D[5VQNC<"3U5,^$V]GL[FZ#%YG*K44,R&"GEDE#1.
M+>DV]U[ITW?W[T5U]O;8W6F_>Z.J-D]C=G"=NMMA;M[#VEMS>>_UI6"5#;+V
MQE\O1YK="PNP5C10SV8V^OOW7N@]PWS*^,N8[0[DZ<;NGK7#]B=$;DVSM;L3
M;.=W]LK&9;%Y'=NP\?V)A)/X9-N`Y2"DJL#63*'J8*=FJ,?6*JLM.[^_=>Z?
M<%\L?BUNBNZMQ>VODET+N#)]X4>5R'2^/PG;VP,K7=MT&"GJ*7-UG6E)0[@G
MGWS38BJI)HJI\8M4L$D3HY5D8#W7NE/C>^^C<SVKE^B<1W+U5E>[=OXC^\&>
MZ>QO8.TZ[M#"8(&E!S.6V#39:7=6.Q8-=!>>:E2(>:/U>M;^Z]U$QOR+^/N9
M[)I^FL/WGT]E>WJO'9K+4O5N-[+V97=B5.+VYE:_![AR%/LNES4NXYJ+`YK%
M55)6R+3%*6III8I2KQNH]U[IL^/OR5Z7^46RLUO_`*2W[MG?6V]M[^WYUIN"
MKV]N+;V?_@F[^O-QU^W<WB\L^WLMEZ;&U-0E)%D:6*:1)Y<774M0T:+.H]^Z
M]U"I?EC\9LKMCN?=^VN^^G]Y83X[8_<&1[PGV9V3LO=$G5<>V,?ELIFJ??L>
M'SE4-HUM'28*L+19$TS`TTH-O&^GW7N@Q^(?S1V=\H_B/M?YBYO'[:Z;ZSW5
MA\_O"&JSO;?7&\L+@=A8JLK!2;DW=OG:&8JMG;9K#B:83Y7'5-4M3@*D2TE;
MHG@E`]U[I6;:^676O8DVXZKJ3.;([1VEAL;T5E\3V'M7L[8];L#==!W;V#N3
M8</\!W;39*KP=57;=FVO/**99WFR=1)#1TP-3*BGW7NAZ;?NQEQM'F&WEM88
MC([F&R\?E/[P8K^'UV\#GYMJ_P!U*.L%7]O4[C&YZ:7'&B1FJ171O`4\JLH]
MU[H,<O\`)+I_8>R\/OCNGLSJ?I?#[AWSGNOL#7[Z[:V%C<%FMR8O=>=VSC<+
MB=S5F9H<+D=R9A<(96Q<,CUM',9*69!-!*![KW3&ORTZ-P'4$?=_;W9'7G17
M7TV\]Z[*BW+VQV%M#9VVY<EM#L+<W7T)AW-GLIC,),^X:K;35-)$DQD:*91R
M03[]U[I>[][[Z,ZJVO1[W[/[FZIZZV9D<)+N7'[MWSV%M+:>VLAMV%\/'-GJ
M'.9W+T&,K,-%)N+'JU3'*T(-=3C5>:/5[KW4;>/R(Z`Z\VCL_?\`O[O'J#9&
MQ.PJS"X[8.]=W=E;-VYM+>]?N2G%7MZBVCN/,9FCP^Y*K.4C"6C2CFF:IB]<
M89>??NO=(#%?,+H"';^P,OV/VIUET[D>UM];]Z^ZSVYV1V7LK;68["S^P^P<
MQU[44NQX,ME\>^[:K)5V-@FB@H%J)52N@1AJ==7NO=&@!!`((((!!!N"#R""
M.""/?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KQ`(((N#P0>00?J"
M/?NO=$F^=.*KJGH<[?I_B!2?,WK:?(QTG9O1V'S6UL#O=-D4&"RU509_J?&[
MLJ<%MS-[TP&XZ/'K240R^%JXX9'FHJH5,,<4GNO=(;^77M7MK;?5/8@WCL3M
MCIWJG+[[CJ?C'T5WSO:G[$[HZAZ@I=A;1Q7]VMZ[IAW=OZ>FAK=[T.5K,5AJ
MG.9>IP6-GAI6JBBI#![KW19]E=']W]1_#3^6UV`>G-X[U[2^$YI-S]A?'_;-
M=M6'L?<6!W)T_P!B]2[RQ6S'SF;QFT\KOC;$6^(LI28^?*4<&22CEIDJ4FDB
MO[KW6$[,^1>9QNV?G=D_C-V#CM[;;^8>Z/D7'\2:?.[`J>]JCI#,?&"'XI04
MKN<[3;!/<HQ%!%NL[=;<#THC=L8F0^Y"W]U[HZ7Q%HNTMS;,[X[C[1ZGSO2.
MY/D3VMF.P=O=0[MR>WLIOK9^R<3UEU_U1LR#?\FV*G)X+&[UW'C^O?XM6XZF
MR.2@QG\02E^X=XI/?NO=%[ZJ^(&%SDNQ,CWI\<MG;YJMK_RT?CQT3#%OW:6R
MMUU-#NO%-V!/V9UACY,]]Y34;U,O\(%<H>.CJ&6`M*PCNONO=!QG_C!W?'UG
M\2-I[(V/EL'DN^OC'T=\0?F=6QY'$43]9=>==[9Q6\\CN;/)#4M49?*4F`BW
MML"F&.G>89#>M'/Y!3T9=?=>Z)Y\V_@KW3O#Y=?(BJK\!\WMX]0_*+'=78CK
M*;XFX[X,9?8^RZ?:O4F$ZVW#M'M7-_*/:>8[+Z62AS>!7*T.=V[528]TRK30
M4T60HYY)_=>Z6'RF^*_>>`^7^S<YT5U+WYOC<>Z8_CD-V;U[&ZR^*'R0^*7:
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MVYL_N+<E(T.=R4>^]T;SQ8K1!+5-555;%).H"%T]U[HT/SQZ]WMV=T)C=K[`
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M3Q18L&A:9?=>Z%;;O4_>&.RW\S&3;>`J<#F>\^Y-IS]2[AK,A1429#;M?\:.
MBNL\]O7"U"5H,%3M3)XC+&F2H,+25N-"V*,I;W7N@S[HQO<_Q+[I[>WOT1\4
M>Q?DOM_Y,=)=+=2;,PO5&6Z[VWBNI>QNEZ/LC:^WZ+LX;OW)M8[7Z>SFW=]4
M4QSN+BRLV+;'5,3T!#TQ?W7NB:]S?`R@ZSWKA<QVU\'MU?S$,?O?XE_&GH#8
M-)LBKV%-BOCSWQT7MK>.U,MO:6A[$WEL*FZ]P_8,&X,34P]A82"7/X(8,Q>&
M-?!Y/=>ZMCW?U=VI)\>/B]L?/3UG8G9.P.Q?B!D.RL^M>N1GR=5UUOG860[%
MWC49/(ICI\G%%_":NNEG>-*FH4%_'Y&T^_=>Z+>_Q"Q.+V[MS=V(^..T$[AE
M_F99_O3*[WQ^T]DTV^J/:&8^6F[<Q6=H5VZI&@S<\.1Z3JXZ:0Q3RUKXJI6G
M:+QAT3W7N@1_FT=`;_WSV'UAV;U-U%\A]V;]/76X.J1NWI[J[XL_)CK?(8;,
M;GH<W/US\A/CO\I\[M#'#8&319YH]Q;8S..R*O-+3UC/%'2H?=>Z5G;WQR[X
M[#INQNMHNE-N[5[-[^_ED]>=2S=[;+I]IXWK#8W;/5^<WV-_]#YC,450>Q-L
M[2[)Q7:%)28N:@I*W'MC,?5!_720K)[KW0093XZ]F_)S#=\5_3'PHSOP.I*?
MX9]B?&&LZY[!;K+K6@^0>^-P;LV-N'$;5I_]`N[-PP3=2;0VSM',X&AW1634
M=0T.]:L4E)'$E5K]U[IM[.Z9[!^273W:^%Z0_EZ[_P#@/F9)/A_ULN]:9NE]
MI=L559UM\L=A[XW'6]:;$V%FM[=79?K[I/9E-6YK#;KRS1U=75LU-!C)*995
M;W7NK+_A;U?OSI#K?L;XT;BPN;IH^K-V9RGZ_P"^\E-CLEE/D!M;L".IW9C.
MUMYY.D@H9\GW909;)5./WG/4P1/DLQ0_Q*.T&0BCB]U[JO3XQ_'3L7#;T^'_
M`$C-\.]Q=&;^^&N^<CO'O'YJ4]+U93[%^0V.EV!V)MK/P==[QV]N.?MGL2I^
M2&[=YT6X-RT6?Q6+3%RQ3FL:HK::E\ONO=6)?%[HI.IOAQ1;%I.M,/L7?^<V
M%N^;>6'Q6)PV-RV<WMGI-RUU36[AK<;Z,OF\GD,N\LE1/-*S23L2W)]^Z]T7
MS;GP]P>Z<1GLAW%\;]F[_P`]2_RU/C9T/A%WMM'9.Y\HVYMNT?R`J.PNK<36
M;@-1!0-_$,[AONU,L%%-+-`QE81ED]U[HG?:7QS[5V[@-\X;=G\O&#YE;G^2
MOP8Z.Z1V+N3)577$M+TYV'L#I;=>V=T=2=U9K?6^\1FNMNLIMU5ZYJ'<&T8*
MFJGRF2J8W!J8:*5?=>Z!/Y%_!KY#5/:>WLQNC;'S4W9UMW!\3/BUTC%@/B=@
M_A#OBGZ^WML#9FYMH]@;2[=Q_P`OMM[@RNR]MU<F?2M3<6VJV.BO-.M53O/#
M%.WNO=&T[U^&W;^<S_QLW;MKK'>&_P#!_!;I3JNDWYMGL?>6#S>\/G]'@8Z#
M+TG16\,EALKA-N;FGZ.RN*&\L;E,U0G$Y7L%J>GAIHZ-\A,?=>ZN8VKV0-T[
MWWMLH;'W[M\;,P>P,ZNZMR8:BQ^U-U)OVCSM6,9M>MARM77U&;V@V",6:I:N
MEHY*.2JIBOE28./=>Z(3MOXO-NOLCX]UW;?3&W]V[>Z[[/\`YCV\@=[8#;>Y
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MONO=-6&Z?[![2W)\O^P]@_R\,M\1=O=@_P`O7<O0&V<1FJ?JC;6_^S>T\)N?
M?9CVYDMF=6;RW'LS';:P]+F(%VUE)9HJG+4];.TOCIX::-/=>Z,C\A/B'B.P
ML5_,KWA7?&_:'8O9G:FVMJX_I[/9+:>R,GO'<U3LSX_[6QNS1MW<.X&CJ<8=
ME]FM73T)>HIFI:\2S0>ME9O=>ZK;[N_N?MK?6>ZBJ?A]UIV?V/F/YK/5O:]'
M\Q,+OCI_(XF@CW%\N.O\G31Y2N_TCUG?%'\F.J]MY(;1_N2F$7'_`,)Q*UEX
M\86A'NO=7K=P=,X_LKY,?&7=^YNN\'O?:766TN_JQLIN+#XC-X_9^]-QGJ*C
MVGD:2FRJS-2YRMQN/RT5/4PQ-)%&LPUIK&KW7NJ)/C%\`N^=H?)+KO9O;\7S
MZK,]TY\DMU]Y4W;6!3X*X_XG;EV^W:>[]QX3,4W;"[._V;W)?WRVKND4F9VE
M6551E&BJZNDGK'I$$@]U[JTS9_Q<&Z>Q?COD.W^E-N;KP/7.\/YC^YU.]MO[
M:W-C]HY7N/Y&0YKKK-T5'E/XA'2Y#>'7F2KVIYH8VE2BJ)8Y#&793[KW00Y3
MX]=V]4_'GJS=?QNZ<_N=WOUYV=\I^G-F;(Q;;3P-!LKH7Y/_`"`[!Q^W\Y-!
M0S5>`CV/T\]1LWL%<?1NTAQ6W9:.F19:CQ^_=>Z++\XO@UVCM;N?I3<FQ,;\
MO]Z_'S;?Q+V)\7:7"?$/;7P_[%WUMO=^S-Z;CRCY_?NQ?F1@=Q8F;:F_-M[D
M4U6:P-73U5)4XCQ9!:F.II7@]U[H)>[OA!WIUGFOC]ANDNGOD]O7L*7HSH;K
MG)YSL_8'PC^5_P`>]Z?Z*HL[%MK9WRG.]*KK?<_26X^KI,S24<6Z^N))<;54
M5*E?%05E?3MK]U[HZ_>?QJW9V+\OJ?%97XHIN'8]?\U/BO\`)S<?<1P_7N1V
M!NW9&UOC3O7JS.8#/M+7Q;PKLYUMV=M:DKVH<E0RTS4^6HZF`LQE5?=>Z;\G
M\&ZW`X;M*LVG\9]E8O,_\.U=`=]]:U.V]L;-H,U1=,X'LWXU9[?.]\)5Q2))
MMC%PC;.XZBII:5J-ZB))W-/(]2[3^Z]T4+XK_`/O;9GR3ZRVAV]#\^:K<'2/
MR(W5W7%VQB(_@KC?B9NG!'L?>.:PV8H^UJ;9R_+S-Q[YVKNE:7,;2KJF;*>.
MMJJ6IK)*:+R>_=>ZL?P?Q#Q^V\!T3NO"_'3:.,[;QO\`,-[5[GWCO3%;4V50
M[VQ.U=[]U=_Y;)]B9C=*&#.5T6Z-B[JHX*@Q3U%7-29)(I(A&L@B]U[I<=3]
M,]A9CXA_,/XY[>ZYK/C'V'FNP?F+LS8^]GH]L8S;^\).VMP;RW9UKWEM2KV!
M75=;-MZ7";_QM+))5PT>8HZW$U-.8+4\,DGNO=%+ZGZ)W3V'NC!1[8^!>?\`
MA?A?CU\3.]/C_P!BXW+XCIBAVS\C=R[[VAL_:^U.N]A'K?<N<;M#J+:V2VI6
MY:FSFX*?&`S34JPT2O5UA@]U[H;=S_&#?+_RP_BET_C>AMN[VW)TUM_X@;R[
M.^+V1?;NW,7V<O4\VQ\[V;UI5%LCBMDS[DFK\=4UU/'DYWP^2S5#%'7&6GFE
M)]U[H+NH^G.QMVY'Y8=F;;^$N2^*&U^[.UOY=&\]C;!R8V)AM_;LQW3O;VWL
MAV9O;L;9FQ-V[EV7L;=FW<1AW$M#1U;R2XF@I*B3753R+[]U[HRN!^/G8M!\
MQYMJ0;7J,9\4MK[ZW%\U,7N(5='_``K/]_=GX>KV-5]6TF,@J(<I3+M#=L6X
M>PZVHE5J2HK]ST,<:L]/(4]U[HLFY>DNP.L=X=+=R;[^$^6^7FT\'2_,+K:?
MK;"476FY-^]3[@[E^6.3W[LSLW";4[2WIMS8N0VEV%LN2.FSU?!(V8Q-#%3N
M`:>2L@;W7NB4;[^#_P`GMH=3?!_=M5U)\BM@[7Z=ZH^2O5W8?QV^#@^+?;6]
M>J,_V)W]0;YV"VVMN?+C%;MV!O\`Z]@VYBOX<:_%ST>;HZ=*>8RRTKS0CW7N
MK*OC9\&,'M&B^%.V.Q^K]U]C;4Z;ZN^7M32O\G:3I?L+>G6.YNW.R.GLOM?!
MU2==X6CZSP-=4[3@S-+0T>W:,4&(Q<;XY)/'&NOW7N@)I/CYN[I"?XY]A[A^
M`M9\CNN-D;1^4G2N)Z*VKB>H\ONOX^2=D?**MW9UKN?:VQ]^;XP/6'^C[=/7
M,=+C<O4XZ63(8/%T5)X@:1JJ!O=>Z)5V7\*?D%L[I;XQ4^TOBAV_LCNNEZ:W
MIT[D]D=0=??%+Y=_%S#XE^\.V=T[>Z.[RZW^3.ZMN9C#=9[>QN_%FQ>\=J9R
M*JK*2L<UL<_\.I(6]U[K9PV!NC=+5^/Z_P!V=?YG"9C`=7[`W!G-YXFFQG^B
M3(;GS(RV+S^R=DUYR[;BGR&U*S`^>:.IQM/`F/KZ-HYI9&ECA]U[H6??NO=>
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M0R*)(W'OW7NE3V9\@^A>EAM-NXN[.I>J5WYEZ/;^QV['[%VAL@;QSN0_X`8?
M:YW+E\:,]DJS_=4-+Y9'_`/OW7NFOLGY/_&OIK=^U.ONW?D%TGU;OS?CT\>R
M-E=B=I['V7NS=[U=?'BJ1=L[>W'G,=ELX:K*3+31?;0R>2=A&MWX]^Z]T_[9
M[3H-R=F]L=:IBJFAJ.J*+8%=7YJHJ:=J++1[]Q.7RT`I85`FI?X7%B&64R&S
MEP5X!]^Z]TIH.P-AU-/LJKIMZ[3J*3LEHUZ[JH-Q8B:GWXTN#K-SQ#9LT=6T
M>YC)MO'5&07[(S7HH))Q^TC,/=>Z26P^_>BNT]V;YV%UEW/U5V)OCK&J@H>R
M-G;&["VGNS=&P*VJEJ(*>DWG@,%EJ_*;8J9YZ25%2MBA8O$Z@75@/=>Z9>N?
ME#\:>X=W;NV!U+\A.D>S]][`%0V^ME]?=J;&WENO9RT==)BZM]T;?V[G,CEL
M$E+DHFIY3511".<&-K-Q[]U[I7[#[AZE[3CW/-UCVAU[V+#LK+C;^\9]C;SV
M[NR#:N=.-H\S_!=Q38'(U\6&RO\`",A!5?;U!CE%/,DFG2RD^Z]TG=A_(_X]
M=IXK?V=ZR[VZ=[$PG55=D<9V?F-C=E[-W7B^NLCB*>IK,K0[XK\%F:^EVI58
MZDHYI9TKG@:*.)V8`(Q'NO=3MA=^]%]J9+>^&ZQ[GZI[%R_6E5#0]C8O8O8>
MTMVY#85940S5%/2[RH\#EZ^HVS43P4\CHE:L+,L;D?I:WNO=!#C?F?TGOBIR
MB])[\ZQ[NP^,ZJ[B['J-X;`[<Z_RVQZ')]/9/9&*RVS-P;NH,OD,'MBOJJG>
M\32U=;-'3X^&GDDGLHN/=>Z$G=_R5^/?7&7VYMKLOO/IOKO=>Z\KM_;V`VMO
M/M'9&W<[F=R[IIGJMO;?PV.R^:HJS+Y7-Q1.U%#3QO)5JA:(,/?NO=3]Z?(7
MH/K?>N#ZV[#[NZCV)V)N?"9;<VV]B;Q['V?MG>.>VY@*:KK,YG\/MK-9BBS.
M2PN'I*">6IJH87@@C@D9V`1B/=>Z#WY3]][_`.B]F[$R74?1N0^1W8?979&+
MZZVAUOB>Q-F]8??SUFTMX[WR.9GWGOEEVY1T6)V[LBKE\;GR5#E$CNS`'W7N
M@\^._P`O][=C=AY;I+Y%_&C?'Q*[JIME5?9VV]M[IWQU_P!G['[!ZZQN8H\!
MGLULCL_KW*56$K\ULS*Y2A7.XFIIZ2KQT.3HIE\T,Y>/W7NC$]9=_P#1'==+
MNZMZ<[IZH[7H]@9JIVYOJKZW[#VEO>FV9N"CCDEJL+NF?;67R<6`RM/%$[/!
M5&*554DBP/OW7NL/7?R'Z![>QF\\UU1W?U%V;ANN<M6X'L'+;`['V?O#&;&S
M>.A>IK\3N^OV_F,A2[;R-%3QM)+#6/#(B*6(`!/OW7NHNR?DK\=.RMA3]J]=
M=]=,[\ZQI-P0;3JNQ-G=G;+W+L>EW359#&XFFVW4[KPV:K,'3YZHR>9HZ>.D
M>=:AYJJ%`A:5`WNO=)T?,3XD-0[>R:_*+X\-C=V]BY'J':N07NCKEJ+<G:^(
MGBI<KUI@:H;C,&6W]C:F>-)\1`TE?$TB!H@76_NO=(WJKYL](]C]@;QZHS&[
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M44L20J@#@#W[KW6;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T`W^RL_&C_3<
MWR6_T`=-_P"S#O0+BV[P_P!&^T?]*S4"4(QB4QWY_"?[RE%Q@%,/\IN*<>*^
MCT^_=>Z'GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1JT2M1U:PB\QIIQ$`
M%-Y3$XC%F])N]OKQ[]U[JLWX&?RV?C5\7]K=,]L;=Z?S6Q?D/'TIM7!=@9'(
M]J=L[F%+N3/[5P,G8./EVON#L+<.Q::9MPTTJ_Y+1+'3:2E,8X[#W[KW5=_R
MO^*G;:=9?'7<NWND/DI5]M[<Q7>_7LV<Z1Z]^*WR-P%-M[?W>=5OJ+8G?/QP
M^46>VWM7.=9;NP]&E4,YMS.8W,4[.U+52>&6-??NO=#!V!U%VMUQNC`;[[I_
MEX8_YJUW:?PGZ,^.=+MSJ.DZGJ,%T)V;M2AWD>Q>MZG;_9&\MOXCKSH+L#*[
MEHIYMP;:-;)0'$K%/!4I%CV7W7NB@?S*_C1\ZNV\)W'T9L+XP[@J*;?'Q/ZT
MV-T;/\=-F_%O.;3@W-M'KRG_`+Y[6^0/RX^2E3-W5B,/MO<PR>,P6.P>VXJK
M,8M:&>#)4>1K:M8?=>ZV`NF-E;MP/=O?FY\_A*N@PF[-J?'RCP.3J7IVBRU9
MM;9NX:#<D,21SS3K)BZZLCCE\BJ"S^DL+GW[KW5>?2716[.R-Y?*?IO!;DPD
M/6?QDQWR`ZN^*W8^+R]?N"'%;S^8VWH.R:^M-5C,D(,7D/C9M_=J;4Q]+3,*
MFFQ>0E5/`DD0/NO=%(_E]_##Y"]?=A=>Y_<NT?F[M[N3XS=)[QV3$WR!J_@S
MM_XD[NWSN'K+^ZE+MW!;N^-VP\/WWW3UEE=S8BDK1/E$IY*'[2FJJI9*U5#^
MZ]U#^$WQY^9%3\U/CUW!V;T)VMUM@.I_CM\F.GNV*W-=6_#WH/IW']E[Q'7V
M0VIB^A.O/C_E]T=C;JV$\>W)Z*/<^XLW/!71T%&8J"@E>53[KW5F>;^(6YJ_
M^4WGOBET_MO!=(]O;U^&^/Z_^TP%)B-I-0=KUO4^-PV5&8R6&A-&,U6YZ&2E
MJLC+]TNMS++YD#*WNO=5U_&KX:]IU^'^3V\,ML;^8!@M\S_#;O3X[C:/R=IO
M@9M/8&^=S;NV_0OCML[*Q?Q.VCMG*=HXZFSD,PQ&X\X]'14\<DPAA5JZ8)[K
MW1S/D#\%_P"*8_<NQ_CIT)UQUY%NG^7AV]TA55^"PFW^OMG;EW&=X])U^P.E
M]W5NRZK![E@P>4PN%S]$)T"PT%#D*IH9E=W4^Z]T"NW.G^P.R]\?(3?>Q?Y<
M-9\/<!E_Y;G>7QGQM-E3U+A-Z=@]KKN#&R8+8U)MKJK>.?VC/U[C*=I?[KYZ
MH-+495*JJUI!!%"GOW7NC$=S_$#'=A8C^8-N3</QRVCV-OSLCXS[$V%U3DL]
MM38^:W-N3+[0Z7WG38;;>WLSN,Z\6VW.PMP/+2ZYZ6."OJ&GC8.=?OW7NJX_
MYBC;8V10?S'=K;O^'_6/R@WGWCL3K_,;>[:K-_\`3L;]/3[9Z(V/@L9U_P!Z
MC=G9&+[=ZVR>S]P8>7<NQXML8>J&Z*S.K#3HM:9YI/=>ZNE^8F=WQL+:GQO[
M.V;TGVW\@)^J>]<'NC<O7G36/VED.QZG`9'I?N#8,N6QV,WMN[8N`GBQ><WG
M1/5K)D89$@9V17*Z3[KW1#^]^MODY_,CV?WCNC"]#=K?#QMN?$'Y`="=%47>
MF9V%M[MS?W:O?<NS*C=&3JL+L#=G8V`V1L3;^&ZQH<=CZ^MR4TF0K<Y--)1B
MFH;5/NO=%HZ0^#?>._-C_*V;'8#YR[$[(W=\5]]_'>/#_,%_A#UQUIO+-93)
M[=SG]T]N5/PNVEMC>.Z=M9!J7(8VFW;734<-)09"K\%,6JI%3W7NA)[9^/\`
MVG\J>@OD%M;H#^7EN3X'[IQG6W1NRZ2NR.?Z+ZZW]VME.F^^=J=I9?IWK3";
M4K.Q.E\CUPFU=NUM'AMW[KA2DJ*W*+32XM\:U:![KW06;)^#&_\`?'0_R/RZ
M];_.7,5_<&Z_AMLO.=7?,S#?##9)W?MCJGY4[4WQO7.8SK'XIX;`[;^UVUL:
M*M\^7S=3)597&53TD$6BF4-[KW1H/DU\"CN/#?S5SL'XP=?5<O<G2G2U%T1_
M!=I;)H\AN?LK;.Q-Z8W<E3MR!VIH,!FL;63XF-<AHH9Y9D7]^04\?B]U[I'Y
M7XV=C8_>/R*ZW;X,5.=[$^2WSRS/=O7WRXQR]/U>W.M]E;8SG2FX\/V1V'O#
M,9M.R]I;BP&'VU5Q[<Q>,Q>5_B-51"F9Z7S3Z/=>Z+WV-_+_`.]LY\N.\=J[
MW@^?.7VYW1\J*WOOK;L[X_S?!>FZ"V[LRHS6T-YX(;O[.[>V9D?D]U3N_K2O
MP4M`*'&5-;]ZF-@;%-!'6+!%[KW5[/Q^Z=HMF]H_*SLC+]>X3![N[+[[J,QC
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M>Z][]U[KWOW7NJ:OY%'_`&1!N7_Q<'YJ_P#P2G8?OW7NKE??NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=:3G\WK_`+B4/Y6G_:BZL_\`?D;R]^Z]UNQ^
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
;OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>rule.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rule.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`$`)@`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`W6>K>I^L=Y=;XC,;AVKAMSUVY:;>,N;RV3K=F;CJLV^[
M]Y4&X]SRUV8Z\$&S,@V;SVU<?4SF@58S+1QA@)$>\2\H<F\J;YRM#?;G9P7=
MQ=)<F61VM9FE-S<I/.6ELJ6K^+-;PR/X0"ZHUKW!NI3YKYNYHV7F6:RVV[GM
M;>U:W$4:+<PK%]/;-#`%CO*W*>%%/,B>*2=,C4[2O0E571_4=:U8]5L#;D[9
M"3-S5K24=S4R[DWGC>Q,Z\OK]393>^'I<G+_`*JJ@5OQ;V*I?;_DN<NTVVVK
M&4REZK\1GNH[V8G/^B744<[>LB`]!B+GKF^`(L6X7*B,1!:-\(AMGLX@,?@M
MI'A7T1B.NY.D.I)I)99=@;<>2>:LJ)7:CN9)\AV!#VK6R-Z^6J>Q:=,PW]:U
M0_\`A[V_(')DC%WVVU+,S$G3Q+W@W!CQ_%>J+D_\-&KY=>7GKF]%")N%R%4*
M`-7`):&P4</PV9-N/^%FG7<?2/4L4BRQ[!VZDB3T]2KBCY$]+V!)VK3RCU_J
MA[%F;,+_`$K6+_X>_+R!R8C!UVVU#!E:NGS6\.X*>/E>DW(_X:=76FYYYO92
MC;A<E2I%-7DUH+`CAYV8%N?^%BG7&EZ/ZDHGII*78&W('HI<//2M'16,$NW]
M\9'LK"R1G7PV-WYEJG*Q?ZFKF9_S;WJ+D#DN!D:';;56C,96B\##=/?1$9_!
M=R/<+Z2,3UN7GKF^8,LNX7+*XD#5;B);5+*0''X[6-(&]8U`Z]0]'=1XTX]J
M#K_;E*V)?;4F-,-'I-')L[<F:WAM=H3K.DX/<^XJZN@_U%15.W-_?K?V_P"2
M[4Q&WVVU0PF`I1?A-M/+<P4S_H4\\LJ>CR,?/KT_/7.%R)!<;A<N)A,'JWQ"
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M9V9M=(/6=*X/:NX:VAI_KHIZEU_-_?K?V^Y*M1$+?;+5!`(!'1?A%M!+:P`9
M_P!"MYI8D]$=AY]>GY\YQNC*;C<;ES,9B]6^(W$\=S.3C_19X8I7]713Y==4
MO174%$E)'2]>[;@2@BQ,-&L=%84\6"V/D>M</''ZS9<?L/+U.*C_`-323,OY
MO[U%[>\DP*BP[9:JL8C"T7@(;5[&(#/X+21[=?2-B.MR\^<XS,[2[C<LTAD+
M5;B9;I+V0G'X[J-)V]9%!ZZ3HGIZ.)(4Z\VTL4<4,*(*+TK%3]?R=501@:_T
MQ==2MAP/^5)BG^/OR^WG)"H$7;+4(``!I\ELSMX''RLB;8?\*.GY]>;G[G)F
M+MN-T6))KJ\VNQ?D\/.\`N/^:HU=>FZ)Z?J(YH9NO=MR1U$59!.C45Q+#D-@
MTW5E;&_KY6IZ\HXL0P_-$@3_`!]^?V]Y)E5DDVRU*L&!&GB'LUV]@<_BLE6V
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MC4>76K?GSG&T\+Z;<;E/`,!CHWP&VEEG@IC'A332R)Z,['SZY9'HWJ++MEFR
M?7^W*UL]_>W^,&>BU'(_W[BP$.\/N?6-?]X8MK8Y:G_5BCC^FGWZZ]O^2[TS
M&[VVUD-Q]1XE5^/ZL0BYU9SXPMX0_KX:^G7K;GOG"S$(M=QN4%O]/X=&^#Z4
MRFWTXQX)GF*>GB-Z]>R'1O465.4.1Z_VY6'-G=1RQFHM1KSOC*X'.;M-1ZQK
M.?R^U\?45'^KDI(SQ;WNY]O^2[PS&ZVVU<S_`%'B57X_JI(9;BN?]&DMX7?U
M:-3Y=>M^>^<+3PA;;C<IX'@>'1O@^ECEBM].,>%'/,B>@D8>?7=9T=U'D'KG
MK>O]N5+Y.3<,U>TM'<U<N[-V8C?6Y))CK&ILSN_`T>0G/]JIID;BUO?I_;_D
MNY,C3[;:NTIF+U7XC<7$=W.3G_1;F&*9O5T4^76H.>N<+81K!N%RHB$(2C?"
M+>WDM80,?Z';RR0KZ([#SZ[J.D.I*N2>6IV!MR:2JFR=14/)17::?,[[HNSL
MI*_K]3UW8&.@RTG]:R)7_%O?I.0.3)F9Y=MM69V=F)7B9;M;^0G/X[Q$N#_P
MQ0>O1\]<WPJJ1;A<JJ*@`#<!':M8Q@8_#:.UN/\`A;$==GI'J4R^8[`VZ9?.
MU3K-'ZO._80[7:6^O];=CC^,?]1OK_P][_J#R9K\3]VVNO5JKI\_K/WA7C_R
MF_XS_P`U>[K7]>N;PF@;A<Z-.FFKR^D^@IP_Y0_\7_YI=O74'2'4E++3S4^P
M-N12TL^-J:=TH[-#48??M5VAC)4.LV>B[!KILO'_`$K)"_YM[]'R!R9$ZO'M
MMJ'1D92%X&.[:_C(SQ6\=K@?\-);K<G/7-\JLDFX7)1U=2-7$26JV+@XX-:*
MMN?^%@#KJCZ/ZCQ[4+T77^W*9L9)M^6@,5%8TLFU=VY;?FW7A]9TMB-XYVLR
M,/\`J:FH=OS;WJ#V_P"2[8QM!MMJAB,)2B_";>YDNX2,_P"AW,TLR^CNQ\^O
M3<]<X7`D$^XW+"42AZM\0GMX[68''^B6\4<+>J(!UZ@Z.ZCQ9Q9Q_7^W*0X5
MMJMBC#1:?L&V/F,]G]HM3^LZ&P&:W/D*FG/]B6KD/-_?K;V_Y+M/!-MMMJG@
M&W,=%^#Z626:VTYQX,L\SIZ-(Q\^O7'/?.%T)1<;C<N)Q/XE6^/ZJ.**XKC_
M`$6."%']5C4>776.Z-ZBQ'\)_AO7VVZ+^`KM)</X*+3_``]=AKGTV<*;UG1_
M=U=TY$4WUT?=R?6_O5K[?\E67@_2[;:Q_3BW\.B_!])XPMM.<>#]1-H]/$;U
MZW<\]\X7GC?5;C<O]1]1XE6^/ZKPC<5Q_HW@0Z_7PU].NJ#HSJ'%C%C']?;;
MI!A$VO'B1#1:?L$V5@\YMK:BT]W.C^`X'<M?2T_^HAJI!S?WZV]ON2K3P1;;
M;:I].+<1T7X!:Q2P6^G/^@PSS1IZ+(P\^O7'/G.-WXOU.XW+^.9S)5OC-S+%
M-<5Q_HLL,4C^K1J?+KJCZ+Z@H$H(Z/KW;=/'C(L##CTCHK+21;7V;E>O=OI"
M-9TC$[*S=7C8?]32U#K^;^]0>WO)-LL:0;9:JL(A"`+\(@MI+.$#/^AVLLD"
M^D;D=;FY]YQN&D:;<;EFE,I>K?$9[F.[F)Q_HES%',WJZ`^774/173]/%##!
MU[MN.*GBHX846B],<6/V#5]642+=S84W7E=-B%_I12%/\??D]O>28T5$VRU"
M*%`&G@$LVV]1Q_#9.UL/^%$KUY^?><I&9WW&Z+L6).KB7NUOF/#\5XJW!_X8
M`W7FZ)Z?>)H&Z\VTT+Q/"T9HO2T4G7Z=52(1K_2W742X<_\`3$-'^/OQ]O.2
M2GAG;+700133Y&S&WD<?.R`MO^:7;\^O#GWG)7$@W&YU@@UU>8NS?@\/^4PF
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MOUU[?<E7HF%UMMK(+@7`DJOQB[2*.YU9_P!&2"%7]1&OIUJVY\YQL_!-MN-R
MG@&`QT;X/I7EDMZ8_P!!>>5D]#(WKURR/1W4>7_BO\2Z_P!N5O\`'/[VG+^>
MCU??G?E5@*W>/W'K&K^\55M;'O4_36U)']+<[N?;_DN]\;ZK;;63ZCZCQ*K\
M?U;0M<ZLY\9K>$OZF-?3K5MSWSA:>%]-N-RG@?3^'1O@^E65;>F/]!6>8)Z"
M1O7KU=T=U'DOXC]_U_MRJ_B[;F;)^:CU?>MO/<>$W=NHS^L:CG=R[;H:VH_U
M<]+&WX]^N/;_`)+N_%^IVVU?Q_'\2J_%]5-%<7%<Y\6>"*5_5XU/EUZ#GOG"
MV\+Z?<;E/!\#11OA^FAEMX*8_P!"AFEC3T5V'GUZJZ/ZDK7JY*O8&W)WKI<W
M/5M)1W-1-N/>N.[&SLDAU^ILIOG$TV4F_P!55PJWXM[]-R!R9.SM-MMJS2-*
M6JOQ&>Z2]E)S_HEW&D[>LB@]>BYZYO@5%AW"Y58Q$%HW`0VSV<0&/P6LCP+Z
M1L1UW)TAU++(\LFP-N/))-4U$CFBY::L[!A[5JI#Z_U3]C4Z9AOZUJA_\/>V
MY`Y,=B[;;:EBS,3I\VO!N#'CYWH%R?\`AH#?+K2\\\WHH1=PN0H50.[R6T-@
MH_*S)MQ_PLE>NX^D>I8I(Y8]@;<22*:FJ(W6CY2:C[`F[5I9%]?#0]BU#YA?
M^FUB_P#A[\O(')B,'7;;4,&4@Z>!6\.X*>/E>L;D?\-.KKS<\\WNI1MPN2I5
M@>[B&M!8,.'G9@6__-,4ZZI>D.I*)Z22DV!MR!Z"7"3T;1T=C33;;WMD>Q\%
M)%Z_2V+WUEZG*1?ZFKF9OS;WJ'D#DNW9&AVVU5HS$5HOPF"Z>]A(S_H=W(]P
MOI(Q/6Y>>N;YPZS;A<LL@E#5;B)K9+.4''X[6-(&]8U`ZZH>C^H\:<<U!U_M
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MVVUC^G%N(Z+\`M$FCMM.<>"D\RIZ"1O7K=SSYSC>>-]5N-R_U!G,E6^/ZIXI
M+C5C/BO!$S^IC7TZ]0]%]08P8T8_KW;=(,.FW(L8(:+2**/:.ULQLC;20>OT
M#"[2W!6T$'^IIZEUYO?WZW]ON2K01"VVVU00B`1T7X1;6\MK!3/^A6\TL*>B
M.P\^O3\^<XW1E-QN-RYF,Q>K?$;B>.YFKC_1+B&*5O5T4^775+T5T_11TL5)
MU[MN".BBQ4-(D=%9:>+![%K^LL3'&-?I6@V#E*C%1_THY63\W]ZA]O>2;=42
M';+55C$84!?A$5H]C&!G\%G(]NOI&Q7K<O/O.4[.\NXW+,YD+$MQ,MTE[(3C
M\=VB3G_AB@]=+T3T^D:Q)U[MM8TB2%4%$;+%'U])U2D8]?"KUS*V'_Z@CH_Q
M]^'MYR2JA!MEJ$``II\A9G;P./\`RA$VW_-+M^?7CS[SDS%SN-SJ)K75YF[%
M_7A_RF`7'_-7NZ[FZ*Z?J$GBFZ]VW)'4Q5L$Z-1<2Q9'85)U=71MZ_TU77M!
M#B''YHXU3\7]^?V]Y)E5DDVRU*N&!&GB'LUL'''\5FBVQ_X4H7KR<^\Y1LK)
MN-R&4J1W<"EVU\IX?ANW:X'_``PD]>J^BNH*Y*^.LZ]VW4)DXL]!D%DHKBKB
MW1LW%=>[ACF]8U+E]DX2DQLP_M4M.B_B_OTWM[R3<"19MLM6683!ZK\0N+:.
MSF!S_HEK%'`WK&BCRZ]#SYSC`8VAW&Y4Q&(I1OA,%S)=PD8_T.YEDF7T=R?/
MKNOZ,ZARG\5_B'7VVZO^-Q[HBRWFHM0KX]ZX/![;W6E1ZQJ7.X';=!2U'TUP
MTL8XM[W<>WW)5WXWU.VVK_4"X$E5^,7444%P#G_1H8(8W]5C4>76K?GSG&U\
M+Z?<;E/`,!CHWP&VEEF@(Q_H4LTLB>C2,?/KO(]&]19;^+G)=?;;K/X\N[4S
M'GHM7\17?:[?3>*U/K&L;B3:N.%3_JQ1Q_2WOUS[?<E7OC?5;;:O]2+CQ:K\
M?U?@BYU9SXPMX=?KX:^G7K;GOG"T\'Z;<;E/I_I_#HWP?2^*;?3C'@^/-H]/
M$;UZ[K^CNH\H<H<AU_MRK.:.ZFRIFHM7WYWOE\#G]VFH]8U_Q_,[8Q]34_ZN
M6DC/%O>[CV_Y+N_&-SMMJYG^H\2J_']5)#-<:LY\:6"%W]6C4^76K?GKG"U\
M+Z?<;E/`\#PZ-\'TT<L5O3'^A1SS(GHLC#SZ]6='=1U[5SUG7^W*ELF^X)*]
MI:+4:M]U;NQ&_=Q--Z_4<QO+`4>1F_U533(WXM[]-[?\EW)D,^VVK&4S%ZK\
M1N+F.\FKG_1+F&*9O61%/EUZ'GKF^W$8AW"Y41"$)1OA$%O):PTQ_H=M+)"O
MHCL//KN?I#J6IDGFGV!MR66JFR-14.]'=II\MORD[0R4LAU^IJWL&AARS_UK
M(P_^'O<G(/)DKL\FVVI=V=F)7B9+M;^0G/XKQ%N#_P`-`;K4?/7-\2JD>X7(
M5%0`:N`CM6L4`_TMHS6X_P"%DCKL=(]2B3S#8.W/)YEJ=?V7/G7L/_2PLGZ_
MU#LC_<S_`-1WK_P]^_J#R9JU_NVUUZJUT^?UG[QKQ_Y3?\9_YJ]WRZ]_7GF_
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M%O':S5Q_HEO%'"WJB*/+KU!T=U'B_P"%_P`/Z_VY2'"G:IQ)AHM)H#L?*Y[.
M;2^W.OT?P#+;HR%13_ZB2KD/-_?K?V_Y+M/!^FVVU3Z?Z?PZ+\'TLDTMOISC
MP9+B9T]&D8^?7KCGOG"[\7ZG<;E_'\?Q*M\?U4<45Q7&?%C@A1_41KZ==8[H
MWJ+$G$G&]?[;HC@1M(8<P46G^'C8<.X(-G"F]9T#;L.ZLBM-_J!62?6_O5K[
M?\E67@FUVVUC-O\`3^%1?@^D$PMM.?\`01<3!/02-Z];N>>^<+SQOJ=QN7^H
M^H\2K?']48C<:L?Z,8(2_KX:^G75!T7U#C/X6,?U]MND&%CVQ%BA#1:10Q[+
MP&;VMM5(/6=*X+;VY*^CIQSHAJI!S?WZV]ON2K3P?IMLM4\`0".B_`+6&6WM
MP,_Z%#/+&GHLC#SZ]/SYSC=>+]1N-R_CF<R5;XC<RQ3SDX_T6:&*1_5D4^77
M5)T7U!0I0QT?7NVZ=,9'@X:!8Z*PI8MM;+RO76!2+UG2N*V/G*O&0_ZFEJ'7
M\W]ZA]O>2;=8UAVRU58A$$HOPB"UDLH0,_Z':2R0+Z1NP\^MS<^<XSF1IMQN
M6:4REZM\1FN8[R4G'^B744<[>LB`]=1=$]/PQQ0Q=>;:2*".DAA047ICBH-@
MU'5E'&HU_IINO*N7$*/Q1.4_Q]^3V]Y)C143;+4(H4`:>`2S;;U''\-DS6P_
MX42OSZ\W/O.3LSON-T68L2=7$O=B^8\/.\5;@_\`#`#UZ3HGI^6-XI.O=M/'
M)'-"ZM17#15'7T?5,Z'UW*R]<Q+AS_TQ#1_C[\WMYR2ZE&VRU*D$$:?)K,;>
M1Q\[("V_YI#3\^O+S[SDK!UW&Y#`@_%YB[-^#P\KPFX_YJG5UW5]%=05R5<=
M7U[MNH2OCRT-8LE%<5,6=V/CNMLPDOK]2Y#8>)IL5)_6DA5?Q?WZ;V]Y)N%=
M9MLM6602!JK\0EM$L9`<_CM(TMV_X6H'7HN?.<8"C0[C<JT9C*T;@8KI[V,C
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M\-=M7'2U/^K:CC^FGWNZ]O\`DN]\;ZK;;63ZCZCQ*K77]6T+W.K.?&>WA9_4
MQKZ=:MN>^<+/POI=QN4\#Z?PZ-31]*LJ6^G&/!6>94]!(WKUW7=']1Y(Y!J_
MK_;E4<J^Y9,D9J+4:R3>.Y<+O'=#S^OUMF]T;=H:Z?\`U4]+&W%K>_7'M_R7
M=&4W&VVKF8SEZK\1N9XKF<G/^BSPQ2OZO&I\NO0<]<X6PC%ON%R@A$(2C?"+
M>&2W@IC'A032Q)Z([#SZ[J>D.I*V2IEJM@;<GDK9<Q/5/)1:FGFW!OC'=E9J
M20Z_4V2WYB:;*R_ZJKA5_P`6]^EY`Y+G9WFVVU9I#*6JO$S727TI.?QW<:7#
M>LB@]>BYZYOA55BW"Y54$86C<!%:O91@?Z2UD>!?2-B.NWZ0ZEDD::38&W6E
M>>>I=S1^IIZGL&+M6HE/K_7+V-"N8)_Y75#_`.'O;<@<F,Q=MMM2Y8M73YM>
M#<&/'B;T"Y/_``T:OEUI>>>;U4(NX7(0*%`U>2VAL`.'E9DVX_X6:=>BZ0ZE
M@DCEBV!MQ)(9:.>)UHN4FQ_8$_:M%(MW_53=BU,F83^E:Y?_``]^3D'DR-@Z
M;;:AE92#IX%+P[@IX_AO6-R/^&DMUY^>N;Y%*/N%R5(8'NXA[06##_;68%N?
M^%#3UQI.C^HZ%J1Z38&W*=J"7!ST;1T=C3R[:WGDNQ,#)%ZSI;%;WS%5DX?]
M353LWYM[U#R!R7;E&AVVU4QF(K1?A,%T]["1G_0[J62=?21R>MS<]<X3AUFW
M"Y82"4-5N(FMDLY0<?Z):QI`WK&H'7J'H[J/&?PTT'7^W*4X=MKOC/#1:?LF
MV5N#.;JVHT'K.@X'<6Y:^LI_]1-52'\^_6_(')=KX7T^VVJ>`;<QT7X#:S2W
M%O3/^@S3S2)Z-(Q\^O3\]\X77B_4;C<OXWCZZM\7U,44%Q7'^BPPQ1OZK&H\
MNNL=T;U%B?X3_#>O]N4?\"_NE_"/!1:?X?\`W$FS]1L_[?UG1_=Z?=.0:F^N
M@U<GUO[];>W_`"79^#]+MMJGT_T_AT7X/I#,;;3G'@FXF*>GB-Z]>N>>^<+O
MQOJ=QN7\?ZCQ*M\?U0B%Q7&?&$$(?U\-?3KK']&=0XK^%?P[K[;='_`TVI'B
M/#1:?L$V-B\[A-HK3W<Z!M_$[GR%/3?71'5R#F_O5M[?<E6?@_2[;:I].+<1
MT7X!:1S16VG/^@QSS(GHLC#SZW<<^<XW?B_4[C<OXYG,E6^/ZJ2*6XKC_19(
M(G?U,:^G75%T7U!CDQR4/7NVZ5,3'MZ+&K%1:11Q[4VIE]C;<2`:SI7#;0SU
M9CX/]335#K^;^_6_M]R5:B);?;+5!"(0E%^$6]O):04S_H5M-+"GHCL//KT_
M/G.-R9&GW&Y<S&8O5OB-Q/'=3$X_T2XBCF;U=%/7J?HKI^DBIH:;KW;<,5&F
M,CI42BL($PVPZ[K#%JGK-A0]?Y.HQ,?]*.5D_P`?>HO;WDF%$2+;+5401A0%
MX"*T>PCIG\%G(]N/2-B/GUN3GWG*9F>7<;EF<N6.KB9+I+Z2N/Q7:)<'_AB@
M]=#HGI\0BG'7FVA"(Q"(_LO2(EZ_/52I;7^D==,</_U!>C_'WK_6\Y(T>'^[
M+7PZ4II\OH_W?3C_`,H7^+?\TNWKW]?><B_B?O&YUUK75Y_5_7UX?\IG^,?\
MU>[KT_173]3%/#4=>[;EBJH\A%4(]%=98\KL&CZMR*OZ^16=>X^#$/\`UHXU
M3_'WN3V]Y)F1HY=LM2CAP1IXB2S6P?S_`!6:+;'_`(4H7KT?/O.43*\>XW(9
M"A!U<#'=M?)Y?ANW:X'_``QB>NZSHOJ#()7QUO7NVZE,I'GXLBLM%J%7'NG:
M.*V%N%)AK&H9?9N#I,=-_JJ:G1?Q?WZ?V]Y)N5D6?;+5EE$P>J_$+BVCLY@<
M_P"B6T4<+>J(!UJ'GSG&W,;0;C<JT1B*4;X3!<27<-,?Z'<RR3+Z.Y/7=?T9
MU#E/XK_$.OMMU?\`&TW2F6\U%J^_3>^&P6WMVK4>L:QG\)MF@IJC_5Q4D8XM
M[W<^WW)5WXWU.VVK_4"X$E5^,7444-QJSGQHH(8W]5C4>77K?GSG&U\+Z?<;
ME/`,!CHWP?322S6],?Z%+/*Z>C2,?/KOI"J%;U7M"J%='DA+1UI%;#G-F[EC
MG"Y;((&3.=?8K";.R`73IU4-+"BVTN#(KL=\@3"?E"RF$@E#(W<);:<']1_]
M%LXXK9_2L4:@<&JP8GW/41@YLO(BAC(=>TQ7,)'Z:?Z%=O+<)ZTE=B>(HI4`
M5O8PZ"77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
(=>]^Z]U__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LICENSE AND SUPPLY AGREEMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock', window );">LICENSE AND SUPPLY AGREEMENT</a></td>
        <td class="text"><div>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt">NOTE 2 -</font> LICENSE AND SUPPLY
AGREEMENT</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
On November&#xA0;30, 2009, Protalix Ltd. and Pfizer entered into
the Pfizer Agreement pursuant to which Pfizer was granted an
exclusive, worldwide license to develop and commercialize
taliglucerase alfa, except in Israel. Under the terms and
conditions of the Pfizer Agreement, Protalix Ltd. retained the
right to commercialize taliglucerase alfa in Israel. Under the
Pfizer Agreement, Pfizer made an upfront payment to Protalix Ltd.
of $60,000 in connection with the execution of the agreement and
shortly thereafter paid Protalix Ltd. an additional $5,000 upon the
Company&#x2019;s filing of a proposed pediatric investigation plan
to the Pediatric Committee of the EMA. Protalix Ltd. is also
eligible to receive additional potential milestone payments
totaling up to $50,000 for the successful achievement of other
regulatory milestones. Protalix Ltd. is entitled to 40% of the
profits earned on Pfizer&#x2019;s sales of taliglucerase alfa. Such
profit will be calculated while, in addition to other adjustments,
taking into account Protalix Ltd.&#x2019;s cost of goods sold and
Pfizer&#x2019;s commercial expenses, with certain expenses capped or
borne solely by one party ("Collaboration Operation"). Of the
losses incurred by the Collaboration Operation through December 31,
2011, 40% will be deducted from the Company's share in the profits
from future years. This deduction will limited to a certain
percentage of any quarterly profit. As of December 31, 2011, the
Company accrued a liability in respect of these losses equal to
$7,888, out of which $6,566 is classified as a long term liability,
and the remainder is included in accounts payable and
accruals-other.</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
The Company has determined that the initial, non-refundable upfront
license fee payment of $60,000 together with the first $5,000
payment will be recognized on a straight line basis as revenue over
the estimated relationship period. The Company has estimated that
the relationship period for its arrangement with Pfizer will be
approximately 14 years (commencing upon the Company&#x2019;s receipt
of the up-front license payment) based on the Company&#x2019;s last
material patent relating to taliglucerase alfa to expire.</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
The Company&#x2019;s deliverables under this collaboration include
an exclusive license to taliglucerase alfa as an enzyme replacement
therapy for the treatment of Gaucher disease, certain research and
development services as required under the Pfizer Agreement for
taliglucerase alfa, manufacturing of taliglucerase alfa and
optional participation in a joint steering committee.</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
According to the terms and conditions of the Pfizer Agreement, the
Company retained manufacturing rights and sells its products to
Pfizer. In addition, Pfizer is required to reimburse the Company
for certain costs it incurs in connection with certain development
expenses for taliglucerase alfa. In connection with the payments
received under the Pfizer Agreement, Protalix Ltd. is obligated to
pay certain royalties. See Note 6a.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeAndLicenseArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative and License Arrangement Disclosure [Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeAndLicenseArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>28
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V
M93`V968U.64B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S
M8C,V93`V968U.64-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S8R
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7T)!3$%.0T5?4TA%1513/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0T].4T],241!5$5$7T)!3$%.0T5?4TA%15137U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!5$5$
M7U-4051%345.5%-?3T9?3U!%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].4T],241!5$5$7U-4051%345.5%]/1E]#2$%./"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].4T],241!
M5$5$7U-4051%345.5%]/1E]#2$%.,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7T-!
M4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)
M1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DQ)0T5.4T5?04Y$7U-54%!,65]!1U)%14U%
M3E0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y04D]0
M15)465]!3D1?15%525!-14Y4/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^24Y614Y43U))15,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y,24%"24Q)5%E?1D]27T5-4$Q/645%7U))1TA4
M4U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TU-
M251-14Y44SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-(05)%7T-!4$E404P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y405A%4U]/3E])3D-/344\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y355!03$5-14Y405)97T9)3D%.0TE!3%]35$%4
M14T\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y214Q!
M5$5$7U!!4E197U1204Y304-424].4SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E-50E-%455%3E1?159%3E13/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X
M8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS
M:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C
M=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R
M;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X
M.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^
M/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P
M86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@
M;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S8R935C,69?.#1C9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,V,F4U8S%F7S@T8V1?
M-&$S,U]A-#%F7S-B,S9E,#9E9C4Y92]7;W)K<VAE971S+U-H965T,#$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5654%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M
M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(S+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@
M26YF;W)M871I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C$P+4L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y$96,@,S$L#0H)"3(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!&:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y&63QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/E!,6#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4%)/5$%,25@@0DE/5$A%4D%0
M155424-3+"!)3D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#$P,#8R.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@
M1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!796QL+6MN;W=N(%-E87-O;F5D($ES
M<W5E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3F\\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%9O;'5N=&%R>2!&:6QE<G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@1FEL97(@
M0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D%C8V5L
M97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP+#@Q
M-2PS.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,S8U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S,V,F4U8S%F7S@T8V1?-&$S,U]A-#%F
M7S-B,S9E,#9E9C4Y90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S
M-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64O5V]R:W-H965T
M<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%345!1SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^
M/'-T<F]N9SY#3TY33TQ)1$%4140@0D%,04Y#12!32$5%5%,@*%531"`D*3QB
M<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-54E)%3E0@05-31513.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W+#`P,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S4L
M.3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%C8V]U;G1S(')E8V5I=F%B;&4Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,W-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,#$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX,S<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(S,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT
M;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,R+#0Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0V+#,S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1E5.1%,@24X@4D534$5#5"!/1B!%
M35!,3UE%12!224=(5%,@55!/3B!2151)4D5-14Y4/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDT,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4%)/4$525%D@04Y$($5154E0
M345.5"P@3D54/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PR
M-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-RPT-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4Q+#@P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8T+#<R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT<R!P87EA
M8FQE(&%N9"!A8V-R=6%L<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5')A9&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPR-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#4T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@L,#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPQ,C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#4V,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$X+#8Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X+#DP,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,3TY'(%1%4DT@3$E!0DE,
M251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E9F5R<F5D(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,"PY,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-2PT.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<@=&5R;2!L:6%B:6QI='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-38V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6%B:6QI='D@
M9F]R(&5M<&QO>65E(')I9VAT<R!U<&]N(')E=&ER96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L;VYG
M('1E<FT@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4Y+#$X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4W+#$T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-RPX.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-BPP-3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%
M3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%0251!3"!$149)0TE%3D-9.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@4W1O8VLL("0P+C`P,2!P87(@=F%L=64Z($%U=&AO<FEZ960@+2!A<R!O
M9B!$96-E;6)E<B`S,2P@,C`Q,"!A;F0@,C`Q,2P@,34P+#`P,"PP,#`@<VAA
M<F5S.R!I<W-U960@86YD(&]U='-T86YD:6YG("T@87,@;V8@1&5C96UB97(@
M,S$L(#(P,3`@86YD(#(P,3$L(#@Q+#(T."PT-S(@86YD(#@U+#8S,"PQ-3<@
M<VAA<F5S+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#4L.#$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(T+#`T-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3<Q+#DW-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,S4L-#0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-A<&ET86P@9&5F:6-I96YC
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8L,#<W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#,R
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!N970@;V8@8V%P:71A;"!D969I8VEE
M;F-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4Q+#@P-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-C0L-S(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S8R935C,69?.#1C9%\T83,S7V$T
M,69?,V(S-F4P-F5F-3EE+U=O<FMS:&5E=',O4VAE970P,RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14-%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].4T],241!5$5$
M($)!3$%.0T4@4TA%1513("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N(%-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL($%U=&AO
M<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:RP@:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-2PV,S`L,34W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$L,C0X+#0W,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N(%-T;V-K+"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#4L-C,P+#$U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q+#(T."PT-S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,V,F4U8S%F7S@T8V1?-&$S
M,U]A-#%F7S-B,S9E,#9E9C4Y90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64O5V]R
M:W-H965T<R]3:&5E=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%15%!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY#3TY33TQ)1$%4140@4U1!5$5-14Y44R!/1B!/4$52
M051)3TY3("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@
M9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,#D\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)%5D5.5453/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,S@V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V+#8T,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S@X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M3TU004Y9)U,@4TA!4D4@24X@0T],3$%"3U)!5$E/3B!!1U)%14U%3E0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L-#$X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-C`R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#3U-4
M($]&(%)%5D5.5453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#4R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T+#,X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S+#4W-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y'4D]34R!04D]&250@*$Q/4U,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0T,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#8Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPQ.#<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M15-%05)#2"!!3D0@1$5614Q/4$U%3E0@15A014Y315,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,W+#@Q."D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-RPV.3$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<L,SDP*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5S
M<R`M(&=R86YT<R!A;F0@<F5I;6)U<G-E;65N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L-S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPW-#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#<U,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)%4T5!4D-(($%.
M1"!$159%3$]0345.5"!%6%!%3E-%4RP@3D54/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S,2PP-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,CDL.34Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q+#8S."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=%3D5204P@
M04Y$($%$34E.25-44D%4259%($584$5.4T53/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@V+#DS,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+#@W-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#$T-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/4$52051)3D<@
M3$]34SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S8L-3,Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y
M+#DV-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S,2PY-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&24Y!3D-)04P@24Y#3TU%("T@3D54/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3D54($Q/4U,@1D]2
M(%1(12!914%2/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,V
M+#4R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#(X+#DY."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#,Q+#0T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S('!E<B!S:&%R92!O
M9B!C;VUM;VX@<W1O8VL@+2!B87-I8R!A;F0@9&EL=71E9#H\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XT,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XS-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XT,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@879E<F%G92!N=6UB97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!U<V5D(&EN(&-O;7!U=&EN9R!L;W-S('!E<B!S:&%R92!O9B!C;VUM;VX@
M<W1O8VLL(&)A<VEC(&%N9"!D:6QU=&5D.CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#0L-C0U+#,V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+#DV,"PS,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-BPY-#(L.#0P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-C)E-6,Q
M9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,S8R935C,69?.#1C9%\T83,S7V$T,69?,V(S-F4P
M-F5F-3EE+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U704D^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0T].4T],241!5$5$(%-4051%345.
M5"!/1B!#2$%.1T53($E.(%-(05)%2$],1$524R<@15%52519("A#05!)5$%,
M($1%1DE#245.0UDI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@
M4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y4;W1A;#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY#;VUM;VX@
M4W1O8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D:71I
M;VYA;"!P86ED+6EN($-A<&ET86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^06-C=6UU;&%T960@9&5F:6-I=#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@870@1&5C
M+B`S,2P@,C`P.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M-"PS-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,3DL
M,C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@W-2PP,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A
M="!$96,N(#,Q+"`R,#`X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW-2PY,S@L,#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-H86YG97,@9'5R:6YG('1H92!Y96%R/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV.#,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#8X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N
M=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N+65M<&QO>65E<R`H:6YC;'5D97,@
M;F5T(&5X97)C:7-E*2`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PY,#,L,3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y
M965S(&%N9"!N;VXM96UP;&]Y965S("AI;F-L=61E<R!N970@97AE<F-I<V4I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S$L-#0P*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,Q+#0T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@
M,S$L(#(P,#D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#@X
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(R+#(U,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P-BPT
M-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;F1I;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R
M,#`Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PX-#$L,C,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG
M97,@9'5R:6YG('1H92!Y96%R/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PR.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#(X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO
M>65E<R!A;F0@;F]N+65M<&QO>65E<R`H:6YC;'5D97,@;F5T(&5X97)C:7-E
M*2`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#`W+#(S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N+65M
M<&QO>65E<R`H:6YC;'5D97,@;F5T(&5X97)C:7-E*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C@L.3DX*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(X+#DY."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@
M,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#,R
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R-"PP-#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S4L
M-#0X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16YD:6YG($)A;&%N8V4@*&EN('-H87)E<RD@870@1&5C+B`S,2P@
M,C`Q,#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$L,C0X+#0W
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N
M9V5S(&1U<FEN9R!T:&4@>65A<CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!C87-H("AN970@;V8@:7-S=6%N
M8V4@8V]S=',@;V8@)#$L-#$P*2`H<V5E(&YO=&4@-V,I("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!I<W-U
M960@9F]R(&-A<V@@*&YE="!O9B!I<W-U86YC92!C;W-T<R!O9B`D,2PT,3`I
M("AS964@;F]T92`W8RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+#4Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PU.#8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S
M(&%N9"!N;VXM96UP;&]Y965S("AI;F-L=61E<R!N970@97AE<F-I<V4I("AI
M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.#$L
M-C@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O
M9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S(&%N9"!N;VXM96UP;&]Y
M965S("AI;F-L=61E<R!N970@97AE<F-I<V4I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,CDX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,S8L-3(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,V+#4R
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N9&EN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C8L,#<W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$T-2PX,30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$W,2PY-S<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I
M;F<@0F%L86YC92`H:6X@<VAA<F5S*2!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-2PV,S`L,34W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#8^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O
M;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELQ73PO=&0^#0H@
M("`@("`@(#QT9"!C;VQS<&%N/3-$-2!V86QI9VX],T1T;W`^4F5P<F5S96YT
M<R!A;B!A;6]U;G0@;&5S<R!T:&%N("0Q+CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S8R935C,69?.#1C9%\T
M83,S7V$T,69?,V(S-F4P-F5F-3EE+U=O<FMS:&5E=',O4VAE970P-BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14M$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3E-/3$E$
M051%1"!35$%414U%3E0@3T8@0TA!3D=%4R!)3B!32$%214A/3$1%4E,G($51
M54E462`H0T%0251!3"!$149)0TE%3D-9*2`H4&%R96YT:&5T:6-A;"D@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:R!I<W-U960@9F]R(&-A<V@L(&ES<W5A;F-E(&-O<W1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#$P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-C)E-6,Q9E\X-&-D7S1A
M,S-?830Q9E\S8C,V93`V968U.64-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO,S8R935C,69?.#1C9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE+U=O
M<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14\T04<^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^0T].4T],241!5$5$(%-4051%345.5%,@3T8@0T%3
M2"!&3$]74R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$P/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,#D\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($]015)!5$E.1R!!
M0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@S-BPU,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@R."PY.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@S,2PT-#`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%D:G5S
M=&UE;G1S(')E<75I<F5D('1O(')E8V]N8VEL92!N970@;&]S<R!T;R!N970@
M8V%S:"!P<F]V:61E9"!B>2`H=7-E9"!I;BD@;W!E<F%T:6YG(&%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PR.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#8X,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!W
M<FET92!D;W=N(&]F(&9I>&5D(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPV,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#$S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3DP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:6YA;F-I86P@97AP96YS
M97,@*&EN8V]M92DL(&YE="`H;6%I;FQY(&5X8VAA;F=E(&1I9F9E<F5N8V5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3DQ*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-H86YG97,@:6X@86-C<G5E9"!L:6%B:6QI='D@9F]R(&5M<&QO>65E(')I
M9VAT<R!U<&]N(')E=&ER96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V%I;B!O;B!A;6]U;G1S(&9U;F1E9"!I;B!R
M97-P96-T(&]F(&5M<&QO>65E(')I9VAT<R!U<&]N(')E=&ER96UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@Q*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O
M;B!S86QE(&]F(&9I>&5D(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S
M<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@9&5F
M97)R960@<F5V96YU97,@*&EN8VQU9&EN9R!N;VXM8W5R<F5N="!P;W)T:6]N
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPP,#4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PU-C,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C0L-C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$96-R96%S92`H:6YC<F5A<V4I(&EN(&%C8V]U;G1S(')E8V5I
M=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#DQ/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPX
M-C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,2PR,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$96-R96%S92`H26YC<F5A<V4I(&EN(&EN=F5N=&]R:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#$X.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M8W)E87-E("AD96-R96%S92D@:6X@86-C;W5N=',@<&%Y86)L92!A;F0@86-C
M<G5A;',@*&EN8VQU9&EN9R!L;VYG('1E<FT@*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPQ-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`R.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#<X-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R
M;W9I9&5D(&)Y("AU<V5D(&EN*2!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C,L-3<P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,X+#0V-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PT
M-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($E.5D535$E.1R!!0U1)5DE4
M2453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#<P-2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#@U-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#$Y-2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@<V%L92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W5N=',@9G5N
M9&5D(&EN(')E<W!E8W0@;V8@96UP;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E
M;65N="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-C4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L.#8X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<L.3DR
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#8L,3<T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@1DE.04Y#24Y'($%#
M5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F('-H87)E<RP@;F5T(&]F(&ES<W5A;F-E(&-O
M<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#8U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M+#DR-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^149&14-4($]&($580TA!3D=%(%)!5$4@0TA!3D=%4R!/
M3B!#05-(/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.#@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.150@24Y#4D5!4T4@*$1%0U)%05-%*2!)3B!#05-(($%.1"!#05-(
M($5154E604Q%3E13/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X
M+#@Y.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T-2PS-C8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S@L-C<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"04Q!3D-%($]&($-!4T@@04Y$($-!4T@@
M15%5259!3$5.5%,@050@0D5'24Y.24Y'($]&(%E%05(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,U+#DP,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q+#(V-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#4Y-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0D%,04Y#
M12!/1B!#05-(($%.1"!#05-(($5154E604Q%3E13($%4($5.1"!/1B!914%2
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPP,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-2PY,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,2PR-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%262!)3D9/4DU!5$E/3B!/3B!)
M3E9%4U1)3D<@04Y$($9)3D%.0TE.1R!!0U1)5DE42453($Y/5"!)3E9/3%9)
M3D<@0T%32"!&3$]74SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT-S,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<R,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-3(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U86YC92!C;W-T(&YO="!Y970@<&%I9"!A;F0@86-C<G5A;',@
M+2!O=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,V,F4U8S%F7S@T8V1?-&$S
M,U]A-#%F7S-B,S9E,#9E9C4Y90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64O5V]R
M:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TE'3DE&
M24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/&1I=CX-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M:6X[($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M="<^/&(^3D]412`Q("T\+V(^/"]F;VYT/B`\8CY324=.249)0T%.5`T*04-#
M3U5.5$E.1R!03TQ)0TE%4SPO8CX\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF(WA!,#L\+V9O;G0^/"]P
M/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L
M9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM
M0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^/"]T9#X-"CQT9"!S
M='EL93TS1"=724142#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@;F]R;6%L)SYA+CPO9F]N=#X\+W1D/@T*/'1D/D=E;F5R86P\+W1D
M/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3`N,C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B!B
M;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^/"]T9#X-"CQT
M9"!S='EL93TS1"=724142#H@,"XR-6EN)SXQ+CPO=&0^#0H\=&0^3W!E<F%T
M:6]N/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*4')O=&%L:7@@0FEO5&AE<F%P975T:6-S
M+"!);F,N("AC;VQL96-T:79E;'D@=VET:"!I=',@<W5B<VED:6%R:65S+`T*
M)B-X,C`Q0SM4:&4@0V]M<&%N>28C>#(P,40[*2P@86YD(&ET<R!W:&]L;'DM
M;W=N960@<W5B<VED:6%R>2P-"E!R;W1A;&EX($QT9"X@*'1H92`F(W@R,#%#
M.TES<F%E;&D@4W5B<VED:6%R>28C>#(P,40[(&]R#0HF(W@R,#%#.U!R;W1A
M;&EX($QT9"XF(W@R,#%$.RDL(&%R92!B:6]P:&%R;6%C975T:6-A;"!C;VUP
M86YI97,-"F9O8W5S960@;VX@=&AE(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C
M:6%L:7IA=&EO;B!O9B!R96-O;6)I;F%N=`T*=&AE<F%P975T:6,@<')O=&5I
M;G,@8F%S960@;VX@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<')O<')I971A<GD-
M"E!R;T-E;&Q%>#QS=7`^)B-X044[/"]S=7`^('!R;W1E:6X@97AP<F5S<VEO
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M)B-X,C`Q.3MS(&QE860@<')O9'5C=`T*9&5V96QO<&UE;G0@8V%N9&ED871E
M(&ES('1A;&EG;'5C97)A<V4@86QF82!F;W(@=&AE('1R96%T;65N="!O9@T*
M1V%U8VAE<B!D:7-E87-E('=H:6-H('1H92!#;VUP86YY(&ES(&1E=F5L;W!I
M;F<@=7-I;F<@4')O0V5L;$5X+B!);@T*861D:71I;VX@=&\@=&%L:6=L=6-E
M<F%S92!A;&9A+"!T:&4@0V]M<&%N>2!I<R!D979E;&]P:6YG(&-E<G1A:6X-
M"F]T:&5R('!R;V1U8W1S('5S:6YG(%!R;T-E;&Q%>"X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I);B!397!T96UB97(@
M,C`P.2P@=&AE($-O;7!A;GD@<W5C8V5S<V9U;&QY(&-O;7!L971E9"!I=',@
M<&AA<V4@24E)#0IP:79O=&%L('1R:6%L(&]F('1A;&EG;'5C97)A<V4@86QF
M82X@26X@2G5L>2`R,#$P+"!T:&4@52Y3+B!&;V]D#0IA;F0@1')U9R!!9&UI
M;FES=')A=&EO;B`H)B-X,C`Q0SM&1$$F(W@R,#%$.RD@;F]T:69I960@=&AE
M($-O;7!A;GD-"G1H870@:70@:&%D(&%C8V5P=&5D(&9O<B!R979I97<@=&AE
M($-O;7!A;GDF(W@R,#$Y.W,@;F5W(&1R=6<-"F%P<&QI8V%T:6]N("@B3D1!
M(BD@9F]R('1A;&EG;'5C97)A<V4@86QF82!F;W(@=&AE('1R96%T;65N="!O
M9@T*1V%U8VAE<B!D:7-E87-E(&%N9"!T:&%T(&ET(&=R86YT960@=&\@=&%L
M:6=L=6-E<F%S92!A;&9A(&$-"E!R97-C<FEP=&EO;B!$<G5G(%5S97(@1F5E
M($%C="`H4$151D$I(&%C=&EO;B!D871E(&]F($9E8G)U87)Y(#(U+`T*,C`Q
M,2X@/&9O;G0@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY/;@T*1F5B<G5A<GD@,C4L(#(P,3$L('1H92!&
M1$$@:7-S=65D(&$@0V]M<&QE=&4@4F5S<&]N<V4@3&5T=&5R#0HH(D-23"(I
M(&EN9&EC871I;F<@=&AA="!T:&4@1D1!)B-X,C`Q.3MS(')E=FEE=R!O9B!T
M:&4@=&%L:6=L=6-E<F%S90T*86QF82!.1$$@=V%S(&-O;7!L971E(&)U="!Q
M=65S=&EO;G,@<F5M86EN('1H870@<')E8VQU9&5D('1H90T*87!P<F]V86P@
M;V8@=&AE($Y$02!I;B!I=',@=&AE;B!C=7)R96YT(&9O<FTN($EN($%U9W5S
M="`R,#$Q+"!T:&4-"D-O;7!A;GD@<W5B;6ET=&5D(&$@<F5V:7-E9"!.1$$@
M:6X@<F5S<&]N<V4@=&\@=&AE($-23"X@1'5R:6YG('1H90T*<V%M92!M;VYT
M:"P@=&AE($9$02!N;W1I9FEE9"!T:&4@0V]M<&%N>2!T:&%T(&ET(&AA9"!A
M8V-E<'1E9"!T:&4-"G)E=FES960@3D1!(&9O<B!R979I97<L(&AA9"!D965M
M960@=&AE(')E<W5B;6ES<VEO;B!A(&-L87-S(#(L(&]R#0HV+6UO;G1H+"!R
M97-P;VYS92!A;F0@97-T86)L:7-H960@1F5B<G5A<GD@,2P@,C`Q,B!A<R!T
M:&4@;F5W(%!$549!#0ID871E+B!);B!$96-E;6)E<B`R,#$Q+"!T:&4@1D1!
M(&YO=&EF:65D('1H92!#;VUP86YY('1H870@:70@:&%D#0ID96-I9&5D('1O
M(&5X=&5N9"!T:&4@4$151D$@9&%T92!T;R!-87D@,2P@,C`Q,BX\+V9O;G0^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X
M03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M26X@=&AE(&9O=7)T:"!Q=6%R=&5R(&]F(#(P,3`L(%!F:7IE<B!);F,N("@B
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M;W(@80T*,3`M>65A<B!M87)K970@97AC;'5S:79I='D@<&5R:6]D(&-O;6UE
M;F-I;F<@87,@;V8@=&AE($%U9W5S="`R,#$P#0IM87)K971I;F<@875T:&]R
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M>2!T;R!B92!G<F%N=&5D+`T*8F%S960@;VX@82!N=6UB97(@;V8@9F%C=&]R
M<RP@:6YC;'5D:6YG(&-O;G1R:6)U=&EO;B!T;R!P871I96YT#0IC87)E+"!C
M;&EN:6-A;"P@<W5P<&QY+"!C87!A8VET>2!A;F0@;W1H97)S+CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"D9O;&QO=VEN
M9R!T:&4@<W5B;6ES<VEO;B!O9B!T:&4@=&%L:6=L=6-E<F%S92!A;&9A($U!
M02!T;R!T:&4@14U!+`T*82!G;V]D(&UA;G5F86-T=7)I;F<@<')A8W1I8V5S
M+"!O<B!'35`L(&%U9&ET(&]F('1H92!#;VUP86YY)W,-"FUA;G5F86-T=7)I
M;F<@9F%C:6QI='D@=V%S('!E<F9O<FUE9"!A;F0@:70@=V%S(&9O=6YD(&-O
M;7!L:6%N=`T*=VET:"!%34$@1TU0(&EN($1E8V5M8F5R(#(P,3$N/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*26X@2F%N
M=6%R>2`R,#$P+"!T:&4@14U!)W,@0V]M;6ET=&5E(&9O<B!/<G!H86X@365D
M:6-I;F%L(%!R;V1U8W1S+`T*869T97(@<F5V:65W:6YG(&%L;"!R96QE=F%N
M="!C;&EN:6-A;"!D871A+"!R96-O;6UE;F1E9"!T:&%T('1H90T*175R;W!E
M86X@0V]M;6ES<VEO;B!G<F%N="!O<G!H86X@9')U9R!D97-I9VYA=&EO;B!T
M;R!T86QI9VQU8V5R87-E#0IA;&9A(&9O<B!T:&4@=')E871M96YT(&]F($=A
M=6-H97(@9&ES96%S92!A;F0@:6X@36%R8V@@,C`Q,"P@=&AE#0I%=7)O<&5A
M;B!#;VUM:7-S:6]N(&=R86YT960@;W)P:&%N(&1E<VEG;F%T:6]N('1O('1A
M;&EG;'5C97)A<V4-"F%L9F$N($EN(%-E<'1E;6)E<B`R,#`Y+"!T:&4@1D1!
M)B-X,C`Q.3MS($]F9FEC92!O9B!/<G!H86X@4')O9'5C=`T*1&5V96QO<&UE
M;G0@9W)A;G1E9"`\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/G1A;&EG;'5C97)A<V4-"F%L9F$\
M+V9O;G0^($]R<&AA;B!$<G5G(%-T871U<RX\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*3VX@3F]V96UB97(F
M(WA!,#LS,"P@,C`P.2P@4')O=&%L:7@@3'1D+B!A;F0@4&9I>F5R(&5N=&5R
M960@:6YT;R!A;@T*17AC;'5S:79E($QI8V5N<V4@86YD(%-U<'!L>2!!9W)E
M96UE;G0@*'1H92`F(W@R,#%#.U!F:7IE<@T*06=R965M96YT)B-X,C`Q1#LI
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M(&%L9F$@:6X@27-R865L+B!3964@3F]T90T*,BX\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE
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M960@=')E871M96YT<RX@26X@2G5L>2`R,#`Y+"!F;VQL;W=I;F<-"F$@<F5Q
M=65S="!B>2!T:&4@1D1!+"!T:&4@0V]M<&%N>2!S=6)M:71T960@82!T<F5A
M=&UE;G0@<')O=&]C;VP@=&\-"G1H92!&1$$@:6X@;W)D97(@=&\@861D<F5S
M<R!A;B!E>'!E8W1E9"!S:&]R=&%G92!O9B!T:&4@8W5R<F5N=`T*96YZ>6UE
M(')E<&QA8V5M96YT('1H97)A<'D@87!P<F]V960@9F]R($=A=6-H97(@9&ES
M96%S92X@5&AE#0IT<F5A=&UE;G0@<')O=&]C;VP@=V%S(&%P<')O=F5D(&)Y
M('1H92!&1$$@:6X@075G=7-T(#(P,#DL(&%N9"!T:&4-"D-O;7!A;GD@:7,@
M8V]N=&EN=6EN9R!T;R!T<F5A="!P871I96YT<R!I;B!T:&4@56YI=&5D(%-T
M871E<R!U;F1E<@T*=&AI<R!P<F]T;V-O;"X@3VX@2G5L>2`Q,RP@,C`Q,"P@
M=&AE($-O;7!A;GD@86YN;W5N8V5D('1H870@=&AE#0I&<F5N8V@@<F5G=6QA
M=&]R>2!A=71H;W)I='D@:&%D(&=R86YT960@86X@075T;W)I<V%T:6]N(%1E
M;7!O<F%I<F4-"F0G571I;&ES871I;VX@*$%452DL(&]R(%1E;7!O<F%R>2!!
M=71H;W)I>F%T:6]N(&9O<B!5<V4L(&9O<@T*=&%L:6=L=6-E<F%S92!A;&9A
M(&9O<B!T:&4@=')E871M96YT(&]F($=A=6-H97(@9&ES96%S92X@06X@0515
M(&ES#0IT:&4@<F5G=6QA=&]R>2!M96-H86YI<VT@=7-E9"!B>2!T:&4@1G)E
M;F-H($AE86QT:"!0<F]D=6-T<R!A;F0-"E-A9F5T>2!!9V5N8WD@=&\@;6%K
M92!N;VXM87!P<F]V960@9')U9W,@879A:6QA8FQE('1O('!A=&EE;G1S(&EN
M#0I&<F%N8V4@=VAE;B!A(&=E;G5I;F4@<'5B;&EC(&AE86QT:"!N965D(&5X
M:7-T<RX@5&AI<R!!5%4@86QL;W=S#0I'875C:&5R(&1I<V5A<V4@<&%T:65N
M=',@:6X@1G)A;F-E('1O(')E8V5I=F4@=')E871M96YT('=I=&@-"G1A;&EG
M;'5C97)A<V4@86QF82!B969O<F4@;6%R:V5T:6YG(&%U=&AO<FEZ871I;VX@
M9F]R('1H92!P<F]D=6-T#0II<R!G<F%N=&5D(&EN('1H92!%=7)O<&5A;B!5
M;FEO;BX@4&%Y;65N="!F;W(@=&%L:6=L=6-E<F%S92!A;&9A#0IH87,@8F5E
M;B!S96-U<F5D('1H<F]U9V@@9V]V97)N;65N="!A;&QO8V%T:6]N<R!T;R!H
M;W-P:71A;',N($EN#0IA9&1I=&EO;B!T;R!T:&4@56YI=&5D(%-T871E<R!A
M;F0@1G)A;F-E+"!T86QI9VQU8V5R87-E(&%L9F$@:7,-"F-U<G)E;G1L>2!B
M96EN9R!P<F]V:61E9"!T;R!'875C:&5R(&1I<V5A<V4@<&%T:65N=',@=6YD
M97(@<W!E8VEA;`T*86-C97-S(&%G<F5E;65N=',@;W(@3F%M960@4&%T:65N
M="!P<F]V:7-I;VYS(&EN($)R87II;"!A;F0@:6X-"F]T:&5R(&-O=6YT<FEE
M<RX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF
M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0I/;B!!=6=U<W0@,3`L(#(P,3`L(%!F:7IE<B!E;G1E<F5D(&EN=&\@82!S
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M($1U<FEN9R!T:&4@<F5M86EN9&5R(&]F(#(P,3`@86YD('1H92!F:7)S="!Q
M=6%R=&5R(&]F#0HR,#$Q+"!T:&4@0V]M<&%N>2!A;F0@4&9I>F5R(&-O;7!L
M971E9"!T:&4@<W5P<&QY(&]F('!R;V1U8W1S#0ID96QI=F5R86)L92!U;F1E
M<B!T:&4@<VAO<G0M=&5R;2!S=7!P;'D@86=R965M96YT+B!$=7)I;F<@,C`Q
M,2P-"E!F:7IE<B!R96-O<F1E9"!A;B!A;&QO=V%N8V4@9F]R('-A;&5S(')E
M='5R;G,@:6X@8V]N;F5C=&EO;B!W:71H#0IT:&4@<W5P<&QY(&%G<F5E;65N
M="!B96-A=7-E('1H92!"<F%Z:6QI86X@36EN:7-T<GD@;V8@2&5A;'1H#0IR
M97%U97-T960@=&AA="!09FEZ97(@8V]N<VED97(@=&AE(')E<&QA8V5M96YT
M(&]F(&-E<G1A:6X@=FEA;',-"G1H870@;6EG:'0@97AP:7)E(&1U<FEN9R`R
M,#$R+B!2979E;G5E+"!N970@;V8@86QL;W=A;F-E(&9O<B!S86QE<PT*<F5T
M=7)N<RP@9V5N97)A=&5D(&9R;VT@=&AE($)R87II;&EA;B!-:6YI<W1R>2!O
M9B!(96%L=&@@=V%S#0IR96-O<F1E9"!B>2!09FEZ97(L(&%N9"!T:&4@0V]M
M<&%N>2!R96-O<F1E9"!I=',@<VAA<F4@;V8@<W5C:`T*<F5V96YU97,@:6X@
M86-C;W)D86YC92!W:71H('1H92!T97)M<R!A;F0@8V]N9&ET:6]N<R!O9B!T
M:&4@4&9I>F5R#0I!9W)E96UE;G0N/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@
M1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^,BX\+W1D/@T*/'1D
M/DQI<75I9&ET>2!A;F0@1FEN86YC:6%L(%)E<V]U<F-E<SPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M<R!I;G1E<FYA=&EO;F%L;'DN($5A8V@@1D1!(&%N9`T*14U!(&%P<')O=F%L
M('1R:6=G97)S(&$@)#(U+#`P,"!M:6QE<W1O;F4@<&%Y;65N="!F<F]M(%!F
M:7IE<BP-"G!U<G-U86YT('1O('1H92!09FEZ97(@06=R965M96YT+B!4:&5R
M92!C86X@8F4@;F\@87-S=7)A;F-E('1H870-"G1H92!#;VUP86YY('=I;&P@
M<F5C96EV92!R96=U;&%T;W)Y(&%P<')O=F%L(&]F(&%N>2!O9B!I=',@<')O
M9'5C=`T*8V%N9&ED871E<RP@86YD(&$@<W5B<W1A;G1I86P@86UO=6YT(&]F
M('1I;64@;6%Y('!A<W,@8F5F;W)E('1H90T*0V]M<&%N>2!A8VAI979E<R!A
M(&QE=F5L(&]F(')E=F5N=65S(&%D97%U871E('1O('-U<'!O<G0@:71S#0IO
M<&5R871I;VYS+"!I9B!A="!A;&PN(%1H92!#;VUP86YY(&%L<V\@97AP96-T
M<R!T;R!I;F-U<@T*<W5B<W1A;G1I86P@97AP96YD:71U<F5S(&EN(&-O;FYE
M8W1I;VX@=VET:"!T:&4@<F5G=6QA=&]R>2!A<'!R;W9A;`T*<')O8V5S<R!F
M;W(@96%C:"!O9B!I=',@<')O9'5C="!C86YD:61A=&5S(&1U<FEN9R!T:&5I
M<B!R97-P96-T:79E#0ID979E;&]P;65N=&%L('!E<FEO9',N($]B=&%I;FEN
M9R!M87)K971I;F<@87!P<F]V86P@=VEL;"!B90T*9&ER96-T;'D@9&5P96YD
M96YT(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&%B:6QI='D@=&\@:6UP;&5M
M96YT('1H90T*;F5C97-S87)Y(')E9W5L871O<GD@<W1E<',@<F5Q=6ER960@
M=&\@;V)T86EN(&UA<FME=&EN9R!A<'!R;W9A;"!I;@T*=&AE(%5N:71E9"!3
M=&%T97,@86YD(&EN(&]T:&5R(&-O=6YT<FEE<RX@5&AE($-O;7!A;GD@8V%N
M;F]T#0IP<F5D:6-T('1H92!O=71C;VUE(&]F('1H97-E(&%C=&EV:71I97,N
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"D)A<V5D(&]N(&ET<R!C=7)R96YT(&-A<V@@<F5S;W5R8V5S(&%N
M9"!C;VUM:71M96YT<RP@86YD(&-A<V@-"G)E8V5I=F5D(&EN(&$@<'5B;&EC
M('5N9&5R=W)I='1E;B!O9F9E<FEN9R!O;B!&96)R=6%R>2`R,#$R("AS964-
M"FYO=&4@,3%B*2P@=&AE($-O;7!A;GD@8F5L:65V97,@:70@=VEL;"!B92!A
M8FQE('1O(&UA:6YT86EN(&ET<PT*8W5R<F5N="!P;&%N;F5D(&1E=F5L;W!M
M96YT(&%C=&EV:71I97,@86YD('1H92!C;W)R97-P;VYD:6YG(&QE=F5L#0IO
M9B!E>'!E;F1I='5R97,@9F]R(&%T(&QE87-T('1H92!N97AT(#$R(&UO;G1H
M<RP@86QT:&]U9V@@;F\-"F%S<W5R86YC92!C86X@8F4@9VEV96X@=&AA="!I
M="!W:6QL(&YO="!N965D(&%D9&ET:6]N86P@9G5N9',@<')I;W(-"G1O('-U
M8V@@=&EM92X@268@=&AE<F4@87)E('5N97AP96-T960@:6YC<F5A<V5S(&EN
M(&=E;F5R86P@86YD#0IA9&UI;FES=')A=&EV92!E>'!E;G-E<R!O<B!R97-E
M87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS97,L('1H90T*0V]M<&%N>2!M
M87D@;F5E9"!T;R!S965K(&%D9&ET:6]N86P@9FEN86YC:6YG(&1U<FEN9R!T
M:&4@;F5X="`Q,@T*;6]N=&AS+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,"XU:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^
M#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B!B;VQD
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"
M3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O
M<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!N;W)M86PG/F(N/"]F;VYT/CPO=&0^#0H\=&0^0F%S:7,@;V8@<')E
M<V5N=&%T:6]N/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*5&AE($-O;7!A;GDF
M(W@R,#$Y.W,@9FEN86YC:6%L('-T871E;65N=',@:&%V92!B965N('!R97!A
M<F5D(&EN#0IA8V-O<F1A;F-E('=I=&@@9V5N97)A;&QY(&%C8V5P=&5D(&%C
M8V]U;G1I;F<@<')I;F-I<&QE<R!I;B!T:&4-"E5N:71E9"!3=&%T97,@*"8C
M>#(P,4,[52Y3+B!'04%0)B-X,C`Q1#LI+CPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,"XU:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQF
M;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C>$$P.SPO9F]N
M=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!
M4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SX\+W1D/@T*
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!N;W)M86PG/F,N/"]F;VYT/CPO=&0^#0H\=&0^57-E(&]F
M(&5S=&EM871E<R!I;B!T:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L#0IS
M=&%T96UE;G1S/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@
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M('1H92!R97!O<G1E9"!A;6]U;G1S(&]F(')E=F5N=65S(&%N9`T*97AP96YS
M97,@9'5R:6YG('1H92!R97!O<G1I;F<@<&5R:6]D+B!!8W1U86P@<F5S=6QT
M<R!M87D@9&EF9F5R#0IF<F]M('1H;W-E(&5S=&EM871E<RX\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P>"`P<'@@
M,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF
M(WA!,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I
M;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SYD+CPO9F]N=#X\+W1D/@T*
M/'1D/D9U;F-T:6]N86P@8W5R<F5N8WD\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!
M,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0I4:&4@9&]L;&%R(&ES('1H92!C=7)R96YC>2!O9B!T:&4@<')I;6%R>2!E
M8V]N;VUI8R!E;G9I<F]N;65N="!I;@T*=VAI8V@@=&AE(&]P97)A=&EO;G,@
M;V8@=&AE($-O;7!A;GD@86YD(&ET<R!3=6)S:61I87)I97,@87)E#0IC;VYD
M=6-T960N(%1H92!#;VUP86YY)B-X,C`Q.3MS(')E=F5N=65S(&%R92!D97)I
M=F5D(&EN(&1O;&QA<G,N#0I-;W-T(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&5X<&5N<V5S(&%N9"!C87!I=&%L(&5X<&5N9&ET=7)E<R!A<F4-"FEN8W5R
M<F5D(&EN(&1O;&QA<G,L(&%N9"!T:&4@;6%J;W(@<V]U<F-E(&]F('1H92!#
M;VUP86YY)B-X,C`Q.3MS#0IF:6YA;F-I;F<@:&%S(&)E96X@<')O=FED960@
M:6X@9&]L;&%R<RX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@
M,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
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M=&AE<B!I=&5M<R`H<W1A=&5D#0IB96QO=RD@<F5F;&5C=&5D(&EN('1H92!S
M=&%T96UE;G1S(&]F(&]P97)A=&EO;G,L('1H92!F;VQL;W=I;F<-"F5X8VAA
M;F=E(')A=&5S(&%R92!U<V5D.B`H:2D@9F]R('1R86YS86-T:6]N<R`F(W@R
M,#$S.R!E>&-H86YG90T*<F%T97,@870@=&AE('1R86YS86-T:6]N(&1A=&5S
M(&]R(&%V97)A9V4@<F%T97,[(&%N9"`H:6DI(&9O<B!O=&AE<@T*:71E;7,@
M*&1E<FEV960@9G)O;2!N;VXM;6]N971A<GD@8F%L86YC92!S:&5E="!I=&5M
M<R!S=6-H(&%S#0ID97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;BP@971C
M+BD@)B-X,C`Q,SL@:&ES=&]R:6-A;"!E>&-H86YG90T*<F%T97,N($-U<G)E
M;F-Y('1R86YS86-T:6]N(&=A:6YS(&%N9"!L;W-S97,@87)E(&-A<G)I960@
M=&\-"F9I;F%N8VEA;"!I;F-O;64@;W(@97AP96YS97,L(&%S(&%P<')O<')I
M871E+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XU:6X[($U!
M4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)
M1TA4.B!N;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\
M='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P
M+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/F4N
M/"]F;VYT/CPO=&0^#0H\=&0^0V%S:"!E<75I=F%L96YT<SPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
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M86QE;G1S+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XU:6X[
M($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!N;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^
M#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG
M/F8N/"]F;VYT/CPO=&0^#0H\=&0^26YV96YT;W)I97,\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N
M-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@
M,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0I);G9E;G1O<FEE<R!A<F4@=F%L=65D(&%T('1H92!L;W=E
M<B!O9B!C;W-T(&]R(&UA<FME="X@0V]S="!O9B!R87<-"F%N9"!P86-K86=I
M;F<@;6%T97)I86QS(&%N9"!P=7)C:&%S960@<')O9'5C=',@:7,@9&5T97)M
M:6YE9"!U<VEN9PT*=&AE("8C>#(P,4,[;6]V:6YG(&%V97)A9V4F(W@R,#%$
M.R!B87-I<RX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X
M(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P
M<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
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M90T*8V%P:71A;&EZ960N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M/&(^)B-X03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I#;W-T(&]F(&9I
M;FES:&5D('!R;V1U8W1S('1H870@87)E(&-A<&ET86QI>F5D(&ES(&1E=&5R
M;6EN960@87,-"F9O;&QO=W,Z('1H92!V86QU92!O9B!T:&4@<F%W(&%N9"!P
M86-K86=I;F<@;6%T97)I86QS(&-O;7!O;F5N="!I<PT*9&5T97)M:6YE9"!P
M<FEM87)I;'D@;VX@82!U<VEN9R!T:&4@)B-X,C`Q0SMM;W9I;F<@879E<F%G
M928C>#(P,40[#0IB87-I<SL@=&AE('9A;'5E(&]F('1H92!L86)O<B!A;F0@
M;W9E<FAE860@8V]M<&]N96YT(&ES(&1E=&5R;6EN960-"F]N(&%N(&%V97)A
M9V4@8F%S:7,@;W9E<B!T:&4@<')O9'5C=&EO;B!P97)I;V0N/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@,'!X
M(#!P>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^
M)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XU
M:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^9RX\+V9O;G0^/"]T9#X-
M"CQT9#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)
M3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#`N,C5I;B<^,2X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!N;W)M86PG/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@87)E#0IS
M=&%T960@870@8V]S="P@;F5T(&]F(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO
M;B!A;F0-"F%M;W)T:7IA=&EO;BX\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)
M3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#`N,C5I;B<^,BX\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!N;W)M86PG/E1H92!#;VUP86YY)B-X,C`Q.3MS(&%S<V5T<PT*
M87)E(&1E<')E8VEA=&5D(&)Y('1H92!S=')A:6=H="UL:6YE(&UE=&AO9"!O
M;B!T:&4@8F%S:7,@;V8@=&AE:7(-"F5S=&EM871E9"!U<V5F=6P@;&EV97,@
M87,@9F]L;&]W<SH\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@
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M03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,B4G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([(%=)1%1(.B`Q-24G/@T*665A<G,\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-
M"CQT9#Y,86)O<F%T;W)Y(&5Q=6EP;65N=#PO=&0^#0H\=&0^)B-X03`[/"]T
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M0T%,+4%,24=..B!T;W`G/D-O;7!U=&5R(&5Q=6EP;65N="8C>$$P.SPO=&0^
M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/C,\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N
M-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@
M,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0I,96%S96AO;&0@:6UP<F]V96UE;G1S(&%R92!A;6]R=&EZ
M960@8GD@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D#0IO=F5R('1H92!E>'!E
M8W1E9"!L96%S92!T97)M+"!W:&EC:"!I<R!S:&]R=&5R('1H86X@=&AE(&5S
M=&EM871E9`T*=7-E9G5L(&QI9F4@;V8@=&AE(&EM<')O=F5M96YT<RX\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P
M>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R
M;6%L)SXF(WA!,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C5I;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SYH+CPO9F]N=#X\
M+W1D/@T*/'1D/DEM<&%I<FUE;G0@:6X@=F%L=64@;V8@;&]N9RUL:79E9"!A
M<W-E=',Z/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM
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M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@
M,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA
M;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM
M5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@
M,"XU:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O
M;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^:2X\+V9O;G0^/"]T
M9#X-"CQT9#Y);F-O;64@=&%X97,\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P>"`P
M<'@@,'!X(#$N,C5I;CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS
M1"=724142#H@,"XW-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P
M+C(U:6XG/C$N/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(
M5#H@;F]R;6%L)SY$969E<G)E9"!I;F-O;64-"G1A>&5S/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X
M(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
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M+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
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M:6QI=&EE<RX\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N-6EN
M.R!-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@8F]L9"`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-
M"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/
M5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX-"CQT9"!S='EL93TS1"=724142#H@,"XW-6EN)SX\+W1D/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`P+C(U:6XG/C(N/"]T9#X-"CQT9#X\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SY5;F-E<G1A:6YT>2!I;B!I;F-O
M;64-"G1A>&5S/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E1A>"!B96YE9FET
M<R!R96-O9VYI>F5D(&EN('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!A<F4@
M=&AO<V4@=&AA=`T*=&AE($-O;7!A;GDF(W@R,#$Y.W,@;6%N86=E;65N="!D
M965M<R!A="!L96%S="!M;W)E(&QI:V5L>2!T:&%N(&YO=`T*=&\@8F4@<W5S
M=&%I;F5D+"!B87-E9"!O;B!T96-H;FEC86P@;65R:71S+B!4:&4@86UO=6YT
M(&]F(&)E;F5F:71S#0IR96-O<F1E9"!F;W(@=&AE<V4@=&%X(&)E;F5F:71S
M(&ES(&UE87-U<F5D(&%S('1H92!L87)G97-T(&)E;F5F:70-"G1H92!#;VUP
M86YY)B-X,C`Q.3MS(&UA;F%G96UE;G0@9&5E;7,@;6]R92!L:6ME;'D@=&AA
M;B!N;W0@=&\@8F4-"G-U<W1A:6YE9"X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[
M/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[
M(%=)1%1(.B`Q,#`E.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&YO<FUA;"<^:BX\+V9O;G0^/"]T9#X-"CQT9#Y2
M979E;G5E(%)E8V]G;FET:6]N/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/
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M97AI<W1S+`T*9&5L:79E<GD@;V8@9V]O9',@;W(@<V5R=FEC97,@:&%S(&]C
M8W5R<F5D+"!T:&4@<V%L97,@<')I8V4@:7,-"F9I>&5D(&]R(&1E=&5R;6EN
M86)L92!A;F0@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D
M+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XU:6X[($U!4D=)
M3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P
M<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D
M('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#`N,C5I;B<^,2X\+W1D/@T*/'1D/CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!N;W)M86PG/E)E=F5N=65S(&9R;VT@=&AE(&QI8V5N<V4@
M86YD#0IS=7!P;'D@86=R965M96YT('=I=&@@4&9I>F5R/"]F;VYT/CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X
M(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"E1H92!#;VUP86YY(')E8V]G;FEZ97,@<F5V96YU92!A
M;F0@;6EL97-T;VYE('!A>6UE;G1S(')E8V5I=F5D#0IP=7)S=6%N="!T;R!T
M:&4@4&9I>F5R($%G<F5E;65N="!I;B!A8V-O<F1A;F-E('=I=&@@9W5I9&%N
M8V4-"G)E9V%R9&EN9R!R979E;G5E(')E8V]G;FET:6]N(&%N9"!A8V-O=6YT
M:6YG(&9O<B!R979E;G5E#0IA<G)A;F=E;65N=',@=VET:"!M=6QT:7!L92!D
M96QI=F5R86)L97,N($%S('1H92!A<G)A;F=E;65N="!W:71H#0I09FEZ97(@
M<F5Q=6ER97,@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]N=&EN=65D(&EN=F]L
M=F5M96YT('=I=&@-"G)E<W!E8W0@=&\@=&AE('!R;W!O<V5D(&-O;6UE<F-I
M86QI>F%T:6]N(&]F('1A;&EG;'5C97)A<V4@86QF82P-"G1H92!N;VXM<F5F
M=6YD86)L92P@=7`M9G)O;G0@;&EC96YS92!P87EM96YT('1H92!#;VUP86YY
M(')E8V5I=F5D#0IF<F]M(%!F:7IE<B!W87,@9&5F97)R960@86YD(')E8V]G
M;FEZ960@;W9E<B!T:&4@<F5L871E9`T*<&5R9F]R;6%N8V4@<&5R:6]D+B!4
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M97,N/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%2
M1TE..B`P<'@@,'!X(#!P>"`Q+C(U:6X[($9/3E0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ
M(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^/"]T9#X-"CQT9"!S='EL93TS
M1"=724142#H@,"XR-6EN)SXR+CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&YO<FUA;"<^4F5V96YU97,@9G)O;2!S96QL:6YG#0IP
M<F]D=6-T<R!T;R!09FEZ97(\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*5&AE
M($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E<R!F<F]M('!R;V1U8W1S('-O
M;&0@=&\@4&9I>F5R('5P;VX-"F1E;&EV97)Y+"!W:&5N('1H92!S86QE<R!P
M<FEC92!I<R!F:7AE9"!O<B!D971E<FUI;F%B;&4@86YD#0IC;VQL96-T86)I
M;&ET>2!I<R!R96%S;VYA8FQY(&%S<W5R960N/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q+C(U
M:6X[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
M-S5I;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SXS+CPO
M=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^
M0V]M<&%N>28C>#(P,3D[<R!S:&%R92!I;B!T:&4-"F-O;&QA8F]R871I;VX@
M86=R965M96YT/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C>$$P
M.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-
M05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@;F]R;6%L)SY5;F1E<B!T:&4@=&5R;7,@86YD(&-O;F1I=&EO;G,@
M;V8-"G1H92!09FEZ97(@06=R965M96YT+"!T:&4@0V]M<&%N>2!I<R!E;G1I
M=&QE9"!T;R`T,"4@;V8@=&AE('!R;V9I=',-"F]R(&QO<W,@9G)O;2!S86QE
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M(&]U='-I9&4@=&AE(%5N:71E9`T*4W1A=&5S+"!F:6YA;F-I86P@:6YF;W)M
M871I;VX@:7,@:6YC;'5D960@8F%S960@;VX@=&AE(&9I<V-A;"!Y96%R#0IE
M;F1I;F<@3F]V96UB97(@,S`L('=H:6QE(&9I;F%N8VEA;"!I;F9O<FUA=&EO
M;B!F;W(@=&AE(%4N4RX@96YT:71Y#0II<R!I;F-L=61E9"!B87-E9"!O;B!T
M:&4@9FES8V%L('EE87(@96YD:6YG($1E8V5M8F5R(#,Q+CPO9F]N=#X\+W`^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P
M>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R
M;6%L)SXF(WA!,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C5I;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SYK+CPO9F]N=#X\
M+W1D/@T*/'1D/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T<SPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C
M;W-T<R!A<F4@97AP96YS960@87,@:6YC=7)R960@86YD(&-O;G-I<W0-"G!R
M:6UA<FEL>2!O9B!P97)S;VYN96PL('-U8F-O;G1R86-T;W)S(&%N9"!C;VYS
M=6QT86YT<R`H;6%I;FQY(&EN#0IC;VYN96-T:6]N('=I=&@@8VQI;FEC86P@
M=')I86QS*2P@9F%C:6QI=&EE<RP@97%U:7!M96YT(&%N9`T*<W5P<&QI97,@
M9F]R(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!A8W1I=FET:65S+B!'<F%N
M=',@<F5C96EV960-"F)Y('1H92!)<W)A96QI(%-U8G-I9&EA<GD@9G)O;2!T
M:&4@3V9F:6-E(&]F('1H92!#:&EE9B!38VEE;G1I<W0@;V8-"DES<F%E;"8C
M>#(P,3D[<R!-:6YI<W1R>2!O9B!);F1U<W1R>2P@5')A9&4@86YD($QA8F]R
M("AT:&4-"B8C>#(P,4,[3T-3)B-X,C`Q1#LI(&%R92!R96-O9VYI>F5D('=H
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M<R!A<F4@:6YC=7)R960N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@
M,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*4F5I;6)U<G-E;65N=',@<F5C96EV960@
M9G)O;2!09FEZ97(@87)E(')E8V]G;FEZ960@=VAE;B!T:&4-"G)E:6UB=7)S
M96UE;G1S(&)E8V]M92!R96-E:79A8FQE+"!P<F]V:61E9"!T:&5R92!I<R!R
M96%S;VYA8FQE#0IA<W-U<F%N8V4@=&AA="!T:&4@0V]M<&%N>2!W:6QL(&-O
M;7!L>2!W:71H('1H92!C;VYD:71I;VYS(&%T=&%C:&5D#0IT;R!T:&4@<F5I
M;6)U<G-E;65N=',@86YD('1H97)E(&ES(')E87-O;F%B;&4@87-S=7)A;F-E
M('1H90T*<F5I;6)U<G-E;65N=',@=VEL;"!B92!R96-E:79E9"X@5&AE(')E
M:6UB=7)S96UE;G1S(&%R92!D961U8W1E9`T*9G)O;2!T:&4@<F5S96%R8V@@
M86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S(&%S('1H92!A<'!L:6-A8FQE(&-O
M<W1S#0IA<F4@:6YC=7)R960N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,'!X.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
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M="!T:&4@<'5R8VAA<V4@9&%T92X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.
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M<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XU:6X[($U!4D=)3CH@
M,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N
M;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/FPN/"]F;VYT
M/CPO=&0^#0H\=&0^0V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P
M>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*5&AE($-O;7!A;GD@:&%S(&YO(&]T:&5R(&-O;7!R96AE;G-I
M=F4@;&]S<R!C;VUP;VYE;G1S(&]T:&5R('1H86X-"FYE="!L;W-S(&9O<B!T
M:&4@<F5P;W)T960@<&5R:6]D<RX\+W`^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF(WA!,#L\+V9O;G0^/"]P
M/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L
M9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM
M0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T
M;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^/"]T9#X-"CQT9"!S
M='EL93TS1"=724142#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5=%
M24=(5#H@;F]R;6%L)SYM+CPO9F]N=#X\+W1D/@T*/'1D/D-O;F-E;G1R871I
M;VX@;V8@8W)E9&ET(')I<VMS(&%N9"!T<F%D92!R96-E:79A8FQE/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X
M(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M97(@;V8@<&]L:6-Y+`T*;&EM:71S('1H92!A;6]U;G1S(&]F(&-R961I="!E
M>'!O<W5R92!T;R!A;GD@;VYE(&9I;F%N8VEA;`T*:6YS=&ET=71I;VXN(%1H
M92!#;VUP86YY(&AA<R!N;W0@97AP97)I96YC960@86YY(&-R961I="!L;W-S
M97,@:6X-"G1H97-E(&%C8V]U;G1S(&%N9"!D;V5S(&YO="!B96QI979E(&ET
M(&ES(&5X<&]S960@=&\@86YY#0IS:6=N:69I8V%N="!C<F5D:70@<FES:R!O
M;B!T:&5S92!I;G-T<G5M96YT<RX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.
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M:7IE<B!T;R!P;W-T(&-O;&QA=&5R86P@=VET:`T*<F5S<&5C="!T;R!T:&4@
M<F5C96EV86)L97,N(%1H92!#;VUP86YY('!E<F9O<FUS('!E<FEO9&EC(&-R
M961I=`T*979A;'5A=&EO;G,@;V8@4&9I>F5R)B-X,C`Q.3MS(&9I;F%N8VEA
M;"!C;VYD:71I;VX@86YD(&)E;&EE=F5S#0IT:&5R92!I<R!N;R!S:6=N:69I
M8V%N="!R:7-K('=I=&@@<F5S<&5C="!T;R!09FEZ97(F(W@R,#$Y.W,@<&%Y
M;65N=`T*;V8@=&AE(')E8V5I=F%B;&5S+CPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X
M(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF(WA!
M,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P
M>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^
M/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SYN+CPO9F]N=#X\+W1D/@T*/'1D
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M86YT:6-I<&%T960@9G5T=7)E(&-O;F1I=&EO;G,N/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*5&AE($-O;7!A
M;GD@96QE8W1E9"!T;R!R96-O9VYI>F4@8V]M<&5N<V%T:6]N(&-O<W0@9F]R
M(&%N(&%W87)D#0IW:71H(&]N;'D@<V5R=FEC92!C;VYD:71I;VYS('1H870@
M:&%S(&$@9W)A9&5D('9E<W1I;F<@<V-H961U;&4-"G5S:6YG('1H92!A8V-E
M;&5R871E9"!M971H;V0@8F%S960@;VX@=&AE(&UU;'1I<&QE+6]P=&EO;B!A
M=V%R9`T*87!P<F]A8V@N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@
M,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
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M+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ
M(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M;F]R;6%L)SXF(WA!,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)
M1%1(.B`P+C5I;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN
M)SX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SYO+CPO9F]N
M=#X\+W1D/@T*/'1D/DYE="!,;W-S('!E<B!S:&%R93PO=&0^#0H\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"D)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@<&5R('-H87)E("@F
M(W@R,#%#.TQ04R8C>#(P,40[*2!A<F4@8V]M<'5T960-"F)Y(&1I=FED:6YG
M(&YE="!L;W-S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S
M:&%R97,@;V8-"G1H92!#;VUP86YY)W,@0V]M;6]N(%-T;V-K+"!P87(@=F%L
M=64@)#`N,#`Q('!E<B!S:&%R92`H=&AE(")#;VUM;VX-"E-T;V-K(BD@;W5T
M<W1A;F1I;F<@9F]R(&5A8V@@<&5R:6]D+CPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"D1I;'5T960@3%!3(&1O
M97,@;F]T(&EN8VQU9&4@;W!T:6]N<R!T;R!P=7)C:&%S92`Q,"PV-C`L-#0W
M+`T*-RPW-C$L,38X(&%N9"`W+#0V.2PP.#@@<VAA<F5S(&]F($-O;6UO;B!3
M=&]C:R!F;W(@=&AE(&9I<V-A;"!Y96%R<PT*96YD960@1&5C96UB97(@,S$L
M(#(P,#DL(#(P,3`@86YD(#(P,3$L(')E<W!E8W1I=F5L>2P@8F5C875S92!T
M:&4-"F5F9F5C="!W;W5L9"!B92!A;G1I+61I;'5T:79E+CPO<#X-"CPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S8R
M935C,69?.#1C9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S,V,F4U8S%F7S@T8V1?-&$S,U]A-#%F7S-B
M,S9E,#9E9C4Y92]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!
M1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,24-%3E-%($%.1"!355!03%D@
M04=2145-14Y4/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,24-%3E-%($%.1"!355!03%D@04=2145-14Y4/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/DY/
M5$4@,B`M/"]F;VYT/B!,24-%3E-%($%.1"!355!03%D-"D%'4D5%345.5#PO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XU:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X
M03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0I/;B!.;W9E;6)E<B8C>$$P.S,P+"`R,#`Y+"!0<F]T86QI>"!,=&0N(&%N
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M(&%N('5P9G)O;G0@<&%Y;65N="!T;R!0<F]T86QI>"!,=&0N#0IO9B`D-C`L
M,#`P(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@97AE8W5T:6]N(&]F('1H92!A
M9W)E96UE;G0@86YD#0IS:&]R=&QY('1H97)E869T97(@<&%I9"!0<F]T86QI
M>"!,=&0N(&%N(&%D9&ET:6]N86P@)#4L,#`P('5P;VX@=&AE#0I#;VUP86YY
M)B-X,C`Q.3MS(&9I;&EN9R!O9B!A('!R;W!O<V5D('!E9&EA=')I8R!I;G9E
M<W1I9V%T:6]N('!L86X-"G1O('1H92!0961I871R:6,@0V]M;6ET=&5E(&]F
M('1H92!%34$N(%!R;W1A;&EX($QT9"X@:7,@86QS;PT*96QI9VEB;&4@=&\@
M<F5C96EV92!A9&1I=&EO;F%L('!O=&5N=&EA;"!M:6QE<W1O;F4@<&%Y;65N
M=',-"G1O=&%L:6YG('5P('1O("0U,"PP,#`@9F]R('1H92!S=6-C97-S9G5L
M(&%C:&EE=F5M96YT(&]F(&]T:&5R#0IR96=U;&%T;W)Y(&UI;&5S=&]N97,N
M(%!R;W1A;&EX($QT9"X@:7,@96YT:71L960@=&\@-#`E(&]F('1H90T*<')O
M9FET<R!E87)N960@;VX@4&9I>F5R)B-X,C`Q.3MS('-A;&5S(&]F('1A;&EG
M;'5C97)A<V4@86QF82X@4W5C:`T*<')O9FET('=I;&P@8F4@8V%L8W5L871E
M9"!W:&EL92P@:6X@861D:71I;VX@=&\@;W1H97(@861J=7-T;65N=',L#0IT
M86MI;F<@:6YT;R!A8V-O=6YT(%!R;W1A;&EX($QT9"XF(W@R,#$Y.W,@8V]S
M="!O9B!G;V]D<R!S;VQD(&%N9`T*4&9I>F5R)B-X,C`Q.3MS(&-O;6UE<F-I
M86P@97AP96YS97,L('=I=&@@8V5R=&%I;B!E>'!E;G-E<R!C87!P960@;W(-
M"F)O<FYE('-O;&5L>2!B>2!O;F4@<&%R='D@*")#;VQL86)O<F%T:6]N($]P
M97)A=&EO;B(I+B!/9B!T:&4-"FQO<W-E<R!I;F-U<G)E9"!B>2!T:&4@0V]L
M;&%B;W)A=&EO;B!/<&5R871I;VX@=&AR;W5G:"!$96-E;6)E<B`S,2P-"C(P
M,3$L(#0P)2!W:6QL(&)E(&1E9'5C=&5D(&9R;VT@=&AE($-O;7!A;GDG<R!S
M:&%R92!I;B!T:&4@<')O9FET<PT*9G)O;2!F=71U<F4@>65A<G,N(%1H:7,@
M9&5D=6-T:6]N('=I;&P@;&EM:71E9"!T;R!A(&-E<G1A:6X-"G!E<F-E;G1A
M9V4@;V8@86YY('%U87)T97)L>2!P<F]F:70N($%S(&]F($1E8V5M8F5R(#,Q
M+"`R,#$Q+"!T:&4-"D-O;7!A;GD@86-C<G5E9"!A(&QI86)I;&ET>2!I;B!R
M97-P96-T(&]F('1H97-E(&QO<W-E<R!E<75A;"!T;PT*)#<L.#@X+"!O=70@
M;V8@=VAI8V@@)#8L-38V(&ES(&-L87-S:69I960@87,@82!L;VYG('1E<FT@
M;&EA8FEL:71Y+`T*86YD('1H92!R96UA:6YD97(@:7,@:6YC;'5D960@:6X@
M86-C;W5N=',@<&%Y86)L92!A;F0-"F%C8W)U86QS+6]T:&5R+CPO<#X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XU:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I4:&4@
M0V]M<&%N>2!H87,@9&5T97)M:6YE9"!T:&%T('1H92!I;FET:6%L+"!N;VXM
M<F5F=6YD86)L92!U<&9R;VYT#0IL:6-E;G-E(&9E92!P87EM96YT(&]F("0V
M,"PP,#`@=&]G971H97(@=VET:"!T:&4@9FER<W0@)#4L,#`P#0IP87EM96YT
M('=I;&P@8F4@<F5C;V=N:7IE9"!O;B!A('-T<F%I9VAT(&QI;F4@8F%S:7,@
M87,@<F5V96YU92!O=F5R#0IT:&4@97-T:6UA=&5D(')E;&%T:6]N<VAI<"!P
M97)I;V0N(%1H92!#;VUP86YY(&AA<R!E<W1I;6%T960@=&AA=`T*=&AE(')E
M;&%T:6]N<VAI<"!P97)I;V0@9F]R(&ET<R!A<G)A;F=E;65N="!W:71H(%!F
M:7IE<B!W:6QL(&)E#0IA<'!R;WAI;6%T96QY(#$T('EE87)S("AC;VUM96YC
M:6YG('5P;VX@=&AE($-O;7!A;GDF(W@R,#$Y.W,@<F5C96EP=`T*;V8@=&AE
M('5P+69R;VYT(&QI8V5N<V4@<&%Y;65N="D@8F%S960@;VX@=&AE($-O;7!A
M;GDF(W@R,#$Y.W,@;&%S=`T*;6%T97)I86P@<&%T96YT(')E;&%T:6YG('1O
M('1A;&EG;'5C97)A<V4@86QF82!T;R!E>'!I<F4N/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E1H92!#;VUP86YY
M)B-X,C`Q.3MS(&1E;&EV97)A8FQE<R!U;F1E<B!T:&ES(&-O;&QA8F]R871I
M;VX@:6YC;'5D90T*86X@97AC;'5S:79E(&QI8V5N<V4@=&\@=&%L:6=L=6-E
M<F%S92!A;&9A(&%S(&%N(&5N>GEM92!R97!L86-E;65N=`T*=&AE<F%P>2!F
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M>"`P<'@@,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M<'@@,'!X(#!P>"`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
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M-F$N/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U
M.64-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S8R935C,69?.#1C
M9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE+U=O<FMS:&5E=',O4VAE970Q,"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!23U!%
M4E19($%.1"!%455)4$U%3E0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!23U!%4E19($%.1"!%455)4$U%3E0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0G/CQB/DY/5$4@,R`M/"]B/CPO9F]N=#X@/&(^4%)/4$52
M5%D-"D%.1"!%455)4$U%3E0\+V(^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO
M<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^
M#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE
M/3-$)U=)1%1(.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!N;W)M86PG/F$N/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&YO<FUA;"<^0V]M<&]S:71I;VX@;V8@<')O<&5R='D@
M86YD#0IE<75I<&UE;G0@9W)O=7!E9"!B>2!M86IO<B!C;&%S<VEF:6-A=&EO
M;G,@:7,@87,-"F9O;&QO=W,Z/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L
M92!S='EL93TS1"=724142#H@-C`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,6EN)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)U9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0V/D1E8V5M8F5R(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B8C>$$P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P,3`\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^,C`Q
M,3PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,"XQ
M:6X[(%=)1%1(.B`U."4G/@T*3&%B;W)A=&]R>2!E<75I<&UE;G0\+W1D/@T*
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3@E)SXQ,2PT
M-S@\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C
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M969T.R!415A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N,6EN
M)SX-"D9U<FYI='5R92!A;F0@8V]M<'5T97(@97%U:7!M96YT/"]T9#X-"CQT
M9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/C$L,S`V/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^,2PU,C(\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,"XQ:6XG
M/@T*3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ,2PR,C$\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M,7!T.R!415A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N,6EN
M)SX-"D5Q=6EP;65N="!U;F1E<B!C;VYS=')U8W1I;VX\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H
M="<^#0HQ+#`S.#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/@T*,2PQ,3,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,30N-35P="<^)B-X03`[
M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXR-2PP-#,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
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M1$E.1RU,1494.B`Q-BXR<'0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M3D<M0D]45$]-.B`Q<'0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M
M3$5&5#H@,38N,G!T)SX-"DQE<W,@)B-X,C`Q,SL@86-C=6UU;&%T960@9&5P
M<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=.
M.B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0HH
M-RPU.#D\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0G/BD\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
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M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U)
M3D1%3E0Z("TP+C%I;CL@4$%$1$E.1RU,1494.B`P+C%I;B<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^#0HQ-RPT-30\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G
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M6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@-"XS<'0[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X
M03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.
M+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&YO<FUA;"<^8BX\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SY$97!R96-I871I;VX@86YD(&%M
M;W)T:7IA=&EO;@T*:6X@<F5S<&5C="!O9B!P<F]P97)T>2!A;F0@97%U:7!M
M96YT('1O=&%L960@)#$L.3DP+"`D,RPQ,S,@86YD#0HD,RPV,S$@9F]R('1H
M92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`P.2P@,C`Q,"!A;F0@,C`Q
M,2P-"G)E<W!E8W1I=F5L>2P@;W5T(&]F('=H:6-H('1H92!#;VUP86YY(')E
M8V]R9&5D(&$@=&]T86P@=W)I=&4@9&]W;@T*;V8@)#`L("0T,R!A;F0@)#$P
M+"!R97-P96-T:79E;'DN/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?,S8R935C,69?.#1C9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,V,F4U8S%F7S@T8V1?-&$S,U]A
M-#%F7S-B,S9E,#9E9C4Y92]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/4DE%4SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24Y614Y4
M3U))15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQB/DY/5$4@-"`M/"]B/CPO
M9F]N=#X-"CQB/DE.5D5.5$]22453/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF(WA!,#L\
M+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'
M3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&YO<FUA;"<^82X\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SY);G9E;G1O<GD@870-"D1E
M8V5M8F5R)B-X03`[,S$L(#(P,3`@86YD(#(P,3$@8V]N<VES=&5D(&]F('1H
M90T*9F]L;&]W:6YG.CPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y
M;&4],T0G5TE$5$@Z(#8P)3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE.+4Q%1E0Z(#%I;B<@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@
M8F]L9"<@8V]L<W!A;CTS1#8^1&5C96UB97(@,S$L/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R/C(P,3`\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]5
M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(
M.B`U."4G/E)A=R!M871E<FEA;',\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!724142#H@,3@E)SXU-3,\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT
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M)SY&:6YI<VAE9`T*9V]O9',\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0HV,S8\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"BT\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^5&]T86P-"FEN=F5N=&]R>3PO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
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M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX-"C(W.3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I
M;CL@34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^
M#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG
M/F(N/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&YO<FUA;"<^1'5R:6YG('1H92!Y96%R(&5N9&5D#0I$96-E;6)E<B`S
M,2P@,C`Q,"!A;F0@,C`Q,2P@/&9O;G0@<W1Y;&4],T0G0T],3U(Z(&)L86-K
M)SYT:&4@0V]M<&%N>0T*<F5C;W)D960@82`D,BPV.3(\+V9O;G0^(&%N9"`D
M,S8S+"!R97-P96-T:79E;'DL('=R:71E+61O=VX@;V8-"FEN=F5N=&]R>2!U
M;F1E<B!C;W-T(&]F(')E=F5N=65S+B!3964@3F]T92`Y9"X\+V9O;G0^/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q
M9E\S8C,V93`V968U.64-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M,S8R935C,69?.#1C9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE+U=O<FMS:&5E
M=',O4VAE970Q,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DQ)04))3$E462!&3U(@14U03$]9144@4DE'2%13(%503TX@4D54
M25)%345.5#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3$E!0DE,2519($9/4B!%35!,3UE%12!224=(5%,@55!/3B!2151)4D5-
M14Y4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T)SX\8CY.3U1%(#4@+3PO8CX\+V9O
M;G0^(#QB/DQ)04))3$E460T*1D]2($5-4$Q/645%(%))1TA44R!54$].(%)%
M5$E214U%3E0\+V(^/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X
M(#!P>"`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M>"`P<'@@,'!X(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
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M('-A;&%R>2`M(&]N90T*;6]N=&@F(W@R,#$Y.W,@<V%L87)Y(&9O<B!E86-H
M('EE87(@96UP;&]Y960I(&ES(')E8V]R9&5D(&]N('1H90T*0V]M<&%N>28C
M>#(P,3D[<R!B86QA;F-E('-H965T<R!U;F1E<B`F(W@R,#%#.TQI86)I;&ET
M>2!F;W(@96UP;&]Y964-"G)I9VAT<R!U<&]N(')E=&ER96UE;G0N)B-X,C`Q
M1#L@5&AE(&QI86)I;&ET>2!I<R!R96-O<F1E9"!A<R!I9B!I=`T*=V5R92!P
M87EA8FQE(&%T(&5A8V@@8F%L86YC92!S:&5E="!D871E(&]N(&%N('5N9&ES
M8V]U;G1E9`T*8F%S:7,N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@
M,'!X(#!P>"`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ
M(#!P>"`P<'@@,'!X(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
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M9&5D(&EN('1H92!#;VUP86YY)B-X,C`Q.3MS(&)A;&%N8V4@<VAE971S('5N
M9&5R#0HF(W@R,#%#.T9U;F1S(&EN(')E<W!E8W0@;V8@96UP;&]Y964@<FEG
M:'1S('5P;VX@<F5T:7)E;65N="XF(W@R,#%$.PT*5&AE<V4@<&]L:6-I97,@
M87)E('1H92!#;VUP86YY)B-X,C`Q.3MS(&%S<V5T<RX@2&]W979E<BP@=6YD
M97(@;&%B;W(-"F%G<F5E;65N=',@86YD('-U8FIE8W0@=&\@8V5R=&%I;B!L
M:6UI=&%T:6]N<RP@86YY('!O;&EC>2!M87D@8F4-"G1R86YS9F5R<F5D('1O
M('1H92!O=VYE<G-H:7`@;V8@=&AE(&EN9&EV:61U86P@96UP;&]Y964@9F]R
M('=H;W-E#0IB96YE9FET('1H92!F=6YD<R!W97)E(&1E<&]S:71E9"X@26X@
M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+`T*,C`P.2P@,C`Q,"!A;F0@
M,C`Q,2P@=&AE($-O;7!A;GD@9&5P;W-I=&5D("0W.2P@)#$W-"!A;F0@)#$X
M,2P-"G)E<W!E8W1I=F5L>2P@=VET:"!I;G-U<F%N8V4@8V]M<&%N:65S(&EN
M(&-O;FYE8W1I;VX@=VET:"!I=',-"G-E=F5R86YC92!P87EM96YT(&]B;&EG
M871I;VYS+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,"XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X
M(#!P>"`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
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M90T*87!P;&EC86)L92!I;G-U<F%N8V4@8V]M<&%N:65S("AT:&4@)B-X,C`Q
M0SM#;VYT<FEB=71I;VX-"E!L86YS)B-X,C`Q1#LI+CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XU:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C5I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I4:&4@86UO=6YT
M<R!O9B!S979E<F%N8V4@<&%Y(&5X<&5N<V5S('=E<F4@)#0X."P@)#$L,3$X
M(&%N9"`D.#$V#0IF;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#`Y+"`R,#$P(&%N9"`R,#$Q+"!R97-P96-T:79E;'DL#0IO9B!W:&EC:"`D
M,S,U+"`D-3,Q(&%N9"`D-C0Q(&EN('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`P.2P-"C(P,3`@86YD(#(P,3$L(')E<W!E8W1I=F5L>2P@=V5R
M92!I;B!R97-P96-T(&]F(&$@0V]N=')I8G5T:6]N#0I0;&%N+B!'86EN(&]N
M(&%M;W5N=',@9G5N9&5D(&EN(')E<W!E8W0@;V8@96UP;&]Y964@<FEG:'1S
M('5P;VX-"G)E=&ER96UE;G0@=&]T86QE9"`D.#$L("0R-B!A;F0@)#$T(&9O
M<B!T:&4@>65A<G,@96YD960@1&5C96UB97(-"C,Q+"`R,#`Y+"`R,#$P(&%N
M9"`R,#$Q+"!R97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'@@,'!X(#!P>"`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!P>"`P<'@@,'!X(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E1H92!#;VUP86YY(&5X<&5C=',@
M=&\@8V]N=')I8G5T92!A<'!R;WAI;6%T96QY("0W-SD@:6X@=&AE('EE87(-
M"F5N9&EN9R!$96-E;6)E<B`S,2P@,C`Q,B!T;R!I;G-U<F%N8V4@8V]M<&%N
M:65S(&EN(&-O;FYE8W1I;VX@=VET:`T*:71S('-E=F5R86YC92!L:6%B:6QI
M=&EE<R!F;W(@:71S(&]P97)A=&EO;G,@9F]R('1H870@>65A<BP@)#8P-R!O
M9@T*=VAI8V@@=VEL;"!B92!C;VYT<FEB=71E9"!T;R!O;F4@;W(@;6]R92!#
M;VYT<FEB=71I;VX@4&QA;G,N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M<'@@,'!X(#!P>"`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>"`P<'@@,'!X(#`N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
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M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S8R935C,69?
M.#1C9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,V,F4U8S%F7S@T8V1?-&$S,U]A-#%F7S-B,S9E,#9E
M9C4Y92]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TU-251-14Y44SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34E4345.5%,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0G/CQB/DY/5$4@-B`M/"]B/CPO9F]N=#X-"CQB/D-/
M34U)5$U%3E13/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,"XU:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ
M(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$
M)U=)1%1(.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N
M;W)M86PG/F$N/"]F;VYT/CPO=&0^#0H\=&0^4F]Y86QT>2!C;VUM:71M96YT
M<SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@
M8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/
M3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XW-6EN)SX\+W1D
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/C$N/"]T9#X-"CQT9#X\
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M86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"DEN('1H92!C87-E(&]F(&9A:6QU<F4@;V8@82!P<F]J96-T('1H870@=V%S
M('!A<G1L>2!F:6YA;F-E9"!A<PT*9&5S8W)I8F5D(&%B;W9E+"!T:&4@0V]M
M<&%N>2!I<R!N;W0@;V)L:6=A=&5D('1O('!A>2!A;GD@<W5C:`T*<F]Y86QT
M:65S(&]R(')E<&%Y(&9U;F1I;F<@<F5C96EV960@9G)O;2!T:&4@3T-3+CPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E5N
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M<&QU<RP@8V]M;65N8VEN9R!U<&]N($IA;G5A<GDF(WA!,#LQ+"`R,#`Q+"!I
M;G1E<F5S="!A=`T*86YN=6%L(')A=&4@8F%S960@;VX@3$E"3U(N($EN(&%D
M9&ET:6]N+"!I9B!T:&4@0V]M<&%N>2!R96-E:79E<PT*87!P<F]V86P@=&\@
M;6%N=69A8W1U<F4@<')O9'5C=',@9&5V96QO<&5D('=I=&@@9V]V97)N;65N
M="!G<F%N=',-"F]U='-I9&4@=&AE(%-T871E(&]F($ES<F%E;"P@:70@=VEL
M;"!B92!R97%U:7)E9"!T;R!P87D@86X-"FEN8W)E87-E9"!T;W1A;"!A;6]U
M;G0@;V8@<F]Y86QT:65S("AP;W-S:6)L>2!U<"!T;R`S,#`E(&]F('1H90T*
M9W)A;G0@86UO=6YT<R!P;'5S(&EN=&5R97-T*2P@9&5P96YD:6YG(&]N('1H
M92!M86YU9F%C='5R:6YG('9O;'5M90T*=&AA="!I<R!P97)F;W)M960@;W5T
M<VED92!T:&4@4W1A=&4@;V8@27-R865L+"!A;F0L('!O<W-I8FQY+"!A;@T*
M:6YC<F5A<V5D(')O>6%L='D@<F%T92X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-
M05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0I2;WEA;'1Y(&5X<&5N<V5S('1O('1H
M92!/0U,@87)E(&EN8VQU9&5D(&EN('1H92!S=&%T96UE;G0@;V8-"F]P97)A
M=&EO;G,@87,@82!C;VUP;VYE;G0@;V8@=&AE(&-O<W0@;V8@<F5V96YU97,@
M86YD('=E<F4-"F%P<')O>&EM871E;'D@)#$L.34P+"`D-S8Y(&%N9"`D,34X
M(&1U<FEN9R!T:&4@>65A<G,@96YD960-"D1E8V5M8F5R)B-X03`[,S$L(#(P
M,#DL(#(P,3`@86YD(#(P,3$L(')E<W!E8W1I=F5L>2X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I!="!$96-E;6)E<B8C
M>$$P.S,Q+"`R,#$Q+"!T:&4@;6%X:6UU;2!R;WEA;'1Y(&%M;W5N="!P87EA
M8FQE(&)Y#0IT:&4@0V]M<&%N>2!U;F1E<B!T:&5S92!F=6YD:6YG(&%R<F%N
M9V5M96YT<R!I<R!A<'!R;WAI;6%T96QY#0HD,3DL.#(P("AW:71H;W5T(&EN
M=&5R97-T+"!A<W-U;6EN9R`Q,#`E(&]F('1H92!F=6YD<R!A<F4-"G!A>6%B
M;&4I+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-
M05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@
M,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT
M9"!S='EL93TS1"=724142#H@,"XW-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$
M)U=)1%1(.B`P+C(U:6XG/C(N/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=&
M3TY4+5=%24=(5#H@;F]R;6%L)SY4:&4@0V]M<&%N>2!I<R!A('!A<G1Y('1O
M#0IC97)T86EN(')E<V5A<F-H(&%N9"!L:6-E;G-E(&%G<F5E;65N=',N(%5N
M9&5R('1H92`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/F%G<F5E;65N
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M=V5R90T*87!P<F]X:6UA=&5L>2`D,2PV,C4L("0Q,34@86YD("0Q.2!D=7)I
M;F<@=&AE('EE87)S(&5N9&5D#0I$96-E;6)E<B8C>$$P.S,Q+"`R,#`Y+"`R
M,#$P(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN/"]F;VYT/CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
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M('1H92!R97-E87)C:`T*86YD(&QI8V5N<V4@86=R965M96YT<R!A<F4@;65T
M+"!T:&4@86=G<F5G871E(&UI;&5S=&]N92!P87EM96YT<PT*<&%Y86)L92!W
M;W5L9"!B92!A<'!R;WAI;6%T96QY("0Y-3`@86YD('=O=6QD(&)E('!A>6%B
M;&4L(&EF(&%T#0IA;&PL(&%S('1H92!#;VUP86YY)B-X,C`Q.3MS('!R;VIE
M8W1S('!R;V=R97-S(&]V97(@=&AE(&-O=7)S92!O9B!A#0IN=6UB97(@;V8@
M>65A<G,N($EN(&%D9&ET:6]N+"!M:6QE<W1O;F4@<&%Y;65N=',@;V8@)#<P
M(&%N9"`D,3`P#0IW97)E('!A:60@:6X@<F5S<&5C="!O9B!T:&4@<V%I9"!A
M9W)E96UE;G1S(&1U<FEN9R!T:&4@>65A<G,@96YD960-"D1E8V5M8F5R(#,Q
M+#(P,#D@86YD(#(P,3`L(')E<W!E8W1I=F5L>2X\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE
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M)U1%6%0M24Y$14Y4.B`M,"XU:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C>$$P.SPO
M9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&
M3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SX\+W1D
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!N;W)M86PG/F(N/"]F;VYT/CPO=&0^#0H\=&0^4W5B
M8V]N=')A8W1I;F<@06=R965M96YT<SPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"E1H92!#;VUP86YY(&AA<R!E;G1E<F5D(&EN=&\@<W5B+6-O;G1R86-T:6YG
M(&%G<F5E;65N=',@=VET:`T*<V5V97)A;"!C;&EN:6-A;"!P<F]V:61E<G,@
M86YD(&-O;G-U;'1A;G1S(&EN($ES<F%E;"P@=&AE(%5N:71E9`T*4W1A=&5S
M(&%N9"!C97)T86EN(&]T:&5R(&-O=6YT<FEE<R!I;B!C;VYN96-T:6]N('=I
M=&@@:71S('!R:6UA<GD-"G!R;V1U8W0@9&5V96QO<&UE;G0@<')O8V5S<R!A
M;F0@=VET:"!E>'!E;F1I='5R92!O9B!T:&4-"F-O;7!A;GDF(W@R,#$Y.W,@
M;6%N=69A8W1U<FEN9R!F86-I;&ET:65S+B!!<R!O9B!$96-E;6)E<B`S,2P@
M,C`Q,2P-"G1O=&%L(&-O;6UI=&UE;G1S('5N9&5R('-A:60@86=R965M96YT
M<R!W97)E(&%P<')O>&EM871E;'D-"B0X,C$N/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XU:6X[($U!4D=)3CH@,'!X(#!P>"`P
M<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C
M>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN
M)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/CQF;VYT('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/F,N/"]F;VYT/CPO=&0^#0H\
M=&0^3&5A<V4@06=R965M96YT<SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E1H
M92!#;VUP86YY(&ES(&$@<&%R='D@=&\@82!N=6UB97(@;V8@;&5A<V4@86=R
M965M96YT<R!F;W(@:71S#0IF86-I;&ET:65S+"!T:&4@;&%T97-T(&]F('=H
M:6-H(&5X<&ER97,@:6X@,C`Q-RX@5&AE($-O;7!A;GD@:&%S#0IT:&4@;W!T
M:6]N('1O(&5X=&5N9"!C97)T86EN(&]F('-U8V@@86=R965M96YT<R!O;B!T
M:')E92!O8V-A<VEO;G,-"F9O<B!A9&1I=&EO;F%L(&9I=F4M>65A<B!P97)I
M;V1S+"!F;W(@82!T;W1A;"!O9B`Q-2!A9&1I=&EO;F%L#0IY96%R<RX@56YD
M97(@=&AE(&QE87-E<RP@=&AE(&%G9W)E9V%T92!M;VYT:&QY(')E;G1A;"!P
M87EM96YT<R!A<F4-"F%P<')O>&EM871E;'D@)#<U+B!!<R!O9B!$96-E;6)E
M<B`S,2P@,C`Q,2P@=&AE($-O;7!A;GD@<')O=FED960-"F)A;FL@9W5A<F%N
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M.B`R,#$R("T@)#DP,2P@,C`Q,R`M("0X.3`L(#(P,30@+2`D.#@S+`T*,C`Q
M-2`F(W@R,#$S.R`D.#@S(&%N9"`R,#$V("8C>#(P,3,[("0V,S@N($QE87-E
M(&5X<&5N<V5S('1O=&%L960-"B0W.#`L("0X.3$@86YD("0Y.30@9F]R('1H
M92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`P.2P@,C`Q,"!A;F0-"C(P
M,3$L(')E<W!E8W1I=F5L>2X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3`N-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL
M93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF(WA!,#L\+V9O;G0^/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]4
M5$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^/"]T9#X-"CQT9"!S='EL
M93TS1"=724142#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(
M5#H@;F]R;6%L)SYD+CPO9F]N=#X\+W1D/@T*/'1D/E9E:&EC;&4@3&5A<V4@
M86YD($UA:6YT96YA;F-E($%G<F5E;65N=',\+W1D/@T*/"]T<CX-"CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF
M(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N
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M90T*>65A<G,@96YD:6YG($1E8V5M8F5R(#,Q+"`R,#$R+"`R,#$S(&%N9"`R
M,#$T(&%R92`D-3$T+"`D,C8W(&%N9`T*)#<P+"!R97-P96-T:79E;'DN/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P
M<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO
M<FUA;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=72414
M2#H@,"XU:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^92X\+V9O;G0^
M/"]T9#X-"CQT9#Y4979A($%G<F5E;65N=#PO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"D]N(%-E<'1E;6)E<B`Q-"P@,C`P-BP@=&AE($-O;7!A;GD@96YT97)E
M9"!I;G1O(&%N(&%G<F5E;65N="`H=&AE#0HF(W@R,#%#.U1E=F$@06=R965M
M96YT)B-X,C`Q1#LI('=I=&@@5&5V82!0:&%R;6%C975T:6-A;"!);F1U<W1R
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M96QO<&5D('5N9&5R('1H92!A9W)E96UE;G0@8G5T#0II;B`R,#`Y+"!B;W1H
M(&]F('1H92!P<F]J96-T<R!W97)E('1E<FUI;F%T960@9F]R(&-O;6UE<F-I
M86P-"G)E87-O;G,N($]T:&5R(&5L96UE;G1S(&]F('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&-O;&QA8F]R871I;VX@=VET:`T*5&5V82!A<F4@8W5R<F5N=&QY
M(&]N9V]I;F<N/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C5I
M;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L92!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S
M='EL93TS1"=724142#H@,"XU:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA
M;"<^9BX\+V9O;G0^/"]T9#X-"CQT9#Y9:7-S=6T@06=R965M96YT/"]T9#X-
M"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'@@,'!X(#!P
M>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M+"!.97<-"EEO<FLL('1O(&1E=F5L;W`@82!P<F]P<FEE=&%R>2!P;&%N="!C
M96QL+6)A<V5D#0IA8V5T>6QC:&]L:6YE<W1E<F%S92`H04-H12D@86YD(&ET
M<R!M;VQE8W5L87(@=F%R:6%N=',@9F]R('1H92!U<V4-"FEN('-E=F5R86P@
M=&AE<F%P975T:6,@86YD('!R;W!H>6QA8W1I8R!I;F1I8V%T:6]N<RP@:6YC
M;'5D:6YG(&$-"F)I;V1E9F5N<V4@<')O9W)A;2!A;F0@;W)G86YO<&AO<W!H
M871E+6)A<V5D('!E<W1I8VED92!T<F5A=&UE;G0N#0I0=7)S=6%N="!T;R!T
M:&4@86=R965M96YT+"!T:&4@0V]M<&%N>2!H87,@<F5C96EV960@86X@97AC
M;'5S:79E#0IW;W)L9'=I9&4@<FEG:'0@86YD(&QI8V5N<V4@=&\@8V5R=&%I
M;B!T96-H;F]L;V=Y+"!I;F-L=61I;F<-"G!A=&5N=',@86YD(&%D9&ET:6]N
M86P@<&%T96YT(&%P<&QI8V%T:6]N<R!R96QA=&EN9R!T;R!!0VA%("AT:&4-
M"B8C>#(P,4,[3&EC96YS960@5&5C:&YO;&]G>28C>#(P,40[*2P@9F]R(&%L
M;"!T:&5R87!E=71I8R!A;F0-"G!R;W!H>6QA8W1I8R!I;F1I8V%T:6]N<RX@
M26X@8V]N<VED97)A=&EO;B!F;W(@=&AE(&QI8V5N<V4L('1H90T*0V]M<&%N
M>2!I<R!R97%U:7)E9"!T;R!M86ME(&-E<G1A:6X@;6EL97-T;VYE('!A>6UE
M;G1S(&5Q=6%L('1O('5P#0IT;R`D-S`P+"!I;B!T:&4@86=G<F5G871E+"!U
M<&]N(&ET<R!A8VAI979E;65N="!O9B!C;&EN:6-A;`T*;6EL97-T;VYE<R!A
M;F0@<F]Y86QT:65S(&9R;VT@<V%L97,@9&5R:79E9"!F<F]M(&%N>2!D<G5G
M<PT*9&5V96QO<&5D(&)Y('1H92!#;VUP86YY('=I=&@@=&AE($QI8V5N<V5D
M(%1E8VAN;VQO9WDN(%1H90T*86=R965M96YT(&1O97,@;F]T('1E<FUI;F%T
M92!U;G1I;"!E:71H97(@<&%R='D@=&\@=&AE(&%G<F5E;65N=`T*96QE8W0@
M=&\@=&5R;6EN871E('1H92!A9W)E96UE;G0L('-U8FIE8W0@=&\@8V5R=&%I
M;B!T97)M<R!A;F0-"F-O;F1I=&EO;G,@<V5T(&9O<G1H('1H97)E:6XN/"]P
M/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S8R935C,69?.#1C9%\T83,S
M7V$T,69?,V(S-F4P-F5F-3EE+U=O<FMS:&5E=',O4VAE970Q-"YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14%$/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-(05)%($-!4$E4
M04P\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-(
M05)%($-!4$E404P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P
M>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0H\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQB/DY/5$4@-R`M
M/"]B/CPO9F]N=#X@/&(^4TA!4D4-"D-!4$E404P\+V(^/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@,'!X(#!P
M>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X
M03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^82X\+V9O;G0^/"]T9#X-"CQT
M9#Y2:6=H=',@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@0V]M;6]N(%-T;V-K
M/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*5&AE($-O;7!A;GDF(W@R,#$Y.W,@
M8V]M;6]N('-T;V-K(&ES(&QI<W1E9"!O;B!T:&4@3EE312!!;65X(&%N9"P-
M"G-I;F-E(%-E<'1E;6)E<B`V+"`R,#$P+"!O;B!T:&4@5&5L($%V:78@4W1O
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M;W0@9&5C;&%R960@86YY#0ID:79I9&5N9',N/"]P/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F
M;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/
M3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&YO<FUA;"<^8BX\+V9O;G0^/"]T9#X-"CQT9#Y3=&]C
M:R!B87-E9"!C;VUP96YS871I;VX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\
M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I/
M;B!$96-E;6)E<B`Q-"P@,C`P-BP@=&AE($)O87)D(&]F($1I<F5C=&]R<R!A
M9&]P=&5D('1H92!0<F]T86QI>`T*0FEO5&AE<F%P975T:6-S+"!);F,N(#(P
M,#8@4W1O8VL@26YC96YT:79E(%!L86X@*'1H90T*)B-X,C`Q0SM0;&%N)B-X
M,C`Q1#LI+B!4:&4@9W)A;G0@;V8@;W!T:6]N<R!T;R!)<W)A96QI(&5M<&QO
M>65E<PT*=6YD97(@=&AE(%!L86X@:7,@<W5B:F5C="!T;R!T:&4@=&5R;7,@
M<W1I<'5L871E9"!B>0T*4V5C=&EO;G,F(WA!,#LQ,#(@86YD(#$P,D$@;V8@
M=&AE($ES<F%E;&D@26YC;VUE(%1A>"!/<F1I;F%N8V4N#0I%86-H(&]P=&EO
M;B!G<F%N="!I<R!S=6)J96-T('1O('1H92!T<F%C:R!C:&]S96X@8GD@=&AE
M($-O;7!A;GDL#0IE:71H97(@4V5C=&EO;B`Q,#(@;W(@4V5C=&EO;B`Q,#)!
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M;&]Y965S+"!T:&4@<VAA<F4@;W!T:6]N('!L86X@:7,@<W5B:F5C=`T*=&\@
M4V5C=&EO;B`S*&DI(&]F('1H92!)<W)A96QI($EN8V]M92!487@@3W)D:6YA
M;F-E+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"`T-RPY,C`@<VAA
M<F5S(&]F($-O;6UO;B!3=&]C:R!R96UA:6X-"F%V86EL86)L92!F;W(@9W)A
M;G0@=6YD97(@=&AE(%!L86XN/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P
M<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
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M(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)
M3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"D9R;VT@2F%N=6%R>2`Q+"`R,#`Y('1H
M<F]U9V@@1&5C96UB97(@,S$L(#(P,3$L('1H92!#;VUP86YY(&=R86YT960-
M"F]P=&EO;G,@=&\@8V5R=&%I;B!E;7!L;WEE97,@86YD(&YO;BUE;7!L;WEE
M97,@87,@9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3`N,C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(&)O;&0@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B!B
M;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)
M3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ
M('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^/"]T9#X-"CQT
M9"!S='EL93TS1"=724142#H@,"XR-6EN)SXQ+CPO=&0^#0H\=&0^3W!T:6]N
M<R!G<F%N=&5D('1O(&5M<&QO>65E<SH\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P
M<'@@,'!X(#!P>"`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=72414
M2#H@,6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/F$I
M/"]T9#X-"CQT9#Y"96QO=R!I<R!A('1A8FQE('-U;6UA<FEZ:6YG(&%L;"!O
M9B!T:&4@;W!T:6]N(&=R86YT<R!T;PT*96UP;&]Y965S(&9O<B!E86-H(&]F
M('1H92!T:')E92!Y96%R<R!I;B!T:&4@<&5R:6]D(&5N9&5D($1E8V5M8F5R
M#0HS,2P@,C`Q,3H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G5TE$
M5$@Z(#@P)3L@1D].5#H@.'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM3$5&5#H@,2XR-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L
M9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/EEE87(F(WA!,#MO9CQB
M<B`O/@T*1W)A;G0\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^#0HF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/DYO+B8C>$$P.V]F)B-X03`[
M;W!T:6]N<SQB<B`O/@T*9W)A;G1E9#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
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M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^17AE<F-I
M<V4\8G(@+SX-"G!R:6-E)B-X03`[<F%N9V4\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R
M87`],T1N;W=R87`^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N
M;W=R87`^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/E9E<W1I;F<F(WA!,#MP
M97)I;V0\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S
M;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/D9A:7(F(WA!,#MV86QU93QB
M<B`O/@T*870F(WA!,#MG<F%N=#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.
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M.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^17AP:7)A=&EO
M;CQB<B`O/@T*4&5R:6]D/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P
M/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@8V]L<W!A
M;CTS1#(^,C`P.2H\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXU,#0L,#`P/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<@;F]W<F%P/3-$
M;F]W<F%P/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)R!N;W=R87`],T1N;W=R87`^,BXV-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^57!O;B!A8VAI979E
M;65N="!O9B!C97)T86EN#0IM:6QE<W1O;F5S*CPO=&0^#0H\=&0^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,2PP-C@\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXQ,"!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G(&-O;'-P86X],T0R/C(P,#D\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXQ,C`L-#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<@;F]W<F%P/3-$;F]W<F%P/B0\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)R!N;W=R87`],T1N
M;W=R87`^,BXV-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<B<^-"!Y96%R<SPO=&0^#0H\=&0^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,C$R/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,3`@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G(&-O;'-P86X]
M,T0R/C(P,3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXQ+#`Q-BPP,#`\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)R!N;W=R87`],T1N
M;W=R87`^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M(&YO=W)A<#TS1&YO=W)A<#XV+CDP/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)SXS('EE87)S(&-O;6UE
M;F-I;F<@=7!O;B!A8VAI979E;65N=`T*;V8@82!C97)T86EN(&UI;&5S=&]N
M93PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^-2PV-S,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXQ,"!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G(&-O;'-P86X],T0R/@T*,C`Q,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-
M.B`Q<'0G/C0R."PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,7!T)R!N;W=R87`],T1N;W=R87`^#0HD/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P
M/3-$;F]W<F%P/@T*-BXS,BTD.2XV-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@4$%$1$E.
M1RU"3U143TTZ(#%P="<^-"!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P="<^,BPQ-#<\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT.R!0041$24Y'+4)/5%1/33H@,7!T)SXQ,"!Y96%R<SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q,"4G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q)3L@1D].5"U325I%.B`Q<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!L969T.R!724142#H@,24[($9/3E0M4TE:13H@,7!T
M)SX-"B8C>$$P.R8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@5TE$
M5$@Z(#$P)3L@1D].5"U325I%.B`Q<'0G/@T*)B-X03`[)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24[($9/
M3E0M4TE:13H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)R!N
M;W=R87`],T1N;W=R87`^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!724142#H@,S4E)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET
M93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR+#`V."PT,#`\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)R!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<B<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@
M,'!X(#!P>"`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'@@,'!X(#!P>"`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T**B!4:&4@;6EL97-T;VYE('=A<R!A8VAI
M979E9"!A<R!O9B!$96-E;6)E<B`S,2P@,C`P.2!A;F0@=&AE#0IO<'1I;VYS
M('9E<W1E9"!I;B!F=6QL+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X
M(#!P>"`P<'@@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^)B-X03`[/"]B/CPO<#X-
M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'@[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q+C(U:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q
M+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*4V5T(&9O<G1H(&)E;&]W(&%R92!G<F%N=',@;6%D92!B>2!T:&4@
M0V]M<&%N>2!T;R!E;7!L;WEE97,-"BAI;F-L=61I;F<@<F5L871E9"!P87)T
M:65S*2!D=7)I;F<@=&AE('1H<F5E+7EE87(@<&5R:6]D(&5N9&5D#0I$96-E
M;6)E<B`S,2P@,C`Q,2`H<W5C:"!G<F%N=',@87!P96%R(&EN('1H92!T86)L
M92!A8F]V92DZ/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U
M:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,2XU:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L
M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
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M1TA4.B!N;W)M86PG/DEN($9E8G)U87)Y+"`R,#`Y+"!T:&4-"D-O;7!A;GDF
M(W@R,#$Y.W,@0F]A<F0@;V8@1&ER96-T;W)S(&%P<')O=F5D('1H92!G<F%N
M="!O9B!O<'1I;VYS('1O#0IP=7)C:&%S92`V,C0L-#`P('-H87)E<R!O9B!#
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M='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P>"`P<'@@,'!X
M(#$N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C
M>$$P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN
M.R!-05)'24XZ(#!P>"`P<'@@,'!X(#$N-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!N;W)M86PG/BAI*2`U,#0L,#`P(&]F('1H92!O<'1I;VYS
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M92!W:71H:6X@82!P97)I;V0@;V8@,3`@>65A<G,@9G)O;0T*=&AE(&1A=&4@
M;V8@9W)A;G0N(%1H92!V97-T:6YG(&-O;F1I=&EO;G,@;V8@=&AE<V4@;W!T
M:6]N<R!W97)E#0IS871I<V9I960@<')I;W(@=&\@1&5C96UB97(@,S$L(#(P
M,#DN($%C8V]R9&EN9VQY+"!T:&5S92!O<'1I;VYS#0IW97)E(&9U;&QY('9E
M<W1E9"!A="!$96-E;6)E<B`S,2P@,C`P.2!A;F0@=&AE($-O;7!A;GD@<F5C
M;V=N:7IE9`T*86QL(&]F('1H92!E>'!E;G-E<R!F;W(@=&AE<V4@;W!T:6]N
M<R!D=7)I;F<@,C`P.2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q+C5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF(WA!,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'@@
M,'!X(#!P>"`Q+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R
M;6%L)SXH:6DI(#$R,"PT,#`@;V8@=&AE(&]P=&EO;G,@=F5S=`T*87,@9F]L
M;&]W<SH@,C4E('=I=&AI;B!O;F4@>65A<B!F<F]M('1H92!D871E(&]F(&=R
M86YT+"!W:71H('1H90T*<F5M86EN9&5R('9E<W1I;F<@:6X@,3(@97%U86P@
M<75A<G1E<FQY('1R86YC:&5S(&]V97(@,S8@;6]N=&AS+@T*5&AE(&]P=&EO
M;G,@97AP:7)E('=I=&AI;B!A('!E<FEO9"!O9B`Q,"!Y96%R<R!F<F]M('1H
M92!D871E(&]F#0IG<F%N="X@5&AE($-O;7!A;GDF(W@R,#$Y.W,@;6%N86=E
M;65N="!A<W-U;65D('1H92!S:6UP;&EF:65D(&UE=&AO9`T*=&\@<F5F;&5C
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M/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@
M,'!X(#!P>"`P<'@@,2XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-
M05)'24XM5$]0.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
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M/DEN($9E8G)U87)Y(#(P,3`L('1H90T*0V]M<&%N>28C>#(P,3D[<R!";V%R
M9"!O9B!$:7)E8W1O<G,@87!P<F]V960@=&AE(&=R86YT(&]F(&]P=&EO;G,@
M=&\-"G!U<F-H87-E(#$L,#$V+#`P,"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K
M+"!I;B!T:&4@86=G<F5G871E+"!T;R!T:&4-"D-O;7!A;GDF(W@R,#$Y.W,@
M0VAI968@17AE8W5T:79E($]F9FEC97(@86YD(&-E<G1A:6X@;V9F:6-E<G,@
M86YD#0IE;7!L;WEE97,@;V8@=&AE($-O;7!A;GD@=VET:"!A;B!E>&5R8VES
M92!P<FEC92!E<75A;"!T;R`D-BXY,"!P97(-"G-H87)E+B!4:&4@;W!T:6]N
M<R!V97-T('%U87)T97)L>2!O=F5R(&$@=&AR964M>65A<B!P97)I;V0-"F-O
M;6UE;F-I;F<@=7!O;B!T:&4@1D1!)B-X,C`Q.3MS(&%P<')O=F%L(&]F('1A
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M;B!E>'!E;G-E('=A<R!R96-O9VYI>F5D(&%S(&]F($1E8V5M8F5R(#,Q+`T*
M,C`Q,2XF(WA!,#LF(WA!,#M4:&4@0V]M<&%N>2!W:6QL('-T87)T(')E8V]R
M9&EN9R!T:&5S92!E>'!E;G-E<PT*9F]L;&]W:6YG('1H92!&1$$F(W@R,#$Y
M.W,@;6%R:V5T:6YG(&%P<')O=F%L(&]F('1A;&EG;'5C97)A<V4@86QF82P-
M"FEF(&%T(&%L;"X\+V9O;G0^/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!X(#!P
M>"`P<'@@,2XU:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA
M;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM
M5$]0.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M(&YO<FUA;"<^26X@1F5B<G5A<GD-"C(P,3`L('1H92!#;VUP86YY)B-X,C`Q
M.3MS($)O87)D(&]F($1I<F5C=&]R<R!A<'!R;W9E9"!T:&4@9W)A;G0@;V8-
M"F]P=&EO;G,@=&\@<'5R8VAA<V4@,38P+#`P,"8C>$$P.W-H87)E<R!O9B!#
M;VUM;VX@4W1O8VL@=VET:"!A;@T*97AE<F-I<V4@<')I8V4@97%U86P@=&\@
M)#8N.#$@<&5R('-H87)E('1O(&$@;F5W(&5X96-U=&EV92!O9F9I8V5R#0IO
M9B!T:&4@0V]M<&%N>2X@5&AE(&]P=&EO;G,@97AP:7)E(&]N('1H92!T96YT
M:"!A;FYI=F5R<V%R>2!O9B!T:&4-"F1A=&4@;V8@9W)A;G0L('5N;&5S<R!T
M97)M:6YA=&5D(&5A<FQI97(N(%1H92!F:7)S="`R-24@;V8@=&AE#0IO<'1I
M;VYS('9E<W0@;VX@=&AE(&9I<G-T(&%N;FEV97)S87)Y(&]F('1H92!D871E
M(&]F(&=R86YT(&%N9"!T:&4-"G)E;6%I;FEN9R`W-24@=F5S="!I;B`Q,B!E
M<75A;"!T<F%N8VAE<R!O;B!A('%U87)T97)L>2!B87-I<R!F;W(-"G1H<F5E
M('EE87)S('1H97)E869T97(N/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ
M(#!P>"`P<'@@,'!X(#$N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4
M.B!N;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE
M/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q+C(U:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^
M/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^-"X\+V9O;G0^
M/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L
M)SY);B!397!T96UB97(F(WA!,#LR,#$P+"!T:&4-"D-O;7!A;GDF(W@R,#$Y
M.W,@0F]A<F0@;V8@1&ER96-T;W)S(&%P<')O=F5D('1H92!G<F%N="!O9B!O
M<'1I;VYS('1O#0IP=7)C:&%S92`Q-C`L,#`P('-H87)E<R!O9B!#;VUM;VX@
M4W1O8VL@=&\@82!N97<@97AE8W5T:79E(&]F9FEC97(-"F]F('1H92!#;VUP
M86YY('=I=&@@86X@97AE<F-I<V4@<')I8V4@97%U86P@=&\@)#<N-34@<&5R
M('-H87)E(&%N9`T*;W!T:6]N<R!T;R!P=7)C:&%S92`T,"PP,#`@<VAA<F5S
M(&]F($-O;6UO;B!3=&]C:R!T;R!A(&YE=R!E;7!L;WEE90T*;V8@=&AE($-O
M;7!A;GD@=VET:"!A;B!E>&5R8VES92!P<FEC92!E<75A;"!T;R`D-BXS,B!P
M97(@<VAA<F4N(%1H90T*;W!T:6]N<R!V97-T(&]V97(@82!F;W5R+7EE87(@
M<&5R:6]D+"!W:71H('1H92!F:7)S="`R-24@=F5S=&EN9R!O;@T*=&AE(&9I
M<G-T(&%N;FEV97)S87)Y(&]F('1H92!A<'!L:6-A8FQE(&1A=&4@;V8@=&AE
M(&=R86YT(&%N9"!T:&4-"G)E;6%I;FEN9R`W-24@=F5S=&EN9R!I;B!E<75A
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M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'3CH@
M8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X
M(#$N-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/B8C
M>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q+C(U:6XG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&YO<FUA;"<^-2X\+V9O;G0^/"]T9#X-"CQT9#X\
M9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SY);B!.;W9E;6)E
M<B8C>$$P.S(P,3`L('1H90T*0V]M<&%N>28C>#(P,3D[<R!";V%R9"!O9B!$
M:7)E8W1O<G,@87!P<F]V960@=&AE(&=R86YT(&]F(&]P=&EO;G,@=&\-"G!U
M<F-H87-E(#8X+#`P,"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K('1O(&$@;F5W
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M/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,2XU:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@
M<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO
M<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(#$P
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M)T9/3E0M5T5)1TA4.B!N;W)M86PG/DEN(%-E<'1E;6)E<B`R,#$P+"!T:&4-
M"D-O;7!A;GDF(W@R,#$Y.W,@0F]A<F0@;V8@1&ER96-T;W)S(&UO9&EF:65D
M('1H92!T97)M<R!O9B!T:&4-"F]P=&EO;G,@<')E=FEO=7-L>2!G<F%N=&5D
M('1O(&%N(&5X96-U=&EV92!I;B`R,#`Q+"!B>2!E>'1E;F1I;F<-"G1H92!L
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M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P<'@@
M,'!X(#!P>"`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@
M,6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/F(I/"]T
M9#X-"CQT9#Y4:&4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960@9'5R
M:6YG('1H92!Y96%R<R!E;F1E9`T*1&5C96UB97(@,S$L(#(P,#D@86YD(#(P
M,3`@=V5R92`D,2PR.#`@86YD("0W+#@R,"!R97-P96-T:79E;'DN(%1H90T*
M9F%I<B!V86QU92!O9B!E86-H(&]P=&EO;B!G<F%N=&5D(&ES(&5S=&EM871E
M9"!O;B!T:&4@9&%T92!O9B!G<F%N=`T*=7-I;F<@=&AE($)L86-K+5-C:&]L
M97,@;W!T:6]N+7!R:6-I;F<@;6]D96PL('=I=&@@=&AE(&9O;&QO=VEN9PT*
M=V5I9VAT960@879E<F%G92!A<W-U;7!T:6]N<SH\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>#L@1D].5#H@8F]L9"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO
M<#X-"CQT86)L92!S='EL93TS1"=724142#H@-C`E.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM3$5&5#H@,2XR
M-6EN)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXR,#`Y/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!C96YT97(G(&-O;'-P86X],T0R/C(P,3`\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U)
M3D1%3E0Z(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%=)1%1(.B`U."4[(%!!
M1$1)3D<M4DE'2%0Z(#!P>"<^#0I$:79I9&5N9"!Y:65L9#PO=&0^#0H\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!724142#H@,24G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T.R!724142#H@,24G/@T*
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3@E
M)SX-"C`E/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(.B`Q)2<^#0H\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5TE$5$@Z(#$E)SXF
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M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$585"U)3D1%3E0Z
M(#!P>#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D<M4DE'2%0Z(#!P>"<^
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M1$1)3D<M0D]45$]-.B`R+C5P="<^/"]T9#X-"CQT9"!S='EL93TS1"=0041$
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M1$1)3D<M0D]45$]-.B`R+C5P="<^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#
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M1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX-"C,N,C,E/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/CPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M24Y$14Y4.B`P<'@[(%!!1$1)
M3D<M3$5&5#H@,'!X.R!0041$24Y'+5))1TA4.B`P<'@G/@T*17AP96-T960@
M;&EF92`F(W@R,#$S.R!I;B!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
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M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,2XR-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
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M(&EN#0ID;VQL87(@=&5R;7,N(%1H92!#;VUP86YY)B-X,C`Q.3MS(&UA;F%G
M96UE;G0@=7-E<R!T:&4@8V]N=')A8W1U86P-"G1E<FT@;W(@:71S(&5X<&5C
M=&%T:6]N<RP@8F%S960@;VX@:&ES=&]R:6-A;"!I;F-I9&5N8V4@;V8@;W!T
M:6]N#0IE>&5R8VES97,L(&%S(&%P<&QI8V%B;&4@*&1U<FEN9R`R,#`Y("T@
M=7-I;F<@=&AE('-I;7!L:69I960-"FUE=&AO9"DL(&]F(&5A8V@@;W!T:6]N
M(&%S(&ET<R!E>'!E8W1E9"!L:69E+B!4:&4@<')E+79E<W1I;F<-"F9O<F9E
M:71U<F4@<F%T92!O9B!A<'!R;WAI;6%T96QY(#8N,R4@:7,@97-T:6UA=&5D
M(&)A<V5D(&]N#0IP<F4M=F5S=&EN9R!F;W)F96ET=7)E(&5X<&5R:65N8V4N
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q+C(U:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q
M+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*5&AE('1O=&%L('5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S
M="!O9B!E;7!L;WEE92!S=&]C:R!O<'1I;VYS#0IA="!$96-E;6)E<B`S,2P@
M,C`Q,2!I<R`D-BPR,3@@*&YE="!O9B!F;W)F96ET=7)E(')A=&4I(&]U="!O
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M('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E1H
M92!T;W1A;"!C87-H(')E8V5I=F5D(&9R;VT@96UP;&]Y965S(&%S(&$@<F5S
M=6QT(&]F(&5M<&QO>65E#0IS=&]C:R!O<'1I;VX@97AE<F-I<V5S(&9O<B!T
M:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P,#DL(#(P,3`-"F%N9"`R
M,#$Q('=A<R`D,CDS+"`D-3`Q(&%N9"`D,C<W+"!R97-P96-T:79E;'DN(%1H
M92!#;VUP86YY(&1I9"!N;W0-"G)E86QI>F4@86YY('1A>"!B96YE9FET(&EN
M(&-O;FYE8W1I;VX@=VET:"!T:&5S92!E>&5R8VES97,N/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q+C(U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q+C(U:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*1'5R:6YG
M(#(P,3$L('1H92!#;VUP86YY(&ES<W5E9"`Q.#$L-C@U('-H87)E<R!O9B!#
M;VUM;VX@4W1O8VL@:6X-"F-O;FYE8W1I;VX@=VET:"!T:&4@97AE<F-I<V4@
M;V8@,3@R+#`Y,R!O<'1I;VYS(&)Y(&-E<G1A:6X-"F5M<&QO>65E<R!O9B!T
M:&4@0V]M<&%N>2X@5&AE($-O;7!A;GD@<F5C96EV960@8V%S:"!P<F]C965D
M<R!E<75A;`T*=&\@)#(V."!I;B!C;VYN96-T:6]N('=I=&@@<W5C:"!E>&5R
M8VES97,N($]F('-U8V@@;W!T:6]N<RP@,BPQ,S(-"F]P=&EO;G,@=V5R92!E
M>&5R8VES960@;VX@82`F(W@R,#%#.VYE="UE>&5R8VES928C>#(P,40[(&)A
M<VES+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TP+C(U:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B!B;VQD
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[
M/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@
M8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'
M24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^,BX\+W1D/@T*/'1D/D]P=&EO
M;G,@9W)A;G1E9"!T;R!C;VYS=6QT86YT<RP@9&ER96-T;W)S+"!A;F0@;W1H
M97(@<V5R=FEC90T*<')O=FED97)S.CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!X(#!P
M>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG
M/B8C>$$P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&
M3TY4+5=%24=(5#H@;F]R;6%L)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2P@
M=&AE#0I#;VUP86YY(&AA<R!R96-O9VYI>F5D(&%N9"!R96-O<F1E9"!A;&P@
M8V]M<&5N<V%T:6]N(&-O<W1S(')E;&%T960-"G1O(&]U='-T86YD:6YG(&]P
M=&EO;G,@9F]R(&-O;G-U;'1A;G1S+"!D:7)E8W1O<G,@86YD(&]T:&5R#0IS
M97)V:6-E<R!P<F]V:61E<G,N/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$
M)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"DYO(&-A<V@@=V%S(')E8V5I=F5D
M(&9R;VT@8V]N<W5L=&%N=',@87,@82!R97-U;'0@;V8@8V]N<W5L=&%N=`T*
M<W1O8VL@;W!T:6]N(&5X97)C:7-E<R!F;W(@=&AE('EE87)S(&5N9&5D($1E
M8V5M8F5R(#,Q+"`R,#`Y+"`R,#$P+`T*86YD("0P+C(@=V%S(')E8V5I=F5D
M(&EN(#(P,3$N(%1H92!#;VUP86YY(&1I9"!N;W0@<F5A;&EZ92!A;GD@=&%X
M#0IB96YE9FET<R!I;B!C;VYN96-T:6]N('=I=&@@=&AE<V4@97AE<F-I<V5S
M+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"D1U<FEN9R`R,#`Y+"!T:&4@0V]M<&%N>2!I<W-U960@,RPX-3,L-#0Q('-H
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M(&]N(&$-"B8C>#(P,4,[;F5T+65X97)C:7-E)B-X,C`Q1#L@8F%S:7,N/"]P
M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*1'5R
M:6YG(#(P,3$L('1H92!#;VUP86YY(&ES<W5E9"`R,#`L,#`P('-H87)E<R!O
M9B!#;VUM;VX@4W1O8VL@:6X-"F-O;FYE8W1I;VX@=VET:"!T:&4@97AE<F-I
M<V4@;V8@,C`P+#`P,"!O<'1I;VYS(&)Y(&-E<G1A:6X-"F-O;G-U;'1A;G0@
M;V8@=&AE($-O;7!A;GDN(%1H92!#;VUP86YY(')E8V5I=F5D(&-A<V@@<')O
M8V5E9',@97%U86P-"G1O("0P+C(@:6X@8V]N;F5C=&EO;B!W:71H('-U8V@@
M97AE<F-I<V4N/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U
M:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B!B;VQD(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]4
M5$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CPO=&0^#0H\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#`N,C5I;B<^,RX\+W1D/@T*/'1D/CQF;VYT('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/D$@<W5M;6%R>2!O9B!S:&%R92!O
M<'1I;VX-"G!L86YS+"!A;F0@<F5L871E9"!I;F9O<FUA=&EO;BP@=6YD97(@
M86QL(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS#0IE<75I='D@:6YC96YT:79E
M('!L86YS(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(F(WA!,#LS,2P@
M,C`P.2P-"C(P,3`@86YD(#(P,3$@87)E(&%S(&9O;&QO=W,Z/"]F;VYT/CPO
M=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,"XR-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]4
M5$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q:6XG/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#`N,C5I;B<^82X\+W1D/@T*/'1D/D]P=&EO;G,@9W)A;G1E
M9"!T;R!E;7!L;WEE97,Z/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y
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M<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[
M($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#8^,C`P.3PO=&0^
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M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0V/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\
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M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX-"E=E:6=H=&5D
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[
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M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B
M;VQD)R!C;VQS<&%N/3-$,CX-"F]F/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$
M,CX-"F5X97)C:7-E/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX-"F]F/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX-"F5X97)C:7-E/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD
M)R!C;VQS<&%N/3-$,CX-"F]F/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX-
M"F5X97)C:7-E/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9"<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T
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M5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R/G!R:6-E/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0R/F]P=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^<')I8V4\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!C96YT97(G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/B8C
M>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^
M)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$
M,CXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97(G(&-O;'-P86X]
M,T0R/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<B<@8V]L<W!A
M;CTS1#(^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)R!C;VQS
M<&%N/3-$,CXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M
M3$5&5#H@,"XQ:6X[(%=)1%1(.B`R,B4G/@T*3W5T<W1A;F1I;F<@870@8F5G
M:6YN:6YG(&]F('EE87(\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!7
M24142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C4L.#DP+#8T,3PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXR
M+C$Q.#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!7
M24142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C4L,S8V+#<R.3PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXR
M+C0W-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!7
M24142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C8L,S8W+#DW.3PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXS
M+C4W-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$
M5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+
M1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z
M("TP+C%I;CL@4$%$1$E.1RU,1494.B`P+C%I;B<^#0I#:&%N9V5S(&1U<FEN
M9R!T:&4@>65A<CH\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N,6EN.R!0
M041$24Y'+4Q%1E0Z(#$V+C)P="<^1W)A;G1E9#PO=&0^#0H\=&0^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXV,C0L-#`P
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^,BXV-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ+#0T-"PP,#`\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXW+C`W
M-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,38N,G!T)SY&;W)F96ET960@86YD#0I%
M>'!I<F5D/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/C$L-#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BXV-3`\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ
M,RPT-#$\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXS+C4U,3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C0T+#@U-CPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8N
M,C`W/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4E.1$5.
M5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#$V+C)P="<^#0I%>&5R8VES960@
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M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G
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M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
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M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@<FEG:'0G/@T*,2XV,#(\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX-"C$X,BPP.3,\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
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M+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N,6EN)SX-"D]U='-T
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M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S
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M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT
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M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B0\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G/@T*,RXU-S8\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HV+#$T,2PP,S`\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
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M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!415A4+4E.1$5.5#H@+3`N
M,6EN.R!0041$24Y'+4Q%1E0Z(#`N,6EN)SX-"D5X97)C:7-A8FQE(&%T(&5N
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M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$
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M3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^#0HT+#(V-RPX-3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT
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M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!4
M15A4+4%,24=..B!R:6=H="<^#0HT+#8T-RPX,S0\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B0\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*,BXU.#$\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TP+C)I;CL@34%21TE..B`P<'@@,'!X(#!P>"`X-"XY
M-7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M($U!4D=)3BU43U`Z(#!P>#L@5$585"U)3D1%3E0Z(#!I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@-G!T.R!-05)'24XM3$5&5#H@,6EN)SX-"B@J*2!4:&4@=&]T86P@:6YT
M<FEN<VEC('9A;'5E(&]F(&]P=&EO;G,@97AE<F-I<V5D(&1U<FEN9R!T:&4@
M>65A<G,-"F5N9&5D($1E8V5M8F5R(#,Q+"`R,#`Y+"`R,#$P(&%N9"`R,#$Q
M+"!W87,@)#<L,C4X+"`D,RPP-3`@86YD#0HD,2PR-3(L(')E<W!E8W1I=F5L
M>2X\+W`^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E
M;G1E<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/@T*/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@[($9/
M3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>#L@1D].5#H@
M8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\+W`^
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M;F1E9"!$96-E;6)E<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#8^,C`P.3PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
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M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0V/C(P,3$\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B
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M(&-O;'-P86X],T0R/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$
M,CX-"E=E:6=H=&5D/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@
M8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
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M03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX-"F]F/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD
M)R!C;VQS<&%N/3-$,CX-"F5X97)C:7-E/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&
M3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N
M/3-$,CX-"F]F/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L
M9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX-"F5X97)C:7-E
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CX-"F]F/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C
M;VQS<&%N/3-$,CX-"F5X97)C:7-E/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4
M+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\
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M.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R/G!R:6-E/"]T9#X-"CQT9"!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/F]P=&EO;G,\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4
M.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(^<')I8V4\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!415A4+4E.1$5.
M5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N,6EN.R!724142#H@,C(E)SX-
M"D]U='-T86YD:6YG(&%T(&)E9VEN;FEN9R!O9B!Y96%R/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!724142#H@,24G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#%P=#L@5TE$5$@Z(#$E)SX-"B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%=)1%1(.B`Q,"4G/@T*-2PS,#0L-S@U/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!72414
M2#H@,24G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
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M0D]45$]-.B`Q<'0[(%=)1%1(.B`Q)2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,7!T
M.R!724142#H@,3`E)SX-"C$L-#,X+#8Y,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5TE$5$@Z
M(#$E)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%=)1%1(
M.B`Q)2<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%=)1%1(.B`Q,"4G/@T*-"XV.3<\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0[(%=)1%1(.B`Q)2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T.R!724142#H@,24G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@
M5TE$5$@Z(#$P)2<^#0HQ+#0S."PV.3(\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%=)1%1(.B`Q
M)2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!724142#H@
M,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0
M041$24Y'+4)/5%1/33H@,7!T.R!724142#H@,3`E)SX-"C0N-CDW/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@,7!T.R!724142#H@,24G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!
M1$1)3D<M3$5&5#H@,"XQ:6XG/@T*0VAA;F=E<R!D=7)I;F<@=&AE('EE87(M
M17AE<F-I<V5D("@J*3PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C,L.#8V+#`Y,SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
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M.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U325I%.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#%P="<^#0HF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/
M3E0M4TE:13H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#%P=#L@1D].5"U325I%.B`Q<'0G/@T*)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G/@T*,C`P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT
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M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U
M+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P=#L@5$58
M5"U)3D1%3E0Z("TP+C%I;CL@4$%$1$E.1RU,1494.B`P+C%I;B<^#0I/=71S
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M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
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M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
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M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C4N,S@U
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)
M3D<M3$5&5#H@,"XQ:6XG/@T*17AE<F-I<V%B;&4@870@96YD(&]F('EE87(\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C$L-#`W+#(S-#PO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N
M-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HT+C8W-#PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G
M/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C$L-#(Q
M+#<S-#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^
M#0HT+C8U,SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX-"C$L,C,U+#4V-SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
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M>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
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M<V5D(&1U<FEN9R!T:&4@>65A<G,-"F5N9&5D($1E8V5M8F5R(#,Q+"`R,#`Y
M+"`R,#$P(&%N9"`R,#$Q+"!W87,@)#0Q+#(X,2P@)#`@86YD("0Q+#@X-BP-
M"G)E<W!E8W1I=F5L>2X\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3$T<'0[($U!4D=)3CH@,'!X(#!P>"`P<'@@
M-S<N.'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
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M(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q.CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L
M92!S='EL93TS1"=724142#H@-S`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P(&%L:6=N/3-$8V5N=&5R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%
M24=(5#H@8F]L9"<@8V]L<W!A;CTS1#$V(&YO=W)A<#TS1&YO=W)A<#Y$96-E
M;6)E<B`S,2P@,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
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M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^#0HF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@
M8F]L9"<@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P/D]P=&EO;G,@97AE
M<F-I<V%B;&4\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^#0HF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#Y.=6UB97(@;V8\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(
M5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/@T*5V5I9VAT960\+W1D/@T*/'1D('-T>6QE/3-$
M)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^3G5M8F5R
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M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(
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M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
M;W!T:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T9/
M3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^879E<F%G93PO
M=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R
M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%
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M/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^#0IR96UA:6YI;F<\+W1D
M/@T*/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^97AE<F-I<V%B;&4\+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"CQT
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M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^17AE<F-I<V4\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/F%T(&5N9"!O9CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M#0IC;VYT<F%C='5A;#PO=&0^#0H\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O
M;'-P86X],T0R(&YO=W)A<#TS1&YO=W)A<#YA="!E;F0@;V8\+W1D/@T*/'1D
M('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/F-O;G1R86-T=6%L/"]T9#X-"CQT9"!S='EL
M93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P
M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L
M9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/G!R:6-E<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G
M(&YO=W)A<#TS1&YO=W)A<#X-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^>65A<CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X-
M"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD
M)R!N;W=R87`],T1N;W=R87`^;&EF93PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#X-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/
M3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^
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M/3-$,B!N;W=R87`],T1N;W=R87`^;&EF93PO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A
M<#TS1&YO=W)A<#X-"B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0[(%=)1%1(.B`Q-24G/C`N,#`Q/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$U)2<^
M-S$Y+#(P-SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q
M)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M=#L@5TE$5$@Z(#$U)2<^,RXU-#PO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$U)2<^-S$Y+#(P-SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(
M.B`Q-24G/C,N-30\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXP+C$R,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/CDX-RPS-38\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^,BXS,#PO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXY.#<L,S4V/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^,BXS,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.
M1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C`N,SDY/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^,C8L-C<S/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C,N,S4\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,C8L-C<S/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^,RXS-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXP+CDW,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$L,S(U+#DX.#PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXT+C0W/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/C$L,S(U+#DX.#PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!
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M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$V,"PP,#`\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^-BXX,CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXQ,C`L,#`P/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-BXX,CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI
M=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXR+C8U,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8P-"PY-38\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-RXQ
M-3PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SXU-S,L-34P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-RXQ-3PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T
M*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/C,N,#(P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^-3`L,#`P/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8N,3`\
M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^-#8L.#<U/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^-BXQ,#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXU+C`P
M,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/C$L-S(P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXV+C$P/"]T9#X-"CQT9#XF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$L
M-34Y+#(Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/C8N,3`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
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M03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C$V,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^."XQ,#PO=&0^#0H\=&0^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXW
M,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
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M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8N.3`P/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M,2PP,3`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C@N,34\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-RXU-3`\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXQ-C`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C@N-C8\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-3`L,#`P/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^."XV-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXY+C8V,#PO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C8X+#`P,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXX+C@T/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C$W+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D
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M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'
M+4)/5%1/33H@,7!T)SXQ-BXW,#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX-"C,X-RPU-#(\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$1$E.1RU"
M3U143TTZ(#%P="<^-2XP,#PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C,X-RPU-#(\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/
M33H@,7!T)SXU+C`P/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX-"C<L,S<Y+#<R,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX-"C4L.#@S+#0P,3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E1H92!A9V=R96=A=&4@
M:6YT<FEN<VEC('9A;'5E(&]F('1H92!T;W1A;"!O=71S=&%N9&EN9R!A;F0@
M;V8@=&]T86P-"G9E<W1E9"!A;F0@97AE<F-I<V%B;&4@;W!T:6]N<R!A<R!O
M9B!$96-E;6)E<B`S,2P@,C`Q,2!I<R`D,34L-34Q#0IA;F0@)#$U+#,W,2P@
M<F5S<&5C=&EV96QY+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+30Y+C5P=#L@34%21TE..B`P<'@@,'!X
M(#!P>"`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@34%21TE.+4)/5%1/33H@-G!T)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU
M<W1I9GD[(%9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)
M1%1(.B`Q:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#`N,C5I;B<^9"X\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&IU<W1I9GDG/E1H92!F;VQL;W=I;F<@=&%B;&4@:6QL=7-T<F%T
M97,@=&AE#0IE9F9E8W0@;V8@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(&]N
M('1H92!S=&%T96UE;G0@;V8-"F]P97)A=&EO;G,Z/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`V-24[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`Q:6XG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L
M<W!A;CTS1#$P/EEE87(@96YD960@1&5C96UB97(@,S$L/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L
M9"<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N
M=&5R)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^
M,C`P.3PO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@
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M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].
M5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.
M1$5.5#H@+3$R+C9P=#L@4$%$1$E.1RU,1494.B`Q,BXV<'0[(%=)1%1(.B`T
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M.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C
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M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q-"4G/C0R,CPO=&0^#0H\=&0@
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M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-
M"C8U,CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0
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M1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,BXU<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H="<^#0HR+#8X,SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H="<^#0HQ+#(X,CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<^#0HX.#8\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TP+C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-
M"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&YO<FUA;"<^8RX\+V9O;G0^/"]T9#X-"CQT9#Y0=6)L:6,@3V9F97)I;F<\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0I/;B!-87)C:"`R,RPF(WA!,#LR,#$Q
M+"!T:&4@0V]M<&%N>2!I<W-U960@86YD('-O;&0@-"PP,#`L,#`P#0IS:&%R
M97,@;V8@0V]M;6]N(%-T;V-K(&EN(&%N('5N9&5R=W)I='1E;B!P=6)L:6,@
M;V9F97)I;F<@870@80T*<')I8V4@=&\@=&AE('!U8FQI8R!O9B`D-2XU,"!P
M97(@<VAA<F4N(%1H92!N970@<')O8V5E9',@=&\@=&AE#0I#;VUP86YY('=E
M<F4@87!P<F]X:6UA=&5L>2`D,C`L-3DP)B-X03`[*&YE="!O9B!U;F1E<G=R
M:71I;F<-"F-O;6UI<W-I;VYS(&%N9"!I<W-U86YC92!C;W-T<R!O9B`D,2PT
M,3`I+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"DEN($9E8G)U87)Y(#(P,3(L('1H92!#;VUP86YY(&ES<W5E
M9"!A;F0@<V]L9"`U+#$W-2PP,#`@<VAA<F5S(&]F#0I#;VUM;VX@4W1O8VLN
M(%-E92!.;W1E(#$Q8BX\+W`^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S,V,F4U8S%F7S@T8V1?-&$S,U]A-#%F
M7S-B,S9E,#9E9C4Y90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S
M-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64O5V]R:W-H965T
M<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^5$%815,@3TX@24Y#3TU%/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y405A%4R!/3B!)3D-/344\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0G/CQB/DY/5$4@."`M/"]B/CPO9F]N=#X@/&(^5$%815,@3TX-
M"DE.0T]-13PO8CX\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N
M,C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y;&4]
M,T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X03`[/"]F;VYT/CPO<#X-"CQT
M86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-
M"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG/CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&YO<FUA;"<^82X\+V9O;G0^/"]T9#X-"CQT9#Y4:&4@0V]M<&%N>3PO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@
M,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX-"E!R;W1A;&EX($)I;U1H97)A<&5U=&EC<RP@
M26YC+B!I<R!T87AE9"!A8V-O<F1I;F<@=&\@52Y3+B!T87@@;&%W<RX-"E1H
M92!#;VUP86YY)W,@:6YC;VUE(&ES+"!O<B!W:6QL(&)E+"!T87AE9"!I;B!T
M:&4@56YI=&5D(%-T871E<R!A=`T*=&AE(')A=&4@;V8@=7`@=&\@,SDE+CPO
M<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XU:6X[($U!4D=)3CH@
M,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N
M;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!X.R!724142#H@,3`P)3L@1D].5#H@8F]L9"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P
M<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/F(N/"]F;VYT
M/CPO=&0^#0H\=&0^4')O=&%L:7@@3'1D+CPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"E1H92!)<W)A96QI(%-U8G-I9&EA<GD@:7,@=&%X960@86-C;W)D:6YG
M('1O($ES<F%E;&D@=&%X(&QA=W,Z/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4
M.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@
M1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^,2X\+W1D/@T*/'1D
M/DUE87-U<F5M96YT(&]F(')E<W5L=',@9F]R('1A>"!P=7)P;W-E<SPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X
M(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"E-I;F-E(#(P,#@L('1H92!#;VUP86YY(&AA<R!M96%S
M=7)E9"!T:&4@<F5S=6QT<R!O9B!T:&4@27-R865L:0T*4W5B<VED:6%R>2!F
M;W(@=&%X('!U<G!O<V5S(&EN(&YO;6EN86P@=&5R;7,@:6X@3DE3+B!0=7)S
M=6%N="!T;PT*=&AE($ES<F%E;"!);F-O;64@5&%X($QA=R`H061J=7-T;65N
M=',@9F]R($EN9FQA=&EO;BDL(#$Y.#4@*'1H90T*)B-X,C`Q0SM!9&IU<W1M
M96YT<R!,87<F(W@R,#%$.RDL('1H92!3=6)S:61I87)Y)B-X,C`Q.3MS(')E
M<W5L=',@9F]R#0IT87@@<'5R<&]S97,@:&%V92!B965N(&UE87-U<F5D('1H
M<F]U9V@@,C`P-R!O;B!A(')E86P@8F%S:7,L(&)A<V5D#0IO;B!C:&%N9V5S
M(&EN('1H92!)<W)A96P@8V]N<W5M97(@<')I8V4@:6YD97@N/"]P/@T*/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!X(#!P
M>"`P<'@@,6EN.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)
M1%1(.B`P+C<U:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I
M;B<^,BX\+W1D/@T*/'1D/E1A>"!R871E<SPO=&0^#0H\+W1R/@T*/"]T86)L
M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P
M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E1H
M92!I;F-O;64@;V8@=&AE($ES<F%E;&D@4W5B<VED:6%R>2P@;W1H97(@=&AA
M;B!I;F-O;64@9G)O;0T*)B-X,C`Q0SM!<'!R;W9E9"!%;G1E<G!R:7-E<RPF
M(W@R,#%$.R!I<R!T87AE9"!I;B!)<W)A96P@870@=&AE#0IR96=U;&%R(')A
M=&4N(%-E92`S(&)E;&]W+B!!8V-O<F1I;F<@=&\@=&AE('!R;W9I<VEO;G,@
M;V8@=&AE($QA=PT*9F]R($%M96YD:6YG('1H92!)<W)A96P@26YC;VUE(%1A
M>"!/<F1I;F%N8V4L(#(P,#4L(&-O<G!O<F%T92!T87@-"G)A=&5S('=I;&P@
M8F4@9W)A9'5A;&QY(&QO=V5R960L(')E<W5L=&EN9R!I;B!A(&-O<G!O<F%T
M92!T87@@<F%T90T*9F]R(#(P,#D@86YD('1H97)E869T97(Z(#(P,#D@)B-X
M,C`Q,SL@,C8E(&%N9"!F;W(@,C`Q,"!A;F0-"G1H97)E869T97(@)B-X,C`Q
M,SL@,C4E+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"D]N($IU;'D@,30L(#(P,#DL('1H92!)<W)A96P@16-O;F]M:6,@
M169F:6-I96YC>2!,87<@*$QE9VES;&%T:6]N#0I!;65N9&UE;G1S(&9O<B!!
M<'!L>6EN9R!T:&4@16-O;F]M:6,@4&QA;B!F;W(@,C`P.2!A;F0@,C`Q,"DL
M(#(P,#DL#0IB96-A;64@969F96-T:79E+"!S=&EP=6QA=&EN9RP@86UO;F<@
M;W1H97(@=&AI;F=S+"!A;B!A9&1I=&EO;F%L#0IG<F%D=6%L(&1E8W)E87-E
M(&EN('1A>"!R871E<R!I;B`R,#$Q(&%N9"!T:&5R96%F=&5R+"!A<R!F;VQL
M;W=S.@T*,C`Q,2`F(W@R,#$S.R`R-"4L(#(P,3(@)B-X,C`Q,SL@,C,E+"`R
M,#$S("8C>#(P,3,[(#(R)2P@,C`Q-"`F(W@R,#$S.PT*,C$E+"`R,#$U("8C
M>#(P,3,[(#(P)2!A;F0@,C`Q-B!A;F0@=&AE<F5A9G1E<B`F(W@R,#$S.R`Q
M."4N/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*
M)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/@T*3VX@1&5C96UB97(@-2P@,C`Q,2P@=&AE(")487@@0G5R9&5N($1I<W1R
M:6)U=&EO;B!,87<B("AH97)E:6YA9G1E<@T*+2!T:&4@,C`Q,2!A;65N9&UE
M;G0I('=A<R!O9F9I8VEA;&QY('!U8FQI<VAE9"P@9&ES8V]N=&EN=6EN9R!A
M#0IP<F5V:6]U<VQY(&%P<')O=F5D(&=R861U86P@9&5C<F5A<V4@:6X@8V]R
M<&]R871E('1A>"!P<F]V:61E9"!I;@T*=&AE(#(P,#D@86UE;F1M96YT+"!A
M;F0@<V5T=&EN9R!T:&4@8V]R<&]R871E('1A>"!R871E(&EN($ES<F%E;`T*
M9F]R(#(P,3(@86YD('1H97)E869T97(@=&\@,C4E+CPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T
M>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"D-A<&ET86P@9V%I;B!I
M<R!S=6)J96-T('1O(&-A<&ET86P@9V%I;B!T87@@86-C;W)D:6YG('1O(&-O
M<G!O<F%T90T*=&%X(')A=&4@:6X@=&AE('EE87(@;V8@<V5L;&EN9R!T:&4@
M87-S971S+CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[
M($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I
M;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SXS+CPO=&0^
M#0H\=&0^5&AE($QA=R!F;W(@=&AE($5N8V]U<F%G96UE;G0@;V8@0V%P:71A
M;"!);G9E<W1M96YT<RP@,3DU.2`H=&AE#0HF(W@R,#%#.T5N8V]U<F%G96UE
M;G0@;V8@0V%P:71A;"!);G9E<W1M96YT<R!,87<F(W@R,#%$.RD\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@
M,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P
M<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0I5;F1E<B!T:&4@16YC;W5R86=E;65N="!O9B!#87!I=&%L
M($EN=F5S=&UE;G1S($QA=RP@:6YC;'5D:6YG#0I!;65N9&UE;G0@3F\N(#8P
M('1O('1H92!%;F-O=7)A9V5M96YT(&]F($-A<&ET86P@26YV97-T;65N=',@
M3&%W(&%S#0IP=6)L:7-H960@:6X@07!R:6P@,C`P-2P@8GD@=FER='5E(&]F
M('1H92`F(W@R,#%#.T%P<')O=F5D#0I%;G1E<G!R:7-E)B-X,C`Q1#L@;W(@
M)B-X,C`Q0SM"96YE9FET960@16YT97)P<FES928C>#(P,40[('-T871U<R!T
M:&4-"DES<F%E;&D@4W5B<VED:6%R>2!I<R!E;G1I=&QE9"!T;R!V87)I;W5S
M('1A>"!B96YE9FET<R!A<PT*9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3,W+C%P=#L@34%21TE..B`P<'@@,'!X(#!P>"`Q+C5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X
M.R!724142#H@,3`P)3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,
M24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`Q:6XG/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^82X\+W1D/@T*/'1D/CQB/E)E
M9'5C960@=&%X(')A=&5S/"]B/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"DEN
M8V]M92!D97)I=F5D(&9R;VT@=&AE($%P<')O=F5D($5N=&5R<')I<V4@9'5R
M:6YG(&$@,3`M>65A<B!P97)I;V0-"F-O;6UE;F-I;F<@=7!O;B!T:&4@>65A
M<B!I;B!W:&EC:"!T:&4@96YT97)P<FES92!F:7)S="!R96%L:7IE<PT*=&%X
M86)L92!I;F-O;64@:7,@=&%X(&5X96UP="P@<')O=FED960@=&AA="!T:&4@
M;6%X:6UU;2!P97)I;V0@=&\-"G=H:6-H(&ET(&ES(')E<W1R:6-T960@8GD@
M=&AE($5N8V]U<F%G96UE;G0@;V8@0V%P:71A;"!);G9E<W1M96YT<PT*3&%W
M(&AA<R!N;W0@96QA<'-E9"X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0I4:&4@27-R865L:2!3=6)S:61I87)Y
M(&AA<R!A;B`F(W@R,#%#.T%P<')O=F5D($5N=&5R<')I<V4F(W@R,#%$.PT*
M<&QA;B!S:6YC92`R,#`T(&%N9"`F(W@R,#%#.T)E;F5F:71E9"!%;G1E<G!R
M:7-E)B-X,C`Q1#L@<&QA;B!S:6YC90T*,C`P.2X@5&AE('!E<FEO9"!O9B!B
M96YE9FET<R!I;B!R97-P96-T(&]F('1H92!M86EN(&5N=&5R<')I<V4@;V8-
M"G1H92!#;VUP86YY(&AA<R!N;W0@>65T(&-O;6UE;F-E9"X@5&AE('!E<FEO
M9"!D=7)I;F<@=VAI8V@@=&AE#0I#;VUP86YY(&ES(&5N=&ET;&5D('1O(&)E
M;F5F:71S(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@0F5N969I=&5D#0I%;G1E
M<G!R:7-E(&5X<&ER97,@:6X@,C`R,2X\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I)9B!T:&4@27-R865L:2!3
M=6)S:61I87)Y('-U8G-E<75E;G1L>2!P87ES(&$@9&EV:61E;F0@;W5T(&]F
M#0II;F-O;64@9&5R:79E9"!F<F]M('1H92`F(W@R,#%#.T%P<')O=F5D($5N
M=&5R<')I<V4F(W@R,#%$.R!O<@T*)B-X,C`Q0SM"96YE9FET960@16YT97)P
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M9"X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X
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M(')A=&4@:7,-"F-U<G)E;G1L>2`Q-24N/"]P/@T*/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-
M"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'@[
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M93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR
M-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ
M(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T
M>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)
M1%1(.B`Q:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^
M8RX\+W1D/@T*/'1D/CQB/D-O;F1I=&EO;G,@9F]R(&5N=&ET;&5M96YT('1O
M('1H92!B96YE9FET<SPO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I4:&4@
M27-R865L:2!3=6)S:61I87)Y)B-X,C`Q.3MS(&5N=&ET;&5M96YT('1O('1H
M92!B96YE9FET<PT*9&5S8W)I8F5D(&%B;W9E(&ES('-U8FIE8W0@=&\@:71S
M(&9U;&9I;&QI;F<@=&AE(&-O;F1I=&EO;G,-"G-T:7!U;&%T960@8GD@=&AE
M(&QA=RP@<G5L97,@86YD(')E9W5L871I;VYS('!U8FQI<VAE9"!T:&5R975N
M9&5R+`T*86YD('1H92!I;G-T<G5M96YT<R!O9B!A<'!R;W9A;"!F;W(@=&AE
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M0V5N=&5R+CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN
M.R!-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T
M>6QE/3-$)U=)1%1(.B`Q:6XG/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#`N,C5I;B<^9"X\+W1D/@T*/'1D/CQB/D%M96YD;65N="!O9B!T:&4@3&%W
M(&9O<B!T:&4@16YC;W5R86=E;65N="!O9B!#87!I=&%L#0I);G9E<W1M96YT
M<RP@,3DU.3PO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S
M='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#$N,C5I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I4:&4@16YC;W5R
M86=E;65N="!O9B!#87!I=&%L($EN=F5S=&UE;G1S($QA=R!W87,@86UE;F1E
M9"!A<R!P87)T(&]F#0IT:&4@16-O;F]M:6,@4&]L:6-Y($QA=R!F;W(@=&AE
M('EE87)S(#(P,3$M,C`Q,BP@=VAI8V@@=V%S('!A<W-E9`T*8GD@=&AE($ES
M<F%E;&D@2VYE<W-E="!O;B!$96-E;6)E<B`R.2P@,C`Q,"`H=&AE("8C>#(P
M,4,[0V%P:71A;`T*26YV97-T;65N=',@3&%W($%M96YD;65N="8C>#(P,40[
M*2X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,'!X.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C
M>$$P.SPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P
M>"`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@
M,'!X(#!P>"`Q+C(U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/@T*5&AE($-A<&ET86P@26YV97-T;65N=',@3&%W($%M
M96YD;65N="!S971S(&%L=&5R;F%T:79E(&)E;F5F:70-"G1R86-K<R!T;R!T
M:&]S92!C=7)R96YT;'D@:6X@969F96-T('5N9&5R('1H92!P<F]V:7-I;VYS
M(&]F('1H90T*16YC;W5R86=E;65N="!O9B!#87!I=&%L($EN=F5S=&UE;G1S
M($QA=RX\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#$N
M,C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@
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M,3`M>65A<B!P97)I;V0N(%1H90T*8F5N969I=',@<VAA;&P@8F4@9W)A;G1E
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M>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-
M"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,2XR-6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"E5N9&5R
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M="!T:&4@)B-X,C`Q0SMY96%R#0IO9B!E;&5C=&EO;B8C>#(P,40[(&YO(&QA
M=&5R('1H86X@=&%X('EE87(@,C`Q,BP@<')O=FED960@=&AA="!T:&4-"FUI
M;FEM=6T@<75A;&EF>6EN9R!I;G9E<W1M96YT('=A<R!M861E(&YO="!L871E
M<B!T:&%N('1H92!E;F0@;V8-"C(P,3`N($]N(&5A8V@@>65A<B!D=7)I;F<@
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M<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ
M(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL
M93TS1"=-05)'24XM5$]0.B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-
M"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL
M93TS1"=724142#H@,"XW-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C(U:6XG/C0N/"]T9#X-"CQT9#Y4:&4@3&%W(&9O<B!T:&4@16YC;W5R
M86=E;65N="!O9B!);F1U<W1R>2`H5&%X871I;VXI+`T*,3DV.3H\+W1D/@T*
M/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@
M,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P
M<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0I4:&4@27-R865L:2!3=6)S:61I87)Y(&ES(&%N("8C>#(P
M,4,[:6YD=7-T<FEA;"!C;VUP86YY+"8C>#(P,40[(&%S#0ID969I;F5D('5N
M9&5R('1H92!,87<@9F]R('1H92!%;F-O=7)A9V5M96YT(&]F($EN9'5S=')Y
M("A487AA=&EO;BDL#0HQ.38Y("AT:&4@)B-X,C`Q0SM,87<@9F]R('1H92!%
M;F-O=7)A9V5M96YT(&]F($EN9'5S=')Y)B-X,C`Q1#LI+B!!<PT*<W5C:"P@
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M/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*56YD
M97(@=&AE('!R;W9I<VEO;G,@;V8@=&AE($EN8V]M92!487@@4F5G=6QA=&EO
M;G,-"B8C>#(P,4,[06-C96QE<F%T960@1&5P<F5C:6%T:6]N(&EN(')E<W!E
M8W0@;V8@17%U:7!M96YT(&%C<75I<F5D#0ID=7)I;F<@=&AE($1E9FEN960@
M4&5R:6]D)B-X,C`Q1#L@*%1E;7!O<F%R>2!/<F1E<G,I+"!I;F1U<W1R:6%L
M#0IC;VUP86YI97,@=VAO<V4@;W!E<F%T:6]N<R!A<F4@;6]S=&QY("8C>#(P
M,4,[96QI9VEB;&4-"F]P97)A=&EO;G,F(W@R,#%$.R!A<F4@96YT:71L960@
M=&\@8VQA:6T@86-C96QE<F%T960@9&5P<F5C:6%T:6]N(&%T#0IA(')A=&4@
M;V8@-3`E(&]N(&UA8VAI;F5R>2!A;F0@97%U:7!M96YT(&%C<75I<F5D(&9R
M;VT@2G5N92`Q+"`R,#`X#0IT;R!-87D@,S$L(#(P,#DN/"]P/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'@@,'!X(#!P
M>"`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^)B-X
M03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XU:6XG
M/CPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/&9O;G0@<W1Y
M;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^8RX\+V9O;G0^/"]T9#X-"CQT
M9#Y487@@;&]S<V5S(&-A<G)I960@9F]R=V%R9"!T;R!F=71U<F4@>65A<G,\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!P
M>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0I!<R!O9B!$96-E;6)E<B`S,2P@,C`Q
M,2P@=&AE($-O;7!A;GD@:&%D(&%G9W)E9V%T92!N970@;W!E<F%T:6YG#0IL
M;W-S("A.3TPI(&-A<G)Y+69O<G=A<F1S(&5Q=6%L('1O(&%P<')O>&EM871E
M;'D@)#8S+#`T,"!T:&%T(&%R90T*879A:6QA8FQE('1O(')E9'5C92!F=71U
M<F4@=&%X86)L92!I;F-O;64@87,@9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P<'@@,'!X(#!P>"`Q
M:6X[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y;&4],T0G
M5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
M-S5I;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SXQ+CPO
M=&0^#0H\=&0^5&AE($-O;7!A;GD\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^
M#0H\<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I4:&4@3D],
M(&-A<G)Y+69O<G=A<F0@;V8@=&AE($-O;7!A;GD@97%U86P@=&\@87!P<F]X
M:6UA=&5L>2`D,3$L-S0P#0IM87D@8F4@<F5S=')I8W1E9"!U;F1E<B!396-T
M:6]N(#,X,B!O9B!T:&4@26YT97)N86P@4F5V96YU92!#;V1E#0HH)B-X,C`Q
M0SM)4D,F(W@R,#%$.RDN($E20R!396-T:6]N(#,X,B!A<'!L:65S('=H96YE
M=F5R(&$@8V]R<&]R871I;VX-"G=I=&@@3D],(&5X<&5R:65N8V5S(&%N(&]W
M;F5R<VAI<"!C:&%N9V4N($%S(&$@<F5S=6QT(&]F($E20PT*4V5C=&EO;B`S
M.#(L('1H92!T87AA8FQE(&EN8V]M92!F;W(@86YY('!O<W0@8VAA;F=E('EE
M87(@=&AA="!M87D-"F)E(&]F9G-E="!B>2!A('!R92UC:&%N9V4@3D],(&UA
M>2!N;W0@97AC965D('1H92!G96YE<F%L($E20PT*4V5C=&EO;B`S.#(@;&EM
M:71A=&EO;BP@=VAI8V@@:7,@=&AE(&9A:7(@;6%R:V5T('9A;'5E(&]F('1H
M90T*<')E+6-H86YG92!E;G1I='D@;75L=&EP;&EE9"!B>2!T:&4@25)#(&QO
M;F<M=&5R;2!T87@@97AE;7!T#0IR871E+CPO<#X-"CQP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,"XR-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@
M1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS1"=615)4
M24-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@,"XW-6EN
M)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG/C(N/"]T9#X-
M"CQT9#Y0<F]T86QI>"!,=&0N/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'`@<W1Y;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`Q:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*070@1&5C96UB
M97(@,S$L(#(P,3$L('1H92!)<W)A96QI(%-U8G-I9&EA<GD@:&%D(&%P<')O
M>&EM871E;'D-"B0U,2PS,#`@;V8@3D],(&-A<G)Y+69O<G=A<F1S('1H870@
M87)E(&%V86EL86)L92!T;R!R961U8V4@9G5T=7)E#0IT87AA8FQE(&EN8V]M
M92!W:71H(&YO(&QI;6ET960@<&5R:6]D(&]F('5S92X\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,'!X.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/"]P/@T*
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!X
M(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX-"CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N
M;W)M86PG/B8C>$$P.SPO9F]N=#X\+W`^#0H\=&%B;&4@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!X.R!&3TY4.B!B;VQD(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P>"<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^#0H\=&0@<W1Y;&4],T0G5TE$
M5$@Z(#`N-6EN)SX\+W1D/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C(U:6XG
M/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/F0N/"]F;VYT
M/CPO=&0^#0H\=&0^1&5F97)R960@:6YC;VUE('1A>&5S.CPO=&0^#0H\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@
M,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P
M>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX-"E1H92!C;VUP;VYE;G1S(&]F('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&YE="!D969E<G)E9"!T87@@87-S971S(&%T#0I$96-E;6)E<B`S
M,2P@,C`Q,"!A;F0@,C`Q,2!W97)E(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y
M;&4],T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*
M/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`W,"4[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@86QI9VX],T1C96YT97(^#0H\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#8^1&5C96UB97(@,S$L/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^#0H\=&0@
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M3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0^26X@<F5S<&5C="!O9CH\+W1D
M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU,1494.B`Q,BXV<'0[(%=)1%1(.B`W,"4G/@T*4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT(&5X<&5N<V5S/"]T9#X-"CQT9"!S='EL93TS1"=7
M24142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3(E)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$R)2<^-"PQ,3D\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU,1494.B`Q,BXV<'0G/E!R;W!E<G1Y(&%N9`T*97%U
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M1494.B`Q,BXV<'0G/DAO;&ED87D@86YD#0IR96-R96%T:6]N('!A>3PO=&0^
M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXR.38\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
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M3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$V-#PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M3$5&5#H@,3(N-G!T)SY$969E<G)E9`T*<F5V96YU97,\
M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^,RPV.3$\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXT+#<T-CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`Q,BXV<'0G/DYE="!O<&5R871I
M;F<-"FQO<W,@8V%R<GD@9F]R=V%R9',\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,RPU.3D\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXT+#4W.3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G
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M;W1T;VTG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HM/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^#0HF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*+3PO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#(N-7!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\
M<"!S='EL93TS1"=-05)'24XZ(#!P>"`P<'@@,'!X(#`N-S5I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0I$969E<G)E
M9"!T87AE<R!A<F4@8V]M<'5T960@=7-I;F<@=&AE('1A>"!R871E<R!E>'!E
M8W1E9"!T;R!B92!I;@T*969F96-T('=H96X@=&AO<V4@9&EF9F5R96YC97,@
M<F5V97)S92X@5&AE($-O;7!A;GD@=7-E9"!T87@@<F%T97,-"F]F(#,Y)2P@
M,C4E(&%N9"`P)2X\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3`N
M-6EN.R!-05)'24XZ(#!P>"`P<'@@,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&
M3TY4+5=%24=(5#H@;F]R;6%L)SXF(WA!,#L\+V9O;G0^/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P
M<'@G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/@T*/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D
M('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^/"]T9#X-"CQT9"!S='EL93TS1"=7
M24142#H@,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R
M;6%L)SYE+CPO9F]N=#X\+W1D/@T*/'1D/E)E8V]N8VEL:6%T:6]N(&]F('1H
M92!T:&5O<F5T:6-A;"!T87@@97AP96YS92!T;R!A8W1U86P@=&%X#0IE>'!E
M;G-E/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G
M34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
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M(&]F('-U8V@@=&%X(&)E;F5F:71S("AS964-"F%B;W9E*2X\+W`^#0H\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3`N-6EN.R!-05)'24XZ(#!P>"`P<'@@
M,'!X(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SXF
M(WA!,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'@G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I
M;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,"XR-6EN)SX\9F]N="!S
M='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SYF+CPO9F]N=#X\+W1D/@T*
M/'1D/E1A>"!A<W-E<W-M96YT<SPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO
M<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"DEN
M(&%C8V]R9&%N8V4@=VET:"!T:&4@26YC;VUE(%1A>"!/<F1I;F%N8V4L(&%S
M(&]F($1E8V5M8F5R(#,Q+`T*,C`Q,2P@86QL(&]F(%!R;W1A;&EX($QT9"XF
M(W@R,#$Y.W,@=&%X(&%S<V5S<VUE;G1S('1H<F]U9V@@=&%X('EE87(-"C(P
M,#<@87)E(&-O;G-I9&5R960@9FEN86PN/"]P/@T*/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'@@,'!X(#!P>"`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*02!S=6UM87)Y(&]F(&]P
M96X@=&%X('EE87)S(&)Y(&UA:F]R(&IU<FES9&EC=&EO;B!I<R!P<F5S96YT
M960-"F)E;&]W.CPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!X(#!P>"`P
M<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@
M-3`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&%L:6=N/3-$8V5N=&5R/@T*/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
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M)SXR,#`X+3(P,3$\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX-"CQT9#Y5;FET960@4W1A=&5S("@J*3PO=&0^#0H\
M=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^,C`P,BTR,#$Q/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ('1O<"<^#0H\=&0^3F5T:&5R;&%N9',\+W1D/@T*/'1D/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(P
M,#DM,C`Q,3PO=&0^#0H\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)TU!
M4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B8C>$$P.SPO<#X-"CQP('-T>6QE
M/3-$)TU!4D=)3CH@,'!X(#!P>"`P<'@@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"B@J*2!);F-L=61E<R!F
M961E<F%L+"!S=&%T92!A;F0@;&]C86P@*&]R('-I;6EL87(@<')O=FEN8VEA
M;`T*:G5R:7-D:6-T:6]N<RD@=&%X('!O<VET:6]N<RX\+W`^#0H\+V1I=CX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,V,F4U
M8S%F7S@T8V1?-&$S,U]A-#%F7S-B,S9E,#9E9C4Y90T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\S-C)E-6,Q9E\X-&-D7S1A,S-?830Q9E\S8C,V
M93`V968U.64O5V]R:W-H965T<R]3:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U504$Q%345.5$%262!&24Y!3D-)
M04P@4U1!5$5-14Y4($E.1D]234%424]./&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y355!03$5-14Y405)9($9)3D%.0TE!3"!3
M5$%414U%3E0@24Y&3U)-051)3TX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-
M05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQB
M/DY/5$4@.2`M/"]B/CPO9F]N=#X-"CQB/E-54%!,14U%3E1!4ED@1DE.04Y#
M24%,(%-4051%345.5"!)3D9/4DU!5$E/3CH\+V(^/"]P/@T*/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^)B-X03`[/"]B
M/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3<N,W!T.R!-05)'
M24XZ(#!P>"`P<'@@,'!X(#<Q+C-P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H\8CY"86QA;F-E('-H965T<SH\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/@T*/"]P/@T*/'1A8FQE('-T>6QE/3-$)U=)
M1%1(.B`Y,"4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@86QI9VX]
M,T1C96YT97(^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%
M24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
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M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z
M(&)O;&0G(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!415A4+4E.1$5.5#H@+3(V
M+C0U<'0[(%!!1$1)3D<M3$5&5#H@,C8N-#5P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/@T*82XF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#LF
M(WA!,#LF(WA!,#M!8V-O=6YT<PT*<F5C96EV86)L92`M(&]T:&5R.CPO=&0^
M#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
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M15A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N-FEN.R!72414
M2#H@-S`E)SX-"D1E9F5R<F5D(&-O<W1S*CPO=&0^#0H\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$R)2<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(
M.B`Q,B4G/C$L-34X/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,"XV:6XG/@T*26YS=&ET=71I;VYS
M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SXV,S0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
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M1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N-FEN)SY3=&%T90T*;V8@
M27-R865L("AS964@3F]T928C>$$P.S9A("D\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^.#<X/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^,2PR.38\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$
M14Y4.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,"XV:6XG/@T*4F5S=')I8W1E
M9"!D97!O<VET/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C(R-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(P.#PO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,"XV
M:6XG/@T*4')E<&%I9"!E>'!E;G-E<SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS-30\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR
M,S4\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M24Y$14Y4
M.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@,"XV:6XG/@T*4W5N9')Y/"]T9#X-
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<^#0HQ-C4\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*
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M:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C(L,C,Q/"]T
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M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C,L.#,W
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M;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
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M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=&3TY4+5=%
M24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT
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M04Q)1TXZ(&QE9G0[($9/3E0M5T5)1TA4.B!B;VQD)SYB+@T*)B-X03`[)B-X
M03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[06-C;W5N
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M6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[
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M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,"XQ
M:6X[(%!!1$1)3D<M3$5&5#H@,"XV:6XG/@T*4&%Y<F]L;"!A;F0@<F5L871E
M9"!E>'!E;G-E<SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^,2PQ.3D\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT
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M.R!415A4+4E.1$5.5#H@+3`N,6EN.R!0041$24Y'+4Q%1E0Z(#`N-FEN)SX-
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M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^,2PR,C$\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)3D<M3$5&5#H@
M,"XV:6XG/@T*06-C<G5E9"!E>'!E;G-E<SPO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR+#`S,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
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M;CL@4$%$1$E.1RU,1494.B`P+C9I;B<^#0I2;WEA;'1I97,@<&%Y86)L93PO
M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXX.#0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SXX.3PO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@5$585"U)3D1%3E0Z("TP+C%I;CL@4$%$1$E.1RU,1494.B`P+C9I
M;B<^#0I,:6%B:6QI='D@:6X@8V]N;F5C=&EO;B!W:71H(&-O;&QA8F]R871I
M;VX@;W!E<F%T:6]N+2!C=7)R96YT#0IP;W)T:6]N/"]T9#X-"CQT9#XF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
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M3TTZ(#%P=#L@5$585"U)3D1%3E0Z("TP+C%I;CL@4$%$1$E.1RU,1494.B`P
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M3CH@<FEG:'0G/@T*,BPW,C`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX-"C$L-#<S/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U
M-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[
M(%!!1$1)3D<M3$5&5#H@,"XV:6XG/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
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M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/@T*-RPU-#`\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CPO
M='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G34%21TE..B`P<'@[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^)B-X
M03`[/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE..B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/@T*)B-X03`[/"]P/@T*/'`@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!-05)'24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^#0H\+W`^#0H\<"!S='EL93TS1"=-05)'
M24XZ(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3$W+C-P=#L@34%21TE..B`P<'@@,'!X(#!P>"`W,2XS<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&(^4W1A=&5M
M96YT(&]F(&]P97)A=&EO;G,Z/"]B/CPO<#X-"CQP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,3<N,W!T.R!-05)'24XZ(#!P>"`P<'@@,'!X(#<Q+C-P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\
M8CXF(WA!,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M-RXS<'0[($U!4D=)3CH@,'!X(#!P>"`P<'@@-S$N,W!T.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX-"CPO<#X-"CQT86)L
M92!S='EL93TS1"=724142#H@,3`P)3L@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X-"CQT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)
M1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#$P/EEE87(@96YD960@1&5C96UB97(@,S$L/"]T9#X-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q
M<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O
M;&0G(&-O;'-P86X],T0R/C(P,#D\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&
M3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(^,C`Q,#PO=&0^#0H\=&0@
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M3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[
M/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<B<@8V]L<W!A;CTS1#(^)B-X03`[/"]T9#X-"CQT9#XF(WA!
M,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*/'1D/B8C
M>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!C96YT97(G(&-O;'-P86X],T0R/B8C>$$P.SPO=&0^#0H\=&0^
M)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
M3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,
M1494.B`P<'@[($9/3E0M5T5)1TA4.B!B;VQD)SX-"F,N)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X
M03`[)B-X03`[)B-X03`[4F5V96YU97,Z/"]T9#X-"CQT9#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`Q<'0[(%1%6%0M24Y$14Y4.B`M,"XQ:6X[(%!!1$1)
M3D<M3$5&5#H@-3(N,G!T.R!724142#H@-34E)SX-"D1E9F5R<F5D(')E=F5N
M=65S(&9R;VT@=&AE(&QI8V5N<V4@86YD('-U<'!L>2!A9W)E96UE;G0@=VET
M:`T*4&9I>F5R/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P=#L@5TE$5$@Z(#$E
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@4$%$
M1$E.1RU"3U143TTZ(#%P=#L@5TE$5$@Z(#$R)2<^#0HS.#@\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q
M<'0[(%=)1%1(.B`Q)2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`Q<'0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,7!T.R!724142#H@,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@,7!T.R!724142#H@,3(E)SX-
M"C0L-38S/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,7!T.R!724142#H@,24G/@T*)B-X03`[/"]T9#X-
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M3D<M0D]45$]-.B`Q<'0[(%!!1$1)3D<M3$5&5#H@-#5P="<^#0I2979E;G5E
M<R!F<F]M('-E;&QI;F<@<')O9'5C=',@=&\@4&9I>F5R/"]T9#X-"CQT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#%P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,7!T
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@1D].5"U325I%
M.B`Q<'0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5-)6D4Z(#%P="<^
M#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T)SX-"B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!R:6=H="<^#0HR+#`W.3PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0HF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0G/@T*,RPX,C,\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C
M>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0[(%!!1$1)3D<M3$5&5#H@-2XS
M-7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H="<^#0HS.#@\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S
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M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT
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M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P
M-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU,1494.B`U+C,U<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^)B-X03`[/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P>#L@
M4$%$1$E.1RU,1494.B`P<'@[($9/3E0M5T5)1TA4.B!B;VQD)SX-"F0N)B-X
M03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[0V]S=`T*;V8@4F5V96YU97,Z/"]T
M9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`U,'!T
M)SY#;W-T(&]F('!R;V1U8W1S#0IS;VQD/"]T9#X-"CQT9#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXX
M,#<\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P
M.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^.3@U/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`U,'!T
M)SY7<FET92!D;W=N(&]F#0II;G9E;G1O<FEE<SPO=&0^#0H\=&0^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXR+#8Y,CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/C,V,SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU,1494.B`U,'!T)SY2;WEA;'1I97,-"F5X<&5N
M<V5S/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H="<^#0HS+#4W-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-
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M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<^#0HQ-S<\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,BXU<'0[(%!!1$1)3D<M3$5&5#H@-2XS-7!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G
M/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HS+#4W-3PO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE
M9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HT+#,X,SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0HQ+#4R
M-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4Q%
M1E0Z(#4N,S5P=#L@1D].5"U714E'2%0Z(&)O;&0G/B8C>$$P.SPO=&0^#0H\
M=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-
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M,#LF(WA!,#M297-E87)C:`T*86YD(&1E=F5L;W!M96YT(&5X<&5N<V5S("T@
M;F5T.CPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
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M03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXQ,RPQ-S8\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL
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M1$E.1RU,1494.B`U,'!T)SY3=6)C;VYT<F%C=&]R<R!A;F0-"F-O;G-U;'1A
M;G1S/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C<L-#8Y/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3$L-34P/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3$L
M,S$T/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!
M,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2
M.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-
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M3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^-"PY-#<\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS+#0R-3PO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M3$5&5#H@-3!P="<^4F5N="P@:6YS=7)A;F-E#0IA;F0@
M;6%I;G1E;F%N8V4\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^,BPR,S@\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS+#0U-SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/C0L,3$S/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4Q%1E0Z(#4P<'0G/E!A=&5N=`T*<F5G:7-T<F%T:6]N(&%N9"!L:6-E;G-I
M;F<\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^,S@W/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^-3<Q/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^-#0Y/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`U,'!T)SY$97!R96-I871I;VX@
M86YD#0IW<FET92!D;W=N/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C$L-SDY/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,BPT-38\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXS+#`U-SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=2
M3U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU,1494.B`U,'!T)SY/=&AE<CPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"C$L,38V
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!L969T
M)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0HQ+#4S-#PO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'
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M5$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX-"CQT9"!S='EL93TS1"=0041$24Y'+4Q%1E0Z(#4N-'!T)SXF(WA!,#L\
M+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!R:6=H="<^,C<L,SDP/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^,S<L-CDQ/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,S<L.#$X
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R
M9V(H,C`T+#(U-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT
M9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#`N
M-6EN)SY,97-S("T@9W)A;G1S(&%N9`T*<F5I;6)U<G-E;65N=',Z/"]T9#X-
M"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-
M"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M3$5&5#H@-#5P="<^1&5V96QO<&UE;G0@
M8V]S=',-"G)E:6UB=7)S96UE;G1S(&9R;VT@4&9I>F5R/"]T9#X-"CQT9#XF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/C,L.3(R/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,RPT,S`\+W1D/@T*/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0[(%!!1$1)3D<M
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M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX-"C,L.#$X/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^
M#0HS+#,T-3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M+C5P=#L@4$%$1$E.1RU,1494.B`U+C1P="<^)B-X03`[/"]T9#X-"CQT9"!S
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M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX-"C(Y+#DU,3PO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF(WA!,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P
M="!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4
M+4%,24=..B!R:6=H="<^#0HS,2PP-#,\+W1D/@T*/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M<F=B*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P
M>#L@4$%$1$E.1RU,1494.B`P<'@[($9/3E0M5T5)1TA4.B!B;VQD)SX-"F8N
M)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[)B-X
M03`[)B-X03`[)B-X03`[)B-X03`[)B-X03`[1V5N97)A;`T*86YD(&%D;6EN
M:7-T<F%T:79E(&5X<&5N<V4Z/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF
M(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/B8C
M>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X
M03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
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M/C(L.#`T/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
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M93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4Q%1E0Z(#4P<'0G/DUA;F%G96UE;G0@86YD#0IC
M;VYS=6QT:6YG(&9E97,\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^-C@Q/"]T9#X-"CQT9"!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,C(Q/"]T9#X-
M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*
M/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^,C$U/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF
M(WA!,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/
M3$]2.B!W:&ET93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`U,'!T)SY2
M96YT+"!I;G-U<F%N8V4-"F%N9"!M86EN=&5N86YC93PO=&0^#0H\=&0^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXS-#<\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO
M=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SXT-C,\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
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M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^,BPR-S0\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR+#,R-CPO
M=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T
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M="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C,P.#PO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9#XF(WA!,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C(R.3PO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L
M,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`U,'!T)SY$97!R96-I
M871I;VX\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^,3DQ/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,S`Y/"]T9#X-"CQT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)B-X03`[
M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,S8S/"]T
M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D
M/@T*/"]T<CX-"CQT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET
M93L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`U,'!T)SY/=&AE<CPO=&0^
M#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T
M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)
M1TXZ(')I9VAT)SX-"C4Y-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^)B-X03`[/"]T9#X-"CQT
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M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4
M+4%,24=..B!L969T)SX-"B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R:6=H
M="<^#0HX,3D\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B8C>$$P.SPO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T*/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R+C5P=#L@4$%$1$E.1RU,1494.B`U+C1P="<^)B-X03`[
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M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X
M03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G
M/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B0\+W1D/@T*
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0G/@T*-BPX-S8\+W1D/@T*/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^
M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU
M<'0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B0\+W1D
M/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*-BPY,S$\+W1D/@T*/"]T<CX-
M"CPO=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7S,V,F4U8S%F7S@T8V1?-&$S,U]A-#%F7S-B,S9E,#9E
M9C4Y90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-C)E-6,Q9E\X
M-&-D7S1A,S-?830Q9E\S8C,V93`V968U.64O5V]R:W-H965T<R]3:&5E=#$W
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4D5,
M051%1"!005)462!44D%.4T%#5$E/3E,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)%3$%4140@4$%25%D@5%)!3E-!0U1)3TY3
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'@[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/@T*/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T)SX\8CY.3U1%(#$P("T\+V(^/"]F;VYT
M/B`\8CY214Q!5$5$#0I005)462!44D%.4T%#5$E/3E,\+V(^/"]P/@T*/'`@
M<W1Y;&4],T0G34%21TE..B`P<'@[($9/3E0Z(&)O;&0@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^#0HF(WA!,#L\+W`^#0H\<"!S='EL
M93TS1"=-05)'24XZ(#!P>#L@1D].5#H@8F]L9"`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\+W`^#0H\=&%B;&4@<W1Y;&4],T0G5TE$
M5$@Z(#DS)3L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@34%21TE.+4Q%1E0Z(#,V<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O
M='1O;2<^#0H\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$
M24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M
M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R
M.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#$P/EEE87(@96YD960@
M1&5C96UB97(@,S$L/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^#0H\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^#0HF(WA!,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD
M)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(
M5#H@8F]L9"<@8V]L<W!A;CTS1#(^,C`P.3PO=&0^#0H\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G/B8C>$$P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G/B8C>$$P.SPO=&0^#0H\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,CXR,#$P/"]T9#X-
M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B-X03`[/"]T9#X-"CQT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R/C(P,3$\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXF(WA!,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%1%6%0M24Y$
M14Y4.B`M,C`N-W!T.R!0041$24Y'+4Q%1E0Z(#(P+C=P=#L@5TE$5$@Z(#4U
M)2<^#0H\8CYA+B`F(WA!,#LF(WA!,#LF(WA!,#LF(WA!,#L\+V(^36%N86=E
M;65N="!A;F0@8V]N<W5L=&EN9R!F965S('1O#0IT:&4@0VAA:7)M86X@;V8@
M=&AE($)O87)D/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,BXU<'0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0[(%=)1%1(.B`Q)2<^#0HD/"]T9#X-"CQT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!724142#H@,3(E)SX-"C,S/"]T9#X-"CQT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0[(%=)1%1(.B`Q
M)2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R+C5P=#L@5TE$5$@Z(#$E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F=#L@5TE$5$@Z(#$E)SX-"B0\+W1D/@T*/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0[(%=)1%1(.B`Q,B4G/@T*-CPO=&0^#0H\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!724142#H@
M,24G/@T*)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,BXU<'0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)
M1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^#0HF(WA!,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!
M3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,B4G/@T*+3PO=&0^#0H\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T.R!7
M24142#H@,24G/@T*)B-X03`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R+C5P=#L@5$585"U)3D1%3E0Z("TR,"XW<'0[(%!!1$1)3D<M
M3$5&5#H@,C`N-W!T)SX-"CQB/F(N)B-X03`[)B-X03`[)B-X03`[)B-X03`[
M)B-X03`[/"]B/D-O;7!E;G-A=&EO;B!T;R!T:&4-"FYO;BUE>&5C=71I=F4@
M9&ER96-T;W)S("AE>&-E<'0@=&AE($-H86ER;6%N(&]F('1H92!";V%R9"!I
M;B`R,#`Y+`T*86YD(&EN8VQU9&5S('1H92!I;G1E<FEM($-H86ER;6%N(&]F
M('1H92!";V%R9"!I;B`R,#$P(&%N9`T*,C`Q,2D\+W1D/@T*/'1D('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(&QE9G0G/@T*)#PO=&0^#0H\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!R:6=H
M="<^#0HR,#D\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R+C5P="<^)B-X03`[/"]T9#X-"CQT9"!S='EL
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M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX-"C(Q-3PO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S8R935C,69?
M.#1C9%\T83,S7V$T,69?,V(S-F4P-F5F-3EE#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S,V,F4U8S%F7S@T8V1?-&$S,U]A-#%F7S-B,S9E,#9E
M9C4Y92]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY354)315%514Y4($5614Y44SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U5"4T51545.5"!%
M5D5.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P>#L@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^#0H\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0G/CQB/DY/5$4@,3$@+3PO8CX\
M+V9O;G0^(#QB/E-50E-%455%3E0-"D5614Y44SPO8CX\+W`^#0H\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3(P+C=P=#L@34%21TE..B`P<'@@,'!X(#!P
M>"`U-BXW<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/@T*/&9O;G0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&YO<FUA;"<^
M)B-X03`[/"]F;VYT/CPO<#X-"CQT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
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M8VAA<V4@,3`L,C,Y#0IS:&%R97,@;V8@0V]M;6]N(%-T;V-K(&)Y(&-E<G1A
M:6X@96UP;&]Y965S(&]F('1H92!#;VUP86YY+B!4:&4-"D-O;7!A;GD@<F5C
M96EV960@86=G<F5G871E(&-A<V@@<')O8V5E9',@97%U86P@=&\@87!P<F]X
M:6UA=&5L>2`D-0T*:6X@8V]N;F5C=&EO;B!W:71H('1H92!E>&5R8VES92!O
M9B!S=6-H(&]P=&EO;G,N/"]F;VYT/CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,C`N-W!T.R!-05)'24XZ(#!P
M>"`P<'@@,'!X(#4V+C=P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^#0H\9F]N="!S='EL93TS1"=&3TY4+5=%24=(5#H@
M;F]R;6%L)SXF(WA!,#L\+V9O;G0^/"]P/@T*/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!X)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"CQT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@=&]P)SX-"CQT9"!S='EL93TS1"=724142#H@
M,S9P="<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,C`N-W!T)SX\9F]N
M="!S='EL93TS1"=&3TY4+5=%24=(5#H@;F]R;6%L)SYB+CPO9F]N=#X\+W1D
M/@T*/'1D/CQF;VYT('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!N;W)M86PG/D]N
M($9E8G)U87)Y(#(R+"8C>$$P.S(P,3(L#0IT:&4@0V]M<&%N>2!I<W-U960@
M86YD('-O;&0@-2PQ-S4L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@:6X@
M86X-"G5N9&5R=W)I='1E;B!P=6)L:6,@;V9F97)I;F<@870@82!P<FEC92!T
M;R!T:&4@<'5B;&EC(&]F("0U+C(U('!E<@T*<VAA<F4N(%1H92!N970@<')O
M8V5E9',@=&\@=&AE($-O;7!A;GD@=V5R92!A<'!R;WAI;6%T96QY#0HD,C4L
M,S@Y)B-X03`[*&YE="!O9B!U;F1E<G=R:71I;F<@8V]M;6ES<VEO;G,@86YD
M(&ES<W5A;F-E(&-O<W1S(&]F#0HD,2PU-C<I+B!4:&4@;V9F97)I;F<@:6YC
M;'5D960@=&AE(&5X97)C:7-E(&)Y('1H92!U;F1E<G=R:71E<G,@;V8-"F%N
M(&]V97(M86QL;W1M96YT(&]P=&EO;B!T;R!P=7)C:&%S92`V-S4L,#`P('-H
M87)E<R!O9B!#;VUM;VX-"E-T;V-K+CPO9F]N=#X\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S,V,F4U8S%F7S@T8V1?-&$S,U]A-#%F7S-B,S9E,#9E9C4Y
M90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-C)E-6,Q9E\X-&-D
M7S1A,S-?830Q9E\S8C,V93`V968U.64O5V]R:W-H965T<R]F:6QE;&ES="YX
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/'AM;"!X;6QN<SIO/3-$(G5R;CIS8VAE;6%S+6UI8W)O<V]F="UC
M;VTZ;V9F:6-E.F]F9FEC92(^#0H@/&\Z36%I;D9I;&4@2%)E9CTS1"(N+B]7
M;W)K8F]O:RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^#0H\
M+WAM;#X-"BTM+2TM+3U?3F5X=%!A<G1?,S8R935C,69?.#1C9%\T83,S7V$T
3,69?,V(S-F4P-F5F-3EE+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>29
<FILENAME>0001144204-12-011082-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-011082-xbrl.zip
M4$L#!!0````(`+*!6T"6?N9Y[HD``&P:!0`0`!P`<&QX+3(P,3$Q,C,Q+GAM
M;%54"0`#__%+3__Q2T]U>`L``00E#@``!#D!``#L7>]SXCC2_IZJ_`]Z\^Y>
MS5P!L0T8G.SL%4G(+._.AA3)[,[>ERECBZ!;8W.R2<+^]6^W;`,VYH<``YG=
MK;J;8&3I4:O[4:M;$C_\ZW7@D&?*?>:Y'\[4DG)&J&MY-G.?/IR-_*+I6XR=
M$3\P7=MT/)=^.!M3_^Q?/YZ>_/`_Q2)IWGQL=$C;=9A+2:OX"PTX>R5?+.I0
M;@;PR,57+4IN/&LTH&Y0(%W3IS;Q7/+EJO.):"65D'X0#"_.SU]>7DK4?C)Y
MT1,5EBQO<$Z*Q;BQ7T.<%X3H);5<JL]\U?%&KGU!U)E'UYR:`10G-@"Y()JB
M:D5%*VK51T6[T+2+:OG?LZ6]X9BSIWY`WEGOH;!2+<(;:J*#!>B.52(-QR$=
M+.J3#O4I?Z9V*:KIM<L=`B)U_0]G,YW"QR6//YU#O>5S%LGD+"QY@=\Z2\I#
MTW^@T";E\4&B_$M9E%8-PS@7W\9%F>]5-+6V#$Q88E*WS[)JAJ+J^9=?/CU8
M?3HPB^D>6"#]@(\G;XHF?&J5GKSG\^C+<Q1G45&+935^S:8L^Q7X(J,X<Y^I
M'V2_$7Z7\9+KN>YHD"T`.^#GP7A(SZ%0$4I1SJS)>ZM?2KXP=%X3+PRY%Y@.
M>Q5*C+A4;8H*+.O)-(>3%WJFWQ6U1U]D=`2^P6;]S'?$-QDO(6H[)>1H//7S
M\,M$T2"S:#4L&IR!BA,BE-RY\(4J=&B/"(V[0`@?SGPV&#JH%^*9R2WN.70]
MW19O]#GM?3@#619CD95>?7L#S5_?J,[#7H'.733=@`7C:V\P\-R'P+/^>.B;
MG/KM42`($$B16)X;T->@@S"IYWR];U;U6KD(_P%<I?BS`I+]^O!X\U7YBHRC
M:%KY*Y#JR&7A.[ZH\8S8U&(#TX'A;-W=GOUH*'6U6C;T'\[7PY'&?#_J.LRZ
M=3PSD(2H*GI924",*.'KYX>;69S*V8]EO:J(_V9ASC0=HHIT^.+:]/L-U\9_
MFO\=L6?3`?[W&\&UR?D8^O"KZ8RH'%J0$JC$.FB+Y;,?*UK5T`5:*4C)7@CY
M]SW'ALD'WPG&N4*NE"NU!.3Y]O/!][52U0RE^EJI*(:V)MIBK:JHBAS<[2QJ
M'FVE6E=7VU>M:I3K2M68`9IM4OF)-05TB5AK^F$UH%K6C?IZ4%75T.JJ%-P\
M:,&0L3'HKGYX6I""K%;K]?)^E<+8@A9@3JE4]\L+<W#7XX6Z4J_`F[7]\<(J
MH$L5][`J(,,+FJ95-2FXGYC990X+&/6O1YR#!4IZ,HJ41=4-)6E1\^TG\34L
ML9+Q[\VQV75H.^A3O@>@=46O)W`NP9$$?$-[%![;'?I,W1'=`]9*54_*-!M"
M$F:'!B8LKNVFR5TP-Q_Z-QJ,'%BTV_`ZLUBND(MJN5JI)"6\&E&V9G2H16'R
M@$&YH\$>Q%U3U'*F:F0!24'V?1KX>8+3*S5@C00ZT682A]#>*5Q_/X*#15F2
M2A?#F#,I5(PKZL(?P;UCNF&G;CV.'Z+G_IWG6OGWPJAH:6.3`[>4+O;3AVJU
M4M>74<8BM#.+XPT<1DD*3BI+NNDDL)8+N`./CT&'<IW`<`:;A37;\+RL6#`0
M/BUXN8`)6(VZ%LQTNT7XZK,+ESD?S@(^FD96,B;8/2E73:T8B^;X-11KV^C/
M/-A%7JBJ5>K`EYDZML(A#6U\'Y.[7BZ7,P@]DRCOJ8NA>E`W0:WWGA]P&C!.
M40OGB<K?NVZH>LI5V0GBW%>Z<ITL5PTEN0S;8*6;\C<?N6GOPY?4M9JVS.^=
MQ;'0@N]-WN8/`7INHF?WE`MSVB7PKT/*O\X;-G1!*2F*FFG3BW`M)$P8LVV7
M<]NZ;ZO0I+3&MAEFWTSGWF1VR[TVARPPG1D9Y&K=6D6I5)+JLQ+0;E?/LLL0
MM:S)17CFIHB6[X^H?<`Y*@20F@BX!_81C)$S`]`;[,D0*35O]ZA6J2858!F2
M%9)MC(*^Q]F?^4E7C1(KV6YF&L5"FLAUM:DKJ8C.3,/YV,YFP<?Y!7W.P<=Y
MN&L&'^=,*N?@XTJ@QQ-\G(,J%7R<8__<@X^J7/!1-PX5?)0"6A,<>K#@HQ16
M7=62*GJ0X*,4Y*):4XU:,M][P."CG`Z7:Y5,U<@I^"@%KJK6E>K^@H]2V,KU
M<G+$CR7X*#?\2F4NU'\,T4<Y-0&W8FG"(J?HHQ3(5'PTM^BC%"BMMO_@XPJ`
M^0<?Y73+2`=H]QM\G`>[R`O%I)U:K>T[^"A'FEK%4#,(_6B"CW+D64NM]7((
M/HJ*]MXSO9K:6K,81OZQ4DE&4Y14GN>0L5+)>:Q\-+'2I<#?3*QT2V_SP+%2
M.3+"&,"!8Z5RJR9-5VIRFV1W$RO=Y92:<ZQ4,ARAU9+4=XA8Z=K2/4RL5"YN
M4JO7]Q4K5;>)E<[''_*.E<[!73-6.F=2><=*5P%=?\F6>ZPT#54F5CK/_JO@
M?N2>[P-#]&2"8V6]*KWKN5A6ZTGEG&DZ/87^9^2'J\Q';\'T)11&G#X$NAB"
MQRV.!W8H=-%G`7V@_)E9Z%XP#];_EO?DBEHD/<]-.JKIJ=W=>7=G;MZQ*+7]
M6^X-Q."WAUC2;[Y2;C%?ALDWZGTJ%KX2SA+TX*.W>PMGKWS[45O2C>6XDAW"
M^!^L.:#T,[-AW3?^#'UNN2UQQ!%XKF$%[%ER"MO(_'0U%>)='UDZ*F5Q"IIZ
M0\-_6^Y\L#C?OJB:ENS*.I#2J0(1$LQ9Z.5Z>B]RV*I$A",*%&"HC;/N2-A.
MOJ!3N4%I=&OI?WN(1\KWJ/\XXVOKZ'\&LK3JL$%WQ'TA@&A$\\5>K:6@9T'(
M<.RNTO/)GB>^;!#KLDD4[@#%@R<<UE<;N?L;<7^MOBZ_+`.9LG)S+%P`3*',
M3";"J/8^&Z3T21);RH,TF?L)/+FVFS$Q[FFV+J:VMZV'*<-Q#U?R-R,.'0Z]
M+>%B'8$C)0UOCH=!B[T!1;'D[NE74CL-$JVGZ=2G)K<P.'L#3.9X8FB:K\@7
M>7OJM;*AI(AU"9@D;K`5RI[<,!!KC1^Y"?QFX1#$RO?9!;)PY((G&[E#J2B]
M#+)T_,</VKV]S&EEF-1249^9MK.I$U9/%M@NIP=:$^BJ4<WDS=7`4NF<V,?8
MHTD:>I(B,S#(*O@5[4&91_,U[\G*D-3O";!UTE(ACZ:G^+P7!GHM%?24P);L
M5;/7HQ:83O/5ZION$^V8`6V[V?7EVRLC.4XRP.171/N9(?24P:\/;)6;F]J<
MDC-S57156^'2I@"EG#SH&S<=]'/M`7,9]!O(XYGN911J:FH#Z`HT:ZU`;YEK
MNM8>?>ZT0[<^KI2]1WL)X]0I++"8A0X+<T;!KGV-!3E>#7.\E9D4[PI080^&
MSNO%#1URJ$:L!!L#CP?LS_!O&$O<!-(:#$W&\Y_+52-R_>1`33L2&U#+G5GR
MA0NH0_@FE:I6G?1'&MNT6[$'/./^8D'WB;F4XK(CLC&I+.9&YJ+JY?JD1Q*P
MIGWYC>+%?M1N/`-;/-&[T:!+N=#,2"VW2'\M[-*\L2AXW,*H:/5*U!EY7#FL
MY39*,4JM[!:L6,/.[71%+9M_K!A*6:W55RZNET`]4.Q@DP1FTH79,HYPK+FY
M3=*E!\[4[5]I9&13SSAUM;G:;)%FECSJ6M>3^8LWDV66/12;VI/RQK/,DI=!
M*'-;G&2RS/DE924/"M<,8ZVDU$&2LM*&E_0,]I>4E02JIZ[:.5!65O*6HV2,
M]VBSLI(&4*Y7]+6V)>PE+2MYAKJ6\H7WE9;=<J8XGK2L[+4*BI8^J'3T>5G)
ML4J=)MPJ,9N[?RDY9V==+GR@A*:DXFEUPZBG66HO"4W)*X)J>NI@U9$D-"4U
M)=6)`R4T)6_4*J<6DP=):$K.8/7JT20T94W2,-*'TPZ8T)2\ZS%U">Q1)C0E
MQP-C"^O<PWWHC*8D$]7?0$I3=HY(N1B[2VG&Y\;S=Y/FK\M<@B7G3*RTH:3N
M*CQL)E9VD9_Z.8,CR<1N%STZDDSL1C<3BDQL63^J3*PD(:G13:1'FXF5C-2(
MJRZ/.A,KV2'#J*K'GHE=ZW8^!6_@-W3\K8#M,K'XKI@NT4'ST4/+F[,JNJ)-
MQB#=]!04\IA#_<FBN=V;74KG[-9.\"U'D<,Z?J-DMM2J/O]D]J87#U:4FE:N
MOJ%<]A87%Q)F?SCKN<R&=PV8QC7U*_@CZM?H$+D!D^$WF^G>[A+%@V8+]Z]2
M$K+945P2?T,O_EW46^9;($SQWBT\D^>U^(*"'V]_#W^>;V'5T]:;XA?\?O6<
MD1N8?'S+',JW:/G.F_UAP%2UTU;Q.AH0TL-XT/6<S5N[__0E;"Y17[IS'?HD
MEAAN<&<.Y"UHVEJG_=CXU/I"KEKMQY^:G<9]\_-CZ_JA0%IWUZ79?B=;3..)
MKN'IT"&ZJH`Z,(-M1OMWZB=^-#*S^BF(!FB$+;3",>4]IDFK/;`%&K:;J#'=
M6S'TUV9`GSPN<:M!NKF&%?^BL$U$E;-=3K2QR+)^!P]T2[O"O[,L:U+U?-N/
MX^$6*H=?)AO$^N9;"4V["0LV_,GEK?I75+5B.=7+1/5SZ@P%8#7?<FWZ^C/=
M8H@5<?V6KM75A#HGJT^W_AMUG)]=[\5]@!63Y\(2'$F8[XK!%E0_11%9VU0/
MMAZ$XNP(+*I^=QNE)&^*2MWY^78V2LG=N)FZO^6M[Y.2O`<O%>R5VR<U?WG,
MG1?0&]!@Q_-'G#X"\"M'ZDJSM(G\PPDN;?;\CZ?@\O0$/PR)'XSQ9Z8?FU\>
MBZV[F^;=XP51F'M)?FET/K;NX,/P]9+<MO&YJ@P#\L@&L/R^HR^DXPU,MQ`^
M*!`8)]8[FU;=`Y!Q[?AZ\:'U[V98ARB%9;KXQUW[L4EJI(@/SKOQ5^?X/GX@
MDX(//S4ZS=.3Z\9]"_R)5/'AJDX5E5(UU:_)_U3\8A=]_*W9^O@3U.)Z'/0B
M[*<Y&%[^[VM#278K#3H0F\:BND*,Q<?V?4+^X*/9:P",^UB\:C\^MG\159P1
M<`,<?VABB!5C,^+ST+3M^/,+LX/^AS.82;Z?Z6'`8TR_-CO@M#4^%<&5^PCR
M"[SA;#D[+O=;Z^;Q)V@3I3T9Z//`7EI6FRV\CE3-TKPTDVW@WQT,./G$ZY&@
M3PG2B^F.HP$!NS`N?1+>?T:$\<W5<A[PV0\X1!EJEJ512JE6W42IDLJ2I=0[
M;.UQD5"L4"B^N$"1^<0!KQS8$QZA'.]^?V@2\%U?B>G:A=,3G[D6A8J'`<6(
M'M$+!!>)A;C\(W5(XYD]AT(F<3JO1)JFU2<BT')Z`F,T.Q38*D5/PH%V`P^J
MHN09Z+!$$'3$DCBP89P&_@)BF'T?K]\$9O82M7"Q%Y(2X$!F@^_MDY<^=>DS
M@.Z-X./I";[FT"?3<<;$?#:9@V->$,6PMX3UD/0=*&:3[EAT[\HSN2T`W#!H
M(/"X7R(/0B8,E`__$+Q?F%5"TC=]T.=@6AL\/#V9`"O]36I_/5+KKD5JH7X+
MAPD-=>(Q_=78J^V2&[!G03EJ!3E'T0L)BR03@R2F[0V1PO!K\,O`[62OIR=7
MS`,ZX>:0C@)F0?TMURJ)BB(6@<_('T`9F#LB[^#U23>!XZXO\?'T\\WE^Y"@
MGC"&@0B\*!<`Y-/RN4D=1NA@Z'AC2H%M@',`O,"$U0/G^:/N?P`REL?'`>4#
M>!BP8?@[%L`YIR</5&Q7\:?B5A5-L!/\VXAGN[BY,,9.<)]-F]LBRTI+IR>"
M>T-T$=J,UKF)WF;?\X'](K:+^`MHGS),C)`(#;9-O,3')5!@]&(L!8%\..+^
M"%$D.HX-4*^79$XFB!.HVG&\EY#7@4+9`"J"<78)C7+S/4`30*^AZB'TP`]K
M,0=BR^KIB06DRX+P_<F0B"I(-]R(44#N=D8B01:]AC.(QVVD:ZC"-X&ZQW%Q
MI/K%?H89[97%2J$6?XARQDDCUA`Q"&DX206!>0AD+C[2UVA6$77@DQ>/_U%D
MH80C1((>8.9TL2L]G&$*,-^@:/%6]'AZ%@W#U&/B['H+0HN'R_7<X@1**#TQ
MV\9J,TSJ+,#P)L-??L?>KZ6)^V"*_?)20_@E$VHJJ\(=@O^OU`J&IDP]EJ3#
MP^G`9"ZH=>QU"`4.33.I!M^@S%#M8CM%R<1:BJ:'W>Z9C)-G$;^(E"IE-D+Y
M9LP8*"5#?3,M$S"93V(#%AGYR,K9#<X.UK<X`MP;D/\SW1$RFE!9Q8!^<V_T
MU,]2YEE&GHS!S&QG48Z_QK1L3)!L>QZRN'^QMKNKK>/OKNE3KA3TM^>_UC9R
M8-72`E^TO63RNMC0(948\>B[G1G6.N/]1H9:W62<S?<+QOF*@I7B7&^22$:C
MP<#D[$_A&SE.DI5#=4`:`"]Q8NTXG5'A=89E@5PH)6-J\HGG-!1!7EBRHX<5
MD\[I2<PZFVK45J',]90EDF5=^3YNH;ZVFGQJWB*B<!A6Z<DZJM'U@L`;9&K'
M5;MST^Q,-+/KH(>O`E3?<YA]283Q1=7@TH?RL#^3Y2K2'8#R$*.+.R*!TU]@
M!?7A+/Q7M(H)EZG@O)X(X7)R'B+ZB-JQ1"_O&S<WK;N/$Y``+Q-$1L-SXW6H
M%O8CYSNOE!#S].^0EY-RCTCZ;\GO0/)Q#B<IX2%G%IVBY!CF_%O<ZX@[`\"O
MX8'+*8IP=O@6>KM"N6YA\3&%(U8A23TS@^G73W^SZ<YL>LCX))0ZE?;]H?0N
MX=U,I_NKQO7/'SOMSW<WQ>OVIW;G@O"G[CM-J12T:K4`_[Z_)!(NP:SP'-H+
M$G+"%W`I^,\EW9^K("-#,.]2KC7P\E5GO<DQ#2A>K8*0%$4YDLYD*<1W4GW*
MJD$KZ=7#=S`T0U'YYR$L"<#Q9_0Y#+/``B`*#YR>#)@#/.^YU,]2L>T414Z6
M8J%;4/3ZX86W"U57E7!MM<,FU^:CESX+Z.Y)Z!L9&$TI5/[FH/UR4&6A,>R;
M8C15.[QDWCK!Y.WPJ,=BGMN.44%1]6_>X]%+QA%T<(9MRE%8$_=147&JF8Q2
M3I#8\61.TB03-^@(&*I:T&OEP\OSK7/4]D[0)<E86<ZQU>F))%]E5[NVI+=Z
M><=8YD9]<7T5K2Y)A,<OI^R(@I3%RU2LE\I:\3NCI.MO4(IQ7&BA?JQDBCTI
M_@Z&3S@Q!;52>X/CM%]6V&""V`C<83S;2Q)G@[_?9C#B2I2=U")1R>25*)P:
M'2&1T069T'$*9V:CB8#MK@%$RCJ5]VX@R/91;FQVHQ-9,\ZFQCZCKULD'7:K
MP=M-6E$UY>K^FMX)?\P/R($(Y"\G@WW&:O>\O#OR-:>&.80CC_!NV+V=5+6?
M$,QQZL8Q">MH^[/YN:6=;PC-H[5_BA-"DX`?><$S)V%@$(^59!P>4`RQ>5H<
M/HJW6.-UY%">N:0W<ARY#>GYB2G+=]GV('DW0UW"9_M$<03"W6%K#S3`_;A!
MGW3%SEX\U1-MVAV8-DT=]DILZSX]>3<]%L5I>"QM:'*\:_$]L<4E3M/]O45<
M72?V]9Z>S)TF(._\D=6/`9C#(;X3;0D.=]F:7>^9OM_)*8'21J/C[/U<[%O9
M9YX\YKK<#]_@3*RZUIG8=6MKN>26=CD><@F)M1"R:N;!H*QCI,,A]YZC<Z09
MASQ/3X8C;O7Q!G!=JZ`3N.BX5W3.,:MA@`.S08\T7ZDU$H=/V[T>L\!@<!:(
M,T9>^"P\5S/=91]NKI_T*#PQ*$Y%AAM6B=BC2NA_1Z:#(+[#5#T::`A4'%]-
MSC)SQW06CL4&YSO25XT<EYT>%68\41GM7TL?@L-A.CUA@P&U&?"Q,P[3C>*\
M:^:^*V(YS&46J`!H#PXW#3<^P@/XLX>-XOT%T\U9>`4"`XZ>/B&#$>A&%Y1E
MXKR@KJ%FNN&QCA@EGBS%OR-[X0GH+\QQ3D^ZXK1CC^*!W/`$=?P]Q4V9-*[:
MC*<2J"X.W9(>]P;AJ;U$2V$]T<^VX)TYX>U#L8GX,Q@HWD"!I^C]'L/9#)K@
M:!QS?EB)X&_>X.'5)V=<2%9S>H+U"'=L'+MG9K#8EYO,KCR\U.A/G!MGSM)$
MYYC#@S-)P-$L*Q"]'05^FT8'5A?MV,JVNAEV)%KU^SDC0.V<-X/I4>[3D_#D
M+Y[PC945WE>UB*/A_SAXL*!3>#&BU4>.QPM+RCJ!V23H^Z7P(A=)@YF%%!T-
M"0UFU1E9T_='@V@&]!G,.TS8S(`&?2\\ALMISQ&W"$1*;*$E0#$*WSR9PGB2
M^IQH^/1DY"^J'@43FI"?L"";V>(RE;[YC(8\PJF1(=@^\_%G"?Z_O3=M:AQ)
M%X6_.\+_05&W^HVJ$\)E>:>W"*J@^C!3!5R@YMP^7RJ$+8.Z9<FC!8KY]>^S
M9*92LFQL;(,7=4Q/@Y%3F4\^^XJ,3@E`.+2-Q#WF#O0`HI!ZU)%.=F-'+C9F
M0/;)'`]U7[B5$8)*G0:KDX$*'2G&/7=$O004L`$0@'34`,:A7EY2#\`M`M=T
M?&.<W'ANG^\5].+G$'*IZ>Z0IMM8EZ8KNC&M2]%5.6935%U3FG+V[2TR@-@Q
M!=E,V<ZBVJ]>9)IM]?6T]HNI8TBUP#64^IMA\!K_);9K3]JUU4H^SPNW\/GX
M*'LL!JG-\MWVW%LO@1,@!&UO:&.'#BSLP6K:##\$]N#8LG6-_0`W187SFIIV
MP+V`^&^PAC\PC5L`'.[#CF5AK5+JE":$];Q!$D?(!#.VR#B(T`K!-H-AX)GX
M#33X:0\S%WP03:W@H#=(^-CA)G:]&=^P^W%"S;:"?C_!QEE'$3'D*/%`1OJ!
MN)>#R79'JL\+OC15H0H\:)0@96F5DNE/UQE<`=TKBN&V19>75$Y)5:Q:85$O
M71P3=SRRP[\=$N%/W#9HZT-#W/;*C:I2+.R06&@^2RR(X!YE&^1JT8J%!&<1
MSFB3,J^0R'0!285$IT[9=PH]IKA%!,,&ECZ=8_>LU%^!']F&#_CA*'DA9`-E
MV&K'*;0K!;..05G$]_KP_3!"F2G]*#FM/?%QU(;!W6F(+8,<\%PGY-6';@@B
M`\T`^?V,+!%OXZ<FWY:SE)7/GPT$Y"I=6)E6TBV$U"Y`?3^55Z3+HO6(QG':
M:X&::ME#>*;D/"7GF0'1UJH54M4B-+VK-:NFS'5F^&#GY!U/*Y+=6EMSHTJW
MVB0C;,VY(Z'1+KX13-*=[<\5>NPP2$)=C=6ZRZ5L3'HD`E_TQ9K&NN!6P)HE
MXI)<++V?&9Q,N#OFY&2&+7A9)JZD<31CEB`D/,S`8SXID'/=H%8[30I,4LPJ
MV.LJ8YFO$\1]F1=MVME*L;B#8K&]:K%X!@SY):5BIS>7"!*B</&((A:(E!)H
MMR10R<EVD)-UUJ;@/\?E/`H&'.M)^S_GC>AQZ-R[01)YCWK'2>9%0H'G")%E
M8@J3\P/H"2^'.0>%H'(Q//9/PJ8Z->,HSI`:[Z=/SD8S$YG5X\:9>&_6<9MU
MF](>0D?X2+&U-$_]!J;CBKFUTE&>Z3LK7;YH4-`*.)P>5Q`=I2FX#8SV%I#9
M=Q@B-T[:J!J#_8'O<U_F:D5Q6/UXT8M[`LK&G5.)_CD4?S.M<>?U1"_C?+]Q
M+6./_4/%67HB;P'IFO'^K64V>G7Z\&W7[#7JLJLY4*'W**1^]M5.ON<\HF>D
MPJNJ(WE&V&$\6&[P(\K0@ZO^7>"AB*:5#E#]P`<`H1U/5R&DJQX3,WCRL&'S
MZ&$.8C,@5MA4="UMA\5E=]+.H@L@\DNV%GU.(OY*JD<7[PZW:'>AUZN,7<G9
M9G8'V*)BUOQ6&[4V=MK+Y@DA.<H'&?WI(T%&[=Y/Z9\O68=!+L\;.!;C=XQ'
MU_$6Z?@G=O*,2K'""Z;EC$&0`!^86:*Z2#WC@F_*E:WUY+OJ/\UXQ]QW-G&"
M$M:O!^M7;6FR"!%/)=P3F9AU'WB@T7IN_+@H1JT5C=:-.V+];GL%"/.4]EE"
M;W'H;:/$G$ILEV[T]\$0`\HN*ASHT,/YTON(,HU:MU62W//AUZPUFJ]/=)LO
MULAUE7K0FK^@6V?1?D4[@S6'M45::,[$F><8<#L#QUYMD5['SX3CCE=S7^M%
M#JGVB7XMSED5/BVM$D%[2@[ORXZNI5A5$)$/#%->[9`<0O2C[SJB7B*48KA:
MR<AAS;F5V45P$SGA/7F$M:<Q81A#A^,0*\=DK5&NTD&XHGD><-Z!B%V\!X'G
MV2%[[><K(\%1:[0H91ES&C#`@MX6<MT$;8']TV9Z#`V0KM]'<[VO^373Q,&(
MYT&F0<%W6M64<6"D7L6TS*1:X3J3]V;>70E+I7L2#)D/.@Z=`Q%&Q/1@*F)+
M0H>O`GM\(G1_D(/3>S0ZM>9/69^G/!A.#U$K&=I"^,[0=18>EK@UY!/C.%8C
M\;4D[DRB=S^(*)@M<Z*R>$A)\Y,EY0#CMQVS8?6,=[Y#7\_=S7O,?2<"Y#J?
MMVVSTSRDNU&XKR(I8ELO7`&0QJH+X?&VW2W8+X:X\QN>\'^G16'UVB$K$CN-
M7'T[NI/3OP=<_Y:;^<HE!SJ:52LZGJET!U6/J8=+)JL\>08Z56,P0F+<[VWC
ML&G"O=4MCILTNEUS,FR2+VO#&P5L^0]F%3[22%LYWS43VU.1#RI8$)O=P5L]
MEFP\/X;2!;D'5V'U++/3:T_+;T%Q50"T-)T%*R5[#;-^V%2B[N8Q'5@QK=8H
M>W4*UPCS@.S[CC.(.,F$BB3?-CJ]HONC3ACI]1GG0_Y(;`70RK2:C30D3K$X
M^?R`TU92KO/I%V!^!_+/Z>?'OW!&RZ:@QR:FY97C1-<U3K2QP#A1H`]DS#:-
MSA[(9!$>&AY@/H2!6JW;=U!_HH+><#631Z<7G+]^CM,&[7CJM.M,SN!=KD8/
M+B^=I.YYD_I-)%L+$;/$*D5``:K(DXP/I7`Q<J2X`2*<D2,R%'+,66>],C@^
M4S8^XU5G`4L;41"IZ3H:G/+:3OJG5>@[)BL\;X'8L]N@M"S+*M1OC)QZ@^U`
M2+^)5J_@;/8-'J<6:J%JTS1[[:;9:EG+*#>P2*<S5;V9F]^F%)57A%CQGKQD
M0H6<0C1%`]+,>$)8SKW3%:$BQ4?=U>HUGRW!FRDJ,2#4K)3O>;!&+C$;9Y;4
MB9%M/*433[^X4K?;`-VN.4VWFUNA$+/%*?6=B^FD:V_LV;Y@1;+QH.M34P'*
MT342:J*C)>H6=U<3#5E<'RT-9$FT[DPQE]Z[DG=<,&TH^YZJ_M;8*:U,J'W)
MA%I[`1-%>02V))44`3OWE/HMRQHMFKN[7*1NF3'#G(#Y)SJ*)]7FM1]L2OQ[
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MYM2)EX)AO=9M-DOX/1M^K<:AV9Q9V5A"\`DJKG7J)04O`3_NJE="<!D,;*\=
M`S>N;?K3X8]<V!XG^#P=L-_9MM[/"_MN:Y/T6?'"I28[+!I!WE8`KAL=GQ>,
MWE9HK@D=%X]K;RL`UX^.5LLRZ\U%/%;;"\WUH6-G.45N\=D1&S8VZ6FM1+@[
MJ`-3J94TS4ZO;C9[^S&Z94UT9]6ZO?9>`'#=Z`B\`K22WD*!B^V%YMJ49*OW
M`F)@`P"X?G3LM``=FZV]@.;:T+'=6RS)?8T3K?+*0F-:[\Y>JW;8E@51ZQNK
MP`>>:.69V69]D1ZB$\T].^,X/WA<Z4+O_NN]D8YC<?TX=/W([4^.I4\[.N<'
MTU<K,UN/JTZL)H]:Z8(RV#.-MTVSWJYS&@".K&\W<A-7Y@+>2F92+'9?ZQ^#
ML:-G6\\Y]KTA[LV&SNQ88^_<5;UC)BJ5/7E7%RHI>_+N7H%YV9.W[,E;]N1]
M"I9E+]%5'*GL][KY1RKO:/./5/;D70$0RZZB&WV>\GHV^CSE]90,M>PMNC4'
M*N]F<P]4WLT&\]%-=\J4?3-?OV_FMD&EQ)826TILV0YLV90,W7GKD=?0^+-P
M*RMIC#?'RG/Z#R<RIIY87"4:M,TF7-JR2:?/W_BK`G?!5H3S0=2J-?83FNM&
M5<ML-7MFYW#I`LEM!.Y:4+55ZQPNTJIB9Z!9HFJ)JD]!\U7+I!=2=\0[IO2(
M/=C;KBQ-L]?IE!T)EH)AO5:WEJM+719^PFBY.OW?DS7"4S_SZR\^)X,H`,PR
M`J*$\TO`>;OY0:->7[!]:<E1)SAJ?;DBIE7V>-G(PNJRW4NVN=PJC(D]+QU<
MWG[8%@"6Z%BBXP8!</WHV"C1<5D@MFO-EV@[L86=Y\H>+SG>7^\"P95=#);C
M_=W]`.`+H&/#,KLE.BZ)CNVRQ\NJ5)&VV>[LAV*W0ZK(:S0?V*%^$YUFK2<A
M/OWB9.BM)1XM#D;ASR_;1Z8%9-N#7][R7]Y:9J_7,:N5R28RB^-/5MG$HQ>W
M".IV$8)E-Y-"A'E.-Y/^M&XFB%O#P/."!\(9!%-D1,EH9(?N?QQ`N&$0CFQ$
M,>QRTG="3!*K5@+=(PE8XFAF@<1(0";`SQS66=8*&Y^L&C$$W+II:Y(YWO#D
M_=N>>^O_]D;+='\*`V;8=:O.G;0Z;PP_>`CM\6]O^+_TVHE;6T#B3DFL+'K-
M<Q(.7A%8AX6'D`V!-)IX!6BM[]3%&'*>E3M$M-N((XLG&Q=M\ID%0)NPU&H`
MP/6GQH*U4UMT_D+,?%;A?WE3KWK^E[BSDBUMR&4_72RSU:<O9$K/J9TOK^D5
M3_\"%U8RI`VYZ_F,A*V&0"%3"IV1[?HO=NK57-9\MLU67]83$'B1:]L4YG3R
MG&X)NW/7*IR_J^<O9$S]P(]#NQ\GMK=1F]WWRWKB_"]T;9OG@RP&!Q6_KZ`G
MP!)NQ^US;!:#\CG5[_L)R((->.[P-=S`)8YL*2!?"5]>JQQDJ<)@^>4V?WOQ
MNIEG%#ROI$9ZR46*C]^U#N%&%DLM>GD`%.^]66O/2M$K@;ZQ`'CBYI;8Q0OF
M@B_.?`3#L1J+%#H^#?=GW^X25TI?/>QUS69[D3KN-1TFW5*C5CBAMP31*@XS
M!;C/?=WKJ`_/)MOFX2*CR#?Y&CMFI[M(;O;:J;99:Q8EY^X]A%9QEBFP73O1
MOJ*`/>PN4K:WP7=GF<U&VSSL]5[_..FF6K56D>I:`FDUQYD"WKT0LJ!@+#19
M>X.OT>HLVM%D[83;J?6*^.+K@:BQ(2!:Q6&F`'=WQ6RCUMD56NT`VSO<!",M
MW5*W9FV41MSN-LWVKMSW%.#NA8AMUNJ[XGYJ;XCXT(5`X6C5U],E.V:ONTI4
M?U4!.W-L[>X)V'9M([![-29:=U-TO<TE5@L$[*'96"F6[R&];H*0!6-@5ZYQ
M`^W8WH81;G=#(+2*LTR![>Y*V4[M<%?NSC+KUH:@8@:A-LJ07=-+=^L\6R5L
MN[6=<4QLI+#M%#G&7@U$FV+TKT;8%L)V=X7M(1QX1^ZNT]L,/-2QJ5>45/=Z
MS*R[&1!:#:46PG:[Y.OTEO_+SU82XJO6+8<X++AV9K10KVNV6TN/]WHA""Z`
M&>C++"]R&RYR!7M9'5ZL9&.OWQY\I:!;8L7M[@R[CN5UFNV:S>ZAV6UL4\O_
MU>/+SEYOV^SUFF9KR2%)KW>]N\U?7K-Y:='RZ;^U;AMG.2SX-FP(:]_>ALZM
M'3M%#8=CU8TXWP06_XA_J%;NG2AV!HMVAC7<R'AKM<UVVZI6N/=P&U@;_'6R
M]_":H3`'S'7\D06P:[[FE;]RYHM4G^;6(8\**8*O13V&-[]3<P<H^:E.O47*
ME@[ROY(H=H>/DXK6\AV;)YG19`_G05$/YQG[I"\5]'<V7,^#)T*@[PBIN5IQ
MAD.@+J3)Z,X.G8,;&_N(]X/1V/$C;OX,_T/"!WJ/G1&@'CQ<K01C)Z0_1YO?
MU+G37J"ILT(?'H"#%_@<Y%FJ@]%2)E11E?Q:[-*Y>DPS=/YT[-"8;$6_]H.M
MH[W4[EQ.@UZ-XP!>\!#;`I29*05["Y05-(-?E>=CQ6[FK-YC-6J=<9R?AB8_
M%7*E=2BG.EPZ$7"X_AVIO0,'=-5@3*+2^8%R=&9[IC5T/'AF=Y'63R(EH]5;
MI&IX4_H\+'?JSD)EXKMQYM:"?J--[&@Q94[Y_.0LWO*'XX-&ZQ$%VX.1Z[ND
M)X/=.0\1[UPPP#*MP^5FR>UW5*S3WI9`RB9"K]59.^Z]C)XQ9?+J"E7%;1]R
MUS`[O?V8N;@F`.+,MFT*_VP<`'N]11+:UAHKR&HM]1KY5PM]K\]QO,*;A@$8
M)>)E&2;DXZPWK^@4^!7Z>):G;8JW=LX)D1LQ7(^@_92S=M(U.R]4Q1B^##0G
M$\4N`%7=OG$^'#IA4>OUA5VK+Q`-6>';SGWC*]G1C::9OIDG5*(/^E,P&MO^
MH^%&42*"3!&B6`NS]O#?:H7<V!1D@H='@6]<Q0&P`M>'IXW$'SCA0^C&L>,;
M8X9U(&"-,\WM:H7:*0.NT/O4(\;;=JU=-\9.R'[RFH'>==^)C7$8]!UG$(FO
M5"MRCP].Z!CV&/[^PQW9L>,]&F\;=;-]6$]/]@Y7@-75OFC"8A\V#B?D>!D<
M$4]K^["K?A#%=+2W8*-;]?>;$@];X=M.?>.S<Q,F=OB(@<'&['MOFU:WC?=N
MJ&NG"U#W7H/%'>,LB!W#LFXFX/5AX-[C;[]^2**#6]L>_TS?NH.UG3`Z^7?B
MQH_XY6,WZGM!E(3.M?,C_NC!,[]7*X;QJ_P:OM.-T>43%3R+\S-C^.72&?[V
MQ@F\[Q<G[4ZW>0#_6)95/_@GG*#S_>KZ^'NST_Z.Z&XUFM;W^IO?<9-BC[-$
M13TG)U8C&ZY.__>$UU"<[@9_.#N_/C$ZQ@%!\$9Q,\G:>#7Z_-/YUZ^GUU]A
MCU>YAY\./9;2;X>DGSV7]+L,'FTO?C3Z*36M2)%JS(-++SG/>KMPH_LLY+"F
M31Z>%VNN,ZS?"$`88VK*`#8,@MI^-$)"&->1TM<X_W2%\6HEE(=A,.+HM>U1
M"@O\99#TXZA:$6YZ6(T>"J>Y\&U,/G'Y)7>@(Z!<KU:&*+('IC&VP]BU/>_1
M-&X>C=O0!IQ-WPK;J1E',2?.P+72#_Q0M4(*0NCT'?<>5XJ2?M^)HF'B95XO
MTFY"QZ.3P_[_<F#_.+"[6O$#V%^$LF;P!($]7W%\%K-]GL[PG%>=<G9"WX[H
M?H>VZP$X\$=;`DO<FQW1;8$>-G1]U*=`D2`\B/JA>X._W03W3E[A,!#&.N89
MB'CX-[BPNVHE1<$@A%O"/R)NH$(I[S:+#VN'R`L"_QOJK8S=3CB*)+)*`-@A
MH/HM)8T`PKKQG02"F5)NM0)?:OZ$@.W\!-]P$+Z<,N874JZ1)5S4V`5),$TB
M':K7/-RY0-*P(N\!M$3/HQMU?B"#,-$N(*U=Y;V9!K)->1)[%"0I$1+EIM?Z
M;A!XGAU6*Y[K_^T,W@,W\!*`$(HOQT?N;"1C.,4_;!_UV?1>*.FM;N';`6Y.
M!$0<8]H;/.89F)QC<!H.?/?+Z<?SRYH!6([\'1-NX%O##(Z*_0`DR=JXAS4`
MF'!ER1"GY"!$)T%'MW$+^![ZQ&8D4\+$/G?`C.H*,W[P[*=1:#L>O!BHR`4`
MWB`_`N4XU`FB6G']?NC0QCE),`5>2B3OQ@%8-C=`A,D8O]M,@5VM,'SY:Q$!
M4T$(@#MPQ@[CE<",](CXX7W@)2-8A(@=Z!9L-1Q@CV"<=29@]W!O8E-F[ARA
M4$CP3G:*<*6F)4-;NOQ$&@00>`D2DSL[^0OS.6U*%PM\35JAH4KW#OCF)PZ;
ML2PX<Q:Q91ZVZZ;QMMLY-$3>9\\8\(WB2CAN)>+4H6I%Y@ZE@.+\T?HA99'6
M:07V%CP_;73#;PZTB6E@D%Z2D0WP348*>P4=2KYZ\XA$DO*/1#+Q:`KG!F+*
MW%JU\M8Z-'N-NO$.V0B0ER)3D]21$2ZALU%<-D+$(K4-=S'#=U'J[AN@NS=6
MK+O;I'L]DN;>=\+8!L:24;D]MX^<R+!!#C/>U8Q4O<B_5<3FR,W/!J;ZVH0"
MIY2WC(8L!)>NP('<N`<Y3:H;9<B2WN:29D%R5+(S]OXIE4%?0Q(9$Q5J&U*3
M4!O$/8'T9#&-'D<GQ!PL^Y;=EN@21)V'?A%0&:0B7##DV('/:X;@X]6*8N2*
MFO4WOC!+[S3:P-(MJRU8^N%Z./K^&3M,$(Z--"-O=P+?;2\*)BR6:F7D`D[%
M<*>FP"I5NP'?#U,=66@"?9093DCVK7"L9I"*:4!]:RK:@0XFJ0HP1:AVE&0#
M?XR2&S;0`D5Y_<!G/1>P^W2H41#/ZX1'4+5VA#TAD((47GF^HDU)5L/%)9.\
MAG8S<@0PTR*8R465!#,>@@3DP,V$DQ\4&B8.^7?Q!5+<2='W4.^,]'L3.`28
M?OA+E!KY\`/L)`+PWXN#P+6$;.D"Y_`3RJ2&7XBH<F9"`4`P=-"M"ZK$:`GY
M(,:V2UQ!`E-0?(0?:R!ZBH8QHQLI5])L?8>UL#,$ZR1GOR/>.71_(-V!1>SZ
M7$(Q0/O!N%+8#OS:#CT7[U1["DF%B1'-#Z``,T?JZFDR]H8Q2AA#2M,<,NBE
M'ZB!N2'P;[),P[X+L@=%#-G>R#7R8J:(G-&_D7OG!`8:4A_$;[H^(*(H(1GF
M7TVX"*\F\WW:*^?7$<M0P<Z$"F[F"A4`+<DYP(CB1XH&]RUDKNO9R'XHFY^T
M/)")(%\/=#!IK`HIM5J)0)O#K->^!]3:AQ_0@>1B\).X.'PW2KR8G-K`8J3/
M!(GT&U`W<G]RJ(BG!2=B'D8*1(B2&CZ"A7P4!,`+2&Z[)-Q`9(8:!]#=WN3!
MCX26B=\@!1=$FW#N"H6@0'AFO4+PD^N1][YF'!77GIJ@V9"_2@L["6Z4%X&3
M,7VPA7L-:R[9MA5EH1M;B5KR^!WB\?,E0WU!)VS)VB==*/!CJGAY!"6-2:$:
MZ:*ADO(^9MD8060CGL,BP%+=D/DS\,$N6W2:+&&+CROW\:W.C]C1V?R00F#Z
MJ\DQ#[\90;]O4P(3[`+U1F&4`),=@C%P@,HB.NC=8`![HR=D8X&A@6X#]7RU
M(DR;U!=$!XXF+#7`I3L/HR$^KJ-,'KO`0]%M3Q<&&6M:2$,0<S>V_[=QF]@8
MH7"$]IK/[>K)<)*A19-0"CO])'08FL/$&[J>)T.[*`>%J4Z^ER1[RHPW[/J.
MXLXD`;$^!5V\_)0ZK(K*P#[(=!`FB@]71Y`7X-3>(QP_("H9KG0;=*_CT!FY
M^$D!"&UI7T0_4YJ6<0!V;YUAV,1?>H=U^J5%O_2:(&3AM[:1RNKF+_0':2UV
M<G_J-'LU@SF`%J2`J\7;>-OM8="@=VBQ+7MXV*)]YVS3_/7J7B7:S]R!@E(6
M[:PL>BIS@G_^EP,L$\#*&(E(]]7&H`<E$NRQC#KUC7\D'N9JUEM9WIDU1(2=
M0=*!V;\G(5FMC#10Y@39/<,]$B++)B_\;>+9(7*A$9,YI<+`-M7#^!BM/V"A
M!OP7Y8(2$OSN(3)RS8N?8^BM#G]9\EID0WWTJ.:8KF`\DK6*&'5>LC0$;Q3L
MKD5[?-NV`&IO&YTN`^)M=VZG6<F1=I8C.7-QI&OGWDX9S[[QG7,??AW'3&)(
M1,"`.C,8D.UKGLQW1*ZIOO$I#TSUE^-?WK/[@1ZXN+/ADOI.$I.OY-0?8#,=
M2F+Z$@.K>9=?,KL0*UW,R/2-TL8XJ;&/&44W`>4`B2R7J8F)J-L]!*BCQH[K
M4^#F!HX%^JH?NT.7,Z%HW_A-[86FD5#PYR(,/@&AG/Q@/H>/5BL*"!Q'4JM%
MNA(/+#)V0F9]Z9;A;Z`H._&#X_B%+R87>`0Z*JR)R3:9[7,L4=L]G4<=7Z3]
MIQE,12[JFR3&]!VAZMT$L=*`T[Q)=.$H/_I`'$'ZIJL5X7JO&>?DQ7(\1X5.
MIL9K,B`0GC4^?ZAD#TB4P+\-`.XE3]]#GCZ<BZ?_B04NHZ6Y^F3-XNOUQUOY
M^X'S'R6WP'B-'G'];I;K1^ZM3[Q"8PLJ]93AF^O7<JSQ5,4A.<>B?^<'7G#[
M:,1@]T=#C'V%(Q4+_V_G)H2M?O-!50LC-WY$)O$/)TPPP#4R]11#6N]C\`@*
M[O4=O"-"5GGJ1[$;)S$'R2\\3'Z4.S,Q&^53$/J`]=H;8-'XSN[;)@*I6ODS
M"/\F%X-@BYSS/`:1%&,!U9B61,+AOFZ@XO8=N*+^7>"Y/C9J#%&3?7?TZ>[D
M/9>:`:<;!9[31PT;8_*NK:FX(#<<XJ^I.@__&9,\I*_CR^\>/8PV]$'N#D!,
MDE_#%-DG%(,`&>$&`V=((7B*<-LC3D0(;VT?%@BB\1WP9M&+;@S[=/N4OPF\
MF=SSM6KE(@FQ*"Z6Z0I3TB$P(J+R=0$GG!^PC8@<(0]!Z`T><%TJ!LXD(<&B
MTLN5(H%V"$P"B!V5R9`*1OX874.>/#NG[E,<-C`0T@7JQQ<9?[U6;\NH#L)'
MYDU`G((GA2"G9`",WV`T)XTODVN)WV9FZQ7=*)/4.[+_=A00"E()5`93,L;X
M">85U(O\7Y0!C6AE]^]<0!NINLB(DY:8PM!,<ZDH_8J#Q7"&-),>=SL(D]M,
M$8?(^E;5EY+D"T`K7&DI?Q@$#N?Y*[T`M(O8]0S'%;DQPN^:P;1J!90#SCU)
MOY?#12W!)44HS)2GNTMS78"B8KP?WG0("M$<M8JSBPZS!8H?[<B-SH<7J$[Y
M,>'#D3^X`F8)RE8?".FH3P$[P-,+8`Z88;/3Y8O6U/)%0SUX!0+L]#/H$&?7
MH!=_^G3^[>SZ].P/X^+\R^FGTY.RI'&O-;KY2AI%6ZEE%+DR%7I#RQC/9<[L
M"ITO&Y[W=A%B",;]87QT@^M4%8&G3OU^S7B'EK#T7::9'B`%00UQ;725F#G'
M2Y%-31J/5$<?0%GU'@^"!U3KU4J/IK89=KY0GKBV-*O?+OD<^#OZ&T#;S.XD
MLUI^+V#'@](ZSOI_./V$W#_#H)^(BBW<1J9^E/)HI(/!_8_*B`.]-!C=8"EB
M3/:$TNN42T15@<W*%)7:/L&#_3EX]5$RUGG_">.&^%2^`GW:F%^*.XH>P1X`
MV^A=#BAB21T@I%NF[C?VMF1O@TNO,-V6LX&FW*(>\+0?E)?ES,$O@?4RB,C>
MR*</X3,G"9S=`9W^JP-*+YHS8#<[?O_1>/?FY.O1F_?DT)=JN$HH@M7XFYEP
M=Q:JZ)?2<196HK@#&(!".\[@.2ML(J,WBU17VBH9I)K^<L^Q51ZF4G`)D_K8
M<']`O?GA50#K6R_ILPEG>T-;Z??*3B)+]0\[Z>,-#-R(XA:3_D=7%092R6+>
M-W@*IJHT<4C9G7CS1`JZMIQ*%15IYK*.(?^:M;.NEZU)SE-'QD6A*KT]ZG4P
M]AST1%).W!W"]/3T%`P[]YXR(N+0Y;R(2;@3'8KP&Z9;4UY>[:IF?`Z"`:>Z
M'X.=9!QI_2SA#C,4_OGX*.NE!H(5_M=TR[*J,@:#&NQ=V/Y8^DY#Y]X%8$SE
M4!B70V,M2XWOWIP=`XDRRCX7D]FOPONBTE&FS8+U;&2.5.?-R2P$E6\1K/79
M<8PC,-#>71Q_^WSTGJK]1<(VPCSM1=/F#`:K-E&+1`KBYZ.OIU_^_'D.]#@'
M6M"7U=).X"Y4BQN")B(&NH3`AHXP]HQ>=^#0;SY=?@'@26N?4KSM6"Z1A;^X
M'SF]0X<-5B(`<.`FJ#A>8B)ZT8U_)^AV8??%B,Q6?`,("U%$Q$73LMY8LFW<
M/UO[\*NOPJXH#`A7A>-.G3CU/@"['6%;)CPY;AD%GU@NE.<7!C@<OF8<JV*$
M:B6R1R+_)P5C$18;A4A,2^BO3+':I"<':,P/9"P&]\D"TS;ZG@T2I6&2+M$Y
M$%M0^Z49*!%J?VZ$\0MUZR(B+&M`D$0(_8#=4Z$`0$J%C[/8\=2Q4&"@KVR@
MY6OAH[0\8S7\X:NM]E!@Q.P.$Z:$JR!!K\J_`?`Q)\PQK[P8NO^!WUEM?<._
MO7F?Q<K_SQX'$<5W\NH;>H3`L#.-H>MA&P&EE62_B2X>55D':B1V-_O;X8SU
M)+X+0KG>488W?CT2O!'X[B0S2S6@KT>4QX:;4<ED'&-*R9Y=U;"B*;\#".VA
M/YEH#5"3OJL/]!G#"K&*)X+H1Q4Q=;$)/HXE8$>`\EQ?`K87F`%:L`M%/C!J
M4(LC;EK`N!Z$(.)\D@BP#W36\Z%Y7A`[9]&3+OAYM2)>"OO^H#2^3ZI!&F[R
M7Q>7I_^"N[]SL9;)Z\M;>_>&/D)%,"\YE%R1'2+Z5*LUIN+&6!11BYL""&2N
MJE`22\>GVN(W7WI<0?98=4YYX34SY^0D2+UEA*VTX)1;UC%'1F+.Q'8(`,4[
MT/%#80+KPH,D="093$5@(X._+B(TMM!P_%O<";U8/BEN5IR1#`Q-8T\+]0IQ
M>IQSYY]\RV`*I_S$="#RW4[]NTS93&,6W-L!$V$?TY35]!P.6YIT4Q0?<%2^
M:WR'E;K:97%$6J"FB4FAPC[3\W&Q]B`(,R$/*L%P0:R*A<>P57(@]VV\`^D*
M1W<QT-8C?&*C6P1+]V5]9K13"O+G3&V:)E.+U!3&$,1;B1Q?CP#XMG$+6FZN
MW&-,E2Y]?!]<Z!]?+^!VX0[BB?"]8,^%Q2*/W"M(]0]A3P1]"-*$S7E@@62W
M$W(C4X5W(0EFY/9.W=FI:F2C61MP<DG_'(V('8YFGC-U"ML<5,0+8?B9LG*1
M)10Q-,_#()ES3]%*68D$RHIMLI-$I/E))1?(OT`2</.8:?(E;Q<(W;?(T#"*
M[`Q7=2:59Y^Q"V0*8A]/;J'0EU*HR9\/A]B:%#8H@'LAG01Z!%MN8$DKI6"G
MV2B)V`-94E@#ELS'H;:B(FF#BJ"VD%&<^\99<)]OZU"7"?A9/R'2EE#%<_EZ
M0%\R6"^#N/3T%<G(-$=FTO'+ZVFI;%D'AZYKL/:7W9*D(+$MW(E*&P!%2:4-
M:,D"*OTBY^MUBI0=4V@9:46E7MU2'!X6XDMLZ2@-,&>W'CKH:U-&+>4UD+=2
MV](4[57N1/;+K58:.R6^CCRL3+^]*SH^9HE@^/\1%-<;3%YDQP9[N+@?LU:Z
M;DK]C?/,;QS28U"`R+YJ!<Q39",*)7T8VB,',.GO8KTD%8+D_!/H(%M`1C%H
M-")9@GSC\%42/I2WD.;4``!0Y\9MV^1PU%(>X&^^C;J-.`JKS6G+:>6LI86$
M&!,YJH#T6(+$TEC*38:%?6^['H4-`>ND&%70@LUZB)+4=@"S<E`Z@2FC6M\H
ML*?+ZBY.Y!ZJJP$J@)BO@A5MPD8$B9EWM*9.I53"HVD2]`./;1'I=@/=,R0:
M#`QA\;(]('+^Y3Y5.QPV=!$:_WD<H6=H[-E]T:6!8CF/&2S**Q7"CBG8%:J9
MZIOIR7"'RB!$2(BLLDP"#W=(242R$2V>`7^L"K<-4;=-\1<$@QNI+=2,<P%S
MJVEJRI[*5_9]4(/[&8WL,T"C?R<-L0"41&&FQH_D1)-,U<93P-]=,5STVAF-
M@]!V,?=WP.C_+08E7/SYW='UM_>DRXL'8>&LYP1A^PV3F::Y2^91\<!,AGU=
M?R,+EQU]ZAPC!TQ%WXU&1J(Y0<1Y_]NQ@:\HY98)]<H>.O&CC$;)7"H_\`_4
MO5+Z4I9<M'M"<%(QS`-Z4<'0<?!.53OZ.WZICTGCS@\WXN)`N$`\@4U5>9,N
M#QT-Q.KP4I$;IP&'LY<+X'CC`"0UOTC.#Z',;:F4PG[DI4]Q35QP+MF4($"U
M@FR9V#$74"*ZA<3"M;Z5>%R9:`?GP=Q!%]:*"L)6$[B/%,2@,`N%(GH[E#^+
MV;PL"-7YVP2$1>\`YKV8<\F=#+0RV=`X(^Y[,<E]`58?0_L_KB?XNPR<J78*
M.R65TV1>JRY93:$ZR`SX`+4CX271$_B4]^HKQ[G(TR-H$WX2`)U0_+)]$#55
M],Z^=[2[GL0-.>QAYOOFX3R42>JRI$MC&B+H,D@=UBJ)F!OYI.YL6<<ZY21I
M>)$]+:0[Y_I@DS=8ZUI'3^;!K7?^$AL5S3/$F]!2#P<B]1J9$/$8JB:F%$[0
M39/0+^H&PM>0?PU07-]&=892IPFB+GH4)B".FA'I`5(@J:-S\JL`:"J?,?M4
M)&/>HWHEHILC4I>Y*%XVNZ(0B7')/>],0XSK*#@>;H+.9R*W1H^IWO=YUO:Y
MD[>"'L@7Z9/-5<^D$':YE3%W0A%MJ&5;/DQ$Z.-S+$`D82BSPIAF56CV4MF;
M<Z,3TJ;VYOSB_CMQ!])O_)FZG*/Z?^E$01+V"R98[FRBVE7:35^P0,V]7)BH
MD.L^1(8/YU!0/!L+0)0NP6F@AM8TDY)>L$,1?IURWH,;Y#!DJ0"S@[V@[JKK
MQR)XKHT+0#5_'+I!R%TC/`]9$+7R4&DS2-!%BKR*8CA@J!6^IEH9H9R]<<3.
M6(G!MXAN3*K!*/`*=EGB7(.:<8*-)'!KI-RBKSOM,QZZM[?4+,IXV^!!/!.E
M`GP\P=/@)+E(3]ZE0881ELT!L[Q!K9D''+#">F?'69E-[<BE$EMP:M%E3D9'
ME7*J4JD$X&S*]\)&5VZF<7GL8FJ!_6B@B2U5X(S5)<H:$`0>8E"V1^H`RR0X
MZ([R#60JWV>*.:(K),J4;`,6*K]D^Y-46]<'9;1:T?>I]<0J[+*5LV0D4`B=
M2"=%\27[A&CP23/-]*Z/;JB5IF<RT[#PA9NY@.DHT5ZW%.1MB.[Q&!F&2T.U
M.B6:66F.MHC?(1B0F*69/86T0!489ZM9&.6+MH0:=K%I,-G)+'M!?;2#8P0F
M!CDX:APD,;`;Z25`;5%-#RG=XZ5['!?]*(/&2'`R0ZIO1Q0C9S&M_,BBNH=Y
M%#Y#BB)7LZ&B)ST"F;EV:J!=D)NE9KR+'(>&QM`TM/=9H^$&[`!B9-J4!^F;
MH`8=-J=V*:.8R@M1C$R9EB/55U!&.25JP%V&X&'R`&:X%\7?8VJM$8NDJ!]@
M%#8XKPLA(/VW?@!268D$(29N`22^2H2B[:-#EUPD>O,IZD-/(I:*UB@9`'D\
M]1J.2?"@6IWXRO$GAT$0@[U-AX2C<Z%P2CC/@9E2LR\?RF6_H83Q'2F1G;^S
M#;-(C0/0:0UX!71`IA-XRI+RS=3O-Z!1*A7^L<6?EOZMT`[8BFXA4Y/MA\I&
M4NWP(_;^D.-QC`.=V`E%?KR,62V8`?HL9"ZIK8HHD<G`PF//D8YW[-ZNJQB9
M+&S*VO[CZ.@B6V=1DO7^D?5\O3&_<1-X3-(>$3H)HY`Q5J4&*OP&PT$A^#Y2
M_S2XZ'3/%A0F?5$.&-(XTF6U@H0IS0EJ,&S?"A-$Q';2:R!C$IM,C$5,@DQ6
M&U0R82'`/L`*1%XA9B&@A1I%CN@EX+ELZ[A*1QBHTFYNHRYF(,13OF6(0@!9
MP4!K%!Y7ZF=%.]*G?&C#10:ZAQJ_19R.3+\:EE'0_#('6T9'I-,,7-1%X?WL
MX0@B#50E<]M#YC9?L\7/B=\7VB_;&OW'?>19/%Y09LY+2*0=K:A]NN$`2PA&
M8`0Z_KT;!AP617TE+?33_)19#Z@JLM7K%+G?*X8)$K2`9M1)IEP"(R:B10=P
M4=YX!)SSJY@:--6SHU@+6[@4O,U:AK0;<GZ%F=73^,C(_@O#,&0[SWJ9XH/`
MM%1L647YM'V_Q`6_,#JA^YIKVQC4-[:'FBQ:J^ZM2YY>N$%$)&Z+ED)#C&UC
MZP&E1"R<@?*;4F[4C(]R41Q'$O@'<CZF0%V!6^Q+]\1K,'M.O(A+0N_`I(:E
M^VQF:XDV/S`/X]:1L[G@RO$=8`!SLR-\6/TBCV>BPT1KIVE\%E\3M!7GX<(>
M/]#31Z"AD[#$&A2PWQ_>8P&P)YT"'"1-A2F6T&@^7:X\4JE*N;V3BR%R!C\;
M[UQ1`ZGO(],(67X5#L+?%=.$TR\8[*A%!PK&<>5;?J'SO'/%&^A@0$A\LDP_
MG0P8!>2,Z,YQ8@$(KIF@6#%6`+IIR0Y</2@!_Q'U(4[<K[W/;E^[S=Q):L8G
MR='TP]S:KK@*4'I$]VE@#&'HBO2S5)<!ID"^UE!SJ\CD*>".,V=VECK&SNH8
M\[5/_80>5U3I[VUO7XTB%<D0F1(1E6*DJ1\FD.\M]4NFP#(0W#VH[^R2EOJ%
M&"NH)XQ0KWQ@%4'DRKG/2E:`Z@\VA#92#J<%L!,3"=FCJ)2,ATH;9@R2'0OC
M3?;P(D>@R`M.'`7>0E*)8F3XKD%H/V#@+Z1<6#EI+G3L@4OE]G`&8%GLV*Y6
M_O:#!U^W?-#+;HI*KWX.1TIVLH?L9+[.G:<^5HX&J#_O&R?1CDZD!L22*#T1
MI/@#9['Q`%%9!`O27PX4M1\XS0(PYF_[EB/'P$=DXKNB?GT(*F9;<-,][`0<
MD9*5+P,9@6*/D5Y6BC+-5V[0*;Z#:O[73#DC0IP5Y8*X/MZ44)N(>V8G9!;%
MK'+1;R4S"C,,TA1#_:7,5C%WG-+O3-DTE)[3)M937TN1!U.4U4'QLH"262+D
M5(E/@B-]5.M-01.`.>&%JJ%1F95SLF="2\\2,90!.G-?2C()2];]#P/7%23R
MB&G)*;7@RY25+D*/5(4044<)_!46OI%16'E:M+HSDQ8+MF(**S[=QYKR#SS1
M+#&'Z'.T1=RCE(2M8!Z2(0\QJGVGLUNE=>EHG>7!-C5!$Q.!$"=)"DAO#/!X
M8QJ+3R=-NV1AJB79P>52XW3#%MZ!^9D\E>>[8`9/[(9ZM;.U#U^[PWY;^B:T
M8P$?\RF?61C6-QQ,E<-X!8"H[0`[P4L%<?\4Q-NY%,0+K'T)16HNVA3C91N\
MEVG8&]H7=%[$*48)%MSL>D0E&O62M/*@WT]&"?M.\\XX&J^NO'%/(&6)9UN#
M9U/3_>?%LZGQ&XX@LZ*IL"FM<<34-JR).<!A`<;(`853=2.]D6E%%`NH5F18
M%ZTQ![/NL:@HTN<$K@(?"Q2VM6";N(1N_:=?C(_GE\<GEP>?SK]\.;JX.OF9
MI[V,(V<!,?TDJF&%F?_;&U9,ET*VBZ/CX].S/PZ^G'R&O?6LFC6.?S'$@7K-
MGXH4@9F8V%C@*P)6DLIN/-#W#-@`VBWNX!>C2`D7K[':DLC^Q#%JLQ%D?K#@
MSU]X-@^:1],%KR"I>4XY>0IZ9?NI/1>M-6W_GY/0IP#H:C?ZBY%_X4T0Q\&(
M!5K]P%KI(9#I)%BFF()]UK;7=:[FOGGD:$CE'3)&=T0%YUJ'!E819C-Y,'ND
MB9,;>LA1`>'YC]CI3T_:+!:4&*A6E!P8*L-+WTUI*FVFCK)64^EN/E\ZJ"IN
M*/)84M/="_S;`X\G^9#B\O.^T;7N?\51WM$D3'CZMP9`K'_3Y@*19U;[N^P?
MP>4/!DX?$Z491/5BW#0%PH:HQE'4;N"@CRAVF+C%B]\E/J8J8B!-],R3+DJJ
M*,0^+?T[.[QUHO?DZ2&/K6(<&.%_)$^.JKT360>X>*92A8NE;WW@8M2C13L-
MI@RP4QF+83!A$:-[^%VQ22XZS"JL0_@V8UF$G1>]OK"O5'?''#0X)5.<,X5,
MR=#VD*&Y<P8'*5$EMG\\.SHX/PX)([VTQ3?2YW,LATAP\A)VVI%(L3K;>%M*
M(14P"`@BBS0-ZV(?J/](IW]QMGNU(MP2F5$I&F]G^07K&P[EX*L,6$Y-=S!)
M,!U:RPU69'Z95LU#J::PR`U5`F92]D&2:=GWVE1:;I--L3OX)HXWJ1GZB562
M(CM@^FPL#;1`!S[$67]*!'$8$">W<$D!=HC"T#>FUFM'HM3<D!I;D6@33D+5
MMT2TU<<5A$!/MR6.Q@W!1&[LT!00IM8&N+<'A]JEX+?3-E8./D[]E%R*I(RP
M7-YS_\8I*23J:<@>1I,BD;F'"4>R-771+E0I)XT"%I',3"#ZSN;^"+Q3V\"Q
M&H5GSO6AIKQG^4JB0_'.G6JPA)"Z35PN6P,HW;DW8CR#(;0H61*3@7Z&Q/":
MA/K$@4`W<CA)2\>X0AI"74W6B<R@H4P!BXHVCL#DY&0`E1&&S;[2HH`GTH=S
M":<R81Q6YQH5/@,_0SG+N31=U*2!G']0=@DW*?N!V2CC@+(A/N&0AW26-9+\
M#5BW!FJB`%/TT.L\)H]^V<Z=-)8:\7PBR9CY0JJ\%U%)#H2K4$5+-6*37?K?
M9`I-_$@35TIEHG*-K,7QP32-(T-9B(J,BDO@J)M+$!6TELE&2K2:/QP'$Z6]
M"HI$'/46P&R=).+$(U/33W`,+;&G$6P^%EE5J=4KCZ"U!!-]Y")6"-094;X*
M#BDGR7AD7\?RF44.5"RJ>02(.D?9PV0-"4.[XQZ0H9PZQLW6S\TWWSWPUUSN
M`=%>T+A,%;)]]FQJWCU18,A]<,FRLT/L+16EXQQIQA+WN-0"$_0%^6V:;"ZR
MUJ@Y"\UQ0D3FZF98$UDTYV"Z-/DC2FQJ/"\-&IY*1JO988@ZHN8]-54332K.
MQ+$DI#Q&3GB/LTBHV##H<P(I:XK<$G,<XD`'EPH3?_#FI/TKMR<G3<H.6'R6
M*,`''KDUVBRV7.I[&Z'O+>TVNI25MJDEE(Y$0`&=ZYU*Q@:WUMM7=7`V1Z%J
MT7RKPDBV$AP\W:>PJ-&J-+11=[NUPX$8Q$8OU*UM*DI*G4MBX"`^AJX@Q5Y$
M[=0(3%5L)&-HG7HC2F4GFU-C1]Q,5_7C%?TJINJ`HEL\Z<CW@7>O+Z(9JB+3
M%:W>*9.,"V9<L.J)E:5@T";^`#=M&LGX`!`8`S4">V6/R%R;6W$'6N=(:HNO
M3%\$H*;BJVBU&)$`M\?#F]CK(?I3Z!B1>@CI=!-/DT_*:ADXMBW"L=9J/)MR
M@&D--O+C&^@$8UGX7JU,/3;\ESBD:OJK^0\GNO*^SSHY>9@C*?U1G,Y/&L/'
MOFQC'-$\CVH%!WH8C5Q_R<%?221<09,`H+Z4HHJ":VG-[.LU]R;64(@"?C?L
M)R/L3]DOO1`;+Y66]D)DI9)H6*LUJT4O5RF#ILD@`38%+:KM42`C1I,JEF:J
M`V=U1V.JZHB*<:D[;CV5-I>ETD+9S^WC96<Z2FFE)$E23]3<K!60;0:+ZAOL
MVMB@'1=,`\NV[6?M:G(:F*Y&X>Q2T.]BCZ.&K?I/:>>@@#V,6'`?R()[9BO%
MVIQ0N#@O1M:#IEUYU$2S?(R#UU33Q8B)<0-M/9E'="-70]:T-LTTP@RU&!=5
M$W'@&U+*1FEK(1QU%OT=B5T^@.8=\6[E("345PJAE.L/I%.%!)/J12(_3ZTL
M-^-H1LK!AM2Q*"\VIK#_S/0&GV?E#EVJC<;7:-&N"9M#:6`<5:->O4)=CO0^
MZV@1CK!X3H7/95<V.;XJ)?A[O4EUJG_JXU7D(!--YY-*=1Y5IXV4,#DQ#8^N
MMYH2/7.P67$28SVQUMF^6I&M[?66+Z2G$IMR(]E\(A?^'[H1^M=1=\?Y7&2&
MR8F$!@XB?+AS/6?*JO*LU)&3".B19AD]^2I#O$E-@&U:<PY7WQT'\#9*Y;4Z
M@/^>TP$\I5TTU:3OFR]X-C0F&A>HRGPA)8'U4E-^53P\)(<NCD:@"=LW-(V;
MAW2K[P!OM-'A\@X[G8OI]?EI"KFAC.]-.2^:>G5J]7O*(R=K_*>V`]>F`QA_
MA';6`R42]%ETNFF+OL?4"9B.!":9=N<Z0^.JC^.DW(AS<_C;6=U/GT%TZ@\2
M_!EN(K0'[!>C>AD:JZJNGFJMSS]=92>I<F,=)0"5A<*CF&]P=#-/1L(CL0<H
M':HEO>W*)'%RDSZR:H)@RQH4*#6(?/^/Z;@+34VRX]CNW['V0V?A;8FN@3-?
M+H\@^^#+2ZF)A!KZ(U6*<X_$]$:>[/Q.E?(Y89HBMD3F'>Q-<NFXHYLDC)RL
MIU576Z8A%*)0YLN,6L:\B*4/#,ACUMQH1$%]ON+,7N;"IXD33&`6:8OYI2DA
MDE%,4POGP;&\OD8HQHF&FX9CNQS;WUIJ/9V<)B3[,&FY>Z;JG(83B-6$8!P6
MXM^Z@@I$W<4-][P4<TOL,':QT"(K'#-3A9"D_^*VV4"RU)0?IT%Y8CP5_"JR
M>ZG/&V;04GD)$^I4&A&\EGF`/!(YTS>%'E;XMK/`3\,OACVX9P^_C':A;C(9
MK29PJTE-=&>DPZ"E)[*1!.#GT&NXFT$F<).6(*:-5#CHHG@S;XJSHD$Y&U$G
MEDR()]TN=4GB^,5JO)FED;5E1I8W7\-/$/&A`QH%N9C0T[)OAE4N:QZYJ1QP
ME@=-VA`I$L]@3B![M]AEJ,A1#`^0`^!*`MP_`AS-28`^ZEKI$(X^#LZ+C=1W
M&Y,)FFKU^T:@GS6/)!CE"4MIDHKC`,/Z+O5ICY*;O^0X$54.')##8BJ`I6=$
MSB6BA3#=6._56\OR"-7"EY./]3V10BB:`XM9QVG)!S[HQHEHA:X\*LJ3@>_D
M:@SNUXW-X'B8-1P3#)9'$VNJ1K).16_.RP<".X<'HN!D<)SNZ3M3WC]1*D1I
MS6@GA2[F]0WH^V)9T7!<3(2DX8U]H=VB?A,XD:A$HD%YHL2)]L).!O)3H!KL
M#L'J0EU3@S\[C+-@W$&-,\\R/IU_.;\4G6`FFQ%QN@R1?8:#:#Q@CB5#1TPG
MB!2NL+V1\3'(Q"A36L>JDRE/&/`>TU`*5Z497$F@!>OE&EFT4I@A4JZD-P,V
M,<8@%05;8AH<6)A<E1XV%S02:FTDA*O;%QA5K3BJP(WH0F193!EMIIP9//E!
MS'DD)&>O!2@".MH2ODZ4*Q6\0A@25):4/T@9^MASI>"I#G3\\Q4&0@\XIH8Z
M)^B@]KXGP"NQ0^.91V,O>'2<@O0-`39%A39'OOL>.F.&+H='D"5ABT'^6UI;
M3#[L`THB3!M@R')J9D/IY]2.8_*5V;$E;J1UYJ!WV[YT2>HIFK"A")N'"`M>
M,#?9XC#3F2,(APZ/`2I.WXST1U1DMEK)%(%*6<_.!U"B4/W1FYLH7^\.RN,,
MU#Q50Z[N*4-TW*.=1O'ZC#&B;#5`#4[>E^8;%YXYU.%N48@/#!P0@2@6H<L\
M\<B!I$KX^\#1'%87B\KV9:+S03!F:<4[H!Q4NW^W@[?S/QC@`%3M@WXH!@:B
M.XMHDTE(MEE/DQ.DXTLK>K]YS`0QTSE&F'\M&8AHHB-C5SS/E)O8X++9M(8,
MY8N`B+:/-$@IW`"37\B>RHVB!/.$J$`'6Q/([@#(,K!R&?"+BQF1L1>Q'UQ3
MKB;AXU+_!U$"24VBAS1DA)M3"E^B@]`8%OD.!>?ACO>Y7)Y<1GGN*RD?Q4ZM
MDPW42B_('BH\P5P*SQE(N2_H00-,8IFZ;ZH.3J3NLTGM>M3QQ,O`(SL9^<M%
M0=*![)5"21(#%[@@DJ-R3HK,"6Y1@GQ4M&_W$TK,DLI,FDF9,TCAUQ&PDRMD
M82;&J@0;>ENOU>N6OE/\\AM^'-/5X/DW[RF5+;8Y&XQ4.!!>3S:(W]KK/!:7
M"!>56L)R*I3DV&@*RUB;53<[G;K9:G7-:J5K=CN6:75ZA!!=L]4Y-.N]7GI!
MF<M0;F<M[RZB'#_8@)9X9QJ->OT0_]^JT\+P`WRHCP(T,8G`3B(1GI?M=(+$
M0Q.9],0#PD]X>N+6/@#.X6^_?DBB@UO;'O],8];/AQ?:D/4C?W"56M5'JM[K
M`GU<KA-=.S_BCQZ<ZO=JQ3!^E2M=8&6K,X@^A\'HRO8<7)3[A%]XN(X_.%&I
M1IC*!*M<.L/?WCB!]_WBI-WI-@_@'\NRZ@?_K-?KG>]7U\??FYWV=X2!U6A:
MWX&S)K[+WW*CH-6PNM^_71V_,09.']1J+_KMS4'SS>\`PGIZP`6VE3T/,#R<
MM78AE)6/C]]`T3CU3WVA*AZEL<*U'N>@W>OT,D>:?V?9$YWZ?<SS<`#AZ+^G
MOKC<Z%(Y0-9\EF;OT,J<99X]94^ABG?6NM->L]?);%2^-KN9(RI&(Z?H=7`T
M8/O"]BYL%R[D$T\=(0YP2HHD_C^&LC]1,'^M![!:"&CM`,ML-4?I&'`C/G&.
MVOH%/!$ZL1M2]L]';N'Q"9,5W1MVIJ_[I%F"7W1W<Y']N4SX?C&R;S3;W?H\
M=%^PM3S%:-E9LFG#6C??Z7;;.>J9W$)VD^10^XC&W*>L9;].(L_1>/$>YF6B
M%UP4"X@'GX1`0E^TYF#K!;?5ZL[)56=M,D?E(MOF<Q#J,I2(ZL6%H-7)XM."
MF\N>[`_;]=&4.?<+%((74E(.LB)]OBWE*":Y$7W<3NZ)JTN][-D[_QUU1*$B
M+E)<MAJ#_^KT?T]X#66^WI#E>7Y]8EB6<4`:[(VR457033UY]>WCU<G__09[
MK%9._@7_N<I]Y6G/1@.L"1P\461HM#O\M\WW;FR)8Z/9T>[ZB6D>="\+^37L
MN?P:\ZYVS-,6_V'[B9S:_MFY"?&7:@5HJ)&O8HQHF"B`(+8I*`OF8Z-Y.,5`
MQ.#_1.(J>0%_8->*R.%![85&*:PJ*@`G[4[TL'+#/1604;5N8JODM,0I>MDN
M%H9]>XO=0&+117TLV"P&9K"6)."1C3\HGN$]&F_;<YV!FJ.+@ZQAU%-)OCM#
MOC<K)=]S7Y&KT6B8Z641Z6:\:8IV@<2IMT';M+IM$X3F-.\.IH;[U0K5H&(#
M_]CQ@4)O/+</CPX=8AS8&U8T/Y"]:>030#NU1AL];8*..8X@2FR9ZL1W5/$'
MC5W5";!:>=MHFV!?IT=[)X:OJ7WQN-C1"`[(,1N*'["=)Q+,T;/XUC)!7WC/
MNU`'4(6D&9(6+DOU"IH!BPU8?(I%'&`;8S(Z!=%GF%=G"EB%2W(9_C#IZ9JJ
M+N6TJM0$9I9_00[0?Z$CE?YVSLSK1$!@L&9GUN%AUD19='N+F^[1L1OU/4I4
MVVF5LCV'1OGE].CCZ9?3ZS^KE<_GE\;)UXLOYW^>G!B7R&"NC&\7YV?&Y<GU
MZ>7)5SC&'-IFL0/[1;WESPW'%Q1T4O"1<L<H.C^R_\:.@Q$&2O6*#=D3QHV0
M];`Z9*<:B8EU&MR?BAO!R#Q0?D!T+:M6I":3[=9$7"KS2M52^E&R3:7[5"OO
MM'[PGN/?8I;`4(5)15&<@<%3:I+KQY@J"GO&XQY@QF:U0I_F\EKX`14UX<)Z
M?NO@O0S24E?<0)0&%K8W$:WU@2,Z6'[$70TR825U-#W)!AM)8,,)/E9*T;7,
M]/AK:K^7Z:HC]H3ER)@V6*V08)'MO4!FT6DRNQ(-Q&B^L#XZ1\PM7C12M!6H
MGX$:UB5Q/1A6@Z4EM$JL80:F+XHHJY6Q")L@D@MI":@%\'6C.Q:,6.A-;)F6
M%DG*\`H<?>10;9G(9Y8MH?$IO?]RQ!5J@.SX)Y&OFVF%+^HG68"+9>9&P&PU
M]6?:8V80@\)#8PXT)(AB+SD)%SO;6:5HU&?-^._@`4G<%"1!34"T5A^LRZ@$
M\T!9/92/;8N4;LI-I4QM8%6/5"9&F6"R,3TSB^#!!RWFSAVK\6\^A6K1[%$'
M1>I[P`[<.(2#Q&9Z-:R=B5O#$ME3!C@WY9L,^J']6!#UT_4]M9CQM@M/OK6Z
M+7KRK=7#[V<#A(0_"@,IZ&S[+C>TR=MGU$]GDF$'@)ZW]K.2RS:>H$\G&V!2
MIA"G4^M"1T,O[J3`2%6MY'*3Y"VA_$.N>DL%HHILL]\MNAA*79/9D]3G`3N@
M48(4,>"T(#I]-]XF<F_*UXZ<?B+(J#CQ4B-,:ETD*3.3GDC,S:.$<LJU%D7N
M^*<,BJ2C8QXG\JUIOV3EJXW:0ZR2``IA^)#T4[6<@(@WSIWM#26UR:_5<O+*
M9G\U:0(:ZV%FESHWI`27G)&Y-27/JZ9+BEJTGD@#,6ICRCB+N>2U2M'/OEPM
M*KBIR$O#2^9^KFE/^ZQK1AU&R@?D>5E5AXN0J,CX!J>8N(#$]T&?$M,F>1LE
M)<K2^B)$I,00G=OKD;)J!=W142:M9>>X@RY523'4H:T:%1"'?]OJ]9`7FY;%
M:2!O>U9'3%R9P>[GR/&@R@1N"OZVV6S#2]I-BU_1:5E2@,]^`7DEIV>1T`FR
M4MPV)F^[9F!H@M2]+$X_K0#H?(;=H`Z!"$[3Z`CIU3)F0:M:F0M<.XF#*OF9
M)FB1`Z@O;\?)^UZ[W4,=*53WL!Q66`V:'S679@"""IN>*?37)QW)EFBB"QJZ
MDO@:P6#`]\,-=^I=\@,Q$LNN(>D)B"-A_1M\CT9XZ*AG$)_9N6L5(03.`[MW
M#LA(%(FY/&V^Z,Y8$TP=]!I"($L2Q0!JNHH`JR)(V?<Y51QDMB![1S4U':2A
MD^NUK*H.(M7D0"F\D;(3Y?6Z(T1([#(U1^;9<UU1$^D:/*7R"U=_KS5YJ=-N
M'.8S,M*WYY,NN,<$G.\X[3!Q(LI*UKK19K=G]7+I%S,VD]WW9R!&]];_)$:5
M7:>5,C)&_<U74RG6#.]V-O]ED:UE#X5)3.?#%TE]L=J-;*I"YMWS^YJ!E=!?
MUHS4C7K[L#ZWAUEMJCA5Y#HXZI,W\)4R/]O=>G&:R-,;RQY(I52])&]I9C,C
M"_:P**5^=$`L.SA@[`43;A?85CZS"N,R0?BX)_&'UM3X`Z]&GY^>81[+^>7I
MR>*Y+'71WWR-9?)E,/R%BG16F\RB2,W`Z8%2XTPO3:B>J<$EVW`X`^5%41KK
MSZM(XUA/X[P,?@G@=](A;PN@UI>3S_@%N+553'>[">(X&!6B4U&+O\PU8N5:
M$8T58]S%T?'QZ=D?BC0LF0'SS/4^GE\>GURJY:B9!2Z*F1+NX!=CONUC:PD`
MH?_;FPXG5VDVS]H/DT'(\HZ>OJ,&O1KYP0L>8FN`8KT6PGX\^O3//R[/OYT=
M'XC6,N'MS;M&O64VVFT3_OO^%^.92.TYPUB-Q6SW6$!>V@^&M.\G>]!-"#GK
MI_DO9^J[Q2)OY_PN>1_3+XN-M]O-)=X]UP$V[LR-[N%ZSCPW,C[<N;&S)`86
MT`]]\S-V`J?>QM1Q<S$*7`_/P`T7ZR/+KTU7+!;O-#L+7>Q2`-@YZ!VL&W:O
MQ:OS6VW4VF*SUQAYP;"S4/D7N.YTD>=?"JUA#(($-/&I=SZ+URVXJG[;EFGU
M%F.#2T)@UP"XJ!1YUOF?D^=?NC9VQ[6QVD1_+<@FIQNAGI"/JNFQY/S2$XT:
MM90,;A7&29/&VX;9.6QD=L]Q[6:G.1%OQ^3X@T'PX%-<5+%CD=#6%U/!9-M&
M&H!JT/S3P\%J$^%G^5DG6CH4>\OWQ$/;G"-#_.+R_`+(Z<]JY>CLV#CYO]].
M+^9,!=^UEDHE-\/G5NNH1:Z#280B(7XL"))G3J2CFV[#(!ESON#(_BL(52_%
MOBW[F-'\'O;91J7'=KT>V]WQ<NV(>W9W+J3TQ>ZG+S:O+)!.((_$K$Y\F//:
M5BM?>&`JZII*8CPM^C;'E0DJ>JO;6^+UV^G!M9IF?2><N/.BKECN<Q+ZU!A9
M#+FDCHGA3-1]]HT][ZY3#XEE-NN+N&.??M\K'J7=:*SP?9O.*"5SQ/9(=UCE
M[XZP+S&7^VS4Q5AFHS%+L&T3DC7-;KW]&EBVIFC4POB69D)*OP^-5>D7S@[8
MX4",9=:;B\GT,I"5"VU8BT6U-SN8-9N"K%:M/5<D93G.MI#"QC9'VZRW%KF'
M#3S"H=FR%M$S7YLG/X$JG5IC_9BRA`Q<TTMWZSR;$D:?5\1K6(<Z911I1;3-
M7[!V.1DE/)%A@%._^JZM!EN)N;+%XX-V6(2]ZYKM)</S$@;O]PIN8!%8K=4H
M3Y.`6R/W+LP.6%B#WLM$#*MKMMJMI:Y\SU-9K)[9Z"YB1K]<-DL^LJW^;=6:
MSVE8.5]PK8SBOEQ.RBR13VU3M58*>HPW]7JF#10L\_"P;AIOFZ;5;'(@&'[N
M-*V9K12F-I[(-P\*$MH%U^WKO4BTO!?N:4L9+09FM%"[BK>XJ593-':H%[5H
M6%4&RR)Y*;E"8#O"(FC\#W[I'D"*3=&IPC7?-'W=#<![N=:.B^PM>ZH3&@)S
M/CSYT;^S_5OG$A3-<[]XO;4/^,A6GB^RM8E&^\$(JT3W)-FH-T>RT?71_SNY
M,L[/JI73LT_G7T]R7]B7DM!R>-N"Z4;Z\.KG*2Q;.^8+9`4(*_>'\=$-``RA
M/7:2V.W#4\!@:I@8%=L_4*I12SA*'0V,;[6K&GYN>/9#;KJ\[)[B$GN"[U/W
M4M$!Q12+B5X\WWQJV7<54P,5++6ET8S4/W-H)&-\5?/PIWV8NBA#T_4TEVN=
M5+SYA#N?AJFP]TLLLH#WB'2G-QTN(%GYH*3:GU<@$36JFA-95V*";9=XZSZ+
M3*Q);.:?O_)<7-D-$8R(Q!,CQ?%JQTD(_->9C-`_GQ:>Q3N?1PC/>=65B^W7
MP'3K99N-XOAJ-4281_XRJ$0/24$0L$!*.GDHHJ#R@Q$-'\;>V_3!V2D(OXLD
MQ+D`:'>RU.+E#-;*#>PI\\5^,-YI4^5H]5-_Z)%9^]XTK,->FSI*5C,-A/6O
MP!J9=I)\Q'3'N2:F*3+`IO1SI`TP-9"$07)[AY#K\I!E[`W%,Y9-'AL-=JMO
ML%VBFBN+<])<ZA'8S3RRP05C^L?\<KID*:_`4AK36`HB*RI=>\0TKJEM-9%J
MEAUHM&6*8>LQ$(!\&/O]YJAU3&E1`^,$\W"!&H#<3)UF4WD,%"2H1W8*E*V0
M$?I<T=0$*O6"AYIQI`MOZG&+8PUY+HG8,C`'[J9Z-!+]+(L9T3FN@TTJR</5
M-H%X@2V0F@T;@UV0^BV;%-Z&-K;R]AX-V(<38F]@YBL\Y`3X1.;KM'?>!KK/
M9$M>X"78U?AG_C`3[&MT?J*G^"OL:R,>*KZ3>[H]0__?0LP[]XU_)`!<JR7]
MC=JEG0!;!7'3-TZ&0VS^[O<?68Q\<6[=R!/^4+KN5*0`!GJ/\O;5"NC[,S*W
M@K!^KYK?XI1DP`^>C^S>`VY$L3O&&"PL9:('%E:4!``?47MXPU9S4:L5@2CH
MX6)_($H(R4KP%VJ,E,4'Z@`MJVRH`Z^5N^[63Z(3:_;C)G_<S'W<X(];F8]A
M78L_;^<>K_\D(=');2S[H-7;.:13CNZVUC75>(/\X6,2#D`S.':CM,,L8-T;
MXQV"!U@'`JA:.:!O\*5*#'QO/%#C<,16XADTM`E;3Y@&C;[`R=@)S7>J5L:A
M<^\&202/V9)K%B%1EK^,Q3A7:FS..T"$ECLP>;*!$\>2!";94\IY):,"_,K=
M/W#976,U8FBQ<8L=JD$*Z>,?]#\AF#*VHH(@:Y$2A*IFF/I^>YX$N)A!L0F@
M*ZJ,64\AWOI>62K1&ZQ$-Z<JT:R0J2#C">A?2:C-+9#4R.-W27RC"=@^+#`!
MY_GRA&VX/]K[-TH-GQ?*""A33/<!;-+T)^,LJ!F=NM2PYUV,2H65H$/.>`1Z
MOR>4ZYM'X]X-XT19%D760K62F@L98R'(CK,2?;XSYD7F^2BVXT3,#"GV!<*N
MW=CCAO+W=H@"F#B^ZE(^4?C\-/-I=FO6M#&BUHH;S2_L-]]<E[GU'(YC3^,X
M*NIYZ0R2/EYPQHZ_*7S3$CQ!")P78@O/>YNP>H$]N&H\#])@@95N#+@3B@VK
MZZ,&JA4<`0JF%_Y13@=@O0<H/<W[<-*5AFX8Q89HK1Z1TB0FR(@8&%V-\\,9
MC4%?50JMG!A@C.P?[B@9R5D'Z%+D][@QCZ%#Q9R&[8@!:?-P*BQL?2`O*([6
M<3Q['#F#!96T;;CR*5$0/#@8K$^X:G1>"CP=;>9(^I-Y@MA"W#A=@&>6\;0(
M<:UP38KG9E.:&`=P!G6*4]@$)^_.QHM\=&)#("B.3M/6%_BL,#0=B9&3`OHN
MBN91JV/J4@KG:KBA-.P;U@YBTNDT3R!:3F(V+IJX]B.@ED$S[T"1$!EAF*96
MS'L60$$:8+40Q@W2=DXIC\';9*0P<4R-<NUI!J!-CPOFQJ.+T&"7TV<R^A*B
M4%^@4OJM2,V!,H4_DPU%,=$F2,`84&&'S&"M.WO`$]`$Q!"M*3;!N]])+G6:
M^LZDNIGQ4S!A,>KEAN9ADB[-8LQ<'U(KUN72[:=729D9HDF6$8&0P,E<F$P9
M^(JEJ-ER(WN@IFW+U\G9131S&IG3Q1"$6I@BW>$O(%K$[&WB(HG2QOE1XT@.
MC6/VE-\INQ-@$3%1$)VALSPO"]B]J\:$'4H(?I;N>?.D[GG4AWWC((Y<Y<[^
MJJ#3LS)T&=SW;'>$7C<)/1ICJ\!'?G*E*(+6)U?TV)850[)0[<1169S23&G&
M:N88C9VCX9CHGC-S*L=-XA)%PN9'\)#K.^%$URP:FBLTSB(%6DY?+-072GK>
M0'KN/TG/GP*?I13'E@3*B@Q[NFVI/984GJ7P;"K&#,`AI4=]4+0P1>L&B"KG
MFW=IB*0W=%,/>U_="F@!(DR7TB;QA##QQ'17#BKS':9>*@IUD*@V4:,;B,G-
MV%Q!#)H=BJ@,F)'2B8GL`KOD&:ZR*RD$S/H<,X349JD9K$&'=")2)FS7H^E[
MCU-3;BC<,!I[C\K^B/3SFAG0J;'4?0QGTPA@>11M27X(X$`CK8C=AHZ<_"V4
M5N*5^M(F6_>!1R,7Q?!R-2L:C@CGSPS_HTZG#JGZ-C!A3!%RX1QTY:*218(S
M/P.8D&`1LT#9$JE];WPBP)=L=@/9;$$J:EYM4B[H-)?CR=`!6A&YV,%^,^&Y
M'?88I*:(,1)K1*2MK*$T8R+P7)%OD:T4PY#W`<:,36G<TAH19<AE69OQ3]]!
M=0O-,15Q;\BBLLGIT0472QM0^)&)\,QE%V]%C'.#PJI;30'3$#[E+QB:-VP/
MX.?;--)="#Q`_M#N_QVQ=A*@T%7F.'HB*2](L^TGTL]0V9^/_';0G7.M*R6W
MH>W':H:\4>2S2]/K$M]S1VPLH1D'2YOTV=].5M/1%B4M#,"JV5F.EFQH9&=(
MB^6)A^5C&Z3`:`.*HSM;)?W)MZ5#KRD^0<O^.[$]=RAZL8/VA96MH6LC<DEC
M%)307Q3?'&&W=E:@!&[);]@A.K)@BYCV*!UA\H_\0M0?M87S6);FM>21'N`1
MA%*#5@E".XA]:?P[QNFA(B.O($-T+DV"X^.Z#S#GJXAM0$Y[<`\H`DLI\L\&
MD>]!U2>U+WDR.#\I[HIO#I:*74\$V]+!BNEX;79QHT0?P"=^6E@V]YNSX[PE
M"=D8#!>TY\033GP>(8_N%8]#)QE=W0\,M,Y$WC`"B0B0]8>)V%^U,G)]"OX)
M&N,L6Z7EHZI!;EITDNOK*J!0%F6]9IS[[.ZAMVEA@0EPQ9,G!G,.KP[.2T=*
M(Y-%I);*%O3I/PHJ5M$FDTU`:K7^MQZ;X+S0O.V;(HZLI!#KU(PC7T$87T+!
MA"<WQ9$&PF$WQ)K\>R?$Y<OBA(W.JVH].Z_JU!\D40QF_[MK^X<HK:E6K,/.
MX<_[DQ$UW>F<BX&[#"U4)T1(+UNL8)-[BIEIRLF?>0&3!L]<"V5M'N,(G5Y)
M_T[/E'_:M9YM(Q93>)8RC`>"$9%[,^OKQC39%#XXE/O>C1]-`DK6[5;L8V.`
M33TCR0QY2,Y;QJC^(/`Q5+<1^;.KS]";5$JTRI3+%(PYAY@65LITA\E&,=)N
ML3;/K\<P2BKZC@4B<X^0#)Z_NW9&&'T%]#D/8:_1>U.[>\H!$EKP`RFP*JP2
MH0I+"BX(&7W+@)2W+C`4N&7U;):T0F=V"&@29VU5#-^N_X0^A4RL1D-?>7SV
M%/XC`8SB?C8]D*F!\=5^5`UN]J&:?AOEYEJKZ?OSM<'`VO`@0G.U;X>ARU;D
M@QT2O@X3ZCI//K$52M:M*+4_(NZ5'Y)FY2N.0:F]O079@$2+*1*"$V`2#<+5
M>'=V_N4]P?;Q0$`V0BK&\N*`XP4_7)PA#+SE;:=IUEMUUL7);-959>""F/0I
M+R67<:@5695J[R:KO5/+_#6S=+^T6*"0+(%(M4%2V31R`6KLMNI@3\OHGTJ:
M9;7L2EB2S5XCU43(+>J!'L()4Y^"`=#9.UVLGUY^RNFC\$EF,<IL(T4!+&VP
M-K4*62K7I.@?'LOY@28X)FZ26AX\@""/[MRQ*+%'39>J\+'8EO3ART_5BO8F
M4YK2.JF3FP_`,D:7&R_$+@#B&P`,=)A@A1YZ,D!SM4$C<P[$@[@KA!=E"/_H
M.Z)3PBT<)$0#.[<!]BV*!!61H1QQ*HKMAK!2^#>\Y-[VDM1+I+V-E)]'8X2U
MQ`@R%<!&B'J!?WN`/1:T/$8N32XM]XUF85/;"JRK-\^&,[&C>)J>4)BE/LCR
ML6KE;1NGYM21@"9X8:2T`6.Z,C!1?T`,"-V2(C*0YJ,GL_*TMBW`MT$QQ;*I
MX&OSLK5:4T\-'.:?CYVA$X;D5B(RI"SO5?HDM\)RNJ;TM=$X\&66F:;,97/F
MT&(:2*!147K$T>MXUGQJ#AC.8_&\"`R+!K1V%RE.?)I80*C>^K^]T49W/D4N
M>SH,M)S.NF$74DYGW>7IK/CSJ>Z?GQ1VNS:'9]?.\RKS`L6(H$:M,TZ'M':5
M)GCI1(X=8B&+C\&@>\<+..B!_A2_J-?E6J?6/N_*TE4:+[V7S9G<*X[>,JV%
M!JJM8W#OFN9BZ:C\1CA!U+0*K;9JY8QD\;EV[ZS%!_,5S9%Z-08(!UAX+-^+
MSG-:`$W^&U4'6V!)2+W0N(K;GG3_OR+(&X<[,LVY^3I3=E^*ZUQA'`)+I!"!
MJI7@!BS&M"QW0^[`:LZR`K8(F:S.(I/'-EX%$T8S^V&0&U%L;*-F?C?-SN&.
MC/QNF=W6*IGJQO&BLX(\"`IJR-R2#<.L]N$JA_V^*F:UN]LTMWBN@9S_LKU$
MQ-4I2Q^%W(PS[MYPTR[<ZFH&F^_94-BFV5U(3J]E*.Q23'=;)Y:N8WG];@^6
MNM42BB\&Q1T/=1YKL4N'\\0Q\IE0#EHT60J%_LM^+'OR47]S47:+J62B<G+@
MPD<A)XVA*AYBGPV]:(TJ%]2B5&/0/,3V]VUN=E_?B_EI98Y"#JK.7#D*ETX_
M\/NNYZJ6482B=TX0.K';QT1+RL8C1SLE7?;CA#\%9.6/]XW,KV6WSE`"#TLV
M8V<4`17'#X[#U9G4F3D.PL>TZ9W,B92D*WO7J"$<LC=>MG*&<CR'B>=1:F5>
M^\WW$M6K<JD:)&-L\?PWRO''4AG5_B^!E<(83A4_2BS@?K8*,:AC8V;U=Y%#
ME:/!O3.C-47)8W:6QPSGKBK!3)XHHE+=?6,7V/F3AFL0L:HFN\7SF>R).A,>
MDF-B33IUX\PDU6;2I^(LG`TYX$V6H%-+XJY02_S('3A4,(:=JQ:K/=P*L!\!
MPQJ-,,>6FR*FI?B10;7I?P%3_2L)W6C@<H*[BQT7G0@S-K"O#X[AVL!<LC;F
MD@DU'XS*+T<75R<_8S()-?A^W32S:=PH9Y4\N/X@>,#YY+KE+L[7ZOTT+;&E
M6OF'=E]%R24Y6+6F+O4<8ZIXV]/#W3-/\B<BXA/)H/,#&G_F[/)5.2"UF%^]
MWCLHS$Y:8K/9R<_O_FME@>7,OALKW_>9@\TM/%#<5N:USNSX<(X=[YZ(A/M'
M>>@E`ZS+=P98?&22`LU-9KT`+9%WP+!EYR#2C?T^E6KK3#QZSS/#`FZ*,SF4
MZL/`O<???OV01`>WMCW^F04QR.%C-^J#9IR$SC70^$=XZ=^_5RN&\:M\\@*L
M'5CTR!^<(Q9<!%&,5A(/XQ7-F4Z$J823SV"52V?XVQLG\+Y?G+0[W>8!_&-9
M5OW@G_5ZO?/]ZOKX>[/3_HYW;C6:UG?@N@E0!GW+C8)6P^I^_W9U_`;'H[F@
M=46_O3EHOOG=:K?A^^D1%MA8]D2GHB?"L9B^=NIC3Q4?K!8L:%OK&0X.0<G5
M#S%S+T]M6[I>9"'?>K?>K-?;3^P]MZ'L_B\=:B1Q88?QXS5V<+(9>0LP\-DG
M^1VQ72#[+(NLGC/'5F."79W^[PFOH0R*&^*?Y]<G\+'!SL8;935($\)03UZ>
M?#FZ/CFN5BZ.+J__-*XOC\ZNCCY=GYZ?7>6^.V?MTJKJ_E;UCGF4O</F<Z8:
M<0BVB0'850PU6BA7O3!J,ET-VHD$;HOAB"J=P3U&M[[D8!^OL:&4L!<\Q+8`
MI:S8V,6*C07C>P)2RIG;`'U_/)'[(S^5#HNV[LHDL6W7#.W(LW]2LOZK[<M>
M86@3H`M+#"4?.MBL5'8/O+/=<&2K6,;'P`X'"UR3..@SDN:?$=K-OZ=:F97'
M_9S@[D3R?;727"Y]I!!`SQ0!NP_L15+[=AK6:TM?*`#Z"E(9%CK`JV;&+<R9
M\]SXIC8W,RY@RQC+=,""U2:;52M^X!\X/YQ^0D'-@1LZ?;#C(^,=-ID9B]:R
M18R:IPO6#\6,$E<ZA7A8"7:)'LWZ(I>%<\ADD?2V%TOB637'$<LV9NJLNY,#
MM2[P68M4@Y3@FP-\,SW6DT[8!3QB65?:']RJZL@?'`VPDW84AS3FX$7\L)W#
MII7Q`SZQF^S6C\0\2-O[3.%?U_9._2%&U_'3/?$%'DYU!6H2ZNK;Q<67DZ^P
MQZ/+/XW/IV='9Y].C[X85]='U_2Q<7KV^?SRZQ&Z!W^>PSVX^E/?%)#O`GLX
ML+JUYK2)ZEV+__;<;7VT/<H]B.X<)X[F@<^:^S"MLN=2H=MTJ_JM[+2K9$=:
ML.ST'94^OOWT\>5,QDZMU2ZP&>7'TWS_]G/,QYD_'?7[-%=<3E@D#G]@!!C;
M+EO*;-MY7M0YDD\VIISB+$+7:QW\<*+-C*K>Z`=1'/W7#`B4364VL*F,9;;;
MO?6<^@7Y\QRHJ]**H]B-$QXSL6H>LG@WF4YSE3T07I$'-KNOTAGD)9D?+4>I
MESR1AA)'J9K#.`MB)SU.QS8VJN-/K[L(A6\PDEGF:COI;(8&^23/NDQ[\@\<
MRM'<I$MI-':DN5&CODHRV5P65JU<A,[8=@>S.@&^GB!I[XA$;#2WKU=6H6&^
M(')=)?X@+&J_-N,EZ_%7O%23#*NY7!AQ(0#L'O0ZRT41YP#`&GEQ&=/,QC3-
M1G.1#F-E4#@'P*;9:W;7#\#5.OL56/[+^&K[R1"['=`T2?()8<*)*VI2'LUJ
MA52/FT?C8NC^QPE-XR:):9+2P/'<>RRNG3899W><>[MVGC4RV"5B&TM\=9+,
M5K28\,)MRM8V91\;!Z+7<@T4;_2FEE'"5AHNPEZW-@W@Q=1!N]\/$]N+M!F]
MS5^FQY!*/"I)[<5(;7[AL6?B=]?.LR5^V0O[,0P\C^IJ0L[$7)]+;?'8DF5:
M&]63]UDGV".?K-ZV[-[NBW'VA%N;.MC`,E?KY7S=HS16V1M]2WC8$>I[Z^1;
MRWC0S?JNS#IHF,W&(FZ=;>9DE\&C[<78"458%IMT$;W>CH27>J_2H_YUF=47
MU[YQ/1R&[OI8U>&+&>O4'9!ZN=V(\?%R=$+@'QC])`P=/ZY6QD&X:<-<=LT<
ML(#/-;:5SZTB^JD/+C/4W#(C2L9CSW7"&:#9N<!>P^PV%A'?96`T%Q@U6RL:
M6?'JG'^NXNLG:6LO`X(]L]Y9+$&WC*AF`-@UVZWEV-!ZAC2\9+VD.)XLX%ES
MG>+*7SGM12]QCA<I-:6L8E(4N.LRJZYSU9R^W"871[MU;^NI@E;L![_"BM8B
M05F61^Y5>[\=OJ^RCU]9X[LM-;XO3\7/\HN(U@=YR"WWHG(GKV/#3K<3A*4J
ME="B:N_^RJN]Y_U)=-(N&)I0NCW+\VQD5L=K^G+;C5JCL`NKJG.7@[UY2AAV
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M'BD$\U.D0Z!:`:.C:$;4;MW"LN=9O.RM5U]EJ<C+[_^PM[6](*>@_O^$L#2H
MN@\X/:=:<=,)NR7ZK^\\#;-SN,IB@E<\2G,AA_.6"095\%6MS"@C?#W?VL*6
M[5P.M?9"'6]+AV3.+;!0'5X)O5QI2'>Y'F&E,W<[G6G+<YT]]T:VS&9O!7-<
M]Q>`EMENO``&EN[<_53YR_-LFD6\E#O7><6TU\BQP_X==[4;./>.%W`IMC11
MC`/#=^+2RUN>9TNH^66,>:VI&0X2V[RN9G6SM5`JT.;Y1ZVF:74W:6C&,X[0
M,NL+Y45LE$R;@OI7R0V."@YMGKI.%``?1(D7VWZ\4:[>KMGJ;!(1+'$4"T>0
M[4B;+SA+TUIE@ZD-$PY?01J$+K8'3HECA(77&T4<3;/7WI&X0<L\;&U2,'"I
M6VDMY#G8!HEQ"0:%:;A`!2&."F=C8V2[?NS@:/J-ZGR'HSEV9`X<H%)[1ZBB
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MLG/#[-4W:5[E<T[0LC9I0O"S3M#;A<'`4U,Z??N66U7K"<_8^77H;%9>9V>E
M]_":<:"53II^S8.LE+8W02)L4T9G<U=2@ULK[8[RF@<YW+TH8JHLA<'0B2(W
M\-&TV#3AT#`;W4U2E<JC\%&:C56FWFV"B+@.[7O'VR@H+^3%VF!T:=9WI$*A
MT7B5O.67$01Z"O,F`=W:F7RDF3,8M^D@K]/V;HW,?^\RE-N'97[R,FWN2N@M
M`3UK[3-?7K;15!G/GG[97=-J+9?*O^?!V([96ZBK2`G`"0`>-B<UR`R'^$!C
MYK7?!^X]_O;KAR0ZN+7M\<]'@X$;DX_DLXL>0]?V3OUA$(Y(73YVH[X71$GH
M7#L_XH]>T/_[]VK%,'Z57S]SXD]V='<1!O?NP!E\?/P6.8-37ZSEWQ[U8_?>
MQ6:[!O8J@44NG>%O;YS`^WYQTNYTFP?PCV59]8-_UNOUSO>KZ^/OS4[[.TYK
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M>?9-P!DT`((O//#W*`QMGV.G!7S]V<?Z'06+D"LL9<92N'T]NOSC]$S+.^*$
M(\,"\]2X=D<@%<Z<!^,R&-F^R1^8QA7<U5!32X>P+[F@/F)2FKAGY]<G1L,X
M(/F&#^.'QI?33R=G5R?&T=FQ<?7MXN++G]7*T1^7)R=?3\ZNZ='Q[`VG_V)9
MDMS^_#O/JA3K?=FY;YP%]PZB2/K>9MTT&O7ZH6D`20//<G\87^)!C=I9<$F(
M0;/M0::Y?AQ4*S@;6OSA2,V#'B<ALK88QZD^W+G]._G(@QUQ@19\W_:QE7[?
M2R)`.--X"$)O\`!25XV:AB^+GI;T^GXP&CDAZAJP%+P8_GOK)7W`=!Q+[0UM
MTX#E'#B]ZQNG46@[7LWXY@_@M;A)V/0H;>G$^DN$HUZ*3I`_?NC$-C"$`3Y<
MK9`^A=O+;,F8W%'A3N2@[,S;^).1/<`)VT8R'H:(P&/[D>")4VGU_=`,I[>=
MN@GDA>^``_E.G[HMX"AN.I+SP^DG])$X8SJNFX`0W8%,]1[Q3\#2AP`>>)T[
MF+AWPU;*GO&V36],QK`JG>13`%+8?Q3X`_1]^$MD#%V:J0NOM7&.SC@`'<H8
M.P.0Y:';-W"P2!2[M]P=8NPA'L`!Z1K40[#PR(UCQY&[/_EZ5,OMS87K]"+`
M00?@[H+*BG`"G<'!%$!MU^,`^[/`)1DCUX-7![XC(1OAJW%)V&\RQN^_;3-4
M09NE]T9)O^]$T3#Q#+M_YP(^$@AA5P%"CKJ^))X=!^%CNGQ4L%7<0NPA"@5&
MJ_Z3.%>U`A`:NJ"1@!1"!`.0B-*K#$PC&Y:F[TP@6<VX2K`'+"\$".!YQHUC
M]&VOGW"R%Y"@YV#`7T$%-T'[AT_^2J*88&$B4?V-H$#2AN/V@P2.FCE)=E=]
M,2WI-@@&$3HZ!HQ;12=(:44EGYF,K7`6I*ZT:6W?'H\1%`!=$$AP6["R`ZAZ
M\VCPW8&F8;Q[HTDL.-$Y*"#TTYOW->-<`!?$%2[H^OV$YMK?$+X;4[X)?PN#
MY/;..`8D0KYH-"T`"HHMD^Y,PA9,@Z2/D*52.5Y1$`)@.UX7RED$./Y-W'"U
M0D\/DQ@DJ/$(]PUH<GT'J,'+,?7""SP74)\1Q9;`@>L%X*$:>4LD`>\R_IT`
M()P0`,-OJ!E'A"+Z[@W>O$ZL>+%A@@P8WL1*W"-N%12#,3`1@9B`7`)X#KS'
M,Y#7O^V:O5[/-(*$GF+._K9CMCL=Q/"^9T>1.W1QZ0A7#P"5D.VF[S$YUP2A
M$CJ8<8(\T:4+\I(!"16)=Q'2*!JBC%*T:2#W`T+;VJX)X^L4AXP[&U$"`2=$
MCAT3Q%S0!(%\3,,/_(/0&2;^@.`CI`5@NQ"<0T<Q.$,3%'%PZQ#-*QDQ=$,@
M8.;J@&'B*Q++@94&MSY0,G$EV\#T:I)\P"X=XP;4R@@O.N19@@;H$B'K`\C>
M1\1Y*-T4!>V=.P81$+K!`'$^>];T<3PJ+U'P16+)R"GM5"7EHTCE@O<-N#(&
M@OA!:P)Q6"TF-N,=L2"RXY4(,PHE&`F1,8]*Q(>2\0$+9`EA`:KW"`4&S]2U
M@"A@H9%H*@G?1&$DSH?T$13I#?`I<$,W='89T;-P&H`41[,%&VV"T</*$G*5
M#*\6C`+9B*&41UUC+``F,B-XVO\/W!D`'C2./B$/85IHCQ^5L(]!$XHEV?QA
M@UB%70S<"$U>4\FI4)B,S)CTMNN1$][#5@19@`V,,B=1*NB$GCQ$$5>DR`+T
MDJ'=!TDA-*FB8^';@[%4<D`6N'UW+,$$]/I7X)(1Q'8L"6!2J78.IXY`8H0#
M24VZKF_,H^IGA*/2]+-70"H_+QDYGA<1(Y)#(DDX\KHUXS35LI1>[VKH0#JJ
MJ+?7N0:H!X"%$L>H,A]>PJI+5*3DRT<U!$QGDS%*%^B*I\760JH/"P5Z%M[F
MK2,X7G#CH49/YR-)DE*+')P&>FI:*3V!@ZF3^=G.B-2700'L/^#MT1?68=;J
M4#IHMZR><BCEWYWN"H#6=YQ!]!G40.G[.Q^BI1/XY!`\<^+SX8G2@M?K^NZT
M4R_E8CO3?$9V=`?L.CKY@9I]!-^AI\_'3''K=N/)[<_>QD3LX=0'5NC@[3QW
MA]];[<9AO?VCU:H?-N;%$E@"OI2+-J1[R6Y3.8B=P3%QH`O2@=A_IY].GOG9
M,8;T+*UVSYKI;SP]^PQP[UF=7CL]Q.([G>ND_[*]Q'F9@\YR?F?N:^&MSG]2
M$'#TEQ6@Y/RG:\U].K6]!;!T?4>:@IEXG'E.E-M>]DA'J3_D.DCCG!>V.SCU
M/]EC%^0>+4":/\INX(FD=%VBA(_`<K]B+9!?=LE&%#Y`D%P:&.UFY[`WW_WV
M>IT,/-9]MM<F[`5`TSCL;1]I+W*^>CMW^0N0M]BGX0Z6V2>M!:N1X_-1_`:_
MNP/\9.B"1AF!@34"4^`NCL<_?_CP\/!0BYQ^[3:X__#I])]O?H<7`0?N-'K6
MKQ_2KZ5+1<XM!1E__7$3>@/W9]!^P11TXZ_L_QJ`J>!C+<=O;U(H@)**W\$(
M9?R(.![X2!!'/]SHS>^3"0X9XN!U?_U0^+K??_T@]R-._B%S]%_9C:'M/@:;
M[1CV\SO"\*"._X,UU*?J0<<?I(]9C8.FA4L/M(=`#TH7__6#N,#5W"9SWVV^
M34V1W<\;)"UUFV_P4ECE,J5EGZYQ[1>WI>"IEU)G:62OSW>;]9>_S5+J;/T-
MEE)GBZ]QLZ3.QH"G?EA*G661O7XXUVW"8R]^FZ74V?H;+*7.%E_C1DF=30!/
MO?2O/1O571^SW..,.2H_6_<5E8)D,Z^EE`Z;=C>OSO)?\LRESVI9M*R_]!65
MG'PSKZ7DY)MV-YO$R==]YM(/M"Q:IF;32UU1R<DW\UI*3KYI=[-!G'S]9^Z5
MG'Q)M.R]]!65G'PSKZ7DY)MV-YO$R==]9OBDTZQOU)DQ7:IST*RO[\R->J/1
MW*PS-P[JC8-&<Y$S8THS'5BD]LNOC!P;2[Q^YX]__2!_YR7P6[GOZRG1^47$
MWWZ&ORVVDMYP2RXZ<+%#6'I^_-Y9,L).`D'*J>9Y.\.F^/NT[+'C!R/7G[9P
M$6S2-2>__.L';>_ZT9')>3\/@R#V@]CYXOI_&S\\^/^?P\#+H@T^60O"VP]`
MU<T/^.</^.`;\7S\.(;GX7(=?^`,%,AX?2_HB\?N0DQB_S]#WQV`"#EL`^98
MWSN`A-_;7,EQ*!?T[!O'^^W-'$_RJ^$=>.`W'[*OED?+K2H^%2LW6V\6.+;\
M<O;]<!]!$O;QTQ&<V/9O`1S^P;>K-[]?8ENSR.$1Y88]HA8;6+R&Q>^^\=:J
ML;1)=UM\AJ-0@A&[2LP'FV#&8>VP_\1YQ1,?L"CV(#UW$`Z<\+<W5JV>A0$\
M+N"?/Q!B%OR!/X8?_G]02P,$%`````@`LH%;0)<'V&K>"0``Q'L``!0`'`!P
M;'@M,C`Q,3$R,S%?8V%L+GAM;%54"0`#__%+3__Q2T]U>`L``00E#@``!#D!
M``#M75]OXS82?R_0[Z!S7^Z`RHZ=V[8;;%HX3K(PD&X,)ULL^E(P$IT0E4B7
MI!*[G_Z&LFQ)L2B+MK64TGN)8WDXG-^(Y/SA4/KPRR(,G&?,!6'TO-/OGG0<
M3#WF$_IXWOE\YP[O1N-QYY>?O_WFP[]<U[FZ_#B<.K<T(!0[8_=7+#E9.%\\
M'&".)';NT8)1%BZ=$0J\*$`2V#HWA/[Y@`3^WE%_?0<N?;F8WCB#;M]QGJ2<
MG_5Z+R\O7>P_(NZRF'G78V'/<=UUQ[^M1#QS?NCV3[L_97Z9LHCZ9TX_<VG$
M\:IG'V0Z<P8G_8%[,G`'[^Y/!F>#P=F[T]^SU&R^Y.3Q23K_]OX#Q"?O7&C1
MSV']WAE3K^L,@\"9*E+A3+'`_!G[W813D(!T0*%4G'<RN!8//.@R_M@#WJ>]
M-6'GVV^<%?'90I!<@Y?3-7F_]^77FSOO"8?()51(1+U<0\6LJ&G__?OWO?C7
M%;4@9R+F<L.\6#45!'2T%.J;NR9SU247-'S:[RZ$W_E9=?B!LP!/\<R)93B3
MRSD^[P@2S@/<2:X]<3P[[\R#1:SM_F#5_+M+YD4AIG+]B:A_1261RS&=,1[&
MPG<<Q?[S=)Q#,>=,HH`LXJ$CDX'84Y2]2DQ[!TH^A89_W$D8<JJ+V]DUH7"[
M"`HF3!#5PRA`0I`9P;XQ@(ILOR*$">+8_$88\)9/6!(/!4<'!3.9A?@0T1,.
M1Q',(VZ&\]T30']B@0_+W=5?$8S0(?5O015\Q,(Y_(2I(,_X<`AF'=E&>O!@
M,^^MMN$W0N+I.F`O8DQ]PK$G#\&US>PHXGYB$HM[MIFBFQ[%!1)$W,XF',P?
MK*-JWH(F[\@CA9GK(2J'G@<&68+_,&$!\0CPP0MY$3#O3V.@-8E1LXI&+`C0
M`P-_"$842'5#/!A=>,@YHH\QR2417L!$Q'$=NMFO_YJ5,N%LCKE<3@)U<\#\
MPB2<UZ\+HVYK5L&8/L,'X\MZ(9=V4_==5LMH/!7CM14LN^2PC/+XUPM,\8Q(
M4?,=WU>$VE>%,"0R_K?NZ5_:4<TP[R1TDC.TBK9>Q-7[K'V&*_<!8N"Z9WA)
M-S5#'/I^[*RC8/-C)H:J%[=YWS4K8XH#^%>%*W)Y#]95($])4O,$-^FU[MD>
M/0C\5P3_7BFC4XNKI^\C`>>EJ2:5:<J!!%I,?15PKZZJOHZ:-%B)T'LE0[V"
M54P&Q$*`&*"K7->!2@$QGK_S2<]QGF>&Q$.<[(F$^XC0O*>&1`\'4JROQ(/$
M/>DG.9_ODLM_)%ZWF*`E>@CP*L"*N`JGUMV!:XJ#\TZ5%CW["&!^^=@(0:Z%
M3013[&'RK$3ZA&4U"(5-K&#8K/031/PQ':$Y@=F@7!M&8W.O0[*[H14\0F`I
M=#*O?K0GUX[!D:.Q(:5*<H`_KSZ4>_>,@M@;D"/$^1(B_-]0$&&-]-7:6D&5
MCLE2`*_);,AZB6<8[K\_Q6""HQT+HH:X`7)_8M0S$3U#;TEZ0K&?!*TJA;&:
MB]>,JR_K8+8**D,^-M!N\A9@>S1`<B0V9+PAZ($$8&&P;C'/4EB64"5$MR+C
MW6(7-[.,I7S%*2"T+._..5E,:T/JV.4V$;VD@37Y4\]5[/1V2QK8D+\T8;F]
M=`N36W4<WE:THDO<ZZU#:1,;&*98(J7A*\0IN)H"PJPHC.+DC=*]1W1(*C2T
M@:>R-2FS'YFDR)#G14?<6S.$?[<R(OD:E(2B)Z)PE8IQB<3ANOV,LW`KPEIW
MQG3!C<,XB!R70;T[.>DX+UC5^L3?X=N<$\8!RWEGT'$B`<*Q^2K6;"JZ/1S(
M5`,_O`4-E"\C*=@?VP;VE8G+8JX8+J?@^V\(?'GV*\4\>$.8RSR@%/'I&T*<
MCQ53C/]M#\:"4#*+L"CVV>#LMVC&5L=9:(;Z+3+$56-O#?XLZA89WWU0%U%M
MP(,$;01?P2@5;BJEJ]=/;QQW?CLPQ?W^K>'6I<O3^=W.(;Z=;RA!7;R<M\CO
MJ@R\+(.6(F^1_U49^9%R5ZF26N3`5;-TV[M\*=@6!9W5P%;9MD_AM\C<58-?
M)=^7PM_'ZC6RT"A_7,*RG,F!%2O[^0+Z3XR?=C,_2V,CAWO-.`PYNG))O&S]
MX$<8NS=,B`L\`YI[M-!@,.%@`^%'L#<<!6"3AGY(*`&3%)^$N%K,U3$(#:I=
MK:P@X:#,"6<S[49!EL*&A)^P7$TX==LU,N9IK.P0SM7A9%B1=\I:1&DF\58%
M+5Q8.8AJ=@C%<:MVH)#$SH85"1\B+N*UM'PE*R2U([/`8,I5QOL2Q`A8G-XO
MG^SE;8YPP]<=9+BKS0?Z".X!YC"^DKZV-S--6]M1>7R[=9-H\[-5EZU@\<S[
M:FL,K=P'T:`K7FQ:N>NQX_Z]\K8TVQQNLS$6FL]<9J'(<K4R<;83JI%CVLI$
M6HD;DE5$;N"W<FMK!U!C`ZG9IF_XY*YZNW>%*YK]@8:BW]/[R9OF4H^N534Z
M1U%'D5.NJ=.I.BKL)6C,'CS2)F$;E0?;?C!(8P[N3&#0,Q]TQC$2^!*O/G49
M,Q,61XC<+C'<5H^L5H>0<4G^7C]=)*Y*&8=S1'BX77)KV-A&W'8UF\%`N)U=
M+;PG]2B0*8R66UJL8<WM,&+1S/SF9PJ#)2!_IU/,.,&986$E+YB(<4OO0-/J
M*3B9(L=-A:,N95BML9T30/GY/*:O"@C4//(\'F%_]T&</9DU"W=:U&>,,M.T
M&9A>E0=4!O2Z73/0K"L0309@MHVE;+U:HF'&/Q/P,"Z6GP4&(YIL[=''(2QR
MSV5SRH!!@_`IM0MY`+XB!@W"MPDT]\57Q.#_NTG:DTEH&3^71!VBX,S#V!?7
M$.O%44'UH6;*Q2;2>S;TP#'@6'N:8@?("@P:=_(N*5L:,2HY>8CB)^SH8!KS
M:2K:\FTS$PY'",6R\V(L1*2>?0R!;5I,!&N!BD3B#HOV5`T96#KFN!&QP!^O
M,L<,.%A'J)1^&V>BQ-4"<X\(;12VNYV5(Y`J(72AGF*N$D`P;I+G41="T!!;
MS4KODY+)9B--?)!65OW6I*!"SZ"5YSUJ4E!A%')8M61+%626IFOEL1GS2'2]
M<6CJ%+2RVGH_]1A8W%8689N']SFM&`0SFD,;#=UR/9)^3#S15A[8.,[XJ1SV
M:XZPMG,0E>287MGVXDJE%I76':8!78#0RAJ\_51ANHW:RD<4'#9*S'8I-45@
M;WHE,<I6M:HDZ.OIYU7N\L"2H5:JJ>I6>3M+#`_3384MVE8^F^#86BG:C-?4
M8/_#QDMN$UQ3D_T/4TFUBI7#GN3SE:L*:WH+5[.@[/?2K&9A,'K95;-$+WUI
M5;-$W?L%4\V"L>,U4<T2MOH;GIHE=^F;FIHEJOG+E9HEO\E;D9HEN?X%1UHY
M/VQ>T@Q?_@=02P,$%`````@`LH%;0.T0.(JY$@``<E0!`!0`'`!P;'@M,C`Q
M,3$R,S%?9&5F+GAM;%54"0`#__%+3__Q2T]U>`L``00E#@``!#D!``#M7>MS
MZC86_[XS_1]8^F5WIH0\]G9[,S?MD%>':9ID2&[;W2\=8PNBK;&H9">D?_U*
MML$V2$8R-I*YZH>&"WJ<W]'C')V'].F'Q<SOO`),(`HNNB='Q]T."%SDP6!Z
MT?W\U!L\70V'W1^^_^IOG_[>ZW5NKG\<C#H/@0\#T!GV?@8AAHO.;R[P`79"
MT'EV%BA`L_?.-9C``(:TU<X=#/X8.P1\TV'_]SKTJ]\N1W>=TZ.33N<E#.?G
M_?[;V]L1\*8.[J&X[2,7S?J=7F_9[R\)A>>=;X].SHZ^R_TR0E'@G7=.<E]=
M8>#$/7N4I//.Z?'):>_XM'?ZX?GX]/ST]/S#V7_SI='\'</I2]CYA_M/6OCX
M0X_6."E`_:8S#-RCSL#W.R-6E'1&@`#\"KRCM"4_!=FA_`S(13>':S'&_A'"
MTSYM^ZR_+-C]ZF^=I/#Y@L!"A;>S9?&3_F\_WSVY+V#F]&!`0B=P"Q598[RJ
M)Q\_?NS'O^9+4SJ\<%4\3]:'?O)C4IK`<Q+W>8?<F)$2<#K"$NQ?O66Q'ONJ
M1\?C[.1H0;SN]ZS#3QCY8`0FG9CB\_!]#BZZ!,[F/NBFW[U@,+GHSOU%/#8G
MITGUKZ^1&\U`$"[_.H%W$X0P?!\&$X1G,?'=#FO^\VA80#''*'1\N(@G6IC.
MVCXKV9=JM+\CY2-:\?>GD$Y0UL7#Y!8&='"AXS\B$B^;*]\A!$X@\)0!2#:[
M1PB/#@;J`Z'0=O@"0N@Z?NV@Z+I',[`+Z6D+M1#FPEZNY:<7"OT%^1[='&_^
MC.@,'03>`V4%OD*S.?T)!`2^@MTAJ'6D&^G.DTV]M\:FWY5#7FY]]$:&@0<Q
M<,-=<&TV5@NY]R@$Y!FMENBJ1W+I$$@>)H^8"DNZC[)U2SGY!*<!7;FN$X0#
MUZ7B.Z3*QB/RH0MI.V`17OK(_4,9:$-D-,RB*^3[SAA1Y8G.*$K5'73I[`(#
MC)U@&A>YAL3U$8DP:((WU?IOF"F/&,T!#M\??38X5/S213AOGA=*W3;,@F'P
M2O\@_-XLY-)NFAYEMHW&2S'>6ZED#S'=1G'\ZR4(Z`DB)`V/>%42&M\59C,8
MQA^;7OZE'34,\RFDG10$+2O;+&+Y/AM?X4Q]H`?FIE=X23<-0QQX7JRL._[J
MQ]P9JEG<ZGTWS(P1\.E'=EP)WY^I="6.RRAI>(&K]-KT:H_&!/P9T8\W3.@T
MHNJ)^TC!.=B5Q2>P:"QM)<R4\2'&[?A^MY,VG$>QJ@6#L._!63\MTV<5&J2'
M=I7(M9X')D[DAVK4;5;?#ZUHYL"@,JE)[28IC7OHS<!L#+`BF86J#=+X0IO`
M;C0&O15GU"CE-9#2ZZTLNLR@6Z"9+C(0>,Q2E7S+FJK5VA930&F@*[G0L<\,
ME`ASN15C),`]FJ+7O@=@G^U5[$.\:?6.3U(;Y-?TJ]\'M&N/=7_K.]-E<_1@
M!/R+[N;O_<;IN8HP,RO<TEW:\?\#''P3>-=TD^.0)BS:/)7+,4OZ?@08(N^6
M?D<X9(K+[IM.QB,Y*K.2^Z,Q-^WI.@-#*MC*".46WQ^UR3B*)R>_W/[H>Z;-
MEI`5_]P\-?&&QJQ*SMCGD5/\?4_TO%]1!F"F%7M@\1-X%]&U46YO]-&S*0KB
M\UILD24/4<A<8,PW*2:VK-+>*$^VY!&8(\RLBDP_Y6XWI<7W1>UUJG@)J+O.
M:U;-4W,+?8"OZ"XQ15@\)XNE]D7;8S3VH7OK(R<44I8OLR^Z1F`*"5VC07CO
MS(0;S'JQ?5'W"_(CJM?A9-#$RV"]W+[H^Q7X_D\!>@N>@$-0`+PA(1'`0CI%
MY9NG]PY,'3\A8K"`/$ZNEVB>IF?LL+WUZ7TV1CZ'HN+O*WJRT\0`%RFC1Y%E
M,^FI1.Y`G=:98#234)&672*>!.X@[`%\T3TY/CXZIO_1TO%!ZYR93(!WT0UQ
M!+(O41#2$]"-'YL@Z`D.3-F';F=.=1Y,1^*B>]KM1(3B0//$)-44'];.J+MP
MI*A!+1ER='S"V-%J9&MGO0S::>NA"=3R#.+9P4#<.,ME(/]U8"`+!^L,YH?6
MPUR3'1FT;UL/C:^890C_?2`(-PZ1&<3O6@]1;(7+4'YL/<HM6O`*ZLGQ@4`5
M'<\SI.U7<@1'KPQB^Y4=KKT@`]A^54?&#);A;;_6PS&R9/`T:3M<C]HZ2*Y]
M=XEJX]">R0Y=&^J&SW4=D,#04!RHI=U0%<^G?M&5V*A[43(6OK*99.*0<<SD
MB/2FCC-/;"7`#\GRFW6C2?KU[VG0*7ETWMFT&00>_09'P+N#SACZ\81*)=5@
MS)1(=]WHN$M+U0U#M2%.(JH3NN20%6H8@("=7X`2@D(-G0A&P`7PE9%T#T(Y
M"-PJIF&07"JE5;5@6H6K/3K0&P97SAS2/2TG_$6(ME?4@H<0$*Y;J-=^U$?7
MMEE2+*2/SBT+LU!&.Y523#5AK;$\&"HDV1\6`?SJ^''`:'CE8/Q.M>I?'#]:
M]Z*IU=6"*@OE9@2B.)\%!"R;182EI(8N!.F>53H$Z\5TT'H-)H#.9&\$7D$0
M;5$"!(4-H/L>!:X*Z;GRFJBGAT<OS<Q@>3K)KG*+,/O',F-#!I5B.X<2C%&=
M]ZM4(:HQ"=A:*')8[O#J?,L=P@1LRY?03"'+B]Q(D-E.-K^:B5BV*"G2U35C
M*Y<WG()FT"O/?1/TQ!PY6R4*OZPQ5,LSGE-'!XK8U*,R`"45M-&?61G(5BM+
M204=])=FQFZJ3T1EJ.II6PM71!GB8IVHM(H.#",0.HS#-PX.Z'F/#%PWFD5Q
MEB#CO0M%2"0JZL"SLO!O^)76Z.<4U$HO+QM`4$@/G9)ZH"&:G[*N)Z/=[<U7
M*O`7J'B%F'=.RE&AW:FJC0]%EU/&!_/BS:KX.GC`^7X>DX.T=D5>IGF9'+95
M[J$HC"W?ZKX"=VKPLMX*KH*)+P-N\#K>"KQ<M\PPFA<YJCIS\V@,WG_*?%MY
M4)+NI`RSZ7O/CN*%LR.=F1<ZJ@RY:/_.H)D7*ZH^FD5G<X9-5Y"HW@`U'6.E
M:K?.#U^92FQR=E/-V'G63I,SGVJ&;W8&5!U@2R,<3,Z+J@-\66F3$Z=JGN4"
M!Z7)B57R[K`2RX6<`<3D7)UJ;!#%V9B<JU,-*<^[:W*ZCI*_L61(N2?YDU8L
M8SF\9:[,#+"Y!V%EP#7Y#C/>F'M@5N;--JRGFC;NC1LTMKO7BMI)T:EU@!=H
MJ#%DW19F<EZB&C)Y14Y[;N+6Y+URGZS!&7PR@ZEZM"J&7F<[DKD*EAI&F12;
M#+6Y"I<::IEPCPRUR9O3;J?E/$JY[<C`/-7B8S-Z4S0H+0\X)MN+MXQ'@./\
M=$&TA4Q-S4DG27K](`I?Z,3X*QM',9*-&D8@B&_ND*8^+6T$Y>(;/J6J'$J2
M1@/4_'YJ$S*^Q(#!QAQSRY<%6NZ9J]/32->8?D3V(%_O<5=*XVF#EU49[J8Z
MU`9O:D682YVI#3[4BA#Y]T;I<I>:8IO1=<I+'TO5HG43VG_J?1&JV?DR.K2>
MI;UBN<FR1SS=0>!=0S\*A:>;;;6,TLFU\/4680"G0>)B=/-O@OU(2;I#A%R"
M"2WS["P$/%9I00?"'T$`L.,SC[DWHZN868G8ZZ8WBSE[VE2`:ELM+4@P9>8C
M1A-A3E:^A#W?)3RY!V&RN;*I*.!;L8R6!%$J_AP6P+255EY)-8HW7NJC7R1N
M:;9B"6MQXW(";A$]^8IP-HXPB>5FN=3B%M5#,P%4T6%AX=>4#!_%@?SE&U!Y
MG1H&?-E!KG669A!,J18),)U?:5^;N:RJM?6P/!YNT2):_6PM3B:DJ'(GZ*]4
MK7BA6MK@E6YX4W`?L2-0K,&EZMLV(W'%1MI@6[*6I8.S+&4[5OO-1WR%XI#L
M184S\^%8B0I'#.U&H1K75JD"UH:`>5F@/.VX#>'PVS<4)86U#2GMDDMRF_VB
M#5GL<E"YA^`V)#'(P5.RM;4AHT$.]IH!I@U)#'+`MMJDVQ_E6_4<9F-]-?N3
MXC$IQD>F^1=7:#:G/S&>O`)];B=!^.W/A:DJ=[E]6D?//?W_BTB2@_J,!.3%
M0S%VZ"F6L9[R/7[V9@3HJ!`8@B>`7Z$+DE?]1L!%TV1FE-UYW7BWFL/_2F?!
M9CGKQDN6.!MH%+"L*AZAY65;2?5.88R[W'WM8D!7UC5(_@Z#S0#S$?)]JO"]
M.5CDG%9MQ3KTVN306T^T*-W2!(6U&/LE(Z_K#+>NP36QMCT0SOR5JV,=0B8X
MA+[@.TN3T,/KB%FT$NTL66KWX"W^23PWI"H;ARO^\2$^-9&;!3VT02*,YZK0
MD$%X8]6ZXC"NU34-50V#6-*./NM(J88J"*]=2OHV6'^D\6TYKFNW]]2)5:2Z
MM>&BY(I'DXUD60DIU`:O4G/L6-_,V^!PJH$;S1N\VN#.:GJ5"<1I&UQA#:^X
MK9PQUUM6`V>,<Z4=6$S;EH16):M#P5/(5SU,PLL9OWKAVG38`PQ:+$TE;+M_
MO_QF47,/=7+HE,61]BA'4WSZ)@*3W*M3J*<'%;Z@_1HDJ4-1IM2R_SN!"U@4
ML<@,N%.3A^(//RR_Y1?EY;'G#*N&[O%ZU9TV8.T:JRF*C2YIS]Y*NO71&QG2
M,P0&;JA=B#.S9.#"^!VCS.+RC!BECQB]0@KZ\OTS75W#8!6U/G!#^)K<A%O^
MU&0C76D)V9-[ZXK+!+FZYJ!*C)#KIR8E<((F=&%D2X[=.DX_LM>L2#RQ`B^]
M<#0_R:XA8;(DPF#+S-ZYV1KRAAD-/B`K\S`]3>2,QFN$2U2H@:1K0,\L+HS]
M((,9PB'\*_D<>/'-X,/9W($X$<,;Y"E4UA+$.9G0'?MA<K-P7YQ@"D9T6W\(
M^`M`%-NITL2A'&Z:O+/G<T!W%K_DTEJE)K3<=9.2\1`\T7%_F!2>PUR]A2E`
M)UG9C-!AF9=]I".(I1HS"W?V9J0RREQ5,S"MO64C#6B]GAEHED]<JDS`?!TS
M4*QTYO0<N$6#46B@!L5@V=LPR"U0]K:QZ/5?CGZ@WH:UR*W<Z;Q3%D=3%4P6
MA0;,QK=E451HR""\V2FDXGCR&C`;7[7Q+&O((+P<*X@:3EX#9N.K-IZFF8O:
MD;E%=>?8-)>(4!<`C]QB-(N]C_);B6HK.I$^HX%+E0,,9-6."@UHP5?V\F#Z
MY"![-QC#<<0S#E5OQU2TY7=.JK10@_*;7Q=+E\S#))=)0?<"9A2*.^09[A0;
MT#(H.1(YQ@B9-:;0@G:$"FE`V^MI2W^]7(]=%SF_^85M<($)*:3<+><IFL\3
MQ[?C/TPF\;5ARV<KR\)RU.KJ<Y<WZ<3<B/OD+),L(MW<F_2:YI&JPZ<-KUSO
M:UZIN3;:\%SVOCBGI/VUX2UMDQBW=DC0_CRW0>R3==2UX0'A??%,Q4G1AB>(
MZPHF64K/"EZ1%9O.S)U>=;-)09G-V//ES*)M<4`93\Q-Y5%W9Y;O,QL.ZC9<
M?5TW$WB1!^V\S&`W/A3\^^V\OZ">B5`>>J/_0H(#RWZ0&.GJGNOE[J]J7&[#
MW0J[<47!8-N&ZQ3J889*"(C^ZQ8J<T4B1*`P110<@]JS9_;'%15?3AL2Q>N=
M+-+^<NV)Y'MCC4I`4AM>VZD>L")UBTWK5HHB\&;L2VVX>Z^VB2,=#Z;]LCZ;
MXUO[,S+5E\:IN5O+3NA+Y5&&WMR-82?TI;I^AMY<>2KYSI!2AEV&VUR+GN0K
MBTIYN!EN<RUXN^#>R*K.`)MKL9,'O)OE/[/EM_<*I_9=X7"/0D`UUG2,V!4;
M*3;"G@<C['P,"'-/I:$O3W`:P`ETV6$Y,;VRRSV1#UTZK,^4DDL?N7_HN/QA
M)WI3>M:"UW9J\E"2G`\K7^R+"K*T/@Q[NMN?"K#;!JS=!FW%?T'\7R&?[C(H
M>:B8CN,==)F;;8`Q.[^P(ID25U'N\Z]^J=1O<5^LWHX5VE9H6Z%MA?;!"^T=
MMEHKJ<V2U$(/]LX"VLJW_<@+I1'D2Q.E)JP,MS+<RO#6R_!JVX<5WV:)[V4(
M]_L!B^M=+H,KX0Y_4RZM8E4.*XZM.+;BN-%7F<JV+"M^S1*_,KGCY(!%\V&)
MM<JC*3A55VW.BG0KTJU(/QB17GU;L>+>+''/LD=ADK]1JU#?X1F7<HKXV^*6
M2M:-;:)R8@6T%=!60#<3?KYE$[5BV"PQO/E.-2MKC]E6DIDGR?9*I^RR$$&0
MK6_EM)73&N2TP@2W(MLLD9U<</#L+`Y82N_T:)F8._S-NK2*U32^0$W#RF(K
MB_?IIR[;LJSX-4O\#CP/)G2M?AP&$X1G<:*=(;9L=2+Y&Z1Z.];B;:6WE=Y6
M>G\QTKO"5FM%NEDB?01\^M%[='"8?R;'1INU1;RI#"!?EJBT8`6X%>!6@!^,
M`%?:/*SH-DMT/T5C`OZ,Z,<;%NQ?Q\UG5E!;,=8Z?[5P&0A(%I:W0M@*81W^
M:/$$MB)7+'(_]5D78X<`^H__`U!+`P04````"`"R@5M`TH`+@*(A``#.J@$`
M%``<`'!L>"TR,#$Q,3(S,5]L86(N>&UL550)``/_\4M/__%+3W5X"P`!!"4.
M```$.0$``-1=;7/;.)+^OE7['_I\5W5)E>679+,[DYO9+5JF$];*DDZ2/<FE
MKJ9H"I*Y0Y$:DG*L^?6'!DB)E`CP11+`JYI)%`G=Z`:>IYL`\?+3/UX7'KR0
M,'(#_^>SZXNK,R"^$TQ=?_[SV<.X8XR[EG7VC[__^4\__5NG`^;M)V,$`]]S
M?0)6YY[$H?L*7QSBD="."4SLU\`/%FOHV4_$BZ#G^K\]V1$Y!_QS"H$/7VY&
M/7AW<0WP',?+CY>7W[]_OR#3N1UV`J;WP@D6E]#II'4^<NL^PE\OKM]?_)#Y
M912L_.E'N,Y\U0V)'=/2,*7F?(1W5]?O.E?O.N\^3*[>?7SW[N.']_^3+1TL
MUZ$[?X[AC?.6%K[ZT*$2USDWS\'RG0LP/`]&6#2"$8E(^$*F%XDF+W$2:%OZ
MT<]G&;]>GT+O(@CGEU3W^\NTX-F?_P2\\,?7R,T)?'^?%K^^_'+?&SO/9&%W
M7#^*;=_)":*R(M'K'W_\\9+]RDM'[L>(:>D%#FN:"@:"L`3^JY,6Z^!7'=K"
M[Z\O7J/IV=^QPI_"P",C,@-FP\=XO20_GT7N8NF1L^2[YY#,BJWPPO`2Y2]]
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M@R_IJ75]F;AN4]=M5&9[T<<B[XPP#V4[=%(KZ<<2]Y(2ETY``^LR[N3Z=Q8&
MB\/0EQH6'-Y4E_JI.XB?29C85@T(.0E]5,R:495R3"8E6"M85<$+5J1%)"E"
MC(0,>QZV`/23T)Z26J#/2>@#?=:,JJ!G,JT"?04O6)$6@;X(,1+0[WFH$_0C
MXA#W!<WJD[@:Z@M%-,"^R(XRW&]E@`JU`_@U_&@-\F6P*8*^T,>V8;_BB$0J
MVA(N5'WP+N9$:X88A[@6;F1;,9*H`KBJ[-$_5IA.79Q8LKT[U[=]Q[4]RY\%
MX8)--]VZD>,%T2HD$_(:WU`[?A/U<VT]*OE5US@1(C=Z8*,(,II@JPJ^H3)@
MVG11[TA>CQ^&PYYY;_8GQN@KW%E]H]^UC!Z,)\:$?0U6_VXPNC<FUJ"OE:!-
ML9QC:Z-6TTO=H>U.+;]K+]W8]KK!8A'XX[@*5X6"6L@ILJ:<C2A)B0B)+'!A
M8-*ZR=?<JR65[+@^.%RV'=0JPUHQEZ2-T"+RW)/%$PGK]6DBHY\RW)#Z;/G&
M!;6GJ4;.I"3IMI8D>4Q5X$?&=3W4^-<JBA?TZ32:!`(3Q\]V2-AK84KF)?$C
MEAU'Y/>5&[DQ&9/PQ77(D(1N,*7/O<'<9UH>;6]%A#@X<;5*"7I:7X2TV%0+
MDP`DE-]6#MG:85,])/4#-P`R%@`S05>PT-*P3&6'MY>34:HWVJBA:3Y@*6C^
MUL8\?&"QHFA%IO@GKNGH!E$<'0)5D<JVQ2J!G8?'(50,7#.DJH'I;G&`J=<:
MR6`D8JZZW%4ZH*2/]='S.?N".>V(G&Y50"GA0.U@(6M*[8$`PY/ON&S"SO)I
MX">](*+?=VG/#</@Q9V2Z<WZ@88ZRQ\L<16=Z\\-)W9?V'J`LEGH4U2E*W`<
MR?YJ`653&9OJYM4!UH<_8HV05@DW:\!*,>9LJH5MO?KGQ_4T8HCI.*3M$@<X
MO9ZTID];T\-FI-_B9XQ0L$R;\FD-;U;8EJ[_%H)-8]J;^O7.SI^0N,*H=LP.
M:Q[M(N)<S(.7RREQ>:"C'W;C&_WJ5X-:/47+[SQ[OH/'_=\51)*]2D7(3<L`
M%E)+U./9>&HF"+L8X5OLAI8,&T5$_-#,?U29Q5B-HDYE/YX&<+A<6)H99(:Q
MQ<9@"\U3%G5SG9F+DUOS]:&L[`DL7T@YZLH2-BND_Q&EDJWCL3D9ZX>B-'7O
M.Z(/FB6KM')EE`.S9!T6Q^5)EUU5BXXEZZQ8D'22E3!M"9:R=59[3FG'9Z4(
MJG/I5)$!E7#;DKA:S?3NPVB$*RUXF-4[T)+!0XAF[5'WQH[<:#`;TJZDYK`Y
M:<.?CMVY[\Y<QZ86\F5:=(`V##S7H<.SLC5/!ZE4R)%#[!3@D:F$P0RR2ME^
MIXQ:V.J%5'$+UD6=H#G&UJ>^=6=U#:1HMSMXZ$^L_B<8#GI6US*U/A8=`_=9
M5A_<>CK(C_,QU$K\R_Q]Y;[8'L[?&''7#L,UM53V7KJ:K$(Z5S)(E$=P1@]I
MRCYDQ,&((55PPA>\2_;:S_2G,H(>XN"-T3/Z71,&=]`UQI_!Z-_R#^9_/UB/
M1H\FT3$8$S#I][3,5],8G=#1<6R'L6Y7;\Q/5K^/\>B4#I>&W8-ABUM*V8PT
MV8KKC*RU@DHVA%9OB?;$2OZ^WO*=D-@1N27\[UI=+5"A/7(6VU4[@"8+95(]
MD"K2,SX^@JM]$U=V=T>F,3;AS:W)/[VEWXGC3?OX*`=N.2TE3::+G7=>\+U/
MVX-^M/P7$K&72OXT6:^>?<&T7:Y>,HX_6*UB%A]BJXS9J!<2Q;#1S`B_T9U]
M?9S=\*%Y.N%$S9+?_9'9Z0'T/ZO_:([94`>#0;(U!/_5G5B/UH0.?:`_P"CR
M..@]X@\L7MSU!K_HG<,X%HMVP\?![5\OI"R]5Q8GKM\E48)^P>SP2!29KR1T
MW(@,9FR1S6")0[7=]VX5!([,[&G@K!;IR+&V-1+NHA"01`J"6;+@*N"")^%D
M490ZW(=4"J=7^/JXP0E]$,:5QHZ8F3Y(6A_FH>W'?+D)62R]8$V(EF?WZ@1!
M:E=L@F.0-O"HM0$N$'G!PV5ZKD/\B!@A;;<Y0;Z4;\5LKD<UQ9L8*5Q<F='%
MAHB)-LBH4[HO4Q@43N:UT0*OY6'DB*[WK*[9IP,2?.!@SR9?P?@T,MD3BK:(
M<@A[-X&F<2-I&8<$BX7+E\'AF"E@$[[$Q^E>T?.I1$+EZ$%LAF3]=B+!1_Y9
M&4W/^O6=&-S?6Y-[[6/T<MCDGJE+_-2,_.K'(Y0(Z<%_G7RSI4`KLLIAWK2.
M"Q7/)JC@K2Y&)/NYI?NG]\LIQGVN<OEN'3[PTKLSNHG)N@%=B(-=#.\[I1FV
M0SL<A.,8C_%E+U^&)&3;&,L[1BBI!]HB<ZJ`G<K"(`0NS=\!XTL-OE=8.P,.
M\.P<EM2U%]%+;0WT*,.;@##2-M!,(69(9*SBYR!T_]B><2WNT3T)/939-:,*
M5;@,;(6TTZ.!%^<E]FO@A0A$`CX4.MT*'O`MK56[+2FM$__<A!K8YP(MP7UE
MZ\^3#=BMPGL>+%*L9QQM!<X'JQAOM\`K1ZKV559$)^(S=M2`?4:J)=BOY\<Y
M!'(/M+&@`$I2*NSZK9D/TB6DN\7TX%ZZPBZ+=8T'_#0P]QS^X^KBZNIZ^Y3_
M,?-D`QVP(WP5>4L<-MZ$]]?G>+?0%7M;A!U[#M<?KLZOKMC_$#%T_5=Z4@<6
MRE"FDKH?KL_?_>6'\[_\[1W[\H</YW]]?W5^_>%OB?)SH'\L"2X&(-ZZ)2P4
M+U<LZA(];(OBP6Q$7H@OH5JVC%*>92H6HC:*\:U^4NHPAE6X->D`2P?C"2X7
M'IF/9O]![PZ&PF[/`W37H=.?I9!L:[IS(\?VOA([-/WI+6WTG3:7%E5TPH*H
M?E'7)]OC>'E``:`2@"+JCUXXL?$JSF0H@TIZ/(/451WQ]I;,"#5IFC!+OF-9
M4%AA!"ZV0`"4M'`:B_5>(M',])"7UKH)0HZ1;)26^-@"<..JS3KXSI37!_&M
M$551OI5H!="K.]!"K.]#1@+W'4\U(=[UR?2&^/1#/*3MS'=HWP4A_B/Y/JK"
MA)IZU#*DGG%BX*$>2`0`A2$Y0(#JXO].M;6!5D?Q^NZA?SO&#3XC<SPTNVP(
M8-X/>X.OI@DCZ]/GR1@>A@/\?6*-M*VY.QC1.T1MT'9'6/-[2Y8A<5R^A7H1
MA+'[1[J=FEE@+9:V&R[VB5A36/'JWNJ6B8YM>29@S^<A&\0">5VRA:TA/RKX
M#W;^(,2T3'JP"]]J2[^R8[`]UOXDXB5PO!W,(*;J778K*2<P3LJX_NZW<9"H
MBKBNIX3ZB#E8\?7LJ)47QUNEHX"J<;S5-*WOV0[G:+R-ESX#?83W77^.IRU&
M*X]M)&*ZL.CW$`_9G@;??52;6)#^ZN+AL,E>;#:AA;;Q[V>T[?AW%TI7+Q_<
MJUD%D-7`;\E%';!5HGZ-\G$=1(3ENWCFON)LHK9#B)I%G'1Q<LW6.49T3,),
M^C=M4=./W7B=N8U'L*FQMKCJ"%G#-A'8$E'HP.8C8H[KR=U)=>)]B<*`<40G
M,SHT>"@/&RWJ2R4AI`$M-T&D;EN=?AHW-85/NO&]WG?TN]U-#/*RBB9RA0:4
M`2N9#4U.*&`BZF=R3VV]BJG<4KBD<[ER9U7C&B>3JZ%Z6U(+IC?55\0$F]]O
M!9Z/:[EZ+.]!I!C)>3?5X3B3(7ITM&[%9"$#<V%QQ8@NLJ$,'+E<CU+`Q!0_
MUZCT0B7292#:A;O0;W68'Z9GI0G>*Q>74XSR7.5EP$A2N+ZWR:>R6B6*"V&Q
M"]]]!]7A=D+52MJ>_:P8I5AG63=C&7V(/,1"E>C+=NXNZ#8^Z'B[92:3K>F>
M&#RGU#$H`5QO)5X+52:E\,U5B2FBPU;2.>;-3BU@@FQ6-1'5\TZJF3_]]`JB
M)?6'K9;$R5,G>X5:!YZ8ASA',N7*M!XF51%YV7=.5=I&"XEF,^+$@YGYZCSC
MJ1,CFCT&?O'!>*)NKZ-");UJV"7B&E.!"SA3)8!:8."#\%A(3=P[@K-W=^D+
MX"_=ST;_DPDC8V("_SS&T]_P,#>MQ&N`UAP+Z[;2Z9^AV'PH'IEM/WE%#U'Y
MWQ4]1>4J%<$E*0/?6"D-(]9C6:GB::JPF]/'J7U'%.%NW:5(#VW/\J?D]9]D
M+6KDO7(J<;A;N:RGUY`4!E8::'%-N#R!U<IP*H)%#J^%#BK#;?5MB16%U"*Z
M_I:^%"AMVJ%X;(?.*WJDD`@5]RS6:`EE%.&+I49DB8LW_#F>(E'X/DA:7"TM
M"FTHP4^R)FPC!%Q*&Q-.[(-"[$L!M(-ZL=>J\'X;+&QW=_'-WL]*\<SKE/?]
M-UY(U^/SP3:JPV.^@_/XRWBA"F]WKD?"+AU`SH-0_."<+Z44?;FJY1W,BD):
M5A<4CVJP.EP6`B$/SWW/5*%TN'KR7.?."^S=-9/%990B-%.QO+MY06`E=:'S
M:,:J0V9!Y^=QN>N3*E2.R-S%57]^W+<7PEFOW6)*L9FO6][CV[*`A74A],@F
MJ\-I,1SR4"UP3A5:'P-OY<=VR,.X>`BU6TXI7G<JE_?^IC!/I-H&2T<W6AUF
M!:#(@[;(/U6H_85XWC_]X+L_)G84^&3*3A+;/:FWO+Q2%`N,D`,#A8!)02K&
M#ZL+=>&ZL1N=WZJZH0[I)4#*(U[FN9;WV[^O^*3<DAJ#&Q$*)@GD956^L2XR
M0`0:5A8VA35-))S<=&6OEF5`R;U#%GJJ`]]W04C<N<_GWYSUA#X@1;:#BU@_
M4;-Z013=D!DM,[%?!3U71X-"+M0P2[2UG6N`5`5D=``J`=0"7`U0/7J8<P1'
M^2U\1@\O[QS<F]"!OJEUFWX#5&8I5K=)VDF\!S\DMB<Y&;N6BE91;VO78=S;
MZM%T,MXQ7.57/=I>>G!!!&]<WPD6Y.TY^"2&-Y@@O#7].5E"-G5G,X+UD>AM
MNUFZ#^%Z--UI/!T\34T9^&/;(X/9,`R6)(S7>-)'C+E\67#>1DUAA=RL9I$`
MJEOB#>@8@\KCRL94`SO@)H:-#DV,/,A!YALN&T;?6G`$0S,09CE6HSFTL(OX
M)+0]/!1BNG!]-D.'9]R:/!2*^KA$2B6?Y*:(B,2E^$$F.3E(!'6QIYD[9M\<
MT<='O&'1N+VW^M9X,C(FUJ,)YI<A7KZH]3C8BB#+T:9".VCA2TBY3#D\<X4I
M)U-")0^VU8I`@B6`%SG-2"F(;4\V4JI@XV@P'L-P-+BS)O"F1_^A]0&KH+=S
M(-WQ1P<@+?:DRFX8PD0B.%^GK+1"H`I,$`""EX9-<6TGQR@Q7Q6N2T"3Q;C,
M7WUXG]BOU6_RE(HH1WZQ'7+\4)EV7>+9P)6)\87O0>)S7/KA+\?0/@<DWFHB
M`AV;1^26\+\MWW"<8.7'T=!>XSX4?'9RG'!%ICW7?G(]MD-%W)]-E*DE3P,+
MQ;1B2B#5!I8/J3Y(%/+!`5<)&9W:&'<"_]],$W5O\8A..VV!9=("N%_71J6V
MQR?%O!6[4<4+Z!_4Y`5H?3P[C`([#&_:NNWB_H@XQ'TIV(I82[05O-[:TXC%
M6W%-0_D#/-LXA)PKX&<H]4T__?916(UL.PW3#FKM'`M?N;=WY;22:L>8.HS:
MO9&@+?FOIDOY5#?=O:4@F][\P.]LCJK&_3"!W[(\)\"DG&5%#=8.BED^M8C6
M5N<!-2NCE5H90^K0*B/6F@15[LHV,UG9S.3*G=%'E`)DR4FRVP3M(,A@27#^
MVY]W[:4;VU[Y-%]5!5JI([*J#H\V.B!1TH8IPL/\[+)E!A$2*]AXE[D(P=L.
M0;0>HU0?IW+N29NI'41D^\*?`V]*0<`7$HX"S[L+PN]V6#W.RK5HI:34M#J\
MS"J"9,7H-]0%B;+6L+.)RRE%IZL0R8GW@ZR)K66A]X%@E5.RO&V.<'%$6JWE
M9R97\#*?[%H)PY^*5OLTTZ'X"HG:!I:1C6:'3"*`61#",M%U#DNV%@B3!3G.
M>J":=TD<W5L:43*:^(5>^85/.%U[I,5/3:Z5.);'0VK5L\WO+DK[L[PC55PD
MT9BFZ6T2S9I(3^+GHX!UG;>,$A&E*5ULAY!DB4C;7C+6]Z3_:/8G@Y&E=\%3
M%?CD\VZ)IUHYT"?B<6:FB`Z,TWI+,4W+:,9ON97:YTWVN[H0GZDGI]\#VR-S
MV^-;$HU7MVC/]FX)1?M<=ZH5+63&4NE]4-^PH(8#@HYJJHK]JH).3W>H%OFC
M(S*6KZ?0M$BB_,W_R=<QE*T!+3=Q@BJR0QN=D;%DW4`;%@-D;*#/SOL#]O*.
M*!;3@]M"6\K!S$9_!5-.VD%>QY\]Y+/M9WB8?C*S/24SUW%QKU9+."$%G(`H
MXA9I(WM*WK14%F\1FTK>/E1@E?97+(>Z:!DW5L^:T&$B[K3&(_.[QM":&#VX
M->^LKF7VNU_;3#'9>Y5:;:.9<MW\)>_B7DX+ZJ%1-W.-O)PP24GM:4=N,4\T
MZ1*7]CUJ[<!"@.ZLC^W`<?5DL2N@%=<U$D)ZTG&+$D`U)[H/HY'9GT`F]&M]
M=UX.'CGJVQ3%^]3=JH$\4U8/YK<&5(#[MK#VB%YJ=S)ZV"S-;U]8W\>)`.,[
MOK8&WM7C>X&,;KC7B/);H38%^NJN#/J?8&*.[ML8[<5H*B6#]IC?)S%>LC4,
M@Q=W2J8WZX>(3"T_.4''GQM.[+[(YD5K*%!(E^I62:Y`9-?(I2K@9@VH!)<M
M;-3`5H^>;'(4/QWT<YGZ^;2&V<8_6^J?*J[5!VF6>#7;J-TL+,E7#12UDI4E
MZ:`V.[4GO:.YCO<]PEUO\,L8[D:#>TA.&J3IT>A.K$?]B;$YEIN1MJTI%-^P
M1_$!*;1(@7ZR%EC5A*0;-6U-H?7\9"ETA;XE6V>X;ZU.GQ*`5F"BJ'W:S<!F
MZ5.FJ)6,/"1]%C&SK>FSONN[Z1.7%XXG[4^?%;#<C+1M39^;G4--TV>1`OUD
M+;"J"4FW6^1:FC[K^;DW`GV3Y-*WV>UR;4ZF$KA6X*6HM=K-QV;)5*:HE?P\
M))D6\;2MR;2^Z[O)=#`T\8S2UB?3"EAN1MHV)%-^M!D>4"SN_DP9M93;5BQA
M4W)$'I;21I!*AI[.P@I9M]Q"<P)XWBK<#48P^6S"5],8:6;C/CAWB+;CU1&V
MHO:#F$238',GP.;@2U'^JBBD>+-IN44B&*`@Q`%L;T78RIXZ%Q6%@R-X,]'C
MC72WJ)8.4K%)M#J!TEVA%9M"1X+<).W2-%E44F&R+*A>@)_M,^;)$V=96JIA
M].91$5.4SJPD040V-XE<.T*&&L3/),1;)2+4NC?/45A$<?;9K5_4JUB,7284
M`2^H-*NTRTIIMJAH:G=P/S3Z7_]S#.//QL@$JP_=0:]GW`R0/8,^&)]&IGEO
M]K7<+28#;YH+"AW5$OG1D#I+'"4"*O.`T`HINE4N>2P;3M5VH;>WXE'K[JAR
MY.02A=Q;;=#?GL0:X81&.?2+!51#O]`**?0S$L`FY[1CO[8/VM$N!<L>VL7^
MZ4#[T%ZSL08_AL8A9!K=40^9I=479=35HI`7-4T3G4J4:$D/7F)Z`!4!Y]'Q
MEV@T/M?T.!X;"W[6]FSE3_E*#6KMDCAL0RY9++U@30B$[OR9%EHM`_P]=D,V
M<F7W1NJD94-49[G:I!5U$G@2&,[O*]H!54^-:Z!``VW+K2IC["2`1,4)3TP[
MF*S-_6SE>6G-T5G$P8J-HX5^Q(_<P*>VL,@P#*)X&P=OB$]F;MP-_#ATGU8X
M72#,H+7UJ"1C7>-$6.5Z&/%XVLRK@D07Y)3I8N:1G&:7UE*G[0,2JE8*-T5X
MCLF-&K.MA);?#EM'0\M(++]FM3)]CW*';--!Y.%^9LX?MY/[KS93*^R<V?_G
M;)7<.UNW\=K*T*CZP:6-U;6,NT4V'DCDJ%T'HAZY%=+-L5_9F@_S?M@;?#5-
M&%F?/D_&\#`<]&'T?]U=VX[;-A#]%3X4:`)LV@8HT&>OK:`&7-M9>[<-\E!H
M;7HC0)9<T\KE[\LA)5NRQ9LL<YB\)+LK#C5#GL,9\3*,EN,'M!6#O@#O2G!E
M&P;']A%7-Z/K4F_X*F`NBQ;]U!W*.&"K<-=!H:S_Z.7%&X):.[EE\TQ^B`C`
ME3#60X=3Z_:P#:`^)S=FK(AYN\PVPWR[S>6E#5-ZF&W*4*5MDX!C!9ZW$+AI
MIV)T8YZZJH;,-D16)%/;B64?_K>J,J^;$'XT.[7;&'HQ]FA>OB'L4\R5O*O2
M9";5HQ6G)M86AV[$K#9`=&@BE*"DIN8B3KF*SK/N#C7X###LU;(B(]0!I`OG
MKI(;6`K@)PPL#7,.WAVL#;?OV%#H?(1A8K83LXC15[I?)4P]QVN4P^)>FS)V
MC!.^KA0E1]D`2.9@4O4<")7OE*L`*`S2P4O)&Z7M2&QIYZ_#I)E+%7XY9*V7
MFDY*5Q78?%@/QC[`WO+E!S*8CDCT_G$\1Y_LZ@#.,]JY-4I0#%3?-:05"8%A
MZEM^M(Q"NYZHBR&M;+F#'.I!4D9QG9'1<@Q*/-!D^USP/@-%SNYU/^NYUJ(>
M*=#V?@5B&D5)618'[PY:3RACY`UYV<=9>>7ROBZ,&HOI<%('N=)<''"GL--D
M'G/6+7FK,DC/P6-!^X#+I0:O5+!62\D040,159!Z'6$%6SU8&DT&RVA$Y@-P
M(<N'P70!F1]F4]03?1V@V:296[/@L(]1WB*?N*L;\8$@S86STV_BT<MX99A&
M$26GI(P(M6I2_6S,Z;RCKI,IT2(:/`S_%"'7*'J*)C,1=)'HGWDT7>#><VH%
MK"9;3"W0P])8]9+:&R#(RUZ2C%*XKKU\W^6WAJNTYT4Q!]5,Q*B30GR/G"JI
M2')WLT\3U6*87_NN-\\\$(@[&6YCJ6E<0/LJZTC!:@7,M6EP'.HAAM7^*-YG
M7",V6''B%B(0&(DK^E23&!:"7EVK21LES:0@J21)3924LEAA:D>;ZA:LU1;X
M<ZVV$&OZ5ROK0^#,7W3[3/>6O5@61N2&U,":#Q]E>;1O-0?E`P=^$R<ZL->L
MQ`&XF&-1'7`Z/O8*8OE.)6SE8RR0ZI7C,<WT$?O[IMFE3?35U,?`VP(V/]W'
MC*Z'^19"HK;/!D-ACUALUT#1^:(P$:5)O3@.4CNH_BQ47QE4]X5C/53JJ-:8
MBH9Q-BL.[!!G:S[(ZWJH4<XWLNLOUR&#D5K!F\!YQ[^2<O[!M#9"VD+G2#SD
M3$S%QLI7259NNGQ]0]T7AWA_Z$/[>\J_&C,'`[P2L@W7%UR\L!*%AE5*1GF#
M-`P->28R-'Y-5/&.7L8G/76*J*A:R507GI^DR$>00PKLK[+ESLD8;U2PP5:#
M%L8V0*7(A'^2C/F/1EZ<"F*0X?AV(P,^0E$BRF*COC^EO:/[`A:MD&X:B(KC
MV0;2V+]+\R^FJQNT(AC8;M'#"!@X+`/W,@@I]$L7KC(E=S#%.P\TL&IEA*H!
MD+EQS%8]SUD"GTCV'%&+XG!%J8\-9TY9R"OID+C3W;2\@VD(7#+"4,$I?<,@
M<TL<%OB4IVO>TS+&LR>71A:'76J%;.A5EZZB]X#X=85Q>=.XG^VL0Z"8&8T*
MCAD:!Y5D2TB_:NI?60B#-N+-YAA?%,-FP=6Z>L=TH_-;P7NR"0>EY\11]L%%
M0:]H/7^[$@47@SCBQ*^MULV97]397EN5+Z9[<>XUL=97[`XCJWB7P/]R[9UF
M*]3T]6KR-4>*5A/#&"V,T6(8(:)SZ!1B*.AHQ'`P'R\'$S**WHV'XV@Z_(!Z
MXZ-K;!=@0'>N$MRF97^JQEX>E1H*I1R8`C6$=9[F:BO%%3\EH<(BD0&#>D[I
M6@&-8I"*AZY'!>P_GLNH12S.3ND7\4B]V&,E[)M<1HUTS")2FDAQ(N5)N;F!
MUR"?(VTJN\J\,EL6$U8FTDI(=B<N''_5EF2*P5]^>GOW^]O?7I-7C%*2P4#S
MQ^IU,#L-G.![04V[I@R.ERXY<#I4%`I?75+*F+D;5.:<WNQN2:4C#W;S9CCD
MQT26\IAWEF=O3G_A%%ZEQ9K_!-RG947?![6MT_1T;.B`*/\4IP7MZ(G/9/&)
MW53(G<M"/E0W;&5<GUXX0'JVH]6"D2V-%QH)>W"[FGH"(6=/3E<2]7OPN<Y6
M]^]R0^7QM5[6T+0H_"Z>&?VO@/V5GV%7I7$*25G>)U]52JAX>2Q/I$`($T*N
M-CS>+Z+WC^+,]Q/_%_6DE!$U#3)H+>TA`\2BV.U2L9(9I[/-1AP;'V3K(PDA
M<AA"X'#6%6ZRGK,_6"NFQ/Q)GH_,L@(Q!)]"K5-(Y37Q0Z^F516(O`\G!RQ,
M&][,-&WB\VOM&]>[!H);\HU[QUV<K$7_B4N:XA12EN58%P)WHEV5\\&M?;I[
M1497O[SDGW]=TT0Z1/[#N1_D?_IWN8]A\7OQ;?N<G_?GY7,/?N[BI:H595F&
MR$)^@=Z?CK?&JK*+`8_M9O3@E/ZF<%4*70\^TWW\0J<%G%:_CUFR&B5IP1^8
M#CMVK,2SFW+74(&3JB)2UD1D56+GX,5)2O*%CWOBQ'"R$F-B^3("AW'YF$A8
MO*5E)L==OA=/^/<'85PVI80;<9O-(BJ/=_-6DBU1M8*GHZ=:)]B_R7%I<G8$
MAIR5A9]6]5FD@LD+1^$\=B$N*4]SQLB."PF)<X$[.+]=`FDME4/9IW#=L%%Y
MUXX-+\>-TNP)KY#_SG_C/\#A=O[+_U!+`P04````"`"R@5M`'1_\]]T3``#0
MF0$`%``<`'!L>"TR,#$Q,3(S,5]P<F4N>&UL550)``/_\4M/__%+3W5X"P`!
M!"4.```$.0$``.U=;7/J-A;^OC/]#VSZ97>FA(3L[;:9>]LA;QVF:9(AN6UW
MO]QQ;$&T-1*5#('^^I5LP!@D6_(+-D+]T'!!DL]Y+!T].CI'^OCC?.RW9H!0
MB-&GD_/3LY,60"[V(!I].OG\W.X]7_?[)S_^\-7?/OZ]W6[=WOS4&[0>D0\1
M:/7;OX"`P'GK=Q?X@#@!:+TX<XSP>-%Z(H`"%#@!:[=U#]$?KPX%W[3X_[T6
M^^KWJ\%]JWMZWFJ]!<'DLM-Y?W\_!=[((6T<MG[JXG&GU6ZOGOQK).-EZ]O3
M\XO3[S9^&>`I\BY;YQM?71,0/=EC0EVVNF?GW?99M]W]\'+6O>QV+S]<_'>S
M-)XL"!R]!:U_N/]DA<\^M%F-\X2RW[3ZR#UM]7R_->!%:6O`%"0SX)TN6_*7
M2K88HHA^.MG0:_Y*_%-,1AW6]D5G5?#DJ[^UHL*7<PH3%=XO5L7/.[__<O_L
MOH&QTX:(!@YR$Q5Y8Z*JY]]__WTG_#4J3>$E#5NYQVX(C8*`+6D)_J_VJEB;
M?]5F"%^<G\ZI=_(#?^!'@GTP`,-6*,-EL)B`3R<4CB<^.%E^]T;`\-/)Q)^'
M:)]WH^I?WV!W.F9=9_770=XM"F"PZ*,A)N-0^),6;_[SH)_08D)PX/AP'G:=
M8-D3.[QD1ZG13D')!ZSBEV?6YP%_Q./P#B+VNJ#C/V$*^1.N?8=2.(3`TU9`
ML=D]JO#D$*#_(C3:#MY``%W'+UTI-I+Q&!01?=E"*8*YL+W1\O,;4_T-^QXS
M=[=_3ED/[2'OD4%!KO%XPGX"B,(9**Z"WH/JUK1P9]-_6F7=[]JA;W<^?J=]
MY$$"W*"(7KN-E2+N`PX`?<'K(;I^(KUR**2/P\WYG2'Y#$>(C5S704'/==F$
M'#`"\81]Z$+6#I@'5SYV_]!6M"(Q*H;H&ON^\XH9(6(]BDEU#UW6NT"/$`>-
MPB(WD+H^IE,"JL`FW_,K!N6)X`D@P>+)YR^'3;]L$$ZJQT+KL15#T$<S]@>3
M1;4JISZFZK?,S6@X%$/;RF;V@#`S2L)?KP`"0QC0BM]X7A$JMPKC,0S"CU4/
M_]0'5:SF<\`>DIAH>=EJ-59_9N4CG-,'M@BN>H2G/*9B%7N>%Y)UQU__N+&&
MJE9O_6=7#,8`^.PC7ZX$BQ<VNU+'Y9)4/,!UGEKU:)^^4O#GE'V\Y9-.)51/
M_HRE<I,-$LA=30DM66&`/+[BCK[E#RO5:Q#*P*1@$B4>['-'"R9)?)?/#;TI
M%+BG(SSK>`!V..;\0PA^^^Q\Z4OYFGWUI<<>[?''W_G.:-4<(WC`_W2R^WNG
M<GFNIX0OC^Y8;W/\_P"'W"+OAKTL@6C2HGI2[O1*]L47E9?3>V63O\-76`G1
MM*M7#^I*C`BJ)T`@]N[8=U2`JKSLON7DKU1-RKCD_F3<>)/,+(`^LR=I@@J+
M[T_:Z#W*QY*XW/[D>V'-IH@5_ER]-.$8Y8MYY]47B9/\?4_R+*X9`(23$0_,
M?P8+F5P[Y?8F'UL28!32Y-`11A^G`=]+X-L\<F'3*NU-\F@&&8`))MR9PVF!
MT-RD%M^7M#=X[$`DE6[Y\[ZDN8,^(-?,2HPPD??)9*E]R?8T??6A>^=C9WMR
M%I?9EUP#,()\TD?!@S.6&ICM8ON2[E?L3QE5(=%+DP^#[7+[DN\WX/L_(_R.
MGH%#,0)>G](I(%(Y9>6KE_<>C!P_$J(WAR(DMTM4+Q-;RW';^KP8OV)?(%'R
M][4\F\N?'DG*YA!WU1#[N+/V2>[J+DMT)N'V1]M]@_YZV30D>)R#.*^$P:+9
MN86)!T@8=<#^.VDQ18:`V6_O/M)9*F@H9<`Z-@A+\IH0$R;"IY/N26M*F9)X
M$CD*:H%)E82N8$E2K!B5\Z-&96O=&\/2/6I8).N%&)X+"X]H@1H#]"\+D-C3
M$$/TX:@AVIJ(8UB^/6I8Q`PY1N??%IU=3T`,SW='#8_<:QPC]/U1(Y2QA%K#
M='[<9#G=+Q2C=-SD6>(OB.$Y;A(M=)#%X!PWA5;Q&<=8'3>;%G@S8VC,8]'"
M[9<5%CL^-9/].ZE(I/>@%2QG9R8"(_&L)@?,:J-D?SWD8V<[3*3BX!'%C(W<
M7N6A0U]#0*:T/7*<2>1:!GY`5]]L^YB77W]9AD;3)V?!.V\/>>P;,F6H0^<5
M^F&W7O(K20!%D9;R^]%+TSB*^X_D4M,L4:,!&G`/!=#2(%&C3@T&P`5PQD5Z
M`(&:"L(J3=-!<:BD5JU%IW50Y9,#O3ZZ=B:0V;0-^B?3*+MB+?I0"H+M#;VM
M'^N3*ZN7)`O5)V?&P$R4J5U*)5";,-9XMA:;)/D?'J<^<WS`PYJ#:X>0!5M7
M_>KXT^V@`[VZM6@5)QQP`7&8=040S[F2Z9)2HRX-EC8K]15L%ZM#UILE11Z`
M&4#3#!(@*=P`N1\P<G5$WRA?D_1L`><M\X=X-EED5>XPX?]8Y16I:*79CBFQ
M:_FQ7R>T,<8D@351Q*SHH?RX;2S")+!MEJA90IZ]NY/&E2VVN%H3=<D@*<K5
M:]8M?;X1%&R&O.KH-X$G;HB3.:.(RS9&:G7@!77JT")T]>B\@)0*M<D?>QEH
MII<EI4(=\J?F;^_2)ZKSJLIINQ949.<8R#E1:I4Z=!B`P.$(WSH$L?4>[;GN
M=#P-<UDY]BZ4::)0L0Y]UA[^G=W!+?D%!6N55[`CD6&FE:K6JI,H(4Q2J!XY
M%;EM0]BL-G]58:Q[W(F4[(+H['7Q'4NE[1=3-_RKQ3"Y"1=C:%:,;9Z=(Q%H
MXETS4X-+BZ*6QH%-#3=-WV=*]"GQWLD:F*ZA9BP3F!Q.WA@T0^U6)FCI*Y,8
M'[.R`W1'VR82>6PU#S,Z!"04C+/B)FB,E\EVNB`%$%CO"[-""K7A2NX6Q;"8
ME0^@WXN281TQ+GD2`9IKC1H<@5I/!]'=EMKL,VGK.U/3L4O&3;018FJJ=LG0
M%4W9;JZ1*@.HU*`K4Q.YRP`NK;2IF=XECTQ)K$:Q3/"#&J[Z[DXUKZFI2;[Y
M()2%.IJ:Y)L/)5%P3K$\WX,:BO)0DY2N)'3AG9OIHM+&*BT")@;+S!T';;!*
M"E>)<373VZ6-:Q9.W3P39/,-FSRF9->9(Z(-9JXHU5!19[>FGEZ0)](GN39*
M1M.8[AP31P\=W7D&V7"D#41SCS-0#X;:]LPDD\GB2<O,]8H>/BH)QS%B9GJ7
M]1!3"9R-$3.5`A1S\FTB5+4WN:%GC22OM:PWS9;)\DA"L;W02#X!$IXR)8DN
M5:E9<^)P=$A6;QJ\L<[Q5_P>Y9KLU&B$!N%Y@\K2+TLW0G+YI19*54Q)M#4K
MB=4F61QXDH4-_FC`@B[5;Z(T+9L>[Z$-U>Y\;WI<1TZ(5H3"U`/X"\(C/E;5
MT,`-ZYBTCDDC'9-U+OFCZZ#K6=!3]OSEGKITS;59I@[ZNG*;K<C,E4.AVT/>
M#?2G@72IFU7+E.5B?ESO,`%PA**@$W?S*NJ?F$CWF-(K,&1E7IRY!&.=%NK0
M\">``'%\'KOEC2$*[ST)X`S<SB<`45F/SZI5BR:$@?E$\%!ZR,)FB7I.^>)6
M;&W6,M;*LM+6;1+A\P""""(^B"08)LO4<E;-!/"A@4:9LHI*ZDDLO$0\C-GA
MMH;R%G?.21,6J>?H%#A^G3(^PCM[^GPK+%J/S!0PBL=S_6Z8&#X.LT+336=Z
MG1)>^.H!&ZWSG%4T8K01$-:_EL_:/59'MW8]D(>O6S:(UC];1VX33I81=M#?
M&"%Z8_RR-V,&;P0>IN-70$+NN22>67L=.1NI<WF7,?4?HR/`NK)S>==B`WC<
M_FHQM[$.:H'30LTM'8HT74\:$22AQ>T@-DQ#-\)!HY)8(!9S0YL299U!8-62
M!8WO..*EB:FWPJJ;7ZV5AMI!7ME]Z86/O0,%3=GIIG:"E_$#3^@\*99`:HKE
MUO),FYY-J@;9EL/0]`12-5`R=XZ.._$JK[_B:-*O[.Z]W;W/VKT/QT<RL6&9
M2WR-QTR`-YY@/`/U;?)+\G5^`7RD2_RBZ77JN>;P?U,:G9?S@B7BA:_BU:'`
MX]`SW,,7/P#LK5`8@&=`9M#E,9$0>P/@XA$*6TF[,JSRQ]8<>9_:"W;+V:")
M:(CS%XT1ZQ5"0=/+UK0Y3P#KH3<@^MM'NQE6`^S[C'B_.T064J/;BMW,/Z3-
M_.TLQ533("E<RT:?8O)0F1E#-4C[I5OO-NJ6,:."\:96QVY>:V4AY;C)0Z6N
MF5OR9<EYZ)>]*,M;FU5A@D2))3=3[DR/V'%D]![`>_B3?(PJ56Z<7N&/C^'*
ME=[.`7$AE48OYVBH0?J&2YN<KW&K;M.T*N$EIK13IYLG=64C28%:<433_:C*
MV&0X6TSWG"KC)%MLF'X75\Z%^,[9*`ISI^E;^-5!N3U]F7Y-5PE(5N^>-?W>
MKZHM@X2XF'YB=<56(A-5,V,22D"UU("%YB)F`\%EN\EI#L5$$(>84QX-3L+0
MC11W<J'(^4DT8P0."8R`)_6:BQQK5</PT;;C]A`8V>9,L:#[J%_=(L\(>$1N
MYF*7\QP:/BK[-L>8%V=#[#3A4*1-2X"Z%B`;@Y@1@UC[,<)*OJ)XS<W_[R`7
M\+P_V5Y2H29-"6HS*VC*AFP<?,B&=;,T8,),9>K%3/'1Y.A;-F_9O"6K)9'5
M:X>^W?GXG?:1!PE@(ZAN#LHW&Y$+?9#8DWC!7-(G@F>0*7VU^$R9`43KK-V>
M&\!9=%E9^N1>R:-J21MA,O*[JMD?;@)GCA^N/X-KAY`%$S,MCT:MKI%:U11B
M*98MVKK<=OMJJ2=IHBX=N2GA-TRRCWTT`S0<,,A;'D^].7AN('5]3*<$9(S8
MPLV6<(X8E\$'=+VIO*0@RZWF+<$5*I0@T@U@TX,+HYETC$D`_XH^(R^\T+(_
MGCB0<$,G$$^C<BUI7<,AFXD>A[=S]\U!(S!@T]4C$@\`2:_1:L(4GT.5IP]_
M1LRR^"EW,6DU4<NIO4LQ'M$S>^^/0S;#LSD]6/";A$-'[D0P6C0K-R.=L.>Z
M>,HG!V?!.2\?U:Y+V))QXU)7B9XY&VN6WHS7`3:XY3X2I:K-T&GKKG5EA;;K
M-4,;/GLC]C2=#KA9IQE:K-<"2Z=,]O':J@V40`Q63^NCC0'*C'/"8O'#LR06
M+U\;UE&^#J03K1X%3%72630::+9^&8,B1T,-TC=>A>1\GZ(&FJU?OO>9UE"#
M]!5X=_3T%#70;/WRO<^FN<$.XS0'QIU#EV,TA;H`>/2.X'$8%*!N2G1;J5/3
M%]QS&3D@0)5VY&B@%OUX\$;H*`EA?\*L[X.`B<DEN@((#&%PC5%`X.M4Y!S*
MWTY3M4V_@T*GA1+([^:X6.V//@XW<F29+>!.H?"!(L>=9@.UO)0-$07.")4Q
MIM%"[1IJI'AGUZOMD)FK[4P[6?2&N+"-^=&*^5GO:JJ'^NQ6.;@(G_QF\WDZ
MF?AADX[_.!R&)VHS*[`.-I%%_.G5K3,*H,HMYIUD!,%@CS/J<L3;'T"41=7X
MZFYYQ7B;F6^_K_ZLMS$4HU[LY/VCAUV+>,>HFYF,WR30M]9V:^B[:4%BML-G
M8J^Z.1L#GI;+;P'/!%QG5RL&W<S0XK(BEU9$)<<6W!KB"S//J"@;8HT52PRM
M[;TJT&8%N\5XFGF\G/Y^?[I=W8G@*)1[?80`BL)ZU,Y3.V`>4#:(B<B;LFY(
M.QKTU"+J3#T5S>;S;76O_%$PJTE6=Z/*])/ABB&JL7%D^F%PY0"I$\9F^NUV
M^4.D$EU3(S!"+97W@*?GDB#5V0@W_;KN<GNI<J"2\1=^EX.K3ABIZ?>%YP]1
M5#JQ]*B&MR9HU3B733]'O[0.JQQY7.S@_>:;`.5;E//WQ:Z9=J`0<JF35HR<
MF:.X$'*IRZ<8.3.OR5"\WELK:3O&S$P?N!IF>L="Q)CEB6DR9590/"(D!BO'
M-2&&'2RM>C+*!F@Y'-B'=BIP)F3%-E7C;5(S/;8JX=;V&+;M4&Y[#)L]AFUU
M#-L##@!;;R_M"3_;<0D`O7(HI-R=N?&:D/<,1P@.H<M]F]%^)+_^!OO092;H
MA4ERY6/WCSH.<"LD[U*>K22'0DV:<J!/4\Y&$":-R+NO).M&L9+-=;(G`1LW
M#>H-&,N;LOAYL1GG:,Y*MMS3<D]-[GF-?3:/8.YBG_%`MWOH\ABD'B'<J\>+
MQ*O=G*13?,9FKN?N,HQ\[5C&:!FC98R6,39G\K*,L1S&6&!NL331TD1+$\4&
M2!IJ69@=6G)U].1*JW.)J8Q6$Y9`6@)IW+1F"62Y+D<]HV2YH^6.ECN*;<\J
M%WEA,%<L<M]`"CKB:3>UBN6[C>>[E@M:+FBY8+,F\E0NF&ZC+?>SW,]R/XG?
M4.&016HP+[2<:E\^Q+P=3>)/S-N<Y9.63QHW]5D^6;)O,;>QLES3<DW+-66A
MC.,QC(Z[*)51%K@C/5TB\<274<F&+EIF;-FA98?-F:PL.RPY&3UCUK`<T')`
MRP'%UB8\!O8-^TQYRB,V@@4O:QV,ED99&J5!H_8JI^J(E:F@6M^21$L2&XR0
M'DG4&#:6+UJ^:/FB+#:1GX3[XLP-IHA%8A-3T!%/QZE5+,VU-+=)--<204L$
MFX>0;FQBFHVVW,]R/\O])+;&\V`DV_K'/AIB,@Z%:,@6LKZ0XBE0OQV[T6RI
MHZ6.ECHV9Y:SU+%<ZIAC;K%\TO))RR?%!F@`?/;1>W)(L'@A#J+,&+&GV_06
MRZT*<Q6=OB4F,CHM6/9HV:-Q<YIEC^6R1RV39'FCY8V6-TIB%J>O%/PY91]O
M^3$#9=SM8EGB4;+$H^)0^Y13.D(E(DO+6P9H&6"#$=*,090/"\OW+-]K/M_[
MV.%ROCH4L'_\'U!+`P04````"`"R@5M`JT-CT&<(``#+.@``$``<`'!L>"TR
M,#$Q,3(S,2YX<V155`D``__Q2T__\4M/=7@+``$$)0X```0Y`0``[5O?;]LX
M$GY?8/\'KE^N"U16[&RZK9%TH=A*(L"1O++3;>^EH"7:)E8F59)*G/OK;TA;
ML?Q+L97VL,'Y)9;$^8;#^89#4IJ<_S&;)NB>"$DYNZ@UZB<U1%C$8\K&%[6[
MON7TVYY7^^/CSS^=_V)9R.U<.R$*6$(909YU2Y2@,_0Y(@D16!$TP#/.^/01
M]:,)F>*W:(@EB1%GZ/-EV$7->@.AB5)IR[8?'A[J)!YC87&CKA[QJ8TL*^_J
MT]RH%GI7;YS6WQ=:0IZQN(4:A4=M0;`":12#%2W4/&DTK9.FU3P;G#1;S6;K
M[/3?16F>/@HZGBCT)OH5A$_.+$`T5D;W%GDLJB,G25"H124*B23BGL3UA29I
MAHC`@4Q>U`JC>CBM<S&V06_#_GS;G;NB]O-/:"[;F@U%0E<0^DF..;4IDPJS
MB!0@8-'?)0C=K#U=[&0#LC"K\>'#!]NT%J0S:8TQ3I_D1U@.C?2BP=;^L4X:
MUFEC%:4>4R*WPDS+=ER:S%8L2P57.*$S$P(:T6BNR#/.6#;=/OY8"5MW98.0
M!5)$T*@(?1ZW@=$RL7J"%5U]9L\;"](11*,2CZOBDD3U,;^W%XW;W1`3NAT%
M#=L1E-T3J;:#YFWK.(7%F"@?3XE,<43V=#M,YREAZHJ+:8>,<)9`G]\RD!U1
M$M<05C#MAYDB*P(96XI\U%K.,6/0@YZ7YEX_25/*1GQQ"P]T'+8$3\@`N$#Z
MXB[T=ENI%OG%UI)VAT>9MC/_Q2QVF:+JT8,^Q-3T7$,TOJCM)?ED56Y73$:4
M46-_XP32#<KAQ4M0A>:Z4$'9N;VN85UY!HDQ8!_-=823*$L,L`OW"_!"H@R8
M"DA*3%5`+BW;C5L\S>GY3JSUP5P37L'HBC)(=!0G/2Z-+>T$2[F(,LU;"("O
M>P+*Z3L%SIX4P74[\/M!U^LX`[>#+IVNX[==U+]QW4'_R-T+N>MA`2(3HB@X
MYV`B#?H9-G_;GTWT9L6<7X_L[L,N;'[XE&SG;M%6SM!9&4/]`?S<NCZP$URA
MH.>&SL`#@2,W^W#3GT!`3W@2PP[9_9;!RN.P.(``%VT^A;%-")/TGFQ0&%&K
MLI9RLM_M1;;FNGWC^-=N'WD^3$\G=&^";L<-^_]"[I]WWN`+>M-V>M[`Z:*.
M>^6U/==O?SG.V.\?%;LR]`M"9)^T_?L/C9-CIJ\2-VTL)U<)?Y`>BZD@D=J>
M]#?%RJE^OW_^;SO]&W35#?XZYO_=C/E<$3G@3_NF)]_*2RRI#$:]PJ!@FO;I
MF,%V*L),.9$YAE(V[O&$1A3TD)FZ3'CT=X'K']1!>91\T"<I*J.$RTP0'3+>
MM>_!C'8@#3CM=G#G#SS_&O4@=&"6'P.D2H"T>9+@(1<PG'L"S'5I!(F;.$)@
M-C8B2PH.BXQJFDM#HG&R'A+`O.OW7>3XD#CN>KWN%^1<AZ[)'\=XJ!`//<%3
M(M1C+]%SE\5Z:4]?$@8'*2QGO['.?B_4QP-8\37]>O'O'7FOR+O'[N&'B\>J
M/)<J*.>UN<ZKYW\"'H/PF-0K3F*]]S8+L=F0][A4`O:]PK1>$@8F*UEY0E=5
M7AX$IYNIW;GTNGH_?Q6$R+WM=8,OKHM"[_H&MH9WO<!'H3OPPF.NK[[V3Z=4
MF<OJBWRIBG+*?UNGO!W<WGH#L_<_$EJ!T+X"IZ^<R;5L56[WUU9.\]G&/EX?
MVM'BD'XDNM)JK=^J#/"L^FI=HJ"<SG?K=`Z<SRZ<U7U8MF$"NT="*Q#JQ+&Q
M""=/C84/AE59/EQK.?6_;\QD?>0R"[`3PCKM^8[?]IQNX76=Y\/J?6O>X!\#
MHT)@A`1\8+Y[J<<!G)PECK2!E1?L0_25!\/[]6`(W:YY@==S])%L$#I^WVD?
M/]U47LRSH23?,KAT]<GJP/=RN]'EK&Z^=+N[[,/16L]E]]/_R<Y,_]$E4R$9
M(5,-U=+50!<U2:=I0FJ+9UA$&E]>1V6G\_<?E$@[5YLKV$"O%FZ9^%CSW\*J
M7,-$D-%%+4UF5EZB\Q4`]=DTR2445;J3]E(-TGKD6X23I&;_<P>^RN+SXP;Y
M+>/N/&EY)<-.\)`D^XT81+>,N*L5O)+!KL_QY\<,B"UC+GY]V#;T<[M86P9W
MJ[5GYS!R+A1B6ROA=M1?HGF)9Y='1E$)1-]9.<[2CZQ&TSIMU&<R7IAXB`5+
M1Q]F08X[U(*M)8[[]IT#=*=G>W576B:ZJUO3Y=:Z5)LD2C[ILI:Z#O?^1E7H
M7DY81VE/?-#N;[Q[B0F%@M8#S>#,KV9)6=WO"XC13P[EY;DZVE)SMN'RFQ<9
MLE::NY<1.49?O*CSS1+?O?HOP!;7.ZQ8E/T:,_1^0DX2(J4[(R*BD@0C\[8H
M2,UA8KY#A<3]]3FY^=)CBMY;4\Z(PN+1@RVLWI35$!Y*)>"`<E$;X<0L+480
MEAS*XX&!QIE8E/+.VX8XT6D6&LB00IYB5'^%U(N$$IG.F;`OAE4CTYAKP;,T
M[YU"KSO&6OT3J7%!-?C<,_/J]I;*GU?TS7?P0H?`V@MG#/.%?PH!2?^3?^UW
MI"3*FZ:8"@U8#OT0S&N(A'TJQ9V%I04O'(0J^@&>43;>YH7Y$'XPY1Z+!($=
M@P>;,SRD"=4;O2LN=G[278ZY`O3'!0"8$G^G""AYU[;!^SZR_R"VS=>\:PP;
MU2Z'R5E(XILMKX(KB+6(D%A>"3[UI,QT!\%(?['BS*Q"/E'!R)VE.AT7AGLH
M[C5D+OW_:7"DFW3(/4FXF7%Z]K$Q983HL%L,!X:V=,1!H-?@A7Z6IO,'.`E&
M(S,&7:VF2<V9;G.I"L%P`.153(J_B/Z'11([]T3@,8&CP)`(7<07=6B208.I
MZY5!IO1Y5?^KY](75;`K"<XT_\^V,.?V?`,,E_\%4$L!`AX#%`````@`LH%;
M0)9^YGGNB0``;!H%`!``&````````0```*2!`````'!L>"TR,#$Q,3(S,2YX
M;6Q55`4``__Q2T]U>`L``00E#@``!#D!``!02P$"'@,4````"`"R@5M`EP?8
M:MX)``#$>P``%``8```````!````I($XB@``<&QX+3(P,3$Q,C,Q7V-A;"YX
M;6Q55`4``__Q2T]U>`L``00E#@``!#D!``!02P$"'@,4````"`"R@5M`[1`X
MBKD2``!R5`$`%``8```````!````I(%DE```<&QX+3(P,3$Q,C,Q7V1E9BYX
M;6Q55`4``__Q2T]U>`L``00E#@``!#D!``!02P$"'@,4````"`"R@5M`TH`+
M@*(A``#.J@$`%``8```````!````I(%KIP``<&QX+3(P,3$Q,C,Q7VQA8BYX
M;6Q55`4``__Q2T]U>`L``00E#@``!#D!``!02P$"'@,4````"`"R@5M`'1_\
M]]T3``#0F0$`%``8```````!````I(%;R0``<&QX+3(P,3$Q,C,Q7W!R92YX
M;6Q55`4``__Q2T]U>`L``00E#@``!#D!``!02P$"'@,4````"`"R@5M`JT-C
MT&<(``#+.@``$``8```````!````I(&&W0``<&QX+3(P,3$Q,C,Q+GAS9%54
L!0`#__%+3W5X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"```WY@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 1 -</b></font> <b>SIGNIFICANT
ACCOUNTING POLICIES</b></p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">a.</font></td>
<td>General</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td>Operation</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Protalix BioTherapeutics, Inc. (collectively with its subsidiaries,
&#x201C;The Company&#x201D;), and its wholly-owned subsidiary,
Protalix Ltd. (the &#x201C;Israeli Subsidiary&#x201D; or
&#x201C;Protalix Ltd.&#x201D;), are biopharmaceutical companies
focused on the development and commercialization of recombinant
therapeutic proteins based on the Company&#x2019;s proprietary
ProCellEx<sup>&#xAE;</sup> protein expression system
(&#x201C;ProCellEx&#x201D;). In September 2009, Protalix Ltd. formed
another wholly-owned subsidiary under the laws of the Netherlands
in connection with the European Medicines Agency ("EMA")
application process in Europe. The Company&#x2019;s two subsidiaries
are referred to collectively herein as the
&#x201C;Subsidiaries.&#x201D; The Company&#x2019;s lead product
development candidate is taliglucerase alfa for the treatment of
Gaucher disease which the Company is developing using ProCellEx. In
addition to taliglucerase alfa, the Company is developing certain
other products using ProCellEx.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
In September 2009, the Company successfully completed its phase III
pivotal trial of taliglucerase alfa. In July 2010, the U.S. Food
and Drug Administration (&#x201C;FDA&#x201D;) notified the Company
that it had accepted for review the Company&#x2019;s new drug
application ("NDA") for taliglucerase alfa for the treatment of
Gaucher disease and that it granted to taliglucerase alfa a
Prescription Drug User Fee Act (PDUFA) action date of February 25,
2011. <font style="FONT-FAMILY: Times New Roman, Times, Serif">On
February 25, 2011, the FDA issued a Complete Response Letter
("CRL") indicating that the FDA&#x2019;s review of the taliglucerase
alfa NDA was complete but questions remain that precluded the
approval of the NDA in its then current form. In August 2011, the
Company submitted a revised NDA in response to the CRL. During the
same month, the FDA notified the Company that it had accepted the
revised NDA for review, had deemed the resubmission a class 2, or
6-month, response and established February 1, 2012 as the new PDUFA
date. In December 2011, the FDA notified the Company that it had
decided to extend the PDUFA date to May 1, 2012.</font></p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
In the fourth quarter of 2010, Pfizer Inc. ("Pfizer"), the
Company's commercialization partner, filed, with the Company's
cooperation, a Marketing Authorization Application ("MAA") for
taliglucerase alfa with the EMA. As part of its ongoing review of
the MAA, the EMA delivered a list of outstanding points to be
addressed by the applicant. Among the topics currently in
discussion, is the orphan drug designation and exclusivity granted
by the EMA/European Commission to VPRIV, Shire plc's ("Shire")
Gaucher disease treatment, which could prevent the marketing
authorization of taliglucerase alfa in the European Union for a
10-year market exclusivity period commencing as of the August 2010
marketing authorization of VPRIV in the European Union. As part of
the MAA procedure, Pfizer, with the Company's cooperation, is
challenging VPRIV's orphan market protection with respect to
taliglucerase alfa pursuant to the EU orphan drug regulation. The
EU orphan drug regulation provides for the possibility of such a
challenge, and for an exception to this exclusivity to be granted,
based on a number of factors, including contribution to patient
care, clinical, supply, capacity and others.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Following the submission of the taliglucerase alfa MAA to the EMA,
a good manufacturing practices, or GMP, audit of the Company's
manufacturing facility was performed and it was found compliant
with EMA GMP in December 2011.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
In January 2010, the EMA's Committee for Orphan Medicinal Products,
after reviewing all relevant clinical data, recommended that the
European Commission grant orphan drug designation to taliglucerase
alfa for the treatment of Gaucher disease and in March 2010, the
European Commission granted orphan designation to taliglucerase
alfa. In September 2009, the FDA&#x2019;s Office of Orphan Product
Development granted <font style="FONT-FAMILY: Times New Roman, Times, Serif">taliglucerase
alfa</font> Orphan Drug Status.</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
On November&#xA0;30, 2009, Protalix Ltd. and Pfizer entered into an
Exclusive License and Supply Agreement (the &#x201C;Pfizer
Agreement&#x201D;) pursuant to which Protalix Ltd. granted Pfizer an
exclusive, worldwide license to develop and commercialize
taliglucerase alfa, except in Israel. Under the terms and
conditions of the Pfizer Agreement, Protalix Ltd. retained the
right to commercialize taliglucerase alfa in Israel. See Note
2.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Although taliglucerase alfa has not yet been approved for
commercial sale, patients are being treated with taliglucerase
alfa, both in the framework of the Company's clinical trials and
related studies and in compassionate use programs, special access
agreements, named patient provisions and other programs designed to
ensure that treatments are available to Gaucher patients in light
of recent shortages of approved treatments. In July 2009, following
a request by the FDA, the Company submitted a treatment protocol to
the FDA in order to address an expected shortage of the current
enzyme replacement therapy approved for Gaucher disease. The
treatment protocol was approved by the FDA in August 2009, and the
Company is continuing to treat patients in the United States under
this protocol. On July 13, 2010, the Company announced that the
French regulatory authority had granted an Autorisation Temporaire
d'Utilisation (ATU), or Temporary Authorization for Use, for
taliglucerase alfa for the treatment of Gaucher disease. An ATU is
the regulatory mechanism used by the French Health Products and
Safety Agency to make non-approved drugs available to patients in
France when a genuine public health need exists. This ATU allows
Gaucher disease patients in France to receive treatment with
taliglucerase alfa before marketing authorization for the product
is granted in the European Union. Payment for taliglucerase alfa
has been secured through government allocations to hospitals. In
addition to the United States and France, taliglucerase alfa is
currently being provided to Gaucher disease patients under special
access agreements or Named Patient provisions in Brazil and in
other countries.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
On August 10, 2010, Pfizer entered into a short-term supply
agreement with the Ministry of Health of Brazil pursuant to which
the Company and Pfizer have provided taliglucerase alfa to the
Ministry of Health of Brazil for the treatment of Gaucher disease
patients. During the remainder of 2010 and the first quarter of
2011, the Company and Pfizer completed the supply of products
deliverable under the short-term supply agreement. During 2011,
Pfizer recorded an allowance for sales returns in connection with
the supply agreement because the Brazilian Ministry of Health
requested that Pfizer consider the replacement of certain vials
that might expire during 2012. Revenue, net of allowance for sales
returns, generated from the Brazilian Ministry of Health was
recorded by Pfizer, and the Company recorded its share of such
revenues in accordance with the terms and conditions of the Pfizer
Agreement.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td>Liquidity and Financial Resources</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Successful completion of the Company&#x2019;s development programs
and its transition to normal operations is dependent upon obtaining
necessary regulatory approvals from the FDA prior to selling its
products within the United States, and foreign regulatory approvals
must be obtained to sell its products internationally. Each FDA and
EMA approval triggers a $25,000 milestone payment from Pfizer,
pursuant to the Pfizer Agreement. There can be no assurance that
the Company will receive regulatory approval of any of its product
candidates, and a substantial amount of time may pass before the
Company achieves a level of revenues adequate to support its
operations, if at all. The Company also expects to incur
substantial expenditures in connection with the regulatory approval
process for each of its product candidates during their respective
developmental periods. Obtaining marketing approval will be
directly dependent on the Company&#x2019;s ability to implement the
necessary regulatory steps required to obtain marketing approval in
the United States and in other countries. The Company cannot
predict the outcome of these activities.</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Based on its current cash resources and commitments, and cash
received in a public underwritten offering on February 2012 (see
note 11b), the Company believes it will be able to maintain its
current planned development activities and the corresponding level
of expenditures for at least the next 12 months, although no
assurance can be given that it will not need additional funds prior
to such time. If there are unexpected increases in general and
administrative expenses or research and development expenses, the
Company may need to seek additional financing during the next 12
months.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">b.</font></td>
<td>Basis of presentation</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company&#x2019;s financial statements have been prepared in
accordance with generally accepted accounting principles in the
United States (&#x201C;U.S. GAAP&#x201D;).</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">c.</font></td>
<td>Use of estimates in the preparation of financial
statements</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The preparation of financial statements in conformity with U.S.
GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results may differ
from those estimates.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">d.</font></td>
<td>Functional currency</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The dollar is the currency of the primary economic environment in
which the operations of the Company and its Subsidiaries are
conducted. The Company&#x2019;s revenues are derived in dollars.
Most of the Company&#x2019;s expenses and capital expenditures are
incurred in dollars, and the major source of the Company&#x2019;s
financing has been provided in dollars.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Transactions and balances originally denominated in dollars are
presented at their original amounts. Balances in non-dollar
currencies are translated into dollars using historical and current
exchange rates for non-monetary and monetary balances,
respectively. For non-dollar transactions and other items (stated
below) reflected in the statements of operations, the following
exchange rates are used: (i) for transactions &#x2013; exchange
rates at the transaction dates or average rates; and (ii) for other
items (derived from non-monetary balance sheet items such as
depreciation and amortization, etc.) &#x2013; historical exchange
rates. Currency transaction gains and losses are carried to
financial income or expenses, as appropriate.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">e.</font></td>
<td>Cash equivalents</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company considers all short-term, highly liquid investments,
which include short-term bank deposits with original maturities of
three months or less from the date of purchase, that are not
restricted as to withdrawal or use and are readily convertible to
known amounts of cash, to be cash equivalents.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">f.</font></td>
<td>Inventories</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Inventories are valued at the lower of cost or market. Cost of raw
and packaging materials and purchased products is determined using
the &#x201C;moving average&#x201D; basis.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Manufacturing costs for product candidates are expensed as research
and development expenses. The Company considers regulatory approval
of product candidates to be uncertain, and product manufactured
prior to regulatory approval may not be sold unless regulatory
approval is obtained. As such, the manufacturing costs for product
candidates incurred prior to regulatory approval are not
capitalized as inventory. Inventories for which there are orders or
are probable to be sold even without the regulatory approval, are
capitalized.</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Cost of finished products that are capitalized is determined as
follows: the value of the raw and packaging materials component is
determined primarily on a using the &#x201C;moving average&#x201D;
basis; the value of the labor and overhead component is determined
on an average basis over the production period.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">g.</font></td>
<td>Property and equipment</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td><font style="FONT-WEIGHT: normal">Property and equipment are
stated at cost, net of accumulated depreciation and
amortization.</font></td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td><font style="FONT-WEIGHT: normal">The Company&#x2019;s assets
are depreciated by the straight-line method on the basis of their
estimated useful lives as follows:</font></td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 70%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: top">
<td style="PADDING-LEFT: 81.1pt; WIDTH: 83%">&#xA0;</td>
<td style="WIDTH: 2%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 15%">
Years</td>
</tr>
<tr style="VERTICAL-ALIGN: top">
<td>Laboratory equipment</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center">5</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top">Furniture</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom">10-15</td>
</tr>
<tr>
<td style="VERTICAL-ALIGN: top">Computer equipment&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center; VERTICAL-ALIGN: bottom">3</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Leasehold improvements are amortized by the straight-line method
over the expected lease term, which is shorter than the estimated
useful life of the improvements.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">h.</font></td>
<td>Impairment in value of long-lived assets:</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company tests long-lived assets for impairment if an indication
of impairment exists. If the sum of expected future cash flows of
definite life assets (undiscounted and without interest charges) is
less than the carrying amount of such assets, the Company
recognizes an impairment loss, and writes down the assets to their
estimated fair values, calculated based on expected future
discounted cash flows.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">i.</font></td>
<td>Income taxes</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td><font style="FONT-WEIGHT: normal">Deferred income
taxes</font></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Deferred taxes are determined utilizing the assets and liabilities
method based on the estimated future tax effects of the differences
between the financial accounting and tax bases of assets and
liabilities under the applicable tax laws. Deferred tax balances
are computed using the tax rates expected to be in effect when
those differences reverse. A valuation allowance in respect of
deferred tax assets is provided if, based upon the weight of
available evidence, it is more likely than not that some or all of
the deferred tax assets will not be realized. The Company has
provided a full valuation allowance with respect to its deferred
tax assets.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
The guidance prohibits the recognition of deferred tax liabilities
or assets that arise from differences between the financial
reporting and tax bases of assets and liabilities that are measured
from the local currency into dollars using historical exchange
rates, and that result from changes in exchange rates or indexing
for tax purposes. Consequently, the above mentioned differences
with respect to Protalix Ltd. were not reflected in the computation
of deferred tax assets and liabilities.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td><font style="FONT-WEIGHT: normal">Uncertainty in income
taxes</font></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Tax benefits recognized in the financial statements are those that
the Company&#x2019;s management deems at least more likely than not
to be sustained, based on technical merits. The amount of benefits
recorded for these tax benefits is measured as the largest benefit
the Company&#x2019;s management deems more likely than not to be
sustained.</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">j.</font></td>
<td>Revenue Recognition</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company recognizes revenue when the earnings process is
complete, which is when revenue is realized or realizable and
earned, there is persuasive evidence a revenue arrangement exists,
delivery of goods or services has occurred, the sales price is
fixed or determinable and collectability is reasonably assured.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td><font style="FONT-WEIGHT: normal">Revenues from the license and
supply agreement with Pfizer</font></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
The Company recognizes revenue and milestone payments received
pursuant to the Pfizer Agreement in accordance with guidance
regarding revenue recognition and accounting for revenue
arrangements with multiple deliverables. As the arrangement with
Pfizer requires the Company&#x2019;s continued involvement with
respect to the proposed commercialization of taliglucerase alfa,
the non-refundable, up-front license payment the Company received
from Pfizer was deferred and recognized over the related
performance period. The Company estimated the performance period of
14 years (commencing upon the date of the Company's receipt of the
up-front license payment payable by Pfizer under the Pfizer
Agreement) based on the date the last relevant patent expires. See
Note 2. The Company adjusts the performance periods, if
appropriate, based on the applicable facts and circumstances.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td><font style="FONT-WEIGHT: normal">Revenues from selling
products to Pfizer</font></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
The Company recognizes revenues from products sold to Pfizer upon
delivery, when the sales price is fixed or determinable and
collectability is reasonably assured.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1.25in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">3.</td>
<td><font style="FONT-WEIGHT: normal">Company&#x2019;s share in the
collaboration agreement</font></td>
</tr>
</table>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">Under the terms and conditions of
the Pfizer Agreement, the Company is entitled to 40% of the profits
or loss from sales of taliglucerase alfa, and related expenses
incurred, except with respect to sales in Israel, where the Company
retained exclusive marketing rights. Since Pfizer bears most of the
risks and rewards relating to the agreement, the Company&#x2019;s
share in the profits and loss in the agreement is recognized on a
net basis. The Company recognizes its share of net profit or loss
from the Pfizer Agreement based on reports it receives from Pfizer
summarizing the results of the collaborative activities under the
agreement for the applicable period. Under the terms of the Pfizer
Agreement, for its subsidiaries operating outside the United
States, financial information is included based on the fiscal year
ending November 30, while financial information for the U.S. entity
is included based on the fiscal year ending December 31.</font></p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">k.</font></td>
<td>Research and development costs</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Research and development costs are expensed as incurred and consist
primarily of personnel, subcontractors and consultants (mainly in
connection with clinical trials), facilities, equipment and
supplies for research and development activities. Grants received
by the Israeli Subsidiary from the Office of the Chief Scientist of
Israel&#x2019;s Ministry of Industry, Trade and Labor (the
&#x201C;OCS&#x201D;) are recognized when the grant becomes
receivable, provided there is reasonable assurance that the Company
or the Subsidiary will comply with the conditions attached to the
grant and there is reasonable assurance the grant will be received.
The grant is deducted from the research and development expenses as
the applicable costs are incurred.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Reimbursements received from Pfizer are recognized when the
reimbursements become receivable, provided there is reasonable
assurance that the Company will comply with the conditions attached
to the reimbursements and there is reasonable assurance the
reimbursements will be received. The reimbursements are deducted
from the research and development expenses as the applicable costs
are incurred.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
In connection with purchases of assets, amounts assigned to
intangible assets to be used in a particular research and
development project that have no alternative future use are charged
to research and development costs at the purchase date.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Nonrefundable advance payments for goods or services that will be
used or rendered for future research and development activities are
deferred and amortized over the period that the goods are consumed
or the related services are performed.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">l.</font></td>
<td>Comprehensive loss</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company has no other comprehensive loss components other than
net loss for the reported periods.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">m.</font></td>
<td>Concentration of credit risks and trade receivable</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Financial instruments that potentially subject the Company to
concentration of credit risk consist principally of bank deposits.
The Company deposits these instruments with highly rated financial
institutions, mainly in Israeli banks, and, as a matter of policy,
limits the amounts of credit exposure to any one financial
institution. The Company has not experienced any credit losses in
these accounts and does not believe it is exposed to any
significant credit risk on these instruments.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
<font style="COLOR: black">The Company's trade</font> receivable
<font style="COLOR: black">represents amounts to be received from
Pfizer, as the Company currently receives all of its revenues from
Pfizer. The Company does not require Pfizer to post collateral with
respect to the receivables. The Company performs periodic credit
evaluations of Pfizer&#x2019;s financial condition and believes
there is no significant risk with respect to Pfizer&#x2019;s payment
of the receivables.</font></p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">n.</font></td>
<td>Share-based compensation</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company accounts for employee&#x2019;s share-based payment
awards classified as equity awards using the grant-date fair value
method. The fair value of share-based payment transactions is
recognized as an expense over the requisite service period, net of
estimated forfeitures. The Company estimates forfeitures based on
historical experience and anticipated future conditions.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company elected to recognize compensation cost for an award
with only service conditions that has a graded vesting schedule
using the accelerated method based on the multiple-option award
approach.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
When stock options are granted as consideration for services
provided by consultants and other non-employees, the grant is
accounted for based on the fair value of the consideration received
or the fair value of the stock options issued, whichever is more
reliably measurable. The fair value of the options granted is
measured on a final basis at the end of the related service period
and is recognized over the related service period using the
straight-line method.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">o.</font></td>
<td>Net Loss per share</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Basic and diluted loss per share (&#x201C;LPS&#x201D;) are computed
by dividing net loss by the weighted average number of shares of
the Company's Common Stock, par value $0.001 per share (the "Common
Stock") outstanding for each period.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Diluted LPS does not include options to purchase 10,660,447,
7,761,168 and 7,469,088 shares of Common Stock for the fiscal years
ended December 31, 2009, 2010 and 2011, respectively, because the
effect would be anti-dilutive.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation, or accounting, and significant accounting policies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 27,001<span></span></td>
        <td class="nump">$ 35,900<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Accounts receivable:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade</a></td>
        <td class="nump">1,374<span></span></td>
        <td class="nump">7,013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other</a></td>
        <td class="nump">3,837<span></span></td>
        <td class="nump">2,231<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">279<span></span></td>
        <td class="nump">1,189<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">32,491<span></span></td>
        <td class="nump">46,333<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">1,043<span></span></td>
        <td class="nump">942<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">18,271<span></span></td>
        <td class="nump">17,454<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">51,805<span></span></td>
        <td class="nump">64,729<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump">5,032<span></span></td>
        <td class="nump">6,272<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump">7,540<span></span></td>
        <td class="nump">8,068<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">6,121<span></span></td>
        <td class="nump">4,563<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">18,693<span></span></td>
        <td class="nump">18,903<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump">50,923<span></span></td>
        <td class="nump">55,486<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Long term liability</a></td>
        <td class="nump">6,566<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump">1,700<span></span></td>
        <td class="nump">1,663<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">59,189<span></span></td>
        <td class="nump">57,149<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">77,882<span></span></td>
        <td class="nump">76,052<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>CAPITAL DEFICIENCY:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.001 par value: Authorized - as of December 31, 2010 and 2011, 150,000,000 shares; issued and outstanding - as of December 31, 2010 and 2011, 81,248,472 and 85,630,157 shares, respectively</a></td>
        <td class="nump">86<span></span></td>
        <td class="nump">81<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">145,814<span></span></td>
        <td class="nump">124,044<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(171,977)<span></span></td>
        <td class="num">(135,448)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total capital deficiency</a></td>
        <td class="num">(26,077)<span></span></td>
        <td class="num">(11,323)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
        <td class="nump">$ 51,805<span></span></td>
        <td class="nump">$ 64,729<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6962843&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6410544&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability for underfunded plans recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement defined benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6962843&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6962843&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6410544&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6962843&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Common stock issued for cash, issuance costs</a></td>
        <td class="nump">$ 1,410<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EO4AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">$ (36,529)<span></span></td>
        <td class="num">$ (28,998)<span></span></td>
        <td class="num">$ (31,440)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump">886<span></span></td>
        <td class="nump">1,282<span></span></td>
        <td class="nump">2,683<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">3,631<span></span></td>
        <td class="nump">3,133<span></span></td>
        <td class="nump">1,990<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses (income), net (mainly exchange differences)</a></td>
        <td class="nump">350<span></span></td>
        <td class="num">(591)<span></span></td>
        <td class="num">(166)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump">155<span></span></td>
        <td class="nump">377<span></span></td>
        <td class="nump">265<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num">(14)<span></span></td>
        <td class="num">(26)<span></span></td>
        <td class="num">(81)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of fixed assets</a></td>
        <td class="nump">8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenues (including non-current portion)</a></td>
        <td class="num">(3,005)<span></span></td>
        <td class="num">(4,563)<span></span></td>
        <td class="nump">64,612<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
        <td class="nump">3,891<span></span></td>
        <td class="num">(6,860)<span></span></td>
        <td class="num">(1,224)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (Increase) in inventories</a></td>
        <td class="nump">910<span></span></td>
        <td class="num">(1,189)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals (including long term )</a></td>
        <td class="nump">6,147<span></span></td>
        <td class="num">(1,029)<span></span></td>
        <td class="nump">7,784<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
        <td class="num">(23,570)<span></span></td>
        <td class="num">(38,464)<span></span></td>
        <td class="nump">44,452<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(5,705)<span></span></td>
        <td class="num">(7,855)<span></span></td>
        <td class="num">(6,195)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">73<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num">(165)<span></span></td>
        <td class="num">(137)<span></span></td>
        <td class="num">(52)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(5,868)<span></span></td>
        <td class="num">(7,992)<span></span></td>
        <td class="num">(6,174)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses', window );">Issuance of shares, net of issuance cost</a></td>
        <td class="nump">20,650<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="nump">277<span></span></td>
        <td class="nump">501<span></span></td>
        <td class="nump">293<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">20,927<span></span></td>
        <td class="nump">501<span></span></td>
        <td class="nump">293<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="num">(388)<span></span></td>
        <td class="nump">589<span></span></td>
        <td class="nump">99<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(8,899)<span></span></td>
        <td class="num">(45,366)<span></span></td>
        <td class="nump">38,670<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</a></td>
        <td class="nump">35,900<span></span></td>
        <td class="nump">81,266<span></span></td>
        <td class="nump">42,596<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</a></td>
        <td class="nump">27,001<span></span></td>
        <td class="nump">35,900<span></span></td>
        <td class="nump">81,266<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">1,473<span></span></td>
        <td class="nump">2,720<span></span></td>
        <td class="nump">4,525<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalOfferingAndStockIssuanceCosts', window );">Issuance cost not yet paid and accruals - other</a></td>
        <td class="nump">60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CashlessExerciseOfStockOptions', window );">Exercise of options granted to employees</a></td>
        <td class="nump">$ 31<span></span></td>
        <td class="nump">$ 9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CashlessExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cashless exercise of stock options</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CashlessExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Issuance Of Common Stock Net Of Expenses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalOfferingAndStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental offering and stock issuance costs</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalOfferingAndStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Represents the aggregate of gains (losses) on transactions that are unsettled as of the balance sheet date, which is therefore an adjustment to reconcile income (loss) from continuing operations to net cash provided by or used in continuing operations. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting entity's financial statements. For certain entities, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3095-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitContributions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, issued</a></td>
        <td class="nump">85,630,157<span></span></td>
        <td class="nump">81,248,472<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, outstanding</a></td>
        <td class="nump">85,630,157<span></span></td>
        <td class="nump">81,248,472<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 10 -</b></font> <b>RELATED
PARTY TRANSACTIONS</b></p>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"></p>
<table style="WIDTH: 93%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 36pt" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2009</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -20.7pt; PADDING-LEFT: 20.7pt; WIDTH: 55%">
<b>a. &#xA0;&#xA0;&#xA0;&#xA0;</b>Management and consulting fees to
the Chairman of the Board</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%">
33</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%">
6</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -20.7pt; PADDING-LEFT: 20.7pt">
<b>b.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</b>Compensation to the
non-executive directors (except the Chairman of the Board in 2009,
and includes the interim Chairman of the Board in 2010 and
2011)</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
209</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
215</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
215</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 23, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PROTALIX BIOTHERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90,815,396<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 365,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 11 -</b></font> <b>SUBSEQUENT
EVENTS</b></p>
<p style="TEXT-INDENT: -20.7pt; MARGIN: 0px 0px 0px 56.7pt; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 20.7pt"><font style="FONT-WEIGHT: normal">a.</font></td>
<td><font style="FONT-WEIGHT: normal">During January and February
2012, the Company issued a total of 10,239 shares of Common Stock
in connection with the exercise of options to purchase 10,239
shares of Common Stock by certain employees of the Company. The
Company received aggregate cash proceeds equal to approximately $5
in connection with the exercise of such options.</font></td>
</tr>
</table>
<p style="TEXT-INDENT: -20.7pt; MARGIN: 0px 0px 0px 56.7pt; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 36pt"></td>
<td style="WIDTH: 20.7pt"><font style="FONT-WEIGHT: normal">b.</font></td>
<td><font style="FONT-WEIGHT: normal">On February 22,&#xA0;2012,
the Company issued and sold 5,175,000 shares of Common Stock in an
underwritten public offering at a price to the public of $5.25 per
share. The net proceeds to the Company were approximately
$25,389&#xA0;(net of underwriting commissions and issuance costs of
$1,567). The offering included the exercise by the underwriters of
an over-allotment option to purchase 675,000 shares of Common
Stock.</font></td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EEQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
        <td class="nump">$ 8,386<span></span></td>
        <td class="nump">$ 6,642<span></span></td>
        <td class="nump">$ 388<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="num">(5,418)<span></span></td>
        <td class="nump">4,602<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num">(1,525)<span></span></td>
        <td class="num">(4,383)<span></span></td>
        <td class="num">(3,575)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT (LOSS)</a></td>
        <td class="nump">1,443<span></span></td>
        <td class="nump">6,861<span></span></td>
        <td class="num">(3,187)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num">(37,818)<span></span></td>
        <td class="num">(37,691)<span></span></td>
        <td class="num">(27,390)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReimbursementRevenue', window );">Less - grants and reimbursements</a></td>
        <td class="nump">6,775<span></span></td>
        <td class="nump">7,740<span></span></td>
        <td class="nump">5,752<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num">(31,043)<span></span></td>
        <td class="num">(29,951)<span></span></td>
        <td class="num">(21,638)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num">(6,931)<span></span></td>
        <td class="num">(6,876)<span></span></td>
        <td class="num">(7,144)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(36,531)<span></span></td>
        <td class="num">(29,966)<span></span></td>
        <td class="num">(31,969)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">FINANCIAL INCOME - NET</a></td>
        <td class="nump">2<span></span></td>
        <td class="nump">968<span></span></td>
        <td class="nump">529<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE YEAR</a></td>
        <td class="num">$ (36,529)<span></span></td>
        <td class="num">$ (28,998)<span></span></td>
        <td class="num">$ (31,440)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock - basic and diluted:</a></td>
        <td class="nump">$ 0.43<span></span></td>
        <td class="nump">$ 0.36<span></span></td>
        <td class="nump">$ 0.41<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WeightedAverageNumberBasicDilutedSharesOutstanding', window );">Weighted average number of shares of common stock used in computing loss per share of common stock, basic and diluted:</a></td>
        <td class="nump">84,645,364<span></span></td>
        <td class="nump">80,960,300<span></span></td>
        <td class="nump">76,942,840<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other Gains Losses</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_OtherGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research Development And Engineering Expense, Net</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ResearchDevelopmentAndEngineeringExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WeightedAverageNumberBasicDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_WeightedAverageNumberBasicDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 2<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReimbursementRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 45<br><br> -Section 45<br><br> -Paragraph 23<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6743974&amp;loc=d3e60722-111653<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReimbursementRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 5 -</b></font> <b>LIABILITY
FOR EMPLOYEE RIGHTS UPON RETIREMENT</b></p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
The Israeli Subsidiary is required to make a severance payment upon
dismissal of an employee, or upon termination of employment in
certain circumstances. The severance pay liability to the employees
(based upon length of service and the latest monthly salary - one
month&#x2019;s salary for each year employed) is recorded on the
Company&#x2019;s balance sheets under &#x201C;Liability for employee
rights upon retirement.&#x201D; The liability is recorded as if it
were payable at each balance sheet date on an undiscounted
basis.</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
The liability is funded in part from the purchase of insurance
policies or by the establishment of pension funds with dedicated
deposits in the funds. The amounts used to fund these liabilities
are included in the Company&#x2019;s balance sheets under
&#x201C;Funds in respect of employee rights upon retirement.&#x201D;
These policies are the Company&#x2019;s assets. However, under labor
agreements and subject to certain limitations, any policy may be
transferred to the ownership of the individual employee for whose
benefit the funds were deposited. In the years ended December 31,
2009, 2010 and 2011, the Company deposited $79, $174 and $181,
respectively, with insurance companies in connection with its
severance payment obligations.</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
In accordance with the current employment agreements with certain
employees, the Company makes regular deposits with certain
insurance companies for accounts controlled by each applicable
employee in order to secure the employee&#x2019;s rights upon
retirement. The Company is fully relieved from any severance pay
liability with respect to each such employee after it makes the
payments on behalf of the employee. The liability accrued in
respect of these employees and the amounts funded, as of the
respective agreement dates, are not reflected in the
Company&#x2019;s balance sheets, as the amounts funded are not under
the control and management of the Company and the pension or
severance pay risks have been irrevocably transferred to the
applicable insurance companies (the &#x201C;Contribution
Plans&#x201D;).</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
The amounts of severance pay expenses were $488, $1,118 and $816
for the years ended December 31, 2009, 2010 and 2011, respectively,
of which $335, $531 and $641 in the years ended December 31, 2009,
2010 and 2011, respectively, were in respect of a Contribution
Plan. Gain on amounts funded in respect of employee rights upon
retirement totaled $81, $26 and $14 for the years ended December
31, 2009, 2010 and 2011, respectively.</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
The Company expects to contribute approximately $779 in the year
ending December 31, 2012 to insurance companies in connection with
its severance liabilities for its operations for that year, $607 of
which will be contributed to one or more Contribution Plans.</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif">
During the five-year period following December 31, 2011, the
Company expects to pay future benefits to one employee upon the
employee's normal retirement age. The Company anticipates that the
benefits payable will be immaterial.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 87<br><br> -Paragraph 264<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 158<br><br> -Paragraph 7, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS106-2<br><br> -Paragraph 20, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Implementation Guide (Q and A)<br><br> -Number FAS88<br><br> -Paragraph 63<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 30<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-2<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 8<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph q<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 106<br><br> -Paragraph 518<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 4 -</b></font>
<b>INVENTORIES</b></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">a.</font></td>
<td><font style="FONT-WEIGHT: normal">Inventory at
December&#xA0;31, 2010 and 2011 consisted of the
following:</font></td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; WIDTH: 58%">Raw materials</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 18%">553</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 18%">279</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Finished
goods</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
636</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total
inventory</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,189</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
279</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">b.</font></td>
<td><font style="FONT-WEIGHT: normal">During the year ended
December 31, 2010 and 2011, <font style="COLOR: black">the Company
recorded a $2,692</font> and $363, respectively, write-down of
inventory under cost of revenues. See Note 9d.</font></td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 3<br><br> -Section A<br><br> -Paragraph 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>TAXES ON INCOME<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 8 -</b></font> <b>TAXES ON
INCOME</b></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">a.</font></td>
<td>The Company</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Protalix BioTherapeutics, Inc. is taxed according to U.S. tax laws.
The Company's income is, or will be, taxed in the United States at
the rate of up to 39%.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">b.</font></td>
<td>Protalix Ltd.</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Israeli Subsidiary is taxed according to Israeli tax laws:</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td>Measurement of results for tax purposes</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Since 2008, the Company has measured the results of the Israeli
Subsidiary for tax purposes in nominal terms in NIS. Pursuant to
the Israel Income Tax Law (Adjustments for Inflation), 1985 (the
&#x201C;Adjustments Law&#x201D;), the Subsidiary&#x2019;s results for
tax purposes have been measured through 2007 on a real basis, based
on changes in the Israel consumer price index.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td>Tax rates</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
The income of the Israeli Subsidiary, other than income from
&#x201C;Approved Enterprises,&#x201D; is taxed in Israel at the
regular rate. See 3 below. According to the provisions of the Law
for Amending the Israel Income Tax Ordinance, 2005, corporate tax
rates will be gradually lowered, resulting in a corporate tax rate
for 2009 and thereafter: 2009 &#x2013; 26% and for 2010 and
thereafter &#x2013; 25%.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
On July 14, 2009, the Israel Economic Efficiency Law (Legislation
Amendments for Applying the Economic Plan for 2009 and 2010), 2009,
became effective, stipulating, among other things, an additional
gradual decrease in tax rates in 2011 and thereafter, as follows:
2011 &#x2013; 24%, 2012 &#x2013; 23%, 2013 &#x2013; 22%, 2014 &#x2013;
21%, 2015 &#x2013; 20% and 2016 and thereafter &#x2013; 18%.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
On December 5, 2011, the "Tax Burden Distribution Law" (hereinafter
- the 2011 amendment) was officially published, discontinuing a
previously approved gradual decrease in corporate tax provided in
the 2009 amendment, and setting the corporate tax rate in Israel
for 2012 and thereafter to 25%.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Capital gain is subject to capital gain tax according to corporate
tax rate in the year of selling the assets.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">3.</td>
<td>The Law for the Encouragement of Capital Investments, 1959 (the
&#x201C;Encouragement of Capital Investments Law&#x201D;)</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Under the Encouragement of Capital Investments Law, including
Amendment No. 60 to the Encouragement of Capital Investments Law as
published in April 2005, by virtue of the &#x201C;Approved
Enterprise&#x201D; or &#x201C;Benefited Enterprise&#x201D; status the
Israeli Subsidiary is entitled to various tax benefits as
follows:</p>
<p style="TEXT-INDENT: -37.1pt; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">a.</td>
<td><b>Reduced tax rates</b></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
Income derived from the Approved Enterprise during a 10-year period
commencing upon the year in which the enterprise first realizes
taxable income is tax exempt, provided that the maximum period to
which it is restricted by the Encouragement of Capital Investments
Law has not elapsed.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The Israeli Subsidiary has an &#x201C;Approved Enterprise&#x201D;
plan since 2004 and &#x201C;Benefited Enterprise&#x201D; plan since
2009. The period of benefits in respect of the main enterprise of
the Company has not yet commenced. The period during which the
Company is entitled to benefits in connection with the Benefited
Enterprise expires in 2021.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
If the Israeli Subsidiary subsequently pays a dividend out of
income derived from the &#x201C;Approved Enterprise&#x201D; or
&#x201C;Benefited Enterprise&#x201D; during the tax exemption period,
it will be subject to a tax on the amount distributed, including
any company tax on these amounts, at the rate which would have been
applicable had such income not been exempted.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
In addition to the corporate taxes in Israel, the Company might be
subject to a withholding tax on the U.S. revenue source portion of
the payments made to the Company for its share of Pfizer&#x2019;s
net profits under the Pfizer Agreement. The withholding tax rate is
currently 15%.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">b.</td>
<td><b>Accelerated depreciation</b></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The Israeli Subsidiary is entitled to claim accelerated
depreciation, as provided by Israeli law, in the first five years
of operation of each asset, in respect of buildings, machinery and
equipment used by the Approved Enterprise and the Benefited
Enterprise.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">c.</td>
<td><b>Conditions for entitlement to the benefits</b></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The Israeli Subsidiary&#x2019;s entitlement to the benefits
described above is subject to its fulfilling the conditions
stipulated by the law, rules and regulations published thereunder,
and the instruments of approval for the specific investment in an
approved enterprise. If there is any failure by the Israeli
Subsidiary to comply with these conditions, the benefits may be
cancelled and the Subsidiary may be required to refund the amount
of the benefits, in whole or in part, with interest. The Company
received a final implementation approval with respect to its
&#x201C;Approved Enterprise&#x201D; from the Investment Center.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">d.</td>
<td><b>Amendment of the Law for the Encouragement of Capital
Investments, 1959</b></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The Encouragement of Capital Investments Law was amended as part of
the Economic Policy Law for the years 2011-2012, which was passed
by the Israeli Knesset on December 29, 2010 (the &#x201C;Capital
Investments Law Amendment&#x201D;).</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The Capital Investments Law Amendment sets alternative benefit
tracks to those currently in effect under the provisions of the
Encouragement of Capital Investments Law.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The benefits granted to the Benefited Enterprises will be unlimited
in time, unlike the benefits granted to special Benefited
enterprises, which will be limited for a 10-year period. The
benefits shall be granted to companies that will qualify under
criteria set in the law; for the most part, those criteria are
similar to the criteria that were set in the Encouragement of
Capital Investments Law prior to its amendment.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
Under the transitional provisions of the Encouragement of Capital
Investments Law, the Company is entitled to take advantage of the
tax benefits available under the Encouragement of Capital
Investments Law prior to its amendment until the end of the
benefits period, as defined in the Encouragement of Capital
Investments Law. The Company will be allowed to set the &#x201C;year
of election&#x201D; no later than tax year 2012, provided that the
minimum qualifying investment was made not later than the end of
2010. On each year during the benefits period, the Company will be
able to elect that the Capital Investments Amendment apply to the
Company, thereby making the tax rates described above available to
the Company. An election to have the Capital Investments Amendment
apply is irrecoverable.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">4.</td>
<td>The Law for the Encouragement of Industry (Taxation),
1969:</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
The Israeli Subsidiary is an &#x201C;industrial company,&#x201D; as
defined under the Law for the Encouragement of Industry (Taxation),
1969 (the &#x201C;Law for the Encouragement of Industry&#x201D;). As
such, the Israeli Subsidiary is entitled to claim depreciation at
increased rates for equipment used in industrial activity, as
stipulated by regulations published under Law for the Encouragement
of Industry, and has done so.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Under the provisions of the Income Tax Regulations
&#x201C;Accelerated Depreciation in respect of Equipment acquired
during the Defined Period&#x201D; (Temporary Orders), industrial
companies whose operations are mostly &#x201C;eligible
operations&#x201D; are entitled to claim accelerated depreciation at
a rate of 50% on machinery and equipment acquired from June 1, 2008
to May 31, 2009.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">c.</font></td>
<td>Tax losses carried forward to future years</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
As of December 31, 2011, the Company had aggregate net operating
loss (NOL) carry-forwards equal to approximately $63,040 that are
available to reduce future taxable income as follows:</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td>The Company</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
The NOL carry-forward of the Company equal to approximately $11,740
may be restricted under Section 382 of the Internal Revenue Code
(&#x201C;IRC&#x201D;). IRC Section 382 applies whenever a corporation
with NOL experiences an ownership change. As a result of IRC
Section 382, the taxable income for any post change year that may
be offset by a pre-change NOL may not exceed the general IRC
Section 382 limitation, which is the fair market value of the
pre-change entity multiplied by the IRC long-term tax exempt
rate.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td>Protalix Ltd.</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
At December 31, 2011, the Israeli Subsidiary had approximately
$51,300 of NOL carry-forwards that are available to reduce future
taxable income with no limited period of use.</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">d.</font></td>
<td>Deferred income taxes:</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The components of the Company&#x2019;s net deferred tax assets at
December 31, 2010 and 2011 were as follows:</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 70%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td>In respect of:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt; WIDTH: 70%">
Research and Development expenses</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 12%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 12%">4,119</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt">Property and
equipment</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">(143</td>
<td style="TEXT-ALIGN: left">)</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">(149</td>
<td style="TEXT-ALIGN: left">)</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt">Holiday and
recreation pay</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">296</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">305</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt">Severance pay
obligation</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">130</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">164</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt">Deferred
revenues</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,691</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">4,746</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 12.6pt">Net operating
loss carry forwards</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,599</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">4,579</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Valuation
allowance</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
(7,573</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
(13,764</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
-</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
Deferred taxes are computed using the tax rates expected to be in
effect when those differences reverse. The Company used tax rates
of 39%, 25% and 0%.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">e.</font></td>
<td>Reconciliation of the theoretical tax expense to actual tax
expense</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The main reconciling items between the statutory tax rate of the
Company and the effective rate is the provision for full valuation
allowance in respect of tax benefits from carry forward tax losses
due to the uncertainty of the realization of such tax benefits (see
above).</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">f.</font></td>
<td>Tax assessments</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
In accordance with the Income Tax Ordinance, as of December 31,
2011, all of Protalix Ltd.&#x2019;s tax assessments through tax year
2007 are considered final.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
A summary of open tax years by major jurisdiction is presented
below:</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: top">
<td style="BORDER-BOTTOM: windowtext 1pt solid; WIDTH: 48%; FONT-WEIGHT: bold">
Jurisdiction:</td>
<td style="WIDTH: 4%; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: windowtext 1pt solid; TEXT-ALIGN: right; WIDTH: 48%; FONT-WEIGHT: bold">
Years:</td>
</tr>
<tr style="VERTICAL-ALIGN: top">
<td>Israel</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">2008-2011</td>
</tr>
<tr style="VERTICAL-ALIGN: top">
<td>United States (*)</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">2002-2011</td>
</tr>
<tr style="VERTICAL-ALIGN: top">
<td>Netherlands</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">2009-2011</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
(*) Includes federal, state and local (or similar provincial
jurisdictions) tax positions.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>COMMITMENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 6 -</b></font>
<b>COMMITMENTS</b></p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">a.</font></td>
<td>Royalty commitments</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td><font style="FONT-WEIGHT: normal">The Company is obligated to
pay royalties to the OCS on proceeds from the sale of products
developed from research and development activities that were
funded, partially, by grants from the OCS. At the time the grants
were received, successful development of the related projects was
not assured.</font></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
In the case of failure of a project that was partly financed as
described above, the Company is not obligated to pay any such
royalties or repay funding received from the OCS.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Under the terms of the funding arrangements with the OCS, royalties
of 3% to 6% are payable on the sale of products developed from
projects funded by the OCS, which payments shall not exceed, in the
aggregate, 100% of the amount of the grant received (dollar
linked), plus, commencing upon January&#xA0;1, 2001, interest at
annual rate based on LIBOR. In addition, if the Company receives
approval to manufacture products developed with government grants
outside the State of Israel, it will be required to pay an
increased total amount of royalties (possibly up to 300% of the
grant amounts plus interest), depending on the manufacturing volume
that is performed outside the State of Israel, and, possibly, an
increased royalty rate.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Royalty expenses to the OCS are included in the statement of
operations as a component of the cost of revenues and were
approximately $1,950, $769 and $158 during the years ended
December&#xA0;31, 2009, 2010 and 2011, respectively.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
At December&#xA0;31, 2011, the maximum royalty amount payable by
the Company under these funding arrangements is approximately
$19,820 (without interest, assuming 100% of the funds are
payable).</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td><font style="FONT-WEIGHT: normal">The Company is a party to
certain research and license agreements. Under the <font style="COLOR: black">agreements, the Company is obligated</font> to pay
royalties at varying rates from its future revenues. The aggregate
royalties payable under all of the agreements is equal to a
percentages of net sales of licensed products in the teens. Royalty
expenses under the agreements are included in the statement of
operations as a component of the cost of revenues and were
approximately $1,625, $115 and $19 during the years ended
December&#xA0;31, 2009, 2010 and 2011, respectively.</font></td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
Under each agreement, the Company is also obligated to pay
milestone, licensing and other payments to the counterparties of
the agreement. The payments under the agreements are for varying
amounts and are subject to varying conditions. If all of the
contingencies with respect to milestone payments under the research
and license agreements are met, the aggregate milestone payments
payable would be approximately $950 and would be payable, if at
all, as the Company&#x2019;s projects progress over the course of a
number of years. In addition, milestone payments of $70 and $100
were paid in respect of the said agreements during the years ended
December 31,2009 and 2010, respectively.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
None of the agreements has a fixed termination date. Subject to
earlier termination for other reasons, each agreement terminates
after a certain number of years following the first commercial sale
of any licensed product under the agreement or after a certain
number of years without the initiation of commercial sales of any
product under the agreement.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">b.</font></td>
<td>Subcontracting Agreements</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company has entered into sub-contracting agreements with
several clinical providers and consultants in Israel, the United
States and certain other countries in connection with its primary
product development process and with expenditure of the
company&#x2019;s manufacturing facilities. As of December 31, 2011,
total commitments under said agreements were approximately
$821.</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">c.</font></td>
<td>Lease Agreements</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company is a party to a number of lease agreements for its
facilities, the latest of which expires in 2017. The Company has
the option to extend certain of such agreements on three occasions
for additional five-year periods, for a total of 15 additional
years. Under the leases, the aggregate monthly rental payments are
approximately $75. As of December 31, 2011, the Company provided
bank guarantees of approximately $208, in the aggregate, to secure
the fulfillment of its obligations under the lease agreements. The
future minimum lease payments required in each of the next five
years under the operating leases for such premises are
approximately as follows: 2012 - $901, 2013 - $890, 2014 - $883,
2015 &#x2013; $883 and 2016 &#x2013; $638. Lease expenses totaled
$780, $891 and $994 for the years ended December 31, 2009, 2010 and
2011, respectively.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">d.</font></td>
<td>Vehicle Lease and Maintenance Agreements</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
In July 2004, the Company entered into several three-year lease and
maintenance agreements for vehicles which are regularly amended as
new vehicles are leased. The current monthly lease fees aggregate
approximately $46. The minimum expected lease payments for the
years ending December 31, 2012, 2013 and 2014 are $514, $267 and
$70, respectively.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">e.</font></td>
<td>Teva Agreement</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
On September 14, 2006, the Company entered into an agreement (the
&#x201C;Teva Agreement&#x201D;) with Teva Pharmaceutical Industries
Ltd. (&#x201C;Teva&#x201D;) under which the Company agreed to
collaborate on the research and development of two proteins to be
identified by Teva and the Company, using ProCellEx. The Teva
Agreement also identifies additional matters for collaboration
between Teva and the Company. Subsequently, two proteins were
identified to be researched and developed under the agreement but
in 2009, both of the projects were terminated for commercial
reasons. Other elements of the Company&#x2019;s collaboration with
Teva are currently ongoing.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">f.</font></td>
<td>Yissum Agreement</td>
</tr>
</table>
<p style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
On August 8, 2007, the Company signed an agreement with the Yissum
Research and Development Company, the technology transfer arm of
the Hebrew University of Jerusalem, Israel, and the Boyce Thompson
Institute for Plant Research, at Cornell University, Ithaca, New
York, to develop a proprietary plant cell-based
acetylcholinesterase (AChE) and its molecular variants for the use
in several therapeutic and prophylactic indications, including a
biodefense program and organophosphate-based pesticide treatment.
Pursuant to the agreement, the Company has received an exclusive
worldwide right and license to certain technology, including
patents and additional patent applications relating to AChE (the
&#x201C;Licensed Technology&#x201D;), for all therapeutic and
prophylactic indications. In consideration for the license, the
Company is required to make certain milestone payments equal to up
to $700, in the aggregate, upon its achievement of clinical
milestones and royalties from sales derived from any drugs
developed by the Company with the Licensed Technology. The
agreement does not terminate until either party to the agreement
elect to terminate the agreement, subject to certain terms and
conditions set forth therein.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 7<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHARE CAPITAL</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 7 -</b></font> <b>SHARE
CAPITAL</b></p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">a.</font></td>
<td>Rights of the Company&#x2019;s Common Stock</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The Company&#x2019;s common stock is listed on the NYSE Amex and,
since September 6, 2010, on the Tel Aviv Stock Exchange. Each share
of Common Stock is entitled to one vote. The holders of shares of
Common Stock are also entitled to receive dividends whenever funds
are legally available, when and if declared by the Board of
Directors. Since its inception, the Company has not declared any
dividends.</p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">b.</font></td>
<td>Stock based compensation</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
On December 14, 2006, the Board of Directors adopted the Protalix
BioTherapeutics, Inc. 2006 Stock Incentive Plan (the
&#x201C;Plan&#x201D;). The grant of options to Israeli employees
under the Plan is subject to the terms stipulated by
Sections&#xA0;102 and 102A of the Israeli Income Tax Ordinance.
Each option grant is subject to the track chosen by the Company,
either Section 102 or Section 102A of the Israeli Income Tax
Ordinance, and pursuant to the terms thereof, the Company is not
allowed to claim, as an expense for tax purposes, the amounts
credited to employees as a benefit, including amounts recorded as
salary benefits in the Company&#x2019;s accounts, in respect of
options granted to employees under the Plan, with the exception of
the work-income benefit component, if any, determined on the grant
date. For Israeli non-employees, the share option plan is subject
to Section 3(i) of the Israeli Income Tax Ordinance.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
As of December 31, 2011, 47,920 shares of Common Stock remain
available for grant under the Plan.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
For purposes of determining the fair value of the options granted
to employees and non-employees, the Company&#x2019;s management uses
the fair value of the Common Stock.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
From January 1, 2009 through December 31, 2011, the Company granted
options to certain employees and non-employees as follows:</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">1.</td>
<td>Options granted to employees:</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">a)</td>
<td>Below is a table summarizing all of the option grants to
employees for each of the three years in the period ended December
31, 2011:</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 80%; FONT: 8pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Year&#xA0;of<br />
Grant</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">No.&#xA0;of&#xA0;options<br />
granted</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Exercise<br />
price&#xA0;range</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">Vesting&#xA0;period</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Fair&#xA0;value<br />
at&#xA0;grant</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Expiration<br />
Period</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left" colspan="2">2009*</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">504,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left" nowrap="nowrap">$</td>
<td style="TEXT-ALIGN: right" nowrap="nowrap">2.65</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center">Upon achievement of certain
milestones*</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">1,068</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">10 years</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left" colspan="2">2009</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">120,400</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left" nowrap="nowrap">$</td>
<td style="TEXT-ALIGN: right" nowrap="nowrap">2.65</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center">4 years</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">212</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">10 years</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left" colspan="2">2010</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,016,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left" nowrap="nowrap">$</td>
<td style="TEXT-ALIGN: right" nowrap="nowrap">6.90</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center">3 years commencing upon achievement
of a certain milestone</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">5,673</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">10 years</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt" colspan="2">
2010</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">428,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt" nowrap="nowrap">
$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt" nowrap="nowrap">
6.32-$9.66</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt">4 years</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">2,147</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">10 years</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 10%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%; FONT-SIZE: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 1pt">
&#xA0;&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 1pt">
&#xA0;&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 1pt">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%" nowrap="nowrap">
&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: center; WIDTH: 35%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,068,400</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: right" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
* The milestone was achieved as of December 31, 2009 and the
options vested in full.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
Set forth below are grants made by the Company to employees
(including related parties) during the three-year period ended
December 31, 2011 (such grants appear in the table above):</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1.25in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">1.</font></td>
<td><font style="FONT-WEIGHT: normal">In February, 2009, the
Company&#x2019;s Board of Directors approved the grant of options to
purchase 624,400 shares of Common Stock to the Company&#x2019;s
Chief Executive Officer and certain officers and employees of the
Company with an exercise price equal to $2.65 per share. The
options vest as follows:</font></td>
</tr>
</table>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">(i) 504,000 of the options vest
immediately upon the achievement of certain clinical and
operational performance milestones, which milestones must be
achieved within one year of the date of grant or the options will
be forfeited. The options expire within a period of 10 years from
the date of grant. The vesting conditions of these options were
satisfied prior to December 31, 2009. Accordingly, these options
were fully vested at December 31, 2009 and the Company recognized
all of the expenses for these options during 2009.</font></p>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">(ii) 120,400 of the options vest
as follows: 25% within one year from the date of grant, with the
remainder vesting in 12 equal quarterly tranches over 36 months.
The options expire within a period of 10 years from the date of
grant. The Company&#x2019;s management assumed the simplified method
to reflect the expected life regarding these options. The Company
used the simplified method in 2009 as the Company did not have
sufficient historical exercise data to provide a reasonable basis
upon which to estimate expected term due to the limited period of
time its equity shares have been publicly traded.</font></p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1.25in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">2.</font></td>
<td><font style="FONT-WEIGHT: normal">In February 2010, the
Company&#x2019;s Board of Directors approved the grant of options to
purchase 1,016,000 shares of Common Stock, in the aggregate, to the
Company&#x2019;s Chief Executive Officer and certain officers and
employees of the Company with an exercise price equal to $6.90 per
share. The options vest quarterly over a three-year period
commencing upon the FDA&#x2019;s approval of taliglucerase alfa, if
at all. The Company treated the awards as performance-based awards
and, given that the performance condition is outside the Company's
control, concluded that the performance condition was not probable
until the performance condition actually occurs. As a result, no
share-based compensation expense was recognized as of December 31,
2011.&#xA0;&#xA0;The Company will start recording these expenses
following the FDA&#x2019;s marketing approval of taliglucerase alfa,
if at all.</font></td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1.25in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">3.</font></td>
<td><font style="COLOR: black; FONT-WEIGHT: normal">In February
2010, the Company&#x2019;s Board of Directors approved the grant of
options to purchase 160,000&#xA0;shares of Common Stock with an
exercise price equal to $6.81 per share to a new executive officer
of the Company. The options expire on the tenth anniversary of the
date of grant, unless terminated earlier. The first 25% of the
options vest on the first anniversary of the date of grant and the
remaining 75% vest in 12 equal tranches on a quarterly basis for
three years thereafter.</font></td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1.25in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">4.</font></td>
<td><font style="FONT-WEIGHT: normal">In September&#xA0;2010, the
Company&#x2019;s Board of Directors approved the grant of options to
purchase 160,000 shares of Common Stock to a new executive officer
of the Company with an exercise price equal to $7.55 per share and
options to purchase 40,000 shares of Common Stock to a new employee
of the Company with an exercise price equal to $6.32 per share. The
options vest over a four-year period, with the first 25% vesting on
the first anniversary of the applicable date of the grant and the
remaining 75% vesting in equal tranches on a quarterly basis for a
three-year period thereafter. <font style="COLOR: black">The
options expire on the tenth anniversary of the date of grant,
unless terminated earlier.</font></font></td>
</tr>
</table>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1.25in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">5.</font></td>
<td><font style="FONT-WEIGHT: normal">In November&#xA0;2010, the
Company&#x2019;s Board of Directors approved the grant of options to
purchase 68,000 shares of Common Stock to a new officer of the
Company with an exercise price equal to $9.66 per share. The
options vest over a four-year period, with the first 25% vesting on
the first anniversary of the applicable date of the grant and the
remaining 75% vesting in equal tranches on a quarterly basis for a
three-year period thereafter. <font style="COLOR: black">The
options expire on the tenth anniversary of the date of grant,
unless terminated earlier.</font></font></td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.5in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1.25in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">6.</font></td>
<td><font style="FONT-WEIGHT: normal">In September 2010, the
Company&#x2019;s Board of Directors modified the terms of the
options previously granted to an executive in 2001, by extending
the life of the options until 2016. At the date of modification,
all of the options were fully vested. The Company concluded that
there was no incremental increase in the value of the awards and
therefore no accounting charges need to be recorded in connection
with the modifications.</font></td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">b)</td>
<td>The fair value of options granted during the years ended
December 31, 2009 and 2010 were $1,280 and $7,820 respectively. The
fair value of each option granted is estimated on the date of grant
using the Black-Scholes option-pricing model, with the following
weighted average assumptions:</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1.25in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2009</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; WIDTH: 58%; PADDING-RIGHT: 0px">
Dividend yield</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 18%">
0%</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">
</td>
<td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 18%">
0%</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">
</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px">
Expected volatility</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
75%</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"></td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
75%</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"></td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px">
Risk-free interest rate</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
2.74%</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"></td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
3.23%</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"></td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px">
Expected life &#x2013; in years</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
9.2</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
8.8</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The expected volatility is based on the historical volatility of
the Common Stock and those of comparable companies. The risk-free
interest rate assumption is based on observed interest rates
appropriate for the expected term of the stock options granted in
dollar terms. The Company&#x2019;s management uses the contractual
term or its expectations, based on historical incidence of option
exercises, as applicable (during 2009 - using the simplified
method), of each option as its expected life. The pre-vesting
forfeiture rate of approximately 6.3% is estimated based on
pre-vesting forfeiture experience.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The total unrecognized compensation cost of employee stock options
at December 31, 2011 is $6,218 (net of forfeiture rate) out of
which $5,639 is expected to be recognized over a three-year period
commencing upon the FDA&#x2019;s approval of taliglucerase alfa, if
at all. The remaining compensation cost of $579 is expected to be
recognized over a weighted average period of 0.9 years.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
The total cash received from employees as a result of employee
stock option exercises for the years ended December 31, 2009, 2010
and 2011 was $293, $501 and $277, respectively. The Company did not
realize any tax benefit in connection with these exercises.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
During 2011, the Company issued 181,685 shares of Common Stock in
connection with the exercise of 182,093 options by certain
employees of the Company. The Company received cash proceeds equal
to $268 in connection with such exercises. Of such options, 2,132
options were exercised on a &#x201C;net-exercise&#x201D; basis.</p>
<p style="MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">2.</td>
<td>Options granted to consultants, directors, and other service
providers:</td>
</tr>
</table>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">As of December 31, 2011, the
Company has recognized and recorded all compensation costs related
to outstanding options for consultants, directors and other
services providers.</font></p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
No cash was received from consultants as a result of consultant
stock option exercises for the years ended December 31, 2009, 2010,
and $0.2 was received in 2011. The Company did not realize any tax
benefits in connection with these exercises.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
During 2009, the Company issued 3,853,441 shares of Common Stock in
connection with the exercise of 3,866,093 options by certain
consultants, directors, and other service providers of the Company.
The Company did not receive cash proceeds in connection with such
exercises as all of such options were exercised on a
&#x201C;net-exercise&#x201D; basis.</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
During 2011, the Company issued 200,000 shares of Common Stock in
connection with the exercise of 200,000 options by certain
consultant of the Company. The Company received cash proceeds equal
to $0.2 in connection with such exercise.</p>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1in; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.75in"></td>
<td style="WIDTH: 0.25in">3.</td>
<td><font style="FONT-WEIGHT: normal">A summary of share option
plans, and related information, under all of the Company&#x2019;s
equity incentive plans for the years ended December&#xA0;31, 2009,
2010 and 2011 are as follows:</font></td>
</tr>
</table>
<p style="TEXT-INDENT: -0.25in; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">a.</td>
<td>Options granted to employees:</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 100%; FONT: 8pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22">Year ended December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2009</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Weighted</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Weighted</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Weighted</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Number</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
average</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Number</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
average</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Number</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
average</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
of</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
exercise</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
of</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
exercise</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
of</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
exercise</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 22%">
Outstanding at beginning of year</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">5,890,641</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">2.118</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">5,366,729</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">2.476</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">6,367,979</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 10%">3.576</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Changes during the year:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt">Granted</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">624,400</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2.650</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,444,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">7.076</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt">Forfeited and
Expired</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,400</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2.650</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">13,441</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3.551</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">44,856</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">6.207</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt">
Exercised (*)</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,146,912</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
0.733</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
429,309</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1.602</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
182,093</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1.652</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Outstanding at end of year</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
5,366,729</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
2.476</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
6,367,979</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
3.576</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
6,141,030</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
3.563</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Exercisable at end of year</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
3,680,382</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1.785</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
4,267,850</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
2.183</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
4,647,834</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
2.581</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.2in; MARGIN: 0px 0px 0px 84.95pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: left; MARGIN-TOP: 0px; TEXT-INDENT: 0in; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 6pt; MARGIN-LEFT: 1in">
(*) The total intrinsic value of options exercised during the years
ended December 31, 2009, 2010 and 2011, was $7,258, $3,050 and
$1,252, respectively.</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">b.</td>
<td>Options granted to consultants, directors, and other service
providers:</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif"></p>
<table style="WIDTH: 100%; FONT: 8pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="22">Year ended December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2009</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Weighted</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Weighted</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Weighted</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Number</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
average</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Number</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
average</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
Number</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
average</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
of</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
exercise</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
of</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
exercise</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
of</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">
exercise</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">options</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">price</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 22%">
Outstanding at beginning of year</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%">
5,304,785</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%">
1.285</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%">
1,438,692</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%">
4.697</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%">
1,438,692</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 10%">
4.697</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Changes during the year-Exercised (*)</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
3,866,093</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
0.016</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
200,000</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
0.001</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Outstanding at end of year</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,438,692</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
4.697</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,438,692</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
4.697</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,238,692</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
5.385</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Exercisable at end of year</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,407,234</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
4.674</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,421,734</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
4.653</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,235,567</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
5.385</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: bold 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 63.8pt"></td>
<td style="WIDTH: 14pt">(*)</td>
<td>The total intrinsic value of options exercised during the years
ended December 31, 2009, 2010 and 2011, was $41,281, $0 and $1,886,
respectively.</td>
</tr>
</table>
<p style="TEXT-INDENT: -14pt; MARGIN: 0px 0px 0px 77.8pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="WIDTH: 0.25in">c.</td>
<td>The following tables summarize information concerning
outstanding and exercisable options as of December 31, 2011:</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 70%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: bottom">
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="16" nowrap="nowrap">December 31, 2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="9" nowrap="nowrap">Options outstanding</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6" nowrap="nowrap">Options exercisable</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">
Weighted</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Number of</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Weighted</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">
average</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">options</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">average</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">outstanding</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">
remaining</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">exercisable</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">remaining</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">Exercise</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">at end of</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">
contractual</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">at end of</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">contractual</td>
<td style="FONT-WEIGHT: bold" nowrap="nowrap">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">prices</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">year</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap">life</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">year</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">life</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%">0.001</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%">719,207</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%">3.54</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%">719,207</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 15%">3.54</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">0.120</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">987,356</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">2.30</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">987,356</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2.30</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">0.399</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">26,673</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">3.35</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">26,673</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3.35</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">0.972</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,325,988</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">4.47</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,325,988</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">4.47</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">2.350</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">160,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">6.82</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">120,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">6.82</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">2.650</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">604,956</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">7.15</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">573,550</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">7.15</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">3.020</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">50,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">6.10</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">46,875</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">6.10</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">5.000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,720,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">6.10</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,559,210</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">6.10</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">6.810</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">160,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">8.10</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">70,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">8.10</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">6.900</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,010,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">8.15</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">7.550</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">160,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">8.66</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">50,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">8.66</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">9.660</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">68,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: right">8.84</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">17,000</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">8.84</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">16.700</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
387,542</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">5.00</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
387,542</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt">5.00</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
7,379,722</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
5,883,401</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
The aggregate intrinsic value of the total outstanding and of total
vested and exercisable options as of December 31, 2011 is $15,551
and $15,371, respectively.</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="TEXT-INDENT: -49.5pt; MARGIN: 0px 0px 0px 1.25in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 6pt" cellspacing="0" cellpadding="0">
<tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top">
<td style="WIDTH: 1in"></td>
<td style="TEXT-ALIGN: left; WIDTH: 0.25in">d.</td>
<td style="TEXT-ALIGN: justify">The following table illustrates the
effect of share-based compensation on the statement of
operations:</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 65%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2009</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt; WIDTH: 49%">
Research and development expenses</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">1,489</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">630</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 14%">422</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -12.6pt; PADDING-LEFT: 12.6pt">
General and administrative expenses</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,194</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
652</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
464</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
2,683</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,282</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
886</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: bold 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">c.</font></td>
<td>Public Offering</td>
</tr>
</table>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
On March 23,&#xA0;2011, the Company issued and sold 4,000,000
shares of Common Stock in an underwritten public offering at a
price to the public of $5.50 per share. The net proceeds to the
Company were approximately $20,590&#xA0;(net of underwriting
commissions and issuance costs of $1,410).</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px 0px 0px 0.75in; FONT: 10pt Times New Roman, Times, Serif">
In February 2012, the Company issued and sold 5,175,000 shares of
Common Stock. See Note 11b.</p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 9 -</b></font>
<b>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</b></p>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif">
<b>Balance sheets:</b></p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<table style="WIDTH: 90%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -26.45pt; PADDING-LEFT: 26.45pt; FONT-WEIGHT: bold">
a.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Accounts
receivable - other:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in; WIDTH: 70%">
Deferred costs*</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: right; WIDTH: 12%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 12%">1,558</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Institutions</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">634</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">375</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">State
of Israel (see Note&#xA0;6a )</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">878</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,296</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Restricted deposit</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">226</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">208</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Prepaid expenses</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">354</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">235</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Sundry</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
139</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
165</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
2,231</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
3,837</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left">* Manufacturing costs of inventory,
paid by Pfizer, but not delivered.</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">b.
&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Accounts payable
and accruals &#x2013; other:</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
<td style="FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: right; FONT-WEIGHT: bold">&#xA0;</td>
<td style="TEXT-ALIGN: left; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Payroll and related expenses</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">1,199</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">1,108</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Provision for vacation and recreation pay</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,235</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,221</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Accrued expenses</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,030</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,327</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Royalties payable</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">884</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">89</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Liability in connection with collaboration operation- current
portion</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,322</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
Property and equipment supplier</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
2,720</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,473</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.6in">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
8,068</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
7,540</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-ALIGN: center; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
</p>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif">
<b>Statement of operations:</b></p>
<p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif">
<b>&#xA0;</b></p>
<p style="TEXT-INDENT: -17.3pt; MARGIN: 0px 0px 0px 71.3pt; FONT: 10pt Times New Roman, Times, Serif">
</p>
<table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="10">Year ended December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2009</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center; FONT-WEIGHT: bold">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: center" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 0px; FONT-WEIGHT: bold">
c.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Revenues:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 52.2pt; WIDTH: 55%">
Deferred revenues from the license and supply agreement with
Pfizer</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 12%">
388</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 12%">
4,563</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; WIDTH: 12%">
4,563</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%">
&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt">
Revenues from selling products to Pfizer</td>
<td style="PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT-SIZE: 1pt">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT-SIZE: 1pt">
&#xA0;</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT-SIZE: 1pt">
&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
2,079</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
3,823</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
388</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
6,642</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
8,386</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold">
d.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Cost
of Revenues:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Cost of products
sold</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">807</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">985</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Write down of
inventories</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,692</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">363</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Royalties
expenses</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">$</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
3,575</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
884</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
177</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
3,575</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
4,383</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
1,525</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-LEFT: 5.35pt; FONT-WEIGHT: bold">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold">
e.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Research
and development expenses - net:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Payroll and
related expenses</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">10,479</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">13,176</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">14,042</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Subcontractors and
consultants</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">7,469</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">11,550</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">11,314</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Materials and
consumables</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,852</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">4,947</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,425</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Rent, insurance
and maintenance</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,238</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,457</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">4,113</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Patent
registration and licensing</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">387</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">571</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">449</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Depreciation and
write down</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,799</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,456</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,057</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Other</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,166</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,534</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,418</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-LEFT: 5.4pt">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">27,390</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">37,691</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">37,818</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 0.5in">Less - grants and
reimbursements:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 45pt">Development costs
reimbursements from Pfizer</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,922</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">3,430</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 45pt">Grants
(see Note 6a)</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
5,752</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
3,818</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
3,345</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.4pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
21,638</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
29,951</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
31,043</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold">
f.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;General
and administrative expense:</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Payroll and
related expenses</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">2,804</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">2,415</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">2,481</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Management and
consulting fees</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">681</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">221</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">215</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Rent, insurance
and maintenance</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">347</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">463</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">498</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Professional
fees</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,274</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,274</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">2,326</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Travel</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">251</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">308</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">229</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Depreciation</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">191</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">309</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">363</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-LEFT: 50pt">Other</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
596</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
886</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
819</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 5.4pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
7,144</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
6,876</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
6,931</td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalFinancialInformationDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EMWAI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th" colspan="2">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional paid-in Capital</div>
        </th>
        <th class="th">
          <div>Accumulated deficit</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2008</a></td>
        <td class="nump">$ 44,347<span></span></td>
        <td class="nump">$ 76<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 119,281<span></span></td>
        <td class="num">$ (75,010)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2008</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75,938,059<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes during the year</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">2,683<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">2,683<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,903,178<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise)</a></td>
        <td class="nump">293<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">288<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">(31,440)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(31,440)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2009</a></td>
        <td class="nump">15,883<span></span></td>
        <td class="nump">81<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">122,252<span></span></td>
        <td class="num">(106,450)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2009</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">80,841,237<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes during the year</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">1,282<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,282<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">407,235<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise)</a></td>
        <td class="nump">510<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">510<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">(28,998)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(28,998)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2010</a></td>
        <td class="num">(11,323)<span></span></td>
        <td class="nump">81<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">124,044<span></span></td>
        <td class="num">(135,448)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">81,248,472<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes during the year</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs of $1,410) (see note 7c) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs of $1,410) (see note 7c)</a></td>
        <td class="nump">20,590<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">20,586<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
        <td class="nump">886<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">886<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">381,685<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (includes net exercise)</a></td>
        <td class="nump">299<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">298<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">(36,529)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(36,529)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2011</a></td>
        <td class="num">$ (26,077)<span></span></td>
        <td class="nump">$ 86<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 145,814<span></span></td>
        <td class="num">$ (171,977)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85,630,157<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="6"></td>
      </tr>
      <tr>
        <td colspan="6">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Represents an amount less than $1.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
        <td class="text"><div>
<p style="TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-SIZE: 10pt"><b>NOTE 3 -</b></font> <b>PROPERTY
AND EQUIPMENT</b></p>
<p style="TEXT-INDENT: -0.5in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif">
<font style="FONT-WEIGHT: normal">&#xA0;</font></p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">a.</font></td>
<td><font style="FONT-WEIGHT: normal">Composition of property and
equipment grouped by major classifications is as
follows:</font></td>
</tr>
</table>
<p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 1in" cellspacing="0" cellpadding="0">
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">December 31,</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: center">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2010</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td>
<td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in; WIDTH: 58%">
Laboratory equipment</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 18%">11,478</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
<td style="WIDTH: 1%">&#xA0;</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">$</td>
<td style="TEXT-ALIGN: right; WIDTH: 18%">13,079</td>
<td style="TEXT-ALIGN: left; WIDTH: 1%">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Furniture and computer equipment</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,306</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">1,522</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Leasehold improvements</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">11,221</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">13,705</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
Equipment under construction</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,038</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
1,113</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 14.55pt">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">25,043</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">$</td>
<td style="TEXT-ALIGN: right">29,419</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td>&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
<td style="TEXT-ALIGN: right">&#xA0;</td>
<td style="TEXT-ALIGN: left">&#xA0;</td>
</tr>
<tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom">
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 16.2pt">
Less &#x2013; accumulated depreciation and amortization</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
(7,589</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td>
<td style="PADDING-BOTTOM: 1pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">
&#xA0;</td>
<td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">
(11,148</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">)</td>
</tr>
<tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom">
<td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -0.1in; PADDING-LEFT: 0.1in">
&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
17,454</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="PADDING-BOTTOM: 2.5pt">&#xA0;</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">
$</td>
<td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right">
18,271</td>
<td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&#xA0;</td>
</tr>
</table>
<p style="TEXT-INDENT: 0in; MARGIN: 0px 0px 0px 4.3pt; FONT: 10pt Times New Roman, Times, Serif">
&#xA0;</p>
<table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%">
<tr style="VERTICAL-ALIGN: top">
<td style="WIDTH: 0.5in"></td>
<td style="WIDTH: 0.25in"><font style="FONT-WEIGHT: normal">b.</font></td>
<td><font style="FONT-WEIGHT: normal">Depreciation and amortization
in respect of property and equipment totaled $1,990, $3,133 and
$3,631 for the years ended December 31, 2009, 2010 and 2011,
respectively, out of which the Company recorded a total write down
of $0, $43 and $10, respectively.</font></td>
</tr>
</table>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>30</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/DocumentDocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsBasisOfPresentationAndSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - LICENSE AND SUPPLY AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCollaborativeAndLicenseArrangementDisclosureTextBlock</Role>
      <ShortName>LICENSE AND SUPPLY AGREEMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsInventoryDisclosureTextBlock</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>LIABILITY FOR EMPLOYEE RIGHTS UPON RETIREMENT</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsCommitmentsDisclosureTextBlock</Role>
      <ShortName>COMMITMENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>SHARE CAPITAL</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - TAXES ON INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>TAXES ON INCOME</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsAdditionalFinancialInformationDisclosureTextBlock</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 108 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20111231.xml</File>
    <File>plx-20111231.xsd</File>
    <File>plx-20111231_cal.xml</File>
    <File>plx-20111231_def.xml</File>
    <File>plx-20111231_lab.xml</File>
    <File>plx-20111231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
